<SEC-DOCUMENT>0000950123-24-008858.txt : 20250107
<SEC-HEADER>0000950123-24-008858.hdr.sgml : 20250107
<ACCEPTANCE-DATETIME>20240815145601
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-24-008858
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		19
FILED AS OF DATE:		20240815
<PUBLIC-REL-DATE>20250107
DATE AS OF CHANGE:		20240815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Maze Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001842295
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-07295
		FILM NUMBER:		241211855

	BUSINESS ADDRESS:	
		STREET 1:		171 OYSTER POINT BOULEVARD, SUITE 300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6508505070

	MAIL ADDRESS:	
		STREET 1:		171 OYSTER POINT BOULEVARD, SUITE 300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Confidential draft no. 3 submitted to the Securities and Exchange Commission on August 15, 2024
</B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein
remains </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>strictly confidential. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="right"><B>Registration No.&nbsp;333-&#8195;&#8195;&#8195;&#8195;&#8195; </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13pt; font-family:arial" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:arial" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:13pt; font-family:arial" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:arial" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933
</I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:15pt; font-family:arial" ALIGN="center"><B>MAZE THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:arial" ALIGN="center"><B>(Exact name of
registrant as specified in its charter) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">82-2635018</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7.5pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of incorporation or<BR>organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:arial" ALIGN="center"><B>171 Oyster Point Blvd., Suite 300 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:arial" ALIGN="center"><B>South San Francisco, California 94080 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:arial" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">850-5070</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8.5pt; font-family:arial" ALIGN="center"><B>Jason Coloma, Ph.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:arial" ALIGN="center"><B>Chief Executive
Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:arial" ALIGN="center"><B>Maze Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:arial" ALIGN="center"><B>171 Oyster Point Blvd., Suite 300 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:arial" ALIGN="center"><B>South
San Francisco, California 94080 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:arial" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">850-5070</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Effie Toshav, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Amanda Rose, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Ryan Mitteness,
Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Chelsea Anderson, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Fenwick&nbsp;&amp; West LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>555 California
Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>San Francisco, California 94104</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">875-2300</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Alan Denenberg, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Emily Roberts, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Davis Polk&nbsp;&amp;
Wardwell LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>1600 El Camino Real</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Menlo Park, California 94025</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(650) <FONT
STYLE="white-space:nowrap">752-2000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after the effective date of this registration statement. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:arial">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933 check
the following box.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:arial">If this Form is filed to register additional securities for an offering pursuant to
Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:arial">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:arial">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration
number of the earlier effective registration statement for the same offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:arial">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated
filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer&#8194;&nbsp;</FONT><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7pt; font-family:arial">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a
further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT COLOR="#8b3f4e"><B>The information in this preliminary prospectus is not complete and may be changed. We may not
sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities, and we are not soliciting offers to buy these securities in
any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><FONT COLOR="#8b3f4e"><B>Subject to completion, dated&#8195;&#8195;&#8195;&#8195; , 2024 </B></FONT></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B>Preliminary prospectus </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><I>&#8195;&#8195;&#8195;&#8195;shares </I></B></P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%">


<IMG SRC="g769642g76l04.jpg" ALT="LOGO" STYLE="width:0.765972in;height:0.772917in;">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><I>Common stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
offering&#8195;&#8195;&#8195;&#8195;shares of our common stock. This is our initial public offering and no public market currently exists for our common stock. We expect the initial public offering price to be between
$&#8195;&#8195;&#8195;&#8195;and $&#8195;&#8195;&#8195;&#8195;per share. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have applied to list our common stock on the Nasdaq Global Market , or Nasdaq, under the
symbol &#147;MAZE.&#148; It is a condition to the closing of this offering that the common stock offered hereby has been approved for listing on Nasdaq. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an
&#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; as defined under the federal securities laws and, as such, we have elected to comply with certain reduced reporting requirements for this prospectus and may elect to do
so in future filings. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Per&nbsp;share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Initial public offering price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8195;&#8195;&#8195;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8195;&#8195;&#8195;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Underwriting discounts and commissions(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Proceeds to Maze Therapeutics, Inc., before expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See the section entitled &#147;Underwriting&#148; for a description of the compensation payable to the underwriters. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
have granted the underwriters an option for a period of 30 days after the date of this prospectus to purchase up to&#8195;&#8195;&#8195;&#8195;additional shares of our common stock from us at the initial public offering price, less underwriting
discounts and commissions. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Investing in our common stock involves a high degree of risk. Please read the section entitled</B>&#8201; <B>&#147;<A HREF="#toc769642_3">Risk
 factors</A>&#148;</B>&#8201; <B>beginning on page&nbsp;14 of this prospectus.</B> </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters expect to deliver the shares of common stock against payment in New York, New York, on&#8195;&#8195;&#8195;&#8195;, 2024. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:16pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:16pt">
<TD VALIGN="bottom"><B>J.P.&nbsp;Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>TD&nbsp;Cowen</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Leerink&nbsp;Partners</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Guggenheim&nbsp;Securities</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B>Prospectus dated&#8195;&#8195;&#8195;&#8195;, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc"></A>Table of contents </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_1">Prospectus summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_2">The offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_3">Risk factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_4">Special note regarding forward-looking statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_5">Use of proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_6">Dividend policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_9">Management&#146;s discussion and analysis of financial condition and results of operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_12">Executive compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_13">Certain relationships and related party transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_14">Principal stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_15">Description of capital stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_16">Shares eligible for future sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_17">Material U.S. federal income tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.
</FONT> holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_18">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_19">Legal matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_20">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_21">Where you can find additional information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc769642_22">Index to financial statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Through and including&#8195;&#8195;&#8195;&#8195;, 2024 (the 25th day after the date of this prospectus), all dealers effecting
transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter
and with respect to an unsold allotment or subscription<I>.</I> </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Neither we nor the underwriters have
authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no
assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information
contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or the time of any sale of shares of our common stock. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For investors outside of the United States: Neither we nor any of the underwriters have done anything that would
permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must
inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_1"></A>Prospectus summary </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making
your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our financial statements and the related notes thereto and the information set forth under the sections entitled &#147;Risk
factors&#148; and &#147;Management&#146;s discussion and analysis of financial condition and results of operations,&#148; in each case included in this prospectus. Some of the statements in this prospectus constitute forward-looking statements that
involve risks and uncertainties. See the section entitled &#147;Special note regarding forward-looking statements&#148; for additional information. Unless the context otherwise requires, we use the terms &#147;Maze,&#148; &#147;the company,&#148;
&#147;we,&#148; &#147;us&#148; and &#147;our&#148; in this prospectus to refer to Maze Therapeutics, Inc. </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with
common diseases, with a focus on renal, cardiovascular and related metabolic diseases, including obesity.&nbsp;We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then
link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.&nbsp;Our Compass platform has been purpose-built to inform all phases of our drug discovery and
development process through clinical trial design.&nbsp;We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is
to bring novel precision medicines to patients with common diseases, which is where we believe we can maximize our impact on human health. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">CKD is a serious,
progressive condition that affects approximately 37&nbsp;million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical
categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated
with reduced disease burden and improved kidney function in distinct groups of CKD patients. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our most advanced lead program, MZE829, is an oral, small molecule
inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal
dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the
clinical setting. We expect to initiate a Phase 2 trial of MZE829 in&#8195;&#8195;&#8195;&#8195; . </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our second lead program, MZE782, is an oral, small molecule
inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a
potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do
not adequately respond to today&#146;s standard of care. We submitted an Investigational New Drug Application, or IND, to the United States Food and Drug Administration, or FDA, for MZE782 in July 2024. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Compass platform supports <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> variant identification and functionalization
capabilities as well as advanced research tools and methodologies for drug development.&nbsp;We believe the process of variant </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us
apart from others in the field. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our programs </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our programs include
our clinical stage pipeline as well as additional earlier stage research programs. Our wholly owned clinical pipeline consists of small molecule precision medicines for patients living with common diseases, with a focus on renal, cardiovascular and
related metabolic, or CVRM, diseases, including obesity.&nbsp;In areas outside of our focus, we have an additional program in development, MZE001 in Pompe disease, through a partnership arrangement with Shionogi&nbsp;&amp; Co., Ltd., or Shionogi. In
addition to our clinical pipeline, we have several earlier stage research programs. These include wholly owned small molecule programs within our CVRM core focus. We also have additional partnered programs, including ATXN2 and UNC13A, each of which
we were developing for amyotrophic lateral sclerosis, or ALS, with two separate biotechnology companies.&nbsp;Our programs are summarized below. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g769642g94f07.jpg" ALT="LOGO" STYLE="width:6.04559in;height:2.07274in;">
 </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g36i96.jpg" ALT="LOGO" STYLE="width:6.05522in;height:2.36308in;">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of APOL1 for the treatment of patients with AKD, a
subset of CKD estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant of the APOL1 gene,
N264K. MZE829 is designed to phenocopy N264K and </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
mimic its protective characteristics. Through our preclinical work in AKD, we have demonstrated MZE829&#146;s potential as a disease modifying treatment for patients suffering from this disease.
Preclinical <I>in vivo</I> studies demonstrated MZE829&#146;s significant potency in a model of APOL1-induced kidney injury, suggesting the ability to address a broader population of AKD than has previously been possible in the clinical setting.
Additionally, MZE829 has demonstrated the potential to stop or reverse critical features of kidney disease, specifically the breakdown of the kidney&#146;s filtering system and loss of protein in urine, or proteinuria. We expect to initiate a Phase
2 trial of MZE829 in&#8195;&#8195;&#8195;&#8195;. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our second most advanced lead program, MZE782, is an oral, small molecule that targets the solute transporter,
SLC6A19, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a
significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today&#146;s standard of care.
We identified SLC6A19 using non-public sets of matched, genetic and longitudinal clinical data and discovered a bidirectional allelic series with variants that either improve or worsen renal function. We then applied variant functionalization
techniques to understand the characteristics of the naturally occurring protective variants and designed our proprietary small molecule to mimic their inhibitory effects. We plan to apply a <FONT STYLE="white-space:nowrap">non-invasive</FONT>
biomarker strategy in our Phase 1 trial to establish proof of mechanism and to select doses for a Phase 2 trial. We submitted an IND to the FDA for MZE782 in July&nbsp;2024. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to our two lead programs in CKD, our Compass platform has also produced a pipeline across other therapeutic areas and modalities, including MZE001, our first
clinical program developed for the treatment of patients with Pompe disease. Within approximately three years, MZE001 progressed from discovery to the clinic and demonstrated proof of mechanism in a Phase 1 trial, suggesting its potential as an oral
therapy for the treatment of patients with Pompe disease and demonstrating the potential of our Compass platform. Given our focus on common diseases, where we believe we can maximize our impact on human health, we strategically enter into
partnerships with third parties to advance programs that address diseases outside of our core focus areas. In March 2024, following the completion of our Phase 1 trial, we exclusively licensed MZE001 to Shionogi for an upfront payment of
$150&nbsp;million and the potential for additional milestones and royalties. We have also exclusively licensed our ATXN2 and UNC13A programs to other biotechnology companies. Additionally, we formed a <FONT STYLE="white-space:nowrap">spin-out</FONT>
company, Broadwing Bio LLC, or Broadwing, to develop therapeutic candidates treating ophthalmic diseases. As of June 30, 2024, we owned approximately 48% of the outstanding equity of Broadwing. We believe these collaborations validate the potential
of our Compass platform and our ability to generate new targets and assets of therapeutic interest across a wide range of indications and therapeutic areas. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our approach to precision medicine: Compass platform </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Compass platform
and its associated methodologies give us the ability to aggregate matched, genetic, and longitudinal clinical data at scale to identify genes associated with disease, utilizing a combination of private and publicly-available paired clinical data.
More importantly, this process uncovers genetic variants of these genes that provide insight into a therapeutic approach to the applicable target. Using machine learning and statistical modeling, variant functionalization tools, and traditional and
computational drug discovery technologies, targets are then prioritized based on their roles in biological pathways, their roles as potential drivers of disease, and their structural properties. These insights ultimately inform our clinical
development and patient selection strategies, which we believe have the potential to improve the overall likelihood of technical, regulatory and commercial success of our precision medicine candidates, although we cannot provide any assurance that
the application of our Compass platform will result in the ultimate regulatory approval of </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
any of our therapeutic candidates. The power of our Compass platform and its methodologies is best exhibited through our clinical and preclinical programs and multiple contributions to the
scientific community over the past five years, including the publication in <I>Nature</I> and other leading scientific journals of discoveries made through our Compass platform in the fields of human genetics, molecular biology and medicinal
chemistry. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:13%; text-indent:-13%">


<IMG SRC="g769642g02g02.jpg" ALT="LOGO" STYLE="width:7.5in;height:3.04741in;">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Compass platform follows a sequential, three phase workflow consisting of: (1)&nbsp;variant discovery, in which we analyze
multiple large-scale genetic databases to identify relevant genetic variants; (2)&nbsp;variant function identification, in which we attempt to understand the linkage between genetic variants identified and the biology underpinning disease; and
(3)&nbsp;translation into therapy, in which we develop the assays, models, molecules and data necessary to support advancing our programs into clinical development. This workflow creates an iterative learning loop that improves as we onboard,
analyze and generate additional data. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>A new era of precision medicine: Maze&#146;s opportunity in common diseases </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Over the past 20 years, significant advances in human genetics and in the understanding of the biological processes underpinning disease have opened the door to a
multitude of potentially new therapeutic targets and treatment approaches, which we believe presents a unique opportunity for a new approach to precision medicine. More recently, the availability of matched, genetic, and longitudinal clinical data
and advanced computational methods to analyze these data has enabled the characterization of genetic variants that are strongly correlated with disease susceptibility and severity. Advancements in functional genomics have also provided new tools to
help unravel how genetic variants impact disease progression from a mechanistic perspective. Nevertheless, the process of successfully translating genetic insights into effective precision medicines is a challenge that has inspired our mission as a
company as well as our name, Maze Therapeutics. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on insights from our Compass platform, we design our therapeutic candidates to modulate the target of
interest, either by mimicking the beneficial effects of certain protective variants or by blocking the unwanted activity associated with toxic variants, to address the underlying biological drivers of disease. Our process of designing precision
medicines that take into account the genetic drivers of disease in defined patient groups parallels many of the foundational principles of precision oncology, which has revolutionized the treatment landscape in cancer, and, we believe, may help
streamline our development efforts and increase our odds of clinical success. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our team </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our leadership
team and board of directors have significant experience discovering, developing and commercializing therapies. Our existing shareholders include investors with renowned life sciences experience and a shared, dedicated goal of transforming the lives
of patients by creating a leading precision medicine company in the CVRM disease spaces. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Jason Coloma, Ph.D., M.P.H., </I></B>our Chief Executive Officer,
brings over 20 years of life science leadership experience. He most recently operated as a venture partner at Third Rock Ventures, LLC, or Third Rock Ventures, during which time he served as the Chief Operating Officer of Maze before being appointed
CEO. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Harold Bernstein, M.D., Ph.D., </I></B>our President, Research&nbsp;&amp; Development and Chief Medical Officer, brings over 30 years of experience in
scientific research, translational medicine and clinical development. Dr.&nbsp;Bernstein most recently was Chief Medical Officer and Head of Global Clinical Development at BioMarin Pharmaceuticals Inc. He previously served as Head of Translational
Medicine at Vertex Pharmaceuticals Incorporated, or Vertex, and held roles of increasing responsibility at Merck and Co., Inc., including Head of Early Development for Cardiometabolic Diseases. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Atul Dandekar, </I></B>our Chief Strategy and Business Officer, brings over 20 years of experience in strategy, clinical development and commercialization.
Mr.&nbsp;Dandekar most recently was VP, Global Franchise Head for Ophthalmology at Genentech, Inc., or Genentech, and F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche AG, or Roche, and previously served as Senior Global Program Head in
Neuroscience at Novartis AG. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our strategy </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We leverage our Compass
platform to discover and develop precision medicines in subsets of common diseases to achieve improved treatment outcomes for patients. Our focus on common CVRM diseases, including obesity, is driven in part by the emerging understanding of the
interconnectivity of these diseases. By focusing on these common diseases, we believe we can maximize our impact on human health. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The core elements of our business
strategy are to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B><I>Advance the clinical development of MZE829 and MZE782 for the treatment of CKD, a disease affecting a large patient
population with high unmet need. </I></B> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B><I>Leverage our proprietary Compass platform to expand our pipeline of precision medicine candidates. </I></B>
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B><I>Enhance our Compass platform and methodology.</I></B><I> </I> </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B><I>Maximize the commercial potential of our pipeline</I></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Summary of risks affecting us </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our business and our ability to implement our
business strategy are subject to numerous risks, as more fully described in the section entitled &#147;Risk factors&#148; immediately following this prospectus summary. You should read these risks before you invest in our common stock. We may be
unable, for many reasons, including those that are beyond our control, to implement our business strategy. In particular, risks associated with our business include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate
the success of our business to date and to assess our future viability. Since our inception, we have incurred significant operating losses and have not generated any revenue. We expect to incur continued losses for the foreseeable future and may
never achieve or maintain profitability. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Even if this offering is successful, we will require substantial additional capital to finance our operations and achieve
our goals. If we are unable to raise capital when needed or on terms acceptable to us, we may be forced to delay, reduce or eliminate our research or product development programs, any future commercialization efforts or other operations.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We are early in our development efforts and highly dependent on the success of our lead programs. If we are unable to
commercialize our therapeutic candidates or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Preclinical and clinical drug development is a lengthy and expensive process, with uncertain timelines and outcomes. If
preclinical studies or clinical trials of our therapeutic candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our therapeutic candidates or any of our future
therapeutic candidates on a timely basis or at all. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may not be successful in applying our Compass platform to identify targets with therapeutic potential or to discover and
develop safe, effective or commercially viable therapeutic candidates. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our Compass platform relies on access to high quality data repositories with paired genetic and clinical data and loss of
such access, or the inability to use such data, could have a material adverse effect on our business, financial condition, results of operations and prospects. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have entered, and may in the future enter, into strategic collaborations, transactions and licensing partnerships for
research, development or commercialization of our programs, including our first therapeutic candidate MZE001, and we may not be able to realize the full value of these partnerships or our partnered programs. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We face significant competition in an environment of rapid technological change and there is a possibility that our
competitors may achieve regulatory approval before us or develop therapies or technologies that are more advanced or effective than ours, which may harm our business and financial condition, and our ability to successfully market or commercialize
our therapeutic candidates. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our success depends in part on our and our partners&#146; ability to obtain, maintain, enforce and protect our intellectual
property and proprietary rights. It is difficult and costly to protect our intellectual property rights and technologies, and we may not be able to ensure their protection. If we are unable to adequately protect our technologies or obtain and
maintain patent protection for our technologies and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies and products similar or identical to ours, and our
ability to successfully commercialize our technologies and products may be impaired. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">If we are sued for infringing, misappropriating or otherwise violating intellectual property or proprietary rights of third
parties, such litigation or disputes could be costly and time-consuming and could prevent or delay us from developing or commercializing our therapeutic candidates<B><I>. </I></B> </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Certain of the diseases we, or which our partners, seek to treat have low prevalence and/or have available therapies, and
it may be difficult for us or our partners to identify patients with these diseases or face competition in the recruitment of these limited groups of patients, which may lead to difficulties in enrolling clinical trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Corporate information </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We were incorporated under the laws of the State of
Delaware on August&nbsp;29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July&nbsp;5, 2018 to Modulus Therapeutics, Inc. and on September&nbsp;25, 2018, to Maze Therapeutics, Inc. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California
94080, and our telephone number is (650) <FONT STYLE="white-space:nowrap">850-5070.</FONT> Our website address is www.mazetx.com. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated by
reference into, this prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The mark &#147;Maze Therapeutics,&#148; the Maze logo, &#147;Maze Compass&#148; and all product names are our registered or common
law trademarks. All other service marks, trademarks and trade names appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and tradenames referred to in this prospectus appear without the <SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under
applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Implications of being an emerging growth company and a
smaller reporting company </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a company with less than $1.235&nbsp;billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth
company,&#148; or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An EGC may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies. These
provisions include, but are not limited to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">being permitted to present only two years of audited financial statements and only two years of reduced related
&#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; disclosure in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of
2002, as amended, or the Sarbanes-Oxley Act, on the effectiveness of our internal controls over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reduced disclosure obligations regarding executive compensation arrangements; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval
of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will remain an EGC until the earliest to occur of: (1)&nbsp;the last day of our
fiscal year in which we have more than $1.235&nbsp;billion in annual revenue; (2)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; as defined under Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act
of 1934, as amended, or the Exchange Act; (3)&nbsp;the date on which we have issued, in any three-year period, more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; or (4)&nbsp;the last day of our
fiscal year ending after the fifth anniversary of the completion of this offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have elected to take advantage of certain of the reduced disclosure
obligations for EGCs in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be
different than you might receive from other public reporting companies in which you hold equity interests. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The JOBS Act provides that an EGC can take advantage of
an extended transition period for complying with new or revised accounting standards, until those standards apply to private companies. We have elected to use this extended transition period to enable us to comply with new or revised accounting
standards that have different effective dates for public and private companies until the earlier of the date we (i)&nbsp;are no longer an EGC or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS
Act. As a result, our financial statements may not be comparable to companies that comply with such new or revised accounting standards. Until the date that we are no longer an EGC or affirmatively and irrevocably opt out of the exemption provided
by Section&nbsp;7(a)(2)(B) of </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the Securities Act of 1933, as amended, or the Securities Act, upon issuance of a new or revised accounting standard that applies to our financial statements and that has a different effective
date for public and private companies, we will disclose the date on which adoption is required for <FONT STYLE="white-space:nowrap">non-EGCs</FONT> and the date on which we will adopt the recently issued accounting standard. We are also a
&#147;smaller reporting company,&#148; or SRC, meaning that the market value of our capital stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering
is less than $700.0&nbsp;million and our annual revenue is less than $100.0&nbsp;million during our most recently completed fiscal year. We may continue to be a SRC after this offering if either (i)&nbsp;the market value of our capital stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue was less than $100.0&nbsp;million during our most recently completed fiscal year and the market value of our capital stock held
by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are a SRC at the time we cease to be an EGC, we may continue to rely on exemptions from certain disclosure requirements that are available to SRCs.
Specifically, as a SRC, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and we are not required to comply with the auditor
attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act and, similar to EGCs, SRCs have reduced disclosure obligations regarding executive compensation. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_2"></A>The offering </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Common stock offered by us </B></P></TD>
<TD>&#8195;&#8195;&#8195;&#8195;shares </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Option to purchase additional shares </B></P></TD>
<TD>We have granted the underwriters an option, exercisable for 30 days after the date of this prospectus, to purchase up to an additional&nbsp;&#8195;&#8195;&#8195;&#8195;shares from us at the initial public offering price per share less the
underwriting discounts and commissions. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Common stock to be outstanding immediately after this offering </B></P></TD>
<TD>&#8195;&#8195;&#8195;&#8195;shares (or&nbsp;&#8195;&#8195;&#8195;&#8195;shares, if the underwriters exercise their option to purchase additional shares in full). </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Use of proceeds </B></P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $&nbsp;&#8195;&#8195;&#8195;&#8195;million (or approximately $&nbsp;&#8195;&#8195;&#8195;&#8195;million if the underwriters exercise their option to purchase additional
shares in full), based upon an assumed initial public offering price of $&nbsp;&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus, after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="28%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund the clinical development of MZE829, MZE782 and our other discovery and preclinical programs, to conduct
research, to broaden the pipeline of product candidates, to fund the further development of our Compass platform, and for working capital and other general corporate purposes. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="28%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See the section entitled &#147;Use of proceeds&#148; for additional information. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Risk factors </B></P></TD>
<TD>You should read the section entitled &#147;Risk factors&#148; in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Proposed Nasdaq Global Market symbol </B></P></TD>
<TD>&#147;MAZE&#148; </TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of our common stock to be outstanding after this offering is based on (i)&nbsp;23,369,733&nbsp;shares of
our common stock outstanding as of June 30, 2024, including 289,230&nbsp;shares that are unvested and subject to repurchase or forfeiture, (ii)&nbsp;the automatic conversion of all shares of our outstanding redeemable convertible preferred stock
into an aggregate of 203,415,024&nbsp;shares of our common stock immediately prior to the completion of this offering and (iii)&nbsp;the automatic conversion of all principal and accrued and unpaid interest on our outstanding convertible promissory
notes into &#8195;&#8195;&#8195;&#8195; shares of our common stock immediately prior to </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the completion of this offering, based upon an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the estimated price range set forth on the
cover of this prospectus, and excludes: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">35,335,588 shares of our common stock issuable upon the exercise of options to purchase shares of our common stock
outstanding as of June 30, 2024 under our 2019 Equity Incentive Plan, or the 2019 Plan, with a weighted-average exercise price of $1.50&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our common stock issuable upon the exercise of options to purchase shares of our
common stock granted after June 30, 2024 under our 2019 Plan, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share; and </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195;&nbsp;shares of our common stock reserved for future issuance under our equity compensation
plans, consisting of: </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">3,057,291&nbsp;shares of our common stock reserved for future issuance under our 2019 Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock to be reserved for future issuance under our 2024 Equity Incentive
Plan, or the 2024 Plan, which will become effective immediately prior to the date of the effectiveness of the registration statement of which this prospectus forms a part; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock to be reserved for future issuance under our 2024 Employee Stock
Purchase Plan, or the ESPP, which will become effective on the date of the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our 2024 Plan and our ESPP provide for automatic annual increases in the number of shares of our common stock reserved thereunder, and our 2024 Plan provides for
increases to the number of shares that may be granted thereunder based on shares under our 2019 Plan or 2018 Stock Option and Grant Plan, or the 2018 Plan, that expire, are tendered to or withheld by us for payment of an exercise price or for
satisfying tax withholding obligations or are forfeited or otherwise repurchased by us. Upon completion of this offering, any remaining shares of our common stock available for issuance under our 2019 Plan will be added to the shares reserved under
our 2024 Plan and we will cease granting awards under our 2019 Plan. See the section entitled &#147;Executive compensation&#151;Equity compensation plans and other benefit plans&#148; for additional information. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Except as otherwise indicated, all information in this prospectus assumes or gives effect to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of
&#8195;&#8195;&#8195;&#8195;shares of our common stock immediately prior to the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the automatic conversion of all principal and accrued and unpaid interest on our outstanding convertible promissory notes
into&#8195;&#8195;&#8195;&#8195;shares of our common stock immediately prior to the completion of this offering, based upon an assumed initial public offering price of $&#8195;&#8195;&#8195;per share, which is the midpoint of the estimated price
range set forth on the cover of this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a&#8195;&#8195;&#8195;&#8195; <FONT STYLE="white-space:nowrap">-for-&#8195;&#8195;&#8195;&#8195;</FONT> reverse stock split
of our outstanding common stock and redeemable convertible preferred stock to be effected on&#8195;&#8195;&#8195;&#8195;, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the filing and effectiveness of our restated certificate of incorporation and restated bylaws in connection with the
completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no exercise of outstanding options after June 30, 2024; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no exercise of the underwriters&#146; option to purchase additional shares of our common stock. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Summary financial data </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following tables set forth our summary statements of operations and comprehensive income (loss) and balance sheet data. The summary statement of operations and
comprehensive loss data presented below for the years ended December&nbsp;31, 2022 and 2023 are derived from our audited financial statements included elsewhere in this prospectus. The summary statement of operations and comprehensive income (loss)
data presented below for the six months ended June 30, 2023 and 2024 and balance sheet data as of June&nbsp;30, 2024 are derived from our unaudited interim condensed financial statements included elsewhere in this prospectus. The following summary
financial data should be read in conjunction with &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; and our financial statements and related notes included elsewhere in this prospectus. Our
historical results are not necessarily indicative of the results that may be expected in any future period, and our results of operations for the six months ended June&nbsp;30, 2024 and balance sheet data as of June&nbsp;30, 2024 are not necessarily
indicative of our results to be expected for the year ended December&nbsp;31, 2024 or any future period. The summary financial data in this section are not intended to replace our financial statements and are qualified in their entirety by the
financial statements and related notes included elsewhere in this prospectus. </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(In thousands except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">License revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">(Loss) income from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss on impairment and dissolution of equity method investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Share in net loss of equity method investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">(Loss) income before income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(114,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income and comprehensive (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(114,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Allocation of undistributed earnings to participating securities (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income attributable to common stockholders, basic (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(114,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income attributable to common stockholders, diluted (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(114,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(In thousands except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income per share attributable to common stockholders (1):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average shares used in computing net (loss) income per share attributable to common stockholders
(1):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,379,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,071,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,815,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,794,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,379,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,071,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,815,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,541,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro Forma net (loss) income per share attributable to common stockholders, basic (unaudited)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro Forma net (loss) income per share attributable to common stockholders, diluted (unaudited)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average shares outstanding used in computing pro forma net (loss) income per share attributable to
common shareholders, basic (unaudited)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average shares outstanding used in computing pro forma net (loss) income per share attributable to
common shareholders, diluted (unaudited)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See note 13 to our audited financial statements and note 12 to our unaudited condensed financial statements included elsewhere in this prospectus for further details on the calculation of historical net (loss) income
per share attributable to common stockholders and the weighted average number of shares of common stock used in the computation of per share data. The unaudited pro forma basic and diluted net (loss) income per share attributable to common
stockholders were computed using the weighted-average number of shares of common stock outstanding, including the pro forma effect of the automatic conversion of all outstanding shares of redeemable convertible preferred stock into shares of common
stock, and the automatic conversion of the convertible promissory notes into common stock as of the beginning of the period. </TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="12" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of June 30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;forma(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Pro&nbsp;Forma</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>as&nbsp;adjusted(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Working capital(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">94,265</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">(289,124</TD>
<TD NOWRAP VALIGN="top">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">(262,373</TD>
<TD NOWRAP VALIGN="top">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pro forma amounts give effect to (i)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of &#8195;&#8195;&#8195;&#8195; shares of our common stock
immediately prior to the completion of this offering and (ii)&nbsp;the automatic conversion of all principal and accrued and unpaid interest on our outstanding convertible promissory notes into an aggregate of&#8195;&#8195;&#8195;&#8195; shares of
our common stock immediately prior to the completion of this offering, based upon an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the midpoint of the estimated price range set forth on the cover of this
prospectus. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pro forma as adjusted amounts reflect pro forma adjustments described in footnote (1)&nbsp;as well as the sale of&#8195;&#8195;&#8195;&#8195; shares of our common stock in this offering, based upon an assumed initial
public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us. The pro forma as adjusted information is illustrative only, and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in
the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of
cash and cash equivalents, working capital, total assets and total stockholders&#146; equity by $&#8195;&#8195;&#8195;&#8195; million, assuming the number of shares offered by us, as set forth on the cover of this prospectus, remains the same and
after deducting estimated underwriting discounts and commissions. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered would increase (decrease) the pro forma as adjusted amount of each of cash and cash
equivalents, working capital, total assets and total stockholders&#146; equity by $&#8195;&#8195;&#8195;&#8195; million, assuming that the assumed initial public offering price remains the same and after deducting estimated underwriting discounts
and commissions. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_3"></A>Risk factors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you should carefully consider the
risks described below, together with the other information contained in this prospectus, including in the sections titled &#147;Special note regarding forward-looking statements&#148; and &#147;Management&#146;s discussion and analysis of financial
condition and results of operations&#148; and in our financial statements and the related notes included elsewhere in this prospectus. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that
we are unaware of or that we deem immaterial may also become important factors that adversely affect our business. We cannot assure you that any of the events discussed below will not occur. These events could have a material and adverse impact on
our business, financial condition, results of operations and prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment. </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our limited operating history, financial position and need for capital </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate the success of our business to date and
to assess our future viability. Since our inception, we have incurred significant operating losses and have not generated any revenue. We expect to incur continued losses for the foreseeable future and may never achieve or maintain profitability.
</I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Investment in drug development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical-stage biopharmaceutical
company with a limited operating history. Our lead programs are still in early clinical and preclinical development, and we are subject to the risks of failure inherent in the development of therapeutic candidates based on novel technologies. We
have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biotechnology industry. Furthermore, we do not expect to
generate any revenue from commercial sales for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of clinical trials, preclinical studies, research and development, and
the regulatory approval process of our therapeutic candidates. For the years ended December&nbsp;31, 2022 and 2023, we incurred a net loss of $114.9&nbsp;million and $100.4&nbsp;million, respectively. As of June 30, 2024, we had an accumulated
deficit of $289.1&nbsp;million. We expect to continue to incur significant research and development and other expenses related to our ongoing operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our
inception, we have focused substantially all of our efforts and financial resources on research and development activities for our programs and on establishing arrangements and collaborations with third parties for the development of our therapeutic
candidates. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of our equity and convertible promissory notes, as well as <FONT STYLE="white-space:nowrap">one-time,</FONT>
nonrefundable, upfront licensing payments. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our prior losses, combined with expected future losses, have had, and will continue to have, an adverse effect on
our stockholders&#146; equity and working capital. We expect our research and development expenses to significantly increase in connection with clinical trials for our lead programs, MZE829 and MZE782, further development of our Maze Compass
platform, or our Compass platform, planned preclinical studies, IND filings and clinical trials for future therapeutic candidates. We will also incur substantial additional expenses as we seek to expand our intellectual property portfolio, including
through potential <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities, and hire additional personnel as we scale up our operations. Once we are a public company, we will incur additional costs associated with operating as a public
company. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict
the extent of any future losses or when we will become profitable, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any
revenue apart from upfront licensing payments, and we do not know when, or if, we will generate any sales, milestone, or royalty revenue. We do not expect to generate additional significant revenue from licensing arrangements in the near term. We do
not expect to generate significant revenue unless and until we obtain marketing approval for, and begin to sell, our therapeutic candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To become and remain
profitable, we must succeed in designing, developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including therapeutic candidate selection,
preclinical testing and clinical trials of our therapeutic candidates, continuing to discover and develop&nbsp;additional therapeutic candidates, establishing arrangements with third parties for the manufacture of preclinical and clinical supplies,
obtaining regulatory approval for any therapeutic candidates that successfully complete clinical trials,&nbsp;manufacturing, marketing and selling any products for which we may obtain marketing approval and obtaining coverage and adequate
reimbursement from government and third-party payors for any such products. We are only in the preliminary stages of development and clinical trials, and we may never succeed in these activities and, even if we do, may never generate revenues that
are significant enough to achieve profitability or meet outside expectations for our profitability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because of the numerous risks and uncertainties associated with
pharmaceutical development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, or if, we will be able to achieve profitability. If we decide to or are required by the U.S. Food and Drug
Administration, or FDA, or regulatory authorities in other jurisdictions to perform preclinical studies or clinical trials in addition to those currently expected, or if there are any delays in establishing appropriate manufacturing arrangements
for, in initiating clinical trials or preclinical studies for, or in the development of any of our therapeutic candidates, our expenses could increase materially and profitability could be further delayed. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. We expect our financial condition and
operating results to fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year</FONT></FONT> due
to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. Our failure to become and remain profitable would
depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations. A decline in the value of our
company could also cause you to lose all or part of your investment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if this offering is successful, we will require substantial additional capital to
finance our operations and achieve our goals. If we are unable to raise capital when needed or on terms acceptable to us, we may be forced to delay, reduce or eliminate our research or product development programs, any future commercialization
efforts or other operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Developing pharmaceutical products, including conducting clinical trials and preclinical studies, is a very time-consuming,
expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase substantially in connection with our ongoing research and development
activities, particularly as we advance our developmental programs, advance our current clinical trial and preclinical studies, commence additional clinical trials and preclinical studies and expand the breadth of our Compass platform. In addition,
even if we obtain marketing approval for any of our therapeutic candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, upon the closing of this
offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional capital in connection with our continuing operations. Adequate additional financing may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
not be available to us on favorable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have
sufficient funds for our current or future operating plans. If we are unable to raise capital when needed or on favorable terms, we could be forced to delay, reduce or eliminate our clinical and preclinical development, research and development
programs, our commercialization plans or other operations. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June 30, 2024, our cash and cash equivalents were $175.1&nbsp;million. Based on our current
operating plan, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements through at
least&#8195;&#8195;&#8195;&#8195;. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Changes beyond our control may occur that would cause us to use our
available capital before that time, including changes in and progress of our development activities and changes in regulation. Our future capital requirements will depend on many factors, including, but not limited to: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs associated with the type, scope, progress and results of research and discovery, preclinical development,
laboratory testing and clinical trials for our current or future therapeutic candidates, including MZE829 and MZE782; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we develop, <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other pipeline therapeutic
candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number and development requirements of other therapeutic candidates that we may pursue, and other indications for our
current therapeutic candidates that we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs related to entering into partnerships or other arrangements with third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs, timing and outcome of obtaining regulatory approvals of our current or future therapeutic candidates we may
pursue; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs and fees associated with the discovery, acquisition or <FONT STYLE="white-space:nowrap">in-license</FONT> of our
products or technologies, including to maintain and expand our Compass platform; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope and costs of making arrangements with third-party manufacturers for preclinical, clinical and commercial supplies
of our current or future therapeutic candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope and costs involved in growing our organization to the size needed to allow for the research, development and
potential commercialization of our current or future therapeutic candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs associated with commercializing any approved therapeutic candidates, including establishing sales, marketing and
distribution capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs associated with completing any post-marketing studies or trials required by the FDA or other regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the revenue, if any, received from commercial sales of our current or future therapeutic candidates, if any are approved;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs associated with addressing any potential interruptions or delays resulting from factors related to overall global
affairs, such as conflicts overseas; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining, defending and enforcing our
intellectual property and proprietary rights and defending intellectual property-related claims that we may become subject to, including any litigation costs and the outcome of such litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs associated with potential product liability claims, including the costs associated with obtaining insurance
against such claims and with defending against such claims; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to establish and maintain collaboration arrangements on favorable terms, if at all and the timing and amount of
any milestone, royalty or other payments we are required to make or are eligible to receive under such collaborations, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if this
offering is successful, we will require additional capital for our research and development programs. Our ability to raise additional funds will be dependent on financial, economic and market conditions, geopolitical issues and other factors, over
which we may have limited or no control. If adequate funds are not available on commercially acceptable terms when needed, we may be forced to delay, reduce or terminate our research and development activities of all or part of our research programs
or therapeutic candidates or we may be unable to take advantage of future business opportunities. Furthermore, any additional capital-raising efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our current and future therapeutic candidates, if approved. Changing circumstances, some of which may be beyond our
control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to
relinquish rights to our technologies or therapeutic candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Until such time, if ever, as we can generate substantial product revenue, we expect to
finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. In addition, we may seek additional capital due to favorable market
conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership
interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements
that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to
relinquish valuable rights to our technologies, future revenue streams, research programs or therapeutic candidates, including granting licenses to our technologies, on terms that may not be favorable to us. If we are unable to raise additional
funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to third parties to develop and
market therapeutic candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our loan and security agreement provides our lender with a first
priority lien against substantially all of our assets, except for intellectual property, and contains restrictive and financial covenants that may limit our operating flexibility. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our loan and security agreement, dated June&nbsp;27, 2022, between us and Banc of California (f/k/a Pacific Western Bank), as amended as of the date hereof, or the Loan
Agreement, is a line of credit secured by a lien covering substantially all of our personal property, excluding intellectual property. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Loan Agreement contains
customary representations and warranties, events of default and affirmative and negative covenants, including covenants that limit or restrict our ability to, among other things, dispose of assets, make changes to our business, management, ownership
or business locations, merge or consolidate, incur additional indebtedness, pay dividends or other distributions or repurchase equity, make investments and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
certain capital expenditures, and enter into certain transactions with affiliates, in each case subject to certain exceptions. Our ability to comply with these and other covenants is dependent on
several factors, some of which are beyond our control. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we have not drawn on the Loan Agreement to date, the restrictions and covenants in the Loan Agreement,
as well as those contained in any future debt financing agreements that we may enter into, may restrict our ability to finance our operations and engage in, expand or otherwise pursue our business activities and strategies. Our ability to comply
with these covenants and restrictions may be affected by events beyond our control, and breaches of these covenants and restrictions could result in a default under the Loan Agreement or under any future financing agreements that we may enter into,
which would give our lenders the right to terminate their commitments to provide loans and to declare all borrowings outstanding, together with accrued and unpaid interest and fees, to be immediately due and payable. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, the interest rate for any future term loan drawn under the Loan Agreement will be based on the published prime rate, a floating rate, subject to a maximum rate
equal to the greater of (i) 0.75% above the published prime rate as then in effect and (ii) 4.50%. The Federal Reserve has raised, and may in the future further raise, interest rates to combat the effects of recent high inflation. An increase in the
prime rate resulting in interest rates above the set minimum rate would increase our debt service obligations, which could have a negative impact on our cash flow, financial position or operating results, or result in increased borrowing costs in
the future. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to discovery and development of our therapeutic candidates </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are early in our development efforts and highly dependent on the success of our lead programs. If we are unable to commercialize our therapeutic candidates or
experience significant delays in doing so, our business will be materially harmed. </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our therapeutic candidates are in early stages of development. We do
not have any products that are approved for sale in any jurisdiction. Our most advanced lead program, MZE829, is being tested in a Phase 1 clinical trial that was initiated in December 2023. We submitted an IND to the FDA for our second lead
program, MZE782, in July 2024. Our other programs are at an early research stage, with no therapeutic candidates identified. Our research programs may not result in viable therapeutic candidates for some time, if ever, and our therapeutic candidates
in development may not achieve success in our current or any future clinical trials, or obtain regulatory approval. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our ability to generate product revenues,
which may not occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our therapeutic candidates. The success of our therapeutic candidates will depend on several factors, including, but not
limited to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">timely and successful completion of, and timely enrollment of patients in, clinical trials with favorable results;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">submission of new drug applications, or NDAs, or other regulatory applications, and receipt and related terms of regulatory
approvals from applicable regulatory authorities, including the completion of any required post-marketing studies or trials and available funding to perform any post-marketing commitments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">raising additional funds necessary to complete clinical development of and commercialize our therapeutic candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">timely and successful completion of preclinical studies with favorable results; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">submission of INDs or other regulatory applications, and authorizations to initiate clinical trials from the FDA and
foreign regulatory agencies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">demonstration of safety, efficacy and acceptable risk-benefit profiles of our therapeutic candidates to the satisfaction of
the FDA and foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">obtaining, maintaining, defending and enforcing patent, trade secret and other intellectual property and proprietary
protection and regulatory exclusivity for our therapeutic candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">making arrangements with third-party suppliers and manufacturers for preclinical, clinical and commercial supplies of our
therapeutic candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developing and implementing marketing and reimbursement strategies, as well as adequate demand forecasts for supply and
sales planning; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when
approved, whether alone or in collaboration with others in a market where promotional sales approaches are rapidly moving to digital platforms; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">effectively competing with other therapies, including those that have not yet entered the market; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">obtaining and maintaining third-party payor coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">obtaining appropriate support from patient advocacy organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">addressing any delays in our clinical trials, or in the manufacture or distribution of our therapeutic candidates, if
approved, resulting from any major natural disasters, health pandemics or significant political events; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">maintaining a continued acceptable safety profile of the products following approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many of these factors are beyond our control, and it is possible that none of our therapeutic candidates will ever obtain regulatory approval, even if we expend
substantial time and resources seeking such approval. Even if we do obtain regulatory approval, it is possible that one or more of these factors could cause significant delays or an inability to successfully commercialize our therapeutic candidates,
which would materially harm our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, clinical or regulatory setbacks to other companies developing similar products or within adjacent fields,
may impact the clinical development of and regulatory pathway for our current or future therapeutic candidates, or may negatively impact the perceptions of value or risk of our technologies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Preclinical and clinical drug development is a lengthy and expensive process, with uncertain timelines and outcomes. If preclinical studies or clinical trials of
our therapeutic candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our therapeutic candidates or any of our future therapeutic candidates on a timely basis or at
all. </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have limited experience designing and implementing clinical trials. Our most advanced lead program, MZE829, is being tested in a Phase 1
clinical trial that was initiated in December 2023. We submitted an IND to the FDA for our second most advanced lead program, MZE782, in July 2024. Failure to design any one of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
clinical trials adequately, or incorrect assumptions about the design of the trial, could adversely affect the ability to initiate the trial, enroll patients, complete the trial, or use the
clinical trial&#146;s results to support an application for regulatory approval, as well as lead to increased or unexpected costs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our programs are in the early
stages of development, and the risk of failure is high. Our programs may fail to identify potential therapeutic candidates for clinical development for a number of reasons. We are unable to predict when or if our programs will lead to therapeutic
candidates or when or if our therapeutic candidates will prove effective and safe in humans or will obtain marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any of our therapeutic candidates, we must
complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our therapeutic candidates in humans. Our potential therapeutic candidates may be shown to have harmful side effects in animal
model studies, may not show promising signals of therapeutic effect in such experiments or studies, or may have other characteristics that may make the therapeutic candidates impractical to manufacture, unmarketable, or unlikely to receive marketing
approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are currently focused on advancing the development of our lead programs, MZE829 and MZE782; however, even with significant investment of time and
funding to advance these therapeutic candidates, we cannot guarantee that our clinical and preclinical development efforts will be successful. The start or end of a clinical trial may be delayed or halted due to delays in or failure to obtain
regulatory approval to commence the trial, delays in or failure to reach agreement on acceptable terms with prospective clinical research organizations, or CROs, or clinical trial sites, delays in or failure to obtain Institutional Review Board, or
IRB, approval at each site, changing regulatory requirements, manufacturing challenges, clinical sites or CROs deviating from the trial protocol or failing to comply with regulatory requirements or meet contractual obligations, slower than
anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparative therapeutic or required prior therapy, clinical outcomes, failure of patients to complete the trial or return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up,</FONT> or financial constraints. Delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development times, requirements to manufacture
additional drug supply, or termination of a clinical trial. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Clinical trials of a new therapeutic candidate require the enrollment of a sufficient number of
patients, which may include patients who are suffering from the disease the therapeutic candidate is intended to treat and who meet other eligibility criteria, which may require genetic testing of prospective patients. Rates of patient enrollment
are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity of
patients to clinical sites, and the availability of effective treatments or competing academic and other clinical trials for the relevant disease. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A therapeutic
candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for therapeutic candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care, and other
variables. The novelty of our Compass platform may mean our failure rates are higher than historical norms. We will have to conduct additional trials in our proposed indications to support any future regulatory submissions. A number of companies in
the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical trials. Moreover, clinical data are often
susceptible to varying interpretations and analyses. We do not know whether our clinical trials will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use that is sufficient to receive regulatory
approval or market our therapeutic candidates. To the extent that the results of the clinical trials are not satisfactory to the FDA or foreign regulatory agencies for supporting a marketing application, we may be required to expend significant
resources, which may not be available to us, to conduct additional clinical trials in support of potential approval of our therapeutic candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We, the FDA, an IRB, an independent ethics committee, or EC, or other applicable regulatory authorities may suspend
clinical trials of a therapeutic candidate at any time for various reasons, including a belief that subjects participating in such trials are being exposed to unacceptable health risks or adverse side effects. Similarly, an IRB or EC may suspend a
clinical trial at a particular trial site. We may not have the financial resources to continue development of, or to enter into collaborations for, a therapeutic candidate if we experience any problems or other unforeseen events delaying or
preventing clinical development or regulatory approval of, or our ability to commercialize, therapeutic candidates, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">negative or inconclusive results from our clinical trials, or the clinical trials of others for therapeutic candidates
similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using
therapeutics similar to our therapeutic candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">serious drug-related side effects experienced in the past by individuals using therapeutics similar to our therapeutic
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays in submitting IND applications or clinical trial applications, or comparable foreign applications, or delays or
failure in obtaining the necessary approvals from regulators or IRBs to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">conditions imposed by the FDA or comparable foreign authorities, such as the European Medicines Agency, or EMA, regarding
the scope or design of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays or difficulty in enrolling research subjects in clinical trials, for a variety of reasons including, but not limited
to, change in priorities for clinical trial sites, the clinical trials of other therapeutic candidates or approval of a competitor&#146;s product for the same indication; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">high <FONT STYLE="white-space:nowrap">drop-out</FONT> rates of research subjects; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">inadequate supply or quality of therapeutic candidate or therapeutic candidate components, or materials or other supplies
necessary for the conduct of our clinical trials, including those owned, manufactured, or provided by companies other than ours; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">greater than anticipated clinical trial costs, including the cost of any approved drugs used in combination with our
therapeutic candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">poor effectiveness of our therapeutic candidates during clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their
contractual obligations in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays and changes in regulatory requirements, policies, and guidelines, including the imposition of additional regulatory
oversight around clinical testing generally or with respect to our technology in particular; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">varying interpretations of data by the FDA and similar foreign regulatory agencies. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are impacted by one or more of these factors and are unable to remediate the issue in a timely manner or at all, then we could experience significant delays or an
inability to successfully obtain regulatory approvals for our therapeutic candidates. Without regulatory approval, we will be unable to commercialize our therapeutic candidates, which would materially harm our business and potentially make it
impossible to continue our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Results of preclinical studies or early-stage clinical trials of any therapeutic candidates may not be
predictive of the results of future preclinical studies or clinical trials. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Clinical testing is expensive, difficult to design and implement, can take many
years to complete and is uncertain as to the outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later preclinical
studies or clinical trials or of clinical trials of the same therapeutic candidates in other indications, and interim or preliminary results of a clinical trial do not necessarily predict final results. For example, even if successful, the results
of our preclinical studies of our lead programs may not be predictive of the results of outcomes in subsequent clinical trials on human subjects. Later-stage clinical trials could differ in significant ways from early-stage clinical trials,
including changes to inclusion and exclusion criteria, efficacy endpoints, dosing regimen and statistical design. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we encounter delays or difficulties
enrolling patients in our clinical trials and/or retaining patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may experience difficulties in patient enrollment in our clinical trials for a variety of external reasons beyond our control, including supply chain disruptions,
staffing shortages and other business and economic disruptions resulting from geopolitical actions, including war and terrorism, natural disasters, including earthquakes, typhoons, floods and fires, as well as other disruptions resulting from the
impact of public health factors, including pandemics or other health crises, business disruptions of our strategic partners, third-party manufacturers, suppliers and other third parties upon which we rely. Our therapeutic candidates are developed
using a precision medicine approach intended to identify specific genetic targets amenable to therapeutic intervention in common diseases. As a result, the potential population of patients eligible for enrollment in our clinical trials will be
smaller than the population eligible for enrollment in trials targeting the entire population with the disease, and it may be difficult to identify and enroll adequate numbers of patients in our trials. For example, our therapeutic candidate MZE829
is targeted to treat kidney disease associated with genetic variations in the APOL1 gene, which are most prevalent in people of West African ancestry, including many who identify as Black, African American, Afro-Caribbean and Latina/Latino, which
narrows the patient population eligible for enrollment in these trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the eligibility criteria of our clinical trials will further limit the pool of
available trial participants. For our therapeutic candidate MZE829, we depend on and expect to perform genetic screening in order to identify candidates with the applicable genetic variations for our clinical trials. As we expect future therapeutic
candidates to also target specific genetic subgroups of common conditions, as identified through our Compass platform, it is likely that future therapeutic candidates will also require identification of patients with the applicable genotype, which
will require genetic screening and further costs and timing delays in identifying patients eligible for our clinical trials. Genetic screening could involve more time consuming, costly and invasive procedures than patients may be willing to accept.
If patients are not willing to undergo genetic screening, or any other eligibility criteria we have for our clinical trials, it would lead to greater costs and/or timing delays for us in order to identify eligible and the necessary patients for our
clinical trials. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of eligible patients who remain in the trial until completion of treatment and
adequate <FONT STYLE="white-space:nowrap">follow-up.</FONT> In general, the enrollment and retention of patients depends on many factors, including, but not limited to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">inability to enroll, or delay in enrollment of, patients due to infectious disease outbreaks and public health crises;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the patient eligibility criteria defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the perceived risks and benefits of the therapeutic candidate being studied; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the size of the patient population required for analysis of the trial&#146;s primary endpoints; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the proximity of patients to trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the design of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the ability to obtain and maintain patient consent; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">geopolitical events in countries where we have or seek to have clinical trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reporting of the preliminary results of any of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential approval and commercial availability of a competitor&#146;s product for the same indication; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion of treatment and adequate <FONT
STYLE="white-space:nowrap">follow-up.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our clinical trials will compete with other clinical trials for therapeutic candidates
that are in the same therapeutic areas as our therapeutic candidates, and this competition will reduce the number and types of patients available to or retained by us because patients who might have opted to enroll in our trials may instead opt to
enroll in a trial being conducted by one or more of our competitors. Other biopharmaceutical companies are currently conducting clinical trials, and may in the future conduct clinical trials, that compete for the same patient population as us. Since
the number of qualified clinical investigation sites is limited, and often associated with a small number of academic centers, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which
will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Unanticipated geopolitical events in countries where we may seek to have clinical trial sites could also negatively impact our ability to
enroll or retain patients in our trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our therapeutic candidates may cause undesirable side effects or have other properties that could halt their clinical
development, prevent their regulatory approval, require expansion of the trial size, limit their commercial potential, or result in significant negative consequences. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If serious adverse events or undesirable side effects arise, we could be required to suspend, delay, or halt our clinical trials. Additionally, serious adverse events or
undesirable side effects could cause regulatory authorities to deny approval or require us to limit development of that therapeutic candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less
prevalent, less severe or more acceptable from a risk-benefit perspective. Undesirable side effects could also result in an expansion in the size of our clinical trials, increasing the expected costs and timeline of our clinical trials. Side effects
that are observed during trials, whether treatment related or not, could also affect patient recruitment for future trials or the ability of enrolled patients to complete the trial or result in potential product liability claims. Many compounds that
initially show promise in clinical or preclinical testing are later found to cause undesirable or unexpected side effects that prevent further development of the compound. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, if serious adverse events or undesirable side effects are identified during development or after approval and are determined to be attributed to any of our
therapeutic candidates, we may be required to develop Risk Evaluation and Mitigation Strategies, or REMS, to ensure that the benefits of treatment with such therapeutic candidate outweigh the risks for each potential patient. A REMS may include,
among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and other processes that would make our therapeutic candidate more restricted or costly to distribute to
patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our two lead programs are intended to treat chronic kidney disease, or CKD, which is a progressive condition
associated with severe and often life-threatening <FONT STYLE="white-space:nowrap">co-morbidities.</FONT> Clinical trials that involve patients with significant <FONT STYLE="white-space:nowrap">co-morbidities</FONT> are associated with increased
risks as such participants may be particularly susceptible to safety and toxicity risks. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as safety and toxicity monitoring may be
complicated and difficult to manage, which could result in patient death or other significant issues. Additionally, it can be difficult to determine if the serious adverse or unexpected side effects were caused by our therapeutic candidate or
another factor, especially in subjects who may suffer from other medical conditions and take other medications. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any of these occurrences may materially harm our
business, financial condition and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may not be successful in applying our Compass platform to identify targets with therapeutic potential or to
discover and develop safe, effective or commercially viable therapeutic candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We use our Compass platform to identify and prioritize potential drug
targets, to assess the likelihood that we can develop a therapeutic candidate that interacts with the applicable target to elicit the desired therapeutic effect, and to transition these insights efficiently into well-supported therapeutic
candidates. We believe our use of our Compass platform, which identifies and prioritizes targets using statistical modeling, variant functionalization tools, and traditional and computational drug discovery technologies, augmented with machine
learning and artificial intelligence, or AI, increases our likelihood of producing therapies that provide meaningful clinical benefit, but past success in identifying potential therapeutic candidates does not assure similar future success with our
other programs. We may not succeed in applying our Compass platform to identify targets or promising therapeutic candidates in the future. We therefore cannot provide any assurance that we will be able to successfully identify additional therapeutic
candidates or advance any of our programs or future therapeutic candidates into clinical development, nor can we provide any assurance whether the application of our Compass platform will result in the ultimate regulatory approval of any of our
therapeutic candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Efforts to identify, acquire <FONT STYLE="white-space:nowrap">or&nbsp;in-license,&nbsp;and</FONT> then develop therapeutic candidates
require substantial technical, financial and human resources, whether or not any therapeutic candidates are ultimately identified. We apply our Compass platform to discover potential genetic targets for which we may be able to develop precision
therapeutic candidates. Our efforts may initially show promise in identifying potential targets linked to diseases or conditions, yet fail to yield therapeutic candidates for clinical development or regulatory approval for many reasons, including
the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the platform methodology used may not be successful in identifying potential therapeutic candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">competitors may develop alternatives that render any therapeutic candidates we develop obsolete; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any therapeutic candidates we develop may nevertheless be covered by third parties&#146; patents or other exclusive rights;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a therapeutic candidate may be shown, in subsequent preclinical or clinical investigations, to have harmful side effects or
characteristics that indicate it is unlikely to be effective, or otherwise would not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a therapeutic candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a therapeutic candidate may not be accepted as safe and/or effective by physicians, patients, the medical community or
third-party payors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Certain of the diseases we, or which our partners, seek to treat have low prevalence and/or have available
therapies, and it may be difficult for us or our partners to identify patients with these diseases or face competition in the recruitment of these limited groups of patients, which may lead to difficulties in enrolling clinical trials. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Genetically defined diseases generally, and especially some of those which our <FONT STYLE="white-space:nowrap">out-licensed</FONT> programs target, including Pompe
disease, have low prevalence and incidence. This could pose obstacles to the timely recruitment, enrollment and retention of a sufficient number of eligible patients into our partners&#146; trials or limit a therapeutic candidate&#146;s commercial
potential, and thus the milestone payments and royalties we would receive for those licenses. Other companies have ongoing clinical trials for therapeutic candidates that treat the same indications as our wholly owned and our <FONT
STYLE="white-space:nowrap">out-licensed</FONT> therapeutic candidates, and patients who otherwise would be eligible for our or our partners&#146; planned clinical trials instead may enroll in clinical trials of our competitors&#146; therapeutic
candidates. In addition, where there are currently available therapies or if our competitors&#146; therapeutic candidates gain regulatory approval and become commercially available, patients may be reluctant to enroll in a clinical trial. As more
companies begin to focus attention and resources on therapeutic candidates to treat the same indications as the ones we have <FONT STYLE="white-space:nowrap">out-licensed,</FONT> our licensees may experience delays or be unable to successfully
recruit and enroll a sufficient number of eligible patients in their clinical trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our licensees&#146; inability to enroll a sufficient number of patients with
these diseases into their planned clinical trials would result in significant delays and could cause them to not initiate or abandon one or more clinical trials altogether, potentially depriving us of milestone payments and royalties potentially
associated with these licenses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may experience delays in commencing and completing, or ultimately be unable to complete, the development and/or
commercialization of our therapeutic candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before we can initiate clinical trials of a therapeutic candidate in any indication, we must submit the
results of preclinical studies to the FDA or to comparable foreign authorities, along with other information, including information about the therapeutic candidate&#146;s chemistry, manufacturing and controls, and our proposed clinical trial
protocol, as part of an IND or comparable foreign regulatory filings. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA may require us to conduct additional preclinical studies for any therapeutic candidate
before it allows us to initiate clinical trials under any IND, which may lead to additional delays and increase the costs of our preclinical development programs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any delays in the commencement or completion of preclinical studies or clinical trials could significantly affect our development costs. We may experience numerous
unforeseen events during, or as a result of, preclinical studies or clinical trials that could delay or prevent our ability to obtain marketing approval or commercialize our therapeutic candidates, including, but not limited to: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulators, IRBs or ECs may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial
at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA may disagree as to the design or implementation of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may experience delays in reaching, or fail to reach, agreement on acceptable preclinical studies or clinical trial
contracts or clinical trial protocols with prospective CROs and prospective trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the cost of our preclinical studies and clinical trials may be greater than we anticipate, and we may lack adequate funding
to continue preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our third-party partners may fail to obtain regulatory approval of companion diagnostic tests on which we may rely, if
required, on a timely basis, or at all; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our third-party contractors may fail to meet their contractual obligations to us in a timely manner, or at all, or may fail
to comply with regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may have to suspend or terminate clinical trials for various reasons, including a finding by us or by a Data Monitoring
Committee that the participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our therapeutic candidates may produce negative or inconclusive results, or have undesirable side effects or other
unexpected characteristics, and we may decide, or our investigators, regulators or IRBs/ECs may require us, to conduct additional preclinical studies or clinical trials, or delay, halt or abandon our development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our clinical trials may be negatively impacted or delayed by changes to clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the supply or quality of our therapeutic candidates or other materials necessary to conduct clinical trials may be
insufficient or inadequate and result in delays or suspension of our clinical trials; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">global health crises or geopolitical conflict may increase the likelihood that we encounter such difficulties or delays in
initiating, enrolling, conducting or completing our planned clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Delays, including delays caused by the above factors and other
factors described in this &#147;Risk factors&#148; section, can be costly and could negatively affect our ability to complete preclinical studies or clinical trials or obtain timely marketing approvals. We do not know whether any of our planned
preclinical studies or clinical trials will begin on or be completed on a timely basis, or at all. For example, the FDA may place a partial or full clinical hold on any of our clinical trials for a variety of reasons, including safety concerns and
noncompliance with regulatory requirements. If we are not able to complete successful clinical trials, we will not be able to obtain regulatory approval and will not be able to commercialize our therapeutic candidates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our therapeutic candidates
or allow our competitors to bring products to market before we do, which may impair our ability to successfully commercialize our therapeutic candidates and harm our business and results of operations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may expend our limited resources to pursue a particular therapeutic candidate or indication and fail to capitalize on therapeutic candidates or indications that
may be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because we have limited financial and managerial resources, we focus on
research programs and therapeutic candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic candidates or for other indications that later prove to have greater
commercial potential. Our resource allocation decisions and spending on current and future research and development programs may not yield any commercially viable products or profitable market opportunities, which may adversely affect our business,
financial condition, results of operations and prospects. If we do not accurately evaluate the commercial potential or target market for a particular therapeutic candidate, we may relinquish valuable rights to that therapeutic candidate through
collaboration, licensing or other royalty collaborations or arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such therapeutic candidate. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If ethical and other concerns surrounding the use of genetic information become widespread, there may be limitations on our ability to access genetic information
for our Compass platform. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">One of the pillars of our Compass platform is our ability to access and aggregate numerous and varied genomic and phenotypic data
collections, particularly those that pair genetic and clinical data. Genetic testing to provide </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
this data has given rise to ethical questions and controversies regarding confidentiality and the appropriate uses of the resulting information. For these reasons, governmental authorities may
call for limits on or regulate the use of genetic data, including by limiting the compilation of genetic information or prohibiting testing for genetic predisposition to various conditions, particularly for those that have no known cure. Some of the
major data sources of genetic and clinical data for our Compass platform derive from publicly funded and managed databases. One of our key objectives is to continue to augment our access to diverse sources of genetic information from multiple
population groups. If our access to these additional sources of human genetic data becomes restricted, due to governmental limitations or otherwise, the capability of our Compass platform may be reduced, and we may be unable to continue to recognize
the benefits of our Compass platform on our expected timeframe, or at all, which would have a negative effect on our business or financial condition. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Interim,
topline and preliminary data from preclinical studies and clinical trials that we or our partners announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could
result in material changes in the final data. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, we or our partners may make public interim, topline or preliminary data from our or their
preclinical studies and clinical trials that are based on a preliminary analysis of then-available data, of which, the results, related findings and conclusions are subject to change following a more comprehensive review of the data or accumulation
of additional data. Interim, topline or preliminary data from clinical trials that we or our partners may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more
patient data become available. Interim, preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the interim, preliminary or topline data that were
previously made public. As a result, interim, topline and preliminary data should be viewed with caution until the final data are available. Adverse differences between interim, topline or preliminary data and final data could significantly harm our
reputation and business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, regulatory agencies, may not accept or agree with our assumptions,
estimates, calculations, analyses or conclusions, or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug candidate, and our
company in general. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval of, and commercialize,
any of our current or future therapeutic candidates may be harmed, which could harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If
we do not achieve our projected development goals in the time frames we announce or expect, the development of our therapeutic candidates may be delayed and, as a result, our stock price may decline. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other therapeutic development goals, which we
sometimes refer to as milestones. These milestones may include the commencement or completion of preclinical studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of
some of these milestones. All of these milestones are and will be based on numerous assumptions, estimates, calculations, conclusions, or analyses. The actual timing of these milestones can vary dramatically compared to our assumptions and
estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, the commercialization of our therapeutics may be delayed or never achieved, which could harm our business, financial
condition, results of operations and prospects and may cause our stock price to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our reliance on third parties </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our Compass platform relies on access to high quality data repositories with paired genetic and clinical data and loss of such access, or the inability to use such
data, could have a material adverse effect on our business, financial condition, results of operations and prospects. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We rely on <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> access to third-party data sources of genetic and paired clinical data for our Compass platform, including, among others, the University of Helsinki, Queen Mary University, the UK Biobank, Biobank
Japan and the Million Veteran Program, as well as specialized databases such as the Chronic Renal Insufficiency Cohort which is managed by the National Institute for Diabetic, Digestive and Kidney Diseases and other genetic data sets we have
acquired or may acquire access to in the future. Our ability to access data from these and similar sources is vital to all phases of our Compass platform, including target identification and variant functionalization. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the most part, we do not control the quantity or type of data that is stored in genetic data repositories, and we may only have access to summary level or aggregate
data. Some institutions only provide access to their data for limited purposes, or will require us to make results publicly available. We cannot guarantee that our access to any particular source of genetic or paired clinical data will be available
in the future, or that the data that is available will meet the needs of our business strategy or our Compass platform. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We pay substantial membership fees to access
certain genetic data repositories. Our memberships provide us with certain preferred access to non-public data, as well as some oversight of the biobanks through membership in the steering committees for these organizations. Most of the other
members of these consortiums are larger and better resourced than we are. Any termination of our arrangements with these organizations would require us to rely more heavily on less well-developed resources or require us to invest in finding
alternative, and potentially more costly, genetic data resources, if such resources are available at all, and could delay or impair our research and development efforts. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, while any loss of access to these or similar genetic data repositories may not directly impact the development of our lead programs, we cannot predict the
effects such loss could have on our preclinical and clinical studies and development efforts and our ability to discover and develop additional therapeutic candidates, or optimize our future clinical trials. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we have not identified any licenses that are required to conduct our genomics work to date, we may in the future identify a third-party technology we need to
license to expand or continue to operate our Compass platform. For example, certain aspects of our Compass platform make use of CRISPR Cas9 technology at the early research stages, and while the patent coverage of such technology remains uncertain,
certain institutions that have rights in CRISPR Cas9 patents have sought and may in the future seek to obtain license fees from biotechnology companies like ours. If we were unable to license or otherwise obtain access to such technology on
reasonable terms or at all, and we were required to cease operation of our Compass platform, it would have a material adverse effect on our business, results of operations, financial condition and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have entered, and may in the future enter, into strategic collaborations, transactions and licensing partnerships for research, development or commercialization
of our programs, including our first therapeutic candidate MZE001, and we may not be able to realize the full value of these partnerships or our partnered programs. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Compass platform has identified, and may identify in the future, genetic targets and therapeutic candidates outside of our core area of focus in common diseases. Our
business strategy includes seeking strategic collaborations to advance these targets. For example, in 2024 we granted exclusive licenses to advance two programs related to targets we were pursuing in amyotrophic lateral sclerosis, or ALS&#151;ATXN2
and UNC13A&#151;to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
other biotechnology companies, as well as an exclusive license with a pharmaceutical partner, Shionogi&nbsp;&amp; Co., Ltd., or Shionogi, to advance our first clinical stage therapeutic
candidate, MZE001. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may face significant competition in seeking appropriate strategic partners, and negotiating partnership or collaboration terms that are
favorable to us, and the negotiation process may be time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our programs and therapeutic candidates
because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our therapeutic candidates as having the requisite potential to obtain marketing approval. Certain kinds of strategic
transactions, including exclusive licenses, may be subject to potential government review, including by antitrust agencies such as the U.S. Federal Trade Commission, or FTC, which can add substantially to the time and expense of completing a
transaction. For example, in 2023, the FTC conducted an investigation of our proposed exclusive license of the MZE001 program to Genzyme Corporation, a subsidiary of Sanofi, and ultimately filed an action to enjoin the transaction based upon
allegations that the Genzyme license would substantially lessen competition among pharmaceutical treatments for Pompe disease. If we are unable to license or collaborate on our programs, we may have to curtail the development of the therapeutic
candidate for which we are seeking a partner, reduce or delay its development program or one or more of our other development programs, increase our expenditures and undertake development activities at our own expense, or accept terms that are for a
lower value than we believe the asset is worth.</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In our arrangements with third parties, we have limited control over the amount and timing of resources that our
partners dedicate to the development or commercialization of our therapeutic candidates. Our ability to generate revenues from these arrangements will depend on our partners&#146; abilities and efforts to successfully perform the functions assigned
to them in these arrangements to meet regulatory and development milestones, and if a product is approved, to commercialize it. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Partnerships involving development
and commercialization of our therapeutic candidates, including our existing exclusive license to Shionogi, pose numerous risks to us, including the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">partners have significant discretion in determining the efforts and resources that they will apply to these collaborations
and may not perform their obligations as expected; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">partners may <FONT STYLE="white-space:nowrap">de-emphasize</FONT> or elect not to pursue development or commercialization
programs based on studies or trials results, changes in the partners&#146; strategic focus, including as a result of a sale or disposition of a business unit or development function or a business combination involving the partner, or available
funding or external factors such as an acquisition that diverts resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">partners may delay or abandon preclinical studies or clinical trials for our therapeutic candidates, provide insufficient
funding for such programs, repeat or conduct new studies or trials or require a new formulation of a therapeutic candidate; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">partners could independently develop, or develop with third parties, therapeutic candidates that compete directly or
indirectly with our therapeutic candidates if the partners believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a partner with marketing and distribution rights to multiple therapeutic candidates may not commit sufficient resources to
the marketing and distribution of our therapeutic candidates relative to others; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">partners may not recognize, properly obtain, maintain, defend or enforce our intellectual property rights or may use our
intellectual property in such a way as to invite litigation or other intellectual property-related proceedings that could jeopardize or invalidate our intellectual property or expose us to potential litigation or other intellectual property-related
proceedings; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">disputes may arise between the partners and us that result in the delay or termination of the research, development or
commercialization of our therapeutic candidates or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">partnerships may be terminated by the partner, and, if terminated, may result in our need for additional capital to pursue
further development or commercialization of the applicable therapeutic candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the strategic arrangements we have entered into may not lead to development or commercialization of our therapeutic
candidates in the most efficient manner or at all. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Failure to recognize the benefit of strategic collaborations or partnerships we have entered or
may enter in the future could adversely affect our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We face risks associated with new
companies we may create, such as joint ventures and spin-outs. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Part of our business model includes creating business partnerships and new corporate entities
to develop and potentially commercialize therapeutic targets identified through our Compass platform that are outside of our core area of expertise. For example, in 2021, we formed a <FONT STYLE="white-space:nowrap">spin-out</FONT> company with
Alloy Therapeutics, Inc., or Alloy, to develop antibody therapies for ANGPTL7 and another undisclosed target in ophthalmic disease. Going forward, we may create or acquire interests in more joint venture enterprises, spin-outs, and other entities to
execute our business strategy. These business collaborations involve risks that&nbsp;our partners may: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">have economic or business interests or goals that are inconsistent with or adverse to ours; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">take actions contrary to our requests or contrary to our policies or objectives, including actions that may violate
applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">be unable or unwilling to fulfill their obligations under the relevant joint venture and
<FONT STYLE="white-space:nowrap">spin-out</FONT> agreements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">have financial or business difficulties; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">consume the time and attention of our senior executives, who may serve on the board of such companies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">take actions that may harm our reputation; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">have disputes with us as to the scope of their or our rights, responsibilities and obligations. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will not be able to fully control all aspects of the operations of these partnerships or entities, and we may not have full visibility or control over the operations
of these enterprises, including their business decisions, compliance practices or their filing, maintenance, protection and enforcement of intellectual property rights, among others. For example, although we have certain <FONT
STYLE="white-space:nowrap">opt-in</FONT> rights to jointly develop and commercialize certain therapeutic candidates developed through our <FONT STYLE="white-space:nowrap">spin-out</FONT> company with Alloy, we do not have the power to control the
operations of Alloy, which owns the applicable programs and therapeutic candidates and the associated intellectual property rights. In addition, if these entities seek further financing, we may be required to contribute additional cash to maintain
our equity stake in these entities or our equity stake may be diluted and our investment impaired. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our present partnerships or spin outs may not be successful. We
may have disputes or encounter other problems with respect to our present or future partners, and our&nbsp;agreements may not be effective or enforceable in resolving these disputes. We may not be able to resolve such disputes and solve such
problems in a timely manner or on favorable economic terms, or at all. Any failure by us to address these potential disputes or conflicts of interest effectively could have a material adverse effect on our business, prospects, financial condition,
results of operations or cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We rely on third parties to conduct current and future clinical trials, and those third parties may not perform
satisfactorily or at all, including failing to meet deadlines for completing such trials, failing to satisfy legal or regulatory requirements or terminating the relationship. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We rely, and expect to continue to rely, on third-party CROs to conduct any current and future clinical trials for our therapeutic candidates. We currently do not plan
to conduct any clinical trials independently. Agreements with these CROs might terminate for a variety of reasons, including for their failure to perform. Entry into alternative arrangements, if necessary, could significantly delay our product
development activities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our reliance on these CROs for research and development activities will reduce our control over these activities but will not relieve us of
our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols in the applicable IND. Moreover, the FDA requires compliance
with standards, commonly referred to as good clinical practices for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and
confidentiality of trial participants are protected, and we will be responsible for ensuring our clinical trials are conducted in compliance with applicable laws and regulation, including good clinical practices. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If these CROs do not successfully carry out their contractual duties, meet expected deadlines or conduct the clinical trials in accordance with regulatory requirements
or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our therapeutic candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our therapeutic
candidates, which may adversely affect our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We rely on third parties to manufacture our
clinical product supplies and therapeutic candidates and we may not be able to obtain adequate supplies at a reasonable cost or in a timely way. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The process
of manufacturing pharmaceutical products is complex and highly regulated. We do not have any manufacturing facilities or plans to establish manufacturing capabilities in the near future. We rely, and expect to continue to rely, on third parties,
including foreign manufacturers, for the manufacture of our therapeutic candidates for preclinical and clinical testing, development purposes, to support regulatory application submissions, as well as for commercial manufacture if any of our
therapeutic candidates obtain marketing approval. This reliance on third parties increases the risk that we will not have sufficient quantities of our therapeutic candidates or such quantities at an acceptable cost or quality, which could delay,
prevent or impair our development or commercialization efforts. In addition, global health crises or geopolitical conflict may result in disruptions to the operations or an extended shutdown of certain businesses, which could include certain of our
contract manufacturers. Further, as our therapeutic candidates are developed through preclinical studies to late-stage clinical trials towards approval and commercialization, we are likely to alter various aspects of the development program, such as
manufacturing methods, to optimize processes and results, which may result in additional cost or delay. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have only limited supply arrangements in place with
respect to our therapeutic candidates, and these arrangements do not extend to Phase 3 clinical or commercial supply. We acquire many key materials on a purchase order basis. As a result, we may not have long-term committed arrangements with respect
to aspects of our therapeutic candidates and other materials. We will need to establish one or more agreements with third parties to develop and scale up the drug manufacturing process, conduct testing, and generate data to support a regulatory
submission, and may be unable to do so on favorable terms. If we obtain marketing approval for any of our therapeutic candidates, we will need to establish an agreement for commercial manufacture with a third party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers
entails additional risks, including, but not limited to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reliance on the third party for regulatory, compliance and quality assurance; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reliance on the third party for product development, analytical testing, and data generation to support regulatory
applications; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or
operations, including the bankruptcy of the manufacturer or supplier, the issuance of an FDA Form 483 notice or warning letter, or other enforcement action by FDA or other regulatory authority; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible infringement, misappropriation, violation or unauthorized disclosure of our intellectual property and
proprietary rights, including our trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and other confidential information; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">competition with other companies for access to manufacturing capacity; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">carrier disruptions or increased costs that are beyond our control; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">failure to deliver our products under specified storage conditions and in a timely manner. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Third-party manufacturers may not be able to comply with current good manufacturing practice, or cGMP, regulations or similar regulatory requirements outside of the
United States. If the FDA determines that our contract manufacturing organizations, or CMOs, are not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may not approve an NDA until the deficiencies are corrected or
we replace the manufacturer in our application with a manufacturer that is in compliance. Moreover, our failure, or the failure of our third-party manufacturers and suppliers, to comply with applicable regulations could result in sanctions being
imposed on us, including clinical holds, fines, injunctions, civil penalties, seizures or recalls of therapeutic candidates, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our
products. In addition, approved products and the facilities at which they are manufactured are required to maintain ongoing compliance with extensive FDA requirements and the requirements of other similar agencies, including ensuring that quality
control and manufacturing procedures conform to cGMP requirements. As such, our CMOs are subject to continual review and periodic inspections to assess compliance with cGMPs. Furthermore, although we do not have <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> control over the operations of our CMOs, we are responsible for ensuring compliance with applicable laws and regulations, including cGMPs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, we rely on third parties located in China for some of our contract manufacturing, and we expect to continue to use such third-party manufacturers for such
purposes. For any activities conducted in China, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable
economic conditions in China. In addition, certain Chinese biotechnology companies may become subject to trade restrictions, sanctions, other regulatory requirements, or proposed legislation by the U.S. government, which could restrict or even
prohibit our ability to work with such entities, thereby potentially disrupting the supply of material to us. For example, the recently proposed BIOSECURE Act introduced in the U.S. House of Representatives, as well as a substantially similar bill
in the U.S. Senate, target U.S. government contracts, grants and loans for entities that use equipment and services from certain named Chinese biotechnology companies. Given the current uncertain political and legislative environment, it is unclear
what form the BIOSECURE Act will take and whether or when </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
it will be enacted into law. If enacted as presently proposed, the BIOSECURE Act would, among other things, prohibit U.S. federal agencies from entering into or renewing any contract with any
entity that uses biotechnology equipment or services produced or provided by a &#147;biotechnology company of concern&#148; to perform that contract. The BIOSECURE Act defines a &#147;biotechnology company of concern&#148; to include WuXi Apptec and
its affiliates, collectively, WuXi, and provides the possibility for additional companies to be designated as &#147;biotechnology companies of concern.&#148; The current House version includes a &#147;grandfathering&#148; provision that provides
that the BIOSECURE Act&#146;s prohibitions will not apply to pre-existing contracts and agreements entered into prior to the legislation&#146;s effective date until 2032. We are presently parties to agreements with WuXi, pursuant to which WuXi
provides development and manufacturing services to us. If these bills become law, or similar laws are passed, we may be restricted in our ability to work with WuXi and other Chinese biotechnology manufacturing companies to the extent we would
contract with, or otherwise receive funding from, the U.S. government. As a result, we may need to seek alternative CMO relationships, but we expect that the grandfathering provision will provide adequate time to identify and execute agreements with
alternative CMOs. While we believe we will be able to identify and contract with such alternative CMOs, we cannot predict the terms of any such alternative arrangement nor what actions may ultimately be taken with respect to trade relations between
the United States and China or other countries, what products and services may be subject to such actions or what actions may be taken by China or the other countries in retaliation. In addition to the BIOSECURE ACT, any unfavorable government
policies on international trade, such as export controls, capital controls or tariffs, new legislation or regulations, renegotiation of existing trade agreements, or any retaliatory trade actions due to recent or future trade tension, may impede,
delay, limit, or increase the cost of manufacturing our therapeutic candidates. Such events could result in our clinical or commercial supply of drug, packaging and other services being interrupted or limited, which could harm our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our third-party manufacturers and suppliers are subject to numerous environmental, health and safety laws and regulations, including those governing the
handling, use, storage, treatment and disposal of waste products, and failure to comply with such laws and regulations could result in significant costs associated with civil or criminal fines and penalties for such third parties. Based on the
severity of regulatory actions that may be brought against these third parties in the future, our clinical or commercial supply of drug and packaging and other services could be interrupted or limited, which could harm our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements
in place for redundant supply or a second source for bulk drug substance. If our current CMOs for preclinical and clinical testing cannot perform as agreed, we may be required to replace such CMOs. Although we believe that there are several
potential alternative manufacturers who could manufacture our therapeutic candidates, we may incur added costs and delays in identifying and qualifying any such replacement manufacturer or be able to reach agreement with any alternative
manufacturer. Further, our third-party manufacturers may experience manufacturing or shipping difficulties due to resource constraints or as a result of natural disasters, labor disputes, unstable political environments, or global health crises. If
our current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our current and anticipated future dependence upon others for the manufacture of our therapeutic candidates may adversely affect our future profit margins and our
ability to commercialize any products that obtain marketing approval on a timely and competitive basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our reliance on third parties requires us to share certain of our trade secrets, which increases the possibility
that a competitor or other third party will discover them or that our trade secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our reliance on third parties may
require us to share certain of our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, and, if applicable,
material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our partners, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These
agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and
other confidential information increases the risk that such trade secrets become known by our competitors or other third parties, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of
these agreements. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets and despite our efforts to protect our trade secrets, a competitor&#146;s or other third party&#146;s
discovery of our proprietary technology and confidential information or other unauthorized use or disclosure of such technology or information would impair our competitive position and may have a material adverse effect on our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to government regulation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The FDA regulatory approval process is lengthy and time-consuming. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of our therapeutic candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United States. Our current
lead programs, MZE829 and MZE782, are both small molecules and will be regulated as drugs. We are not permitted to market any drug in the United States until we receive approval of the respective NDA. We have not previously submitted an NDA to the
FDA or made similar submissions to comparable foreign regulatory agencies. An NDA must include extensive preclinical and clinical data and supporting information to establish the therapeutic candidate&#146;s safety and effectiveness for each desired
indication, which takes many years to collect through clinical and preclinical testing of the therapeutic candidate and is subject to a high failure rate. Further, the NDA must also include significant information regarding the chemistry,
manufacturing, and controls for the product, including storage and handling of the product. The manufacturing facility is also required to maintain a compliance status acceptable to the FDA. In addition, even if such clinical trials are successfully
completed, we cannot guarantee that the FDA or comparable foreign regulatory agencies will interpret the results as we do, and more trials could be required before we submit an NDA, or other foreign marketing application. Further, if there are any
controversial findings in the data, the FDA may call an advisory committee meeting to discuss the product with outside experts, which may further delay approval of our therapeutic candidates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We, as a company, have limited experience in submitting INDs in the United States and we do not have experience in obtaining regulatory approval to initiate
clinical trials in any other jurisdiction. Nor do we have experience in manufacturing or in quality assurance in order to market our therapeutic candidates in the United States or in any other jurisdiction. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have limited experience in submitting INDs in the United States and we do not have experience in obtaining regulatory approval to initiate clinical trials in any
other jurisdiction. Nor do we have experience in manufacturing or in quality assurance in order to market a drug and we expect to rely on third-party CROs, CMOs or other third-party consultants or vendors to assist us in this process. Our
inexperience may result in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
failure or delay in obtaining permission to initiate clinical trials or in obtaining marketing approval for our therapeutic candidates. If we are unable to obtain regulatory and marketing
approval for our therapeutic candidates, or experience significant delays in our efforts to do so, our business could be substantially harmed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our failure to
obtain marketing approval in foreign jurisdictions would prevent our therapeutic candidates from being marketed abroad, and any approval we are granted for our therapeutic candidates in the United States would not assure approval of therapeutic
candidates in foreign jurisdictions. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In order to market and sell our products in any jurisdiction outside the United States, we must obtain separate
marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to
obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be
approved for reimbursement before such product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by
regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able
to submit for marketing approvals and may not receive necessary approvals to commercialize our products in any market. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we decide to pursue a fast track
designation by the FDA, it may not lead to a faster development or regulatory review or approval process. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Some of our therapeutic candidates may be intended
to treat serious or life-threatening conditions and may demonstrate the potential to address an unmet medical need for such conditions, and as such they would be eligible for expedited processes within the FDA such as fast track designation. The FDA
has broad discretion whether or not to grant such designation, so even if we believe a particular therapeutic candidate is eligible for this designation, we cannot guarantee that the FDA would decide to grant it. Even if we do receive fast track
designation, we may not experience a faster development process, review or approval. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we decide to pursue accelerated approval for any of our therapeutic candidates, it may not lead to a faster regulatory review or approval process and does not
increase the likelihood that our therapeutic candidates will receive marketing approval. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As part of our business strategy, we may pursue accelerated
approval for one or more of our therapeutic candidates. Under the FDA&#146;s accelerated approval program, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful product benefit to patients over existing
treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on
irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. We may seek accelerated approval for one or more of our
therapeutic candidates on the basis of a surrogate endpoint that we believe is reasonably likely to predict clinical benefit. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If any of our therapeutic candidates
receive accelerated approval from the FDA, we will be required to undergo one or more confirmatory clinical trials. If such a therapeutic candidate fails to meet its safety and efficacy endpoints in such confirmatory clinical trials, the FDA may
withdraw the accelerated approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Recently, the accelerated approval pathway has come under scrutiny within the FDA and by Congress. The FDA has put
increased focus on ensuring that confirmatory studies are conducted with diligence and, ultimately, that such studies confirm clinical benefit. In addition, the enactment of The Food and Drug Omnibus Reform Act, or FDORA, included provisions related
to the accelerated approval pathway. Pursuant to FDORA, the FDA is authorized to require a post-approval study to be underway prior to approval or within a specified time period following approval. FDORA also requires the FDA to specify conditions
of any required post-approval study and requires sponsors to submit progress reports for required post-approval studies and any conditions required by the FDA. FDORA enables the FDA to initiate enforcement action for the failure to conduct with due
diligence a required post-approval study, including a failure to meet any required conditions specified by the FDA or to submit timely reports. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is no
assurance that any therapeutic candidate will successfully advance through its confirmatory clinical trial(s). Therefore, even if a therapeutic candidate receives accelerated approval from the FDA, such approval may be withdrawn at a later date.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if we, or any of our partners, obtain marketing approval for our therapeutic candidates, the terms of approvals, ongoing regulation of our product,
including enforcement of post-marketing requirements by regulatory agencies or other post-approval restrictions, may require the expenditure of substantial resources, which could materially impair our ability to generate revenue. If we, or any of
our partners or manufacturers, fail to comply with all regulatory requirements or experience unanticipated problems with our products, when and if any of them are approved, we could be subject to substantial penalties, including withdrawal of our
product from the market. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any therapeutic candidate for which we, or any partners obtain marketing approval, as well as the manufacturing processes,
post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include, but are not limited to,
restrictions governing promotion of an approved product, submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance
and corresponding maintenance of records and documents, and requirements regarding drug distribution and the distribution of samples to physicians and recordkeeping. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For instance, even if marketing approval of a product is granted, the FDA may impose requirements for costly post-marketing studies or clinical trials and surveillance
to monitor the safety or efficacy of a product, including the adoption and implementation of a REMS. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We, or any of our partners, must also comply with requirements
concerning advertising and promotion for any of our therapeutic candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions
and must be consistent with the information in the therapeutic candidate&#146;s approved labeling. Thus, we, and any partners, will not be able to promote any products we develop for indications or uses for which they are not approved. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, manufacturers of approved products and those manufacturers&#146; facilities are required to ensure that quality control and manufacturing procedures conform
to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our third-party manufacturers, and any partners and their
third-party manufacturers, and our CMOs would be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accordingly,
assuming we, or any partners, obtain marketing approval for one or more of our therapeutic candidates, we, any partners and our CMOs will continue to expend time, money and effort in all areas of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
regulatory compliance, including manufacturing, production, product surveillance and quality control. If we are not able to comply with post-approval regulatory requirements, we could have the
marketing approvals for our products withdrawn by regulatory authorities and our ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. As a result, the cost of
compliance with post-approval regulations may have a negative effect on our operating results and financial condition. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA as well as other federal and state
agencies, including the U.S. Department of Justice, enforce and closely regulate compliance with all requirements governing drug products, including those requirements pertaining to marketing and promotion of drugs in accordance with the provisions
of the approved labeling and manufacturing of products in accordance with cGMP requirements. For example, the FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of
<FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. Violations of such requirements may lead
to investigations alleging violations of the Federal Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act and other federal and state healthcare fraud and abuse laws as well as state consumer protection laws. Our failure
to comply with all regulatory requirements, and later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, may yield various results, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">litigation involving patients using our products; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">restrictions on such products, manufacturers or manufacturing processes; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">modifications to the labeling or restrictions on the marketing of a product; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">restrictions on distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">warning or untitled letters; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">withdrawal or recall of the product from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">damage to relationships with any potential partners; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unfavorable press coverage and damage to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">refusal to permit the import or export of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product seizure; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-compliance</FONT> by us or any future partner with regulatory requirements, including safety monitoring or pharmacovigilance, and
with requirements related to the development of our products can also result in significant financial penalties. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If generic versions of our small molecule
therapeutic candidates are approved, our revenue and results of operations would be adversely affected. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Drug Price Competition and Patent Term
Restoration Act of 1984, commonly known as the Hatch-Waxman Amendments, permits the FDA to approve abbreviated NDAs, or ANDAs, for generic versions of small molecule </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
branded drugs. We refer to this process as the ANDA process. The ANDA process permits a competitor to obtain marketing approval for a drug with the same active ingredient as a branded drug but
does not generally require the conduct and submission of clinical efficacy studies for the generic product. In place of such clinical studies, an ANDA applicant usually needs only to submit data demonstrating that its product is bioequivalent to the
branded product. The Hatch-Waxman Amendments require an ANDA applicant seeking FDA approval of its proposed generic product prior to the expiration of any patents we may list in the FDA&#146;s Approved Drug Products with Therapeutic Equivalence
Evaluations (commonly known as the Orange Book) to certify that the applicant believes that our patents are invalid or will not be infringed by the manufacture, use or sale of the drug for which the application has been submitted (a Paragraph IV
certification) and notify us of such certification (a Paragraph IV notice). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the Hatch-Waxman Amendments, with regard to a drug that has received five
years of marketing exclusivity as a result of being a new chemical entity, or NCE, FDA cannot receive any ANDA seeking approval of a generic version of that drug during the five-year period of exclusivity unless the application contains a Paragraph
IV certification, in which case the application may be submitted one year prior to expiration of the NCE exclusivity. Accordingly, potential competitors will be permitted to submit ANDA applications for proposed generic versions of any small
molecule products for which we obtain approval four or five years from the date of such approval was granted. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon receipt of a Paragraph IV notice, the
Hatch-Waxman Amendments allow us, with proper basis, to bring an action for patent infringement against the ANDA filer, asking that the proposed generic product not be approved until after our patents expire. If we commence a lawsuit within 45 days
from receipt of the paragraph IV notice, the Hatch-Waxman Amendments provide a <FONT STYLE="white-space:nowrap">30-month</FONT> stay, during which time the FDA cannot finally approve the ANDA application. If the litigation is resolved in favor of
the ANDA applicant during the <FONT STYLE="white-space:nowrap">30-month</FONT> stay period, the stay will be lifted and the FDA may approve the ANDA if it is otherwise ready for approval. The discovery, trial and appeals process in such a lawsuit is
costly, time consuming, and may result in generic competition if the ANDA applicant prevails. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our current and future relationships with customers and
third-party payors may be subject to applicable anti-kickback, fraud and abuse, transparency, health privacy, and other healthcare laws and regulations, which could expose us to significant penalties, including criminal, civil, and administrative
penalties, contractual damages, reputational harm and diminished profits and future earnings. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Healthcare providers, including physicians, and third-party
payors will play a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain marketing approval. Our current and future arrangements with such healthcare providers, third-party payors and customers may
expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, as well as, market, sell and distribute any products for
which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations that may be applicable to our business include the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering,
receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may
be made under a federal healthcare program such as Medicare and Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal civil, including the False Claims Act, which can be enforced by civil whistleblower or qui tam actions on
behalf of the government, and criminal false claims laws and the civil monetary penalties law, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
false or fraudulent claims for payment by a federal government program, or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an
obligation to pay money to the federal government; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other things, knowingly
and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, regardless of the payor (e.g., public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a
material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their
implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of,
individually identifiable health information, relating to the privacy, security, and transmission of such individually identifiable health information; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal transparency requirements under the ACA, requires certain manufacturers of drugs, devices, biologics and
medical supplies to report to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, information related to payments and other transfers of value provided to, and ownership and investment interests held by, physicians, as defined by such
law, and their immediate family members; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">analogous state laws and regulations such as state anti-kickback and false claims laws and analogous <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> fraud and abuse laws and regulations, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT>
third-party payors, including private insurers. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance regulations promulgated by the federal
government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures, or drug pricing, including price increases. State and local
laws require the registration of pharmaceutical sales representatives. State and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws that also govern the privacy and security of personal information (including health information in some
circumstances), many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is
possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from
government funded healthcare programs, such as Medicare and Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional integrity reporting and oversight obligations, and
the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other healthcare providers or entities with whom we expect to do
business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil and administrative sanctions, including exclusions from government funded healthcare programs, which could have a material adverse
effect on our business, results of operations, financial condition and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval
of and commercialize our therapeutic candidates and may affect pricing and third-party payment for our therapeutic candidates and decrease the prices we may obtain. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system
that could, among other things, prevent or delay marketing approval of our therapeutic candidates, restrict or regulate post-approval activities and affect pricing and third-party payment for our therapeutic candidates, which could negatively affect
our ability to profitably sell any therapeutic candidates for which we obtain marketing approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Legislative and regulatory proposals have been made to expand
post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be
changed, or what the impact of such changes on the marketing approvals of our therapeutic candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or prevent
marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, there has been
heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to,
among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Several healthcare reform initiatives culminated in the enactment of the Inflation Reduction Act in August 2022, which allows, among other things, the Department of
Health and Human Services, or HHS, to negotiate the selling price of a statutorily specified number of drugs and biologics each year that CMS reimburses under Medicare Part B and Part D. Only high-expenditure single-source drugs that have been
approved for at least 7 years (11 years for single-source biologics) can qualify for negotiation, with the negotiated price taking effect two years after the selection year. Negotiations for Medicare Part D products begin in 2024 with the negotiated
price taking effect in 2026, and negotiations for Medicare Part B products begin in 2026 with the negotiated price taking effect in 2028. In August 2023, HHS announced the ten Medicare Part D drugs and biologics that it selected for negotiations,
and by October&nbsp;1, 2023, each manufacturer of the selected drugs signed a manufacturer agreement to participate in the negotiations. HHS will announce the negotiated maximum fair prices by September&nbsp;1, 2024, and this price cap, which cannot
exceed a statutory ceiling price, will come into effect on January&nbsp;1, 2026. A drug or biological product that has an orphan drug designation for only one rare disease or condition will be excluded from the Inflation Reduction Act&#146;s price
negotiation requirements, but loses that exclusion if it has designations for more than one rare disease or condition, or if is approved for an indication that is not within that single designated rare disease or condition, unless such additional
designation or such disqualifying approvals are withdrawn by the time CMS evaluates the drug for selection for negotiation. The Inflation Reduction Act also imposes rebates on Medicare Part B and Part D drugs whose prices have increased at a rate
greater than the rate of inflation. In addition, the law eliminates the &#147;donut hole&#148; under Medicare Part D beginning in 2025 by significantly lowering the beneficiary maximum
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost and establishing a new manufacturer discount program, which requires manufacturers that want their drugs to be covered by Medicare Part D to provide
statutorily defined discounts to Part D enrollees. The Inflation Reduction Act also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The Inflation Reduction Act permits the
Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the Inflation Reduction Act may be subject to various penalties, some significant,
including civil monetary penalties. These provisions are taking effect progressively starting in 2023, although they may be subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
legal challenges. For example, the provisions related to the negotiation of selling prices of high-expenditure single-source drugs and biologics have been challenged in multiple lawsuits. Thus,
it is unclear how the Inflation Reduction Act will be implemented but it will likely have a significant impact on the pharmaceutical industry and the pricing of our products and therapeutic candidates. The adoption of restrictive price controls in
new jurisdictions, more restrictive controls in existing jurisdictions or the failure to obtain or maintain timely or adequate pricing could also adversely impact revenue. We expect pricing pressures will continue globally. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, at the state level, individual states have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other
countries and bulk purchasing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect that additional state and federal healthcare reform measures may be adopted in the future. Such reform measures may result
in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability, or commercialize our products. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict
sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes
on the marketing approvals of our therapeutic candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to more
stringent product labeling and post-marketing testing and other requirements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Disruptions at the FDA and other government agencies caused by funding shortages
or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which
could negatively impact our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The ability of the FDA to review and approve new products can be affected by a variety of factors, including
government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#146;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#146;s ability to
perform routine functions. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other
agencies may also slow the time necessary for new therapeutic candidates to be reviewed and/or approved by necessary government agencies, which may adversely affect our business, financial condition, results of operations and prospects. For example,
over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain laws and regulations require us to test our therapeutic candidates on animals before initiating clinical trials involving humans. Animal testing activities have
been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these
activities through protests and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed, or become more expensive. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if we are able to commercialize a drug candidate, coverage and adequate reimbursement may not be available or such drug candidate may become subject to
unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The regulations that govern regulatory
approvals, pricing, and reimbursement for drug products vary widely from country to country. Some countries require approval of the sale price of a drug product before it can be marketed or may require us or our partners to conduct clinical trials
that compare the cost-effectiveness of our therapeutic candidates to other therapies to obtain reimbursement or pricing approval. In many countries, the pricing review period begins after regulatory approval is granted. In some foreign markets,
prescription drug product pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a drug in a particular country, but then be subject to price
regulations that delay our commercial launch of the drug, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the drug in that country. If reimbursement of our products is unavailable or
limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after
reimbursement has been obtained. Reference pricing used by various EU member states, and parallel trade, such as arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states, can further reduce prices. There can
be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries. Adverse pricing
limitations may hinder our ability to recoup our investment in one or more therapeutic candidates, even if any of our current or future therapeutic candidates obtain regulatory approval. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our ability to commercialize any drugs successfully also will depend in part on the extent to which coverage and adequate reimbursement for these drugs and related
treatments will be available from third-party payors, such as government authorities, private health insurers, and other organizations. Even if we succeed in bringing one or more drugs to market, these drugs may not be considered cost-effective, and
the amount reimbursed for any drugs may be insufficient to allow us to sell our drugs on a competitive basis. Moreover, in the United States, no uniform policy requirement for coverage and reimbursement for drugs exists among third-party payors,
which may result in significant variations in coverage and reimbursement from payor to payor. Even if favorable coverage and reimbursement status is attained for one or more drug products for which we receive regulatory approval, less favorable
coverage policies and reimbursement rates may be implemented in the future. If the price we are able to charge for any drugs we develop, or the coverage and reimbursement provided for such drugs, is inadequate in light of our development and other
costs, our return on investment could be affected adversely. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Laws and regulations governing any international operations we may have in the future may
preclude us from developing, manufacturing and selling certain therapeutic candidates outside of the United States and require us to develop and implement costly compliance programs. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in
which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering anything of value, directly or indirectly, to any foreign official, political
party or candidate for the purpose of influencing any act or decision of such third party in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United
States to comply with certain accounting provisions requiring the company to maintain books and records that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
accurately and fairly reflect all transactions of the company, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for
international operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition,
the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in
connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Various
laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security
purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude
us from developing, manufacturing or selling certain therapeutic candidates outside of the United States, which could limit our growth potential and increase our development costs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government
contracting. The Securities and Exchange Commission, or the SEC, also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#146;s accounting provisions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we, or any third-party contractors we engage, fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or
penalties or incur costs that could harm our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We and our third-party contractors are subject to numerous foreign, federal, state and local
environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and
flammable materials, including chemicals and radioactive and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the
risk of contamination, discharge or injury from these materials. In the event of contamination, discharge or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our
resources, including any available insurance. We could be subject to civil damages and criminal penalties in the event of an improper or unauthorized release of, or exposure of individuals to, hazardous materials. Further, it is possible that the
materials we use could contaminate another party&#146;s property. In addition, claimants may sue us for injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed our total assets
and our ability to pay the liability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our leasing and operation of real property may subject us to liability pursuant to certain of these laws or
regulations. Under existing U.S. environmental laws and regulations, current or previous owners or operators of real property and entities that disposed or arranged for the disposal of hazardous substances may be held strictly, jointly and severally
liable for the cost of investigating or remediating contamination caused by hazardous substance releases, even if they did not know of and were not responsible for the releases. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We could incur significant costs and liabilities which may adversely affect our financial condition and operating results for failure to comply with such laws and
regulations, including, among other things, civil or criminal fines and penalties, property damage and personal injury claims, costs associated with upgrades to our facilities or changes to our operating procedures, or injunctions limiting or
altering our operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we maintain liability insurance to cover us for costs and expenses we may incur due to injuries to our employees, this insurance
may not provide adequate coverage against potential liabilities. We do not maintain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
insurance for environmental liability, including claims that may arise from pollution from chemical, radioactive or biological materials, or toxic tort claims that may be asserted against us in
connection with our storage or disposal of biological, hazardous or radioactive materials. Our partners may also be working with various types of hazardous materials in connection with our collaborations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws
and regulations, which are becoming increasingly more stringent, may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are subject to certain U.S. and certain foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We
can face serious consequences for violations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and
regulations prohibit, among other things, companies and their employees, agents, CROs, CMOs, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly
or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of these laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade
privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. We have and expect to continue to have direct or indirect interactions with officials and employees of government agencies
or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities, including those in China, to increase over time. We expect to continue to rely on third parties for research, preclinical studies and
clinical trials and/or to obtain necessary permits, licenses, patent registrations and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly
authorize or have prior knowledge of such activities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any violations of the laws and regulations described above may result in substantial civil and criminal fines
and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are, and may in the future be, subject to stringent and changing obligations related to data privacy and security. Our actual or perceived failure to comply
with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business
consequences. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the ordinary course of business, we collect, receive, store, generate, use, transfer, disclose, make accessible, protect, secure, dispose
of, transmit, share and otherwise process (which we refer to as process or processing) certain personal information and other sensitive information, including our proprietary and confidential business data, trade secrets, employee data, intellectual
property, data we or our CROs collect about trial participants in connection with clinical trials, and other sensitive data. The global data protection landscape is rapidly evolving and we are and may increasingly become subject to numerous data
privacy and security obligations, such as various state, federal and foreign laws, regulations, guidance, directives, industry standards, external and internal privacy and security policies, contractual requirements and other obligations that govern
the processing of sensitive or confidential information by us and on our behalf, and we may be subject to new or additional data protection laws and regulations and face increased scrutiny from regulators as our business grows. The legislative and
regulatory landscape for data privacy and security continues to evolve in jurisdictions worldwide, and there has been an increasing focus on these issues with the potential to affect our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Various federal, state, local and foreign legislative and regulatory bodies, or self-regulatory organizations, may expand current laws, rules or
regulations, enact new laws, rules or regulations or issue revised rules or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
guidance regarding data privacy and security that could result in regulatory investigations, fines or injunctions, as well as civil claims including class actions, and reputational damage.
Implementation standards, interpretation, and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have
on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to process personal information, necessitate the acceptance of more onerous obligations in our contracts, result in
liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or
regulations, our internal or external policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage
to our reputation, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United
States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, data privacy laws, and other similar laws. For example, all 50 states and the District of Columbia have
enacted breach notification laws that may require us to notify patients, customers, employees or regulators in the event of unauthorized access to or disclosure of personal or confidential information experienced by us or our service providers.
These laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. Moreover, HIPAA, as amended by HITECH, imposes among other things, certain requirements relating to the privacy, security,
transmission, and breach of individually identifiable health information. We may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security
requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain states have also
adopted comparable privacy and security laws and regulations, which govern the processing of health-related and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental
authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act of 2018 (as amended by the California Privacy Rights Act of 2020), or CCPA,
imposes obligations on businesses that meet certain thresholds that process the personal information of California residents (including employees based in California). These obligations include, but are not limited to, providing specific disclosures
in privacy notices and affording California residents certain rights related to their personal information, which includes a private right of action for certain data breaches. Although the CCPA exempts some data processed in the context of clinical
trials, the CCPA could increase compliance costs and potential liability. The 2020 amendments to the CCPA also created the California Privacy Protection Agency, a new enforcement agency whose sole responsibility is to enforce the CCPA and is
empowered to create new CCPA regulations. Other states, such as Virginia, Indiana, Oregon, Texas, Tennessee, Montana, Iowa, Delaware, Connecticut, Utah, Washington and Colorado, have also passed comprehensive privacy laws, and similar laws are being
considered in several other states, as well as at the federal and local levels. In addition to government activity and private rights of actions provided by some of the state privacy laws, privacy advocacy groups and technology and other industries
are considering various new, additional or different self-regulatory standards that may place additional burdens on us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Around the world, many countries have
privacy and data protection laws that create potentially complex compliance issues for us, our future customers, and strategic partners. For example, outside the United States, the EU&#146;s General Data Protection Regulation, or EU GDPR, and the
United Kingdom&#146;s GDPR, or UK GDPR, impose strict requirements for processing the personal data of individuals. For example, under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines of
up to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
<FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million or 4% of annual global revenue, whichever is greater. Such fines would be in addition to (i)&nbsp;the rights of individuals
to sue for damages in respect of any data privacy breach which causes them to suffer harm, (ii)&nbsp;the right of individual member states to impose additional sanctions over and above the administrative fines specified in the GDPR and
(iii)&nbsp;the ability of supervisory authorities to impose orders requiring companies to modify their practices. If we are found not to be compliant with the GDPR or similar requirements, we may be subject to significant fines and the risk of civil
litigation. Among other requirements, the GDPR and UK GDPR (and certain other foreign jurisdictions) regulate the cross-border transfer of personal data, which could make it more difficult to transfer information across jurisdictions (such as
transferring or receiving personal data that originates in the EU or the United Kingdom to countries such as the United States which are not considered by the EU or United Kingdom to provide adequate protection of personal data). In October 2022,
the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework, or <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> DPF, was implemented, and the European Commission adopted an adequacy decision on July&nbsp;10, 2023 that set conditions
for personal data transfers from the EU to certified companies in the United States without additional safeguards in place. However, this decision will likely face legal challenges and ultimately may be invalidated by the Court of Justice of the EU.
On October&nbsp;12, 2023, a <FONT STYLE="white-space:nowrap">UK-U.S.</FONT> Data Bridge came into force to operate as an extension of the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> DPF to facilitate transfers of personal data between the United
Kingdom and certified entities in the United States. Such Data Bridge could not only be challenged, but also may be affected by any challenges to the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> DPF. Furthermore, in June 2021, the European
Commission adopted new standard contractual clauses under the GDPR for transfers of personal data outside the European Economic Area to countries that the European Commission has not deemed to provide an adequate level of protection for such
personal data. While we strive to adhere to all requirements to transfer information across jurisdictions using safeguards endorsed by government guidance (such as using the Standard Contractual Clauses approved by the European Commission), we must
still adapt to changing guidance and will follow any anticipated litigation closely. As the regulatory guidance and enforcement landscape in relation to data transfers continue to develop, we could suffer additional costs, complaints and/or
regulatory investigations or fines; we may have to stop using certain tools and vendors and make other operational changes; we may have to implement revised standard contractual clauses for existing arrangements within required time frames; and/or
it could adversely affect our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any such changes in the law related to the use of personal
information or data could compromise our ability to develop an adequate marketing strategy and pursue our growth strategy effectively or even prevent us from providing certain products in jurisdictions in which we currently operate or may operate in
the future. Complying with these numerous, complex, conflicting, and often changing regulations is expensive and difficult, and failure to comply with any data privacy or security laws, whether by us, one of our CROs, CMOs, partners or another third
party, which may adversely affect our business, financial condition, results of operations and prospects., financial condition, results of operations and prospects, including but not limited to: investigation costs; material fines and penalties;
compensatory, special, punitive and statutory damages; litigation; consent orders regarding our privacy and security practices; requirements that we provide notices, credit monitoring services and/or credit restoration services or other relevant
services to impacted individuals; adverse actions against our licenses to do business; reputational damage; and injunctive relief. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to data privacy and
security laws, we are also bound by other contractual obligations related to data privacy and security that could prove to be more burdensome as laws and regulations evolve. We may also be contractually required to indemnify and hold harmless third
parties from the costs or consequences of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any laws, rules and regulations or other legal obligations relating to privacy or any inadvertent or unauthorized use or disclosure of data that we
store or handle as part of operating our business. Any of these events could adversely affect our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations
(including clinical trials); inability to process personal information or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse
publicity; or substantial changes to our business model or operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot assure you that our CROs, CMOs or other third-party service providers with access to our or our
suppliers&#146;, manufacturers&#146;, clinical trial participants&#146; and employees&#146; sensitive information in relation to which we are responsible will not breach contractual obligations imposed by us, or that they will not experience data
security incidents, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, financial condition, results
of operations and prospects. We cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing of such information. Any of the foregoing
could adversely affect our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we endeavor to comply with our public statements and
documentation regarding our handling of personal information, we may at times fail to do so or be perceived to have failed to do so. Our publication of our privacy policies and other statements we publish that provide promises and assurances about
privacy and security can subject us to potential state and federal action if they are found to be deceptive, unfair or misrepresentative of our actual practices. Any actual or perceived failure by us to comply with federal, state or foreign laws,
rules or regulations, industry standards, contractual or other legal obligations, or any actual, perceived or suspected cybersecurity incident, whether or not resulting in unauthorized access to, or acquisition, release or transfer of personal
information or other data, may result in enforcement actions and prosecutions, private litigation, significant fines, penalties and censure, claims for damages by customers and other affected individuals, regulatory inquiries and investigations or
adverse publicity and could cause our customers to lose trust in us, any of which could adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to commercialization of our therapeutic candidates </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We
face significant competition in an environment of rapid technological change and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies or technologies that are more advanced or effective than
ours, which may harm our business and financial condition, and our ability to successfully market or commercialize our therapeutic candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property. While we believe that our platform and our knowledge, experience and scientific
resources provide us with competitive advantages, we face potential competition from major pharmaceutical and biotechnology companies, academic institutions, government agencies and private and public research institutions, among others. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any therapeutic candidates that we or our partners successfully develop and commercialize may compete with existing therapies and new therapies that may become available
in the future that are approved to treat the same indications for which we or they may obtain approval for our therapeutic candidates. It is also possible that we or our partners may face competition from other pharmaceutical approaches as well as
other types of therapies. The key competitive factors affecting the success of all our programs, if approved, include, but are not limited to their efficacy, safety, convenience, adoption by prescribers, price, level of generic competition, and
availability of reimbursement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may face competition from companies developing therapies for CKD and related nephropathies, including but not limited to
established therapies including renin-angiotensin-aldosterone system, or RAAS, inhibitors, SGLT2 inhibitors and glucagon-like peptide 1, or <FONT STYLE="white-space:nowrap">GLP-1</FONT> agonists, as well as novel mechanisms such as therapies being
developed by various companies targeting different pathways implicated in CKD progression. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While there are currently no approved therapies for APOL1 kidney disease,
or AKD, we are aware of companies advancing therapeutic candidates in clinical trials that target APOL1, such as inaxaplin, which is in a Phase 3 clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our second most advanced lead program, MZE782, is a small molecule targeting SLC6A19, a novel target in CKD. While
there are no currently approved therapies directly modulating SLC6A19, we may face competition from other companies pursuing programs targeting SLC6A19 or alternative approaches for renal indications. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research
and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and
management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the biopharmaceutical
industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and
established companies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, precision medicine is a rapidly developing field, with increasing usage within the pharmaceutical and biotechnology industry of
machine learning and AI technologies to analyze genetic data. While we believe our Compass platform has advantages over potential competitors based on our experience in variant functionalization, our access to genetic databases, and the length of
time that we have been engaged in developing precision medicine, other companies may have greater resources or the ability to acquire more advanced technology to identify targets and may acquire access to the same genetic data that we utilize. We
may not be able to keep up with the pace of innovation that is occurring in our field, and we may face increasing competition in developing precision medicines. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we
may develop. Our competitors also may obtain FDA or other applicable regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are
able to enter the market. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if our Compass platform is effective as a research tool, we may be unable to develop or commercialize new drugs, therapies or
other products based on discoveries from our Compass platform. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if our Compass platform performs its intended functions, we may be unable to use the
discoveries resulting from the platform to produce new therapies. Despite recent scientific advances in the life sciences and our improved understanding of biology, the roles of genes and proteins and their involvement in diseases and in other life
processes is not well understood. Therefore, notwithstanding any potential promising results in earlier studies or clinical trials, we may face significant setbacks in current or future studies or clinical trials. If we are unable to use our
platform discoveries platform to develop and market new drugs or therapies, our business may fail or we may never become profitable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We, or the third parties
we rely on, may be unable to develop the diagnostic tests or clinical assays to successfully advance our therapeutic candidates through clinical trials or commercialization. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Some or all of our therapeutic candidates may require companion diagnostic tests for clinical trials or commercialization. If we are unable to successfully develop the
applicable companion diagnostic tests, experience significant delays in doing so, or rely on third parties in the development of such companion diagnostic tests, or if we are required by the FDA to obtain approval of a companion diagnostic test in
connection with approval of any of our therapeutic candidates, and we do not obtain or face delays in obtaining FDA approval of a companion diagnostic test, the full commercial potential of our therapeutic candidates and our ability to generate
revenue will be materially impaired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our approach to drug discovery and developing therapeutic candidates relies on human genetics and functional genomics
to identify targets for therapeutic intervention as well as predictive biomarkers to evaluate the effects of our therapeutic candidates. For those therapeutic candidates that advance to clinical trials, predictive biomarkers, such as a specific
genetic screen, may become necessary for subject selection and thus may require the incorporation of a diagnostic test, or companion diagnostic, into our clinical trial design. If required, we may engage one or more third-party partners to <FONT
STYLE="white-space:nowrap">co-develop</FONT> the necessary companion diagnostic. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If safe and effective use of any of our therapeutic candidates depends on a
companion diagnostic test, then the FDA generally will require approval or clearance of that companion diagnostic, before or at the same time that the FDA approves our therapeutic candidates, if at all. According to FDA guidance, if the FDA
determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion
diagnostic is not also approved or cleared for that indication. If a satisfactory companion diagnostic is not commercially available, we may be required to create or obtain one that would be subject to regulatory approval requirements. In the past,
FDA has issued guidance on the development of companion diagnostics generally as well as for specific disease categories. We will continue to evaluate the impact of FDA guidance on our companion diagnostic development and strategy. This guidance and
any future guidance or policies from the FDA and other regulatory authorities may impact our development of a companion diagnostic for our therapeutic candidates and result in delays in regulatory approval. We may be required to conduct additional
studies or clinical trials to support a broader claim. Also, to the extent other approved diagnostics are able to broaden their labeling claims to include our approved drug products, we may be forced to abandon our companion diagnostic development
plans or we may not be able to compete effectively upon approval, which could adversely impact our ability to generate revenue from the sale of our approved products and our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic candidates that require such tests. If
the FDA, EMA or a comparable regulatory authority requires approval of a companion diagnostic for any of our therapeutic candidates, whether before or after the therapeutic candidate obtains marketing approval, we, and/or future partners, may
encounter difficulties in developing and obtaining approval for such therapeutic candidate. If we or our third-party partners experience any delay in developing or obtaining regulatory approval of a companion diagnostic, we may be unable to enroll
enough patients in future clinical trials, the development of our therapeutic candidates may be adversely affected or we may not obtain marketing approval, and we may not realize the full commercial potential of our therapeutic candidates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may need to invest significant
resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of biopharmaceutical products. To achieve commercial
success for any therapeutic candidate for which we obtain marketing approval, we will need to establish sales, marketing and distribution capabilities, either by ourselves or through collaboration or other arrangements with third parties. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are risks involved with establishing our own sales and marketing capabilities. For example, recruiting and training a sales force is expensive and time-consuming
and could delay any product launch. If the commercial launch of a therapeutic candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have incurred these
commercialization expenses prematurely or unnecessarily. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Factors that may inhibit our efforts to commercialize our products on our own include, but not limited to: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our inability to recruit, train and retain adequate numbers of effective sales, marketing, reimbursement, customer service,
medical affairs, and other support personnel; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage
relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are unable to establish our own sales and marketing capabilities, our revenue from product sales and our profitability, if any, are likely
to be lower than if we ourselves were to market and sell any products that we develop. In addition, we may not be successful in entering into arrangements with third parties to market and sell our therapeutic candidates or may be unable to do so on
terms that are acceptable to us. Any of these third parties may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own
or in collaboration with third parties, we will not be successful in commercializing our therapeutic candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if any of our therapeutic candidates
receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If any of our therapeutic candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party
payors and others in the medical community necessary for commercial success. If our therapeutic candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree
of market acceptance of our therapeutic candidates, if approved for commercial sale, will depend on a number of factors, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the efficacy and potential advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the acceptance of our therapeutic candidates as front-line treatment for various indications; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the prevalence and severity of any side effects, in particular compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limitations or warnings contained in the labeling approved for our therapeutic candidates by the FDA;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the size of the target patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the strength of marketing, sales and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">publicity for our therapeutic candidates and alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the existence of distribution and/or use restrictions, such as through a REMS; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the availability of third-party payor coverage, adequate reimbursement and favorable pricing policies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing of any required marketing approval; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">support from patient advocacy groups; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any restrictions on the use of our products together with other medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if our therapeutic candidates were to display a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of such
therapeutic candidates will not be fully known until after they are launched. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Product liability lawsuits against us could cause us to incur substantial
liabilities and to limit commercialization of any therapeutic candidates that we may develop alone or with partners. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Clinical development does not always
fully characterize the safety and efficacy profile of a new medicine, and it is always possible that a drug or biologic, even after regulatory approval, may exhibit unforeseen side effects. We face an inherent risk of product liability exposure
related to the testing of our therapeutic candidates in human clinical trials and will face an even greater risk if we commercialize any products that we may develop. If we cannot successfully defend ourselves against any claims that our therapeutic
candidates caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">decreased demand for any therapeutic candidates that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">initiation of investigations by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">significant time and costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">diversion of management and scientific resources from our business operations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reduced resources of our management to pursue our business strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the inability to commercialize any products that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a clinical-stage company, we currently hold product liability insurance coverage for our clinical trials. Insurance coverage is increasingly expensive. We may not be
able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. A successful product liability claim or series of claims brought against us could decrease our cash and could adversely affect
our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our estimated market opportunities for our therapeutic candidates are subject to
numerous uncertainties and may prove to be inaccurate. If we have overestimated the size of our market opportunities, our future growth may be limited. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
estimated addressable markets and market opportunities for our therapeutic candidates are based on a variety of inputs, including data published by third parties, our own market insights and internal market intelligence, and internally generated
data and assumptions. We have not independently verified any third-party information and cannot be assured of its accuracy or completeness. Market opportunity estimates, whether obtained or derived from third-party sources or developed internally,
are subject to significant uncertainty and are based on assumptions and estimates that may prove not to be accurate, particularly given the relatively early stage of our therapeutic candidates. Although we believe our market opportunity estimates
are reasonable, such information is inherently imprecise. In addition, our assumptions and estimates of market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
opportunities are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including but not limited to those described in this prospectus. If this third-party or
internally generated data prove to be inaccurate or if we make errors in our assumptions based on that data, or if the facts underlying our assumptions change over time, our actual market may be more limited than we estimate it to be. In addition,
these inaccuracies or errors may cause us to misallocate capital and other critical business resources, which could harm our business. The estimates of our market opportunities included in this prospectus should not be taken as indicative of our
ability to grow our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, prices for novel approved treatments must often be set high in order to recover the sponsor&#146;s development and
manufacturing costs, fund additional research and achieve profitability, and we may be unable to obtain the price necessary to achieve these things. We may also need to fund patient support programs upon the marketing of a therapeutic candidate,
which would negatively affect the revenue of a therapeutic candidate. We may be unable to maintain or obtain sufficient therapy sales volumes at a price high enough to justify our development efforts and our sales, marketing and manufacturing
expenses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our business operations </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our future
success depends on our ability to retain key employees, to engage advisors and consultants and to attract, retain and motivate qualified personnel. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on the
development and management expertise of our scientific founders who are leading researchers in genetics and bioinformatics, as well as the other principal members of our management, scientific and clinical team. We currently do not maintain key
person insurance on these individuals. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, we might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel
among biotechnology, pharmaceutical and other businesses, particularly in the San Francisco Bay Area where we are headquartered, and we may be required to expend significant financial resources in our employee recruitment and retention efforts. Many
pharmaceutical companies with whom we compete for qualified personnel have greater financial and other resources, different risk profiles and longer operating histories in the industry than we do. They also may provide candidates with more diverse
opportunities and better chances for career advancement. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that will harm our ability to implement our business
strategy and achieve our business objectives. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we have scientific and clinical advisors and consultants who assist us in formulating our development and
clinical strategies. These advisors and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, our advisors and consultants may
have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will need to grow our
organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As our development and commercialization plans
and strategies develop, and as we transition into operating as a public company, we expect to expand our employee base for managerial, operational, financial and other resources. In addition, we have limited experience in clinical development and,
as our therapeutic candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. We have to manage additional relationships with partners, suppliers and other
organizations as part of our ongoing and anticipated clinical trials, and we expect to continue to have to manage additional relationships with partners, suppliers and other organizations in the future. Our ability to manage our operations and
future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient
or timely manner and may discover deficiencies in existing systems and controls. In addition, we may need to expand our facilities, including laboratory operations, and may be unable to do so on commercially reasonable terms, or at all. Our
inability to successfully manage our growth and expand our operations could have a material and adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our current or future employees, clinical trial investigators, CROs, CMOs, consultants, vendors and partners may engage in misconduct or other improper activities,
including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements, violations of regulatory standards, and insider trading. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
are exposed to the risk of misconduct by our current or future employees, clinical trial investigators, CROs, CMOs, consultants, vendors and partners. Misconduct by these parties could include fraud or intentional, reckless and/or negligent conduct
or disclosure of unauthorized activities to us that violates: (i)&nbsp;FDA regulations or those of comparable foreign regulatory agencies, (ii)&nbsp;manufacturing or clinical standards, (iii)&nbsp;federal and state health and data privacy, security,
fraud and abuse, government price reporting, transparency reporting requirements, and other healthcare laws and regulations in the United States and abroad, (iv)&nbsp;sexual harassment and other workplace misconduct, or (v)&nbsp;laws that require
the true, complete and accurate reporting of financial information or data. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious
harm to our reputation, or improper or unauthorized use of AI or machine learnings tools that result in the disclosure of confidential information or reliance on inaccurate information. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have adopted a code of conduct applicable to all of our employees prior to completion of this offering, as well as a disclosure program and other applicable policies
and procedures, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us
from governmental investigations or other actions or lawsuits stemming from a failure to comply with laws or regulations. If any actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, such
actions could adversely affect our ability to operate our business and our results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from
government funded healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional integrity reporting and oversight obligations, and the curtailment or restructuring of our operations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our business is dependent on the integrity of information technology systems and failure of such systems could disrupt our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Like most companies, we depend on the efficient and uninterrupted operation of our information technology and communications systems and those of our third-party
vendors, contractors or consultants. Such systems may fail or suffer security breaches, cyberattacks, loss or leakage of data and other disruptions, which could cause adverse consequences resulting from such compromise, including but not limited to
regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We, and third parties on whom we depend, are increasingly dependent on information technology systems, infrastructure
and data to operate our and their businesses. In the ordinary course of business, we process confidential information (including but not limited to intellectual property, proprietary business data and patient data). It is critical that we do so in a
secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our information technology systems and operations to third parties, and as a result we rely on and manage a number of
third-party vendors and other contractors and consultants who have access to and process our confidential information. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we are still in the process of
implementing our internal security controls, policies and other measures, we take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties
upon which we rely). We may not, however, detect and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified
vulnerabilities. Despite the implementation of these security measures, our information technology systems and those of our third-party vendors and other contractors and consultants have been in the past and may be in the future potentially
vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, accidents by our employees or third-party service providers, natural disasters, terrorism, war, global pandemics, and telecommunication and
electrical failures. We may also experience security incidents from inadvertent or intentional actions by our employees, third-party vendors, contractors, consultants, business partners and/or other third parties, including theft, fraud or
unauthorized access to or use of our information technology systems, or attack or damage from hacking, cyberattacks or supply chain attacks by malicious third parties and sophisticated nation-state and nation-state-supported actors (including the
deployment of harmful computer viruses and malware, ransomware, denial or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">degradation-of-service</FONT></FONT> attacks, phishing attacks and other social engineering and other means
to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure, or that of our third-party vendors and other contractors and consultants, impede our ability
to conduct business, delay our financial reporting or lead to data leakage. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we have a security consultant provide annual assessments on our systems
vulnerabilities, the risk of a security incident or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity, and
sophistication of attempted attacks and intrusions from around the world have increased. We may not be able to anticipate all types of security threats, nor implement preventive measures effective against all such security threats. The techniques
used by cyber criminals change frequently, may not be recognized until launched and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations, or
hostile foreign governments or agencies. Cyberattacks or security incidents could remain undetected for an extended period, which could potentially result in significant harm to our information technology systems, as well as unauthorized access to
the information stored on and transmitted by our information technology systems. Even if identified, the full extent of a cyberattack or security incident may not be determined immediately and we may be unable to adequately investigate or remediate
incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. Moreover, recovery of our information technology systems may
be additionally hampered where we have outsourced the operation of information technology systems and information storage to third parties. Any breach, loss or compromise of confidential information may also subject us to liability, government
enforcement actions (for example, investigations, fines, penalties, audits, and inspections); breach notification and additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data);
litigation (including class action litigation); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may prevent or cause customers to stop using our products, deter new customers from
using our products, and negatively impact our ability to grow and operate our business. If the information technology systems of our third-party vendors and other contractors and consultants become subject to disruptions or security incidents, we
may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections,
computers and devices outside our premises or network, including working at home, while in transit and in public locations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Significant disruptions of our
information technology systems or those of our third-party vendors and other contractors and consultants, or security breaches could result in the loss, misappropriation and/or unauthorized access, use, or disclosure of, or the prevention of access
to, confidential information (including trade secrets or other intellectual property or proprietary business information) and claims by our counterparties that we have failed to comply with legal or contractual obligations, which could result in
financial, legal, business, and reputational harm to us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There can be no assurance that the limitations of liability in our contracts would be enforceable or
adequate to protect us from liabilities and damage and we may not have adequate insurance coverage to cover losses, or all types of costs, expenses and losses, we could incur with respect to security breaches or disruptions. The successful assertion
of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or
<FONT STYLE="white-space:nowrap">co-insurance</FONT> requirements), could have an adverse effect on our business. In addition, we cannot be sure that our existing insurance coverage and coverage for errors and omissions will continue to be available
on acceptable terms or that our insurers will not deny coverage as to any future claim. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We utilize third-party open source software, and any failure to comply
with the terms of one or more of these open source software licenses could adversely affect our business, subject us to litigation, or create potential liability. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Compass platform utilizes software licensed by third parties under any one or more open source licenses, including the Apache 2.0 License, MIT, BSD variants, and
others, and we expect to continue to incorporate open source software in our business in the future. We cannot ensure that we have effectively monitored our use of open source software, or validated the quality or source of such software, or that we
are in compliance with the terms of the applicable open source licenses or our current policies and procedures. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Companies that incorporate open source software into
their products have, from time to time, faced claims challenging the use of open source software and compliance with open source license terms. We could be subject to similar suits by parties claiming ownership of what we believe to be open source
software or claiming <FONT STYLE="white-space:nowrap">non-compliance</FONT> with open source licensing terms, which could result in litigation that may cause us to be required to disclose our proprietary source code based on our modifications of
open source code, incur expenses and be liable for damages and such litigation could distract our personnel from their normal responsibilities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, there
are an increasing number of open source software license types, almost none of which have been interpreted by U.S. or foreign courts, and there is a risk that such licenses to which we are subject to could be construed in a manner that imposes
unanticipated conditions or restrictions on our ability to market or provide our products or services. If we are held to have breached or failed to fully comply with any of the terms </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and conditions of an open-source software license, we could face claims for breach of contract, intellectual property infringement or misappropriation or other liability, or be required to seek
costly licenses from third parties that may not be available on commercially reasonable terms, or at all. By the terms of certain open source licenses, we could be required to release the source code of our proprietary software, and to make our
proprietary software available under open source licenses, if we combine our proprietary software with open source software in a certain manner. In the event that portions of our proprietary software are determined to be subject to an open source
license, we could be required to publicly release the affected portions of our source code, <FONT STYLE="white-space:nowrap">re-engineer</FONT> all or a portion of our Compass platform, or otherwise be limited in the licensing of our Compass
platform, each of which could reduce or eliminate the value of our Compass platform. Disclosing our proprietary source code could allow our competitors to create similar products with lower development effort and time, which would materially and
adversely affect our business, financial condition, results of operations and prospects. Furthermore, any such <FONT STYLE="white-space:nowrap">re-engineering</FONT> or other remedial efforts could require significant additional research and
development resources, and we may not be able to successfully complete any such <FONT STYLE="white-space:nowrap">re-engineering</FONT> or other remedial efforts. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, in addition to risks related to license requirements, use of certain open source software carries greater technical and legal risks than does the use of
third-party commercial software. For example, open source software is generally provided without any representations, indemnity, support or warranties or other contractual protections regarding infringement or the quality of the code, including the
existence of security vulnerabilities. In addition, certain open source licenses require that source code for software programs that interact with such open source software be made available to the public at no cost and that any modifications or
derivative works to such open source software continue to be licensed under the same terms as the open source software license. To the extent that our Compass platform depends upon the successful operation of open source software, any undetected
errors or defects in open source software that we use could prevent the deployment or impair the functionality of our systems and injure our reputation. In addition, the public availability of such software may make it easier for others to
compromise our Compass platform. Any of the foregoing risks could materially and adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The use of new and evolving technologies, such as AI in our operations may require us to expend material resources and may present risks and challenges that can
impact our business, including by posing security and other risks to our confidential information, proprietary information and personal information, any of which may result in reputational harm and liability, or otherwise adversely affect our
business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We incorporate AI solutions, including machine learning, into our Compass platform. There are significant risks involved in utilizing AI and no
assurance can be provided that the usage of AI will enhance our business or assist our business in becoming more efficient or profitable. The use of certain AI technology can give rise to intellectual property risks, including compromising the
privacy and security of our proprietary technologies and leading to claims of intellectual property infringement, misappropriation or other violation. In addition, AI may have errors or inadequacies that are not easily detectable. If the data used
to train AI or the content, analyses, or recommendations that AI applications assist in producing are or are alleged to be deficient, inaccurate, incomplete, overbroad or biased, our business, financial condition, and results of operations may be
adversely affected. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, we expect to see increasing government and supranational regulation and ethical concerns related to AI use, which may also
significantly increase the burden and cost of research, development and compliance in this area. The rapid evolution of AI will require the application of significant resources to design, develop, test and maintain our technology and products to
help ensure that AI is implemented in accordance with applicable laws and regulations and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. The legal landscape and subsequent legal protection for the
use of AI remains uncertain, and development of the law in this area could impact our ability to enforce our proprietary rights or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
protect against infringing uses. If we do not have sufficient rights to use the data on which AI relies or to the outputs produced by AI applications, we may incur liability through the violation
of certain laws, third-party privacy or other rights or contracts to which we are a party. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our third-party vendors, contractors and consultants may also incorporate
AI tools into their own offerings, and the providers of these AI tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to intellectual property, privacy and data security. Further, bad actors around
the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these effects could damage
our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our ability to use our net operating loss and certain other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. Unused federal
net operating losses generated in tax years beginning after December&nbsp;31, 2017 will not expire and may be carried forward indefinitely but the deductibility of such federal net operating losses in taxable years beginning after December 31, 2020
is limited to 80% of current year taxable income. In addition, both our current and our future unused losses and other tax attributes (such as research credits) may be subject to limitation under Sections 382 and 383 of the Code if we undergo, or
have undergone, an &#147;ownership change,&#148; generally defined as a greater than 50 percentage point change (by value) in our equity ownership by certain stockholders over a three-year period. As of December&nbsp;31, 2023, we had a
Section&nbsp;382 study prepared which covered the period from inception through March 2024. The study concluded that several ownership changes occurred since the inception of the Company. However, it was determined that the annual available NOLs
under Section&nbsp;382 will be sufficient to utilize in their entirety prior to their respective expiration years. It is possible that we may undergo additional ownership changes in the future, including as a result of the offering or future
transactions or events that may be outside of our control. As a result, even if we attain profitability, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards and other <FONT
STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research tax credits) to offset our post-change income or taxes may be limited. Similar provisions of state tax law may also apply to limit our use of accumulated state tax
attributes. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result of the foregoing, even if
we attain profitability, we may be unable to use all or a material portion of our net operating losses and other tax attributes, which could adversely affect our future cash flows. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, we may consider strategic transactions, such as acquisitions of companies, businesses or assets, joint ventures and spin-outs. Additional potential
transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur <FONT
STYLE="white-space:nowrap">non-recurring</FONT> or other charges, may increase our near term or long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations
and financial results. For example, these transactions may entail numerous operational and financial risks, including, but not limited to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">exposure to unknown liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">write-downs of assets or goodwill or impairment charges; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">increased amortization expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">difficulty and cost in integrating the operations, systems and personnel of any acquired businesses with our operations,
systems and personnel; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and
ownership; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">inability to retain key employees of any acquired businesses. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition, results of operations and prospects, which could lead to a decline
in our stock price. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our results of operations and stock price could be adversely affected by general conditions in the global economy and in the global
financial markets. For example, a global financial crisis could cause extreme volatility and disruptions in the capital and credit markets. Similarly, increased volatility in interest rates and the debt and equity markets, instability in the global
banking system, global health crises and pandemics and geopolitical conflict could cause significant instability and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our
business, including weakened demand for our therapeutic candidates and in our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy also could strain our partners and our suppliers, possibly
resulting in development or supply disruption. We cannot anticipate all of the ways in which the foregoing, and the current economic climate and financial market conditions generally, could adversely impact our business. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to intellectual property </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our success depends in part on
our and our partners&#146; ability to obtain, maintain, enforce and protect our intellectual property and proprietary rights. It is difficult and costly to protect our intellectual property rights and technologies, and we may not be able to ensure
their protection. If we are unable to adequately protect our technologies or obtain and maintain patent protection for our technologies and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could
develop and commercialize technologies and products similar or identical to ours, and our ability to successfully commercialize our technologies and products may be impaired. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success will depend in large part on our and our partners&#146; obtaining, maintaining, enforcing and protecting patent, trademark, trade secret and other
intellectual property and proprietary protection in the United States and other countries for our technologies. Our proprietary technologies include our Compass platform, genetic targets identified by our Compass platform, machine learning used by
our Compass platform, our methods for developing and testing our therapeutic candidates, our therapeutic candidates themselves, and any therapeutic compounds, molecules or agents related to such therapeutic targets, including their respective
components, formulations, combination therapies, methods used to manufacture them and methods of treatment. Our commercial success will also depend, in large part, on successfully defending our trademarks, trade secrets, owned patents and patent
applications and other intellectual property rights against third-party challenges. We seek to protect our intellectual property position by, among other methods, filing patent applications in the United States and abroad related to our
technologies, inventions and improvements that are important to the development and implementation of our business. We also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop
and maintain our intellectual property position. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, importing or otherwise commercializing our technologies or therapeutic candidates is dependent upon the
extent to which we have rights under valid and enforceable patents, trade secrets or other intellectual property or proprietary rights that cover these activities. If we or our current or future partners are unable to secure and maintain patent,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
trade secret or other intellectual property or proprietary protection for any technologies or therapeutic candidates we or they develop, or if the scope of the protection secured is not
sufficiently broad, our competitors could develop and commercialize technologies or therapeutic candidates similar or identical to ours, and our ability to commercialize any technologies or therapeutic candidates we or our partners may develop or to
otherwise compete effectively may be adversely affected. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have filed patent applications, both in the United States and internationally, protecting our inventions
related to our MZE829 and MZE782 candidates as well as our <FONT STYLE="white-space:nowrap">out-licensed</FONT> programs. We currently own two issued U.S. patents. We have eight pending U.S. provisional patent applications, ten pending Patent
Cooperation Treaty, or PCT, patent applications, seven pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, and over fifty pending foreign patent applications. Our MZE001 patent portfolio has been exclusively <FONT
STYLE="white-space:nowrap">out-licensed</FONT> to Shionogi, who also has the exclusive right to make decisions regarding the prosecution and enforcement of patents or patent applications within that portfolio. Our ATXN2 and UNC13A patent portfolios
have been exclusively licensed or assigned, respectively, to other biotechnology companies, who have the exclusive right to make decisions regarding the prosecution and enforcement of those respective portfolios. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A provisional patent application is not eligible to become an issued patent until, among other things, we file a <FONT STYLE="white-space:nowrap">non-provisional</FONT>
patent application within 12 months of filing such provisional application. If we fail to do so, we may lose our priority date with respect to the provisional patent application and any patent protection on the inventions disclosed in the
provisional patent application. The PCT system allows a single application to be filed within 12 months of the original priority date of the patent application, and for the designation of all of the PCT member states in which national patent
applications can later be pursued based on the international patent application filed under the PCT. A PCT application is not eligible to become an issued patent until, among other things, we file one or more national stage patent applications
within the applicable time limit, which is generally 30 or 31 months from the PCT application&#146;s earliest priority date, depending on the jurisdiction, in the countries in which we seek patent protection. If we fail to file a national phase
application in a PCT member state, we may lose our priority date in that member state with respect to the subject matter disclosed in the PCT application, as well as any patent protection in that member state on the inventions disclosed in the PCT
application. While we generally intend to timely file <FONT STYLE="white-space:nowrap">non-provisional</FONT> and national phase patent applications, as applicable, we cannot predict whether any of our current or future patent applications relating
to any therapeutic targets, therapeutic candidates or technologies we have identified or may identify in the future will result in the issuance of patents that effectively protect our therapeutic targets, therapeutic candidates or technologies. If
we or our partners do not successfully obtain patent protection, or, even if we or they do obtain patent protection, if the scope of the patent protection obtained with respect to any therapeutic target, therapeutic candidate and technology is not
sufficiently broad, we or our partners may be unable to prevent others from using our technology or from developing or commercializing technology and products similar or identical to ours or our partners&#146;. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patenting process is expensive and time-consuming, and we and our current or future partners may not be able to file and prosecute all necessary or desirable patent
applications at a reasonable cost or in a timely manner. In addition, we or our partners may not pursue or obtain patent protection in all relevant jurisdictions, particularly in markets where translation costs are high. It is also possible that we
or our partners will fail to identify patentable aspects of our or their research and development output before it is too late to obtain patent protection. Although we seek to enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and
confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, consultants, independent contractors, advisors, CMOs, CROs, hospitals, independent treatment
centers, suppliers, partners and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, publications
of discoveries in the scientific literature often lag behind the actual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&nbsp;months after filing, or in some cases not at all. Therefore, we cannot
be certain that we were the first to make the inventions claimed in our current or future patent applications, or that we were the first to file for patent protection of such inventions. Moreover, in circumstances, including with respect to our
exclusive <FONT STYLE="white-space:nowrap">out-licensing</FONT> or assignment of our MZE001, ATXN2 and UNC13A patent portfolios, where we do not have the right to control the preparation, filing, prosecution, maintenance, defense or enforcement of
patents or patent applications covering technologies that we currently, or may in the future, license from or license to third parties, we will be reliant on our licensors or licensees to do so. If our partners are not fully cooperative or disagree
with us as to the preparation, filing, prosecution, maintenance, defense or enforcement of any licensed patent rights, such patent rights could be compromised. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity,
enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications, if any, may not result in issued patents. Moreover, the coverage claimed in a patent application can be significantly reduced
before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful
protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> may be challenged, narrowed,
circumvented, or invalidated by third parties. Consequently, we do not know whether any of our therapeutic candidates or technologies will be protectable or remain protected by valid and enforceable patents. In addition, any future patents we obtain
may not be sufficiently broad to prevent others from using our technologies or from developing competing therapeutic candidates in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. In addition, given the amount of time required for
the development, testing, and regulatory review of new therapeutic candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent rights may not provide us with
sufficient rights to exclude others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The issuance of a patent is not conclusive as to its inventorship,
scope, validity, or enforceability, and any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party <FONT
STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the United States Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review,<I> inter
partes</I>&nbsp;review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, invalidate, or hold unenforceable,
our patent rights, allow third parties to commercialize our technologies or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent
rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of
invention or other features of patentability. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using
or commercializing similar or identical technologies and products, or limit the duration of the patent protection of our technologies and therapeutic candidates. Such proceedings also may result in substantial cost and require significant time from
our scientists and management, even if the eventual outcome is favorable to us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, some of the patents and patent applications we may own or <FONT
STYLE="white-space:nowrap">in-license</FONT> in the future may be <FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. If we are unable to obtain an exclusive license to any such third-party
<FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patents or patent applications, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
including our competitors, and our competitors could market competing products and technologies. In addition, we may need the cooperation of any such
<FONT STYLE="white-space:nowrap">co-owners</FONT> of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive
position, business, financial conditions, results of operations, and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes to the patent law in the United States and other jurisdictions could
diminish the value of patents in general, thereby impairing our ability to protect our products. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As is the case with other biopharmaceutical companies, our
success may be heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and
inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the
enforcement or defense of issued patents. For example, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, which was signed into law in September 2011, made a number of significant changes to U.S. patent law, affecting the way patent
applications are prosecuted, redefining prior art and providing more efficient and cost-effective avenues for competitors to challenge the validity of patents. In addition, the Leahy-Smith Act has transformed the U.S. patent system from a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> system to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system in which, assuming
that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> provisions require patent applicants such as us to be cognizant of the time from invention to filing of a patent application and be diligent in filing patent
applications. However, circumstances could prevent us from promptly filing patent applications on our inventions. Similar legislation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and
costs surrounding the prosecution of our or our future collaboration partners&#146; patent applications and the enforcement or defense of our or our future collaboration partners&#146; issued patents, if any, all of which could harm our business,
results of operations, financial condition and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the patent positions of companies in the development and commercialization of biologics and
pharmaceuticals are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in
certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Additionally, there have been recent proposals for additional changes to the patent laws of the United
States and other countries that, if adopted, could impact our ability to enforce our intellectual property. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant
<FONT STYLE="white-space:nowrap">law-making</FONT> bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on and weaken our ability to obtain and enforce new
patents and patents that we or our collaboration partners might obtain in the future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may not be able to protect our intellectual property rights
throughout the world. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we have issued patents in the United States and pending patent applications in the United States and other countries, filing,
prosecuting, maintaining, enforcing and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in
the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from
practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we
have not obtained patent protection to develop their own products and, further, may export otherwise infringing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our therapeutic candidates, and our
patents, the patents of our current and future partners, or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign
countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or our partners&#146; patents or marketing of competing products in violation
of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents or the patents of our
partners at risk of being invalidated or interpreted narrowly and our patent applications or the patent applications of our partners at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any
lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accordingly, our efforts to enforce our
intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the
enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or our partners are forced to grant a
license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we are sued for infringing, misappropriating or otherwise violating intellectual property or proprietary rights of third parties, such litigation or disputes
could be costly and time-consuming and could prevent or delay us from developing or commercializing our therapeutic candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success
depends, in part, on our ability to develop, manufacture, market and sell our therapeutic candidates and use our technologies without infringing, misappropriating or otherwise violating the intellectual property and other proprietary rights of third
parties. If any third-party patents, patent applications or other intellectual or proprietary rights are enforced against us and found to be valid, enforceable and cover our therapeutic candidates or their compositions, methods of use or
manufacturing, third parties owning such intellectual or proprietary rights could seek an injunction prohibiting our ability to develop, manufacture, market and sell our therapeutic candidates and technologies, or we may be required to pay damages,
which could be substantial, and we would not be free to manufacture, use or market our therapeutic candidates or to do so without obtaining a license, which may not be available on commercially reasonable terms, or at all. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property or proprietary rights with respect to our
therapeutic candidates and technologies we use in our business. Our competitors or other third parties may assert infringement, misappropriation or other claims against us alleging, for example, that our therapeutic candidates or technologies we use
in our business are covered by their patents. We cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. Our competitors in both the United States and abroad, many of which
have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for or obtain, patents that will prevent, limit or otherwise
interfere with our ability to make, use and sell, if approved, our therapeutic candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public
company, the risk increases that our existing therapeutic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
candidates and any other therapeutic candidates that we may develop or technologies we use in our business may be subject to claims of infringement of the patent rights of third parties.
Furthermore, because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because patent claims can be revised before issuance, there may be applications now pending which may later result
in issued patents that may be infringed by the manufacture, use or sale of our therapeutic candidates or technologies we use in our business. If a patent holder believes our therapeutic candidates or technologies we use in our business infringe on
its patent rights, the patent holder may sue us even if we have received patent protection for our therapeutic candidates or technologies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is a substantial
amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property or proprietary rights with
respect to our therapeutic candidates and technologies, including interference proceedings or post-grant challenges before the USPTO. Third parties may also assert infringement, misappropriation or other claims against us based on existing or future
intellectual property or proprietary rights. The outcome of intellectual property litigation and other disputes is subject to uncertainties that cannot be adequately quantified in advance. The pharmaceutical and biotechnology industries have
produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of technologies, products or methods of using or manufacturing products. The coverage of patents is
subject to interpretation by the courts, and the interpretation is not always uniform. Our analysis of these issues, including interpreting the relevance or the scope of claims in a patent or a pending application, determining applicability of such
claims to our technologies or therapeutic candidates, predicting whether a third party&#146;s pending patent application will issue with claims of relevant scope, and determining the expiration date of any patent in the United States or abroad that
we consider relevant to our therapeutic candidates may be incorrect, which may negatively impact our ability to develop, manufacture, use and market our therapeutic candidates or technologies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we were sued for patent infringement, we would need to demonstrate that our therapeutic candidates, technologies or methods of use, manufacturing or other applicable
activities either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be successful in doing so. Proving invalidity or unenforceability may be difficult. For example, in the
United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we believe third-party intellectual property claims are without merit, there is no
assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are found to infringe, misappropriate or otherwise violate a third party&#146;s intellectual property or proprietary rights and we are unsuccessful in
demonstrating that such intellectual property or proprietary rights are invalid or unenforceable, we could be forced, including by court order, to cease developing, manufacturing, using or commercializing the infringing therapeutic candidate or
technology. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing therapeutic candidate. However, we may not be able
to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain such a license, it could be granted on <FONT STYLE="white-space:nowrap">non-exclusive</FONT> terms, thereby giving our competitors and other
third parties access to the same technologies licensed to us, and it could require us to make substantial licensing, royalty and other payments. In addition, we could be found liable for significant monetary damages, including treble damages and
attorneys&#146; fees if we are found to have willfully infringed such third-party patent rights. A finding of infringement could prevent us from commercializing our therapeutic candidates or force us to cease some of our business operations, which
could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Intellectual property litigation could cause us to spend substantial resources and distract our personnel from
their normal responsibilities. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Litigation and other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and
generally expensive and time consuming and are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common
stock. Moreover, such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of
such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties
from infringing upon, misappropriating or otherwise violating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a
material adverse effect on our ability to compete in the marketplace. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be subject to claims by third parties asserting that we, or our employees or
consultants have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Some of our
employees and consultants are currently or have been previously employed at universities or research institutions, or at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. These employees and
consultants may have executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements, or similar agreements, in connection with such other current or previous
employment. Although we try to ensure that our employees and consultants do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or these
individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of third parties. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to
paying monetary damages, we may lose valuable intellectual property or personnel or sustain damages. Such intellectual property could be awarded to a third party, and we could be required to obtain a license from such third party to develop and
commercialize our therapeutic candidates or technologies. Such a license may not be available on commercially reasonable terms or at all and may not be exclusive to us. Even if we are successful in defending against such claims, litigation could
result in substantial costs and be a distraction to our management. Any of the foregoing would have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While it is our policy to require our employees, consultants and contractors who may be involved in the conception or development of intellectual property to execute
agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, which may result in claims by or
against us related to the ownership of such intellectual property. In addition, such agreements may not be self-executing and the intellectual property subject to such agreements may not be assigned to us without additional assignments being
executed, and we may fail to obtain such additional assignments. Any invention assignment agreements we have with third parties, employees, consultants or contractors may be breached, and it may be difficult or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
impossible to enforce them. In addition, we have several sponsored research agreements relating to our research and development efforts with various academic institutions. Some of these academic
institutions may not have intellectual property assignments or similar agreements with their employees and consultants, or may not permit their employees to assign intellectual property outside the academic institution, which may result in claims by
or against us related to ownership of any intellectual property. Accordingly, we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual
property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property. Even if we are successful in prosecuting or defending against such claims, litigation could result
in substantial costs and be a distraction to our senior management and scientific personnel, which would have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental
patent offices, and any future patent protection could be reduced or eliminated for noncompliance with these requirements. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Periodic maintenance fees,
renewal fees, annuity fees and various other government fees on issued patents and patent applications are due to be paid to the USPTO and patent offices in foreign countries in several stages over the lifetime of the patent. In addition, the USPTO
and patent offices in foreign countries require compliance with a number of procedural, documentary, fee payment and other requirements during the patent application process. We may rely on partners to pay these fees due to U.S. and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies and to comply with other requirements with respect to licensed patents and patent applications. While an inadvertent lapse may, in some jurisdictions and under certain circumstances, be
cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete and
irrevocable loss of a patent or patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions
within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. In such an event, our competitors and other third parties might be able to enter the market with
similar or identical products or technologies, which would have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we are unable to protect the confidentiality of our trade secrets, the value of our therapeutic candidates and technologies could be materially adversely
affected and our business would be harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to the protection afforded by patents, we rely upon trade secrets,
<FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets in part
by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to such knowledge, such as our employees, consultants, independent contractors, advisors, CMOs, CROs, suppliers,
partners and other third parties. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets.
Additionally, our confidentiality agreements and other contractual protections may not be adequate to protect our intellectual property from unauthorized disclosure, third-party infringement or misappropriation (such as a cybersecurity breach). Any
party with whom we have executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party
illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, some courts in the
United States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. Even if we are successful in protecting the confidentiality of our trade secrets, others may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
independently develop the same information or technology, or may be able to discern or reverse engineer our proprietary information or technology from public sources of information. Additionally,
though our agreements with third parties typically restrict their ability to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. If any of our trade secrets were to be lawfully
obtained or independently developed by a competitor or other third party, we would have no right to prevent such third party, or those to whom they communicate such technology or information, from using that technology or information to compete with
us, which could harm our competitive position. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our business, financial condition, results of operations and prospects could be
materially harmed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we fail to comply with our obligations in any agreements under which we may license intellectual property rights to or from third
parties or otherwise experience disruptions to our business relationships with our current partners or any future licensors, we could lose license rights that are important to our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have and may in the future from time to time enter into license or collaboration agreements with third parties to advance our research or allow commercialization of
therapeutic candidates. Such agreements may impose numerous obligations, such as development, diligence, payment, commercialization, <FONT STYLE="white-space:nowrap">non-compete,</FONT> funding, milestone, royalty, sublicensing, patent prosecution,
enforcement and other obligations on us and may require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our best efforts,
our current partners or any future licensors might conclude that we have materially breached any of our license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize
products and technologies covered by these license agreements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any termination of these licenses, or if the underlying patents fail to provide the intended
exclusivity, could result in the loss of significant rights and could harm our ability to commercialize our therapeutic candidates, and competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products
identical to ours and we may be required to cease our development and commercialization of certain of our therapeutic candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Disputes may also arise between us
and our current partners or any future licensors regarding intellectual property subject to a license agreement, including, but not limited to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual
property rights of the licensor or licensee that are not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our therapeutic candidates, and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the priority of invention of any patented technology; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use
of intellectual property by our future licensors and us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The agreements under which we may license intellectual property or
technology from third parties are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe
to be the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could
have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we may license prevent or impair our ability to maintain future licensing arrangements on
acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we cannot acquire or license rights to use technologies on reasonable terms or at all, we may not be able to commercialize our current or any future
products or technologies. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the future, we may identify third-party intellectual property and technology we may need to license in order to engage in our
business, including to develop or commercialize new products or technologies, and the growth of our business may depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use this technology. However, such
licenses may not be available to us on acceptable terms or at all. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire
third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater development or commercialization
capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if such licenses are available, we may be required to pay the licensor in return for the use of such licensor&#146;s
technology, including <FONT STYLE="white-space:nowrap">up-front</FONT> payments, ongoing maintenance fees, payments based on certain milestones such as development and regulatory events and sales volumes, or royalties. In addition, such licenses may
be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could give our competitors and other third parties access to the same intellectual property licensed to us. Moreover, we could encounter delays in the introduction of products while we
attempt to develop alternatives. Failure to obtain any of these licenses on favorable terms could prevent us from commercializing our current and any future therapeutic candidates and technologies. Any of the foregoing could have a material adverse
effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we do not obtain patent term extension and data exclusivity for any
therapeutic candidates we may develop, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Depending upon the timing, duration and specifics of any FDA marketing
approval of any therapeutic candidates we may develop, one or more of our U.S. patents, if issued, may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or the Hatch-Waxman
Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process, although the amount of available extension to any specific patent eligible for
patent term extension depends on a variety of factors, including the date on which the patent issues and certain dates related to the regulatory review period. A patent term extension cannot extend the remaining term of a patent beyond a total of
14&nbsp;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension
because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy
applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. To the extent we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> any U.S. patents, we may not have
control over the patent term extension process and may rely on our partners to obtain a patent term extension. Moreover, under the agreements pursuant to which we <FONT STYLE="white-space:nowrap">out-license</FONT> or assign our MZE001, ATXN2 and
UNC13A patent portfolios, the applicable licensees have the sole right to apply for patent term extensions with respect to the licensed patents and patent applications. If we or our partners are unable to obtain patent term
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
extension or if the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial
condition, results of operations and prospects could be materially harmed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may become involved in lawsuits to protect or enforce any patents we may own or <FONT
STYLE="white-space:nowrap">in-license</FONT> in the future, which could be expensive, time consuming and unsuccessful and any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future covering our therapeutic candidates
could be found invalid or unenforceable if challenged in courts or patents offices. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Competitors and other third parties may infringe, misappropriate or
otherwise violate our intellectual property rights. To counter infringement, misappropriation or other violations, we may be required to file infringement, misappropriation or other claims in order to enforce our intellectual property rights, which
can be expensive and time-consuming and divert the time and attention of our management and business and scientific personnel. In addition, many of our adversaries in these proceedings may have the ability to dedicate substantially greater resources
to prosecuting these legal actions than we can. Our ability to enforce our patents or other intellectual property rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or
methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement in a third party&#146;s product or service. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. In such a
proceeding, a court may decide that an asserted patent is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that the asserted patent or other intellectual property right does not
cover the third-party technology in question. An adverse result in any litigation or defense proceedings could put one or more asserted patents at risk of being invalidated or interpreted narrowly and could put related patent applications at risk of
not issuing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we were to initiate legal proceedings against a third party to enforce a patent we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in
the future covering one or more of our therapeutic candidates, the defendant could counterclaim that the patent covering our therapeutic candidate is invalid and/or unenforceable. In patent litigation in the United States or elsewhere, defendant
counterclaims challenging the validity, enforceability or scope of asserted patents are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of subject matter
eligibility, lack of novelty, obviousness, lack of adequate written description or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of
the patent withheld relevant information from the USPTO or any other applicable patent office, or made a misleading statement during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as
reexaminations, <I>inter partes</I> review or post-grant review, or oppositions or similar proceedings in foreign patent offices, in parallel with litigation or even outside the context of litigation. Such proceedings could result in the revocation
of, cancellation of, or amendment to our patents in such a way that they no longer cover our therapeutic candidates or technology. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the
validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or
unenforceability, we would lose at least part, and perhaps all, of the patent protection on our current or future therapeutic candidates. Such a loss of patent protection would have a material adverse impact on our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, interference, derivation or other proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority
of inventions with respect to our current or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
future patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business
could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license is offered and our competitors or other third parties gain access
to the same technology. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our defense of litigation or interference, derivation or other proceedings may fail and, even if successful, may result in substantial costs
and distract our management and other employees. Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate
remedy. Any of the foregoing could have a material adverse effect on our financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If our trademarks and trade
names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our products. We may design or create new trademarks and apply to
register them, but our trademark applications may not be approved in the United States or any other relevant jurisdiction. Our trademarks and trade names may be challenged, infringed, circumvented, declared generic, lapsed or determined to be
infringing on or dilutive of other marks. Third parties may oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we
could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Competitors or other parties in our industry may adopt trademarks or trade
names similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, third parties may infringe our trademarks and we may not have adequate resources to enforce our trademark rights. If
we attempt to enforce our trademarks and assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior
rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to
compete effectively and our business may be adversely affected. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Intellectual property rights do not necessarily address all potential commercial or
competitive threats. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have
limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may be able to make products similar to any therapeutic candidates we may develop or utilize similar technologies
that are not covered by the claims of patents that we may license or may own in the future; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we, or any current or future partners, might not have been the first to make the inventions covered by an issued patent or
pending patent application that we may license or own in the future; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we, or any current or future partners, might not have been the first to file patent applications covering certain of our or
their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing, misappropriating or otherwise violating any of our owned or licensed intellectual property and proprietary rights; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">it is possible that our pending patent applications or those that we may own or license in the future will not lead to
issued patents; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">it is possible that there are prior public disclosures that could invalidate any patent we may own or license in the
future; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">issued patents that we may hold rights to in the future may not provide us with any competitive advantage, or may be held
invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our competitors or other third parties might conduct research and development activities in countries where we do not have
intellectual property rights and then use the information learned from such activities to develop competitive products for sale in our commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not develop technologies or therapeutic candidates that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the patents or pending or future patent applications of others, if issued, may harm our business; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may choose not to file a patent application in order to maintain certain trade secrets or
<FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent application covering such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our common stock and this offering </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>No public market
for our common stock currently exists, and an active and liquid trading market for our common stock may never develop. As a result, you may not be able to resell your shares of our common stock at or above the initial public offering price.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, no market for our common stock existed and an active trading market for our common stock may never develop or be sustained following
this offering. The initial public offering price for our common stock will be determined through negotiations with the underwriters and the negotiated price may not be indicative of the market price of our common stock after this offering. This
price will not necessarily reflect the price at which investors in the market will be willing to buy and sell shares of our common stock following this offering, and the market value of our common stock may decrease from the initial public offering
price. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the initial public offering price. The lack of an active market may impair your ability to sell your shares of common stock at the
time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares of common stock. Furthermore, an inactive market may also impair our ability to raise capital by
selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies or products by using our shares of common stock as consideration. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The market price of our common stock may be highly volatile, and you could lose all or part of your investment. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The market price of our common stock following this offering may be highly volatile and subject to wide fluctuations in response to various factors, some of which are
outside of our control. As a result of this volatility, you may not be able to sell your shares of common stock at or above the initial public offering price. The market price for our common stock may be influenced by many factors, including the
other risks described in this &#147;Risk factors&#148; section and the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">results of preclinical studies or clinical trials by us or those of our competitors or by existing or future partners;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and enrollment status of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the use and adequacy of our cash reserves; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in the development status of our therapeutic candidates, including variations in the level of expense related to
the development of our programs or funding support by us or by existing or future partners; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations
applicable to our business; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the success of competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">introductions and announcements of new therapeutic candidates by us, our existing or future collaboration partners, or our
competitors, and the timing of these introductions or announcements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">actions taken by regulatory agencies with respect to our therapeutic candidates, preclinical studies, clinical trials,
manufacturing process or sales and marketing terms; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the success of our efforts to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional technologies or
therapeutic candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive
under existing or future arrangements or the termination or modification of any such existing or future arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">announced or completed significant acquisitions, strategic collaborations, joint ventures, spin-outs or capital commitments
by us or our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments or disputes concerning our intellectual property and proprietary rights; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common
stock, other comparable companies or our industry generally; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our failure or the failure of our competitors to meet analysts&#146; projections or guidance that we or our competitors may
give to the market; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">speculation in the press or investment community; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">share price and fluctuations of trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">sales of shares of our common stock by us, insiders or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability or inability to raise additional capital and the terms on which we raise it; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the concentrated ownership of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in accounting principles; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">natural disasters, terrorist acts, acts of war and other calamities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">political instability, including the occurrence of a temporary federal government shutdown; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the impact of geopolitical tensions and ongoing regional military conflicts; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a severe or prolonged economic downturn; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">general economic and geopolitical conditions, including changing interest rates, disruptions in the capital and credit
markets, market volatility and inflation. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the stock market in general, and the markets for pharmaceutical, biopharmaceutical and
biotechnology stocks in particular, have experienced extreme price and volume fluctuations that have been often unrelated or disproportionate to the operating performance of the issuer. Furthermore, the trading price of our common stock may be
adversely affected by third parties trying to drive down the market price. Short sellers and others, some of whom post anonymously on social media, may be positioned to profit if our stock declines and their activities can negatively affect our
stock price. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including
those described in this &#147;Risk factors&#148; section, could have a dramatic and adverse impact on the market price of our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the past, securities
class action litigation has often been brought against public companies following declines in the market price of their securities. This risk is especially relevant for biopharmaceutical companies, which have experienced significant stock price
volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#146;s attention and our resources, which could harm our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>You will experience immediate and substantial dilution with respect to the common stock you purchase in this offering and may experience additional dilution in the
future. </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">You will experience immediate and substantial dilution with respect to the common stock you purchase in this offering. If you purchase common
stock in this offering, assuming an initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the estimated price range set forth on the cover of this prospectus, and assuming that the number of shares offered by us,
as set forth on the cover page of this prospectus, remains the same and that the underwriters do not exercise their option to purchase additional common stock in this offering, you will incur immediate and substantial dilution of
$&#8195;&#8195;&#8195;&#8195;per share, representing the difference between the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share and our pro forma net tangible book value per share as of June 30, 2024 after giving
effect to this offering, and the conversion of all outstanding shares of our redeemable convertible preferred stock and outstanding subordinated convertible promissory notes upon the completion of this offering. Following the completion of this
offering, investors purchasing common stock in this offering will have contributed &#8195;&#8195;&#8195;&#8195;% of the total amount invested by stockholders since inception, but will only own &#8195;&#8195;&#8195;&#8195;% of the shares of common
stock outstanding. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, we issued options in the past to acquire common stock at prices below the initial public offering price. As of June 30, 2024, there
were 35,335,588 shares of common stock subject to outstanding options. To the extent these outstanding options and options granted in the future are ultimately exercised, you will incur further dilution. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For a further description of the dilution you will experience immediately after this offering, see the section entitled &#147;Dilution.&#148; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on 23,369,733 shares of our capital stock outstanding as of June 30, 2024 and after giving effect to (i) the automatic conversion of all outstanding shares of our
redeemable convertible preferred stock into an aggregate of 203,415,024 shares of common stock immediately prior to the completion of this offering and (ii) the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
automatic conversion of all principal and accrued and unpaid interest on our outstanding convertible promissory notes into shares of our common stock immediately prior to the completion of this
offering, based upon an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus, upon completion of this offering, we will have a
total of &#8195;&#8195;&#8195;&#8195;shares of common stock outstanding. Of these shares, only &#8195;&#8195;&#8195;&#8195;shares of common stock sold in this offering, or &#8195;&#8195;&#8195;&#8195;shares if the underwriters exercise their option
to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered or will enter into <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters that restrict their ability to sell or transfer their shares. The <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements pertaining to this offering will expire
180&nbsp;days from the date of this prospectus. However, the representatives of the underwriters may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements to sell shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. After the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements expire, based
on shares outstanding as of June&nbsp;30, 2024, up to an additional &#8195;&#8195;&#8195;&#8195;shares of common stock will be eligible for sale in the public market, approximately &#8195;&#8195;&#8195;&#8195; of which are held by our officers,
directors and their affiliated entities, and will be subject to volume limitations under Rule&nbsp;144 under the Securities Act of 1933, as amended, or the Securities Act. In addition, &#8195;&#8195;&#8195;&#8195; shares of common stock that are
subject to outstanding options as of June&nbsp;30, 2024 will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and
Rules&nbsp;144 and 701 under the Securities Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After this offering, the holders of an aggregate of &#8195;&#8195;&#8195;&#8195;shares of our outstanding common
stock as of June&nbsp;30, 2024 will have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our
stockholders. We also intend to register shares of common stock that we may issue under our equity incentive plans. Once we register these shares, they will be able to be sold freely in the public market upon issuance, subject to the <FONT
STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above and in the section entitled &#147;Underwriting.&#148; See the
section titled &#147;Description of capital stock&#151; Registration rights&#148; for additional information. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot predict what effect, if any, sales of
our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of
our outstanding options, or the perception that such sales may occur, could adversely affect the market price of our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also expect that significant
additional capital may be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity-linked securities </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">in one or more transactions at prices and in a manner we determine from time to time. To the extent that additional capital is raised through the sale and issuance of
shares of our common stock or other securities convertible into shares of our common stock, our stockholders will be diluted. These sales, or the perception in the market that the holders of a large number of shares of our common stock intend to
sell shares, could reduce the market price of our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will have broad discretion in the use of the net proceeds from this offering and may not
use the proceeds in ways you and other stockholders may approve of. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our management will have broad discretion in the use of the net proceeds from this
offering, including for any of the purposes described in the section &#147;Use of proceeds,&#148; and you will be relying on the judgment of our management regarding the use of these proceeds. You will not have the opportunity, as part of your
investment decision, to assess whether we are using the proceeds appropriately. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment. If we do not invest or apply the net
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. Pending their use, we may
invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If securities or industry analysts do not publish
research or reports about our business, or if they issue an adverse or misleading opinion regarding our company, our common stock price and trading volume could decline. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not
currently have and may never obtain research coverage by securities and industry analysts. If no or few securities or industry analysts commence coverage of us, the trading price for our common stock could be impacted negatively. In the event we
obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our current or future clinical
trials, preclinical studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of such analysts cease coverage of us or fail to publish reports on us regularly, we could lose
visibility in the financial markets, which in turn could cause a decline in our stock price or trading volume. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our principal stockholders and management own a
significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on the beneficial
ownership of our common stock as of&#8195;&#8195;&#8195;&#8195; , prior to this offering, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned &#8195;&#8195;&#8195;&#8195;%
of our voting stock and, upon the completion of this offering, that same group will hold &#8195;&#8195;&#8195;&#8195;% of our outstanding voting stock (assuming no exercise of the underwriters&#146; option to purchase additional shares). The voting
power of this group may increase to the extent they convert shares of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock they hold into common stock. As a result, these stockholders, if acting together, will continue to have significant
influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger, consolidation or sale of all or substantially all of our assets and any other
significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change
of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our
common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act of 1934, as amended, or the Exchange Act. We
designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and
reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These inherent limitations include the realities that judgments in decision-making can be
faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related-party
transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. In addition, we do not have a risk management program or processes or
procedures for identifying and addressing risks to our business in other areas. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Anti-takeover provisions in our charter documents and under Delaware law could
prevent or delay an acquisition of us, which may be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our restated certificate of incorporation and our restated bylaws that will be in effect upon completion of this offering contain provisions that could delay or prevent
a change in control of our company. These provisions could also make it difficult for stockholders to elect directors who are not nominated by current members of our board of directors or take other corporate actions, including effecting changes in
our management. These provisions: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish a classified board of directors so that not all members of our board of directors are elected at one time;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">permit only the board of directors to establish the number of directors and fill vacancies on the board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">provide that directors may only be removed &#147;for cause&#148; and only with the approval of <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">authorize the issuance of &#147;blank check&#148; preferred stock that our board of directors could use to implement a
stockholder rights plan; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">eliminate the ability of our stockholders to call special meetings of stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our
stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">prohibit cumulative voting; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that
can be acted upon by stockholders at annual stockholder meetings. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, Section&nbsp;203 of the Delaware General Corporation Law, or DGCL,
may discourage, delay or prevent a change in control of our company. Section&nbsp;203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The exclusive forum provisions in our organizational documents may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable
for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our restated
certificate of incorporation that will be in effect upon completion of this offering, to the fullest extent permitted by law, will provide that the Court of Chancery of the State of Delaware is the exclusive forum for: any derivative action or
proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our restated certificate of incorporation, or our restated bylaws; or any action asserting a
claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act. It could apply, however, to a suit that falls within one
or more of the categories enumerated in the exclusive forum provision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it
finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated
certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created
by the Securities Act or the rules and regulations thereunder. Our restated bylaws will provide that the federal district courts of the United States will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint
asserting a cause of action arising under the Securities Act, or the Federal Forum Provision, including for all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision is intended to
benefit and may be enforced by us, directors, officers, other employees, agents, and the underwriters to any offering giving rise to such complaint, and any other professional person or entity whose profession gives authority to a statement made by
that person or entity and who has prepared or certified any part of the documents underlying the offering. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions
are facially valid under Delaware law. While federal or other state courts may not follow the holding of the Delaware Supreme Court or may determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal
Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court, and our stockholders cannot waive compliance with the
federal securities laws and the rules and regulations thereunder. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought
to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. In addition, neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability
created by the Exchange Act. Accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder must be brought in federal court, and our stockholders cannot waive compliance
with the federal securities laws and the rules and regulations thereunder. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any person or entity purchasing or otherwise acquiring or holding any interest in any of
our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum Provision. These provisions may limit a stockholders&#146; ability to bring a claim, and may result in increased costs for
a stockholder to bring such a claim, in a judicial forum of their choosing for disputes with us or our directors, officers, other employees or agents, which may discourage lawsuits against us and our directors, officers, other employees or agents.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source
of gain. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance
the growth and development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common stock will be your sole source of
gain for the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>General risk factors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance
initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a public company, and particularly after we are no longer an EGC or SRC, we will incur significant legal,
accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq
Stock Market, LLC, or Nasdaq, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance
practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to
make some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur
substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to
attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. The increased costs may require us to reduce costs in other areas of our business or increase the prices of our products once
commercialized. Moreover, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by
regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are an &#147;EGC&#148; and a &#147;SRC&#148; and we cannot be certain if the reduced reporting requirements applicable to EGCs or SRCs will make our common
stock less attractive to investors. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;EGC&#148; as defined in the JOBS Act. For as long as we continue to be an EGC, we may take advantage of
exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including (i)&nbsp;not being required to comply with the auditor attestation requirements of the Sarbanes-Oxley Act, (ii)&nbsp;reduced
disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements and (iii)&nbsp;exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and
stockholder approval of any golden parachute payments not approved previously. In addition, as an EGC, we are only required to provide two years of audited financial statements and two years of selected financial data in this prospectus. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We could be an EGC for up to five fiscal years following the completion of this offering; <I>provided</I>, <I>however</I>, certain circumstances could cause us to lose
that status earlier, including if we are deemed to be a &#147;large accelerated filer,&#148; which occurs when the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> equals or exceeds
$700&nbsp;million, if we have total annual gross revenue of $1.235&nbsp;billion or more, or if we issue more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during any three-year period before that time. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the JOBS Act, EGCs can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to
take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards. Until the date that we are no longer an
&#147;EGC&#148; or affirmatively and irrevocably opt out of the exemption provided by Section&nbsp;7(a)(2)(B) of the Securities Act, upon issuance of a new or revised accounting standard that applies to our financial statements and that has a
different effective date for public and private companies, we will disclose the date on which adoption is required for <FONT STYLE="white-space:nowrap">non-EGCs</FONT> and the date on which we will adopt the recently issued accounting standard. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are also a &#147;SRC.&#148; We may continue to be a SRC after this offering if either (i)&nbsp;the market value of
our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our
stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are a SRC at the time we cease to be an EGC, we may continue to rely on the same exemptions from certain disclosure requirements, including
not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation and the option to present only the two most recent fiscal years of
audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> We cannot predict if investors will find our common stock less attractive if we choose to rely on these exemptions. If some investors find our
common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be
subject to securities litigation, which is expensive and could divert management attention. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The market price of our common stock may be volatile. The stock
market in general, and Nasdaq-listed and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the
past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result
in substantial costs and divert our management&#146;s attention from other business concerns, which could seriously harm our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Unstable market and
economic conditions and adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or nonperformance by financial institutions or transactional counterparties, could adversely
affect our current and projected business operations, and its financial condition and results of operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, the global credit and
financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty
about economic stability. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, terrorism or other geopolitical events. Sanctions imposed by the United States and other
countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic
instability. Russia&#146;s ongoing incursion of Ukraine has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets.
In addition, adverse developments that affect financial institutions, such as events involving liquidity that are rumored or actual, have in the past and may in the future lead to market-wide liquidity problems. For example, in March 2023, Silicon
Valley Bank was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. The closure of any additional national or regional commercial banks could lead to
further economic instability. Although The Department of the Treasury, the Federal Reserve and the FDIC have taken steps to mitigate these risks, widespread demands for customer withdrawals or other liquidity needs of financial institutions for
immediately liquidity may still occur in the future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we have not experienced any adverse impact to our liquidity or to our current and projected business
operations, financial condition or results of operations, uncertainty remains over liquidity concerns in the broader financial services industry, and our business, our business partners, or industry as a whole may be adversely impacted in ways that
we cannot predict at this time. Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, if any of our suppliers or other parties with whom we conduct business are unable to access funds
pursuant to such instruments or lending arrangements with any financial institution, such parties&#146; ability to pay their obligations to us or to enter into new commercial arrangements requiring additional payments to us could be adversely
affected. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flows, financial
condition or results of operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">New income, sales, use or other tax laws, statutes, rules, or regulations could be enacted at any time, which may
adversely affect our business, financial condition, results of operations and prospects. Further, existing tax laws, statutes, rules, or regulations could be interpreted, changed, modified or applied adversely to us. Future changes in corporate tax
rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses could have a material impact on the value of our deferred tax assets, could result in significant <FONT
STYLE="white-space:nowrap">one-time</FONT> charges, and could increase our future U.S. tax expense. For example, for tax years beginning after December&nbsp;31, 2021, current law requires taxpayers to capitalize and amortize certain research and
development expenditures over five years if incurred in the United States and fifteen years if incurred in foreign jurisdictions, rather than deducting them concurrently. Although there have been legislative proposals to repeal or defer the
capitalization requirement to later years, there can be no assurance that the provision will be repealed or otherwise modified. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we fail to maintain proper
and effective internal controls over financial reporting, our ability to produce accurate and timely financial statements could be impaired. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to
Section&nbsp;404 of the Sarbanes-Oxley Act, our management will be required to report upon the effectiveness of our internal control over financial reporting beginning with the annual report for our fiscal year ending December&nbsp;31, 2025. When we
lose our status as an &#147;EGC&#148; or &#147;SRC&#148; and become an &#147;accelerated filer&#148; or a &#147;large accelerated filer,&#148; our independent registered public accounting firm will be required to attest to the effectiveness of our
internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing, and possible
remediation. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we
will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes
as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. This process will be time-consuming, costly and
complicated. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There may be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain
internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations, or cash flows. If we are unable to conclude that our internal control over financial reporting is
effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of
our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control
over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and
procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified
in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the
control system are met. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of
simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement, causing us to fail to make the required related-party transaction disclosures. Additionally, controls
can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or
fraud may occur and not be detected. In addition, we do not have a risk management program or processes or procedures for identifying and addressing risks to our business in other areas. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We, or the third parties upon whom we depend, may be adversely affected by earthquakes, fires, power shortages or other natural disasters our business continuity
and disaster recovery plans may not provide adequate protection or coverage. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our current operations are primarily located in the San Francisco Bay Area. Any
unplanned event, such as earthquake, flood, fire, explosion, extreme weather condition, epidemic, power shortage, telecommunication failure or other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> accident or incident that results in our
being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have
significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our therapeutic candidates or interruption of our business operations, and
have a material adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that
damaged critical infrastructure such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to
continue our business for a substantial period of time. Our disaster recovery and business continuity plans may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature
of our disaster recovery and business continuity plans, which could have a material adverse effect on our business, financial condition, results of operation and prospects. As part of our risk management policy, we maintain insurance coverage at
levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our
facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident, incident or for any other reason, even for a short period of time, any or all of our research and development
programs may be harmed. Any such business interruption could have a material and adverse effect on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_4"></A>Special note regarding forward-looking statements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus, including the sections entitled &#147;Prospectus summary,&#148; &#147;Risk factors,&#148; &#147;Use of proceeds,&#148; &#147;Management&#146;s
discussion and analysis of financial condition and results of operations,&#148; and &#147;Business,&#148; contains forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#147;believe,&#148;
&#147;may,&#148; &#147;will,&#148; &#147;potentially,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;could,&#148; &#147;would,&#148; &#147;project,&#148; &#147;plan,&#148; &#147;expect&#148; and
similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including
those described in &#147;Risk factors&#148; and elsewhere in this prospectus. Moreover, we operate in a competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks,
nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of
these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking
statements. The forward-looking statements in this prospectus include, among other things, statements about: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing of our preclinical studies and clinical trials for our therapeutic candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to develop and obtain regulatory approval for our therapeutic candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">estimates of our addressable market and market growth; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our expectations regarding demand for, and market acceptance of, our therapeutic candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to use our Compass platform to identify new therapeutic targets and advance such targets into clinical
development; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to maintain and expand access to human genetics data; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to compete effectively with existing competitors and new market entrants; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the potential effects of extensive government regulations relating to our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to obtain, maintain, protect and enforce intellectual property and proprietary rights; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property
rights and proprietary technology of third parties; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to establish and maintain collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to expand our pipeline of therapeutic candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to attract and retain key management and technical personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">general economic, industry and market conditions, including rising interest rates, inflation, uncertainty with respect to
the federal debt ceiling and budget and the related potential for government shutdowns, instability in the global banking system, volatile market conditions, supply chain delays, and the ongoing labor shortage; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the impact of natural disasters, terrorist activity, pandemics, regional conflicts around the world and the global
responses thereto and other events beyond our control on any of the above or any other aspect of our business operations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our expectations regarding expenses, future revenue, capital requirements, and our needs for additional financing; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our expected use of the net proceeds from this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The forward-looking statements made in this prospectus relate only to events or information as of the date on which the statements are made in this prospectus. You
should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity,
performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform
these statements to actual results or to changes in our expectations, except as required by law. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">You should read this prospectus and the documents that we reference
in this prospectus and have filed with the SEC as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be
materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Market and industry data </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus contains estimates and other statistical data made by independent parties and by us relating to our industry and the markets in which we operate,
including our general expectations and market position, market opportunity, the incidence of certain medical conditions and other industry data. These data, to the extent they contain estimates or projections, involve a number of assumptions and
limitations, and you are cautioned not to give undue weight to such estimates or projections. Industry publications and other reports we have obtained from independent parties generally state that the data contained in these publications or other
reports have been obtained in good faith or from sources considered to be reliable, but they do not guarantee the accuracy or completeness of such data. The industry in which we operate is subject to risks and uncertainties due to a variety of
factors, including those described in the section entitled &#147;Risk factors.&#148; These and other factors could cause results to differ materially from those expressed in these publications and reports. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_5"></A>Use of proceeds </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that the net proceeds from this offering will be approximately $&#8195;&#8195;&#8195;&#8195;million, or approximately $&#8195;&#8195;&#8195;&#8195;million if
the underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the estimated price range set forth on the cover of this
prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each $1.00 increase (decrease) in
the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus, would increase (decrease) the net proceeds to us from this offering by
$&#8195;&#8195;&#8195;&#8195;million, assuming the number of shares of our common stock offered, as set forth on the cover of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions. Similarly,
each increase (decrease) of 1.0&nbsp;million shares in the number of shares of our common stock offered would increase (decrease) the net proceeds that we receive from this offering by $&#8195;&#8195;&#8195;&#8195;million, assuming that the assumed
initial public offering price remains the same and after deducting the estimated underwriting discounts and commissions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We currently intend to use the net proceeds
we receive from this offering, together with our existing cash and cash equivalents, as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195; to $&#8195;&#8195;&#8195;&#8195; million to fund the clinical development of
MZE829 through &#8195;&#8195;&#8195;&#8195;; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195; to $&#8195;&#8195;&#8195;&#8195; million to fund the clinical development of
MZE782 through &#8195;&#8195;&#8195;&#8195;; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195; to $&#8195;&#8195;&#8195;&#8195; million to fund the further development of
additional common disease programs in CVRM indications, including preclinical studies, IND enabling studies and initiation of clinical trials, as well as further development of our Compass platform; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the remainder for working capital and other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on our planned use of the net proceeds from this offering, we estimate such funds, together with our existing cash and cash equivalents, will be sufficient for us
to fund our operating expenses and capital expenditure requirements through&#8195;&#8195;&#8195;&#8195;. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. The amounts we actually
expend in these areas, and the timing thereof, may vary significantly from our current intentions and will depend on a number of factors, including the success of research and development efforts, the results and timing of any future preclinical
studies and clinical trials, the product approval process with the FDA and other regulatory agencies, any new collaborations or licenses we may enter into, cash generated from future operations and actual expenses to operate our business. We may
also use a portion of the net proceeds of this offering to acquire or invest in complementary businesses, products, or technologies, or to obtain the right to use such complementary technologies. We have no commitments with respect to any
acquisition or investment, and we are not currently involved in any negotiations with respect to any such transaction. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a result, we cannot predict with any
certainty all of the particular uses for the net proceeds or the amounts that we will actually spend on the uses set forth above. Accordingly, our management will have broad discretion in the application of the net proceeds, and investors will be
relying on the judgment of our management regarding the application of the net proceeds of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The expected net proceeds of this offering will not be sufficient for us to fund any of our therapeutic candidates
through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our therapeutic candidates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pending the uses described above, we intend to invest the net proceeds from this offering in short-term, investment-grade interest-bearing securities such as money
market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_6"></A>Dividend policy </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation of
our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial
condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. In addition, the terms of the Loan Agreement place restrictions on our ability to pay cash dividends on
our capital stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_7"></A>Capitalization </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth our cash and cash equivalents and capitalization as of June 30, 2024: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on a pro forma basis, giving effect to (i)&nbsp;the automatic conversion of all outstanding shares of our redeemable
convertible preferred stock into an aggregate of 203,415,024 shares of our common stock immediately prior to the completion of this offering and the related reclassification of the carrying value of the redeemable convertible preferred stock to
permanent equity immediately prior to the completion of this offering, (ii)&nbsp;the automatic conversion of all principal and accrued and unpaid interest on our outstanding convertible promissory notes into &#8195;&#8195;&#8195;&#8195;shares of our
common stock immediately prior to the completion of this offering, based upon an assumed initial public offering price of $&#8195;&#8195; per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus, and
(iii)&nbsp;the filing and effectiveness of our restated certificate of incorporation in connection with the completion of this offering; and </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on a pro forma as adjusted basis giving further effect to (i)&nbsp;the pro forma adjustments described above, and
(ii)&nbsp;the sale of&#8195;&#8195;&#8195;&#8195; shares of our common stock in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share, the midpoint of the estimated price range set forth on the cover of
this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The pro forma
as adjusted information set forth below is illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">You should read this table together with the section entitled &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; and
our financial statements and related notes, each included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;forma&nbsp;(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;forma<BR>as&nbsp;adjusted&nbsp;(2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred stock, par value $0.001 per share; 203,415,024 shares authorized, issued
and outstanding, actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preferred stock, par value $0.001 per share; no shares authorized, issued and outstanding, actual;
&#8195;&#8195;&#8195;&#8195;shares authorized, no shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock, par value $0.001 per share; 268,150,000 shares authorized, 23,369,733 shares issued and
outstanding, actual;&#8195;&#8195;&#8195;&#8195;&nbsp;shares authorized, &#8195;&#8195;&#8195;&#8195; shares issued and outstanding, pro forma; &#8195;&#8195;&#8195;&#8195;shares authorized,&#8195;&#8195;&#8195;&#8195;&nbsp;shares issued and
outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(289,124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(262,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">170,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the
midpoint of the estimated price range set forth on the cover of this prospectus, would increase (decrease) each of our pro forma as adjusted cash and cash equivalents, additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital,</FONT></FONT> total stockholders&#146; equity (deficit) and total capitalization by approximately $&#8195;&#8195;&#8195;&#8195;million, assuming that the number of
shares of our common stock offered remains the same and after deducting the estimated underwriting discounts and commissions. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares of our common stock offered would
increase (decrease) each of our pro forma as adjusted cash and cash equivalents, additional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital,</FONT></FONT> total stockholders&#146; equity (deficit) and total
capitalization by approximately $&#8195;&#8195;&#8195;&#8195;million, assuming the assumed initial public offering price remains the same and after deducting the estimated underwriting discounts and commissions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the underwriters exercise their option to purchase additional shares of our common stock in full, our pro forma as adjusted cash and cash equivalents, additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity (deficit) and total capitalization would increase by approximately $&#8195;&#8195;&#8195;&#8195;million. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of our common stock issued and outstanding, pro forma and pro forma as adjusted in the table above includes&#8195;&#8195;&#8195;&#8195;unvested restricted
shares subject to repurchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The table above excludes the following shares: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">35,335,588 shares of our common stock issuable upon the exercise of options to purchase shares of our common stock
outstanding as of June 30, 2024 under our 2019 Plan, with a weighted-average exercise price of $1.50 per share; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our common stock issuable upon the exercise of options to purchase shares of our
common stock granted after June 30, 2024 under our 2019 Plan, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share; and </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our common stock reserved for future issuance under our equity compensation plans,
consisting of: </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our common stock reserved for future issuance under our 2019 Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our common stock to be reserved for future issuance under our 2024 Plan, which will
become effective immediately prior to the date of the effectiveness of the registration statement of which this prospectus forms a part; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock to be reserved for future issuance under our ESPP, which will become
effective on the date of the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our 2024 Plan and our ESPP provide
for automatic annual increases in the number of shares of our common stock reserved thereunder, and our 2024 Plan provides for increases to the number of shares that may be granted thereunder based on shares under our 2019 Plan or 2018 Plan that
expire, are tendered to or withheld by us for payment of an exercise price or for satisfying tax withholding obligations or are forfeited or otherwise repurchased by us. See the section entitled &#147;Executive compensation&#151;Equity compensation
plans and other benefit plans&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_8"></A>Dilution </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public
offering price per share of our common stock in this offering and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net tangible book deficit per share is determined by dividing our total tangible assets (which excludes deferred offering costs) less our total liabilities and
redeemable convertible preferred stock by the number of shares of our common stock outstanding. Our historical net tangible book deficit as of June&nbsp;30, 2024 was $263.8&nbsp;million, or $11.29 per share, based on 23,369,733 shares of our common
stock outstanding as of that date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our pro forma net tangible book value as of June 30, 2024 was $&#8195;&#8195;&#8195;&#8195; million, or
$&#8195;&#8195;&#8195;&#8195; per share of our common stock. Our pro forma net tangible book value per share represents the amount of our total tangible assets (which excludes deferred offering costs) less our total liabilities and divided by the
total number of shares of our common stock outstanding as of June 30, 2024, after giving effect to&nbsp;(i) the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of 203,415,024 shares of
common stock immediately prior to the completion of this offering and (ii)&nbsp;the automatic conversion of all principal and accrued and unpaid interest on our outstanding convertible promissory notes into &#8195;&#8195;&#8195; shares of our common
stock immediately prior to the completion of this offering, based upon an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net tangible book value dilution per share to new investors in this offering represents the difference between the initial public offering price per shares of our
common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after completion of this offering. After giving effect to (i)&nbsp;the pro forma adjustments set forth above and (ii)&nbsp;our sale in this
offering of&#8195;&#8195;&#8195;&#8195;shares of our common stock at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus,
and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June 30, 2024 would have been approximately
$&#8195;&#8195;&#8195;&#8195;million, or $&#8195;&#8195;&#8195;&#8195;per share of our common stock. This represents an immediate increase in pro forma net tangible book value of $&#8195;&#8195;&#8195;&#8195;per share to our existing stockholders
and an immediate dilution of $&#8195;&#8195;&#8195;&#8195;per share to investors in this offering, as illustrated in the following table: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Assumed initial public offering price, per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Historical net tangible book deficit per share as of June 30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11.29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase attributable to pro forma adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma net tangible book value per share as of June 30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase in pro forma net tangible book value per share attributable to new investors in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the
midpoint of the estimated price range set forth on the cover of this prospectus, would increase (decrease) our pro forma as adjusted net tangible book value by $&#8195;&#8195;&#8195;&#8195;million, or $&#8195;&#8195;&#8195;&#8195;per share and the
dilution in pro forma as adjusted net tangible book value per share to new investors in this offering by $&#8195;&#8195;&#8195;&#8195;per share, assuming the number of shares offered, as set forth on the cover of this prospectus, remains the same,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and after deducting estimated underwriting discounts and commissions. Similarly, each increase of 1.0&nbsp;million shares in the number of shares of our common stock offered in this offering
would increase our pro forma as adjusted net tangible book value by approximately $&#8195;&#8195;&#8195;&#8195;million, or approximately $&#8195;&#8195;&#8195;&#8195;per share, and would decrease dilution per share to new investors in this offering
by approximately $&#8195;&#8195;&#8195;&#8195;per share and each decrease of 1.0&nbsp;million shares in the number of shares of our common stock offered in this offering would decrease our pro forma as adjusted net tangible book value by
approximately $&#8195;&#8195;&#8195;&#8195;million, or approximately $&#8195;&#8195;&#8195;&#8195;per share, and would increase dilution per share to new investors in this offering by approximately $&#8195;&#8195;&#8195;&#8195;per share, assuming
the assumed initial public offering price per share remains the same and after deducting the estimated underwriting discounts and commissions. The pro forma as adjusted information is illustrative only, and we will adjust this information based on
the actual initial public offering price and other terms of this offering determined at pricing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the underwriters exercise their option in full to purchase
additional shares of our common stock, the pro forma as adjusted net tangible book value per share after this offering would be $&#8195;&#8195;&#8195;&#8195; per share, the increase in pro forma as adjusted net tangible book value per share to
existing stockholders would be $&#8195;&#8195;&#8195;&#8195; per share and the dilution to new investors in this offering would be $&#8195;&#8195;&#8195;&#8195; per share. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table shows, as of June 30, 2024, on a pro forma as adjusted basis described above, the differences between the existing stockholders and the new investors
purchasing shares in this offering with respect to the number of shares purchased from us, the total consideration paid, which includes net proceeds received from the issuance of common and redeemable convertible preferred stock, cash received from
the exercise of stock options, and the value of any stock issued for services and the average price paid per share (in thousands, except share and per share data, and percentages): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Shares purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Total consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Weighted-<BR>average<BR>price<BR>per share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="20" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the
midpoint of the estimated price range set forth on the cover of this prospectus, would increase (decrease) total consideration paid by new investors and total consideration paid by all stockholders by approximately
$&#8195;&#8195;&#8195;&#8195;million, assuming that the number of shares offered, as set forth on the cover of this prospectus, remains the same. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares of our common
stock offered in this offering would increase (decrease) total consideration paid by new investors and total consideration paid by all stockholders by approximately $&#8195;&#8195;&#8195;&#8195;million, assuming the assumed initial public offering
price remains the same. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, to the extent that any outstanding options are exercised, investors in this offering will experience further dilution. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Except as otherwise indicated, the above discussion and tables assume no exercise of the underwriters&#146; option to purchase additional shares of our common stock. If
the underwriters exercise their option to purchase additional shares of our common stock in full, our existing stockholders would own&#8195;&#8195;&#8195;&#8195;% and our new investors would own&#8195;&#8195;&#8195;&#8195;% of the total number of
shares of our common stock outstanding upon the completion of this offering. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of our common stock that will be outstanding after this
offering is based on &#8195;&#8195;&#8195;&#8195; shares of our common stock after giving effect to the conversion of our redeemable convertible preferred stock and the conversion of our convertible promissory notes as of June 30, 2024, and excludes
the following: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">35,335,588 shares of our common stock issuable upon the exercise of options to purchase shares of our common stock
outstanding as of June 30, 2024 under our 2019 Plan, with a weighted-average exercise price of $1.50 per share; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our common stock issuable upon the exercise of options to purchase shares of our
common stock granted after June 30, 2024 under our 2019 Plan, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share; </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our common stock reserved for future issuance under our equity compensation plans,
consisting of: </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our common stock reserved for future issuance under our 2019 Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of our common stock to be reserved for future issuance under our 2024 Plan, which will
become effective immediately prior to the date of the effectiveness of the registration statement of which this prospectus forms a part; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock to be reserved for future issuance under our ESPP, which will become
effective on the date of the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our 2024 Plan and ESPP provide for
automatic annual increases in the number of shares of our common stock reserved thereunder, and our 2024 Plan provides for increases to the number of shares that may be granted thereunder based on shares under our 2019 Plan or 2018 Plan that expire,
are tendered to or withheld by us for payment of an exercise price or for satisfying tax withholding obligations or are forfeited or otherwise repurchased by us. See the section entitled &#147;Executive compensation&#151;Equity compensation plans
and other benefit plans&#148; for additional information. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent that these outstanding stock options are exercised, new stock options are issued or we issue
additional shares of our common stock in the future, there will be further dilution to new investors. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have
sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_9"></A>Management&#146;s discussion and analysis of financial condition and results of
operations </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements
and related notes included elsewhere in this prospectus. This discussion contains forward-looking statements based upon our current plans and expectations that involve risks, uncertainties and assumptions, including those described in the section
entitled &#147;Special note regarding forward-looking statements.&#148; Our actual results and the timing of selected events could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to
such differences include, but are not limited to, those identified below and those set forth under the section entitled &#147;Risk factors.&#148; </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients
living with common diseases, with a focus on CVRM diseases, including obesity.&nbsp;We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the
biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.&nbsp;Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through
clinical trial design.&nbsp;We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for CKD. Our goal is to bring novel precision medicines to patients with
common diseases, which is where we believe we can maximize our impact on human health. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have focused substantially all of our efforts and
financial resources on research and development activities for our programs and on establishing arrangements and collaborations with third parties for the development of our therapeutic candidates. To date, we have not generated any revenue from
product sales and we do not expect to generate any revenue from commercial sales for the foreseeable future. Except for the <FONT STYLE="white-space:nowrap">one-time,</FONT> nonrefundable upfront payments we received pursuant to the license
agreements we entered into with several biotechnology companies in 2024, including the exclusive license agreement with Shionogi&nbsp;&amp; Company, Ltd., or Shionogi, we expect to continue incurring significant operating losses for the foreseeable
future due to the cost of research and development, clinical trials, preclinical studies and the regulatory approval process for our therapeutic candidates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other than the net income of $106.6 million we recorded for the six months ended June&nbsp;30, 2024 as a result of license revenue recognized under our license
agreements, we have incurred significant net losses and negative cash flows from operations since our inception. During the years ended December&nbsp;31, 2022 and 2023, we incurred net losses of $114.9&nbsp;million and $100.4&nbsp;million,
respectively, and during the six months ended June 30, 2023, we incurred a net loss of $49.1&nbsp;million. As of June&nbsp;30, 2024, we had an accumulated deficit of $289.1&nbsp;million and do not expect positive cash flows from operations in the
foreseeable future. We expect to continue incurring significant expenses and increasing losses for the foreseeable future. Our net losses may fluctuate significantly from period to period, depending on the timing of and expenditures on our planned
research and development activities, as well as upon revenue from our license agreements. We expect our research and development expenses to significantly increase in connection with the conduct of planned clinical trials for our lead programs,
MZE829 and MZE782, further development of our Compass platform, planned preclinical studies, and potential INDs and clinical trials for future therapeutic candidates. We will also incur substantial additional expenses as we seek to expand our
intellectual property portfolio, including through potential <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities, and hire additional personnel as we scale up our operations. Once we are a public company, we will incur additional
costs associated with operating as a public company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June 30, 2024, we had cash and cash equivalents of $175.1 million. Since our inception, we have financed our
operations primarily through issuances of redeemable convertible preferred stock, license agreements with biotechnology companies and issuances of convertible promissory notes. During the six months ended June 30, 2024, we received <FONT
STYLE="white-space:nowrap">one-time,</FONT> nonrefundable upfront payments of $167.5&nbsp;million in the aggregate from our three license agreements, including our exclusive license agreement with Shionogi. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will require substantial additional capital to develop our therapeutic candidates and fund operations for the foreseeable future. Until such time as we can generate
sufficient revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings, debt financings, collaborations and licensing arrangements. We are party to a loan and security
agreement that provides us with a line of credit of up to $50.0&nbsp;million. To date, we have not drawn down any funds from this debt facility and do not currently intend to do so. Adequate additional financing may not be available to us on
favorable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. If we are unable to raise
capital when needed or on favorable terms, we could be forced to delay, reduce or eliminate our clinical and preclinical development, research and development programs, our commercialization plans or other operations. The amount and timing of our
future funding requirements will depend on many factors including the pace and results of our development efforts. We cannot assure you that we will ever be profitable or generate positive cash flows from operating activities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We selectively pursue strategic collaborations related to the development of certain targets, therapeutic programs, or disease areas where we believe third-party
expertise or resources could be beneficial. In 2021 we formed a <FONT STYLE="white-space:nowrap">spin-out</FONT> company, Broadwing, with Alloy to develop therapeutic antibody therapies for ANGPTL7 and another undisclosed target in ophthalmic
disease, informed by our Compass platform. As of June 30, 2024, we owned approximately 48% of the outstanding equity of Broadwing. We retain certain <FONT STYLE="white-space:nowrap">opt-in</FONT> rights to jointly develop and commercialize certain
therapeutic candidates developed through Broadwing with Alloy. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Exclusive license agreement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Exclusive license agreement with Shionogi </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2024, we entered into an
exclusive license agreement, or the License Agreement, with Shionogi, pursuant to which we granted Shionogi an exclusive, worldwide, sublicensable license to research, develop, manufacture and commercialize MZE001 and certain other small molecule
compounds modulating glycogen synthase 1, or the Licensed Products. As consideration for the licensed rights and the transfer of <FONT STYLE="white-space:nowrap">know-how</FONT> and materials, we received an upfront payment of $150&nbsp;million,
which is the only payment we have received under the License Agreement to date. The License Agreement also requires that Shionogi pay us up to $275&nbsp;million in the aggregate in milestone payments upon the completion of certain clinical and
regulatory milestones and up to $330&nbsp;million in the aggregate in milestone payments if certain sales milestones are achieved. The License Agreement also requires that Shionogi pay us tiered royalties ranging from percentages in the low
double-digits to high teens on net sales of Licensed Products, subject to certain deductions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The License Agreement will expire on a Licensed-Product by
Licensed-Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the expiration of the royalty term for such Licensed Product, which will be the latest of the date when there are no
remaining valid claims covering the applicable Licensed Product, the expiration of regulatory exclusivity for the applicable Licensed Product, or 11 years after the first commercial sale of the applicable Licensed Product, subject to earlier
termination by the parties. As of June 30, 2024, we estimate that the last patent right for the only currently issued patent licensed under the License Agreement will expire in 2042, without giving effect to any potential patent term extensions,
patent term adjustments<B>, </B>or future patents that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
may or may not issue with respect to the Licensed Products. Upon expiration of the License Agreement, the licenses granted to Shionogi will become fully
<FONT STYLE="white-space:nowrap">paid-up,</FONT> perpetual, irrevocable and royalty-free. Shionogi may terminate the License Agreement for convenience following a notice period and either party may terminate the License Agreement for bankruptcy or
an uncured material breach. Upon termination of the License Agreement by Shionogi for convenience or by us for Shionogi&#146;s bankruptcy or uncured material breach, Shionogi will grant us a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
worldwide license under certain patent rights and <FONT STYLE="white-space:nowrap">know-how</FONT> controlled by Shionogi as of the effective date of termination, solely as necessary to research, develop, manufacture and commercialize the Licensed
Products in any field, and Shionogi will assign to us all regulatory materials and regulatory approvals relating to the Licensed Products. In consideration for these reversion rights, we would be required to pay to Shionogi reversion royalties on
any sales of the Licensed Products determined based on the stage of clinical development of the applicable Licensed Product at the time of termination, ranging from percentages in the low-to-mid single digits if termination occurs on or after the
achievement of certain Phase 2 clinical trial milestones and high single digit to mid-teens if termination occurs on or after the achievement of certain Phase&nbsp;3 clinical milestones. Our obligation to pay these reversion royalties would expire
on a Licensed-Product by Licensed-Product and country-by-country basis upon the latest of the date when there are no remaining valid claims covering the applicable Licensed Product, the expiration of regulatory exclusivity for the applicable
Licensed Product, or ten years after the first commercial sale of the applicable Licensed Product. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Components of results of operations </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B></B><I>License revenue</I><B> </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recognize revenue from the various license
agreements we have entered as the identified performance obligations under these arrangements are satisfied. We are also eligible to receive future non-refundable, non-creditable milestone payments upon the achievement of certain development,
regulatory, and commercial milestones. Additionally, we are also eligible to receive certain royalties on net sales of products developed under the license agreements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Operating expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our operating expenses since inception have
consisted solely of research and development expenses and general and administrative expenses. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our research and development expenses consist primarily of external and internal expenses incurred in connection with our research activities and preclinical and
clinical development programs. These expenses include, but are not limited to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">salaries, benefits and other employee-related costs, including stock-based compensation expense, for personnel engaged in
research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">fees paid to vendors that conduct certain research and development activities on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">fees paid to CMOs in connection with the production of research products and clinical trial materials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">fees paid to CROs in connection with clinical trials as well as preclinical and toxicology studies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other expenses associated with laboratory supplies and other materials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">professional service fees for consulting and related services; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">facility costs, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of
facilities and other supplies. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recognize research and development expenses as they are incurred. Nonrefundable advance payments for goods or
services that will be used or rendered for future research and development activities are capitalized and expensed as the goods are delivered or the related services are performed. We have not historically broken out our direct costs between our
clinical programs and our preclinical programs. Additionally, our internal costs, employees and infrastructure are not directly tied to any one program and are deployed across multiple programs. As such, we do not track indirect costs on a specific
program basis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the
development of, and obtain regulatory approval for, MZE829, MZE782 and any of our other potential therapeutic candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our research and development expenses may
vary significantly based on a variety of factors, such as: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and progress of clinical development activities for our therapeutic candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and progress of preclinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number and scope of preclinical and clinical programs we decide to pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to hire clinical, regulatory, manufacturing, quality assurance and scientific personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential additional trials requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs and fees associated with the discovery, acquisition or <FONT STYLE="white-space:nowrap">in-license</FONT> of our
products or technologies, including to maintain and expand our Compass platform; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to establish clinical manufacturing capabilities or secure adequate supply of product from third-party
manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we establish additional strategic collaborations or other arrangements; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the impact of any business interruptions to our operations or to those of the third parties with whom we work.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A change in the outcome of any of these and other variables with respect to the development of any of our therapeutic candidates could
significantly change the costs and timing associated with the development of such therapeutic candidate. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we continue to
identify and develop potential additional therapeutic candidates and as our existing therapeutic candidates, including MZE829 and MZE782, move into later stages of clinical development, which typically have higher development costs than those in
earlier stages of clinical development or preclinical development due to the increased size and duration of later-stage clinical trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The process of conducting
the necessary preclinical and clinical research and development to obtain regulatory approval is costly and time-consuming and the successful development of our therapeutic candidates is highly uncertain. The actual probability of success for our
therapeutic candidates may be affected by a variety of factors. We may never succeed in achieving regulatory approval for any of our therapeutic candidates. Further, a number of factors, including those outside of our control, could adversely impact
the timing and duration of our therapeutic candidates&#146; development, which could increase our research and development expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>General and administrative expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses consist primarily of personnel-related costs, including salaries, bonuses, benefits, and stock-based compensation expense, for
personnel in executive, finance, accounting, corporate development, and other administrative functions. General and administrative expenses also include legal fees, professional fees paid for accounting, auditing, consulting, tax, and investor
relations services, insurance costs, and facility costs not otherwise included in research and development expenses, and following this offering will include public company expenses such as costs associated with compliance with the rules and
regulations of the SEC and Nasdaq. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect that our general and administrative expenses will continue to increase significantly in the foreseeable future as
additional administrative personnel and services are required to manage these functions of a public company and as our pipeline of therapeutic candidates expands. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Interest and other income, net </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest and other income, net
consists of interest income earned on our cash and cash equivalents, interest expense, foreign currency <FONT STYLE="white-space:nowrap">re-measurement</FONT> and transaction gains and losses. We expect interest income to increase as a result of the
<FONT STYLE="white-space:nowrap">one-time,</FONT> nonrefundable upfront payments of $167.5&nbsp;million in the aggregate that we received pursuant to the license agreements we entered into with several biotechnology companies in 2024, including the
exclusive license agreement with Shionogi. However, interest income may vary each reporting period depending on our average cash deposits, money market fund balances, and other investment balances during the period and prevailing market interest
rates. We expect foreign currency gains and losses to vary each reporting period depending on the fluctuations in foreign currency exchange rates. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Change in
fair value of convertible promissory notes </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The convertible promissory notes issued from December 2023 through June 30, 2024 contain automatic conversion
features that are triggered upon a qualified preferred stock financing or a qualified public offering. We elected to apply the fair value option, as per Accounting Standards Codification, or ASC,
<FONT STYLE="white-space:nowrap">Section&nbsp;825-10,</FONT> to the outstanding convertible promissory notes issued. As such, the convertible promissory notes are recognized at fair value with changes in fair value recognized in the statements of
operations and comprehensive income (loss). The fair value of the convertible promissory notes was $20.1&nbsp;million as of December&nbsp;31, 2023. We recorded a loss of $3.8&nbsp;million, reflecting the change in the fair value of the convertible
promissory notes in the statements of operations and comprehensive loss for the year ended December&nbsp;31, 2023. The fair value of the convertible promissory notes was $49.1 million as of June 30, 2024. We recorded an additional loss of $4.5
million, reflecting the change in the fair value of the convertible promissory notes in the condensed statements of operations and comprehensive income (loss) for the six months ended June 30, 2024. The impact of interest expense on the convertible
promissory notes is included within the changes in fair value. We expect the changes in fair value to vary each reporting period while the convertible promissory notes are outstanding. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net loss on impairment and dissolution of equity method investment and share in net loss of equity method investments </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The net loss on impairment and dissolution of equity method investment relates to the dissolution in October 2022 of Contour Therapeutics LLC, or Contour, an entity in
which we had a 30% equity interest. We no longer record any carrying value or losses related to this investment because of its dissolution. Share in net loss of equity method investments consists of our proportionate share of the net earnings or
losses and other comprehensive income or loss of our equity method investees based on our ownership percentage of common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
stock, common stock equivalents or preferred stock during the respective reporting period. Because we have no obligation to provide cash financing or other financial support to our other equity
method investee, Broadwing, and the carrying value of that investment was reduced to zero in 2022, no additional losses were recorded in 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Results of
operations </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comparisons of the years ended December&nbsp;31, 2022 and 2023 </I></B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 73,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss on impairment and dissolution of equity method investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Share in net loss of equity method investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(114,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Research and development expenses </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research
and development expenses were $88.2&nbsp;million for the year ended December&nbsp;31, 2022 compared to $73.9&nbsp;million for the year ended December&nbsp;31, 2023. The decrease of $14.2&nbsp;million was primarily due to a decrease of
$17.7&nbsp;million in clinical trial, manufacturing and outside research and development services which were higher in fiscal year 2022 based on the progression of our preclinical programs and our Phase 1 clinical trial for MZE001 in healthy
volunteers that we completed in 2022. The decrease was partially offset by an increase of personnel-related costs of $2.8&nbsp;million, including higher <FONT STYLE="white-space:nowrap">non-cash</FONT> stock-based compensation expense of
$1.6&nbsp;million, based on an overall increase in headcount, as well as an increase in facilities, depreciation, and other expenses of $0.7&nbsp;million. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&#8195;&#8195;2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Clinical trial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,948</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Manufacturing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outside research and development services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Personnel-related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Facilities, depreciation, and other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>General and administrative expenses </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General
and administrative expenses were $22.8 million for the year ended December 31, 2022, compared to $24.6 million for the year ended December 31, 2023. The increase of $1.8 million was primarily due to higher
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
legal costs, including one-time costs associated with a regulatory review of a proposed out-license agreement in 2023, and an increase of $0.4 million in facilities and other costs, partially
offset by a decrease of $0.4 million in personnel-related costs. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Interest and other income, net </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest and other income, net was $2.0&nbsp;million for each of the years ended December&nbsp;31, 2022 and 2023, reflecting an immaterial change year over year. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Change in fair value of convertible promissory notes </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The convertible
promissory notes issued in December 2023 contain automatic conversion features that are triggered upon a qualified preferred stock financing or a qualified public offering. We elected to apply the fair value option to the convertible promissory
notes issued. As such, the convertible promissory notes are recorded at fair value at each reporting period with changes in fair value recognized in the statements of operations and comprehensive loss. For the year ended December&nbsp;31, 2023, the
change in fair value of the convertible promissory notes resulted in a loss of $3.8&nbsp;million. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Net loss on impairment and dissolution of equity method
investment </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2020, we and BridgeBio Pharma LLC, or BridgeBio, completed the formation of a joint venture entity, Contour, pursuant to which we and
BridgeBio received a 30% and 70% equity interest in Contour, respectively. In May 2022, we and BridgeBio entered into an agreement wherein BridgeBio was formally released from providing any further cash to Contour under its commitment to the joint
venture, and as a result, we were released from our commitment liability to provide <FONT STYLE="white-space:nowrap">in-kind</FONT> services to Contour. Accordingly, in June&nbsp;2022, we determined our investment in Contour was impaired and
recorded a loss on impairment of $5.4&nbsp;million. Contour was dissolved in October 2022. As we were released from our commitment liability to provide <FONT STYLE="white-space:nowrap">in-kind</FONT> services to Contour, we recorded a corresponding
gain of $3.0&nbsp;million for the year ended December&nbsp;31, 2022, resulting in an overall net loss on impairment and dissolution of our equity method investment in Contour of $2.4&nbsp;million. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Share in net loss of equity method investments&#8195; </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Share in net loss of
equity method investments was $3.5&nbsp;million for the year ended December&nbsp;31, 2022, which represents the proportionate share of the net losses of our equity method investees based on our percentage of common stock ownership during the
respective reporting period. Our share of Broadwing&#146;s losses exceeded the carrying amount of our equity investment during the year ended December&nbsp;31, 2022. Accordingly, no additional losses under the equity method were recorded in the year
ended December&nbsp;31, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comparison of the six months ended June 30, 2023 and 2024 </I></B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six months&nbsp;ended</B><br><B>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">License revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">(Loss) income from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">(Loss) income before income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income and comprehensive (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>License revenue </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recognized a
total of $165.0 million of license revenue for the six months ended June 30, 2024 related to the License Agreement with Shionogi, wherein we received an upfront payment of $150.0 million in exchange for the transfer of the license, know-how, and
materials related to the research, development, manufacture and commercialization of MZE001 and certain other small molecule compounds modulating glycogen synthase 1, and the exclusive license agreement with Trace Neuroscience, Inc., or Trace,
wherein we received an upfront payment of $15.0 million in exchange for the transfer of the license, know-how, and materials related to the research, development, manufacture and commercialization of a discovery research program targeting UNC13A for
the treatment of amyotrophic lateral sclerosis, or ALS. We recognized no license revenue for the six months ended June 30, 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Research and development
expenses </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses were $38.4 million for the six months ended June 30, 2023, compared to $41.4 million for the six months ended June
30, 2024. The increase of $3.0 million was primarily due to an increase of $3.5 million in clinical trial expenses and outside research and development services which were higher in fiscal year 2024 based on the progression of our Phase 1 clinical
trial for MZE829 that was initiated in December 2023 and preclinical studies for MZE782. The increase was partially offset by a decrease of personnel-related costs of $0.5 million. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six months&nbsp;ended</B><br><B>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Clinical trial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Manufacturing expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outside research and development services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Personnel-related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(504</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Facilities, depreciation, and other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>General and administrative expenses </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses were $11.8 million for the six months ended June 30, 2023, compared to $12.0 million for the six months ended June 30, 2024. The
increase of $0.2 million was the net result of higher personnel-related costs of $0.6 million, partially offset by lower legal costs of $0.4 million. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Interest
and other income, net </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest and other income, net was $1.2 million for the six months ended June 30, 2023, compared to $1.3&nbsp;million for the six months
ended June 30, 2024. The increase of $0.1 million primarily reflects an increase in interest income as a result of the upfront payments we received pursuant to the license agreements we entered into with several biotechnology companies in 2024 and
the corresponding higher cash and cash equivalent balances held during the six months ended June 30, 2024. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Change in fair value of convertible promissory notes
</I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The convertible promissory notes issued from December 2023 through April 2024 contain automatic conversion features that are triggered upon a qualified
preferred stock financing or a qualified public offering. We elected to apply the fair value option to the convertible promissory notes issued. As such, the convertible promissory notes are recorded at fair value at each reporting period with
changes in fair value recognized in the condensed statements of operations and comprehensive income (loss). For the six months ended June 30, 2024, the change in fair value of the convertible promissory notes resulted in a loss of $4.5 million. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Income tax expense </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Income tax expense was zero for the six months ended June
30, 2023, compared to $1.7 million for the six&nbsp;months ended June 30, 2024. The increase was due to the net income generated during the six months ended June 30, 2024, as a result of the recognition of license revenue under our license
agreements with Shionogi and Trace, as compared to the net loss incurred during the six months ended June 30, 2023. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Liquidity and capital resources
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Liquidity </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have not generated any
revenue from product sales and we do not expect to generate any revenue from commercial sales for the foreseeable future, if at all. We have incurred significant operating losses and negative cash flows from operations. We anticipate that we will
continue to incur net losses for the foreseeable future. To date, we have financed our operations primarily through private placements of redeemable convertible preferred stock, one-time, nonrefundable upfront payments made to us in connection with
our entry into license agreements and through private placements of convertible promissory notes. As of June 30, 2024, we had cash and cash equivalents of $175.1 million and an accumulated deficit of $289.1 million. Based on our current operating
plan, we believe that our existing cash and cash equivalents, together with the estimated net proceeds from this offering, will be sufficient to fund our operations for at least one year from the date of this prospectus. We have based this estimate
on our current assumptions, which may prove to be wrong, and we may exhaust our available capital resources sooner than we expect. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June 30, 2024, we had
convertible promissory notes with an aggregate principal amount of $40.7 million outstanding, and an aggregate amount of $1.4 million of interest was accrued and unpaid on the convertible promissory notes. The notes have a stated interest rate of 8%
on the principal amount and mature in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
December&nbsp;2026. Upon the closing of the offering to which this prospectus relates, the aggregate principal amount of the convertible promissory notes, together with accrued and unpaid
interest through the conversion date, will automatically convert into shares of common stock at a conversion price equal to 80% of the price per share paid by purchasers in this offering. The convertible promissory notes contain other conversion and
settlement provisions if an initial public offering does not occur before the maturity date. We do not intend to issue any additional convertible promissory notes. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I></I></B><B></B><B><I>Funding requirements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not expect to
generate any meaningful future revenue unless and until we obtain regulatory approval and commercialize any of our current or future therapeutic candidates, including MZE829 and MZE782, or receive additional potential revenue from the achievement of
milestones and royalties under our existing license agreements or potential additional partnerships, and we do not know when, or if at all, that will occur. We will continue to require additional capital to develop our therapeutic candidates and
fund operations for the foreseeable future. Our primary uses of cash are to fund our operations, which consist primarily of research and development expenses related to our programs, and to a lesser extent, general and administrative expenses. We
expect our expenses to continue to increase in connection with our ongoing activities as we continue to develop MZE829, MZE782 and our other discovery and preclinical programs, seek to broaden the pipeline of our product candidates and further
develop our Compass platform. In addition, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may seek to raise capital through private or public equity or debt financings, license and collaboration agreements or other arrangements, or through other sources of
financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business
strategies. We anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs associated with the type, scope, progress and results of research and discovery, preclinical development,
laboratory testing and clinical trials for our current or future therapeutic candidates, including MZE829 and MZE782; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we develop, <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other pipeline therapeutic
candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number and development requirements of other therapeutic candidates that we may pursue, and other indications for our
current therapeutic candidates that we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs related to entering into partnerships or other arrangements with third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs, timing and outcome of obtaining regulatory approvals of our current or future therapeutic candidates we may
pursue; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs and fees associated with the discovery, acquisition or <FONT STYLE="white-space:nowrap">in-license</FONT> of our
products or technologies, including to maintain and expand our Compass platform; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope and costs of making arrangements with third-party manufacturers for preclinical, clinical and commercial supplies
of our current or future therapeutic candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope and costs involved in growing our organization to the size needed to allow for the research, development and
potential commercialization of our current or future therapeutic candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the cost associated with commercializing any approved therapeutic candidates, including establishing sales, marketing and
distribution capabilities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the cost associated with completing any post-marketing studies or trials required by the FDA or other regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the revenue, if any, received from commercial sales of our current or future therapeutic candidates, if any are approved;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs associated with addressing any potential interruptions or delays resulting from factors related to overall global
affairs, such as conflicts overseas; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining, defending and enforcing our
intellectual property and proprietary rights and defending intellectual property-related claims that we may become subject to, including any litigation costs and the outcome of such litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs associated with potential product liability claims, including the costs associated with obtaining insurance
against such claims and with defending against such claims; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to establish and maintain collaboration arrangements on favorable terms, if at all and the timing and amount of
any milestone, royalty or other payments we are required to make or are eligible to receive under such collaborations, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we raise
additional funds by issuing equity securities, our stockholders will experience dilution. If we raise additional capital through debt financing, we may be subject to covenants that restrict our operations including limitations on our ability to
incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments, and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms
that are not favorable to us or our stockholders. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third
parties, we may have to relinquish valuable rights to our proprietary technology, future revenue streams, research programs or therapeutic candidates, including granting licenses to our proprietary technologies, on terms that may not be favorable to
us. If we are unable to raise additional funds through equity or debt financings or collaborations, strategic alliances or licensing arrangements with third parties when needed, we may be required to delay, limit, reduce and/or terminate our product
development programs or any future commercialization efforts or grant rights to develop and market therapeutic candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Contractual obligations and commitments </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have an operating lease
for a facility in South San Francisco, California with office and laboratory space, which serves as our corporate headquarters. The lease terminates in November 2030 and provides for one option to extend the lease term for an additional period of
eight years. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have entered into consortium agreements with the University of Helsinki and Queen Mary University to access genomic information from patient
samples and genetic and paired clinical data. As of June 30, 2024, we are obligated to pay $5.3 million under these agreements through the year ended December&nbsp;31, 2027. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We enter into contracts in the normal course of business with third-party contract organizations for preclinical trials,
<FONT STYLE="white-space:nowrap">non-clinical</FONT> trials and testing, and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Cash flows </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comparisons of the years ended December&nbsp;31, 2022 and 2023 </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
following table sets forth the primary sources and uses of cash, cash equivalents, and restricted cash for the periods presented below: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(99,203</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(86,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net decrease in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,645</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(70,883</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net cash used in operating activities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in operating activities was $99.2&nbsp;million and $86.8&nbsp;million for the years ended December&nbsp;31, 2022 and 2023, respectively. The net cash used
in operating activities for the year ended December&nbsp;31, 2022 was primarily due to our net loss of $114.9&nbsp;million, a net change in our operating assets and liabilities of $3.2&nbsp;million, offset by $19.0&nbsp;million in <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges such as depreciation, stock-based compensation, lease expense and losses related to our equity method investments. The net cash used in operating activities for the year ended December&nbsp;31, 2023
was primarily due to our net loss of $100.4&nbsp;million, a net change in our operating assets and liabilities of $6.3&nbsp;million, offset by $19.9&nbsp;million in <FONT STYLE="white-space:nowrap">non-cash</FONT> charges such as depreciation,
stock-based compensation, lease expense and the change in fair value of the convertible promissory notes. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net cash used in investing activities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Cash used in investing activities for the year ended December&nbsp;31, 2022 was $3.2&nbsp;million, which consisted of $2.0&nbsp;million used to purchase property and
equipment and $1.2&nbsp;million of contributions for our investments in equity method investees. Cash used in investing activities for the year ended December&nbsp;31, 2023 was $0.4&nbsp;million, which related to the purchase of property and
equipment. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net cash provided by financing activities </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the
year ended December&nbsp;31, 2022, net cash provided by financing activities was $1.7&nbsp;million, which consisted of proceeds from the issuance of our Series C Preferred Stock of $1.6&nbsp;million and $0.1&nbsp;million from the exercise of stock
option awards, net of repurchases. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the year ended December&nbsp;31, 2023, net cash provided by financing activities was $16.4&nbsp;million, which consisted of
net proceeds from the issuance of convertible promissory notes of $16.2&nbsp;million and $ 0.2&nbsp;million from the exercise of stock option awards, net of repurchases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comparison of the six months ended June 30, 2023 and 2024 </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth the primary sources and uses of cash, cash equivalents, and restricted cash for the periods presented below: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six months&nbsp;ended</B><br><B>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash (used in) provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">167,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (decrease) increase in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">145,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">192,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net cash (used in) provided by operating activities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in operating activities was $46.2 million for the six months ended June 30, 2023, compared to net cash provided by operating activities of $121.6 million
for the six months ended June 30, 2024. The net cash used in operating activities for the six months ended June 30, 2023 was primarily due to our net loss of $49.1&nbsp;million, a net change in our operating assets and liabilities of $5.0 million,
offset by $7.9 million in non-cash charges such as depreciation, stock-based compensation and lease expense. The net cash provided by operating activities for the six months ended June 30, 2024 was primarily due to our net income of $106.6 million,
a net change in our operating assets and liabilities of $2.7 million, combined with $12.4 million in non-cash charges such as depreciation, stock-based compensation, lease expense and the change in fair value of the convertible promissory notes.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net cash used in investing activities </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Cash used in investing
activities for the six months ended June 30, 2023 and 2024 was $0.4 million, which related to the purchase of property and equipment. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net cash provided by
financing activities </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the six months ended June 30, 2023, net cash provided by financing activities was $0.2 million, which consisted of proceeds from
the exercise of stock option awards, net of repurchases. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the six months ended June 30, 2024, net cash provided by financing activities was $24.7 million, which
consisted of net proceeds from the issuance of convertible promissory notes of $24.5 million and $0.4 million from the exercise of stock option awards, net of repurchases, partially offset by the payment of $0.2 million for deferred offering costs.
</P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Critical accounting policies, significant judgments and use of estimates </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us
to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements, as well as the reported expenses incurred during the
reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets
and liabilities that are not readily apparent from other sources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Actual results may differ from these estimates under different assumptions or conditions. We believe that the
accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#146;s judgments and estimates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While our significant accounting policies are described in more detail in the notes to our financial statements included elsewhere in this prospectus, we believe that
the following critical accounting policies are most important to the preparation of our financial statements and to understanding and evaluating our reported financial results. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>License revenue </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have entered into arrangements involving the license of
intellectual property rights for which we determine whether the arrangement is subject to accounting guidance in ASC 606, <I>Revenue from Contracts with Customers</I>, or ASC 606. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Analyzing an arrangement to identify performance obligations requires the use of judgment. In arrangements that include the license of intellectual property and other
promised goods or services, we first identify if the licenses are distinct from the other promises in the arrangement. If the license is not distinct, the license is combined with other promised goods or services into a single performance
obligation. Factors that are considered in evaluating whether a license is distinct from other promises include, for example, whether the counterparty can benefit from the license without the promised goods and service on its own or with other
readily available resources and whether the promised good or service is expected to significantly modify or customize the intellectual property. We then estimate the transaction price, which also requires the use of judgment when evaluating the
fixed consideration and any variable amounts, including milestone payments. For arrangements with certain milestone payments, we re-evaluate the probability of achievement of the related milestone each reporting period, and if necessary, adjust the
estimate of the overall transaction price. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the six months ended June 30, 2024, we have identified only single combined performance obligations for each
license arrangement that we have entered for which revenue is recognized at a point in time. We may enter into arrangements in the future that include the license of intellectual property and other promised goods or services that may result in
multiple performance obligations. In those circumstances, we may need to allocate the transaction price based on the relative standalone selling prices of each of the performance obligations, which will require significant judgment and the
determination of significant assumptions related to such estimates. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expense all research and development expenses as incurred. Research and development expenses include personnel costs related to research and development activities,
including salaries, benefits and stock-based compensation, costs related to research and preclinical studies, costs associated with the conduct of clinical trials, consulting fees, laboratory supplies, facility costs, and fees paid to other entities
that conduct certain research and development activities on our behalf. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are capitalized and expensed as the goods are
delivered or the related services are performed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate and accrue certain research and development expenses as part our process of preparing our financial
statements. This process involves: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">identifying services that have been performed on our behalf and estimating the level of service performed and the
associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">estimating and accruing expenses as of each balance sheet date based on facts and circumstances known to us at the time;
and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">periodically confirming the accuracy of our estimates with selected service providers and making adjustments, if necessary.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to
quotes and contracts with vendors that conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation and vary from contract to contract, which may result in uneven
payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the completion of
scientific milestones. In accruing expenses, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies
from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed
could vary from actuals and result in us reporting amounts that are too high or too low in any particular period. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the periods presented, we have experienced no
material changes in our estimates of accrued research and development expenses after a reporting period. However, due to the nature of estimates, there can be no assurance that we will not make changes to our estimates in the future as we become
aware of additional information about the status or conduct of our clinical studies and other research and development activities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock-based compensation
expense </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We account for stock-based compensation expense by measuring and recognizing compensation expense for all share-based awards made to employees and <FONT
STYLE="white-space:nowrap">non-employees</FONT> based on estimated grant date fair values. We use the straight-line method to allocate compensation cost to reporting periods over the requisite service period for service-based awards, which is
generally the vesting period. We recognize actual forfeitures by reducing the stock-based compensation expense in the same period as the forfeitures occur. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We use
the estimated fair value of our common stock to determine the fair value of restricted stock awards, or RSAs, on the date of grant. We estimate the fair value of service-based options to employees and
<FONT STYLE="white-space:nowrap">non-employees</FONT> using the Black-Scholes option-pricing valuation model, or Black-Scholes model. The <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> model requires the input of subjective assumptions,
including the fair value of common stock, expected term, expected volatility, risk-free interest rate, and expected dividend yield, which are described in greater detail below. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Estimating the fair value of service-based options as of the grant date using the Black-Scholes model is affected by assumptions regarding a number of complex variables.
Changes in the assumptions can materially affect the fair value of common stock and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop.
These inputs are as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Fair value of common stock</I>&#151;Historically, as there has been no public market for our common stock, the fair
value of our common stock was determined by our board of directors based in part on valuations of our common stock prepared by a third-party valuation specialist. See the subsection entitled &#147;Common stock valuations&#148; below.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Expected term</I>&#151;The expected term represents the period that our stock option grants are expected to be
outstanding and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term). We have very limited historical information to develop
reasonable expectations about future exercise patterns and post-vesting employment termination behavior for our stock option grants. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Expected volatility</I>&#151;Since we are a privately-held company and do not have any trading history for our common
stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based
on their similar size, life cycle stage, or area of specialty. We will continue to apply this process until enough historical information regarding the volatility of our own stock price becomes available. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Risk-free interest rate</I>&#151;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect
at the time of grant for periods corresponding with the expected term of the stock options. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Expected dividend</I> <I>yield</I>&#151;We have never paid dividends on our common stock and have no plans to pay
dividends on our common stock. Therefore, we used an expected dividend yield of zero. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For stock options granted to
<FONT STYLE="white-space:nowrap">non-employee</FONT> consultants, the fair value of these stock options is also measured using the Black-Scholes model reflecting the same assumptions as applied to employee stock options in each of the reported
periods, other than the expected term which is assumed to be the remaining contractual life of the stock option. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate the fair value of awards that contain
market-based conditions using a Monte-Carlo option pricing model at the date of grant using similar input assumptions as the Black-Scholes model while incorporating Level&nbsp;3 inputs related to probability estimates of the market conditions being
satisfied. Compensation expense related to awards with a market-based condition is recognized regardless of whether the market condition is ultimately satisfied, and compensation expense is not reversed if the achievement of the market condition
does not occur. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will continue to use judgment in evaluating the expected volatility, expected terms, and interest rates utilized for our stock-based compensation
expense calculations on a prospective basis. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Stock-based compensation expense for employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> is
reflected in the statements of operations and comprehensive income (loss) as follows: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended</B><br><B>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2023 and June 30, 2024, there was $16.4&nbsp;million and $17.5&nbsp;million, respectively, of total
unrecognized compensation cost related to unvested options and RSAs for which the cost was expected to be recognized over a weighted-average period of 2.52 years and 2.56 years, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Common stock valuations </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The grant date fair value of our common stock has been determined by our board of directors with the assistance of management and an independent third-party valuation
specialist. The grant date fair value of our common stock was determined using valuation methodologies which utilizes certain assumptions including probability weighting of events, volatility, time to liquidation, a risk-free interest rate, and an
assumption for a discount for lack of marketability (Level 3 inputs). In determining the fair value of our common stock, the methodologies used to estimate our enterprise value were performed using methodologies, approaches, and assumptions
consistent with the American Institute of Certified Public Accountants&nbsp;Practice Aid,<I></I><I>&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>, or the&nbsp;Practice Aid. The methodology to determine the
fair value of our common stock included estimating the fair value of the enterprise using a market approach, which estimates the fair value of a company by including an estimation of the value of the business based on guideline public companies
under a number of different scenarios. The assumptions used to determine the estimated fair value of our common stock are based on numerous objective and subjective factors, combined with management judgment, including external market conditions
affecting the pharmaceutical and biotechnology industry and trends within the industry; our stage of development; the rights, preferences and privileges of our redeemable convertible preferred stock relative to those of our common stock; the prices
at which we sold shares of our redeemable convertible preferred stock; our financial condition and operating results, including our levels of available capital resources; the progress of our research and development efforts and business strategy;
equity market conditions affecting comparable public companies; general U.S. market conditions; and the lack of marketability of our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Practice Aid
identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date. In accordance with the Practice Aid, we considered the
following methods: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Option Pricing Method. Under the Option Pricing Method, or OPM, shares are valued by creating a series of call options with
exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the preferred and common stock are inferred by analyzing these options. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Hybrid Method. The hybrid method is a Probability-Weighted Expected Return Method, or PWERM, where the equity value in one
of the scenarios is calculated using the OPM. The PWERM is a scenario-based analysis that estimates value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes
available to us, as well as the economic and control rights of each share class. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on our early stage of development and other relevant
factors, we determined that an OPM was the most appropriate method for allocating our enterprise value to determine the estimated fair value of our common stock for valuations prior to the fourth quarter of 2020. After this date, we used the hybrid
method to determine the estimated fair value of our common stock. The hybrid method is appropriate for a company expecting a near-term liquidity event. In determining the estimated fair value of our common stock, we considered the fact that our
stockholders could not freely trade our common stock in the public markets. Accordingly, we applied discounts to reflect the lack of marketability of our common stock based on the weighted-average expected time to liquidity. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Application of these approaches involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding our expected
future revenue, expenses, and cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of future events. Changes in any or all of these estimates and assumptions, or the relationships between those
assumptions, impact our valuations as of each valuation date and may have a material impact on the valuation of common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
stock. The assumptions underlying these valuations represent our management&#146;s best estimate at the time of the valuation, which involve inherent uncertainties and the application of
management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation expense could be materially different. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once a public trading market for our common stock has been established in connection with the closing of this offering, it will no longer be necessary for our board of
directors to estimate the fair value of our common stock in connection with our accounting for stock option grants and other such awards we may grant, as the fair value of our common stock will be determined based on the quoted market price of our
common stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Convertible promissory notes </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From December
2023 through April 2024, we issued convertible promissory notes to various existing investors. We elected the fair value option under ASC 825 and record these convertible promissory notes at fair value with changes in fair value recorded in the
statements of operations and comprehensive income (loss) each reporting period. We measure the fair value of the convertible promissory notes based on significant estimates, including volatility, discount yield, variables for the timing of the
related conversion events and other probability estimates. The impact of interest expense on the convertible promissory notes is included with the changes in fair value. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Emerging growth company status </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an EGC.&nbsp;The JOBS Act permits
companies with EGC status to take advantage of an extended transition period to comply with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. We have elected to use
this extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i)&nbsp;are no longer an EGC or
(ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting standards as of
public company effective dates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we intend to rely on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to
certain conditions set forth in the JOBS Act, if, as an EGC, we intend to rely on such exemptions, we are not required to, among other things: (i)&nbsp;provide an auditor&#146;s attestation report on our system of internal controls over financial
reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, as amended; (ii)&nbsp;provide all of the compensation disclosure that may be required <FONT STYLE="white-space:nowrap">of&nbsp;non-EGCs</FONT> under the Dodd-Frank Wall
Street Reform and Consumer Protection Act; (iii)&nbsp;comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing
additional information about the audit and the financial statements (auditor discussion and analysis); and (iv)&nbsp;disclose certain executive compensation-related items such as the correlation between executive compensation and performance and
comparisons of the chief executive officer&#146;s compensation to median employee compensation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will remain an EGC under the JOBS Act until the earliest of
(i)&nbsp;the last date of our fiscal year in which we have total annual gross revenue of at least $1.235&nbsp;billion, (ii)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; as defined under Rule
<FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act, (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the previous three years, or
(iv)&nbsp;the last day of our first fiscal year following the fifth anniversary of the closing of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Recent accounting pronouncements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Recently adopted accounting pronouncements </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June 2016, the
Financial Accounting Standards Board, or FASB, issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13,</FONT> <I>Financial Instruments &#150; Credit Losses</I> and also issued subsequent amendments to the initial guidance under ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2018-19,</FONT> ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-04,</FONT> ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-05,</FONT> ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-11,</FONT> and ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2020-02,</FONT> or collectively Topic 326. This guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses
is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#147;other-than-temporary&#148; impairment when evaluating <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an
allowance for credit losses on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. We
adopted this standard as of January&nbsp;1, 2023, with no material impact to our financial statements and disclosures. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>New accounting
pronouncements&#151;not yet adopted </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-07,</FONT> <I>Improvements to Reportable
Segment Disclosures</I>, which will require disclosure of incremental segment information on an annual and interim basis for all public entities. The amendments do not change how a public entity identifies its operating segments, aggregates those
operating segments, or applies the quantitative thresholds to determine its reportable segments. ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> is effective for annual reporting beginning with the fiscal year ending December&nbsp;31, 2024, and
for interim periods thereafter. We are currently evaluating the incremental disclosures that will be required in the footnotes to the financial statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-09,</FONT> <I>Improvements to Income Tax Disclosures</I>, which will require incremental income tax disclosures on an annual basis for all public entities. The amendments
require that public business entities disclose specific categories in the rate reconciliation and provide additional information for reconciling items meeting a quantitative threshold. The amendments also require disclosure of income taxes paid to
be disaggregated by jurisdiction, and disclosure of income tax expense disaggregated by federal, state and foreign. ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> is effective for annual reporting beginning with the fiscal year ending
December&nbsp;31, 2025. We are currently evaluating the incremental disclosures that will be required in our financial statements. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Quantitative and qualitative
disclosures about market risk </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Interest rate risk </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
exposed to market risk related to changes in interest rates. As of June 30, 2024, we had cash, cash equivalents and restricted cash of $176.2 million consisting of bank deposits and money market accounts. Due to the short-term duration of our cash
equivalents, an immediate 10% change in interest rates would not have a material effect on their fair market value. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Foreign currency exchange risk
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All of our employees and our operations are currently located in the United States and our expenses are generally denominated in U.S. dollars. However, we
have entered into a limited number of contracts with vendors for research and development services that permit us to satisfy our payment obligations in U.S. dollars (at prevailing exchange rates) but have underlying payment obligations denominated
in foreign currencies, primarily the Euro and British Pound. We are subject to foreign currency transaction gains or losses on our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
contracts denominated in foreign currencies. For the year ended December&nbsp;31, 2023 and for the six months ended June 30, 2024, we recorded an immaterial foreign currency transaction gain and
loss, respectively. To date, foreign currency transaction gains and losses have not been material to our financial statements, and we have not had a formal hedging program with respect to foreign currency. We believe a hypothetical 1% increase or
decrease in exchange rates during any of the periods presented would not have a material effect on our financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Effects of inflation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Inflation generally affects us by increasing our
cost of labor and other research and development costs. We believe that inflation has not had a material effect on our financial statements included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_10"></A>Business </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a clinical-stage biopharmaceutical company harnessing the
power of human genetics to develop novel, small molecule precision medicines for patients living with common diseases, with a focus on renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity.&nbsp;We are advancing a
pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as
variant functionalization.&nbsp;Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design.&nbsp;We are currently advancing two wholly owned lead programs, MZE829 and
MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients with common diseases, which is where we believe we can maximize our impact on
human health. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">CKD is a serious, progressive condition that affects approximately 37&nbsp;million patients in the United States, where it is expected to be the fifth
most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs
are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or
AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our
therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. We expect to initiate a Phase 2 trial of MZE829 in &#8195;&#8195;&#8195; . </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately
five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with
standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today&#146;s standard of care. We submitted an Investigational New Drug
Applicaiton, or IND, to the United States Food and Drug Administration, or FDA, for MZE782 in July 2024. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Compass platform supports <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development.&nbsp;We believe the process of
variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our programs </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our programs include our clinical stage pipeline as well as
additional earlier stage research programs. Our wholly owned clinical pipeline consists of small molecule precision medicines for patients living with common diseases, with a focus on CVRM diseases, including obesity.&nbsp;In areas outside of our
focus, we have an additional program in development, MZE001 in Pompe disease, through a partnership arrangement with Shionogi&nbsp;&amp; Co., Ltd., or Shionogi. In addition to our clinical pipeline, we have several of earlier stage research
programs. These </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
include wholly owned small molecule programs within our CVRM core focus. We also have additional partnered programs, including ATXN2 and UNC13A, each of which we were developing for amyotrophic
lateral sclerosis, or ALS, with two separate biotechnology companies.&nbsp;Our programs are summarized in Figure 1 and Figure 2 below. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g94f07.jpg" ALT="LOGO" STYLE="width:6.04559in;height:2.07274in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 1: Our clinical pipeline </I></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g36i96.jpg" ALT="LOGO" STYLE="width:6.05522in;height:2.36308in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 2: Our research programs </I></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
most advanced lead program, MZE829, is an oral, small molecule inhibitor of APOL1 for the treatment of patients with AKD, a subset of CKD estimated to affect over one million patients in the United States alone. Although the link between APOL1
variants and renal dysfunction has been known for over a decade, we have identified a new protective variant of the APOL1 gene, N264K. MZE829 is designed to phenocopy N264K and mimic its protective characteristics. Through our preclinical work in
AKD, we have demonstrated MZE829&#146;s potential as a disease modifying treatment for patients suffering from this disease. Preclinical <I>in vivo</I> studies demonstrated MZE829&#146;s significant potency in a model of APOL1-induced kidney injury,
suggesting the ability to address a broader population of AKD than has previously been possible in the clinical setting. Additionally, MZE829 has demonstrated the potential to stop or reverse critical features of kidney disease, specifically the
breakdown of the kidney&#146;s filtering system and loss of protein in urine, or proteinuria. We expect to initiate a Phase 2 trial of MZE829 in &#8195;&#8195;&#8195; . </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our second most advanced lead program, MZE782, is an oral, small molecule that targets the solute transporter, SLC6A19, with the potential to address approximately five
million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard
of care, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today&#146;s standard of care. We identified
SLC6A19 using non-public sets of matched, genetic and longitudinal clinical data and discovered a bidirectional allelic series with variants that either improve or worsen renal function. We then applied variant functionalization techniques to
understand the characteristics of the naturally occurring protective variants and designed our proprietary small molecule to mimic their inhibitory effects. We plan to apply a <FONT STYLE="white-space:nowrap">non-invasive</FONT> biomarker strategy
in our Phase 1 trial to establish proof of mechanism and to select doses for a Phase 2 trial. We submitted an IND to the FDA for MZE782 in July 2024. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to
our two lead programs in CKD, our Compass platform has also produced a pipeline across other therapeutic areas and modalities, including MZE001, our first clinical program developed for the treatment of patients with Pompe disease. Within
approximately three years, MZE001 progressed from discovery to the clinic and demonstrated proof of mechanism in a Phase 1 trial, suggesting its potential as an oral therapy for the treatment of patients with Pompe disease and demonstrating the
potential of our Compass platform. Given our focus on common diseases, where we believe we can maximize our impact on human health, we strategically enter into partnerships with third parties to advance programs that address diseases outside of our
core focus areas. In March 2024, following the completion of our Phase 1 trial, we exclusively licensed MZE001 to Shionogi for an upfront payment of $150&nbsp;million and the potential for additional milestones and royalties. We have also
exclusively licensed our ATXN2 and UNC13A programs to other biotechnology companies. Additionally, we formed a <FONT STYLE="white-space:nowrap">spin-out</FONT> company, Broadwing Bio LLC, or Broadwing, to develop therapeutic candidates treating
ophthalmic diseases. As of June 30, 2024, we owned approximately 48% of the outstanding equity of Broadwing. We believe these collaborations validate the potential of our Compass platform and our ability to generate new targets and assets of
therapeutic interest across a wide range of indications and therapeutic areas. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our approach to precision medicine: Compass platform </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Compass platform and its associated methodologies give us the ability to aggregate matched, genetic, and longitudinal clinical data at scale to identify genes
associated with disease, utilizing a combination of private and publicly-available paired clinical data. More importantly, this process uncovers genetic variants of these genes that provide insight into a therapeutic approach to the applicable
target. Using machine learning and statistical modeling, variant functionalization tools, and traditional and computational drug discovery technologies, targets are then prioritized based on their roles in biological pathways, their roles as
potential drivers of disease, and their structural properties. These insights ultimately inform our clinical development and patient selection strategies, which we believe have the potential to improve the overall likelihood of technical, regulatory
and commercial success of our precision medicine candidates, although we cannot provide any assurance that the application of our Compass platform will result in the ultimate regulatory approval of any of our therapeutic candidates. The power of our
Compass platform and its methodologies is best exhibited through our clinical and preclinical programs and multiple contributions to the scientific community over the past five years, including the publication in <I>Nature</I> and other leading
scientific journals of genetic links and other scientific developments identified through our Compass platform. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:13%; text-indent:-13%">


<IMG SRC="g769642g02g02.jpg" ALT="LOGO" STYLE="width:7.5in;height:3.04741in;">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 3: The three phases of our Compass platform and key differentiating features </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Compass platform follows a sequential, three phase workflow consisting of: (1)&nbsp;variant discovery, in which we analyze multiple large-scale genetic databases to
identify relevant genetic variants; (2)&nbsp;variant function identification, in which we attempt to understand the linkage between genetic variants identified and the biology underpinning disease; and (3)&nbsp;translation into therapy, in which we
develop the assays, models, molecules and data necessary to support advancing our programs into clinical development. This workflow creates an iterative learning loop that improves as we onboard, analyze and generate additional data. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>A new era of precision medicine: Maze&#146;s opportunity in common diseases </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Over the past 20 years, significant advances in human genetics and in the understanding of the biological processes underpinning disease have opened the door to a
multitude of potentially new therapeutic targets and treatment approaches, which we believe presents a unique opportunity for a new approach to precision medicine. More recently, the availability of matched, genetic, and longitudinal clinical data
and advanced computational methods to analyze these data has enabled the characterization of genetic variants that are strongly correlated with disease susceptibility and severity. Advancements in functional genomics have also provided new tools to
help unravel how genetic variants impact disease progression from a mechanistic perspective. Nevertheless, the process of successfully translating genetic insights into effective precision medicines is a challenge that has inspired our mission as a
company as well as our name, Maze Therapeutics. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on insights from our Compass platform, we design our therapeutic candidates to modulate the target of
interest, either by mimicking the beneficial effects of certain protective variants or by blocking the unwanted activity associated with toxic variants, to address the underlying biological drivers of disease. Our process of designing precision
medicines that take into account the genetic drivers of disease in defined patient groups parallels many of the foundational principles of precision oncology, which has revolutionized the treatment landscape in cancer, and, we believe, may help
streamline our development efforts and increase our odds of clinical success. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our team and investors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our leadership team and board of directors have significant experience discovering, developing and commercializing therapies. Our existing shareholders include investors
with renowned life sciences experience </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and a shared, dedicated goal of transforming the lives of patients by creating a leading precision medicine company in the CVRM disease spaces. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Jason Coloma, Ph.D., M.P.H., </I></B>our Chief Executive Officer, brings over 20 years of life science leadership experience. He most recently operated as a
venture partner at Third Rock Ventures, LLC, or Third Rock Ventures, during which time he served as the Chief Operating Officer of Maze before being appointed CEO. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Harold Bernstein, M.D., Ph.D., </I></B>our President, Research&nbsp;&amp; Development and Chief Medical Officer, brings over 30 years of experience in scientific
research, translational medicine and clinical development. Dr.&nbsp;Bernstein most recently was Chief Medical Officer and Head of Global Clinical Development at BioMarin Pharmaceuticals Inc. He previously served as Head of Translational Medicine at
Vertex Pharmaceuticals Incorporated, or Vertex, and held roles of increasing responsibility at Merck and Co., Inc., including Head of Early Development for Cardiometabolic Diseases. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Atul Dandekar, </I></B>our Chief Strategy and Business Officer, brings over 20 years of experience in strategy, clinical development and commercialization.
Mr.&nbsp;Dandekar most recently was VP, Global Franchise Head for Ophthalmology at Genentech, Inc., or Genentech, and F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche AG, or Roche, and previously served as Senior Global Program Head in
Neuroscience at Novartis AG. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have raised approximately $424.0&nbsp;million from leading life science investors, including our 5% or greater
stockholders, Third Rock Ventures, ARCH Venture Partners, Matrix Capital Management and Google Ventures. Prospective investors should not rely on the investment decisions of our existing investors, as these investors may have different risk
tolerances and strategies and purchased their shares in prior offerings at prices lower than the price offered to the public in this offering. In addition, some of these investors may not be subject to reporting requirements under Section&nbsp;16 of
the Securities Exchange Act of 1934, as amended, or the Exchange Act, and, thus, prospective investors may not necessarily know the total amount of investment by each of our existing investors and if and when our existing investors may decide to
sell any of their shares. See the sections titled &#147;Certain relationships and related person transactions&#148; and &#147;Principal stockholders&#148; for more information on prior purchases by and current holdings of these stockholders. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our strategy </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We leverage our Compass platform to discover and develop
precision medicines in subsets of common diseases to achieve improved treatment outcomes for patients. Our focus on common CVRM diseases, including obesity, is driven in part by the emerging understanding of the interconnectivity of these diseases.
By focusing on these common diseases, we believe we can maximize our impact on human health. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The core elements of our business strategy are to: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B><I>Advance the clinical development of MZE829 and MZE782 for the treatment of CKD, a disease affecting a large patient
population with high unmet need. </I></B>We are currently advancing our two lead proprietary programs, MZE829 and MZE782, both novel approaches to treating CKD, which affects approximately 37&nbsp;million patients in the United States alone. MZE829
is an oral, small molecule inhibitor of APOL1 for the treatment of patients with AKD. We expect to initiate a Phase 2 trial of MZE829 in &#8195;&#8195;&#8195;. MZE782 is an oral, small molecule inhibitor of SLC6A19 with the potential to be used as
an option for those patients who do not adequately respond to today&#146;s standard of care, or as a complementary treatment to current approved regimens. We submitted an IND to the FDA for MZE782 in July 2024. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B><I>Leverage our proprietary Compass platform to expand our pipeline of precision medicine candidates. </I></B>We plan to
add new programs into our pipeline by applying our Compass platform to identify novel drug targets in subsets of common diseases with significant unmet need within CVRM therapeutic areas. Our Compass
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
platform aims to leverage new genetic insights to identify well-validated targets and discover therapeutic agents designed to mimic the activity of protective genetic variants, correct the
effects of toxic genetic variants, or target genetic modifiers and ultimately guide the development of these potential new medicines. We will continue evaluating strategic partnering opportunities that can complement our internal capabilities.<I>
</I>Our goal is to bring novel precision medicines to patients with common diseases, which is where we believe we can maximize our impact on human health. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B><I>Enhance our Compass platform and methodology.</I></B><I> </I>We continue to make investments in our Compass platform
and improve our drug development process through access to non-public, matched, genetic and longitudinal clinical data, development of variant functionalization tools, and application of cutting edge computational and experimental drug discovery
tools (e.g., Cryogenic electron microscopy, or <FONT STYLE="white-space:nowrap">Cryo-EM,</FONT> virtual screening and machine learning DNA encoded libraries). We plan to enhance our Compass platform to remain at the forefront of genetically informed
drug development and continue to access relevant biobanks and other repositories of genetic and clinical data. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B><I>Maximize the commercial potential of our pipeline</I></B>. We plan to independently advance MZE829 and MZE782 towards
commercialization in geographies where we believe we can ultimately be successful on our own. We intend to build a highly targeted sales forces in these geographies to support the adoption of these treatments. Given the magnitude of the global
market opportunity, we will maximize the value of these programs by partnering with third parties on therapeutic candidates in geographies we believe are better served by the resources and expertise of other biopharmaceutical companies.
</P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Background </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Overview of precision medicine </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Human evolution has given rise to significant genetic diversity worldwide. Because of population migrations and mixing, genetic drift, and founder effects, different
populations carry distinct genetic variants. Certain of these variants increase an individual&#146;s susceptibility to disease, while other variants can protect individuals from disease. Using the tools of modern human genetics, the scientific
community is learning how variations in different genes may impact disease at an unprecedented pace. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Therapeutic targets supported by human genetic evidence are
more likely to yield treatments that provide clinical benefit to patients. Precision medicine holds the promise of therapeutics specifically tailored to address the particular drivers of an individual patient&#146;s disease state to optimize
treatment outcome, but the realization of this promise through clinical implementation has proven elusive. Although more than 100,000 associations between particular genomic regions and specific diseases have been identified, developing medicines to
target the drivers of a disease remains challenging. This is due to difficulties in selecting the most pharmacologically relevant genomic associations, difficulties in identifying the mechanism by which these genomic associations cause diseases and
challenges in developing therapeutics for newly identified targets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Addressing differences in response to treatment requires a more advanced understanding of and
appreciation for the molecular complexity of disease. This is particularly true for common diseases, the complexity of which can be vast. A disease may involve thousands of genes across multiple cell types in different parts of the body. Because
current clinical diagnostic technologies do not have the capability to assess change at such scale, current translational research or clinical practice cannot address disease complexity at this level. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that we are pioneering the effort to translate genetic insights into therapeutic innovations by leveraging the technological convergence between biological
sciences and information technology, and that our approach to drug discovery and development significantly mitigates its inherent risks with the key feature of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
variant functionalization. We leverage our Compass platform to discover and develop precision medicines in subsets of common diseases to achieve improved treatment outcomes for patients. Our
focus on CVRM diseases, including obesity, is driven in part by the emerging understanding of the interconnectivity of these diseases. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Overview of chronic
kidney disease (CKD) </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">CKD is a serious, progressive condition characterized by the gradual loss of kidney function over time, posing significant health risks and
economic burdens. CKD affects approximately 37&nbsp;million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040, and an estimated 700&nbsp;million patients worldwide. CKD manifests through
various stages, culminating in <FONT STYLE="white-space:nowrap">end-stage</FONT> renal disease, or ESRD, necessitating dialysis or kidney transplantation for survival. Current treatments for CKD consider patients as falling into clinical categories
and focus on slowing disease progression, but do not target the underlying genetic drivers of disease. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the early stages of CKD, most patients may not have
symptoms. However, as kidney function gradually diminishes over time, health problems such as high blood pressure, anemia, muscle weakness and nerve damage, kidney failure and cardiovascular, or CV, disease may develop, leading to premature death.
Once the disease progresses to ESRD, the only definitive treatment is kidney transplant, with dialysis serving as a bridge to transplant. As of 2018, the five-year survival rate for all people in the United States who started dialysis was under 50%,
presenting a significant and urgent need for alternative treatments for CKD. In addition to the significant impacts on patients and their families, this disease has put a significant burden on the healthcare system in the United States, with more
than 550,000 patients requiring dialysis and approximately 230,000 patients living with a kidney transplant. An estimated 14% of the United States population has CKD, with the Medicare program spending an outsized amount, more than 24% or
$130&nbsp;billion of total yearly expenditures, on patients with CKD. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Individuals of African ancestry are at significantly greater risk of developing ESRD than
individuals of European ancestry, and account for approximately 33% of patients who experience kidney failure in the United States. The cumulative risk of ESRD is approximately 7.5% of Americans with African ancestry as compared to approximately 2%
of Americans with European ancestry. Understanding the genetic drivers of this difference in CKD progression may accelerate the development of treatment strategies and reduce the excess burden. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">CKD can also increase the risk of CV diseases, such as heart failure, or HF. Depending on the stage of CKD and the age of the patient, up to 50% of patients diagnosed
with CKD will also experience HF. CKD patients who are more likely to develop HF typically have similar risk factors including diabetes, obesity, and hypertension. If CKD is identified and addressed early enough, treatment can help slow disease
progression, preserve renal function and reduce CV complications, including HF. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Limitations of current CKD therapies </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Despite advances in medical science, current treatments for CKD consider patients as falling into clinical categories and focus on slowing disease progression but do not
target the underlying genetic drivers of disease. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to lifestyle modifications, the standard of care for CKD includes three main categories of treatment:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Established therapies that slow progression: renin-angiotensin-aldosterone system, or RAAS, inhibitors, SGLT2 inhibitors
and glucagon-like peptide 1, or <FONT STYLE="white-space:nowrap">GLP-1</FONT> agonists. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Medications that mitigate the effects of CKD: medicines to control blood pressure, blood glucose levels, anemia, bone and
mineral disorders, fluid overload, and levels of cholesterol and other lipids. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Dialysis and kidney transplantation: the typical final treatment option for ERSD patients. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Only 50% to 70% of CKD patients respond to lifestyle modification and standard of care treatment, and ultimately almost all CKD patients progress to ESRD. Furthermore,
existing therapies are associated with adverse side effects and patients experience substantial healthcare costs. Given the escalating prevalence of CKD, and its profound impact on patient well-being and healthcare systems, there exists a critical
and pressing need for innovative treatments capable of halting or reversing disease progression, improving patient outcomes, and mitigating the socioeconomic burden associated with CKD. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our two lead wholly owned programs, MZE829 and MZE782, are novel precision medicine-based approaches for CKD that inhibit APOL1 and SLC6A19, respectively. Our CKD
programs are designed to modulate these targets directly, either by mimicking the beneficial effects of certain protective variants or by blocking the unwanted activity associated with toxic variants, to address the underlying biological drivers of
disease. We believe this approach has the potential to be disease modifying and ultimately lead to better treatment outcomes for patients living with CKD. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Overview of APOL1 kidney disease (AKD) </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">AKD is a life threatening,
genetically driven form of CKD. People who have high-risk coding variants in both copies of the APOL1 gene have a heightened risk of developing CKD. Patients who develop AKD have one or both of the two high-risk variants of the APOL1 gene, G1 and
G2, in both copies of their APOL1 gene, which can lead to kidney injury and interference with the kidney&#146;s ability to filter harmful substances from the blood. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g62f25.jpg" ALT="LOGO" STYLE="width:6.26666in;height:3.54579in;">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 4: Prevalence of AKD and associated risk factors </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The high-risk APOL1 gene variants are most prevalent in people of West African ancestry, including many who identify as Black, African American, Afro-Caribbean and
Latina/Latino. These high-risk APOL1 gene variants likely evolved to protect individuals from Human African trypanosomiasis, or HAT, which causes sleeping sickness. HAT is endemic in <FONT STYLE="white-space:nowrap">sub-Saharan</FONT> Africa and
caused by protozoan parasites transmitted by infected tsetse fly bites. Without treatment, HAT is usually fatal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, approximately six million, or 13%, of African Americans have mutations of both copies of the
high-risk APOL1 gene variants, and are at risk for developing AKD. It is currently estimated that approximately 20%, or over one million, of those individuals have AKD. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">APOL1 is a channel-forming innate immunity protein found in circulating high-density lipoproteins in humans and certain primates. In addition to circulating forms, APOL1
is also found locally in kidney endothelial cells and podocytes. Circulating APOL1 mediates resistance to infection from the parasite Trypanosoma brucei. The high-density lipoprotein particle binds to the cell membrane of the parasite, allowing for
the uptake of APOL1, which forms a <FONT STYLE="white-space:nowrap">pH-gated</FONT> cation channel in the membrane of the lysosome. The lysosome then swells and ruptures into the body of the parasite, resulting in its demise. The G1 and G2 variants
of APOL1 evolved in response to parasites that became resistant to normal APOL1. However, individuals with two copies of the G1 and/or G2 variants were found to be at higher risk for developing CKD and progressing to ESRD. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Rare individuals lacking APOL1 altogether appear to have no higher risk of developing CKD than the general population, suggesting that AKD is the result of toxicity
associated with the risk variants, rather than APOL1 inactivation. This observation also suggests that it may be safe to inhibit APOL1 activity to reduce the risk and progression of AKD. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">AKD has various clinical presentations, including focal segmental glomerulosclerosis, or FSGS, hypertension-associated kidney disease,
<FONT STYLE="white-space:nowrap">HIV-associated</FONT> nephropathy and lupus nephritis. Published third-party studies and internal analysis also suggest that AKD may be responsible for increasing the likelihood of progression to ESRD in individuals
with diabetes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">AKD represents a significant unmet medical need, as there are currently no approved therapies that address its underlying genetic causes or
efficacious treatment options for individuals with high-risk APOL1 gene variants. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Third-party clinical trials evaluating the use of a small molecule APOL1 inhibitor
have demonstrated a statistically significant and clinically meaningful reduction in proteinuria at 13 weeks compared to baseline in APOL1-mediated FSGS patients. All clinical trials to date have been limited to AKD patients in the nephrotic or <FONT
STYLE="white-space:nowrap">sub-nephrotic</FONT> range, who represents a small percentage of the AKD population, and have excluded patients with hypertensive kidney disease and diabetes, who make up the majority of AKD patients. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Role of SLC6A19 in kidney disease </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">SLC6A19 encodes the protein BoAT1, a
sodium-dependent neutral amino acid transporter expressed primarily in the proximal tubule of the kidney and on the brush border of the small intestine. In the kidney, SLC6A19 plays a role in minimizing the excretion of amino acids in urine by
transporting these key nutrients from the urine back into the bloodstream. We identified SLC6A19 as a potentially novel therapeutic target for CKD based the finding that
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> variants in SLC6A19 were associated with improved renal function and protection from CKD. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As shown in Figure 5 below, while treatment strategies for patients with CKD have evolved with the use of RAAS inhibitors and more recently SGLT2 inhibitors and <FONT
STYLE="white-space:nowrap">GLP-1</FONT> agonists, of the approximately 14&nbsp;million CKD patients in the United States with clinical symptoms requiring treatment, only approximately 7&nbsp;million are receiving treatment. Of these, we estimate
that up to five million patients may have an inadequate response and could benefit from novel treatments. Additionally, we believe there is potential for SLC6A19-based therapies to be used either alone or in combination with other available
treatment options in an even larger group of CKD patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g31l38.jpg" ALT="LOGO" STYLE="width:4.5in;height:4.5in;">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 5: Initial target populations for MZE782 in the United States</I> </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our lead programs for CKD: MZE829 and MZE782 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our wholly owned pipeline
consists of small molecule precision medicines for patients living with common diseases, with a focus on CVRM diseases, including obesity. Our two lead wholly owned programs, MZE829 and MZE782, are novel precision medicine-based approaches for CKD
that inhibit APOL1 and SLC6A19, respectively. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>MZE829 for APOL1 kidney disease (AKD) </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of APOL1 that seeks to treat patients with AKD, a subset of CKD estimated to affect over one
million patients in the United States alone. Our approach to treating AKD aims to block the ability of APOL1 to conduct current at the cell membrane. Based on compelling human genetics and functional genomics data derived from our Compass platform
linking the role of the G1 and G2 APOL1 risk variants to CKD, along with a further understanding of APOL1&#146;s function and clinical observation of its localization, we believe a pore-blocking strategy will reduce ion conductance in podocytes and
thus reduce APOL1-associated renal toxicity. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While the genetic link between APOL1 and kidney disease has been well established, the mechanism by which it induces
kidney injury remained unclear for over a decade. Through our Compass platform and the research we have conducted with our partners, we have identified the mechanism of a naturally occurring genetic variant of APOL1, called N264K. When present, this
variant has been shown to reduce the conductance of ions through the APOL1 pore in the presence of the high-risk G1 and G2 APOL1 alleles, thereby suppressing the toxicity of APOL1 in kidney cells and reducing disease progression. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The genesis of our therapeutic hypothesis was based upon human genetics involving an individual from Ghana who
developed an atypical trypanosome infection. Under normal circumstances, protections afforded by APOL1 would have prevented infection from this particular trypanosome. However, a third party&#146;s sequencing of the APOL1 gene from this individual
revealed that the genetic mutation responsible for N264K occurred in a separate part of the APOL1 gene from where the disease-driving mutations occur and established that the mutation resulted in the inability of APOL1 to direct the elimination of
trypanosomes. This led us to consider whether the mechanism by which APOL1 promoted trypanosome lysis may also have a causal connection to toxicity in kidney disease. We tested the consequences of the N264K variant in cultured kidney cells, in which
expression of the G1 and G2 APOL1 risk variants are toxic. When the risk variant of APOL1 was altered to contain the N264K variant, its toxicity in kidney cells was substantially reduced. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To further validate the finding, we conducted a cross-sectional analysis of 121,492 participants of African ancestry from the Million Veteran Program, or MVP, to
determine if the presence of N264K modified the association between the G1 and G2 risk variants and CKD and ESRD. As depicted in Figure 6 below, the results showed a strong association between N264K and a statistically significant risk reduction (p
&lt; 0.001) of CKD (left) and ESRD (right) among carriers of the G1 and G2 risk variants. The results were further replicated by research from the Vanderbilt University Medical Center&#146;s Biobank (BioVU; n&#061; 14,386) and the National Institute
of Health&#146;s All of Us program (All of Us; n&#061; 14,704), also reflected in Figure 6 below. A meta-analysis across all cohorts demonstrated a 57% reduced risk of CKD and an 81% reduced risk of ESRD in APOL1 high-risk patients carrying the
N264K protective variant. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g77q77.jpg" ALT="LOGO" STYLE="width:6.05315in;height:2.64678in;">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 6: APOL1 N264K variant shown to protect against AKD (CKD) and ESRD </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We then used human kidney cell models to demonstrate that the N264K mutation blocked APOL1 pore-forming function and ion conductance, and reduced toxicity of the APOL1
high-risk mutations (the G2 variant shown in Figure 7 below). We generated kidney cell lines in which expression of the toxic G2 APOL1 protein was induced with doxycycline. We then measured calcium ion flow into these cells using a calcium sensitive
fluorescent protein. As demonstrated in the left panel below, an increase in calcium uptake occurred in cells where expression of the G2 variant was induced (G2, &#043;Dox) but not in cells in which G2 was not expressed (G2, <FONT
STYLE="white-space:nowrap">-Dox).</FONT> This demonstrated that the G2 APOL1 variant can form an ion permeable pore in the plasma membrane of these cells. As shown in the right panel below, cells designed to express a version of toxic G2 APOL1 with
the N264K mutation (G2 N264K) did not show evidence of increased ion flux in the presence of doxycycline. This demonstrated that the protective APOL1 variant N264K blocked G2 APOL1 dependent ion flux in a cell model as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
measured by calcium uptake, demonstrating that N264K acts by impairing APOL1 pore function. These data informed our therapeutic hypothesis for the treatment of AKD by phenocopying the effects of
the N264K variant and blocking the unregulated ion flow that occurs in the presence of the high risk APOL1 variants, G1 and G2. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g30x67.jpg" ALT="LOGO" STYLE="width:5.70667in;height:2.62619in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 7: Protective N264K variant corrected ungated ion flux that occurs with G2 risk variant </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Discovery of MZE829</U> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In order to validate the assertion that inhibition of
pore function would limit toxicity, we conducted several small molecule screening campaigns. These screens resulted in our identification of several chemical series that were capable of blocking the influx of ions through APOL1. Kidney cells
expressing APOL1 were exposed to pore-blocking molecules from our lead series at a range of concentrations at two different resting membrane potentials. Measurement of the current flowing through the APOL1 pore showed that these molecules inhibited
the flow of current in a dose dependent manner. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, in studies to assess the ability of our lead compounds to protect against APOL1-mediated toxicity, human
kidney cells expressing the G1 and G2 APOL1 risk variants were cultured in the presence and absence of our lead compounds. As the concentration of our lead series APOL1 inhibitor increased, the rate of kidney cell toxicity decreased and kidney cell
viability percentage increased in a dose dependent manner. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Conducting the various <I>in vitro</I> and cell-based assays allowed us to evaluate potency and effect of
APOL1 compounds. While these assays are informative, they are limited, artificially constructed systems, and often provide incomplete data on how the compounds may interact in a human setting. Because of these complexities, we believe a humanized
<I>in vivo</I> mouse model measuring proteinuria reduction is the preferred surrogate for patient improvement. We conducted an <I>in vivo</I> experiment with our development candidate, MZE829, using a transgenic mouse model that simulates human
disease with two copies of high-risk APOL1 alleles that drive high levels of proteinuria in response to an inflammatory stimulus driven by expression of interferon gamma. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Findings from this study demonstrated the potential of MZE829 to ameliorate disease manifestations of AKD, specifically proteinuria and the histopathological
manifestations of kidney damage. In this study, we treated mice homozygous for a bacterial artificial chromosome, or BAC, transgene expressing the G2 APOL1 variant with interferon gamma to induce APOL1 expression in the kidney. This treatment led to
G2 APOL1 upregulation and kidney injury that could be monitored by urinary albumin excretion or urinary albumin-creatinine ratio, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
uACR. Mice were treated with interferon gamma and MZE829, and urine was collected from 24 through 48 hours after treatment. As shown in Figure 8 below, MZE829 dose dependently blocked APOL1
induced kidney injury in this translationally relevant G2 APOL1 BAC transgenic mouse model as measured by decreases in uACR. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g66t55.jpg" ALT="LOGO" STYLE="width:4.00334in;height:2.55035in;">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 8: MZE829 inhibited APOL1 dependent proteinuria, as measured by uACR, in a model of AKD </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also compared MZE829 to an independently synthesized sample of the publicly disclosed structure of inaxaplin, or <FONT STYLE="white-space:nowrap">VX-147,</FONT> in
this mouse model of AKD. Inaxaplin, or VX-147, is an APOL1 function inhibitor currently in clinical development sponsored by Vertex. Different doses of MZE829 and the synthesis of inaxaplin were given to mice treated with interferon gamma. uACR and
free plasma drug concentrations were determined for each dose group, and the exposure-response relationships for both compounds was analyzed as shown in Figure 9 below. The free plasma drug concentrations associated with a 50% reduction in uACR was
approximately 100 times lower for MZE829 compared to the synthesis of inaxaplin. These data demonstrated that MZE829 was substantially more potent than our synthesis of inaxaplin in a translationally relevant animal model, and suggest that
meaningful efficacy in the clinic may be achievable at lower levels of free drug. Therefore, we believe MZE829 may be more suitable for clinical exploration in a broader range of patients, with lower risk of
<FONT STYLE="white-space:nowrap">off-target</FONT> safety effects. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g72u41.jpg" ALT="LOGO" STYLE="width:5.42236in;height:2.44958in;">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 9: MZE829 was approximately 100 times more potent than an independently synthesized sample of inaxaplin in a model of AKD
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While the mouse model of AKD described above simulated acute onset and treatment of disease, we also developed
additional models that more closely resemble chronic disease. In these models, mice harboring BAC transgenes with one copy each of both G1 and G2 were exposed to an adeno-associated virus chronically expressing interferon gamma to produce the
manifestations of AKD in humans. Treatment after seven days of continuing interferon expression with a mouse-tool compound <FONT STYLE="white-space:nowrap">(MZ-302)</FONT> with similar pharmacochemical characteristics to MZE829 demonstrated the
ability to significantly reduce uACR in a dose-dependent manner, as shown in Figure 10 below, with almost complete reversal after three weeks of treatment. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g769642g72h13.jpg" ALT="LOGO" STYLE="width:5.00502in;height:2.55224in;">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 10: Reversal of established proteinuria, as measured by uACR, by a Maze APOL1 inhibitor
<FONT STYLE="white-space:nowrap">(MZ-302)</FONT> in a chronic mouse model of AKD</I><B><I> </I></B><I> </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Treatment also was shown to resolve kidney tissue
abnormalities (disruption of glomeruli, or glomerulosclerosis as shown in insets) within the same time frame, as reflected in Figure 11 below. This demonstrated that in both acute and chronic mouse models of AKD, our specific and potent APOL1
inhibitors were able to both arrest and reverse disease, providing further validation of our therapeutic hypothesis. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g55f74.jpg" ALT="LOGO" STYLE="width:6.10001in;height:1.61916in;">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 11: Treatment with <FONT STYLE="white-space:nowrap">MZ-302,</FONT> a Maze APOL1 inhibitor, significantly reduced glomerular
scarring in a chronic mouse model of AKD </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>MZE829 clinical trials </U></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
recently completed a Phase 1 randomized, placebo-controlled clinical trial evaluating MZE829 in 111 healthy volunteers with single ascending dose, or SAD, and multiple ascending dose, or MAD, cohorts. The primary objective of the Phase 1 trial was
to assess the safety and tolerability of single and multiple doses of MZE829 in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
healthy volunteers. The secondary objectives were to evaluate the pharmacokinetics of single and multiple doses of MZE829. As a part of the Phase 1 program, we are also investigating potential
drug-drug interactions to guide the use of <FONT STYLE="white-space:nowrap">standard-of</FONT> care medicines in Phase 2. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on the Phase 1 trial results, we
plan to initiate a Phase 2 clinical trial in patients with AKD to determine which patients may derive a clinically significant benefit from MZE829. We expect the Phase 2 clinical trial to be a basket design, including AKD patients carrying the two
high-risk APOL1 alleles (G1, G2), stratified by clinical phenotype and level of proteinuria, as well as patients who have type 2 diabetes. We intend to enroll patients with a wide array of characteristics to reflect the full range of AKD. The trial
will include patients from the more severe patient population with nephrotic range proteinuria, as in FSGS, patients with lower levels of proteinuria and hypertensive nephropathy, and patients with proteinuria and diabetic kidney disease, a
subpopulation that genetic analyses of the N264K protective variant suggest could benefit from an APOL1-directed therapy. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g98g45.jpg" ALT="LOGO" STYLE="width:5.26667in;height:3.22226in;">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 12: Maze plans to explore an expanded population of AKD patients in the United States in clinical trials </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Phase 2 evaluation of MZE829 clinical development will aim to address a larger population than current third-party clinical trials, which are limited to patients in
the nephrotic or <FONT STYLE="white-space:nowrap">sub-nephrotic</FONT> range only, comprised of <FONT STYLE="white-space:nowrap">non-diabetic</FONT> patients with FSGS and a small portion of patients with hypertensive nephropathy and heavy
proteinuria. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Data from Phase 2 are intended to demonstrate proof of concept and provide appropriate criteria for selection of patient populations and dose range in
a subsequent pivotal clinical program. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Phase 2 endpoints </U></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to
use reduction of proteinuria, as measured by the percentage of subjects with a 30% or greater reduction from baseline in uACR at week 12, as a primary endpoint for the Phase 2 trial. uACR is a sensitive measure of proteinuria in earlier stages of
glomerular kidney disease, particularly in hypertension and diabetes, and has been used to assess risk of CV disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Patient identification and selection </U></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to use clinical genotyping to identify individuals who carry the APOL1 G1 and G2 mutations in connection with enrollment of our Phase 2 clinical trial.
Additionally, the APOL1 G1 and G2 variants are included in most currently used standard genetic screening panels for kidney disease. We do not intend to genotype participants for the N264K variant as this is a rare finding and these individuals are
unlikely to meet the criteria for AKD as they are relatively protected. We are currently exploring the development of an APOL1 G1/G2 companion diagnostic for commercialization. Various sponsors, including kidney societies, patient advocacy groups,
academic programs and other biopharmaceutical companies, are currently conducting global genotyping efforts. These are promoted by the Kidney Health Initiative, a public-private partnership among the FDA, the American Society of Nephrology, and
other member organizations, including us. We believe that these genotyping efforts will increase as additional positive data and potential therapies become available. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>MZE782 for CKD, targeting SLC6A19 </I></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that MZE782 is an oral,
small molecule targeting the solute transporter, SLC6A19, with the potential to address approximately five million of the CKD patients in the United States who have inadequate responses to currently available CKD therapies. Beyond its use as a
potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens, or as an alternative option for those patients who do
not adequately respond to the current standard of care. We plan to apply a <FONT STYLE="white-space:nowrap">non-invasive</FONT> biomarker strategy in our Phase 1 trial in healthy volunteers to establish proof of mechanism and select doses for a
Phase 2 trial in CKD patients. We submitted an IND to the FDA for MZE782 in July 2024. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Using our Compass platform, we identified SLC6A19 as a target through
genetic association with a bidirectional allelic series that included genetic variants that either improve or worsen renal function. We then applied variant functionalization techniques to understand the characteristics of the naturally occurring
protective variants, and designed a small molecule inhibitor to mimic those protective characteristics. Using computational tools integrated with established small molecule screening methods, we were able to identify a lead compound series. <FONT
STYLE="white-space:nowrap">Cryo-EM</FONT> structural analysis revealed a novel allosteric binding site that allowed for further optimization toward a lead compound. This approach facilitated the identification of our development candidate, MZE782,
with a <FONT STYLE="white-space:nowrap">250-fold</FONT> increase in potency relative to earlier compounds in development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Identification of SLC6A19 as a therapeutic target using our Compass platform</U> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">SLC6A19 emerged as a novel therapeutic target for the treatment of CKD based on our analyses of independent sets of human genetic data matched with longitudinal clinical
data for kidney health. Through these analyses, we identified a link between <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> variants in SLC6A19 with improved renal function and protection from CKD.
As illustrated in Figure 13 below, SLC6A19 variants plotted by allele frequency on the <FONT STYLE="white-space:nowrap">X-axis</FONT> were statistically significantly associated (p&lt; 5x10<SUP STYLE="font-size:75%; vertical-align:top">-8 </SUP>)
with improvement in kidney function (as measured by decreases in serum creatinine) on the <FONT STYLE="white-space:nowrap">Y-axis.</FONT> One <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> missense
variant (D173N) had the largest beneficial effect on kidney function. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g96l94.jpg" ALT="LOGO" STYLE="width:4.15833in;height:2.177in;">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 13: Analysis of matched clinical-genetic data from the UK Biobank prioritized novel CKD target SLC6A19 </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Analysis of the D173N <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> variant and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">gain-of-function</FONT></FONT> Expression Quantitative Trait Loci, or eQTLs, across the UK Biobank data set established a bidirectional allelic series (both protective and risk alleles) for kidney function. As shown in
Figure 14 below, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> D173N variant was associated with decreased levels of serum creatinine and cystatin C, as well as increased eGFR, consistent with
better kidney function. An eQTL that leads to higher levels of SLC6A19 expression was associated with increased levels of serum creatinine and cystatin C and lower eGFR, consistent with worse kidney function. Missense variants that decrease SLC6A19
activity and eQTLs that increase SLC6A19 activity have directionally opposite effects across multiple distinct biomarkers of kidney function supporting the model that loss of function in SLC6A19 protects from CKD. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g98o36.jpg" ALT="LOGO" STYLE="width:5.33334in;height:2.47936in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 14: SLC6A19 variants had bidirectional and consistent effects across biomarkers of renal function </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Preclinical models of SLC6A19 inhibition </U></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To gain further confidence in
SLC6A19 as a relevant therapeutic target for improving kidney health, we generated a preclinical knockout mouse model to recapitulate the effects of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT>
protective variants. As demonstrated in the histopathological images in Figure 15 below, the kidney from a representative wild type mouse (far left) showed marked damage, as indicated by vacuolization (excessive white spaces) in the kidney
parenchyma along with breakdown of the normal architecture of glomeruli (the filtration units in the kidney) in response to treatment with the proximal tubule toxin, aristolochic acid, or AAI. In contrast, the kidney from a representative SLC6A19
knockout mouse (inner left) showed normal kidney parenchyma with healthy glomeruli in response to AAI treatment. This demonstrated protection of the kidney from AAI damage in mice that did not express SLC6A19. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, complete knockout of SLC6A19 in this model was well tolerated with normal kidney parenchyma (far right), and no impact on body weight, eGFR or other measures of
kidney health, or function of other organs. In addition, Hartnup syndrome, a genetic disorder in which individuals are homozygous for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> mutations in
SLC6A19, is characterized by benign loss of amino acids in urine. Patients with Hartnup syndrome can live healthy lives with appropriate dietary supplementation. Heterozygous Hartnup carriers are clinically normal without intervention. Together,
these observations provide <I>in vivo</I> evidence that pharmacologic inhibition of SLC6A19 function could be well tolerated in patients with CKD and protect the kidney from injury. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g05f43.jpg" ALT="LOGO" STYLE="width:4.41667in;height:2.39628in;">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 15: Targeted genetic knockout of SLC6A19 in a preclinical model protected against
<FONT STYLE="white-space:nowrap">AAI-induced</FONT> kidney injury </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Correlation of SLC6A19 inhibition with clinically meaningful effect </U></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Individuals with one copy of the D173N variant displayed clinically meaningful protection of kidney function in the UK Biobank data set. Functionalization of this
variant enabled us to estimate the degree of inhibition required for a clinically significant effect. SCL6A19 harboring the protective D173N variant and other variants associated with SLC6A19 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">loss-of-function</FONT></FONT> were expressed in a Xenopus oocyte system. Introduction of the D173N mutation resulted in an approximately 50% decrease in transporter activity as measured by uptake of the neutral amino
acid, leucine, a natural cargo for the transporter, compared to wild type SLC6A19. Because a protective effect on kidney function is seen in the presence of a single copy of the D173N variant, these data suggest that a clinically meaningful effect
could be seen with as little as 50% inhibition of the target. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Discovery of MZE782 </U></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based
on our genetic analyses, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> variants were protective against kidney dysfunction in human beings against kidney injury in the preclinical AAI treatment
model. As a result, we launched a drug discovery program to identify small molecule inhibitors of SLC6A19 function. Inhibitors of SLC6A19 were identified in a screen of 200,000 compounds in a cellular fluorometric membrane potential assay. Several
hit series were identified (potencies &lt;10 &micro;M), and the acquisition of dozens of Cryo-EM protein-ligand complex structures revealed that all compounds bound in a specific, cryptic allosteric pocket. Structurally enabled hybridization of the
hit series and further optimization using a cellular radiometric leucine uptake assay produced compounds with potencies &lt;500 nM. Further lead optimization benefited from the introduction of polarity which allowed for the best balance of potency
and <I>in vivo</I> pharmacokinetic performance. Ultimately, our efforts resulted in MZE782, with an IC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB>&nbsp;&lt; 300 nM reflecting a <FONT STYLE="white-space:nowrap">ten-fold</FONT>
improvement in potency compared to the initial hit. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Development of translational biomarkers of SLC6A19 inhibition </U></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because SLC6A19 transports (and therefore, reabsorbs) neutral amino acids from the urine back into the bloodstream, the excretion of neutral amino acids in the urine
should allow for the measure of SLC6A19 inhibition in the kidney. A mouse tool compound, <FONT STYLE="white-space:nowrap">MZ-401,</FONT> was dosed at 100, 300 and 1000 milligrams per kilogram in a mouse model of phenylketonuria, Pahenu2, in which
circulating levels of phenylalanine, or Phe, are elevated. Urine was collected for eight hours post-dose and urinary levels of Phe, glutamine, or Gln, and creatinine were determined by an <FONT STYLE="white-space:nowrap">LC-MS</FONT> assay. As
depicted in Figure 16 below, we observed dose dependent increases in urinary Phe (left) and Gln (right) normalized to creatinine. Although the levels of circulating Phe, but not Gln, are elevated in this specific mouse strain, we believe these data
still confirm the utility of urinary excretion of neutral amino acids as a relevant pharmacodynamic measure with which to establish an exposure-response with SLC6A19 inhibition. <FONT STYLE="white-space:nowrap">MZ-401</FONT> induced dose dependent
increases in urinary phenylalanine and glutamine, consistent with &gt;50% target engagement based on genetic analysis of humans and mice. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g81q05.jpg" ALT="LOGO" STYLE="width:4.56388in;height:2.15784in;">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Figure 16: A Maze SLC6A19 inhibitor <FONT STYLE="white-space:nowrap">(MZ-401)</FONT> achieved a response consistent with &gt;50%
target engagement based on dose dependent increases in urinary neutral amino acids </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>MZE782 clinical development plans </U></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to clearance of our IND to the FDA, we expect to dose the first participant in our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1 clinical trial for MZE782 in&#8195;&#8195;. We expect our Phase 1 trial to be a randomized, double-blind, placebo-controlled single and multiple
ascending dose study in approximately 104 healthy volunteers to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics as measured by urinary excretion of neutral amino acids. We expect the Phase 1 trial to demonstrate clinical proof
of mechanism by demonstrating a dose-dependent increase in the excretion of urinary amino acids. We submitted an IND to the FDA for MZE782 in July 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on supporting data from Phase 1, our current plan is for Phase 2 to focus on CKD patients with inadequate
response to the current standard of care. Our ongoing analysis of matched genetic-clinical-metabolomic data in CKD cohorts and exploration of metabolite profiles in these data sets as well as in our Phase 1 cohort may lead to potential approaches to
further stratify patient <FONT STYLE="white-space:nowrap">sub-populations</FONT> for our Phase 2 program. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Additional CKD and CVRM research programs </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to our two lead programs in CKD, we are exploring additional targets that we have identified as potential next generation small molecule candidates. Using
our Compass platform, we identified a CKD target through genetic association with a bidirectional allelic series that included genetic variants that either improve or worsen renal function, then applied variant functionalization techniques to
understand the characteristics of the naturally occurring protective variants. Based on these analyses, we have initiated assay development for a high-throughput compound screen designed to identify a small molecule inhibitor to mimic those
protective characteristics. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have further identified an additional CVRM target through genetic analysis as described above, and are applying variant
functionalization techniques to define the characteristics of the naturally occurring protective variants. We are currently scaling assays that we have developed to be used in a high-throughput screen to identify quality compounds that would serve
as leads for further chemical optimization. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Other development opportunities including small molecule research in CVRM </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also have research efforts underway for our next-generation programs in common diseases. We are focusing our early research efforts and evaluating genetic targets in
CVRM diseases, including obesity, driven in part by the emerging understanding of the interconnectivity of these common diseases affecting the heart and kidney through metabolic drivers, such as obesity. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patients who are more likely to develop CKD and other diseases such as heart failure, HF, typically have similar comorbidities, including obesity, and we believe our
precision medicine approach through our Compass platform will allow for additional targets in these therapeutic areas. We aspire to ultimately guide the development of new medicines utilizing new genetic insights to identify valid targets and
discover therapeutic agents designed to mimic the activity of protective genetic variants or correct the effects of toxic genetic variants. We expect that our commitment to a pragmatic development approach will improve the likelihood of success and
patient impact. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In metabolism, we have identified a key set of potential targets to address obesity and are utilizing our statistical, computational and functional
genomics research engine to explore <FONT STYLE="white-space:nowrap">non-central</FONT> nervous system-driven mechanisms that affect body mass index and weight distribution. With our programs, we will look to complement the existing CKD therapy of <FONT
STYLE="white-space:nowrap">GLP-1</FONT> receptor agonists, which are primarily driven by a central nervous system mechanism of action, and potentially address the unmet needs of patients who do not respond or cannot tolerate the current therapeutic
options, or seek a maintenance option for ongoing weight control. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our partnered programs </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Using our Compass platform, we have validated targets and new therapeutic approaches targeting diseases outside of our core focus areas, including neurology,
ophthalmology and rare diseases. We have entered into partnership arrangements with third parties with respect to several of these targets. These programs are not only sources of revenue, but also demonstrate the power of our Compass platform. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>MZE001 for Pompe disease </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our first program to enter the clinic, MZE001, has the potential to be a novel therapeutic approach to treating Pompe disease. MZE001 is an investigational oral, small
molecule inhibitor of muscle-specific glycogen synthase, or glycogen synthase 1, which is encoded by the gene glycogen synthase 1, aimed at reducing the glycogen concentration in muscles. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pompe disease is a rare, inherited lysosomal storage disorder caused by mutations in the gene coding for acid alpha-glucosidase that can lead to the buildup of glycogen,
a complex sugar, in skeletal, respiratory and cardiac muscle resulting in progressive weakness, HF and respiratory compromise. Shionogi, the licensee for this program, estimates that approximately 50,000 patients are living with Pompe disease
worldwide. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Compass platform enabled Maze to progress a therapeutic candidate, MZE001, from discovery to the clinic within approximately three years. Our Phase 1
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trial, which was completed in December 2022, demonstrated proof of mechanism in 129 healthy volunteers. This clinical trial was a randomized,
double-blind, placebo-controlled, SAD and MAD study in healthy volunteers. The primary and secondary objectives, respectively, were to demonstrate the safety and tolerability, and evaluate the pharmacokinetics, of single and multiple doses of MZE001
in healthy adults. An exploratory objective was to evaluate biomarkers of glycogen metabolism to demonstrate proof of mechanism, i.e., that MZE001 treatment would result in a reduction in muscle glycogen. In the Phase 1 trial, MZE001 was well
tolerated at all doses tested, with no serious adverse events observed. Importantly, the exploratory analyses showed that MZE001 inhibited the synthesis of muscle glycogen and reduced total muscle glycogen compared to placebo. We believe these data
support MZE001&#146;s potential as an oral therapy for the treatment of patients with Pompe disease. MZE001 has the potential to be used either as a monotherapy or as an <FONT STYLE="white-space:nowrap">add-on</FONT> to enzyme replacement therapy,
the current standard of care. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2024, we exclusively licensed MZE001 to Shionogi for the rights to develop and commercialize MZE001. Under the terms of the
agreement, Shionogi acquired an exclusive, worldwide, sublicensable license to research, develop, manufacture and commercialize MZE001 as well as related compounds, <FONT STYLE="white-space:nowrap">know-how</FONT> and intellectual property. Shionogi
paid an upfront fee of $150&nbsp;million, and we will be eligible to receive milestone payments based on development, regulatory and commercial achievements plus tiered royalties based upon future net sales. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Application of our Compass platform to advance MZE001 </U></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The buildup of
glycogen in skeletal, respiratory and cardiac muscle tissues is the primary driver of disease progression in patients with Pompe disease. While enzyme replacement therapy, the current standard of care, has brought significant benefit to patients,
glycogen accumulation in muscle continues to allow the disease to progress, specifically impacting ambulation and respiratory function, and has been only partially effective at clearing toxic glycogen accumulation in these tissues. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Inhibition of muscle glycogen synthase is a form of substrate reduction therapy, which has the potential to decrease muscle glycogen synthesis and its subsequent
accumulation. By leveraging large sources of matched, genetic and longitudinal clinical data with our Compass platform, we sought to address longstanding questions around safety and efficacy that previously precluded the development of a substrate
reduction therapy, and designed MZE001 to address the therapeutic gap in current standard of care. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While glycogen synthase 1 has long been a therapeutic target of
interest, there were two main challenges to previous drug targeting efforts. First, there were concerns about the unknown clinical safety implications of chronically lowering muscle glycogen levels. Second, glycogen synthase 1 is a complex protein,
closely related to liver-specific glycogen synthase 2, which plays an important role in glucose control. While both enzymes are tetramers made up of two asymmetric dimers, their molecular structures were unknown. As a result, efforts to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
target glycogen synthase 1 without inhibiting glycogen synthase 2 had proven difficult. Through the use of our Compass platform, we were able to overcome both of these challenges. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">First, our Compass platform provided insight into the impact of chronic reduction in muscle glycogen levels and identified a likely therapeutic window. PPP1R3A, a gene
that encodes the protein phosphatase 1 regulatory subunit 3A, is a key regulatory protein in the glycogen metabolic pathway. A common variant in the PPP1R3A gene involving a frameshift mutation predicted to lead to a truncated form of the protein
was previously identified in healthy European individuals. In a study using magnetic resonance spectroscopy in individuals with this PPP1R3A gene variant, those heterozygous for the mutation were found to have chronically lower levels of muscle
glycogen, by as much as 65%. These individuals were not found to have any associated clinical abnormalities. We were able to confirm and expand on this finding using our Compass platform by analyzing a much larger data set of individuals with the
PPP1R3A gene variant, including a small number of individuals homozygous for the PPP1R3A frameshift mutation. In both heterozygous and homozygous states, no clinically relevant differences in exercise capacity, cardiac function or glucose levels
could be detected compared to reference control populations. These findings provided reassurance that a wide therapeutic index would support substrate reduction therapy for Pompe disease. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Second, our Compass platform used both novel chemical matter and advanced molecular visualization technologies, including
<FONT STYLE="white-space:nowrap">Cryo-EM,</FONT> to solve the molecular structure of glycogen synthase 1. This identified a previously cryptic allosteric binding site that ultimately informed the development of a potent and selective small molecule
inhibitor, MZE001. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Neurology portfolio: ATXN2 and UNC13A </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>Overview of
ALS </U></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">ALS is a progressive and fatal neurodegenerative disease primarily affecting the upper and lower motor neurons, ultimately resulting in the loss of muscle
control. Gradual onset of progressive muscle weakness is the most common initial symptom, which leads to difficulty in speaking, chewing, swallowing and breathing. The time from first symptom to diagnosis is approximately 12 months with death,
typically from neuromuscular respiratory failure, occurring within three to five years of symptom onset. Up to 50% of patients with ALS develop cognitive impairment associated with frontotemporal dementia, or FTD. The cumulative lifetime risk of ALS
is about 1 in 400 and the incidence is one to two per 100,000 people per year, equating to about 5,760 to 6,400 new diagnoses annually. The total number of cases is approximately five per 100,000 people and the Center for Disease Control and
Prevention estimates the prevalence of ALS in the United States is approximately 16,000 patients. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While many of the genetic drivers underlying ALS are known, a high
variability in disease phenotype is observed. A small number of ALS patients live well beyond the three to five-year life expectancy. With differences in life expectancy not explained by the underlying mutations, genetic modifiers are likely
present. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>ATXN2 program </U></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In earlier studies of model organisms, we
identified ATXN2 as a genetic modifier whereby the inhibition was shown to limit the toxicity of a protein, <FONT STYLE="white-space:nowrap">TDP-43,</FONT> found to be pathologically aggregated in up to 97% of all ALS patients. We subsequently
validated the function of ATXN2 as a genetic modifier using our Compass platform. We utilized our functional genomics and human genetics tools to develop a microRNA gene therapy that targets ATXN2 to reduce aggregation of <FONT
STYLE="white-space:nowrap">TDP-43.</FONT> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In May 2024, we exclusively licensed our ATXN2 program to Neurocrine Biosciences, Inc. As consideration for such license,
we received upfront payment, and we will be eligible to receive milestone payments upon the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
completion of certain regulatory, development and commercial achievements, as well as royalties based upon future annual net sales. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><U>UNC13A program </U></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Genome-wide association studies have established that single
genetic traits, or variants, in the UNC13A gene are associated with ALS and FTD in humans, but how those variants increase the risk for disease was previously unknown. Maze and its partners uncovered a connection between genetic variation in UNC13A,
a gene critical to the function of the nervous system, and the abnormal <FONT STYLE="white-space:nowrap">build-up</FONT> of <FONT STYLE="white-space:nowrap">TDP-43,</FONT> a hallmark molecular characteristic of ALS and FTD. These findings were
published in <I>Nature</I>, and fill a long-standing gap in the understanding of how ALS and FTD, two serious neurodegenerative diseases that have no known cures or broadly effective treatments, develop. These findings were further validated in
<I>in vitro</I> models that showed that removal of <FONT STYLE="white-space:nowrap">TDP-43</FONT> from the nucleus causes cryptic exons to form in UNC13A which, in turn, decreased the levels of the UNC13A protein. We built our Compass platform with
the aim of finding genetic insights like this, which is a key step in translating such genetic insights into therapies for patients. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2024, we exclusively
licensed our UNC13A program to Trace Neurosicence, Inc. As consideration for such license, we received an upfront payment, and we will be eligible to receive milestone payments upon the completion of certain development, regulatory and commercial
achievements, as well as royalties based upon future annual net sales. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Ophthalmology portfolio </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our work in ophthalmology is another example of the application of our Compass platform and variant functionalization at work, where we identified and characterized the
genetic relevance of ANGPTL7 as a potential drug target for certain ophthalmic diseases like glaucoma. We identified certain genetic variants that enabled us to derive insight into how natural human genetic diversity correlates with the clinical
diagnosis of glaucoma and with enhanced elevated or diminished reduced intraocular pressure, a risk factor for glaucoma and glaucoma risk. Next, we identified targets for therapeutic intervention with an established role in human biology. Out of
these targets, we found multiple rare protein-altering variants in one putative target, the gene ANGPTL7, that were associated with lower IOP and reduced risk for glaucoma. In November 2020, together with Alloy Therapeutics, Inc., or Alloy, we
created Broadwing, a <FONT STYLE="white-space:nowrap">spin-out</FONT> company to develop antibody therapies for ANGPTL7 and another undisclosed target in ophthalmic disease for geographic atrophy, targets that were genetically validated by our
Compass platform. We made an initial cash and <FONT STYLE="white-space:nowrap">in-kind</FONT> contributions, including facilities and operational services, to Broadwing in exchange for a 50% equity interest. Alloy contributed cash and its antibody
discovery services for the other 50% equity interest. As of June 30, 2024, we owned approximately 48% of the outstanding equity of Broadwing. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our Compass
platform </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our pipeline of precision medicine candidates is built upon our Compass platform. Our Compass platform supports <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-to-end</FONT></FONT> variant identification and functionalization capabilities and methodologies for drug development, and has been purpose-built to inform different phases of our drug discovery and development process
through clinical trial design. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe variant functionalization, the process of understanding how genetic variants affect the function of a target protein, is a
foundational aspect of precision medicine. Variant functionalization through our Compass platform allows us to elevate drug discovery tractability considerations as a component of target selection. Our approach to developing new, transformational
therapies for common diseases is premised on understanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
how genetic variants impact the function of target proteins, which in turn provides insight into how best to modulate the identified target variant and an understanding of patient populations
that will benefit. We believe this approach enables highly predictive identification and validation of those genetically supported targets that are most likely to have clinical relevance and actionability, thereby increasing the probability for
clinical success and accelerating the expansion of our candidate pipeline. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to variant functionalization, our Compass platform and its associated
methodologies give us the ability to aggregate matched, genetic and longitudinal clinical datasets at scale to identify genes associated with disease, but more importantly, to determine how genetic variants of these genes provide insight into a
therapeutic approach to the applicable target. Targets are then prioritized based on their roles in biological pathways, their roles as potential drivers of disease, and their structural properties, using machine learning and statistical modeling,
variant functionalization tools, and traditional and computational drug discovery technologies. These insights ultimately inform our clinical development and patient selection strategies, which we believe have the potential to improve the overall
likelihood of technical, regulatory and commercial success of our medicines, although we cannot provide any assurance that the application of our Compass platform will result in the ultimate regulatory approval of any of our therapeutic candidates.
The power of our platform and its methodologies is best exhibited through our clinical and preclinical programs, and multiple contributions to the scientific community over the past five years, including the publication in <I>Nature</I> and other
leading scientific journals of discoveries made through our Compass platform in the fields of human genetics, molecular biology and medicinal chemistry. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have
built and utilized the Compass platform upon the confluence of three ongoing advancements to gain an understanding of the relationship between genes, the protein products encoded by these genes, and specific, observable human characteristics, or
traits and to translate these insights into innovative therapeutics. These trends are: the increasing availability of human genetic data paired with clinical data; the rapid evolution of experimental functional genomic technologies that can probe
gene function and interactions between genes in parallel; and advances in computational power and speed that enable the integration and analysis of vast amounts of data. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In summary, the Compass platform provides us with a differentiated ability to: analyze and visualize the vast and proliferating volume of patient-level genetic data and
paired clinical data worldwide with efficiency and speed, augmented with advanced data science tools and technologies; experimentally validate and characterize the linkages between specific genes and diseases identified through our data mining
activities and the strategic application of advanced functional genomic technologies; and apply insights derived through variant functionalization and structure-based design to develop an optimal therapy for the intended target. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Competition </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The pharmaceutical and biotechnology industries are
characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property. While we believe that our Compass platform and our knowledge, experience and scientific resources provide us with competitive
advantages, we face potential competition from major pharmaceutical and biotechnology companies, academic institutions, government agencies and private and public research institutions, among others. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any therapeutic candidates that we or our partners successfully develop and commercialize may compete with existing therapies and new therapies that may become available
in the future that are approved to treat the same indications for which we or our partners may obtain approval for our or their therapeutic candidates. It is also possible that we or our partners may face competition from other pharmaceutical
approaches as well as other types of therapies. The key competitive factors affecting the success of all our programs, if approved, include, but are not limited to be their efficacy, safety, convenience, adoption by prescribers, price, level of
generic competition, and availability of reimbursement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may face competition from companies developing therapies for CKD and related nephropathies, including but not
limited to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Established therapies: including RAAS inhibitors, SGLT2 inhibitors and <FONT STYLE="white-space:nowrap">GLP-1</FONT>
agonists. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Novel mechanisms: various companies developing therapies targeting different pathways implicated in CKD progression.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While there are currently no approved therapies for AKD, we are aware of companies advancing therapeutic candidates in clinical trials that target
APOL1. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our second most advanced lead program, MZE782, is a small molecule targeting SLC6A19, a novel target in CKD. While there are no currently approved therapies
directly modulating SLC6A19, we may face competition from other companies pursuing programs targeting SLC6A19 or alternative approaches for renal indications. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many
of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials,
obtaining regulatory approvals, and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient
registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the biopharmaceutical industries may result in even more resources being concentrated among a
smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through partnership arrangements with large and established companies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, precision medicine is a rapidly developing field, with increasing usage within the pharmaceutical and biotechnology industry of machine learning and AI
technologies to analyze genetic data. While we believe our Compass platform has advantages over potential competitors based on our experience in variant functionalization, our access to genetic databases, and the length of time that we have been
engaged in developing precision medicine, other companies may have greater resources or the ability to acquire more advanced technology to identify targets and may acquire access to the same genetic data that we utilize. We may not be able to keep
up with the pace of innovation that is occurring in our field, and we may face increasing competition in developing precision medicines. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial opportunity
could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our
competitors also may obtain FDA or other applicable regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the
market. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Intellectual property </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Intellectual property is of vital
importance in our field and in biotechnology generally. We seek to protect and enhance proprietary technologies, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, and defending
intellectual property rights, including patent rights. We may also seek to rely on regulatory protection afforded through inclusion in expedited development and review, data exclusivity, market exclusivity and/or patent term extensions where
available. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success will depend in part on obtaining and maintaining patent protection of our current and future therapeutic candidates and the
methods used to develop and manufacture them, as well as successfully defending our patents against third-party challenges, and operating without infringing on, misappropriating or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
otherwise violating the intellectual property and proprietary rights of others. The development of our therapeutic candidates is at a relatively early stage and as a consequence, our patent
portfolio is also at an early stage. We cannot be sure that patents will be granted based on our currently pending patent applications or patent applications we may file in the future. Nor can we be sure that any of our granted patents or patents
that may be granted to us in the future will be commercially useful in protecting our therapeutic candidates, technologies and processes. In addition, any patents that we may hold, whether owned or licensed, may be challenged, circumvented or
invalidated by third parties. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The term of individual patents depends upon the law in the countries in which they are obtained. In most countries, including the
United States, the term of a patent is 20 years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application, unless otherwise extended or adjusted. U.S.
<FONT STYLE="white-space:nowrap">non-provisional</FONT> applications and/or Patent Cooperation Treaty, or PCT, applications may be filed that claim priority to an earlier-filed patent application, provided that the earlier-filed patent application
was filed within 12 months of the U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> or PCT filing date. The PCT system allows for the designation of PCT member states in which national or regional patent applications may later be pursued.
A PCT application cannot mature into a patent until, among other things, one or more national or regional stage patent applications are filed within the applicable time limit, which is generally 30 or 31 months from the PCT application&#146;s
earliest priority date, depending on the jurisdiction. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The ability to obtain patent protection and the degree of such protection depends on several factors,
including whether an invention is directed to patentable subject matter, the novelty and <FONT STYLE="white-space:nowrap">non-obviousness</FONT> of the claimed invention, and the ability to satisfy the requirements of applicable patent laws, such as
enablement and written description, in addition to other administrative requirements for obtaining a patent. In addition, the claim scope in a patent application may be significantly narrowed before a patent is issued, and the scope of issued claims
can be reinterpreted or further altered even after patent issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our proprietary technologies or current or future therapeutic candidates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to patent protection, we also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> other proprietary information and continuing
technological innovation to develop and maintain our competitive position. We seek to protect and maintain the confidentiality of trade secrets and other proprietary information to protect aspects of our business that are not amenable to, or that we
do not consider appropriate for, patent protection. For example, we seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our
information technology systems. However, such security measures may be breached and we may not have adequate remedies for such breaches. We also seek to protect our proprietary information and trade secrets by entering into confidentiality and
invention assignment agreements with our employees, consultants and other parties who have access to such information. These agreements generally provide that all confidential information concerning our business or financial affairs developed or
made known to the individual during the course of the individual&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Our agreements with employees also generally provide that
all inventions conceived by the employee in the course of employment with us or from the employee&#146;s use of our confidential information are our exclusive property. However, we cannot guarantee that we have entered into such agreements with each
party that has or may have had access to our trade secrets or other proprietary information or has been involved in the development of intellectual property. Additionally, these agreements can be breached and we may not have adequate remedies for
any such breach. Moreover, our trade secrets may otherwise become known or be independently discovered by competitors, and to the extent that our employees, consultants, contractors or partners use intellectual property or proprietary information
owned by others in their work for us, disputes may arise as to our intellectual property rights. For all of these reasons, we may not be able to adequately protect proprietary information, trade secrets,
<FONT STYLE="white-space:nowrap">know-how</FONT> and inventions important to the development of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The intellectual property positions of biotechnology companies like ours are generally uncertain and involve complex
legal, scientific and factual questions. Our commercial success will also depend in part on avoiding infringing upon, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. Third-party patents
could require us to alter our development or commercial strategies, or our products or processes, obtain licenses or cease certain activities. Our breach of any license agreements or our failure to obtain a license to proprietary rights required to
develop or commercialize our future products may have a material adverse impact on us. For more information regarding the risks related to intellectual property, see &#147;Risk factors&#151;Risks related to intellectual property.&#148; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our policy is to seek patent protection for the technologies, inventions and improvements that we develop and that we consider important to the advancement of our
business. As of June&nbsp;30, 2024, we have been granted two issued U.S. patents, including a patent covering MZE001 composition of matter and uses, which expires in 2042 unless extended or otherwise adjusted, and a patent covering MZE829
composition of matter and uses, which expires in 2043 unless extended or otherwise adjusted. We have filed eight pending U.S. provisional patent applications, ten pending PCT patent applications, seven pending U.S.
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, and over fifty pending foreign patent applications in various jurisdictions including but not limited to Australia, Brazil, Canada, China, the European Patent Office, Hong
Kong, Israel, India, Japan, Republic of Korea, Mexico, Russia, Saudi Arabia, Singapore, and Taiwan. The pending applications are directed to compositions of matter, uses and processes, and, if issued, are projected to expire between 2042 and 2045
unless extended or otherwise adjusted. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For our small molecule APOL1 program, as of June 30, 2024, we own patent families that cover composition of matter of our
APOL1 compounds, including MZE829, methods of use, and processes. These patent families include one issued U.S. patent, five pending U.S. provisional patent applications, four pending PCT patent applications, three pending U.S. non-provisional
patent applications, and over ten pending foreign patent applications. Any currently issued patents or patents that may issue in the future in our APOL1 program are projected to expire between 2042 and 2045 unless extended or otherwise adjusted.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For our small molecule SLC6A19 program, as of June 30, 2024, we own patent families that cover composition of matter of our SLC6A19 compounds, including MZE782,
methods of use, and processes. These patent families include three pending U.S. provisional patent applications, three pending PCT patent applications, and one pending U.S non-provisional patent application. Any currently issued patents or patents
that may issue in the future in our SLC6A19 program are projected to expire between 2043 and 2044 unless extended or otherwise adjusted. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have entered into
three agreements to exclusively license or assign our patent portfolios associated with programs that are outside our areas of core focus. Pursuant to these agreements, we no longer have control of the prosecution of the issued patents and pending
patent applications in each of these portfolios. We cannot guarantee that our licensees will successfully develop, obtain marketing authorization for, or commercialize products that would result in our receiving royalties pursuant to such license
agreements. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have exclusively licensed our GYS1 patent portfolio, which includes the issued patent covering MZE001, to Shionogi. At the time we entered into
the License Agreement, our GYS1 patent portfolio included a pending U.S. non-provisional patent application, three pending PCT applications, and over twenty-five pending foreign patent applications in various jurisdictions. The patent portfolio we
licensed to Shionogi is directed to compositions of matter, uses and processes, and any currently issued patents or patents that may issue in the future in this portfolio are projected to expire between 2042 and 2043 unless extended or otherwise
adjusted. Shionogi controls the prosecution of this patent portfolio. We have exclusively licensed our patent portfolio relating to our program for ATXN2 gene therapy to another biotechnology company who controls the prosecution of this portfolio.
At the time we entered into this agreement, no patents had been issued. Our ATXN2 gene therapy patent portfolio included two pending non-provisional patent applications and over fifteen pending foreign patent applications in various jurisdictions.
The ATXN2 gene therapy patent portfolio is directed to compositions of matter and uses, and any patents that may issue in the future in this portfolio are projected to expire between 2041 and 2042 unless extended or otherwise adjusted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to our owned and out-licensed patent portfolios described above, we assigned our UNC13a ASO patent
portfolio in April 2024 to another biotechnology company. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Manufacturing </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not have any clinical manufacturing facilities. We currently rely, and expect to continue to rely, on third party contract manufacturing organizations, or CMOs,
including foreign CMOs, for clinical manufacturing of MZE829, MZE782 and our future therapeutic candidates, as well as for commercial manufacturing if our therapeutic candidates receive marketing approval. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We use multiple CMOs, including foreign CMOs, to manufacture our clinical-stage therapeutic candidates to conduct our clinical trials. As part of our strategy, we seek
to develop or advance therapeutic candidates that can be produced cost-effectively at contract manufacturing facilities without the need for unusual manufacturing equipment. All of our current therapeutic candidates are small molecule drug products
that we believe will require between 12 and 14 months to manufacture from initiation of drug substance manufacturing to completion of drug product, assuming we are able to obtain manufacturing slots with the appropriate CMOs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to enter into commercial supply agreements with commercial manufacturers prior to any potential approval of any of our therapeutic candidates. We believe our
current CMOs are able to adequately support manufacturing for our current and planned clinical trials and additional CMOs may be&nbsp;onboarded&nbsp;at later stages of clinical development and commercialization. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent any of our therapeutic candidates require companion diagnostics, which are assays or tests to identify an appropriate patient population, we generally
rely, and expect to continue to rely, on third parties to manufacture such assays or tests. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Governmental regulation and product approval </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, extensively regulate, among other things,
the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical
products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the
expenditure of substantial time and financial resources. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>FDA approval process </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or FDCA, and other federal and
state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and
import and export of pharmaceutical products. Pharmaceutical products&#151;such as small molecule drugs and biological products, or biologics&#151;used for the prevention, treatment, or cure of a disease or condition of a human being are subject to
regulation under the FDCA. Failure to comply with applicable United States requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending new drug applications, or NDAs,
warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pharmaceutical product development for a new product or certain changes to an approved product in the United States
typically involves preclinical laboratory and animal tests, the submission to the FDA of an IND, which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and
effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA <FONT STYLE="white-space:nowrap">pre-market</FONT> approval requirements typically takes many years and the actual time required may vary
substantially based upon the type, complexity, and novelty of the product or disease. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Preclinical tests include laboratory evaluation of product chemistry,
formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including Good Laboratory
Practices. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term
nonclinical tests, such as tests of reproductive toxicity and carcinogenicity in animals, may continue after the IND is submitted. A <FONT STYLE="white-space:nowrap">30-day</FONT> waiting period after the submission of each IND is required prior to
the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this <FONT STYLE="white-space:nowrap">30-day</FONT> period, the clinical trial proposed in the IND may begin. Clinical trials involve
the administration of the investigational drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with GCP,
an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&nbsp;under protocols detailing the objectives of the trial, the
parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is
not being conducted in accordance with FDA regulations or presents an unacceptable risk to the clinical trial patients. Imposition of a clinical hold may be full or partial. The study protocol and informed consent information for patients in
clinical trials must also be submitted to an Institutional Review Board, or IRB, for approval. The IRB will also monitor the clinical trial until completed. The IRB may also require the clinical trial at the site to be halted, either temporarily or
permanently, for failure to comply with the IRB&#146;s requirements, or may impose other conditions. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a
data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase 1, the initial
introduction of the drug into healthy human subjects or patients, the product is tested to assess safety, dosage tolerance, metabolism, pharmacokinetics, pharmacological actions, side effects associated with drug exposure, and to obtain early
evidence of a treatment effect if possible. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, determine optimal dose and regimen, and to identify common adverse
effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain additional information about clinical effects and confirm efficacy and
safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the product.
In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the safety and efficacy of the drug. In rare instances, a single Phase 3 trial may be sufficient when either (1)&nbsp;the trial is a large,
multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible or (2)&nbsp;the single trial is supported
by other confirmatory evidence. Approval on the basis of a single trial may be subject to a requirement for additional post-approval studies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the
manufacturer of an investigational drug in a Phase 2 or Phase 3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for
expanded access to such investigational drug. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the
NDA is required before marketing and distribution of the product may begin in the United States. The NDA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product&#146;s pharmacology,
chemistry, manufacture, and controls. The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee. Under an approved NDA, the applicant is also subject to an
annual program fee. These fees typically increase annually. The FDA has 60 days from its receipt of an NDA to determine whether the application will be filed based on the FDA&#146;s determination that it is adequately organized and sufficiently
complete to permit substantive review. Once the submission is filed, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review. The FDA has agreed to certain performance goals to complete the review of NDAs. Most applications are
classified as Standard Review products that are reviewed within ten months of the date the FDA files the NDA; applications classified as Priority Review are reviewed within six months of the date the FDA files the NDA. An NDA can be classified for
Priority Review when the FDA determines the drug has the potential to treat a serious or life-threatening condition and, if approved, would be a significant improvement in safety or effectiveness compared to available therapies. The review process
for both standard and priority reviews may be extended by the FDA for three or more additional months to consider certain late-submitted information, or information intended to clarify information already provided in the NDA submission. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA may also refer applications for novel drugs, as well as drugs products that present difficult questions of safety or efficacy, to be reviewed by an advisory
committee&#151;typically a panel that includes clinicians, statisticians and other experts&#151;for review, evaluation, and a recommendation as to whether the NDA should be approved. The FDA is not bound by the recommendation of an advisory
committee, but generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the
drug product is manufactured. The FDA will not approve the product unless compliance with current good manufacturing practices, or cGMPs, is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective
in the claimed indication. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After the FDA evaluates the NDA and completes any clinical and manufacturing site inspections, it issues either an approval letter or a
complete response letter. A complete response letter generally outlines the deficiencies in the NDA submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application for approval. If, or
when, those deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of
information included. An approval letter authorizes commercial marketing and distribution of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a Risk Evaluation and
Mitigation Strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure a product&#146;s safe
use, or ETASU. An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring, and the use of patient-specific
registries. The requirement for a REMS can materially affect the potential market and profitability of the product. Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product&#146;s safety or efficacy.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems
are identified following initial marketing. Changes to some of the conditions established in an approved NDA, including changes in indications, product labeling, manufacturing processes or facilities, require submission and FDA approval of a new
NDA, or supplement to an approved NDA, before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in
reviewing NDA supplements as it does in reviewing original NDAs. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fast track designation and priority review </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or
condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Fast track designation may be granted for products that are intended to treat a serious or life-threatening
disease or condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific
indication for which it is being studied. Any product submitted to FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement
in safety and effectiveness compared to available therapies. FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Accelerated approval </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accelerated approval may be granted for a
product that is intended to treat a serious or life-threatening condition and that generally provides a meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on the basis
of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible
morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement of laboratory
or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or survives. The accelerated approval pathway is most often used in settings in which the course of a disease is long and an
extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development
and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large studies to
demonstrate a clinical or survival benefit. The accelerated approval pathway is contingent on a sponsor&#146;s agreement to conduct additional post-approval confirmatory studies to verify and describe the product&#146;s clinical benefit. The FDA
must specify conditions for the post-approval study which may include details regarding enrollment targets, the study protocol and study milestones. These confirmatory trials must be completed with due diligence and the FDA may require that the
trial be designed, initiated, and/or fully enrolled prior to submission of the application or approval. Sponsors are also required to submit regular reports regarding the progress of conducting these post-approval studies. Failure to conduct
required post-approval studies in accordance with FDA&#146;s conditions and with due diligence, or submit the progress reports as well as failure to confirm a clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
benefit during post-marketing studies, would allow the FDA to undertake enforcement action or withdraw the product from the market on an expedited basis. All promotional materials for product
candidates approved under accelerated approval regulations are subject to prior review by the FDA. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Disclosure of clinical trial information </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sponsors of clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products, including drugs, are required to register and disclose certain clinical
trial information on the website www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of a clinical trial are then made public as part of the
registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of clinical trials can be delayed in certain circumstances for up to two years after the date of completion of the
trial. Competitors may use this publicly available information to gain knowledge regarding the progress of clinical development programs as well as clinical trial design. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Pediatric information </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Pediatric Research Equity Act, or
PREA, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for
which the drug is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any drug with orphan product designation except a product with a
new active ingredient that is a molecularly targeted cancer product intended for the treatment of an adult cancer and directed at a molecular target determined by FDA to be substantially relevant to the growth or progression of a pediatric cancer
that is subject to an NDA submitted on or after August&nbsp;18, 2020. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Best Pharmaceuticals for Children Act, or BPCA, provides a
<FONT STYLE="white-space:nowrap">six-month</FONT> extension of any exclusivity-patent or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-patent-for</FONT></FONT> a drug if certain conditions are met. Conditions for exclusivity
include the FDA&#146;s determination that information relating to the use of a new drug in the pediatric population may produce health benefits in that population, FDA making a written request for pediatric studies, and the applicant agreeing to
perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Post-approval requirements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once an NDA is approved, a product will be
subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, <FONT STYLE="white-space:nowrap">off-label</FONT> promotion, industry-sponsored scientific and educational activities and promotional
activities involving the Internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Adverse
event reporting and submission of periodic safety summary reports are required following FDA approval of an NDA. The FDA also may require post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved
product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval.
Drugs manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which
the agency inspects a drug&#146;s manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality-control
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with required regulatory standards, if it
encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The Hatch-Waxman amendments </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Orange book listing </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Drug Price Competition and Patent Term
Restoration Act of 1984, commonly referred to as the Hatch Waxman Amendments, NDA applicants are required to identify to FDA each patent whose claims cover the applicant&#146;s drug or approved method of using the drug. Upon approval of a drug, the
applicant must update its listing of patents to the FDA in timely fashion and each of the patents listed in the application for the drug is then published in the FDA&#146;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly
known as the Orange Book. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated NDA, or
ANDA. An ANDA provides for marketing of a drug product that has the same active ingredient(s), strength, route of administration, and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent
to the listed drug. An approved ANDA product is considered to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or
clinical tests to prove the safety or effectiveness of their drug product. Drugs approved under the ANDA pathway are commonly referred to as &#147;generic equivalents&#148; to the listed drug and can often be substituted by pharmacists under
prescriptions written for the original listed drug pursuant to each state&#146;s laws on drug substitution. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The ANDA applicant is required to certify to the FDA
concerning any patents identified for the reference listed drug in the Orange Book. Specifically, the applicant must certify to each patent in one of the following ways: (i)&nbsp;the required patent information has not been filed; (ii)&nbsp;the
listed patent has expired; (iii)&nbsp;the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv)&nbsp;the listed patent is invalid, unenforceable or will not be infringed by the new
product. A certification that the new product will not infringe the already approved product&#146;s listed patents, or that such patents are invalid or unenforceable, is called a Paragraph IV certification. For patents listed that claim an approved
method of use, under certain circumstances the ANDA applicant may also elect to submit a statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">method-of-use</FONT></FONT> rather than certify to a listed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patent, which is called a Section VIII statement. If the applicant
does not challenge the listed patents through a Paragraph IV certification, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. If the ANDA applicant has provided a Paragraph IV
certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the <FONT STYLE="white-space:nowrap">NDA-holder</FONT> and patentee(s) once the ANDA has been accepted for filing by the FDA (referred to as the
&#147;notice letter&#148;). The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice letter. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification
automatically prevents the FDA from approving the ANDA until the earlier of 30 months from the date the notice letter is received, expiration of the patent, the date of a settlement order or consent decree signed and entered by the court stating
that the patent that is the subject of the certification is invalid or not infringed, or a decision in the patent case that is favorable to the ANDA applicant. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
ANDA application also will not be approved until any applicable <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity listed in the Orange Book for the referenced product has expired. In some instances, an ANDA applicant may receive
approval prior to expiration of certain <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity if the applicant seeks, and FDA permits, the omission of such exclusivity-protected information from the ANDA prescribing information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Exclusivity </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon NDA
approval of a new chemical entity, or NCE, which is a drug that contains no active moiety that has been approved by FDA in any other NDA, that drug receives five years of marketing exclusivity during which FDA cannot receive any ANDA seeking
approval of a generic version of that drug unless the application contains a Paragraph IV certification, in which case the application may be submitted one year prior to expiration of the NCE exclusivity. If there is no listed patent in the Orange
Book, there may not be a Paragraph IV certification, and, thus, no ANDA for a generic version of the drug may be filed before the expiration of the exclusivity period. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain changes to an approved drug, such as the approval of a new indication, the approval of a new strength, and the approval of a new condition of use, are associated
with a three-year period of exclusivity from the date of approval during which FDA cannot approve an ANDA for a generic drug that includes the change. In some instances, an ANDA applicant may receive approval prior to expiration of the three-year
exclusivity if the applicant seeks, and FDA permits, the omission of such exclusivity-protected information from the ANDA package insert. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Patent term extension
</I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Hatch Waxman Amendments permit a patent term extension as compensation for patent term lost during the FDA regulatory review process. Patent term extension,
however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. After NDA approval, owners of relevant drug patents may apply for the extension. The allowable patent term extension depends on a
number of factors and is on a case by case basis, generally calculated as half of the drug&#146;s testing phase (the time between IND application and NDA submission) and all of the review phase (the time between NDA submission and approval) that
occurs after patent issuance up to a maximum of five years and subject to the 14 year cap. The time can be reduced for any time FDA determines that the applicant did not pursue approval with due diligence. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The United States Patent and Trademark Office, or USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.
However, the USPTO may not grant an extension because of, for example, an applicant failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to
expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than requested. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The total patent term after the extension may not extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may
be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be enforced during the extension period. The application for the extension must be submitted prior to the expiration of the
patent, and for patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by up to one year and may be renewed up to four times. For each
interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim
patent extensions are not available for a drug for which an NDA has not been submitted. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>FDA approval and regulation of companion diagnostics </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If safe and effective use of a therapeutic product depends on an&nbsp;<I>in</I> <I>vitro</I>&nbsp;diagnostic, then the FDA generally will require approval or clearance
of that diagnostic, known as a companion diagnostic, before or at the same time that the FDA approves the product. In August 2014, the FDA issued final guidance clarifying the requirements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
that will apply to approval of therapeutic products and <I>in</I> <I>vitro</I> companion diagnostics. According to the guidance, if FDA determines that a companion diagnostic device is essential
to the safe and effective use of a new therapeutic product or indication, FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic device is not approved or cleared for that indication.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in
the intended population. The review of <I>in</I> <I>vitro</I> companion diagnostics in conjunction with the review of a therapeutic product will, therefore, likely involve coordination of review by CDER and the FDA&#146;s Office of In Vitro
Diagnostics and Radiological Health. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the FDCA, <I>in</I> <I>vitro</I> diagnostics, including companion diagnostics, are regulated as medical devices. In the
United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval,
registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval
from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA. The vast majority of
companion diagnostics require PMA approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA,
can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#146;s safety and effectiveness and information about the device and its
components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate
and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, a PMA application typically requires data regarding analytical and
clinical validation studies. As part of the PMA review, the FDA will typically inspect the manufacturer&#146;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other
quality assurance requirements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">PMA approval is not guaranteed, and the FDA may ultimately issue a not approvable letter to a PMA submission based on deficiencies
in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA&#146;s evaluation of the PMA application is favorable, the FDA
typically issues an approvable letter requiring the applicant&#146;s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the
PMA. If the FDA&#146;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where
practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted
and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant.
The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. Once granted, PMA approval
may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards are not maintained, or problems are identified following initial marketing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may
be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also register their establishments and list their devices with the FDA. A medical device manufacturer&#146;s manufacturing processes and
those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical
devices. Domestic and foreign facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Other U.S. healthcare
laws and compliance requirements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, pharmaceutical and biotechnology company activities are potentially subject to regulation by various
federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, or HHS, (e.g., the Office
of Inspector General and the Office for Civil Rights), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, sales, marketing and scientific/educational grant
programs, may have to comply with the anti-fraud and abuse provisions of the Social Security Act, the federal false claims laws, the privacy and security provisions of the federal Health Insurance Portability and Accountability Act of 1996, or
HIPAA, and similar state laws, each as amended, as applicable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly
and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering, recommending or arranging for the purchase, lease or
order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to
arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and/or formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from
prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an
exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the
arrangement will be evaluated on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of its facts and circumstances. Practices may not in all cases meet all of the
criteria for protection under a statutory exception or regulatory safe harbor. In addition, the statutory exceptions and regulatory safe harbors are subject to change. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, the intent standard under the Anti-Kickback Statute was amended by the ACA, to a stricter standard such that a person or entity no longer needs to have
actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute
constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The civil monetary penalties statute imposes penalties
against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is
false or fraudulent. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Federal false claims laws, including the federal civil False Claims Act, prohibit, among other things, any person or entity from knowingly
presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any request or
demand&#148; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the civil False Claims Act even when they do not submit claims directly to government payors if they are deemed to
&#147;cause&#148; the submission of false or fraudulent claims. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the
customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#146; marketing of the product for unapproved, and thus generally <FONT
STYLE="white-space:nowrap">non-reimbursable,</FONT> uses and purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">HIPAA created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means
of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying,
concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the
Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in
several states, apply regardless of the payor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Data privacy and security regulations by both the federal government and the states in which business is conducted
may also be applicable. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes among other things, certain requirements relating to the privacy, security,
transmission and breach of individually identifiable health information. HIPAA requires covered entities to limit the use and disclosure of protected health information to specifically authorized situations, and requires covered entities to
implement security measures to protect health information that they maintain in electronic form. Among other things, HITECH made HIPAA&#146;s security standards directly applicable to business associates, independent contractors or agents of covered
entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties
directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with
pursuing federal civil actions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, certain states have also adopted data privacy and security laws and regulations, which govern the processing of
health-related and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues. For example, CCPA, imposes
obligations on businesses that meet certain thresholds that process the personal information of California residents (including employees based in California). These obligations include, but are not limited to, providing specific disclosures in
privacy notices and affording California residents certain rights related to their personal information, including the ability to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales of personal information. The CCPA provides for a
private right of action for certain data breaches, which may increase the likelihood of, and risks associated with, data breach litigation. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA could increase
compliance costs and potential liability. The 2020 amendments to the CCPA also created the California Privacy Protection Agency, a new enforcement agency whose sole responsibility is to enforce the CCPA and is empowered to create new CCPA
regulations. Other states have also passed comprehensive privacy laws, and similar laws are being </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
considered in several other states, as well as at the local and federal levels, including discussion in the U.S. of a new comprehensive federal data privacy law. In addition to government
activity and private rights of actions provided by some of the state privacy laws, privacy advocacy groups and technology and other industries are considering various new, additional or different self-regulatory standards that may place additional
burdens on companies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Internationally, many countries have privacy and data protection laws that create potentially complex compliance issues . For example, the EU
GDPR and UK GDPR impose strict requirements for processing the personal data of individuals, including, for example, requirements to establish a legal basis for processing, higher standards for obtaining consent from individuals to process their
personal data, more robust disclosures to individuals and a strengthened individual data rights regime, requirements to implement safeguards to protect the security and confidentiality of personal data that requires the adoption of administrative,
physical and technical safeguards, shortened timelines for data breach notifications to appropriate data protection authorities or data subjects, limitations on retention and secondary use of information, increased requirements pertaining to health
data, regulation of the transferring of personal data across jurisdiction and additional obligations when third-party processors are contracted in connection with the processing of the personal data. EU member states are tasked under the EU GDPR to
enact, and have enacted, certain implementing legislation that adds to and/or further interprets the EU GDPR requirements and potentially extends the obligations and potential liability for failing to meet such obligations. Under the EU GDPR,
government regulators may impose temporary or definitive bans on data processing, as well as fines of up to <FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million or 4% of annual global revenue, whichever is greater. Such fines would
be in addition to (i)&nbsp;the rights of individuals to sue for damages in respect of any data privacy breach which causes them to suffer harm, (ii)&nbsp;the right of individual member states to impose additional sanctions over and above the
administrative fines specified in the GDPR and (iii)&nbsp;the ability of supervisory authorities to impose orders requiring companies to modify their practices. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, the federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices,
biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of
value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and
teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members. Manufacturers are also required to report such information regarding its relationships with physician
assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants and certified nurse midwives during the previous year. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Commercial distribution of products requires compliance with state laws that require the registration of manufacturers and wholesale distributors of drug in a state,
including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and
distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain.
In addition, several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing,
pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology
companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. Certain local jurisdictions also require drug manufacturers to report information related to payments and other transfers of value to physicians
and other healthcare providers or marketing expenditures. Sales and marketing activities are also potentially subject to federal and state consumer protection and unfair competition laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Violation of any of the federal and state healthcare laws described above or any other governmental regulations may
result in penalties, including without limitation, significant civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, imprisonment,
injunctions, private &#147;qui tam&#148; actions brought by individual whistleblowers in the name of the government, refusal to enter into government contracts, oversight monitoring, contractual damages, reputational harm, administrative burdens,
diminished profits and future earnings. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Coverage, pricing and reimbursement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which regulatory approval is obtained. In the United States and
markets in other countries, sales of any products for which regulatory approval is received for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such
products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage
for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list,
also known as a formulary, which might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and
reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. Expensive pharmaco-economic studies may need to be conducted in order to demonstrate the medical necessity and
cost-effectiveness of product candidates, in addition to the costs required to obtain the FDA approvals. Product candidates may not be considered medically necessary or cost-effective. A payor&#146;s decision to provide coverage for a product does
not imply that an adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party
reimbursement may not be available to enable the maintenance of price levels sufficient to realize an appropriate return on investment in product development. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and
reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a
reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available
therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being
erected to the entry of new products. In addition, in some countries, cross-border imports from <FONT STYLE="white-space:nowrap">low-priced</FONT> markets exert a commercial pressure on pricing within a country. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The marketability of any product candidates for which regulatory approval is received for commercial sale may suffer if the government and other third-party payors fail
to provide coverage and adequate reimbursement. In addition, emphasis on managed care in the United States has increased and is expected to continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement
rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which regulatory approval is received, less favorable coverage policies and reimbursement rates may be implemented in the
future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Healthcare reform </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Healthcare reforms that have been adopted, and that may be adopted in the future, could result in further reductions in coverage and levels of reimbursement for
pharmaceutical products, increases in rebates payable under U.S. government rebate programs and additional downward pressure on pharmaceutical product prices. Healthcare reform proposals recently culminated in the enactment of the Inflation
Reduction Act, which will eliminate, beginning in 2025, the coverage gap under Medicare Part D by significantly lowering the enrollee maximum <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost and
requiring manufacturers to subsidize, through a newly established manufacturer discount program, 10% of Part D enrollees&#146; prescription costs for brand drugs below the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> maximum, and 20% once the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> maximum has been reached. The
Inflation Reduction Act will also allow HHS to directly negotiate the selling price of a statutorily specified number of drugs each year that CMS reimburses under Medicare Part B and Part D. Only high-expenditure single-source drugs that have been
approved for at least 7 years (11 years for biologics) can qualify for negotiation, with the negotiated price taking effect two years after the selection year. Negotiations for Medicare Part D products begin in 2024 with the negotiated price taking
effect in 2026, and negotiations for Medicare Part B products begin in 2026 with the negotiated price taking effect in 2028. In August 2023, HHS announced the ten Medicare Part D drugs and biologics that it selected for negotiations, and by
October&nbsp;1, 2023, each manufacturer of the selected drugs signed a manufacturer agreement to participate in the negotiations. HHS will announce the negotiated maximum fair prices by September&nbsp;1, 2024, and this price cap, which cannot exceed
a statutory ceiling price, will come into effect on January&nbsp;1, 2026. A drug or biological product that has an orphan drug designation for only one rare disease or condition will be excluded from the Inflation Reduction Act&#146;s price
negotiation requirements, but loses that exclusion if it has designations for more than one rare disease or condition, or if is approved for an indication that is not within that single designated rare disease or condition, unless such additional
designation or such disqualifying approvals are withdrawn by the time CMS evaluates the drug for selection for negotiation. The Inflation Reduction Act also imposes rebates on Medicare Part B and Part D drugs whose prices have increased at a rate
greater than the rate of inflation. The Inflation Reduction Act permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the
Inflation Reduction Act may be subject to various penalties, some significant, including civil monetary penalties. The Inflation Reduction Act also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces
through plan year 2025. These provisions are taking effect progressively starting in 2023, although they may be subject to legal challenges. For example, the provisions related to the negotiation of selling prices of high-expenditure single-source
drugs and biologics have been challenged in multiple lawsuits. Thus, while it is unclear how the Inflation Reduction Act will be implemented, it will likely have a significant impact on the pharmaceutical industry and the pricing of pharmaceutical
products, particularly pharmaceutical products indicated for prevalent conditions. It is unclear to what extent other statutory, regulatory, and administrative initiatives will be enacted and implemented in the future. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Employees and human capital resources </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June 30, 2024, we had 108
employees, all of whom were full-time and 87 of whom were engaged in research and development activities. Approximately 47 of our employees hold Ph.D. or M.D. degrees. None of our employees are represented by labor unions or covered by collective
bargaining agreements. We consider our relationship with our employees to be an asset. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our human capital resources objectives include, as applicable,
identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. It is important that we not only attract and retain the best and brightest diverse talent, but also ensure they remain
engaged and can thrive in an environment that is committed to helping them grow, succeed and contribute directly to achieving our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
purpose. The principal purposes of our equity and cash incentive plans are to attract, retain and motivate personnel through the granting of stock-based and cash-based compensation awards in
order to increase the success of our Company by motivating such individuals to perform to the best of their abilities in the furtherance of our objectives. We also strive to foster career growth and internal mobility by providing a broad range of
training, mentoring and other development opportunities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Facilities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
corporate headquarters is located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California, where we lease and occupy approximately 67,000 square feet of office and laboratory space. Our lease, entered into on September&nbsp;27, 2019,
has a term of approximately 10 years. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe our existing facility is sufficient for our needs for the foreseeable future. To meet the future needs of our
business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Legal proceedings </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, we may become involved in litigation or
other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an
adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_11"></A>Management </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Executive officers and directors </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table provides
information, including ages as of June 30, 2024, regarding our executive officers and directors: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="63%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Position</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jason Coloma, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Harold S. Bernstein, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">President, Research and Development and Chief Medical&nbsp;Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Atul Dandekar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Strategy and Business Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Courtney Phillips</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General Counsel and Corporate Secretary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Non-Employee Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Charles Homcy, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board, Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nancy C. Andrews, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sekar Kathiresan, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jonathan Lim, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard Scheller, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Catherine Angell Sohn, Pharm. D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Daniel Spiegelman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jeffrey Tong, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Andy Tran</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="7" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Compensation Committee. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Audit Committee. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Nominating and Governance Committee. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Executive officers </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Jason Coloma, Ph.D.,</B> has served as our President, Chief Executive Officer, and member of our board of directors since July 2019. Prior to that, he served as a
venture partner at Third Rock Ventures, a venture capital firm, from June 2016 to July 2019. Previously, he held several roles at Roche, a multinational healthcare company, and Genentech, a biotechnology company, between August 2007 and July 2016,
including Vice President&nbsp;&amp; Global Therapeutic Area Head of Oncology Partnering as well as Global Head of Research Technology Partnering. Before joining Roche and Genentech, Dr.&nbsp;Coloma was a consultant in the life sciences practice at
L.E.K. Consulting LLC, a global strategy consulting firm. He also worked in research at the University of California, San Francisco, and Cytokinetics, Incorporated, late-stage biopharmaceutical company. Dr.&nbsp;Coloma holds a Ph.D. and M.P.H. from
the University of California, Berkeley, an M.B.A. from the Tuck School of Business at Dartmouth College, and a B.S. in Biology from the University of San Francisco. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Harold S. Bernstein M.D., Ph.D.,</B> has served as our President, Head of Research and Development, and Chief Medical Officer since October 2022. Prior to working at
our company, Dr.&nbsp;Bernstein was Chief Medical Officer, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Head of Global Clinical Development and Senior Vice President of Worldwide Research and Development at BioMarin Pharmaceutical Inc., global biotechnology company, from October 2021 to September
2022. Before that, Dr.&nbsp;Bernstein served as Head of Translational Medicine and Vice President of Global Medicines Development and Medical Affairs at Vertex, a biopharmaceutical company, from October 2017 to September 2021. Prior to that,
Dr.&nbsp;Bernstein served as Head of Cardiometabolic Diseases Early Clinical Development and Executive Director at Merck&nbsp;&amp; Co., Inc., multinational pharmaceutical company, from January 2013 to September 2017. Since July 2013,
Dr.&nbsp;Bernstein has served as Adjunct Professor of Pediatrics (Cardiology) at the Mindich Child Health Development Institute at the Icahn School of Medicine at Mount Sinai. Dr.&nbsp;Bernstein also served as Professor of Pediatrics and a Senior
Investigator at the Cardiovascular Research Institute and the Broad Center of Regeneration Medicine and Stem Cell Research at the University of California, San Francisco (UCSF) from January 1997 to June 2013. Dr.&nbsp;Bernstein holds an A.B. in
Biological Sciences from Harvard College and an M.Phil., Ph.D. and M.D. from the Icahn School of Medicine at Mount Sinai. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Atul Dandekar</B> has served as our
Chief Strategy and Business Officer since July 2024, and previously served as our Chief Strategy Officer from March 2021 to July 2024. In this role, Mr.&nbsp;Dandekar is responsible for our business development, partnering, portfolio management and
corporate strategy. Prior to working at our company, Mr.&nbsp;Dandekar held various positions at Genentech, a biotechnology corporation, including Vice President and Head of Global Ophthalmology Business Franchise, from January 2014 to March 2021.
Prior to Genentech, Mr.&nbsp;Dandekar served in various positions at Novartis AG, a multinational pharmaceutical corporation, from February 2007 to December 2013, most recently as its Senior Global Program Head, Neurology. He is the <FONT
STYLE="white-space:nowrap">co-founder</FONT> of Ollin Biosciences, a private biotechnology company. Since March 2021, Mr.&nbsp;Dandekar has served as a director at Broadwing, a private biotechnology company. Mr.&nbsp;Dandekar holds a bachelor&#146;s
degree in medicine and a masters in marketing from Mumbai University, as well as a post-graduate marketing degree from Monash University. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Courtney Phillips</B>
has served as our General Counsel and Corporate Secretary since July 2024. Prior to Maze, Ms.&nbsp;Phillips served as General Counsel and Corporate Secretary at Atreca, Inc., or Atreca, a biotechnology company, from July 2019 through June 2024.
Prior to Atreca, Ms. Phillips was Vice President of Corporate Law at Global Blood Therapeutics, Inc., or Global Blood Therapeutics, a biotechnology company, from November 2017 through June 2019. Prior to Global Blood Therapeutics, Ms. Phillips
served as Senior Corporate Counsel and then Vice President and Associate General Counsel at Relypsa, Inc., or Relypsa, a biotechnology company, from December 2013 through March 2017. Prior to Relypsa, Ms. Phillips was Corporate Counsel at Affymax,
Inc., a biotechnology company. Earlier in her career, Ms. Phillips was a corporate/finance attorney at the law firms of Morrison Foerster LLP and Reed Smith LLP, where she represented biotechnology and technology companies in IPOs and other equity
financings, mergers and acquisitions, securities law matters, and corporate governance. Ms.&nbsp;Phillips holds a B.A. from the University of California, Berkeley and a J.D. from Georgetown University Law Center. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Charles Homcy, M.D.</B>, has served as the chairman of our board of directors since June 2018. Dr.&nbsp;Homcy previously served as a partner at Third Rock Ventures, a
venture capital firm, from September 2010 to October 2019 where he currently serves in an advisory capacity. Dr.&nbsp;Homcy is also a <FONT STYLE="white-space:nowrap">co-founder</FONT> of BridgeBio Pharma, Inc., a publicly traded biotechnology
company, and has served as a member of its board of directors since November 2018, as Chairman of Pharmaceuticals since February 2019, and as lead director since February 2020. In 2003, Dr.&nbsp;Homcy
<FONT STYLE="white-space:nowrap">co-founded</FONT> Portola Pharmaceuticals, LLC, a clinical biotechnology company, and served as President and Chief Executive Officer until 2010. Prior to that, Dr.&nbsp;Homcy served as director and the President of
Research and Development at Millennium Pharmaceuticals, Inc. He was previously President of the medical research division of American Cyanamid&nbsp;&amp; Chemical Corporation&#146;s American Cyanamid-Lederle Laboratories. Dr.&nbsp;Homcy was a
clinical professor of medicine at the University of California, San Francisco Medical School, and attending physician at the San Francisco Veterans Affairs Hospital from 1997 to 2008. He was previously a member of the Cardiac Unit of the
Massachusetts General Hospital and an Associate Professor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
of Medicine at Harvard Medical School. Dr.&nbsp;Homcy holds an A.B. in Biology and an M.D. from Johns Hopkins University and is an Emeritus Trustee. Dr.&nbsp;Homcy is a <FONT
STYLE="white-space:nowrap">co-founder</FONT> of multiple privately held biotechnology companies including Global Blood Therapeutics, Inc., MyoKardia, Inc., Relay Therapeutics, Inc., Pliant Therapeutics Inc., and Marea Therapeutics. We believe
Dr.&nbsp;Homcy is qualified to serve on our board of directors based on his significant experience building and leading successful biotechnology companies and his scientific expertise. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Nancy C. Andrews, M.D., Ph.D</B>., has served as a member of our board of directors since January 2021. Dr.&nbsp;Andrews has served as Executive Vice President and
Chief Scientific Officer at Boston Children&#146;s Hospital since December 2021. She is also Professor in Residence of Pediatrics at Harvard Medical School. She was previously at Duke University from October 2007 to December 2021, where she served
as Dean of the School of Medicine, Vice Chancellor for Academic Affairs, Professor of Pediatrics and Professor of Pharmacology&nbsp;&amp; Cancer Biology. From 2003 to 2007, she served as Dean for Basic Sciences and Graduate Studies and Professor of
Pediatrics at Harvard University Medical School. From 1999 to 2003, she served as director of the Harvard-Massachusetts Institute of Technology M.D./Ph.D. Program, and the principal investigator of its MSTP grant. From 1993 to 2006, she was a
biomedical research investigator of the Howard Hughes Medical Institute. Dr.&nbsp;Andrews is an elected member of the American Academy of Arts and Sciences, the National Academy of Medicine, and the National Academy of Sciences, where she currently
serves as Home Secretary. She has also served on the board of trustees of the Massachusetts Institute of Technology, the MIT Corporation. Since July&nbsp;2018, she has served as a member of the Scientific Advisory Board of Dyne Therapeutics, Inc.,
clinical-stage muscle disease company. Dr.&nbsp;Andrews has also served on the board of directors of Novartis AG, a multinational pharmaceutical corporation since February 2015, and Charles River Laboratories, Inc, a pharmaceutical company, since
February 2020. She received her B.S. and M.S. from Yale University, her Ph.D. from Massachusetts Institute of Technology, and her M.D. from Harvard Medical School. We believe Dr.&nbsp;Andrews is qualified to serve on our board of directors due to
her extensive scientific leadership and expertise in oncology, genetics, and pediatric research. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Sekar Kathiresan, M.D.</B> has served as a member of our board
of directors since April 2022. Dr.&nbsp;Kathiresan is the <FONT STYLE="white-space:nowrap">co-founder</FONT> and since July 2019 has served as the Chief Executive Officer and as member of the board of directors of Verve Therapeutics, Inc. Since July
2022, Dr. Kathiresan has served on the board of directors of Relay Therapeutics, Inc. From June 1997 until September 2021, Dr.&nbsp;Kathiresan served as a Physician (Cardiology) at Massachusetts General Hospital, where he was also the Director of
Preventative Cardiology from June 2006 to June 2016 and the Director of the Center for Genomic Medicine from April 2016 to June 2019. Dr.&nbsp;Kathiresan has served as an Honorary Physician in the Department of Medicine at Massachusetts General
Hospital since September 2021. Dr.&nbsp;Kathiresan served as a Professor of Medicine at Harvard Medical school from July 2018 to July 2021 and is currently at Lecturer in Medicine at Harvard Medical School. From February 2008 to June 2019,
Dr.&nbsp;Kathiresan served as a Principal Investigator at the Broad Institute of MIT and Harvard, where he also served as a <FONT STYLE="white-space:nowrap">Co-Director</FONT> of the Program in Medical and Population Genetics from June 2014 to June
2019. Dr.&nbsp;Kathiresan holds a B.A. in History from the University of Pennsylvania and an M.D. from Harvard Medical School. We believe that Dr.&nbsp;Kathiresan is qualified to serve on our board of directors based on his significant medical
expertise and his significant experience researching genetics and CV disease. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Jonathan Lim, M.D.</B>,<B> </B>has served as a member of our board of directors
since October 2019. Dr.&nbsp;Lim has served as a Venture Partner at ARCH Venture Partners, LLC, a venture capital firm, since December 2018. Dr.&nbsp;Lim <FONT STYLE="white-space:nowrap">co-founded</FONT> Erasca, Inc., a clinical-stage precision
oncology company, in July 2018 and currently serves as the Chairman of its board of directors and Chief Executive Officer. Since December 2018, Dr.&nbsp;Lim has also served as the Chairman and <FONT STYLE="white-space:nowrap">Co-founder</FONT> at
Boundless Bio, Inc., a biotechnology company. Dr.&nbsp;Lim is also the Managing Partner and Founder of City Hill, LLC, a venture capital firm. Previously, Dr.&nbsp;Lim <FONT STYLE="white-space:nowrap">co-founded</FONT> Ignyta, Inc., a pharmaceutical
company, in 2011 and served as the Chairman of its board of directors, President and Chief Executive Officer until its acquisition by Roche, a multinational healthcare company, in December 2018. He also
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
previously served as Chairman and <FONT STYLE="white-space:nowrap">Co-founder</FONT> of Bonti, Inc., a clinical-stage biotechnology company, from August 2015 until its October 2018 acquisition by
Allergan PLC, a pharmaceutical company; Chairman, Chief Executive Officer and <FONT STYLE="white-space:nowrap">Co-founder</FONT> of Eclipse Therapeutics, LLC, a private biotechnology company, from 2011 until its 2012 acquisition by Bionomics Ltd.,
clinical-stage biopharmaceutical company; and President, Chief Executive Officer and Chairman-then-Director of Halozyme Therapeutics, Inc., a biotechnology company, from 2003 to 2010. From 2001 to 2003, Dr.&nbsp;Lim was a management consultant at
McKinsey&nbsp;&amp; Company, a global management consulting firm, where he specialized in the healthcare industry. From 1999 to 2001, Dr.&nbsp;Lim was a recipient of a National Institutes of Health Postdoctoral Fellowship, during which time he
conducted clinical outcomes research at Harvard Medical School. Dr.&nbsp;Lim&#146;s prior experience also includes two years of clinical training in general surgery at the New York Hospital-Cornell Medical Center and Memorial Sloan-Kettering Cancer
Center. Dr.&nbsp;Lim received an M.P.H. in Health Care Management from Harvard University, an M.D. from McGill University, and a B.S. and M.S. in Biological Sciences from Stanford University. We believe Dr.&nbsp;Lim is qualified to serve on our
board of directors based on his significant experience building and leading successful biotechnology companies and his scientific and clinical expertise. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Richard
Scheller, Ph.D.,</B> has served as a member of our board of directors since June 2019. Dr.&nbsp;Scheller is currently the Chair of Research and Development at BridgeBio Pharma Inc., a biotechnology company, a role he has served since January 2019,
and served as a member of its board of directors from January 2018 to February 2021. He was previously the Head of Therapeutics and Chief Scientific Officer at 23andMe, Inc., a personal genomics company, from 2015 to 2019 and since early 2019 has
served on that company&#146;s board of directors. He also serves on the board of directors of Alector, Inc. From 2001 to 2014, Dr.&nbsp;Scheller spent 14 years at Genentech, a biotechnology company, where he was Executive Vice President of Research
and Early Development. From 1982 to 2001, Dr.&nbsp;Scheller served on the faculty of Stanford University as a professor in the Department of Biological Sciences and the Department of Molecular and Cellular Physiology and was an investigator at the
Howard Hughes Medical Institute of Stanford University Medical Center. Since 2004, Dr.&nbsp;Scheller has served as an adjunct professor in the Department of Biochemistry and Biophysics at the University of California, San Francisco. He has published
more than 200 primary research papers during his career. Dr.&nbsp;Scheller received the Kavli Prize in Neuroscience (2010)&nbsp;and is a Member of the National Academy of Sciences and the National Academy of Medicine. Dr.&nbsp;Scheller received a
Ph.D. in Chemistry from California Institute of Technology and a B.S. in Biochemistry from the University of Wisconsin-Madison. We believe Dr.&nbsp;Scheller is qualified to serve on our board of directors based on his significant experience building
and leading successful biotechnology companies and his scientific expertise. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Catherine Angell Sohn, Pharm. D.,</B> has served as a member of our board of
directors since January 2021. Since January 2011, Dr.&nbsp;Sohn has consulted for pharmaceutical, biotechnology, medical device and consumer healthcare companies in the areas of business strategy, business development, strategic product development
and commercial launch at Sohn Health Strategies, LLC, which she founded and serves as President. Since March 2023, Dr.&nbsp;Sohn has served on the board of directors of Altimmune Inc, a public biopharmaceutical company, and she is a <FONT
STYLE="white-space:nowrap">non-executive</FONT> chair at BioEclipse Therapeutics, a privately held biotechnology company. Dr.&nbsp;Sohn served at GlaxoSmithKline plc and its predecessor companies, SmithKline Beecham and SK&amp;F, most recently as
Senior Vice President. From 1994 to 1998, she was Vice President of Worldwide Strategic Product Development for Cardiovascular, Pulmonary and Metabolic Therapeutic Areas. Earlier in her career, as an entrepreneur within a large company, she started
the U.S. Vaccine Business and led the launch of SmithKline Beecham&#146;s first vaccine in the United States and helped shape the global vaccine portfolio pipeline as a member of the International Vaccine Steering Committee. Dr.&nbsp;Sohn received a
Pharm. D. from the University of California, San Francisco, a Corporate Directors Certificate from Harvard Business School, a Certificate of Professional Development from the Wharton School at the University of Pennsylvania, and a Certificate from
Berkeley Law for ESG: Navigating the Board&#146;s Role, and is a Certified Licensing Professional Emeritus. Since 2016, she has also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
served as an Adjunct Professor at the University of California, San Francisco. We believe Dr.&nbsp;Sohn is qualified to serve on our board of directors based on her significant experience
building and leading successful biopharmaceutical&nbsp;portfolios, her business development expertise and her governance experience as a public company board member. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Daniel Spiegelman</B> has served as a member of our board of directors since October 2020. From May 2012 to February 2020, Mr.&nbsp;Spiegelman served as the Executive
Vice President and Chief Financial Officer of Biomarin Pharmaceuticals Inc., a global biotechnology company. From 1998 to 2009, Mr.&nbsp;Spiegelman served as Senior Vice President and Chief Financial Officer at CV Therapeutics, Inc., a
biopharmaceutical company acquired in 2009 by Gilead Sciences, Inc., a research-based biopharmaceutical company. From 1991 to 1998, Mr.&nbsp;Spiegelman was an employee at Genentech, serving most recently as its Treasurer. Mr.&nbsp;Spiegelman serves
on the board of directors of several publicly traded biopharmaceutical companies, including as the Audit Committee Chairman at Spruce Biosciences, Inc. since September 2020, as the Audit Committee Chairman at Kyverna Therapeutics, Inc. since April
2021, and on the board of directors of vTv Therapeutics Inc. since June 2024. Mr.&nbsp;Spiegelman has also served on the board of directors of Tiizona Therapeutics, Inc., a privately held biotechnology company since May 2019. Mr.&nbsp;Spiegelman
previously served as a member of the boards of directors of a number of additional publicly traded and privately held biotechnology companies, including, but not limited to, Affymax, Inc., Relypsa Inc, Anthera Pharmaceuticals, Inc. and Cascadian
Therapeutics, Inc. Mr.&nbsp;Spiegelman received his B.A. in Economics and M.B.A. from Stanford University. We believe Mr.&nbsp;Spiegelman is qualified to serve on our board of directors based on his significant experience and his significant
insights into financial strategy and organizational development. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Jeffrey Tong, Ph.D.</B> has served as a member of our board of directors since November 2018.
Dr.&nbsp;Tong is currently a partner with Third Rock Ventures, where he has worked since May 2016. Since 2022, Dr. Tong has served as a member of the board of directors at Rapport Therapeutics, Inc. From 2018 to 2021, he served as a member of the
board of directors of Nurix Therapeutics, Inc. and Asher Biotherapeutics, and as Chairman of the board of directors of Ambys Medicines, Inc. Prior to joining Third Rock Ventures, from 2016 to 2017, Dr.&nbsp;Tong served as Executive Chairman of the
board of directors of Delinia, Inc. (acquired by Celgene Corporation in 2017), a company developing novel therapeutics for the treatment of autoimmune diseases. From 2010 to 2015, he was the President and Chief Executive Officer of Nora
Therapeutics, Inc. Prior to that, from 2001 to 2010, he was a member of the founding management team at Infinity Pharmaceuticals, Inc. where he led its corporate as well as product development activities. Earlier in his career, Dr.&nbsp;Tong worked
at McKinsey&nbsp;&amp; Company and was a founding researcher at the Harvard Bauer Center for Genomics Research Over the course of his career, Dr.&nbsp;Tong has raised significant capital from both equity markets and pharma partnerships, led teams
from preclinical through Phase&nbsp;3 development, and developed integrated science/business strategies for building innovative biotechnology companies. Dr.&nbsp;Tong received his educational training at the interface of molecular biology, organic
chemistry, and medicine. He holds an A.B. in Biochemical Sciences from Harvard College, an A.M. in Chemistry from Harvard University, a M.M.S. in Medicine from Harvard Medical School and a Ph.D. in Chemistry from Harvard University. He brings
significant operational experience in building and growing early-stage biotechnology companies. We believe Dr.&nbsp;Tong is qualified to serve on our board of directors based on his significant experience building and leading successful
biotechnology companies and his scientific expertise. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Andy Tran</B> has served as a member of our board of directors since December 2021. Since May 2021,
Mr.&nbsp;Tran has worked for Matrix Capital Management, a technology and life sciences investment firm, and currently serves as a Principal. From April 2018 to April 2021, Mr.&nbsp;Tran served as an Investment Partner at Andreessen Horowitz&#146;s
(a16z) Bio Fund, an investment fund investing in early-stage ventures in the life sciences. Mr.&nbsp;Tran currently serves as a member of the board of directors at GentiBio, Inc., an early stage biotherapeutics company, since September 2021.
Mr.&nbsp;Tran also serves as a Board Observer at Recode Therapeutics. In addition, over the past several years, Mr.&nbsp;Tran has led investments in and served as a board observer of various private </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
biotechnology companies including Scribe Therapeutics Inc., a genetic medicines company, insitro, a biopharmaceutical company, Genesis Therapeutics Inc., a biotechnology company, Asimov, Inc., a
biotechnology company, and Freenome Holdings, Inc., a biotechnology company. Prior to that, Mr.&nbsp;Tran served in the Global Technology Investment Banking Group at Morgan Stanley from June 2017 to April 2018. From 2013 to 2017, Mr.&nbsp;Tran
worked as a biomedical researcher at Harvard Medical School in the Department of Genetics and Synthetic Biology. Mr.&nbsp;Tran holds a B.A. in Bioengineering and Computer Science from Harvard University. We believe Mr.&nbsp;Tran is qualified to
serve on our board of directors based on his significant insight into building and leading successful biotechnology portfolios, working with and serving on the boards of multiple biotechnology companies, and his business development expertise. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Election of executive officers </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our executive officers are appointed by, and
serve at the discretion of, our board of directors. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Family relationships </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are no family relationships among any of our executive officers or directors. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Board composition </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors currently consists of ten members.
&#8195;&#8195;&#8195; of our directors are independent within the meaning of the independent director guidelines of Nasdaq. Pursuant to our current certificate of incorporation and our amended and restated stockholders agreement, Dr.&nbsp;Homcy,
Dr.&nbsp;Tong and Mr.&nbsp;Tran have been designated to serve as members of our board of directors. Dr.&nbsp;Homcy and Dr.&nbsp;Tong were designated by Third Rock Ventures IV, L.P. and Mr.&nbsp;Tran was designated by Matrix Capital Management Master
Fund LP. The amended and restated stockholders agreement and the provisions of our current certificate of incorporation that govern the election and designation of our directors will terminate in connection with this offering, after which no
contractual obligations will concern the election of our directors. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Classified board of directors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In accordance with the terms of our restated certificate of incorporation and restated bylaws that will become effective upon the completion of this offering, our board
of directors will be divided into three staggered classes of directors. At each annual meeting of our stockholders, a class of directors will be subject to <FONT STYLE="white-space:nowrap">re-election</FONT> for a three-year term. As a result, only
one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Our directors will be divided among the three classes as follows: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the Class&nbsp;I directors will
be&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;and their terms will expire at the first annual meeting of our stockholders held following the completion of the offering; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the Class&nbsp;II directors will
be&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;and their terms will expire at the second annual meeting of our stockholders held following the completion of the offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the Class&nbsp;III directors will
be&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;and their terms will expire at the third annual meeting of our stockholders held following the completion of the offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each director&#146;s term continues until the election and qualification of his or her successor, or his or her earlier death, resignation or removal. Our restated
certificate of incorporation and restated bylaws that will be in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
effect upon the completion of this offering authorize only our board of directors to fill vacancies on our board of directors. Any increase or decrease in the number of directors will be
distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. This classification of our board of directors may have the effect of delaying or
preventing changes in control of our company. See the section entitled &#147;Description of capital stock&#151;Anti-takeover provisions&#151;Restated certificate of incorporation and restated bylaw provisions&#148; for additional information. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Director independence </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we have applied to
list our common stock on Nasdaq. Under the Nasdaq listing rules, independent directors must comprise a majority of a listed company&#146;s board of directors within one year following the company&#146;s listing date. In addition, the Nasdaq listing
rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and governance committees be independent. Under the Nasdaq listing rules, a director will only qualify as an
&#147;independent director&#148; if, in the opinion of that company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a
director. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Audit committee members must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange
Act. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the
board of directors or any other board committee: (i)&nbsp;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries or (ii)&nbsp;be an affiliated person of the listed
company or any of its subsidiaries. We intend to satisfy the audit committee independence requirements of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> as of the completion of this offering. Additionally, compensation committee members must not
have a relationship with us that is material to the director&#146;s ability to be independent from management in connection with the duties of a compensation committee member. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors has undertaken a review of the independence of each director and considered whether each director has a material relationship with us that could
compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. As a result of this review, our board of directors determined that all of our directors, except for Dr.&nbsp;Coloma and Dr.&nbsp;Homcy, are
&#147;independent directors&#148; as defined under the current Nasdaq listing standards and SEC rules and regulations. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with
regard to each director&#146;s business and personal activities and relationships as they may relate to us and our management, including the beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT>
director and the transactions involving them as described in the section entitled &#147;Certain relationships and related party transactions.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Leadership
structure of the board </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our corporate governance guidelines provide our board of directors with flexibility to combine or separate the positions of chair of the
board of directors and Chief Executive Officer. This structure allows our Chief Executive Officer to focus on our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business while our chairman leads our board
of directors in its fundamental role of providing advice to, and oversight of, management. We believe Dr.&nbsp;Homcy is especially qualified for this role based on his operational and risk oversight expertise through his significant experience
building and leading successful biotechnology companies and his scientific expertise. Further, our board of directors believes such separation is appropriate, as it enhances the accountability of the Chief Executive Officer to the board of
directors. Dr.&nbsp;Homcy currently serves as the chairman of our board of directors and Dr.&nbsp;Coloma currently serves as our Chief Executive Officer. Our board of directors also intends to appoint a lead independent director to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
preside over executive sessions of the board and provide feedback to management, which will further strengthen the independence of the board of directors from management. Our board of directors,
in its sole discretion, may seek input from our stockholders on the leadership structure of the board of directors. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Role of board in risk oversight process
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Risk assessment and oversight are an integral part of our governance and management processes. Our board of directors encourages management to promote a culture
that incorporates risk management into our corporate strategy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business operations. Management discusses strategic and operational risks at regular
management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks facing us. Throughout the year, senior management reviews these risks with the board of
directors at regular board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors does not have a standing risk management committee, but rather administers this oversight function directly through our board of directors as a
whole, as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. While our board of directors is responsible for monitoring and assessing strategic risk exposure, our
audit committee is responsible for overseeing our major financial risk exposures and the steps our management has taken to monitor and control these exposures. The audit committee also approves or disapproves any related person transactions. Our
nominating and corporate governance committee monitors the effectiveness of our corporate governance guidelines and other compliance policies, as well as climate and other corporate sustainability risks. Our compensation committee assesses and
monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Committees of the board of directors
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors has an audit committee, a compensation committee and a nominating and governance committee, each of which will have the composition and
responsibilities described below as of the completion of this offering. Each of the below committees has a written charter approved by our board of directors. Upon completion of this offering, copies of each charter will be posted on the investor
relations page of our website at www.mazetx.com. The reference to our website address in this prospectus does not include or incorporate by reference the information on our website into this prospectus. Members that serve on these committees will
serve until their resignation or until otherwise determined by our board of directors. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Audit committee </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Effective upon the effectiveness of the registration statement of which this prospectus is a part, our audit committee will be composed of &#8195;&#8195;&#8195;&#8195;,
&#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;, with &#8195;&#8195;&#8195;&#8195; as the chairperson of our audit committee. Our board of directors has determined that the composition of our audit committee meets the requirements for
independence under the current Nasdaq listing standards and SEC rules and regulations, and that each member of our audit committee is financially literate. In addition, our board of directors has determined that &#8195;&#8195;&#8195;&#8195; is an
&#147;audit committee financial expert&#148; as defined in Item 407(d)(5)(ii) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated under the Securities Act. This designation does not impose on him or her any duties, obligations or
liabilities that are greater than are generally imposed on members of our audit committee and our board of directors. Our audit committee is directly responsible for, among other things: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">selecting and hiring our independent registered public accounting firm; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the qualifications, independence and performance of our independent registered public accounting firm;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the preparation of the audit committee report to be included in our annual proxy statement; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our compliance with legal and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our controls and procedures for mitigating cybersecurity and other information technology risks, including our plans to
respond to data breaches; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our accounting and financial reporting processes, including our financial statement audits and the integrity of our
financial statements; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and approving related-person transactions. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Compensation committee </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Effective upon the effectiveness of the
registration statement of which this prospectus is a part, our compensation committee will be composed of &#8195;&#8195;&#8195;&#8195;, &#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;, with &#8195;&#8195;&#8195;&#8195; as the
chairperson of our compensation committee. Our board of directors has determined that each member of our compensation committee is a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as defined by Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, and meets the requirements for independence under the current Nasdaq listing standards and SEC rules and regulations. Our compensation committee is responsible for,
among other things: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">evaluating, recommending, approving and reviewing executive officer compensation arrangements, plans, policies and
programs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">evaluating and recommending <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation arrangements for
determination by our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">administering our cash-based and equity-based compensation plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">overseeing our compliance with regulatory requirements associated with the compensation of directors, executive officers
and employees. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Nominating and governance committee </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Effective upon the effectiveness of the registration statement of which this prospectus is a part, our nominating and governance committee will be composed
of&#8195;&#8195;&#8195;&#8195;, &#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;, with &#8195;&#8195;&#8195;&#8195; as the chairperson of our nominating and governance committee. Our board of directors has determined that each member of
our nominating and governance committee meets the requirements for independence under the current Nasdaq listing standards. Our nominating and governance committee is responsible for, among other things: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">identifying, considering and recommending candidates for membership on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">overseeing the process of evaluating the performance of our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">advising our board of directors on environmental, social other corporate governance and compliance matters.
</P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Compensation committee interlocks and insider participation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">None of the members of our compensation committee has been an officer or employee of our company. None of our executive officers currently serves, or in the past year
has served, as a member of the board of directors or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
compensation committee (or other board committee performing equivalent functions) of any entity that has one or more of its executive officers serving on our board of directors or compensation
committee. See the section entitled &#147;Certain relationships and related party transactions&#148; for additional information. Prior to establishing the compensation committee, our full board of directors made decisions relating to the
compensation of our officers. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Code of business conduct and ethics </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior
to the completion of this offering, our board of directors will adopt a code of business conduct and ethics that applies to all of our employees, officers and directors, including our Chief Executive Officer, President and other executive and senior
officers. The full text of our code of business conduct and ethics will be posted on the investor relations page of our website at www.mazetx.com. The reference to our website address in this prospectus does not include or incorporate by reference
the information on our website into this prospectus. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics, or waivers of these provisions, on our website at www.mazetx.com or in public filings to
the extent required by the applicable rules. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Non-employee</FONT> director compensation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our employee directors have not received any compensation or reimbursement of any expenses (other than customary expenses in connection with the attendance of meetings
of our board of directors) for their services as directors for the year ended December&nbsp;31, 2023. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth information concerning the
compensation paid to certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for the year ended December&nbsp;31, 2023. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Fees<BR>earned<BR>or paid<BR>in&nbsp;cash&nbsp;($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Option<BR>awards<BR>($)(1)(2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>All other<BR>compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Charles Homcy, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,000</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nancy C. Andrews, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Brendan Bulik-Sullivan, Ph.D.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sekar Kathiresan, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jonathan Lim, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard Scheller, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Catherine Angell Sohn, Pharm. D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Daniel Spiegelman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jeffrey Tong, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Andy Tran</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amounts reflect the full grant date fair value of awards of stock or options granted during the year ended December&nbsp;31, 2023 computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by
the named individual. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The following table sets forth the aggregate number of shares of our common stock subject to outstanding options held by our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as of December&nbsp;31, 2023:
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number of shares<BR>underlying options<BR>held as of<BR>December&nbsp;31,&nbsp;2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Charles Homcy, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">830,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nancy C. Andrews, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Brendan Bulik-Sullivan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sekar Kathiresan, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jonathan Lim, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard Scheller, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Catherine Angell Sohn, Pharm. D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Daniel Spiegelman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jeffrey Tong, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Andy Tran</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Homcy received compensation pursuant to a consulting agreement entered into with us in 2019. For additional information regarding Dr.&nbsp;Homcy&#146;s consulting arrangement with us, see the section entitled
&#147;Certain relationships and related party transactions &#151; Consulting agreement with Charles Homcy, M.D.&#148; </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr. Bulik-Sullivan resigned from the Board of Directors in July 2024. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Scheller received compensation pursuant to an advisor agreement entered into with us in 2021. For additional information regarding Dr.&nbsp;Scheller&#146;s advisor arrangement with us, see the section entitled
&#147;Certain relationships and related party transactions &#151; Advisor agreement with Richard Scheller, Ph.D.&#148; </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT
STYLE="white-space:nowrap">Non-employee</FONT> director compensation policy </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, we did not have a formal policy to provide any cash or
equity compensation to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their service as directors. In connection with this offering, our board of directors expects to approve annual
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation, which will take effect following the completion of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_12"></A>Executive compensation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following tables and accompanying narrative disclosure set forth information about the compensation earned by our named executive officers during the year ended
December&nbsp;31, 2023. Our named executive officers, who are our principal executive officer and the two most highly compensated executive officers (other than our principal executive officer) serving as executive officers as of December&nbsp;31,
2023, are: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Jason Coloma, Ph.D., Chief Executive Officer; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Atul Dandekar, Chief Strategy and Business Officer; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Harold Bernstein, M.D., Ph.D, President, Research and Development and Chief Medical Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Summary compensation table </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents summary information
regarding the total compensation for services rendered in all capacities that was awarded to, earned by or paid to our named executive officers for the year ended December&nbsp;31, 2023. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name&nbsp;and&nbsp;principal&nbsp;position</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Salary($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Bonuses<BR>($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B><FONT STYLE="white-space:nowrap">Non-equity</FONT><BR>incentive<BR>plan&nbsp;compensation</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>($)(1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Option<BR>awards</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>($)(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>All other<BR>compensation<BR>($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Jason Coloma, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">490,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,958,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,673,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Harold Bernstein, M.D., Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">510,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">793,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><I>President, Research and Development and Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Atul Dandekar</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">398,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">447,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,008,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><I>Chief Strategy and Business Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="28" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For additional information regarding the <FONT STYLE="white-space:nowrap">non-equity</FONT> incentive plan compensation, see the section entitled &#147;Annual performance-based bonuses.&#148; </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents the grant date fair value of options awarded during the year ended December&nbsp;31, 2023 as computed in accordance with ASC Topic 718. The assumptions used in calculating the grant date fair value of the
stock options reported in the Options Award column are set forth in Note 7 to our financial statements included elsewhere in this prospectus. Note that the amounts reported in this column reflect the aggregate accounting cost for these awards, and
do not necessarily correspond to the actual economic value that may be received by each named executive officer from the options. </TD></TR></TABLE>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2023 base
salaries </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Base salary is the only fixed component of our named executive officers&#146; total cash compensation and provides competitive and stable pay to
attract and retain our executives. We make annual salary decisions by taking into account competitive data, the skills and experience that each executive brings to us, and the performance contributions of each executive. The base salaries for our
named executive officers for the year ended December 31, 2023 is included in the Summary compensation table above. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Annual performance-based bonuses </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Annual bonuses for our executive officers are based on the achievement of corporate and, for all of the executive officers other than our Chief Executive Officer,
individual performance objectives. The 2023 target bonus amounts for our named executive officers, expressed as a percentage of annual base salary, were 45% for Dr.&nbsp;Coloma, 40% for Dr.&nbsp;Bernstein and 35% for Mr.&nbsp;Dandekar. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Outstanding equity awards at 2023 fiscal <FONT STYLE="white-space:nowrap">year-end</FONT> table </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the number of shares of common stock underlying outstanding equity incentive plan awards for each of our named executive officers as of
December&nbsp;31, 2023. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="24" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-size:8pt"><B>Option awards</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Grant<BR>date(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>options<BR>exercisable</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>options<BR>unexercisable</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Equity</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>incentive</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>plan<BR>awards:<BR>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options(#)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Option<BR>exercise<BR>price($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Option<BR>expiration<BR>date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Jason Coloma, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/2/2021</TD>
<TD NOWRAP VALIGN="top">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,639,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,910,417</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/17/2022</TD>
<TD NOWRAP VALIGN="top">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/16/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial"><I>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/9/2023</TD>
<TD NOWRAP VALIGN="top">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">633,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/8/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial"><I>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/9/2023</TD>
<TD NOWRAP VALIGN="top">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/8/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Harold Bernstein, M.D., Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10/27/2022</TD>
<TD NOWRAP VALIGN="top">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,089,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,645,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/26/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial"><I>President, Research and Development and Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Atul Dandekar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4/12/2021</TD>
<TD NOWRAP VALIGN="top">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">945,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468,750</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/11/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial"><I>Chief Strategy and Business Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/16/2022</TD>
<TD NOWRAP VALIGN="top">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/15/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial"><I>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/4/2023</TD>
<TD NOWRAP VALIGN="top">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/3/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="24" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All outstanding stock option awards were granted under the 2019 Plan and all unvested RSAs were granted under the 2018 Plan. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vests monthly over the four-year period starting on February&nbsp;1, 2021, subject to continued service through such date. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The unvested portion of this option grant is early exercisable pursuant to the terms of the grant agreement. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vests monthly over the four-year period starting on February&nbsp;1, 2022, subject to continued service through such date. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vests monthly over the four-year period starting on March&nbsp;1, 2023, subject to continued service through such date. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">100% of the shares subject to the option will vest in the event (i)&nbsp;our stock price is equal to or greater than $8.00 per share (as may be adjusted for stock splits) on average over a
<FONT STYLE="white-space:nowrap">20-day</FONT> trading period or (ii)&nbsp;if we are acquired at a stock price equal or greater than $8.00 per share (as may be adjusted for stock splits), in each case subject to the grantee&#146;s continued service
to the company through the vesting date (the &#147;Performance Goal&#148;). If the Performance Goal is not achieved within four years of the grant date, the option will terminate. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vests as to a quarter of the shares on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of October&nbsp;3, 2022, and thereafter vests monthly over three years, in each case subject to continued service
on each vesting date. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vests as to a quarter of the shares on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of March&nbsp;17, 2021, and thereafter vests monthly over three years, in each case subject to continued service on
each vesting date. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Employment agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to
enter into new employment agreements with certain senior management personnel in connection with this offering, including our named executive officers. We expect that each of these agreements will provide for
<FONT STYLE="white-space:nowrap">at-will</FONT> employment and include each officer&#146;s base salary, a discretionary annual incentive bonus opportunity and standard employee benefit plan participation. We also anticipate adopting arrangements for
our executive officers, including our named executive officers, that provide for payments and benefits upon a qualifying termination of employment or upon a termination in connection with a change in control of our company. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Equity compensation plans and other benefit plans </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that our
ability to grant equity-based awards is a valuable compensation tool that enables us to attract, retain, and motivate our employees, consultants, and directors by aligning their financial interests with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
those of our stockholders. The principal features of our equity plans are summarized below. These summaries are qualified in their entirety by reference to the actual text of the plans, which are
filed as exhibits to the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2018 Stock Option and Grant Plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our 2018 Plan was initially adopted by our board of directors and approved by our stockholders in November 2018. Our 2018 Plan terminated on the date that our 2019 Plan
became effective (as defined and described below). </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Share reserve</I>.&#8195;As of June 30, 2024, restricted stock awards, or RSAs, for 11,191,476 shares of
restricted stock have been granted under our 2018 Plan, of which 50,000 shares are unvested and remain subject to repurchase. Only RSAs have been granted under the 2018 Plan, and no additional grants will be made under the 2018 Plan. Outstanding
shares of restricted stock granted under our 2018 Plain prior to its termination will remain outstanding until they are terminated, forfeited or repurchased in accordance with the terms of the 2018 Plan and the applicable award agreements evidencing
such awards. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Administration.</I>&#8195;Our board of directors or a committee thereof appointed by our board of directors, referred to as the compensation
committee, administers the 2018 Plan and awards granted thereunder. While no new awards may be granted under the 2018 Plan, subject to the terms of the 2018 Plan, the compensation committee has the authority to, among other things, interpret the
terms and provisions of our 2018 Plan and any award under the 2018 Plan as well as to adopt, alter and repeal rules, guidelines and practices for administration of the 2018 Plan. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Types of awards; Eligibility.</I>&#8195;Our 2018 Plan provided for the grant of incentive stock options, or ISOs,
<FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, or NQSOs, restricted stock units, or RSUs, and RSAs to our employees, directors, and consultants; provided that ISOs could only be granted to employees. Only RSAs have been granted
under our 2018 Plan and no additional awards may be granted under the 2018 Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Restricted Stock Awards.</I>&#8195;An RSA is an offer by us to sell shares of
our common stock subject to restrictions which could lapse based on terms and conditions determined by the compensation committee, as set forth in our 2018 Plan and an award agreement. These restrictions may be based on completion of a specified
period of service with us or upon the achievement of performance goals during a performance period. The compensation committee determines the price of an RSA. Unless otherwise set forth in the award agreement, vesting will cease on the date the
participant no longer provides services to us, and at that time unvested shares will be subject to repurchase by us. Holders of restricted stock are entitled to vote, subject to such conditions contained in the award agreement, and are entitled to
receive all dividends and distributions with respect to such shares. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Limited transferability.</I>&#8195;Unless otherwise determined by the compensation
committee, shares of restricted stock granted under our 2018 Plan generally may not be sold, assigned, transferred, pledged, hypothecated, given away, or in any other manner disposed of or encumbered unless (i)&nbsp;the transfer is in compliance
with the terms of the applicable award agreement, securities laws and the 2018 Plan and (ii)&nbsp;the transferee consents in writing to be bound by the provisions of the 2018 Plan and applicable award agreement. Transfers of shares may also be made
to certain permitted transferees specified under the 2018 Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Change in control.</I>&#8195;In the event of a &#147;Sale Event&#148; (as defined in the 2018
Plan), all then-unvested shares of restricted stock (other than those becoming vested as a result of the Sale Event, if applicable) issued under the 2018 Plan shall be forfeited immediately prior to the effective time of any such Sale Event unless
assumed, continued or substituted by the successor entity or a parent thereof, with an equitable or proportionate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
adjustment as to the number and kind of shares subject to such awards as such parties shall agree (after taking into account any acceleration under the 2018 Plan and/or pursuant to the terms of
any award agreement, if applicable). In the event of the forfeiture of unvested shares of restricted stock, such shares shall be repurchased from the holder at a price per share equal to the lower of the original per share purchase price paid by the
holder (subject to adjustment as provided in the 2018 Plan, if applicable) or the current fair market value of such shares, determined immediately prior to the effective time of the Sale Event. Notwithstanding the foregoing, in the event of a Sale
Event, we shall have the right, but not the obligation, to make or provide for a cash payment to the holders of unvested shares of restricted stock, without consent of the holders, in exchange for the cancellation thereof, in an amount equal to the
value as determined by the compensation committee of the consideration payable on a per share basis for our common stock times the number of shares subject to such awards, to be paid at the time of such Sale Event or upon the later vesting of such
awards. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Adjustments.</I>&#8195;If, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or
other similar change in our capital stock, the outstanding shares are increased or decreased or are exchanged for a different number or kind of shares or other securities of the company, or additional shares or new or different shares or other
securities of the company or other <FONT STYLE="white-space:nowrap">non-cash</FONT> assets are distributed with respect to such shares or other securities, in each case, without the receipt of consideration by the company, or, if, as a result of any
merger or consolidation, or sale of all or substantially all of our the assets, the outstanding shares are converted into or exchanged for other securities of our company or any successor entity (or a parent or subsidiary thereof), the compensation
committee shall make an appropriate and proportionate adjustment in (i)&nbsp;the number and kind of shares or other securities subject to any then outstanding awards under the 2018 Plan and (ii)&nbsp;the repurchase price, if any, per share subject
to each outstanding award. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Amendment; termination</I>.&#8195;Our 2018 Plan was terminated upon adoption of our 2019 Plan. The compensation committee may amend or
cancel any outstanding award granted under the 2018 Plan for the purpose of satisfying changes in law or for any other lawful purpose, provided that the award holder&#146;s consent will be required if such action shall adversely affect rights under
any outstanding award. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2019 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our 2019
Equity Incentive Plan, or 2019 Plan, was initially adopted by our board of directors and approved by our stockholders in August 2019. Our 2019 Plan will terminate on the date that our 2024 Plan becomes effective (as defined and described below).
</P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Share reserve</I>.&#8195;As of June 30, 2024, 41,916,715 shares of our common stock had been reserved for issuance pursuant to grants under our 2019 Plan, of
which 3,057,291 remained available for grant. Only options have been granted under our 2019 Plan, and no additional grants will be made under the 2019 Plan following the date our 2024 Plan becomes effective. As of June 30, 2024, options to purchase
4,236,410 shares had been exercised, and options to purchase 35,335,588 shares remained outstanding, with a weighted-average exercise price of $1.50 per share. As of June 30, 2024, 139,230 shares of stock acquired upon the early exercise of options
granted under our 2019 Plan remained outstanding and subject to repurchase. Outstanding options (and shares of restricted stock issued upon the early exercise of options) prior to its termination will remain outstanding until they are exercised, as
applicable, or are terminated, forfeited or repurchased in accordance with the terms of the 2019 Plan and the applicable award agreements evidencing such awards. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Administration.</I>&#8195;Our board of directors, or a committee thereof appointed by our board of directors, referred to as the compensation committee, administers
the 2019 Plan and awards granted thereunder. Subject to the terms of the 2019 Plan, the compensation committee has the authority to, among other things, select the persons to whom awards would be granted, construe and interpret our 2019 Plan as well
as to prescribe, amend, expand, modify, and rescind or terminate rules and regulations relating to the 2019 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Types of awards; Eligibility.</I>&#8195;Our 2019 Plan provides for the grant of the awards described below to our
employees, consultants, directors and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Pursuant to the 2019 Plan, ISOs may be granted only to our employees. We may grant all other types of awards to our employees, directors and
consultants. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Options.</I>&#8195; The 2019 Plan provides for the grant of ISOs and NQSOs. ISOs may be granted only to our employees or employees of our parent and
subsidiaries. NQSOs may be granted to eligible employees, consultants and directors or any of the foregoing of our parent or subsidiaries. We are able to issue no more than 122,900,000 shares pursuant to the grant of ISOs under the 2019 Plan. The
compensation committee determines the terms of each option award, provided that ISOs are subject to statutory limitations. The compensation committee also determines the exercise price for an option, provided that the exercise price of an option may
not be less than the fair market value of our common stock on the date of grant (with certain additional requirements for certain ISOs). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Options granted under the
2019 Plan vest at the rate and/or subject to performance requirements specified by the compensation committee and such vesting schedule is set forth in the option agreement to which such option grant relates. The compensation committee determines
the term of options granted under the 2019 Plan, up to a term of 10 years (with certain additional requirements for certain ISOs). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After the option holder ceases to
provide services to us, he or she is able to exercise his or her vested option for the period of time stated in the stock option agreement to which such option relates. Generally, the vested option will remain exercisable for three months after an
optionee&#146;s cessation of service, except in the case of termination due to death, disability or termination for cause. An option may not be exercised later than its expiration date. Any unvested shares of restricted stock issued in connection
with the early exercise of an option (if any) are subject to our right to repurchase unvested shares upon the holder&#146;s termination of service, as permitted under the 2019 Plan. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Restricted stock awards.</I>&#8195;An RSA is an offer by us to sell shares of our common stock subject to restrictions that the compensation committee may impose.
These restrictions may be based on completion of a specified period of service with us or upon the achievement of performance goals during a performance period. The compensation committee determines the price of a restricted stock award. Unless
otherwise set forth in the award agreement, vesting will cease on the date the participant no longer provides services to us, and at that time unvested shares will be forfeited to us or subject to repurchase by us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Stock appreciation rights.</I>&#8195;A SAR provides for a payment, in cash or shares of our common stock, to the holder based upon the difference between the fair
market value of our common stock on the date of exercise and a predetermined exercise price, multiplied by the number of shares. The exercise price of a SAR must be at least the fair market value of a share of our common stock on the date of grant.
SARs may vest based on service or achievement of performance conditions. The maximum term of a SAR granted under our 2019 Plan is ten years from the date of grant. SARs have not been granted under the 2019 Plan. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Restricted stock units.</I>&#8195;RSUs represent the right to receive shares of our common stock at a specified date in the future, subject to forfeiture of such
right due to termination of employment or failure to achieve specified performance goals. If the RSUs have not been forfeited, then on the date specified in the award agreement we will deliver to the holder of the RSUs shares of our common stock,
cash or a combination of our common stock and cash as specified in the applicable award agreement. The maximum term of an RSU granted under our 2019 Plan is ten years from the date of grant. RSUs have not been granted under the 2019 Plan. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Limited transferability.</I>&#8195;Unless otherwise determined by the compensation committee, awards granted under our 2019 Plan generally may not be pledged,
assigned, hypothecated, transferred or assigned in any manner other than by will or the laws of descent and distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Change in control.</I>&#8195;In the event of an &#147;acquisition&#148; or &#147;other combination&#148; (as
defined in the 2019 Plan), outstanding awards acquired under our 2019 Plan will be subject to the agreement evidencing such transaction, which need not treat all outstanding awards in an identical manner. Such agreement, without the
participant&#146;s consent, shall provide for one or more of the following: (i)&nbsp;the continuation of the outstanding awards (if we are the successor entity); (ii)&nbsp;the assumption of the outstanding awards by the surviving corporation or its
parent (if any); (iii)&nbsp;the substitution by the surviving corporation or its parent of substantially equivalent awards for the outstanding awards; (iv)&nbsp;the full or partial exercisability or vesting and accelerated expiration of awards;
(v)&nbsp;the settlement of the fair market value of the outstanding awards (whether or not then vested or exercisable) in cash, cash equivalents, or securities of the successor entity (or its parent, if any), followed by the cancellation of such
awards, provided however, that such awards may be cancelled without consideration if such awards have no value, as determined by the compensation committee, in its discretion; or (vi)&nbsp;the termination of any outstanding award, without payment of
any consideration, that was not exercised in accordance with its terms upon or before the closing of the transaction. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Adjustments.</I>&#8195;In the event that
our common stock is changed by a stock dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification, or other change in our capital structure affecting shares without consideration, then in order to
prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the 2019 Plan (a)&nbsp;the number and class of shares reserved for issuance under the 2019 Plan, (b)&nbsp;the exercise prices of and number
and class of shares subject to outstanding options and SARs, and (c)&nbsp;the purchase prices of and/or number and class of shares subject to other outstanding awards will (to the extent appropriate) be proportionately adjusted, subject to any
required action by the board of directors or the stockholders of the Company and compliance with applicable securities or other laws; <I>provided</I>, <I>however</I>, that fractions of a share will not be issued but will either be paid in cash at
the fair market value of such fraction of a Share or will be rounded down to the nearest whole share, as determined by the compensation committee. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Exchange,
repricing and buyout of awards</I>.&#8195;The compensation committee may, with the consent of the respective participants, issue new awards in exchange for the surrender and cancellation of any or all outstanding awards. The compensation committee
may also, without prior stockholder approval, reprice, or reduce the exercise price, of options or buy an award previously granted with payment in cash, shares (including restricted stock) or other consideration, in each case, subject to the terms
of the 2019 Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Amendment; termination</I>.&#8195;Our 2019 Plan will terminate on the date that our 2024 Plan becomes effective. No termination or amendment of
the 2019 Plan may affect any share previously issued or any then-outstanding award without the consent of the affected participant. Outstanding options may be terminated upon our dissolution or liquidation. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>2024 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to adopt the 2024 Plan that will
become effective on the day prior to the date of the effectiveness of the registration statement for which this prospectus will form a part, and will serve as the successor to the 2019 Plan. The 2024 Plan authorizes the award of ISOs, NSOs, RSAs,
SARs, RSUs, cash awards, performance awards and stock bonus awards. We have initially reserved&#8195;&#8195;&#8195;&#8195;shares of our common stock, plus (a)&nbsp;any reserved shares not issued or subject to outstanding grants under the 2019 Plan
on the effective date of the 2024 Plan, (b)&nbsp;shares that are subject to stock options or other awards granted under the 2019 Plan or the 2018 Plan that cease to be subject to such stock options or other awards by forfeiture or otherwise after
the effective date of the 2024 Plan; (c)&nbsp;shares issued under the 2019 Plan or the 2018 Plan before or after the effective date of the 2024 Plan pursuant to the exercise of stock options that are, after the effective date, forfeited;
(d)&nbsp;shares issued under the 2019 Plan or the 2018 Plan that are repurchased by the Company at the original purchase price or are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
otherwise forfeited and (e)&nbsp;shares that are subject to stock options or other awards under the 2019 Plan or the 2018 Plan that are used to pay the exercise price of a stock option or
withheld to satisfy the withholding obligations related to any award, for issuance pursuant to awards granted under our 2024 Plan. The number of shares reserved for issuance under our 2024 Plan will increase automatically on January&nbsp;1 each of
2025 through 2034 by the number of shares equal to the lesser of&#8195;% of the aggregate number of outstanding shares of our common stock as of the immediately preceding December&nbsp;31, or a number as may be determined by our board of directors.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the following shares will again be available for issuance pursuant to awards granted under our 2024 Plan: (a)&nbsp;shares subject to options or SARs
granted under our 2024 Plan that cease to be subject to the option or SAR for any reason other than exercise of the option or SAR, (b)&nbsp;shares subject to awards granted under our 2024 Plan that are subsequently forfeited or repurchased by us at
the original issue price, (c)shares subject to awards granted under our 2024 Plan that otherwise terminate without such shares being issued, (d)&nbsp;shares subject to awards granted under our 2024 Plan that are surrendered, cancelled or exchanged
for cash or a different award (or combination thereof); and (e)&nbsp;shares used to pay the exercise price, or withheld to satisfy the tax withholding obligations related to an award, granted under our 2024 Plan. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Administration.</I>&#8195;Our 2024 Plan is expected to be administered by our compensation committee, all of the members of which are outside directors as defined
under applicable law, or by our board of directors acting in place of our compensation committee. Subject to the terms and conditions of the 2024 Plan, the compensation committee will have the authority, among other things, to select the persons to
whom awards may be granted, construe and interpret our 2024 Plan as well as to determine the terms of such awards and prescribe, amend and rescind the rules and regulations relating to the 2024 Plan or any award granted thereunder. Our 2024 Plan
provides that the board of directors or compensation committee may delegate its authority, including the authority to grant awards, to one or more executive officers to the extent permitted by applicable law, <I>provided that</I> awards granted to <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors may only be determined by our board of directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Types of awards; Eligibility.</I>&#8195;Our 2024 Plan
provides for the grant of the awards described below to our employees, consultants, directors and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Pursuant to the 2024 Plan, ISOs may be granted only to our employees. We may grant all
other types of awards to our employees, directors and consultants. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Options.</I>&#8195; The 2024 Plan provides for the grant of ISOs and NQSOs. ISOs may be
granted only to our employees or employees of our parent, subsidiaries and affiliates. NQSOs may be granted to eligible employees, consultants and directors or any of the foregoing of our parent, subsidiaries or affiliates. We are able to issue no
more than <U>&#8195;&#8195;&#8195;&#8195;</U> shares pursuant to the grant of ISOs under the 2024 Plan. The compensation committee determines the terms of each option award, provided that ISOs are subject to statutory limitations. The compensation
committee also determines the exercise price for an option, provided that the exercise price of an option may not be less than the fair market value of our common stock on the date of grant (with certain additional requirements for certain ISOs).
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Options granted under the 2024 Plan vest at the rate and/or subject to performance requirements specified by the compensation committee and such vesting schedule is
set forth in the option agreement to which such option grant relates. The compensation committee determines the term of options granted under the 2024 Plan, up to a term of 10 years (with certain additional requirements for certain ISOs). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After the option holder ceases to provide services to us, he or she is able to exercise his or her vested option for the period of time stated in the stock option
agreement to which such option relates. Generally, the vested option will remain exercisable for three months after an optionee&#146;s cessation of service, except in the case of termination due to death, disability or termination for cause. An
option may not be exercised later than its expiration date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Restricted stock awards.</I>&#8195;An RSA is an offer by us to sell shares of our common stock subject to
restrictions that the compensation committee may impose. These restrictions may be based on completion of a specified period of service with us or upon the achievement of performance goals during a performance period. The compensation committee
determines the price of a restricted stock award. Unless otherwise set forth in the award agreement, vesting will cease on the date the participant no longer provides services to us, and at that time unvested shares will be forfeited to us or
subject to repurchase by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Stock appreciation rights.</I>&#8195;A SAR provides for a payment, in cash or shares of our common stock (up to a specified maximum
of shares, if determined by our compensation committee), to the holder based upon the difference between the fair market value of our common stock on the date of exercise and a predetermined exercise price, multiplied by the number of shares. The
exercise price of a SAR must be at least the fair market value of a share of our common stock on the date of grant. SARs may vest based on service or achievement of performance conditions. The maximum term of a SAR granted under our 2024 Plan is ten
years from the date of grant. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Restricted stock units.</I>&#8195;RSUs represent the right to receive shares of our common stock at a specified date in the future,
subject to forfeiture of such right due to termination of employment or failure to achieve specified performance goals. If the RSUs have not been forfeited, then on the date specified in the award agreement we will deliver to the holder of the RSUs
shares of our common stock, cash or a combination of our common stock and cash as specified in the applicable award agreement. The maximum term of an RSU granted under our 2024 Plan is ten years from the date of grant. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Performance awards.</I>&#8195; A performance award is an award that is based upon the attainment of performance goals, as established by the compensation committee,
and other terms and conditions specified by the compensation committee, and may be settled in cash, shares (which may consist of, without limitation, restricted stock), other property, or any combination thereof. These awards are subject to
forfeiture because of termination of employment or failure to achieve the performance conditions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Stock bonus awards.</I>&#8195; A stock bonus is an award of
shares of our common stock for past or future services to us. No payment from the participant is required. The compensation committee determines the number of shares to be issued as stock bonus and any restrictions on those shares. These
restrictions may be based on completion of a specified period of service with us or upon the achievement of performance goals during a performance period. Unless otherwise set forth in the award agreement, vesting ceases on the date the participant
no longer provides services to us, and at that time unvested shares will be forfeited to us or are subject to repurchase by us. A stock bonus award provides for payment in the form of cash, shares of our common stock or a combination thereof, based
on the fair market value of shares subject such award as determined by our compensation committee. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Cash awards.</I>&#8195;A cash award is an award that is
denominated in, or payable to an eligible participant solely in, cash. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Dividend equivalents rights.</I>&#8195;Dividend equivalent rights may be granted at the
discretion of our compensation committee, and represent the right to receive the value of dividends, if any, paid by us in respect of the number of shares of our common stock underlying an award. Dividend equivalent rights will be subject to the
same vesting or performance conditions as the underlying award and will be paid only at such time as the underlying award has become fully vested. Dividend equivalent rights may be settled in cash, shares or other property, or a combination of
thereof as determined by our compensation committee. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Change of control.</I>&#8195;Our 2024 Plan provides that, in the event of a &#147;corporate
transaction&#148; (as defined in the 2024 Plan), outstanding awards under the 2024 Plan shall be subject to the agreement evidencing the corporate transaction, which need not treat all outstanding awards in an identical manner. Any or all
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
outstanding awards (i)&nbsp;may be continued by the company, if we are the successor entity; (ii)&nbsp;may be assumed or substituted by the successor corporation, or a parent or subsidiary of the
successor corporation, for substantially equivalent awards (including, but not limited to, a payment in cash or the right to acquire the same consideration paid to our stockholders pursuant to the corporate transaction), in each case after taking
into account appropriate adjustments for the number and kind of shares and exercise prices or (c)&nbsp;the successor corporation may also issue, as replacement of our outstanding shares held by a participant, substantially similar shares, or other
property subject to repurchase restrictions no less favorable to the participant. In the event such successor corporation refuses to assume, substitute or replace any award in accordance with the 2024 Plan, then notwithstanding any other provision
in the 2024 Plan to the contrary, each such award shall become fully vested and, as applicable, exercisable and any rights of repurchase or forfeiture restrictions thereon will lapse, immediately prior to the consummation of the corporate
transaction. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If an award vests in lieu of assumption or substitution in connection with a corporate transaction as provided above, the board of directors or the
compensation committee will notify the holder of such award in writing or electronically that such award will be exercisable for a period of time determined by the board of directors or the compensation committee, in its sole discretion, and such
award will terminate upon the expiration of such period without consideration. Any determinations by the board of directors or the compensation committee need not treat all outstanding awards in an identical manner, and shall be final and binding on
each applicable participant. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The vesting of all awards granted to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors under our 2024 Plan shall
accelerate in full in the event of a corporate transaction. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Adjustment.</I>&#8195;In the event of a change in the number or class of outstanding shares of our
common stock, without consideration, by reason of a stock dividend, extraordinary dividend or distribution (whether in cash, shares, or other property, other than a regular cash dividend), recapitalization, stock split, reverse stock split,
subdivision, combination, consolidation, reclassification, <FONT STYLE="white-space:nowrap">spin-off</FONT> or similar change in our capital structure, proportional adjustments will be made to the number and class of shares reserved for issuance
under our 2024 Plan; the exercise prices, number and class of shares subject to outstanding options or SARs; the number and class of shares subject to other outstanding awards; and any applicable maximum award limits with respect to ISOs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Exchange, repricing and buyout of awards.</I>&#8195;Without prior stockholder approval, our compensation committee may (a)&nbsp;reprice options or SARs (and where
such repricing is a reduction in the exercise price, the consent of the affected Participants is not required) and (b)&nbsp;with the consent of the respective participants, pay cash or issue new awards in exchange for the surrender and cancellation
of any or all outstanding awards. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Director compensation limits</I>.&#8195;No <FONT STYLE="white-space:nowrap">non-employee</FONT> director may receive awards
under our 2024 Plan with a grant date value that when combined with cash compensation received for his or her service as a director, exceeds $&#8195;&#8195;&#8195;&#8195;in a calendar year or $&#8195;&#8195;&#8195;&#8195;in the calendar year of his
or her initial service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director with us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Clawback.</I>&#8195;All awards will be subject to clawback or
recoupment pursuant to any compensation clawback or recoupment policy adopted by our board of directors (or a committee thereof) or required by law, to the extent set forth in such policy or applicable agreement. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Transferability of Awards.</I> Unless the compensation committee provides otherwise, the 2024 Plan does not allow for the transfer of awards, other than by will or
the laws of descent and distribution, and generally only the recipient of an award may exercise it during his or her lifetime. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Foreign Award Recipients</I>. In
order to comply with the laws in other countries in which we and our subsidiaries and affiliates operate or have employees or other individuals eligible for awards, the compensation committee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
will have the power and authority to modify the terms and conditions of any award granted to individuals outside the United States to comply with applicable foreign laws, establish subplans and
modify exercise procedures and other terms and procedures, and take any action that the compensation committee determines to be necessary or advisable to comply with any local governmental regulatory exemptions or approvals. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Amendment and termination.</I>&#8195;Our board of directors may amend our 2024 Plan at any time, subject to stockholder approval as may be required. Our 2024 Plan
will terminate ten years from the date our board of directors adopts the 2024 Plan unless it is terminated earlier as provided by the terms of the 2024 plan. No termination or amendment of the 2024 Plan may adversely affect any then-outstanding
award without the consent of the affected participant, except as is necessary to comply with applicable law, regulation or rule, or as otherwise provided by the terms of the 2024 Plan. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2024 Employee Stock Purchase Plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to adopt our ESPP that
will become effective on the date of the effectiveness of the registration statement of which this prospectus forms a part. Our ESPP will permit eligible employees to purchase shares of our common stock at a discount, using accumulated payroll
deductions, beginning on a date to be determined by our board of directors or our compensation committee. Our ESPP is intended to qualify under Section&nbsp;423 of the Code, provided that the compensation committee may adopt <FONT
STYLE="white-space:nowrap">sub-plans</FONT> under our ESPP designed to be outside of the scope of Section&nbsp;423 of the Code for participants who are <FONT STYLE="white-space:nowrap">non-U.S.</FONT> residents. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Shares available.</I>&#8195;We have initially reserved&#8195;&#8195;&#8195;&#8195;shares of our common stock for sale under our ESPP. The aggregate number of shares
reserved for sale under our ESPP will increase automatically on January 1st of each of 2025 through 2034 by the number of shares equal to the lesser of % of aggregate number of shares of all classes of our common stock, plus the total number of
shares of our common stock as of the immediately preceding December&nbsp;31 (rounded to the nearest whole share) or a number of shares as may be determined by our board of directors or our compensation committee in any particular year. The aggregate
number of shares issued over the term of our ESPP, subject to stock-splits, recapitalizations or similar events, may not exceed&#8195;&#8195;&#8195;&#8195;shares of our common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Administration.</I>&#8195;Our ESPP is expected to be administered by our compensation committee. Among other things, the administrator will have the authority to
determine eligibility for participation in the ESPP, designate separate offerings under the ESPP, and construe, interpret and apply the terms of the ESPP. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Eligibility.</I>&#8195;Employees eligible to participate in any offering pursuant to the ESPP generally include any employee that is employed by us or certain of our
designated subsidiaries at the beginning of the offering period. However, our compensation committee may exclude the following employees from the ESPP (other than where such exclusion is prohibited by applicable law): employees who do not meet
eligibility requirements that the compensation committee may choose to impose (within the limits permitted by the Code); employees who are not employed by the company or a designated subsidiary prior to the beginning of an offering period or prior
to such other time period as specified by the compensation committee, employees who have been employed for less than two years, employees who are customarily employed for 20 hours or less per week, or for five months or less in a calendar year,
certain &#147;highly compensated&#148; employees as determined in accordance with applicable tax laws, or employees resident in a foreign jurisdiction whose participation is either prohibited under local law, or where compliance with local law would
violate Section&nbsp;423 of the Code, may not be eligible to participate in the ESPP or individuals who provide services to the company or any of its designated subsidiaries who are reclassified as common law employees for any reason except for
federal income and employment tax purposes . In addition, any employee who owns (or is deemed to own as a result of attribution) 5% or more of the total combined voting power or value of all classes of our capital stock, or the capital stock of one
of our qualifying subsidiaries, or who will own such amount as a result of participation in the ESPP, will not be eligible to participate in the ESPP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Offerings.</I>&#8195;Under our ESPP, eligible employees will be offered the option to purchase shares of our common
stock at a discount over a series of offering periods, which may be consecutive or overlapping, through accumulated payroll deductions over the period. Each offering period may itself consist of one or more purchase periods. No offering period may
be longer than 27 months. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Participation.</I>&#8195;Participating employees will be able to purchase the offered shares of our common stock by accumulating funds
through payroll deductions. Participants may select a rate of payroll deduction between&nbsp;1% and&nbsp;15% of their eligible compensation. A participant may not purchase more than&#8195;&#8195;&#8195;&#8195;(or such greater or lesser number as the
compensation committee may determine) shares during any one purchase period. A participant may not subscribe for more than $25,000 in fair market value of shares of our common stock (determined as of the date the offering period commences) in any
calendar year in which the offering is in effect, however, the administrator, in its discretion, may set a lower maximum amount of shares which may be purchased. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The purchase price for shares of our common stock purchased under the ESPP will be&nbsp;85% of the lesser of the fair market value of our common stock on (i)&nbsp;the
first trading day of the applicable offering period or (ii)&nbsp;the last trading day of each purchase period in the applicable offering period. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once an employee
becomes a participant in an offering period, the participant will be automatically enrolled in each subsequent offering period at the same contribution level. A participant may reduce his or her contribution in accordance with procedures set forth
by the compensation committee and may withdraw from participation in the ESPP at any time prior the end of an offering period, or such other time as may be specified by the compensation committee. Upon withdrawal, the accumulated payroll deductions
will be returned to the participant without interest. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Adjustments upon recapitalization.</I>&#8195;If the number of outstanding shares of our common stock is
changed by stock dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in our capital structure without consideration, then our compensation committee will proportionately adjust
the number and class of common stock that is available under the ESPP, the purchase price and number of shares any participant has elected to purchase as well as the maximum number of shares which may be issued under the ESPP and which may be
purchased by a participant. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Change of control.</I>&#8195; In the event of a &#147;corporate transaction&#148; (as defined in the ESPP), each outstanding right to
purchase common stock will be assumed or an equivalent option substituted by the successor corporation or a parent or a subsidiary of the successor corporation. In the event that the successor corporation refuses to assume or substitute for the
purchase right, any offering period that commenced prior to the closing of the proposed change of control transaction will be shortened and terminated on a new purchase date. The new purchase date will occur on or prior to the closing of the
proposed corporate transaction, and our ESPP will then terminate on the closing of the corporate transaction. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Transferability.</I>&#8195;A participant may not
assign, transfer, pledge or otherwise dispose of payroll deductions credited to his or her account, or any rights with regard to an election to purchase shares pursuant to the ESPP other than by will or the laws of descent or distribution. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Amendment; Termination.</I>&#8195;The administrator may amend, suspend or terminate the ESPP at any time without stockholder consent, except to the extent such
amendment would increase the number of shares available for issuance under our ESPP, change the class or designation of employees eligible for participation in the ESPP or otherwise as required by law. If our ESPP is terminated, the compensation
committee may elect to terminate all outstanding offering periods immediately, upon the next purchase date (which may be sooner than originally scheduled) or upon the last day of such offering period. If any offering period is terminated prior to
its scheduled completion, all amounts credited to participants which have not been used to purchase shares will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
returned to participants as soon as administratively practicable. Our ESPP will continue until the earlier to occur of (a)&nbsp;termination of the ESPP by our board of directors,
(b)&nbsp;issuance of all of the shares reserved for issuance under the ESPP, or (c)&nbsp;the tenth anniversary of the effective date under the ESPP. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>401(k)
plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We sponsor a retirement savings plan that is intended to qualify for favorable tax treatment under Section&nbsp;401(a) of the Code and contains a cash
or deferred feature that is intended to meet the requirements of Section&nbsp;401(k) of the Code. Participants may make <FONT STYLE="white-space:nowrap">pre-tax</FONT> and certain <FONT STYLE="white-space:nowrap">after-tax</FONT> (Roth) salary
deferral contributions to the 401(k) plan from their eligible earnings up to the statutorily prescribed annual limit under the Code. Participants who are projected to reach 50 years of age or older during a calendar year may contribute additional
amounts based on the statutory limits for <FONT STYLE="white-space:nowrap">catch-up</FONT> contributions. Participant contributions are held in trust as required by law. Currently, we match each participant&#146;s contribution up to a safe harbor
maximum of 3% of his or her eligible compensation, not to exceed $3,000 per plan year, with participants vesting immediately and fully in such matching contributions. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Other benefits </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our named executive officers are eligible to
participate in our employee benefit plans on the same basis as our other employees, including our health and welfare plans. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Limitations on liability and
indemnification matters </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our restated certificate of incorporation that will become effective in connection with the completion of this offering contains
provisions that limit the liability of our directors and officers for monetary damages to the fullest extent permitted by the Delaware General Corporation Law, or DGCL. Consequently, our directors and officers will not be personally liable to us or
our stockholders for monetary damages for any breach of fiduciary duties as directors or officers, except liability for: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any breach of the director&#146;s or officer&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">with respect to directors, unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in
Section&nbsp;174 of the DGCL; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our restated certificate of incorporation and our restated bylaws that will become effective in connection with the completion of this offering require us to indemnify
our directors and officers to the maximum extent not prohibited by the DGCL and allow us to indemnify other employees and agents as set forth in the DGCL. Subject to certain limitations, our restated bylaws will also require us to advance expenses
incurred by our directors and officers for the defense of any action for which indemnification is required or permitted, subject to very limited exceptions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have
entered, and intend to continue to enter, into separate indemnification agreements with our directors, executive officers and certain of our key employees, in addition to the indemnification provided for in our restated certificate of incorporation
and restated bylaws. These agreements, among other things, require us to indemnify our directors, officers and key employees for certain expenses, including attorneys&#146; fees, judgments, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
penalties, fines and settlement amounts actually incurred by these individuals in any action or proceeding arising out of their service to us or any of our subsidiaries or any other company or
enterprise to which these individuals provide services at our request. Subject to certain limitations, our indemnification agreements also require us to advance expenses incurred by our directors, officers and key employees for the defense of any
action for which indemnification is required or permitted. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that these indemnification provisions and agreements are necessary to attract and retain
qualified directors, officers and key employees. We also maintain directors&#146; and officers&#146; liability insurance. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The limitation of liability and
indemnification provisions in our restated certificate of incorporation and restated bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the
likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the
costs of settlement and damage awards against directors and executive officers as required by these indemnification provisions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At present, there is no pending
litigation or proceeding involving any of our directors or executive officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us, we have been informed
that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_13"></A>Certain relationships and related party transactions </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to the compensation arrangements, including any employment, termination of employment and change in control arrangements, with our directors and executive
officers, including those discussed in the sections entitled &#147;Management&#148; and &#147;Executive compensation,&#148; the following is a description of each transaction since January&nbsp;1, 2021 and each currently proposed transaction in
which: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we have been or are to be a participant; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the amounts involved exceeded or will exceed the lesser of $120,000 and 1.0% of our average total assets at <FONT
STYLE="white-space:nowrap">year-end</FONT> for the prior two completed fiscal years; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any of our directors, executive officers or holders of more than 5.0% of our capital stock, or an affiliate or immediate
family member of the foregoing persons, had or will have a direct or indirect material interest. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other than as described below, there have not
been, nor are there any currently proposed, transactions or series of similar transactions to which we have been or will be a party other than compensation arrangements, which are described where required under the section entitled &#147;Executive
compensation.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Series B Preferred Stock financing </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From December
2020 through February 2021, we sold an aggregate of 57,563,188 shares of our Series B Preferred Stock, at a price per share of $2.75 for total gross proceeds of $158.3&nbsp;million. Each share of our Series B Preferred Stock will automatically
convert into&#8195;&#8195;&#8195;&#8195;shares of our common stock immediately prior to the completion of this offering. Pursuant to the Investor Rights Agreement, or IRA, holders of our Series B Preferred Stock are entitled to certain registration
rights. See the section entitled &#147;Description of capital stock&#151;Registration rights&#148; for additional information. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the
Series B Preferred Stock purchased by members of our board of directors or their affiliates and holders of more than 5% of our outstanding capital stock. The terms of these purchases were the same for all purchasers of our Series B Preferred Stock.
Please refer to the section entitled &#147;Principal stockholders&#148; for additional information regarding the shares held by these entities. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name of stockholder</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares of<BR>Series&nbsp;B<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total cash<BR>purchase<BR>price($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with ARCH Ventures(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,727,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entity affiliated with GV(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,363,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,500,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Foresite Capital Fund IV, L.P.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">City Hill, LLC(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,231,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,136,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Charles Homcy, M.D.(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares purchased by ARCH Venture Fund X, L.P. and ARCH Venture Fund X Overage, L.P. ARCH Ventures holds more than 5% of our outstanding capital stock. Jonathan Lim, M.D., a member of our board of directors,
is affiliated with ARCH Ventures. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares purchased by GV 2019, L.P., which, together with its affiliate GV 2023, L.P., holds more than 5% of our outstanding capital stock. Richard Scheller, Ph.D., a member of our board of directors, is
affiliated with GV 2019, L.P. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares purchased by Foresite Capital Fund IV, L.P. and Foresite Capital Fund V, L.P., which as of such financing, held more than 5% of our outstanding capital stock. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares purchased by City Hill, LLC. Jonathan Lim, M.D., a member of our board of directors, is affiliated with City Hill, LLC. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares purchased by Charles Homcy, M.D., a member of our board of directors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Series C Preferred Stock financing </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From December 2021 through March 2022, we sold an aggregate of 40,866,704 shares of our Series C Preferred Stock, at a price per share of $2.9515 for total gross
proceeds of $120.6&nbsp;million. Each share of our Series C Preferred Stock will automatically convert into &#8195;&#8195;&#8195; shares of our common stock immediately prior to the completion of this offering. Pursuant to the IRA, holders of our
Series C Preferred Stock are entitled to certain registration rights. See the section entitled &#147;Description of capital stock&#151;Registration rights&#148; for additional information. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the Series C Preferred Stock purchased by members of our board of directors or their affiliates and holders of more than 5% of our
outstanding capital stock. The terms of these purchases were the same for all purchasers of our Series C Preferred Stock. Please refer to the section entitled &#147;Principal stockholders&#148; for additional information regarding the shares held by
these entities. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name of stockholder</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares of<BR>Series C<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Total cash<BR>purchase</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>price($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Matrix Capital Management Master Fund L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,328,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,999,998.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Charles Homcy, M.D(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499,998.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares purchased by Matrix Capital Management Master Fund, L.P. which holds more than 5% of our outstanding capital stock. Andy Tran, a member of our board of directors, is affiliated with Matrix Capital
Management Master Fund, L.P. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares purchased by Charles Homcy, M.D., a member of our board of directors. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Convertible promissory
notes financing </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From December 2023 through April 2024, we sold $40.7&nbsp;million aggregate principal amount of our convertible promissory notes to certain
purchasers in a private placement. The notes&nbsp;bear interest at a rate of 8% per annum, compounded annually. Upon occurrence of an initial public offering pursuant to which all shares of our preferred stock are converted into common stock
resulting in aggregate gross proceeds to us of at least $50.0&nbsp;million, the outstanding convertible promissory notes shall be converted automatically into an amount of common stock equal to (i)&nbsp;the sum of (a)&nbsp;all then outstanding
principal amount of convertible promissory notes, (b)&nbsp;all then accrued but unpaid interest and (c)&nbsp;all other amounts (including fees and expenses) then accrued but unpaid under <FONT STYLE="white-space:nowrap">the-then</FONT> principal
amount of convertible promissory notes outstanding multiplied by (ii) 80% of the price per share to the public of the shares of common stock issued in the initial public offering. The notes mature on December&nbsp;15, 2026. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the notes purchased by members of our board of directors or their affiliates and holders of more than 5% of our outstanding capital stock.
The terms of these purchases were the same for all purchasers of the notes. Please refer to the section entitled &#147;Principal stockholders&#148; for additional information regarding the shares held by these entities. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name of stockholder</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Aggregate<BR>principal amount<BR>of notes<BR>purchased ($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with ARCH Ventures(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Affiliates of Third Rock Ventures(2).</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entity affiliated with GV(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with Charles Homcy, M.D.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="4" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of notes purchased by ARCH Venture Fund X, L.P. and ARCH Venture Fund X Overage, L.P. ARCH Ventures holds more than 5% of our outstanding capital stock. Jonathan Lim, M.D., a member of our board of directors,
is affiliated with ARCH Ventures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of notes purchased by Third Rock Ventures IV, L.P. Entities affiliated with Third Rock Ventures hold more than 5% of our outstanding capital stock. Charles Homcy, M.D. and Jeffrey Tong, Ph.D., each a member of
our board of directors, are affiliated with Third Rock Ventures. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of notes purchased by GV 2023, L.P. which, together with its affiliate GV 2019, L.P., holds more than 5% of our outstanding capital stock. Richard Scheller, Ph.D., a member of our board of directors, is
affiliated with GV 2019, L.P. and GV 2023, L.P. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of notes purchased by Charles J. Homcy Revocable Trust UA 11/4/1998, of which Charles Homcy, M.D., a member of our board of directors, is the trustee. </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Consulting agreement with Charles Homcy, M.D. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2019, we entered
into a consulting agreement with Charles Homcy, M.D., a member of our board of directors, for consulting services after receiving the unanimous written consent of the disinterested directors. Pursuant to the consulting agreement, we make payments of
$240,000 per year to Dr.&nbsp;Homcy for such consulting services, payable monthly in arrears. In addition, in April 2024, Dr.&nbsp;Homcy was granted an option to purchase 450,000 shares of our common stock, which vest monthly over the three-year
period starting March&nbsp;1, 2024 subject to Dr.&nbsp;Homcy&#146;s continued provision of services to the Company. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Advisor agreement with Richard Scheller,
Ph.D. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In July 2021, we entered into an advisor agreement with Richard Scheller, Ph.D., a member of our board of directors, for advisory services after receiving
the unanimous written consent of the disinterested directors. Pursuant to the advisor agreement, we make payments of $60,000 per year for such advisory services, payable monthly in arrears. In addition, pursuant to the advisor agreement, we granted
Dr.&nbsp;Scheller an option to purchase 78,185 shares of our common stock under the 2019 Plan, which vested monthly over the <FONT STYLE="white-space:nowrap">one-year</FONT> period immediately following the date of grant. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Investors&#146; rights agreement </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We entered into the IRA with certain
holders of our redeemable convertible preferred stock, including entities with which certain of our directors are affiliated and who hold more than 5% of our outstanding capital stock. These stockholders are entitled to rights with respect to the
registration of their shares under the Securities Act following this offering. See the section entitled &#147;Description of capital stock&#151;Registration rights&#148; for additional information. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Indemnification agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we intend to
enter into new indemnification agreements with each of our directors and executive officers. The indemnification agreements, our restated certificate of incorporation and our restated bylaws will require us to indemnify our directors to the fullest
extent not prohibited by Delaware law. Subject to certain limitations, our restated bylaws also require us to advance expenses incurred by our directors and executive officers. See the section entitled &#147;Executive compensation&#151;Limitations
on liability and indemnification matters&#148; for additional information. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Policies and procedures for related party transactions </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we intend to adopt a written related person transactions policy that provides that our executive officers, directors, nominees for
election as a director, beneficial owners of more than 5% of our common stock, and any members of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a material related person
transaction with us without the review and approval of our audit committee, or a committee composed solely of independent directors in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
event it is inappropriate for our audit committee to review such transaction due to a conflict of interest. We expect the policy to provide that any request for us to enter into a transaction
with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of our common stock or with any of their immediate family members or affiliates in which the amount involved exceeds the lesser of $120,000 and
1.0% of our total assets will be presented to our audit committee (or the committee composed solely of independent directors, if applicable) for review, consideration and approval. In approving or rejecting any such proposal, we expect that our
audit committee (or the committee composed solely of independent directors, if applicable) will consider the relevant facts and circumstances available and deemed relevant to the audit committee (or the committee composed solely of independent
directors, if applicable), including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related
person&#146;s interest in the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_14"></A>Principal stockholders </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table and accompanying footnotes set forth certain information with respect to the beneficial ownership of shares of our common stock as of June 30, 2024,
and as adjusted to reflect the shares of our common stock to be issued and sold in this offering, for: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">all of our current directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each person, or group of affiliated persons, known by us to be the beneficial owner of more than 5% of the outstanding
shares of our common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes
below, to our knowledge, the persons and entities named in the table below have sole voting and sole investment power with respect to all shares of our common stock that they beneficially owned, subject to applicable community property laws. </P>
 <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beneficial ownership prior to this offering is based on &#8195;&#8195;&#8195;&#8195; shares of our common stock outstanding as of June 30, 2024, assuming
(i)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into shares of our common stock immediately prior to the completion of this offering. Beneficial ownership after this offering is based
on&#8195;&#8195;&#8195;&#8195; shares of our common stock outstanding, assuming (i)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into shares of our common stock outstanding as described above,
(ii)&nbsp;the automatic conversion of all principal and accrued and unpaid interest on our outstanding convertible promissory notes into &#8195;&#8195;&#8195;&#8195; shares of our common stock immediately prior to the completion of this offering,
based upon an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus, and (iii)&#8195;&#8195;&#8195;&#8195;shares of our common
stock issued by us in this offering, assuming that the underwriters do not exercise their option to purchase up to an additional&#8195;&#8195;&#8195;&#8195;shares of our common stock from us in part or in full. In computing the number of shares of
common stock beneficially owned by a person and the percentage ownership of that person, we deemed to be outstanding all shares of our common stock subject to stock options held by that person or entity that are currently exercisable or that will
become exercisable within 60 days of June 30, 2024. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o&nbsp;Maze Therapeutics, Inc., 171 Oyster Point Blvd., Suite 300, South
San Francisco, California 94080. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>shares<BR>beneficially<BR>owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Percentage of<BR>shares<BR>beneficially<BR>owned (%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name of beneficial owner</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Before<BR>offering</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>After<BR>offering</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Before<BR>offering</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>After<BR>offering</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Directors and named executive officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jason Coloma, Ph.D.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Harold Bernstein, M.D., Ph.D(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Atul Dandekar(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Charles Homcy, M.D.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nancy C. Andrews, M.D., Ph.D.(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>shares<BR>beneficially<BR>owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Percentage of<BR>shares<BR>beneficially<BR>owned (%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name of beneficial owner</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Before<BR>offering</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>After<BR>offering</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Before<BR>offering</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>After<BR>offering</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sekar Kathiresan, M.D.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jonathan Lim, M.D.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard Scheller, Ph.D.(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Catherine Angell Sohn, Pharm. D.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Daniel Spiegelman(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jeffrey Tong, Ph.D.(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Andy Tran(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">All executive officers and directors as a group (13 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Other 5% stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with ARCH Venture Partners and related entities(13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with GV(14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with Third Rock Ventures(15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Matrix Capital Management Master Fund, L.P.(16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents (i) &#8195;&#8195;&#8195;&#8195; shares of common stock, of which &#8195;&#8195;&#8195;&#8195; are unvested and subject to repurchase by the Company if Dr.&nbsp;Coloma ceases to provide service to the Company
prior to the vesting of the shares, and (ii) &#8195;&#8195;&#8195;&#8195; shares underlying options to purchase common stock that are exercisable within 60 days of June 30, 2024. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents (i) &#8195;&#8195;&#8195;&#8195; shares of common stock, of which are unvested and subject to repurchase by the Company if Dr.&nbsp;Bernstein ceases to provide service to the Company prior to the vesting of
the shares, and (ii)&#8195;&#8195;&#8195;&#8195; shares underlying options to purchase common stock that are exercisable within 60 days of June 30, 2024. </TD></TR></TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents&#8195;&#8195;&#8195;&#8195; shares of common stock, all of which are unvested and subject to repurchase by the Company if Mr.&nbsp;Dandekar ceases to provide service to the Company prior to the vesting of the
shares. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents (i) &#8195;&#8195;&#8195;&#8195; shares of common stock, and (iii) &#8195;&#8195;&#8195;&#8195; shares underlying options to purchase common stock that are exercisable within 60 days of June 30, 2024.
Dr.&nbsp;Homcy, chair of our board of directors, was a partner of Third Rock Ventures, LLC, an affiliate of Third Rock Ventures IV, L.P. and Third Rock Ventures V, L.P., until October 2019 and now serves in an advisory capacity. Dr.&nbsp;Homcy does
not have voting or dispositive power over the shares held by Third Rock Ventures IV, L.P. and Third Rock Ventures V, L.P. See note (16)&nbsp;below for more information regarding Third Rock Ventures IV, L.P. and Third Rock Ventures V, L.P.
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents &#8195;&#8195;&#8195;&#8195; shares underlying options to purchase common stock that are exercisable within 60 days of June 30, 2024. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents&#8195;&#8195;&#8195;&#8195;shares underlying options to purchase common stock that are exercisable within 60 days of June 30, 2024. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents (i)&nbsp;stock options of &#8195;&#8195;&#8195;&#8195; shares of common stock of which &#8195;&#8195;&#8195;&#8195; are unvested and subject to repurchase by the Company if Dr.&nbsp;Lim ceases to provide
service to the Company prior to the vesting of the shares, and (ii) &#8195;&#8195;&#8195;&#8195;shares of common stock held by City Hill, LLC. Dr.&nbsp;Lim, a member of our board of directors, is Managing Partner and Founder of City Hill, LLC and is
a venture partner at ARCH Venture Partners, LLC, an affiliate of ARCH Venture Fund X, L.P. and ARCH Venture Fund X Overage, L.P. Dr.&nbsp;Lim does not have voting or dispositive power over the shares held by ARCH Venture Fund X, L.P. and ARCH
Venture Fund X Overage, L.P. See note (14)&nbsp;below for more information regarding ARCH Venture Fund X, L.P. and ARCH Venture Fund X Overage, L.P. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents (i) &#8195;&#8195;&#8195;&#8195; shares of common stock, of which &#8195;&#8195;&#8195;&#8195; shares are unvested shares and subject to repurchase if Dr.&nbsp;Scheller ceases to provide services to the
Company prior to the vesting of the shares, and (ii) &#8195;&#8195;&#8195;&#8195; shares underlying options to purchase common stock that are exercisable within 60 days of June 30, 2024. Dr.&nbsp;Scheller, a member of our board of directors, is an
advisor at GV, an affiliate of GV 2019, L.P. and GV 2023, L.P. Dr.&nbsp;Scheller does not have voting or dispositive power over the shares held by GV 2019, L.P. and GV 2023, L.P.] See note (15)&nbsp;below for more information regarding GV 2019, L.P.
and GV 2023, L.P. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(9)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents &#8195;&#8195;&#8195;&#8195; shares underlying options to purchase common stock that are exercisable within 60 days of June 30, 2024. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(10)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents &#8195;&#8195;&#8195;&#8195; shares underlying options to purchase common stock that are exercisable within 60 days of June 30, 2024. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(11)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents&#8195;&#8195;&#8195;&#8195;shares. Dr.&nbsp;Tong, a member of our board of directors, is a partner of Third Rock Ventures, an affiliate of Third Rock Ventures IV, L.P. Dr.&nbsp;Tong does not have voting or
dispositive power over the shares held by Third Rock Ventures IV, L.P. and Third Rock Ventures V, L.P. See note (16)&nbsp;below for more information regarding Third Rock Ventures IV, L.P. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(12)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents&#8195;&#8195;&#8195;&#8195;shares. Mr.&nbsp;Tran, a member of our board of directors, is a principal at Matrix Capital Management LP. Mr.&nbsp;Tran does not have voting or dispositive power over the shares
held by Matrix Capital Management Master Fund, L.P. See note (17)&nbsp;below for more information regarding Matrix Capital Management Master Fund, L.P. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(13)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents&#8195;&#8195;&#8195;&#8195;shares held of record by ARCH Venture Fund X, L.P., or ARCH X, and shares held of record by ARCH Venture Fund X Overage, L.P., or ARCH X Overage. ARCH Venture Partners X, L.P., or
AVP X LP, is the sole general partner of ARCH X. ARCH Venture Partners X Overage, L.P., or AVP X Overage LP, is the sole general partner of ARCH X Overage. ARCH Venture Partners X, LLC, or AVP X LLC, is the sole general partner of each of AVP X LP
and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen, collectively the AVP X Committee Members, comprise the investment committee of AVP X LLC. AVP X LP and AVP X Overage LP may be deemed to beneficially own the
shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and
vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members disclaims beneficial ownership except to any pecuniary interest therein. The address of the ARCH Venture Partners
entities is 8755 W. Higgins Road, Suite 1025, Chicago, IL 60631. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(14)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents&#8195;&#8195;&#8195;&#8195; shares held of record by GV 2019, L.P. and&#8195;&#8195;&#8195;&#8195; shares held of record by GV 2023, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP,
L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may
be deemed to share power to vote or dispose of the shares held directly by GV 2019, L.P. GV 2023 GP, L.P. (the general partner of GV 2023, L.P.), GV 2023 GP, L.L.C., (the general partner of GV 2023 GP, L.P.), Alphabet Holdings LLC (the sole member
of GV 2023 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may be deemed to share power to vote or dispose of the shares held directly by GV 2023, L.P.
The principal business address of each of the entities listed above is 1600 Amphitheatre Parkway, Mountain View, California 94043. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(15)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents&#8195;&#8195;&#8195;&#8195; shares held of record by Third Rock Ventures IV, L.P. and&#8195;&#8195;&#8195;&#8195; shares held of record by Third Rock Ventures V, L.P. The general partner of Third Rock
Ventures IV, L.P. is Third Rock Ventures GP IV, L.P. The general partner of Third Rock Ventures GP IV, L.P. is TRV GP IV, LLC. Neil Exter, Kevin Gillis, Reid Huber, Ph.D., Jeffrey Tong, Ph.D., Abbie Celniker, Ph.D., Robert Tepper, M.D. and Cary
Pfeffer, M.D. are the managing members of TRV GP IV, LLC who collectively make voting and investment decisions with respect to shares held by Third Rock Ventures IV, L.P. The general partner of Third Rock Ventures V, L.P. is Third Rock Ventures GP
V, L.P. The general partner of Third Rock Ventures GP V, L.P. is TRV GP V, LLC. Neil Exter, Kevin Gillis, Reid Huber, Ph.D., Jeffrey Tong, Ph.D., Abbie Celniker, Ph.D., Robert Tepper, M.D. and Cary Pfeffer, M.D. are the managing members of TRV GP V,
LLC who collectively make voting and investment decisions with respect to shares held by Third Rock Ventures V, L.P. Dr.&nbsp;Homcy, chair of our board of directors, was a partner of Third Rock Ventures, LLC, an affiliate of Third Rock Ventures IV,
L.P. and Third Rock Ventures V, L.P., until October 2019 and now serves in an advisory capacity. Dr.&nbsp;Tong, a member of our board of directors, is a partner of Third Rock Ventures, LLC. Neither Dr.&nbsp;Homcy nor Dr.&nbsp;Tong has voting or
dispositive power over the shares held by Third Rock Ventures IV, L.P. and Third Rock Ventures V, L.P. The address for each of Third Rock Ventures IV, L.P. and Third Rock Ventures V, L.P. is 201 Brookline Avenue, Suite 1401, Boston, MA 02215.
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(16)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents&#8195;&#8195;&#8195;&#8195; shares held directly by Matrix Capital Management Master Fund, LP, or the Matrix Fund. Matrix Capital Management Company LP, or the Investment Manager, a Delaware limited
partnership, serves as the investment advisor to the Matrix Fund with respect to the shares directly held by the Matrix Fund. David E. Goel serves as the Managing General Partner of the Investment Manager, and may be deemed to hold voting and
dispositive power with respect to the shares directly held by the Matrix Fund. The business address for each of the Matrix Fund, the Investment Manager and Mr.&nbsp;Goel is c/o Matrix Capital Management Company LP, Bay Colony Corporate Center, 1000
Winter Street, Suite 4500, Waltham, Massachusetts 02451. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_15"></A>Description of capital stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The following description summarizes the most important terms of our capital stock, as will be in effect following this offering. Because it is only a summary, it
does not contain all the information that may be important to you. We expect to adopt a restated certificate of incorporation and restated bylaws that will become effective upon the completion of this offering, and this description summarizes
provisions that are expected to be included in these documents. For a complete description, you should refer to our restated certificate of incorporation and restated bylaws, which are included as exhibits to the registration statement of which this
prospectus forms a part, and to the applicable provisions of Delaware law. </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>General </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, our authorized capital stock will consist of&#8195;&#8195;&#8195;&#8195;shares of our common stock, $0.001 par value per share,
and&#8195;&#8195;&#8195;&#8195;shares of our undesignated preferred stock, $0.001 par value per share. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the provisions of our current certificate of
incorporation, all of our Series A Preferred Stock, Series&nbsp;B Preferred Stock and Series C Preferred Stock will automatically convert into common stock in connection with the completion of this offering. Our Series A Preferred Stock will convert
at a ratio of&#8195;&#8195;&#8195;&#8195;, our Series B Preferred Stock will convert at a ratio of&#8195;&#8195;&#8195;&#8195;, our Series C Preferred Stock will convert at a ratio of &#8195;&#8195;&#8195;&#8195; and our outstanding convertible
promissory notes will convert automatically into an amount of common stock equal to (i)&nbsp;the sum of (a)&nbsp;all then outstanding principal amount of convertible promissory notes, (b)&nbsp;all then accrued but unpaid interest and (c)&nbsp;all
other amounts (including fees and expenses) then accrued but unpaid under <FONT STYLE="white-space:nowrap">the-then</FONT> principal amount of convertible promissory notes outstanding multiplied by (ii) 80% of the price per share to the public of
the shares of common stock issued in the initial public offering. Assuming the effectiveness of this conversion, there were&#8195;&#8195;&#8195;&#8195;shares of our common stock issued, held by approximately&#8195;&#8195;&#8195;&#8195;stockholders
of record, and no shares of our redeemable convertible preferred stock outstanding. Our board of directors is authorized, without stockholder approval, to issue additional shares of our capital stock. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Dividend rights </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled to receive dividends out of
funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. See the section entitled &#147;Dividend policy&#148; for
additional information. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Voting rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Holders of our common
stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our restated certificate of incorporation, which means that holders of
a majority of the shares of our common stock will be able to elect all of our directors. Our restated certificate of incorporation will establish a classified board of directors, to be divided into three classes with staggered three-year terms. Only
one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>No preemptive or similar rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our common stock is not entitled to
preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Right to receive liquidation distributions </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon our liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the assets legally available for distribution to our stockholders would be
distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of
liquidation preferences, if any, on any outstanding shares our of preferred stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Preferred stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After the completion of this offering, no shares of our preferred stock will be outstanding. Pursuant to our restated certificate of incorporation that will become
effective immediately prior to the completion of this offering, our board of directors will be authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number
of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without further vote or action by our
stockholders. Our board of directors will also be able to increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding and not above the number of shares of that
series authorized, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the
holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change
in control of our company and might adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. We have no current plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Stock options </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June 30, 2024, we had outstanding options to
purchase an aggregate of 35,335,588 shares of our common stock, with a weighted-average exercise price of $1.50 per share under our 2019 Plan. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Registration
rights </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the terms of the IRA, immediately following this offering, the holders of&#8195;&#8195;&#8195;&#8195;shares of our common stock will be
entitled to rights with respect to the registration of these shares under the Securities Act as described below. We refer to these shares collectively as registrable securities. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Demand registration rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beginning from the earlier of
December&nbsp;8, 2026 or six months after the completion of this offering, certain holders of not less than 25% of the then-outstanding registrable securities may make a request to us for the registration under the Securities Act of at least 25% of
the registrable securities then outstanding if the anticipated aggregate offering price is at least $60.0&nbsp;million. Within ten days after the date such request is given, we are obligated to provide notice of such request to all holders of
registrable securities and, as soon as practicable and in any event within 60 days after the date such request is given, to file a <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> registration statement under the Securities Act covering all
registrable securities that the initiating holders requested to be registered and any additional registrable securities requested to be included in such registration by any other holders. We are only required to file two registration statements that
are declared effective upon exercise of these demand registration rights. We may postpone taking action with respect to such filing not more than once during any <FONT STYLE="white-space:nowrap">12-month</FONT> period for a total period of not more
than 120 days, if after receiving a request for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
registration, we furnish to the holders requesting such registration a certificate signed by our Chief Executive Officer stating that, in the good faith judgment of our board of directors, it
would be materially detrimental to us and our stockholders; <I>provided that</I> we may not register any securities for our own account or that of any other stockholder during such <FONT STYLE="white-space:nowrap">120-day</FONT> period other than
under certain circumstances. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain holders of at least 10% of the then-outstanding registrable securities can request that we register all or part of their registrable shares on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> if we are eligible to file a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and if the aggregate price to the public of the shares offered, net of selling expenses, is at least
$30.0&nbsp;million. Within ten days after such request is given, we are obligated to provide notice of such request to all holders of registrable securities and as soon as practicable and in any event within 45 days, file a Form <FONT
STYLE="white-space:nowrap">S-3</FONT> registration statement, covering all registrable securities that the initiating holders requested to be registered and any additional registrable securities requested to be included in such registration by any
other holders. We are only required to file two registration statements on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that are declared effective in a <FONT STYLE="white-space:nowrap">12-month</FONT> period. We may postpone taking action with
respect to such filing not more than once during any <FONT STYLE="white-space:nowrap">12-month</FONT> period for a period of not more than 120 days, if after receiving a request for registration, we furnish to the holders requesting such
registration a certificate signed by our Chief Executive Officer stating that, in the good faith judgment of our board of directors, it would be materially detrimental to us and our stockholders; <I>provided that</I> we may not register any
securities for our own account or that of any other stockholder during such <FONT STYLE="white-space:nowrap">120-day</FONT> period other than under certain circumstances. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Piggyback registration rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we register any of our securities
for public sale, holders of then-outstanding registrable securities or their permitted transferees will have the right to include their registrable securities in the registration statement. However, this right does not apply to a registration
related to any employee benefit plan or a corporate reorganization or other transaction covered by Rule 145 promulgated under the Securities Act or&nbsp;a registration on any form that does not include substantially the same information as would be
required to be included in a registration statement covering the sale the registrable securities. The underwriters of any underwritten offering will have the right to limit the number of shares registered by these holders if they determine that
marketing factors require limitation, in which case the number of shares to be registered will be apportioned pro rata among these holders, according to the total number of registrable securities originally requested by such holders to be included
in the registration statement. However, the number of shares to be registered by these holders cannot be reduced unless all other securities (other than those sold by us) are entirely excluded first, and thereafter, that amount can only be reduced
to 30% of the total number of securities to be included in such offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Expenses of registration rights </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will pay all expenses, other than underwriting discounts and selling commissions incurred in connection with each of the registrations described above, including the
reasonable fees and disbursements of counsel (except for the fees and disbursements of one counsel selected by the holders of a majority in interest of the registrable securities and paid for by us), <I>provided </I><I>however</I>, that the
registrations described above are not subsequently withdrawn at the request of the holders of a majority in interest of the registrable securities (in which case all selling holders shall bear such expenses pro rata based upon the number of
registrable securities that were to be included in the withdrawn registration) unless the holders of a majority of the registrable securities agree to forfeit their right to a registration as described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Expiration of registration rights </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The registration rights described above will expire, with respect to any particular holder of these rights, on the earliest to occur of (i)&nbsp;the closing of a deemed
liquidation event, as defined in our restated certificate of incorporation, (ii)&nbsp;such time after this offering as the registrable securities held by such holder may be sold within any three-month period without restriction pursuant to Rule 144
or a similar exemption under the Securities Act or (iii)&nbsp;the fifth anniversary of this offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Anti-takeover provisions </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The provisions of the DGCL, our restated certificate of incorporation and our restated bylaws, as we expect they will be in effect upon the completion of this offering,
could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to
encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the
disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Delaware law
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are subject to the provisions of Section&nbsp;203 of the DGCL regulating corporate takeovers. In general, Section&nbsp;203 prohibits a publicly held
Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years following the date on which the person became an interested stockholder unless: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or
the transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (i)&nbsp;shares owned by persons who are directors and also executive officers and
(ii)&nbsp;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the
corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of transactions together resulting in a
financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a
corporation&#146;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section&nbsp;203 may also
discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Restated certificate of incorporation and restated bylaw provisions </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our restated certificate of incorporation and our restated bylaws, as we expect they will be in effect upon the completion of this offering, include a number of
provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Board of directors vacancies.</I>&#8195;Our restated certificate of incorporation and restated bylaws will authorize
only our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire
board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more
difficult to change the composition of our board of directors but promotes continuity of management. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Classified board.</I>&#8195;Our restated certificate of incorporation and restated bylaws will provide that our board of
directors is classified into three classes of directors, each with staggered three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for
stockholders to replace a majority of the directors on a classified board of directors. See the section entitled &#147;Management&#151;Board composition&#148; for additional information. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Stockholder action; special meetings of stockholders.</I>&#8195;Our restated certificate of incorporation will provide
that our stockholders may not take action by written consent but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our restated bylaws
or remove directors without holding a meeting of our stockholders called in accordance with our restated bylaws. Further, our restated certificate of incorporation and restated bylaws will provide that special meetings of our stockholders may be
called only by a majority of our board of directors, the chairperson of our board of directors, our Chief Executive Officer or our President, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of
our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Advance notice requirements for stockholder proposals and director nominations.</I>&#8195;Our restated bylaws will
provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also will specify
certain requirements regarding the form and content of a stockholder&#146;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our
annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of
directors or otherwise attempting to obtain control of our company. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>No cumulative voting.</I>&#8195;The DGCL provides that stockholders are not entitled to the right to cumulate votes in
the election of directors unless a corporation&#146;s certificate of incorporation provides otherwise. Our restated certificate of incorporation and restated bylaws will not provide for cumulative voting. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Directors removed only for cause.</I>&#8195;Our restated certificate of incorporation will provide that stockholders may
remove directors only for cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding common stock. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Amendment of charter provisions.</I>&#8195;Any amendment of the above expected provisions in our restated certificate of
incorporation will require approval by the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
common stock , unless such amendments are approved by two thirds of our entire board of directors, in which case stockholders can approve by a simple majority. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Issuance of undesignated preferred stock.</I>&#8195;Our board of directors has the authority, without further action by
the stockholders, to issue up to&#8195;&#8195;&#8195;&#8195;shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued
shares of preferred stock would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by merger, tender offer, proxy contest or other means. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Choice of forum.</I>&#8195;Our restated certificate of incorporation will provide that, to the fullest extent permitted
by law, the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising
pursuant to the DGCL, our restated certificate of incorporation or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. Our restated bylaws will provide that the federal district courts
of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, which we refer to as a Federal Forum Provision. Our
decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal courts or state courts
will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty
or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. While neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability
created by the Exchange Act, Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Accordingly,
actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder also must be brought in federal court. Our stockholders will not be deemed to have waived our compliance with the
federal securities laws and the regulations promulgated thereunder. Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum
provisions, including the Federal Forum Provision. These provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, executive officers, other employees or agents of
our company, which may discourage lawsuits against us and our directors, executive officers, and other employees. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Transfer agent and registrar
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, the transfer agent and registrar for our common stock will be&#8195;&#8195;&#8195;&#8195;. The transfer agent and
registrar&#146;s address is &#8195;&#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>The Nasdaq Global Market listing </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have applied to list our common stock on the Nasdaq Global Market under the symbol &#147;MAZE.&#148; The closing of this offering is contingent upon such listing.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_16"></A>Shares eligible for future sale </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has been no public market for our common stock, and we cannot predict the effect, if any, that market sales of shares of our common stock
or the availability of shares of our common stock for sale will have on the market price of our common stock prevailing from time to time. Nevertheless, sales of our common stock, including shares issued upon exercise of outstanding options, in the
public market following this offering could adversely affect market prices prevailing from time to time and could impair our ability to raise capital through the sale of our equity securities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, we will have a total of&#8195;&#8195;&#8195;&#8195; shares of our common stock outstanding, assuming (i)&nbsp;the automatic
conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of&#8195;&#8195;&#8195;&#8195;shares of our common stock, (ii)&nbsp;the automatic conversion of all principal and accrued and unpaid interest on our
outstanding convertible promissory notes into &#8195;&#8195;&#8195;&#8195; shares of our common stock immediately prior to the completion of this offering, based upon an assumed initial public offering price of $per share, which is the midpoint of
the estimated price range set forth on the cover of this prospectus, and (iii)&nbsp;the issuance of&#8195;&#8195;&#8195;&#8195;shares of common stock in this offering. Of these outstanding shares, all of the shares of our common stock sold in this
offering will be freely tradable, except that any shares purchased in this offering by our affiliates, as that term is defined in Rule&nbsp;144 under the Securities Act can only be sold in compliance with the Rule&nbsp;144 limitations described
below. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The remaining outstanding shares of our common stock will be, and shares subject to stock options will be upon issuance, deemed &#147;restricted
securities&#148; as defined in Rule&nbsp;144. Restricted securities may be sold in the public market only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule&nbsp;144 or Rule&nbsp;701
promulgated under the Securities Act, which rules are summarized below. In addition, substantially all of our security holders have, or will have, entered into market standoff agreements with us or <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements with the underwriters under which they have agreed, subject to specific exceptions, not to sell any of our stock for at least 180 days following the date of this prospectus, as described below. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> and market standoff agreements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All of our directors and officers and substantially all of our security holders are, or will be, subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements or
market standoff provisions that prohibit them from offering for sale, selling, contracting to sell, granting any option for the sale of, transferring or otherwise disposing of any shares of our common stock or options to acquire shares of our common
stock or any security or instrument related to our common stock, or entering into any swap, hedge or other arrangement that transfers any of the economic consequences of ownership of our common stock, for a period of 180 days following the date of
this prospectus without the prior written consent of J.P. Morgan Securities LLC, TD Securities (USA) LLC and Leerink Partners LLC, subject to certain exceptions. See the section entitled &#147;Underwriting&#148; for additional information. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Rule 144 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In general, Rule&nbsp;144 provides that once we have been subject
to public company reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act for at least 90 days, a person who is not deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90
days preceding a sale and who has beneficially owned the shares of our common stock proposed to be sold for at least six months, including the holding period of any prior owner other than our affiliates, is entitled to sell those shares without
complying with the manner of sale, volume limitation or notice provisions of Rule&nbsp;144, subject to compliance with the public information requirements of Rule&nbsp;144. If such a person has beneficially owned the shares proposed to be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
sold for at least one year, including the holding period of any prior owner other than our affiliates, then that person would be entitled to sell those shares without complying with any of the
requirements of Rule&nbsp;144. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In general, Rule 144 provides that our affiliates or persons selling shares of our common stock on behalf of our affiliates are
entitled to sell upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> and market standoff agreements described above, within any three-month period, a number of shares of our common stock that does not exceed the greater of: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately
&#8195;&#8195;&#8195;&#8195;&nbsp;shares immediately after the completion of this offering; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the average reported weekly trading volume of share of our common stock during the four calendar weeks preceding the filing
of a notice on Form 144 with respect to that sale. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sales under Rule 144 by our affiliates or persons selling shares of our common stock on behalf
of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Rule 701 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Rule 701 generally allows a stockholder who purchased shares of our
common stock pursuant to a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90 days to sell these shares in reliance upon Rule 144, but without being required to
comply with the public information, holding period, volume limitation or notice provisions of Rule 144. Rule 701 also permits affiliates of our company to sell their Rule 701 shares under Rule 144 without complying with the holding period
requirements of Rule 144. All holders of Rule 701 shares, however, are required to wait until 90&nbsp;days after the date of this prospectus before selling those shares pursuant to Rule 701 and are subject to the
<FONT STYLE="white-space:nowrap">lock-up</FONT> and market standoff agreements described above. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> registration
statement </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we intend to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the
Securities Act covering all of the shares of our common stock subject to outstanding options, outstanding shares of restricted stock and the shares of our common stock reserved for issuance under our stock plans. We expect to file this registration
statement as soon as permitted under the Securities Act. However, the shares registered on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> may be subject to the volume limitations and the manner of sale, notice and public information
requirements of Rule 144 and will not be eligible for resale until expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> and market standoff agreements to which they are subject. Of the 35,335,588 shares of our common stock that were
subject to options outstanding as of June 30, 2024, options to purchase 19,472,987 shares of common stock were vested as of June 30, 2024. Shares of our common stock underlying outstanding options will not be eligible for sale until the expiration
of the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> and market standoff agreements to which they are subject. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Registration rights </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have granted demand, piggyback and Form <FONT
STYLE="white-space:nowrap">S-3</FONT> registration rights to certain of our stockholders to sell our common stock. Registration of the sale of these shares under the Securities Act would result in these shares becoming freely tradable without
restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See the section entitled &#147;Description of capital stock&#151;Registration rights&#148; for additional
information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_17"></A>Material U.S. federal income tax consequences to
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following summary describes the material U.S. federal income tax consequences of the ownership and
disposition of shares of our common stock acquired in this offering by <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below). This discussion does not address all aspects of U.S. federal income taxation, does not discuss the
potential application of the alternative minimum tax or Medicare contribution tax on net investment income, and does not deal with state or local tax laws, any U.S. federal <FONT STYLE="white-space:nowrap">non-income</FONT> tax laws such as gift and
estate tax laws, except to the limited extent provided below, or any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws that may be relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders in light of their particular
circumstances. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Special rules different from those described below may apply to certain <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that are subject to
special treatment under the Code, such as: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">insurance companies, banks, investment funds and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations (including private foundations) and <FONT
STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">foreign governments and international organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">broker-dealers and traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">U.S. expatriates and certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons required for U.S. federal income tax purposes to conform the timing of income accruals to their financial
statements under Section&nbsp;451(b) of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons that own, or are deemed to own, more than 5% of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons that hold our common stock as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion
transaction,&#148; &#147;synthetic security&#148; or integrated investment or other risk reduction strategy; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons who do not hold our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code (generally,
for investment purposes); and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">partnerships and other entities or arrangements treated as pass-through entities for U.S. federal income tax purposes, and
investors in such entities (regardless of their places of organization or formation). </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holders are urged to consult their own tax advisors to determine the U.S. federal, state, local and other tax consequences that may be relevant to them. If an entity or arrangement that is classified as a partnership for U.S. federal income tax
purposes holds our common stock, the U.S. federal income tax treatment of the partnership and the partners thereof generally will depend on the status of the partner and the activities of the partnership. Partnerships holding our common stock and
the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to them of holding and disposing of our common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, the discussion below is based upon the provisions of the Code, U.S. Treasury Regulations promulgated thereunder, published rulings and administrative
pronouncements of the U.S. Internal Revenue Service, or the IRS, and judicial decisions, in each case as of the date hereof, and such authorities may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
repealed, revoked or modified, possibly retroactively, or could be subject to differing interpretations which could result in U.S. federal income tax consequences different from those discussed
below. We have not requested a ruling from the IRS with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS will not take a contrary position regarding the tax consequences
described herein, or that any such contrary position would not be sustained by a court. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS CONSIDERING THE
PURCHASE OF OUR COMMON STOCK PURSUANT TO THIS OFFERING SHOULD CONSULT THEIR OWN TAX ADVISORS CONCERNING THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF OWNING AND DISPOSING OF OUR COMMON STOCK IN LIGHT OF THEIR PARTICULAR SITUATIONS AS WELL AS ANY
CONSEQUENCES ARISING UNDER THE LAWS OF ANY OTHER TAXING JURISDICTION, INCLUDING ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX CONSEQUENCES OR ANY U.S. FEDERAL <FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX
CONSEQUENCES, AND THE POSSIBLE APPLICATION OF TAX TREATIES. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT>
Holder&#148; is a beneficial owner of common stock, other than a partnership or other entity classified as a partnership or other pass-through entity that is not, for U.S. federal income tax purposes, (a)&nbsp;an individual who is a citizen or
resident of the United States, (b)&nbsp;a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes), created or organized in or under the laws of the United States, any state thereof or the District of Columbia,
(c)&nbsp;an estate, the income of which is subject to U.S. federal income taxation regardless of its source, or (d)&nbsp;a trust that (1)&nbsp;is subject to the primary supervision of a court within the United States and one or more U.S. persons
(within the meaning of Section&nbsp;7701(a)(30) of the Code) have the authority to control all substantial decisions of the trust or (2)&nbsp;has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If you are an individual <FONT STYLE="white-space:nowrap">non-U.S.</FONT> citizen, you may, in some cases, be deemed to be a resident alien (as opposed to a
nonresident alien) by virtue of being present in the United States for at least 31 days in the calendar year and for an aggregate of at least 183 days during a three-year period ending in the current calendar year. Generally, for this purpose, all
the days present in the current year, <FONT STYLE="white-space:nowrap">one-third</FONT> of the days present in the immediately preceding year, and <FONT STYLE="white-space:nowrap">one-sixth</FONT> of the days present in the second preceding year,
are counted. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Resident aliens are generally subject to U.S. federal income tax as if they were U.S. citizens. Individuals who are uncertain of their status as
resident or nonresident aliens for U.S. federal income tax purposes are urged to consult their own tax advisors regarding the U.S. federal income tax consequences of the ownership or disposition of our common stock. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Distributions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not expect to make any distributions on our common stock
in the foreseeable future (see &#147;Dividend Policy&#148; above). If we do make distributions on our common stock, however, such distributions will constitute dividends for U.S. tax purposes to the extent paid out of our current or accumulated
earnings and profits (as determined under U.S. federal income tax principles). Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that is applied against and reduces, but not below zero, a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in our common stock. Any remaining excess will be treated as gain realized on the sale or exchange of our common stock as described below under the section entitled
&#147;Material U.S. federal income tax consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders&#151;Gain on disposition of our common stock.&#148; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussions below under the sections titled &#147;Material U.S. Federal Income Tax Consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holders&#151;Backup withholding and information reporting&#148; and &#147;&#151;Foreign accounts,&#148; any distribution on our common stock that is treated as a dividend paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is not
effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#146;s conduct of a trade or business in the United States will generally be subject to U.S. federal withholding tax at a 30% rate or such lower rate as may be
specified by an applicable income tax treaty </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
between the United States and the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s country of residence. To obtain a reduced rate of withholding under an income tax treaty, a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will be required to provide the applicable withholding agent with a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other appropriate form, certifying the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s entitlement to benefits under the treaty. Such form must be provided prior to the payment of
dividends and generally must be updated periodically. If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds stock through a financial institution or other agent acting on the holder&#146;s behalf, the holder will be required to provide
appropriate documentation to such agent. The holder&#146;s agent may then be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S.
withholding tax under an income tax treaty, you should consult with your own tax advisor to determine if you are able to obtain a refund of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We (or any applicable withholding agents) generally are not required to withhold tax on dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that
are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent
establishment that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains in the United States) if a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> stating that the dividends are so connected, is furnished
to the applicable withholding agent. In general, such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the same rates applicable to U.S. persons. A corporate
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder receiving effectively connected dividends may also be subject to an additional &#147;branch profits tax,&#148; which is imposed, under certain circumstances, at a rate of 30% (or such lower
rate as may be specified by an applicable treaty) on the corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s effectively connected earnings and profits, subject to certain adjustments. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Gain on disposition of our common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussions below
under the sections entitled &#147;Material U.S. federal income tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders&#151;Backup withholding and information reporting&#148; and &#147;&#151;Foreign accounts,&#148; a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income or withholding tax with respect to gain realized on a sale or other disposition of our common stock unless (a)&nbsp;the gain is effectively
connected with a trade or business of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment that the holder maintains in
the United States), (b) the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien who is an individual and is present in the United States for 183 or more days in the taxable year of the disposition and certain other
conditions are met, or (c)&nbsp;we are or have been a &#147;United States real property holding corporation&#148; within the meaning of Code Section&nbsp;897(c)(2) at any time within the shorter of the five-year period preceding such disposition or
the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period in the common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If you are a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder described in (a)&nbsp;above, you will be required to pay tax on the net gain derived from the sale at the same U.S. federal income tax rates applicable to U.S. persons. A corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
described in (a)&nbsp;above may also be subject to the additional branch profits tax at a 30% rate (or such lower rate as may be specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as
adjusted for certain items. If you are an individual <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in (b)&nbsp;above, you will be required to pay a flat 30% tax on the gain derived from the sale, which gain may be offset by
certain U.S. source capital losses (even though you are not considered a resident of the United States), provided you have timely filed U.S. federal income tax returns with respect to such losses. With respect to (c)&nbsp;above, in general, we would
be a United States real property holding corporation if U.S. real property interests as defined in the Code and the U.S. Treasury Regulations comprised (by fair market value) at least half of our worldwide real property interests plus our other
assets used or held for use in a trade or business. We believe that we are not, and do not anticipate becoming, a United States real property holding corporation. However, there can be no assurance that we will not become a United States real
property holding corporation in the future. Even if we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
were to be treated as a U.S. real property holding corporation, gain realized by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder on a disposition of our common stock would not be
subject to U.S. federal income tax so long as (1)&nbsp;the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, directly, indirectly or constructively, no more than 5% of our common stock at all times within the shorter of (i)&nbsp;the
five-year period preceding the disposition or (ii)&nbsp;the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period and (2)&nbsp;our common stock is regularly traded on an established securities market. There can be no
assurance that our common stock will qualify as regularly traded on an established securities market. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>U.S. federal estate tax </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The estates of nonresident alien individuals generally are subject to U.S. federal estate tax on property with a U.S. situs. Because we are a U.S. corporation, our
common stock will be U.S. situs property and, therefore, will be included in the taxable estate of a nonresident alien decedent, unless an applicable estate tax treaty between the United States and the decedent&#146;s country of residence provides
otherwise. The terms &#147;resident&#148; and &#147;nonresident&#148; are defined differently for U.S. federal estate tax purposes than for U.S. federal income tax purposes. Investors are urged to consult their own tax advisors regarding the U.S.
federal estate tax consequences of the ownership or disposition of our common stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Backup withholding and information reporting </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Generally, we or certain financial middlemen must report information to the IRS with respect to any distributions we pay on our common stock including the amount of any
such distributions, the name and address of the recipient, and the amount, if any, of tax withheld. A similar report is sent to the holder to whom any such dividends are paid. Pursuant to tax treaties or certain other agreements, the IRS may make
its reports available to tax authorities in the recipient&#146;s country of residence. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Distributions paid by us (or our paying agents) to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may also be subject to U.S. federal backup withholding. U.S. federal backup withholding generally will not apply to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder who provides a properly
executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> or IRS Form <FONT STYLE="white-space:nowrap">W-8</FONT> ECI, as applicable, or
otherwise establishes an exemption, <I>provided that</I> the applicable withholding agent does not have actual knowledge or reason to know the holder is a U.S. person. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under current U.S. federal income tax law, U.S. information reporting and backup withholding requirements generally will apply to the proceeds of a disposition of our
common stock effected by or through a U.S. broker or a U.S. office of any broker, U.S. or <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> unless the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder provides a properly executed IRS Form <FONT
STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> or IRS Form <FONT STYLE="white-space:nowrap">W-8</FONT> ECI, as applicable, or otherwise establishes an
exemption. Generally, U.S. information reporting and backup withholding requirements will not apply to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder where the transaction is effected outside the
United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker. Information reporting and backup withholding requirements may, however, apply to a payment of disposition
proceeds if the broker has actual knowledge, or reason to know, that the holder is, in fact, a U.S. person. For information reporting purposes, certain brokers with substantial U.S. ownership or operations will generally be treated in a manner
similar to U.S. brokers. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Backup withholding is not an additional tax. If backup withholding is applied to you, you should consult with your own tax advisor to
determine whether you have overpaid your U.S. federal income tax, and whether you are able to obtain a tax refund or credit of the overpaid amount. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Foreign
accounts </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, U.S. federal withholding taxes may apply under the Foreign Account Tax Compliance Act, or FATCA, on certain types of payments, including
dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends on our common stock paid to a &#147;foreign financial institution&#148;
or a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (1)&nbsp;the foreign financial institution agrees to undertake certain diligence and reporting obligations, (2)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States
owner, or (3)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. The 30% federal withholding tax described in this paragraph cannot be
reduced under an income tax treaty with the United States. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in (1)&nbsp;above, it must enter into an agreement with the U.S. Department of the
Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United States persons&#148; or &#147;United States-owned foreign entities&#148; (each as defined in the Code), annually report certain
information about such accounts, and withhold 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT> foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions
that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally also would apply to payments
of gross proceeds from the sale or other disposition of our common stock. Under proposed regulations, however, no withholding will apply with respect to payments of gross proceeds. The preamble to the proposed regulations specifies that taxpayers
and withholding agents are permitted to rely on such proposed regulations pending finalization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prospective investors should consult their tax advisors regarding
the potential application of withholding under FATCA to their investment in our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING
THE TAX CONSEQUENCES OF HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> OR
U.S. FEDERAL <FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS SUCH AS ESTATE AND GIFT TAX OR UNDER ANY APPLICABLE TAX TREATY. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_18"></A>Underwriting </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are offering the shares of our common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC, TD Securities (USA) LLC,
Leerink Partners LLC and Guggenheim Securities, LLC are acting as book-running managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject to the terms and
conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover of this
prospectus, the number of shares of our common stock listed next to its name in the following table: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number<BR>of&nbsp;shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">TD Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Guggenheim Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters are committed to purchase all the shares of our common stock offered by us if they purchase any shares. The underwriting
agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. The offering of the shares by the
underwriters is subject to receipt and acceptance and subject to the underwriters&#146; right to reject any order in whole or in part. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters propose to
offer the shares of our common stock directly to the public at the initial public offering price set forth on the cover of this prospectus and to certain dealers at that price less a concession not in excess of $&#8195;&#8195;&#8195;&#8195;per
share. Any such dealers may resell shares of our common stock to certain other brokers or dealers at a discount of up to $&#8195;per share from the initial public offering price. After the initial offering of the shares to the public, if all of the
shares of our common shares stock are not sold at the initial public offering price, the underwriters may change the offering price and the other selling terms. Sales of any shares of our common stock made outside of the United States may be made by
affiliates of the underwriters. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters have an option to buy up to&#8195;&#8195;&#8195;&#8195;additional shares of our common stock from us to cover sales
of shares of our common stock by the underwriters which exceed the number of shares of our common stock specified in the table above. The underwriters have 30 days from the date of this prospectus to exercise this option to purchase additional
shares of our common stock. If any shares of our common stock are purchased with this option to purchase additional shares of our common stock, the underwriters will purchase shares of our common stock in approximately the same proportion as shown
in the table above. If any additional shares of our common stock are purchased, the underwriters will offer the additional shares of our common stock on the same terms as those on which the shares of our common stock are being offered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriting fee is equal to the public offering price per share of our common stock less the amount paid by the
underwriters to us per share of our common stock. The underwriting fee is $&#8195;&#8195;&#8195;&#8195;per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both
no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Without<BR>option to</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>purchase</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>additional<BR>shares<BR>exercise</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>With full<BR>option to</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>purchase</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>additional<BR>shares<BR>exercise</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and
accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $&#8195;&#8195;&#8195;&#8195;million. We have also agreed to reimburse the underwriters for reasonable fees and expenses of counsel related to the
review by the Financial Industry Regulatory Authority, Inc. of the terms of sale of the shares of our common stock offered hereby in an amount not to exceed $&#8195;&#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A prospectus in electronic format may be made available on the websites maintained by one or more underwriters, or selling group members, if any, participating in the
offering. The underwriters may agree to allocate a number of shares of our common stock to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to
underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We<I> </I>have agreed that, subject to certain
exceptions, we will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of,
directly or indirectly, or submit to, or file with, the SEC a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common
stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii)&nbsp;enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership
of any shares of our common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the
prior written consent of J.P. Morgan Securities LLC, TD Securities (USA) LLC and Leerink Partners LLC, for a period of 180 days after the date of this prospectus, other than the shares of our common stock to be sold in this offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our directors, executive officers, and substantially all of our securityholders, or the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties, will enter into <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering pursuant to which each <FONT STYLE="white-space:nowrap">lock-up</FONT> party, with limited exceptions, for a period of 180 days
after the date of this prospectus, or the restricted period, may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC, TD Securities (USA) LLC and Leerink Partners
LLC, (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly,
any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such <FONT
STYLE="white-space:nowrap">lock-up</FONT> parties in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant, (collectively with the common stock,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic
consequences of ownership of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction described in clause (1)&nbsp;or (2)&nbsp;above is to be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT>
securities, in cash or otherwise, (3)&nbsp;make any demand for, or exercise any right with respect to, the registration of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, or (4)&nbsp;publicly disclose the intention to do any of the
foregoing. Such persons or entities have further acknowledged that these undertakings preclude them from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or
entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or
disposition or transfer (by any person or entity, whether or not a signatory to such agreement) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT STYLE="white-space:nowrap">lock-up</FONT>
securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The restrictions described in the immediately preceding paragraph and contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements between the
underwriters and the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties do not apply, subject in certain cases to various conditions, to certain transactions, including (a)&nbsp;transfers or dispositions of
<FONT STYLE="white-space:nowrap">lock-up</FONT> securities: (i)&nbsp;as bona fide gifts, including bona fide gifts to a charity or educational institution, or for bona fide estate planning purposes, (ii)&nbsp;upon death, by will, other testamentary
document or intestacy, (iii)&nbsp;to any trust for the direct or indirect benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or any immediate family member, or if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a
trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust, (iv)&nbsp;to any corporation, partnership, limited liability company or other entity of which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party
or its immediate family members are the beneficial owner of all of the outstanding equity securities or similar interests, (v)&nbsp;to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses
(i)&nbsp;through (iv), (vi) if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a corporation, partnership, limited liability company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability
company, trust or other business entity that is an affiliate of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party or its affiliates or (B)&nbsp;as part of a distribution to stockholders, partners, members or other equityholders of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, (vii)&nbsp;by operation
of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree, separation agreement or related court order, (viii)&nbsp;to us, (A)&nbsp;from an employee or other service provider upon death, disability or termination of
service of such person, or (B)&nbsp;pursuant to a right of first refusal that we have with respect to transfers of such <FONT STYLE="white-space:nowrap">lock-up</FONT> securities or other securities, (ix)&nbsp;as part of a sale of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party&#146;s <FONT STYLE="white-space:nowrap">lock-up</FONT> securities acquired from the underwriters in this offering or in open market transactions after the completion of this offering, (x)&nbsp;to us in
connection with the vesting, settlement or exercise of RSUs, options, warrants or other rights to purchase shares of our common stock (including, in each case, by way of &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of
exercise price and tax and remittance payments due as a result of the vesting, settlement, or exercise of such RSUs, options, warrants or rights, or (xi)&nbsp;pursuant to a bona fide third-party tender offer, merger, consolidation or other similar
transaction approved by our board of directors and made to all of our stockholders involving a change in control of us, <I>provided that</I> if such transaction is not completed, all such <FONT STYLE="white-space:nowrap">lock-up</FONT> securities
would remain subject to the restrictions in the immediately preceding paragraph; (b)&nbsp;exercise of outstanding options, settlement of RSUs or other equity awards granted pursuant to plans described in this prospectus, <I>provided that</I> any <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities received upon such exercise, vesting or settlement would be subject to restrictions similar to those in the immediately preceding paragraph; (c)&nbsp;the conversion of outstanding preferred stock
into shares of our common stock, <I>provided that</I> any common stock received upon such conversion would be subject to restrictions similar to those in the immediately preceding paragraph; and (d)&nbsp;the establishment by <FONT
STYLE="white-space:nowrap">lock-up</FONT> parties of trading plans under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, <I>provided that</I> (1)&nbsp;such plan does not provide for the transfer of <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities during the restricted period and (2)&nbsp;no filing by any party under the Exchange Act or other public announcement shall be made voluntarily in connection with such trading plan during the
restricted period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">J.P. Morgan Securities LLC, TD Securities (USA) LLC and Leerink Partners LLC, in their sole discretion, may release
the securities subject to any of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters described above, in whole or in part at any time. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have applied to list our common stock on the Nasdaq Global Market under the symbol &#147;MAZE.&#148; The closing of this offering is contingent upon such listing.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of common
stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of common stock, which involves
the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short sales. Short sales may be
&#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional shares referred to above, or may be &#147;naked&#148; shorts, which are short positions in excess of that
amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will
consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely
to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a
naked short position, they will purchase shares in the open market to cover the position. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters have advised us that, pursuant to Regulation M of the
Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common
stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the
common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may
carry out these transactions on Nasdaq, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has been no public market for our common stock. The initial public offering price will be determined by negotiations between us and the
representatives of the underwriters. In determining the initial public offering price, we and the representatives of the underwriters expect to consider a number of factors including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the information set forth in this prospectus and otherwise available to the representatives of the underwriters;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our prospects and the history and prospects for the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an assessment of our management; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our prospects for future earnings; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the general condition of the securities markets at the time of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other factors deemed relevant by the underwriters and us. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither we nor the underwriters can assure investors that an active trading market will develop for our shares of common stock, or that the shares will trade in the
public market at or above the initial public offering price. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Other relationships </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial
banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time
to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or
loans, and may do so in the future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which
may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and
<FONT STYLE="white-space:nowrap">non-financial</FONT> activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to persons and
entities with relationships with the issuer, for which they received or will receive customary fees and expenses. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Selling restrictions </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>General </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other than in the United States, no action has been taken by
us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or
indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in
compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of
this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in Canada </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock
may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the
Securities Act (Ontario), and are permitted clients, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of common
stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for
rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, <I>provided</I> <I>that</I> the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the
securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with
a legal advisor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts, or NI <FONT
STYLE="white-space:nowrap">33-105,</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in the European Economic Area </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
relation to each Member State of the European Economic Area, each a Relevant State, no shares of common stock have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus
in relation to the shares of common stock which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in
accordance with the Prospectus Regulation, except that offers of shares of common stock may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters; or </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 1(4) of the Prospectus Regulation; </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>provided</I> <I>that</I> no such
offer of shares of common stock shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who
initially acquires any shares of common stock or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and us that it is a &#147;qualified investor&#148; within the meaning of
Article 2(e) of the Prospectus Regulation. In the case of any shares of common stock being offered to a financial intermediary as that term is used in the Prospectus Regulation, each such financial intermediary will be deemed to have represented,
acknowledged and agreed that the shares of common stock acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or
resale to, persons in circumstances which may give rise to an offer of any shares of common stock to the public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent
of the underwriters have been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of this provision, the expression an &#147;offer to the public&#148;
in relation to shares of common stock in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or
subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in the United
Kingdom </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No shares of common stock have been offered or will be offered pursuant to this offering to the public in the United Kingdom prior to the
publication of a prospectus in relation to the shares of common stock that either: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
(i)&nbsp;has been approved by the Financial Conduct Authority or (ii)&nbsp;is to be treated as if it had been approved by the Financial Conduct Authority in accordance with the transitional
provision in Article 74 (transitional provisions) of the Prospectus Amendment etc. (EU Exhibit) Regulation 2019/1234, except that the shares of common stock may be offered to the public in the United Kingdom at any time: </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(i) to any legal entity which is a qualified investor as defined in Article 2 of the UK Prospectus Regulation; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(ii) to fewer than 150 natural or legal persons (other than qualified investors as defined in Article 2 of the UK Prospectus Regulation), subject to obtaining the prior
consent of the underwriters for any such offer; or </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(iii) in any other circumstances falling within Section&nbsp;86 of the Financial Services and Markets Act 2000,
or FSMA, </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>provided that</I> no such offer of the shares of common stock shall require us or any underwriter to publish a prospectus pursuant to Section&nbsp;85 of
the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares of common stock in the United&nbsp;Kingdom
means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of common stock to be offered so as to enable an investor to decide to purchase or subscribe for any shares of common stock and
the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, in the United Kingdom, this prospectus is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at
persons who are &#147;qualified investors&#148; (as defined in the Prospectus Regulation)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005, as amended, or the Order, and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons
together being referred to as &#147;relevant persons&#148;) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares of common stock in the United Kingdom within the meaning of the FSMA. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this prospectus or use it as basis for taking any
action. In the United Kingdom, any investment or investment activity that this prospectus relates to may be made or taken exclusively by relevant persons. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in Switzerland </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus does
not constitute an offer to the public or a solicitation to purchase or invest in any shares of common stock. No shares of common stock have been offered or will be offered to the public in Switzerland, except that offers of shares of common stock
may be made to the public in Switzerland at any time under the following exemptions under the Swiss Financial Services Act, or FinSA: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any person which is a professional client as defined under the FinSA; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 500 persons (other than professional clients as defined under the FinSA), subject to obtaining the prior consent of the underwriters for any such offer; or </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 36 FinSA in connection with Article 44 of the Swiss Financial Services Ordinance, </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided that no such offer of shares of common stock shall require the Company or any investment bank to publish a prospectus pursuant to Article 35 FinSA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have not been and will not be listed or admitted to trading on a trading venue in
Switzerland. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither this prospectus nor any other offering or marketing material relating to the shares of common stock constitutes a prospectus as such term is
understood pursuant to the FinSA and neither this document nor any other offering or marketing material relating to the shares of common stock may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in Australia </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth), or the
Corporations Act; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission, or the ASIC, as a
disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the
categories of investors, available under section 708 of the Corporations Act (Exempt Investors). </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock may not be directly or
indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares of common
stock may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for
the shares of common stock, you represent and warrant to us that you are an Exempt Investor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As any offer of shares of common stock under this prospectus will be
made without disclosure in Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section&nbsp;707 of the Corporations Act, require disclosure to investors under
Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the shares of common stock, you undertake to us that you will not, for a period of 12 months from the date of issue of the shares of common stock, offer,
transfer, assign or otherwise alienate those shares of common stock to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document
is prepared and lodged with ASIC. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in Japan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none
of the shares of common stock nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including
any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to
an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in Hong Kong </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the SFO, of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the document
being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong), or the CO, or which do not constitute an offer to the public within the meaning of the CO. No advertisement,
invitation or document relating to the shares of common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of
which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares of common stock which are or are intended to be disposed of only to persons
outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in
Singapore </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each underwriter has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore.
Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares of common stock or caused the shares of common stock to be made the subject of an invitation for subscription or purchase and will not offer or sell
any shares or cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the
offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time, or the SFA) pursuant to Section&nbsp;274 of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified
in Section&nbsp;275 of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Where the
shares of common stock are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities-based
derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or
that trust has acquired the shares of common stock pursuant to an offer made under Section&nbsp;275 of the SFA except: </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&nbsp;275(1A) or 276(4)(i)(B) of the SFA; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Singapore SFA Product Classification&#151;In connection with Section&nbsp;309B of the SFA and the CMP Regulations&nbsp;2018, unless otherwise specified before an offer
of shares, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares are &#147;prescribed capital markets products&#148; (as defined in the CMP Regulations 2018) and Excluded
Investment Products (as defined in MAS Notice <FONT STYLE="white-space:nowrap">SFA&nbsp;04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment
Products). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in China </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This
prospectus will not be circulated or distributed in the People&#146;s Republic of China, or PRC, and the shares of common stock will not be offered or sold, and will not be offered or sold to any person for
<FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any residents of the PRC (for such purposes, not including the Hong Kong and Macau Special Administrative Regions or Taiwan), except pursuant to any applicable
laws and regulations of the PRC. Neither this prospectus nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in Korea </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common
stock have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and regulations thereunder, or the FSCMA, and the shares of common stock have been and will be offered in Korea
as a private placement under the FSCMA. None of the shares of common stock may be offered, sold or delivered directly or indirectly, or offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or
indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder, or the FETL. The
shares of common stock have not been listed on any of the securities exchanges in the world including, without limitation, the Korea Exchange in Korea. Furthermore, the purchaser of the shares of common stock shall comply with all applicable
regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the shares. By the purchase of the shares of common stock, the relevant holder thereof will be deemed to represent and warrant that
if it is in Korea or is a resident of Korea, it purchased the shares of common stock pursuant to the applicable laws and regulations of Korea. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to
prospective investors in Taiwan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have not been and will not be registered with the Financial Supervisory Commission of Taiwan
pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that
requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the shares of common
stock in Taiwan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in Saudi Arabia </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as issued by the
board of the Saudi Arabian Capital Market Authority, or the CMA, pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated 4&nbsp;October 2004 as amended by resolution <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">number&nbsp;1-28-2008,</FONT></FONT> as amended, or the CMA Regulations. The CMA does not make any representation as to the accuracy or completeness of this prospectus and expressly
disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this prospectus. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the
information relating to the securities. If you do not understand the contents of this prospectus, you should consult an authorized financial adviser. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice
to prospective investors in the Dubai International Financial Centre (DIFC) </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus relates to an Exempt Offer in accordance with the Markets Law,
DIFC Law No.&nbsp;1 of 2012, as amended. This prospectus is intended for distribution only to persons of a type specified in the Markets Law, DIFC Law No.&nbsp;1 of 2012, as amended. It must not be delivered to, or relied on by, any other person.
The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for this
prospectus. The securities to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not
understand the contents of this prospectus you should consult an authorized financial advisor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to its use in the DIFC, this prospectus is strictly
private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may
not be offered or sold directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in the United Arab Emirates </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the DIFC) other than
in compliance with the laws of the United Arab Emirates (and the DIFC) governing the issue, offering and sale of securities. Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates (including the DIFC)
and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the DFSA. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in Bermuda </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Shares of common stock may
be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons
(including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in the British Virgin Islands </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
shares of common stock are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on our behalf. The shares of common stock may be offered to companies incorporated under the
BVI Business Companies Act, 2004 (British Virgin Islands), or BVI Companies, but only where the offer will be made to, and received by, the relevant BVI Company entirely outside of the British Virgin Islands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in South Africa </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Due to restrictions under the securities laws of South Africa, no &#147;<I>offer to the public</I>&#148; (as such term is defined in the South African Companies Act,
No.&nbsp;71 of 2008 (as amended or <FONT STYLE="white-space:nowrap">re-enacted),</FONT> or the South African Companies Act) is being made in connection with the issue of the shares of common stock in South Africa. Accordingly, this prospectus does
not, nor is it intended to, constitute a &#147;<I>registered prospectus</I>&#148; (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or filed
with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The shares of common stock are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South
Africa or to a person with an address in South Africa, unless one or other of the following exemptions stipulated in section 96 (1) applies: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Section&nbsp;96&nbsp;(1)(a)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">the offer, transfer, sale, renunciation or delivery is to:</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(i) persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent;</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(ii) the South African Public Investment Corporation;</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(iii) persons or entities regulated by the Reserve Bank of South Africa;</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(iv) authorised financial service providers under South African law;</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(v) financial institutions recognised as such under South African law;</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(vi) a wholly owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as
agent in the capacity of an authorised portfolio manager for a pension fund, or as manager for a collective investment scheme (in each case duly registered as such under South African law); or</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial">(vii) any combination of the person in (i)&nbsp;to (vi); or</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Section&nbsp;96&nbsp;(1)(b)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of
South Africa pursuant to section 96(2)(a) of the South African Companies Act.</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Information made available in this prospectus should not be considered as &#147;<I>advice</I>&#148; as defined in the South African
Financial Advisory and Intermediary Services Act, 2002. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Notice to prospective investors in Israel </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Israeli Securities Law, and has not been filed with or approved by
the Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the shares of common stock is directed only at, (i)&nbsp;a limited number of persons in accordance with the Israeli
Securities Law and (ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment
advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to
time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are
required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_19"></A>Legal matters </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The validity of the shares of our common stock offered by this prospectus will be passed upon for us by Fenwick&nbsp;&amp; West LLP, San Francisco, California. Davis
Polk&nbsp;&amp; Wardwell LLP, Menlo Park, California, is acting as counsel for the underwriters in connection with this offering. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_20"></A>Experts </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ernst&nbsp;&amp; Young LLP, independent
registered public accounting firm, has audited our financial statements at December&nbsp;31, 2022 and 2023, and for each of the two years in the period ended December&nbsp;31, 2023, as set forth in their report. We have included our financial
statements in the prospectus and elsewhere in the registration statement in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc769642_21"></A>Where you can find additional information </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have
filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File Number 333-&#8195;&#8195;&#8195;&#8195;) under the Securities Act with respect to the shares of our common stock offered hereby. This prospectus,
which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits filed therewith. For further information about us and the common stock offered hereby, reference
is made to the registration statement and the exhibits filed therewith. Statements contained in this prospectus concerning the contents of any contract or any document that has been filed as an exhibit to the registration statement are not
necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. The exhibits to the registration statement should be
reviewed for the complete contents of these contracts and documents. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We currently do not file periodic reports with the SEC. Upon the completion of this offering,
we will be required to file periodic reports, proxy statements and other information with the SEC pursuant to the Exchange Act. The SEC maintains a website that contains reports, proxy and information statements and other information regarding
registrants that file electronically with the SEC. The address of the website is www.sec.gov. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also maintain a website at www.mazetx.com. Upon completion of this
offering, you may access these materials at our website free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that can be accessed through, our website
is not part of, and is not incorporated into, this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="index"></A><A NAME="toc769642_22"></A>Index to financial statements </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin769642_1">Report of independent auditors (PCAOB ID: 42)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">&#8199;F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Financial statements as of and for the years ended December&nbsp;31, 2022 and 2023:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin769642_2">Balance sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin769642_3">Statements of operations and comprehensive loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin769642_4">Statements of redeemable convertible preferred stock and stockholders&#146;
deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin769642_5">Statements of cash flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin769642_6">Notes to the financial statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Unaudited condensed financial statements as of and for the six months ended June 30, 2023 and 2024: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#fin769642_7">Condensed balance sheets</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#fin769642_8">Condensed statements of operations and comprehensive income (loss)</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#fin769642_9">Condensed statements of redeemable convertible preferred stock and stockholders&#146; deficit</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#fin769642_10">Condensed statements of cash flows</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#fin769642_11">Notes to the condensed financial statements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin769642_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the Stockholders and the Board of Directors of Maze Therapeutics, Inc. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Opinion
on the financial statements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have audited the accompanying balance sheets of Maze Therapeutics, Inc. (the Company) as of December&nbsp;31, 2022 and 2023, the
related statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#146; deficit and cash flows for each of the two years in the period ended December&nbsp;31, 2023, and the related notes (collectively
referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2022 and 2023, and the results of its operations and
its cash flows for each of the two years in the period ended December&nbsp;31, 2023, in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Basis for
opinion </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the
U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We conducted our audits in accordance
with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to
obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">/s/ Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have served as
the Company&#146;s auditor since 2019. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">San Mateo, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">June&nbsp;21, 2024 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Maze Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin769642_2"></A>Balance sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands, except share and
per share data) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 99,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 149,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commitments and contingencies (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred stock, $0.001 par value; 203,415,024 shares authorized as of
December&nbsp;31, 2022 and 2023; 203,415,024 shares issued and outstanding as of December&nbsp;31, 2022 and 2023; aggregate liquidation preference of $383,902 as of December&nbsp;31, 2022 and 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock, $0.001 par value; 257,000,000 and 261,000,000 shares authorized as of December&nbsp;31, 2022
and 2023, respectively; 22,868,289 and 22,996,976 shares issued and outstanding as of December&nbsp;31, 2022 and 2023, respectively; 1,576,649 and 603,930 shares subject to repurchase as of December&nbsp;31, 2022 and 2023, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(295,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(395,686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(282,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(373,848</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 149,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Maze Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin769642_3"></A>Statements of operations and comprehensive loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands, except share and per share data) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 88,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 73,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss on impairment and dissolution of equity method investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Share in net loss of equity method investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(114,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average shares of common stock outstanding used to compute net loss per share, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,379,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,071,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Maze Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin769642_4"></A>Statements of redeemable convertible preferred stock and stockholders&#146; deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands, except share data) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Redeemable convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Common&nbsp;stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Total<BR>stockholders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Balance as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,881,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">382,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,935,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(180,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(174,698)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Issuance of Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Issuance of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Repurchase of unvested restricted stock<BR>and early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(236,473</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Vesting of restricted stock and early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="29" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Balance as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,415,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,868,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(295,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(282,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Issuance of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Repurchase of unvested restricted stock and early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Vesting of restricted stock and early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="29" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Balance as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,415,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,996,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(395,686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(373,848</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="32" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Maze Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin769642_5"></A>Statements of cash flows </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Operating&nbsp;activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(114,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net loss on impairment and dissolution of equity method investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-cash</FONT> share of net loss in equity method investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Change in fair value of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Other items, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,574</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99,203</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Contributions for equity method investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,204</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from issuance of Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from issuance of convertible promissory notes, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from exercise of stock option awards, net of repurchases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net decrease in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100,645</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,883</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cash, cash equivalents, and restricted cash at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cash, cash equivalents, and restricted cash at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 101,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 30,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing
activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Purchases of property and equipment recorded in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Vesting of restricted stock and stock options subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Equity method investment obtained by accrued commitment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Initial fair value of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">line-of-credit</FONT></FONT> success fee derivative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Reconciliation to cash, cash equivalents, and restricted cash:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 99,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 29,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Total cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 101,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 30,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Maze Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin769642_6"></A>Notes to the financial statements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>1.
Organization and principal activities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Description of business </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Maze Therapeutics, Inc., or the Company, is a clinical stage biopharmaceutical company harnessing the power of human genetics and variant functionalization with its Maze
Compass platform to develop small molecule precision medicines for the treatment of common diseases. The Company was incorporated in Delaware in August 2017 and is located in South San Francisco, California. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Liquidity and capital resources </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has incurred significant
losses and negative cash flows from operations since its inception and expects to incur significant and increasing losses as a result of its continued research and development activities. During the year ended December&nbsp;31, 2023, the Company
incurred a net loss of $100.4&nbsp;million and used $86.8&nbsp;million of cash in operations. As of December&nbsp;31, 2023, the Company had an accumulated deficit of $395.7&nbsp;million. Historically, the Company has financed its operations
primarily through private placements of its redeemable convertible preferred stock and issuances of convertible promissory notes. The Company may seek to raise capital through debt financings, private or public equity financings, license agreements,
or other sources of financing. There can be no assurance that such financing will be available or will be at terms acceptable to the Company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of
December&nbsp;31, 2023, the Company had cash and cash equivalents of $29.2&nbsp;million. The Company entered into exclusive license agreements with several biotechnology companies after December&nbsp;31, 2023, including the exclusive license
agreement with Shionogi&nbsp;&amp; Co., Ltd., or Shionogi, pursuant to which the Company received aggregate <FONT STYLE="white-space:nowrap">one-time,</FONT> nonrefundable, upfront payments of $167.5&nbsp;million. The Company believes that its cash
and cash equivalents as of December&nbsp;31, 2023, together with the upfront payments for the exclusive license agreements and the additional $24.5&nbsp;million in proceeds received from the issuance of convertible promissory notes subsequent to
December&nbsp;31, 2023 through the date these financial statements were issued, will be sufficient to fund the Company&#146;s operations for at least one year from the issuance date of these financial statements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2. Summary of significant accounting policies </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Basis of presentation
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or
GAAP, and include all adjustments considered necessary for the fair presentation of the Company&#146;s financial position and operating results for the periods presented. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Use of estimates </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The preparation of financial statements in
conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other
relevant assumptions that it believes are reasonable under the circumstances. Assets and liabilities reported in the Company&#146;s balance sheet and expenses reported are affected by estimates and assumptions, which are used for, but are not
limited to, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
determining the fair value of assets and liabilities, common stock valuation, income tax uncertainties, measurement of stock-based compensation expense, and certain accruals. Actual results could
differ from such estimates or assumptions. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Concentration of credit risk and other risks and uncertainties </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains bank
deposits in accounts at two separate federally insured financial institutions and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institution holding its cash to the
extent recorded in the balance sheet. The Company has not experienced any losses on its deposits of cash. The Company is also subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the
need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its preclinical testing or clinical trials, the need to obtain regulatory and
marketing approvals for therapeutic candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of therapeutic candidates, the success of efforts to protect its proprietary
technology, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any therapeutic candidates, it will be unable to generate product revenue or
achieve profitability. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Operating segments </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company operates
and manages its business as one reportable and operating segment, which is the business of harnessing its understanding of human genetics and variant functionalization to develop small molecule precision medicines. The Company&#146;s chief executive
officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating and evaluating financial performance. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fair value measurement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Fair value is defined as the exchange price
that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date, and
establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company determined the fair value of financial assets and liabilities using the fair value hierarchy that describes three levels of inputs that may be used to
measure fair value, as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Level 1&#151;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active
markets; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Level 2&#151;Observable inputs, other than Level&nbsp;1 prices, such as quoted prices for similar assets or liabilities,
quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Level 3&#151;Unobservable inputs reflecting the Company&#146;s own assumptions incorporated in valuation techniques used to
determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For
certain financial instruments, including cash and accounts payable, as well as certain accrued liabilities, the recorded amount approximates estimated fair value due to their relatively short maturity period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Cash, cash equivalents and restricted cash </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company considers all highly liquid financial instruments with original maturities of 90 days or less at the date of purchase to be cash equivalents. As of
December&nbsp;31, 2022 and 2023, cash equivalents consisted of money market funds. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Restricted cash is comprised of cash that is restricted as to withdrawal or use
under the terms of certain contractual agreements. Restricted cash as of December&nbsp;31, 2022 and 2023 included $1.0&nbsp;million and $1.1&nbsp;million, respectively, as collateral for a letter of credit related to the Company&#146;s headquarters
building lease in South San Francisco, California. As of December&nbsp;31, 2022 and 2023, restricted cash also included $0.2&nbsp;million and zero, respectively, as collateral for the Company&#146;s credit card program. Restricted cash is classified
as a noncurrent asset on the balance sheet. As of December&nbsp;31, 2022 and 2023, restricted cash consisted of money market funds. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Property and equipment,
net </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Property and equipment are presented at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the
estimated useful life. Depreciation begins at the time the asset is placed in service. Maintenance and repairs that do not improve or extend the life of the assets are charged to expense as incurred and costs of major replacements or improvements
are capitalized. The Company&#146;s estimated useful lives of its property and equipment are as follows:</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Laboratory&nbsp;equipment</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:2.00pt solid #000000">5&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Shorter&nbsp;of&nbsp;remaining&nbsp;lease&nbsp;term<BR>or estimated useful life</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Impairment of long-lived assets </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the asset or asset group may not be recoverable. The recoverability of assets to be held and used is measured by comparing the carrying amount
to the estimated undiscounted future cash flows expected to be generated by the asset or asset group. If the carrying amount exceeds the estimated undiscounted future cash flows, an impairment loss is recognized. There have been no such impairments
of long-lived assets for the years ended December&nbsp;31, 2022 and 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Equity method investments </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company uses the equity method to account for investments in entities when the Company can exercise significant influence, but not control, over the operating and
financial decisions of an equity method investee. Generally, the ability to exercise significant influence is presumed when an investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on
specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. The Company applies the equity method to investments in common stock, common stock equivalents, preferred stock and to other
investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#146;s common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In applying the equity method, the investment is recorded at cost. The carrying amount of the investment is
subsequently increased or decreased by the Company&#146;s proportionate share of the net earnings or losses and other comprehensive income or loss of the investee based on its ownership percentage of common stock, common stock equivalents or
preferred stock during the respective reporting period. Payments to investees such as additional investments, loans and expenses incurred on behalf of investees, as well as payments from investees such as dividends, distributions and repayments of
loans are recorded as adjustments to the carrying value of the investment. In the event that net losses of the investee reduce the carrying amount to zero, additional net losses may be recorded if the Company holds other investments in the investee
not accounted for under the equity method, has guaranteed obligations of the investee, or is otherwise committed to provide further financial support for the investee. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the equity method of accounting, the Company reviews its related investments for indicators of impairment at each reporting period and such investments are written
down to fair value if there is evidence of a loss in value that is other-than-temporary. Factors that may be indicative of an impairment include, but are not limited to, a series of operating losses of an investee, the absence of an ability to
recover the carrying amount of the investment, the inability of the investee to sustain an earnings capacity and a current fair value of an investment that is less than its carrying amount. Indicators that a decline in value may be
other-than-temporary include the length of time and the extent to which the estimated fair value or market value has been below the carrying value, the financial condition and the near-term prospects of the investee, the intent and ability of the
Company to retain the investment in the investee for a period of time sufficient to allow for any anticipated recovery in market value and general market conditions. The estimation of fair value and whether an other-than-temporary impairment has
occurred requires the application of significant judgment and future results may vary from current assumptions. The carrying value of the Company&#146;s equity method investments was zero as of December&nbsp;31, 2022 and 2023. The Company recognized
a loss on impairment of $5.4&nbsp;million during the year ended December&nbsp;31, 2022 related to its equity method investment in Contour Therapeutics LLC, or Contour. No impairment losses related to the Company&#146;s equity method investments were
recognized during the year ended December&nbsp;31, 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Leases </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company determines if an arrangement is a lease at the inception of the arrangement. Operating leases are included in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets, operating lease liabilities, current, and operating lease liabilities, net of current portion in its balance sheets.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets represent the Company&#146;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease
payments arising from the lease. Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and liabilities are recognized at the lease commencement date based on the present value of lease
payments over the lease term. In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets also include any lease payments made and exclude lease incentives. The Company&#146;s lease terms may include options to extend or terminate the
lease when it is reasonably certain that the Company will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. The Company has elected not to separate lease and
<FONT STYLE="white-space:nowrap">non-lease</FONT> components, such as common area maintenance charges, and instead it accounts for these as a single lease component. Leases with an initial term of 12 months or less are not recorded on the balance
sheet, unless they include an option to purchase the underlying asset or to extend the lease that the Company is reasonably certain to exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Convertible promissory notes </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2023, the Company entered into Convertible Note Purchase Agreements with various existing investors to issue up to $25.0&nbsp;million of convertible
promissory notes. As permitted under Accounting Standards Codification 825, <I>Financial Instruments</I>, or ASC 825, the Company elected the fair value option for recognition of the convertible promissory notes. In accordance with ASC 825, the
Company records these convertible promissory notes at fair value and remeasures the convertible promissory notes at fair value each reporting period with changes in fair value recorded in the statements of operations and comprehensive loss. As a
result of applying the fair value option, direct costs and fees related to the convertible promissory notes were recognized in earnings as incurred and not deferred. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Redeemable convertible preferred stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company records
convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#146;s control, including a deemed liquidation event, holders of the convertible preferred
stock can cause redemption for cash. Therefore, redeemable convertible preferred stock is classified outside of stockholders&#146; deficit on the balance sheet as events triggering the redemption are not solely within the Company&#146;s control. The
carrying values of the redeemable convertible preferred stock are adjusted to their redemption value if and when it becomes probable that the preferred stock will become redeemable. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and development expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development, or
R&amp;D, expenses are recorded in the period that services are rendered or goods are received. R&amp;D expenses consist of personnel related costs, including salaries, benefits and stock-based compensation, related to R&amp;D activities, laboratory
supplies and facility costs, as well as fees paid to third parties that conduct certain R&amp;D activities on behalf of the Company. Nonrefundable advance payments for goods or services that will be used or rendered for future R&amp;D activities are
capitalized and expensed as the goods are delivered or the related services are performed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As part of the process of preparing its financial statements, the Company
is required to estimate and accrue certain R&amp;D expenses. This process involves the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">identifying services that have been performed on the Company&#146;s behalf and estimating the level of service performed
and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">estimating and accruing expenses in the Company&#146;s financial statements as of each balance sheet date based on facts
and circumstances known to it at the time; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">periodically confirming the accuracy of the Company&#146;s estimates with selected service providers and making
adjustments, if necessary. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Examples of estimated R&amp;D expenses that the Company may accrue include costs for: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">clinical research organizations, or CROs, in connection with clinical trials as well as preclinical and toxicology studies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">investigative sites in connection with clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">contract manufacturing organizations, or CMOs, in connection with the production of product and clinical trial materials;
and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">professional service fees for consulting and related services. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company bases its expense accruals related to clinical studies on its estimates of the services received and
efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical studies on the Company&#146;s behalf. The financial terms of these agreements vary from contract to contract and may result in
uneven payment flows. Payments under some of these contracts depend on factors, such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which
services will be performed and the level of effort to be expended in each period. If the Company does not identify costs that it has begun to incur or if it underestimates or overestimates the level of services performed or the costs of these
services, the Company&#146;s actual expenses could differ from its estimates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, the Company has not experienced significant changes in its estimates of
accrued R&amp;D expenses after a reporting period. However, due to the nature of estimates, there is no assurance that the Company will not make changes to its estimates in the future as it becomes aware of additional information about the status or
conduct of its clinical studies and other R&amp;D activities. Such changes in estimates will be recognized as R&amp;D expenses in the period that the change in estimate occurs. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock-based compensation expense </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recognizes stock-based
compensation expense for service-based stock options and restricted stock awards on a straight-line basis over the requisite service period. The Company measures the fair value of service-based stock options at the grant date using the Black-Scholes
option-pricing model. Inputs to the Black-Scholes option-pricing model include the fair value of its common stock, the expected term of the awards, the expected common stock price volatility over the term of the awards, risk-free interest rates, and
the expected dividend yield. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of restricted stock awards is determined on the date of grant based on the estimated fair value of the Company&#146;s
common stock on that date. Stock-based compensation expense is adjusted for actual forfeitures of unvested awards in the same period as the forfeitures occur. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
fair value of awards that contain market-based conditions is measured using a Monte-Carlo option pricing model at the date of grant using similar input assumptions as the Black-Scholes model while incorporating Level&nbsp;3 inputs related to
probability estimates of the market conditions being satisfied. Compensation expense related to awards with a market-based condition is recognized regardless of whether the market condition is ultimately satisfied, and compensation expense is not
reversed if the achievement of the market condition does not occur. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Income taxes </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax
consequences of events that have been included in the financial statements or tax returns subject to a determinable valuation allowance. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Deferred tax assets and
liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results,
ongoing tax planning and forecasts of future taxable income on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">jurisdiction-by-jurisdiction</FONT></FONT> basis. In the event the Company determines that it would be able to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income
taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made.
As of December&nbsp;31, 2022 and 2023, the Company recorded a full valuation allowance on its deferred tax assets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recognizes uncertain income tax
positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in
recognition or measurement are reflected in the period in which judgment occurs. The Company&#146;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of the provision for income tax. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Foreign currency transaction gain (loss) </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Gains and losses arising
from transactions and remeasurement of balances denominated in currencies other than U.S. dollars are recorded in interest and other income, net on the statement of operations and comprehensive loss. The Company recorded immaterial gains on foreign
currency transactions for the years ended December&nbsp;31, 2022 and 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comprehensive loss </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from
<FONT STYLE="white-space:nowrap">non-owner</FONT> sources. During the years ended December&nbsp;31, 2022 and 2023, the Company did not have any transactions that would be reported separately to derive comprehensive loss. Thus, comprehensive loss is
the same as net loss for the periods presented. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net loss per share </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period less common shares subject to
vesting or forfeiture, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the
period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, unvested restricted stock subject to repurchase and common stock options are considered to be potentially dilutive securities. Because the
Company reported a net loss for the years ended December&nbsp;31, 2022 and 2023, and the inclusion of the potentially dilutive securities would be antidilutive, diluted net loss per share is the same as basic net loss per share for the periods
presented. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Commitments and contingencies </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Liabilities for loss
contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded if and when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in
connection with loss contingencies are expensed as incurred. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Emerging growth company status </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company is an emerging growth company, or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may take advantage of reduced
reporting requirements that are otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
applicable to public companies. Section&nbsp;107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private
companies are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Recently adopted accounting pronouncements </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June 2016, the
Financial Accounting Standards Board, or FASB, issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> <I>Financial Instruments &#150; Credit Losses</I> and also issued subsequent amendments to the initial guidance under ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2018-19,</FONT> ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-04,</FONT> ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-05,</FONT> ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-11,</FONT> and ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2020-02</FONT> (collectively Topic 326). This guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses
is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#147;other-than-temporary&#148; impairment when evaluating <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an
allowance for credit losses on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The
Company adopted Topic 326 as of January&nbsp;1, 2023. The adoption of this standard did not have a material impact on the accompanying financial statements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>New accounting pronouncements&#151;Not yet adopted </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2023,
the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-07,</FONT> <I>Improvements to Reportable Segment Disclosures</I>, which will require disclosure of incremental segment information on an annual and interim basis for all public entities. The
amendments do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> is
effective for annual reporting beginning with the fiscal year ending December&nbsp;31, 2024, and for interim periods thereafter. The Company is currently evaluating the incremental disclosures that will be required in the footnotes to the financial
statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-09,</FONT> <I>Improvements to Income Tax Disclosures</I>, which will require
incremental income tax disclosures on an annual basis for all public entities. The amendments require that public business entities disclose specific categories in the rate reconciliation and provide additional information for reconciling items
meeting a quantitative threshold. The amendments also require disclosure of income taxes paid to be disaggregated by jurisdiction, and disclosure of income tax expense disaggregated by federal, state, and foreign. ASU
<FONT STYLE="white-space:nowrap">2023-09</FONT> is effective for annual reporting beginning with the fiscal year ending December&nbsp;31, 2025. The Company is currently evaluating the incremental disclosures that will be required in its financial
statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>3. Fair value measurements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following tables summarize the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Refer to Note 10
on convertible promissory notes and other debt agreements regarding the Company&#146;s methodology of measuring the fair value of the convertible promissory notes and the credit line success fee derivative. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Fair value measurements</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Credit line success fee derivative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Credit line success fee derivative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There were no transfers between Level&nbsp;1, 2, or 3 during the years ended December&nbsp;31, 2022 and 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>4. Balance sheet components </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Property and equipment, net </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Property and equipment, net, consisted of the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Office furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Fixed assets <FONT STYLE="white-space:nowrap">in-progress</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Depreciation expense was $3.8&nbsp;million and $4.1&nbsp;million for the years ended December&nbsp;31, 2022 and 2023,
respectively. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Accrued expenses and other current liabilities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accrued expenses and other current liabilities consisted of the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued compensation expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued professional expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other accrued expenses and current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>5. Equity method investments </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Broadwing
Bio LLC </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2020, the Company entered into a series of agreements with Alloy Therapeutics, Inc., or Alloy Therapeutics. Pursuant to the agreements,
the Company agreed to commit capital for a 50% ownership interest in a joint venture entity, Broadwing Bio LLC, or Broadwing, which was formed to develop targeted antibody therapies for the treatment of ophthalmic diseases. The Company&#146;s Chief
Executive Officer is a member of the board of directors of Alloy Therapeutics. The Company made an initial contribution of $1.7&nbsp;million of cash and committed to make additional <FONT STYLE="white-space:nowrap">in-kind</FONT> contributions of
$0.6&nbsp;million, including facilities and operational services, in exchange for an initial 50% equity interest in Broadwing. The commitment to make additional <FONT STYLE="white-space:nowrap">in-kind</FONT> contributions was recorded in other
current liabilities. Alloy Therapeutics contributed cash and committed to provide its antibody discovery services for the other initial 50% equity interest in Broadwing. Under the terms of the agreement, the Company and Alloy Therapeutics have the
option to continue to fund Broadwing to advance its programs through preclinical and clinical development. Under such terms and as of the inception of the agreement, the Company may opt to make additional cash contributions. The Company and Alloy
Therapeutics will retain certain rights to participate in the development and commercialization of products originating from Broadwing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company determined as of
December&nbsp;31, 2022 and 2023 it had a variable interest in Broadwing through its equity investment and Broadwing is a variable interest entity due to the equity investment at risk being insufficient to finance its activities. The Company has
evaluated the significant activities of Broadwing under the variable interest entity model and concluded that the significant activities consist primarily of research and development activities. As the Company does not have the sole power to direct
such activities, the Company is not the primary beneficiary and accounts for the investment in Broadwing under the equity method. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2022, the Company opted
to make an additional contribution of $1.2&nbsp;million of cash and a commitment to provide additional <FONT STYLE="white-space:nowrap">in-kind</FONT> contributions of $0.3&nbsp;million consisting of facilities and operational services. This
commitment was recorded as a commitment liability initially and was relieved in full during fiscal year 2022 as the Company provided the related services. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the
year ended December&nbsp;31, 2022, the Company recorded a $2.7&nbsp;million loss for its share of Broadwing&#146;s operating losses. As of December&nbsp;31, 2022 and 2023 the carrying amount of the investment was zero, which represents the
Company&#146;s maximum exposure to loss as a result of its involvement in Broadwing as of those </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
dates. During the years ended December&nbsp;31, 2022 and 2023, the Company&#146;s share of Broadwing&#146;s losses exceeded the carrying amount of the equity investment. Since the Company has no
obligation to provide cash financing to Broadwing, no additional losses are being recorded beyond the investment&#146;s carrying amount. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Contour Therapeutics
LLC </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2020, the Company and BridgeBio Pharma LLC, or BridgeBio, completed the formation of a joint venture entity, Contour. Contour was formed to
further development of therapeutic candidates and approaches designed to treat cardiovascular disease. The Company contributed <FONT STYLE="white-space:nowrap">know-how</FONT> of $4.6&nbsp;million and committed to make additional <FONT
STYLE="white-space:nowrap">in-kind</FONT> contributions of $4.0&nbsp;million required to advance the program via <FONT STYLE="white-space:nowrap">in-kind</FONT> services in exchange for an initial 30% equity interest in Contour. This initial
commitment liability was initially recorded with $1.0&nbsp;million in other current liabilities and $3.0&nbsp;million in other long-term liabilities based upon when the Company expected to provide the <FONT STYLE="white-space:nowrap">in-kind</FONT>
contributions. BridgeBio contributed cash and committed to provide its expertise in research and clinical development for cardiovascular diseases for the other initial 70% equity interest in Contour. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company determined it had a variable interest in Contour through its equity investment and Contour is a variable interest entity due to the equity investment at risk
being insufficient to finance its activities. The Company evaluated the significant activities of Contour under the variable interest entity model and concluded that the significant activities consist primarily of research and development
activities. As the Company does not have the sole power to direct such activities, the Company is not the primary beneficiary and accounts for the investment under the equity method. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In May 2022, Maze and BridgeBio entered into an agreement wherein BridgeBio was formally released from providing any further cash to Contour under its commitment to the
joint venture. Accordingly, in June 2022, the Company determined its investment in Contour was impaired and recorded a loss on impairment of $5.4&nbsp;million. Contour was dissolved in October 2022 and the Company no longer records any carrying
value related to this investment. As the Company was released from its commitment liability to provide <FONT STYLE="white-space:nowrap">in-kind</FONT> services, the Company recorded a corresponding gain of $3.0&nbsp;million for the year ended
December&nbsp;31, 2022, resulting in an overall $2.4&nbsp;million net loss on impairment and dissolution of equity method investment. The Company recorded its share of Contour&#146;s operating losses up until its dissolution in October 2022, which
amounted to $0.8&nbsp;million for the year ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>6. Capital structure </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Common stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2022 and 2023, the Company was
authorized to issue 257,000,000 and 261,000,000 shares, respectively, of $0.001 par value common stock. Of the total common shares issued and outstanding, 3,000,000 shares were purchased by Third Rock Ventures, LLC, or TRV, upon the founding of the
Company. TRV also purchased 55,000,000 shares of Series A redeemable convertible preferred stock. The remaining common shares issued and outstanding as of December&nbsp;31, 2023 are restricted stock awards granted and stock option awards exercised
under the plans discussed in Note 7 on Equity incentive plan and stock-based compensation expense. Common stockholders are entitled to dividends if and when declared by the Board of Directors of the Company, or the Board of Directors, subject to the
prior rights of holders of all classes of stock outstanding having priority rights as to dividends. The holder of each share of common stock is entitled to one vote. As of December&nbsp;31, 2022 and 2023, no dividends were declared. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Common stock reserved for future issuance, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, consisted
of the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,985,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,985,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,563,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,563,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,866,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,866,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Shares reserved under 2019 Equity Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,317,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">583,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stock options, issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,976,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,031,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,709,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,030,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Redeemable convertible preferred stock </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2021, the Company executed a Preferred Stock Purchase Agreement, or the Series C Purchase Agreement, with certain other investors to sell shares of Series C
redeemable convertible preferred stock. Under the Series C Purchase Agreement, the Company issued a total of 40,866,704 shares of Series C preferred stock, or Series C Preferred Stock, (533,164 shares were issued during the twelve months ended
December&nbsp;31, 2022 at a price of $2.9515 per share for total net proceeds of $1.6 million) pursuant to the terms of the Series C Purchase Agreement. No additional redeemable convertible preferred shares were issued during the twelve months ended
December&nbsp;31, 2023. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Issued and outstanding redeemable convertible preferred stock as of December&nbsp;31, 2022 and 2023 consisted of the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Series</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares<BR>authorized</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares&nbsp;issued<BR>and&nbsp;outstanding</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Original<BR>issue&nbsp;price<BR>per share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Aggregate<BR>liquidation<BR>amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Net&nbsp;carrying<BR>value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,985,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,985,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,563,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,563,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">158,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">158,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,866,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,866,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.9515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,415,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,415,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>As of December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,985,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,985,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,563,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,563,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">158,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">158,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,866,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,866,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.9515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,415,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,415,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="20" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of redeemable convertible preferred stock have various rights and preferences including the following: </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Conversion and voting rights </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each holder of redeemable convertible preferred
stock is entitled to the number of votes equal to the number of shares of common stock into which such shares of redeemable convertible preferred stock held by such holder could then be converted. Each share is convertible at the holder&#146;s
option at any time into the number of shares of common stock determined by dividing the original issue price by the conversion price. The conversion price for Series A, Series B and Series C is currently set equal to the original issue price of
$1.00, $2.75 and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
$2.9515, respectively, and is subject to adjustments for anti-dilution in certain circumstances. Conversion is automatic immediately prior to the closing of a qualifying initial public offering
and upon the election of holders of a majority of the then outstanding shares of preferred stock, voting together as a single class. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Dividends </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of redeemable convertible preferred stock are entitled to receive dividends out of any assets legally available only when, as, and if declared by the Board
of Directors, prior to and in preference to any declaration or payment of any dividend on the common stock. Such dividends are noncumulative. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Liquidation
preference </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or Liquidation Events, or deemed Liquidation
Event, the holders of shares of the redeemable convertible preferred stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment shall be made to the holders
of common stock. The amount per share shall be equal to the greater of (i) $1.00 for Series A, $2.75 for Series B and $2.9515 for Series C, plus any dividends declared but unpaid or (ii)&nbsp;such amount per share as would have been payable had all
shares of the redeemable convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution or winding up of the Company or deemed Liquidation Event. In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Company or deemed Liquidation Event, after the payment of all preferential amounts required to be paid to the holders of shares of redeemable convertible preferred stock, the remaining assets of the
Company available for distribution to its stockholders shall be distributed among the holders of the shares of common stock, pro rata based on the number of shares held by each such holder. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Redemption </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon a written request from the holders of a majority of the then
outstanding shares of redeemable convertible preferred stock, which request can be made at any time after December&nbsp;8, 2026, holders of the redeemable convertible preferred stock can cause the Company to redeem the redeemable convertible
preferred stock for cash. Shares of redeemable convertible preferred stock must be redeemed by the Company at the original issue price for the redeemable convertible preferred stock plus any declared and unpaid dividends in three annual
installments. On each of the three annual redemption dates, the Company must redeem the number of outstanding shares of redeemable convertible preferred stock determined by dividing the total number of outstanding shares of redeemable convertible
preferred stock by the number of remaining redemption dates. Additionally, in the event a deemed Liquidation Event does not effect a dissolution of the Company under the Delaware General Corporation Law within 90 days, the holders of redeemable
convertible preferred stock have the option (subject to the required vote) to redeem all outstanding shares of the redeemable convertible preferred stock from the net proceeds received for such deemed Liquidation Event at a price equal to the
redeemable convertible preferred stock liquidation amount. As of December&nbsp;31, 2022 and 2023, the carrying value of each series of redeemable convertible preferred stock was recorded at its redemption value. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Classification </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the occurrence of certain change in control events that
are outside the Company&#146;s control, including liquidation, sale, or transfer of the Company, holders of the redeemable convertible preferred stock can effectively cause redemption for cash. As a result, the Company has classified the redeemable
convertible preferred stock as mezzanine equity on the balance sheets as the stock is contingently redeemable. The redeemable convertible preferred stock classified in mezzanine equity is subject to subsequent measurement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
under the guidance provided under ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99-3A,</FONT></FONT></FONT> <I>Accounting for
Redeemable Equity Investments</I>. The Company has elected to recognize changes in redemption value immediately as they occur through adjustments to the carrying amounts of the instruments at the end of the reporting period with the corresponding
amount recorded to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. No such changes were identified or recorded during the years ended December&nbsp;31, 2022, and 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>7. Equity incentive plan and stock-based compensation expense </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2018
Stock Option and Grant Plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2018, the Company adopted the 2018 Stock Option and Grant Plan, or the 2018 Plan, which allowed for the granting of
up to 17,000,000 equity awards to the founders, employees, members of the Board of Directors and consultants of the Company. The unvested shares of restricted common stock issued under the 2018 Plan are subject to repurchase by the Company at the
original issuance price in the event of the holder&#146;s termination, either voluntarily or involuntarily. Consideration received for unvested stock-based awards is initially recorded as a liability and subsequently reclassified into
stockholders&#146; deficit as the related awards vest. Restricted common stock granted under the 2018 Plan generally vests over four years. Certain of the restricted common stock granted under the 2018 Plan vests upon achievement of certain
performance conditions. The awards expire no more than 10 years from the date of grant. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Restricted stock awards (2018 Plan) </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes restricted common stock activity during the years ended December&nbsp;31, 2022 and 2023: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Restricted<BR>stock&nbsp;awards</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Weighted-<BR>average<BR>grant&nbsp;date<BR>fair&nbsp;value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested balance as of January&nbsp;1, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,004,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,258,131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested restricted stock awards as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">692,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(642,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested restricted stock awards as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The total number of shares under the 2018 Plan that were vested as of December&nbsp;31, 2022 and 2023 was 10,053,828 and 10,696,924,
respectively. As of December&nbsp;31, 2022 and 2023, there were immaterial amounts recorded in accrued expenses and other current liabilities related to shares held by employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> that were
unvested and subject to repurchase under this plan. During the years ended December&nbsp;31, 2022 and 2023, any repurchased shares under the 2018 Plan were transferred to the 2019 Equity Incentive Plan. As of December&nbsp;31, 2022 and 2023, no
awards were available for issuance under the 2018 Plan. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Restricted stock awards (outside of the 2018 Plan) </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2018, the Company issued 6,162,612 shares of restricted stock to founders and advisors outside of the 2018 Plan. The shares were issued under the terms of respective
restricted common stock agreements, and unvested shares are subject to repurchase by the Company upon the holder&#146;s termination of its relationship with the Company at the original purchase price per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the changes in the Company&#146;s unvested restricted common stock awards granted to
founders and advisors outside of the 2018 Plan during the years ended December&nbsp;31, 2022 and 2023: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Restricted<BR>stock&nbsp;awards</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Weighted-<BR>average<BR>grant&nbsp;date<BR>fair&nbsp;value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested balance as of January&nbsp;1, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,520,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,170,372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested restricted stock awards as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested restricted stock awards as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The total number of shares outside of the 2018 Plan that were vested as of December&nbsp;31, 2022 and 2023 was 5,812,612. As of
December&nbsp;31, 2022 and 2023, there were immaterial amounts recorded in other liabilities related to shares held by employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> that were unvested and subject to repurchase outside of the
2018 Plan. The unvested awards as of December&nbsp;31, 2022 and 2023 vest upon the achievement of future performance milestones. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2019 Equity Incentive Plan
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2019, the Company&#146;s Board of Directors approved the establishment of the 2019 Equity Incentive Plan, or the 2019 Plan. The 2019 Plan allows
for the granting of restricted common stock, incentive stock options, or ISOs, and <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, or NSOs, to the employees, members of the Board of Directors and consultants of the Company.
Restricted common stock granted under the 2019 Plan is generally vested upon issuance. Unvested shares of restricted common stock are subject to repurchase by the Company at the original issuance price in the event of the employee&#146;s
termination, either voluntarily or involuntarily. ISOs are granted only to the Company&#146;s employees, including officers and directors who are also employees. NSOs are granted to consultants, employees, and
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors of the Company. Stock options granted under the 2019 Plan generally expire 10 years from the date of grant. The 2019 Plan allows the holder of the stock option to early exercise the
stock option in whole or in part prior to the full vesting of the stock option. Unvested stock options are subject to repurchase by the Company at the original issuance price in the event of the employee&#146;s termination, either voluntarily or
involuntarily. Early exercises of stock options are not deemed to be substantive exercises for accounting purposes and accordingly, consideration received for unvested stock options is initially recorded as a liability and subsequently reclassified
into stockholders&#146; deficit as the related stock options vest. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There were 2,317,524 and 583,767 equity incentive awards authorized and available for issuance
under the 2019 Plan as of December&nbsp;31, 2022 and 2023, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock options (2019 Plan) </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes stock option activity under the 2019 Plan for the year ended December&nbsp;31, 2023: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Options&nbsp;outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total<BR>options<BR>outstanding</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Weighted-<BR>average<BR>exercise<BR>price</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Weighted-<BR>average<BR>remaining<BR>contractual<BR>life (years)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Aggregate<BR>intrinsic<BR>value</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>(in&nbsp;thousands)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,976,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,342,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Exercised(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,112,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,031,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested and expected to vest as of December&nbsp;31,&nbsp;2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,501,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested and exercisable as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,347,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2023, 203,930 options exercised to date were subject to repurchase. During the year ended December&nbsp;31, 2023, none of the 175,104 total exercised options were exercised early and were subject
to repurchase at the time of exercise. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The total intrinsic value of options exercised was less than $0.1&nbsp;million and $0.1&nbsp;million during the
years ended December&nbsp;31, 2022 and 2023, respectively. The intrinsic value is the difference between the estimated fair value of the Company&#146;s common stock at the time of exercise and the exercise price of the stock option. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The total fair value of options that vested during the years ended December&nbsp;31, 2022 and 2023 was $5.7&nbsp;million and $8.0&nbsp;million, respectively. The
weighted average grant-date fair value of employee options granted during the years ended December&nbsp;31, 2022 and 2023 was $1.42 and $1.37 per share, respectively. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2022 and 2023, there were immaterial amounts recorded in other liabilities related to shares held by employees and
<FONT STYLE="white-space:nowrap">non-employees</FONT> from early exercised options subject to vesting and repurchase under the 2019 Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There were no market-based
awards granted or expensed for the year ended December&nbsp;31, 2022. For the year ended December&nbsp;31, 2023, the Company granted 500,000 options that had a fair value of $0.9&nbsp;million on the grant date that vest upon the Company&#146;s
common stock meeting certain market-based price targets. The fair value of these market-based awards is being recognized through April 2026. For the year ended December&nbsp;31, 2023, the Company recognized $0.2&nbsp;million of share-based
compensation expense related to these awards. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Restricted stock awards (2019 Plan) </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the years ended December&nbsp;31, 2022 and 2023, there were 50 shares and 250 shares, respectively, of restricted stock issued under the 2019 Plan. The weighted
average grant-date fair value of restricted stock granted during the years ended December&nbsp;31, 2022 and 2023 was $2.00 and $1.84 per share, respectively. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fair value measurement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company estimated the fair value of
service-based stock options using the Black-Scholes option-pricing model. The fair value of service-based stock options is being amortized on the straight-line basis over the requisite service period of the awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of the shares of common stock underlying stock options has historically been determined by the Board of
Directors. Because there has been no public market for the Company&#146;s common stock, the Board of Directors has determined the fair value of the common stock at the time of grant of the option by considering a number of objective and subjective
factors including: (i)&nbsp;third-party valuations of the Company&#146;s common stock; (ii)&nbsp;the Company&#146;s stage of development; (iii)&nbsp;the status of research and development efforts; (iv)&nbsp;the rights, preferences, and privileges of
the Company&#146;s redeemable convertible preferred stock relative to those of the Company&#146;s common stock; (v)&nbsp;the Company&#146;s operating results and financial condition, including the Company&#146;s levels of available capital
resources; (vi)&nbsp;equity market conditions affecting comparable public companies; (vii)&nbsp;general U.S. market conditions; and (viii)&nbsp;the lack of marketability of the Company&#146;s common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Black-Scholes option-pricing model requires the use of highly subjective assumptions which determine the fair value of stock-based awards. These assumptions include:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Risk-free interest rate</I>&#151;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect
at the time of grant for periods corresponding with the expected term of the stock option. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Expected volatility</I>&#151;Since the Company is privately held and does not have any trading history for its common
stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based
on their similar size, stage in the life cycle or area of specialty. The Company will continue to apply this process until enough historical information regarding the volatility of its own stock becomes available. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Expected term</I>&#151;The expected term represents the period that the stock option grants are expected to be
outstanding. The Company used the simplified method to determine the expected term. The simplified method is based on the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of
historical exercise data. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Expected dividend</I> <I>yield</I>&#151;The Company has never paid dividends on its common stock and has no plans to pay
dividends on its common stock. Therefore, the Company used an expected dividend yield of zero. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of service-based stock options
granted to employees and non-employees during the years ended December&nbsp;31, 2022 and 2023 was estimated using the following weighted-average assumptions: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.86%-4.05%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.41%-4.74%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5-6.25&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0-6.25&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of awards that contain market-based conditions issued during fiscal year 2023 was measured using a Monte-Carlo option
pricing model at the date of grant using input assumptions that include a risk-free rate of 4.35%, volatility of 80%, and a discount rate of 25%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock-based compensation expense </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the components of stock-based compensation expense recognized in the Company&#146;s statement of operations and comprehensive loss during
the years ended December&nbsp;31, 2022 and 2023: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the year ended December&nbsp;31, 2022 and 2023, the Company recognized $0.6&nbsp;million and $0.2&nbsp;million, respectively, in
stock-based compensation expense related to restricted stock issued to founders, employees, and <FONT STYLE="white-space:nowrap">non-employees.</FONT> For the years ended December&nbsp;31, 2022 and 2023, the Company recognized $6.2&nbsp;million and
$8.5&nbsp;million, respectively, in stock-based compensation related to stock option grants issued to employees and <FONT STYLE="white-space:nowrap">non-employees.</FONT> As of December&nbsp;31, 2022 and 2023, there was $17.7&nbsp;million and
$16.4&nbsp;million, respectively, of total unrecognized compensation cost related to unvested options and restricted stock awards for which the cost is expected to be recognized over a weighted-average period of 2.87 years and 2.52 years,
respectively.</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>8. Commitments and contingencies </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Legal proceedings
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a
liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. No contingent
liabilities have been recorded as of December&nbsp;31, 2022 and 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In accordance with the Company&#146;s amended and restated certificate of incorporation and amended and restated bylaws, the Company has indemnification obligations to
its officers and directors for certain events or occurrences, subject to certain limits, while they are serving in such capacity. There have been no claims to date, and the Company has a directors and officers liability insurance policy that may
enable it to recover a portion of any amounts paid for future claims. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Consortium agreements </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since November 2019, the Company entered into a Consortium Agreement and certain related amended agreements with the University of Helsinki and other parties for access
to a collaborative <FONT STYLE="white-space:nowrap">pre-competitive</FONT> research project. The project aims to collect genomic information from patient samples in biobanks across Finland to which the Company is granted access. Under the agreement,
the Company is obligated to pay certain installments through the year 2027. The Company paid $1.5&nbsp;million and $0.9&nbsp;million during the years ended December&nbsp;31, 2022 and 2023, respectively, under the related agreements. As of
December&nbsp;31, 2023, the Company is obligated to pay approximately $5.4&nbsp;million under this agreement, of which $0.8&nbsp;million, $0.7&nbsp;million, $1.1&nbsp;million, and $2.8&nbsp;million will be paid in each of the years ended
December&nbsp;31, 2024, 2025, 2026, and 2027, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2021 the Company entered into a Genes and Health Industry Consortium Agreement with Queen Mary University
to source genetic and paired clinical data from a long-term community-based study run jointly by government, academic and <FONT STYLE="white-space:nowrap">non-profit</FONT> institutions. Under the agreement, the Company is obligated to pay certain
installments through the year 2025. The Company paid $1.8&nbsp;million and $1.2&nbsp;million during the years ended December&nbsp;31, 2022 and 2023, respectively under the related agreement. As of December&nbsp;31, 2023, the Company is obligated to
pay approximately $1.4&nbsp;million under this agreement, of which $0.9&nbsp;million and $0.5&nbsp;million will be paid in each of the years ended December&nbsp;31, 2024 and 2025, respectively. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>9. Operating Leases </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In September 2019, the Company entered into a lease in
South San Francisco, California for approximately 67,200 square feet of office and laboratory space, which serves as the Company&#146;s corporate headquarters, or Headquarters. The lease commenced in May 2020 and terminates in November 2030 with an
option to extend the lease term for an additional period of eight years. The Company determined that given the length of time between lease commencement and the renewal period for this lease agreement (more than 10 years from the commencement date)
and the uncertainty of business and market conditions in the future, it is not reasonably certain that the renewal option will be exercised. The Company is obligated to make total fixed payments over the lease term of approximately
$53.5&nbsp;million. The Company has provided the landlord with a letter of credit in the amount of $1.1&nbsp;million. The security for the letter of credit is classified as restricted cash under long term assets on the balance sheet. Under this
lease, the Company received reimbursement of $4.4&nbsp;million for the costs associated with the design, development and construction of certain improvements that are deemed to be the property of the landlord. Such expenditures for lessor assets are
recorded as prepaid rent and then reduced upon reimbursement. Total rent expense for this lease was $5.1&nbsp;million for each of the years ended December&nbsp;31, 2022 and 2023. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The lease costs, which are included in operating expenses in the statements of operations and comprehensive loss, were as follows: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash paid for operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2023, the weighted-average remaining lease term was 6.9 years, and the weighted-average discount rate was 9.0%.
As of December&nbsp;31, 2023, the Company recorded current operating lease liabilities of $4.5&nbsp;million, <FONT STYLE="white-space:nowrap">non-current</FONT> operating lease liabilities of $25.1&nbsp;million, and a corresponding <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset of $26.1&nbsp;million on the balance sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table reconciles the undiscounted future minimum lease payments required to the operating leases
recorded on the Company&#146;s balance sheet as of December&nbsp;31, 2023: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Year&nbsp;Ending&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total undiscounted future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: Imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,942</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;29,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Sublease </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company was a sublessor in a
sublease agreement for approximately 6,500 rentable square feet of space in the Company&#146;s Headquarters, the term of which expired in June 2022. Total sublease income was $0.3&nbsp;million and zero for the years ended December&nbsp;31, 2022 and
2023, respectively, and recorded in interest and other income. There were no future undiscounted cash flows relating to the sublease agreement as of December&nbsp;31, 2022 and 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>10. Convertible promissory notes and other debt agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Convertible
promissory notes </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2023, the Company entered into a convertible note purchase agreement with certain existing investors to issue up to
$25.0&nbsp;million in convertible promissory notes, or the Convertible Promissory Notes. The Convertible Promissory Notes bear interest at a rate of 8% per annum and mature in December 2026. The Company issued $16.2&nbsp;million of the Convertible
Promissory Notes, net of issuance costs of $0.1&nbsp;million, as of December&nbsp;31, 2023. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Convertible Promissory Notes contain automatic conversion features
that are triggered upon a qualified preferred stock financing or a qualified public offering. In the event of a qualified preferred stock financing or a qualified public offering, the total outstanding principal and accrued interest will
automatically convert into preferred stock or common stock, respectively, at a conversion price equal to 80% of the price per share paid by other purchasers of the respective financing or offering. If the Convertible Promissory Notes have not been
repaid or converted before they mature, the holders may convert the outstanding principal and accrued interest into Series C Preferred Stock at $2.9515 per share. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company elected to apply the fair value option, as per ASC 825, to the outstanding Convertible Promissory Notes. As such, the Convertible Promissory Notes are
recognized at fair value with changes in fair value recognized in the consolidated statements of operations and comprehensive loss. The fair value of the Convertible Promissory Notes is based on significant inputs, including volatility, discount
yield, variables for the timing of the related conversion events and other probability estimates, which are deemed to be Level&nbsp;3 inputs in the fair value hierarchy. The assumptions used to determine the fair value of the Convertible Promissory
Notes included an estimated 90% probability of conversion of the promissory notes at a 20% discount, an assumed discount rate of 25%, the assumed value of the convertible preferred stock, and an estimated time to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
settlement of up to 1.3 years. The fair value of the Convertible Promissory Notes was $20.1&nbsp;million as of December&nbsp;31, 2023. The Company recorded a loss of $3.8&nbsp;million reflecting
the change in fair value of the Convertible Promissory Notes in the statements of operations and comprehensive loss for the year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Loan and security agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June 2022, the Company entered into a
loan and security agreement with a bank that provides a three-year revolving line of credit of up to $50.0&nbsp;million that is secured by substantially all of the Company&#146;s assets, except for its intellectual property. The Company has not
elected to draw down any funds from this debt facility during the years ended December&nbsp;31, 2022 and 2023. Advances under the revolving line may be prepaid and reborrowed by the Company without penalty. If a certain funding milestone is met due
to the sale of equity securities and/or upfront <FONT STYLE="white-space:nowrap">non-refundable</FONT> payments from strategic partnerships, the Company has the option to convert the aggregate principal amount into a term loan. Advances under the
line of credit accrue interest at a variable annum rate of the greater of (i) 0.75% above the Prime Rate (as defined below) and (ii) 4.50%. The Prime Rate is defined as the variable rate of interest, per annum, most recently announced by the bank,
as its &#147;prime rate,&#148; whether or not such announced rate is the lowest rate available from the bank. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the loan and security agreement, the Company is
required to pay the bank a success fee of up to $2.0&nbsp;million depending on if the Company closes a sale of substantially all of its assets, consummates a reorganization where the voting stockholders before such transaction hold less than 50% of
the voting securities after such transaction, or the sale of the Company&#146;s securities in connection with an initial public offering, reverse merger or other similar transaction wherein the Company&#146;s securities may thereafter be traded in a
public market. This success fee was deemed to be a freestanding derivative instrument that was bifurcated from the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">line-of-credit</FONT></FONT> instrument and is initially and
subsequently measured at fair value each reporting period. The fair value of this success fee derivative was estimated utilizing a probability-weighted cash flow approach, including variables for the timing of the related events and other
probability estimates, which are deemed to be Level&nbsp;3 inputs in the fair value hierarchy. The fair value of this success fee derivative was approximately $0.1&nbsp;million as of December&nbsp;31, 2022 and 2023, respectively, and is recorded in
accrued expenses and other current liabilities. The change in fair value of the derivative of less than $0.1&nbsp;million is recorded in interest and other income, net. Total issuance costs and the debt discount arising from the success fee amounted
to $0.3&nbsp;million and were recorded in other assets, which are amortized as interest expense over the commitment period. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>11. Related party transactions
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company paid fees to its founders and certain board members in exchange for consulting services. During each of the years ended December&nbsp;31, 2022 and
2023, the Company recorded such fees of $0.3&nbsp;million as research and development expenses and $0.2&nbsp;million as general and administrative expenses. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>12.
Income taxes </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No provision for, or benefit from, income taxes was recorded for the years ended December&nbsp;31, 2022 and 2023. The Company has established a
full valuation allowance against its net deferred tax assets due to the uncertainty surrounding the realization of such assets. All losses to date have been incurred domestically. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The effective income tax rate of the Company&#146;s provision for income taxes differed from the federal statutory
rate as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">State income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.79%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.69%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.08)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.88)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.58)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.89)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.51)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.48%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.53%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23.61)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22.94)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Deferred income taxes reflect the net tax effects: of (a)&nbsp;temporary differences between the carrying amounts of assets and
liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b)&nbsp;operating losses and tax credit carryforwards. The tax effects of significant items comprising the Company&#146;s deferred tax as of
December&nbsp;31, 2022 and 2023 are as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating loss and tax credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 50,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accruals and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Capitalized research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(225</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Right of use asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(93,236</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">ASC 740, Income Taxes, requires that the tax benefit of net operating losses, or NOLs, temporary differences, and credit carryforwards be
recorded as an asset to the extent that management assesses that realization is &#147;more likely than not.&#148; Realization of the future tax benefits is dependent on the Company&#146;s ability to generate sufficient taxable income within the
carryforward period. Because of the Company&#146;s history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and,
accordingly, has provided a valuation allowance. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The realization of deferred tax assets is dependent upon future earnings, if any, of which the timing and amount
are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. During the years ended December&nbsp;31, 2022 and 2023, the valuation allowance increased by $26.9&nbsp;million and $23.0&nbsp;million,
respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due
to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, or the Code, and similar state provisions. The Company had a Section&nbsp;382 study prepared which covered the period from inception through March 2024.
The study concluded that several ownership changes occurred since the inception of the Company. However, it was determined that the annual available NOLs under Section&nbsp;382 will be sufficient to utilize in their entirety prior to their
respective expiration years. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net operating losses and tax credit carryforwards as of December&nbsp;31, 2023 are as follows: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Expiration&nbsp;year</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net operating losses, federal (post-December 31, 2017)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">236,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Do&nbsp;not&nbsp;expire</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net operating losses, federal <FONT STYLE="white-space:nowrap">(pre-January</FONT> 1, 2018)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12/31/2037</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net operating losses, state</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2037&#151;2043</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tax credits, federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2037&#151;2043</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tax credits, state</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2038&#151;2043</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="7" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">ASC Topic <FONT STYLE="white-space:nowrap">740-10</FONT> prescribes a comprehensive model for the recognition, measurement, presentation
and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. The Company had unrecognized tax benefits of $2.8&nbsp;million as of December&nbsp;31, 2022 and $4.6&nbsp;million as
of December&nbsp;31, 2023. The amount of unrecognized tax benefits is not expected to significantly change over the next twelve months. No amounts, outside of valuation allowance, would impact the effective tax rate on continuing operations. The
beginning and ending gross unrecognized tax benefits amounts are as follows:</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unrecognized tax benefit&#151;beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gross increase/(decrease)&#151;prior period tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gross increase/(decrease)&#151;current period tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unrecognized tax benefit&#151;end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">It is the Company&#146;s policy to include penalties and interest expense related to income taxes as a component of income tax expense as
necessary. Management determined that no accrual for interest and penalties was required as of December&nbsp;31, 2022 and 2023. The Company&#146;s tax jurisdictions are the United States (federal) and the states of California, Colorado, Idaho,
Maine, Massachusetts, New Hampshire, New York, and Utah. The Company&#146;s tax years from inception in 2017 forward remain open for examination by the federal and state authorities due to the carryover of unused net operating losses and tax
credits. The Company is not currently subject to income tax examinations by any authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>13. Net loss and net loss per share </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(114,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average shares of common stock outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,848,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,949,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: weighted-average common shares subject to vesting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,468,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(877,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average shares of common stock outstanding used in the calculation of basic and diluted net loss
per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,379,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,071,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (5.93)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since the Company was in a loss position for the period presented, basic net loss per share is the same as diluted net loss per share for
the period as the inclusion of all common stock equivalents outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,985,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,985,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,563,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,563,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,866,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,866,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Shares subject to outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,976,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,031,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested restricted stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,042,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested exercised options subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,968,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,050,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to the above, the Company has excluded common shares from the assumed conversion of the Convertible Promissory Notes
outstanding at December&nbsp;31, 2023 from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect. As described in Note 10 on Convertible promissory notes and other debt
agreements, the Convertible Promissory Notes are convertible into either common stock or into preferred shares of the Company, which would then be convertible into common shares as described in the Convertible Promissory Note agreements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>14. Employee 401(k) plan </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2019, the Company implemented a defined
contribution savings plan under Section&nbsp;401(k) of the Code. Employees are eligible to participate in the plan on the first day of the month after their hire date and may contribute up to the current statutory limits under IRS regulations. The
401(k) plan permits the Company to make additional matching contributions on behalf of all employees. The Company incurred and accrued matching contributions of $0.3&nbsp;million for each of the years ended December&nbsp;31, 2022 and 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>15. Subsequent events </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company evaluated subsequent events for recognition and measurement purposes through June&nbsp;21, 2024, the date the financial statements were available for issuance. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In January 2024, the Company completed the second closing of the issuance of the Convertible Promissory Notes for gross proceeds of $8.8&nbsp;million. Additionally, in
February 2024, the Company executed an amendment to the convertible note purchase agreement for the sale of additional Convertible Promissory Notes of up to $75.0&nbsp;million in total, including the $25.0&nbsp;million issued in the initial and
second closings. From February 2024 through April 2024, the Company issued an additional $15.7&nbsp;million in Convertible Promissory Notes, resulting in the Company receiving $24.5&nbsp;million in gross proceeds subsequent to December&nbsp;31,
2023, and issuing a total of $40.7&nbsp;million aggregate principal amount of Convertible Promissory Notes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2024, the Company entered into an exclusive
license agreement with a biotechnology company pursuant to which the Company granted an exclusive worldwide license to a discovery research program targeting UNC13A for the treatment of amyotrophic lateral sclerosis. As consideration for the
licensed rights and the transfer of <FONT STYLE="white-space:nowrap">know-how</FONT> and materials, the Company received an upfront payment of $15.0&nbsp;million. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2024, the Company entered into an exclusive license agreement with Shionogi pursuant to which the Company granted Shionogi an exclusive, worldwide,
sublicensable license to research, develop, manufacture and commercialize MZE001 and certain other small molecule compounds modulating glycogen synthase 1. As consideration for the licensed rights and the transfer of
<FONT STYLE="white-space:nowrap">know-how</FONT> and materials, the Company received an upfront payment of $150.0&nbsp;million. The license agreement also requires that Shionogi pay the Company up to $275.0&nbsp;million in the aggregate in milestone
payments upon the completion of certain clinical and regulatory milestones and up to $330.0&nbsp;million in the aggregate in milestone payments if certain sales milestones are achieved. The License Agreement also requires that Shionogi pay the
Company tiered royalties ranging from percentages in the low double-digits to high teens on net sales of licensed products, subject to certain deductions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April
2024, the Company amended its Amended and Restated Certificate of Incorporation to increase its authorized shares to 268,150,000 of $0.001 par value common stock in connection with an amendment its 2019 Plan to increase the number of shares of
common stock reserved for future issuance under the plan by 7,150,000 shares. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From January&nbsp;1, 2024 through June&nbsp;21, 2024, the Company granted a total of
5,126,650 stock options with an exercise price of $1.46 per share, including 450,000 stock options granted to a member of the board of directors, and 150 fully vested restricted stock awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin769642_7"></A>Maze Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Condensed balance sheets (unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands, except share and per
share data) </B></P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 29,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 175,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 71,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 215,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commitments and contingencies (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred stock, $0.001 par value; 203,415,024 shares authorized as of
December&nbsp;31, 2023 and June&nbsp;30, 2024; 203,415,024 shares issued and outstanding as of December&nbsp;31, 2023 and June&nbsp;30, 2024; aggregate liquidation preference of $383,902 as of December&nbsp;31, 2023 and June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock, $0.001 par value; 261,000,000 and 268,150,000 shares authorized as of December&nbsp;31, 2023
and June&nbsp;30, 2024, respectively; 22,996,976 and 23,369,733 shares issued and outstanding as of December&nbsp;31, 2023 and June&nbsp;30, 2024, respectively; 603,930 and 289,230 shares subject to repurchase as of December&nbsp;31, 2023 and
June&nbsp;30, 2024, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(395,686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(289,124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(373,848</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(262,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 71,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 215,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin769642_8"></A>Maze Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Condensed statements of operations and comprehensive income (loss) (unaudited) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands, except share and per share data) </B></P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six months&nbsp;ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">License revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 165,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">(Loss) income from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">(Loss) income before income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 108,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income and comprehensive (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 106,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Allocation of undistributed earnings to participating securities (see Note 12)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income attributable to common stockholders, basic (see Note 12)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 10,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income attributable to common stockholders, diluted (see Note 12)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 10,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income per share attributable to common stockholders (see Note 12):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average shares used in computing net (loss) income per share attributable to common stockholders
(see Note 12):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,815,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,794,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,815,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,541,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin769642_9"></A>Maze Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Condensed statements of redeemable convertible preferred stock and stockholders&#146; deficit (unaudited) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands, except share data) </B></P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Redeemable convertible</B><br><B>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Common&nbsp;stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">paid-in</FONT></B><br><B>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Accumulated</B><br><B>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Total</B><br><B>stockholders&#146;</B><br><B>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Balance as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,415,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,868,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(295,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(282,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Issuance of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Repurchase of unvested restricted stock and early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Vesting of restricted stock and early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="29" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Balance as of June&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,415,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,968,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(344,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(327,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="32" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Redeemable convertible</B><br><B>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Common&nbsp;stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">paid-in</FONT></B><br><B>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Accumulated</B><br><B>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Total</B><br><B>stockholders&#146;</B><br><B>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Balance as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,415,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,996,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(395,686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(373,848</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372,607</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Issuance of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Vesting of restricted stock and early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Net income and comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="29" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Balance as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,415,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,369,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(289,124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(262,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="32" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">See accompanying notes to these financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin769642_10"></A>Maze Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Condensed statements of cash flows (unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands) </B></P>
 <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Operating&nbsp;activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other items, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash (used in) provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Payment of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds from exercise of stock option awards, net of repurchases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds from issuance of convertible promissory notes, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (decrease) increase in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash, cash equivalents, and restricted cash at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash, cash equivalents, and restricted cash at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 54,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">176,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing
activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of property and equipment recorded in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vesting of restricted stock and stock options subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred offering costs recorded in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Reconciliation to cash, cash equivalents, and restricted cash:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 53,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 54,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">176,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin769642_11"></A>Maze Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to the condensed financial statements (unaudited) </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>1. Organization
and principal activities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Description of business </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Maze
Therapeutics, Inc., or the Company, is a clinical stage biopharmaceutical company harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small molecule precision medicines for the treatment of
common diseases. The Company was incorporated in Delaware in August 2017 and is located in South San Francisco, California. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Liquidity and capital resources
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other than the net income of $106.6&nbsp;million generated during the six months ended June&nbsp;30, 2024, the Company has incurred significant losses and
negative cash flows from operations since its inception and expects to incur significant and increasing losses as a result of its continued research and development activities. As of June&nbsp;30, 2024, the Company had an accumulated deficit of
$289.1&nbsp;million. Historically, the Company has financed its operations primarily through private placements of its redeemable convertible preferred stock, issuances of convertible promissory notes and license agreements. The Company may seek to
raise capital through debt financings, private or public equity financings, or other sources of financing. There can be no assurance that such financing will be available or will be at terms acceptable to the Company. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June&nbsp;30, 2024, the Company had cash and cash equivalents of $175.1&nbsp;million. The Company believes that its cash and cash equivalents as of June&nbsp;30,
2024, will be sufficient to fund the Company&#146;s operations for at least one year from the issuance date of these condensed financial statements. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2. Summary
of significant accounting policies </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Basis of presentation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
condensed balance sheet as of June&nbsp;30, 2024, condensed statements of operations and comprehensive income (loss), condensed statements of redeemable convertible preferred stock and stockholders&#146; deficit and condensed statements of cash
flows for the six months ended June&nbsp;30, 2023 and 2024 and related notes to the condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared on the same basis as the Company&#146;s
annual financial statements and, in the opinion of management, reflect all adjustments that are necessary for the fair statement of the Company&#146;s financial position, results of operations and cash flows for the periods presented. The condensed
results of operations for the six months ended June&nbsp;30, 2024 are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed balance sheet as of December&nbsp;31,
2023 included herein was derived from the audited financial statements as of that date. These interim condensed financial statements should be read in conjunction with the Company&#146;s audited financial statements included elsewhere in this
prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the six months ended June&nbsp;30, 2024, there were no significant changes to the Company&#146;s significant accounting policies as described in
the Company&#146;s audited financial statements as of and for the year ended December&nbsp;31, 2023 included elsewhere in this prospectus except as described below. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Use of estimates </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The preparation of condensed financial statements in
conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the amounts reported in the condensed financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that
it believes are reasonable under the circumstances. Assets and liabilities reported in the Company&#146;s condensed balance sheet and expenses reported are affected by estimates and assumptions, which are used for, but are not limited to, measuring
and recognizing revenue, and determining the fair value of assets and liabilities, including the convertible promissory notes, common stock valuation, income tax uncertainties, measurement of stock-based compensation expense, and certain accruals.
Actual results could differ from such estimates or assumptions. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Cash, cash equivalents and restricted cash </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company considers all highly liquid financial instruments with original maturities of 90 days or less at the date of purchase to be cash equivalents. As of
December&nbsp;31, 2023, and June&nbsp;30, 2024 cash equivalents consisted of money market funds. Restricted cash is comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. Restricted cash as of
December&nbsp;31, 2023 and June&nbsp;30, 2024 included $1.1&nbsp;million as collateral for a letter of credit related to the Company&#146;s headquarters building lease in South San Francisco, California. Restricted cash is classified as a noncurrent
asset on the balance sheet. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company
recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606. To determine the appropriate amount and timing of revenue to be recognized under this guidance, the Company performs the following steps:
(i)&nbsp;identifies the contract(s) with a customer; (ii)&nbsp;identifies the performance obligations in the contract; (iii)&nbsp;determines the transaction price, including variable consideration, if any; (iv)&nbsp;allocates the transaction price
to the performance obligations in the contract; and (v)&nbsp;recognizes revenue when (or as) the entity satisfies a performance obligation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has entered
into arrangements involving the license of intellectual property. Analyzing the license arrangements to identify performance obligations requires the use of judgment. In arrangements that include the license of intellectual property and other
promised services, the Company first identifies if the licenses are distinct from the other promises in the arrangement. For the license of intellectual property that is distinct, the Company recognizes revenue from consideration allocated to the
license when the license is transferred and the customer is able to benefit from the license. If the license is not distinct, the license is combined with other services into a single performance obligation and the Company recognizes revenue when
(or as) the performance obligation is satisfied. Factors that are considered in evaluating whether a license is distinct from other promised services include, for example, whether the counterparty can benefit from the license without the promised
service on its own or with other readily available resources and whether the promised service is expected to significantly modify or customize the intellectual property. Promised goods and services that are not material in the context of the
contract are not considered performance obligations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The transaction price is the amount of consideration to which the Company expects to be entitled in exchange
for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. <FONT STYLE="white-space:nowrap">Non-refundable</FONT> upfront payments are
considered fixed consideration and included in the transaction price. If an arrangement includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and
estimates the amount to be included in the transaction price using the most likely amount method. The Company includes the amount of estimated variable consideration, including milestones, in the transaction price to the extent that it is probable
that a significant reversal of cumulative revenue recognized will not occur. Milestone payments that are not within the Company&#146;s control or the licensee&#146;s control, such as regulatory approvals, are generally not considered probable of
being achieved until </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
those approvals are received. At the end of each reporting period, the Company <FONT STYLE="white-space:nowrap">re-evaluates</FONT> the probability of achievement of the milestones and any
related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which will affect revenue in the period of
adjustment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales,
and if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&nbsp;when the related sales occur or (ii)&nbsp;when the performance
obligation to which the royalty has been allocated has been satisfied. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Amounts received prior to satisfying the revenue recognition criteria are recorded as
deferred revenue in the Company&#146;s balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are
recorded as contract assets in the Company&#146;s condensed balance sheets. If the Company expects to have an unconditional right to receive consideration in the next twelve months, this will be classified in current assets. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Deferred offering costs </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company defers offering costs consisting
of legal, accounting and other fees and costs directly associated with <FONT STYLE="white-space:nowrap">in-process</FONT> equity financings until such financings are consummated. After consummation of the equity financing, these costs are classified
in stockholders&#146; deficit as a reduction of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital recorded as a result of the financing. If the <FONT STYLE="white-space:nowrap">in-process</FONT> financing is abandoned, the deferred
offering costs are expensed immediately as a charge to operating expenses in the statements of operations and comprehensive income (loss). As of June&nbsp;30, 2024, approximately $1.4&nbsp;million of deferred offering costs were recorded within
other assets in the accompanying balance sheets. As of December&nbsp;31, 2023, no such costs were deferred. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net (loss) income per share </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net (loss) income per share attributable to common stockholders is calculated using the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for companies
with participating securities. The Company considers its convertible preferred stock to be participating securities as the holders are entitled to receive noncumulative dividends in the event that a dividend is paid on common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Basic net (loss) income per share attributable to common stockholders is computed by dividing net (loss) income attributable to common stockholders by the
weighted-average number of common shares outstanding during the period less common shares subject to vesting or forfeiture, without consideration for potentially dilutive securities. Diluted net (loss) income per share is computed by dividing net
(loss) income by the weighted-average number of common shares and the number of common shares that would be issued assuming exercise and conversion of all potentially dilutive instruments. In calculating diluted net (loss) income per share, the
Company applies the more dilutive of the two-class method or the if-converted method to the redeemable convertible preferred stock, applies the treasury stock method to equity awards, and applies the if-converted method to the convertible promissory
notes, if dilutive. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Distributed and undistributed earnings are allocated to participating securities based on their participation rights and are subtracted from net
income in determining net income attributable to common stockholders for basic and diluted net income per share, only in periods of net income. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>New
accounting pronouncements&#151;Not yet adopted </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2023, the FASB issued Accounting Standards Update, or ASU,
<FONT STYLE="white-space:nowrap">2023-07,</FONT> <I>Improvements to Reportable Segment Disclosures</I>, which will require disclosure of incremental segment information on an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
annual and interim basis for all public entities. The amendments do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the
quantitative thresholds to determine its reportable segments. ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> is effective for annual reporting beginning with the fiscal year ending December 31, 2024, and for interim periods thereafter. The
Company is currently evaluating the incremental disclosures that will be required in its financial statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2023, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2023-09,</FONT> <I>Improvements to Income Tax Disclosures</I>, which will require incremental income tax disclosures on an annual basis for all public entities. The amendments require that public business entities disclose
specific categories in the rate reconciliation and provide additional information for reconciling items meeting a quantitative threshold. The amendments also require disclosure of income taxes paid to be disaggregated by jurisdiction, and disclosure
of income tax expense disaggregated by federal, state, and foreign. ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> is effective for annual reporting beginning with the fiscal year ending December 31, 2025. The Company is currently evaluating
the incremental disclosures that will be required in its financial statements. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>3. Fair value measurements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following tables summarize the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Refer to Note 9
on Convertible promissory notes and other debt agreements regarding the Company&#146;s methodology of measuring the fair value of the convertible promissory notes and the credit line success fee derivative. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Fair value measurements</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8194;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Credit line success fee derivative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>June&nbsp;30, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Credit line success fee derivative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There were no transfers between Level&nbsp;1, 2, or 3 during the six months ended June&nbsp;30, 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>4. Balance sheet components </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accrued expenses and other current liabilities consisted of the following: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued compensation expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued professional expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other accrued expenses and current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>5. Capital structure </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Common
stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June 30, 2024, the Company was authorized to issue 268,150,000 shares of $0.001 par value common stock. Of the total common shares issued and
outstanding, 3,000,000 shares were purchased by Third Rock Ventures, LLC, or TRV, upon the founding of the Company. TRV also purchased 55,000,000 shares of Series A redeemable convertible preferred stock. The remaining common shares issued and
outstanding as of June 30, 2024 are restricted stock awards granted and stock option awards exercised under the plans discussed in Note 6 on Equity incentive plan and stock-based compensation expense. Common stockholders are entitled to dividends if
and when declared by the Board of Directors of the Company, or the Board of Directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. The holder of each share of common stock is
entitled to one vote. As of June 30, 2024, no dividends were declared. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Common stock reserved for future issuance, on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis, consisted of the following: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,985,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,985,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,563,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,563,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,866,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,866,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Shares reserved under 2019 Equity Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">583,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,057,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stock options, issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,031,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,335,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,030,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241,807,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Redeemable convertible preferred stock </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Issued and outstanding redeemable convertible preferred stock as of December 31, 2023 and June&nbsp;30, 2024 consisted of the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><B>Series</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>authorized</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Shares&nbsp;issued</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>and&nbsp;outstanding</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Original</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>issue&nbsp;price</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>per share</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>liquidation</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>amount</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Net&nbsp;carrying</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>value</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="right"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,985,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,985,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,563,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,563,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">158,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">158,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,866,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,866,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.9515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,415,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,415,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">383,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="20" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December 31, 2023 and June&nbsp;30, 2024, the carrying value of each series of redeemable convertible preferred stock was
recorded at its redemption value. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>6. Equity incentive plan and stock-based compensation expense </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2018 Stock Option and Grant Plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Restricted stock awards </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes restricted common stock activity under the 2018 Stock Option and Grant Plan, or the 2018 Plan, during the six months ended June&nbsp;30,
2024: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Restricted<BR>stock&nbsp;awards</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Weighted-<BR>average<BR>grant&nbsp;date<BR>fair&nbsp;value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested restricted stock awards as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested restricted stock awards as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June 30, 2024, there were immaterial amounts recorded in accrued expenses and other current liabilities related to shares
held by employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> that were unvested and subject to repurchase under this plan. As of June&nbsp;30, 2024, no awards were available for issuance under the 2018 Plan. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Restricted stock awards </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the changes in
the Company&#146;s unvested restricted common stock awards granted to founders and advisors outside of the 2018 Plan during the six months ended June&nbsp;30, 2024: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Restricted<BR>stock&nbsp;awards</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Weighted-</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>average<BR>grant&nbsp;date<BR>fair&nbsp;value</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested restricted stock awards as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested restricted stock awards as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June&nbsp;30, 2024, there were immaterial amounts recorded in other liabilities related to shares held by
employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> that were unvested and subject to repurchase outside of the 2018 Plan. The unvested awards as of June&nbsp;30, 2024 vest upon the achievement of future performance milestones.
During the six months ended June&nbsp;30, 2024, a termination agreement was entered into with an advisor to the Company wherein the vesting of 250,000 restricted common stock awards became accelerated. This resulted in the recognition of incremental
stock-based compensation expense of $0.4&nbsp;million recorded in research and development expenses during the six months ended June&nbsp;30, 2024. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2019
Equity Incentive Plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There were 3,057,291 equity incentive awards authorized and available for issuance under the 2019 Equity Incentive Plan, or 2019 Plan,
as of June&nbsp;30, 2024. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Stock options (2019 Plan) </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table
summarizes stock option activity under the 2019 Plan for the six months ended June&nbsp;30, 2024: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Options&nbsp;outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>options</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>outstanding</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Weighted-</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>average</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>exercise</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>price</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Weighted-</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>average</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>remaining</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>contractual<BR>life (years)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>intrinsic</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>value</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>(in&nbsp;thousands)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,031,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,126,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(372,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(450,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,335,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June&nbsp;30, 2024, 139,230 options exercised to date were subject to repurchase. During the six months ended
June&nbsp;30, 2024, none of the exercised options were exercised early and were subject to repurchase at the time of exercise. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Restricted stock awards (2019
Plan) </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the six months ended June&nbsp;30, 2024, there were 150 shares of restricted stock issued under the 2019 Plan. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Stock-based compensation expense </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the
components of stock-based compensation expense recognized in the Company&#146;s statement of operations and comprehensive income (loss) during the six months ended June&nbsp;30, 2023 and 2024: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of June&nbsp;30, 2024, there was $17.5&nbsp;million of total unrecognized compensation cost related to unvested
options and restricted stock awards for which the cost is expected to be recognized over a weighted-average period of 2.56 years. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>7. License agreements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company entered into exclusive license agreements with several biotechnology companies during the six months ended June&nbsp;30, 2024. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Trace License Agreement </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2024, the Company entered into an exclusive
license agreement with Trace Neuroscience, Inc., or Trace, pursuant to which the Company granted an exclusive worldwide license to a discovery research program targeting UNC13A for the treatment of amyotrophic lateral sclerosis, or the Trace License
Agreement. As consideration for the licensed rights and the transfer of <FONT STYLE="white-space:nowrap">know-how</FONT> and materials, the Company received an upfront payment of $15.0&nbsp;million in April 2024. Thereafter, the Company is entitled
to potential subsequent payments of up to an aggregate of $80.0&nbsp;million based on development and regulatory milestones and up to an aggregate of $250.0&nbsp;million based on sales milestones. The Company is also entitled to tiered royalties
ranging from percentages in the low single-digits to <FONT STYLE="white-space:nowrap">sub-teens</FONT> on net sales of any licensed product if successfully commercialized. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company assessed the Trace License Agreement in accordance with ASC 606 and concluded that it was a contract with a customer. The Company determined that there is
one performance obligation relating to the license to the UNC13A discovery program, including the underlying <FONT STYLE="white-space:nowrap">know-how</FONT> and certain related materials, and that the transaction price consisted of the
$15.0&nbsp;million <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront cash payment. The potential future development and regulatory milestones represent variable consideration and were constrained, as it was concluded that it was not
probable that a significant reversal in cumulative revenue recognized will not occur and therefore not included in the transaction price as of June&nbsp;30, 2024. Potential sales milestones and royalties on net product sales will be recognized in
the same period that the underlying net product sales occur as they were determined to relate to the license. The $15.0&nbsp;million transaction price was recorded as license revenue in the condensed statements of operations and comprehensive income
(loss) during the six months ended June&nbsp;30, 2024 at the point in time when control of the license and related <FONT STYLE="white-space:nowrap">know-how</FONT> was transferred to Trace. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Shionogi License Agreement </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2024, the Company entered into an
exclusive license agreement with Shionogi&nbsp;&amp; Co., Ltd, or Shionogi, pursuant to which the Company granted Shionogi an exclusive, worldwide, sublicensable license to research, develop, manufacture and commercialize MZE001 and certain other
small molecule compounds modulating glycogen synthase 1, or the Shionogi License Agreement. As consideration for the licensed rights and the transfer of <FONT STYLE="white-space:nowrap">know-how</FONT> and materials, the Company received an upfront
payment of $150.0&nbsp;million in May 2024 upon the effectiveness of the Shionogi License Agreement. The Shionogi License Agreement also requires that Shionogi pay the Company up to $275.0&nbsp;million in the aggregate in milestone payments upon the
completion of certain clinical and regulatory milestones and up to $330.0&nbsp;million in the aggregate in milestone payments if certain sales milestones are achieved. The Shionogi License Agreement also requires that Shionogi pay the Company tiered
royalties ranging from percentages in the low double-digits to high teens on net sales of licensed products, subject to certain deductions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company assessed the
Shionogi License Agreement in accordance with ASC 606 and concluded that it was a contract with a customer. The Company determined that there is one performance obligation relating to the license to the MZE001 program, including the underlying <FONT
STYLE="white-space:nowrap">know-how</FONT> and certain related materials, and that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
transaction price consisted of the $150.0&nbsp;million <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront cash payment. The potential clinical and regulatory milestones represent
variable consideration and were constrained as it was concluded that it was not probable that a significant reversal in cumulative revenue recognized will not occur and therefore not included in the transaction price as of June&nbsp;30, 2024.
Potential sales milestones and royalties on net product sales will be recognized in the same period that the underlying net product sales occur as they were determined to relate to the license. The $150.0&nbsp;million transaction price was recorded
as license revenue in the condensed statements of operations and comprehensive income (loss) during the six months ended June&nbsp;30, 2024 at the point in time when control of the license and related <FONT STYLE="white-space:nowrap">know-how</FONT>
and materials was transferred to Shionogi. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Neurocrine License Agreement </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In May 2024, the Company entered into an exclusive license agreement with Neurocrine Biosciences, Inc., or Neurocrine, pursuant to which the Company granted Neurocrine
an exclusive worldwide license to a discovery research program targeting ATXN2, or the Neurocrine License Agreement. As consideration for the licensed rights and the transfer of <FONT STYLE="white-space:nowrap">know-how</FONT> and materials, the
Company received an upfront payment of $2.5&nbsp;million in June 2024. Thereafter, the Company is entitled to potential subsequent payments of up to an aggregate of $24.8&nbsp;million based on research and development milestones and up to an
aggregate of $175.0&nbsp;million based on sales milestones. The Company is also entitled to tiered royalties ranging in the low single-digit percentages on net sales of any licensed product if successfully commercialized. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company assessed the Neurocrine License Agreement in accordance with ASC 606 and concluded that it was a contract with a customer. The Company determined that there
is one performance obligation relating to the license to the ATXN2 discovery program, including the underlying <FONT STYLE="white-space:nowrap">know-how</FONT> and certain related materials, and that the transaction price consisted of the
$2.5&nbsp;million upfront cash payment. The potential research and development milestones represent variable consideration and were constrained as it was concluded that it was not probable that a significant reversal in cumulative revenue recognized
will not occur and therefore not included in the transaction price as of June&nbsp;30, 2024. Potential sales milestones and royalties on net product sales will be recognized in the same period that the underlying net product sales occur as they were
determined to relate to the license. As of June&nbsp;30, 2024, the Company had not yet completed the transfer of the <FONT STYLE="white-space:nowrap">know-how</FONT> and materials related to this license. As such, for the six months ended
June&nbsp;30, 2024, the Company had not recognized any revenue related to this agreement. As of June&nbsp;30, 2024, $2.5&nbsp;million related to this agreement was recorded on the condensed balance sheet as deferred revenue in accrued expenses and
other current liabilities as the Company expects to satisfy the related performance obligation within one year from the balance sheet date. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>8. Commitments and
contingencies </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Legal proceedings </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, the
Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can
be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. No contingent liabilities have been recorded as of June&nbsp;30, 2024. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Indemnification </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In accordance with the Company&#146;s amended and
restated certificate of incorporation and amended and restated bylaws, the Company has indemnification obligations to its officers and directors for certain events or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
occurrences, subject to certain limits, while they are serving in such capacity. There have been no claims to date, and the Company has a directors and officers liability insurance policy that
may enable it to recover a portion of any amounts paid for future claims. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>9. Convertible promissory notes and other debt agreements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Convertible promissory notes </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2023, the Company entered
into a convertible note purchase agreement with certain existing investors to issue up to $25.0&nbsp;million in convertible promissory notes, or the Convertible Promissory Notes. The Convertible Promissory Notes bear interest at a rate of 8% per
annum and mature in December 2026. The Company issued $16.2&nbsp;million of the Convertible Promissory Notes, net of issuance costs of $0.1&nbsp;million, as of December 31, 2023. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In January 2024, the Company completed the second closing of the issuance of the Convertible Promissory Notes for gross proceeds of $8.8&nbsp;million. Additionally, in
February 2024, the Company executed an amendment to the convertible note purchase agreement for the sale of additional Convertible Promissory Notes of up to $75.0&nbsp;million in total, including the $25.0&nbsp;million issued in the initial and
second closings. From February 2024 through April 2024, the Company issued an additional $15.7&nbsp;million in Convertible Promissory Notes, resulting in the receipt of $24.5&nbsp;million of cash during the six months ended June&nbsp;30, 2024. As of
June&nbsp;30, 2024, the Company issued a total of $40.7&nbsp;million aggregate principal amount of Convertible Promissory Notes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Convertible Promissory Notes
contain automatic conversion features that are triggered upon a qualified preferred stock financing or a qualified public offering. In the event of a qualified preferred stock financing or a qualified public offering, the total outstanding principal
and accrued interest will automatically convert into preferred stock or common stock, respectively, at a conversion price equal to 80% of the price per share paid by other purchasers of the respective financing or offering. If the Convertible
Promissory Notes have not been repaid or converted before they mature, the holders may convert the outstanding principal and accrued interest into Series C Preferred Stock at $2.9515 per share. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company elected to apply the fair value option, as per ASC 825, to the outstanding Convertible Promissory Notes. As such, the Convertible Promissory Notes are
recognized at fair value with changes in fair value recognized in the condensed statements of operations and comprehensive income (loss). The fair value of the Convertible Promissory Notes is based on significant inputs, including volatility,
discount yield, variables for the timing of the related conversion events and other probability estimates, which are deemed to be Level&nbsp;3 inputs in the fair value hierarchy. The assumptions used to determine the fair value of the Convertible
Promissory Notes included an estimated 90% probability of conversion of the promissory notes at a 20% discount, an assumed discount rate of 25%, the assumed value of the convertible preferred stock, and an estimated time to settlement of up to 1.3
years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents the change in fair value of the Convertible Promissory Notes: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Convertible</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Promissory&nbsp;Notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Issuance of additional convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of the Convertible Promissory Notes was $20.1&nbsp;million as of December 31, 2023. The Company recorded a loss
of $4.5&nbsp;million reflecting the change in fair value of the Convertible Promissory Notes in the condensed statements of operations and comprehensive income (loss) for the six months ended June&nbsp;30, 2024. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Loan and security agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June 2022, the Company entered into a
loan and security agreement with a bank that provides a three-year revolving line of credit of up to $50.0&nbsp;million that is secured by substantially all of the Company&#146;s assets, except for its intellectual property. The Company has not
elected to draw down any funds from this debt facility as of June&nbsp;30, 2024. Advances under the revolving line may be prepaid and reborrowed by the Company without penalty. The Company has the option to convert the aggregate principal amount
into a term loan. Advances under the line of credit accrue interest at a variable annum rate of the greater of (i) 0.75% above the Prime Rate (as defined below) and (ii) 4.50%. The Prime Rate is defined as the variable rate of interest, per annum,
most recently announced by the bank, as its &#147;prime rate,&#148; whether or not such announced rate is the lowest rate available from the bank. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the loan
and security agreement, the Company is required to pay the bank a success fee of up to $2.0&nbsp;million depending on if the Company closes a sale of substantially all of its assets, consummates a reorganization where the voting stockholders before
such transaction hold less than 50% of the voting securities after such transaction, or the sale of the Company&#146;s securities in connection with an initial public offering, reverse merger or other similar transaction wherein the Company&#146;s
securities may thereafter be traded in a public market. This success fee was deemed to be a freestanding derivative instrument that was bifurcated from the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">line-of-credit</FONT></FONT> instrument and is initially and subsequently measured at fair value each reporting period. The fair value of this success fee derivative was estimated
utilizing a probability-weighted cash flow approach, including variables for the timing of the related events and other probability estimates, which are deemed to be Level&nbsp;3 inputs in the fair value hierarchy. The fair value of this success fee
derivative was approximately $0.1&nbsp;million and $0.2&nbsp;million as of December&nbsp;31, 2023 and June&nbsp;30, 2024, respectively, and is recorded in accrued expenses and other current liabilities on the condensed balance sheets. The change in
fair value of the derivative of approximately $0.1&nbsp;million for the six months ended June&nbsp;30, 2024 is recorded in interest and other income, net in the condensed statements of operations and comprehensive income (loss). Total issuance costs
and the debt discount arising from the success fee amounted to $0.3&nbsp;million and were recorded in other assets, which are amortized as interest expense over the commitment period. The unamortized debt discount balance as of June&nbsp;30, 2024
amounted to approximately $0.1&nbsp;million and is recorded in other current assets as the commitment period ends within one year of the balance sheet date. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>10.
Related party transactions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company paid fees to its founders and certain board members in exchange for consulting services. During the six months ended
June&nbsp;30, 2023 and 2024, the Company recorded such fees of $0.1&nbsp;million as research and development and $0.1&nbsp;million as general and administrative expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>11. Income taxes </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company&#146;s provision for income taxes is determined using an estimate of the Company&#146;s annual effective tax rate, adjusted for discrete items, if any. For the six months ended June&nbsp;30, 2024, the Company recorded an income tax provision
of $1.7&nbsp;million with a corresponding amount recorded in accrued expenses and other current liabilities. No income tax provision was recorded for the six months ended June&nbsp;30, 2023. The primary difference in income tax expense for the six
months ended June&nbsp;30, 2024, as compared to the same period in the prior year, is the result of recognition of revenue from the Company&#146;s license agreements as discussed in Note 7 on License agreements resulting in taxable income to the
Company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on the available objective evidence during the six months ended June&nbsp;30, 2024, the Company believes it is more likely than not that its net
deferred tax assets may not be realized. The primary difference between the effective tax rate and the statutory tax rate relates to the Company&#146;s change in valuation allowance against deferred taxes. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>12. Net (loss) income per share </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth the
computation of basic and diluted net income (loss) per share (in thousands, except share and per share data): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Six months ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Basic (loss) income per share:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Allocation of undistributed earnings to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income attributable to common stockholders, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average shares of common stock outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,914,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,198,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: weighted average shares of common stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,098,924</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(403,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average shares of common stock outstanding used in the calculation of (loss) income per share
attributable to common stockholders, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,815,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,794,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income per share attributable to common stockholders, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Diluted (loss) income per share:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income attributable to common stockholders, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">After tax effect of assumed conversion of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(323</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income attributable to common stockholders, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average shares of common stock outstanding, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,815,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,794,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average dilutive effect of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,526,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average dilutive effect of equity awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,220,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Diluted weighted-average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,815,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,541,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net (loss) income per share attributable to common stockholders, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The potential shares of common stock that were excluded from the computation of diluted net (loss) income per
share attributable to common stockholders for the periods presented because including them would have been antidilutive are as follows: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,985,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,563,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,866,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Shares subject to outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,146,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,414,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested restricted stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested exercised options subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,292,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,294,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,985,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>13. Subsequent events </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From
July&nbsp;1, 2024 through August&nbsp;15, 2024, the Company granted a total of 2,225,000 stock options with an exercise price of $2.05 per share and a fully vested restricted stock award for 25 shares of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769642g76l04.jpg" ALT="LOGO" STYLE="width:0.766303in;height:0.773586in;">
 </P>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:24pt; font-family:arial" ALIGN="center"><B>Maze Therapeutics, Inc. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>Common stock </I></B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:24pt; font-family:arial" ALIGN="center"><B>Preliminary prospectus
</B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:16pt">
<TD VALIGN="top"><B>J.P.&nbsp;Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>TD&nbsp;Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Leerink&nbsp;Partners</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Guggenheim&nbsp;Securities</B></TD></TR>
</TABLE> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8195;&#8195;&#8195;&#8195;&#8195;, 2024 </P> <P STYLE="font-size:16pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Part II </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Information not
required in prospectus </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;13. Other expenses of issuance and distribution. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth all costs and expenses, other than underwriting discounts and commissions, paid or payable by the Registrant in connection with the sale
of the common stock being registered. All amounts shown are estimates except for the SEC registration fee, the FINRA filing fee and the Nasdaq Global Market listing fee: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount<BR>paid or<BR>to&nbsp;be&nbsp;paid</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">The Nasdaq Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Blue Sky, qualification fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be completed by amendment. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;14. Indemnification of directors and officers. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;145 of the DGCL, authorizes a court to award, or a corporation&#146;s board of directors to grant, indemnity to directors and officers under certain
circumstances and subject to certain limitations. The terms of Section&nbsp;145 of the DGCL are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the
Securities Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As permitted by the DGCL, the Registrant&#146;s restated certificate of incorporation to be effective in connection with the completion of this
offering contains provisions that eliminate the personal liability of its directors and officers for monetary damages for any breach of fiduciary duties as a director or officer, except liability for the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any breach of the director&#146;s or officer&#146;s duty of loyalty to the Registrant or its stockholders;
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">with respect to directors, under Section&nbsp;174 of the DGCL (regarding unlawful dividends and stock purchases);
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any transaction from which the director or officer derived an improper personal benefit; or </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">with respect to officers, any action by or in the right of the Registrant. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As permitted by the DGCL, the Registrant&#146;s restated bylaws to be effective in connection with the completion of this offering, provide that: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the Registrant is required to indemnify its directors and officers to the fullest extent permitted by the DGCL, subject to
limited exceptions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the Registrant may indemnify its other employees and agents as set forth in the DGCL; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the Registrant is required to advance expenses, as incurred, to its directors and officers in connection with a legal
proceeding to the fullest extent permitted by the DGCL, subject to limited exceptions; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the rights conferred in the restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to the completion of this offering, the Registrant intends to enter into indemnification agreements with each of its current directors and executive officers to
provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the Registrant&#146;s restated certificate of incorporation and restated bylaws and to provide additional
procedural protections. There is no pending litigation or proceeding involving a director or executive officer of the Registrant for which indemnification is sought. Reference is also made to the underwriting agreement to be filed as Exhibit 1.1 to
this registration statement, which provides for the indemnification of executive officers, directors and controlling persons of the Registrant against certain liabilities. The indemnification provisions in the Registrant&#146;s restated certificate
of incorporation, restated bylaws and the indemnification agreements entered into or to be entered into between the Registrant and each of its directors and executive officers may be sufficiently broad to permit indemnification of the
Registrant&#146;s directors and officers for liabilities arising under the Securities Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Registrant has directors&#146; and officers&#146; liability insurance
for securities matters. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;15. Recent sales of unregistered securities. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following lists set forth information regarding all securities sold or granted by the Registrant from&#8195;&#8195;&#8195;&#8195;, 2021 through the date of this
prospectus that were not registered under the Securities Act, and the consideration, if any, received by the Registrant for such securities: </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>(a) Equity
grants </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Stock Option Grants</I>. From&#8195;&#8195;&#8195;&#8195; , 2021 through the date of this prospectus, the Registrant has granted to its employees,
directors, consultants and other service providers options to purchase an aggregate of &#8195;&#8195;&#8195;&#8195;shares of its common stock under the 2019 Plan, with exercise prices ranging from $&#8195;&#8195;&#8195;&#8195;to
$&#8195;&#8195;&#8195;&#8195;per share. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The issuances of the securities described in this section (a)&nbsp;of Item 15 were deemed to be exempt from registration
pursuant to Section&nbsp;4(a)(2) of the Securities Act or Rule 701 promulgated under the Securities Act as transactions pursuant to compensatory benefit plans. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>(b) Common stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From &#8195;&#8195;&#8195;&#8195; , 2021 through the
date of this prospectus, the Registrant issued an aggregate of &#8195;&#8195;&#8195;&#8195; shares of restricted common stock, for cash with purchase prices ranging from $0.15 to $2.00 per share, or for services rendered, to the Registrant&#146;s
employees, directors, advisors and consultants pursuant to the 2018 Plan or the 2019 Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The issuances of shares of common stock described in this section
(b)&nbsp;of Item 15 were issued pursuant to either (i)&nbsp;restricted stock purchase agreements, pursuant to Section&nbsp;4(a)(2) under the Securities Act or (ii)&nbsp;written compensatory plans or arrangements with the Registrant&#146;s employees,
directors, advisors and consultants, in reliance on the exemption provided by Rule&nbsp;701 promulgated under the Securities Act or pursuant to Section&nbsp;4(a)(2) under the Securities Act. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>(c) Preferred stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On December&nbsp;8, 2021, the Registrant sold an
aggregate of 40,333,540 shares of Series C Preferred Stock, at a price per share of $2.9515 for total gross proceeds of $119.0&nbsp;million. These transactions were exempt from the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
registration requirements of the Securities Act in reliance upon Section&nbsp;4(a)(2) of the Securities Act or Regulation D promulgated under the Securities Act. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On March&nbsp;21, 2022, the Registrant sold an aggregate of 363,759 shares of Series C Preferred Stock, at a price per share of $2.9515 for total gross proceeds of
$1.1&nbsp;million. These transactions were exempt from registration requirements of the Securities Act in reliance upon Section&nbsp;4(a)(2) of the Securities Act or Regulation D promulgated under the Securities Act. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On March&nbsp;29, 2022, the Registrant sold an aggregate of 169,405 shares of Series C Preferred Stock, at a price per share of $2.9515 for total net proceeds of
$0.5&nbsp;million. These transactions were exempt from registration requirements of the Securities Act in reliance upon Section&nbsp;4(a)(2) of the Securities Act or Regulation D promulgated under the Securities Act. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>(d) Convertible promissory notes </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Between December&nbsp;15, 2023 and
April&nbsp;3, 2024, the Registrant sold $40.7&nbsp;million in aggregate principal amount of convertible promissory notes to certain accredited investors, which notes are convertible into shares of the Registrant&#146;s common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions or any public offering, and the Registrant believes each transaction
was exempt from the registration requirements of the Securities Act as stated above. All recipients of the foregoing transactions either received adequate information about the registrant or had access, through their relationships with the
Registrant, to such information. Furthermore, the Registrant affixed appropriate legends to the share certificates and instruments issued in each foregoing transaction setting forth that the securities had not been registered and the applicable
restrictions on transfer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;16. Exhibits and financial statement schedules. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>(a) Exhibits. </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" COLSPAN="3" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial"><B>number</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Description of document</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Form of Underwriting Agreement.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="top">**&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Certificate of Incorporation, as amended, as currently in effect.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Form of Restated Certificate of Incorporation to be effective upon the completion of this
offering.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="top">**&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Bylaws, as currently in effect.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Form of Restated Bylaws to be effective upon the completion of this offering.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Form of Common Stock Certificate.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="top">**&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Amended and Restated Investors&#146; Rights Agreement, dated December&nbsp;8, 2021, by and among Maze
Therapeutics, Inc. and certain of its stockholders, as amended as of July 31, 2024.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="top">**&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Form of Convertible Promissory Note.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Opinion of Fenwick&nbsp;&amp; West LLP.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Form of Indemnity Agreement.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="top">**&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2018 Stock Option and Grant Plan, as amended, and forms of award agreements.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="top">**&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2019 Equity Incentive Plan, as amended, and forms of award agreements.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2024 Equity Incentive Plan, to become effective on the date the registration statement is declared
effective, and forms of award agreements.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2024 Employee Stock Purchase Plan, to become effective on the date the registration statement is declared
effective, and forms of award agreements.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.6^</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Lease Agreement, dated September&nbsp;27, 2019, by and among Maze Therapeutics, Inc. and HCP Oyster
Point&nbsp;III LLC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.7</TD>
<TD NOWRAP VALIGN="top">**&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Consulting Agreement, dated November&nbsp;1, 2019, by and among Maze Therapeutics, Inc. and Charles
Homcy, M.D.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.8</TD>
<TD NOWRAP VALIGN="top">**&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Advisor Agreement, dated July&nbsp;1, 2021, by and among Maze Therapeutics, Inc. and Richard Scheller,
Ph.D.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.9</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Form of Executive Officer Employment Agreement.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.10</TD>
<TD NOWRAP VALIGN="top">**&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loan and Security Agreement, dated June&nbsp;27, 2022, by and between Maze Therapeutics, Inc. and Pacific
Western Bank, as amended.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.11</TD>
<TD NOWRAP VALIGN="top">&#134;^**&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">License Agreement, dated as of March&nbsp;25, 2024, by and between Maze Therapeutics, Inc. and
Shionogi&nbsp;&amp; Co., Ltd.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">23.1</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Consent of Independent Registered Public Accounting Firm.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">23.2</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Consent of Fenwick&nbsp;&amp; West LLP (included in Exhibit&nbsp;5.1).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24.1</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Power of Attorney (included in the signature page to this registration statement).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Filing Fee Table</P></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">**</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Registrant has omitted portions of the exhibit (indicated by &#147;[***]&#148;) as permitted under Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">^</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Registrant has omitted schedules and exhibits pursuant to Item 601(a)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> The Registrant agrees to furnish supplementally a copy of the omitted schedules and
exhibits to the SEC upon request. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>(b) Financial statement schedules. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or notes. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;17. Undertakings. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or
paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement
in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was
declared effective. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Signatures </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the
requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the
City of South San Francisco, State of California, on the&#8195;&#8195;&#8195;&#8195;day of&#8195;&#8195;&#8195;&#8195;, 2024. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MAZE THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jason Coloma, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>Chief Executive Officer</I></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Power of attorney </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">KNOW ALL
PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Jason Coloma, Ph.D., Amy Bachrodt and Courtney Phillips, and each one of them, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> proxies and agents, each with full power of substitution and resubstitution and full power to act without the other, for him or her in any and all capacities, to sign any and all amendments
to this registration statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought), and to file
the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT>
proxies and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying
and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> proxies and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue
hereof. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> has
been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Signature</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Title</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Date</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Jason Coloma, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial" ALIGN="center">Chief Executive Officer and Director<BR>(Principal Executive Officer and
Principal Financial Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#8195;&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;&#8195;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Amy
Bachrodt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial" ALIGN="center">SVP, Finance<BR>(Principal Accounting Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#8195;&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Charles Homcy, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#8195;&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Nancy C. Andrews, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#8195;&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Sekar Kathiresan, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#8195;&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Jonathan Lim, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#8195;&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Richard Scheller, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#8195;&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Catherine Angell Sohn, Pharm. D.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">&#8195;&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Signature</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Title</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Date</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Daniel Spiegelman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#8195;&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Jeffrey Tong, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#8195;&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">Andy Tran</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">&#8195;&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>THE COVE AT OYSTER POINT </U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>LEASE </U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This Lease (the &#147;Lease&#148;), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the
&#147;Summary&#148;), below, is made by and between <B>HCP OYSTER POINT III LLC,</B> a Delaware limited liability company (&#147;Landlord&#148;), and <B>MAZE </B><B>THERAPEUTICS, INC.</B>, a Delaware corporation (&#147;<B>Tenant</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><U><B>SUMMARY OF BASIC LEASE INFORMATION </B></U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" COLSPAN="5">TERMS OF LEASE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">DESCRIPTION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">September 27, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Premises</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">(<U>Article 1</U>).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Building:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">That certain four-story building containing approximately 132,368 rentable square feet of space (&#147;<B>RSF</B>&#148;) located at:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">171 Oyster Point Boulevard South San Francisco, California 94080</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Premises:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Approximately 67,185 RSF on the second (2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP>) floor and the third (3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP>) floor of the Building, as further set forth in
<B><U>Exhibit A</U> </B>to the Lease.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Lease Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">(<U>Article 2</U>).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Length of Term:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Approximately ten (10) years commencing on the Lease Commencement Date and ending on the Lease Expiration Date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lease Commencement Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The earlier to occur of (i) the date upon which Tenant first commences to conduct business in the Premises (other than the &#147;Early Occupancy Premises&#148; as that term is defined in and pursuant to the terms of <U>Section
1.3</U> below), and (ii) the date that occurs seven (7) months following the date upon which Landlord delivers the Premises to Tenant in the &#147;Delivery Condition&#148; (as that term is defined in Section 1.1.1 below (the &#147;<B>Delivery
Date</B>&#148;).</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lease Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If the Lease Commencement Date shall be the first day of a calendar month, then the day immediately preceding the tenth (10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) anniversary of the Lease Commencement Date; or, if
the Lease Commencement Date shall be other than the first day of a calendar month, then the last day of the month in which the tenth (10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) anniversary of the Lease Commencement Date occurs, or if
Tenant exercises its option in accordance with Section 2.2 below, the last day of the Option Term.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Base&nbsp;Rent</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">(<U>Article
3</U>):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom" ALIGN="center"><U>Lease Year</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Annual</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><U>Base&nbsp;Rent</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Monthly&nbsp;Installment<BR><U>of&nbsp;Base Rent</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Approximate</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Monthly&nbsp;Base</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Rent&nbsp;per&nbsp;Rentable<BR><U>Square&nbsp;Foot</U></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman" ALIGN="center">1 (months 1 through 6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$1,138,802.07</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$189,800.45</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$5.65</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman" ALIGN="center">1 (months 7 through 12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$2,277,571.50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$379,595.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$5.65</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman" ALIGN="center">2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$4,714,573.01</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$392,881.08</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$5.85</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman" ALIGN="center">3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$4,879,583.06</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$406,631.92</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$6.05</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman" ALIGN="center">4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$5,050,368.47</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$420,864.04</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$6.26</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman" ALIGN="center">5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$5,227,131.36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$435,594.28</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$6.48</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman" ALIGN="center">6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$5,410,080.96</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$450,840.08</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$6.71</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman" ALIGN="center">7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$5,599,433.80</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$466,619.48</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$6.95</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman" ALIGN="center">8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$5,795,413.98</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$482,951.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$7.19</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman" ALIGN="center">9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$5,998,253.47</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$499,854.46</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$7.44</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman" ALIGN="center">10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$6,208,192.34</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$517,349.36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">$7.70</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">*Note that for the first six (6) months of the Lease Term, Tenant&#146;s Base Rent obligation has been calculated as if the
Premises contained only 33,593 rentable square feet. Such calculation shall not affect Tenant&#146;s right to use the entire Premises, or Tenant&#146;s rights or obligations under this Lease with respect to the entire Premises, including without
limitation, Tenant&#146;s obligation to pay Tenant&#146;s Share of Direct Expenses with respect to the Premises which shall be as provided in Section 6 of this Summary, all in accordance with the terms and conditions of this Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">5.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Tenant Improvement Allowance</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">(<B><U>Exhibit B</U></B>):</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">An amount equal to $65.00 per rentable square foot of the Premises (<I>i.e.</I>,
$4,367,025.00 based upon 67,185 rentable square feet in the Premises).</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">6.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Tenant&#146;s Share</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">(<U>Article 4</U>):</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">50.76%.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">7.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Permitted Use</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">(<U>Article 5</U>):</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">The Premises shall be used only for general office, research and development, engineering, laboratory, vivarium, storage
and/or warehouse uses, including, but not limited to, administrative offices and other lawful uses reasonably related to or incidental to such specified uses, all (i)&nbsp;consistent with first class life sciences projects in South San Francisco,
California (&#147;<B>First Class</B><B></B><B>&nbsp;Life Sciences Projects</B>&#148;), and (ii)&nbsp;in compliance with, and subject to, Applicable Laws and the terms of this Lease.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">8.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Letter of Credit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">(<U>Article 21</U>):</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$1,034,698.72.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">9.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Parking</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">(<U>Article 28</U>):</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">2.4 unreserved parking spaces for every 1,000 rentable square feet of the Premises, subject to the terms of <U>Article
28</U> of the Lease.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">10.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Address of Tenant</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">(<U>Section 29.18</U>):</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>MAZE THERAPEUTICS</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">131 Oyster Point Boulevard, Floor 2</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">South San Francisco, CA
94080</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Attn: Chief Business Officer</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">With copies to:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Attn: Senior Manager, Operations</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">And</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Attn: Corporate Controller</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">(Prior to Lease Commencement Date)</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">The Premises</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Attention: Chief Business Officer</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">With copies to:</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Attn: Senior Manager, Operations</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">And</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Attn: Corporate Controller</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">(After Lease Commencement Date)</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">11.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Address of Landlord</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">(<U>Section 29.18</U>):</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">See <U>Section&nbsp;29.18</U> of the Lease.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">12.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Broker(s)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">(<U>Section 29.24</U>):</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">CBRE, Inc.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>PREMISES, BUILDING, PROJECT, AND COMMON AREAS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.1&#8194;&#8195;<B><U>Premises, Building, Project and Common Areas</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.1.1&#8194;&#8195;<B><U>The Premises</U></B>. Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the
premises set forth in <U>Section</U><U></U><U>&nbsp;2.2</U> of the Summary (the &#147;<B>Premises</B>&#148;). The outline of the Premises is set forth in <B><U>Exhibit A</U></B><B> </B>attached hereto. The outline of the &#147;Building&#148; and the
&#147;Project,&#148; as those terms are defined in <U>Section</U><U></U><U>&nbsp;1.1.2</U> below, are further depicted on the Site Plan attached hereto as <B><U>Exhibit A</U></B>. The parties hereto agree that the lease of the Premises is upon and
subject to the terms, covenants and conditions herein set forth, and covenant as a material part of the consideration for this Lease to keep and perform each and all of such terms, covenants and conditions by it to be kept and performed and that
this Lease is made upon the condition of such performance. The parties hereto hereby acknowledge that the purpose of <B><U>Exhibit A</U></B><B> </B>is to show the approximate location of the Premises only, and such Exhibit is not meant to constitute
an agreement, representation or warranty as to the construction of the Premises, the precise area thereof or the specific location of the &#147;Common Areas,&#148; as that term is defined in <U>Section</U><U></U><U>&nbsp;1.1.3</U>, below, or the
elements thereof or of the accessways to the Premises or the &#147;Project,&#148; as that term is defined in <U>Section</U><U></U><U>&nbsp;1.1.2</U>, below. Except as specifically set forth in this Lease and in the Tenant Work Letter attached hereto
as <B><U>Exhibit B</U></B><B> </B>(the &#147;<B>Tenant Work Letter</B>&#148;), Landlord shall not be obligated to provide or pay for any improvement work or services related to the improvement of the Premises. Tenant also acknowledges that neither
Landlord nor any agent of Landlord has made any representation or warranty regarding the condition of the Premises, the Building or the Project or with respect to the suitability of any of the foregoing for the conduct of Tenant&#146;s business,
except as specifically set forth in this Lease and the Tenant Work Letter. The commencement of business operations from the Premises by Tenant shall presumptively establish that the Premises and the Building were at such time in good and sanitary
order, condition and repair, subject only to (i)&nbsp;minor &#147;punchlist&#148; matters related to the Building brought to Landlord&#146;s attention within ten (10)&nbsp;days after the Lease Commencement Date, and (ii)&nbsp;Landlord&#146;s ongoing
repair and maintenance obligations set forth in Article 7, below. Landlord shall deliver the Premises to Tenant fully decommissioned, in good, vacant, broom clean condition, and otherwise in substantially the same condition as of the date of this
Lease, in compliance with all Applicable Laws (to the extent required to allow the legal occupancy of the Premises or completion of the Tenant Improvements), free of Hazardous Materials (as defined below), free of all other tenancies and other
occupancy rights, with the Building&#146;s roof water-tight and shall cause the plumbing, electrical systems, fire sprinkler system, lighting, and all other building systems serving the Premises to be in good operating condition and repair on or
before the Lease Commencement Date (the &#147;<B>Delivery Condition</B>&#148;). The date of Landlord&#146;s delivery of the Premises to Tenant in the Delivery Condition is the &#147;<B>Delivery Date</B>&#148;, which date is currently estimated to be
May&nbsp;1, 2020 and Tenant shall have no obligation to accept delivery of the Premises prior to May&nbsp;1, 2020. Landlord shall use commercially reasonable and diligent efforts to deliver the Premises in the Delivery Condition by May&nbsp;1, 2020.
Notwithstanding anything in this Lease to the contrary, Landlord shall, at Landlord&#146;s sole cost and expense (which shall not be deemed an &#147;Operating Expense,&#148; as that term is defined in Section&nbsp;4.2.4), repair or replace any
failed or inoperable portion of the Building systems serving the Premises during the first twelve (12)&nbsp;months of the initial Lease term (&#147;<B>Warranty Period</B>&#148;), provided that the need to repair or replace was not caused by the
misuse, misconduct, damage, destruction, omissions, and/or negligence of Tenant, its subtenants and/or assignees, if any, or any company which is acquired, sold or merged with Tenant (collectively, &#147;<B>Tenant Damage</B>&#148;), or by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
any modifications, Alterations or improvements constructed by or on behalf of Tenant. Landlord shall coordinate such work with Tenant and shall utilize commercially reasonable efforts to perform
the same in a manner designed to minimize interference with Tenant&#146;s use of the Premises. To the extent repairs which Landlord is required to make pursuant to this Section&nbsp;1.1.1 are necessitated in part by Tenant Damage, then Tenant shall
reimburse Landlord for an equitable proportion of the cost of such repair. Landlord will be responsible for causing, at its sole expense, the exterior of the Building, the existing Building entrances, and all Common Areas (including required
striping and handicapped spaces in the parking areas) to be in compliance with Applicable Laws, to the extent required to allow the legal occupancy of the Premises or completion of the Tenant Improvements (except to the extent such compliance is
triggered specifically by Tenant&#146;s particular Tenant Improvements). Any process utilities shall be provided without warranty, in their currently existing, <FONT STYLE="white-space:nowrap">&#147;as-is&#148;</FONT> condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.1.2&#8194;&#8195;<B><U>The Building and The Project</U></B>. The Premises constitutes the entire building set forth in
<U>Section</U><U></U><U>&nbsp;2.1</U> of the Summary (the &#147;<B>Building</B>&#148;). The Building is part of an office/laboratory project currently known as &#147;The Cove at Oyster Point.&#148; The term &#147;<B>Project</B>,&#148; as used in
this Lease, shall mean (i)&nbsp;the Building and the Common Areas, (ii)&nbsp;the land (which is improved with landscaping, parking facilities and other improvements) upon which the Building and the Common Areas are located, and (iii)&nbsp;the other
office/laboratory buildings located within The Cove at Oyster Point, and the land upon which such adjacent office/laboratory buildings are located. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.1.3&#8194;&#8195;<B><U>Common Areas</U></B>. Tenant shall have the <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
right to use in common with other tenants in the Project, and subject to the rules and regulations referred to in <U>Article 5</U> of this Lease, those portions of the Project which are provided, from time to time, for use in common by Landlord,
Tenant and any other tenants of the Project including, without limitation, entrances, lobbies, fire vestibules, mechanical areas, ground floor corridors, elevators and elevator foyers, parking areas, loading and unloading areas, plaza areas, if any,
ramps, drives, stairs, and similar access ways and service ways in, adjacent to or serving the Project (such areas, together with such other portions of the Project designated by Landlord, in its discretion, are collectively referred to herein as
the &#147;<B>Common Areas</B>&#148;). The manner in which the Common Areas are maintained and operated shall be at the sole discretion of Landlord (provided the same shall at all times be consistent with comparable landlords of First Class&nbsp;Life
Sciences Projects) and the use thereof shall be subject to the &#147;Rules and Regulations&#148; (as set forth and subject to Section&nbsp;5.2 below). Landlord reserves the right to close temporarily, make alterations or additions to, or change the
location of elements of the Project and the Common Areas; provided that (i)&nbsp;none of the foregoing materially and adversely affects Tenant&#146;s use of, or access to, the Building, the Premises or the parking areas serving the Building or the
size of the Premises, and (ii)&nbsp;Landlord uses commercially reasonable efforts to minimize interference with the conduct of Tenant&#146;s business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.2&#8194;&#8195;<B><U>Rentable Square Feet of Premises</U></B>. The rentable square footage of the Premises is hereby deemed
to be as set forth in <U>Section</U><U></U><U>&nbsp;2.2</U> of the Summary, and shall not be subject to measurement or adjustment during the Lease Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.3&#8194;&#8195;<B><U>Early Occupancy of Portion of Premises</U></B>. Following the Delivery Date, Tenant shall have the
right to occupy a portion of the Premises to be reasonably agreed to by Landlord and Tenant (the &#147;<B>Early Occupancy Premises</B>&#148;) prior to the Lease Commencement Date (such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
period from the Delivery Date until the Lease Commencement Date shall be referred to herein as the &#147;<B>Early Occupancy Period</B>&#148;), provided that (A)&nbsp;Tenant shall give Landlord at
least ten (10)&nbsp;days&#146; prior notice of any such occupancy of the Early Occupancy Premises, (B)&nbsp;a temporary certificate of occupancy shall have been issued by the appropriate governmental authority for the Early Occupancy Premises, and
(C)&nbsp;all of the terms and conditions of this Lease shall apply to the Early Occupancy Premises (and not the remainder of the Premises) as though the Lease Commencement Date had occurred (although the Lease Commencement Date shall not actually
occur until the occurrence of the same pursuant to Section&nbsp;3.2 of the Summary) upon such occupancy of the Early Occupancy Premises by Tenant. During the Early Occupancy Period, Tenant shall pay &#147;Base Rent,&#148; as that term is defined in
Article 3 below, in the amount of $5.65 per rentable square foot of the Early Occupancy Premises, and Tenant shall pay &#147;Tenant&#146;s Share&#148; of the annual &#147;Direct Expenses,&#148; as those terms are defined in Article 4, below and
utilities costs for the Early Occupancy Premises during the Early Occupancy Period (with such Tenant&#146;s Share being based on the RSF of the Early Occupancy Premises). Following the determination of the location and size of the Early Occupancy
Premises, Landlord and Tenant shall execute an amendment to this Lease documenting the RSF and location of the Early Occupancy Premises, and setting forth the Base Rent and Tenant&#146;s Share applicable to such space. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.4&#8194;&#8195;<B><U>Delivery of the Premises</U></B>. If Landlord has not delivered possession of the entire Premises to
Tenant in the Delivery Condition on or before July&nbsp;1, 2020 (the &#147;<B>Outside Delivery Date</B>&#148;), then, as Tenant&#146;s sole remedy for such delay, Tenant shall receive one (1)&nbsp;day of free Base Rent for each day that the Delivery
Date is delayed beyond such Outside Delivery Date. The Outside Delivery Date shall be extended to the extent of any delays in delivery of possession caused by war, terrorism, acts of God, natural disaster, civil unrest, governmental strike or
area-wide or industry-wide labor disputes, inability to obtain services, labor, or materials or reasonable substitutes therefor, or delays due to utility companies that are not the result of any action or inaction of Landlord (provided that any such
delay shall not extend any such date by more than ninety (90)&nbsp;days), or delays caused by Tenant. If Landlord has not delivered possession of the entire Premises to Tenant by November&nbsp;1, 2020, Tenant shall have the right to terminate this
Lease upon written notice to Landlord at any time prior to delivery of possession of the entire Premises to Tenant, whereupon any monies previously paid by Tenant to Landlord shall be reimbursed to Tenant. Upon such termination, neither party shall
have any further obligation to the other under this Lease. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>LEASE TERM; OPTION TERM </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.1&#8194;&#8195;<B><U>Lease Term</U></B>. The terms and provisions of this Lease shall be effective as of the date of this
Lease. The term of this Lease (the &#147;<B>Lease Term</B>&#148;) shall be as set forth in <U>Section</U><U></U><U>&nbsp;3.1</U> of the Summary, shall commence on the date set forth in <U>Section</U><U></U><U>&nbsp;3.2</U> of the Summary (the
&#147;<B>Lease Commencement Date</B>&#148;), and shall terminate on the date set forth in <U>Section</U><U></U><U>&nbsp;3.3</U> of the Summary (the &#147;<B>Lease Expiration Date</B>&#148;) unless this Lease is sooner terminated or extended as
hereinafter provided. For purposes of this Lease, the term &#147;<B>Lease Year</B>&#148; shall mean each consecutive twelve (12)&nbsp;month period during the Lease Term. At any time during the Lease Term, Landlord may deliver to Tenant a notice in
the form as set forth in <B><U>Exhibit C</U></B>, attached hereto, as a confirmation only of the information set forth therein, which Tenant shall execute and return to Landlord within five (5)&nbsp;days of receipt thereof if Tenant agrees with the
contents thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2&#8194;&#8195;<B><U>Option Term</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.1&#8194;&#8195;<B><U>Option Right</U></B>. Landlord hereby grants the Tenant originally named in this Lease (the
&#147;<B>Original Tenant</B>&#148;), and any assignee of Original Tenant&#146;s entire interest in the Lease that has been approved in accordance with the terms of <U>Article 14</U>, below (a &#147;<B>Permitted Assignee</B>&#148;) or any Permitted
Transferee Assignee (as that term is defined in Section&nbsp;14.8 below), one (1)&nbsp;option to extend the Lease Term for a period of eight (8)&nbsp;years (the &#147;<B>Option Term</B>&#148;). Such option to extend shall be exercisable only by
written notice delivered by Tenant to Landlord not more than twelve (12)&nbsp;months nor less than nine (9)&nbsp;months prior to the expiration of the initial Lease Term, stating that Tenant is thereby irrevocably exercising its option to lease the
Premises during the Option Term. Upon the proper exercise of the option to extend, and provided that, at Landlord&#146;s option, as of the date of delivery of such notice, Tenant is not in default under this Lease (beyond the applicable notice and
cure periods) and has not previously been in default under this Lease (beyond the applicable notice and cure periods) more than twice, and as of the end of the initial Lease Term Tenant is not in default under this Lease (beyond the applicable
notice and cure periods), the Lease Term shall be extended for a period of eight (8)&nbsp;years. The rights contained in this <U>Section</U><U></U><U>&nbsp;2.2</U> shall be personal to Original Tenant, any Permitted Assignee and any Permitted
Transferee Assignee (and not any other assignee, sublessee or &#147;Transferee,&#148; as that term is defined in <U>Section</U><U></U><U>&nbsp;14.1</U>, below, of Tenant&#146;s interest in this Lease). In the event that Tenant fails to timely and
appropriately exercise its initial option to extend the Lease Term, in accordance with the terms of this <U>Section</U><U></U><U>&nbsp;2.2</U>, then such option shall automatically terminate and shall be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.2&#8194;&#8195;<B><U>Option Rent</U></B>. The annual Base Rent payable by Tenant during the Option Term (the
&#147;<B>Option Rent</B>&#148;) shall be equal to the &#147;Fair Rental Value,&#148; as that term is defined below, for the Premises as of the commencement date of the Option Term. The &#147;<B>Fair Rental Value</B>,&#148; as used in this Lease,
shall be equal to the annual rent per rentable square foot (including additional rent and considering any &#147;base year&#148; or &#147;expense stop&#148; applicable thereto), including all escalations, at which tenants (pursuant to leases
consummated within the twelve (12)&nbsp;month period preceding the first day of the Option Term), are leasing <FONT STYLE="white-space:nowrap">non-sublease,</FONT> <FONT STYLE="white-space:nowrap">non-encumbered,</FONT> <FONT
STYLE="white-space:nowrap">non-equity</FONT> space which is not significantly greater or smaller in size than the subject space, for a comparable lease term, in an arm&#146;s length transaction, which comparable space is located in the Building or
in &#147;Comparable Buildings,&#148; as that term is defined in this <U>Section</U><U></U><U>&nbsp;2.2.2</U>, below (transactions satisfying the foregoing criteria shall be known as the &#147;<B>Comparable Transactions</B>&#148;), taking into
consideration the following concessions (the &#147;<B>Concessions</B>&#148;): (a) rental abatement concessions, if any, being granted such tenants in connection with such comparable space; (b)&nbsp;tenant improvements or allowances provided or to be
provided for such comparable space, and taking into account the value, if any, of the existing improvements in the subject space, such value to be based upon the age, condition, design, quality of finishes and layout of the improvements; and
(c)&nbsp;other reasonable monetary concessions being granted such tenants in connection with such comparable space; provided, however, that in calculating the Fair Rental Value, no consideration shall be given to (i)&nbsp;the fact that Landlord is
or is not required to pay a real estate brokerage commission in connection with Tenant&#146;s exercise of its right to extend the Lease Term, or the fact that landlords are or are not paying real estate brokerage commissions in connection with such
comparable space, and (ii)&nbsp;any construction period, if any, granted to tenants in Comparable Transactions in connection with the design, permitting and construction of tenant improvements in such comparable spaces. The Concessions
(A)&nbsp;shall be reflected in the effective rental rate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
(which effective rental rate shall take into consideration the total dollar value of such Concessions as amortized on a straight- line basis over the applicable term of the Comparable Transaction
(in which case such Concessions evidenced in the effective rental rate shall not be granted to Tenant)) payable by Tenant, or (B)&nbsp;at Landlord&#146;s election, all such Concessions shall be granted to Tenant in kind. The term &#147;<B>Comparable
Buildings</B>&#148; shall mean the Building and those other buildings which are comparable to the Building in terms of age (based upon the date of completion of construction or major renovation of the building), quality of construction, level of
services and amenities, size and appearance, and located in First Class&nbsp;Life Sciences Project in South San Francisco, California, Brisbane, California and the surrounding commercial area. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.3&#8194;&#8195;<B><U>Determination of Option Rent</U></B>. In the event Tenant timely and appropriately exercises its
option to extend the Lease Term in accordance with Section&nbsp;2.2.1, Landlord shall notify Tenant of Landlord&#146;s determination of the Option Rent on or before the date that is thirty (30)&nbsp;days following Landlord&#146;s receipt of the
Option Exercise Notice. If Tenant, on or before the date which is thirty (30)&nbsp;days following the date upon which Tenant receives Landlord&#146;s determination of the Option Rent, in good faith objects to Landlord&#146;s determination of the
Option Rent, then Landlord and Tenant shall attempt to agree upon the Option Rent using their good-faith efforts. If Landlord and Tenant fail to reach agreement within thirty (30)&nbsp;days following Tenant&#146;s objection to the Option Rent (the
&#147;<B>Outside Agreement Date</B>&#148;), then each party shall thereafter make a separate determination of the Option Rent, within five (5)&nbsp;business days of the Outside Agreement Date, and such determinations shall be submitted to
arbitration in accordance with <U>Sections 2.2.3.1</U> through <U>2.2.3.8</U>, below. If Tenant fails to object to Landlord&#146;s determination of the Option Rent within the time period set forth herein, then Tenant shall be deemed to have rejected
Landlord&#146;s determination of the Option Rent, and the matter shall be submitted to arbitration in accordance with the terms hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.3.1&#8194;&#8195;Landlord and Tenant shall each appoint one arbitrator who shall be, at the option of the appointing
party, a MAI appraiser, a real estate broker, who shall have been active over the five (5)&nbsp;year period ending on the date of such appointment in the leasing or appraisal, as the case may be, of life science properties in South San Francisco,
California. Each such arbitrator shall be appointed within twenty (20)&nbsp;days after the Outside Agreement Date. Landlord and Tenant may consult with their selected arbitrators prior to appointment and may select an arbitrator who is favorable to
their respective positions. The arbitrators so selected by Landlord and Tenant shall be deemed &#147;<B>Advocate Arbitrators</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.3.2&#8194;&#8195;The two (2)&nbsp;Advocate Arbitrators so appointed shall be specifically required pursuant to an
engagement letter within ten (10)&nbsp;days of the date of the appointment of the last appointed Advocate Arbitrator to agree upon and appoint a third arbitrator (&#147;<B>Neutral Arbitrator</B>&#148;) who shall be qualified under the same criteria
set forth hereinabove for qualification of the two Advocate Arbitrators, except that neither the Landlord or Tenant or either parties&#146; Advocate Arbitrator may, directly or indirectly, consult with the Neutral Arbitrator prior or subsequent to
his or her appointment and the Neutral Arbitrator shall not have been engaged by either Landlord or Tenant within the seven (7)&nbsp;years preceding. The Neutral Arbitrator shall be retained via an engagement letter jointly prepared by
Landlord&#146;s counsel and Tenant&#146;s counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.3.3&#8194;&#8195;The three arbitrators shall, within thirty
(30)&nbsp;days of the appointment of the Neutral Arbitrator, reach a decision as to whether the parties shall use </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
Landlord&#146;s or Tenant&#146;s submitted Option Rent, and shall notify Landlord and Tenant thereof. The determination of the arbitrators shall be limited solely to the issue of whether
Landlord&#146;s or Tenant&#146;s submitted Option Rent is the closest to the actual Option Rent, taking into account the requirements of <U>Section</U><U></U><U>&nbsp;2.2.2</U> of this Lease, as determined by the arbitrators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.3.4&#8194;&#8195;The decision of the majority of the three arbitrators shall be binding upon Landlord and Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.3.5&#8194;&#8195;If either Landlord or Tenant fails to appoint an Advocate Arbitrator within twenty (20)&nbsp;days after
the Outside Agreement Date, then either party may petition the presiding judge of the Superior Court of San Mateo County to appoint such Advocate Arbitrator subject to the criteria in <U>Section</U><U></U><U>&nbsp;2.2.3.1</U> of this Lease, or if he
or she refuses to act, either party may petition any judge having jurisdiction over the parties to appoint such Advocate Arbitrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.3.6&#8194;&#8195;If the two (2)&nbsp;Advocate Arbitrators fail to agree upon and appoint the Neutral Arbitrator within
ten (10)&nbsp;business days after the appointment of the last appointed Advocate Arbitrator, then either party may petition the presiding judge of the Superior Court of San Mateo County to appoint the Neutral Arbitrator, subject to criteria in
<U>Section</U><U></U><U>&nbsp;2.2.3.2</U> of this Lease, or if he or she refuses to act, either party may petition any judge having jurisdiction over the parties to appoint such arbitrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.3.7&#8194;&#8195;The cost of the arbitration shall be paid by Landlord and Tenant equally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.3.8&#8194;&#8195;In the event that the Option Rent shall not have been determined pursuant to the terms hereof prior to
the commencement of the Option Term, Tenant shall be required to pay as Option Rent, an amount equal to 103% of the Base Rent payable by Tenant as of the expiration of the initial Lease Term, and upon the final determination of the Option Rent, the
payments made by Tenant shall be reconciled with the actual amounts of Option Rent due, and the appropriate party shall make any corresponding payment to the other party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>3.&#8195;&#8194;BASE RENT </B>Tenant shall pay, without prior notice or demand, to Landlord or Landlord&#146;s agent at the management
office of the Project, or, at Landlord&#146;s option, at such other place as Landlord may from time to time designate in writing, by a check for currency which, at the time of payment, is legal tender for private or public debts in the United States
of America, base rent (&#147;<B>Base Rent</B>&#148;) as set forth in Section 4 of the Summary, payable in equal monthly installments as set forth in Section 4 of the Summary in advance on or before the first day of each and every calendar month
during the Lease Term, without any setoff or deduction whatsoever. The Base Rent for the first full month of the Lease Term shall be paid on or before January 15, 2020. If any Rent payment date (including the Lease Commencement Date) falls on a day
of the month other than the first day of such month or if any payment of Rent is for a period which is shorter than one month, the Rent for any fractional month shall accrue on a daily basis for the period from the date such payment is due to the
end of such calendar month or to the end of the Lease Term at a rate per day which is equal to 1/365 of the applicable annual Rent. All other payments or adjustments required to be made under the terms of this Lease that require proration on a time
basis shall be prorated on the same basis.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>ADDITIONAL RENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.1&#8194;&#8195;<B><U>General Terms</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.1.1&#8194;&#8195;<B><U>Direct Expenses; Additional Rent</U></B>. In addition to paying the Base Rent specified in
<U>Article 3</U> of this Lease, Tenant shall pay &#147;<B>Tenant&#146;s Share</B>&#148; of the annual &#147;<B>Direct Expenses</B>,&#148; as those terms are defined in <U>Sections 4.2.6 and 4.2.2</U> of this Lease, respectively. Such payments by
Tenant, together with any and all other amounts payable by Tenant to Landlord pursuant to the terms of this Lease, are hereinafter collectively referred to as the &#147;<B>Additional Rent</B>&#148;, and the Base Rent and the Additional Rent are
herein collectively referred to as &#147;<B>Rent</B>.&#148; All amounts due under this <U>Article 4</U> as Additional Rent shall be payable for the same periods and in the same manner as the Base Rent. Without limitation on other obligations of
Tenant which survive the expiration of the Lease Term, the obligations of Tenant to pay the Additional Rent provided for in this <U>Article 4</U> shall survive the expiration of the Lease Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.1.2&#8194;&#8195;<B><U>Triple Net Lease</U></B>. Landlord and Tenant acknowledge that, except as otherwise provided to the
contrary in this Lease, it is their intent and agreement that this Lease be a &#147;<B>TRIPLE NET</B>&#148; lease and that as such, the provisions contained in this Lease are intended to pass on to Tenant or reimburse Landlord for the costs and
expenses reasonably associated with this Lease, the Building and the Project, and Tenant&#146;s operation therefrom, subject to the terms and provisions of this Lease. To the extent such costs and expenses payable by Tenant cannot be charged
directly to, and paid by, Tenant, such costs and expenses shall be paid by Landlord but reimbursed by Tenant as Additional Rent, subject to the terms and conditions of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2&#8194;&#8195;<B><U>Definitions of Key Terms Relating to Additional Rent</U></B>. As used in this <U>Article 4</U>, the
following terms shall have the meanings hereinafter set forth: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.1&#8194;&#8195;Intentionally Deleted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.2&#8194;&#8195;&#147;Direct Expenses&#148; shall mean &#147;Operating Expenses&#148; and &#147;Tax Expenses.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.3&#8194;&#8195;&#147;<B>Expense Year</B>&#148; shall mean each calendar year in which any portion of the Lease Term
falls, through and including the calendar year in which the Lease Term expires, provided that Landlord, upon notice to Tenant, may change the Expense Year from time to time to any other twelve (12)&nbsp;consecutive month period, and, in the event of
any such change, Tenant&#146;s Share of Direct Expenses shall be equitably adjusted for any Expense Year involved in any such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.4&#8194;&#8195;&#147;<B>Operating Expenses</B>&#148; shall mean, subject to the terms of this Section&nbsp;4.2.4 below,
all expenses, costs and amounts of every kind and nature which Landlord pays or accrues during any Expense Year because of or in connection with the ownership, management, maintenance, security, repair, replacement, restoration or operation of the
Project, or any portion thereof, in accordance with sound real estate management and accounting practices, consistently applied. For the avoidance of doubt, whether any given type of Operating Expenses shall be included either as paid or as accrued
during an Expense Year (but not both as paid and as accrued) and the manner of accounting as to such type of Operating Expense shall be maintained consistently throughout the Lease Term. Without limiting the generality of the foregoing, Operating
Expenses shall specifically include any and all of the following: (i)&nbsp;the cost of supplying </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
all utilities to the Project, but excluding the cost of electricity consumed in the Premises and the cost of utilities consumed in the premises of other tenants of the Project, the cost of
operating, repairing, maintaining, and renovating the utility, telephone, mechanical, sanitary, storm drainage, and elevator systems, and the cost of maintenance and service contracts in connection therewith; (ii)&nbsp;the cost of licenses,
certificates, permits and inspections and the cost of contesting any governmental enactments which may affect Operating Expenses, and the costs incurred in connection with a governmentally mandated transportation system management program or similar
program; (iii)&nbsp;the cost of all insurance carried by Landlord in connection with the Project and Premises as reasonably determined by Landlord; (iv)&nbsp;the cost of landscaping, relamping, and all supplies, tools, equipment and materials used
in the operation, repair and maintenance of the Project, or any portion thereof; (v)&nbsp;the cost of operation, repair, restoration, and maintenance of the parking areas serving the Premises; (vi)&nbsp;fees and other costs, including management
and/or incentive fees, consulting fees, legal fees and accounting fees, of all contractors and consultants in connection with the management, operation, maintenance and repair of the Project, provided that if any such fees are paid to parties who
provide such services for more than one building or project, then only the prorated portion of those fees reflecting the percentage of such parties&#146; time devoted to the Project shall be included in Operating Expenses; (vii)&nbsp;payments under
any equipment rental agreements and the fair rental value of any management office space; (viii)&nbsp;subject to item (f), below, wages, salaries and other compensation and benefits, including taxes levied thereon, of all persons engaged in the
operation, maintenance and security of the Project; (ix)&nbsp;costs under any instrument pertaining to the sharing of costs by the Project (other than persons who are higher than the rank of the person who supervises property managers that manage
the Project and other projects of Landlord or its affiliates); (x) operation, repair, maintenance and replacement of all systems and equipment and components thereof of the Project, but only to the extent such costs would otherwise qualify as
Operating Expenses hereunder; (xi)&nbsp;the cost of janitorial, alarm, security and other services, replacement of wall and floor coverings, ceiling tiles and fixtures in common areas, maintenance and replacement of curbs and walkways, repair to
roofs and <FONT STYLE="white-space:nowrap">re-roofing</FONT> (subject to item (xiii)&nbsp;below) (but excluding any of the foregoing provided to the premises of other tenants of the Project to the extent Tenant is providing such services to the
Premises hereunder); (xii) amortization (including commercially reasonable interest on the unamortized cost) over the useful life in accordance with sound real estate management and accounting practices, consistently applied, of the cost of
acquiring or the rental expense of personal property used in the maintenance, operation and repair of the Project, or any portion thereof; (xiii)&nbsp;the cost of capital improvements (A)&nbsp;which are intended to effect economies in the operation
or maintenance of the Project, or any portion thereof, or to reduce current or future Operating Expenses (to the extent of cost savings reasonably anticipated by Landlord (based on reasonable industry standards)) or to enhance the safety or security
of the Project or its occupants, (B)&nbsp;which are required to comply with present or future mandatory conservation programs, (C)&nbsp;which are replacements or modifications of nonstructural items located in the Common Areas required to keep the
Common Areas in good order or condition, (D)&nbsp;that are required under Applicable Laws enacted or first enforced after the Lease Commencement Date (the &#147;<B>Reimbursable Capital Improvements</B>&#148;); provided, however, that any capital
expenditure shall be amortized (including interest on the amortized cost) over such period of time as Landlord shall reasonably determine, in accordance with sound real estate management and accounting principles, consistently applied; and
(xiv)&nbsp;costs, fees, charges or assessments imposed by, or resulting from any mandate imposed on Landlord by, any federal, state or local government for fire and police protection, trash removal, community services, or other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
services which do not constitute &#147;Tax Expenses&#148; as that term is defined in <U>Section</U><U></U><U>&nbsp;4.2.5</U>, below, (xv)&nbsp;cost of tenant relation programs reasonably
established by Landlord, and (xvi)&nbsp;payments under any easement, license, operating agreement, declaration, restrictive covenant, or instrument pertaining to the sharing of costs by the Building, including, without limitation, any covenants,
conditions and restrictions affecting the property, and reciprocal easement agreements affecting the property, any parking licenses, and any agreements with transit agencies affecting the Property (collectively, &#147;<B>Underlying
Documents</B>&#148;) provided, however, Tenant shall not be charged twice for the same expense. Notwithstanding the foregoing or anything to the contrary in this Lease, Operating Expenses shall not, however, include: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(a)&#8195;any costs, including legal fees, space planners&#146; fees, advertising and promotional expenses
(except as otherwise set forth above), and brokerage fees incurred in connection with the original construction or development of the Project, or the original, current or future leasing of the Project, and costs, including permit, license and
inspection costs, incurred with respect to the installation of tenant improvements made for any tenants or other occupants of the Project or incurred in renovating or otherwise altering, improving, decorating, painting or redecorating space for
tenants or other occupants of the Project; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(b)&#8195;except as set forth in items (xii), (xiii), and
(xiv)&nbsp;above, depreciation, interest and principal payments on mortgages and other debt costs, if any, penalties and interest; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(c)&#8195;costs for which the Landlord is reimbursed by any tenant or occupant of the Project or by insurance
by its carrier or any tenant&#146;s carrier or by anyone else, and electric power costs for which any tenant directly contracts with the local public service company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(d)&#8195;any bad debt loss, rent loss, or reserves for bad debts or rent loss; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(e)&#8195;any costs associated with the operation of the business of the partnership or entity which
constitutes Landlord, as the same are distinguished from the costs of operation of the Project (which shall specifically include, but not be limited to, accounting costs associated with the operation of the Project). Costs associated with the
operation of the business of the partnership or entity which constitutes the Landlord include costs of partnership accounting and legal matters, costs of defending any lawsuits with any mortgagee (except as the actions of the Tenant may be in
issue), costs of selling, syndicating, financing, mortgaging or hypothecating any of Landlord&#146;s interest in the Project, and costs incurred in connection with any disputes between Landlord and its employees, between Landlord and Project
management, or between Landlord and any other tenants or occupants; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(f)&#8195;the wages and benefits of
any employee who does not devote substantially all of his or her employed time to the Project unless such wages and benefits are prorated to reflect time spent on operating and managing the Project <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">vis-a-vis</FONT></FONT> time spent on matters unrelated to operating and managing the Project; provided, that in no event shall Operating Expenses for purposes of this Lease include wages and/or benefits attributable to
personnel above the level of Project manager; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(g)&#8195;amount paid as ground rental or rental for the
Project by Landlord; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(h)&#8195;except for a Project management fee to the extent allowed pursuant to
item (v)&nbsp;below, overhead and profit increment paid to the Landlord or to subsidiaries or affiliates of the Landlord for services in the Project to the extent the same exceeds the costs of such services rendered by qualified, first- class
unaffiliated third parties on a competitive basis; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(i)&#8195;any compensation paid to clerks, attendants
or other persons in commercial concessions operated by the Landlord, provided that any compensation paid to any concierge at the Project shall be includable as an Operating Expense; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(j)&#8195;rentals and other related expenses incurred in leasing air conditioning systems, elevators or other
equipment which if purchased the cost of which would be excluded from Operating Expenses as a capital cost, except equipment not affixed to the Project which is used in providing engineering, janitorial or similar services and, further excepting
from this exclusion such equipment rented or leased to remedy or ameliorate an &#147;Emergency&#148; condition in the Project (as defined below); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(k)&#8195;all items and services for which Tenant or any other tenant in the Project reimburses Landlord or
which Landlord provides selectively to one or more tenants (other than Tenant) without reimbursement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(l)&#8195;any costs expressly excluded from Operating Expenses elsewhere in this Lease; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(m)&#8195;rent for any office space occupied by Project management personnel to the extent the size or rental
rate of such office space exceeds the size or fair market rental value of office space occupied by management personnel of Comparable Buildings, with adjustment where appropriate for the size of the applicable project; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(n)&#8195;costs arising from the negligence or willful misconduct of Landlord in connection with this Lease;
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(o)&#8195;costs incurred to comply with Applicable Laws relating to the removal of Hazardous
Material (as defined below) which was in existence in the Building or on the Project prior to the Lease Commencement Date; and costs incurred to remove, remedy, investigate, monitor, contain, or treat Hazardous Material, which Hazardous Material is
not brought into the Building or onto the Project Tenant or any Tenant Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(p)&#8195;Landlord&#146;s
general corporate overhead and general and administrative expenses; provided that nothing herein should be deemed to prohibit Landlord from charging the management fee allowed pursuant to clause (v)&nbsp;below; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(q)&#8195;any costs of correcting major and/or latent defects in, or design error relating to, the design or
construction of the Project; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(r)&#8195;any costs arising from Landlord&#146;s political
or charitable contributions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(s)&#8195;any costs, other than those incurred in ordinary maintenance and
repair, for sculpture, paintings, fountains or other objects of art; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(t)&#8195;any costs of capital
repairs, replacements, alterations, improvements and equipment other than Reimbursable Capital Improvements; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(u)&#8195;any costs in connection with services or other benefits which are not offered and/or provided to
Tenant or for which Tenant is charged directly but which are provided to another tenant or occupant of the Project without a separate charge; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(v)&#8195;fees payable by Landlord for management of the Project in excess of percent (3%) (the
&#147;<B>Management Fee Cap</B>&#148;) of Landlord&#146;s gross rental revenues, adjusted and grossed up to reflect a one hundred percent (100%) occupancy of the Project with all tenants paying full rent, as contrasted with free rent, half-rent and
the like, including base rent, pass-throughs, and parking fees from the Project for any calendar year or portion thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(w)&#8195;any costs incurred in the performance of any Landlord warranty given hereunder or as a result of
Landlord&#146;s breach of any warranty given hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(x)&#8195;costs to remedy, or penalties relating
to, any violation of Applicable Laws by Landlord or Landlord Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.5&#8194;&#8195;<B><U>Taxes</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.5.1&#8195;&#147;<B>Tax Expenses</B>&#148; shall mean all federal, state, county, or local governmental or municipal
taxes, fees, charges or other impositions of every kind and nature, whether general, special, ordinary or extraordinary (including, without limitation, real estate taxes, general and special assessments, transit taxes, leasehold taxes or taxes based
upon the receipt of rent, including gross receipts or sales taxes applicable to the receipt of rent, unless required to be paid by Tenant, personal property taxes imposed upon the fixtures, machinery, equipment, apparatus, systems and equipment,
appurtenances, furniture and other personal property used in connection with the Project, or any portion thereof), which shall be paid or accrued during any Expense Year (without regard to any different fiscal year used by such governmental or
municipal authority) because of or in connection with the ownership, leasing and operation of the Project, or any portion thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.5.2&#8195;Tax Expenses shall include, without limitation: (i)&nbsp;Any tax on the rent, right to rent or other income
from the Project, or any portion thereof, or as against the business of leasing the Project, or any portion thereof; (ii)&nbsp;Any assessment, tax, fee, levy or charge in addition to, or in substitution, partially or totally, of any assessment, tax,
fee, levy or charge previously included within the definition of real property tax; (iii)&nbsp;Any assessment, tax, fee, levy, or charge allocable to or measured by the area of the Premises or the Rent payable hereunder, including, without
limitation, any business or gross income tax or excise tax with respect to the receipt of such rent, or upon or with respect to the possession, leasing, operating, management, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
maintenance, alteration, repair, use or occupancy by Tenant of the Premises, or any portion thereof; and (iv)&nbsp;Any assessment, tax, fee, levy or charge, upon this transaction or any document
to which Tenant is a party, creating or transferring an interest or an estate in the Premises or the improvements thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.5.3&#8195;Any costs and expenses (including, without limitation, reasonable attorneys&#146; and consultants&#146; fees)
incurred in attempting to protest, reduce or minimize Tax Expenses shall be included in Tax Expenses in the Expense Year such expenses are incurred. Tax refunds shall be credited against Tax Expenses and refunded to Tenant regardless of when
received, based on the Expense Year to which the refund is applicable, provided that in no event shall the amount to be refunded to Tenant for any such Expense Year exceed the total amount paid by Tenant as Additional Rent under this Article 4 for
such Expense Year. If Tax Expenses for any period during the Lease Term or any extension thereof are increased after payment thereof for any reason, including, without limitation, error or reassessment by applicable governmental or municipal
authorities, Tenant shall pay Landlord within thirty (30)&nbsp;days after receipt of Landlord&#146;s invoice therefor Tenant&#146;s Share of any such increased Tax Expenses. Notwithstanding anything to the contrary contained in this
<U>Section</U><U></U><U>&nbsp;4.2.5</U>, there shall be excluded from Tax Expenses (i)&nbsp;all excess profits taxes, franchise taxes, gift taxes, capital stock taxes, inheritance and succession taxes, estate taxes, federal and state income taxes,
and other taxes to the extent applicable to Landlord&#146;s net income (as opposed to rents, receipts or income attributable to operations at the Project), (ii) any items included as Operating Expenses, (iii)&nbsp;any items paid by Tenant under
<U>Section</U><U></U><U>&nbsp;4.5</U> of this Lease, (iv)&nbsp;any delinquent Tax Expenses for any period prior to the first Expense Year regardless of when actually paid; and (v)&nbsp;any penalties or interest that derive from Landlord&#146;s
failure to pay Tax Expenses to the applicable governmental authority on a timely basis; . </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.6&#8195;&#147;<B>Tenant&#146;s Share</B>&#148; shall mean the percentage set forth in <U>Section</U><U></U><U>&nbsp;6</U>
of the Summary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.3&#8194;&#8195;<B><U>Allocation of Direct Expenses</U></B>. The parties acknowledge that the Building
is a part of a multi- building project and that the costs and expenses incurred in connection with the Project (i.e., the Direct Expenses) should be equitably, reasonably, and consistently shared between the Building and the other buildings in the
Project. Accordingly, as set forth in <U>Section</U><U></U><U>&nbsp;4.2</U> above, Direct Expenses are determined annually for the Project as a whole, and a portion of the Direct Expenses, which portion shall be determined by Landlord on an
equitable and consistent basis, shall be allocated to the Building (as opposed to other buildings in the Project). Such portion of Direct Expenses allocated to the Building shall include all Direct Expenses attributable solely to the Building and an
equitable portion of the Direct Expenses attributable to the Project as a whole, and shall not include Direct Expenses attributable solely to other buildings in the Project. For purposes of allocating such Direct Expenses, those Direct Expenses not
reasonably attributable exclusively to a building shall be allocated on a rentable square foot basis except where otherwise dictated by prudent commercial property management and accounting practices or to achieve an equitable and customary
allocation of Direct Expenses; provided, in either case, that such method of allocation is consistent with standard industry practice and Landlord does not discriminate against Tenant in connection with the determination of the method of allocation.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.4&#8194;&#8195;<B><U>Calculation and Payment of Additional Rent</U></B>.
Tenant shall pay to Landlord, in the manner set forth in <U>Section</U><U></U><U>&nbsp;4.4.1</U>, below, and as Additional Rent, Tenant&#146;s Share of Direct Expenses for each Expense Year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.4.1&#8194;&#8195;<B><U>Statement of Actual Direct Expenses and Payment by Tenant</U></B>. Landlord shall give to Tenant
following the end of each Expense Year, an itemized statement (the &#147;<B>Statement</B>&#148;) which shall state the Direct Expenses actually incurred or accrued for the preceding Expense Year, and the amount of Tenant&#146;s Share of such Direct
Expenses. Landlord shall endeavor to deliver such Statement within five (5)&nbsp;months following the end of the applicable Expense Year. Upon receipt of the Statement for each Expense Year commencing or ending during the Lease Term, Tenant shall
pay, with its next installment of Base Rent due (which is at least thirty (30)&nbsp;days following the date of Tenant&#146;s receipt of the Statement), the full amount of Tenant&#146;s Share of Direct Expenses for such Expense Year, less the
amounts, if any, paid during such Expense Year as &#147;<B>Estimated Direct Expenses</B>,&#148; as that term is defined in <U>Section</U><U></U><U>&nbsp;4.4.2</U>, below, and if Tenant paid more as Estimated Direct Expenses than the actual
Tenant&#146;s Share of Direct Expenses, Tenant shall receive a credit in the amount of Tenant&#146;s overpayment against Rent next due under this Lease. The failure of Landlord to timely furnish the Statement for any Expense Year shall not prejudice
Landlord or Tenant from enforcing its rights under this <U>Article 4</U>. Even though the Lease Term has expired and Tenant has vacated the Premises, when the final determination is made of Tenant&#146;s Share of Direct Expenses for the Expense Year
in which this Lease terminates, Tenant shall immediately pay to Landlord such amount, and if Tenant paid more as Estimated Direct Expenses than the actual Tenant&#146;s Share of Direct Expenses, Landlord shall, within thirty (30)&nbsp;days, deliver
a check payable to Tenant in the amount of the overpayment. The provisions of this <U>Section</U><U></U><U>&nbsp;4.4.1</U> shall survive the expiration or earlier termination of the Lease Term. Notwithstanding the immediately preceding sentence,
Tenant shall not be responsible for Tenant&#146; s Share of any Direct Expenses attributable to any Expense Year which are first billed to Tenant more than two (2)&nbsp;calendar years after the earlier of the expiration of the applicable Expense
Year or the Lease Expiration Date, provided that in any event Tenant shall be responsible for Tenant&#146; s Share of Direct Expenses levied by any governmental authority or by any public utility companies at any time following the Lease Expiration
Date which are attributable to any Expense Year (provided that Landlord delivers Tenant a bill for such amounts within two (2)&nbsp;years following Landlord&#146; s receipt of the bill therefor). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.4.2&#8194;&#8195;<B><U>Statement of Estimated Direct Expenses</U></B>. In addition, Landlord shall give Tenant a yearly
expense estimate statement (the &#147;<B>Estimate Statement</B>&#148;) which shall set forth Landlord&#146;s reasonable estimate (the &#147;<B>Estimate</B>&#148;) of what the total amount of Direct Expenses for the then-current Expense Year shall be
and the estimated Tenant&#146;s Share of Direct Expenses (the &#147;<B>Estimated Direct Expenses</B>&#148;). Landlord shall endeavor to deliver such Estimate Statement within five (5)&nbsp;months following the end of the applicable Expense Year. The
failure of Landlord to timely furnish the Estimate Statement for any Expense Year shall not preclude Landlord from enforcing its rights to collect any Estimated Direct Expenses under this <U>Article 4</U>, nor shall Landlord be prohibited from
revising any Estimate Statement or Estimated Direct Expenses theretofore delivered to the extent necessary. Thereafter, Tenant shall pay, with its next installment of Base Rent due, a fraction of the Estimated Direct Expenses for the then-current
Expense Year (reduced by any amounts paid pursuant to the last sentence of this <U>Section</U><U></U><U>&nbsp;4.4.2</U>). Such fraction shall have as its numerator the number of months which have elapsed in such current Expense Year, including the
month of such payment, and twelve (12)&nbsp;as its denominator. Until a new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
Estimate Statement is furnished (which Landlord shall have the right to deliver to Tenant at any time), Tenant shall pay monthly, with the monthly Base Rent installments, an amount equal to <FONT
STYLE="white-space:nowrap">one-twelfth</FONT> (1/12) of the total Estimated Direct Expenses set forth in the previous Estimate Statement delivered by Landlord to Tenant. Landlord shall maintain complete records with respect to the Direct Expenses in
accordance with sound real estate management and accounting practices, consistently applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.5&#8194;&#8195;<B><U>Taxes
and Other Charges for Which Tenant Is Directly Responsible</U></B>. Tenant shall be liable for and shall pay before delinquency, taxes levied against Tenant&#146;s equipment, furniture, fixtures and any other personal property located in or about
the Premises, subject to Tenant&#146;s right to contest such taxes in accordance with Applicable Laws. If any such taxes on Tenant&#146;s equipment, furniture, fixtures and any other personal property are levied against Landlord or Landlord&#146;s
property or if the assessed value of Landlord&#146;s property is increased by the inclusion therein of a value placed upon such equipment, furniture, fixtures or any other personal property and if Landlord pays the taxes based upon such increased
assessment, which Landlord shall have the right to do regardless of the validity thereof but only under proper protest if requested by Tenant, Tenant shall upon demand repay to Landlord the taxes so levied against Landlord or the proportion of such
taxes resulting from such increase in the assessment, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.6&#8194;&#8195;<B><U>Landlord&#146;s Books
and Records</U></B>. Within one hundred twenty (120)&nbsp;days after receipt by Tenant of a Statement, if Tenant disputes the amount of Additional Rent set forth in the Statement, a member of Tenant&#146;s finance department, or an independent
certified public accountant (which accountant is a member of a nationally recognized accounting firm and is not working on a contingency fee basis) (&#147;<B>Tenant&#146;s Accountant</B>&#148;), designated and paid for by Tenant, may, after
reasonable notice to Landlord and at reasonable times, inspect Landlord&#146;s records with respect to the Statement at Landlord&#146;s offices, provided that there is no existing Event of Default and Tenant has paid all amounts required to be paid
under the applicable Estimate Statement and Statement, as the case may be. In connection with such inspection, Tenant and Tenant&#146;s agents must agree in advance to follow Landlord&#146;s reasonable rules and procedures regarding inspections of
Landlord&#146;s records, and shall execute a commercially reasonable confidentiality agreement regarding such inspection. Tenant&#146;s failure to dispute the amount of Additional Rent set forth in any Statement within one hundred twenty
(120)&nbsp;days of Tenant&#146;s receipt of such Statement shall be deemed to be Tenant&#146;s approval of such Statement and Tenant, thereafter, waives the right or ability to dispute the amounts set forth in such Statement. If after such
inspection, Tenant still disputes such Additional Rent, a determination as to the proper amount shall be made, at Tenant&#146;s expense, by an independent certified public accountant (the &#147;<B>Accountant</B>&#148;) selected by Landlord and
subject to Tenant&#146;s reasonable approval; provided that if such Accountant determines that Direct Expenses were overstated by more than five percent (5%), then the cost of the Accountant and the cost of such determination shall be paid for by
Landlord, and Landlord shall reimburse Tenant for the cost of the Tenant&#146;s Accountant (provided that such cost shall be a reasonable market cost for such services). Following such final determination of Direct Expenses, Landlord or Tenant shall
promptly make or credit the appropriate amounts to the other. Tenant hereby acknowledges that Tenant&#146;s sole right to inspect Landlord&#146;s books and records and to contest the amount of Direct Expenses payable by Tenant shall be as set forth
in this <U>Section</U><U></U><U>&nbsp;4.6</U>, and Tenant hereby waives any and all other rights pursuant to Applicable Law to inspect such books and records and/or to contest the amount of Direct Expenses payable by Tenant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>5.&#8194;&#8195;USE OF PREMISES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.1&#8194;&#8195;<B><U>Permitted Use</U></B>. Tenant shall use the Premises solely for the Permitted Use set forth in
<U>Section</U><U></U><U>&nbsp;7</U> of the Summary and Tenant shall not use or knowingly permit the Premises or the Project to be used for any other purpose or purposes whatsoever without the prior written consent of Landlord, which may be withheld
in Landlord&#146;s sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.2&#8194;&#8195;<B><U>Prohibited Uses</U></B>. Tenant further covenants and agrees
that Tenant shall not use, or knowingly suffer or permit any person or persons to use, the Premises or any part thereof for any use or purpose in violation of Applicable Laws including, without limitation, any such Applicable Laws relating to
Hazardous Materials, or any Underlying Documents. Landlord shall have the right to impose reasonable and customary rule and regulations (&#147;<B>Rules and Regulations</B>&#148;) regarding the use of the Project, as reasonably deemed necessary by
Landlord with respect to the orderly operation of the Project, and Tenant shall comply with such reasonable rules and regulations; provided that (i)&nbsp;Landlord shall not enforce, change or modify such rules and regulations in a discriminatory
manner, (ii)&nbsp;such rules and regulations shall do not unreasonably interfere with the normal and customary conduct of Tenant&#146;s business, (iii)&nbsp;any such rules and regulations shall not materially increase Tenant&#146;s obligations
hereunder, materially decrease Tenant&#146;s rights hereunder, or materially decrease Landlord&#146;s obligations hereunder, and (iv)&nbsp;Landlord shall provide Tenant with at least thirty (30)&nbsp;days&#146; prior written notice of any such rules
and regulations. To the extent there is any conflict between the provisions of this Lease and any such rules and regulations, the provisions of this Lease shall control. Tenant shall not do or permit anything to be done in or about the Premises
which will in any way obstruct or interfere with the rights of other tenants or occupants of the Building, or injure or annoy them or use or allow the Premises to be used for any improper, unlawful or objectionable purpose, nor shall Tenant cause,
maintain or permit any nuisance in, on or about the Premises. Tenant shall comply with, and Tenant&#146;s rights and obligations under the Lease and Tenant&#146;s use of the Premises shall be subject and subordinate to, all recorded easements,
covenants, conditions, and restrictions now or hereafter affecting the Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3&#8194;&#8195;<B><U>Hazardous
Materials</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.1&#8194;&#8195;<B><U>Tenant&#146;s Obligations</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.1.1&#8194;&#8195;<B><U>Prohibitions</U></B>. As a material inducement to Landlord to enter into this Lease with Tenant,
Tenant has fully and accurately completed Landlord&#146;s <FONT STYLE="white-space:nowrap">Pre-Leasing</FONT> Environmental Exposure Questionnaire (the &#147;<B>Environmental Questionnaire</B>&#148;), which is attached as <B><U>Exhibit E</U></B>.
Tenant agrees that except for those chemicals or materials, and their respective quantities, specifically listed on the Environmental Questionnaire (as the same may be updated by Tenant) and ordinary office and cleaning supplies, neither Tenant nor
Tenant&#146;s employees, contractors and subcontractors of any tier, entities with a contractual relationship with Tenant (other than Landlord), or any entity acting as an agent or <FONT STYLE="white-space:nowrap">sub-agent</FONT> of Tenant
(collectively, &#147;<B>Tenant&#146;s Agents</B>&#148;) will produce, use, store or generate any &#147;Hazardous Materials,&#148; as that term is defined below, on, under or about the Premises, nor cause or permit any Hazardous Material to be
brought upon, placed, stored, manufactured, generated, blended, handled, recycled, used or &#147;Released,&#148; as that term is defined below, on, in, under or about the Premises in violation of Environmental Law. Upon Landlord&#146;s written
request (but no more than once each Lease Year), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
or in the event of any material change in Tenant&#146;s use of Hazardous Materials resulting in a new class or category of Hazardous Materials being used in the Premises from that set forth in
the Environmental Questionnaire then in place (i.e., changes in non Hazardous Materials or reasonable changes to the amounts or types of Hazardous Materials in the same category are exempt), Tenant shall deliver to Landlord an updated Environmental
Questionnaire. Landlord&#146;s prior written consent shall be required to any Hazardous Materials use for the Premises not described on the initial Environmental Questionnaire, to the extent such use would result in a new class or category of
Hazardous Materials being used in the Premises, such consent to be withheld in Landlord&#146;s reasonable discretion. Tenant shall not install or permit any underground storage tank on the Premises. For purposes of this Lease, &#147;<B>Hazardous
Materials</B>&#148; means all flammable explosives, petroleum and petroleum products, waste oil, radon, radioactive materials, toxic pollutants, asbestos, polychlorinated biphenyls (&#147;<B>PCBs</B>&#148;), medical waste, chemicals known to cause
cancer or reproductive toxicity, pollutants, contaminants, hazardous wastes, toxic substances or related materials, including without limitation any chemical, element, compound, mixture, solution, substance, object, waste or any combination thereof,
which is or may be hazardous to human health, safety or to the environment due to its radioactivity, ignitability, corrosiveness, reactivity, explosiveness, toxicity, carcinogenicity, infectiousness or other harmful or potentially harmful properties
or effects, or defined as, regulated as or included in, the definition of &#147;hazardous substances,&#148; &#147;hazardous wastes,&#148; &#147;hazardous materials,&#148; or &#147;toxic substances&#148; under any Environmental Laws. The term
&#147;Hazardous Materials&#148; for purposes of this Lease shall also include any mold, fungus or spores, whether or not the same is defined, listed, or otherwise classified as a &#147;hazardous material&#148; under any Environmental Laws, if such
mold, fungus or spores may pose a risk to human health or the environment or negatively impact the value of the Premises. For purposes of this Lease, &#147;<B>Release</B>&#148; or &#147;<B>Released</B>&#148; or &#147;<B>Releases</B>&#148; shall mean
any release, deposit, discharge, emission, leaking, spilling, seeping, migrating, injecting, pumping, pouring, emptying, escaping, dumping, disposing, or other movement of Hazardous Materials into the environment, not in compliance with
Environmental Laws or a validly issued permit. Landlord acknowledges that Tenant will be installing and using fume hoods in the Premises and that emissions of Hazardous Materials into the air in compliance with all Environmental Laws shall not be
considered Releases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.1.2&#8194;&#8195;<B><U>Notices to Landlord</U></B>. Tenant shall notify Landlord in writing as
soon as reasonably possible after discovery by Tenant but in no event later than five (5)&nbsp;days after (i)&nbsp;Tenant becomes aware of the occurrence of any actual Release of any Hazardous Material caused by Tenant or Tenant&#146;s Agents at or
from the Premises, or (ii)&nbsp;Tenant receives written notice of any regulatory actions, inquiries, inspections, investigations, directives, or any cleanup, compliance, enforcement or abatement proceedings (including any threatened or contemplated
investigations or proceedings) by governmental agencies against Tenant or a Tenant Agent relating to Releases of Hazardous Materials at the Premises, or (iii)&nbsp;Tenant receives written notice of any claims against Tenant or a Tenant Agent brought
by any person or entity relating to Releases of Hazardous Materials at or from, the Premises, whether relating to damage, contribution, cost recovery, compensation, loss or injury. Collectively, the matters set forth in clauses (i), (ii) and
(iii)&nbsp;above are hereinafter referred to as &#147;<B>Hazardous Materials Claims</B>&#148;. Tenant shall promptly forward to Landlord copies of all orders, notices, permits, applications and other communications and reports in connection with any
Hazardous Materials Claims. Tenant shall not enter into any legal proceeding or other action, settlement, consent decree or other compromise with respect to any Hazardous Materials Claims without first notifying Landlord of Tenant&#146;s intention
to do so </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
and affording Landlord, at Landlord&#146;s sole cost and expense, the opportunity to join and participate, as a party if Landlord so elects, in such proceedings and in no event shall Tenant enter
into any agreements which are binding on Landlord or the Premises without Landlord&#146;s prior written consent. If Landlord opts to join in such proceedings, Landlord shall not enter into any agreements which are binding on Tenant without
Tenant&#146;s prior written consent. Landlord shall have the right to appear at and participate in, any and all legal or other administrative proceedings concerning any Hazardous Materials Claim, at Landlord&#146;s sole cost and expense. For
purposes of this Lease, &#147;<B>Environmental Laws</B>&#148; means all applicable present and future laws relating to the protection of human health, safety, wildlife or the environment, including, without limitation, (i)&nbsp;all requirements
pertaining to reporting, licensing, permitting, investigation and/or remediation of emissions, discharges, Releases, or threatened Releases of Hazardous Materials, whether solid, liquid, or gaseous in nature, into the air, surface water,
groundwater, or land, or relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport, or handling of Hazardous Materials; and (ii)&nbsp;all requirements pertaining to the health and safety of employees or the
public. Environmental Laws include, but are not limited to, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 USC &#167; 9601, et seq., the Hazardous Materials Transportation Authorization Act of 1994, 49 USC
&#167; 5101, et seq., the Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976, and Hazardous and Solid Waste Amendments of 1984, 42 USC &#167; 6901, et seq., the Federal Water Pollution Control Act, as amended
by the Clean Water Act of 1977, 33 USC &#167; 1251, et seq., the Clean Air Act of 1966, 42 USC &#167; 7401, et seq., the Toxic Substances Control Act of 1976, 15 USC &#167; 2601, et seq., the Safe Drinking Water Act of 1974, 42 USC &#167;&#167; 300f
through 300j, the Occupational Safety and Health Act of 1970, as amended, 29 USC &#167; 651 et seq., the Oil Pollution Act of 1990, 33 USC &#167; 2701 et seq., the Emergency Planning and Community <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Right-To-Know</FONT></FONT> Act of 1986, 42 USC &#167; 11001 et seq., the National Environmental Policy Act of 1969, 42 USC &#167; 4321 et seq., the Federal Insecticide, Fungicide and Rodenticide Act of 1947, 7 USC &#167;
136 et seq., California Carpenter-Presley-Tanner Hazardous Substance Account Act, California Health&nbsp;&amp; Safety Code &#167;&#167; 25300 et seq., Hazardous Materials Release Response Plans and Inventory Act, California Health&nbsp;&amp; Safety
Code, &#167;&#167; 25500 et seq., Underground Storage of Hazardous Substances provisions, California Health&nbsp;&amp; Safety Code, &#167;&#167; 25280 et seq., California Hazardous Waste Control Law, California Health&nbsp;&amp; Safety Code,
&#167;&#167; 25100 et seq., and any other state or local law counterparts, as amended, as such Applicable Laws, are in effect as of the Lease Commencement Date, or thereafter adopted, published, or promulgated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.1.3&#8194;&#8195;<B><U>Releases of Hazardous Materials</U></B>. If any Release of any Hazardous Material by Tenant or
Tenant&#146;s Agents at or from the Premises caused by Tenant or Tenant&#146;s Agents shall occur at any time during the Lease Term, in addition to notifying Landlord as specified above, Tenant, at its sole cost and expense (as between Landlord and
Tenant), shall with respect to such Release (i)&nbsp;immediately comply with any and all reporting requirements imposed on Tenant pursuant to any and all Environmental Laws, (ii)&nbsp;provide a written statement to Landlord indicating that Tenant
has complied with all such reporting requirements, (iii)&nbsp;take any and all required investigation, corrective and remedial action in accordance with any and all applicable Environmental Laws, utilizing an environmental consultant reasonably
approved by Landlord, all in accordance with the provisions and requirements of this <B><U>Section</U></B><B><U></U></B><B><U>&nbsp;5.3</U></B>, including, without limitation, <B><U>Section</U></B><B><U></U></B><B><U>&nbsp;5.3.4</U></B>, and
(iv)&nbsp;cause the Premises to be remediated to the condition required to continue to allow the Permitted Use in the Building. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.1.4&#8194;&#8195;<B><U>Indemnification</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.1.4.1&#8194;&#8195;<B><U>In General</U></B>. Without limiting in any way Tenant&#146;s obligations under any other
provision of this Lease, Tenant shall protect, defend, indemnify and hold Landlord and the Landlord Parties harmless from and against any and all third-party claims, judgments, losses, damages, costs, expenses, penalties, enforcement actions, taxes,
fines, remedial actions, liabilities (including, without limitation, reasonable attorneys&#146; fees, litigation, arbitration and administrative proceeding costs, expert and consultant fees and laboratory costs) including, without limitation,
consequential damages and sums paid in settlement of claims, which arise during or after the Lease Term, whether foreseeable or unforeseeable, in whole or in part, directly or indirectly arising out of or attributable to the Release of Hazardous
Materials in, on, under or about the Premises by Tenant or Tenant&#146;s Agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.1.4.2&#8194;&#8195;<B><U>Limitations</U></B>. Notwithstanding anything in
<B><U>Section</U></B><B><U></U></B><B><U>&nbsp;5.3.1.4</U></B>, above, to the contrary, Tenant&#146;s indemnity of Landlord as set forth in <B><U>Section</U></B><B><U></U></B><B><U>&nbsp;5.3.1.4</U></B>, above, shall not be applicable to claims
based upon Hazardous Materials not Released by Tenant or Tenant&#146;s Agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.1.4.3&#8194;&#8195;<B><U>Landlord
Indemnity</U></B>. Under no circumstance shall Tenant be liable for, and Landlord shall indemnify, defend, protect and hold harmless Tenant and Tenant&#146;s Agents from and against, all third party losses, costs, claims, liabilities and damages
(including attorneys&#146; and consultants&#146; fees) arising out of any Hazardous Materials that exist in, on or about the Project as of the date hereof, or Hazardous Material Released by Landlord or any Landlord Parties. Landlord will provide
Tenant with any Hazardous Material reports relating to the Building or Project that Landlord has in its possession, or control. The provision of such reports shall be for informational purposes only, and Landlord does not make any representation or
warranty as to the correctness or completeness of any such reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.1.5&#8194;&#8195;<B><U>Compliance with
Environmental Laws</U></B>. Without limiting the generality of Tenant&#146;s obligation to comply with Applicable Laws as otherwise provided in this Lease, Tenant shall, at its sole cost and expense, comply with all Environmental Laws related to the
use of Hazardous Materials by Tenant and Tenant&#146;s Agents. Tenant shall obtain and maintain any and all necessary permits, licenses, certifications and approvals required under Environmental Laws for the use, handling, storage, and disposal of
any Hazardous Materials used, stored, generated, transported, handled, blended, or recycled by Tenant on the Premises. Landlord shall have a continuing right, without obligation, to require Tenant to obtain, and to review and inspect any and all
such permits, licenses, certifications and approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.2&#8194;&#8195;<B><U>Assurance of Performance</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.2.1&#8194;&#8195;<B><U>Environmental Assessments In General</U></B>. Landlord may, but shall not be required to, engage
from time to time such duly qualified and licensed environmental consultants as Landlord determines to be appropriate to perform environmental assessments of a scope reasonably determined by Landlord (an &#147;<B>Environmental Assessment</B>&#148;)
to assess Tenant&#146;s compliance with the requirements of this Lease with respect to Hazardous Materials. . </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.2.2&#8194;&#8195;<B><U>Costs of Environmental Assessments</U></B>. All
costs and expenses incurred by Landlord in connection with any such Environmental Assessment initially shall be paid by Landlord; provided that if any such Environmental Assessment shows that Tenant has caused a Release of Hazardous Materials at or
from the Premises, then all of the costs and expenses of such Environmental Assessment shall be reimbursed by Tenant as Additional Rent within ten (10)&nbsp;days after receipt of written demand therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.3&#8194;&#8195;<B><U>Tenant&#146;s Obligations upon Surrender</U></B>. At the expiration or earlier termination of the
Lease Term, Tenant, at Tenant&#146;s sole cost and expense, shall: (i)&nbsp;cause an Environmental Assessment of the Premises to be conducted in accordance with <B><U>Section</U></B><B><U></U></B><B><U>&nbsp;15.3</U></B>; (ii) cause all Hazardous
Materials brought onto the Premises by Tenant or Tenant&#146;s Agents to be removed from the Premises and disposed of in accordance with all Environmental Laws and as necessary to allow the Premises to be used for the purposes allowed as of the date
of this Lease; and (iii)&nbsp;cause to be removed all containers installed or used by Tenant or Tenant&#146;s Agents to store any Hazardous Materials on the Premises, and cause to be repaired any damage to the Premises caused by such removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.4&#8194;&#8195;<B><U><FONT STYLE="white-space:nowrap">Clean-up</FONT></U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.4.1&#8194;&#8195;<B><U>Environmental Reports; <FONT STYLE="white-space:nowrap">Clean-Up</FONT></U></B>. If any written
report, including any report containing results of any Environmental Assessment (an &#147;<B>Environmental Report</B>&#148;) shall indicate (i)&nbsp;that Tenant or Tenant&#146;s Agents caused a Release of Hazardous Materials at the Premises, which
Release of Hazardous Materials requires an investigation, characterization, monitoring, assessment, repair, closure, remediation, removal, or other <FONT STYLE="white-space:nowrap">clean-up</FONT> (the
&#147;<B><FONT STYLE="white-space:nowrap">Clean-up</FONT></B>&#148;) under Environmental Laws, Tenant shall immediately prepare and submit to Landlord within forty-five (45)&nbsp;days after receipt of the Environmental Report, a comprehensive plan,
subject to Landlord&#146;s reasonable review and comment, which review and comment Landlord shall promptly conduct and provide to Tenant specifying the actions to be taken by Tenant to perform the <FONT STYLE="white-space:nowrap">Clean-up</FONT> so
that the Premises are restored to the conditions required by this Lease. Upon Landlord&#146;s approval of the <FONT STYLE="white-space:nowrap">Clean-up</FONT> plan, which approval shall not be unreasonably withheld or delayed, Tenant shall, at
Tenant&#146;s sole cost and expense, without limitation on any rights and remedies of Landlord under this Lease, immediately implement such plan with a consultant reasonably acceptable to Landlord and proceed to
<FONT STYLE="white-space:nowrap">Clean-Up</FONT> Hazardous Materials Released by Tenant or Tenant&#146;s Agents, in accordance with Environmental Laws. If, within forty-five (45)&nbsp;days after receiving a copy of such Environmental Report, Tenant
fails either (a)&nbsp;to complete such <FONT STYLE="white-space:nowrap">Clean-up,</FONT> or (b)&nbsp;with respect to any <FONT STYLE="white-space:nowrap">Clean-up</FONT> that cannot be completed within such forty-five (45)&nbsp;day period, fails to
complete the <FONT STYLE="white-space:nowrap">Clean-up</FONT> in accordance with Environmental Laws and any governmental extensions granted to complete the <FONT STYLE="white-space:nowrap">Clean-up,</FONT> then Landlord shall have the right, but not
the obligation, and without waiving any other rights under this Lease, after written notice to Tenant and providing a reasonable time period for Tenant to cure, to carry out any <FONT STYLE="white-space:nowrap">Clean-up</FONT> recommended by the
Environmental Report or required by any governmental authority having jurisdiction over the Premises, and tender an indemnification claim to Tenant under Section&nbsp;5.3.1.4.1 of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.4.2&#8194;&#8195;<B><U>No Rent Abatement</U></B>. Tenant shall continue to pay all Rent due or accruing under this Lease
during any <FONT STYLE="white-space:nowrap">Clean-up,</FONT> and shall not be entitled to any reduction, offset or deferral of any Base Rent or Additional Rent due or accruing under this Lease during any such
<FONT STYLE="white-space:nowrap">Clean-up.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.4.3&#8194;&#8195;<B><U>Surrender of Premises</U></B>. Tenant shall
complete any <FONT STYLE="white-space:nowrap">Clean-up</FONT> prior to surrender of the Premises upon the expiration or earlier termination of this Lease. Tenant shall obtain and deliver to Landlord a letter or other written determination from the
overseeing governmental authority confirming that the <FONT STYLE="white-space:nowrap">Clean-up</FONT> has been completed in accordance with all requirements of such governmental authority and that no further response action of any kind is required
for the unrestricted use of the Premises (&#147;<B>Closure Letter</B>&#148;). Upon the expiration or earlier termination of this Lease, Tenant shall also be obligated to close all permits obtained in connection with Hazardous Materials used by
Tenant or Tenant&#146;s Agents in accordance with Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.4.4&#8194;&#8195;<B><U>Failure to Timely <FONT
STYLE="white-space:nowrap">Clean-Up</FONT></U></B>. Should any <FONT STYLE="white-space:nowrap">Clean-up</FONT> for which Tenant is responsible not be completed, or should Tenant not receive the Closure Letter and any governmental approvals required
under Environmental Laws in conjunction with such <FONT STYLE="white-space:nowrap">Clean-up</FONT> prior to the expiration or earlier termination of this Lease (in any such case, except as due to delays caused by Landlord&#146;s failure to promptly
review, comment and approve the <FONT STYLE="white-space:nowrap">Clean-up</FONT> plans and/or the condition of the Premises), then, commencing on the later of the termination of this Lease and three (3)&nbsp;business days after Landlord&#146;s
delivery of notice of such failure and that it elects to treat such failure as a holdover, Tenant shall be liable to Landlord as a holdover tenant (as more particularly provided in <B><U>Article 16</U></B>) until Tenant has fully complied with its
obligations under this <B><U>Section</U></B><B><U></U></B><B><U>&nbsp;5.3</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.5&#8194;&#8195;<B><U>Confidentiality</U></B>. Unless compelled to do so by Applicable Law, Tenant agrees that Tenant
shall not disclose, discuss, disseminate or copy any information, data, findings, communications, conclusions and reports regarding the environmental condition of the Premises to any Person (other than Tenant&#146;s consultants, attorneys, property
managers and employees, shareholders and potential and actual investors, insurers, accountants, lenders, business and merger partners, subtenants and assignees that have a need to know such information), including any governmental authority, without
the prior written consent of Landlord, which consent shall not be unreasonably withheld or delayed. In the event Tenant reasonably believes that disclosure is compelled by Applicable Law, it shall provide Landlord ten (10)&nbsp;days&#146; advance
notice of disclosure of confidential information so that Landlord may attempt to obtain a protective order. Tenant may additionally release such information to bona fide prospective purchasers or lenders, subject to any such parties&#146; written
agreement to be bound by the terms of this <B><U>Section</U></B><B><U></U></B><B><U>&nbsp;5.3</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.6&#8194;&#8195;<B><U>Copies of Environmental Reports</U></B>. Within thirty (30)&nbsp;days of receipt thereof, Tenant
shall provide Landlord with a copy of any and all environmental assessments, audits, studies and reports regarding <FONT STYLE="white-space:nowrap">Clean-up</FONT> at the Premises. Tenant shall be obligated to provide Landlord with a copy of such
materials without regard to whether such materials are generated by Tenant or prepared for Tenant, or how Tenant comes into possession of such materials; provided that nothing herein shall be construed as obligating Tenant to provide to Landlord
documents or communications protected by the attorney-client privilege, attorney-work product doctrine or any other legally recognized privilege. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.7&#8194;&#8195;<B><U>Intentionally Omitted</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.8&#8194;&#8195;<B><U>Signs, Response Plans, Etc</U></B>. Tenant shall be responsible for posting on the Premises any
signs required under applicable Environmental Laws. Tenant shall also complete and file any business response plans or inventories required by any Applicable Laws. Tenant shall concurrently file a copy of any such business response plan or inventory
with Landlord. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3.9&#8194;&#8195;<B><U>Survival</U></B>. Each covenant, agreement and
indemnification made by Tenant and Landlord set forth in this <B><U>Section</U></B><B><U></U></B><B><U>&nbsp;5.3</U></B><B> </B>shall survive the expiration or earlier termination of this Lease and shall remain effective until all of Tenant&#146;s
and Landlord&#146;s obligations under this <B><U>Section</U></B><B><U></U></B><B><U>&nbsp;5.3</U></B><B> </B>have been completely performed and satisfied. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>SERVICES AND UTILITIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6.1&#8194;&#8195;<B><U>In General</U></B>. Landlord will be responsible, at Tenant&#146;s sole cost and expense (subject to
the terms of <U>Section</U><U></U><U>&nbsp;6.2</U>, below), for the furnishing of heating, ventilation and <FONT STYLE="white-space:nowrap">air-conditioning,</FONT> electricity, and water services to the Premises, adequate to reasonably support the
Permitted Use and in a manner consistent with First Class&nbsp;Life Science Projects, 24 hours per day, 7 days per week, 365 days per year, during the Lease Term. Landlord shall not provide janitorial or telephone services for the Premises. Tenant
shall be solely responsible for performing all janitorial services and other cleaning of the Premises, all in compliance with Applicable Laws. The janitorial and cleaning of the Premises shall be adequate to maintain the Premises in a manner
consistent with First Class&nbsp;Life Sciences Projects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Tenant shall reasonably cooperate with Landlord at all times and
abide by all regulations and requirements that Landlord may reasonably prescribe for the proper functioning and protection of the HVAC, electrical, mechanical and plumbing systems. Landlord shall reasonably cooperate with Tenant regarding
Tenant&#146;s requirements with respect to the HVAC temperature management and BMS systems serving the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Provided
that Landlord agrees to provide and maintain and keep in continuous service utility connections to the Project, including electricity, water and sewage connections, as provided above, then except as set forth above in this
<U>Section</U><U></U><U>&nbsp;6.1,</U> Landlord shall have no obligation to provide any other services or utilities to the Building, including, but not limited to telephone, janitorial and interior Building security services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6.2&#8194;&#8195;<B><U>Allocation of Utilities Costs</U></B>. Electricity is separately metered or submetered to the Premises,
and shall be contracted for and paid directly by Tenant to the applicable utility provider or to Landlord based on the metered or submetered use. Other utilities (including without limitation, gas, sewer and water) to the Building are not separately
metered to the Premises, and Tenant shall pay to Landlord, within thirty (30)&nbsp;days after billing, an equitable portion of the Building utility costs, which portion shall generally be based on the proportionate RSF of the tenants of the
Building, with reasonable adjustments if required to account for any disproportionate use by a particular tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6.3&#8194;&#8195;<B><U>Interruption of Use</U></B>. Tenant agrees that Landlord shall not be liable for damages, by abatement
of Rent (except as set forth in Section&nbsp;19.5.2 below) or otherwise, for failure to furnish or delay in furnishing any service (including telephone and telecommunication services), or for any diminution in the quality or quantity thereof, when
such failure or delay or diminution is occasioned, in whole or in part, by breakage, repairs, replacements, or improvements, by any strike, lockout or other labor trouble, by inability to secure electricity, gas, water, or other fuel at
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
the Building or Project after reasonable effort to do so, by any riot or other dangerous condition, emergency, accident or casualty whatsoever, by act or default of Tenant or other parties, or by
any other cause; and such failures or delays or diminution shall never be deemed to constitute an eviction or disturbance of Tenant&#146;s use and possession of the Premises or (except as set forth in <U>Section</U><U></U><U>&nbsp;19.5.1</U>, below)
relieve Tenant from paying Rent or performing any of its obligations under this Lease. Furthermore, Landlord shall not be liable under any circumstances for a loss of, or injury to, property or for injury to, or interference with, Tenant&#146;s
business, including, without limitation, loss of profits, however occurring, through or in connection with or incidental to a failure to furnish any of the services or utilities as set forth in this <U>Article 6</U> (provided that the foregoing
shall not limit Landlord&#146;s liability, if any, pursuant to Applicable Law for personal injury and property damage to the extent caused by the negligence or willful misconduct of Landlord, its agents, employees or contractors). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6.4&#8194;&#8195;<B><U>Emergency Generator</U></B>. Landlord and Tenant hereby acknowledge that there is an existing generator
currently serving the Building (&#147;<B>Emergency Generator</B>&#148;), and Tenant shall have the right to connect to the Emergency Generator for up to Tenant&#146;s Share of the electrical capacity available to tenants which is provided by such
Emergency Generator. Tenant&#146;s use of the Emergency Generator shall be at Tenant&#146;s sole risk. Landlord represents that the Emergency Generator is currently in place and shall be in good operating condition on the Lease Commencement Date,
and during the Lease Term Landlord shall maintain the Generator in good condition and repair, and Tenant shall be responsible for a share of the costs of such maintenance and repair based on the proportion of the Generator capacity allocated to the
Premises. Tenant hereby waives any claims against Landlord or any Landlord Parties resulting from Tenant&#146;s use of the Emergency Generator, or any failure of the Emergency Generator to operate as designed, and agrees that Landlord shall not be
liable for any damages resulting from any failure in operation of the Emergency Generator, including, without limitation any injury or damage to, or interference with, Tenant&#146;s business, including but not limited to, loss of profits, loss of
rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, or loss to equipment, inventory, scientific research, scientific experiments, laboratory animals, products, specimens, samples, and/or scientific, business,
accounting and other records of every kind and description kept at the Premises and any and all income derived or derivable therefrom. Tenant acknowledges that Operating Expenses shall include Landlord&#146;s costs incurred in maintaining and
operating the Emergency Generator (including all permit costs and fees). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6.5&#8194;&#8195;<B><U>Supplemental HVAC
Units</U></B>. Notwithstanding anything <FONT STYLE="font-family:Times New Roman; font-size:12pt" COLOR="#008000">to the contrary in this Lease,</FONT><FONT STYLE="font-family:Times New Roman"> at any time during the Lease Term, Tenant shall have
the right, but not the obligation, to install in accordance with Article 8 below (or in accordance with the Work Letter if installed as part of the Tenant Improvements), in the Premises, at Tenant&#146;s sole cost (subject to the application of the
Tenant Improvement Allowance, if desired by Tenant) one (1)&nbsp;or more &#147;Supplemental HVAC Units&#148; (at that term is defined below) in order to provide the Premises with additional heating and cooling capacity. As used herein, the term
&#147;<B>Supplemental HVAC Unit</B>&#148; shall mean a self-enclosed electric heating and cooling unit of the size and tonnage, and having the specifications, approved by Landlord, which approval shall not be unreasonably withheld, conditioned or
delayed. At Landlord&#146;s election prior to the expiration or earlier termination of this Lease, Tenant shall leave the Supplemental HVAC Unit in the Premises upon the expiration or earlier termination of this Lease, in which event the
Supplemental HVAC Unit shall be surrendered with the Premises upon the expiration or earlier termination of this Lease, and Tenant shall thereafter have no further rights with respect thereto. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6.6&#8194;&#8195;<B><U>Chemical Storage Room</U></B>. Tenant shall have the
right to utilize storage space in the chemical storage room in the Building (the &#147;<B>Chemical Storage Room</B>&#148;), for up to Tenant&#146;s Share of the Chemical Storage Room&#146;s storage capacity, provided that Tenant shall be responsible
for providing any equipment or modifications (e.g., self- contained bunkers, dedicated exhaust, additional fire rating, etc.) to support Tenant&#146;s specific usage. During the Term, Landlord shall maintain the Chemical Storage Room in good
condition and repair, and Tenant shall be responsible for a share of the costs of such maintenance and repair based on the proportion of the capacity of the Chemical Storage Room allocated to Tenant&#146;s use (subject to the provisions of
<U>Section</U><U></U><U>&nbsp;4.2.4</U> above). Notwithstanding the foregoing, Landlord shall not be liable for any damages whatsoever resulting from any failure in operation of the Chemical Storage Room, or the failure of the Chemical Storage Room
to provide suitable or adequate storage of Tenant&#146;s chemicals, including but not limited to, loss of profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, in each case, however occurring, or
loss to inventory, scientific research, scientific experiments, laboratory animals, products, specimens, samples, and/or scientific, business, accounting and other records of every kind and description kept at the Chemical Storage Room or the
Premises and any and all income derived or derivable therefrom. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>REPAIRS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.1&#8194;&#8195;<B><U>Tenant Repair Obligations</U></B>. Tenant shall, throughout the Term, at its sole cost and expense,
maintain, repair or replace as required, the interior, <FONT STYLE="white-space:nowrap">non-structural</FONT> portions of the Premises in a good standard of maintenance, repair and replacement as required, and in good and sanitary condition, all in
accordance with the standards of First Class&nbsp;Life Sciences Projects, except for the Landlord Repair Obligations, whether or not such maintenance, repair, replacement or improvement is required in order to comply with Applicable Laws
(&#147;<B>Tenant&#146;s Repair Obligations</B>&#148;), including without limitation, all electrical facilities and equipment, including lighting fixtures, lamps, fans and any exhaust equipment and systems, electrical motors and all other appliances
and equipment of every kind and nature located in the Premises; all communications systems serving the Premises; all of Tenant&#146;s security systems in or about or serving the Premises; Tenant&#146;s signage; interior, <FONT
STYLE="white-space:nowrap">non-loadbearing</FONT> demising walls and partitions (including painting and wall coverings), Tenant&#146;s equipment, and floor coverings. Tenant shall additionally be responsible, at Tenant&#146;s sole cost and expense,
to furnish all expendables, including light bulbs, paper goods and soaps, used in the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.2&#8194;&#8195;<B><U>Landlord&#146;s Right to Perform Tenant&#146;s Repair Obligations</U></B>. Tenant shall notify Landlord
in writing at least thirty (30)&nbsp;days prior to performing any material Tenant&#146;s Repair Obligations, which shall mean any Tenant&#146;s Repair Obligation which affect the Building Systems or which is reasonably anticipated to cost more than
$200,000.00. Upon receipt of such notice from Tenant, Landlord shall have the right to either (i)&nbsp;perform such material Tenant&#146;s Repair Obligation by delivering notice of such election to Tenant within thirty (30)&nbsp;days following
receipt of Tenant&#146;s notice, and Tenant shall pay Landlord the cost thereof (including Landlord&#146;s reasonable supervision fee) within thirty (30)&nbsp;days after receipt of an invoice therefor, or (ii)&nbsp;require Tenant to perform such
Tenant&#146;s Repair Obligation at Tenant&#146;s sole cost and expense. If Tenant fails to perform any Tenant&#146;s Repair Obligation within a reasonable time period, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
reasonably determined by Landlord, then Landlord may, but need not, following delivery of notice to Tenant of such election, make such Tenant Repair Obligation, and Tenant shall pay Landlord the
cost thereof, (including Landlord&#146;s reasonable supervision fee) within thirty (30)&nbsp;days after receipt of an invoice therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.3&#8194;&#8195;<B><U>Landlord Repair Obligations</U></B>. Landlord shall, throughout the Lease Term, at its sole cost and
expense (except to the extent the cost or expense is reimbursable to Landlord pursuant to <U>Section</U><U></U><U>&nbsp;4.4</U> above) maintain, repair, replace and improve as reasonably required but at all times commensurate with Comparable
Buildings: (1)&nbsp;exterior windows, window frames, window casements (including the repairing, resealing, cleaning and replacing of exterior windows); (2) exterior doors, door frames and door closers; (3)&nbsp;the Building (as opposed to the
Premises) and Project plumbing, sewer, drainage, electrical, fire protection, life safety and security systems and equipment, existing heating, ventilation and <FONT STYLE="white-space:nowrap">air-conditioning</FONT> systems, and all other
mechanical and HVAC systems and equipment (including rebalancing thereof to the extent deemed reasonably necessary by Landlord) (collectively, the &#147;<B>Building Systems</B>&#148;), (4) the exterior glass, exterior walls, interior loadbearing
walls, foundation and roof of the Building, the structural portions of the floors of the Building, including, without limitation, any painting, sealing, patching and waterproofing of exterior walls, (5)&nbsp;repairs to the elevator in the Building
and underground utilities, and (6)&nbsp;the Common Areas (the &#147;<B>Landlord Repair Obligations</B>&#148;); provided, however, that if such repairs are due to the negligence or willful misconduct of Tenant, Landlord shall nevertheless make such
repairs at Tenant&#146;s expense, or, if covered by Landlord&#146;s insurance, Tenant shall only be obligated to pay any deductible in connection therewith. Costs expended by Landlord in connection with the Landlord Repair Obligations shall be
included in Operating Expenses to the extent allowed pursuant to the terms of <U>Article 4</U>, above. Landlord shall cooperate with Tenant to enforce any warranties that Landlord holds that could reduce Tenant&#146;s maintenance obligations under
this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.4&#8194;&#8195;<B><U>Tenant&#146;s Right to Make Repairs</U></B>. Notwithstanding any provision to the
contrary contained in this Lease, if Tenant provides written notice to Landlord of an event or circumstance which requires the action of Landlord under this Lease with respect to repair and/or maintenance required in the Premises, including repairs
to the portions of the Building located within the Premises that are Landlord&#146;s responsibility under <U>Section</U><U></U><U>&nbsp;7.3</U> (the &#147;<B>Base Building</B>&#148;), which event or circumstance with respect to the Base Building
materially and adversely affects the conduct of Tenant&#146;s business from the Premises, and Landlord fails to commence corrective action within a reasonable period of time, given the circumstances, after the receipt of such notice, but in any
event not later than thirty (30)&nbsp;days after receipt of said notice (unless Landlord&#146;s obligation cannot reasonably be performed within thirty (30)&nbsp;days, in which event Landlord shall be allowed additional time as is reasonably
necessary to perform the obligation so long as Landlord begins performance within the initial thirty (30)&nbsp;days and diligently pursues performance to completion), or, in the event of an Emergency (as defined below), not later than five
(5)&nbsp;business days after receipt of such notice, then Tenant shall have the right to undertake such actions as may be reasonably necessary to make such repairs if Landlord thereafter fails to commence corrective action within five
(5)&nbsp;business days following Landlord&#146;s receipt of a second written notice from Tenant specifying that Tenant will undertake such actions if Landlord fails to timely do so (provided that such notice shall include the following language in
bold, capitalized text: &#147;<B>IF LANDLORD FAILS TO COMMENCE THE REPAIRS DESCRIBED IN THIS LETTER WITHIN FIVE (5)</B><B></B><B>&nbsp;BUSINESS DAYS FROM LANDLORD&#146;S RECEIPT OF THIS </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
<B>LETTER, TENANT WILL PERFORM SUCH REPAIRS AT LANDLORD&#146;S EXPENSE</B>&#148;; provided, however, that in no event shall Tenant undertake any actions that could materially or adversely affect
the Base Building. Notwithstanding the foregoing, in the event of an Emergency, no second written notice shall be required as long as Tenant advises Landlord in the first written notice of Tenant&#146;s intent to perform such Emergency repairs if
Landlord does not commence the same within such five (5)&nbsp;business day period, utilizing the language required in second notices. If such action was required under the terms of this Lease to be taken by Landlord and was not commenced by Landlord
within such five (5)&nbsp;business day period and thereafter diligently pursued to completion, then Tenant shall be entitled to prompt reimbursement by Landlord of the reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-</FONT></FONT> pocket third-party costs and expenses actually incurred by Tenant in taking such action. If Tenant undertakes such corrective actions pursuant to this
<U>Section</U><U></U><U>&nbsp;7.4</U>, then (a)&nbsp;the insurance and indemnity provisions set forth in this Lease shall apply to Tenant&#146;s performance of such corrective actions, (b)&nbsp;Tenant shall proceed in accordance with all Applicable
Laws, (c)&nbsp;Tenant shall retain to perform such corrective actions only such reputable contractors and suppliers as are duly licensed and qualified, (d)&nbsp;Tenant shall effect such repairs in a good and workmanlike and commercially reasonable
manner, (e)&nbsp;Tenant shall use new or like new materials, and (f)&nbsp;Tenant shall take reasonable efforts to minimize any material interference or impact on the other tenants and occupants of the Building. Promptly following completion of any
work taken by Tenant pursuant to the terms of this <U>Section</U><U></U><U>&nbsp;7.4</U>, Tenant shall deliver a detailed invoice of the work completed, the materials used and the costs relating thereto, and Landlord shall reimburse Tenant the
amounts expended by Tenant in connection with such work, provided that Landlord shall have the right to object if Landlord claims that such action did not have to be taken by Landlord pursuant to the terms of this Lease or that the charges are
excessive (in which case Landlord shall pay the amount it contends would not have been excessive). For purposes of this Lease, an &#147;<B>Emergency</B>&#148; shall mean an event threatening immediate and material danger to people located in the
Building or immediate, material damage to the Building, Base Building, or creating a realistic possibility of an immediate and material interference with, or immediate and material interruption of a material aspect of Tenant&#146;s business
operations. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>ADDITIONS AND ALTERATIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">8.1&#8194;&#8195;<B><U>Landlord&#146;s Consent to Alterations</U></B>. Tenant may not make any improvements, alterations,
additions or changes to the Premises or any mechanical, plumbing or HVAC facilities or systems pertaining to the Premises (collectively, the &#147;<B>Alterations</B>&#148;) without first procuring the prior written consent of Landlord to such
Alterations, which consent shall be requested by Tenant not less than fifteen (15)&nbsp;days prior to the commencement thereof, and which consent shall not be unreasonably withheld, conditioned or delayed by Landlord, provided it shall be deemed
reasonable for Landlord to withhold its consent to any Alteration which adversely affects the structural portions or the systems or equipment of the Building or is visible from the exterior of the Building. If Landlord reasonably disapproves of any
proposed Alterations, Landlord shall respond, in writing, stating the grounds for such disapproval, within fifteen (15)&nbsp;business days after receipt of Tenant&#146;s request for approval of the proposed Alterations. If Landlord fails to respond
with its approval or disapproval within fifteen (15)&nbsp;business days after receipt of Tenant&#146;s request, then Tenant may send Landlord a reminder notice setting forth such failure containing the following sentence at the top of such notice in
bold, capitalized font at least twelve (12)&nbsp;points in size: &#147;<B>LANDLORD&#146;S FAILURE TO RESPOND TO THIS NOTICE WITHIN FIVE (5)</B><B></B><B>&nbsp;BUSINESS DAYS SHALL RESULT IN LANDLORD&#146;S DEEMED APPROVAL OF </B>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
<B>TENANT&#146;S ALTERATION</B>&#148; (the &#147;<B>Alterations Reminder Notice</B>&#148;). Any such Alterations Reminder Notice shall include a complete copy of Tenant&#146;s request for consent
(e.g., plans, specifications for such Alteration). If Landlord fails to respond within five (5)&nbsp;business days after receipt of an Alterations Reminder Notice, then Tenant&#146;s Alteration for which Tenant requested Landlord&#146;s approval
shall be deemed approved by Landlord. Notwithstanding the foregoing, Tenant shall be permitted to make Alterations following ten (10)&nbsp;business days&#146; notice to Landlord, but without Landlord&#146;s prior consent, to the extent that such
Alterations (i)&nbsp;do not affect the Building Systems or equipment, (ii)&nbsp;are not visible from the exterior of the Building, and (iii)&nbsp;cost less than $150,000.00 for a particular job of work (the &#147;<B>Exempt Alterations</B>&#148;).
The construction of the initial improvements to the Premises shall be governed by the terms of the Tenant Work Letter and not the terms of this <U>Article&nbsp;8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">8.2&#8194;&#8195;<B><U>Manner of Construction</U></B>. Landlord may impose, as a condition of its consent to any and all
Alterations or repairs of the Premises or about the Premises, such requirements as Landlord in its reasonable discretion may deem desirable, including, but not limited to, the requirement that upon Landlord&#146;s request, Tenant shall, at
Tenant&#146;s expense, remove such Alterations upon the expiration or any early termination of the Lease Term, provided, however, Landlord may only require such removal if such Alterations are Specialty Improvements. For the avoidance of doubt,
Tenant shall only be responsible for removing Specialty Improvements (hereafter defined), if at the time of its consent to such Specialty Improvements, Landlord advises in writing in its consent that Tenant is obligated to remove such Specialty
Improvements at the expiration of the Term. &#147;<B>Specialty Improvements</B>&#148; means, collectively, any alterations, additions or improvements to the Premises which are not typical alterations, additions or improvements found in Comparable
Buildings (and typical general laboratory improvements will not be deemed to be Specialty Improvements). Tenant shall construct such Alterations and perform such repairs in a good and workmanlike manner, in conformance with any and all applicable
federal, state, county or municipal laws, rules and regulations and pursuant to a valid building permit, issued by the city in which the Building is located (or other applicable governmental authority). Tenant shall not use (and upon notice from
Landlord shall cease using) contractors, services, workmen, labor, materials or equipment that, in Landlord&#146;s reasonable judgment, would disturb labor harmony with the workforce or trades engaged in performing other work, labor or services in
or about the Building or the Common Areas. Upon completion of any Alterations (other than Exempt Alterations), Tenant shall deliver to Landlord final lien waivers from all contractors, subcontractors and materialmen who performed such work. In
addition to Tenant&#146;s obligations under <U>Article 9</U> of this Lease, upon completion of any Alterations (other than Exempt Alterations), Tenant agrees to cause a Notice of Completion to be recorded in the office of the Recorder of the County
of San Mateo in accordance with Section&nbsp;3093 of the Civil Code of the State of California or any successor statute, and Tenant shall deliver to the Project construction manager a reproducible copy of the &#147;<B>as built</B>&#148; drawings of
the Alterations (other than Exempt Alterations)as well as all permits, approvals and other documents issued by any governmental agency in connection with the Alterations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">8.3&#8194;&#8195;<B><U>Payment for Improvements</U></B>. Tenant shall pay to Landlord, as Additional Rent, the reasonable,
actual, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of Landlord&#146;s third party engineers and other third party consultants (but not Landlord&#146;s
<FONT STYLE="white-space:nowrap">on-</FONT> site management personnel) which are reasonably required to be engaged by Landlord for review of all plans, specifications and working drawings for the Alterations, within thirty (30)&nbsp;days after
Tenant&#146;s receipt of invoices from Landlord together with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
reasonable supporting evidence; provided, however, Tenant shall only be obligated to pay such costs for Alterations which are not Exempt Alterations. Landlord shall not be entitled to receive an
administrative or supervision fee with regard to repairs, Alterations or any other work arising from or related to this Lease except as expressly set forth herein unless Tenant hires Landlord to perform the Alterations, in which case, an
administrative fee will be negotiated between Landlord and Tenant at that time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">8.4&#8194;&#8195;<B><U>Construction
Insurance</U></B>. In addition to the requirements of <U>Article 10</U> of this Lease, in the event that Tenant makes any Alterations, prior to the commencement of such Alterations, Tenant shall provide Landlord with evidence that Tenant carries
&#147;<B>Builder&#146;s All Risk</B>&#148; insurance in an amount approved by Landlord covering the construction of such Alterations, it being understood and agreed that all of such Alterations shall be insured by Tenant pursuant to <U>Article
10</U> of this Lease immediately upon completion thereof. In addition, Tenant&#146;s general contractor shall be required to carry (i)&nbsp;Commercial General Liability Insurance with commercially reasonable coverage limits, with Landlord, and, at
Landlord&#146;s option, Landlord&#146;s property manager and project manager, as additional insureds in an amount approved by Landlord, and (ii)&nbsp;workers compensation insurance to the extent required by Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">8.5&#8194;&#8195;<B><U>Landlord&#146;s Property</U></B>. All Alterations, improvements, fixtures, equipment and/or
appurtenances which may be installed in or about the Premises by Tenant (excluding Tenant&#146;s removable trade fixtures, furniture and <FONT STYLE="white-space:nowrap">non-affixed</FONT> office and lab equipment), from time to time, shall be at
the sole cost of Tenant and shall be and become the property of Landlord and remain in place at the Premises following the expiration or earlier termination of this Lease. Notwithstanding the foregoing, Landlord may, by written notice to Tenant
prior to the end of the Lease Term, or given following any earlier termination of this Lease, require Tenant, at Tenant&#146;s expense, to remove any Specialty Improvements within the Premises and to repair any damage to the Premises and Building
caused by such removal and return the affected portion of the Premises to a building standard tenant improved condition as determined by Landlord. If Tenant fails to complete such removal and/or to repair any damage caused by the removal of any
Specialty Improvements in the Premises and return the affected portion of the Premises to a building standard tenant improved condition as reasonably determined by Landlord, Landlord may do so and may charge the cost thereof to Tenant. Tenant hereby
protects, defends, indemnifies and holds Landlord harmless from any liability, cost, obligation, expense or claim of lien in any manner relating to the installation, placement, removal or financing of any such Alterations, improvements, fixtures
and/or equipment in, on or about the Premises, which obligations of Tenant shall survive the expiration or earlier termination of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>9.</B>&#8194;&#8195;<B>COVENANT AGAINST LIENS</B><B> </B>Tenant shall keep the Project and Premises free from any liens or encumbrances
arising out of the work performed, materials furnished or obligations incurred by or on behalf of Tenant, and shall protect, defend, indemnify and hold Landlord harmless from and against any claims, liabilities, judgments or costs (including,
without limitation, reasonable attorneys&#146; fees and costs) arising out of same or in connection therewith. Tenant shall give Landlord notice at least fifteen (15)&nbsp;days prior to the commencement of any such work on the Premises (or such
additional time as may be necessary under Applicable Laws) to afford Landlord the opportunity of posting and recording appropriate notices of <FONT STYLE="white-space:nowrap">non-responsibility</FONT> (to the extent applicable pursuant to then
Applicable Laws). Tenant shall remove any such lien or encumbrance by bond or otherwise within fifteen (15)&nbsp;business days after notice by Landlord, and if Tenant shall fail to do so, Landlord may pay the amount necessary to remove such lien or
encumbrance, without being responsible for investigating the validity thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>INSURANCE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10.1&#8194;&#8195;<B><U>Indemnification and Waiver</U></B>. Except to the extent due to the negligence, willful misconduct or
violation of this Lease by Landlord or the Landlord Parties, and subject to the waiver of subrogation set forth in <U>Section</U><U></U><U>&nbsp;10.5</U>, below, Tenant hereby waives all claims against Landlord and its partners, subpartners and
their respective officers, agents, employees, lenders, any property manager and independent contractors (collectively, &#147;<B>Landlord Parties</B>&#148;) damage either to person or property in or upon the Premises, or resulting from the loss of
use thereof, which damage is sustained by Tenant or by other persons claiming through Tenant. Except to the extent due to the negligence, willful misconduct or violation of this Lease by Landlord or the Landlord Parties, Tenant shall indemnify,
defend, protect, and hold harmless the Landlord Parties from any and all claims, loss, cost, damage, injury, expense and liability (including without limitation court costs and reasonable attorneys&#146; fees) incurred to the extent arising from any
acts or omissions by Tenant or any person claiming by, through or under Tenant, or of the contractors, agents, employees, invitees, guests or licensees of Tenant or any such person (collectively, &#147;<B>Tenant Parties</B>&#148;), in, on or about
the Premises, or from any negligence or willful misconduct of Tenant or any Tenant Parties in, on or about the Project, or any breach of the terms of this Lease, either prior to, during, or after the expiration of the Lease Term. Notwithstanding
anything to the contrary in this Lease, Landlord shall not be released or indemnified from, and shall indemnify, defend, protect and hold harmless Tenant, its agents, contractors and employees, from, all losses, damages, liabilities, demands,
claims, actions, attorneys&#146; fees, costs and expenses arising from the negligence or willful misconduct of Landlord or its agents, contractors, licensees or invitees, or a violation of Landlord&#146;s obligations or representations under this
Lease. The provisions of this <U>Section</U><U></U><U>&nbsp;10.1</U> shall survive the expiration or sooner termination of this Lease with respect to any claims or liability arising in connection with any event occurring prior to such expiration or
termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10.2&#8194;&#8195;<B><U>Tenant&#146;s Compliance With Landlord&#146;s Property Insurance</U></B>. Landlord
shall insure the Building and Project during the Lease Term against loss or damage under an &#147;all risk&#148; property insurance policy. Such coverage shall be for the full replacement cost of the Building and shall be issued by an insurance
company possessing a rating of not less than <FONT STYLE="white-space:nowrap">A-:VII</FONT> in Best&#146;s Insurance Guide. Additionally, at the option of Landlord, such insurance coverage may include the risks of earthquakes and/or flood damage and
additional hazards, a rental loss endorsement and one or more loss payee endorsements in favor of the holders of any mortgages or deeds of trust encumbering the interest of Landlord in the Building or the ground or underlying lessors of the
Building, or any portion thereof. Tenant shall, at Tenant&#146;s expense, comply with all insurance company requirements pertaining to the use of the Premises. If Tenant&#146;s conduct or use of the Premises causes any increase in the premium for
such insurance policies then Tenant shall reimburse Landlord for any such increase. Tenant, at Tenant&#146;s expense, shall comply with all rules, orders, regulations or requirements of the American Insurance Association (formerly the National Board
of Fire Underwriters) and with any similar body. Tenant shall also provide Landlord and Landlord&#146;s insurer(s) with such information regarding the use of the Premises and any damage to the Premises as they may reasonably require in connection
with the placement of insurance for the Premises or the adjusting of any losses to the Premises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10.3&#8194;&#8195;<B><U>Tenant&#146;s Insurance</U></B>. During the Lease
Term, Tenant shall maintain the following coverages in the following amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10.3.1 Commercial General Liability
Insurance on an occurrence form covering the insured against claims of bodily injury, personal injury and property damage (including loss of use thereof) arising out of Tenant&#146;s operations, and contractual liabilities including a contractual
coverage, for limits of liability (which limits may be met together with umbrella liability insurance) of not less than: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD ROWSPAN="4" VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#cceeff">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP BGCOLOR="#cceeff">Bodily Injury and</TD>
<TD VALIGN="bottom" BGCOLOR="#cceeff">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP BGCOLOR="#cceeff">$3,000,000 each occurrence</TD>
<TD VALIGN="bottom" ROWSPAN="4">&nbsp;&nbsp;</TD>
<TD ROWSPAN="4" VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Property Damage Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$3,000,000 annual aggregate</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom" BGCOLOR="#cceeff">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP BGCOLOR="#cceeff"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">Personal Injury Liability</P></TD>
<TD VALIGN="bottom" BGCOLOR="#cceeff">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP BGCOLOR="#cceeff"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">$3,000,000 each occurrence</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$3,000,000 annual aggregate</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10.3.2 Property Insurance covering (i)&nbsp;all office furniture, business and trade
fixtures, office equipment, free-standing cabinet work, movable partitions, merchandise and all other items of Tenant&#146;s property on the Premises installed by, for, or at the expense of Tenant, (ii)&nbsp;the &#147;<B>Tenant
Improvements</B>,&#148; as that term is defined in the Tenant Work Letter, and any other improvements which exist in the Premises as of the Lease Commencement Date (excluding the Base Building) (the &#147;<B>Original Improvements</B>&#148;), and
(iii)&nbsp;all other improvements, alterations and additions to the Premises. Such insurance shall be written on an &#147;<B>all risks</B>&#148; of physical loss or damage basis, for the full replacement cost value (subject to reasonable deductible
amounts) new without deduction for depreciation of the covered items and in amounts that meet any <FONT STYLE="white-space:nowrap">co-insurance</FONT> clauses of the policies of insurance and shall include coverage for damage or other loss caused by
fire or other peril including, but not limited to, vandalism and malicious mischief, theft, water damage of any type, including sprinkler leakage, bursting or stoppage of pipes, and explosion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10.3.3 Intentionally omitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10.3.4 Worker&#146;s Compensation and Employer&#146;s Liability or other similar insurance pursuant to all applicable state
and local statutes and partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10.4&#8195;<B><U>Form of Policies</U></B>. The minimum limits of policies of insurance
required of Tenant under this Lease shall in no event limit the liability of Tenant under this Lease. Such insurance shall (i)&nbsp;name Landlord, its subsidiaries and affiliates, its property manager (if any) and any other party the Landlord so
specifies in writing, as an additional insured or loss payee, as applicable, including Landlord&#146;s managing agent, if any; (ii)&nbsp;be issued by an insurance company having a rating of not less than
<FONT STYLE="white-space:nowrap">A-:VII</FONT> in Best&#146;s Insurance Guide or which is otherwise acceptable to Landlord and licensed to do business in the State of California; (iv)&nbsp;be primary insurance as to all claims thereunder and provide
that any insurance carried by Landlord is excess and is <FONT STYLE="white-space:nowrap">non-contributing</FONT> with any insurance required of Tenant, provided, however, only to the extent of liabilities covered by Tenant&#146;s indemnity
obligations pursuant to the terms of this Lease; and (v)&nbsp;be in form and content reasonably acceptable to Landlord. Tenant shall promptly provide written notice of cancellation received by Tenant from its insurer. Tenant shall deliver
certificates of said insurance policies to Landlord on or before the Lease Commencement Date and within a reasonable period of time after renewal dates of such policies. In the event Tenant shall fail to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
procure such insurance, Landlord may, at its option, after giving Tenant at least five (5)&nbsp;business days prior written notice with Tenant thereafter failing to procure such insurance,
procure such policies for the account of Tenant, and the cost thereof shall be paid to Landlord within five (5)&nbsp;days after delivery to Tenant of bills therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10.5&#8194;&#8195;<B><U>Subrogation</U></B>. Landlord and Tenant hereby agree to look solely to, and seek recovery only from,
their respective property insurance carriers in the event of a property loss to the extent that such coverage is agreed to be provided hereunder. The parties each hereby waive all rights and claims against each other for such losses, and waive all
rights of subrogation of their respective insurers, provided such waiver of subrogation shall not affect the right to the insured to recover thereunder. The parties agree that their respective insurance policies do now, or shall, contain the waiver
of subrogation. The parties hereby represent that their respective property insurance policies include a waiver of (i)&nbsp;subrogation by the insurers, and (ii)&nbsp;all rights based upon an assignment from its insured, against Landlord and/or any
of the Landlord Parties or Tenant and/or any of the Tenant Parties (as the case may be) in connection with any property loss risk thereby insured against. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10.6&#8194;&#8195;<B><U>Additional Insurance Obligations</U></B>. Tenant shall carry and maintain during the entire Lease
Term, at Tenant&#146;s sole cost and expense, increased amounts of the insurance required to be carried by Tenant pursuant to this <U>Article 10</U> and such other reasonable types of insurance coverage and in such reasonable amounts covering the
Premises and Tenant&#146;s operations therein, as may be reasonably requested by Landlord, but in no event in excess of the amounts and types of insurance then being required by landlords of Comparable Buildings. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>DAMAGE AND DESTRUCTION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">11.1&#8194;&#8195;<B><U>Repair of Damage to Premises by Landlord</U></B>. To the extent Landlord does not already have actual
knowledge of such damage, Tenant shall promptly notify Landlord of any damage to the Premises resulting from fire or any other casualty. If the Building (including the Premises) and/or any Common Areas (including parking facilities) serving or
providing access to the Premises shall be damaged by fire or other casualty (a &#147;<B>Casualty</B>&#148;), Landlord shall promptly and diligently, subject to reasonable delays for insurance adjustment or other matters beyond Landlord&#146;s
reasonable control, and subject to all other terms of this <U>Article 11</U>, restore the Building (including the Premises) and/or such Common Areas. Such restoration shall be to substantially the same condition of the Base Building and the Common
Areas prior to the casualty, except for modifications required by zoning and building codes and other laws, provided that access to the Premises shall not be materially impaired. Within sixty (60)&nbsp;days after the occurrence of any Casualty,
Landlord shall deliver to Tenant an estimate (the &#147;<B>Casualty Estimate</B>&#148;), prepared by a qualified, independent, experienced and reputable architect and/or general contractor and addressed to Tenant, of the number of days (assuming no
Force Majeure delay), measured from the date of the Casualty, that will be required for Landlord to substantially complete the repair and restoration of the Building (including the Premises) and the Common Areas (when such repairs are made without
the payment of overtime or other premiums). Landlord shall use commercially reasonable efforts to minimize interference with Tenant&#146;s business during any such repairs. If this Lease does not terminate pursuant to
<U>Section</U><U></U><U>&nbsp;11.2</U> below or for any other reason, and Landlord complies with its obligations set forth in this <U>Article 11</U>, Tenant shall, at its sole cost, subject to reasonable delays for insurance adjustment or other
matters beyond Tenant&#146;s reasonable control, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
repair any damage to the Tenant Improvements (and any subsequent Alterations) installed in the Premises by Tenant (&#147;<B>Tenant&#146;s Restoration Work</B>&#148;). Prior to the commencement of
construction, Tenant shall submit to Landlord, for Landlord&#146;s review and approval, all plans, specifications and working drawings relating thereto (other than Exempt Alterations which shall not be subject to Landlord&#146;s approval) which
Landlord approval shall not be unreasonably withheld, conditioned or delayed. Landlord shall not be liable for any inconvenience or annoyance to Tenant or its visitors, or injury to Tenant&#146;s business resulting in any way from such damage or the
repair thereof; provided however, that if such fire or other casualty shall have damaged the Building, Premises or Common Areas (including parking facilities) necessary to Tenant&#146;s use and occupancy, and the Premises are not occupied by Tenant
as a result thereof (other than for the purpose of performing Tenant&#146;s Restoration Work), then during the time and to the extent the Premises are unfit for occupancy, the Rent shall be abated in proportion to the ratio that the amount of
rentable square feet of the Premises which is unfit for occupancy for the purposes permitted under this Lease bears to the total rentable square feet of the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">11.2&#8194;&#8195;<B><U>Landlord&#146;s Option to Repair</U></B>. Notwithstanding the terms of
<U>Section</U><U></U><U>&nbsp;11.1</U> of this Lease, Landlord may elect not to rebuild and/or restore the Building and/or Common Areas, and instead terminate this Lease, by notifying Tenant in writing of such termination within sixty (60)&nbsp;days
after the date of the Casualty, such notice to include a termination date giving Tenant sixty (60)&nbsp;days to vacate the Premises, but Landlord may so elect only if the Building and Common Areas shall be damaged by fire or other Casualty or cause
and one or more of the following conditions is present: (i)&nbsp;according to the Casualty Estimate, repairs to the Building and Common Areas cannot be completed within twelve (12)&nbsp;months after the date of discovery of the damage (when such
repairs are made without the payment of overtime or other premiums); (ii) the holder of any mortgage on the Building or Project shall require that the insurance proceeds or any portion thereof in excess of Two Million Dollars ($2,000,000.00) be used
to retire the mortgage debt; (iii)&nbsp;at least Two Million Dollars ($2,000,000.00) of the damage is not fully covered by Landlord&#146;s insurance policies; or (iv)&nbsp;the damage occurs during the last twelve (12)&nbsp;months of the Lease Term
and according to the Casualty Estimate restoration and repair of the Building and Common Areas cannot be completed within sixty (60)&nbsp;days after the date of discovery of the damage (when such repairs are made without the payment of overtime or
other premiums), Notwithstanding anything to the contrary herein, Tenant may elect to terminate this Lease by notifying Landlord in writing of such termination within sixty (60)&nbsp;days after receipt of the Casualty Estimate, such notice to
include a termination date giving Tenant up to sixty (60)&nbsp;days to vacate the Premises, but Tenant may so elect only if one or more of the following conditions is present: (A)&nbsp;according to the Casualty Estimate, repairs to the Base Building
and Common Areas cannot be completed within twelve (12)&nbsp;months after the date of discovery of the damage (when such repairs are made without the payment of overtime or other premiums) or (B)&nbsp;the damage occurs during the last twelve
(12)&nbsp;months of the Lease Term and according to the Casualty Estimate restoration and repair of the Building and Common Areas cannot be completed within sixty (60)&nbsp;days after the date of discovery of the damage (when such repairs are made
without the payment of overtime or other premiums). In addition, if neither Landlord nor Tenant has terminated this Lease and the repairs are not actually completed within ninety (90)&nbsp;days of the period of time set forth in the Casualty
Estimate, Tenant shall have the right to terminate this Lease by notice to Landlord (the &#147;<B>Damage Termination Notice</B>&#148;), effective as of a date set forth in the Damage Termination Notice (the &#147;<B>Damage Termination
Date</B>&#148;), which Damage Termination Date may be up to sixty (60)&nbsp;days after delivery of the Damage Termination Notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">11.3&#8194;&#8195;<B><U>Waiver of Statutory Provisions</U></B>. The
provisions of this Lease, including this <U>Article 11</U>, constitute an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, all or any part of the Premises, the Building or the Project, and any
statute or regulation of the State of California, including, without limitation, Sections 1932(2) and 1933(4) of the California Civil Code, with respect to any rights or obligations concerning damage or destruction in the absence of an express
agreement between the parties, and any other statute or regulation, now or hereafter in effect, shall have no application to this Lease or any damage or destruction to all or any part of the Premises, the Building or the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>12.</B>&#8194;&#8195;<B>NONWAIVER</B><B> </B>No provision of this Lease shall be deemed waived by either party hereto unless expressly
waived in a writing signed thereby. The waiver by either party hereto of any breach of any term, covenant or condition herein contained shall not be deemed to be a waiver of any subsequent breach of same or any other term, covenant or condition
herein contained. The subsequent acceptance of Rent hereunder by Landlord shall not be deemed to be a waiver of any preceding breach by Tenant of any term, covenant or condition of this Lease, other than the failure of Tenant to pay the particular
Rent so accepted, regardless of Landlord&#146;s knowledge of such preceding breach at the time of acceptance of such Rent. No acceptance of a lesser amount than the Rent herein stipulated shall be deemed a waiver of Landlord&#146;s right to receive
the full amount due, nor shall any endorsement or statement on any check or payment or any letter accompanying such check or payment be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to
Landlord&#146;s right to recover the full amount due. No receipt of monies by Landlord from Tenant after the termination of this Lease shall in any way alter the length of the Lease Term or of Tenant&#146;s right of possession hereunder, or after
the giving of any notice shall reinstate, continue or extend the Lease Term or affect any notice given Tenant prior to the receipt of such monies, it being agreed that after the service of notice or the commencement of a suit, or after final
judgment for possession of the Premises, Landlord may receive and collect any Rent due, and the payment of said Rent shall not waive or affect said notice, suit or judgment.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>13.</B><B>&#8194;&#8195;</B><B>CONDEMNATION</B> If the whole or any part of the Premises, Building or Project shall be taken by power of
eminent domain or condemned by any competent authority for any public or quasi-public use or purpose, or if any adjacent property or street shall be so taken or condemned, or reconfigured or vacated by such authority in such manner as to require the
use, reconstruction or remodeling of any part of the Premises, Building or Project, or if Landlord shall grant a deed or other instrument in lieu of such taking by eminent domain or condemnation, Landlord shall have the option to terminate this
Lease effective as of the date possession is required to be surrendered to the authority. Notwithstanding the foregoing, Landlord shall only have the right to terminate this Lease if Landlord terminates all of the leases within the Project similarly
affected by such taking. If more than twenty-five percent (25%) of the rentable square feet of the Premises is taken, or if access to the Premises is substantially impaired, in each case for a period in excess of one hundred twenty (120)&nbsp;days,
Tenant shall have the option to terminate this Lease effective on not less than ninety (90)&nbsp;days prior written notice or, if sooner as of the date possession is required to be surrendered to the authority. Tenant shall not because of such
taking assert any claim against Landlord or the authority for any compensation because of such taking and Landlord shall be entitled to the entire award or payment in connection therewith, except that Tenant shall have the right to file any separate
claim available to Tenant for any taking of Tenant&#146;s personal property and fixtures belonging to Tenant and removable by Tenant upon expiration of the Lease Term pursuant to the terms of this Lease, and for moving expenses, so long as such
claims do not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
diminish the award available to Landlord, its ground lessor with respect to the Building or Project or its mortgagee, and such claim is payable separately to Tenant. All Rent shall be apportioned
as of the date of such termination. If any part of the Premises shall be taken, and this Lease shall not be so terminated, the Rent shall be proportionately abated. Tenant hereby waives any and all rights it might otherwise have pursuant to
Section&nbsp;1265.130 of The California Code of Civil Procedure. Notwithstanding anything to the contrary contained in this Article 13, in the event of a temporary taking of all or any portion of the Premises for a period of one hundred and eighty
(180)&nbsp;days or less, then this Lease shall not terminate but the Base Rent and the Additional Rent shall be abated for the period of such taking in proportion to the ratio that the amount of rentable square feet of the Premises taken bears to
the total rentable square feet of the Premises. Landlord shall be entitled to receive the entire award made in connection with any such temporary taking. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>ASSIGNMENT AND SUBLETTING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.1&#8194;&#8195;<B><U>Transfers</U></B>. Subject to the terms of Section&nbsp;14.8 and Section&nbsp;14.9 below, Tenant shall
not, without the prior written consent of Landlord, assign, mortgage, pledge, hypothecate, encumber, or permit any lien to attach to, or otherwise transfer, this Lease or any interest hereunder, permit any assignment, or other transfer of this Lease
or any interest hereunder by operation of law, sublet the Premises or any part thereof, or enter into any license or concession agreements or otherwise permit the occupancy or use of the Premises or any part thereof by any persons other than Tenant
and its employees and contractors (all of the foregoing are hereinafter sometimes referred to collectively as &#147;<B>Transfers</B>&#148; and any person to whom any Transfer is made or sought to be made is hereinafter sometimes referred to as a
&#147;<B>Transferee</B>&#148;). If Tenant desires Landlord&#146;s consent to any Transfer, Tenant shall notify Landlord in writing, which notice (the &#147;<B>Transfer Notice</B>&#148;) shall include (i)&nbsp;the proposed effective date of the
Transfer, which shall not be less than twenty (20)&nbsp;days nor more than one hundred eighty (180)&nbsp;days after the date of delivery of the Transfer Notice, (ii)&nbsp;a description of the portion of the Premises to be transferred (the
&#147;<B>Subject Space</B>&#148;), (iii) all of the terms of the proposed Transfer and the consideration therefor, including calculation of the &#147;<B>Transfer Premium</B>&#148;, as that term is defined in <U>Section</U><U></U><U>&nbsp;14.3</U>
below, in connection with such Transfer, the name and address of the proposed Transferee, and a copy of all existing executed documentation pertaining to the proposed Transfer, and (iv)&nbsp;current financial statements of the proposed Transferee
certified by an officer, partner or owner thereof (provided, that the submission of such financial statements shall not be required if the proposed Transferee is a publicly-traded company whose financial statements are publicly available through the
Securities and Exchange Commission) and any other information reasonably required by Landlord which will enable Landlord to determine the financial responsibility, character, and reputation of the proposed Transferee, nature of such
Transferee&#146;s business and proposed use of the Subject Space. Any Transfer made without Landlord&#146;s prior written consent shall, at Landlord&#146;s option, be null, void and of no effect, and shall, at Landlord&#146;s option, constitute a
default by Tenant under this Lease. Whether or not Landlord consents to any proposed Transfer, Tenant shall pay Landlord&#146;s reasonable review and processing fees, as well as any reasonable professional fees (including, without limitation,
attorneys&#146;, accountants&#146;, architects&#146;, engineers&#146; and consultants&#146; fees) incurred by Landlord, within thirty (30)&nbsp;days after written request by Landlord, provided that such fees shall not exceed Two Thousand and 00/100
Dollars ($2,000.00) for any such Transfer in the ordinary course of business. For purposes of this Lease, &#147;in the ordinary course of business&#148; shall include, without limitation, the review of documents on no more than three
(3)&nbsp;occasions in connection with any particular Transfer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.2&#8194;&#8195;<B><U>Landlord&#146;s Consent</U></B>. Landlord shall not
unreasonably withhold or delay its consent to any proposed Transfer of the Subject Space to the Transferee on the terms specified in the Transfer Notice. Landlord shall approve or disapprove of any proposed Transfer within fifteen (15)&nbsp;business
days after receipt of a complete Transfer Notice. If Landlord fails to respond within such fifteen (15)&nbsp;business day period, then Tenant may send Landlord a reminder notice setting forth such failure containing the following sentence at the top
of such notice in bold, capitalized font at least twelve (12)&nbsp;points in size: &#147;<B>LANDLORD&#146;S FAILURE TO RESPOND TO THIS NOTICE WITHIN FIVE (5)</B><B></B><B>&nbsp;BUSINESS DAYS SHALL RESULT IN LANDLORD&#146;S DEEMED APPROVAL OF
TENANT&#146;S REQUEST FOR TRANSFER</B>&#148; (the &#147;<B>Transfer Reminder Notice</B>&#148;). Any such Transfer Reminder Notice shall include a complete copy of Tenant&#146;s Transfer Notice. If Landlord fails to respond within five
(5)&nbsp;business days after receipt of a Transfer Reminder Notice, then Tenant&#146;s Transfer for which Tenant requested Landlord&#146;s approval shall be deemed approved by Landlord. Without limitation as to other reasonable grounds for
withholding consent, the parties hereby agree that it shall be reasonable under this Lease and under any Applicable Law for Landlord to withhold consent to any proposed Transfer where one or more of the following apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.2.1 The Transferee is of a character or reputation or engaged in a business which is not consistent with the quality of
the Building or the Project; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.2.2 The Transferee is either a governmental agency or instrumentality thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.2.3 The Transferee is not a party of reasonable financial worth and/or financial stability in light of the
responsibilities to be undertaken in connection with the Transfer on the date consent is requested; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.2.4 The
proposed Transfer would cause a violation of another lease for space in the Project, or would give an occupant of the Project a right to cancel its lease; provided, that, within ten (10)&nbsp;business days after request from Tenant, Landlord shall
provide Tenant a list of any such use or competitor restrictions and cancellation rights then in effect at the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">If Landlord consents to any Transfer pursuant to the terms of this <U>Section</U><U></U><U>&nbsp;14.2</U> (and does not
exercise any recapture rights Landlord may have under <U>Section</U><U></U><U>&nbsp;14.4</U> of this Lease), Tenant may within six (6)&nbsp;months after Landlord&#146;s consent, but not later than the expiration of said <FONT
STYLE="white-space:nowrap">six-month</FONT> period, enter into such Transfer of the Premises or portion thereof, upon substantially the same terms and conditions as are set forth in the Transfer Notice furnished by Tenant to Landlord pursuant to
<U>Section</U><U></U><U>&nbsp;14.1</U> of this Lease, provided that if there are any changes in the terms and conditions from those specified in the Transfer Notice such that Landlord would initially have been entitled to refuse its consent to such
Transfer under this <U>Section</U><U></U><U>&nbsp;14.2</U>, Tenant shall again submit the Transfer to Landlord for its approval and other action under this <U>Article 14</U> (including Landlord&#146;s right of recapture, if any, under
<U>Section</U><U></U><U>&nbsp;14.4</U> of this Lease). Notwithstanding anything to the contrary in this Lease, if Tenant or any proposed Transferee claims that Landlord has unreasonably withheld or delayed its consent under
<U>Section</U><U></U><U>&nbsp;14.2</U> or otherwise has breached or acted unreasonably under this <U>Article 14</U>, their sole remedies shall be a suit for contract damages (other than damages for injury to, or interference with, Tenant&#146;s
business including, without limitation, loss of profits, however occurring) or declaratory judgment and an injunction for the relief sought, and Tenant hereby waives all other remedies, including, without limitation, any right at law or equity to
terminate this Lease, on its own behalf and, to the extent permitted under all Applicable Laws, on behalf of the proposed Transferee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.3&#8194;&#8195;<B><U>Transfer Premium</U></B>. If Landlord consents to a
Transfer, as a condition thereto which the parties hereby agree is reasonable, Tenant shall pay to Landlord fifty percent (50%) of any &#147;<B>Transfer Premium</B>,&#148; as that term is defined in this <U>Section</U><U></U><U>&nbsp;14.3</U>,
received by Tenant from such Transferee. &#147;<B>Transfer Premium</B>&#148; shall mean all rent, additional rent or other consideration payable by such Transferee in connection with the Transfer in excess of the Rent and Additional Rent payable by
Tenant under this Lease during the term of the Transfer on a per rentable square foot basis if less than all of the Premises is transferred, and after deduction of (i)&nbsp;any costs of alterations, modifications or improvements made to the Subject
Space in connection with such Transfer, (ii)&nbsp;brokerage commissions paid in connection with such Transfer, (iii)&nbsp;reasonable legal fees incurred in connection with such Transfer, and (iv)&nbsp;any free base rent, improvement allowance and
other economic concessions provided to the Transferee (collectively, &#147;Transfer Costs&#148;). &#147;<B>Transfer Premium</B>&#148; shall also include, but not be limited to, key money, bonus money or other cash consideration paid by Transferee to
Tenant in connection with such Transfer, and any payment in excess of fair market value for services rendered by Tenant to Transferee or for assets, fixtures, inventory, equipment, or furniture transferred by Tenant to Transferee in connection with
such Transfer. The determination of the amount of Landlord&#146;s applicable share of the Transfer Premium shall be made on a monthly basis as rent or other consideration is received by Tenant under the Transfer. Notwithstanding anything set forth
herein to the contrary, in no event shall Tenant be required to pay a Transfer Premium in connection with a Transfer pursuant to <U>Section</U><U></U><U>&nbsp;14.8</U> of this Lease, below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.4&#8194;&#8195;<B><U>Landlord&#146;s Option as to Subject Space</U></B>. Notwithstanding anything to the contrary contained
in this <U>Article&nbsp;14</U>, in the event Tenant contemplates a Transfer which, together with all prior Transfers then remaining in effect, would cause fifty percent (50%) or more of the Premises to be Transferred for more than fifty percent
(50%) of the then remaining Lease Term (taking into account any extension of the Lease Term which has irrevocably exercised by Tenant), Tenant shall give Landlord notice (the &#147;<B>Intention to Transfer Notice</B>&#148;) of such contemplated
Transfer (whether or not the contemplated Transferee or the terms of such contemplated Transfer have been determined). The Intention to Transfer Notice shall specify the portion of and amount of rentable square feet of the Premises which Tenant
intends to Transfer (the &#147;<B>Contemplated Transfer Space</B>&#148;), the contemplated date of commencement of the Contemplated Transfer (the &#147;<B>Contemplated Effective Date</B>&#148;), and the contemplated length of the term of such
contemplated Transfer, and shall specify that such Intention to Transfer Notice is delivered to Landlord pursuant to this <U>Section</U><U></U><U>&nbsp;14.4</U> in order to allow Landlord to elect to recapture the Contemplated Transfer Space.
Thereafter, Landlord shall have the option, by giving written notice (the &#147;<B>Recapture Notice</B>&#148;) to Tenant within thirty (30)&nbsp;days after receipt of any Intention to Transfer Notice, to recapture the Contemplated Transfer Space.
Notwithstanding the foregoing sentence, however, if Landlord delivers a Recapture Notice to Tenant, Tenant may, within ten (10)&nbsp;business days after Tenant&#146;s receipt of such Recapture Notice, deliver written notice to Landlord indicating
that Tenant is rescinding its request for consent to the proposed Transfer, in which case such Transfer shall not be consummated and this Lease shall remain in full force and effect as to the portion of the Premises that was the subject of the
proposed Transfer. Such recapture shall cancel and terminate this Lease with respect to such Contemplated Transfer Space as of the Contemplated Effective Date. In the event of a recapture by Landlord, if this Lease shall be canceled with respect
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
to less than the entire Premises, the Rent reserved herein shall be prorated on the basis of the number of rentable square feet retained by Tenant in proportion to the number of rentable square
feet contained in the Premises, and this Lease as so amended shall continue thereafter in full force and effect, and upon request of either party, the parties shall execute written confirmation of the same. If Landlord declines, or fails to elect in
a timely manner, to recapture such Contemplated Transfer Space under this <U>Section</U><U></U><U>&nbsp;14.4</U>, then, subject to the other terms of this <U>Article 14</U>, for a period of nine (9)&nbsp;months (the &#147;<B>Nine Month
Period</B>&#148;) commencing on the last day of such thirty (30)&nbsp;day period, Landlord shall not have any right to recapture the Contemplated Transfer Space with respect to any Transfer made during the Nine Month Period, provided that any such
Transfer is substantially on the terms set forth in the Intention to Transfer Notice, and provided further that any such Transfer shall be subject to the remaining terms of this <U>Article 14</U>. If such a Transfer is not so consummated within the
Nine Month Period (or if a Transfer is so consummated, then upon the expiration of the term of any Transfer of such Contemplated Transfer Space consummated within such Nine Month Period), Tenant shall again be required to submit a new Intention to
Transfer Notice to Landlord with respect any contemplated Transfer, as provided above in this <U>Section</U><U></U><U>&nbsp;14.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.5&#8194;&#8195;<B><U>Effect of Transfer</U></B>. If Landlord consents to a Transfer, (i)&nbsp;the terms and conditions of
this Lease shall in no way be deemed to have been waived or modified, (ii)&nbsp;such consent shall not be deemed consent to any further Transfer by either Tenant or a Transferee, (iii)&nbsp;Tenant shall deliver to Landlord, promptly after execution,
an original executed copy of all documentation pertaining to the Transfer in form reasonably acceptable to Landlord, (iv)&nbsp;Tenant shall furnish upon Landlord&#146;s request a complete statement, certified by an independent certified public
accountant, or an officer of Tenant, setting forth the computation of any Transfer Premium Tenant has derived and shall derive from such Transfer, and (v)&nbsp;no Transfer relating to this Lease or agreement entered into with respect thereto,
whether with or without Landlord&#146;s consent, shall relieve Tenant or any guarantor of the Lease from any liability under this Lease, including, without limitation, in connection with the Subject Space. Landlord or its authorized representatives
shall have the right at all reasonable times to audit the books, records and papers of Tenant relating to any Transfer, and shall have the right to make copies thereof. If the Transfer Premium respecting any Transfer shall be found understated,
Tenant shall, within thirty (30)&nbsp;days after demand, pay the deficiency, and if understated by more than four percent (4%), Tenant shall pay Landlord&#146;s costs of such audit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.6&#8194;&#8195;<B><U>Additional Transfers</U></B>. For purposes of this Lease, the term &#147;<B>Transfer</B>&#148; shall
also include if Tenant is a partnership, the withdrawal or change, voluntary, involuntary or by operation of law, of fifty percent (50%) or more of the partners, or transfer of fifty percent (50%) or more of partnership interests, within a twelve
(12)-month period, or the dissolution of the partnership without immediate reconstitution thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.7&#8194;&#8195;<B><U>Occurrence of Default</U></B>. Any Transfer hereunder shall be subordinate and subject to the
provisions of this Lease, and if this Lease shall be terminated during the term of any Transfer, Landlord shall have the right to: (i)&nbsp;treat such Transfer as cancelled and repossess the Subject Space by any lawful means, or (ii)&nbsp;require
that such Transferee attorn to and recognize Landlord as its landlord under any such Transfer. If Tenant shall be in default under this Lease, beyond all applicable notice and cure periods expressly set forth in this Lease, Landlord is hereby
irrevocably authorized to direct any Transferee to make all payments under or in connection with the Transfer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
directly to Landlord (which Landlord shall apply towards Tenant&#146;s obligations under this Lease) until such default is cured. Such Transferee shall rely on any representation by Landlord that
Tenant is in default hereunder, without any need for confirmation thereof by Tenant. Upon any assignment, the assignee shall assume in writing all obligations and covenants of Tenant thereafter to be performed or observed under this Lease. No
collection or acceptance of rent by Landlord from any Transferee shall be deemed a waiver of any provision of this <U>Article 14</U> or the approval of any Transferee or a release of Tenant from any obligation under this Lease, whether theretofore
or thereafter accruing. In no event shall Landlord&#146;s enforcement of any provision of this Lease against any Transferee be deemed a waiver of Landlord&#146;s right to enforce any term of this Lease against Tenant or any other person. If
Tenant&#146;s obligations hereunder have been guaranteed, Landlord&#146;s consent to any Transfer shall not be effective unless the guarantor also consents to such Transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.8&#8194;&#8195;<B><U><FONT STYLE="white-space:nowrap">Non-Transfers</FONT></U></B>. Notwithstanding anything to the
contrary contained in this <U>Article 14</U>, (i) an assignment or subletting of all or a portion of the Premises to an affiliate of Tenant (an entity which is controlled by, controls, or is under common control with, Tenant), (ii) an assignment of
the Premises to an entity which acquires all or substantially all of the assets or interests (partnership, stock or other) of Tenant, (iii)&nbsp;an assignment of the Premises to an entity which is the resulting entity of a merger or consolidation of
Tenant with another entity, or (iv)&nbsp;a sale of corporate shares of capital stock in Tenant in connection with a public offering of Tenant&#146;s stock on a nationally- recognized stock exchange (collectively, a &#147;<B>Permitted
Transferee</B>&#148;), shall not be deemed a Transfer under this <U>Article</U> <U>14</U>, provided that (A)&nbsp;Tenant notifies Landlord of any such assignment or sublease and promptly supplies Landlord with any documents or information requested
by Landlord regarding such assignment or sublease or such affiliate, (B)&nbsp;such assignment or sublease is not a subterfuge by Tenant to avoid its obligations under this Lease, (C)&nbsp;such Permitted Transferee shall be of a character and
reputation consistent with the quality of the Building, and (D)&nbsp;such Permitted Transferee shall have a tangible net worth (not including goodwill as an asset) computed in accordance with generally accepted accounting principles (&#147;<B>Net
Worth</B>&#148;) at least equal to the Net Worth of Tenant on the day immediately preceding the effective date of such assignment or sublease. An assignee of Tenant&#146;s entire interest that is also a Permitted Transferee may also be known as a
&#147;<B>Permitted Transferee Assignee</B>&#148;. &#147;<B>Control</B>,&#148; as used in this <U>Section</U><U></U><U>&nbsp;14.8</U>, shall mean the ownership, directly or indirectly, of at least <FONT STYLE="white-space:nowrap">fifty-one</FONT>
percent (51%) of the voting securities of, or possession of the right to vote, in the ordinary direction of its affairs, of at least <FONT STYLE="white-space:nowrap">fifty-one</FONT> percent (51%) of the voting interest in, any person or entity. No
such permitted assignment or subletting shall serve to release Tenant from any of its obligations under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.9&#8194;&#8195;<B><U>Permitted Occupancy</U></B>. Landlord acknowledges that one of Tenant&#146;s uses of the Premises is
for a business incubator. Accordingly, Tenant shall have the right to sublease or license portions of the Premises to &#147;Permitted Occupants&#148; (defined below) pursuant to a commercially reasonable sublease agreement per the terms of this
Section&nbsp;14, without (i)&nbsp;Landlord approval, (ii)&nbsp;Landlord having a right to recapture the Premises, (iii)&nbsp;notice to Landlord, (iv)&nbsp;Landlord sharing in any profit or income from such sublease; and (v)&nbsp;payment of the
Transfer Premium. Notwithstanding any provision contained in the Lease to the contrary, Landlord hereby acknowledges and agrees that, Tenant may, subject to the applicable terms and conditions of the Lease, permit no more than twenty-five percent
(25%) of the Premises (the &#147;<B>Permitted Occupant Space</B>&#148;) to be occupied and utilized for the use permitted by the Lease by any individual third parties that have a sublease or license agreement with Tenant (the &#147;<B>Permitted
Occupants</B>&#148;) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
without Landlord&#146;s consent; provided however, (a)&nbsp;such Permitted Occupants shall be of a character and reputation consistent with the first-class quality of the Building and shall not
violate the terms of any other lease in the Building; and (b)&nbsp;such occupancy shall not be a subterfuge by Tenant to avoid its obligations under the Lease, or the restrictions on Transfers pursuant to <U>this Article 14</U>. Tenant shall
promptly supply Landlord with the name of any such Permitted Occupants, a copy of the fully-executed sublease or license with such Permitted Occupant and any documents or information reasonably requested by Landlord regarding any such Permitted
Occupants and/or their occupancy of the Permitted Occupant Space. The occupancy of the Permitted Occupant Space by any Permitted Occupants permitted under this <U>Section</U><U></U><U>&nbsp;14.9</U> shall not be deemed a Transfer. Notwithstanding
the foregoing, no such occupancy by any such Permitted Occupants shall relieve Tenant from any liability under the Lease. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>SURRENDER OF PREMISES; OWNERSHIP AND REMOVAL OF TRADE FIXTURES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">15.1&#8194;&#8195;<B><U>Surrender of Premises</U></B>. No act or thing done by Landlord or any agent or employee of Landlord
during the Lease Term shall be deemed to constitute an acceptance by Landlord of a surrender of the Premises unless such intent is specifically acknowledged in writing by Landlord. The delivery of keys to the Premises to Landlord or any agent or
employee of Landlord shall not constitute a surrender of the Premises or effect a termination of this Lease, whether or not the keys are thereafter retained by Landlord, and notwithstanding such delivery Tenant shall be entitled to the return of
such keys at any reasonable time upon request until this Lease shall have been properly terminated. The voluntary or other surrender of this Lease by Tenant, whether accepted by Landlord or not, or a mutual termination hereof, shall not work a
merger, and at the option of Landlord shall operate as an assignment to Landlord of all subleases or subtenancies affecting the Premises or terminate any or all such sublessees or subtenancies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">15.2&#8194;&#8195;<B><U>Removal of Tenant Property by Tenant</U></B>. Upon the expiration of the Lease Term, or upon any
earlier termination of this Lease, Tenant shall, subject to the provisions of this <U>Article 15</U>, quit and surrender possession of the Premises to Landlord in as good order and condition as when Tenant took possession and as thereafter improved
by Landlord and/or Tenant, reasonable wear and tear, casualty, condemnation and repairs which are specifically made the responsibility of Landlord hereunder excepted. Upon such expiration or termination, Tenant shall, without expense to Landlord,
remove or cause to be removed from the Premises all debris and rubbish, and such items of furniture, equipment, free-standing cabinet work, movable partitions and other articles of personal property owned by Tenant or installed or placed by Tenant
at its expense in the Premises, and such similar articles of any other persons claiming under Tenant, as Landlord may, in its sole discretion, require to be removed, and Tenant shall repair at its own expense all damage to the Premises and Building
resulting from such removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">15.3&#8194;&#8195;<B><U>Environmental Assessment</U></B>. In connection with its surrender
of the Premises, Tenant shall submit to Landlord, at least sixty (60)&nbsp;days prior to the expiration date of this Lease (or in the event of an earlier termination of this Lease, as soon as reasonably possible following such termination), an
environmental Assessment of the Premises by a competent and experienced environmental engineer or engineering firm reasonably satisfactory to Landlord (pursuant to a contract approved by Landlord and providing that Landlord can rely on the
Environmental Assessment). If such Environmental Assessment reveals that remediation or <FONT STYLE="white-space:nowrap">Clean-up</FONT> is required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
under any Environmental Laws, Tenant shall submit a remediation plan prepared by a recognized environmental consultant and shall be responsible for all costs of remediation and <FONT
STYLE="white-space:nowrap">Clean-up,</FONT> as more particularly provided in <B><U>Section</U></B><B><U></U></B><B><U>&nbsp;5.3</U></B>, above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">15.4&#8194;&#8195;<B><U>Condition of the Building and Premises Upon Surrender</U></B>. In addition to the above requirements
of this <U>Article 15</U>, upon the expiration of the Lease Term, or upon any earlier termination of this Lease, Tenant shall, surrender the Premises and with Tenant having complied with all of Tenant&#146;s obligations under this Lease, including
those relating to improvement, repair, maintenance, compliance with law, testing and other related obligations of Tenant set forth in <U>Article 7</U> of this Lease. In the event that the Premises shall be surrendered in a condition which does not
comply with the terms of this <U>Section</U><U></U><U>&nbsp;15.4</U>, because Tenant failed to comply with its obligations set forth in Lease, then following thirty (30)&nbsp;days&#146; notice to Tenant, during which thirty (30)&nbsp;day period
Tenant shall have the right to cure such noncompliance, Landlord shall be entitled to expend all reasonable costs in order to cause the same to comply with the required condition upon surrender and Tenant shall immediately reimburse Landlord for all
such costs upon notice, commencing on the later of the termination of this Lease and three (3)&nbsp;business days after Landlord&#146;s delivery of notice of such failure (i.e., given after the expiration of the
<FONT STYLE="white-space:nowrap">30-day</FONT> period set forth above) and that it elects to treat such failure as a holdover, and that Tenant shall be deemed during the period that Tenant or Landlord, as the case may be, perform obligations
relating to the Surrender Improvements, to be in holdover under <U>Article 16</U> of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>16.</B>&#8194;&#8195;<B>HOLDING
OVER</B><B> </B>If Tenant holds over after the expiration of the Lease Term or earlier termination thereof, with the express or implied consent of Landlord, such tenancy shall be from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-to-month</FONT></FONT> only, and shall not constitute a renewal hereof or an extension for any further term. If Tenant holds over after the expiration of the Lease Term of
earlier termination thereof, without the express or implied consent of Landlord, such tenancy shall be deemed to be a tenancy by sufferance only, and shall not constitute a renewal hereof or an extension for any further term. In either case, Base
Rent shall be payable at a monthly rate equal to 150% of the Base Rent applicable during the last month of the Lease Term under this Lease, prorated on a daily basis for each day of holdover. Such month-
<FONT STYLE="white-space:nowrap">to-month</FONT> tenancy or tenancy by sufferance, as the case may be, shall be subject to every other applicable term, covenant and agreement contained herein. Nothing contained in this Article 16 shall be construed
as consent by Landlord to any holding over by Tenant, and Landlord expressly reserves the right to require Tenant to surrender possession of the Premises to Landlord as provided in this Lease upon the expiration or other termination of this Lease.
The provisions of this Article 16 shall not be deemed to limit or constitute a waiver of any other rights or remedies of Landlord provided herein or at law. If Tenant fails to surrender the Premises within thirty (30)&nbsp;days following the
termination or expiration of this Lease, in addition to any other liabilities to Landlord accruing therefrom, Tenant shall protect, defend, indemnify and hold Landlord harmless from all loss, costs (including reasonable attorneys&#146; fees) and
liability resulting from such failure, including, without limiting the generality of the foregoing, any claims made by any succeeding tenant founded upon such failure to surrender and any lost profits to Landlord resulting therefrom.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>17.</B><B>&#8194;&#8195;</B><B>ESTOPPEL CERTIFICATES</B> Within ten (10)&nbsp;business days following a request in writing by Landlord,
Tenant shall execute and deliver to Landlord an estoppel certificate, which, as submitted by Landlord, shall be substantially in the form of <B><U>Exhibit D</U></B>, attached hereto (or such other commercially reasonable form as may be required by
any prospective mortgagee or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
purchaser of the Project, or any portion thereof), indicating therein any exceptions thereto that may exist at that time, and shall also contain any other information reasonably requested by
Landlord or Landlord&#146;s mortgagee or prospective mortgagee. Any such certificate may be relied upon by any prospective mortgagee or purchaser of all or any portion of the Project. Tenant shall execute and deliver other commercially reasonable
instruments as may be reasonably required for such purposes. At any time during the Lease Term (but not more than once in any calendar year unless in connection with the sale or proposed sale, or the financing/refinancing, of the Project or any
portion thereof), Landlord may require Tenant to provide Landlord with a current financial statement and financial statements of the two (2)&nbsp;years prior to the current financial statement year. Such statements shall be prepared in accordance
with generally accepted accounting principles and, if such is the normal practice of Tenant, shall be audited by an independent certified public accountant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>18.</B>&#8194;&#8195;<B>SUBORDINATION</B><B> </B>As of the date of this Lease the Project is not subject to any ground lease, or to the
lien of any mortgage or deed of trust. This Lease shall be subject and subordinate to all present and future ground or underlying leases of the Building or Project and to the lien of any mortgage, trust deed or other encumbrances now or hereafter in
force against the Building or Project or any part thereof, if any, and to all renewals, extensions, modifications, consolidations and replacements thereof, and to all advances made or hereafter to be made upon the security of such mortgages or trust
deeds, unless the holders of such mortgages, trust deeds or other encumbrances, or the lessors under such ground lease or underlying leases, require in writing that this Lease be superior thereto. The subordination of this Lease to any such future
ground or underlying leases of the Building or Project or to the lien of any mortgage, trust deed or other encumbrances, shall be subject to Landlord utilizing commercially reasonable efforts to deliver to Tenant a commercially reasonable
subordination, <FONT STYLE="white-space:nowrap">non-disturbance,</FONT> and attornment agreement in favor of Tenant. Tenant covenants and agrees in the event any proceedings are brought for the foreclosure of any such mortgage or deed in lieu
thereof (or if any ground lease is terminated), to attorn, without any deductions or <FONT STYLE="white-space:nowrap">set-offs</FONT> whatsoever, to the lienholder or purchaser or any successors thereto upon any such foreclosure sale or deed in lieu
thereof (or to the ground lessor), if so requested to do so by such purchaser or lienholder or ground lessor, and to recognize such purchaser or lienholder or ground lessor as the lessor under this Lease, provided such lienholder or purchaser or
ground lessor shall agree to accept this Lease and not disturb Tenant&#146;s occupancy, so long as Tenant timely pays the rent and observes and performs the terms, covenants and conditions of this Lease to be observed and performed by Tenant.
Landlord&#146;s interest herein may be assigned as security at any time to any lienholder. Tenant shall, within fifteen (15)&nbsp;business days of request by Landlord, execute such further instruments or assurances as Landlord may reasonably deem
necessary to evidence or confirm the subordination or superiority of this Lease to any such mortgages, trust deeds, ground leases or underlying leases. Tenant waives the provisions of any current or future statute, rule or law which may give or
purport to give Tenant any right or election to terminate or otherwise adversely affect this Lease and the obligations of the Tenant hereunder in the event of any foreclosure proceeding or sale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>DEFAULTS; REMEDIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19.1&#8194;&#8195;<B><U>Events of Default</U></B>. The occurrence of any of the following shall constitute a default of this
Lease by Tenant (each, an &#147;<B>Event of Default</B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19.1.1 Any failure by Tenant to pay when due any Rent or
any other charge required to be paid under this Lease, or any part thereof, when due unless such failure is cured within five (5)&nbsp;business days after notice; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19.1.2 Any failure by Tenant to observe or perform any other provision, covenant or condition of this Lease (except those
failures referred to in Sections 19.1.1 and 19.1.4) to be observed or performed by Tenant where such failure continues for thirty (30)&nbsp;days after written notice thereof from Landlord to Tenant; provided that if the nature of such default is
such that the same cannot reasonably be cured within a thirty (30)&nbsp;day period, Tenant shall not be deemed to be in default if it diligently commences such cure within such period and thereafter diligently proceeds to rectify and cure such
default; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19.1.3 Abandonment (as defined by Applicable Laws) of all or a substantial portion of the Premises by
Tenant; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19.1.4 The failure by Tenant to observe or perform according to the provisions of <U>Articles 5</U>,
<U>14</U>, <U>17</U> or <U>18</U> of this Lease where such failure continues for more than three (3)&nbsp;business days after notice from Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The notice periods provided herein are in lieu of, and not in addition to, any notice periods provided by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19.2&#8194;&#8195;<B><U>Remedies Upon Default</U></B>. Upon the occurrence of any event of default by Tenant, Landlord shall
have, in addition to any other remedies available to Landlord at law or in equity (all of which remedies shall be distinct, separate and cumulative), the option to pursue any one or more of the following remedies, each and all of which shall be
cumulative and nonexclusive, without any notice or demand whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19.2.1 Terminate this Lease, in which event Tenant
shall immediately surrender the Premises to Landlord, and if Tenant fails to do so, Landlord may, without prejudice to any other remedy which it may have for possession or arrearages in rent, enter upon and take possession of the Premises and expel
or remove Tenant and any other person who may be occupying the Premises or any part thereof, without being liable for prosecution or any claim or damages therefor; and Landlord may recover from Tenant the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(i)&#8195;The worth at the time of award of the unpaid rent which has been earned at the time of such
termination; plus </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(ii)&#8195;The worth at the time of award of the amount by which the unpaid rent which
would have been earned after termination until the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(iii)&#8195;The worth at the time of award of the amount by which the unpaid rent for the balance of the
Lease Term after the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(iv)&#8195;Any other amount necessary to compensate Landlord for all the detriment proximately caused by
Tenant&#146;s failure to perform its obligations under this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
Lease or which in the ordinary course of things would be likely to result therefrom, specifically including but not limited to, brokerage commissions and advertising expenses incurred, expenses
of remodeling the Premises or any portion thereof for a new tenant, whether for the same or a different use, and any special concessions made to obtain a new tenant; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(v)&#8195;At Landlord&#146;s election, such other amounts in addition to or in lieu of the foregoing as may
be permitted from time to time by Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The term &#147;<B>rent</B>&#148; as used in this
<U>Section</U><U></U><U>&nbsp;19.2</U> shall be deemed to be and to mean all sums of every nature required to be paid by Tenant pursuant to the terms of this Lease, whether to Landlord or to others. As used in <U>Sections</U> <U>19.2.1(i)</U> and
<U>(ii)</U>, above, the &#147;worth at the time of award&#148; shall be computed by allowing interest at the rate set forth in <U>Article 25</U> of this Lease, but in no case greater than the maximum amount of such interest permitted by law. As used
in <U>Section</U><U></U><U>&nbsp;19.2.1(iii)</U> above, the &#147;<B>worth at the time of award</B>&#148; shall be computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one
percent (1%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19.2.2 Landlord shall have the remedy described in California Civil Code Section&nbsp;1951.4 (lessor may
continue lease in effect after lessee&#146;s breach and abandonment and recover rent as it becomes due, if lessee has the right to sublet or assign, subject only to reasonable limitations). Accordingly, if Landlord does not elect to terminate this
Lease on account of any Event of Default by Tenant, Landlord may, from time to time, without terminating this Lease, enforce all of its rights and remedies under this Lease, including the right to recover all rent as it becomes due. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19.2.3 Landlord shall at all times have the rights and remedies (which shall be cumulative with each other and cumulative and
in addition to those rights and remedies available under <U>Sections 19.2.1</U> and <U>19.2.2</U>, above, or any law or other provision of this Lease), without prior demand or notice except as required by Applicable Law, to seek any declaratory,
injunctive or other equitable relief, and specifically enforce this Lease, or restrain or enjoin a violation or breach of any provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19.3&#8194;&#8195;<B><U>Subleases of Tenant</U></B>. Whether or not Landlord elects to terminate this Lease on account of any
Event of Default by Tenant, as set forth in this <U>Article 19</U>, Landlord shall have the right to terminate any and all subleases, licenses, concessions or other consensual arrangements for possession entered into by Tenant and affecting the
Premises or may, in Landlord&#146;s sole discretion, succeed to Tenant&#146;s interest in such subleases, licenses, concessions or arrangements. In the event of Landlord&#146;s election to succeed to Tenant&#146;s interest in any such subleases,
licenses, concessions or arrangements, Tenant shall, as of the date of notice by Landlord of such election, have no further right to or interest in the rent or other consideration receivable thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19.4&#8194;&#8195;<B><U>Efforts to Relet</U></B>. No <FONT STYLE="white-space:nowrap">re-entry</FONT> or repossession,
repairs, maintenance, changes, alterations and additions, reletting, appointment of a receiver to protect Landlord&#146;s interests hereunder, or any other action or omission by Landlord shall be construed as an election by Landlord to terminate
this Lease or Tenant&#146;s right to possession, or to accept a surrender of the Premises, nor shall same operate to release Tenant in whole or in part from any of Tenant&#146;s obligations hereunder, unless express written notice of such intention
is sent by Landlord to Tenant. Tenant hereby irrevocably waives any right otherwise available under any law to redeem or reinstate this Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19.5&#8194;&#8195;<B><U>Landlord Default</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19.5.1 <B><U>In General</U></B>. Notwithstanding anything to the contrary set forth in this Lease, Landlord shall not be in
default in the performance of any obligation required to be performed by Landlord pursuant to this Lease unless Landlord fails to perform such obligation within thirty (30)&nbsp;days after written notice thereof from Tenant to Landlord specifying in
detail Landlord&#146;s failure to perform; provided, however, if the nature of Landlord&#146;s obligation is such that the same cannot reasonably be cured within a thirty (30)&nbsp;day period, then Landlord shall not be in default under this Lease
if it shall diligently commence such cure within such thirty (30)&nbsp;day period and thereafter diligently pursue the same to completion. Upon any such default by Landlord under this Lease, Tenant may, except as otherwise specifically provided in
this Lease to the contrary, exercise any of its rights provided under this Lease at law or in equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19.5.2
<B><U>Abatement of Rent</U></B>. In the event that Tenant is prevented from using, and does not use, the Premises or any portion thereof, as a result of (i)&nbsp;any repair, maintenance or alteration performed by Landlord, or which Landlord failed
to perform, and required by this Lease, or (ii)&nbsp;any failure to provide services, utilities or access to the Premises as required by this Lease, each as a direct result of Landlord&#146;s, negligence or willful misconduct or breach of this Lease
(and except to the extent such failure is caused by the action or inaction of Tenant) (any such set of circumstances as set forth in items (i)&nbsp;or (ii), above, to be known as an &#147;<B>Abatement Event</B>&#148;), then Tenant shall give
Landlord notice of such Abatement Event, and if such Abatement Event continues for five (5)&nbsp;consecutive business days after Landlord&#146;s receipt of any such notice (the &#147;<B>Eligibility Period</B>&#148;), then the Base Rent,
Tenant&#146;s Share of Direct Expenses, and Tenant&#146;s obligation, if any, to pay for parking (to the extent not utilized by Tenant) shall be abated or reduced, as the case may be, after expiration of the Eligibility Period for such time that
Tenant continues to be so prevented from using, and does not use for the normal conduct of Tenant&#146;s business, the Premises or a portion thereof, in the proportion that the rentable area of the portion of the Premises that Tenant is prevented
from using, and does not use, bears to the total rentable area of the Premises; provided, however, in the event that Tenant is prevented from using, and does not use, a portion of the Premises for a period of time in excess of the Eligibility Period
and the remaining portion of the Premises is not sufficient to allow Tenant to effectively conduct its business therein, and if Tenant does not effectively conduct its business from such remaining portion, then for such time after expiration of the
Eligibility Period during which Tenant is so prevented from effectively conducting its business therein, the Base Rent and Tenant&#146;s Share of Direct Expenses for the entire Premises and Tenant&#146;s obligation to pay for parking, if any, shall
be abated for such time as Tenant continues to be so prevented from using, and does not use, the Premises. If, however, Tenant reoccupies any portion of the Premises during such period, the Rent allocable to such reoccupied portion, based on the
proportion that the rentable area of such reoccupied portion of the Premises bears to the total rentable area of the Premises, shall be payable by Tenant from the date Tenant reoccupies such portion of the Premises. In addition, if, as a result of
an Abatement Event, Tenant is prevented from using, and does not use, the Premises or any portion thereof for a continuous period of seventy five (75)&nbsp;days, then Tenant shall have the right to terminate this Lease upon ten (10)&nbsp;days&#146;
written notice to Landlord, in which event this Lease shall terminate upon the expiration of such ten (10)&nbsp;day period unless such use is restored within </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
such ten (10)&nbsp;day period. In the event of any Abatement Event, Landlord shall diligently pursue the remedy of the same as promptly as possible. To the extent an Abatement Event is caused by
an event covered by Articles 11 or 13 of this Lease, then Tenant&#146;s right to abate rent shall be governed by the terms of such Article 11 or 13, as applicable, and the Eligibility Period shall not be applicable thereto. Except as provided in
this <U>Section</U><U></U><U>&nbsp;19.5.2</U>, nothing contained herein shall be interpreted to mean that Tenant is excused from paying Rent due hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>20.&#8194;&#8195;COVENANT OF QUIET ENJOYMENT</B> Landlord covenants that Tenant, so long as no Event of Default exists, shall, during the
Lease Term, peaceably and quietly have, hold and enjoy the Premises subject to the terms, covenants, conditions, provisions and agreements hereof without interference by any persons lawfully claiming by or through Landlord. The foregoing covenant is
in lieu of any other covenant express or implied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>21.&#8194;&#8195;LETTER OF CREDIT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">21.1&#8194;&#8195;<B><U>Delivery of Letter of Credit</U></B>. Tenant shall deliver to Landlord, concurrently with
Tenant&#146;s execution of this Lease, an unconditional, clean, irrevocable letter of credit (the &#147;<B><FONT STYLE="white-space:nowrap">L-C</FONT></B>&#148;) in the amount set forth in <U>Section</U><U></U><U>&nbsp;8</U> of the Lease Summary
(the &#147;<B><FONT STYLE="white-space:nowrap">L-C</FONT> Amount</B>&#148;), which <FONT STYLE="white-space:nowrap">L-C</FONT> shall be issued by a money-center, solvent and nationally recognized bank (a bank which accepts deposits, maintains
accounts, has a local San Francisco Bay Area office which will negotiate a letter of credit, and whose deposits are insured by the FDIC) reasonably acceptable to Landlord (such approved, issuing bank being referred to herein as the
&#147;<B>Bank</B>&#148;), which Bank must have a rating from Standard and Poors Corporation of <FONT STYLE="white-space:nowrap">A-</FONT> or better (or any equivalent rating thereto from any successor or substitute rating service selected by Lessor)
and a letter of credit issuer rating from Moody&#146;s Investor Service of A3 or better (or any equivalent rating thereto from any successor rating agency thereto)) (collectively, the &#147;<B>Bank&#146;s Credit Rating Threshold</B>&#148;), and
which <FONT STYLE="white-space:nowrap">L-C</FONT> shall be in the form of <B>Exhibit F </B>attached hereto. Notwithstanding the foregoing, Landlord hereby approves the form of <FONT STYLE="white-space:nowrap">L-C</FONT> attached hereto as
<B><U>Exhibit F</U></B>. Tenant shall pay all expenses, points and/or fees incurred by Tenant in obtaining the <FONT STYLE="white-space:nowrap">L-C.</FONT> The <FONT STYLE="white-space:nowrap">L-C</FONT> shall (i)&nbsp;be &#147;callable&#148; at
sight, irrevocable and unconditional, (ii)&nbsp;be maintained in effect, whether through renewal or extension, for the period commencing on the date of this Lease and continuing until the date (the
&#147;<B><FONT STYLE="white-space:nowrap">L-C</FONT> Expiration Date</B>&#148;) that is no less than sixty (60)&nbsp;days after the expiration of the Lease Term as the same may be extended, and Tenant shall deliver a new <FONT
STYLE="white-space:nowrap">L-C</FONT> or certificate of renewal or extension to Landlord at least sixty (60)&nbsp;days prior to the expiration of the <FONT STYLE="white-space:nowrap">L-C</FONT> then held by Landlord, without any action whatsoever on
the part of Landlord, (iii)&nbsp;be fully assignable by Landlord, its successors and assigns, (iv)&nbsp;permit partial draws and multiple presentations and drawings, and (v)&nbsp;be otherwise subject to the Uniform Customs and Practices for
Documentary Credits <FONT STYLE="white-space:nowrap">(1993-Rev),</FONT> International Chamber of Commerce Publication #500, or the International Standby <FONT STYLE="white-space:nowrap">Practices-ISP</FONT> 98, International Chamber of Commerce
Publication #590. Landlord, or its then managing agent, shall have the right to draw down an amount up to the face amount of the <FONT STYLE="white-space:nowrap">L-C</FONT> if any of the following shall have occurred or be applicable: (A)&nbsp;such
amount is due to Landlord under the terms and conditions of this Lease, and has not been paid within applicable notice and cure periods (or, if Landlord is prevented by law from providing notice, within the period for payment set forth in the
Lease), or (B)&nbsp;Tenant has filed a voluntary petition under the U. S. Bankruptcy Code or any state bankruptcy code (collectively, &#147;Bankruptcy Code&#148;), or (C)&nbsp;an involuntary petition has been filed against Tenant under the
Bankruptcy Code that is not dismissed within thirty (30)&nbsp;days, or (D)&nbsp;the Lease has been rejected, or is deemed rejected, under Section&nbsp;365 of the U.S. Bankruptcy Code, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
following the filing of a voluntary petition by Tenant under the Bankruptcy Code, or the filing of an involuntary petition against Tenant under the Bankruptcy Code, or (E)&nbsp;the Bank has
notified Landlord that the <FONT STYLE="white-space:nowrap">L-C</FONT> will not be renewed or extended through the <FONT STYLE="white-space:nowrap">L-C</FONT> Expiration Date, and Tenant has not provided a replacement
<FONT STYLE="white-space:nowrap">L-C</FONT> that satisfies the requirements of this Lease at least thirty (30)&nbsp;days prior to such expiration, or (F)&nbsp;Tenant is placed into receivership or conservatorship, or becomes subject to similar
proceedings under Federal or State law, or (G)&nbsp;Tenant executes an assignment for the benefit of creditors, or (H)&nbsp;if any of the Bank&#146;s Fitch Ratings (or other comparable ratings to the extent the Fitch Ratings are no longer available)
have been reduced below the Bank&#146;s Credit Rating Threshold, and Tenant has failed to provide Landlord with a replacement letter of credit, conforming in all respects to the requirements of this <U>Article 21</U> (including, but not limited to,
the requirements placed on the issuing Bank more particularly set forth in this <U>Section</U><U>&nbsp;21.1</U> above), in the amount of the applicable <FONT STYLE="white-space:nowrap">L-C</FONT> Amount, within ten (10)&nbsp;business days following
Landlord&#146;s written demand therefor (with no other notice or cure or grace period being applicable thereto, notwithstanding anything in this Lease to the contrary) (each of the foregoing being an
&#147;<B><FONT STYLE="white-space:nowrap">L-C</FONT> Draw Event</B>&#148;). The <FONT STYLE="white-space:nowrap">L-C</FONT> shall be honored by the Bank regardless of whether Tenant disputes Landlord&#146;s right to draw upon the <FONT
STYLE="white-space:nowrap">L-C.</FONT> In addition, in the event the Bank is placed into receivership or conservatorship by the Federal Deposit Insurance Corporation or any successor or similar entity, then, effective as of the date such
receivership or conservatorship occurs, said <FONT STYLE="white-space:nowrap">L-C</FONT> shall be deemed to fail to meet the requirements of this <U>Article 21</U>, and, within ten (10)&nbsp;business days following Landlord&#146;s notice to Tenant
of such receivership or conservatorship (the &#147;<B><FONT STYLE="white-space:nowrap">L-C</FONT> FDIC Replacement Notice</B>&#148;), Tenant shall replace such <FONT STYLE="white-space:nowrap">L-C</FONT> with a substitute letter of credit from a
different issuer (which issuer shall meet or exceed the Bank&#146;s Credit Rating Threshold and shall otherwise be acceptable to Landlord in its reasonable discretion) and that complies in all respects with the requirements of this <U>Article
21</U>. If Tenant fails to replace such <FONT STYLE="white-space:nowrap">L-C</FONT> with such conforming, substitute letter of credit pursuant to the terms and conditions of this <U>Section</U><U></U><U>&nbsp;21.1</U>, then, notwithstanding anything
in this Lease to the contrary, Landlord shall have the right to declare Tenant in default of this Lease for which there shall be no further notice or grace or cure periods being applicable thereto (other than the aforesaid ten (10)&nbsp;business day
period). Tenant shall be responsible for the payment of any and all Tenant&#146;s and Bank&#146;s costs incurred with the review of any replacement <FONT STYLE="white-space:nowrap">L-C,</FONT> which replacement is required pursuant to this Section
or is otherwise requested by Tenant. In the event of an assignment by Tenant of its interest in the Lease (and irrespective of whether Landlord&#146;s consent is required for such assignment), the acceptance of any replacement or substitute letter
of credit by Landlord from the assignee shall be subject to Landlord&#146;s prior written approval, in Landlord&#146;s reasonable discretion, and the actual and reasonable attorney&#146;s fees incurred by Landlord in connection with such
determination shall be payable by Tenant to Landlord within thirty (30)&nbsp;days of billing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">21.2&#8194;&#8195;<B><U>Application of L</U></B><U>-</U><B><U>C</U></B>. Tenant hereby acknowledges and agrees that Landlord
is entering into this Lease in material reliance upon the ability of Landlord to draw upon the <FONT STYLE="white-space:nowrap">L-C</FONT> upon the occurrence of any <FONT STYLE="white-space:nowrap">L-C</FONT> Draw Event. In the event of any <FONT
STYLE="white-space:nowrap">L-C</FONT> Draw Event, Landlord may, but without obligation to do so, and without notice to Tenant (except in connection with an <FONT STYLE="white-space:nowrap">L-C</FONT> Draw Event under
<U>Section</U><U></U><U>&nbsp;21.1(H)</U> above), draw upon the <FONT STYLE="white-space:nowrap">L-C,</FONT> in part or in whole, in the amount necessary to cure any such <FONT STYLE="white-space:nowrap">L-C</FONT> Draw Event and/or to compensate
Landlord for any and all damages of any kind or nature sustained or which Landlord reasonably estimates that it will sustain resulting from Tenant&#146;s breach or default of the Lease or other <FONT STYLE="white-space:nowrap">L-C</FONT> Draw Event
and/or to compensate Landlord for any and all damages arising out of, or incurred in connection with, the termination of this Lease, including, without limitation, those specifically identified in Section
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
1951.2 of the California Civil Code. The use, application or retention of the <FONT STYLE="white-space:nowrap">L-C,</FONT> or any portion thereof, by Landlord shall not prevent Landlord from
exercising any other right or remedy provided by this Lease or by any Applicable Law, it being intended that Landlord shall not first be required to proceed against the <FONT STYLE="white-space:nowrap">L-C,</FONT> and such <FONT
STYLE="white-space:nowrap">L-C</FONT> shall not operate as a limitation on any recovery to which Landlord may otherwise be entitled. Tenant agrees and acknowledges that (i)&nbsp;the <FONT STYLE="white-space:nowrap">L-C</FONT> constitutes a separate
and independent contract between Landlord and the Bank, (ii)&nbsp;Tenant is not a third party beneficiary of such contract, (iii)&nbsp;Tenant has no property interest whatsoever in the <FONT STYLE="white-space:nowrap">L-C</FONT> or the proceeds
thereof, and (iv)&nbsp;in the event Tenant becomes a debtor under any chapter of the Bankruptcy Code, Tenant is placed into receivership or conservatorship, and/or there is an event of a receivership, conservatorship or a bankruptcy filing by, or on
behalf of, Tenant, neither Tenant, any trustee, nor Tenant&#146;s bankruptcy estate shall have any right to restrict or limit Landlord&#146;s claim and/or rights to the <FONT STYLE="white-space:nowrap">L-C</FONT> and/or the proceeds thereof by
application of Section&nbsp;502(b)(6) of the U. S. Bankruptcy Code or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">21.3&#8194;&#8195;<B><U>Maintenance of <FONT
STYLE="white-space:nowrap">L-C</FONT> by Tenant</U></B>. If, as a result of any drawing by Landlord of all or any portion of the <FONT STYLE="white-space:nowrap">L-C,</FONT> the amount of the <FONT STYLE="white-space:nowrap">L-C</FONT> shall be less
than the <FONT STYLE="white-space:nowrap">L-C</FONT> Amount, Tenant shall, within five (5)&nbsp;days thereafter, provide Landlord with additional letter(s) of credit in an amount equal to the deficiency, and any such additional letter(s) of credit
shall comply with all of the provisions of this <U>Article 21</U>. Tenant further covenants and warrants that it will neither assign nor encumber the <FONT STYLE="white-space:nowrap">L-C</FONT> or any part thereof and that neither Landlord nor its
successors or assigns will be bound by any such assignment, encumbrance, attempted assignment or attempted encumbrance. Without limiting the generality of the foregoing, if the <FONT STYLE="white-space:nowrap">L-C</FONT> expires earlier than the <FONT
STYLE="white-space:nowrap">L-C</FONT> Expiration Date, Landlord will accept a renewal thereof (such renewal letter of credit to be in effect and delivered to Landlord, as applicable, not later than thirty (30)&nbsp;days prior to the expiration of
the <FONT STYLE="white-space:nowrap">L-C),</FONT> which shall be irrevocable and automatically renewable as above provided through the <FONT STYLE="white-space:nowrap">L-C</FONT> Expiration Date upon the same terms as the expiring <FONT
STYLE="white-space:nowrap">L-C</FONT> or such other terms as may be acceptable to Landlord in its sole discretion. If Tenant exercises its option to extend the Lease Term pursuant to <U>Section</U><U></U><U>&nbsp;2.2</U> of this Lease then, not
later than thirty (30)&nbsp;days prior to the commencement of the Option Term, Tenant shall deliver to Landlord a new L C or certificate of renewal or extension evidencing the <FONT STYLE="white-space:nowrap">L-C</FONT> Expiration Date as thirty
(30)&nbsp;days after the expiration of the Option Term. However, if the <FONT STYLE="white-space:nowrap">L-C</FONT> is not timely renewed, or if Tenant fails to maintain the <FONT STYLE="white-space:nowrap">L-C</FONT> in the amount and in accordance
with the terms set forth in this <U>Article 21</U>, Landlord shall have the right to present the <FONT STYLE="white-space:nowrap">L-C</FONT> to the Bank in accordance with the terms of this <U>Article 21</U>, and the proceeds of the <FONT
STYLE="white-space:nowrap">L-C</FONT> may be applied by Landlord against any Rent payable by Tenant under this Lease that is not paid when due and/or to pay for all losses and damages that Landlord has suffered or that Landlord reasonably estimates
that it will suffer as a result of any breach or default by Tenant under this Lease. In the event Landlord elects to exercise its rights as provided above, (I)&nbsp;any unused proceeds shall constitute the property of Landlord (and not Tenant&#146;s
property or, in the event of a receivership, conservatorship, or a bankruptcy filing by, or on behalf of, Tenant, property of such receivership, conservatorship or Tenant&#146;s bankruptcy estate) and need not be segregated from Landlord&#146;s
other assets, and (II)&nbsp;Landlord agrees to pay to Tenant within thirty (30)&nbsp;days after the <FONT STYLE="white-space:nowrap">L-C</FONT> Expiration Date the amount of any proceeds of the <FONT STYLE="white-space:nowrap">L-C</FONT> received by
Landlord and not applied against any Rent payable by Tenant under this Lease that was not paid when due or used to pay for any losses and/or damages suffered by Landlord (or reasonably estimated by Landlord that it will suffer) as a result of any
breach or default by Tenant under this Lease; provided, however, that if prior to the <FONT STYLE="white-space:nowrap">L-C</FONT> Expiration Date a voluntary petition is filed by Tenant, or an involuntary petition is filed against Tenant by any of
Tenant&#146;s creditors, under the Bankruptcy Code, then </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
Landlord shall not be obligated to make such payment in the amount of the unused <FONT STYLE="white-space:nowrap">L-C</FONT> proceeds until either all preference issues relating to payments under
this Lease have been resolved in such bankruptcy or reorganization case or such bankruptcy or reorganization case has been dismissed. If Landlord draws on the <FONT STYLE="white-space:nowrap">L-C</FONT> due to Tenant&#146;s failure to timely renew
or provide a replacement <FONT STYLE="white-space:nowrap">L-C,</FONT> such failure shall not be considered a default under this Lease and Landlord shall return such cash proceeds upon Tenant&#146;s presentation of a replacement <FONT
STYLE="white-space:nowrap">L-C</FONT> that satisfies the requirements of this Lease, subject to reasonable satisfaction of any preference risk to Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">21.4&#8194;&#8195;<B><U>Transfer and Encumbrance</U></B>. In the event of a transfer of Landlord&#146;s interest in under this
Lease, Landlord shall transfer the <FONT STYLE="white-space:nowrap">L-C,</FONT> in whole or in part, to the transferee and thereupon Landlord shall, without any further agreement between the parties, be released by Tenant from all liability therefor
accruing after the date of the assignment provided the assignee agrees in writing to be bound by this Article 21, and it is agreed that the provisions hereof shall apply to every transfer or assignment of the whole of said <FONT
STYLE="white-space:nowrap">L-C</FONT> to a new landlord. In connection with any such transfer of the <FONT STYLE="white-space:nowrap">L-C</FONT> by Landlord, Tenant shall, at Tenant&#146;s sole cost and expense, execute and submit to the Bank such
applications, documents and instruments as may be reasonably necessary to effectuate such transfer and, Tenant shall be responsible for paying the Bank&#146;s transfer and processing fees in connection therewith; provided that, Landlord shall have
the right (in its sole discretion), but not the obligation, to pay such fees on behalf of Tenant, in which case Tenant shall reimburse Landlord within thirty (30)&nbsp;days after Tenant&#146;s receipt of an invoice from Landlord therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">21.5&#8194;&#8195;<B><U><FONT STYLE="white-space:nowrap">L-C</FONT> Not a Security Deposit</U></B>. Landlord and Tenant
(1)&nbsp;acknowledge and agree that in no event or circumstance shall the <FONT STYLE="white-space:nowrap">L-C</FONT> or any renewal thereof or substitute therefor or any proceeds thereof be deemed to be or treated as a &#147;security deposit&#148;
under any law applicable to security deposits in the commercial context, including, but not limited to, Section&nbsp;1950.7 of the California Civil Code, as such Section now exists or as it may be hereafter amended or succeeded (the
&#147;<B><U>Security Deposit Laws&#148;</U></B>), (2) acknowledge and agree that the <FONT STYLE="white-space:nowrap">L-C</FONT> (including any renewal thereof or substitute therefor or any proceeds thereof) is not intended to serve as a security
deposit, and the Security Deposit Laws shall have no applicability or relevancy thereto, and (3)&nbsp;waive any and all rights, duties and obligations that any such party may now, or in the future will, have relating to or arising from the Security
Deposit Laws. Tenant hereby irrevocably waives and relinquishes the provisions of Section&nbsp;1950.7 of the California Civil Code and any successor statute, and all other provisions of law, now or hereafter in effect, which (x)&nbsp;establish the
time frame by which a landlord must refund a security deposit under a lease, and/or (y)&nbsp;provide that a landlord may claim from a security deposit only those sums reasonably necessary to remedy defaults in the payment of rent, to repair damage
caused by a tenant or to clean the premises, it being agreed that Landlord may, in addition, claim those sums specified in this <U>Article 21</U> and/or those sums reasonably necessary to (a)&nbsp;compensate Landlord for any loss or damage caused by
Tenant&#146;s breach of this Lease, including any damages Landlord suffers following termination of this Lease, and/or (b)&nbsp;compensate Landlord for any and all damages arising out of, or incurred in connection with, the termination of this
Lease, including, without limitation, those specifically identified in Section&nbsp;1951.2 of the California Civil Code<I>. </I>Tenant agrees not to interfere in any way with any payment to Landlord of the proceeds of the <FONT
STYLE="white-space:nowrap">L-C,</FONT> either prior to or following a &#147;draw&#148; by Landlord of all or any portion of the <FONT STYLE="white-space:nowrap">L-C,</FONT> regardless of whether any dispute exists between Tenant and Landlord as to
Landlord&#146;s right to draw down all or any portion of the <FONT STYLE="white-space:nowrap">L-C.</FONT> No condition or term of this Lease shall be deemed to render the <FONT STYLE="white-space:nowrap">L-C</FONT> conditional and thereby afford the
Bank a justification for failing to honor a drawing upon such <FONT STYLE="white-space:nowrap">L-C</FONT> in a timely manner. Tenant shall not request or instruct the Bank of any <FONT STYLE="white-space:nowrap">L-C</FONT> to refrain from paying
sight draft(s) drawn under such <FONT STYLE="white-space:nowrap">L-C.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">21.6&#8194;&#8195;<B><U><FONT STYLE="white-space:nowrap">Non-Interference</FONT> By Tenant</U></B>. Tenant agrees not to
interfere in any way with any payment to Landlord of the proceeds of the <FONT STYLE="white-space:nowrap">L-C,</FONT> either prior to or following a &#147;draw&#148; by Landlord of all or any portion of the <FONT STYLE="white-space:nowrap">L-</FONT>
C, regardless of whether any dispute exists between Tenant and Landlord as to Landlord&#146;s right to draw down all or any portion of the <FONT STYLE="white-space:nowrap">L-C.</FONT> No condition or term of this Lease shall be deemed to render the <FONT
STYLE="white-space:nowrap">L-C</FONT> conditional and thereby afford the Bank a justification for failing to honor a drawing upon such <FONT STYLE="white-space:nowrap">L-C</FONT> in a timely manner. Tenant shall not request or instruct the Bank of
any <FONT STYLE="white-space:nowrap">L-C</FONT> to refrain from paying sight draft(s) drawn under such <FONT STYLE="white-space:nowrap">L-C.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">21.7&#8194;&#8195;<B><U>Waiver of Certain Relief</U></B>. Tenant unconditionally and irrevocably waives (and as an independent
covenant hereunder, covenants not to assert) any right to claim or obtain any of the following relief in connection with the <FONT STYLE="white-space:nowrap">L-C:</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">21.7.1 A temporary restraining order, temporary injunction, permanent injunction, or other order that would prevent, restrain
or restrict the presentment of sight drafts drawn under any <FONT STYLE="white-space:nowrap">L-C</FONT> or the Bank&#146;s honoring or payment of sight draft(s); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">21.7.2 Any attachment, garnishment, or levy in any manner upon either the proceeds of any
<FONT STYLE="white-space:nowrap">L-C</FONT> or the obligations of the Bank (either before or after the presentment to the Bank of sight drafts drawn under such <FONT STYLE="white-space:nowrap">L-C)</FONT> based on any theory whatever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">21.8&#8194;&#8195;<B><U>Remedy for Improper Drafts</U></B>. Tenant&#146;s sole remedy in connection with the improper
presentment or payment of sight drafts drawn under any <FONT STYLE="white-space:nowrap">L-C</FONT> shall be the right to obtain from Landlord a refund of the amount of any sight draft(s) that were improperly presented or the proceeds of which were
misapplied, and reasonable actual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> attorneys&#146; fees, provided that at the time of such refund, Tenant increases the amount of such <FONT
STYLE="white-space:nowrap">L-C</FONT> to the amount (if any) then required under the applicable provisions of this Lease. Tenant acknowledges that the presentment of sight drafts drawn under any <FONT STYLE="white-space:nowrap">L-C,</FONT> or the
Bank&#146;s payment of sight drafts drawn under such <FONT STYLE="white-space:nowrap">L-C,</FONT> could not under any circumstances cause Tenant injury that could not be remedied by an award of money damages, and that the recovery of money damages
would be an adequate remedy therefor. In the event Tenant shall be entitled to a refund as aforesaid and Landlord shall fail to make such payment within ten (10)&nbsp;business days after demand, Tenant shall have the right to deduct the amount
thereof from the next installment(s) of Base Rent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">21.9&#8194;&#8195;<B><U>Return of
<FONT STYLE="white-space:nowrap">L-C</FONT></U></B>. Landlord shall return the <FONT STYLE="white-space:nowrap">L-C,</FONT> or any proceeds thereof drawn by Landlord to the extent not applied to cure a default by Tenant to Tenant, within sixty
(60)&nbsp;days after the expiration of the Term. If Landlord fails to return the <FONT STYLE="white-space:nowrap">L-C,</FONT> and any proceeds thereof, to Tenant (or to the Bank, as applicable) by the date established by this Section&nbsp;21.9, the
face amount of the Letter of Credit, and any proceeds drawn upon, shall bear interest owing by Landlord to Tenant at the rate of ten percent (10%) per annum. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>22.</B><B> </B><B>COMMUNICATIONS AND COMPUTER LINE </B>Tenant may install, maintain, replace, remove or use any communications or computer
wires and cables serving the Premises </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
(collectively, the &#147;<B>Lines</B>&#148;), provided that Tenant shall obtain Landlord&#146;s prior written consent, use an experienced and qualified contractor approved in writing by Landlord
(for Tenant&#146;s work in the Building risers, and Tenant may use its own contractor for distribution of the Lines within the Premises), and comply with all of the other provisions of Articles 7 and 8 of this Lease. Tenant shall pay all costs in
connection therewith. Landlord reserves the right, upon notice to Tenant prior to the expiration or earlier termination of this Lease, to require that Tenant, at Tenant&#146;s sole cost and expense, remove any Lines located in or serving the
Premises prior to the expiration or earlier termination of this Lease. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>SIGNS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">23.1&#8195;<B><U>Exterior Signage</U></B>. Subject to Landlord&#146;s prior written approval, which shall not be unreasonably
withheld, conditioned or delayed, and provided all signs are in keeping with the quality, design and style of the Building and Project, Tenant, at its sole cost and expense, may install (i)&nbsp;identification signage on the monument sign outside
the front entrance to the Building, (ii)&nbsp;internal directional and lobby identification signage, (iii)&nbsp;signage in the elevator lobby on the floor containing the Premises, and (iv)&nbsp;one (1) sign on the south elevation of the Building
consistent with that certain Master Signage Program dated June 2019 and prepared by DES Architects + Engineers (collectively, &#147;<B>Tenant Signage</B>&#148;); provided, however, in no event shall Tenant&#146;s Signage include an
&#147;Objectionable Name,&#148; as that term is defined in <U>Section</U><U></U><U>&nbsp;23.3</U>, of this Lease. All such signage shall be subject to Tenant&#146;s obtaining all required governmental approvals. Landlord shall cooperate with any
reasonable requests in connection with obtaining such approvals. All permitted signs shall be maintained by Tenant at its expense in a first-class and safe condition and appearance. Upon the expiration or earlier termination of this Lease, Tenant
shall remove all of its signs at Tenant&#146;s sole cost and expense. The graphics, materials, color, design, lettering, lighting, size, illumination, specifications and exact location of Tenant&#146;s Signage (collectively, the &#147;<B>Sign
Specifications</B>&#148;) shall be subject to the prior written approval of Landlord, which approval shall not be unreasonably withheld, conditioned or delayed, and shall be consistent and compatible with the quality and nature of the Project.
Tenant hereby acknowledges that, notwithstanding Landlord&#146;s approval of Tenant&#146;s Signage, Landlord has made no representation or warranty to Tenant with respect to the probability of obtaining all necessary governmental approvals and
permits for Tenant&#146;s Signage. In the event Tenant does not receive the necessary governmental approvals and permits for Tenant&#146;s Signage, Tenant&#146;s and Landlord&#146;s rights and obligations under the remaining terms and conditions of
this Lease shall be unaffected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">23.2&#8195;<B><U>Objectionable Name</U></B>. Tenant&#146;s Signage shall not include a
name or logo which relates to an entity which is of a character or reputation, or is associated with a political faction or orientation, which is inconsistent with the quality of the Project, or which would otherwise reasonably offend a landlord of
the Comparable Buildings (an &#147;<B>Objectionable Name</B>&#148;). The parties hereby agree that the following name, or any reasonable derivation thereof, shall not be deemed to constitute an Objectionable Name: &#147;Maze Therapeutics.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">23.3&#8195;<B><U>Prohibited Signage and Other Items</U></B>. Any signs, notices, logos, pictures, names or advertisements
which are installed and that have not been separately approved by Landlord may be removed by Landlord upon not less than three (3)&nbsp;business days&#146; prior written notice to Tenant at the sole expense of Tenant. Any signs, window coverings, or
blinds (even if the same are located behind the Landlord-approved window coverings for the Building), or other items visible from the exterior of the Premises or Building, shall be subject to the prior approval of Landlord, in its sole discretion.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">23.4&#8195;<B><U>Termination of Right to Tenant&#146;s Signage</U></B>. The
rights contained in this <U>Article 23</U> shall be personal to Original Tenant and its Permitted Assignee, and may only be exercised and maintained by such parties (and not any other assignee, sublessee or other transferee of the Original
Tenant&#146;s interest in this Lease) to the extent (<I>x</I>)&nbsp;they are not in default under this Lease (beyond any applicable notice and cure period) <I><U>and</U></I><I> </I>(y)&nbsp;if they occupy not less than seventy-five percent (75%) of
the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>24.</B><B></B><B>&#8195;COMPLIANCE WITH LAW </B>Landlord shall promptly comply with and be responsible, at its sole cost
and expense, except to the extent permitted to be included in Operating Expenses pursuant to <U>Section&nbsp;4.2.4</U> above, to comply with all Applicable Laws with respect to the Base Building and Common Areas. Tenant shall not do anything or
suffer anything to be done in or about the Premises or the Project which will in any way conflict with any law, statute, ordinance or other governmental rule, regulation or requirement now in force or which may hereafter be enacted or promulgated
(&#147;<B>Applicable Laws&#148;),</B> and Tenant&#146;s use of the Premises will comply with Applicable Laws. At its sole cost and expense, Tenant shall promptly comply with all such Applicable Laws (except to the extent such are Landlord&#146;s
responsibility) (including the making of any alterations to the Premises required by such governmental measures) which relate to (i) the Alterations or the Tenant Improvements in the Premises, or (ii) the &#147;Base Building&#148; (which shall
include the Building Structure, and the public restrooms, elevators, exit stairwells and the Building Systems located in the internal core of the Buildings on the floor or floors on which the Premises is located), but, as to the Base Building, only
to the extent such obligations are triggered by Tenant&#146;s Alterations, Tenant&#146;s particular Tenant Improvements (as opposed to the fact that tenant improvements are being performed generally), or Tenant&#146;s specific (i.e., any use other
than general office use or general laboratory use) use of the Premises. Should any standard or regulation now or hereafter be imposed on Landlord or Tenant by a state, federal or local governmental body charged with the establishment, regulation and
enforcement of occupational, health or safety standards for employers, employees, landlords or tenants, then Tenant agrees, at its sole cost and expense, to comply promptly with such standards or regulations. The judgment of any court of competent
jurisdiction or the admission of Tenant in any judicial action, regardless of whether Landlord is a party thereto, that Tenant has violated any of said governmental measures, shall be conclusive of that fact as between Landlord and Tenant. For
purposes of Section 1938 of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges, that the Project, Building and Premises have not undergone inspection by a Certified Access Specialist (CASp). As required by
Section 1938(e) of the California Civil Code, Landlord hereby states as follows: &#147;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable
construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp
inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the
payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.&#148; In furtherance of the foregoing, Landlord and Tenant hereby
agree as follows: (a) any CASp inspection requested by Tenant shall be conducted, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
at Tenant&#146;s sole cost and expense, by a CASp approved in advance by Landlord; and (b)&nbsp;pursuant to Article 24 below, Tenant, at its cost, is responsible for making any repairs within the
Premises to correct violations of construction- related accessibility standards; and, if anything done by or for Tenant in its use or occupancy of the Premises shall require repairs to the Building (outside the Premises) to correct violations of
construction-related accessibility standards, then Tenant shall, at Landlord&#146;s option, either perform such repairs at Tenant&#146;s sole cost and expense or reimburse Landlord upon demand, as Additional Rent, for the cost to Landlord of
performing such repairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>25.&#8195;LATE CHARGES</B> If any installment of Rent or any other sum due from Tenant shall not be received
by Landlord or Landlord&#146;s designee within five (5)&nbsp;business days after Tenant&#146;s receipt of written notice from Landlord that said amount is due, then Tenant shall pay to Landlord a late charge equal to four percent (4%) of the overdue
amount plus any reasonable attorneys&#146; fees incurred by Landlord by reason of Tenant&#146;s failure to pay Rent and/or other charges when due hereunder; provided, however, with regard to the first such failure in any twelve (12)&nbsp;month
period, Landlord will waive such late charge to the extent Tenant cures such failure within five (5)&nbsp;business days following Tenant&#146;s receipt of written notice from Landlord that the same was not received when due. The late charge shall be
deemed Additional Rent and the right to require it shall be in addition to all of Landlord&#146;s other rights and remedies hereunder or at law and shall not be construed as liquidated damages or as limiting Landlord&#146;s remedies in any manner.
In addition to the late charge described above, any Rent or other amounts owing hereunder which are not paid within ten (10)&nbsp;days after the date they are due shall bear interest from the date when due until paid at a rate per annum equal to the
lesser of (i)&nbsp;the annual &#147;Bank Prime Loan&#148; rate cited in the Federal Reserve Statistical Release Publication G.13(415), published on the first Tuesday of each calendar month (or such other comparable index as Landlord and Tenant shall
reasonably agree upon if such rate ceases to be published) plus three (3)&nbsp;percentage points, and (ii)&nbsp;the highest rate permitted by applicable law. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>26.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>LANDLORD&#146;S RIGHT TO CURE DEFAULT; PAYMENTS BY TENANT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">26.1&#8195;<B><U>Landlord&#146;s Cure</U></B>. All covenants and agreements to be kept or performed by Tenant under this Lease
shall be performed by Tenant at Tenant&#146;s sole cost and expense and without any reduction of Rent, except to the extent, if any, otherwise expressly provided herein. If Tenant shall fail to perform any obligation under this Lease, and such
failure shall continue in excess of the time allowed under <U>Section</U><U></U><U>&nbsp;19.1.2</U>, above, unless a specific time period is otherwise stated in this Lease, Landlord may, but shall not be obligated to, make any such payment or
perform any such act on Tenant&#146;s part without waiving its rights based upon any default of Tenant and without releasing Tenant from any obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">26.2&#8195;<B><U>Tenant&#146;s Reimbursement</U></B>. Except as may be specifically provided to the contrary in this Lease,
Tenant shall pay to Landlord, upon delivery by Landlord to Tenant of statements therefor: (i)&nbsp;sums equal to expenditures reasonably made and obligations incurred by Landlord in connection with the remedying by Landlord of Tenant&#146;s defaults
pursuant to the provisions of <U>Section</U><U></U><U>&nbsp;26.1</U>; (ii) sums equal to all losses, costs, liabilities, damages and expenses referred to in <U>Article 10</U> of this Lease; and (iii)&nbsp;sums equal to all expenditures made and
obligations incurred by Landlord in collecting or attempting to collect the Rent or in enforcing or attempting to enforce any rights of Landlord under this Lease or pursuant to law, including, without limitation, all reasonable legal fees and other
amounts so expended within thirty (30)&nbsp;days after receipt of invoice together with reasonable supporting evidence. Tenant&#146;s obligations under this <U>Section</U><U></U><U>&nbsp;26.2</U> shall survive the expiration or sooner termination of
the Lease Term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>27.</B>&#8195;<B>ENTRY BY LANDLORD</B><B> </B>Landlord reserves the right at all
reasonable times and upon not less than twenty-four (24)&nbsp;hours&#146; notice to Tenant (except in the case of an emergency) to enter the Premises to (i)&nbsp;inspect them; (ii)&nbsp;show the Premises to prospective purchasers, or to current or
prospective mortgagees, ground or underlying lessors or insurers or, during the last twelve (12)&nbsp;months of the Lease Term, to prospective tenants; (iii)&nbsp;post notices of nonresponsibility (to the extent applicable pursuant to then
applicable law); or (iv)&nbsp;alter, improve or repair the Premises or the Building, or for structural alterations, repairs or improvements to the Building or the Building&#146;s systems and equipment. Landlord may make any such entries without the
abatement of Rent, except as otherwise provided in this Lease, and may take such reasonable steps as required to accomplish the stated purposes. In an emergency, Landlord shall have the right to use any means that Landlord may deem proper to open
the doors in and to the Premises. Any entry into the Premises by Landlord in the manner hereinbefore described shall not be deemed to be a forcible or unlawful entry into, or a detainer of, the Premises, or an actual or constructive eviction of
Tenant from any portion of the Premises. Landlord shall use commercially reasonable efforts to minimize any interference with Tenant&#146;s use of or access to the Premises in connection with any such entry and shall comply with Tenant&#146;s
reasonable security measures, including that Tenant may require that Landlord be accompanied by an employee of Tenant during any such entry into the Premises by Landlord (except in the event of an Emergency in which case no escort shall be
required); provided, however, that in no event shall the unavailability of such escort at the time that Landlord is permitted to enter the Premises delay Landlord&#146;s entry into the Premises as permitted hereunder. Notwithstanding anything to the
contrary set forth in this <U>Article 27</U>, Tenant may designate from time to time certain reasonable areas of the Premises, which may vary from time to time based upon Tenant&#146;s particular operations in those areas of the Premises, as
&#147;<B>Secured Areas</B>&#148; should Tenant require such areas for the purpose of conducting laboratory work or securing certain valuable property or confidential information. In connection with the foregoing, Landlord shall not enter such
Secured Areas except in the event of an emergency. Landlord shall only maintain or repair such Secured Areas to the extent (i)&nbsp;such repair or maintenance is required in order to maintain and repair the Base Building; (ii)&nbsp;as required by
applicable law, or (iii)&nbsp;in response to specific requests by Tenant and in accordance with a schedule reasonably designated by Tenant, subject to Landlord&#146;s reasonable approval. Landlord shall use commercially reasonable efforts to
minimize any interference with Tenant&#146;s use of or access to the Premises in connection with any such entry and shall comply with Tenant&#146;s reasonable security measures. Landlord shall hold confidential any information regarding
Tenant&#146;s business that it may learn as a result of any such entry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>28.</B><B></B><B>&#8195;TENANT PARKING </B>Tenant shall have
the right to use, at no additional charge, the amount of parking set forth in Section 9 of the Summary, in the on-site and/or off-site, as the case may be, parking facility (or facilities) which serve the Project. Except when and where Tenant&#146;s
right of access is specifically excluded in this Lease, Tenant shall have the right of access to the Project parking facility twenty-four (24) hours per day, seven (7) days per week during the Lease Term. Tenant shall abide by all reasonable rules
and regulations which are prescribed from time to time for the orderly operation and use of the parking facility where the parking passes are located (including any sticker or other identification system established by Landlord and the prohibition
of vehicle repair and maintenance activities in the parking facilities), and shall cooperate in seeing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
that Tenant&#146;s employees and visitors also comply with such rules and regulations. Tenant&#146;s use of the Project parking facility shall be at Tenant&#146;s sole risk and Tenant
acknowledges and agrees that Landlord shall have no liability whatsoever for damage to the vehicles of Tenant, its employees and/or visitors, or for other personal injury or property damage or theft relating to or connected with the parking rights
granted herein or any of Tenant&#146;s, its employees&#146; and/or visitors&#146; use of the parking facilities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>29.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS PROVISIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.1&#8195;<B><U>Terms; Captions</U></B>. The words &#147;<B>Landlord</B>&#148; and &#147;<B>Tenant</B>&#148; as used herein
shall include the plural as well as the singular. The necessary grammatical changes required to make the provisions hereof apply either to corporations or partnerships or individuals, men or women, as the case may require, shall in all cases be
assumed as though in each case fully expressed. The captions of Articles and Sections are for convenience only and shall not be deemed to limit, construe, affect or alter the meaning of such Articles and Sections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.2&#8195;<B><U>Binding Effect</U></B>. Subject to all other provisions of this Lease, each of the covenants, conditions and
provisions of this Lease shall extend to and shall, as the case may require, bind or inure to the benefit not only of Landlord and of Tenant, but also of their respective heirs, personal representatives, successors or assigns, provided this clause
shall not permit any assignment by Tenant contrary to the provisions of <U>Article 14</U> of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.3&#8195;<B><U>No Air Rights</U></B>. No rights to any view or to light or air over any property, whether belonging to
Landlord or any other person, are granted to Tenant by this Lease. If at any time any windows of the Premises are temporarily darkened or the light or view therefrom is obstructed by reason of any repairs, improvements, maintenance or cleaning in or
about the Project, the same shall be without liability to Landlord and without any reduction or diminution of Tenant&#146;s obligations under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.4&#8195;Intentionally Omitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.5&#8195;<B><U>Transfer of Landlord&#146;s Interest</U></B>. Tenant acknowledges that Landlord has the right to transfer all
or any portion of its interest in the Project or Building and in this Lease, and Tenant agrees that in the event of any such transfer, Landlord shall automatically be released from all liability under this Lease and Tenant agrees to look solely to
such transferee for the performance of Landlord&#146;s obligations hereunder after the date of transfer and such transferee shall be deemed to have fully assumed and be liable for all obligations of this Lease to be performed by Landlord, including
the return of any Security Deposit, and Tenant shall attorn to such transferee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.6&#8195;<B><U>Prohibition Against
Recording</U></B>. Except as provided in <U>Section</U><U></U><U>&nbsp;29.4</U> of this Lease, neither this Lease, nor any memorandum, affidavit or other writing with respect thereto, shall be recorded by Tenant or by anyone acting through, under or
on behalf of Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.7&#8195;<B><U>Landlord&#146;s Title</U></B>. Landlord&#146;s title is and always shall be
paramount to the title of Tenant. Nothing herein contained shall empower Tenant to do any act which can, shall or may encumber the title of Landlord. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.8&#8195;<B><U>Relationship of Parties</U></B>. Nothing contained in this
Lease shall be deemed or construed by the parties hereto or by any third party to create the relationship of principal and agent, partnership, joint venturer or any association between Landlord and Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.9&#8195;<B><U>Application of Payments</U></B>. Landlord shall have the right to apply payments received from Tenant
pursuant to this Lease, regardless of Tenant&#146;s designation of such payments, to satisfy any obligations of Tenant hereunder, in such order and amounts as Landlord, in its sole discretion, may elect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.10&#8195;<B><U>Time of Essence</U></B>. Time is of the essence with respect to the performance of every provision of this
Lease in which time of performance is a factor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.11&#8195;<B><U>Partial Invalidity</U></B>. If any term, provision or
condition contained in this Lease shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term, provision or condition to persons or circumstances other than those with respect to which it is
invalid or unenforceable, shall not be affected thereby, and each and every other term, provision and condition of this Lease shall be valid and enforceable to the fullest extent possible permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.12&#8195;<B><U>No Warranty</U></B>. In executing and delivering this Lease, Tenant has not relied on any representations,
including, but not limited to, any representation as to the amount of any item comprising Additional Rent or the amount of the Additional Rent in the aggregate or that Landlord is furnishing the same services to other tenants, at all, on the same
level or on the same basis, or any warranty or any statement of Landlord which is not set forth herein or in one or more of the exhibits attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.13&#8195;<B><U>Landlord Exculpation</U></B>. The liability of Landlord or the Landlord Parties to Tenant for any default by
Landlord under this Lease or arising in connection herewith or with Landlord&#146;s operation, management, leasing, repair, renovation, alteration or any other matter relating to the Project or the Premises shall be limited solely and exclusively to
an amount which is equal to the interest of Landlord in the Building (including any rental, insurance, sale and/or condemnation proceeds derived therefrom). Neither Landlord, nor any of the Landlord Parties shall have any personal liability
therefor, and Tenant hereby expressly waives and releases such personal liability on behalf of itself and all persons claiming by, through or under Tenant. The limitations of liability contained in this <U>Section</U><U></U><U>&nbsp;29.13</U> shall
inure to the benefit of Landlord&#146;s and the Landlord Parties&#146; present and future partners, beneficiaries, officers, directors, trustees, shareholders, agents and employees, and their respective partners, heirs, successors and assigns. Under
no circumstances shall any present or future partner of Landlord (if Landlord is a partnership), or trustee or beneficiary (if Landlord or any partner of Landlord is a trust), have any liability for the performance of Landlord&#146;s obligations
under this Lease. Notwithstanding any contrary provision herein, neither Landlord nor the Landlord Parties shall be liable under any circumstances for injury or damage to, or interference with, Tenant&#146;s business, including but not limited to,
loss of profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, in each case, however occurring, or loss to inventory, scientific research, scientific experiments, laboratory animals, products,
specimens, samples, and/or scientific, business, accounting and other records of every kind and description kept at the premises and any and all income derived or derivable therefrom; similarly, notwithstanding any contrary provision herein, except
and then only to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
extent as set forth in <U>Article 16</U> above, neither Tenant nor the Tenant Parties shall be liable under any circumstances for injury or damage to, or interference with, Landlord&#146;s
business, including but not limited to, loss of profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, in each case, however occurring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.14&#8195;<B><U>Entire Agreement</U></B>. It is understood and acknowledged that there are no oral agreements between the
parties hereto affecting this Lease and this Lease constitutes the parties&#146; entire agreement with respect to the leasing of the Premises and supersedes and cancels any and all previous negotiations, arrangements, brochures, agreements and
understandings, if any, between the parties hereto or displayed by Landlord to Tenant with respect to the subject matter thereof, and none thereof shall be used to interpret or construe this Lease. None of the terms, covenants, conditions or
provisions of this Lease can be modified, deleted or added to except in writing signed by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.15&#8195;<B><U>Right to Lease</U></B>. Landlord reserves the absolute right to effect such other tenancies in the Project
as Landlord in the exercise of its sole business judgment shall determine to best promote the interests of the Building or Project. Tenant does not rely on the fact, nor does Landlord represent, that any specific tenant or type or number of tenants
shall, during the Lease Term, occupy any space in the Building or Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.16&#8195;<B><U>Force Majeure</U></B>. Any
prevention, delay or stoppage due to strikes, lockouts, labor disputes, acts of God, acts of war, terrorist acts, inability to obtain services, labor, or materials or reasonable substitutes therefor, governmental actions, civil commotions, fire or
other casualty, and other causes beyond the reasonable control of the party obligated to perform, except with respect to the obligations imposed with regard to Rent and other charges to be paid by one party to the other pursuant to this Lease
(collectively, a &#147;<B>Force Majeure</B>&#148;), notwithstanding anything to the contrary contained in this Lease, shall excuse the performance of such party for a period equal to any such prevention, delay or stoppage and, therefore, if this
Lease specifies a time period for performance of an obligation of either party, that time period shall be extended by the period of any delay in such party&#146;s performance caused by a Force Majeure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.17&#8195;<B><U>Waiver of Redemption by Tenant</U></B>. Tenant hereby waives, for Tenant and for all those claiming under
Tenant, any and all rights now or hereafter existing to redeem by order or judgment of any court or by any legal process or writ, Tenant&#146;s right of occupancy of the Premises after any termination of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.18&#8195;<B><U>Notices</U></B>. All notices, demands, statements, designations, approvals or other communications
(collectively, &#147;<B>Notices</B>&#148;) given or required to be given by either party to the other hereunder or by law shall be in writing, shall be (A)&nbsp;sent by United States certified or registered mail, postage prepaid, return receipt
requested (&#147;<B>Mail</B>&#148;), (B) delivered by a nationally recognized overnight courier, or (C)&nbsp;delivered personally. Any Notice shall be sent, transmitted, or delivered, as the case may be, to Tenant at the appropriate address set
forth in <U>Section</U><U></U><U>&nbsp;10</U> of the Summary, or to such other place as Tenant may from time to time designate in a Notice to Landlord, or to Landlord at the addresses set forth below, or to such other places as Landlord may from
time to time designate in a Notice to Tenant. Any Notice will be deemed given (i)&nbsp;three (3) days after the date it is posted if sent by Mail, (ii)&nbsp;the date the overnight courier delivery is made, or (iii)&nbsp;the date
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
personal delivery is made. As of the date of this Lease, any Notices to Landlord must be sent, transmitted, or delivered, as the case may be, to the following addresses: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:31%; font-size:12pt; font-family:Times New Roman">HCP OYSTER POINT III LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:31%; font-size:12pt; font-family:Times New Roman">c/o
HCP, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:31%; font-size:12pt; font-family:Times New Roman">1920 Main Street, Suite 1200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:31%; font-size:12pt; font-family:Times New Roman">Irvine, CA 92614 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:31%; font-size:12pt; font-family:Times New Roman">Attn: Legal
Department </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:31%; font-size:12pt; font-family:Times New Roman">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:31%; font-size:12pt; font-family:Times New Roman">HCP Life
Science Estates </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:31%; font-size:12pt; font-family:Times New Roman">950 Tower Lane, Suite 1650 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:31%; font-size:12pt; font-family:Times New Roman">Foster City, CA 94404 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:31%; font-size:12pt; font-family:Times New Roman">And
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:31%; font-size:12pt; font-family:Times New Roman">Allen Matkins Leck Gamble Mallory&nbsp;&amp; Natsis LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:31%; font-size:12pt; font-family:Times New Roman">1901 Avenue of the Stars, Suite 1800 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:31%; font-size:12pt; font-family:Times New Roman">Los Angeles, California 90067 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:31%; font-size:12pt; font-family:Times New Roman">Attention: Anton N. Natsis, Esq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.19&#8195;<B><U>Joint and Several</U></B>. If there is more than one tenant, the obligations imposed upon Tenant under this
Lease shall be joint and several. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.20&#8195;<B><U>Authority</U></B>. Tenant hereby represents and warrants that Tenant
is a duly formed and existing entity qualified to do business in the State of California and that Tenant has full right and authority to execute and deliver this Lease and that each person signing on behalf of Tenant is authorized to do so. Landlord
represents and warrants that Landlord is a duly formed and existing entity qualified to do business in the State of California and that Landlord has full right and authority to execute and deliver this Lease and that each person signing on behalf of
Landlord is authorized to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.21&#8195;<B><U>Attorneys&#146; Fees</U></B>. In the event that either Landlord or
Tenant should bring suit for the possession of the Premises, for the recovery of any sum due under this Lease, or because of the breach of any provision of this Lease or for any other relief against the other, then all costs and expenses, including
reasonable attorneys&#146; fees, incurred by the prevailing party therein shall be paid by the other party, which obligation on the part of the other party shall be deemed to have accrued on the date of the commencement of such action and shall be
enforceable whether or not the action is prosecuted to judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.22&#8195;<B><U>Governing Law; WAIVER OF TRIAL BY
JURY</U></B>. This Lease shall be construed and enforced in accordance with the laws of the State of California. IN ANY ACTION OR PROCEEDING ARISING HEREFROM, LANDLORD AND TENANT HEREBY CONSENT TO (I)&nbsp;THE JURISDICTION OF ANY COMPETENT COURT
WITHIN THE STATE OF CALIFORNIA, (II)&nbsp;SERVICE OF PROCESS BY ANY MEANS AUTHORIZED BY CALIFORNIA LAW, AND (III)&nbsp;IN THE INTEREST OF SAVING TIME AND EXPENSE, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
TRIAL WITHOUT A JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY EITHER OF THE PARTIES HERETO AGAINST THE OTHER OR THEIR SUCCESSORS IN RESPECT OF ANY MATTER ARISING OUT OF OR IN
CONNECTION WITH THIS LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, TENANT&#146;S USE OR OCCUPANCY OF THE PREMISES, AND/OR ANY CLAIM FOR INJURY OR DAMAGE, OR ANY EMERGENCY OR STATUTORY REMEDY. IN THE EVENT LANDLORD COMMENCES ANY SUMMARY PROCEEDINGS
OR ACTION FOR NONPAYMENT OF BASE RENT OR ADDITIONAL RENT, TENANT SHALL NOT INTERPOSE ANY COUNTERCLAIM OF ANY NATURE OR DESCRIPTION (UNLESS SUCH COUNTERCLAIM SHALL BE MANDATORY) IN ANY SUCH PROCEEDING OR ACTION, BUT SHALL BE RELEGATED TO AN
INDEPENDENT ACTION AT LAW. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.23&#8195;<B><U>Submission of Lease</U></B>. Submission of this instrument for examination
or signature by Tenant does not constitute a reservation of, option for or option to lease, and it is not effective as a lease or otherwise until execution and delivery by both Landlord and Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.24&#8195;<B><U>Brokers</U></B>. Landlord and Tenant hereby warrant to each other that they have had no dealings with any
real estate broker or agent in connection with the negotiation of this Lease, excepting only the real estate brokers or agents specified in <U>Section</U><U></U><U>&nbsp;12</U> of the Summary (the &#147;<B>Brokers</B>&#148;), and that they know of
no other real estate broker or agent who is entitled to a commission in connection with this Lease. Each party agrees to indemnify and defend the other party against and hold the other party harmless from any and all claims, demands, losses,
liabilities, lawsuits, judgments, costs and expenses (including without limitation reasonable attorneys&#146; fees) with respect to any leasing commission or equivalent compensation alleged to be owing on account of any dealings with any real estate
broker or agent, other than the Brokers, occurring by, through, or under the indemnifying party. The terms of this <U>Section</U><U></U><U>&nbsp;29.24</U> shall survive the expiration or earlier termination of the Lease Term. Landlord shall pay the
Brokers pursuant to the terms of separate commission agreements with Brokers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.25&#8195;<B><U>Independent
Covenants</U></B>. This Lease shall be construed as though the covenants herein between Landlord and Tenant are independent and not dependent and Tenant hereby expressly waives the benefit of any statute to the contrary and agrees that if Landlord
fails to perform its obligations set forth herein, Tenant shall not be entitled to make any repairs or perform any acts hereunder at Landlord&#146;s expense or to any setoff of the Rent or other amounts owing hereunder against Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.26&#8195;<B><U>Project or Building Name, Address and Signage</U></B>. Landlord shall have the right at any time to change
the name and/or address of the Project or Building and to install, affix and maintain any and all signs on the exterior and on the interior of the Project or Building (other than the Premises) as Landlord may, in Landlord&#146;s sole discretion,
desire (subject to Tenant&#146;s signage rights set forth in this Lease). Tenant shall not use the name of the Project or Building or use pictures or illustrations of the Project or Building in advertising or other publicity or for any purpose other
than as the address of the business to be conducted by Tenant in the Premises, without the prior written consent of Landlord. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.27&#8194;<B><U>Counterparts</U></B>. This Lease may be executed in
counterparts with the same effect as if both parties hereto had executed the same document. Both counterparts shall be construed together and shall constitute a single lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.28&#8194;<B><U>Confidentiality</U></B>. Landlord and Tenant each acknowledges that the content of this Lease and any
related documents are confidential information. Landlord and Tenant shall keep such confidential information strictly confidential and shall not disclose (except as may be required by applicable law, judicial proceeding or court order) such
confidential information to any person or entity other than Landlord&#146; s and Tenant&#146;s respective financial, legal, accounting and space planning consultants, lenders, assignees, purchasers, partners, members and investors, and any
Transferee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.29<B>&#8194; <U>Development of the Project</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.29.1<B> <U>Subdivision</U></B>. Landlord reserves the right to subdivide all or a portion of the buildings and Common
Areas. Tenant agrees to execute and deliver, upon demand by Landlord and in the form requested by Landlord, any additional documents needed to conform this Lease to the circumstances resulting from a subdivision and any all maps in connection
therewith. Notwithstanding anything to the contrary set forth in this Lease, the separate ownership of any buildings and/or Common Areas by an entity other than Landlord shall not affect the calculation of Direct Expenses or Tenant&#146;s payment of
Tenant&#146;s Share of Direct Expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.29.2 <B><U>Construction of Property and Other Improvements</U></B>. Tenant
acknowledges that portions of the Project may be under construction following Tenant&#146;s occupancy of the Premises, and that such construction may result in levels of noise, dust, obstruction of access, etc. which are in excess of that present in
a fully constructed project. Landlord shall use commercially reasonable efforts to minimize the impact of such construction. Tenant hereby waives any and all rent offsets or claims of constructive eviction which may arise in connection with such
construction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.30&#8194;<B><U>No Violation</U></B>. Tenant hereby warrants and represents that neither its execution of
nor performance under this Lease shall cause Tenant to be in violation of any agreement, instrument, contract, law, rule or regulation by which Tenant is bound, and Tenant shall protect, defend, indemnify and hold Landlord harmless against any
claims, demands, losses, damages, liabilities, costs and expenses, including, without limitation, reasonable attorneys&#146; fees and costs, arising from Tenant&#146;s breach of this warranty and representation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29.31&#8194;<B><U>Transportation Management</U></B>. Tenant shall fully comply with all present or future mandatory programs
intended to manage parking, transportation or traffic in and around the Project and/or the Building, and in connection therewith, Tenant shall take responsible action for the transportation planning and management of all employees located at the
Premises by working directly with Landlord, any governmental transportation management organization or any other transportation-related committees or entities. Such programs may include, without limitation: (i)&nbsp;restrictions on the number of
peak-hour vehicle trips generated by Tenant; (ii)&nbsp;increased vehicle occupancy; (iii)&nbsp;implementation of an <FONT STYLE="white-space:nowrap">in-house</FONT> ridesharing program and an employee transportation coordinator; (iv)&nbsp;working
with employees and any Project, Building or area-wide ridesharing program manager; (v)&nbsp;instituting employer-sponsored incentives (financial or <FONT STYLE="white-space:nowrap">in-kind)</FONT> to encourage employees to rideshare; and
(vi)&nbsp;utilizing flexible work shifts for employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, Landlord and Tenant have caused this Lease to be
executed the day and date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-size:12pt"><U>LANDLORD</U>:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:12pt"><U>TENANT</U>:</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">HCP OYSTER POINT III LLC,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">a
Delaware limited liability company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">MAZE THERAPEUTICS, INC.,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">a Delaware
corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="5"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" NOWRAP><FONT STYLE="font-size:12pt">By: <U>&#8195;/s/&#8201;Scott&nbsp;Bohn&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" NOWRAP><FONT STYLE="font-size:12pt">By:<U>&#8195; /s/&#8201;Jason&nbsp;Coloma&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8196;&#8195;</U></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" NOWRAP><FONT STYLE="font-size:12pt">&#8195;&#8194;Name:<U>&#8195;&#8201;Scott&nbsp;Bohn&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;</U></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" NOWRAP><FONT STYLE="font-size:12pt">&#8195;&#8194;Name:<U>&#8195;&#8201;Jason&nbsp;Coloma&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;</U></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" NOWRAP><FONT STYLE="font-size:12pt">&#8195;&#8194;Its:<U>&#8195;&#8195;</U><U>&#8194;Senior Vice President&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" NOWRAP><FONT STYLE="font-size:12pt">&#8195;&#8194;Its:<U>&#8195;&#8201;&#8195;&#8194;CEO&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;&#8194;&#8195;&#8195;</U></FONT></TD>
</TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>THE COVE AT OYSTER POINT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>OUTLINE OF PREMISES; PROJECT SITE PLAN</U> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT&nbsp;A </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>THE COVE AT OYSTER POINT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>TENANT WORK LETTER</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:1%; margin-right:7%; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This Tenant Work Letter shall set forth the terms and conditions relating to the initial
improvement of the Premises for Tenant following the date of this Lease. This Tenant Work Letter is essentially organized chronologically and addresses the issues of construction, in sequence, as such issues will arise during construction in the
Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>SECTION 1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>CONDITION OF PREMISES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Tenant acknowledges that Tenant shall accept the Premises in their existing,
<FONT STYLE="white-space:nowrap">&#147;as-is&#148;</FONT> condition on the date of delivery thereof to Tenant, subject to the delivery obligations set forth in Section&nbsp;1.1.1 of the Lease. Except for the payment of the Tenant Improvement
Allowance as provided in <U>Section</U><U></U><U>&nbsp;2</U>, below, and the delivery obligations set forth in Section&nbsp;1.1.1 of the Lease, Landlord shall have no obligation to make or pay for any improvements to the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>SECTION 2 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>TENANT IMPROVEMENTS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.1&#8194;&#8195;<B><U>Tenant Improvement Allowance</U></B>. Commencing as of the Delivery Date, Tenant shall be entitled to
use the &#147;Tenant Improvement Allowance&#148;, as defined in <U>Section</U><U></U><U>&nbsp;5</U> of the Summary to this Lease, for the costs relating to the initial design and construction of Tenant&#146;s improvements, which are permanently
affixed to the Premises or which are &#147;Tenant Improvement Allowance Items,&#148; as that term is defined in <U>Section</U><U></U><U>&nbsp;2.2.1</U>, below (collectively, the &#147;<B>Tenant Improvements</B>&#148;). In no event shall Landlord be
obligated to make disbursements pursuant to this Tenant Work Letter or otherwise in connection with Tenant&#146;s construction of the Tenant Improvements or any Tenant Improvement Allowance Items, as defined below, in a total amount which exceeds
the sum of the Tenant Improvement Allowance. All Tenant Improvements for which the Tenant Improvement Allowance has been made available shall be deemed Landlord&#146;s property under the terms of the Lease; provided, however, Landlord may, by
written notice to Tenant given concurrently with Landlord&#146;s approval of the &#147;Final Working Drawings&#148;, as that term is defined in <U>Section</U><U></U><U>&nbsp;3.3</U>, below, require Tenant, prior to the end of the Lease Term, or
given following any earlier termination of this Lease, at Tenant&#146;s expense, to remove any Tenant Improvements which are deemed Specialty Improvements and to repair any damage to the Premises and Building caused by such removal and return the
affected portion of the Premises to a Building standard general office condition; provided that Tenant shall have the right to remove certain movable equipment and trade fixtures pursuant to the terms of the Lease (except those which are installed
utilizing the Tenant Improvement Allowance). Notwithstanding the foregoing, Landlord hereby agrees that Tenant shall have no obligation to remove any of the improvements depicted on <U>Schedule 1</U> attached hereto at the expiration or earlier
termination of the Lease Term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT A </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
Any portion of the Tenant Improvement Allowance that is not disbursed or allocated for disbursement by December&nbsp;31, 2021 (the &#147;<B>Outside Allowance Date</B>&#148;), shall revert to
Landlord and Tenant shall have no further rights with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2<B>&#8195;&#8195; <U>Disbursement of the Tenant
Improvement Allowance</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:15%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.1&#8194;&#8195;<B><U>Tenant Improvement Allowance Items</U></B>. Except as otherwise
set forth in this Tenant Work Letter, the Tenant Improvement Allowance and Additional TI Allowance, if applicable, shall be disbursed by Landlord only for the following items and costs (collectively the &#147;<B>Tenant Improvement Allowance
Items</B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.1.1&#8201;Payment of all reasonable fees of the &#147;Architect&#148; and the
&#147;Engineers,&#148; as those terms are defined in <U>Section</U><U></U><U>&nbsp;3.1</U> of this Tenant Work Letter, project management fees, and payment of the fees incurred by, and the cost of documents and materials supplied by, Landlord and
Landlord&#146;s consultants in connection with the preparation and review of the &#147;Construction Drawings,&#148; as that term is defined in <U>Section</U><U></U><U>&nbsp;3.2</U> of this Tenant Work Letter; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.1.2&#8201;The payment of plan check, permit and license fees relating to construction of the Tenant Improvements;
Premises; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.1.3&#8201;The payment for all demolition and removal of existing improvements in the Premises; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.1.4&#8201;The cost of construction of the Tenant Improvements, including, without limitation, testing and inspection
costs, costs incurred for removal of existing furniture, fixtures or equipment in the Premises, hoisting and trash removal costs, costs to purchase and install in the Premises equipment customarily incorporated into laboratory improvements or
laboratory utility systems, including, without limitation, UPS, DI Systems, boilers, air compressors, glass/cage washers and autoclaves, painting, and contractors&#146; fees and general conditions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.1.5&#8201;The cost of any changes in the Base Building when such changes are required by the Construction Drawings
(including if such changes are due to the fact that such work is prepared on an unoccupied basis), such cost to include all direct architectural and/or engineering fees and expenses incurred in connection therewith; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.1.6&#8201;The cost of any changes to the Construction Drawings or Tenant Improvements required by all applicable building
codes (the &#147;<B>Code</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.1.7&#8201;Sales and use taxes; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.1.8&#8201;The cost of the Project Management Fee, pursuant to Section&nbsp;4.1.1 of this Tenant Work Letter, below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.2&#8194;&#8195;<B><U>Disbursement of Tenant Improvement Allowance</U></B>. During the construction of the Tenant
Improvements, Landlord shall make monthly disbursements of the Tenant Improvement Allowance and Additional TI Allowance, if applicable, for Tenant Improvement Allowance Items for the benefit of Tenant and shall authorize the release of monies for
the benefit of Tenant as follows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT <B>B</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.2.1 <B><U>Monthly Disbursements</U></B>. On or before the fifth (5<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP>) day of each calendar month, during the design and construction of the Tenant Improvements (or such other date as Landlord may designate), Tenant may deliver to Landlord: (i)&nbsp;a request for
reimbursement of amounts paid to the &#147;Contractor,&#148; as that term is defined in <U>Section</U><U></U><U>&nbsp;4.1.1</U> of this Tenant Work Letter, approved by Tenant, in a form to be provided by Landlord and reasonably approved by Tenant ,
showing the schedule, by trade, of percentage of completion of the Tenant Improvements in the Premises, detailing the portion of the work completed and the portion not completed in reasonable detail; (ii)&nbsp;invoices from all of
&#147;Tenant&#146;s Agents,&#148; as that term is defined in <U>Section</U><U></U><U>&nbsp;4.1.2</U> of this Tenant Work Letter, for labor rendered and materials for the Premises for which payment is requested; (iii)&nbsp;executed mechanic&#146;s
lien releases, as applicable, from all of Tenant&#146;s Agents who are entitled to file mechanics liens and which shall comply with the appropriate provisions, as reasonably determined by Landlord, of California Civil Code Sections 8132, 8134, 8136
and 8138; and (iv)&nbsp;all other typical and customary additional information reasonably requested by Landlord. Within forty-five (45)&nbsp;days thereafter, Landlord shall deliver a check to Tenant made payable to Tenant in payment of the lesser
of: (A)&nbsp;the amounts so requested by Tenant as set forth in this <U>Section</U><U></U><U>&nbsp;2.2.3.1</U>, above (or, subject to the terms of <U>Section</U><U></U><U>&nbsp;4.2.1</U>, below, a percentage thereof), and (B)&nbsp;the balance of any
remaining available portion of the Tenant Improvement Allowance and Additional TI Allowance, if applicable, provided that Landlord does not reasonably and in good faith dispute any request for payment based on
<FONT STYLE="white-space:nowrap">non-compliance</FONT> of any work with the &#147;Approved Working Drawings,&#148; as that term is defined in <U>Section</U><U></U><U>&nbsp;3.5</U> below, or due to any substandard work. Landlord&#146;s payment of
such amounts shall not be deemed Landlord&#146;s approval or acceptance of the work furnished or materials supplied as set forth in Tenant&#146;s payment request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.2.2&#8201;<B><U>Final Deliveries</U></B>. Following the completion of construction of the Tenant Improvements, Tenant
shall deliver to Landlord properly executed final mechanic&#146;s lien releases in compliance with both California Civil Code Section&nbsp;8134 and either Section&nbsp;8136 or Section&nbsp;8138 from all of Tenant&#146;s Agents, and a certificate
certifying that the construction of the Tenant Improvements in the Premises has been substantially completed. Tenant shall record a valid Notice of Completion in accordance with the requirements of <U>Section</U><U></U><U>&nbsp;4.3</U> of this
Tenant Work Letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2.2.3&#8201;<B><U>Other Terms</U></B>. Landlord shall only be obligated to make disbursements from
the Tenant Improvement Allowance and Additional TI Allowance, if applicable, to the extent costs are incurred by Tenant for Tenant Improvement Allowance Items. All Tenant Improvement Allowance Items for which the Tenant Improvement Allowance and
Additional TI Allowance, if applicable have been made available shall be deemed Landlord&#146;s property under the terms of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.3&#8194;&#8195;<B><U>Building Standards</U></B>. The quality of Tenant Improvements shall be in keeping with Landlord&#146;s
Tenant Improvement Manual. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.4&#8194;&#8195;<B><U>Additional Tenant Improvement Allowance</U></B>. In addition to the
Tenant Improvement Allowance, Tenant shall have the right, by written notice to Landlord given on or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT <B>B</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
before the Outside Allowance Date, to cause Landlord to provide up to $30.00 per RSF of the Premises (i.e., $2,015,550.00) (the &#147;<B>Additional TI Allowance</B>&#148;) towards the payment of
the costs of the Tenant Improvement Allowance Items. In the event Tenant exercises its right to use all or any portion of the Additional TI Allowance, Tenant shall be required to pay Landlord, commencing on the date the Tenant Improvements are
completed (the &#147;<B>Additional Payment Commencement Date</B>&#148;), the &#147;Additional TI Allowance Payment,&#148; as that term is defined below, in consideration of Landlord provision of the Additional TI Allowance. The &#147;<B>Additional
TI Allowance Payment</B>&#148; shall be determined as the missing component of an annuity, which annuity shall have (i)&nbsp;the amount of the Additional TI Allowance utilized by Tenant as the present value amount, (ii)&nbsp;a number equal to the
number of full calendar months then remaining in the Lease Term as the number of payments, (iii)&nbsp;a monthly interest factor equal to seventy-five <FONT STYLE="white-space:nowrap">one-hundredths</FONT> percent (0.75%), which is equal to nine
percent (9%) divided by twelve (12)&nbsp;months per year, and (iv)&nbsp;the Additional TI Allowance Payment as the missing component of the annuity. Following the calculation of the Additional TI Allowance Payment, Landlord and Tenant will enter
into a lease amendment to confirm the amount thereof. Any portion of the Tenant Improvement Allowance as to which Tenant has not properly requested disbursement by the Outside Allowance Date, shall revert to Landlord and Tenant shall have no further
rights with respect thereto. The Additional TI Allowance Payment shall not be subject to annual Base Rent increases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.5&#8194;&#8195;<B><U>Failure to Disburse Tenant Improvement Allowance</U></B>. If Landlord fails to timely fulfill its
obligation to disburse any portion of the Tenant Improvement Allowance as required by this Tenant Work Letter, Tenant shall be entitled to deliver notice (&#147;<B>Payment Notice</B>&#148;) thereof to Landlord. If Landlord fails to fulfill such
obligation within thirty (30)&nbsp;days after Landlord&#146;s receipt of the Payment Notice from Tenant and if Landlord fails to deliver to Tenant within such thirty (30)&nbsp;day period a written objection to the payment of such disbursement,
setting forth with reasonable detail Landlord&#146;s good faith reasons for its claim that Tenant is not entitled to a portion of the disbursement (in which case Landlord shall pay all amounts to which it does not object) (&#147;<B>Refusal
Notice</B>&#148;), Tenant shall be entitled to pay such amounts and to offset the amounts so paid by Tenant against Tenant&#146;s next obligations to pay Rent under the Lease, together with interest accruing from the date due at the rate of ten
percent (10%) per annum.. If Landlord delivers a Refusal Notice, and if Landlord and Tenant are not able to agree on the amounts to be so paid by Landlord, if any, within ten (10)&nbsp;business days after Tenant&#146;s receipt of a Refusal Notice,
Tenant may proceed to claim a default by Landlord, or, if elected by either Landlord or Tenant, the matter shall proceed to resolution by the selection of an arbitrator to resolve the dispute under the expedited commercial dispute rules of JAMS. If
Tenant prevails in the arbitration, the amount of the award (which shall include interest at the rate of ten percent (10%) per annum from the time of delivery of Tenant&#146;s invoice for such expenditures until the date Tenant receives such amount
by payment or offset and attorneys&#146; fees and related costs) may be deducted by Tenant from the Rent next due and owing under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>SECTION 3 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>CONSTRUCTION DRAWINGS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">3.1&#8194;&#8195;<B><U>Selection of Architect</U></B>. Tenant shall retain an architect/space planner (the
&#147;<B>Architect</B>&#148;) approved in advance by Landlord (which approval shall not be unreasonably withheld) to prepare the Final Space Plan and Final Working Drawings as provided in Section&nbsp;3.2
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT <B>B</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
and 3.3, below. Notwithstanding the foregoing, Landlord hereby approves of DGA Architects as the Architect. Tenant shall retain the engineering consultants or design/build subcontractors
designated by Tenant and reasonably approved in advance by Landlord (the &#147;<B>Engineers</B>&#148;) to prepare all plans and engineering working drawings relating to the structural, mechanical, electrical, plumbing, HVAC, lifesafety, and
sprinkler work in the Premises, which work is not part of the Base Building. All such plans and drawings shall comply with the drawing format and specifications reasonably determined by Landlord, and shall be subject to Landlord&#146;s reasonable
approval. Tenant and Architect shall verify, in the field, the dimensions and conditions as shown on the relevant portions of the Base Building plans, and Tenant and Architect shall be solely responsible for the same, and Landlord shall have no
responsibility in connection therewith. Landlord&#146;s review of any plans or drawings as set forth in this <U>Section</U><U></U><U>&nbsp;3</U>, shall be for its sole purpose and shall not imply Landlord&#146;s review of the same, or obligate
Landlord to review the same, for quality, design, Code compliance or other like matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">3.2&#8194;&#8195;<B><U>Final
Space Plan</U></B>. Tenant shall supply Landlord with four (4)&nbsp;copies signed by Tenant of its final space plan for the Premises before any architectural working drawings or engineering drawings have been commenced. The final space plan (the
&#147;<B>Final Space Plan</B>&#148;) shall include a layout and designation of all offices, labs, rooms and other partitioning, their intended use, and equipment to be contained therein. Notwithstanding the foregoing, Landlord hereby approves of the
preliminary plans attached hereto as <U>Schedule 1</U>. Landlord may request clarification or more specific drawings for special use items not included in the Final Space Plan. Landlord shall advise Tenant within five (5)&nbsp;business days after
Landlord&#146;s receipt of the Final Space Plan for the Premises if the same is unsatisfactory or incomplete in any respect. If Tenant is so advised, Tenant shall promptly cause the Final Space Plan to be revised to correct any deficiencies or other
matters Landlord may reasonably require. If Landlord fails to respond to the Final Space Plan within the five (5)&nbsp;business day period set forth above, Tenant may send Landlord a reminder notice setting forth such failure containing the
following sentence at the top of such notice in bold, capitalized font at least twelve (12)&nbsp;points in size: &#147;<B>LANDLORD&#146;S FAILURE TO RESPOND TO THIS NOTICE WITHIN THREE (3)</B><B></B><B>&nbsp;BUSINESS DAYS SHALL RESULT IN
LANDLORD&#146;S DEEMED APPROVAL OF TENANT&#146;S FINAL SPACE PLAN</B>&#148; (the &#147;<B>Final Space Plan Reminder Notice</B>&#148;). Any such Final Space Plan Reminder Notice shall include a complete copy of the Final Space Plan. If Landlord fails
to respond within three (3)&nbsp;business days after receipt of a Final Space Plan Reminder Notice, then the Final Space Plan shall be deemed approved by Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">3.3&#8194;&#8195;<B><U>Final Working Drawings</U></B>. After the Final Space Plan has been approved by Landlord, Tenant shall
supply the Engineers with a complete listing of standard and <FONT STYLE="white-space:nowrap">non-standard</FONT> equipment and specifications, including, without limitation, Title 24 calculations, electrical requirements and special electrical
receptacle requirements for the Premises, to enable the Engineers and the Architect to complete the &#147;Final Working Drawings&#148; (as that term is defined below) in the manner as set forth below. Upon the approval of the Final Space Plan by
Landlord and Tenant, Tenant shall promptly cause the Architect and the Engineers to complete the architectural and engineering drawings for the Premises, and Architect shall compile a fully coordinated set of architectural, structural, mechanical,
electrical and plumbing working drawings in a form which is sufficiently complete to allow all of Tenant&#146;s Agents to bid on the work and to obtain all applicable permits (collectively, the &#147;<B>Final Working Drawings</B>&#148;) and shall
submit the same to Landlord for Landlord&#146;s approval, which shall not be unreasonably withheld, conditioned, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT <B>B</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
or delayed. Tenant shall supply Landlord with four (4)&nbsp;copies signed by Tenant of such Final Working Drawings. Landlord shall advise Tenant within ten (10)&nbsp;business days after
Landlord&#146;s receipt of the Final Working Drawings for the Premises if the same is unsatisfactory or incomplete in any respect. If Tenant is so advised, Tenant shall promptly cause the Final Working Drawings to be revised in accordance with such
review and any disapproval of Landlord in connection therewith. If Landlord fails to respond to the Final Working Drawings within the ten (10)&nbsp;business day period set forth above, Tenant may send Landlord a reminder notice setting forth such
failure containing the following sentence at the top of such notice in bold, capitalized font at least twelve (12)&nbsp;points in size: &#147;<B>LANDLORD&#146;S FAILURE TO RESPOND TO THIS NOTICE WITHIN FIVE (5)</B><B></B><B>&nbsp;BUSINESS DAYS SHALL
RESULT IN LANDLORD&#146;S DEEMED APPROVAL OF TENANT&#146;S FINAL WORKING DRAWINGS</B>&#148; (the &#147;<B>Final Working Drawings Reminder Notice</B>&#148;). Any such Final Working Drawings Reminder Notice shall include a complete copy of the Final
Working Drawings. If Landlord fails to respond within five (5)&nbsp;business days after receipt of a Final Working Drawings Reminder Notice, then the Final Working Drawings shall be deemed approved by Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">3.4&#8194;&#8195;<B><U>Approved Working Drawings</U></B>. The Final Working Drawings shall be approved by Landlord (the
&#147;<B>Approved Working Drawings</B>&#148;) prior to the commencement of construction of the Premises by Tenant. Concurrently with Tenant&#146;s delivery of the Final Working Drawings to Landlord for Landlord&#146;s approval, Tenant may submit the
same to the appropriate municipal authorities for all applicable building permits. Tenant hereby agrees that neither Landlord nor Landlord&#146;s consultants shall be responsible for obtaining any building permit or certificate of occupancy for the
Premises and that obtaining the same shall be Tenant&#146;s responsibility; provided, however, that Landlord shall cooperate with Tenant in executing permit applications and performing other ministerial acts reasonably necessary to enable Tenant to
obtain any such permit or certificate of occupancy. No changes, modifications or alterations in the Approved Working Drawings may be made without the prior written consent of Landlord, which shall not be unreasonably withheld, conditioned, or
delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>SECTION 4 </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>CONSTRUCTION OF THE TENANT IMPROVEMENTS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.1&#8194;&#8195;<B><U>Tenant&#146;s Selection of Contractors</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.1.1&#8194;&#8195;<B><U>The Contractor; Landlord&#146;s Project Manager</U></B>. Tenant shall retain a licensed general
contractor, reasonably approved in advance by Landlord, to construct the Tenant Improvements (&#147;<B>Contractor</B>&#148;). Landlord&#146;s approval of the Contractor shall not be unreasonably withheld. Landlord hereby approves of Landmark
Construction as the Contractor. Landlord shall retain Project Management Advisors, Inc. (&#147;<B>PMA</B>&#148;) as a third party project manager for construction oversight of the Tenant Improvements on behalf of Landlord, and Tenant shall pay a fee
to Landlord with respect to the PMA services equal to $1.63 per rentable square foot of the Premises (the &#147;<B>Project Management Fee</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.1.2&#8194;&#8195;<B><U>Tenant&#146;s Agents</U></B>. All subcontractors, laborers, materialmen, and suppliers used by
Tenant (such subcontractors, laborers, materialmen, and suppliers, and the Contractor to be known collectively as &#147;<B>Tenant&#146;s Agents</B>&#148;). The subcontractors used by Tenant, but not any laborers, materialmen, and suppliers, must be
approved in writing by Landlord, which approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT <B>B</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
shall not be unreasonably withheld, conditioned, or delayed; provided, however, Landlord may nevertheless designate and require the use of particular mechanical, engineering, plumbing, fire life-
safety and other Base Building subcontractors. If Landlord does not approve any of Tenant&#146;s proposed subcontractors, Tenant shall submit other proposed subcontractors for Landlord&#146;s written approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2&#8194;&#8195;<B><U>Construction of Tenant Improvements by Tenant&#146;s Agents</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.1&#8195;<B><U>Construction Contract; Cost Budget</U></B>. Tenant shall engage the Contractor under a commercially
reasonable and customary construction contract (collectively, the &#147;<B>Contract</B>&#148;). Prior to the commencement of the construction of any Phase of the Tenant Improvements, and after Tenant has accepted all bids for the Tenant
Improvements, Tenant shall provide Landlord with a detailed breakdown, by trade, of the final costs to be incurred or which have been incurred in connection with the design and construction of the relevant Phase of the Tenant Improvements to be
performed by or at the direction of Tenant or the Contractor, which costs form a basis for the estimated total costs of the work of the relevant Phase of the Tenant Improvements (each, a &#147;<B>Final Budget</B>&#148;). Any costs of design and
construction of the Tenant Improvements in excess of the Tenant Improvement Allowance shall be paid by Tenant out of its own funds once the Tenant Improvement Allowance is exhausted, but Tenant shall continue to provide Landlord with the documents
described in <U>Sections 2.2.2.1(i)</U>, <U>(ii)</U>, <U>(iii)</U> and <U>(iv)</U>&nbsp;of this Tenant Work Letter, above, for Landlord&#146;s approval, prior to Tenant paying such costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.2&#8195;Tenant&#146;s Agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.2.1&#8201;<B><U>Compliance with Drawings and Schedule</U></B>. Tenant&#146;s and Tenant&#146;s Agent&#146;s construction
of the Tenant Improvements shall comply with the following: (i)&nbsp;the Tenant Improvements shall be constructed in substantial accordance with the Approved Working Drawings; and (ii)&nbsp;Tenant&#146;s Agents shall submit schedules of all work
relating to the Tenant&#146;s Improvements to Contractor and Contractor shall, within five (5)&nbsp;business days of receipt thereof, inform Tenant&#146;s Agents of any changes which are necessary thereto, and Tenant&#146;s Agents shall adhere to
such corrected schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.2.2&#8201;<B><U>Indemnity</U></B>. Tenant&#146;s indemnity of Landlord as set forth in this
Lease shall also apply with respect to any and all costs, losses, damages, injuries and liabilities related in any way to any act or omission of Tenant or Tenant&#146;s Agents, or anyone directly or indirectly employed by any of them, or in
connection with Tenant&#146;s <FONT STYLE="white-space:nowrap">non-payment</FONT> of any amount arising out of the Tenant Improvements and/or Tenant&#146;s disapproval of all or any portion of any request for payment. The foregoing indemnity shall
not apply to claims caused by the gross negligence or willful misconduct of Landlord, its member partners, shareholders, officers, directors, agents, employees, and/or contractors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.2.3&#8201;<B><U>Requirements of Tenant&#146;s Agents</U></B>. Each of Tenant&#146;s Agents shall guarantee to Tenant and
for the benefit of Landlord that the portion of the Tenant Improvements for which it is responsible shall be free from any defects in workmanship and materials for a period of not less than one (1)&nbsp;year from the date of substantial completion
of the work under the Contract (&#147;<B>Substantial Completion</B>&#148;). Each of Tenant&#146;s Agents shall be responsible for the replacement or repair, without additional charge, of all work done or furnished in accordance with its contract
that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT <B>B</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
shall become defective within one (1)&nbsp;year after Substantial Completion. The correction of such work shall include, without additional charge, all additional expenses and damages incurred in
connection with such removal or replacement of all or any part of the Tenant Improvements, and/or the Building and/or common areas that may be damaged or disturbed thereby. All such warranties or guarantees as to materials or workmanship of or with
respect to the Tenant Improvements shall be contained in the Contract or subcontract and shall be written such that such guarantees or warranties shall inure to the benefit of both Landlord and Tenant, as their respective interests may appear, and
can be directly enforced by either. Tenant covenants to give to Landlord any assignment or other assurances which may be necessary to effect such right of direct enforcement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.2.4&#8201;<B><U>Insurance Requirements</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:35%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.2.4.1&#8194;&#8195;<B><U>General Coverages</U></B>. All of Tenant&#146;s Agents shall carry the following insurance with
insurers having a minimum A.M. best rating of <FONT STYLE="white-space:nowrap">A-</FONT> /VII or better (i)&nbsp;worker&#146;s compensation insurance covering all of Tenant&#146;s Agents&#146; respective employees with a waiver of subrogation in
favor of Landlord and the property manager, (ii)&nbsp;general liability insurance with a limit of not less than $1,000,000 per occurrence and $2,000,000 general aggregate, including contractual coverage, and including Landlord and its property
manager as additional insureds, and (ii)&nbsp;if the cost of such Tenant Improvements exceeds $100,000 in the aggregate, then Builders Risk insurance covering the construction of the Tenant Improvements, and such policy shall include Landlord as an
additional insured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:35%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.2.4.2&#8194;&#8195;<U>Intentionally Omitted</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:35%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.2.4.3&#8194;&#8195;<B><U>General Terms</U></B>. Certificates for all insurance carried pursuant to this
<U>Section</U><U></U><U>&nbsp;4.2.2.4</U> shall be delivered to Landlord before the commencement of construction of the Tenant Improvements and before the Contractor&#146;s equipment is moved onto the site. All such policies of insurance must
contain a provision that the company writing said policy will endeavor to give Landlord thirty (30)&nbsp;days prior written notice of any cancellation or lapse of the effective date or any reduction in the amounts of such insurance. In the event
that the Expansion Tenant Improvements are damaged by any cause during the course of the construction thereof, Tenant shall immediately repair the same at Tenant&#146;s sole cost and expense. Tenant&#146;s Agents shall maintain all of the foregoing
insurance coverage in force until the Tenant Improvements are fully completed, except for any Products and Completed Operation Coverage insurance required by Landlord, which is to be maintained for ten (10)&nbsp;years following completion of the
work. Such insurance shall provide that it is primary insurance as respects the owner and that any other insurance maintained by owner is excess and noncontributing with the insurance required hereunder. The requirements for the foregoing insurance
shall not derogate from the provisions for indemnification of Landlord by Tenant under <U>Section</U><U></U><U>&nbsp;4.2.2.2</U> of this Tenant Work Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2.3&#8194;&#8195;<B><U>Governmental Compliance</U></B>. The Tenant Improvements shall comply in all material respects with
the following: (i)&nbsp;all state, federal, city or quasi-governmental laws, codes, ordinances and regulations, as each may apply according to the rulings of the controlling public official, agent or other person; (ii)&nbsp;applicable standards of
the American Insurance Association (formerly, the National Board of Fire Underwriters) and the National Electrical Code; and (iii)&nbsp;building material manufacturer&#146;s specifications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT <B>B</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.3&#8195;<B><U>Inspection by Landlord</U></B>. Landlord shall have the
right to inspect the Tenant Improvements at all times, provided however, that Landlord&#146;s failure to inspect the Tenant Improvements shall in no event constitute a waiver of any of Landlord&#146;s rights hereunder nor shall Landlord&#146;s
inspection of the Tenant Improvements constitute Landlord&#146;s approval of the same. Landlord&#146;s inspection shall not interfere with Tenant&#146;s construction of the Tenant Improvements and shall be scheduled at times reasonably acceptable to
Tenant. Should Landlord reasonably disapprove any portion of the Tenant Improvements, on the grounds that the construction is defective or fails to comply with the Approved Working Drawings, Landlord shall notify Tenant in writing of such
disapproval and shall specify the items disapproved. Any such defects or deviations shall be rectified by Tenant at no expense to Landlord, provided however, that in the event Landlord determines that a defect or deviation exists that might
adversely affect the mechanical, electrical, plumbing, heating, ventilating and air conditioning or life-safety systems of the Building, the structure or exterior appearance of the Building or any other tenant&#146;s use of such other tenant&#146;s
leased premises, Landlord may, take such action as Landlord reasonably deems necessary, at Tenant&#146;s expense and without incurring any liability on Landlord&#146;s part, to correct any such defect, deviation and/or matter, including, without
limitation, causing the cessation of performance of the construction of the Tenant Improvements until such time as the defect, deviation and/or matter is corrected to Landlord&#146;s reasonable satisfaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.3.1&#8195;<B><U>Meetings</U></B>. Commencing upon the commencement of construction activities, Tenant shall hold regular
meetings at a reasonable time (and which may be telephonic), with the Architect and the Contractor regarding the progress of the preparation of Construction Drawings and the construction of the Tenant Improvements, and Landlord and/or its agents
shall receive prior notice of, and shall have the right to attend, all such meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.4&#8195;<B><U>Notice of
Completion; Copy of Record Set of Plans</U></B>. Within ten (10)&nbsp;days after completion of construction of the Tenant Improvements, Tenant shall cause a valid Notice of Completion to be recorded in the office of the Recorder of the county in
which the Building is located in accordance with Section&nbsp;8182 of the Civil Code of the State of California or any successor statute, and shall furnish a copy thereof to Landlord upon such recordation. If Tenant fails to do so, Landlord may
execute and file the same on behalf of Tenant as Tenant&#146;s agent for such purpose, at Tenant&#146;s sole cost and expense. At the conclusion of construction, (i)&nbsp;Tenant shall cause the Architect and Contractor (<I>x</I>)&nbsp;to update the
Approved Working Drawings as necessary to reflect all changes made to the Approved Working Drawings during the course of construction, (<I>y</I>)&nbsp;to certify to the best of their knowledge that the
<FONT STYLE="white-space:nowrap">&#147;record-set&#148;</FONT> of <FONT STYLE="white-space:nowrap">as-built</FONT> drawings are true and correct, which certification shall survive the expiration or termination of this Lease, and (<I>z</I>)&nbsp;to
deliver to Landlord two (2)&nbsp;sets of copies of such record set of drawings (hard copy and CAD files) within ninety (90)&nbsp;days following issuance of a certificate of occupancy for the Premises, and (ii)&nbsp;Tenant shall deliver to Landlord a
copy of all warranties, guaranties, and operating manuals and information relating to the improvements, equipment, and systems in the Premises. Within fifteen (15)&nbsp;days after request by Tenant following the Substantial Completion of the Tenant
Improvements, Landlord will acknowledge its approval of the Tenant Improvements (provided that such approval has been granted) by placing its signature on a Contractor&#146;s Certificate of Substantial Completion fully executed by the Architect,
Contractor and Tenant. Landlord&#146;s approval shall not create any contingent liabilities for Landlord with respect to any latent quality, design, Code compliance or other like matters that may arise subsequent to Landlord&#146;s approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT <B>B</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>SECTION 5</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>MISCELLANEOUS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.1&#8195;<B><U>Tenant&#146;s Entry Into the Premises Prior to Substantial Completion</U></B>. Tenant shall be entitled to
access to the Premises following delivery of the Premises for the purpose of Tenant installing overstandard equipment or fixtures (including Tenant&#146;s data and telephone equipment) in the Premises and constructing the Tenant Improvements. Tenant
shall hold Landlord harmless from and indemnify, protect and defend Landlord against any loss or damage to the Building or Premises and against injury to any persons caused by Tenant&#146;s actions pursuant to this <U>Section&nbsp;5.1</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.2&#8195;<B><U>Tenant&#146;s Representative</U></B>. Tenant has designated Sandra Jamme, of SLJ Business Services, LLC, and
Moses Makunje of Tenant, as its representatives with respect to the matters set forth in this Tenant Work Letter, who shall each have full authority and responsibility to act on behalf of the Tenant as required in this Tenant Work Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3&#8195;<B><U>Landlord&#146;s Representative</U></B>. Landlord has designated PMA, as its sole representatives with respect
to the matters set forth in this Tenant Work Letter, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of the Landlord as required in this Tenant Work Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.4&#8195;<B><U>Time is of the Essence in This Tenant Work Letter</U></B>. Unless otherwise indicated, all references herein
to a &#147;number of days&#148; shall mean and refer to calendar days. If any item requiring approval is timely disapproved by Landlord, the procedure for preparation of the document and approval thereof shall be repeated until the document is
approved by Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.5&#8195;<B><U>Tenant&#146;s Lease Default</U></B>. Notwithstanding any provision to the contrary
contained in the Lease or this Tenant Work Letter, if any monetary or material <FONT STYLE="white-space:nowrap">non-monetary</FONT> default by Tenant under the Lease (beyond the applicable notice and cure periods) or this Tenant Work Letter
(including, without limitation, any failure by Tenant to fund any portion of the Over-Allowance Amount) occurs at any time on or before the substantial completion of the Tenant Improvements and such default remains uncured ten (10)&nbsp;days
following Landlord&#146;s notice of such default to Tenant, then in addition to all other rights and remedies granted to Landlord pursuant to the Lease, Landlord shall have the right to withhold payment of all or any portion of the Tenant
Improvement Allowance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT <B>B</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 TO EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>APPROVED SPACE PLAN </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT B </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT C</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>THE COVE AT OYSTER POINT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF LEASE TERM DATES</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="35%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:12pt">To:&#8195;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Lease dated <U>&#8195;&#8195;&#8195;</U>, 20<U>&#8195;</U> between <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>,
a <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> (&#147;<B>Landlord</B>&#148;), and <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, a <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> (&#147;<B>Tenant</B>&#148;) concerning
Suite<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> on floor(s) <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> of the building located at <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, California. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In accordance with
the Lease (the &#147;<B>Lease</B>&#148;), we wish to advise you and/or confirm as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Lease Term shall commence on or has commenced on <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> for a term
of <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> ending on <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Rent commenced to accrue on <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, in the amount of
<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">If the Lease Commencement Date is other than the first day of the month, the first billing will contain a
pro rata adjustment. Each billing thereafter, with the exception of the final billing, shall be for the full amount of the monthly installment as provided for in the Lease. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Your rent checks should be made payable to <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> at
<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The exact number of rentable/usable square feet within the Premises is
<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> square feet. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Tenant&#146;s Share as adjusted based upon the exact number of usable square feet within the Premises is
<U>&#8195;</U>%. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>&#147;Landlord&#148;:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">a<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">By:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Its:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;&#8195;&#8195;&#8195;</U></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT C </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Agreed to and Accepted as</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">of <U>&#8195;&#8195;&#8195;</U>, 200<U>&#8195;</U>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>&#147;Tenant&#148;:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8194;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">a<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">By:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Its:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8201;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT C </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT D</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>THE COVE AT OYSTER POINT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF TENANT&#146;S ESTOPPEL CERTIFICATE</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The undersigned as Tenant under that certain Lease (the &#147;<B>Lease</B>&#148;) made and entered into as of
<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 20<U>&#8195;</U> by and between <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U><U> </U>as Landlord, and the undersigned as Tenant, for Premises consisting of the entire office building located at
<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, California, certifies as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.&#8195;&#8195;Attached hereto as
<B><U>Exhibit A</U></B><B> </B>is a true and correct copy of the Lease and all amendments and modifications thereto. The documents contained in <B><U>Exhibit A</U></B><B> </B>represent the entire agreement between the parties as to the Premises.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.&#8195;&#8195;The undersigned currently occupies the Premises described in the Lease, the Lease Term commenced on
<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, and the Lease Term expires on <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, and the undersigned has no option to terminate or cancel the Lease or to purchase all or any part of the Premises, the Building
and/or the Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">3.&#8195;&#8195;Base Rent became payable on <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.&#8195;&#8195;The Lease is in full force and effect and has not been modified, supplemented or amended in any way except as
provided in <B><U>Exhibit A</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.&#8195;&#8195;Tenant has not transferred, assigned, or sublet any portion of the
Premises nor entered into any license or concession agreements with respect thereto except as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6.&#8195;&#8195;All monthly installments of Base Rent, all Additional Rent and all monthly installments of estimated
Additional Rent have been paid when due through <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>. The current monthly installment of Base Rent is $<U>&#8195;&#8195;</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.&#8195;&#8195;To the undersigned&#146;s actual knowledge without investigation, all conditions of the Lease to be performed
by Landlord necessary to the enforceability of the Lease have been satisfied and Landlord is not in default thereunder. In addition, the undersigned has not delivered any notice to Landlord regarding a default by Landlord thereunder. To the
undersigned&#146;s actual knowledge without investigation, except to the extent expressly set forth in the Lease, the Lease does not require Landlord to provide any rental concessions or to pay any leasing brokerage commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">8.&#8195;&#8195;No rental has been paid more than thirty (30)&nbsp;days in advance and no security has been deposited with
Landlord except as provided in the Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">9.&#8195;&#8195;To the undersigned&#146;s actual knowledge without
investigation, as of the date hereof, there are no existing defenses or offsets, or, any claims or any basis for a claim, that the undersigned has against Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10.&#8194;&#8195;If Tenant is a corporation or partnership, Tenant hereby represents and warrants that Tenant is a duly formed
and existing entity qualified to do business in California and that Tenant has full right and authority to execute and deliver this Estoppel Certificate and that each person signing on behalf of Tenant is authorized to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT D </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">11.&#8194;&#8195;There are no actions pending against the undersigned under
the bankruptcy or similar laws of the United States or any state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">12.&#8194;&#8195;Intentionally omitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">13.&#8194;&#8195;To the undersigned&#146;s actual knowledge without investigation, all tenant improvement work to be performed
by Landlord under the Lease has been completed in accordance with the Lease and has been accepted by the undersigned and all reimbursements and allowances due to the undersigned under the Lease in connection with any tenant improvement work have
been paid in full [except as follows:]. All work (if any) in the common areas required by the Lease to be completed by Landlord has been completed and all parking spaces required by the Lease have been furnished and/or all parking ratios required by
the Lease have been met [except as follows:]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The undersigned acknowledges that this Estoppel Certificate may be
delivered to Landlord or to a prospective mortgagee or prospective purchaser, and acknowledges that said prospective mortgagee or prospective purchaser will be relying upon the statements contained herein in making the loan or acquiring the property
of which the Premises are a part and that receipt by it of this certificate is a condition of making such loan or acquiring such property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Executed at <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> on the <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> day of
<U>&#8195;&#8195;&#8195;</U>, 20<U>&#8195;</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>&#147;Tenant&#148;:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">a<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">By:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">&#8195;&#8201;Its:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">By:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">&#8195;&#8201;Its:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</U></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT D </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT E</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>THE COVE AT OYSTER POINT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>ENVIRONMENTAL QUESTIONNAIRE</U> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">EXHIBIT E </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT F</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF LETTER OF CREDIT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">IRREVOCABLE STANDBY LETTER OF CREDIT NUMBER <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">ISSUE DATE: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">ISSUING BANK: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">SILICON VALLEY BANK </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">3003 TASMAN DRIVE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">2ND FLOOR, MAIL SORT HF210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">SANTA CLARA, CALIFORNIA 95054 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">BENEFICIARY: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">HCP<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">C/O HCP<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">1920 MAIN STREET, SUITE 1200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">IRVINE, CA 92614 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">ATTENTION: LEGAL DEPARTMENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">APPLICANT: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">MAZE THERAPEUTICS, INC. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">131 OYSTER POINT BOULEVARD, SUITE 200
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">SOUTH SAN FRANCISCO, CA 94080 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman">AMOUNT:
US$<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>.00 (<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> AND 00/100 U.S. DOLLARS) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">EXPIRATION
DATE:<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> (ONE YEAR FROM ISSUANCE) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">PLACE OF EXPIRATION: ISSUING BANK&#146;S COUNTERS AT ITS ABOVE ADDRESS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">DEAR SIR/MADAM: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">WE HEREBY ESTABLISH OUR IRREVOCABLE STANDBY
LETTER OF CREDIT NO. SVBSF <I><U>&#8195;&#8195;&#8195;&#8195;&#8195;</U></I> IN YOUR FAVOR FOR THE ACCOUNT OF <FONT STYLE="font-family:Times New Roman; font-size:12pt" COLOR="#0000ff">MAZE THERAPEUTICS, INC</FONT><FONT
STYLE="font-family:Times New Roman">. UP TO THE AGGREGATE AMOUNT OF US$<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> (<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> AND 00/100 U.S. DOLLARS), EFFECTIVE IMMEDIATELY AND EXPIRING ON
<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> (Expiration Date) AVAILABLE BY YOUR DRAFT(S) DRAWN ON US AT SIGHT IN THE FORM OF EXHIBIT &#147;A&#148; ATTACHED HERETO ACCOMPANIED BY THE FOLLOWING DOCUMENT(S): </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">BENEFICIARY&#146;S SIGNED AND DATED STATEMENT STATING ANY OF THE FOLLOWING: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">&#147;THE UNDERSIGNED HEREBY CERTIFIES THAT THE LANDLORD, EITHER (A)&nbsp;UNDER THE LEASE (DEFINED BELOW), OR (B)&nbsp;AS A RESULT OF THE TERMINATION OF SUCH
LEASE, HAS THE RIGHT TO DRAW DOWN THE AMOUNT OF USD <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> IN ACCORDANCE WITH THE TERMS OF THAT CERTAIN OFFICE LEASE DATED [INSERT LEASE DATE], AS AMENDED (COLLECTIVELY, THE &#147;LEASE&#148;).&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">OR </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">&#147;THE UNDERSIGNED HEREBY CERTIFIES THAT WE HAVE RECEIVED A WRITTEN NOTICE OF SILICON VALLEY BANK&#146;S ELECTION NOT TO EXTEND ITS STANDBY LETTER OF
CREDIT NO. SVBSF <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> AND HAVE NOT RECEIVED A REPLACEMENT LETTER OF CREDIT WITHIN AT LEAST THIRTY (30)&nbsp;DAYS PRIOR TO THE PRESENT EXPIRATION DATE.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">OR </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">&#147;THE UNDERSIGNED HEREBY CERTIFIES THAT
BENEFICIARY IS ENTITLED TO DRAW DOWN THE FULL AMOUNT OF LETTER OF CREDIT NO. SVBSF <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> AS THE RESULT OF THE FILING OF A VOLUNTARY PETITION UNDER THE U.S. BANKRUPTCY CODE OR A STATE BANKRUPTCY CODE BY THE TENANT
UNDER THAT CERTAIN OFFICE LEASE DATED [INSERT LEASE DATE], AS AMENDED (COLLECTIVELY, THE &#147;LEASE&#148;), WHICH FILING HAS NOT BEEN DISMISSED AT THE TIME OF THIS DRAWING. &#147; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">OR </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">&#147;THE UNDERSIGNED HEREBY CERTIFIES THAT
BENEFICIARY IS ENTITLED TO DRAW DOWN THE FULL AMOUNT OF LETTER OF CREDIT NO. SVBSF <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> AS THE RESULT OF AN INVOLUNTARY PETITION HAVING BEEN FILED UNDER THE U.S. BANKRUPTCY CODE OR A STATE BANKRUPTCY CODE
AGAINST THE TENANT UNDER THAT CERTAIN OFFICE LEASE DATED [INSERT LEASE DATE], AS AMENDED (COLLECTIVELY, THE &#147;LEASE&#148;), WHICH FILING HAS NOT BEEN DISMISSED WITHIN THIRTY (30)&nbsp;DAYS.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">OR </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">&#147;THE UNDERSIGNED HEREBY CERTIFIES THAT
BENEFICIARY IS ENTITLED TO DRAW DOWN THE FULL AMOUNT OF LETTER OF CREDIT NO. SVBSF AS THE RESULT OF THE REJECTION, OR DEEMED REJECTION, OF THAT CERTAIN OFFICE LEASE DATED [INSERT LEASE DATE], AS AMENDED, UNDER SECTION 365 OF THE U.S. BANKRUPTCY
CODE.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">SPECIAL CONDITIONS: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">PARTIAL DRAWINGS AND
MULTIPLE PRESENTATIONS MAY BE MADE UNDER THIS STANDBY LETTER OF CREDIT, PROVIDED, HOWEVER, THAT EACH SUCH DEMAND THAT IS PAID BY US SHALL REDUCE THE AMOUNT AVAILABLE UNDER THIS STANDBY LETTER OF CREDIT. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">ALL INFORMATION REQUIRED WHETHER INDICATED BY BLANKS, BRACKETS OR OTHERWISE, MUST BE COMPLETED AT THE TIME
OF DRAWING. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">ALL SIGNATURES MUST BE MANUALLY EXECUTED IN ORIGINALS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">ALL BANKING CHARGES ARE FOR THE APPLICANT&#146;S ACCOUNT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">THIS
LETTER OF CREDIT SHALL BE AUTOMATICALLY EXTENDED FOR AN ADDITIONAL PERIOD OF ONE YEAR, WITHOUT AMENDMENT, FROM THE PRESENT OR EACH FUTURE EXPIRATION DATE UNLESS AT LEAST 60 DAYS PRIOR TO THE THEN CURRENT EXPIRATION DATE WE SEND YOU A NOTICE BY
REGISTERED MAIL OR OVERNIGHT COURIER SERVICE AT THE ABOVE ADDRESS (OR ANY OTHER ADDRESS INDICATED BY YOU, IN A WRITTEN NOTICE TO US THE RECIEPT OF WHICH WE HAVE ACKNOWLEDGED, AS THE ADDRESS TO WHICH WE SHOULD SEND SUCH NOTICE) THAT THIS LETTER OF
CREDIT WILL NOT BE EXTENDED BEYOND THE CURRENT EXPIRATION DATE. IN NO EVENT SHALL THIS LETTER OF CREDIT BE AUTOMATICALLY EXTENDED BEYOND <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 20<U> </U>[INSERT A FINAL EXPIRY DATE]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">THIS LETTER OF CREDIT IS TRANSFERABLE IN WHOLE BUT NOT IN PART ONE OR MORE TIMES, BUT IN EACH INSTANCE ONLY TO A SINGLE BENEFICIARY AS TRANSFEREE AND FOR THE
THEN AVAILABLE AMOUNT, ASSUMING SUCH TRANSFER TO SUCH TRANSFEREE WOULD BE IN COMPLIANCE WITH THEN APPLICABLE LAW AND REGULATION, INCLUDING BUT NOT LIMITED TO THE REGULATIONS OF THE U.S. DEPARTMENT OF TREASURY AND U.S. DEPARTMENT OF </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">COMMERCE. AT THE TIME OF TRANSFER, THE ORIGINAL LETTER OF CREDIT AND ORIGINALS OR COPIES OF ALL AMENDMENTS, IF ANY, TO THIS LETTER OF CREDIT MUST BE
SURRENDERED TO US AT OUR ADDRESS INDICATED IN THIS LETTER OF CREDIT TOGETHER WITH OUR TRANSFER FORM ATTACHED HERETO AS EXHIBIT B DULY EXECUTED. OUR TRANSFER FEE OF US$500.00 SHALL BE PAYABLE BY APPLICANT (PROVIDED THAT BENEFICIARY MAY, BUT SHALL NOT
BE OBLIGATED TO, PAY SUCH FEES TO US ON BEHALF OF APPLICANT, AND SEEK REIMBURSEMENT THEREOF FROM APPLICANT) UNDER THIS LETTER OF CREDIT. IN CASE OF ANY TRANSFER UNDER THIS LETTER OF CREDIT, THE DRAFT AND ANY REQUIRED STATEMENT MUST BE EXECUTED BY
THE TRANSFEREE AND WHERE THE BENEFICIARY&#146;S NAME APPEARS WITHIN THIS STANDBY LETTER OF CREDIT, THE TRANSFEREE&#146;S NAME IS AUTOMATICALLY SUBSTITUTED THEREFOR. <FONT STYLE="font-family:Times New Roman; font-size:12pt" COLOR="#0000ff">ANY
TRANSFER OF THE LETTER OF CREDIT MAY NOT CHANGE THE PLACE OR DATE OF EXPIRATION OF THE LETTER OF CREDIT FROM OUR ABOVE SPECIFIED OFFICE. EACH TRANSFER SHALL BE EVIDENCED BY EITHER (1)&nbsp;OUR ENDORSEMENT ON THE REVERSE OF THE LETTER OF CREDIT AND
WE SHALL FORWARD THE ORIGINAL OF THE LETTER OF CREDIT SO ENDORSED TO THE TRANSFEREE OR (2)&nbsp;OUR ISSUING A REPLACEMENT LETTER OF CREDIT TO THE TRANSFEREE ON SUBSTANTIALLY THE SAME TERMS AND CONDITIONS AS THE TRANSFERRED LETTER OF CREDIT (IN WHICH
EVENT THE TRANSFERRED LETTER OF CREDIT SHALL HAVE NO FURTHER EFFECT).</FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">WE HEREBY AGREE WITH YOU THAT IF DRAFTS ARE PRESENTED TO SILICON VALLEY BANK UNDER THIS LETTER OF CREDIT AT
OR PRIOR TO 10:00 AM, ON A BUSINESS DAY, AND PROVIDED THAT SUCH DRAFTS PRESENTED CONFORM TO THE TERMS AND CONDITIONS OF THIS LETTER OF CREDIT, PAYMENT SHALL BE INITIATED BY US IN IMMEDIATELY AVAILABLE FUNDS BY OUR CLOSE OF BUSINESS ON THE NEXT
SUCCEEDING BUSINESS DAY. IF DRAFTS ARE PRESENTED TO SILICON VALLEY BANK UNDER THIS LETTER OF CREDIT AFTER 10:00 AM, ON A BUSINESS DAY, AND PROVIDED THAT SUCH DRAFTS CONFORM WITH THE TERMS AND CONDITIONS OF THIS LETTER OF CREDIT, PAYMENT SHALL BE
INITIATED BY US IN IMMEDIATELY AVAILABLE FUNDS BY OUR CLOSE OF BUSINESS ON THE SECOND SUCCEEDING BUSINESS DAY. AS USED IN THIS LETTER OF CREDIT, &#147;BUSINESS DAY&#148; SHALL MEAN ANY DAY OTHER THAN A SATURDAY, SUNDAY OR A DAY ON WHICH BANKING
INSTITUTIONS IN THE STATE OF CALIFORNIA ARE AUTHORIZED OR REQUIRED BY LAW TO CLOSE. IF THE EXPIRATION DATE FOR THIS LETTER OF CREDIT SHALL EVER FALL ON A DAY WHICH IS NOT A BUSINESS DAY THEN SUCH EXPIRATION DATE SHALL AUTOMATICALLY BE EXTENDED TO
THE DATE WHICH IS THE NEXT BUSINESS DAY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">PRESENTATION OF A DRAWING UNDER THIS LETTER OF CREDIT MAY BE MADE ON OR PRIOR TO THE THEN CURRENT EXPIRATION
DATE HEREOF BY HAND DELIVERY, COURIER SERVICE, OVERNIGHT MAIL, AT OUR OFFICE (THE &#147;BANK&#146;S OFFICE&#148;) AT: SILICON VALLEY BANK, 3003 TASMAN DRIVE, MAIL SORT HF 210, SANTA CLARA, CA 95054, ATTENTION: GLOBAL TRADE FINANCE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">FACSIMILE PRESENTATIONS ARE ALSO PERMITTED. SHOULD BENEFICIARY WISH TO MAKE A PRESENTATION UNDER THIS LETTER OF CREDIT ENTIRELY BY FACSIMILE TRANSMISSION IT
NEED NOT TRANSMIT THE ORIGINAL OF THIS LETTER OF CREDIT AND AMENDMENTS, IF ANY. EACH FACSIMILE TRANSMISSION SHALL BE MADE AT: (408) <FONT STYLE="white-space:nowrap">496-2418</FONT> OR (408) <FONT STYLE="white-space:nowrap">969-6510;</FONT> AND UNDER
CONTEMPORANEOUS TELEPHONE ADVICE TO: (408) <FONT STYLE="white-space:nowrap">450-5001</FONT> OR (408) <FONT STYLE="white-space:nowrap">654-7176,</FONT> ATTENTION: GLOBAL TRADE FINANCE. ABSENCE OF THE AFORESAID TELEPHONE ADVICE SHALL NOT AFFECT OUR
OBLIGATION TO HONOR ANY DRAW REQUEST. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">WE HEREBY ENGAGE WITH YOU THAT DRAFT(S) DRAWN AND/OR DOCUMENTS PRESENTED UNDER AND IN ACCORDANCE WITH THE TERMS AND
CONDITIONS OF THIS LETTER OF CREDIT SHALL BE DULY HONORED UPON PRESENTATION TO SILICON VALLEY BANK, IF PRESENTED ON OR BEFORE THE EXPIRATION DATE OF THIS LETTER OF CREDIT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">IF THE ORIGINAL OF THIS STANDBY LETTER OF CREDIT NO. SVBSF <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> IS LOST, STOLEN OR DESTROYED, WE WILL ISSUE YOU A
&#147;CERTIFIED TRUE COPY&#148; OF THIS STANDBY LETTER OF CREDIT NO. SVBSF </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> UPON OUR RECEIPT OF YOUR INDEMNITY LETTER TO SILICON VALLEY BANK WHICH WILL BE SENT TO YOU UPON OUR RECEIPT OF YOUR WRITTEN REQUEST THAT THIS
STANDBY LETTER OF CREDIT NO. SVBSF<U> </U><U>&#8195;</U><U> </U>IS LOST, STOLEN, OR DESTROYED. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#0000ff">IF ANY INSTRUCTIONS ACCOMPANYING A
DRAWING UNDER THIS LETTER OF CREDIT REQUEST THAT PAYMENT IS TO BE MADE BY TRANSFER TO YOUR ACCOUNT WITH ANOTHER BANK, WE WILL ONLY EFFECT SUCH PAYMENT BY WIRE TO A U.S. REGULATED BANK, AND WE AND/OR SUCH OTHER BANK MAY RELY ON AN ACCOUNT NUMBER
SPECIFIED IN SUCH INSTRUCTIONS EVEN IF THE NUMBER IDENTIFIES A PERSON OR ENTITY DIFFERENT FROM THE INTENDED PAYEE. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">EXCEPT SO FAR AS OTHERWISE
EXPRESSLY STATED HEREIN, THIS STANDBY LETTER OF CREDIT IS SUBJECT TO THE &#147;INTERNATIONAL STANDBY PRACTICES&#148; (ISP 98) INTERNATIONAL CHAMBER OF COMMERCE (PUBLICATION NO. 590). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">IF YOU HAVE ANY QUESTIONS REGARDING THIS TRANSACTION, PLEASE CONTACT: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> AT <FONT
STYLE="white-space:nowrap">408-</FONT> <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>, ALWAYS QUOTING OUR LETTER OF CREDIT NO.SVBSF<U>&#8195;</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman" ALIGN="center">SILICON VALLEY BANK</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman" ALIGN="center">[<U>BANK USE</U>]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman" ALIGN="center">AUTHORIZED SIGNATURE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">[<U>BANK USE</U>]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">AUTHORIZED SIGNATURE</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT &#147;A&#148;</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">DATE: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>
&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;REF. NO. <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>A</B>T SIGHT OF THIS DRAFT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>P</B>AY TO THE ORDER OF
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> US$ <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">USDOLLARS<U> &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">DRAWN UNDER SILICON VALLEY BANK, SANTA CLARA, CALIFORNIA, STANDBY LETTER OF CREDIT NUMBER NO. <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>
DATED <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">TO:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SILICON VALLEY BANK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3003 TASMAN DRIVE,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">MAIL SORT HF210</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SANTA CLARA, CA 95054</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(BENEFICIARY&#146;S NAME)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman">&#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Authorized Signature</B></TD></TR>
</TABLE> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>GUIDELINES TO PREPARE THE DRAFT</B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">DATE: ISSUANCE DATE OF DRAFT. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">REF. NO.: BENEFICIARY&#146;S REFERENCE NUMBER, IF ANY. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">PAY TO THE ORDER OF: NAME OF BENEFICIARY AS INDICATED IN THE L/C (MAKE SURE BENEFICIARY ENDORSES IT ON THE
REVERSE SIDE). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">US$: AMOUNT OF DRAWING IN FIGURES. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">USDOLLARS: AMOUNT OF DRAWING IN WORDS. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">LETTER OF CREDIT NUMBER: SILICON VALLEY BANK&#146;S STANDBY L/C NUMBER THAT PERTAINS TO THE DRAWING.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">DATED: ISSUANCE DATE OF THE STANDBY L/C. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">BENEFICIARY&#146;S NAME: NAME OF BENEFICIARY AS INDICATED IN THE L/C. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">AUTHORIZED SIGNATURE: SIGNED BY AN AUTHORIZED SIGNER OF BENEFICIARY. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">IF YOU HAVE QUESTIONS RELATED TO THIS STANDBY LETTER OF CREDIT PLEASE CONTACT US AT
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF TRANSFER FORM</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">DATE:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:12pt; font-family:Times New Roman">TO:&#8201;&#8202;SILICON VALLEY BANK</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:12pt; font-family:Times New Roman">3003 TASMAN DRIVE, MAIL SORT: HF210</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:12pt; font-family:Times New Roman">ATTN: GLOBAL TRADE FINANCE</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">RE: IRREVOCABLE
STANDBY LETTER OF CREDIT NO. <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> ISSUED BY SILICON VALLEY BANK, SANTA CLARA, CA 95054 SANTA CLARA</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">L/C AMOUNT:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">GENTLEMEN: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">FOR VALUE RECEIVED,
THE UNDERSIGNED BENEFICIARY HEREBY IRREVOCABLY TRANSFERS TO: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">(NAME OF TRANSFEREE) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">(ADDRESS) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY TO DRAW UNDER THE ABOVE LETTER OF CREDIT UP TO ITS AVAILABLE AMOUNT AS SHOWN ABOVE AS OF THE DATE OF THIS TRANSFER.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">BY THIS TRANSFER, ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY IN SUCH LETTER OF CREDIT ARE TRANSFERRED TO THE TRANSFEREE. TRANSFEREE SHALL HAVE THE SOLE
RIGHTS AS BENEFICIARY THEREOF, INCLUDING SOLE RIGHTS RELATING TO ANY AMENDMENTS, WHETHER INCREASES OR EXTENSIONS OR OTHER AMENDMENTS, AND WHETHER NOW EXISTING OR HEREAFTER MADE. ALL AMENDMENTS ARE TO BE ADVISED DIRECTLY TO THE TRANSFEREE WITHOUT
NECESSITY OF ANY CONSENT OF OR NOTICE TO THE UNDERSIGNED BENEFICIARY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">THE ORIGINAL OF SUCH LETTER OF CREDIT IS RETURNED HEREWITH, AND WE ASK YOU TO
EITHER (1)&nbsp;ENDORSE THE TRANSFER ON THE REVERSE THEREOF, AND FORWARD IT DIRECTLY TO THE TRANSFEREE WITH YOUR CUSTOMARY NOTICE OF TRANSFER, OR (2)&nbsp;ISSUE A REPLACEMENT LETTER OF CREDIT TO THE TRANSFEREE ON SUBSTANTIALLY THE SAME TERMS AND
CONDITIONS AS THE TRANSFERRED LETTER OF CREDIT (IN WHICH EVENT THE TRANSFERRED LETTER OF CREDIT SHALL HAVE NO FURTHER EFFECT). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">SIGNATURE AUTHENTICATED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">SINCERELY,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman">&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">(BENEFICIARY&#146;S NAME)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-right:1.00em; font-size:12pt; font-family:Times New Roman">The name(s), title(s), and signature(s) conform to
that/those on file with us for the company and the signature(s) is/are authorized to execute this instrument.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:14pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:14pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center">(SIGNATURE OF BENEFICIARY)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">(Name of Bank)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" ALIGN="center">(NAME AND TITLE)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">(Address of Bank)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:14pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">(City, State, ZIP Code)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:14pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">(Authorized Name and Title)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">(Authorized Signature)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:14pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">(Telephone number)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:150pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>LEASE</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>THE COVE AT OYSTER POINT </B></P>
<P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>HCP OYSTER POINT III LLC, </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>a Delaware limited liability company, </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>as Landlord, </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>and
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>MAZE THERAPEUTICS, INC., </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>a Delaware corporation, </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>as Tenant. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>TABLE OF CONTENTS</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B><U>Page</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PREMISES, BUILDING, PROJECT, AND COMMON AREAS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">LEASE TERM; OPTION TERM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BASE RENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ADDITIONAL RENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">11</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">USE OF PREMISES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">19</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SERVICES AND UTILITIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">25</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">7.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">REPAIRS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">27</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">8.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ADDITIONS AND ALTERATIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">29</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">9.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">COVENANT AGAINST LIENS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">31</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">10.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">INSURANCE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">32</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">11.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">DAMAGE AND DESTRUCTION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">34</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">12.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">NONWAIVER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">36</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">13.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CONDEMNATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">36</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">14.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ASSIGNMENT AND SUBLETTING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">37</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">15.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SURRENDER OF PREMISES; OWNERSHIP AND REMOVAL OF TRADE FIXTURES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">42</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">16.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HOLDING OVER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">43</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">17.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ESTOPPEL CERTIFICATES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">43</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">18.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SUBORDINATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">44</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">19.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">DEFAULTS; REMEDIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">45</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">20.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">COVENANT OF QUIET ENJOYMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">48</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">21.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">LETTER OF CREDIT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">48</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">22.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">COMMUNICATIONS AND COMPUTER LINE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">52</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">23.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SIGNS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">53</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">24.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">COMPLIANCE WITH LAW</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">54</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">25.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">LATE CHARGES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">26.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">LANDLORD&#146;S RIGHT TO CURE DEFAULT; PAYMENTS BY TENANT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">27.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ENTRY BY LANDLORD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">28.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">TENANT PARKING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">29.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">MISCELLANEOUS PROVISIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">EXHIBITS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom">A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">OUTLINE OF PREMISES</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom">B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">TENANT WORK LETTER</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom">C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">FORM OF NOTICE OF LEASE TERM DATES</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom">D</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">FORM OF TENANT&#146;S ESTOPPEL CERTIFICATE</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom">E</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ENVIRONMENTAL QUESTIONNAIRE</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom">F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">FORM OF LETTER OF CREDIT</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">(i) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>INDEX</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="border-bottom:1.00pt solid #000000"><B>Page(s)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Abatement Event</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Accountant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Advocate Arbitrators</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Alterations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Base Building</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Base Rent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Brokers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Building</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Common Areas</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Comparable Buildings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Comparable Transactions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Concessions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Contemplated Effective Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Contemplated Transfer Space</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Direct Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Eligibility Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Estimate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Estimate Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Estimated Direct Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Expense Year</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Fair Rental Value,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Force Majeure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Intention to Transfer Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Landlord</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Landlord Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">L-C</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">L-C</FONT> Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Lease</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Lease Commencement Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Lease Expiration Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Lease Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Lease Year</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Lines</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Mail</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Management Fee Cap</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Net Worth</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Neutral Arbitrator</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Nine Month Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Objectionable Name</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Operating Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Option Rent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Original Improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">(ii) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Outside Agreement Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Permitted Occupant Space</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Permitted Occupants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Premises</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Project,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Secured Areas</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Sign Specifications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Specialty Improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Subject Space</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Summary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Tax Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Tenant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Tenant Work Letter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Tenant&#146;s Accountant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Tenant&#146;s Share</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Transfer Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Transferee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">(iii) </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g769642g02g02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g02g02.jpg
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M"!<C,S4V0E1S=+)#8H*4)%:BPM+AXO E-T1CLR:#\1@G.&1UHRC_Q  ; 0$
M P$! 0$              0(#! 4&!__$ #\1  (! @,$!@@& P !! ,!   !
M @,1!!(Q!1,A410R05*1T14B,V%Q@:&Q-$)3DL'P!B/A)#5#LO$68H)R_]H
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MZGN-UO,E'7MBV6QN=X+-D@@@=?C6'J,]_P#75';6^%3TQ ?U?&?Z  K>CO\
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MP,.B8FG6J5:,E:5M4^PV$,C98F2,.6/:' ^(KGG*=^F+3Y#_ %!=$:T-:&M
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MD=B=PB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M2X<I?MEY$@11_OAJ'YD@_P V/8G?#4/S)!_FQ[$W;YKQ0Z7#E+]LO(D"*/\
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M+!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MHIPCD<I*YYN*K557C2IRRIKD<VY2^36JT+1T5147&"K;4R.C 9&6EI ST\5
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M'EH]_:/)+_N+IRYCRT>_M'DE_P!Q<N,]C+Y?<]/8WXR'S^S.:(B+PS[@(B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B *>\CGZ>K/Y8_UM4"4]Y'/T]6?RQ_K:NC"^UB<&T_PE3X'7$1%[Q\
M&%Q7\*/]6;-_.._H*[4N*_A1_JS9OYQW]!65?V;.W9_XF!\WHB+RSZX(B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 4]Y'/T]6?RQ_K:H$
MI[R.?IZL_EC_ %M71A?:Q.#:?X2I\#KB(B]X^#"XK^%'^K-F_G'?T%=J7%?P
MH_U9LW\X[^@K*O[-G;L_\3 ^;T1%Y9]<$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0'U\B(NH\,(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MD[1TQ.SZ#@K25%-/3/V:B&2)W4]I'K6<Z4X=96.BEB:-;V<D_F6D1%F;A$1
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M4IQU1TPKTYZ,MHB+,V"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B FMO\
M@%-_";ZE?5BW_ *;^$WU*^NZ.AX<NLPB(I*A<QY:/?VCR2_[BZ<N8\M'O[1Y
M)?\ <7+C/8R^7W/4V-^,A\_LSFB(B\,^Y"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(JX8I)G[$,;Y'=3025.I#:7%E"+=T>EKM58/<QB:>F
M4[/HX^A;VCT(=QK:SRMB;]Y]BZ(82M/2)PUMIX6CUIKY<?L0=5PPR3/V(8WR
M.ZFM)*ZC1Z5M--@]S\\X=,KMKT</0MQ##% S8@C9&WJ8T >A=<-F2?7E8\JM
M_D5-<*4&_CP\SE]'I6[5.#W-S+3TRNV?1Q]"WE'H3@:VL\K8F_>?8IPB[(;.
MHQUXGEUMNXJIU6H_!>=S1T>EK32X/<W/.'3*=KT</0MS#%'"S8AC9&WJ:T *
MM%UPIPAU58\NKB*M9WJ2;^+"(BN8A4R,9(PMD:U[3Q#AD*I$)3MH::LTS::K
M)=2-C<?VHCL>@;EHZS0D9R:.L<WJ;*W/I'L4U1<\\+1GK$[J.TL51ZLW\^/W
M.75FDKM39+86SM'3$[/H."M+44\U,_9J(9(G=3VD>M=K5,D;)6%LC&O:>(<,
MA<D]F0?4=CU*/^158\*L$_AP\SB*+J]9IBTU62ZE;&X],1V?0-RT59H1AR:.
ML<.ILK<^D>Q<<]G5HZ<3U*.WL+4ZUX_%>1!46^K-)W:FR1 V=HZ8G9]'%::>
MGFIW[-1%)$[J>TM/I7).E.'65CU*6(I5O9R3^#+2(BS-PB(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( IYR._K#5_RI_K:H&IYR._K#5_RI_K:N
MC"^UB<&T_P )4^!UU$1>\? A</\ PIOT-8?YB7^D+N"X?^%-^AK#_,2_TA8U
M_9L[=G?B8?WL9\ZHB+S#ZX(B( B(@"(B (B( B(@"(B (B( B(@"(B (ME9K
M#=;U)L6JWU%4<X+HV'9'E=P'G*Z'8>1>ZU.R^\UD%"SICC_*O^X#M*TA2G/J
MHPK8JC1]I)(Y4MC:+)<[Q+L6N@J*HYP3&PD#RG@/.OHFP\E^F;3LN?1FNF'[
M=6=L?5W-]"FD,4<$38X(V1QM&&M8T #R +KA@6^NSRJVVX+A2C?XG [#R,W>
MJV7W>J@H(SQ8W\K)Z/!])71;#R6Z:M6R^2E=7S#]NJ=M#ZHPWM!4Z1=<,-3A
MV'E5MHXBMK*R]W MP0Q4\38J>)D43=S6,:&@>0!7$1;G"$1$(!&1@\%%K]H'
M3EZVG55MBCF=_:T_Y)V>O=N/G!4I15E%25FC2%2=-W@[,XC?>1.9NT^Q7-L@
MZ(JINR?K-W'L"YW?='WZQ[1N-LG9$W^U8-MGUFY \Z^LD7-/!PEIP/2H[8KP
MX3]9'Q<B^J[]H33M[VG5ELA9,[^V@'-OSUDCCY\KG5^Y$WC:?8KF'=4-6W!^
MNWV+DG@ZD=.)ZU':]"IPEZK.,HI#?M%Z@L>T;A;)Q$W^VC'.,^LW('G4>7*X
MN+LT>E"<:BO!W01$4%@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(M]8M'WZ^[)MMLJ)(C_ &KQL1_6=@'S
M*5%R=D5G.,%>3LC0HNQV'D3F?LOOMS;&.F&E;M'ZSMP["NC6'0.G+)LNI;;%
M),/[:H_*NSUC.X>8!=,,'4EKP/-K;7H4^$?6?N/G.Q:1OM]V3;;9421G^U<-
MB/ZSL!=%L/(G._9??;DR(=,5*W:/UCN'85V\# P."+KA@H1ZW$\JMMBO/A#U
M416P\G^F[+LNIK;'-,/[6I_*NSU[]P\P"E0  P-P1%U1BHJT4>9.I.H[S=PB
M(K&81$0!$1 $1$ 6ON]EMMXBYNZ4-/5-Q@<XP$CR'B/,M@BAI/@RT9.+NG8Y
M;?N1FSU>T^T55102'@QWY6/T[_2N=7[DLU+:MI\5*ROA'[=*[:/U3AW8"OI=
M%SSPE.798]"CM7$4N#=U[SXRJ()::5T51%)%*W<YCVEI'E!5M?85VLUMN\/-
M72AIZIG1SK 2/(>(\RY]?N1JS5FT^TU,]OD/!A_*Q]AW^E<D\%-=5W/5H[:I
M2X5%;ZH^?D4[OW)7J6U[3X:9EPA'[5*[+OJG![,J$5-/-33.BJ8I(96[G,D:
M6N'E!7)*$H=9'JTJ].JKTY)EM$15- B(@"(B (B( B(@"(B (B( B(@"(B ^
MOD1%U'AA$1 $1$ 1$0!$1 $1$ 1$0!%Z&EW $^176T\AXC'E5HPE+1&<JD8=
M9EE%EMI1^TXGR*XV%C>#1YUM'#3>O YY8VFM.)A-:YWO02KC:=YXX'E6:BVC
MAHK5G+/'3?55C';3-'OB2KK8F-X-"K1;1IPCHCFE7J3U81$5S((B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B \<UKO? %6G4[#PR
M%>15E",M4:0JSAU68CJ9P]Z05:=$]O%I6P18RPT7H=,,;476XFL1;%S&N]\T
M%6G4S#P)"QEAI+0Z88Z#ZRL8:*^ZF>/>D%6W1N;[YI"QE3E'5'3"M"?590B(
MJ&@1$0!$1 $1$ 1$0!$1 $1$!-;?\ IOX3?4KZL6_P" 4W\)OJ5]=T=#PY=9
MA$125"YCRT>_M'DE_P!Q=.7,>6CW]H\DO^XN7&>QE\ON>IL;\9#Y_9G-$1%X
M9]R$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$5<4;Y7AD3'/<> :,E20W;BRA%N
MJ/3%VJL$4IB;\:4[/HX^A;RCT(XX-;6 ?W8FY])]BWAA*T](G#6VGA:/6FOE
MQ^Q"57%%)*\,B8Y[CT-&2NGT>D[338)@,SATRNSZ.'H6Z@@AIV;$$4<3>IC0
M!Z%V0V9-]=V/+K?Y%2CPI0;^/#S.74>E[M58(I3$WKE.SZ./H6\H]".W&MK
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MUA_F)?Z0NX+A_P"%-^AK#_,2_P!(6-?V;.W9WXF'][&?.J(B\P^N"(B (B(
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M,L-%Z,Z88Z:ZRN:Q%L'1,=Q:/,K3J4?LN(\JQEAIK3B=,,;3>O Q$5YU.\<
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MRYN",N8>&03N._CA:[5VM*/5FOZVVWV_U-GTI0%\893!VU4O:<'.R#Q.2,C
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M+-IMD5=52RSQ"D92EV68CP-OZ1+QO6_OE(>1G1%=46^Z55=<KBZ.EI^Z""V
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M1LE6"<LG'2T;\X)Z\Y"C+S+9[NR1+;SKNV6K6=MTS+#5RW"N#7,=$UI8P.)
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M!QY5.4JJM]4?0:$@ DG "^>K!R?7#6FD9M4ZHU#<17U$;YZ9C7C8C:,X)!X
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M96;&T>+@QH.>U[E-K7(4\S5CIFM+K<+-I^HK+/:Y+I7-<UL=-'G+LN )W;\
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M5K_=+/IV:[P71TIB>W.P!(\/&7#WN",8./O6=R=:3U.>6&LOVK*5P>R!TG=
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M<886EWAMDVB' ;P" T9\2O\ *SI[4>N.3VSUHM?,7>"5\TUN:_+@QV0,$\7
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M.<<=P\BD5MT[=Z_\(&MOM=;YXK721$4\[V^ \B,,&R>G.TXKL**<Q"II<+G
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MZ@U=;#:+/;MDP4<A\-Y!V@,'?O.,D@;@  NX(IS%=VKA$15- B(@"(B (B(
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MG2MQM-=)D8Z\-8WM78T3,%32M[CYPT%0:]T'<+S9[5ILU;ZR1HCK9<B%FSM
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M) \ZFS(4DU=&>BUNG+Y;]16B&YVB<ST<N0QY86[P2#N(!X@K9*"=0B(@"(B
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ME/%*\-?(9)'.(:#QW[/!3I<KQE;CJ8W+]>34W_1M+=H'1&*G965=-&=LM+W
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M6K^HM:6OD[T99VQVQK*JHA;W-;*=V UQ +LG' %W'&23Y5">7"G97ZRT-I2
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M=7/'AUE8<'K:QH ])<I:M>Q$6Y.-SJ5]NU'8[157*Y2B*DIF;;W<?( .DDX
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M=SFF;B<M.,#(!QG.<+3_ (04UOCU5HZPSD06FCC:Z4-!Q'$Y[6<!OW-C*O\
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MGBHYHV;;8QLGG!O( Z&\%>JKI>]-62WMJ8:1C1)S6RUI/@!HQOSQ/A*]K/\
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M4+(:^M)-1,'.)>2[:/$X&_?N2BTM9J+4%5?*6A8RZU(+9:C:<2X'&=Q.!P'
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M,(B \(!!! (/04:UK!AK0T=0&%ZB *ES&NQM-!QPR%4B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!9=K^$N^@?6%B+*MGPAWT#ZPJSZK+PZQM<IE>(N8Z#W*U=
MW^$4_P!!_K:MFM9=OA%/]!_K:K0U(EHS$1$72<ICUE=2T36&KJ(H0\[+3(X-
MR?$LA<TUG%<J[5M)0<_$X.(DIFXW1@_&W;_>YZ5N[O>KE9;=1T4LD=9>JEQ#
M7-;AH&<#=@>(=JBY-B8(N?76X:CTX^DJ;A70U<,KL/B# ,=8S@=JZ T[301P
M.]$[@]6DN=_917VAM8IW2R5."7!V-@$D9QT\"M)6W>[WF_5%NL$L=/#2[I)G
M ')!QU'IW#'4M?IP5M=KU[KHYCZFBB<USF<#CP0?]K*BXL2V'4$$VHI;1'#,
M98VY=)@;(W9^];E0FP7^LJ!J"OG<)::E!,,88!PVB!D#/ !6]/5=\O<;:R&\
MTS'"3PZ3FQX+<]O#AZT3%B=(H?>;S<JV_FS6%\<3XQF:=XSL]?7UCSJJ>YW3
M3EGJIKU-#62[;64I:,;1(.<X W#[E-Q8ER+GU?4ZIH[0+Q/70M9X+C3\V/!:
MX@#H\8Z5DZAU'70VJQW"D>(65)S.W9!SPW;^CWR7%B<(HGJ^[UL-RMMLM$PC
MJ:AV7NV0[#2<#B/*?,L>ZW^KK+Y+:[964]#% /RU5-C>1Q SN_[*7%B:(H9H
M^]UM1<;C25M2RMIJ9I<*IC0!N/BZ]_8M;9+IJ>_Q3BAJ(HF,DR9GM P.A@W>
M?[TN+'145N:5E/3R2S.PR-I<YWB WE02DN6I+Z*FX6V>&DHX7$1QO \/&_&2
M#T>0)<6)^BA&GM0W"JL5ZN=9*TB('F&A@ 8[!./'O+>*UT5WU-6:<?<&5,4,
M%."72.8-N8YZ!C&!N"9A8Z0K-94-I:2>HD]Y$QSSY ,J+#5$M-HJGN=2UKZR
M7,;!C <[)&2.K RM'?)=2P6!]5<:J%U-5M#'0[(#F!W#@!ZTN+$VTW=^_=M[
MK$!@:7E@:7;6<=*VJTVCJ;N73-OCQ@F,2'_%X7WK57V]W"HOK;+83&R<#,T[
MQD,W9]6.U+\ 2Y%"+==+Q;-506F[5,=9'4-RUX: 1G.#N Z0J:V^7FHU=5VV
MT.C+&MV&A[1LQG R\G&=V\=B7%B<K'[NI>[.Y.Z(NZL9YK:&UCR*(Z>NMX9J
M*NL]QJ(ZB5D9<R39  =@$< -V]:&RTU\N.I+C44M; *Z#\G).YHV3^SN&S_=
MZE%Q8G=UU!3VZZT=O?#-)-4D8V ,-!.,GTK<J"V"X7I^L'6VXUD50RG8YTFQ
M&T#WHQ@[(/$A6Z>]7VZ7VYT5JDB$3'EK9)&C9B:"1GAO)\>4N+$^1<[L-YU'
M<G55MIY(75$3SM5;VC$;1D8W#>2>&[K\VRT7?:VIH[L;G()C1>$), 9W.R-W
MT?2I3%C<V?4$%UN5;200S-[F)#I' ;)WX6Y4/TG67>[:<K9Q4QBL?*6PO?&
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MH>=-PN,5? \-,+V,#3TYX='!3<6-PBT.M;G-:;#)/2O#*ASVL8[ ."3OW'Q
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MUHG<6,U$120$1$ 1$0!9%+225)\$8:.+CP5RWT9J'[3]T0X^/Q+>-:&-#6@
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MG7:GHXK9;K;4P![F\_)*W#6XZ,]6=_7NX*K7EMFIK-9Z6EADGI:8XDV&DG(
M )QPSX2GZ*;"Y#-5"JO^D&34M'/$X2B3F'#PRT9&<>?*P;)56S:I8Z?3,[JS
MP6O<Z'P6GI=DYQU\%T%$L+D+U'33U^M[/$(9'4T $CG[!V0<DG?P_9":BIIZ
M_7%GB$,IIH )'/V3L@Y+COX?LA31$L+G/]4/J*/7%'7R44]1311@,$;2<G#O
M3DK)U'#4W34]@C--,V%@;-)EI(82<D$\/V5-T2PN<_O;JFTZ\[YNHIZFG?&
MSFVY_8V<#QY]:6J*XW+7<=;<J22!D41>QI!PP8PT9Z_"RN@(EA<A>D::>;5E
M[N%1#)&TN,<9>TC(+NC/B:%N]8U/<FF;A)G!,?-C_$=G[UN5J-4VA][MG<D=
M0(,R!Y<6[60,[N(\78EK($'LEYK;=IOO=36JI=4S@NBF:TEK@[]KAT+(N6FZ
MNCT)' R-SZKN@5$[&;R!LD8W<<;O2N@T5.VDHX*=ARV&-L8/B PKRC*+G,K[
M<KE=M.T]-2VNIAI8]ADCBTDO<!N &.&[.?(MQK6@J(M&T5)2Q/D$)C;(&#)P
M&D9[<*:HIL+D&N==/6Z#>RGM]3$<QT[6%A+B!C) '1N(6'J2S53-+6,0T[Y1
M3-VIHF@YR[!.[RY'G7142PN0JPU5KEN$#+=IR>*0GPII(@!%X\[_ +EZ::>L
MY2>>?#)W/2Q>"]S"&GP>@^5Q[%-$2PN0L4T]9RDF=\,HIZ6+#7N:0T^#T'RN
M/8L&Z35-OY0)*V2@J*F/8#8>;:3G+ -Q\N5T)$L+D.U3<J2:2>@NEEK)]@ P
MR1LSDD#@>C?NZ>"R>3NWUEOLCVUS7QF20O9&_BT8'1T9ZE*$2W$$,Y18*BN=
M:J*GAE>V28E[FM)#> &3_B*IY0*6:MFL]OIH9'0ND\,L:2&C<!D]&XE35$L+
MD*U]2S5U;9J&""1T)DR\M82UHR!O/1NRK.KH:JAU5;[NREEJ:6)@:X1C.R1M
M=G'*G:)87(#.RKUA>J-YHYJ6UTIVBZ88+SD$]N /$J=5UU-=&5%+/8ZXW&,N
MC@D;'X]QSQ(Z<8/WKH")87(+7VZXT_)PVD>R22H!!>P>$YK-K./-N6YT/5NJ
M++%":.:G;3,;'M2#&V<;R/\ OI4A1+"YI=2W*.@ACCJ;?/64L^TV3FV;0;PQ
MD>/[E&=&6^7W255=04M11VLL+6LFR"XG&[MR5T!$L+G,-+U5TM7?&CAMD[[A
M._\ ..:0UF,[SNX;\^-9VEJ6JH='7FI?!,*J?:#6EAVCX. <<>+BN@HHL+D(
ML]OJJ;DZJHHH9!53LD<8]DAV\XX?1"IT;)/4:8JK4RBGAE9#(.>>-EKGNS@#
MM]"G**;"YS+3UPN=!8ZJUTEKJ>[-I[C*6D-8,;R=W'=N\RR[125-!R=W BGF
M[IJ7.&QL':P<,X<>&2NA(HL+G-*"YW"V:>-FCM%4*V0.#9 TX(?OSPX@''F5
MR[VBJM>B*:WQPR2U-14"281M+L;N&[R-"Z.B6%R :TM,\5/8WQTKZJEHVB.6
M-@SN&SU=!P=ZS].5-MFN,3+9I^:GW$NJ)(@T,W=>_P BF"*;"X4&Y/O],O%\
MN1X22;+#XBXG']*DFH;=67*E9#15[J+>=LM;G:!&,<0JM.V>&R6X4L#B\EQ>
M]Y&"YQZ?0$[00RAJ*G3&I+K)64%3/'4N+HY(FYSX1(]:S]/T5=/=J_4=QIGP
MNYMW,0$>%C&.''@,>/*FZ)87(?R:44U/;:N>JB?'-/-P>T@D <=_C)4P1$2L
M B(I("(B *N&,S2M8WBXX5"V=DBR^20] P%#=D2N)M(8VQ1M8P;@,*I$6!H$
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 7/>6_3SM6Z0-CI;K24%?+**B&.IDV&U CXM
M/3CPFG(!P0%T):#5>CK!JQE.W45LAKN8),1>2"S.,X+2#OP.Q <,AUD7<BVL
M[E06*W6:]TLD=KJ*FV1M9'*"\-VFEO4'NZ3Q!!WJ,ZVLFCVZ0T#IW3S**HU'
M<I:<U%5 X.DQ( '!Y!Z7O&&G@&KZ>I]*V*GT[)88+52,L\C2U]*(QL.SQ)ZS
MN&_CN6MM7)SI&U.I'6^PT<#Z2;NB%X!+FR=#LDY..C.<="$G*K?8;5K'EWU9
M4WB%D]DT_2Q4S8'[XRYK1N>.D MD..L#J4%TOINS#D0UAJZY4+))9I9(;=')
MO;3!SF,#F#H=M. SU,'C7U%0Z7LM"Z[.I+?#$Z[.<^M+<YG)SG:.?[SN'6K#
M]%Z>?IEFGG6J#O*QVT*3?L9VMK/'/$Y0' >4.)E)R4<E>EZVK%(VXS0S3S/=
ML\RS R23P#>>_P!E9TE%IRW\N-@;HN*F906&VRU5RGI'!S2 Q_OW#WSL%H)/
MQO$I]J[D]FU+RH6"LKZ.DFTI;:!\+H)'9VI'!XQL=0RPY_NJ7630VFK';*VW
MVJSTU-25K#'4M;DF5I!!:YQ.T1@G=GI0'SA#/-1?@V7BNDR:[4]YP".+O#!(
M'V3^U2N^:9I;_P KVC='50<^V6&R,=4QM<1M8&"TD=#L1@]8)79Y-%:=DM-N
MMDEIIW6^W2B:E@.=F)X).T-^\Y)X]:S:?3]JI]055\AHHFW:IC$,U3OVGL&,
M-\G@CL0'S#4SBPT_+#==,Q-H:2.>&U0-IQLL8'2%CRW'#<#CJVE3K:QZ.]SW
M)_IK3D=%47ZOFIS555.X.DV7@!VVX=;G9 / -Z%WW4FD(J/2%WH-(V.T2S7"
M833TU<7<S.2X;9<0<[6!NWC!WJ":'Y*[DW6-IO%XM-DL5OM.W)!16Y[I7S2N
M'OY'NSG&XC?T 8XH#JFMZ^:QZ'OE?0-_+T5!-+" ,X<UA+3CJ& OF]U%I*E_
M!XEN-;W%7:INSBX3/(DJC.93N!]\,-&3U[^M?5DC&2QNCD:U['@M<UPR"#Q!
M"B5JY,]&VJZMN5OT]0Q5C7;;'[)<&.ZVM)(:?(!A"#D7*[:'CDJY.=/W&!K[
M[434U&U\C<R1 L >T'B-_-@^1=IJZ2BT9HJZOL%!!2Q45+-4LAAC#6N>UA=D
M@<2=D*&W#26I]4<J5JNVH66^EL%AFEEH8X)"^6<D^ YPX ^"TGR8Z<KJDC&R
M,<R1H<QP(<UPR".HH#X_D;I.GY!I[K='4EPUE>:A[VR/>'U$;^>(SQRT;+2X
M]!+AQR%/N5RQ.M/X.VFXVMV9K4ZDG=XGEI#O]IZZ?#R5Z(AAJ8H]-T(94$&0
M8)S@Y !SN&0#@8&Y26^6>WWVU36V[TL=50S8YR%_!V"".'40"A)\N<HE[J]5
MR:FUU0<XRU6N".T6V7!&T^0XED'^%SQG^^WJ37%AT<;7R?:8TW'15%[K9Z?N
MRKIW!SRQX =MN!Z7.R > ;T=/TPS2MC9IHZ?9:Z868M+#2;/@$$Y[<[\\<[U
MK[3R=Z3M,E%);K%20244AF@>T$N:\C!=DG).X<<XZ$%R!<I(%YY=>3RQ- YJ
MA;)<I&C@,9+<^>''G4%I;Q51:8Y8M9T+G":KKFT%-,WBR/G-DD'KV)&;^L!?
M1IT]:CJ'OZ:*(W;F>Y^Z3G:$?Q>I8U!I"P4%AJ;)26JFCM527.FIMG+9"[&2
M<].X=@0'S%K6RZ0CT'H6PZ?915&I[G+3OGJH7!\H$C<.#R#TO< &G@&E2J6E
MTSJ#\("^#5%11,M%BHHX(*>JE#(Y"QK<@@GP@TEYQY%V.U\F^D+6:5U!8*.%
M]+.*F)X!+FR#@[).3CHSG"ING)GHZZRSRW"P4DTT\[JF20[0>Z0\27 YW]7#
MQ(#YH?*8>2_6<MIB=#:]1:ACI+= !@<VU[Y/!'5C8;YL*7ZCHZ^X\LM'IRE%
MCDIM-6J%M+37ISA3//-LRX-;[YWA#ZGB7>JK2-@JJ2V4LUII336R02T<0;LL
MA<.! &[M6-JC06F-4U4=3?[-35E2QNPV5VTUVSU$M()&\\4!'>1G1K--17RX
MFY6^MJ;M4\Y*RVM#:6 M+O C /07'T#RQ+E:DHKWRV:2T[J.>*+3T%*^NECG
MDV(Y9/RF XDXQ^3 \[ATKL]DM%OL=MBM]HI(J.BBSL11-PT9.3Y\K6ZHT7IW
M5,U-+J"TT]=+3?FGR9!:.K((R/$=R$'S?15=LI-6\INIM$4\5/;[9;.YZ-U.
MW#&RR%C#*P= RV0C&[&]:[55NTC1\CFF**V,HJS5UU?%,^:-P?.PNR7!Q!R!
MDAFR?&<9!*^I*#2.GZ"&Y0T=HI(8;D VKC:SP96@%H!'#&"1@;EK+?R9Z-M[
M(FT>GZ./FJAM4PX<7"1N=DY)R<9.!PWH3<Y)>[#IV;E_L5GN-/;VT%NL[!4"
MH#6MJ'AA8P.S[X@<W@?W5LN56.W5_*YHC25W=!2:7I:5U6Z![A%"XM#PUIX#
M YL-QU.(Z5U>\:)TY>;Y37BZ6BFJ;E3;/-3O!R-DY;D X.#UY56J-&:>U5)3
M/U!:J>N?3YYITF06@]&01D>([D!QODAH[%<^7C5%STM300V6@I!##S#<1ND=
MLM+FC@ =E^,;B-Z^A%J;'INSV&>KFLUNIZ*2KV.>,+=D/V1AHQP  .X!;9"
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M(OI+I>AR(D*(BP- K%<0*27)P,*_T+YS_"=U[66*[4%FH)7,#Z<328=C>7$
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MOVHF-CV22.!<<]"Z..A8M/\ GI_I+)X#>HE)S=V3&*CP1ZB9'6@(/!5+!$1
M$1$ Z%"-?\QW32Y+N>P<]6S[5-UCU%)!48Y^%DA P"X9PI3L0U<Y]?Q:>Y:;
MO=CG?V\=7C\:ET0B&GZ?N?:YK9;L[7%6[7IFFHI9G2[,X?[UKV[FA;&YM#*#
M9: UH(  Z%9/B18TBR*'\^?HGUA8ZOT1Q,?HGUA6GU632ZR-@BHRF5RG65K7
MW'X3!]!_K:LW*P+@<U,'T'^MJM#K(K/JLM(B+K.(U.K*GN33EPES@\T6#RN\
M$>M1&CNCM-Z$I'P!O=E8]SF9&X;_ 'W8!VK?<H-/65=C;34$$DSY)F[08,X:
M,GUX6LU;8:MUOLKJ*G%3W T-?#QVMS>CI][O\JJRR--5W&MI744EOU!/<+C*
M\;=.P%T8\6.''=[%(:JX5E/R@T=+)/(*6>('F<^#G9=]X618JVJEKHF1:;%N
MA.>=F< W QT# SO6!KN@N3KQ;Z^TT\DLL3"W:8,[)!W9[2@+C+I4UNM:GFZF
M2.UV^,F8-/@N(!SGSY^JM,+[)>'5=55WQ]K@C)$%/#G:=XSC>>C_ )*2V73C
MZ/2U72.<.[JR-W.O)X.(( SU#/K6@L(K;32]R3Z6-54L<=F?9&_)Z78/K4<0
M95!>KDS0-;65DCQ.'<W!*=SG X&?'C)W^)5Z?;>9:2FO%SN,C*&"-TAAR<R,
M .]W7D]?0LK6]/<KCIZB@AHW&HD>UTT<>\,PT[L^4^A;NYVYTNFYK?3$;?<_
M-,Z,D# ]2FP(C;S?M10U-U9='4$$;CS,3<[)QOWXZ/&<]*OZ7OU6RPW>\7*9
M\X8\-C83X(=U#J&7!85 W4+--S6B"UOA#&OVIG;BYIR=EHZ2>&1E9[;!5GD\
M[B9$YM:7<\Z([B3M</+@!0@8D(U!+9I-027=T1:#*RG(\!S0>KAOZ-WG5V*Z
MU]/R>RUTU5*ZJGEV8I'.WM&UC=]5RU=[K[NW2E/155":*ECV(7.><.E(X #H
M&[)6VU!:*V;35AMM'3R/ V73%HW,..GSN=V(!J*Z5]!I"SAE5,*ZIV7.D!\,
MC&<9\[5AZ@FO]JDM];47)W/U#_@K-S&8QX..!XX6YU':ZJMU-9(XJ=[J&FV7
M.?CP1OWCL:.U5:GMU7<=5V<,IWNHH,2/DQX(.UDCL:.U+ IU1=*^IOE-8K1-
MS$KQM32CBT8SCQ;M_8M7(;S;]36ZSONTM3$][92_>'%N3D'CT-/2LFZTUTMF
MM9;I1V^2MBF8&@-Z/! WGHX+&TN*NX:]JJFX;//T\;BX-.6L.YH:/)D]A0'1
M'#+2 <'K4(T9>YVVF\2W2H?,ZC=M9><G@=W:/2IPN7R:=NTU[N%%%#)#;JJI
MVY)2/!+ YQ'KX=>%+(1F4%^N%OTI472LG?-45<W-TS9#D-XY<!U<>P*W<X]0
M6BS-ND]XD=), U\#L^!M#=CHR/$ MMKNQS3V6BBM<!>VD=CFF[SLXQG'3P]*
MU6HHM0:A@I!+;7TU.) .:!R[/2]W4!]Z@E&1J&Z5]!I.RM94S=VU.'N>'>&X
M8SC_ &FK+F9>+5:;E=+G<2^5\&RR%I.S"]Q &.C(W*O4%KJ:W55E9%3O-!2A
MKG28\$8.<=C0LOE!IZRKL;::@@DF?),W:#!G#1D^O"D&H=?JVV:)HIGROFN-
M8YPC=)X1:,G?X]V.U85\CO\ 8+7'5S7F21]01&^(DDL)&?!)\G1A;#5]EK1;
M[(Z@@=.: !KHVC).YN_'3[WTK$O=+?=0UEM=5V]U/2<[CF@<E@R,N=YN'D/G
MAA&7JVY5]NLED@AJ)N[9MDO<T^$\AHR/.7+"O4U^M-QMD]3<W2353]],S<QN
M\>#C@>.,K<7VW5=?K2U/%.\T-,T/,F/!!!)^YJ7VW5=?K:U/%/(:&G:'NDQX
M(<"3]S0I!I]?4M55ZEH:+NLNCJ2WFXL;HOV<^/I*F]CHJF@H>9K:U]9-M%W.
M.&-W4HIJ6GN<&LJ6YTUODK88XP&-9PS@C>>C><J;T[GN@C=,P,D+07-!S@XW
MA%J0<^Y1*>IJ;W04@JRZ*J< R#&Z,Y#=KQYR5>OK[E:S9;3'<YI:F>8[<H\$
M[)(#1Y.*O57_ (ARG4[.+*.($^4 GUN"]U?27&/5-ON='125D4+  QF_!!/'
MJXC>HYDF1KBOJX[C:*"@J)(9*B3PRPX."0!]ZL:JNER&K*&WVB4AYCR69\$N
M.=[NL  %6:*VWBMUG27"[4W-QM9M@-WMCP#LMSUYW^=9UKMU7)KRX7"IIWLI
MVL+(GN&YW!HQY@5.H-?;IKM;M;T]OJ;E)6LE9M2!V=D>"3N'1C'0KKZRYZGO
MM726VM?0T%(=ETD?OG'..C!WX/3P"R[5;JN37EPN%53R1T[6%D3W#<[@T8\P
M*U%D9>]-5E?3Q6B2L;.\%DC3AN[.#G'C\2@&3JBDNENTG*VJNSIBV4C.-\K'
M8 :3]8]*PJ6T76WZ6%?#>I*> 0\^(&M/2,@9STY6ZUM17.XZ8I&B#G*H/:^>
M.+?@[)X=>"5:NSKI<=%.@%KE@F<]D0A!R[8;@[1'1O&$!CT>H*NV:'975,KJ
MBLJ97-A,ASCHW^(;)/G5BZ4E_M]D[\3WN<5 V7.IQN:-H@8QG&=_4LO4NG:N
M;2MJ@HX]N>D:-N(<3D;\=>]6[FZ^:HBAH'6Q]OI]H.FEE)WXZ@0.S?T(#W4]
M_K/<Q9YJ>1\-75D.=S9P3@;P/*2%A7^:_P!JJ+=5U%R<Z>I?\%9N8S&/!QP/
M'"VEXLU1+J.PT]/3R&W43&YDQX(P>!^J.U7M1VZKN&K[06T[W45/A[Y,>"#M
M9(_V1VH"C4]SKZN_06*SS<Q(X;4TPXMW9QGHW;_.%K2Z\T&J+=9Y+M+4Q.>V
M4NWAQ;TM=QZ&GI/%7[E372U:UGN=';Y*V*=FRW9X#<!O/1O"N:?MEUDUG-<;
MO 6D1$AP]X"0 &CR D>9 *C_ ,0Y3X6<64<0)^J3ZW!9.F[A5W'5MYS42&C@
MS&R//@@[6 <?X2J=,T%;%J"^W.JI9&%^T(0X;WC).[ZK5AZ=H[M:=-W.HCHY
M#<ZB4!C"-^/C8\[E(,"Y=^HKY%:Z&^5%75/.9-D;+8O*<GH6WOMPN-3>*73U
MJJG1RMC::BI_:X9\V[?Y2L/1T=TME5LS625TM3*.>JY'[PTG?T>?QJ[7T]UM
M.M*FXT=NDK8JAFRW9X#('$]&".Q0"PUUYHM5VZSRW66IBVQ*7;PYS=Y+7<>A
MIZ3Q6-?J&MN&NXZ(5[B\$RQOV=T WN  SX@MIIRV71^L:BXWB$M<(B0X>]R0
M &CR#(\RM3P7:@UQ55T-MDJV3#8C<#AH! &2>C&$!BW)EYME]MM"Z]U%0ZI>
MW.,MV1M8ZSX^Q;.XW&XWO4<MHM-2:.GIP>>G:/")'''G.,>57I;=5U7*%'5R
MP/%'3189(1X).R>'G<>Q:Z&&ZZ<U'<JB&V2U\%6XN:Z,\,N)' '''" O66JN
M-KUB+-55TE=!(S(=)O(\$N!WY(X8XJRRNO-VU7=*.VUCH:=A+"\[VQ-:<$M'
M62/6MAIJTUSKM57V\1B.ID:1% #DM&,>H8[5[H"WU=#37*JKZ>2.HGDSL.&"
M0,GUDJ06-"5E>;Q=:"LJY*N*G) D>23M!V-V>OJ\2FRB/)[;:JC@KZBX0OAJ
M*B7.'C!(&_/:XJ7*5H0PN<\O7ZBC^;C]3ET9<YY>OU%'\W'ZG+*O[.1U8'\1
M#XGSHB(O$/M0OJWDV_42Q_RK%\I+ZMY-OU$L?\JQ=V!Z[^!XNV_91^/\$D1$
M7IGS(1$0!$1 $1$ 1$0 \-W%<KMULN-RU;71LNCQ4T@(-5L[]QV< 9W<3V+J
MB@.E(+M;-0US)[;(]M7-E]03AK6@N)(/3G*JR4+W7W8ZKIK5:JI^W' UCBX^
M"7%I)>X>0@JJ\W&OTY;H+<ZX=T7"ID+C4RG(B9D#IS_WE9NG;=5G6-WN-93O
MCC.61.>/?#( (\S1VJQK2V5CK]0W2GHN[X(F!DD&,YP7'AX\^A"35P5]737Z
MW0VN]U%V,K@)V.!+ ,C/'@,9\F%LKE77*_:EFM-JJW4=-3 \[,SB2-QX;^)Q
MC/6MMIVKJ9ZIS!81;*4-)+W8:7'H&,!1^C@O5CU%=#26QU6*MY,<A.&C+B02
M?/O&Y0"Y8I[L-9MME7<7U$-(QQ>1N#QC=M=9RX=BU<5MN%RUI50-N;^Z:5I(
MJ=GWHZ@,[O?$+?:'M5?37BZUEUC<)GG9#R-S\DDD>+<%BV&"[6W5E>Y]LDE9
M5S;YR<-8S:)+@>G<>" ]OM?=H=26VUVRJ?),R!K7EQW/>0<N</$ "L/NB_V[
M5#K7!<75L\S!OESLL)&=K&_&.*W5HMU7)KJY7&JIWQP!I9$]PW.X-!'F![4L
M=NJW:VNMQJZ=\<6"R)SAN=O !'F;Z4!@V6>Z4.M^]E5<9:V)S"Z3:X#P=K<,
M[M^."M7#4#[K>ZFE%V[UVZGRWG&'#Y7 XW'CUK9Z?MU6=97>XU=/)'&<QQ.<
M/?#( (\S?2M+:Z*ML-96156GS<VO?F.4,#L<>G!QE ;#1UVK3!>'U%1+5V^E
M:YT51*""[&>D^(9\2U=JEO\ =+!653KI)3TU.'R<YD[<A S@'H QZ>E2:ZNN
M-7HVJ:+<8*J4;#*:,[1#2X#U96.^W5=)R>"B@IWNJWQ@.C:-X+G9=Z"5-@:^
MFKKC6\GLU3)7/BFA>[\KC+I&#]G/C)QGQ*YR=6BKBI:>O[N>VDD+W&E#=SC[
MT$G/BSV*_5V>L9R=QT%/"XU.RU[XQ[XY=M$>7V+::*DK#:64];0.HVT[6QLV
MSODZSC&[H1+B#*U56NM^GJZHC<62-9LL<.(). ?2H6!J"HTKWTENLL$<+=J-
MC20Z4;7%SL]G'<%N.5"H+++!3-]]/,-W6 #]^%K*INH;C:X+"+6:9C V.2<G
MP'-;PW\.@'=E'J$7KMJ"L&@Z"J$SHZRHDYLR,W$AI=D^? [5FTL=YHJ"JO%U
MKW'%(XLI1G#'8\'/1GVJQJ"Q5#Y]/VZD@DDHJ8CG9 -W$9)["?.MUKF&JJ-.
MS4]#"^:65S6EK!DXSD^I :"AU!5VS1#:^IE?45=3,YL)E.<='8-DJS=*2_V^
MR=^)[W.*@;+G4XW-&T0,8SC._J63J+3M7-I.U04D6W/2-!?$.))'A8ZSE4W-
MU\U1%#0.MC[?3[0=-+*3OQU @=F_H4 :GO\ 6>Y>SS4\CX:NK(<XQG!.!OQY
M20M]IV@NT-3+67>N,IFC&*=I.S&<Y\G#<M3>+-/+J.PT]/3R&W43&YDQX(P>
M!\S1VJ:J400OE0,[+3"^.J='"Y_-OA _.$[QD^+95-O95:4TY+6U=8ZH:8F"
M&F(PUCW;\<>L^@J]RCT%;74E$:*G?4,BD+I&,&3P&-W;VJK4%)<-0Z3&:/N:
MK;()&TY=DD#(QG=OWY3M)-5)2WZ>P27N>\S0R<V9FP,RUNSQ' XX>)2K1]QF
MNE@IJFJP9CEKG 8VL$C*B\\U_NUGAL\=IDI1LMCEGD)#2UN.&1XO&II9K>RU
MVRGHXCM-B;@NZSQ)[241#(9RHMJ2ZB8RI=S,YV!3@;BX'WWI 5^[1U^F=)U#
M7W.2>:1\<4+@-GF@.@;^H%5Z[HZ^2[VJLI*-]7#3.VBQ@SO#@<'RX&]>:OI;
MG>Z&SQ=PR1F20OG:T[0BZ!D^0E1S)+EEBO+*9EYNMP=S$=,YXILG> W<7=!/
M2L.R7ZLHM'5ESK9GU$[YC' )#D9P/1Q/F4FU;%._3=7!0PNDE>T1M8P;\$@'
MT94;NNGZQ^@J"D@A<:F%PF?$/?'.UD>4;7H4Z Q:AFH**Q=_)KP_;>T.-.X;
M@UQP,= .\'&%[?:NH;R=40JYGRU%7("YSSDEN2X>IJHOC=0WFS4\/>M]/!$6
MM,8]_(X [\=#1]XXK9ZFL]555>GZ&GIWOHZ?9$KP/! RT;_,#VJ 8^HZZIL]
M+8[7%4/HJ=T31-4,;DC& <>O=UJ1Z9I)((I9>^\ESII0#$YYVMG&<[\G/1V+
M7:CK:N26JH9].R5U.?S,C=XX<3N.-^>I9&@[14VBSNCK?!EED,G-YSL# &/+
MN4K4=A)$1%8J$1$ 1$0!$1 $1$ 1$0!$1 $1$ 6^M/P)OE/K6A6^M/P)OE/K
M5)Z%HF6B(LBX1$0!$1 $1$!C5]0R&"0%[1(6.+6YWG 7RQ/*^2JDE>XE[GEQ
M/3G*[UJFY1&Z Q-+C QS''.XY!7 Y1LRO'4XK6FC&HSZBT](Z6PV^21V7NIV
M$D])V0M@OFRX:OO57!!#'5S4]-!&V-K(7%HW#&_'$K=Z*Y0KA;:Z.&ZU$E70
MO.RXR$N<SQ@JK@RRJ+0F_+/;JRNL-,^C8^1D$A=*Q@R<'<#A:CD0ME=3S7"K
MGCDBIGL:QH>,;3L\5LN5_455;K91P6V=T9J\N=+&<'9'4?&M3R-:BKJJX5%M
MK:B2>+F^<C,CB2T@[QGJ4J^4<,YUQ>9'6%R+E$Y0JF.NFMMCDYIL1V9*AOOB
M>D-ZE$64]]J-.3:@-RJ#%'-S1S*[:)W;_2H4"7/L1]&+D'+O._NFUP;1YL->
M_'CW!8.@>4.MI:Z*BO4[JBDD(:)9#ET9\O2%D<NI!N%L(.08G$=H4QC:1$I7
MCP*>0J5XN]PB#CS;H0XCQ@KLZ^8=/WZLL?=3K<X,GG8(^<Z6C.=WC5RGU5?:
M:JY]MTK.<SDA\A(/E!4RA=W*QFDK'TTBB?)YJMNIK6XS!K*V##96C@>IP7/=
M=\H5QGN4]':)W4M+$XLVXSA[R.)ST*BBV[&CDDKG;LCK1?,7?J_,'='=]Q#3
M_:<X_':IWR=<H%8^Y0VV]2\_',=B.9WOFNZ 3TY4N#1"J)G8)7MCC<]YPUHR
M5CVVNBN%-ST&=G)&\*%76[RSB>(3O.)R6CAX(6BNVH[C9['.*"5K"2,$C>W)
MWD*%$ER.N* \LO=$FG:>FI6O>Z:< L8,DX!*Y##JF^15(J&W6L,F<[Y20?*%
MV;2]TFU79:&O#F,JJ-[A,W&YYV2-W5G*G+EXE5)2X'-.22:2#6M/&"6[;7,>
MW_OR+Z!7 .3C;_&)'SS0V3G)-L=1WY6[Y4=;S2UCK79ZAT<,1Q-+&[!>[J!'
M0%,E=D0>6)*=8WJ:VZ@?&:LP0.MTKF G ,F_&/&HA8;M7LO\9DGDCIJMU&:J
MH R2[F]S3Y22M]R3[5^LLW?N!E:VFEV8):ANV1D;P"?^]ZZ VV4+6EK:.  E
MI(#!^S[WLZ%%[<"R6;B9B(BH7"(B B'*9KBBT1875=1B6LD\&FI\[Y'>P+94
M$;KYIN@EN;&Q5<L+9'AO[#B-Z^<[[;[CRO<K5UHZ:L[GHZ#:9$]P+FQM8<<.
MLE;B?DCN]/*8I-=2-<W<0&R;O]I:Y4EKQ,\S;TX'5Y(JVQU>VWWO0X>]<%*K
M1<XKC#EO@RCWS.I:'33J*VZ8HK5<KBZX201!CYY&G+SUK6R2LH+@);?-ML!R
M.C=U%4U+:'0$5FAJ&U5+',S@X945Y5-73:+TJ^[4],RID$K8]A[L#?GV*$K\
M"6[<28(N&:3Y7]37ZY6YC=*.%!53-8ZI9MEK6DX)SC&Y2'ECY3:K05PME/2T
M$-4*N-SR7O+=G!QT*<CO8C.K7.I(H=RCZOFTGHAU]@IF5$@,8YI[L#PO&HOR
M2<KC=;5U905U)'1UD<?.Q-:_(D X\>E%%M7)S*]CK*+F7)3RDU.M;]>;?44$
M5,VA&6O8\DN\/9WJ-\H_+76Z2UG76:*TP5$-,6?E'2$%VTQKCZTR.]B,RM<[
MBBY;KOE6;9-$6745GI8JR.XR!FP]^-CP"2-W2",*;TE_@&D8;[<2VG@-,*F7
M?D-&,J,K)NF;M%RZWZRUIJ2 U^FM.4L5K=GF9*Z8M?,.L <,J<Z4J[O66H2:
MAM\5!7!Q:8HY><! X'/C1JP3N;A%RVVZVU;?+E>(K%8[?-3V^J=3%\M06DD=
M.,*;ON5?1:2EN-SIHH[A# Z62"-^TP.&=P*-6"=S=HH'R4<H4.N+;,9H6TER
M@.9:?:SX)X.'6"MQI+4<E\N>HJ62!L0M=;W*UP.=L;(=D]J--!-,DB(B@D(B
M( B(@"(B LUOP2;Z)4<4CK?@DWT2HXM:>A201$5RH1$0&72?FCY5>5FD_-'R
MJ\N.?69W4^J@B(JE@L>K_9\ZR%C5?%OG6E+K&=7J,QUD6_X9%])8ZR+?\,B^
MDNEZ'(B0HK=3,VGII9G@EL;"\XZ@,KF6AN4.[WF^V2GNU#0PT5\I):RB-.YQ
MDC:P^]DR<$D8X+%)LNVD=17QG^%!3R5?+*V"?:YIU%&6;/5@GUKZ*U#JV_V?
M7=FM/<EKJ:&Z5#HXXXG/-3'$ ,RO_9 R>&/.N=\J7>^NY>=-.I9(Y:F.CF@J
M& 9V2 \C(\A"-6"=S0?@:R/IZG5?/2-92CF0'/./"R[<OJ,.W#&]?'7))2-I
MZ2]U-0UW-35SVM=O+<AQW;NG>OI7D[FECTU$VMD<T;;C"),[09G=G_O@KRIV
M@IW*1G>3B3)"K'=<'RK5@7B_VZTTG=%=5,CCS@;B2X]0'25FDWP1I>QI=3:/
MIKI=&U;:F:FDFPV78 (> , [^!\:D]OHH:"CAI:5NQ#$T-:WQ+3VS45MO4<4
MU#4A[6/P]I!:YI\8*V-;=Z*AIGU%54LCA9Q<59N3]5E5E7K(V"+56S4%MN<+
MY:.K9(UAPX<"WR@K)CN5)*2(ZF)^..R<J,KY$YES,LX )7,*GE'J8[G,^.BB
M=;8I3&<N(D(#B"[JZ."WT^L'F=QIHHC #@%Y.TX=86%3::T_<K@RYD2-9*>>
M=!MGFR_._(\O1P6T89%>HC+/G=H,GD3@]H<.!&0JUC-JJ=O"5J][K@^5:L#8
MR$5CNR#Y5J=V0?*M0%-;_9?3"R5J[G7T\5.9G2-V(@9'8ZAO/J7.(^5.K%:)
MIJ2F[VEPRUI/.!F??=6<;\*\*<I\45E-1U.MKQRQVUL#@")6X(R/(O.[:=V<
M3,..HK-M(ND]3FE175U=JJO[HJZB%M)*1' R0L#0#N) XYXJ;Z>K9Z@-;.XN
MRS:R>C>J:^AM=1715<D,3ZD-(YS>#PZ>M95I=30TK2'-:\C>K3>9IHBFE&+3
M(?>[)7076=T-.ZHBJ)3(QS#P)/ ]7E4NTI;Y+;:&0SD&4N<]P' $G. K]350
M<[#^5;N/6LD5<'RK5I.K*45%F<:2C)R,A%8[L@^5:G=D'RK5D:%]%8[L@^5:
MG=D'RK4!?16.[(/E6IW9!\JU 7T5CNR#Y5J=V0?*M0%]%8[L@^5:G=D'RK4!
M?16.[(/E6KPU<.-TK4!D(N>7GE&[DNL]/14C*B"!VP][G[)<>G9'M4RM=WI;
MA;Z>KAD'-S,#VYX@'K5I0E%796,U)V1L45CNR#Y5J=V0?*M52Q?16.[(/E6I
MW9!\JU 7T5CNR#Y5J\[KA^5:@,A%C]V09_.M3NN#Y5J R$5CNR#Y5J=V0?*M
M0%]%8[L@^5:G=D'RK4!?6+1>\E^FJN[(/E6K'HZF%HE!D;O<@-@J7C:&#P5G
MNR#Y5J=V0?*M0&@DL=LK+?,*F@IWXD)!# T@^4*F^:7LD]BYB:%E)!3@R,DB
M.P8SC><^/&]9T%1$*&8&09+SA8VKZ<773591T\S6S2,&SDX!((.#Y<85HR=U
MQ*N*L^!I.3YNF:.K>RUU3Y[A(S!DGSM.:#P9GH\BGV<KCVDK-7OO=#+4T[Z.
M*DE$CWR$>%CH;CCE=9%5!\JW"O523X.Y6DVUQ19;41PSS"1V"7< LQDC9(]I
MAR#U+0U$K!52O#@YKCQ'6MA02QQ0$22M!)SCJ61H1S75\K;=/24U$\0<ZUSS
M*6AV<= RMMHJYSW6RMGJ@.=#W,+VC ?@XR%>O$5OKJ7FZIL4S0X$!PX++I9:
M2G@9% 8XXVC :T8 6CG'(HI<2BC+-FOP,LNP5Z#E<AUCJ2X>Z*LAAN$E)%3$
M"-C,#(QG:.1O70-)WAUPL%%55KVMGDC!=NQGQX\?%)4W&*D(SS.QOT5CNN#Y
M5J=V0?*M69<OHL?NR#Y5JOM.1GH0'JP[M\#=Y0LQ8=V^!N\H4QU(>AHE>I/S
MQ^B?6%95ZD_/'Z)]86E3JL4NLC+1$7(=@6%7?"H/H/\ 6U9JPJ[X5!]!_K:K
MT^LBL^JRVB(NLX0B(@"(B (B( B(@"P;S;FW2A=3/FFA!(=MQ'!!!R%G(@(M
M3:-I^Z8IKC75E?S1RQDS\M"E*(EK$A$1"".733!K+A-50W6NIC+C;9&_#=PQ
MN[%G6"QTEDAD92[;GR',DLARYRVJ*+$A$120$1$ 1$0!$1 $1$ 6/<*8U=%-
M3MFDA,C=GG(SAS?&%D(@-)I[3E-99)IF2RU%3-N?+*=^.I;M$0D(B(0$1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!<YY>OU%'\W'ZG+HRYSR]?J*/
MYN/U.6-?V<CKP/XB'Q/G1$1>(?:A?5O)M^HEC_E6+Y27U;R;?J)8_P"58N[
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M>[[E3R5=.][31U!/@M<[.6@=&X+<R6^>:2]U$CZB"ZU#C'L10E\98 -EH)'
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M(@"(B (B( B(@"(B .]Z?(M<MB[WI\BURE%X!$126"(B (B( B(@"(B (B(
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MW/?,QX+<8:5'KR]W?>89/ONOQ*8\'P(EQ7$E^F*6:BL-%35..>CB:UV#G>
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M\@6?T*%%1T)E)RU/,X"U-?>&TTQC:T.<.)<[ "VQWA06[0R"Y5!+"[+]V-^
MMZ$%-VD<]>;A&\276ZO;6QD@;+AQ&<K)F YF3Z)4>TE%)').7C#< 8ZBI%-^
M9?\ 1*I5BHR:1>E)RBFS#LX_T"/S^LI:_>3_ ,0KVS_ (_*?6O+7[R?^(50T
M1GH58J*AE.W,AX\!TE44]9%,XM:2'8X'<HS*]B5%M7-93?FZK_OI6=%^BW_1
M*P:;\W5?]]*SHOT6_P"B5) LOP4^59Q6#9?@I\JSB@-75<)_IA;&F_,,\BUU
M5PG^F%L:;\PSR("U<?@KE1%^CO\ "57<?@KE;C_1W^$H#'I/>P?3/J6U6JI/
M>P?3/J6U0%$LC8VESW-:T<2XX 5!YN:$EKFR,(X@Y!4&Y4Q4[-"X[?>\;7.[
M.<;71M>+BL?D^J9:.@KYI3(+=EHB&#@OZ=GQ<%LJ5X9TS+>>ME9,Z"-D<D(C
M8U@P=P&%M%H[-71UDL88US',!RUP6\6333LS2+35T%AW;X&[RA9BP[M\#=Y0
MD=0]#1*DG#AY%4J)#@A7J]1EL/[1%6TFTK6V$VPO//6L7=I6B<U<?T'>MJ;8
M5#3FLC_AN];5I2ZZ,:Z_ULR41%Z!Y(1$0!$1 $1$ 1$0!$1 $1$)"A%YTY%J
M'4UP;=*NL=2P4S!'21RN8TDY\/<>.1A;?6-^M]GM=1W9<XZ*<L)CP09,^)O$
MJ/T.J[1:M(PWB]":EEKV'+)"YTT@&0/?;QNW^=5-81EJD0"P66^ZCTO=GPW:
MID@H 8Z1A>X.#V;\9'$CA@J+TM+<IM)W[45'--"8W,IZAK)3O!QM$C'#AQX*
M16/G[>]K-"7:HCH*YCG.94X,A?G=AO$9R!M=."I1JK2]?8]$ODB[E<VGD;5U
M>P".='!['-WAP()ZE*9V.:C?W]A K'=KHZMK+Y:W07*,TG-2LJV$D$@ M&.G
M<<'J"B;[K>(-J=TTW.U(:^60D.<1O&=KB/\ DNR54EAM\CJ#3D]OMXDI!5U%
M-*\CPP,MP<[G8<?+P*U%]TWI2UV6,T-S+KA(S,SQ)D!A'A$MQNZ@.M2G?B3&
MK%OBB.VJ]76P7N@OO?)E?+-1LYQLX'O22!'D;R=V<J<3\J]Z#I2W3T+:>,-V
MY'3'P=KAT>=174+=-VZWVZDL\<3Z6LD![IJ96NV"!Q< -IO'*TUGN$5!<*^T
MU=THQ;)'Y=41M,PD.-S00-H?\D5GQ)RTZBO):'1[)RAU\[6T=EM=+LP@-D=/
M*0XR%P:2<;L%QXJN@UO>Y;A2&JJ:=E/5R;,0;$  ,D;\^,9X\.E7;)I;3-!:
MQ7Q9%%5#FYV25!#R[.3LG=D'&<<>!"G-JTU8H8*>:DH8GMV6OC>\;1 QN._R
MJIRS<$W9%-!:;7=Z6GN%9:Z4U$HYP[3,C.3O\_%;2I9345MF <RC@:P^&P!H
M9XU9N%YH:"5U/45$<4XA,K&/.SM@9X=!X<%R&OUK='<G<5SU"6$UE>TTC(&
M.=$UQ)ST="DYR!:@TK5=\JZX4C9',=(\$/:X'9_;D<YPW#R[UEZ5Y*Z^[4SW
M2USI:,,=S1H9F/ ?U.W\"I=J&CIM6:BM]L@NM;2T5P8*MU/5OV.=<?VMGI)
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M:$Y:+;J"Y16ZMI.X)7^#&0\N!W'=P ' *TTS.C)+A<ZT"N2_A%7JX6O2T<5
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M>RZ,':!<=^1YECT,]+/'52MJ*=K1[Z1X#"!G.!U[QA8U'3-;=6U]QJYWND:
M06^_8 =D@!+@F=%4.EH(YIP&OV,R < >G'B544YEC:^.*39=O&T-G=UX*T]*
M\V^F;30L<><>Z4-<,D-)SLXX]?D6QI^>DYXR-DB##^3)P-RD%]LDHDQ*QH8X
MX:0<GSJ^L:9KY:=CXC^4;AXZG>+SK(8X/:'#@5(/41%)4(B( B(@"(B (B(
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M'4NJUO\ :_Q&)!QJ^L17HU<(W3D]3;-5,WYE_P!$JH 85,WYE_T2MCD,2S_
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MS#'SK6P\\RJ;&UHV3TG'C6^M<@DHVN#<9)R<YVCUY\?%2@9:(BL5"(B (B(
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MHB+(N%;GB$S"QQ(!ZCA7$0%F"GCA;LQL:P>+I5T#<5ZB \ (7J(@"(B (B(
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M2?=*^7?PE_UXC_AC^EJ^H1G.\KY>_"7_ %XB/7&/Z6J(:FE;J$2Y0?S>G_\
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M^E9#?S3/X;E)4HLWYP_15_\ ]"_Z?WJQ9OSA^BK_ /Z%_P!/[T!CO_\ 5_Q
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M<2!VREU%+#3W^WT99! 262/<TG=Q):5F37FIN=35UDMN=554VS&SF"=H'CD
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M_P#>;]ZPQ7L9? [MF_BJ?Q1S'*]RO$7S1^A'J[!I;]7J#^$%QY=ATM^KUO\
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M B(@"(B (B("Q7'%'-GXJCJWEWDV:0MZ7D!:-:PT*2"(BN5"(B X_P K!_\
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M$ 1$0!9M/^9:L)9M/^9:H966A<1$4% B(@"(B (B( B(@"(B (B( B(@"(B
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M;.*\J5MNEPN=M+*6>;F6D.<UI.-XXK,UWIJHN$]#>;$6NKH(F-D@=[XEHW$
M\>K"ZW+#',W9D8'#QA:V>S1.R87EAZCO"7*6.5^Z/5D\0IHM*1MJ.'.]Q'MW
MC"EEUTS6ZCT(REN%/34EU!$H$8 :7 $#..&<J0=PU\!_(R$CQ.3GKI'Q:X^4
M90',+%?-::8I!:C9)JID9+8BZ%SL>0CB%@NL.J:S65MNEVH)WODFCD>6,);$
MT.X'JP%UWNZX#C$?J)W;<3PB/U$! [-9+E%RO55?)0U#:)SY")BP[!R-V]6M
M?V*]V[6[-1V6E=5@[+BUC2XM<&[."!T8"Z#MW23< X>8!!;:R8_EY<#QNR@.
M9ZPK+WJ?1\+:VV215T=9GFF,/O-D[\<>)4\LE76"RT-+%$YCXX&,<,9.0%NJ
M>SPL.929#U< MC'&R)N(VAH\04 A5C@?47:>E=;*FD@:"YT[XMAKW9Z.ORJ7
MTU'!3C\FP9ZSO*R$0D)A$0!$1 $1$ 1$0!$1 $1$ 1$0!$6#<JP0L,<9_*GT
M!2E<&#=)^=J-EI\%FX>7I6$B+9*W S"(BD@(B(#AW+2<:NB_E&?U/4"VE.N6
MS];XOY1G]3U <KP,3[61]SL_\-#X%S*]RK64RL+'87<KK/(2<QWKRP_[ZY%E
M=;Y!CF*]^6'_ 'UU8+VR_O8>=M;\)/Y?='5ED6_X9%])8ZN4\G,S-DQG9.<+
MVV?&$E1:KOL[Y(=J=]G?)#M661E[HVJ86J[[.^2':G?9WR0[4R,71M-AOQ1V
M)L-^*.Q:OOL[Y(=J=]G?)#M3(Q=&TV&_%'8FPWXH[%J^^SODAVIWV=\D.U,C
M%T;38;\4=B;#?BCL6K[[.^2':G?9WR0[4R,71M-AOQ1V)L-^*.Q:OOL[Y(=J
M=]G?)#M3(Q=&TV&_%'8FPWXH[%J^^SODAVIWV=\D.U,C%T;38;\4=B;#?BCL
M6K[[.^2':G?9WR0[4R,71M-AOQ1V)L-^*.Q:OOL[Y(=J=]G?)#M3(Q=&TV&_
M%'8FPWXH[%J^^SODAVIWV=\D.U,C%T;38;\4=B;#?BCL6K[[.^2':G?9WR0[
M4R,71M-AOQ1V)L-^*.Q:OOL[Y(=J=]G?)#M3(Q=&TV&_%'8FPWXH[%J^^SOD
MAVIWV=\D.U,C%T;38;\4=B;#?BCL6K[[.^2':G?9WR0[4R,71M-AOQ1V)L-^
M*.Q:OOL[Y(=J=]G?)#M3(Q=&TV&_%'8FPWXH[%J^^SODAVIWV=\D.U,C%T;3
M8;\4=B;#?BCL6K[[.^2':G?9WR0[4R,71M-AOQ1V)L-^*.Q:OOL[Y(=J=]G?
M)#M3(Q=&TV&_%'8FPWXH[%J^^SODAVIWV=\D.U,C%T;38;\4=B;#?BCL6K[[
M.^2':G?9WR0[4R,71M-AOQ1V)L-^*.Q:OOL[Y(=J=]G?)#M3(Q=&TV&_%'8F
MPWXH[%J^^SODAVIWV=\D.U,C%T;38;\4=B;#?BCL6K[[.^2':G?9WR0[4R,7
M1M-AOQ1V)L-^*.Q:OOL[Y(=J=]G?)#M3(Q=&TV&_%'8FPWXH[%J^^SODAVIW
MV=\D.U,C%T;38;\4=B;#?BCL6K[[.^2':G?9WR0[4R,71M-AOQ1V)L-^*.Q:
MOOL[Y(=J=]G?)#M3(Q=&TV&_%'8FPWXH[%J^^SODAVIWV=\D.U,C%T;38;\4
M=B;#?BCL6K[[.^2':G?9WR0[4R,71M-AOQ1V)L-^*.Q:OOL[Y(=J=]G?)#M3
M(Q=&TV&_%'8FPWXH[%J^^SODAVIWV=\D.U,C%T;38;\4=B;#?BCL6K[[.^2'
M:G?9WR0[4R,71M-AOQ1V)L-^*.Q:OOL[Y(=J=]G?)#M3(Q=&TV&_%'8FPWXH
M[%J^^SODAVIWV=\D.U,C%T;38;\4=B] PM5WV=\D.U.^SODAVID8NC:K#NWP
M-WE"QN^SODAVJS5UYJ(3&8PW)SG*E1=R&T8*A7*L<62E_F!_2Y350?E;.+'2
M?S(_I<J8OV,CLV9^+A\3F(<O=I8^T@<OG3[RYD;2G')0<W2M_@C^H* ;2G?)
M(<W6N_@C^H+IP?MHG!M1_P#B3^'\G441%]"?!A$1 $1$ 1$0!$1 $1$ 1$0D
M(B*"0B(@"(B PKRVJ=:ZEM!CNDM\#/2HS!)>**&DYLL@RX-=3<QD.>3OR_.[
MS94S6+<*&&OB:R;:\!VVPM)!:[H*SE"[O<UA5RQ<;$(Y1J*YFTQQMN$;H)'$
MSQO RXYRT-'4/N6HK+947<Q5M13Q4=.V/\J7.V'/.1D@;\[LXX<5,*RAJKC<
M)&5,<O<[F-CV'-&R".+P[/HQQ4A[DI]@M,$1:>(+!O64J.>5WH;PQ3I0RK4P
M[)9J&UP@4$;F,=X7A.R<GB5LT1="27!'&VWQ81$4@*W/!%41.BGC9+&[BUXR
M#YE<1 1[4UL8+?--02=R58IW4T1C8#M!W!F/*-W4N315;K%)%2V>CJ'WIV&R
MBK;D;+3[P-'1TKL,MTI77N&CJ&NCE:7; D8<..[!:>'6J;K;:EEP-SM3*=]<
M8Q"YE1G9+02=Q&\'>I3L8SAGXIV9$=06"[D03V26FJZTQ[-QIJAX =G>#NX%
MN3CR+8T\;832\S$Z5E%,\F(@CG'/:.&>D9)5%FT\)JZON5TKN:N54QT9CC.R
M(QY#QX*56ZEDC>QSQ3B.-A:WF1C:)(W^A+W$8W5[6- -,VVZ5(=/"]K^;VI'
MQN+3MD\.Q2&S6FDL],8*%A:PG)VG9).,<5GHEWH3&C",LR2OS"(B@U"(B (B
M( B(I*A$1 $1$ 1$0!$1 $1$ 1$0!1;E'_5W_P"\W[U*5%N4C]7?_O-^]<^*
M]C+X'=LW\53^*.797N52B^;/T$JRNR:5_5VW_P $+C*[-I3]7+?_  6KTMF=
M>7P/GO\ (O8P^/\ !M41%[1\B$1$ 1$0!$1 $1$ 1$0!$1 $1$ 6;3_F6K"6
M;3_F6J&5EH7$1%!0(B( B(@"(B (B( B(@"(B (B(#T*/ZMU#[GZ:%XAYZ68
MD-;Y/_RM^>"@/*MX+;80,^$[=YPN?$S=.FVCOV91A7Q$85%=%AG*/5&-SFVU
MI#3@^#T]JJ'*)6EP:+8S:(SC9/M4.8[8;+(V*0ELA(:6D;1ZE=<PMD<.8FVW
MM+G$-)P%Y2Q-7O'U<MG82/Y#J.E=0&_4\SGP"&6+WS0/&1]RS5%>3 EW?$[)
M;X+1@\>)4J7K86;G339\QM"C"CB)0IZ!$1=)PA$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 6THKE@!E1DCH?[5JT4-)DIV)0QS7MVF.#AUA>J,Q2R
M1',;RT^(K,CND[1AP8_QD86;@RV8W2+4]]G?)#ZR=]G?(CZRC(R<R-LBU/?9
MWR(^LG?9WR(^LF1C,C;(M3WV=\B/K)WV=\B/K)D8S(VR+4]]G?(CZR=]G?(C
MZR9&,R-LBU/?9WR(^LG?9WR(^LF1C,C;(M3WV=\B/K)WV=\B/K)D8S(VR+4]
M]G?(CZR=]G?(CZR9&,R-LBU/?9WR(^LG?9WR(^LF1C,C;(M3WV=\B/K)WV=\
MB/K)D8S(VR+4]]G?(CZR=]G?(CZR9&,R-LBU/?9WR(^LG?9WR(^LF1C,C;(M
M3WV=\B/K)WV=\B/K)D8S(VR+4]]G?(CZR=]G?(CZR9&,R-LBU/?9WR(^LG?9
MWR(^LF1C,C;(M3WV=\B/K)WV=\B/K)D8S(VR+4]]G?(CZR=]G?(CZR9&,R-L
MBU/?9WR(^LG?9WR(^LF1C,C;(M3WV=\B/K)WV=\B/K)D8S(VR+4]]G?(CZR=
M]G?(CZR9&,R-LBU/?9WR(^LG?9WR(^LF1C,C;(M3WV=\B/K)WV=\B/K)D8S(
MVR+4]]G?(CZR=]G?(CZR9&,R-LBU/?9WR(^LG?9WR(^LF1C,C;(M3WV=\B/K
M)WV=\B/K)D8S(VR+4]]G?(CZR=]G?(CZR9&,R-LBU/?9WR(^LG?9WR(^LF1C
M,C;(M3WV=\B/K)WV=\B/K)D8S(VR+4]]G?(CZR=]G?(CZR9&,R-LA( ))  Z
M2M,^Z3$>"UC?2L2:>68_E'EWBZ%*@R,QLJRY-:"RG\)WQN@+4N)<XEQ))XDK
MQ%HDD5;N$1%) 1$0!$1 <(Y;CC6$7\HS^IZ@&TI[RX?KC%_*,_J>N?97@XCV
MLC[C9_X:'P+FTO=I6LIE8'67=I==Y!#F.]^6'_?7'<KL'("?R5\\L/\ OKIP
M?ME_>P\[:WX2?R^Z.M(B+W#XT(B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B *"\KQQ8J/\ F1_2Y3I0+EB.
M+!1_S(_I<N?%>QD=^S/Q4/B<IV@O=H*QM+W:7SQ]T7MI3[D@.;M7_P  ?U!<
M[VET'D<.;O7_ , ?U!=.$]M$X-J?A)_#^3JZ(B^@/A0B(@"(B (B( B(@"(B
M (B(2$1% "(B (B( B(@"(B (B( B(@"(B U]X;31TLE;4PME-*PR-SQ&-^[
MJ*UMAGJHZ1CRV=[)P##3SD\XSKVG'H4A< YI:X @C!!Z5BT5OIJ)SG4[""1C
M)<3@=0SP"$=IKZR*:ZQF)]&Z M!=M28P78W $>-95J$[GR/EIW4["UHV"<Y=
MTG W!;%$%E>X1$0D(B( B(@"(B (B*2 B(@"(B (B( B(@"(B (B( HMRD?J
M[_\ >;ZBI2HKRD[M.?\ WF^HK#%>QE\#MV=^*I_%'+47F4R%\T?H)ZNSZ4_5
MRW?P6KC&5V?2GZN6[^"U>ELSVDO@?/\ ^0^QA\?X-JB(O:/D0B(@"(B (B(
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MZ:^5JOL"G2*7>0Z#B.X_ G2*"_C3TU\K5?8%/QIZ:^5JOL2G2*7>0Z#B.X_
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M>[2M97N4!<VE[E6LIE"2[E,JUE>Y0%W*95K*]VD!<RO<JUE-I 7<IE6]I-I
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MF51E,H"O*]RK>5[E"2O*95&4R@*T5.4R@*T5&5[E 59*9*IRF4!7E-I4Y3*
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M( B(@"*N>)\$TD4HV9(W%KAU$'!5"$)WXH(B(2$1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(BVT&G;I/#'+%2O='(T.:>L$9"LHN6B*3J1AUG8E7*?IE]-6/N]&PFFF.9P!
M[Q_QO(?7Y5S]?2\L;)8W1RM:]CALN:X9!'45R[6')[)"Y]786F2+BZFSX3?H
M]8\7'RKT,5A'=S@?/;*VM'*J%=V:T?F<Y15/8Z-[F/:6O:<%I&""J5YI]&$1
M$)"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M-U'D1HZ4CQNJG@^-@]JH]R8_?3]E_P U*$3,QNH<B+^Y/=NK3]E_S5/N4?\
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M2$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0@(JX(GSS,BB&T]Y#6C.,DKV>"6GF=%/&^.5
MIPYCVD$'R*;=I%U>QU/D=M_-6VLKW#PII!&T_P!UO'TGT+3\L%OYF[TM<P>#
M41[#C_>;_P B.Q=%TK0=[-/4%(1A[(@7C^\=Y])*U/*;;^[M*SO:,R4KA,WR
M#<[T$GS+UYT?_&R]JXGQ]#&WVCO;\&[?+1?P<117Z.DJ*R7FJ6%\K\9(:. Z
MSU#QJPO(L?873=@B(H)"(B$A$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<[>?FFO_ ,N_V+MFBP&Z4M0: !W.T[E:NNK;-:ZY]'753HYV8+FB)SL9&1O
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M=[F&S-I2QDI1E&UC7(B+C/8"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M7#T87'-.6XW6]T=$ =F60!^.AHWN] *[S>:UEJLU75X ;!$2T=&<;AVX"]'
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M]86IJM%Z?J<[=MC8>N-SF8["I"BHZ<9:HVAB*M/J2:^9"*KDULTN3#+5PGH
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M))WU>-MQ=CF!NR?I+TL91G52R(^<V-C*.%<]Z[7MS]YRQ%U#\5D?SL_[ ?\
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M;8S8!\IR3CL7)T*K>UCU5MO"9,U^/*SOY?4R^26WOI=/RU,K2TU4NTW/2T#
M/;E8/+)6-;0T%$#X3Y#,1U # _J/8IU6U5):+>Z:H>RGI86X'0 !P 'W+A&J
MKU)?;S-6/!;'[R)A_98. ^_SKKQ$E1HJDM3RMFPGC,8\5)<%Q\D2CD;_ $U7
M?R_^\%).5W]5X_YEG]+E&^1O]-5W\O\ [P4DY7?U7C_F6?TN5:7X1_,OB?\
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ME>:NN+3)LA@#!AK0.@=I6%3S/IZB*:(XDC<'M)ZP<A6T4.3;N]2\:<81R17
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MHN?T>U3NI\F5>*HK6:\4:!%(H]$ZA>"6VR0?2>P>LJXS0FHG.QWOV?&9F?\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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;"(B (B( B(@"(B (B( B(@"(B (B( B(@/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g769642g05f43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g05f43.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1N44&AO=&]S:&]P(#,N,  X0DE-! 0
M     #P< 5H  QLE1QP"   "   < E  #$IA<V]N($-O;&]M81P"!0 74&]W
M97)0;VEN="!0<F5S96YT871I;VXX0DE-!"4      !"R)>6>P1T&^O+@7B%[
MCDW/.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
M  !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R
M8F]O;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O
M=6) ;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M            0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M                4G-L=%5N=$8C4'AL0&*?9&         *=F5C=&]R1&%T
M86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT
M1B-2;'0               !4;W @56YT1B-2;'0               !38VP@
M56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .
M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      !  E/LB  $  0"4^R(  0 !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!$0      !     "   "0    D      .$))300>
M       $     #A"24T$&@     #00    8              64   *2
M!@!D ', <  Q #  .     $                          0
M   "D@   64                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   64     4F=H=&QO;F<   *2    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   %E     %)G
M:'1L;VYG   "D@    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M9#8'O#O3ES/H_P"D^@S_  U7^E3F:B#2&6[ ^-S60TF?'^3'YC?HK:RMWV3
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MWT5KXK0W&K:'-> T#<SZ)\VPOEI) WU8\GN4.+9^I<EC+,>VNQVQCV.:]W$
MB'.E9+.F=,:ZC;F266-=5+V$EWLA@_>^A^;^^OG!) 7T1C]RCP;/T:[I?27
M_KH#27$@.K'TG;HT'YGT6IOV7T>-OVULMF#OKGCV[M/?M_E+YS21]3)_2?'\
M'Z.'2>FP3]N.PD2-[(F/9V_<5J_#PG4XS'Y ;74S;62YON;#1N]WTOS?HKYG
M22]2)>_8N[Z;/TH[IV#P[*)$")>WLG;T_!;_ -JB3/)<WF5\U))>I'Z[Q?I/
M]G=-U_6N![I>W[W?V?WD;%PL.NVI].07[?HM#FD$1'YH_E?F+YF22/%U0?=H
MW==7_]DX0DE-!"$      %<    ! 0    \ 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '     4 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M "  ,@ P #( -     $ .$))300B      %*34T *@    @ " $2  ,    !
M  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (
M   ?    ?@$R  (    4    G0$[  (    -    L8=I  0    !    P
M .P   "5     0   )4    !061O8F4@4&AO=&]S:&]P(#(U+C @*%=I;F1O
M=W,I #(P,C0Z,#8Z,3@@,3$Z-#DZ,S, 2F%S;VX@0V]L;VUA      .@ 0 #
M     ?__  "@ @ $     0   I*@ P $     0   64         !@$#  ,
M   !  8   $:  4    !   !.@$;  4    !   !0@$H  ,    !  (   (!
M  0    !   !2@("  0    !              !(     0   $@    !.$))
M30/]       (          #_X0%217AI9@  34T *@    @ " $2  ,    !
M  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (
M   ?    ?@$R  (    4    G0$[  (    -    L8=I  0    !    P
M .P   "5     0   )4    !061O8F4@4&AO=&]S:&]P(#(U+C @*%=I;F1O
M=W,I #(P,C0Z,#8Z,3@@,3$Z-#DZ,S, 2F%S;VX@0V]L;VUA      .@ 0 #
M     ?__  "@ @ $     0   I*@ P $     0   64         !@$#  ,
M   !  8   $:  4    !   !.@$;  4    !   !0@$H  ,    !  (   (!
M  0    !   !2@("  0    !              !(     0   $@    !_^+_
M_TE#0U]04D]&24Q%  $)  B <$%$0D4"$   <')T<D--64M,86(@!]  !P :
M  4 *0 U86-S<$%04$P     041"10                    $  /;6  $
M    TRU!1$)%
M               *9&5S8P   /P   !T8W!R=    7     K=W1P=    9P
M   403)",    ;   *(&03)",@   ;   *(&03)",0  H[@  *(&0C)!,  !
M1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@  CBT9V%M=  '[]P  )"19&5S
M8P         :52Y3+B!796(@0V]A=&5D("A35T]0*2!V,@
M
M                              !T97AT     $-O<'ER:6=H=" R,# P
M($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B        "U6@  O&<  )(P;69T
M,@     $ PD   $                    !                     0
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M: ;&" 8),@I2"V4,<@UX#GH/>A!Z$7D2=1-P%&@57A92%T48-QDI&C0;/1Q
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MY(&9B7ZFVH#@=ONC$X!C8ZB?FX F3U.<?X C.72:!8!,'Z&9EH$7  "4CH
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MWHA)?,^O&H;N:U6JHX7M61ZF>H4T1>&BQH3,,/J?[(3$%X&@'(8$  "/RX
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MU*_;>E>L ZNK:.FG>:@Q5M^C2Z6P0_R?E:2>+YR<AJ Q%Q6<%X^;  "-Q8
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M(XY?<.FWO(R58&NRAHLF3SJMLHHE/0"I:HF3*/:F2(GC#]JG!(D"  ",C(
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M+;2;;^VTF[ M7X>O4:SZ3GNJ<*M</("F(*?U*-RBR)N@$+"BN(M(  "+ZX
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M>)0'9AW <)'P5FJZEY!)1B&U%8\D-,2P58[?(5JM((]["<RL0H:@  "*6(
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MU:XBNREV;*DHHS5W&:1^BKUWVJ B<9AXIYP35VQY:YAF.I9Z I6N%%9Y9XW
MZ%!TN;\=T6UU/;CTN?YUSK+_HA-V>JUDB;EW0Z@L<+-X%J-.5I%XV)[K.=9Y
M9IPJ$W)XIHTFYU=T3,L+T'ETRL/JN09U4KT H1EU^;9VB,QVQ+!H;^AWGJKA
M5>=X9*8<.3-XXZ'1$KEX"(RHYI%T ]<IS[AT><\,N#IT]L<QH$5UE+_(A_]V
M7+CW;R]W.++H549X *XM.*9X=Z9-$B5WBXQ$X>.$+G?ES#.#HW@[M?*#+GB8
MGOZ"T7D,AUJ"BWF=;O""77I+56""3WL".2:"F7O3$]^$G7R.X!^"H(*]RO>"
M*8'WM-V!Q8%-G=^!>8#,AB.!0X!T;;.!*8! 5!Z!,( >-^Z!@X L$GB#(("F
MWH2!2HVKR4Z X8O>LU& AXHOG&> 48C#A-2 ,H>,;(: +H:!4PR 0(6.-N>
MC83B$3R!LH1SW.> *IB7QZ1_Q975L:I_=I,ZFNI_1I#4@WQ_/([":UA_2(S>
M4@A_9(LD-?I_K(GA$"N =8?!VV!_/:.2QB1^V)_JL#)^D)QKF8%^:9DD@B]^
M8987:CI^?I-H415^HY#S-2%^XH]*#T!_98I0V@U^A:ZMQ-I^(*HDKNU]U:6]
MF$M]L:&/@15]L)VI:3)]RYH;4#A]^9<+-%Y^,I5?#GM^@(G*V/-]\[GJP\A]
MCK2!K=I]/J\QESQ]&*H@@"-]'J5O:&%]/Z$G3WQ]9YV,,[A]F9MF#=A]PXE<
MV!!]A<59PNM]'[\.K/)\R+C7EE!\F;+C?T1\H*UM9YU\RZB53MI\]Z39,RQ]
M&Z!8#5-]*(D"UV1]-=$7PCQ\T,GGK#!\;L+&E8)\-+OW?H1\.+7-9O=\9;"7
M3E1\EZR6,KI\MZ),#.A\K8BZT<&-47:2O;6+ZW<&J0.*J7=^DWZ)CG@)?3&(
MEWBR9@6'Q7EZ39Z'*'I),CB')7LQ#-:))'QYT#R+\8#'O'R*F8 ^I]J)8W_.
MDFB(57]^?!^';G]79/N&KG]13)2&'G]<,36&&G^8"^R'BX!:SN**J8L;NR&)
M7XF<IJR(*X@WD2^',(<->O*&6(838^*%J85&2X^%)H26,$2%(81$"QZ&)(/"
MS7Z)CY5UN;&(29,7I2:')9#:C\V&+H[/>;&%;(T+8L>$S(MV2IR$48H5+VZ$
M1HE9"FN$[(:WS":(L)_:N%>';)RKH\Z&3IF>CH&%79;">(2$F)0>8<*$")'1
M2<"#DX_0+J^#?H[Q"=*#X8:DRO:( *IHMR^&O:9JHJJ%GJ*(C6B$L)[:=X*#
M[YMO8-.#6)A>2/N"ZI7C+@>"T)4-"5&# (9,R?F'<K49MC>&,;!.H;&%#ZN7
MC'6$(*<:=J>#9J+W8!>"TI]'2%6"6)QU+7N".)I)".:"1H8$R2R' [__M6V%
MQ;IGH-^$G[3>BZ&#J:^2==Z"[ZK"7V>"9J:D1\>![:/Y+02!NIYP"(^!KH7)
MR)&&KLL]M,V%=,38H"^$2;YZBNJ#2[AH=36"CK, 7M6"!JZU1TJ!DZK6+)>!
M7IXF"$J!-86;P@>6O76$KUF4BG8+G V2@W:7A_"0KG<V<OB/!W?S70:-E'C+
M1;F,<GFF*P.,3GJ,!JF,_WR<P+R5?7\LKE.34'[+FQ214WY^AP&/B'Y3<@F-
M[7Y/7!R,B'YM1,Z+;WZ9*B>+0W[Z!BR+;( 7OXZ45XC8K1B2-(>=F?N0-H9U
MA>2.>(6)</^,ZH3&6RB+DH0O0_&*@8.Z*6.*38.Y!;Z*"H,FOF^309*GJ^21
M*)"9F+F/-XZAA,B-<(SC;^N+](MF6C"*J(H<0QF)GHD1**J)98CG!5^(UX.A
MO4>29YR%JL^03IFREYF.89<#@Y6,JI2%;MF+*))!64")ZY!20E.(Y(['* B(
MH([*!0V'T(-JO#R1OZ:&J<6/J:+XEI"-O)^'@I>,!YQ*;?"*AYE16&V)0):[
M0:>(/)3?)WR'\)0[!,B&\X,\NUN1.;"GJ.F/):Q?E;2--:@L@<"+?J0T;2R*
M!*"85\:(O9V#01F'J9N5)PN'59B^!(^&/(,5NJ20S[L!J#:.O;8 E/F,RK$/
M@02+#JQ>;'F)E*@P5RB(5Z370)V'0*+<)JJ&UIHD!&"%IH+VNAJ0?,6ZIZ>.
M;< #E%N,>+I2@&"*MK3R:^*)-[!.5J>'^ZT20"V&[*C$)DB&@9GB!#N%+X+=
MLL.@>G3#H4B=B'5.CSR:QW7B?&B8/7:,:+&5Z7=34^B3VG@R/:&217D,(V>2
M27G4 4J067RZL;"?8'WFH'V<:WV8CGR9K'UC>ZJ7)'U19^R4V'UF4R22TGV=
M/-N10'WA(KF1,WY4 2R.S'_=L+N>1H<.GWF;7(7TC8^8FX3Y>K:6((0S9P63
MW8.<4E"1X8,Q/!V04X+N(AZ0-8,[ 1&-;X"YK[R=4Y QGFB:;8Y@C&Z7M(RV
M>;>5,(LS9A.2^HGZ47Z1!8CS.VZ/>(@Y(96/2HBS /J,0("IKM6<<)F*G7:9
MDY<$BW*6XI2G>+.499)S93&2&Y""4+:0,X[N.LJ.IXW<(1>.;8XO .:+/8"<
MK?.;S*,(G*R8[I_1BJF6.)R^=^"3O)GE9&.1?9=73_^/BI4].CB-_I02(*F-
MMY+@ -:*8X"1K3*;3:R@F^R8;ZC!B>B5MZ3^=R63.J%^8[J0_YYF3VZ/"IOQ
M.<*-:IL"(%6-%I7< ,B)KH"'K)":Z[9JFU"8#;'CB4B54:UU=H62SJE68R"0
MDZ7+3N:.IZ-*.5F- *%;( R,D)6K +V)&X" K!2:G,"=FM.7OKMOB+Z5 +96
M=?>2>+&B8I^0.:W-3GJ.3*M=./R,KJ9E'[Z,/I5V +2(I8!ZI FJD70YDY^F
M['2\@K&C?'5/<06@177\7G.=2G;%2KR:J'>B-5>8OGAK&T"9:WCL  "-GG\1
MHS"IEGSCDPNEYWR;@B2B<'QS<':?-'QP7=J<.7R72B*9FWS>-+^7K7TM&M"8
M-7V8  ",;(  HG.HBH6(DC^DY(2%@6RA9H.D;[*>,8+^71^;/(*(27F8HX)$
M-"R6LH(K&FV7&8+&  "+8(  H;"GE8XOD6.C]HR#@'V@@(K^;MN=1(FR7%6:
M68BK2,N7Q8?A,Z&5T8=X&A.6&H@X  "*=X  H..FU);FD)>C-92:?ZF?PI)_
M;@*<B)"?6YR9B8[V2"R6_8V_,R:5 HTO&<B5+8SM  ")KX  H#JF(I_>C^VB
MB9SS?OR?%IHU;5:;VI>V6OB8VI6&1Z"6.9/E,KN4.Y.)&8245I#J  ")!X
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MQ7NT=C2KGGN098ZGLGN64_ND$7O(03B@Z7P:+(^>R7QI$E2@G7RO  "(Q(
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MU:)+<VBGI9]*8L:CK9RG46Z@ 9J./QN<OYEZ*Q":1IB4$@F;#(PR  "&7H
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M_8'T:EZT)H$N6I:OCX"U2?:K3(!T.!JGK(!L)!.E@8"4"M^F@X$F  "%:X
MAY>\YXJ8>0&W]8D;:>>S(H?46BRN@8;7292J088M-\^FG875(_*D6X88"Q>E
M!X51  "%*8  ASZ\"I)@>*6W%I!B:82R08ZF6<"MGHTS23^I3HP<-X^EK(N6
M(]>C5HP^"TJCN8>B  "$\8  AM^[8II3>%"V9Y?6:36QB)6<676LWY.]2/FH
MC))5-UVDTY'&(\.B:Y'H"W2BE(>_  "$PH  AH>ZWJ)?> FUVI]D:/6P[YRN
M63FL/IIK2,*G[)C;-SFD+)BJ([JAF):C"YRAE(?9  "$FH  ADVZ8JJ5=]6U
M6J<>:,:P:Z/V60^KLZ%E2)JG7I_E-Q2CII\*(ZJ@_)@="\"@M(?R  "$>X
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M<X>>7Q>]$89G4"6WU(6%0%ZS 84"+TJO H3?&ZVM'86$!1*JFX-N  "#'X
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MX:N37PFY.*A;4"JSS*8S0(6NUZ3.+[FJL*!%'+.H,9-G!LBE1H26  "#'(
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M1=6!2H<3*RR!>(9^!Q2!^(0HP52"O9EAKMB"#9;]FW6!>I2=ARF!!9)1<AN
ML) M7#6 A(Y410" :(R\*GB A(P)!J. YH1]P#"![:.^K;B!0*"6FE> JYUD
MAA2 .)I%<1Q_YY=:6U%_MI3"1$1_H9*T*==_L)(3!D1__H0]OT2!2:XWK,N
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MZHD?A,:2QX@-<O:0S8</8!N/$X9!3#F-EH65-L",?H4;'/R,W85F  "&.X
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MX+5;@2./KK#S;SB-H:R_7*J+V*E223>*8*=(-%*),*+7&S>)&))G  ""A(
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M?(]">$>:H8V]9W27]XQ85=&5@8L:0OR3>XHU+FR2#(G1%,J3&XE   "";(
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M>V\7;UVH W O7WFDP'%+3HRANW)H/$&?-W-W)\V=]W0D#2^@N'/%  ""?X
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MEI3-;)BC!9+L7+J?H9$Y3 F<A8_1.C*9W8[T)EN8/X];#4*9)XCW  "  (
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MR76,8Y&PGG7I5(JLJ79B1':I"7;P,NNF)G=U'L2E,'>2!B"E(7C%  "  (
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M$IFV8<:KR9>94KZGKY7$0N*C]I2",=*@WI1Z'GZ?+I*G!TZ=>(3Q  "  (
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M<GM%6":YM7K]2=:U)'KW.HBQ WL2*9ZM\GLX%6ZMWGL$ *.GTWTN  "  (
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MS)X:5[&TU9ON262P%IHZ.CJKTIFV*;>H?9AY%H6G38\Z HV@LX&Z  "  (
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MNDR O72SJ1" C76-EK. 9796@T^ 2W<7;N6 0G?=67" 4'BF0I. >'E:*"Z
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M1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R-\> =I2Z'E& ;))7  "  (
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M8GM]?B&.QGNG;0"-6'O86N",#7P81XZ+ 7Q?,GZ*8WR1&'Z+?'QL  " 6H
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MV*7I>=R*1*+-:-R(R9^W5Q*'B)T/1$"&BYM)+^:%O9HI%KZ%X8]A  "  (
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M;H';<826+8%Y89"4$X$F4'N2-X#J/BJ0LX#"*=Z/XH"I#]*1DH"J  "  (
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M]*K<;I&2FJ>H7H*05J213;2.6Z)1.\^,QJ#U*!^+KYLA#QR+^8HW  "  (
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M)(=X9;6>/(:M5I^;>87Q1I:8^H5<-1N7#X4"(5J60H44"+R5WX/1  "  (
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M.&D(7("LY6J,3ABIO&P"/H>FXFU<+3VDZVYK&+FEEVYL 8FBJG "  "  (
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M=8QR6J^FXXM83%^C>8I8/1Z@:(F:+%^>&(EH&-*=MHF# R.8MH(?  "  (
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M.6[84/6V0F^<0T6R=W!N-%NO+G$Q(W.M2G&<#K6NZ'#F  "=P'@I  "  (
M:<V\YW5D79VXVG6 4-6TSW6X0R:P[789-%&MD'9\(Y&KB':N#QRLR'8F  "<
MB7PB  "  (  ::B[<GQK76&W9GP>4(>S77OI0O*O=WO>-"VL%'OP(Y.I\GOX
M#V>JXGO8  ";:'^A  "  (  :7JZ,8-_736V(X+:4%:R%8)+0K2N*X'7-!2J
MMX&:(Y2HA8&>#ZFI,(&N  ":;(    "  (  :4ZY/(J[71ZU'(G)4$2Q (C<
M0IZM#8@0,_RID8>2(YVG.H? #^:GJX:X  "9D(    "  (  :2FX?Y'^712T
M1Y#(4#^P&(^"0I2L&XYL,_&HFXWA(Z>F,HY%$"*F68KI  "8WX    "  (
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M99&5?@I].I /;/)]&8YW6O5]#HSX1]=]&8NQ,QQ])(K=&<=\^XIF  "  (
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M>)<7<H6$B94Y8F>#J9-&46V"\I&*/U6"99!"*V^!^Y =$>6"'HP9  "  (
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MB'2E:M*1V75D6WN0478>2PR.]7;4.2Z-^G=T)0Z-U'>["QR.R'=]  "  (
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M0IP%9SJ,EYGO6 2*]I?,1^J)DY8:-H^(C)5K(S2'Z905"K:'$(<^  "  (
M@EJ/9*:$=1:-SJ1;9LN,%Z''5Y&*9Y\O1X2(]YU2-CR'Y9QP(NZ'.9>>"I6&
M1H<H  "  (  >I"BI6)P;A.@)F258*N=[F:@4B";YVB*0EB:'FI.,.*8_FO#
M'(&9P6P_ ]^8H6R^  "  '_0>?RA06I[;:">S&OB8#2<?VU!4;F:76Z50@&8
M@&_2,*.72G#4'&:7SW$'!""6$''2  "  (  >6N?HG)8;.Z=0G,A7YV:]'/F
M42&8T72L08*6\G5H,$25L77^'#:6!77[!%*3Q7=-  "  (  >,2>$'H=;#*;
MNWIA7LV9>'J<4'R76'K<0.R5@7L=+].4/'M/&_>49WLQ!'21P'Q,  "  (
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MC:![7(N5)YY<3AR2S)Q$/M*0Q)L9+B>/2YGP&P>.S9)&!-B+4H-&  "  (
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MKW]04X&AV7\K1>.?)G\$-S&<T'[T)IV;<'[R$I*<AG[C  "2Z(    "  (
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M?&)22:&RD&08/&&OPV7#+;NMC&<E')*M1&>X"%RNI&=K  "36'+8  "  (
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M@8.72*.K)(,J.YNG\8+!+6^E2(*#'26D$(*@"B>CS((Y  "-XX    "  (
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M/:ER?<%L5*7R;)=M7Z)K6J5N?9]-1[5OBIT#,U9O_YMX&L1N1Y(9  "  (
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M?X+S=H1WZH*P9DUX4H)251]XQX'[0I9Y2(&T+E=YDH%V%.EY38%3  "  (
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MV(C3:P)^FX@C6\)^7H=62XU^-X:7.?U^+(8))E%^)(79#0U^>H2C  "  (
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M&HW.7^.&)XS*47>%,(NG0AF$:8JR,6"#WHHR'BF#HXJ)!HN"\X1L  "  (
M>02'*I;=;+F&5)6Q7UV%690G4/6$59)\09J#@Y$Q,-2"^)#(';B"FX_6!HF!
MY81K  "  (  >**&DI]-;%*%OIW+7NJ$N)O&4(*#I9FB03:"PI@E,(:")I>V
M'8&!KY/S!GV!%(1C  "  (  <:^;V%RR9?&9]U]"63N88&&T2TZ6_&/[/ J5
MVF8'*N*5?6>>%BZ7A6?'  "3#6F_  "  ']*</>:#F2,96>81V9O6+26HFA
M2N&5(VGX.[:3ZFN#*J^3;FRK%C"5%VR4 "^0OFZV  "  (  <$^8$VQ"9**6
M:FV.6 Z4RV[,2C^336_[.S22$7$)*E:1@G'*%A62W'&% '..<'0S  "  (
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M%Y(U51*.>9$!1VF,TX^Q.+R+=([3*'"*GH\$%1F*QXR@ 1J&T8"^  "  (
M;.^0^)L.85^/?9GX5+F-U)A?1Q",():Q.'**L971*#F)Q94G%/R)R8XP 2>&
M X#(  "  (  96*F5UNP6A*D'UX53?"B(V!E0*N@6V*-,?*?!61H(.>?$V6*
M"_NANV4:  "-E&W2  "  (  9+.DS&,G6::BCF3Q39.@;6:P0&R>>VA6,=*<
M_VF_(/.<U6J*#$^>^FG]  "+^W+,  "  (  9"NBZ&IU60R@N&NX31F>E&SQ
M/_B<FFX>,7^;$6\:(-":P6^5#'V<;&\&  "*>W>B  "  (  8YVA!W&K6&N>
MXG)Z3&B<R7,\/W6:T7/U,1&92'2-()"8WG3##(Z:&715  ")%'OE  "  (
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MKI8D2L67;)3O/;V5*).L+ZN32I-G'[&26Y'O#+^1[(B?  "$G(    "  (
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M@G:*002E_W;J-(JCIG<S)KJA]7=M%@FB77<I!,*?!GCA  "$/H    "  (
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M.YFA=8YE#I=U96YFPY4Z5%YH;9,]0B]ITI&R+I-J+I$E%E9J%8WE  "  (
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MJ'3 ;RERH76M7^ASC7:'3T]T>G=+/6=U3W?[*8YUO7AI$ -V['?P  "  (
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M?YZT:PIKGIQ16]!LH9G>2Z=MG9?2.D5N7Y:N)Q5N"95E#J=PD8GH  "  (
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M"WK<8XQX>7M)52QXVGN91;1Y/WOA-(MYJ7P;(1EYP'P@"*I[H7R6  "  (
M?(]UUX+><"QV:X+?8LUVX8*M5%]W1H)<1.5WK((0,_)X H'?()]WXX'5"(-Z
M'X%<  "  (  >\MT<8MJ;V9U$(K>8@QUB8H04Z5U\8DH1#1V6(A=,UQVH(?9
M($IV.X@/"')XV(55  "  (  >S%S4I/P;LYS^Y+@87-T<Y%_4Q-TU9 $0Z-U
M.8[,,LMU>HXK']QTX(X-"&-WSH6K  "  (  >KYR>)Q\;E=S)YK]8/-SFYD0
M4I-S\I<.0S5T296!,G1T>I42'X%SMI+6""QW"H6&  "  (  =4Z*MU?::8")
M^UKP7+*)?%W>3J2))V";/S2(_F,;+?.)2F4I&7^*^67S ?6*%&<8  "  'Q?
M=%B(&U_G:+.'F6)36^B'+F2>3?B&V6;%/JF&JVBY+8Z&XFI+&4^(,&J[ BR'
M;&OZ  "  '^#<VJ%D6?G9ZR%/FFS6PN$Z6MF32.$H6SY/?B$>&YD+0>$H6]]
M&0"%F6^@ DZ%$W$V  "  (  <G"#/V_?9J&#"'$96?:"QW(X3$J"C',^/32"
M<'0C+&V"CG3*&)R#-G2R EV#"G;-  "  (  <7V!0G?@9;F!'7B160Z ZGDB
M2UV MWF8/)F DWG\*^B J7I"&$B _WH3 FZ!1'O   "  (  <*9_D'_R9.]_
M?X C6%)_58 G2K5_(8 ,/ =^^'_P*[-^Z7_E&#-^\W_H HU_O7_X  "  (
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M%&#]40F0(6,X0\R/465.-1>.S&<?)#Z/'&A;#VF1;6?Z  "&(FYD  "  (
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MYH1W36B'((0O0':&5(/0,EJ%L(.*(H"%6(.)#S.%(8-'  "  (    "  (
M8]Z'@(Q%60V&[XOE32^&'XLD0#^%+(H[,B^$9XFP(C:$!HH!#N6#H(?R  "
M (    "  (  8WR&L9096*V&(9-\3,N%39)3/^&$3Y$&,>.#<Y!N(@*"[9 J
M#MN"78H+  "  (    "  (  7.">\57?4D*=65B?1L"<"%M%.?F:^UVX*XF:
M?5^^&DF;S6"X!H2<2F$$  "#HVU)  "  (  7 :<W5T=4:R;65]51C>9]&%Y
M.968P&-R*U&8%&4,&E"9$66T!M^8W67C  ""$'(Q  "  (  6U^:A61#4/69
M&V7\19^7O6>B.066A&DF*NJ5Q6I6&B:6AVJU!Q>5G&KD  " EW<4  "  (
M6K:80&M:4#B6YVR>1-&5EVW..&J486[C*FJ3GV^Q&=V4,V_.!RZ2L7 C  "
M 'ME  "  (  6@R63'*!3Y*5!'-;1#"3MW0<-\:2?'2W*@*1JW4M&922''4A
M!S&0*G7>  "  '\N  "  (  67.4MWG(3P:3?7I#0[&2+GJ5-U&0Z7K#*9B0
M!'K?&7&0+7K,!SN-^'O1  "  (    "  (  6/"3:X$33I:2/H$[0TR0ZH$C
M-NV/EX#L*2Z.I8#.&2".J8#K!U",'(#@  "  (    "  (  6(B27(A@3B^1
M.H@[0N>/YH?$-I".AH<V*-R-?H<&&+>-<X='!RN*HX39  "  (    "  (
M6#>1CH_E3@F0<H^C0L./%8[.-F^-D(W;*.*,5XW"&/F,"(RA!W*)5(4)  "
M (    "  (  4*:J851-1F*HF%;2.TVG#5D]+NREY%MI((:EV5SW#I>HHUT(
M  "@"&!\  "  '$N  "  (  3\:HE%LJ1<2FS%TW.K^E'E\R+H6CP6#W(%NC
M;6(K#L>ELF('  "=;&45  "  '7X  "  (  3SVF4V'O12VDEF...D&BZV48
M+A&A?F9Y(!.A!V=6#M&BX6<*  ":WFGN  "  'H\  "  (  3L>D"VBG1*.B
M66G>.:2@MFL!+:&?26P '\">OVR1#L:@/VPH  "8=V\K  "  'W_  "  (
M3DNB"V]Q1"N@:W!..3.>Q7$1+2N=3'&D'XR<I7'V#L"=V7&. #66 '4)  "
M (    "  (  3=>@:G9@0\J>TW;P..2=*'=5+.N;GG>1'UB:UW><#MB;J7=>
M '&3VGI4  "  (    "  (  37.?$WU50W^=@WVB.*N;SWVP++>:-WV>'R:9
M77V,#M&9Y7VU +"2"7[.  "  (    "  (  322> X190TJ<<X1Q.(&:MH0R
M+)F9"(/?'PJ8$H/D#JJ8=X-[ +60F8![  "  (    "  (  3/&=*8N/0RB;
ME(N&.&29T(L(+(:8$(J.'Q.6\XJO#MF7'HA$ -V/9X"6  "  (    "  (
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M 81D>"M8,8/Z:!5;)8."5PQ=XX,21-5@)(*Y,1I@](*!&4AAI8*A  "  (
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M77$/  "  'JSC+=>Z&]N?U-A:'#7</YCJW(E8:%EQG-84/YGPW1X/QMI8W6
M*W%IZW9%$I)L1W8,  "  'Y'BT5<#'BX??)>M7EI;ZUA('G\8&!C67IU4!!E
M;'KF/D=G%WM1*M!G:'N=$C1J>GMO  "  (  BA%9H(((?-)<:H(';J)>\H'?
M7V5A1H&@3R=C9X%D/9UE"X$[*DUE)($L$>9H]X$[  "  (  B1E7F8M/>^=:
M?8J>;<5=&(F\7I9??XC(3F1AKH?M//IC2X="*>EC)X;_$;-GL(9#  "  (
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M 6<7:%AM@VDR68UN[FLI29AP0&S_."-Q7FZ>)()QO&^R"V5U@F^*  "  'V
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MU(_V8V1BT(Z[50QDE(UK19]F'HQ0--1G"HNE(BYEV(OI"K-MZH<\  "  (
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M.FU]7+IR3V[^3Q!S17!@/^)T+G&:+R%TWW*6&Z9TNG+B!)]YL70H  "  (
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M&I2.6/=I<),B2V5J@Y&>/+UK6)" +(IKA9!?&=!JM(Z(!&QXAX+]  "  (
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MD'+U45UX)7/U1%%XHG31-B-Y"W6-)<AY8'8#$?5Y^'6>  "  'GB  "  (
M9W-TH'G%7'!U>'IB4(AV'GK50YIVG7LE-7]V_WMD)7UW'WN2$==WN7M@  "
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M7X^)4EC^52N)$5N[2:J(WEY5//6(Q&"\+J&([F+&'<F)^6/X":2*J&/]  "
M &XI  "  (  7I^&06!C5"V&,6*82->&%V2O/"^&!&:6+@6&)&@I'6*&]6C]
M":.'46CK  "  '-D  "  (  7;"#:&?)4S*#=VEZ1]6#<6L-.V>#:FQZ+56#
MB6V<'..$)&X8"8:$9VX,  "  'A;  "  (  7,: Z&\]4DZ!$G!Q1O2!''&%
M.HN!%7)O+,"!)W,M'&>!CG-C"6&!XW.*  "  'RL  "  (  6_1^QW;$48A_
M"G>%1CU_'W@<.=U_%WB.+"-_%'CB'"5_*'CQ"5I_M'F9  "  (    "  (
M6SQ\\'X]4-=]3WZ219E];WZT.4=]9'ZW*YM]3WZZ&]%])'[$"8U]TG\S  "
M (    "  (  6JQ[>87+4'1[^87.149\&X5X.09[\83]*V][MH3#&XU[6H4;
M"5)\7(/?  "  (    "  (  6CMZ2HUL4 5ZUXTK1-EZ_XQM.*=ZS8N2*R=Z
M=8M(&V)YV8LR"4Q[*H9)  "  (    "  (  5*66W% ]2HR5\5-5/XF53U9*
M,R:5 ECZ),^5=UL6$N^84ENH 8*4I5V-  "  &T4  "  (  4YZ3_5<_2;R3
M1%G@/L62IUQ=,HB21%Z;)&>2B&!/$MB4YV"9 =21"F)I  "  ''X  "  (
M4LN1#%X_2-R0>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1I&6. @:-RV=G  "
M ';D  "  (  4@".0F5 2 :-R&;Q/2B-2VB!,2^,Z6GA(U2- 6K0$DJ.DVJ=
M A^*\&RD  "  'L\  "  (  43F+R&Q51T2+:6V6/&N*]VZU,'2*CV^>(N.*
MBG ]$?Z+OF_F BV(>'):  "  '\&  "  (  4(*)JW. 1IF)9W1<.]*(_74-
M+^J(C'6/(FF(:'77$>*)'W6( D6&57A*  "  (    "  (  3^*'XGJI1@R'
MN'LM.UB'5'MU+X"&U7N7(@2&DWNF$:B&Y7N+ G"$@GU7  "  (    "  (
M3V"&8X'$18B&4H'P.MB%]H'7+PR%<(&G(9N%$8&F$2^%&('# F&#$8%U  "
M (    "  (  3OB%-(DS15J%1HE .KF$\XB]+Q"$.(@4(>V#@X@:$>2#'8<D
M M>!M('L  "  (    "  (  2%BB<4Y?/M^A/%%"-&F@9U/V*%F@*%9.&<.A
M<U>_"*.C&UAE  "1E%_D  "  '!Z  "  (  1T>?YE3^/?B>[%=W,WB>&EG%
M)X^=KUN\&46>H5S8"*>?<UU9  ".W&1^  "  '51  "  (  1IN=#5N=/32<
M+5VL,L*;;U^.)MN:^6$D&,.;O6'J")>;SF)0  ",0VE1  "  'FI  "  (
M1@>:/&(Z/(29;V/<,?:8O&56)D"81V:+&$>8[6<&"("83&=?  ")WFY\  "
M 'V   "  (  1627N&CH.]V7#&HI,5Z66&M ):B5TFP*%_N63&Q+"'65#VRO
M  "'QG0O  "  (    "  (  1,65DV^^.TJ5"G"G,.246W%?)4R3OG'3%[B4
M ''0")*2*7)D  "&$'EG  "  (    "  (  1#N3PG:<.L^36G<Y,(*2KG>6
M)/B2 7>\%VB2'G>9"(*/TGB;  "$LGW*  "  (    "  (  0\F207V0.FV1
M]GWM,#*13WWX),.0B'W:%T*0<WW("%*-\'YX  "#18    "  (    "  (
M0X"1!(3&.B60SH3T+_&0,H2S))F/681E%TJ/!82'"(6,68-8  ""<8    "
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MX7P79C941WQO5]]75GRU2'M9]GSY-[);D'U#)/9:S'V)#5)I?'X)  "  (
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MSX'&6^%8L8&F3E!;,H%S/Z!=)H%/+W5=Q(%+'0Q>?H&(!MAT;X%I  "  (
M<SU00XHY9Z]3HXFY6S96GHCX3;-9*H@G/P=;%H>&+MY;?(=!')U<Y(?%!M-T
M>(2=  "  (  <K-.<)*:9RU1[9&B6K!4]9!+32]7@H[B/IA988W2+HI9E(UY
M'$!;GHT9!IUTTX1Y  "  (  <-%Q<TWB909RDU&D6'ASS5552M%U!EC>.\UV
M+5P@*N=W0U[9%IUX,& 6 *=^YF):  "  'C:;P]LZU7<8[MN:ED35U]OW%PN
M2>EQ-E\A.PUR:F'0*E)S6F0#%D-T"637 ,Y^I&<A  "  'R$;99HIUWW8E)J
M>&"15C9L(V,12-AMG65I.B9NW6>(*9IOGVDW%<=P?6FM .!^AFPJ  "  '^\
M;#5DM&878/AFQ&@25.)HG&GW1]YJ-FN].49KA&U-*/!L$6Z"%5UM;FZI /-^
M97&6  "  (  :N-A(VY&7[AC9F^D4[ME9'#M1LIG%W(6.*-H;G,B*&UHPW/G
M%1MJR7/: 1-^+G<>  "  (  :<5> W: 7LA@=G=04N=BEG?_1?1D7'B0-\UE
MHWD1)]EEJGEX%*YHFGEG 1)^,'OT  "  (  :-Q;2WZK7>U=XW[T4AM@'W\,
M139A\G\+-QMC*W\3)T=BWG\O%'%FNW]F 21^$W_Z  "  (  :"59 X; 741;
MNX:/47E>"X871*!?XX6)-HEA"(4I)K1@884F% 9E5(5$ 3!]_H#.  "  (
M9YY7+8[&7,5: (XS4/=<7HTV1")>,HPB-B!?/XMJ)F=>88N)$[!D.(GS 0]^
M-8"X  "  (  9.-Z#$U:6=QZN%#X3@=[B%2"00-\9%?=,G1]3%K;(91^@%T-
M#,R H%UX  "  &6=  "  'NT8T5UPE3?6*AVP5@"3/UWNEL%0"IXI%W8,<AY
M@F!3(1QZ9V(1#+1\K&(]  "  &I(  "  '[T8?%QIUR#5UUR[E\72^YT$F&0
M/R]U#V/7,/IUYF70((%V>&<>#'QY06<:  "  &]6  "  (  8+!MU60R5AMO
M468T2K!PEV@=/C=QK&G?,!YR?FM9']5RLVP_##!V6&P@  "  '31  "  (
M7X1J7&OH50-L!&U?2:1M:6Z\/2QNBV_S+WAO3W#Y'TMO'7&("_YST'%N  "
M 'FR  "  (  7G9G1G.R5 9I&72D2+YJG'5T/&IKQW8B+L]L=':P'P-KVW;]
M"_1QF7<?  "  'W3  "  (  79ADDWMX4TMFE7OS2!MH,WPZ.])I7WQB+C-I
MZ'R+'GII'7RL"]=OPGT]  "  (    "  (  7.=B2H,R4J1D;8-!1WUF(8,'
M.T-G3(*S+:MGLX**'>QFZH*W"XIN7()[  "  (    "  (  7&)@;8KL4B9B
MJHJE1O]D;HGU.LQEE8DM+4MEV(C,':AE)HDJ"UEM/H:J  "  (    "  (
M6/.#7$Q@3JN#ED_=0X2$!%,^-PJ$FE9A*+R%@%D"%U:'B5I<!'&'U5NB  "
M &DU  "  'X:5WA_3E-\381_U5:*0GF 8%EQ-BR \5P;*!.!L5Y)%O&#,U]#
M!(V$"&!N  "  &WQ  "  (  5DA[6EJS3%1\'UU 07M\R5^J-3Y]7V'7)U-^
M F.1%FM^^V0O!(J MF56  "  ',D  "  (  52MWHF'U2S%XDF/]0%9Y567D
M-%AY]V>:)HAZ?VCF%=-Z^&DO!'-]W&IO  "  '@@  "  (  5!IT.6E'2BEU
M4FK./U5V+VPV,V)VT&UL)>)W-VY8%4=WA&Y>!%I[:6_C  "  'QR  "  (
M4R9Q+'"K24-R;W&[/H1S9'*F,J%T!G-G)3=T/7/K%05TAW/3!&)Y0W7?  "
M (    "  (  4E%N=W@*2'-OYWBI/<1P]GD:,?5QEGEK)*%QFWF?%*)R)GF
M!)!X2GMS  "  (    "  (  4:9L)W]T1^]MS'^X/5AN]W^Q,:AOB7^-)&5O
M4G^)%$)P.G^P!%QXHH G  "  (    "  (  425J/X;R1V]L 8;I/-QM089X
M,3EMSH7S)!%M9(7;%!!NI(6X!%%XM8+K  "  (    "  (  3.^-H$K70V"-
M:DXV.-6-@U%I++V-_U1$'E6/7U97#("1W5;V  ")BEPT  "  &RM  "  (
M2Y.)RU&40CB)YE2+-[6*%U=0*\6*?UF^'9F+F%ML##F-%5O6  "&3F#?  "
M '&.  "  (  2H6%^EAG01R&2UKI-KR&E%T\*M>&\U\['-R'U&"$"^2(GF"_
M  "#5&6Z  "  ':(  "  (  28V"5%]'0!>"R&%/-:N#(V,K*@&#@62_'""$
M,66K"XB$MV7"  " JFK>  "  'KK  "  (  2)M^\68\/R=_CV?.-,)__FDW
M*1Z 3VI7&Y6 P6KX"SN!8&K]  "  '!Y  "  'Z^  "  (  1[I[XFU,/DU\
ML&YP,_Y]-F]H*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95  "  (    "  (
M1OAY,71=/95Z+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\-G9L  "  'M'  "
M (    "  (  1D]VT'ML/.MX WO0,KUXO'OX)UUX[7P &?IXA'O["FUZ;WRM
M  "  ']X  "  (    "  (  1=-TVX*\/(=V1(+@,F]W((*?)SIW.8)+&B1V
M<H);"LYXM8(&  "  (    "  (    "  (  0)F914BK-[*8K4OE+:.8E$[4
M(:J945$[$GF<,E)3 U*9OE1@  "$LE^*  "  ' -  "  (  /S>5O$\$-E25
MCE'9+"R5F51B($N60%9F$6Z8H5<O PF5%5D_  "!KF1   "  '4!  "  (
M/D&2%E5X-3J2&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0SUXN  "  &DC  "
M 'ET  "  (  /6^.?5O]-%".GUWV*AB.U5^I'F>/9&#H#_^0UV$J JJ-!F,Z
M  "  &Y6  "  'U8  "  (  /)J+%&*:,W2+:60F*42+K65T'9F,(F9+#Z>-
M$&9G IF)Q6B'  "  '0$  "  (    "  (  .\N'\FE=,J:(AVJ!*)"(Y6MK
M'0:)0FOQ#S^)I&O6 J:' VXP  "  'D[  "  (    "  (  .Q6%*7 I,?2%
M_G#O)_B&=W%Y'(V&OW&T#N>&KG&& I:$Q713  "  'V8  "  (    "  (
M.GR"NW<*,5V#SW=\)W:$97>N'"Z$EW>H#J.$27>2 FZ# GHK  "  (    "
M (    "  (  .@V JGXG,.>!]GY/)PN"K'XQ&^."S'X!#I&"7'XN HF!B'[_
M  "  (    "  (    "  (    #__P  __\  /__  !M9G0R      0#"0
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MJ>JJXJO;K-6MT*[+K\>PQ+'"LL&SP;3"M<6VR+?-N-.YV[KCN^V\^+X$OQ'
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M@Q\FKXF(@D>7F*[.DP.)/*HOD+IZG*67CI=KQZ$&C)9<[9QUBK%..I?DB.%
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MC*-GL+77BL];#*]6B2U.H*BFA[E"B:'-AF4W+YJDA1@LUI,P@^8D'(N8@M:
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MIV50D7NU<6>FCXNBMFGEC9Z/?&P>B[M[]6YOB>AH3'#CB"A4XG-UAE-!P79
MA%HO<GE8@AO&7V0<F]:T,F9]F0.A?6C&EAJ.36L0DR]ZX6UTD$QG9&_^C6I4
M,W*RBGA!2W6<ATDO.'C/@[3%6V,FIA*S-66/HEN@?6?<GG*-46HNFGAY_6RE
MEH9FI6]$DHA3GW(,CF1 ZG42B?XO"'A<A1W$F6)PL""R=F3<JX&?LF<EII2,
M@&EWH81Y,VOXG'EE^&ZLEV)3'W&)DA- EW2@C&\NX'?]AE7$&F'WN>NQ]&1@
MM%*?&6:?KE>+V&CHJ"UXD6MKH@=E;6XIF]!2IW$5E5Q /W1 CHPNP'>PAUK
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M?R4F6())?V:5-8?+AE>($(;(A=)Z1X72A2ML H3EA&Y=?(0,@[%.VX-6@P-
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MGK)N?XJ\FS)A68C?EUU4-(<LDX='0H6IC[$Z\80SB]@O38+GA^HE$(&SA!N
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M8[^?46QY9HR,PFZ9:4UYPW##;!-FEG,(;O!3GW5R<?) Z'@@=3PO"'LL>0+
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M=3Q?*VQZ=LA-TG *>&P\YW/M>D M(7@K?%6QY%GI><:B&5U6>BN1S6"A>I6
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M>Q@Q18SH?!<J.HG8?2,C\8;W?C8>Y(1L?S58]IHB?=!1$9?/?B=(_)4=?E%
MV9(A?G$XWX\,?JDQ0HOZ?OLJ7(CX?V D(H8^?\(?)H/9@!98M9DO@WI0YY;G
M@UM(WI0X@NY Q9$]@F4XT(XQ@?4Q,(LX@9XJ7XA+@5\D2H6E@1H?6X-C@-%8
MBYAOB/50S98IB&%(R9-^AU- N9"%AADXUHUZA/PQ18J-@_TJ=(>V@Q4D8X4L
M@C0?A8,$@6FL?USC52N=,E_]62:-A6,1715]3&8P8/MLGVET9.=;Q&SJ:.]+
M.W"5;2@[$'29<;LL!WCZ=N6JBUCM7V&;L%QO8F",,U_?95=\)V-7:$QKG&;T
M:TE:Z&K&;F%*C&[0<:(ZI7,T=30K]W?R>3ZHO55G:8"9_5D^:X"*Q%S_;7YZ
MT6##;X-J>&2O<999_&C5<\%)WFTW=@PZ0''U>)8KZG<'>W:F\E(]<W.82U9C
M=(*))EID=91Y@%YL=JMI4V*F=])9%&<;>0U).FO.>ETYY7#>>]DKWG8W?8BE
M0D]W?4*6RU/@?6Z'Q5@B?9EX-%QD?<1H6V#<??A8266;?CY(JVJ6?HXYEF_L
M?O0KTW6#?VZCU$T@AO&5BU'"ACV&KU8XA7]W/5JQA+MG?5]=@_M7J&11@T5(
M.&F-@I(Y5&\@@=TKRG3I@2*BJ4LID'.4B4_[CM>%SU2;C2IV>EE BW5FS5X>
MB<17&F-#B!%'WFBMAE8Y(FYTA(<KPW1I@J&AQ$F7F;"3PDZ.ER2%(5--E()U
MXE@0D=IF1%T3CS=6GV)EC(U'A&?[B<\X^6WFANLKO70 @^FA*TAPHH&3-TU[
MGO>$H%)+FUQU<%<AE\5EYUP[E#A66&&JD)U'1&=BC.0XRFURB/HKN7.KA/N@
MU6/S5362U&9I63J$26CG72=U&6MX809E<6XL9.Y5HG$0:/E&+W0H;3<W*W>5
M<=8I6WM8=PJ?*V P7N61HV,/8?N#167@90)T/&B\: )DM&N]:PI5"F[U;C%%
MPW)E<8(V\W8O=2HI8WI+>4F=BES.:'F0 6  :J6!VV,;;,=R[F9!;N=CFVF/
M<1-4*FT9<UI%(7#==<(VGG3X>&LI:GE;>V6;ZEG$<>6.;UT]<S2 76"7='IQ
MP&/]=;MBEF>8=P=37VMM>&A$EV]^>>$V6'/E>X8I;WB)?5N::%<;>S6-#UK0
M>Z]_%UYG?!EPC6(%?'EAN&7;?-]2JFGX?5A$'6Y.?=PV'7+V?G8I='?3?R69
M*%3?A&J+[5C$A ]^$UR+@YIOHV!>@Q5@Z&1F@I%2&6BV@AA#NFU)@:8UZW(K
M@30I>7<X@+Z8)E,!C7"+ E</C#Q]/UK[BN)NY5[WB71@/F,PB A1E6>NAIU#
M;FQLA3 UQW& @[,I?':W@B.78E&%EC&*356PE")\E5FWD=YN35W0CX-?LV(L
MC2Q1&F;6BM-#&VN]B' UIW#SA>XI?W9-@U66W5!JGH^)RE2GFZ-\$EB]F'-M
MTUSGE2I?3V%:D>I0T&8ACJ9"V6LIBT\U>G"#A]0I@77YA%*56VLU55:(E&T$
M659[)V[J73UM!'#G819>9W,#9/M/J75,:0=!4W?$;4DS=GJ-<?$FV7VB=RN3
MYF>C7FJ'8FG789!Z"&P)9*-L#FY,9[!=F7"Q:LE/"'-);@1 XW83<6LS1GDO
M=2<F^'R->5&2@61A9WB&"6;J:<9X_FEA; =K%VOD;D)<TVZ-<(I.=7%P<NY
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MW7H-9PU/EWL6:D=#2WQ ;:DWA'V+<3HL8G\1=1\BI("]>5A\C'1298]Q\G6
M: 9FTG:F:G=;"'?3;.A.\'D8;VU"UGJ$<A,W1WP1=-XL8WW5=^DBYW^W>RQ[
M<'&D;6=PV',*;S-EO71E</1:1G7#<K).37=(='Q":GCQ=E\W$GJ^>%XL9'R^
M>HHC(7[3?-=Z7&],=35OTG#B=E1DSG)J=V!9;'/V>%Y-T'6H>6="$7>->H,V
MZWF2>[$L;'O)?/LC4WX/?E=Y<6U9?.]O$&\7?6AD(W#!?;I8P')S??--,W1-
M?C%!K79:?H$VL7B0?MTL87KZ?T(C?'UJ?ZAXL6NWA'1N6FV3A$5C?&]:@]E8
M*G$L@TM,KW,I@L!!3W5<@D VC7>R@<@L8GI(@4PCGGSA@,MX&FIDB[5MS6Q:
MBN%B]6XVB;57LG =B%M,0W(WAP- \'2.A;(V6'<$A&HL8GFU@Q8CNGQR@<%W
MJ6E<DJYM8&MFD3MBAVU1CTU73&]%C2!+\W%PBO5 O'/>B-0V+'9UAK<L2WE'
MA)4CSWP9@HISS(*,59IIWX)Q66=?;()[7314;(*/80U)&X*A900]T8*_:3 S
M%H+Q;9$I"X-/<E0@8X/4=W-ROG^271QI#'_*8$9>KX &8V]3V8!#9J5(LH"$
M:?8]E(#;;70S"H%)<1\I-('C=1L@QH*=>5EQRGR^9)!H$GT\9Q9=YWVL:9U3
M)WX9;"Q(+GZ0;M(]07\B<9XR[7_,=) I4("@=[\A&X&->QAPTWHM:^YG&7K>
M;=5<]'M];[=2=7P;<9Y'GGS+<Y8\XWV7=:LRQ7Y[=]PI8'^&>CHA98"A?*YO
MZ'?R<SAF07C-=(-<*GF4=<!1LWI;=O9','LS>#D\EGPW>90RIWU0>P$I<GZ.
M?(DAI'_6?AEO%'8+>G-E?7<.>R%;>W?W>[!1)GC>?"Q&O7G;?+ \:7L ?4LR
MFGQ(??,IA'VX?J4AV7\L?U=N9G1X@7YD\'6@@95; G:B@7)0MW>=@2]&5'BZ
M@/4\''H#@,PRAGMH@*\ID'T"@(TB!'Z?@&AMW',RB$ID;W1SA\E:B76*AO%0
M3G:7A>Q%^G?,A/$[SWDVA ,R7'JV@R(IF7QL@C@B)WXM@4UM<G(PCM)D"G.%
MC<!:)W2LC#!/^'7&BF-%NG<)B*$[J'B'ANTR0WHEA44IDWO[@YLB0WW1@@AI
M((KD55Q@#(HC61Q6C8E]7.E,F8C08,U"98@/9-HX28=-:2 NR8:6;9LF"87_
M<F\>J(61=X-H+H@@7&U?5(>J7YE5Z8<J8M%,'8:;9AY"%H8!:8XX*85O;2\N
MVX3K</TF382*=14?'X1->5AG7X5L8VM>?X4S9@-5083B:*-+BX1]:U=!L802
M;B8W\X.V<2 NVH-I=#TF@8,_=Y4?AH,R>P1FD8+P:E-=KX+D;%A4=(*];F!*
M^(*%<'=!/H)/<J,WLH(I=/ NS((2=UDFIX(<>>P?WX(]?(AEQX#'<2Q<\8#C
M<J!3PH#@= U*5X#*=7I WX"^=P W<X#+>)XNNX#F>DXFQ8$@?!D@*H%L?>%E
M$W[U=_)<37\U>-93,W]/>:-)V7]8>F9 >W]J>S<W4G^4?!\NMW_<?14FX8!%
M?A8@:8"\?PUD=GUD?GU;NWW+?M)2LGX!?OM);7XA?Q% )'Y0?S W*'Z8?U\N
MT'[T?Y\G!'^)?]P@G8 K@ YC^WPHA-];:GRTA*]2<7S[A"I)/GT<@WM "'U5
M@N$W!GV_@ELNM'X]@>HG%W[O@6L@QW^U@.5CFGLJBP5;#WO*BD]2'7PCB1I(
M^7Q1AZP_VWR5AE4V\'T.A18NL7VF@^HG)'YX@K<@Z']7@91>XY.(5-E6GI(5
M6)-."I"J7&9%'8\E8&$\!(U^9(XS%(O(:/HJRXH6;9@C38A_<H4=)H<<=Y!>
M")#[6X-5]X_&7K=-=XYV8@-$L8T&97 [R(MY:0DS"HGJ;-@J]HAD<-(CJH;^
M=0P=KX7+>55=6(YG8A5518UD9,-,ZXP]9X-$.HKO:F([?8F-;60R\(@N<)4K
M$(;9<^<C]86G=VP>)H2E>O)<L8O[:))4FXL@:KA,0XH>;.M#R(C[;S8[*X?(
M<:$RS(:;="XK'85Z=M8D,(1[>:,>C8.H?&5<#8G:;P-4 HDF<*)+MXA%<D5#
M2X=!<_$ZZX8U=;XRJX4X=Z<K)(1&>: D88-W>[ >XX+0?:Y;=8@+=6%3>X=^
M=GQ+1X:Z=XA"[X70>)4ZIH3@>;8RGX/_>O8K,8,W?$ DB8*7?9 ?*X(;?LQ:
M\H:'>XU3#88??"=*[85S?)A"J82;?/XZ;H/#?7<RA8+^?@@K1X)-?J<DL('8
M?SP?9X&%?[]:AX5&@7!2I83]@8%*CX1H@51"7(.B@1(Z-(+=@.4R4((W@,HK
M/X&3@,0DVX$R@+ ?EX$,@(I:,X1(ATA2@80GANM*>8.FA@E"7X+/A/0Z8H'[
MA XRH(%:@TTK?(#?@J4D_8"R@>H?O8"L@2]4W)R&5"--BYI:5]=%^Y@@6Z\^
M'Y6N7\ V)I+^9!8N8) U:+$G18UM;7P@[XK,<HH;THA^=YI4!)H\6FI,WIA3
M7:=%598J80H]I).Y9)XUZ9$/:&@N88Y=;&PGA8NU<)4A88D_=/<<;8<@>5)3
M?9>_8)1,3)7\8UI$V9/]9CT].9&G:5(UK(\A;(TN6HR9;_LGMXH?<X4APH?<
M=SL<\H7O>N%3")529J-+R9.O:.Q$3I'0:U$\W(^H;=HU<HU0<(LN3HKZ<U\G
MVXBS=DHB$(:F>54=9(3I?$92B9,I;*5+3I&S;G1#YX_N<%,\@XW><D4U3HNS
M=&0N28F+=J(G]X=W>.LB4(6:>T8=Q80*?8%2#9%4<J-*XI +<_A#EHYC=4H\
M38QI=J8U+XI4>!\N5XA)>;TH&(9A>V0BA82T?0T>%H-0?I)1H8_*>'5*B(ZL
M>5%#5(T;>A \'(LT>L\U"XDV>ZHN4(=&?*$H.X5S?:8BM8/R?J >6(*W?WE1
M2HZ'?AE*08V-?GI#'XP2?J$[_8HU?KHT^8A%?O0N.(9U?T4H.(2Z?ZHBW8-0
M?_\>CH(Z@#E1$8U_@YM*#8R@@WU"](L]@P [Y8EK@FLT_8=_@?PN486\@:DH
M5(0;@6DB_8+1@2 >N8'7@-6B-5:;3ZJ3Y%HI5".%0EV_6)AV'6%X70MFAV5H
M88=6QFF:9B-'9FX*:O8X=W+:<"TJQW?[=@2@*%'*69^2357:73"#X5GL8+IT
M[%X89$-E?6)\9]15ZF<C:X5&OFP-;V<X&G%8<Z<JSW;J>&R>34UQ8XN0DU'Y
M9BB";59W:,-SEUL+:V)D7E_5;@Y5!F3J<-A&'6I$<\HWR'  =PLJUW7X>K&<
M=TF#;56.XDY\;P6 UE-8<+IR5%A(<G)C2%UY=#A4+V+R=A=%C&BS>!4W@&[4
M>D\JWG4B?,Z:M$7^=ON-8$M@=\E_@E"<>)MQ&E7@>6UB;5MF>DM3?6$_>SQ%
M$V=;?#\W1&W3?6HJXW1J?KV9*D+N@':,&4BO@&5^>$Y @%1P/%/7@$)AJ%FG
M@#12_%_)@#1$MV8W@#PW%6SZ@%,JZ'/-@'F7XD!,B;V+#49AB,)]I$P^A\EO
MD5(;AM%A#U@QA=Q2@UZ5A.I$=&5!@_<V\VQ#@OPJ['-*@?Z6WSX?DK.*.41Z
MD,9\_4J6CN!O#U"KC0-@HE;ZBRM2'UV9B4Q$+&1]AV(VV&NMA5XJ[W+>@TN6
M*#QUFR&)GD, F#M\@4E'E6INLD^&DK)@857^D -1]%S'C4-$!&/7BFLVNVLT
MAVHJ\G*(A&&79%UE3_Z*&6!A5&E\;6-S6-%N.V:I73=?G&H08:M0W6VV9D5"
MB7&9:Q@TM'7<<%8H+WIG=C"5>EC'66J(QUQ)7/][6U_-8(]M6V-K9!Y>XF<[
M9[503&M.:VY")F^A;U@TBW18<Z@H3'E/>'V3NE2:8LR'&%B298-Y[EQ\:#9L
M#6!]:NI=S&2S;:I/<FDQ<(I!CVWP<Y(T1G,-=NPH97A7>J:2"%#2;!"%?U4R
M;>QX<UEW;\AJZ5W1<:1<TF)K<XI.M6=+=8M!%&QM=ZLT$''F>@@H>W=]?*:0
M=DUU=3>$'%(P=C]W,U;.=T-IP5M[>$-<"&!H>4U.$V6D>FQ K&L>>Y\SYG#H
M?/DHCG;!?GF/(TJ.?CR"]4^7?G%V.%2#?IIHZ%E^?KU;2EZU?N5-FF0X?QU
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M5/YJ[F]P64->JW&/7912#G/.8?Y%978^9I<Y/'C?:VHMK7O2<*\C>W[X=GN
M8F=A60!U<6FX7))IWVP;8"5=SFZ38[]177$O9VY$Y'0":T<X[W<';U,MHWI9
M<\ CP'W,>)9^[V.+84AT%69.9"-HSVD*9OY<WFO7:=Q0HV[,;,Y$8''];^,X
MIG5@<R,MFGD)=K$C_'S#>HM]B& -:8ERPF,M:ZAGFF8[;<=<#FE6;^I/^VRD
M<A9#\G K=& X<W/D=LPMFW??>78D,7O=?%9\.ES\<;%QJ6!G<QEFE6/ ='I;
M#&<F==9/26K =S]#9&Z=>, X'W*D>E@MB';D?!DD77L6??5[)UI3>;MPK5W]
M>G!EM6&8>PY:1F5$>Z!.I&DA?#Q# FT\?.TWZG&)?:\M?W8(?H4D@GIO?V-Z
M2%@.@8YOY5OP@9!E U_"@6A9J6.H@2U.'&? @/M"HFP6@-@WQW"5@,0M@'5,
M@+0DH7GD@*!YFU8NB1EO25I B&YD<5X_AWY9*6)1AG!-J6:;A6Y"/FLGA'DW
MCV_4@Y M?72R@J DNGES@:UY'E2TD$INUECMCOUC_ET.C458OF% BV!-566K
MB8E"!VI=A\$W8&\WA@(M8W1 A#XDSGD8@HIW;',&405L\71752MB''7,6616
MU7=57;%+0GCP8AT_LGJQ9KTTKWR8:Y@J5W[$<. A9($3=IEUV&\86+UKSW#5
M7$QA+G*>7^)6&W1S8X5*MG9B9T,_5GA^:S TAGK!;T\J;'U$<\LAO7_:>)UT
MAVMQ8()JE&V28VI@-&^M9E9507'1:4M*#G03;%@^XW:&;XPT3WDA<NPJ=7OR
M=I8B"G[(>GMS3&@>:#EI9VJ2:G5?%VSY;+54?&]D;OM);''\<5,^>W3"<\LT
M(7>N=F4J?WK)>3@B37W9?"]R'V4I;^-H4F?E<7->(&J0<P!3HFU"=(M(]G >
M=BD^*G,R=^$T!'9F>; JD'G$>ZDBA7T,?;=Q(6*<=W9G@F67>&%=<&A_>3=2
M^FMP>@1(7FZ)>MX]T7'8>](SU75+?-@JD'CF??(BM7Q@?P]P4V!K?M)FQ6.<
M?QE<QV:Y?S5296G@?T!'WVTQ?U<]>7"U?X(SNG17?[TJF7@H?_TBW'O1@#AO
ML%Z9A>5F-&'WA8U<065!A.]1\&B3A#-'>&P1@X0](6_)@N<SC7.5@EDJH'>*
M@<<B_'M=@3)O.5TDC*IEQV"JB[];UF06BF51CF>(B-M'+FLEAV \\V\ A?DS
M9W+XA)\JCG<7@T8C%7L @?]LTGK-415C2GN'52Y9;7QB66!/*7U%7:]$I'XM
M8B4Z,'\M9M4P58!*:[XG.(&:<0X?@(,$=K)K:'<?6%5B1'@\6^58E7E>7X-.
MA'J"8S5$+WNS9PDY[GT$:P\P2GYR;T<G:( 2<]8?[(&_>*)J0'.G7Z!A+74?
M8I=7NW:+99A-QG?T:*A#I7EP:]8YFGL2;R\P,'S0<K(GBGZY=GL@28"A>FMI
M*'!Z9M]@'7(]:3A6NW/M:Y=-#76>;@1#$7=H<(DY/7E7<S$P#7MA=?HGH7V-
M>/@@F7^J? IH)&VD;@M?,V^I;\95Y'&9<8),1G.,<T-"I'65=1@X\W?.=PXO
M]GH;>1DGNGR&>T@@WG[7?7QG.VLJ=29>7VUM=D15+6^9=U1+MW'$>&%"-70'
M>7TXS79R>KDO\GCZ? 8GU'N@?68A%WXE?L%F?&D'?!%=PVN'?)A4JVWG?/A+
M1G!!?4M!SG*U?; XA'54?BXOY'@%?KXGYWK>?T\A1GV2?]=EY&<]@KE=.6GN
M@JQ4+VQ\@EQ*WF[^@?)!=G&<@9PX.G1J@5POP'="@2XG]7H_@/LA;'T:@,%E
M<F7+B1Q<T&BDB(-3RVM8AX!*AVW[AE-!.'"WA3LX%W.EA#LOJ7:E@TPG\7G(
M@E\ABWRZ@8!BA(+<4.%9](+Q5/=1%(,@62I'TX-+78,^6X-N8@TU X.;9M8L
M38/;:]@D8H1#<34=U83$=L=A0W]J5[=9 W_=6T]01X!*7OM'-H"J8L0]]($(
M9K8TU8%[:M\L6X(";S@DJH*Q<]X>4H-Q>*5@0WP=7I!8#'SA89Y/A'V09+E&
MCWXN9^P]@'[0:T,TF'^,;LDL6H!<<G8DXH%/=F$>OH))>EM?5'D.95Y7(GH7
M9]E.I7L#:E]%\'OD;/H]!WS.;[(T5'W2<I$L3G[I=8\E#8 <>+L?'(%)>^=>
M<'9/;!]63G>8;@9-XWC!;_-%1GG<<>H\I7L&=  T%WQ.=C8L0GVC>($E,'\1
M>NH?:X!N?4==I7/D<LM5EW5L="%-1W;.=6Y$PG@A=L$\07E^>"@S^GKT>:XL
M17R!>T8E4WXH?.D?K7^W?GI<]'')>414\G./>@A,MW4H>K)$3G:K>UD[ZG@U
M?!0ST'G8?.8L77N%?<HE>7U??J\?XW\??X!<9G "?XQ4B'('?\=,9W/1?\9$
M&75S?[([QW<<?[LSIGCL?]TL0GK!@!0ECWR\@$ @#WZD@%Q;_&Z0A9I4)'"_
MA4Q,"W*TA)Y#SW1X@]$[EW8\@R,SD7@I@H\L/7HB@@\EFWQ"@8P@,GY"@0]8
MBHLZ4&%0^(J45(%)&HH 6+Y W8E>72LX<8BG8=,P,H?N9L$HG8=":^0AV(:V
M<54<8(91=ME7<8?]5M=0%8>X6H%(3(=:7D5 /H;B8BXX$(989D@P$H77:IXH
MOX5F;R B-84;<^(<[83Q>*=6F(3574E/.X388'5'G(2X8[,_J(1V9Q,WKX0H
M:IPOZH/H;E@HU8.Y<C8B@8.O=D8=9X.^>DQ5TH'=8Z].=H(=9E-&W((W:0<_
M(X(T:]@W4((H;L\OOX(L<>PHX((_=24BOH)R>($=T(*V>\=5$7\I:@U-P7^K
M;"9&.7_^;DP^EX Q<((W"H!A<N$OFX"D=5\HZ(#T=^XB\8%@>I$>*8'4?1=4
M7WS$<%M-'7V*<>I%L7X7<WH^+7Y\=14VOG[<=LTOB']->*<H\W_2>HLC'(!T
M?'0><X$7?CM3Q7JS=GE,E'NX=X!%0GQ[>'0]V7T,>6XV>WV7>H,O:WXR>[(I
M"'[6?.XC1'^J?B$>L(![?S-307CG?%E,%GHO?-9$U7LF?2T]AGO@?8(V0'R,
M??(O.GU2?G@I WX/?PXC;W[_?Y8>X7_]@ -2X'=Q@AY+S'CV@A=$H'H?@;\]
M<7KM@5@V57NC@1HO:'Q\@/@I)WUC@.@CBGY^@,X?"'^8@*Q.V)/]3Z-(2I*$
M4])!<9$16!TZ/8^%7*0RX8W9878KNXPC9I,E08IZ:^0?E(CV<6\;&8>T=N=-
MS)#Z5;E'4H_M67U @(ZO75\Y?8T_87$R;(NM9<$KEHH=:D\E;(B?;P,@ (=2
M<^4;M89'>*=-%(WX6\M&C(TL7QP_U8PI8H0XZHKH9APR$8F):>,K>8@Q;> E
MD(;M<?<@6X7==B\<.X4)>CY,>(L18=!%ZHI\9*0_,8FO9X\X>XBL:I\QR8>)
M;> K989O<48EKX5J=, @J(27>$T<KX/X>ZI+VHA>9\Y%4X@0:B$^KH=[;(@X
M$(:H;P@QHH6_<;DK7(3B=(HESX07=V(@[(-]>D$=$(,0?.Q+087O;<=$QH7Q
M;Y4^0(69<6XWQ(3V<UXQ<X0Y=7 K8X.)=Z0E\(+Q>=HA)H*,? D=88).?@-*
MO(/0<Y-$3(0@=-P]Y(0"=B(WAH.+=WLQ3(+U>/(K6H)M>H(F$H'W?!<A6X'
M?9P=I(&N?N]*3(( >2]#YX*7>?(]E8*O>I\W5H)>>U@Q+8'J?#(K18&+?2 F
M&H$R?A8AA($9?OD=VH$L?[1)^X!\?J5#EX%2?ML]58&=?N8W,8%L?ODQ)($/
M?S K5(#*?WPF*("6?]$AFH">@!L>!8#$@%0  /__  #__P  __\  &UF=#$
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M__^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MCV?5?H]GU7Z/9]5^CV?5?H]GU7Z/9]5^CV?5?H]GU7Z/9]5^C_^C.2K_GT9
M_YU05?J@4&7OHU%UY*13AMJB6Y;0H&6DR)UPL,6<>[7"G(.YOYJ)OKR5B\*Z
MD(S%N(R/R;:(DLRSA)?/LH&?TJU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_
MHM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9 _YU0
M5?J@4&7OHU%UY*13AMJB6Y;0H&6DR)UPL,6<>[7"G(.YOYJ)OKR5B\*ZD(S%
MN(R/R;:(DLRSA)?/LH&?TJU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M
M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9 _YU05?J@
M4&7OHU%UY*13AMJB6Y;0H&6DR)UPL,6<>[7"G(.YOYJ)OKR5B\*ZD(S%N(R/
MR;:(DLRSA)?/LH&?TJU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3
MK7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9 _YU05?J@4&7O
MHU%UY*13AMJB6Y;0H&6DR)UPL,6<>[7"G(.YOYJ)OKR5B\*ZD(S%N(R/R;:(
MDLRSA)?/LH&?TJU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^B
MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9 _YU05?J@4&7OHU%U
MY*13AMJB6Y;0H&6DR)UPL,6<>[7"G(.YOYJ)OKR5B\*ZD(S%N(R/R;:(DLRS
MA)?/LH&?TJU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_
MHM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9 _YU05?J@4&7OHU%UY*13
MAMJB6Y;0H&6DR)UPL,6<>[7"G(.YOYJ)OKR5B\*ZD(S%N(R/R;:(DLRSA)?/
MLH&?TJU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M
M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9 _YU05?J@4&7OHU%UY*13AMJB
M6Y;0H&6DR)UPL,6<>[7"G(.YOYJ)OKR5B\*ZD(S%N(R/R;:(DLRSA)?/LH&?
MTJU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3
MK7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9 _YU05?J@4&7OHU%UY*13AMJB6Y;0
MH&6DR)UPL,6<>[7"G(.YOYJ)OKR5B\*ZD(S%N(R/R;:(DLRSA)?/LH&?TJU_
MHM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^B
MTZU_HM.M?Z+3K7^BT_^C.2K_GT9 _YU05?J@4&7OHU%UY*13AMJB6Y;0H&6D
MR)UPL,6<>[7"G(.YOYJ)OKR5B\*ZD(S%N(R/R;:(DLRSA)?/LH&?TJU_HM.M
M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_
MHM.M?Z+3K7^BT_^C.2K_GT9 _YU05?J@4&7OHU%UY*13AMJB6Y;0H&6DR)UP
ML,6<>[7"G(.YOYJ)OKR5B\*ZD(S%N(R/R;:(DLRSA)?/LH&?TJU_HM.M?Z+3
MK7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M
M?Z+3K7^BT_^C.2K_GT9 _YU05?J@4&7OHU%UY*13AMJB6Y;0H&6DR)UPL,6<
M>[7"G(.YOYJ)OKR5B\*ZD(S%N(R/R;:(DLRSA)?/LH&?TJU_HM.M?Z+3K7^B
MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3
MK7^BT_^C.2K_GT9 _YU05?J@4&7OHU%UY*13AMJB6Y;0H&6DR)UPL,6<>[7"
MG(.YOYJ)OKR5B\*ZD(S%N(R/R;:(DLRSA)?/LH&?TJU_HM.M?Z+3K7^BTZU_
MHM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^B
MT_^C.2K_GT9 _YU05?J@4&7OHU%UY*13AMJB6Y;0H&6DR)UPL,6<>[7"G(.Y
MOYJ)OKR5B\*ZD(S%N(R/R;:(DLRSA)?/LH&?TJU_HM.M?Z+3K7^BTZU_HM.M
M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C
M.2K_GT9 _YY/5/JA3F3OI$]UY:91A=JE6)71HF*CR9]MK\6?=[7"GH"YOYV(
MOKR9B<.YE(O'MH^-R[.*D,^QAI;4KH.@UZ>!H=6G@:'5IX&AU:>!H=6G@:'5
MIX&AU:>!H=6G@:'5IX&AU:>!H=6G@:'5IX&AU:>!H=6G@:'5IX&AU?^C.2K_
MH$9 _YY.5/JB363PI4YTY:A/A-NG5932I5^ARJ-IK<6B=+3"H7VYOZ"%OKN=
MB,.XF(G(M9.+S;&.CM.NB9;8IX6=VJ&%H-:AA:#6H86@UJ&%H-:AA:#6H86@
MUJ&%H-:AA:#6H86@UJ&%H-:AA:#6H86@UJ&%H-:AA:#6H86@UO^C.2K_H$9
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MJXW)?ZN-R?^G-2K_HT)!_ZP\3?^W-E?RQ3-?X=8V8\WC,7RZTS^1J<A4H9_
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M2?^A3%CYI4UF[Z=/=>:I4X/>J%J0U:9BG,^C;*;)H':NQ9Y_M<&<A[J^EXK
MNI"-QK:+DLNTB)K.LH:DT:: I-&@@:?-GX&GS)^!I\R?@:?,GX&GS)^!I\R?
M@:?,GX&GS)^!I\R?@:?,GX&GS)^!I\R?@:?,GX&GS/^A."+_GD4W_YY,2?^B
M2U?YIDQF\*E.=.>K48+?JU>.UZI?FM"H::3+I7.LQJ-\L\*@A+F^G(C N9:,
MQK61DLNOC9C/JHJATJ"$H].;A*;.FH2GS9J$I\V:A*?-FH2GS9J$I\V:A*?-
MFH2GS9J$I\V:A*?-FH2GS9J$I\V:A*?-FH2GS?^A."+_GD4W_YY+2?^C2E?Z
MITME\*M,<^BM3X#@KU2-V:Y<F-*M9J'-JW"IR*IYL,.G@;>^H83 M9N)QJZ5
MC\RHD97/HHZ>TIJ)HM.6AZ7/E8>FSI6'ILZ5AZ;.E8>FSI6'ILZ5AZ;.E8>F
MSI6'ILZ5AZ;.E8>FSI6'ILZ5AZ;.E8>FSO^A-R+_GD0W_Y]*2?^D25;ZJ$ED
M\:Q+<NFP37_ALU&+VK-:E=2S8Y[/LVZER[-XJ\.L?+>XI8&_KYZ&QJB9C,NA
ME9+0FY*;TY6.HM21C*70D8NFSI&+ILZ1BZ;.D8NFSI&+ILZ1BZ;.D8NFSI&+
MILZ1BZ;.D8NFSI&+ILZ1BZ;.D8NFSO^A-R+_GD0W_Z!)2/^E2%;[JDAD\JY)
M<>JR3'WBMD^)W+A7DM:Z89K3O6V@R;AUJ[ZP>K:SJ7^_JJ*$QJ*=BLN;FI#/
ME9>9TI"5HM2-D*70C)"FSXR0IL^,D*;/C)"FSXR0IL^,D*;/C)"FSXR0IL^,
MD*;/C)"FSXR0IL^,D*;/C)"FS_^A-R+_GD0W_Z!)2/^F1U7[JT=C\[!(<.NU
M2GSDNDZ&WK]5C]K#8)72Q&V<Q;MSJKFS>+:NK7V_I:>"Q9VBB,N6GX[/CYR6
MTHN<HM.(E:30B92ESXF4I<^)E*7/B92ESXF4I<^)E*7/B92ESXF4I<^)E*7/
MB92ESXF4I<^)E*7/B92ES_^B-R+_GT0W_Z%(2/^G1E7\K$5B]+)&;NRX2'KF
MOTR#X<=3BMS-8H[.R&R;P+]QJK2W=[6IL7R^GZR!Q9>GALJ0I(S.BJ*5T8:B
MH=*$FZ70A9JESX6:I<^%FJ7/A9JESX6:I<^%FJ7/A9JESX6:I<^%FJ7/A9JE
MSX6:I<^%FJ7/A9JES_^B-B+_GT,W_Z)&1_^H1%3]KD-A];5$;.Z\1G?IQ$M_
MX\]4A-G498C(RVN:NL)PJ:ZZ=[2CM'R]FJ^!PY*LA<B+J8K,A*>2SX"FG-"
MHZ7/@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"A
MILZ H:;.@*&FSO^B-B+_GT,W_Z-%1_^J0E/^L4%?]KA!:O'!1'/JS$MYX-I6
M?,_57HW S&F;L\-RJ*>[>;.>M7^[E[&#PHZMA<:'JXC*@:F-S7RHELY[J*+-
M>ZFFS7NIILU[J:;->ZFFS7NIILU[J:;->ZFFS7NIILU[J:;->ZFFS7NIILU[
MJ:;->ZFFS?^C-B+_GT,W_Z5#1O^L0%+_M#Y=^;T_9N[(0VWCUDUOU=U.@<33
M69&UR6:?J<%QJZ"[>;.9MH"ZE+*%P(ROAL2&K8C'@*N,R7RJDLIZJYS*>:N?
MRGFKG\IYJY_*>:N?RGFKG\IYJY_*>:N?RGFKG\IYJY_*>:N?RGFKG\IYJY_*
M>:N?RO^C-2+_H$(W_Z9!1?^O/5#^N#M9\\0\8>;10V39WT-SR-Q*A;?05Y6J
MQV6BH,!PK)FZ>;24MH"ZD;.%OHNQAL&%L(C#@:Z+Q7VMD,9ZK9?&>JV:QGJM
MFL9ZK9K&>JV:QGJMFL9ZK9K&>JV:QGJMFL9ZK9K&>JV:QGJMFL9ZK9K&>JV:
MQO^D-"+_H4$W_ZD]0_^S.4WYOC=5ZLPZ6=O=.V++Y3]WN]E(B:O.5YB@QF6D
MF,!QK).[>K.0N(&XC+6$NXBSAKZ%LHG @;&+P7ZPC\)[L)3#>K"6PWJPEL-Z
ML);#>K"6PWJPEL-ZL);#>K"6PWJPEL-ZL);#>K"6PWJPEL-ZL);#>K"6P_^D
M-"+_HSXV_ZTY0?^X-$CPQC--W]DV4,WE-F>^Y#M[K==(C*#-6)F7QF>DDL%R
MJXZ]>[",NH&TB+B#MX2WA;F"M8B[?[2*O7RSC;YZLY&_>K.3OWJSD[]ZLY._
M>K.3OWJSD[]ZLY._>K.3OWJSD[]ZLY._>K.3OWJSD[]ZLY._>K.3O_^F,B+_
MICHT_[(S/?? +D+DTB]!S^0N5;_O,VNOX3M^H-9*C9;.6YF0R&FAC,-SJ(G
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M@X%=WX.!7=^#@5W?@X%=WX.!7=^#@<O0"0.ZX@L3J/\4)IK_(3>-_S%%A/]
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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MGU!0_Z!37?>@6&GOGUUUZ)UD@.&:;HO;EG>4U9& G-".B:/,B8^IR825KL>
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M655B_%Y87OMD6UOY:%U9^&Q>5_=P8%;W<V%5]G9B5/5X8E/U>V-2]'UD4?2
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M94CSGF9(\YYF2/.>9DCSGF9(\YYF2/.>9DCSGF9(\YYF2/.>9LV[!0"]QP8
ML=@' :/_$ B8_Q\4C?\L((/_-RMZ_T$T</]'.VC_34%A_U1%7/]:25C_7TM5
M_V5-4O]J3U#_;E%._W)23/]W4TO_>U1)_W]52/Z$5D?^B%=&_8U71/V36$3\
MEEE$_)991/R6643\EEE$_)991/R6643\EEE$_)991/R66;V_! "PS@0 HN &
M I?_$PB,_R(3@_\N'7G_."5N_SXM9O]%,E__3#=9_U([5?]8/E'_74!/_V)"
M3/]F0TK_:D1)_VY%1_]R1D;_=D=%_WI(0_]^2$+_@DE!_X9*0/^+2S__CTL_
M_X]+/_^/2S__CTL__X]+/_^/2S__CTL__X]+/_^/2Z_& @"BU@( EO<* HO_
M%@>"_R0/=_\M%VS_,QYC_SHD7/]"*%;_22Q1_T\O3O]5,4O_6C-(_UXU1O]B
M-D3_9C=#_VDX0?]L.$#_<#D__W,Z/O]W.CW_>SL\_WX\.O^#/#K_ACTZ_X8]
M.O^&/3K_ACTZ_X8].O^&/3K_ACTZ_X8].O^&/?]U) ;_=C40_W=#'/^ 2B?_
MA5(S_X99/O^%8$C_@6A2_WQO6OQW>6+W<X-H]&^,;O%LDW+O:IIU[6>@>.QE
MI7KK9*I\ZF*O?>EAM7[H8+M_Z%_#@.=?RX'F7M6!X&#;@==BWH'48]^!U&/?
M@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@?]U) ;_=C40_W=#'/^ 2B?_A5(S
M_X99/O^%8$C_@6A2_WQO6OQW>6+W<X-H]&^,;O%LDW+O:IIU[6>@>.QEI7KK
M9*I\ZF*O?>EAM7[H8+M_Z%_#@.=?RX'F7M6!X&#;@==BWH'48]^!U&/?@=1C
MWX'48]^!U&/?@=1CWX'48]^!U&/?@?]U) ;_=C40_W=#'/^ 2B?_A5(S_X99
M/O^%8$C_@6A2_WQO6OQW>6+W<X-H]&^,;O%LDW+O:IIU[6>@>.QEI7KK9*I\
MZF*O?>EAM7[H8+M_Z%_#@.=?RX'F7M6!X&#;@==BWH'48]^!U&/?@=1CWX'4
M8]^!U&/?@=1CWX'48]^!U&/?@?]V) ;_=S40_WE"'/^"22?_AU$R_XA8/?^'
M7TC_@V91_WYN6OMY=V+W=8)I]'&*;O%MDG/N:YEV[&B?>>MFI'OJ9*I]Z6.O
M?^ABM8#G8;R!YV#$@N9?SH+C7]>#W&';@])CW8//9-V#SV3=@\]DW8//9-V#
MSV3=@\]DW8//9-V#SV3=@_]W) ;_>#40_WQ!'/^%2"?_BD\R_XQ6/?^+74?_
MAV11_X)L6OM\=&+W>']I\W2(;_!PD'3M;)=XZVJ>>^EGI'[H9JJ YV2P@N9B
MMH/E8;Z$Y6#'A>5@TX7=8MF%TV3<A<QEVX;)9=N&R67;ALEEVX;)9=N&R67;
MALEEVX;)9=N&R67;AO]X) ;_>#40_WY &_^(1R;_C4XQ_X]5//^.6T;_BV)0
M_X9I6?R <6+W>WMI\W:%<.]RCG7L;I5YZFN<?>AIHX#G9JF"Y66PA.1CMX7D
M8L"'XV'+A]]BU8?59-J'S679B,9GV8G$9]B)Q&?8B<1GV(G$9]B)Q&?8B<1G
MV(G$9]B)Q&?8B?]Y(P;_>300_X _&_^*1B;_D$TP_Y)3._^16D7_CV!/_XIG
M6?R$;F'W?GAI\GF"<.]TBW;K<)-[Z6V;?^=JHH+E9ZF$Y&6PAN-DN8CB8L.)
MXF+0BMADV(K.9MB*QV?7B\!HUHR^:=:,OFG6C+YIUHR^:=:,OFG6C+YIUHR^
M:=:,OFG6C/]Y(P;_>C00_X,^&_^-127_DTPO_Y51.O^45T3_DEU._XYE6/R(
M:V'W@G1I\GQ_<.YWB';K<Y%\Z&^9@.9KH83D:*F'XF:QB>%DNXO@8\>,W&/4
MC,]FUHS':-6-P&G4CKIJU(ZX:]2.N&O4CKAKU(ZX:]2.N&O4CKAKU(ZX:]2.
MN&O4CO]Z(P;_>S00_X4]&O^/1"3_EDHN_Y=../^75$+_E5I,_Y)A5OR.:5_V
MAW!H\H%Z<.U[A7?J=HY\YG&7@>-MGX;@:JB)W6>PC-IFNXW69<>.T6;4C\=H
MTX^_:M.0N6O2D;-LTI&R;=*1LFW2D;)MTI&R;=*1LFW2D;)MTI&R;=*1LFW2
MD?][(P;_?#01_X@\&O^20R3_F$@M_YI,-_^:4D'_F5A*_)=?5/:39EWPC6YF
MZX=W;^: @7;A>XM]W'63@]=QG(?2;J2+SVNLCLQIM9'):,"2QVC/D[]KT9.X
M;-"3LFW0E*UOT).K;]&3JV_1DZMOT9.K;]&3JV_1DZMOT9.K;]&3JV_1D_]\
M(P;_?301_XH[&?^402/_FD8L_YQ+-?^=4#__G59(^)M=4?&88UOKDVMDY(UU
M;=Z&?G78@(=\T7J/@\QVEXG'<I^-Q&^GD<!ML).^;+N5NVO(EK9MSY:P;\Z6
MJW#/EJ9QSY6E<L^5I7+/E:5RSY6E<L^5I7+/E:5RSY6E<L^5I7+/E?]\(P;_
M?301_XPZ&?^70"+_G$4K_Y])-/^@3CS[H51%]*!:3NR=85CEF6EAWI-S:M6,
M>W3.A8-]R'^+A,)ZDXJ^=IN/NG.CD[9QJY:S;[:8L6_"F*UPS9BH<LV8I'/-
MF*!TSI>?=,Z7GW3.EY]TSI>?=,Z7GW3.EY]TSI>?=,Z7GW3.E_]](P;_?S,1
M_XXY&/^9/R'_GD,I_Z%',O^C3#KXI5)#\*182^BC7U3AGVA=UYAP:,Z1>'3&
MBH!]P(2(A;I_CXNU>Y>0L7>?E*UUIY>J<[&9IW.]FZ5SRYN@=<N:G7;,FIIW
MS9F9=\V8F7?-F)EWS9B9=\V8F7?-F)EWS9B9=\V8F7?-F/]^(@;_@#(0_Y X
M&/^;/R#_H$(H_Z1&,/ZF2SCTJ%! [*E71^2I75#<I69:T)UN:,>5=7._CGU]
MN8F$A;.#C(RM?Y.1J7R;E:1YI)FA=ZV;GG>YG)QWR)R9>,J<EWG+FY5ZS)J4
M>LR9E'K,F91ZS)F4>LR9E'K,F91ZS)F4>LR9E'K,F?]^(@;_@C(0_Y(W%_^<
M/1__H4 G_Z9$+ONI237QK$\\Z:Y50^&O74O5J&19RZ%K9\*9<W.YDWI]LHV!
MA:R(B8RFA)"1H8"8EIU]H)J9?*J<EGNVG91[Q)Z2?,J=D7W*G(]]RYN/?<R:
MCWW,FH]]S)J/?<R:CWW,FH]]S)J/?<R:CWW,FO]_(@;_A#$0_Y,V%_^>/![_
MHS\E_ZA"+/BM1S+OL$TYYK14/]VS6TG0K&)9QJ1J9KR=<7*TEW=\K)%^A::,
MAHR@B(V1FH65EI:"GIJ2@*>=CW^RGHV P9Z,@,F>BX#*G8J RYN*@,N;BH#+
MFXJ RYN*@,N;BH#+FXJ RYN*@,N;BH#+F_]_(@;_A3 /_Y4V%O^?.QW_I3TD
M_ZM!*O6P12_LM4PTX[I4.=BW64C+KV%8P:AH9K>A;W*OFW5\IY5\A*"1@XN:
MC8N1E(J3EH^'FYJ+A:6=B(2PGX:$OI^%A<F>A83)G86$RIR%A,N;A83+FX6$
MRYN%A,N;A83+FX6$RYN%A,N;A83+F_^ (@;_AR\/_Y<U%O^@.AS_ISPB_JT_
M)_.S1"SINDLPX;]2-=.Z6$?'LU]7O*QF9;*E;7&IGW-[H9IZA)J6@8N4DHB1
MCH^0EHF,F9J$BJ*=@8JMGW^*NY]^BLB>?XG)G8"(RIR B,N;@(C+FX"(RYN
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M;U"Y[&]0N>QO4+GL;U"Y[&]0N>QO4+GL;_^)$ '_G0X VJ\( ,V[" #$QP<
MO-8+ +/?&@&JWRL'H-XY$I;=0QZ,VDLJ@MA3-7G56C]QTV%&:M)H3&71;U)@
MT'966]!^6E?/AUU3SY%?4,^<84[/J6-,S[AC2]#+8TS0Y6)*SO)E2\CR9DO(
M\F9+R/)F2\CR9DO(\F9+R/)F2\CR9O^2#0#>I@0 SK0& ,*_!@"YS @ L-T,
M *?E'0.>Y2T+E.4Y%HKD0B"!XTHJ=^)0,V_A6#MIX%]!8^!F1E[?;DI:WW5.
M5M]]45+?AE-/WY!63=^;5TO@IUA)X+592.'&64CAWUE'W_!91MSU6T;<]5M&
MW/5;1MSU6T;<]5M&W/5;1MSU6^V<! #1K00 PK@% +?#!0"MT0@ I.T0 9OM
M( 62[2X.B>PZ&(#L0R%V[$HJ;NQ0,6;K5C=@ZUP\6^MD0%?K:T-3ZW)&4.MZ
M24WL@TM*[(Q-2.R63D7MH5!#[:Y10NZ\44'OS%)![^520.WQ44#M\5% [?%1
M0.WQ44#M\5% [?%10.WQ4=2E  #$L@, MKP# *O)!0"@V @ E_03 8_U) >'
M]3$/?O8[&'3V0B!L]D@G9?9/+5[W53%9]ULU5?=B.%'W:#M-^&\]2OAV/T?X
M?D%$^8=#0OF114#ZFT8^^J9'//NQ2#O[ODDZ_,]).?SC23G\XTDY_.-).?SC
M23G\XTDY_.-).?SC2<>M  "WMP( JL," )[0! "3XPD C/T8 H3^)P=[_S$/
M<O\X%FG_0!QB_T8B7/]-)E;_4RI2_UDM3O]?,$K_93)'_VLT1/]Q-4'_>3<_
M_X$X//^*.CK_DSLX_YT\-O^G/37_L3XT_[X^,__*/S/_RC\S_\H_,__*/S/_
MRC\S_\H_,__*/[BR  "JO0  G<H  )'8 @"(^PT!?_\9 G;_) 9N_RT,9O\U
M$E__/!=8_T,;4_])'D[_3R%*_U4D1O];)D/_8"= _V8I/O]K*CO_<BLY_WDM
M-O^!+C3_BB\Q_Y0P,/^<,2[_I3(M_Z\S+/^W,RS_MS,L_[<S+/^W,RS_MS,L
M_[<S+/^W,ZNX  ">Q0  D-(  (/@  !]_P\!<O\6 FC_'@1A_R<(6O\O#%3_
M-Q!._SX32?]$%D7_2AA!_T\9/O]5&SO_61PY_U\=-O]D'C3_:1\R_W @+_]W
M(2W_?R(K_X<C*/^0)"?_F24F_Z$F)?^G)B7_IR8E_Z<F)?^G)B7_IR8E_Z<F
M)?^G)I_   "1S0  @]L  'CV @!O_PT!9/\2 ES_&0-4_R $3O\G!DC_+PA#
M_S8*/_\\##S_0@XX_T</-?],$#/_41$P_U82+O]:$RS_7Q0J_V44*/]K%2;_
M<18C_WD7(O^!&"#_B1@>_Y$9'?^7&1W_EQD=_Y<9'?^7&1W_EQD=_Y<9'?^7
M&?]6)P3_43(%_U8U!_]?/0[_9$46_V9.'_]D6"?_86(O_UYN-?]:>3O_5X0_
M_U2/0_]1F$;_3Z!(_TZG2O]-KDO_3+5,_TN\3?]*Q$[_2<Y/_TG>3_](Z5#_
M2/)0_$GV4/=+^5#Q3/I/ZT[[4.I/^U#J3_M0ZD_[4.I/^U#J3_M0ZD_[4/]6
M)P3_43(%_U@T!_]B.P[_9T06_VE-'_]G5B?_8V O_V!K-?]<=SO_6() _U6-
M1/]3ED?_4)])_T^F2_].K4W_3;1._TR\3_]+Q5#_2L]1_TG@4?])ZU'^2?)2
M^4OW4O--^5'M3_I1YE#Z4N50^E+E4/I2Y5#Z4N50^E+E4/I2Y5#Z4O]7)P/_
M4C$%_UHR!_]D.@[_:D(6_VQ+'_]J5"?_9UXO_V)H-O]>=#S_6H!!_U>+1?]4
ME4C_4IU*_U"E3/]/K4[_3K1/_TV\4?],Q5'_2]%2_TKB4_])[5/[2_-3]4SW
M4^Y/^%/H4/E3X5+Z5.!2^E7@4OI5X%+Z5>!2^E7@4OI5X%+Z5?]8)@/_5# %
M_UTQ!_]G. [_;4 6_V])'O]N4B?_:EPO_V5F-O]A<3S_77U!_UF(1O]6DDG_
M5)Q,_U*D3O]0JU#_3[-1_TZ[4O]-Q%/_3<]4_DS@5?M,ZU7X3/15\$_W5>E1
M^%7B4OA6VU3Y5]E4^5?95/E7V53Y5]E4^5?95/E7V53Y5_]9)@/_5RX%_V O
M!_]J-@W_<3X5_W-('O]R42;_;UHN_VIC-O]E;CS_87I"_UV%1_]:CTK_5YA-
M_U6@4/]4J%+^4J]3_5&W5?Q0P%;Z3\M6^$_<5_5/Z5?R3_-7ZE+V5^%3]UC:
M5?A9T5;X6L]6^%K/5OA:SU;X6L]6^%K/5OA:SU;X6O]9)@/_6BP%_V0M!_]N
M,PW_=3T5_WA&'?]W3R7_=%@M_W!@-?]J:CS_9G9"_V*!1_Y>BTO[6Y1/^5F=
M4OA7I%3V5JQ6]52T5_-3O%CR4\=9\%+56NQ2YEKI4_)9X53U6]=6]ES/5_==
MR%GX7<=9^%W'6?A=QUGX7<=9^%W'6?A=QUGX7?]:)0/_72H%_V<J!O]R,@S_
M>3L4_WQ%'/]\323_>E4L_W5>-/]O9SS\:G)"^69]2/9CATSS7Y!0\5V94^];
MH5;M6:A8ZUBP6NI7N5OH5L-<YE;17.-6Y%S?5O!=U5?U7\Q9]F#&6O9@P%OV
M8;Y<]F&^7/9AOESV8;Y<]F&^7/9AOESV8?];)0/_8"@%_VLH!O]W, O_?CH3
M_X%#&O^"2R+_?U,J_WM;,_EV9#KU<&Y!\6QY2.UH@TWJ9(Q1YV&55>5?G5CC
M7:5:X5NM7-Y:ME[<6<!?VEG.8-59XF#16>]AREKT8L)<]&.\7?1DMU[S9+9?
M\V2V7_-DME_S9+9?\V2V7_-DME_S9/]<) /_8R8$_V\F!?][+PO_@CD1_X9!
M&/^'22#_A5$H^()9,/)]8#CM=VI Z')U1^1N?TWA:8A2W6:15]ECF5K58*%=
MTE^H8,]=L6+-7+MCRUS'9,E<VV7%7>MEOUWR9KA?\6>S8/%GKV'Q9ZYB\6>N
M8O%GKF+Q9ZYB\6>N8O%GKF+Q9_]=) /_9B0$_W(D!?]^+@K_AS<0_XL_%O^,
M1QWYBT\E\HA6+>R#73;F?F<^X'AQ1MMS>TW5;H-3T&J,6,QGE%W)99Q@QF.C
M8\-AK&7!8+5GOU_!:+U?T&FZ8.9IM6'O:J]B[VJK8^]JIV3O::9E\&FF9?!I
MIF7P::9E\&FF9?!IIF7P:?]>(P/_:2($_W8C!/^"+ G_BS8._X\^%/V111OT
MD4PB[8Y3*N:*6C+?A64[UWYM1=!X=DW+=']4QG"'6L)LCUZ_:9=BNV>?9;AE
MIVBV9+!JLV.[:[%CRFRO8^%LJV3M;:9F[6RC9^ULH&CN:Y]H[FN?:.YKGVCN
M:Y]H[FN?:.YKGVCN:_]?(P/_:R #_WDB!/^%*PC_CC0,_Y,\$OB60QCOEDH>
MYY50)N"16"[7BF$ZSH1J1<A^<TW">7M5OG6#6[EQBV"U;I)DLFR:9Z]JHVJL
M:*QLJ6>V;J=GQ&^E9]IOHFCK;YYI[&^;:NQNF6OM;9AK[6V8:^UMF&OM;9AK
M[6V8:^UMF&OM;?]?(P/_;AX#_WLA!/^(*@?_D3(+_Y<Z#_2:017KFT<:XYM-
M(=J652W/CUXYR(EG1,&#;TV[?G=5MGE_6[%VAV"M<X]EJ7"6:*9NGVRC;*AN
MH&NR<)UKP'&<:])RFFSI<9=MZG"4;>MPDF[L;Y)N[&Z2;NQNDF[L;I)N[&Z2
M;NQNDF[L;O]A(0/_<!T#_WX@ _^+*0;_E3$)^YLX#?">/A'GH$06WZ!*'=.:
M4BO*DUPXPHUD0[N';4VT@G14KWY\6ZIZA&&F=XMEHG23:9YRFVV:<*1PEV^O
M<I5OO'.3;\USDG#F<Y!PZ7*.<>IQC7'K<(QQZW",<>MPC''K<(QQZW",<>MP
MC''K</]C( /_<AL#_X ? _^.)P7_ER\(^)XV"^VB.P[DI4 2VJ1&',Z>42K%
MEUHWO9%B0K6,:DROAW)4J8)Y6Z1_@&"??(AEFWF0:I=WF&V3=:%PD'.L<XUS
MN'2+<\EUBG3B=(ETZ'.(=>ERAW7J<8=UZG"'=>IPAW7J<(=UZG"'=>IPAW7J
M</]E'P/_=!H"_X,> O^0)@3_FBT&]*$T">FF-PO@JCT.U*=$&\FA3RG FU@V
MN)5@0K"0:$NIBV]3HX=V6IZ#?F"9@(5EE'V-:I![EFZ,>9]QB7BI<X9WM76$
M=\5V@WC?=8-XZ'2">.ES@GCJ<8)XZG&">.IQ@GCJ<8)XZG&">.IQ@GCJ<?]G
M'0/_=QD"_X4< O^3) /_G2L%\:0P!N:J,PC<KC<,SZI#&L6E3BB\GU<ULYE?
M0:N49DJDD&U3GHMT6IB(>V"3A8-ECH*+:HJ DVZ&?IQQ@GVG=']\LW5]?,-V
M?'W;=GQ]Z'1]?.AS?7SI<GU\ZG%]?.IQ?7SJ<7U\ZG%]?.IQ?7SJ<?]I' +_
M>1@"_X<; O^5(P/[H"D$[J@L!..O+P77LC0+RZU!&<&H3">WHU4TKYU=0*>9
M9$F?E&M2F9!R69.->5^.BH!DB8>(:82%D6V @YIQ?(*D='F!L79W@<!V=H'6
M=G:!YW1W@>AS>(#I<GA_ZG%X?^IQ>'_J<7A_ZG%X?^IQ>'_J<?]K&P+_>Q<"
M_XH: ?^8(0+XHR8#ZJPG ]^T*0/2M3(*Q[! &+RL2R:SIU,SJJ);/J*=8TB:
MF6E1E)5P6(Z2=UZ(CWYD@XV&:7Z*CFUZB9AQ=H>B<W.&KG5QAKUV;X?2=G"'
MZ'1QA>AS<H3I<G.$ZG%SA.IQ<X3J<7.$ZG%SA.IQ<X3J<?]M&0+_?A8!_XT8
M ?^;'@'TIR("YK @ =JZ(0'-N#$)PK0^%[BP222NJU(QI:9:/9VB84>5GFA/
MCIMN5XB8=5V"E7QC?9.$:'B0C&QTCY5P<(V@<FV,K'1JC+MU:8W.=6F-Z'1K
MB^ES;8GJ<6V(ZG%MB.IQ;8CJ<6V(ZG%MB.IQ;8CJ<?]P%P+_@14!_Y 6 ?^>
M&@'PJQL!XK86 -.]'0'(NR\(O;@\%;.T1R.IL% PH*M8.YBH7T60I&9.B:%L
M58*><UM]G'IA=YF!9G*7BFINEI-N:I2><6:4JG-DD[AS8Y3+<V.4YG)EDNIQ
M9X_J<&>.ZG!GCNIP9X[J<&>.ZG!GCNIP9X[J</]S%0+_A1,!_Y04 /RC%0#J
ML!( V;X, ,W!&P'"P"T'N+TZ$ZZY1B&DM4\MFK%6.9*N7D.*JV1,@ZAJ4WRE
M<5EVHWA?<:%_8VR?AVAHGI%K9)V<;F"<J'!>G+9Q79S)<5V<Y'!>FNMP8);K
M;V&5[&]AE>QO897L;V&5[&]AE>QO897L;_]W$@'_B1$!_YD1 /.H#@#7M0H
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M1$#G^$- Y_A#0.?X0T#G^$- Y_A#0.?X0\VC  "]K@$ L+@! *3$ @"9T 4
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M]&.$<O1CA'+T8_]C&@+_<14!_W\8 ?^*' '\E"$"[IPG N.B+ /8I#((S)]
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M9F&0X69AD/)E8X[S9&2,]&-DC/1C9(ST8V2,]&-DC/1C9(ST8_]Q$ '_@@\
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M54JS_E9*L_Y62K/^5DJS_E9*L_Y62K/^5OJ' @#6F   R:4# +VO P"SN $
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M7'%ZXEQQ>_-:<7O[67)Z_%AR>OQ8<GK\6')Z_%AR>OQ8<GK\6/]G$0'_=0\
M_X,. /2.#0#;F0H U*$+ ,RD%0#"I"<#N*(V"K">0A6GFDP?H)=4*9F37#&3
MD&,XC8UJ/XB*<42#B'A)?H9_37J$B%%V@I%5<X&;6&^ IEIM?[1<:W_%7&N
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M5EN1_E5;D/Y56Y#^55N0_E5;D/Y56Y#^5?]S"0#UA 0 V)$# ,R<!0##I04
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M0T.\_T-#O/]#0[S_0]:-  #&FP  N*4  *VN  "BM@  F+\" (W(!@"#T0L
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M430%_U(^"/]22@W_4%42_TUA%_]*;1O_2'@?_T6#(O]#C23_0I4F_T&=)_]
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M#]QO4Q?4:UX?SF9G)LIC<2O&8'DPPEZ!-+]<B3>]6I$ZNEF8/+A8H#ZV5ZA
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M3X!JXT^ :_1.?VO_3']K_TM_:_]+?VO_2W]K_TM_:_]+?VO_2_]>$ '_:PX
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M3FE\_TUJ>_],:GO_3&I[_TQJ>_],:GO_3/]F"@#_=0@ X8$" -2+!0#+DP8
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M1U&6_T=1EO]'49;_1_9W  #8A0  R9$  +^; 0"TH@  JZ@  *&P  ":LA$
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M#RKVJQ I]KP0*/;.$2?WYA$G]?$1)_7Q$2?U\1$G]?$1)_7Q$:.H  "6L@
MB+L  'O%  !OS@  8M<  %;>  !.\ < 2OH0 $;[&0!"^R(!/_PJ 3O],@(X
M_3D"-?X_ S+^1@,P_TP$+O]3!2O_6@4I_V(&)_]K!B3_=@<C_X(((?^0""#_
MG0D?_ZL)'O^Z"1W_R0D<_]T)'/_="1S_W0D<_]T)'/_="9BP  "*N@  ?,0
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M/Y1:Y3^26_4^D5O_/I!<_SV07/\\CUS_/(]<_SR/7/\\CUS_//]5$0#_7PT
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M0G9K_T%V;/] =FS_0'9L_T!V;/] =FS_0/]="@#_:0< ['0# -I\! #0@P8
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M0&%]_T!A??] 87W_0/]G  #C=   TG\  ,>( 0"^CP( MI4! *Z8!@"FFA4
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M(#O#O"$ZP]4A.\+N(3G ^2(XO_\D.+__)#B__R0XO_\D.+__)+V1  "PFP
MI*(  )BJ  ",L0  @+D  '6_  !JQ@0 7LP( %G/$@!7T"$ 5= N 5'0.0).
MT$,$2]!,!DG04PA&T%L+0]!C#4'0:P\^T'41/-& $SK1C!0XT9H6-M&I%S71
MNQ<TTM(7-=#L%C3/]Q@SSO\:,\[_&C/._QHSSO\:,\[_&K.9  "FH0  FJD
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M!!;_R 06_^ $%O_D!!;_Y 06_^0$%O_D!).N  "%MP  >,   &K)  !=T@
M4-D  $3?   ZY   -?<# #+_#  N_Q( *_\: "C_(0 F_R< (_\M "#_,P >
M_SD!'/\_ 1G_10$7_TT!%?]5 1/_7P$1_VH"$/]X @[_AP(._Y8"#?^D @S_
ML (,_[X"#/_" @S_P@(,_\("#/_" H>V  !YOP  :\D  %[3  !0VP  0^
M #CE   O\   *_\  "?_"  D_PX (?\3 ![_&0 ;_QX &/\C !7_*  3_RT
M$?\R !#_.  ._S\ #/]& 0K_3P$'_UD!!/]E 0'_<@$ _X$! /^/ 0#_FP$
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M*:Y*ZBJK2O@KJ4K_*ZA+_RNG2_\KITO_*Z=+_RNG2_\KITO_*_])$@#_4 X
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M-85<_S2$7/\SA%S_,X1<_S.$7/\SA%S_,_]3"@#_708 ]68$ -]M P#5<@8
MT'4) ,EV$0# =R( N'8Q [%T/@>K<4D.IFY2%*%L6QF=:6(=F6=J(I9F<263
M9'@HD&-_*XUAARZ*8) PB%^9,X5?HS6#7J\V@5Z^.(!>T3A_7^HW?E_Z-GY@
M_S5^8/\T?F#_-'Y@_S1^8/\T?F#_-/]5" #_8 0 Z&D  -IP P#0=04 RG@'
M ,-Z#P"[>Q\ LWHO JQX/ >F=48-H7-0$YQP6!B7;F =DVMG(9!J;B6-:'4H
MBF=\*X=FA"Z$9(TQ@6.6-']CH39\8JTW>F*[.7EBSCEX8^@X>&/X-WAD_S9X
M9/\U>&3_-7AD_S5X9/\U>&3_-?]7!0#_8@$ X6P  -1S @#+> 0 Q7L% +Y]
M#0"V?AT KWXL JA\.0:A>40,G'=.$I=T5AB2<ET<CG!D((IN:R2';'(HA&MZ
M*X%J@BY^:8HQ>VB4-'AGGS9V9JHX=&:Y.7-FRSIR9N8Y<F?W.')G_S=R:/\V
M<FC_-7)H_S5R:/\U<FC_-?]9 @#V90  W6X  ,]V 0#'>P, P'\$ +F # "Q
M@AH JH(J J. -P6=?4(+EWM+$9)X5!>-=EL;B71B((5R:22!<7 G?F]W*WMN
M?RYX;8@Q=FR2-'-KG#9P:J@X;FJW.FUJR3IL:N0Z;6OU.&UK_S=M:_\V;6O_
M-FUK_S9M:_\V;6O_-O];  #K9P  V7$  ,QY  ##?@( NX(# +2$"0"MA1@
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M+4>9NBU&FM M1ICK+4:7^2Y&EO\N1I;_+D:6_RY&EO\N1I;_+M%W  #!A
MMHX  *J5  "@FP  E9\  (JD  !]J0  =ZL0 '.K'@!OK"P!:JLW!&6K00=A
MJDD+7:E1#UJI6!-7J%\64Z=F&5"G;AQ-IG8?2J6!(4BEC"1%I9DF0Z2H)T*D
MN"A!I,XG0:/J)T"B^"A H?\I0*#_*4"@_RE H/\I0*#_*<E^  "ZBP  KY0
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M#B_)]0\NR/T1+L?_$B['_Q(NQ_\2+L?_$JZ7  "AG@  E:4  (FM  !\M
M<+L  &3!  !9Q@  3LL# $70"  ^U0X /=4: #S6)@ [US$ .=@[ #C910$V
MV4T!-=E6 C/:7@(QVF@#,-MS!"[;?P4LVXT%*MR=!BG<K08HW<$&*-W>!B?;
M[P<FV?D()MC^"2;8_@DFV/X))MC^":2=  "8I0  BZT  'ZT  !QO   9<,
M %G)  !-S0  0],! #K9!@ UY T ,^06 #'D(  PY2H +N8S "WF/  KYT0
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M 0/_QP$#_\<! __' 8.T  !UO0  9\8  %K/  !+U0  /]P  #/A   IY0
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M$<TW\1/*-_L5R#?_%L8W_Q?%-_\8Q#?_&,0W_QC$-_\8Q#?_&/\[%P#_0!,
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M)9E+_R292_\DF$O_))A+_R282_\DF$O_)/](# #_3P@ _U8( /5;"0#I7@H
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M*GI<_RIZ7/\J>ES_*O]1  #R6P  WF0  ,]J  #';@( P' $ +IP# "R<1H
MJW$I :5P-P.?;D('FFQ+#)9J5!&2:%P5CF9C&(ME:1N(8W >A6)X(8)A?R2
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M  #8:0  QW(  +QY  "S?P  JX(  *&"  "9@PX E(0= (Z$*P&(@S8$@X)
M"'Z 20QY?U$0=7U8%')\7QAN>V4;:WIL'FAY=")E>'TE8G>')V!VDBI==9XL
M6W6K+EITNR]9==$O673L+EET^BU:=/\L6G3_*UIT_RM:=/\K6G3_*^9A  #1
M;0  PW8  +E]  "O@P  IH8  )R&  "4B P CHD9 (F)* &#B30#?H<^!WF&
M1PMTA4\/<(16$VV"71=I@6,:9H!J'6-_<B!@?GHC77V$)EI\CRE8>YPK5GNI
M+%1[N2U3>\XM5'KJ+51Z^2Q4>?\K57G_*E5Y_RI5>?\J57G_*N%E  #,<0
MOWH  +2"  "KAP  H8H  )6+  "-C0D AXX6 (*/) %]CS$">(X[!7.-1 EO
MC$P-:XI4$6>)6A5DB&$888=H&UZ&<!Y;A7@A6(2")%6$C292@YHI4(*G*D^"
MMRM.@LPK3H+H*TZ!^"I/@/\J3X#_*4^ _RE/@/\I3X#_*=MJ  #'=0  NG\
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M'3V=]!X]G/\?/)O_'SR;_R \F_\@/)O_(,)\  "UB   J9   )Z6  "3FP
MAY\  'ND  !OJ   8ZP$ %^M$0!<K1\ 6JXK %>N-@%4KD #4:U(!4ZM3P=+
MK5<)2:U>"T:L9@U$K&X/0:QX$3^KA!,\JY$5.JN@%CFKL!<XJ\,7.*KA%S>I
M\Q@WI_X9-J;_&C:F_QHVIO\:-J;_&KJ$  "NCP  HI8  )>;  "+H0  ?Z8
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M!!_1_P0?T?\$']'_!)^;  "4H@  AZD  'FQ  !MN   8+X  %3#  !)QP
M/LL  #70 0 MU08 )=L+ "3>$@ CWAP (M\E "'@+@ @X#< '^%  ![A2@ =
MXE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6YJP!%>;  13GW0$3Y>\!$^/Z 1/C
M^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8  $C*   ]SP  ,],
M "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT %.\U !/P/0 1\$8
M$/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )]MD "/7M  CU[0 (
M]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2   QV   )]T  !_A
M   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI  K^,  (_S@ !O]!
M  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L  /_.  #_SP  _\\
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M ^P=[@/I'OD$Z![_!>8>_P;E'O\&Y1[_!^4>_P?E'O\'Y1[_!_\K'P#_+1P
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M$;4V_Q*T-O\3LS;_$[,V_Q.S-O\3LS;_$_\Y$ #_/0L _T,- /]'$ #_2!0
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M'8I+_QV*2_\=BDO_'?]%  #_30  Y50  -E9  #/6P, REL& ,1:#P"[6QX
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M)6!FN29?9LTF7V;H)F!F^21@9O\C8&;_(V%F_R)A9O\B86;_(NA8  #38P
MQ&L  +EQ  "P=0  IW<  )YU  "6=@T D'<9 (MX)P"&=S,"@78]!'QU1@=X
M<TX+=7)5#G%Q7!%N<&,4:V]J%FEN<1EF;GH<8VV#'F%LCB%?:YHC76NG)5MK
MMR9::\HF6FOG)5MK]R1;:O\C7&K_(EQJ_R)<:O\B7&K_(N-;  #.9@  P&X
M +9T  "L>0  HWL  )AY  "0>@L BGL6 (5\) "!?#$!?'L[!'=Z1 9S>4P*
M<'A3#6QW6A!I=F$39W5H%F1T;QAA<W@;7G*!'5QQC"!:<9@B6'"F)%9PM255
M<,@E57#E)55P]B16;_\C5F__(E=O_R)7;_\B5V__(M]?  #*:0  O'(  +)X
M  "I?0  GW\  ))^  "*?P< A( 3 ("!(0![@2X!=X Y W* 0@5N?TH(:WY1
M"VA]6 YD?%\18GMF%%]Z;1=<>74967A_'%=XBAY4=Y8A4G:D(E%VLR-0=L8D
M4';C(U!U]2-1=?\B473_(5%T_R%1=/\A473_(=AC  #%;0  N'8  *Y]  "E
M@@  FH,  (V#  "$A , ?840 'F&'@!UARL!<8<V FV&/P1IA4<'981/"F*#
M5@U?@UP/7()C$EJ!:Q57@',85']]&E%_B!Q/?I0?37ZB($M]L2%*?<0B2GWA
M(4M\]"%+>_\@2WO_($M[_R!+>_\@2WO_(-!G  # <@  M'L  *J"  "@A@
ME8@  (>(  !\B@  =HP. '*-&@!NCB< :HXR 6:-/ -CC40%8(Q,"%R+4PI:
MBUH-5XIA$%2):!)1B'$53XAZ%TR'A1I*AI(<2(:@'4:&KQY%A<(>187?'D6$
M\AY%@_X>18+_'D6"_QY%@O\>18+_'LIM  "Z>   KX$  *6'  ":BP  CXT
M (&.  !TD0  ;I,* &F4%0!FE2( 8Y4N 6"5. )<E4$$691)!E:44 A4DU<*
M49->#$Z29@],DFX129%X%$:0@Q9$D) 80H^>&4"/K1H_C\ :/X_<&C^-\1H_
MC/T;/XO_&S^+_QL_B_\;/XO_&\)S  "U?@  JH<  )^,  "4D   B),  'N5
M  !LF0  99L$ &"<$ !=G1T 6YXI %B>- %5GCT"4IU% U"=305-G50'2YQ;
M"4B<8PM&G&L-0YMU#T&;@!$^FHT3/)J;%#J:JQ4YFKT5.9K9%3F8[Q8YE_P6
M.);_%SB5_Q<XE?\7.)7_%[MZ  "OA0  I(P  )B1  "-E0  @9H  '6=  !H
MH   6Z0  %:E# !3IA< 4:<C $^G+P!,IS@!2J=! 4BG20)&IU $0Z=8!4&G
M7P8_IF@(/:9R"CJF?0LXIHH--J69#C2EJ0\SI;L/,Z74#S.D[@\RHOL0,J'_
M$3*A_Q$RH?\1,J'_$;2"  "HC   G9(  )*7  "&G   >:$  &VE  !AJ0
M5:P  $NO!0!'L!  1; < $2Q)P!"L3( 0;([ #^R0P$]LDL!.[)3 CFR6P,W
MLF0$-;)N!3.R>08QLH<'+[&6""ZRI@@MLK@)+++0""RP[ DKK_D**Z[_"RJM
M_PLJK?\+*JW_"ZV+  "@D@  E9@  (F=  !]HP  <:@  &2M  !9L0  3;0
M $*X   [N@H .+L3 #>\'@ UO"D -+TR #.].P RO40 ,;Y, "^^50$NOEX!
M++YH 2J^= (IOH(")[^1 R:_H@,DO[0#([_+ R.^Z ,CO/<$(KO_!2*[_P4B
MN_\%(KO_!:22  "8F   C)X  ("E  !SJP  9[   %NU  !/N0  1+P  #K
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M )*?  "%IP  =ZX  &JU  !=O   4,$  $3%   XR0  +LT  "71   >U0
M%MH! !'>!@ 0YPT #N<2  WH&0 ,Z"$ "^DI  KJ,0 )ZCL !^M%  7K40 $
MZUX  ^MN  'K@   ZI0  .JG  #KO   Z](  .OI  #L[P  [.\  .SO (>G
M  !YKP  :[<  %Z^  !1Q0  0\D  #?-   MT0  (]8  !O;   3WP  #N,
M  SN @ *]@H !_8.  7V$@ #]A@  /4>  #U)0  ]2X  /4W  #V0@  ]DX
M /9=  #V;@  ]H$  /:5  #WIP  ][<  /C'  #XT   ^-   /C0 'NO  !M
MN   8,   %+(  !$S0  -]$  "O7   AW   &.   !'D   ,YP  !^\   3Z
M   !_P,  /\(  #_#0  _A   /X4  #_&@  _R$  /\I  #_,P  _SX  /]+
M  #_6P  _VP  /^   #_D@  _Z$  /^M  #_LP  _[,  /^S /\<)@#_'"0
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M M4<_P/4'/\#TQS_!-(<_P32'/\$TAS_!/\I%P#_*A, _RD2 /\L& #_+"$
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M#J(W_PZB-_\.HC?_#O\W!P#_.P( _T # /)"!0#I0@D Y3\. -@^%@#.0"<
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M&VQ6N!QK5LL=:E;F'&I7]QMJ5_\::E?_&6M7_QEK5_\9:U?_&>M,  #85@
MR%X  +QB  "S90  JV4  *-B  "<8@X EF,< )%D*0",8S4!B&(_ X1A2 6
M8% '?5]7"7I>70MW760-=5QK$'-<<A)P6WL4;EN$%VQ:CQAJ6IH::%JG'&9:
MMAUE6L@=95KD'65:]AQE6O\;95K_&F5:_QEE6O\995K_&>A/  #360  Q&$
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M'59F\QQ79O\;5V;_&E=F_QI79O\:5V;_&MM9  #'8@  NFH  *]P  "F<P
MFG,  (]P  "'<04 @7(1 'QS'@!X<RH =',U 7!S/P-M<D<%:G%.!V=Q50ED
M<%P+8F]C#E]O:A!=;G(26FU\%5AMAA=6;),95&R@&U)KKQQ1:\$<46O<'%%K
M\1M2:_X:4FK_&E)J_QE2:O\94FK_&=1<  ##9@  MFX  *QT  "B=P  EG8
M (EU  "!=@$ >G</ '9X&P!R>2< ;WDR 6MX/ )H>$0$97=,!F)W4PA?=EH*
M775A#%IU: ]8=' 157-Y$U-SA!91<I 83W*>&4UQK1I,<;\;2W'9&TQQ\!I,
M</T:37#_&4UO_QE-;_\936__&<Y@  "^:@  LG(  *AX  "=>P  D'H  (1Z
M  !Z>P  ='P, &]^%P!L?B0 :7\O 69_.0)B?T(#7WY)!5U]4 =:?5<)5WQ>
M"U5\90U2>VX/4'IW$DYZ@A1+>8X627F<%TAXJQA&>+T91GC5&49W[QA'=OP8
M1W;_&$=U_Q='=?\71W7_%\EE  "Z;P  KG<  *1]  "8?P  BW\  'Y_  !S
M@0  ;(,) &B$$P!EA2  8H8L %^&-@%<AC\"685& U>%3@54A54'4H1<"4^#
M8PM-@VL-2X)T#TB"?Q%&@8P31(&:%4* J19!@+H60(#2%D%_[19!?OL607W_
M%D%]_Q9!??\607W_%L)J  "U=0  JGT  )^"  "2@P  A80  'F%  !JB0
M9(H# &",$ !=C1L 6XXG %B.,@!5CCL!4XY# E".2@-.C5(%3(U9!DF,8 A'
MC&@*18MR#$*+?0Y BHD//HJ8$3R*IQ([BK@2.HK/$CN(ZQ([A_H3.X;_$SN&
M_Q,[AO\3.X;_$[QQ  "O>P  I8,  )F'  ",B   ?XD  '.,  !ED   7),
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M!:>)  ";CP  D90  (29  !XG@  :Z(  %^F  !3J@  2*T  #VP   TLP,
M+[4. "VU%@ LM2  *[8I "JV,@ IMSH *+=# ">W3  FN%4 )+A? ".X:P B
MN'@!(+B( 1^XF0$=N:L!'+G  1RXWP$<MO(!&[7\ ANT_P(;M/\"&[3_ I^/
M  "4E0  B)L  'NA  !NI@  8JL  %:P  !*LP  /[8  #6Y   LO   )+\&
M !_"#0 =PA0 ',(> !O#)@ :PR\ &<0X !C$00 7Q$H %L55 !7%80 4QF\
M$\9_ !+&D0 1QZ0 $,>Y  _'U  0QNX $,3Z !##_P 0P_\ $,/_ )>6  "+
MG   ?J(  '&I  !DKP  6+0  $NX  ! NP  -;X  "O!   CQ0  &\D! !3,
M!@ 0T L #M$1  W1&0 -T2$ #-$J  S1-  +TCX "M))  G350 )TV( "--R
M  ;4A  %U)@ !-2K  /5P  !U=P  =7M  '5]@ !U?8  =7V (Z=  " I
M<ZL  &:Q  !9N   3+T  #_    TPP  *L<  "'*   9S@  $M(   W6 0 )
MVP4 !MP-  3<$0 #W1@  =X@  #>*   WS$  . \  #A1P  XE0  .-C  #C
M=   Y(@  .2;  #EK@  Y<$  .75  #FYP  YN<  .;G (.D  !UK   :+,
M %J[  !-P0  0,0  #/(   HS   ']   !?4   0V0  "]T   7A    Y
M .4'  #F#0  YQ$  .@6  #I'0  ZB4  .LN  #M.0  [T4  /!3  #Q9
M\78  /**  #SG   \ZT  /2[  #TR   ],@  /3( '>M  !JM0  7+T  $_$
M  ! R0  ,\T  "?1   =U@  %-P   [@   (XP   >8   #J    [@   .X
M  #O!   \ H  /$.  #S$@  ]!@  /8@  #X*@  ^C4  /U#  #^4@  _V,
M /]V  #_B0  _YH  /^F  #_L   _[   /^P /\6(P#_%2$ _Q$A /\-) #_
M"2L _P8W /\#1 #_ %$ _P!= /\ : #_ '( _P![ /\ @P#_ (H _P"1 /\
ME@#_ )P _P"A /T I@#[ *P ^0"S /< NP#U ,4 \P#1 /( Y #Q /$ [P#Z
M .X _P#N /\ [0#_ .T _P#M /\ [0#_ /\9( #_&!T _Q4= /\0'P#_#BD
M_PPT /\*00#_!TT _P59 /\$9 #_!&X _P-W /\#@ #_ X< _P.- /T"DP#[
M ID ^0*> /<"I #U JH \P&P /$!N #O <( [0'/ .L!XP#J >\ Z +[ .<$
M_P#F!?\ Y@;_ .8&_P#F!O\ Y@;_ /\<&P#_&QD _Q<8 /\5'0#_$R4 _Q$P
M /\0/0#_#DD _PQ5 /\+8 #_"VH _0MS /L+? #Y"H, ]PJ* /4*D #T"I8
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M L ;_P+ &_\"P!O_ O\F#@#_)0L _R@, /\I$ #_*!8 _B8@ /0D*P#L(3@
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M$'Q%N1%[1<L1>D7F$7E&]Q%X1O\0>$;_$'A&_P]X1O\/>$;_#_ _  #?20
MS4\  ,%3  "X5   L5(  *M.!0"D3A$ GD\@ )E0+0"54#D!DD]# 8Y.3 .+
M35,$B4U:!89,80:$2V@(@DMN"8!*=@M^2GX,?$F'#GI)D0]X29P0=DFH$G1)
MMA)S2<@3<DKC$W%*]1)Q2O\1<4O_$7%+_Q!Q2_\0<4O_$.Q#  #93   R%,
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M%F!6\15@5OX48%;_$V%6_Q)A5O\285;_$N!-  #+5@  O5T  +)A  "H8P
MG6$  )5=  "-7@D AUX3 (-?( !_7RP >U\W 7=>0 )T7D@#<5U/!&]<5@5L
M7%P':EMC"6A;:PMF6G,-9%I\#V):AQ%@69,27EF@%%U9KA5;6;\66UG8%EM9
M[Q5;6?T47%G_$UQ9_Q)<6?\27%G_$MQ0  #'60  NF   *]D  "D90  F60
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M$DYE_Q).9?\23F7_$LQ:  "\8P  L&H  *5O  "8;@  C&T  (!L  !W;0
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M#+9O  "J>   GW\  )!^  "#?P  =X   &N"  !>AP  58H  $Z,!@!*CA
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M 2*EE@$@IJ@!'Z6[ 1ZEUP$>I.\!'J+[ AZA_P(>H?\"'J'_ J*&  "7C
MBX\  'V1  !OE   8Y@  %>=  !-H0  0Z4  #BH   PJP  **X' "2O$  C
MKQ< (:\A ""P*0 ?L#$ 'K Z !VQ0@ <L4P &[%6 !JQ80 9LF\ &+)^ !:R
MD  5LJ( %+*V !.RS@ 3L>L $Z_Y !.N_P$3KO\!$Z[_ 9J-  "0D@  A)<
M '6:  !HGP  6Z,  %"H  !%K   .[   #&R   GM0  (+@  !BZ!P 4O X
M$[P5 !*\'@ 1O28 $;TN !"]-P 0OD$ #KY,  Z^5P -OF4 #+]T  N_A@ *
MOID "+ZL  >^P@ 'OM\ "+[P  B]^@ (O?P "+W\ ).4  "'F0  >I\  &RE
M  !@J@  4Z\  $>S   \M@  ,;@  ">[   ?O@  %\$  !'$ 0 ,R @ ",D.
M  ?)%  &R1P !<DD  3*+  #RC8  LI   #+3   RUD  ,MH  #+>0  S(P
M ,N?  #+LP  R\@  ,SB  #,[P  S/$  ,SQ (J:  !\H0  ;Z<  &*M  !5
MLP  2+@  #N[   PO@  )L$  !W$   5R   #\L   K.   $T@(  -,*  #3
M#P  U!0  -4:  #6(@  URH  -DT  #:/P  W$L  -Q:  #=:@  W7T  -V1
M  #=I   WK8  -[(  #>W@  WN(  -[B '^B  !QJ0  9+   %:W  !)O
M/,   "_$   DQP  &\L  !//   -T@  !]8   #;    W@   -\#  #@"0
MX0X  .(2  #C%P  Y1X  .8G  #H,0  ZCT  .Q+  #L6@  [6P  .Z   #N
ME   [J4  .ZT  #NP@  [L8  .[& '2J  !FL@  6+D  $O    ]Q0  +\D
M "3-   9T0  $=8   O;   #W@   .$   #E    Z    .D   #J    ZP8
M .T+  #O#P  \!,  /(:  #T(P  ]RX  /D[  #[2@  _%L  /UM  #]@
M_I,  /ZB  #^K0  _J\  /ZO /\0'P#_#AT _PH= /\!( #_ "@ _P U /\
M00#_ $X _P!: /\ 90#_ &X _P!W /\ ?P#^ (8 _ ", /L D@#Y )< ^ "<
M /< H@#V *< ]0"M /, M0#R +T \0#) .\ W #N .L [0#W .P _P#K /\
MZ@#_ .H _P#J /\ Z@#_ /\3' #_$1D _PT9 /\&' #_ R4 _P Q /\ /@#_
M $H _P!6 /\ 80#_ &L _0!S /H >P#W (, ]0") /0 CP#R )0 \0"9 /
MGP#N *0 [0"K .P L@#J +H Z #& .< U@#E .@ Y #U ., _@#B /\ X0#_
M .$ _P#A /\ X0#_ /\5& #_$Q0 _P\4 /\-&0#_"R( _P@M /\$.0#_ 48
M_P!1 /X 7 #Z &8 ]@!O /( =P#O 'X [0"% .L BP#J )$ Z "6 .< G #F
M *$ Y "H ., KP#A +@ WP## -T T0#; .8 V0#S -< _0#5 O\ U +_ -0#
M_P#4 _\ U /_ /\8$P#_%1  _Q(/ /\2%0#_$1T _PXH /\,- #_"D$ ^0A,
M /4&5P#Q!F$ [09J .D%<@#F!7H Y 6! .(%AP#@!HT WP:2 -T&F #;!IX
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M ?\B! #_(@  _R4" /PD!P#W(0P [!T2 .$:' #8&BH T!LX ,L=10#''5
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M!)4OO023+\\$D3#H!8\P^ 6-,?\%C3'_!8PQ_P6,,?\%C#'_!?\M  #J-0
MW#H  ,X]  #&/   P#<" +LS#0"S-!D KC8G *DW- "E-T  HC=* )\W4P&=
M-EH!FS9A 9DV: *7-6\"E35U Y0U? .2-80$D#6-!(\UE@6--: %BS6K!HHU
MN0:(-<H'AS;E!X4V]@>$-_\'@S?_!X,W_P>"-_\'@C?_!_0R  #C.P  TD$
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M#6Q%[PQK1?T+:T;_"VM&_PIK1O\*:T;_"N5   #/20  P4\  +52  "K4@
MH4\  )M*  "42@P CTL7 (M,) "'3"\ A$PZ (%,0P%^2TL!>TM2 GE*6 -W
M2E\$=4EF!7-);09Q274';TE^"&U(B EK2),+:DB?#&A(K0UG2;T-9DG4#F5)
M[0UE2OP,94K_"V5*_PME2O\+94K_"^!$  #+30  O5(  +)6  "F50  G%(
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M#5=4_PQ75/\,5U3_#-%-  # 5@  LUP  *=>  ":70  CUP  (98  !_60
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M"[]<  "Q9   IFH  )9I  "):0  ?6D  '%I  !G:@  8FP! %UM#0!9;A8
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M!#)_F@4Q?JH&,'Z]!C!^V@8P?? &,'O]!C![_P8P>O\&,'K_!K!L  "D=0
ME'4  (9U  !Y=@  ;G<  &-Y  !7?0  3X$  $>$  !"A@P /X<3 #V('0 \
MB"< .XDP #J).  XB4  -XE( #:)3P TB5@!,XEA 3&); $OB7@"+8F' BR)
MEP,JB*<#*8BZ RF(U ,IANX#*87\!"F$_P0IA/\$*83_!*IT  ">>P  CGH
M (!Z  !T>P  :'X  %V!  !2A0  28D  $&,   YD 4 -9$/ #.2%P RDB$
M,9(I #"3,@ NDSH +9-! "R32@ KE%( *I1< "B49P GE',!)92" 224DP$B
MDZ0!(9.W 2"3SP$ADNP!()#Z B"/_P(@C_\"((__ J1\  "7@   AW\  'N
M  !N@@  8H4  %>)  !-C@  0I(  #J6   RF0  *IP) "B=$0 FG1D )9TB
M "2>*@ CGC( (IXZ "&>0@ @GDL 'Y]5 !Z?8  <GVT &Y]\ !J?C0 8GY\
M%Y^R !:?R0 6GN@ %ISW !:;_P$7F_\!%YO_ 9V#  "/A@  @H8  '2'  !G
MBP  6X\  %"3  !&F   /)P  #.@   KHP  (Z8  !RH"P :J1$ &*D8 !>I
M(0 6JBD %:HQ !2J.0 3JD, $ZM- !*K6  1JV4 $*MT  ZKA@ .JYD #:NL
M  RKP0 ,JM\ #*GR  VH_  -J/\ #:C_ ):*  ")C   >HT  &R1  !@E0
M5)H  $F?   _HP  -:<  "NJ   CK@  &[   !2S 0 /M0H #;80  RV%@ +
MMA\ "K8G  FV+P (MCD ![=#  :W3P $MUL  [=J  *W>P  MXX  +>A  "V
MM   MLL  +;E  "U\0  M?<  +7W (^1  "!E   <I<  &6<  !8H0  3*8
M $&K   WKP  ++(  ".U   :N   $[L   Z]   )P 4  \$-  #!$0  P1<
M ,(>  #")@  PB\  ,,Y  #$1   Q%   ,1>  #%;P  Q8$  ,65  #%J
MQ;P  ,31  #$Y@  Q.X  ,3N (:8  !YG@  :Z,  %VI  !0K@  1+,  #>V
M   LN0  (KP  !F_   1P@  #,4   ;(    RP   ,P'  #,#0  S1$  ,T6
M  #.'0  SR0  - M  #2.   U$0  -12  #580  U7,  -:'  #6FP  UJT
M ->_  #8S@  V-T  -C= 'N@  !NI@  8*T  %.S  !%N   .+P  "N_   A
MP@  %\8  !#)   *S    M    #4    UP   -@   #:!0  VPL  -P.  #>
M$P  WQD  .$A  #C*@  Y38  .=#  #G4P  Z&0  .EW  #IC   ZI\  .JN
M  #JN@  ZL,  .K# '"H  !BKP  5;8  $>\   YP   +,0  "#(   6S
M#M    ?4    V0   -T   #A    XP   .0   #F    YP$  .D'  #K#
M[!   .X5  #P'0  \R<  /8S  #W0P  ^%0  /EF  #Y>@  ^HX  /J>  #[
MJ0  ^[   /NP /\+&P#_!QD _P 9 /\ ' #_ "4 _P R /\ /P#_ $L _P!7
M /\ 8@#_ &L _P!S /T >P#[ (( ^@"( /@ C0#W )( ]@"8 /4 G0#T *(
M\P"I /$ L #O +@ [@## .P T0#K .8 Z0#S .@ _@#H /\ Z #_ .@ _P#H
M /\ Z #_ /\.& #_"A4 _P$4 /\ & #_ "( _P N /\ .P#_ $< _P!3 /T
M7@#Z &< ]P!O /4 =P#S 'X \@"$ /  B0#O (\ [@"4 .P F@#K )\ Z0"E
M .@ K #F +0 Y "_ ., S #A .( WP#P -X ^P#> /\ W0#_ -T _P#< /\
MW #_ /\0$P#_#1$ _P80 /\"%0#_ !X _P I /\ -@#_ $( ^@!. /0 60#Q
M &( [@!K .P <@#J 'D Z !_ .< A0#E (L Y "0 .( E@#A )P WP"B -T
MJ0#: +$ V "[ -4 R #2 -T T0#M -  ^0#/ /\ S@#_ ,T _P#- /\ S0#_
M /\1#P#_#@T _PP- /\+$@#_!QD _P(D /\ , #V #P [P!) .H 4P#G %T
MY !F .$ ;0#? '0 W0![ -L @0#9 (8 U@", -0 D@#2 )@ T "> ,X I@#,
M *X R@"X ,@ Q #& -< Q0#J ,, ]P#" /\ P0'_ , "_P#  O\ P +_ /\4
M"P#_$ 8 _Q ) /\0#@#_#A0 _PH> /4&*0#K!#8 XP-" -\#3@#;!%< U@1@
M -,$: #0!&\ S@5V ,P%? #*!8( R06( ,<%C@#&!90 Q 6; ,(%HP# !JL
MO@:U +T&P@"["-0 N@GI +<+^ "U#/\ M S_ +0,_P"T#/\ M S_ /\7! #_
M%   _Q8# /\4"0#_$0X \@X5 .@,(0#>"BX U@L[ - ,1P#,#%$ R0Q: ,8-
M8@#$#6H P@UQ , -=P"_#7T O0Z# +P.B@"Z#I$ N0Z8 +<.H "V#JD M ^T
M +(/P0"Q$-0 KA'K *L2^@"I$O\ J!/_ *<3_P"G$_\ IQ/_ /\:  #_&P
M^1L  .L9  #E% 8 Y1 . -D.%P#/$28 R!(T ,030 "_%$L O!14 +D570"W
M%60 M15K +05<0"R%7@ L19^ *\6A0"N%HP K!:4 *L7G "I%Z8 IQBP *88
MO0"D&,\ HAKG )\:]P"=&_\!G!O_ 9P;_P&;&_\!FQO_ ?\=  #W(0  Z"0
M -TE  #4(0$ SQL( ,H7$0#"&B  O!PM +<=.@"S'D4 L!Y/ *T>5P"K'E\
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M W\P[P-],?X#?3'_ WPQ_P-\,?\#?#'_ ^TO  #;-P  R3T  +X^  "S/
MK#@  *<S! "B,A$ G30= )DU*@"5-34 DC5  (\U20"--5  BS57 (DU7@&'
M-60!A31K 80T<@*"-'D"@#2" GXTBP-]-)8#>S6A!'DUK@1X-;X%=S;4!78V
M[05T-_P%=#?_!'0W_P1T-_\$=#?_!.<U  #2/0  PT(  +A$  "L0@  I#X
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M!V!%_P9@1/\&8$3_!M9!  ##20  MDX  *=/  ";30  DDL  (Q'  "%1P0
M@$<0 'Q(&@!X2"8 =4DP '-).@!P24( ;DE) 6Q(4 %J2%8!:$A= F9(9 )E
M2&P#8TAU!&%'?P5@1XH&7DB7!UU(I0A;2+0(6TC'"5I(Y A:2?8(6DG_!UI(
M_P9:2/\&6DC_!M%%  "_3   LE(  *-1  "74   C4X  (9*  " 2@$ >DL.
M '9,%P!R3", ;TPM &U--@!J3#\ :$Q& &9,30%D3%,!8DQ: F%,80)?3&D#
M7DQR!%Q,? 5:3(@&64R5!U=,HPA63+((54S&"55,X@E53/4(54S_!U5,_P=6
M3/\&5DS_!LQ(  "\4   KU4  *!4  "34P  B5$  (%-  !Z3@  =4\, '!/
M%0!M4"  :E J &=0,P!E4#P 8U!# &%02@%?4%$!75!8 EQ07P):4&<#65!P
M!%=0>@554(8&5%"3!U)0H0A14+$)4%#$"5!0X0E04/0(45#_!U%/_P=13_\&
M44__!LE+  "Y4P  JU<  )Q6  "/50  A50  'Q0  !U40  <%() &M3$@!H
M5!T 950G &)4,0!@5#D 7E1! %Q42 %:5$\!6516 5=470)65&4#5%1N!%)4
M> 515(0&3U21!TY4H A,5*\(3%3""4M4WPE,5/,(3%/_!TQ3_P=-4_\&35/_
M!L5.  "V5@  IUH  )A9  "+6   @5<  '=4  !P50  :E8& &97$ !B5QH
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M!3]BF@8^8JH&/6*\!SQBU@<]8>\&/6']!CY@_P8^8/\&/F#_!KE9  "K80
MFF$  (MA  !_80  =&$  &EA  !?8@  660  %1F"0!19Q$ 3F<: $QH) !+
M:2T 26DV $AI/@!&:D4 16I, $-J5 %":EP!0&EE CYI;P(\:7L#.VF)!#EI
MF 4X:*@%-VBZ!3=ITP4W:.X%-V?\!3AF_P4X9O\%.&;_!;1>  "G90  E64
M (9D  !Z90  ;V4  &1F  !9:   4FH  $UL! !);@X 1VX6 $5O( !$<"D
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M 2*"R0$B@><!(G_W 2)^_P(B??\"(GW_ J5Q  "3<0  @W$  '9Q  !L<@
M8'4  %9X  !,?   0X   #N#   SA@  +8D* "J*$0 IBQD )XLB ":+*@ E
MC#$ )(PY ".,0@ BC4H (8U4 ""-7@ ?C6L '8UY !R-B@ ;C9P &8VN !B,
MQ  8C., &8KU !F)_P$9B/\!&8C_ 9UW  ",=@  ?78  ')W  !E>0  6GP
M %"   !&A   /(D  #2,   MD   )9," !^5#  =EA( ')8: !N7(@ :ERH
M&9<R !B8.@ 7F$, %IA- !686  4F&0 $YAS !&8A  0F)8 $)BI  Z8OP .
ME]T #Y;R !"5_  0E/\ $)3_ )5]  "%?   >'P  &M^  !?@0  5(8  $J*
M  ! CP  -I,  "V7   FF@  'IT  !>@ P 2H@P $*,2 !"C&0 /HR$ #J0I
M  ZD,0 -I#H #*1%  ND4  *I%P ":1J  >D>P &HXX !*.A  *CM  #HLL
M Z+F  .A\P #H?L  Z'[ (V#  !_@@  <80  &2'  !8C   39$  $*6   X
MF@  +YX  ":B   >I0  %Z@  !&K   ,K@< !Z\-  .O$@ "KQD  :\A  "O
M*0  L#(  + \  "P1P  L%,  +!A  "P<0  L(,  *^7  "OJ@  K[\  *[9
M  "NZP  KO0  *[T (>)  !XB@  :HX  %V3  !1F   19T  #NB   PI@
M)ZH  !ZN   6L0  $+0   NV   %N0,  +H*  "Z#@  NA,  +L9  "[(0
MO"@  +PQ  "]/   OD@  +Y6  "^90  OG<  +Z,  "^GP  O;,  +['  "^
MW@  O>L  +WK '^2  !PE0  8IH  %6?  !)I0  /:L  #*O   HM   'K8
M !6Y   .O   ";\   +"    Q    ,4$  #&"@  Q@X  ,<2  #(&   R1\
M ,HG  #,,   SCP  ,Y)  #/60  SVH  ,]^  #/DP  SZ8  ,^X  #/R
MS]L  ,_; '><  !HH0  6Z<  $ZN  !!M   -+<  "BZ   =O0  $\    W$
M   &QP   ,H   #.    T    -$   #2 @  TP@  -4,  #6$   V14  -L<
M  #=)   X"\  .(\  #C2P  Y%P  .1O  #E@P  Y9@  .6I  #EM@  Y<,
M .7# &RE  !?K   4;(  $2Y   UO   *,   !S$   2R   #,L   //
MTP   -@   #<    WP   -\   #A    XP   .0#  #F"   Z T  .D1  #L
M&   [B(  /$N  #S/   ]$T  /5?  #V<P  ]X<  />9  #XI0  ^+   /BP
M /\#%P#_ !4 _P 5 /\ & #_ ", _P O /\ / #_ $@ _P!4 /\ 7@#_ &<
M_0!O /L =@#Y 'T ^ "# /8 B #U (X ] "3 /( F #Q )X \ "D .X JP#M
M +, ZP"] .H RP#H .$ YP#Q .8 _0#E /\ Y #_ .0 _P#D /\ Y #_ /\'
M$P#_ !$ _P 1 /\ %0#_ !\ _P K /\ -P#_ $0 _@!/ /H 6@#W &, ] !K
M /( <@#P 'D [P!_ .T A #K (H Z@"/ .@ E #G )H Y0"@ .0 IP#B *\
MX "Y -X Q@#< -H V@#L -@ ^0#6 /\ U@#_ -< _P#8 /\ V #_ /\*$ #_
M PX _P - /\ $@#_ !H _P F /P ,@#W #\ ] !* /$ 50#M %X Z@!F .@
M;@#E '0 XP!Z .( @ #@ (4 W@"+ -P D #; )8 V "< -4 HP#3 *L T0"U
M ,X P0#, -$ RP#G ,D ]0#( /\ R #_ ,@ _P#( /\ R #_ /\,# #_!@@
M_P(* /\ #P#_ !4 _  @ /$ + #L #D Z0!% .4 3P#A %D W@!A -L : #7
M &\ U !U -( >P#0 (  S@"& ,P C #+ )( R0"8 ,< H #% *@ PP"Q ,$
MO "_ ,L O0#C +P \@"[ /T NP#_ +H _P"Z /\ N@#_ /\.!0#_"0  _PD%
M /\&"P#_ 1  \  9 .8 )0#A #( W  _ -8 20#1 %, S@!; ,L 8P#( &H
MQ@!P ,4 =@## 'L P0"! ,  AP"^ (X O "4 +L G "Y *0 MP"N +4 N0"S
M ,@ L0#? + ![P"O ?L K@+_ *T#_P"M _\ K0/_ /\0  #_#@  _PT  /8+
M P#R!PH X@$1 -L"'0#2 RL S ,W ,@$0P#$!$T P016 +X%70"\!60 N@5K
M +@%<0"W!78 M05\ +,&@P"R!HD L :1 *\'F0"M!Z$ JP>K *D(MP"H"<8
MI@K= *4+\ "C#/T H@W_ *$-_P"A#?\ H W_ /\1  #\$@  [!,  .(3  #;
M#P, U@D+ ,X(% #&"B( P PP +P-/ "X#48 M0U/ +(.5P"P#E\ K@YE *T.
M:P"K#G$ J@YX *@.?@"G#X4 I0^- *0/E@"B$)\ H!"I )\0M0"=$<4 FQ'>
M )D2\0"7$_\ EA3_ )44_P"5%/\ E!3_ /\5  #M&P  X!\  -(?  #)&P
MQ!0% ,$0#@"Z$AL M!,I + 4-0"L%4  J15) *854@"D%ED HA9@ *$69@"?
M%FP GA9R )P6>0";%X  F1>( )@7D0"6&)L E!BF ),9L@"1&<$ D!K8 (T;
M[@"+'/T BAS_ (H<_P")'/\ B1S_ /0=  #D)0  TRD  ,<J  "\)@  MB
M +09"P"N&A4 J!PC *0=+P"A'CH GAY$ )L>3 "9'E0 EQ]; )4?80"4'V<
MDA]M )$?= "/('P CB"$ (P@C0"*()< B2&B (<AK@"&(KT A2+1 8(CZP&!
M)/L!@"3_ 7\D_P%_)/\!?R3_ >PE  #;+0  R3$  +PQ  "Q+@  JRD  *<D
M!0"C(Q$ GB0= )HE*@"6)C4 DR8_ )$F1P"/)D\ C296 (LG7 "))V( B"=I
M (8G;P"%)W< @R=_ ($GB0& *),!?BB> 7TIJP%[*;D!>BG- 7@JZ %W*_D!
M=BO_ 78K_P%U*_\!=2K_ >4L  #0-   P3@  +,X  "H-0  HC$  )TM  "9
M*@X E"L8 ) L) "-+3  BBTZ (<M0P"%+4H @RU1 ($N6 " +EX ?BYD 'TN
M:P![+G,!>2Y[ 7@NA0%V+H\!="^; 7,OJ )Q+[8"<##) F\PY0)N,?<";3'_
M FTQ_P)M,?\";3'_ M\R  #).0  NSX  *P]  "A.@  FC<  )4S  "0,0H
MC#$4 (<R( "$,RL @3,U '\S/@!],T8 >S-- 'DS5 !W,UH =C-A '0S9P%R
M-&\!<31W 6\T@0%N-(P";#28 FHUI0)I-;,#:#7& V<VX@-F-O4#9C;_ F8V
M_P)F-O\"9C;_ M@W  #$/@  M4(  *9!  ";/P  DSP  (TX  "(-@< A#<1
M ( W' !\."< >C@Q '<Y.@!U.4( <SE) '$Y4 !P.5< ;CE= &PY9 %K.6L!
M:3ET 6@Y?@)F.8D"9#F5 V,ZH@-B.K$#83K# V [X 1?._,#7SO_ U\[_P-?
M._\"7SO_ M$[  # 0@  L$4  *%$  "50P  C4   (<]  "".P( ?3L. 'D\
M& !U/2, <STM ' ]-@!N/3\ ;#U& &L]30!I/5, 9SU: &8]80%D/6@!8SUQ
M 6$^>P)?/H8"7CZ3 UP^H -;/Z\$6C_!!%H_W019/_($63__ UD__P-9/_\#
M63__ \P_  "\1@  JT@  )Q'  "11@  B$0  ()   !\/P  =T , '- %0!O
M02  ;$$J &I!,P!H03L 9D)# &1"2@!C05  84%7 &!"7@%>0F4!74)N EM"
M> ):0H0#6$*0 U="G@160ZT$54._!%1#V@140_$$5$/^ U1#_P-40_\#5$/_
M \A"  "X20  ITL  )A*  "-20  @T<  'U#  !V0P  <40* &U$$@!J11T
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M TA.F01'3Z@$1D^Z!$9/T01&3^T$1D[\!$9._P-'3O\#1T[_ [U,  "N4@
MG%$  (U1  "!40  =U   &Y,  !G3@  8D\  %U0#0!:4!0 5U$> %51)P!3
M43  45(X %!2/P!.4D8 35)- $Q350!*4UT!25-E 4A3;P)&4WL"15.) T-3
MEP-"4Z<$05.X!$%3SP1!4^P$05+[ T)2_P-"4O\#0E'_ [I/  "J5   F%0
M (E4  !]4P  <U,  &E1  !B4@  7%,  %A4"@!451( 4E4; $]6) !.5BT
M3%<U $M7/ !*5T0 2%=+ $=84@!&6%H!1%AC 4-8;0%!6'D"0%B& CY8E0,]
M6*4#/%BW!#Q8S00\5^H#/%?Z SU6_P,]5O\#/5;_ [93  "E5P  E%<  (56
M  !Y5@  ;U8  &55  !<5@  5U@  %)9!P!.6A  3%H8 $I;(0!(7"H 1UPR
M $5<.@!$74$ 0UU( $)=4 ! 75@ /UUA 3U=:P$\778".EV$ CE=DP(X7:,#
M-UVU S9=RP,V7.@#-USY S=;_P,X6_\#.%K_ [)7  "@6@  CUD  (%9  !U
M60  :UD  &!:  !66P  45T  $Q> @!(8 T 16 4 $1A'@!"8B8 0&(N #]B
M-@ ^8SX /6-% #QC30 [8U4 .6-> #AC: $V8W0!-6.! 3-CD0(R8Z$",6.S
M C%CR (Q8N<",6'X C%A_P(R8/\",F#_ JY<  ";70  BET  'Q=  !P70
M9ET  %Q>  !28   3&(  $5E  !!9@H /F<1 #QH&@ [:"( .6DK #AI,@ W
M:CH -FI! #5J20 T:E( ,VI; #%J90 P:G !+FI^ 2UJC@$L:I\!*VJP 2IJ
MQ@$J:>4!*FCV BMG_P(K9_\"*V?_ JEA  "58   A&   '=@  !L80  8F$
M %AC  !.9@  1V@  $!K   Z;@4 -F\. #1P%0 S<!X ,G$F #!Q+@ O<34
M+G(] "UR10 L<DT *W)7 "IR80 I<FT )W)[ "9RBP D<IP!(W*N 2-RPP$C
M<>(!(W#T 2-O_P$C;O\!(V[_ :%E  ".9   ?V0  ')D  !H90  7F8  %1I
M  !);   0F\  #MR   T=0  +G@* "MY$0 J>1@ *7HA "=Z*  F>C  )7LX
M "1[0  C>T@ (GM2 "%[7  @>V@ 'WQV !U\A@ <>Y@ &WNJ !I[OP :>]X
M&GGR !MX_@ ;=_\!&W?_ 9EI  "(:0  >6D  &UI  !C:@  66P  $]O  !%
M<P  /7<  #5Z   N?0  )X$# "*##0 @A!( 'X0: !V$(@ <A2H &X4Q !J%
M.0 9A4( &(9, !>&5@ 6AF, %89Q !2&@0 2AI, $8:F !&%NP 0A=8 $8/O
M !&"^P 2@O\ $H'_ )%N  "!;0  =&X  &EN  !=<   4W,  $EW  ! ?
M-X   "^#   GAP  (8H  !J-!@ 5CPT $Y 3 !*0&@ 2D"( $9 J !"1,@ 0
MD3L #Y%$  Z13P -D5P #)%J  N1>@ *D8T ")"?  >0LP 'C\D !X_F  >.
M]  (C?P "(W_ (ES  ![<P  ;W,  &-U  !7>   37T  $.!   YA@  ,(H
M "B.   AD0  &I4  !.7   .F@@ "YP.  F<$P (G!H !YPB  :<*@ $G#,
M YP]  *=2   G50  )UB  "<<@  G(0  )R7  ";J@  F[\  )K;  ":[
MFO4  )GX ()Y  !V>0  :'H  %Q^  !1@@  1H<  #R,   RD0  *94  "&9
M   9G0  $J    ZC   )I@4  Z<,  "G$   IQ4  *@<  "H(P  J"L  *DT
M  "I/P  J4L  *E9  "I:   J7H  *F.  "IH0  J+4  *C+  "GY   I^\
M *?S 'V   !O@0  880  %6)  !)C@  /I0  #29   JG@  (:(  !FF   2
MJ0  #:P   >O    L@   +,'  "S#   LQ   +05  "T&P  M2(  +8K  "W
M-0  MT   +A.  "X70  N&X  +B"  "XEP  N*H  +>^  "WT@  M^8  +?J
M ':(  !GBP  6I   $Z6  !"G   -Z(  "RG   BJP  &:\  !&S   +M@
M!+D   "\    O@   +X   "_!@  P L  ,$/  #"$P  PQD  ,0@  #%*0
MQS0  ,A"  #)40  R6(  ,EU  #)B@  R9\  ,JQ  #*P0  R=$  ,G9 &Z3
M  !@F   4YX  $:D   ZJP  +[   "2U   9N   $+P   J_   !P0   ,0
M  #(    R@   ,H   #,    S0,  ,X(  #0#0  T1   -,6  #6'@  VB@
M -TT  #>0P  WU0  -]G  #@?   X)$  ."D  #@L@  X+X  .## &:?  !9
MI@  3*T  #^T   RN   )+P  !B_   0PP  ",<   #*    S0   -$   #5
M    V    -D   #;    W0   -\   #A!   XPH  .4.  #G$P  ZAP  .TG
M  #P-0  \48  /)8  #S:P  \X   /24  #THP  ]*X  /2R /\ $P#_ !$
M_P 1 /\ %0#_ !\ _P L /\ .0#_ $4 _P!0 /\ 6@#^ &, ^P!K /D <@#W
M '@ ]0!^ /0 A #R (D \0". /  DP#N )D [0"? .P I@#J *X Z "X .8
MQ0#E -L XP#M .( ^P#B /\ X0#_ .$ _P#A /\ X0#_ /\ $ #_  X _P -
M /\ $@#_ !L _P H /\ - #^ $$ ^P!, /< 5@#T %\ \0!F .\ ;0#L '0
MZ@!Z .D ?P#G (4 Y@"* .4 CP#C )4 X0"; .  H@#> *H VP"T -D P #6
M -  TP#H -( ]P#1 /\ T0#_ -  _P#0 /\ T #_ /\ #0#_  D _P * /\
M#P#_ !8 ^P B /< +P#T #L \ !' .T 40#I %H Y0!B .( :0#@ &\ W@!U
M -P >@#: (  V "% -4 BP#3 )$ T0"7 ,\ G@#- *8 RP"O ,D N@#' ,D
MQ0#B ,0 \@## /X P@#_ ,$ _P#" /\ P@#_ /\#!@#_  $ _P & /\ # #Y
M !$ \0 = .L *0#G #8 XP!! -\ 2P#; %0 U0!< -( 8P#/ &H S0!P ,L
M=0#) 'L R "  ,8 A@#% (P PP"3 ,$ F@"_ *( O0"K +L M@"Y ,0 MP#:
M +8 [0"T /H M #_ +0 _P"T /\ M #_ /\$  #_    _P   /\ !@#L  T
MY0 6 -X (@#7 "\ T0 [ ,T 10#* $X Q@!7 ,0 7@#! &0 OP!J +T < "\
M '4 N@![ +D @0"W (< M0". +, E0"R )X L "G *X L@"L +\ J@#1 *@
MZ "H /< IP#_ *< _P"F /\ I@#_ /\&  #_!0  \0,  .@   #A  < U0 0
M ,T &P#' "< PP S +\ /@"\ $@ N0!1 +8 6 "T %\ L@!E +  :@"O '
MK0!V *P ? "J (( J0") *< D0"E )H HP"D *$ K@"@ +L G@'- )T"Y@"<
M!/0 FP3_ )H%_P":!?\ F07_ /\*  #Q#@  Y!   -D/  #."P  R ,+ ,(
M$P"\ A\ MP,L +,$-P"P!4( K09* *H&4@"H!UD I@=? *4'90"C!VL H@AQ
M * (=P"?"'X G0B% )L)C@":"9< F JA )8*K "5"[H DPO, )(,Y0"0#?8
MCP[_ (X._P".#O\ C0[_ /81  #F%P  UAL  ,<9  "^%0  N1   +<*#0"Q
M"Q< K TD *@., "E#CL H@Y$ )\/3 "=#U, FP]: )H/8 "8$&8 EQ!L )40
M<@"3$'D DA"! ) 0B@"/$90 C1&? (L1J@"*$K@ B!++ (83Y@"%%/< @Q7_
M (,5_P""%?\ @A7_ .T:  #<(0  RB4  +LB  "Q'P  JQH  *D4!@"E$A$
MH!0> )P5*@"9%34 EA8^ )061P"2%DX D!95 (X76P",%V$ BQ=G (D7;0"(
M%W0 AAA\ (48A@"#&9  @1F; ( :IP!^&K4 ?1O' 'P<X@!Z'?4 >1W_ '@=
M_P!X'?\ >!W_ .4B  #0*0  ORP  + J  "G)P  H",  )T?  ":&@X E1P8
M )$=) ".'B\ C!XY (D>00"''TD A1]0 (,?5@""'UP @!]B '\?:0!]('
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M <TT  "\.P  J3H  )LZ  "0.   B34  (,R  !_, $ >R\. '<P%@!T,"$
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M 5$]EP%//:8"3CZW DX^S0)./ND"33[Z DX^_P%./?\!3CW_ < _  "N0P
MG$,  (Y#  ""0@  >D   ',]  !M/   :#T% &0]#@!A/A< 7CXA %P^*0!:
M/C$ 6#XY %<^0 !5/T8 5#]- %,_50!20%P 4$!E $] ;P%.07H!34&' 4M!
ME@%*0:4"24*U DE"RP))0N@"24+Y DE!_P))0?\!24'_ ;U#  "J10  F$4
M (I%  !_10  =D,  &]   !H0   8T$! %]!#0!<010 64(= %=")@!50BX
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M CI.Q@(Z3N0".TWV CM-_P$[3/\!/$S_ ;--  ">3   C4P  '],  !T3
M:DP  &!*  !92P  5$P  %!-!0!,3@X 24\5 $=/'@!%3R8 1% N $)0-0!!
M4#T 0%%$ #]12P ^45, /5)< #Q29@ Z4G( .5)_ 3A2C@$W4IX!-E*O 352
MQ $U4N(!-E+U 391_P$V4/\!-U#_ :Y/  "93P  B4\  'M/  !P3P  9D\
M %Q.  !43P  3U$  $I2 0!&4PP 0U02 $%4&P! 52, /E4K #U6,@ \5CH
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M "-B_0$D8?\!)&'_ 9Q8  ")6   >ED  &Y9  !C60  6EH  %!<  !(7@
M06   #IC   T9@  +V@* "QI$  J:1< *6H? "AJ)@ G:BX )FLU "5K/0 D
M:T8 (VM/ ")L60 @;&4 'VQR !YL@@ =;)0 '&RF !MKN@ ::]0 &VKN !QI
M_  <:/\ '&C_ )5<  "#7   =5P  &E=  !?70  5EX  $QA  !#9   /&<
M #5J   O;0  *' $ "-R#0 A<A( (',: !]S(0 ><R@ '70P !QT.  ;=$
M&G1* !ET5  7=6  %G5N !5U?@ 4=9  $W2B !)TM@ 1=,\ $G/L !)R^@ 3
M<?\ $W'_ (Y@  !]8   ;V$  &5A  !;8@  460  $AG   ^:P  -VX  #!Q
M   I=0  (G@  !Q[!P 7?0X %GT3 !5]&P 4?B( $WXJ !)^,0 1?CH $7Y$
M !!_3@ /?UH #G]H  U_>  ,?XH "WZ=  I^L  )?<8 "GWD  I\]  +>_T
M"WK_ (9E  !W90  :F4  &%F  !6:   3&L  $)O   Y<P  ,7<  "IZ   C
M?@  '($  !6$   0AP@ #8D.  R)%  ,B1L "XDC  J)*P )B3, "(D]  :)
M2  %B50 !(EA  *)<0 !B8,  (F6  "(J0  A[X  (?:  "&[   AO4  (;Z
M 'YJ  !Q:@  9VL  %ML  !0<   1G0  #QX   S?0  *H$  ".%   <B
M%8P  !"/   ,D@8 !I,,  *3$0  E!8  )0=  "4)   E2P  )4U  "50
ME4P  )99  "6:0  E7H  )6.  "4H0  E+4  )/,  "2Y@  DO(  )+W 'AP
M  !M<   8'(  %1U  !)>0  /WX  #6#   LB   (XT  !N1   4E   #Y<
M  J:   $G0,  )X)  "?#@  GQ(  * 7  "@'0  H24  *(M  "B-P  HT,
M *-0  "C7P  HW$  *.$  "BF0  HJT  *'"  "AW   H>L  *#R '-V  !F
M=P  67L  $V   !"A0  .(L  "Z0   DE0  &YH  !2>   .H0  ":0   *G
M    J@   *L$  "K"@  K T  *T1  "M%@  KAP  *\D  "P+0  L3D  +%&
M  "R50  LF8  +)Y  "RC@  L:,  +*W  "QR@  L>   +'I &Q^  !?@@
M4H<  $:-   [DP  ,)D  ":>   <HP  $Z<   VK   'K@   +(   "U
MMP   +@   "Y @  N0@  +H,  "[$   O!0  +T;  "_(P  P2T  ,(Z  #"
M20  PUH  ,-L  #$@@  Q)<  ,2K  #$O   Q,L  ,3: &6)  !8C@  2Y4
M #^;   SH@  **@  !VM   4L0  #;8   :Y    O    +\   ##    Q
M ,4   #&    QP   ,D$  #*"0  RPT  ,T1  #/&   TB$  -4M  #6/
MV$T  -E?  #:<P  VHH  -N>  #;K@  V[H  -S# %Z6  !1G   1*,  #BJ
M   LL0  (+<  !6[   -O@  !,(   #%    R0   ,T   #0    T@   -(
M  #5    U@   -D   #;    W@4  . *  #B#P  Y18  .@@  #L+0  [3X
M .U1  #N90  [WH  .^/  #PGP  \*L  /"S /\ $ #_  X _P . /\ $@#_
M !T _P I /\ -0#_ $$ _P!- /X 5@#[ %\ ^ !F /8 ;0#T '0 \@!Y /$
M?P#P (0 [@") .T CP#K )4 Z@"; .@ H@#F *H Y0"S ., P #A -( X #J
M -\ ^0#= /\ W0#_ -T _P#> /\ W@#_ /\ #0#_  H _P ) /\ #P#_ !@
M_P D /X ,0#[ #T ^ !( /0 4@#P %H [0!B .L :0#I &\ YP!U .4 >@#C
M '\ X@"% .  B@#> )  W "6 -H G0#8 *4 U0"O -( N@#0 ,H S@#C ,T
M] #+ /\ RP#_ ,L _P#+ /\ RP#_ /\ " #_  , _P % /\ # #\ !0 ]P ?
M /( *P#O #< ZP!" .< 3 #D %4 X != -T 9 #: &H V !P -4 =0#2 'H
MT "  ,\ A0#- (L RP"2 ,D F0#' *$ Q0"J ,, M0#! ,, OP#: +X [@"]
M /P O #_ +P _P"\ /\ O #_ /\   #_    _P   /D !P#Q !  Z@ : .0
M)0#? #$ VP \ -< 1P#2 %  S@!7 ,L 7@#) &4 Q@!J ,4 < ## '4 P0!Z
M ,  @ "^ (8 O "- +H E "Y )P MP"E +4 L "S +T L0#/ *\ Z "N /@
MK@#_ *T _P"M /\ K0#_ /\   #_    _0   .X  0#C  P V@ 4 -$ 'P#,
M "L R  V ,4 0 #" $H OP!2 +P 60"Z %\ N !E +8 :@"T &\ LP!U +$
M>@"P ($ K@"( *T CP"K )@ J0"A *< JP"E +@ HP#( *( X@"A /, H #^
M *  _P"@ /\ H #_ /\   #V    Z@   .    #3  8 R0 / ,( & "] "0
MN0 O +8 .@"T $, L0!, *X 4P"L %D J@!? *D 9 "G &H I@!O *0 =0"C
M 'L H0"" *  B@"> ), G "= )H IP"8 +0 E@## )4 W "4 .\ DP#[ ),
M_P"3 /\ D@#_ /D%  #J"P  W T  ,L*  #"!0  O  * +8 $0"Q !P K@ H
M *H ,P"G #T I !% *( 30"@ %, G@!9 )P 7P"; &0 F@!J )@ < "7 '8
ME0!^ ), A@"2 8\ D &9 (X"I ", K$ BP/  (D%U@"(!NT B ?Z (<(_P"&
M"/\ A@C_ .\/  #>%   RA4  +P2  "S$   K@P  *L&#0"G Q4 H@4@ )\'
M+ "<"#8 F0@_ )<)1P"5"4X DPE4 )$*6@"0"E\ C@IE (T*:P"+"G( B@MY
M (@+@@"'"XP A0R7 (,,H@"!#;  @ W  '\-V !]#N\ ? _] 'L/_P![$/\
M>Q#_ .87  #1'@  O1T  *\<  "F&0  H14  )X0! "=#0\ F X9 )0.)0"1
M#R\ CQ Y (P000"*$$@ B!!/ (<050"%$%L A!%A ((19P" $6X ?Q%U 'T1
M?@!\$H@ >A*4 '@2H !W$ZX =1.^ '04U0!S%>X <1;] '$6_P!Q%O\ <!;_
M -P?  #&)0  LR4  *4C  "<(0  EAX  )(9  "1% L C104 (D5'P"&%BD
M@Q8S ($7/ " %T, ?A=* 'P74 !Z%U8 >1A< '<88@!V&&D =!AQ ',9>@!Q
M&80 ;QJ0 &X:G0!L&ZL :QR[ &H<T !I'>P :![[ &@>_P!G'O\ 9Q[_ -$F
M  "]*@  JRH  )TJ  "3*   C24  (@B  "&'08 @QL0 '\<&@!\'20 >ATN
M '<>-@!V'CX =!Y% '(?2P!Q'U$ ;Q]8 &X?7@!L'V4 :R!M &D@=@!H(8$
M9B&- &4BF@!C(J@ 8B.X &$CS0!@).D 8"3Z %\D_P!?)/\ 7R3_ ,HL  "V
M+P  I"\  )8O  ",+0  A2H  ( H  !])   >B(- '8C%0!S(R  <20I &\D
M,@!M)#H :R5! &HE1P!H)4T 9B54 &4E6@!D)F$ 8B9I &$F<@!?)WT 7B>*
M %THEP!;*:4 6BFU %HJR@!9*N< 6"KX %@J_P!8*O\ 6"K_ ,4Q  "O,P
MGC,  ) S  "&,@  ?R\  'DM  !U*@  <B@* &\H$@!K*1L :2DE &<J+0!E
M*C4 8RH] &(J0P!@*DH 7RM0 %XK5P!<*UX 6RQF %DL;P!8+7H 5RV' %8N
ME0!4+J, 4R^S %,OQP!2+^4 4B_W %(O_P!2+_\ 4B__ ,$V  "J-@  F38
M (LV  "!-0  >3,  ',Q  !O+P  :RX& &@M$ !D+A@ 8BXA & O*@!>+S$
M7"\Y %LO0 !9+T8 6"]- %<P4P!6,%L 5#%C %,Q; !2,G< 43*$ $\SD@!.
M,Z$ 33.Q $TTQ0%,-.,!3#3V $PT_P!,-/\ 3#/_ +LY  "F.0  E3D  (<Y
M  !\.0  =#<  &XT  !I,P  93(" &$R#0!>,A0 7#,> %HS)@!8,RX 5C,U
M %4T/ !3-$, 4C1* %$T4 !0-5@ 3C5@ $TV:@!,-G4 2S>" $HWD !).)\
M2#BP 4<XPP%'..$!1SCU 4<X_P%'./\!1SC_ ;<[  "B/   D3P  (,\  !X
M/   <#H  &HW  !D-@  8#8  %PV"P!9-Q( 5C<: %0W(P!2-RL 4#<R $\X
M.0!-.$  3#A' $LX3@!*.54 23E> $@Z: !'.G, 1CN  $4[C@!$/)X 0SRN
M 4(\P@%"/=\!0CSS 4(\_P%"//\!0CO_ ;,]  ">/@  C3X  '\^  !U/@
M;#T  &8Z  !@.0  6SH  %<Z" !3.Q  43L8 $X[( !,.R@ 2SLO $D\-@!'
M/#T 1SQ$ $8]2P!%/5, 1#Y< $,^9@!"/W$ 03]^ $ _C0 _0)P /D"M 3U
MP $]0-T!/4#R 3U _P$^/_\!/C__ :Y   ":0   B4$  'Q!  !Q00  :$
M &$\  !;/0  5CX  %(^!0!./PX 3#\5 $D_'0!'0"4 1D L $1 ,P!#0#H
M0D%" $%!20! 05$ /T): #Y"8P ]0V\ /$-\ #M#BP Z1)L .42K 3E$O@$X
M1-L!.43Q 3E#_@$Y0_\!.4/_ :I"  "60P  AD,  'A#  !N0P  94,  %U
M  !60   44(  $U" @!)0PP 1D,2 $1$&@!"1"( 040J #]%,0 ^13@ /44_
M #Q&1P [1D\ .D97 #E'80 X1VP -T=Z #9(B0 U2)D -$BJ #1(O0 S2-D
M-$CP #1'_0 T1_\ -4;_ *9$  "210  @D8  '5&  !J1@  844  %E$  !1
M1   3$8  $A'  !$1PH 04@0 #])&  ]22  /$DG #I*+@ Y2C8 .$H] #=+
M1  V2TP -4M5 #1,7P S3&H ,DQW #%,A@ P3)< +TVH "Y-NP N3=4 +DSO
M "],_0 O2_\ ,$O_ *%'  ".2   ?D@  '%(  !F20  74@  %5(  !,20
M1TH  $)+   _3 8 .TT. #E.%0 W3AT -D\D #5/*P S3S, ,E Z #%00@ P
M4$H +U%2 "Y17  M46< +%%U "M1A  J4I4 *5*F "E2N0 H4M( *5'N "E0
M_  J4/\ *D__ )Q*  ")2@  >DL  &U+  !C3   6DP  %%,  !(30  0T\
M #U0   Y4@( -5,, #-4$@ Q5!D ,%4A "Y5*  M52\ +%8W "M6/@ J5D8
M*59/ "A760 G5V0 )E=R "57@0 D5Y( (U>D ")7MP B5\\ (E?L "-6^@ C
M5?\ )%7_ )9-  "$3@  =4X  &E.  !?3P  5D\  $U0  !%4@  /U,  #E6
M   S6   +UH( "M;#P J6Q4 *%P= "=<)  F7"L )5PS "1=.@ C74, (EU,
M "%=5@ @7F$ 'UYN !Y>?@ =7H\ '%ZA !M>M  :7<P &UWI !M<^0 <6_\
M'%O_ )!1  !^40  <%$  &12  !;4@  4E,  $I4  !!5P  .UD  #5;   N
M7@  *& # "1B#  B8Q$ (6,8 !]D(  >9"< '60N !QD-@ ;93X &F5' !EE
M40 895T %V5J !9E>@ 598L %&6> !-EL0 29<@ $F3G !-C]P 48O\ %&+_
M (E4  !X50  :U4  &!6  !75@  3U<  $99   ]7   -E\  #!B   I9
M(V<  !UJ!P 9; X &&P3 !9M&@ 5;2$ %&TI !1M,  3;3D $FY" !%N3  0
M;E@ #VYE  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK\P -:_T #6K_ ()9
M  !R60  9ED  %Q:  !46@  2EP  $%?   Y8P  ,68  "II   D;   '6\
M !=R   2=0D #W</  YW%  .=QL #7<C  QW*@ +=S, "G<\  EW1P (=U(
M!W=?  5W;P $=X   W>4  %VIP  =KL  775  %TZP "=/8  G3\ 'M=  !M
M70  8EX  %E>  !.8   16,  #QG   S:P  *VX  "1R   >=0  %WD  !)\
M   -?P8 "8$,  6!$0 #@18  H$=  &!)   @2T  ((V  ""0   @DP  ()9
M  "":   @GD  (*-  "!H   @+0  (#+  !_YP  ?O(  '[Y '1B  !H8@
M7F(  %-D  !)9P  /VL  #9P   M=   )7@  !Y\   7@   $8,   V&   (
MB00  HL*  "+#@  BQ,  (P8  ",'P  C28  (TO  "..0  CD0  (Y1  ".
M8   CG$  (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV &YH  !D9P  6&D
M $UL  !"<0  .'8  "][   F?P  'H0  !:(   0C   #(\   :2    E0
M )8'  "7#   EP\  )@3  "9&   FA\  )LF  ";,   G#L  )Q(  "<5P
MG&@  )Q[  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM  !>;P  47(  $9W
M   [?   ,8(  ">'   >C   %I$  !"5   *F0  !)P   "@    H@   *,!
M  "C!@  I L  *4.  "F$@  IQ<  *@>  "J)@  JS$  *L^  "L30  K%T
M *QP  "LA0  K)L  *NO  "KPP  J]D  *KH &1U  !7>0  2WX  #^$   T
MB@  *9   !^6   6FP  $)\   FC   !IP   *H   "N    L    +    "Q
M    L@,  +0(  "U#0  MA   +<5  "Y'0  NR8  +PS  "]00  O5(  +UD
M  "^>0  OI   +VD  "]MP  O<8  +W7 %Q_  !0A0  1(L  #B2   LF0
M(9\  !>D   0J0  ":X   "R    M@   +D   "]    OP   +\   #
MP0   ,,   #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0-0  T44  -)7  #2
M:P  TX(  -.7  #3J0  TK@  -+$ %6,  !)DP  /9H  #"B   EJ   &JX
M !&T   )N0   +T   #!    Q    ,@   #+    S0   ,T   #/    T
M -(   #4    V    -H&  #=#   X!$  .,:  #F)P  YS@  .A*  #I70
MZG(  .N(  #KFP  [*@  .RR /\ #0#_  L _P + /\ $ #_ !H _P F /\
M,@#_ #T _P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U .X >@#L '\ ZP"$
M .D B@#H )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L VP#F -D ]P#8 /\
MV #_ -< _P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_ !4 _@ A /H + #W
M #@ ] !# /  30#M %4 Z@!= .< 9 #D &H X@!P .  =0#> 'H W0!_ -L
MA0#9 (L U0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#= ,@ \0#' /\ Q@#_
M ,8 _P#& /\ QP#_ /\   #_    _P   /\ "@#X !$ \0 < .P )P#I #(
MY@ ] .( 1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #, '4 R@!Z ,D ?P#'
M (4 Q0", ,, E #! )P OP"E +T L "[ +T N@#0 +@ ZP"W /L M@#_ +8
M_P"V /\ M@#_ /\   #_    _0   /, !0#I  X X0 6 -L (0#5 "T T0 W
M ,X 00#* $H QP!2 ,0 60#" %\ P !E +X :@"\ &\ NP!T +D >@"W (
MM@"' +0 C@"R )< L "@ *X J@"M +< JP#( *D XP"H /4 IP#_ *< _P"G
M /\ I@#_ /\   #^    \0   .4   #7  H S0 1 ,< ' #" "8 OP Q +P
M.P"Z $0 MP!, +0 4P"R %D L0!? *\ 9 "M &D K !O *H = "I 'H IP"!
M *8 B0"D )$ H@"; *  I0"> +( G0#! )L V@": .\ F0#] )@ _P"8 /\
MF #_ /T   #P    X0   -$   #&  0 O0 - +< %0"S "  L  K *T -0"K
M #X J !& *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T ;@"; '4 F@![ )@
M@P"6 (P E0"6 ), H0"1 *T CP"[ (T SP", .D BP#X (P _P", /\ C #_
M /,"  #B!P  S <  +\$  "W    L0 ( *L $ "G !D I  D *  +@"> #<
MG !  )H 1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/ &\ C0!V (L ?@"*
M (@ B "2 (8 G0"% *D @P"X ($ R@"  .4 @ #U '\ _P!_ /\ ?P#_ .@-
M  #0$   OA   +$.  "H#0  HP@  * "# "< !, F  = )4 )P"2 #$ D  Y
M (X!00", 4@ B@). (D"5 "' ED A@)? (0#9 "# VL @0-R ( $>@!^!(0
M?06. 'L%F@!Y!J< > :U '8'R !U"., =0GT '0*_P!S"O\ <PK_ -T5  #$
M%P  L1<  *46  "<$P  EA$  )0-! "3" T C@<5 (L)( "("2H A0HS (,+
M.P"!"T( @ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN '4-=@!T#8  <@V,
M ' -F0!O#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\ :1#_ - =  "Y'@
MJ!X  )L=  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^$"0 >Q M 'D0-@!W
M$3T =A%$ '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2<P!I$WT :!.) &83
ME@!E%*, 8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_ ,<B  "P(P  GR0
M )(C  ")(@  @B   'X=  !\&0  >A4- '<5%0!T%A\ <18H &\7, !N%S@
M;!<_ &L710!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@&7D 7QJ% %T;D@!<
M&Z$ 6QRP %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G  "I*   F2@  (LH
M  "")P  >R4  '8C  !S(   <1P) &X<$0!K'!H :1TC &<=+ !E'3, 8QXZ
M &(>00!@'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8 5B&" %4AD !4(IX
M4R*N %(CP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C+   DRP  (8M  !\
M+   ="H  &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C)P!=(R\ 7",V %HC
M/0!9)$, 5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_ $XGC0!-*)P 3"BL
M $LIO@!+*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P  CC   ($P  !W+P
M;RX  &HK  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6*"L 52@R %,H.0!2
M*4  4"E& $\I30!.*50 32I< $PJ90!**W  22M\ $@LBP!'+9H 1BVJ $4N
MO !%+M8 12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,  'PS  !R,P  :S$
M &4O  !@+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@ 3BTO $TM-@!,+3P
M2BU# $DM2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!,9@ 03*H $ RNP _
M,M, /S+N $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV  !N-0  9C4  &$R
M  !<,   5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L $<Q,@!&,3D 1#%
M $,R1P!",D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8 .S:G #LVN0 Z-M$
M.C;M #LV_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K.   8S<  %TV  !7
M,P  4S0  $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U+P! -38 /S8] #XV
M1  ]-TP /#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE #8ZN  U.L\ -CKL
M #8Z^P V.?\ -SG_ *(X  "..0  ?CH  '([  !H.P  7SH  %DY  !3-@
M3C<  $HX  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [.C0 .CH[ #D[0@ X
M.TH -SM3 #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^M@ Q/LT ,3[J #$^
M^@ R/?\ ,CW_ )X[  "+/   >SP  &X]  !D/0  7#T  %4\  !..@  23L
M $4\  !!/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$ -3\X #0_0  S0$@
M,D!0 #% 6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K0LL +$+I "Q"^0 M
M0?\ +4'_ )D]  "'/@  =S\  &L_  !A0   63\  %(_  !)/@  1#\  $!
M   \000 .4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V "]$/0 N144 +45.
M "Q%6  K1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D )D;G "=&^  H1?\
M*$7_ )5   ""00  <T(  &="  !>0@  54(  $Y"  !%0@  /T0  #M%   W
M1@  -$<* #%($  O2!8 +DD> "Q))0 K22P *DDS "E*.@ H2D( )TI+ "9+
M50 E2V  )$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF "%+]P B2O\ (DK_
M )!#  !^1   ;T0  &1%  !:10  4D4  $I&  !!1P  /$@  #=)   R2P
M+DT' "M.#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B4#\ (5!( "!04@ ?
M45T 'E%J !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0]@ ;3_\ '$__ (I&
M  !Y1P  :T<  &!(  !62   3D@  $=)   ^2P  .4P  #-.   N4   *%,"
M "14"P B51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL &E=$ !E73@ 85UD
M%UAF !58=0 46(< %%B: !-7K  25\( $E?A !-6]  45?\ %%7_ (1)  !T
M2@  9DL  %Q+  !32P  2TP  $1-   \3P  -5$  "]4   I5@  )%D  !Y;
M!P :70T &%T2 !==&0 67B  %5XG !1>+@ 37C< $EY  !%?2@ 17U4 $%]B
M  ]?<0 .7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P #ES_ 'Y-  !N3@
M8DX  %A/  !/3P  2%   $!2   X5   ,%<  "I:   D70  'U\  !EB 0 3
M90D $68/ !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG10 *9U  "6==  =G
M;  &9WT !6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\ '=1  !I4@  75(
M %12  !,4P  0U4  #M8   S6P  *UX  "5A   ?9   &6<  !-J   /;08
M"W ,  AP$0 '<!8 !7 =  1P)  #<"P  G U  !P/P  <$H  '!7  !P90
M<'8  '"*  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6  !C5@  658  %%7
M  !'_^+__TE#0U]04D]&24Q%  0)6   /EL  #9?   N8@  )F8  !]J   9
M;0  $W    YS   +=@0 !7@+  %X#P  >1,  'D9  !Y'P  >B8  'HO  !Z
M.0  >D0  'I0  !Z7P  >G   'J#  !ZF   >JP  'G"  !XWP  >.\  '?W
M &I;  !?6P  5EL  $Q<  !"8   .6,  #!H   H;   ('   !ET   3=P
M#GL   E^   $@0(  (((  "##0  @Q   (04  "%&0  AB   (8H  "',0
MASP  (=)  "'5P  AV@  (=[  "'D   AJ4  (6Z  "%TP  A.H  (3T &5@
M  !<8   46$  $9D   \:0  ,FT  "ER   A=P  &7L  !*    -@P  "(<
M  **    C0   (X$  "."0  CPT  ) 0  "1%   DAD  ),@  "4*0  E3,
M )5   "63@  EE\  )5R  "5B   E9T  )2R  "4R   D^(  )/N &%E  !6
M9@  2FH  #]N   U=   *WD  "%_   9A   $8D   R-   &D0   )0   "8
M    F@   )L   "< @  G0<  )X+  "?#@  H1(  *(8  "C(   I2D  *8V
M  "F1   IE4  *9H  "F?0  II0  *6I  "DO0  I-$  *3D %ML  !/<
M0W4  #A[   M@0  (X<  !F-   1D@  "Y<   2<    H    *,   "F
MJ    *D   "J    K    *T$  "N"0  L T  +$1  "S%P  M2   +8K  "W
M.@  MTL  +A<  "X<0  N(@  +B=  "XL0  M\(  +?0 %1V  !(?   /((
M #&)   FD   &Y<  !*=   ,H@   Z<   "K    K@   +(   "V    N
M +@   "Z    NP   +T   "^    P 4  ,$+  ##$   QA8  ,D@  #*+@
MRSX  ,Q0  #,9   S7H  ,V1  #-I   S;0  ,W  $V#  !!B@  -9$  "F9
M   >H   $Z8   RL   #L0   +8   "Z    O@   ,(   #&    R    ,@
M  #*    RP   ,T   #.    T    -(!  #5"   V0X  -T5  #A(0  XC$
M .1#  #E5@  YFL  .:"  #GE@  YZ4  .:P /\ "0#_  4 _P & /\ #@#_
M !8 _P A /\ +0#_ #@ _0!# /D 30#U %4 \@!= /  8P#N &D [ !O .H
M= #I 'H YP!_ .8 A0#D (L XP"1 .$ F0#? *$ W "J -H M@#7 ,8 U0#A
M -, ] #2 /\ T0#_ -$ _P#/ /\ R@#_ /\  0#_    _P ! /\ # #_ !(
M^@ = /8 * #S #, \  ^ .P 2 #H %  Y0!8 .( 7@#? &0 W0!J -L ;P#9
M '0 U@!Z -0 ?P#2 (4 T ", ,X DP#, )P R0"E ,< L #& +X Q #4 ,(
M[@#! /X P #_ ,  _P"_ /\ O@#_ /\   #_    _P   /H !P#Q  \ ZP 8
M .8 (P#B "X X  X -L 0@#5 $L T0!2 ,X 60#+ %\ R0!E ,< :@#& &\
MQ !T ,( >@#! (  OP"& +T C@"[ )8 N0"@ +< J@"V +< M #* +( Y@"Q
M /@ L #_ *\ _P"O /\ L #_ /\   #_    ]P   .H  @#A  P UP 3 -
M'0#, "@ R0 R ,8 / #" $4 OP!- +P 4P"Z %D N !? +< 9 "U &D M !N
M +( = "Q 'H KP"  *T B "L )$ J@": *@ I0"F +$ I #! *, W "A /(
MH0#_ *  _P"@ /\ H0#_ /\   #W    Z    -D   #+  @ PP 0 +T & "Y
M "( M@ L +0 -@"R #\ KP!' *P 30"K %0 J0!9 *< 7@"F &, I0!H *,
M;@"B '0 H !Z )X @@"< (L FP"5 )D GP"8 *P E@"Z )0 SP"3 .L D@#[
M )( _P"2 /\ D0#_ /<   #G    TP   ,8   "[  ( LP , *T $@"J !P
MIP F *0 , "C #@ H !  )X 1P"< $X F@!3 )D 6 "7 %T E@!C )4 : "3
M &X D@!T )  ? "/ (4 C0"/ (L F@"* *< B "U (8 QP"% .0 A #U (0
M_P"# /\ @P#_ .P   #3    P0$  +0   "L    I@ ' *  #@"= !8 F@ @
M )< *0"5 #( DP Z )$ 00"/ $@ C0!- (P 4P"+ %@ B0!= (@ 8P"' &D
MA0!O (, =P"" (  @ "* 'X E@!] *, >P"P 'H P@!Y -T > #Q '< _0!X
M /\ > #_ -X*  #$"P  L@P  *8+  "="   F00  )4 "@"1 !$ C@ 9 (L
M(P") "P AP T (4 .P"# $( @@!( (  3@!_ %, ?0!8 'P 7@![ &0 >0!J
M '@ <@!V 'L = "& ', D@!Q )\ < "M &X O@!M =8 ;0+M &P#^@!L _\
M; /_ ,X0  "W$0  IA(  )H1  "1$   BPX  (D+ P"'!0P A $3 ($!' !^
M B4 ? ,N 'H#-@!X!#P =P1# '4%2 !T!4X <P54 '$%60!P!E\ ;@9F &T&
M;@!K!W@ :@># &@(D !G"9T 90FL &0)O !C"M0 8POL &(,^@!B#/\ 8@S_
M ,,6  "M%P  G1@  ) 8  "'%@  @10  'T1  !\#@8 ? H. '@*%@!U"Q\
M<@LH ' ,, !O##< ;0P^ &P,1 !K#4H :0U/ &@-50!G#5P 90UC &,.:P!B
M#G4 8 Z! %\.C@!=#YP 7!"K %L0O0!:$-8 61'P %D1_0!9$?\ 61'_ +D;
M  "E'0  E!X  (@>  !^'0  >!L  '08  !Q%0  <1$) &\0$0!L$!D :1 B
M &<1*@!F$3( 9!$Y &,1/P!B$44 8!)+ %\240!=$E@ 7!)? %H3: !9$W(
M5Q1] %84BP!4%9D 4Q6I %(6N@!1%M( 41?M %$7_0!1%_\ 41?_ +(@  ">
M(@  CB(  ($C  !W(@  <"$  &P>  !I&P  9Q@$ &85#@!C%A4 818> %\6
M)@!=%BT 7!<T %H7.P!9%T$ 6!A' %8830!5&%0 4QA< %(99 !1&6X 3QIZ
M $X;B !-&Y< 2QRF $H<N !*'<\ 21WK $D=^P!)'?\ 2AW_ *PD  "8)0
MB"8  'LG  !Q)@  :B4  &8C  !B(0  8!X  %X<"P!;&Q( 61P: %<<(@!5
M'"D 5!PP %,=-P!1'3T 4!U# $\=2@!-'E$ 3!Y8 $L?80!)'VL 2"!W $<@
MA0!&(90 1"*D $0BM@!#(LP 0R/I $,C^@!#(_\ 0R+_ *8G  "3*0  @RH
M '8J  !M*@  92D  & G  !<)0  62,  %<A!P!5(0\ 4B$6 % A'@!.(24
M32(L $PB,P!*(CD 22)  $@B1@!'(TT 12-5 $0D7@!#)&D 0B5U $ F@P _
M)I( /B>C #XGM  ])\H /2CH #TH^0 ])_\ /B?_ *(J  ".*P  ?RT  '(M
M  !H+0  82P  %PK  !8*   5"8  %$F! !.)0T 3"43 $HF&@!()B( 1R8I
M $4F+P!$)C8 0R<\ $$G0P! )TL /RA3 #XI7  ]*68 /"IR #LJ@0 Z*Y
M.2NA #@LL@ W+,@ -RSF #@L^  X+/\ ."S_ )TL  "*+@  >R\  &\P  !E
M,   72\  %@N  !3*P  4"H  $PJ  !)*@L 1BH1 $0J%P!"*A\ 02HE #\J
M+  ^*S, /2LY #PK0  [+$@ .BQ0 #DM60 X+F0 -RYP #8O?P U+X\ -#"?
M #,PL0 R,,< ,C#E #,P]P S,/\ -"__ )DO  "',0  =S(  &LR  !B,@
M6C(  %0Q  !/+P  2RT  $<N  !$+@@ 02X. #\N%  ]+AP .RXB #DO*0 X
M+R\ -R\V #8P/@ U,$8 -3%. #0Q5P S,F( ,C)N #$S?0 P,XT +S2> "XT
ML  M-,4 +33C "XT]@ O,_\ +S/_ )4Q  "#,P  =#0  &@U  !>-0  5S0
M %$T  !+,@  1C$  $(R   _,@4 /#(- #DS$@ X,QD -C,@ #0S)@ S,RT
M,C0T #$T.P P-4, ,#5, "\V50 N-F  +3=L "PW>P K-XL *CB< "DXK@ H
M.,, *#CB "DX]0 J-_\ *C?_ )(T  !_-0  <38  &4W  !;-P  5#<  $TV
M  !'-@  0C4  #TV   Z-@( -S<+ #0W$  R-Q8 ,3@= "\X)  N."L +3DR
M "PY.0 K.4$ *CI) "HZ4P I.UX *#MJ "<[>0 F/(D )3R; "0\K0 C/,(
M(SS@ "0\]  E._\ )3O_ (TV  !\.   ;3D  &(Y  !8.@  43D  $HY  !$
M.0  /3D  #DZ   U.P  ,CL( "\\#@ M/10 +#T: "H](0 I/2@ *#XO "<^
M-@ F/CX )3]' "0_4  C0%L (D!H "% =@ @0(< 'T&9 !]!JP >0<  'D'>
M !] \P ?0/X (#__ (DY  !X.@  :3L  %X\  !5/   33P  $<\  ! /
M.#T  #0^   P0   +4$% "I"#  G0A$ )D,8 "1#'@ C0R4 (D,L "%$,P @
M1#L 'T1$ !Y%3@ =15D '$5E !M%=  :184 &4:7 !E&J0 81KX %T7< !A%
M\0 91/T &D3_ (0\  !S/0  9CX  %L_  !2/P  2C\  $0_   ]0   -D$
M #%#   L1   )T8! "1'"@ A2 \ ($D4 !Y)&P =22( '$DI !M*,  :2C@
M&4I! !A*2P 72U4 %DMB !5+<0 42X( $TN4 !)+IP 22[P $4O9 !)*\  3
M2OP %$G_ '\_  !O0   84$  %="  !.0@  1T(  $%"   Z0P  ,D4  "U'
M   H20  (TL  !Y-!@ ;3PT &% 1 !=0%P 64!X %5 E !10+  3430 $E$]
M !%11P 145( $%%?  ]2;0 .4GX #5&1  U1I  ,4;@ #%'1  U0[  -4/H
M#D__ 'E#  !J1   740  %-%  !+10  1$4  #Y&   V2   +TH  "E,   D
M3P  'U$  !I3   45@D $5<. !!8$P 06!D #U@@  Y8*  -6#  #5@Y  Q8
M0P +6$X "EA:  A8:  '6'D !EB,  58GP $6+, !%?*  57Y@ %5_, !E;\
M '-&  !D1P  64@  %!(  !(2   04D  #I*   R30  *U   "52   @50
M&E@  !5:   0708 #& ,  I@$  )8!4 "& <  =@(P %8"L !& T  -@/0 !
M8$D  &!5  !@8P  8',  &"&  !?F@  7ZX  %_$  !>X@  7O   %[X &Q*
M  !?2P  54L  $Q,  !%3   /4X  #50   N4P  )U8  "!9   :7   %5\
M !!B   -900 "&<+  -G#@  :!,  &@8  !H'P  :28  &DN  !I.   :4,
M &E/  !I70  :6T  &F   !IE   :*D  &B_  !GW   9NX  &;W &9/  !:
M3P  44\  $I/  !!40  .%0  #!7   H6P  (5X  !IB   490  $&@   QK
M   ';@,  7 )  !P#0  <1   '$4  !R&@  <R$  ',H  !S,0  <SP  '1(
M  !S5@  <V8  '-Y  !SC@  <Z,  '*Y  !QT@  <>L  '#T &%3  !64P
M3U,  $55   [6   ,EP  "I@   B9   &V@  !1L   /;P  "W(   9V
M>0   'H&  !Z"@  >PX  'P1  !]%0  ?AL  '\B  " *@  @#4  (!!  "
M3P  @%\  (!Q  " A@  @)T  '^R  !^R@  ?N4  'WQ %Q8  !46   25H
M #]=   U80  +&4  "-J   ;;P  %',   YW   )>P   W\   ""    A
M (8!  "&!@  B H  (D-  "*$   BQ4  (P;  ".(@  CRP  (\X  "/1@
MCU8  (]H  "/?@  CY4  (ZK  "-P0  C=P  (SK %E=  !.7P  0V(  #AF
M   N;   )'$  !QW   4?   #H$   B%    B0   (T   "0    D@   ),
M  "4    E@,  )<(  "8#   F@\  )L3  "=&@  GR,  * N  "@/   H$P
M *!>  "@=   GXP  )^B  "?MP  GLL  )[@ %-D  !':   /&T  #%S   G
M>0  '7\  !2%   -BP  !I    "4    F    )P   "?    H0   *(   "D
M    I0   *<   "H!   J@D  *P-  "M$@  L!D  +(C  "R,0  LD(  +)4
M  "R:0  LH   +*8  "QK   LK\  +'. $QN  ! <P  -7H  "J!   ?B
M%8X   Z5   &F@   )\   "D    J    *P   "O    L0   +$   "S
MM0   +8   "X    N@   +P&  "^#   P!$  ,,9  #%)@  Q3<  ,9)  #&
M70  QW(  ,>*  #(GP  R*\  ,B\ $9Z   Y@0  +HD  "*0   7F   #Y\
M  >E    J@   *\   "S    MP   +P   "_    P0   ,(   #$    Q0
M ,<   #)    RP   ,T   #/ P  T@H  -80  #<&@  W2H  -X\  #?4
MX&4  .%[  #AD0  XJ(  .*M /\  @#_    _P # /\ # #_ !, _P = /\
M* #^ #, ^P ^ /< 2 #S %  \ !7 .T 7@#K &0 Z !I .< ;P#E '0 XP!Y
M .( ?P#@ (4 W@", -P DP#9 )P U@"F -, L0#1 ,  SP#: ,X \0#, /\
MRP#_ ,L _P#& /\ P0#_ /\   #_    _P   /\ " #[ !  ]@ 9 /( ) #O
M "X [0 Y .@ 0@#C $L X !2 -T 60#9 %\ U@!D -, :0#1 &X SP!T ,X
M>0#, '\ R@"& ,@ C@#& )8 Q "@ ,( JP#  +D O@#- +P Z@"[ /P N@#_
M +H _P"Z /\ M@#_ /\   #_    _@   /0 ! #K  T Y  4 -\ 'P#; "D
MV  S -, /0#. $4 R@!- ,< 4P#% %D PP!? ,$ 9 "_ &D O0!N +L <P"Z
M 'D N "  +8 B "T )  L@": +$ I0"O +( K0#$ *P X0"K /8 J@#_ *H
M_P"J /\ J@#_ /\   #]    [@   .(   #5  H S0 1 ,< &0#$ ", P0 M
M +\ -P"[ #\ MP!' +4 3@"R %, L !9 *\ 7@"M &, K !H *L ;0"I ',
MJ !Z *8 @0"D (H HP"4 *$ GP"? *P G@"[ )P T@"; .X F@#_ )H _P"9
M /\ F0#_ /X   #N    W@   ,L   #!  4 N0 - +0 % "Q !X K@ G *L
M, "J #D IP!! *0 2 "B $T H0!3 )\ 6 "> %T G0!B )L 9P": &T F !S
M )< >P"5 (0 E ". )( F0"0 *8 C@"T (T R ", .8 BP#Y (H _P"* /\
MBP#_ /    #;    QP   +H   "P    J  * *0 $ "@ !@ G0 A )L *@":
M #, F  [ )8 00"4 $@ D@!- )$ 4@"/ %< C@!< (P 80"+ &< B@!N (@
M=0"' 'X A0"( (, E "" *  @ "O '\ P !^ -T ?0#R 'T _P!] /\ ?0#_
M .    #&    M0   *H   "B    FP % )4 #0"2 !, D  < (T ) "+ "T
MB@ T (@ .P"& $( A0!' (, 30"" %( @0!7 '\ 7 !^ &( ?0!H 'L < !Z
M 'D > "# '8 CP!U )P = "J '( N@!Q -$ < #L '  ^P!P /\ < #_ ,T$
M  "W!@  IP<  )L&  "3!   C@   (H " "&  \ A  6 ($ '@!_ "< ?0 N
M 'P -@!Z #P >0!" '< 1P!V $P =0!2 ', 5P!R %T <0!C &\ :P!N '0
M; !^ &L B@!I )@ : "F &< M@!F ,L 90#G &4 ]P!E /\ 90#_ , ,  "K
M#0  FPX  (\.  "&#0  @0L  'X' 0!\ 0L >0 1 '< & !U "$ <P I '$
M, !O #8 ;@ \ &P 0@!K $< :@!- &D 4@!H %@ 9@!? &4 9P!C '  8@%Z
M & !AP!? I4 7@*C %P#LP!< \< 6P3D %L%] !;!OX 6P;_ +40  "A$@
MD1,  (43  !\$@  =A$  ',.  !R# 0 <0<- &X$$@!L!!L :04C &<%*@!F
M!C$ 9 8W &,&/0!B!T, 80=) %\'3@!>"%4 70A< %L)8P!:"6T 6 IX %<*
MA0!6"Y, 5 NB %,+LP!2#,< 4@SD %$-]0!1#?\ 40W_ *T5  "9%P  B1@
M 'T9  !T&   ;1<  &H4  !G$0  9PX' &8,#@!C#!4 80P= %\,)0!=#2P
M7 TS %L-.0!:#3\ 6 U% %<-2P!6#E$ 50Y9 %,.80!2#FL 4 ]V $X0@P!-
M$)( 3!"B $L0L@!*$<@ 21'E $D1]P!)$O\ 21'_ *49  "2'   @QT  '8>
M  !M'0  9AP  &(:  !?%P  7A0! %X1"@!;$!$ 61$8 %<1( !5$2< 5!$N
M %,1- !1$3L 4!)! $\21P!.$DX 3!)5 $L37@!)$V< 2!1S $84@ !%%8\
M1!6? $,6L !"%L4 0A?C $(7]@!"%_\ 0A?_ )\=  ",(   ?2$  '$B  !H
M(@  82$  %P?  !9'   5QD  %46!@!4%0X 4144 $\6' !.%B, 3!8J $L6
M, !*%C< 21<] $<70P!&%TH 11A2 $,86@!"&60 01EP #\:?0 ^&XT /1N=
M #P<K@ [',, .QSA #L=]0 ['/\ /!S_ )HA  "'(P  >"0  &PE  !C)0
M7"0  %<C  !3(   41X  $\< @!-&PP 2QH1 $@;& !'&R  11LF $0;+0!#
M'#, 0APY $ <0  _'4< /AU/ #T>6  \'F( .A]M #D?>P X((L -R&; #8A
MK0 U(<$ -2'? #4A\P V(?\ -B'_ )8C  "#)@  ="<  &@H  !?*   6"<
M %,F  !/)   3"(  $D@  !'( D 1!\/ $(?%0! (!P /R C #X@*0 \("\
M.R$V #HA/0 Y(40 ."), #<B50 V(U\ -"-K #,D>0 R)8D ,26: # EJP P
M)K\ +R;< # F\@ P)O\ ,27_ )$F  !_*   <2H  &4J  !<*@  52H  $\I
M  !+*   2"4  $0D  !!) 4 /R0- #TD$@ [)!D .20? #<D)@ V)"P -24S
M #0E.@ S)D$ ,B9* #$G4P P)UT +RAI "XI=P M*8< +"F8 "LJJ@ J*KT
M*BK: "LJ\0 K*OX +"G_ (TH  !\*@  ;2P  &(M  !9+0  42T  $PL  !'
M*P  0R@  #\H   \* ( .2@+ #<H$  U*!8 ,R@< #(H(P P*"D +RDP "\J
M-P N*C\ +2M' "PK40 K+%L *BQG "DM=0 H+84 )RV7 "8NJ  E+KP )2[8
M "8N\  F+OT )RW_ (HK  !X+0  :BX  %\O  !6+P  3B\  $@N  !#+0
M/RP  #LL   W+   -"P) #(L#@ P+1, +BT: "TM(  K+2< *BXM "HN-0 I
M+ST *"]% "<P3@ F,%D )3%E "0Q<P C,8, (C*5 "$RIP A,KL (#+4 "$R
M[P B,?P (C'_ (8M  !U+P  9S   %PQ  !3,0  2S$  $4Q  ! ,   .S
M #8P   S,   ,#$& "TQ#0 K,1$ *3(7 "@R'@ G,B0 )3,K "4S,@ D,SH
M(S1# "(T3  A-5< (#5C !\U<0 >-H$ '3:3 !PVI0 ;-KD &S;2 !PV[0 =
M-OL '37_ ((P  !Q,@  8S,  %DT  !0-   230  $(S   ],P  -S,  #$T
M   N-0  *S4" "@V"P E-Q  )#<5 "(W&P A."( (#@H !\X,  >.#< '3E
M !PY20 ;.E0 &CI@ !DZ;@ 8.G\ %SN1 !<[I  6.[< %3O0 !8Z[  7.OH
M&#G_ 'TR  !M-   8#4  %4V  !--@  1C8  $ V   Z-@  -#8  "XX   J
M.0  )CH  ",["  @/ X 'CT2 !T]&  </1\ &SXE !H^+0 9/C0 %SX] !8_
M1P 5/U$ %#]> !0_;  30'P $D"/ !% H@ 10+8 $$#. !$_ZP 2/_D $C[_
M 'DU  !I-P  7#@  %(Y  !*.0  0SD  #TY   W.0  ,3H  "L\   G/0
M(C\  !Y!!  :0@L &$,0 !=#%0 51!L %$0B !-$*0 31#$ $D0Z !%%0P 0
M14X $$5;  Y%:0 .17D #46,  U%GP ,1;( "T7)  Q%Y0 -1/8 #43_ '0Y
M  !E.@  6#L  $\[  !'/   0#P  #H\   T/   +CX  "A    C0@  'T0
M !I&   52 @ $DH- !%*$@ 02A@ #TL>  Y+)0 -2RT #4LV  Q+0  +2TH
M"DM6  E+9  (2W0 !TN'  5+F@ $2ZX !$K$  5*X  %2O  !DGZ &X\  !@
M/0  5#X  $L^  !$/@  /3X  #<_   Q0   *D(  "1%   ?1P  &DD  !5,
M   13@4 #E$+  M1$  *410 "5$;  A1(@ '42D !5$R  12.P #4D8  5)2
M  !27P  4F\  %*!  !1E@  4:D  %&_  !0W   4.X  %#W &A   !;00
M4$$  $A!  !!00  .T(  #1#   M10  )D@  "!+   ;30  %E   !%3   .
M500 "E@*  98#@ "6!(  %D7  !9'0  624  %DM  !9-@  64$  %E-  !:
M6@  6FD  %E\  !9D   6:4  %BZ  !8U0  5^P  %?V &-$  !610  344
M $5%   _10  -T<  "])   H3   (D\  !M2   650  $5@   U:   )70,
M!%\)  !@#0  8!   &$4  !A&0  8B   &(G  !B,0  8CL  &)'  !B50
M8V0  &)V  !BBP  8J   &&V  !ASP  8.H  &#U %U(  !220  2D@  $-(
M   Z2@  ,DT  "I0   C4P  '%<  !9:   170  #6    AC   #9@$  &<&
M  !H"P  :0X  &H1  !K%0  ;!L  &TB  !M*@  ;30  &U   !M3@  ;5T
M &UO  !MA   ;)H  &RP  !KR   :^8  &KS %A-  !.30  2$P  #Y.   U
M40  +%0  "18   =7   %F   !!D   ,9P  !VL   %N    <    '(#  !R
M!P  <PL  '4.  !V$0  =Q8  '@<  !Y(P  >BT  'HY  !Z1P  >E8  'EH
M  !Z?   >90  'BJ  !XP0  =]\  '?O %11  !,40  0E(  #A5   O60
M)EX  !YB   69P  $&L   MO   %<P   '<   !Z    ?    'X   !_ @
M@ 8  ($*  "##0  A!$  (85  "('   B24  (HP  "*/@  B4T  (E?  ")
M<P  B(L  (BB  "'N0  A]$  (;H %)6  !'5P  /%H  #)?   H9   'VD
M !9O   0=   "GD   )]    @0   (4   "(    B@   (P   "-    CP
M ) $  "2"   DPP  )40  "7%0  F1T  )LG  ";-   FT0  )I6  "::@
MF8(  )J:  "8L   F,<  )?> $M<  ! 8   -64  "MJ   A<0  %W<  !!]
M   )@P   8@   ",    D0   )4   "8    F@   )L   "=    GP   *
M  "B    I 4  *8*  "H#@  JA0  *T=  "M*@  K3D  *U+  "M7P  K7<
M *R0  "KIP  J[H  *O+ $5F   Y:P  +G$  "-X   9?P  $(8   F-
MDP   )@   "=    H0   *4   "H    JP   *L   "N    KP   +$   "S
M    M0   +<!  "Y!P  O T  +\3  #"'P  PBX  ,)   #"5   P6L  ,&#
M  # FP  P:T  ,&\ #YR   R>   )X   !R(   2D   "I<   "=    HP
M *@   "M    L@   +8   "Y    NP   +P   "^    P    ,(   #$
MQ@   ,@   #+    S@4  -$-  #6%   UR,  -@U  #920  VEX  -MU  #;
MC   W)\  -RK /\   #_    _P   /\ "0#_ !  _P 9 /X ) #\ "\ ^0 Y
M /0 0P#P $L [0!2 .H 60#G %\ Y !D .( :0#@ &X W@!S -P >0#: '\
MUP"& -0 C@#1 )8 SP"A ,P K #* +L R #2 ,8 [@#& /\ Q0#_ ,4 _P"_
M /\ N@#_ /\   #_    _P   /X !0#W  X \@ 5 .X 'P#K "H Z0 T .,
M/0#> $4 V0!- -0 4P#1 %D S@!> ,P 8P#* &@ R0!M ,< <P#% 'D PP"
M ,$ B "_ )  O0"; +L I@"Y +0 MP#( +8 Y@"U /L M #_ +0 _P"S /\
MK@#_ /\   #_    ^    .T   #E  L W0 1 -< &@#2 "0 SP N ,L -P#'
M $  PP!' ,  3@"^ %, O !9 +H 7@"X &, M@!H +4 ;0"S ', L0!Y *\
M@0"M (H JP"4 *D H "H *T I@"^ *4 VP"D /0 I #_ *, _P"C /\ H@#_
M /\   #V    Y@   -<   #+  8 Q  . +X %0"[ !\ N0 H +< ,0"T #H
ML !! *T 2 "K $X J0!3 *< 6 "F %P I !A *, 9P"A &P H !S )X >@"=
M (, FP". )D F0"7 *8 E@"V )4 S "4 .L DP#] ), _P"3 /\ DP#_ /<
M  #D    T    ,$   "W  ( KP + *L $0"G !D I0 B *, *P"B #, GP [
M )P 0@"; $@ F0!- )< 4@"6 %< E0!; ), 80"2 &8 D !M (\ = "- 'T
MC "' (H DP"( *  AP"O (4 P@"% .( A #W (0 _P"$ /\ A #_ .4   #-
M    O    *\   "F    G@ ' )H #@"6 !0 E  = )( )0"1 "T D  U (T
M/ ", $( B@!' (@ 3 "' %$ A@!6 (0 6P"# &  @0!G (  ;@!^ '< ?0"!
M 'L C0!Z )H > "I '< N@!V -, =@#O '8 _@!U /\ =0#_ -    "[
MJP   )\   "7    D  " (L "P"( !  A@ 7 (0 ( "" "< @0 O '\ -0!]
M #P ? !! 'L 1@!Y $L > !0 '< 50!V %L = !A ', :0!Q '$ < ![ &X
MAP!M )4 :P"C &H M !J ,D :0#H &D ^0!I /\ :0#_ ,    "L    G (
M ) "  "(    @P   '\ !@![  T >0 2 '< &@!V "( =  I ', , !Q #8
M<  \ &\ 00!M $8 ; !+ &L 4 !J %8 : !< &< 9 !E &P 9 !V &, @@!A
M )  8 "? %\ KP!> ,, 7@#A %X ] != /\ 70#_ +0'  "@"0  D L  (0+
M  !\"@  =P<  '0$  !Q  D ;P / &T %0!K !P :0 C &@ *@!G #$ 90 V
M &0 / !C $$ 8@!& &  3 !? %( 7@!8 %T 7P!; &@ 6@!R %@ ?@!7 (P
M5@"; %4 JP!4 +X 5 #: %, [P!4 /L 5 #_ *D-  "6#@  AQ   'H0  !R
M$   ; X  &D,  !G"0, 9@0+ &0 $ !B !< 8  > %X )0!= "L 7  Q %H
M-P!9 #P 6 !" %<!1P!6 4X 50)4 %,"7 !2 V4 40-O $\$>P!.!(H 3069
M $P%J0!+!;P 2@;4 $H'[0!*!_D 2@?_ *$0  ".$@  ?A0  ',4  !J%
M9!,  & 1  !>#P  70T% %T)#0!:!A( 6 <9 %8'( !5!R< 4P<M %((,P!1
M"#@ 4 @^ $\)1 !."4H 3 E1 $L*60!*"F( 2 MM $<+>@!&#(@ 1 R8 $,,
MJ0!"#;P 0@W5 $(-[@!"#?L 0@W_ )H4  "'%@  >!@  &P9  !C&0  71@
M %D6  !6$P  5!$  %0." !3#0X 40T4 $\-&P!-#2( 3 TH $L-+@!*#30
M20TZ $<.00!&#D< 10Y/ $0.5P!"#V$ 01!L #\0>0 ^$(@ /1&8 #L1J0 [
M$;P .A'6 #H1\  Z$OT .Q'_ ),8  "!&@  <QP  &<=  !>'0  6!P  %,;
M  !0&   3A8  $P3 P!,$0L 2A 0 $@1%P!&$1X 11$D $01*@!"$3  01$W
M $ 2/0 _$D0 /1), #P35  [$UX .11I #@4=@ W%84 -A66 #06IP T%KH
M,Q;3 #,6[@ T%OP -!;_ (X;  !\'0  ;A\  &,@  !:(   4R   $X>  !*
M'0  2!H  $88  !%%@< 0Q4. $$5$P _%1H /A4@ #T5)P [%2T .A8S #D6
M.@ X%D$ -Q=) #4740 T&%L ,QEF #(9<P P&H, +QJ4 "X;I0 M&[@ +1O0
M "T;[  N&_L +AO_ (H>  !X(   :B(  %\C  !6(P  3R(  $HA  !&(
M0QX  $$;   _&@, /1H, #L9$0 Y&18 -QH= #8:(P U&BD -!HP #,;-@ Q
M&SX ,!Q& "\<3P N'5D +1UD "P><0 K'X$ *A^2 "D?I  H(+< )R#. "<@
MZP H(/H *1__ (8@  !T(P  9R0  %PE  !3)0  3"4  $<D  !"(P  /R$
M #T?   Z'@  -QX) #4>#@ S'A, ,1X: # >(  O'B8 +A\M "T?,P L(#L
M*R!# "HA3  I(58 *")B "8B;P E(W\ )".0 ",CH@ B)+4 (B3, "(DZ0 C
M)/D )"/_ ((C  !Q)0  8R8  %DG  !0*   22<  $,G   _)@  .R0  #@B
M   U(@  ,B(& # B#0 N(A$ +"(7 "HB'0 I(B, *",J "<C,0 F)#@ )25!
M "0E2@ C)E0 (B9@ "$G;0 @)WT 'R>/ !XHH0 >*+0 '2C* !THZ  >*/@
M'R?_ 'XE  !N)P  8"D  %8I  !-*@  1BH  $$I   \*   -R<  #0F   P
M)@  +28# "LG"P H)Q  )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D^ !\J
M2  >*E( '2M> !PK:P ;*WL &BR- !DLGP 8++( &"S) !@LYP 9*_< &BO_
M 'HG  !J*@  72L  %,L  !*+   0RP  #XK   Y*P  -"H  # J   K*@
M*2L  "8K"  C+ X (BP2 " L&  ?+!X 'BTE !TM+  <+3, &RX\ !HN10 9
M+U  &"]< !<O:0 6,'D %3"+ !0PG@ 4,+$ $S#' !,PY0 4,/8 %2__ '8J
M  !G+   6BT  % N  !(+@  02X  #LN   V+0  ,2T  "PM   G+P  )"\
M "$P!0 ?,0P '#$0 !LR%0 :,AP &3(B !@R*0 7,S$ %C,Y !4S0P 4-$T
M$S19 !(T9P 1-7< $36) ! UG  0-;  #C7&  \TY  0-/4 $#3_ '(L  !C
M+@  5S   $TP  !%,   /C   #@P   S,   +S   "DQ   D,@  (3,  !TU
M @ :-@D %S<. !4W$P 4.!D $S@? !(X)@ 2."X $3DV ! Y0  0.4L #CE7
M  XZ9  -.G0 ##J&  PZF0 +.:P "CG!  HYW@ +.?$ ##C\ &XO  !?,0
M4S(  $HS  !",P  .S,  #8S   Q,@  +#,  "<T   A-@  '3@  !DY   5
M.P8 $CT, ! ^$  0/A4 #CX<  X^(P -/BH ##XS  P^/  +/T< "C]2  @_
M8  '/V\ !C^!  4_E  $/Z@  SZ\  0^UP %/NP !3[W &DS  !;-   4#4
M $<U   _-0  .34  #0U   N-0  *3<  ",X   >.P  &CP  !8_   2000
M#D,*  Q$#@ *1!, "409  A$(  '1"< !D0O  5$.  #14(  D5.  !%6P
M16H  $5\  !%D   1*0  $2Y  !$T0  1.H  $/U &0V  !7-P  3#@  $,X
M   \.   -S@  #$X   K.0  )3L  " ]   :0   %D(  !)$   .1P0 "TD)
M  =*#0 $2Q$  4L6  !+'   2R,  $LK  !+-   2SX  $Q)  !,5P  3&8
M $QW  !+C   2Z$  $NU  !*S@  2ND  $KU %\Z  !2.P  2#L  $ [   Z
M.P  -#L  "X\   G/@  (D$  !Q#   61@  $DD   Y+   +3@, !U (  )1
M#   41   %(3  !3&   4Q\  %,F  !3+P  4SD  %-%  !34@  4V$  %-R
M  !3AP  4IP  %*Q  !1R@  4><  %'T %D^  !./@  13X  #X^   X/@
M,$   "E"   C1   '4<  !=*   230  #E    M3   &50(  %<'  !8"P
M60X  %H1  !:%0  6QH  %PA  !<*@  7#0  %P_  !<30  7%L  %QL  !<
M@0  6Y<  %NM  !:Q0  6N0  %GS %1"  !*0@  0D(  #Q"   T0P  +$8
M "5)   >3   %T\  !)3   .5@  "ED   5;    7@   & $  !A"   8@P
M &,.  !D$0  918  &8<  !G(P  9RT  &<Y  !G1@  9U4  &=F  !G>@
M9I$  &6H  !EP   9-X  &3P $]&  !'1@  0$4  #='   O2@  )DT  !]1
M   850  $ED   U<   (8    F,   !F    :    &H   !K!   ; @  &T,
M  !O#@  <!(  '(7  !S'0  ="8  '0R  !T/P  =$X  '-?  !T<@  <XH
M '*A  !QN   <=0  '#L $Q*  !%2@  .TL  #).   I4@  (%8  !A;   2
M7P  #60   =H    :P   &\   !R    =0   '8   !W    >0(  'H&  !\
M"@  ?@X  ( 1  ""%@  A!X  (0I  "$-@  A$4  (16  "#:@  @X$  (*9
M  "!L0  @,D  (#E $I.   _4   -5,  "M7   B7   &6(  !)G   ,;
M!7$   !U    >0   'T   "!    @P   (4   "&    B    (D   "+!
MC0@  (\-  "2$   E!8  )8@  "6+   ECL  )9,  "58   E78  )20  "3
MIP  DKT  )+5 $15   Y60  +UT  "1C   ::0  $F\   QU   $>P   (
M  "%    B0   (T   "1    DP   )0   "6    F    )H   "<    G@
M * &  "B"P  I1   *@7  "I(P  J3$  *E#  "I5@  J&T  *:'  "GG@
MIK,  *7' #Y>   R8P  )VH  !UP   3>   #'\   .%    BP   )$   "6
M    FP   )\   "B    I    *4   "G    J0   *L   "M    L    +(
M  "U @  MPD  +L0  "^&   OB8  +XX  "^2P  O6$  +QZ  "[E   NJD
M +JY #=J   K<   ('@  !:    -B   !8\   "6    G    *(   "G
MK    +    "S    M@   +<   "Y    NP   +T   "_    P@   ,4   #(
M    R@   ,X(  #2$   U1L  -4L  #40   U%<  --N  #4A@  U)L  -.K
M /\   #_    _P   /\ !0#_  X _P 5 /P ( #Y "H ]@ T /$ /0#M $8
MZ0!- .8 4P#D %D X0!> -X 8P#< &@ V0!N -4 <P#3 'D T "  ,X B #+
M )$ R0"< ,8 IP#$ +< P@#, ,  [ "_ /\ O@#_ +T _P"W /\ L@#_ /\
M  #_    _P   /H  0#S  L [0 2 .@ &P#E "4 Y  N -\ . #8 $  T@!'
M ,X 3@#+ %0 R !9 ,8 7@#$ &, P@!G ,  ;0"_ ', O0!Z +L @0"Y (L
MM@"5 +0 H0"R *\ L #" *X XP"N /H K #_ *T _P"I /\ I@#_ /\   #_
M    \@   .8   #=  < T@ . ,T %@#* "  R  I ,4 ,@#  #H O !" +D
M2 "W $X M0!3 +, 6 "Q %T L !B *X 9P"L &P J@!S *D >P"G (0 I0".
M *, F@"A *@ GP"Y )X T@"= /( G #_ )T _P"< /\ F0#_ /P   #N
MW0   ,P   #!  ( N@ , +8 $@"R !H L  C *\ + "M #0 J0 \ *8 0@"D
M $@ H@!- *  4@"> %< G0!; )P 8 ": &8 F0!L )< = "5 'T DP"' )$
MDP"0 *$ C@"Q (T Q@", .@ BP#] (P _P", /\ C #_ .T   #8    Q0
M +<   "L    I@ ( *$ #@"? !4 G0 > )L )@": "X EP U )4 / "3 $(
MD0!' )  3 ". %$ C0!5 (L 6@"* &  B0!F (< ;0"% '8 A "  (( C "
M )H ?P"I 'T O !\ -P ? #U 'P _P!\ /\ ? #_ -D   #!    L0   *0
M  "<    E  # )  # "- !$ BP 8 (D ( ") "@ AP O (4 -@"# #P @@!!
M (  1@!_ $L ?0!/ 'P 5 ![ %H >0!@ '@ 9P!V '  =0!Z ', A@!Q ),
M< "B &\ M !N ,P ;@#M &X _@!N /\ ;@#_ ,0   "O    H    )0   ",
M    A@   ($ " !^  X ?  4 'L &P!Y "( >  I '< , !U #8 =  [ '(
M0 !Q $4 < !* &\ 3P!M %0 ; !; &L 8@!I &H : !T &8 @ !E (X 8P"=
M &( K0!A ,( 80#D &$ ^ !A /\ 80#_ +0   "@    D0   (8   !^
M>0   '4  P!Q  L ;P 0 &T %@!L !T :P D &L *@!I #  :  V &8 .P!E
M $  9 !% &, 2@!A $\ 8 !6 %\ 70!= &4 7 !O %H >@!9 (@ 6 "8 %<
MJ !6 +L 5@#8 %8 \0!6 /\ 5@#_ *@!  "4!0  A0<  'H'  !R!@  ; 0
M &D!  !G  < 9  - &, $0!A !@ 8  ? %\ )0!> "L 70 P %L -@!: #L
M60!  %@ 10!7 $L 5@!1 %4 6 !3 &$ 4@!J %  =@!/ (0 3@"3 $T I !,
M +8 3 #- $P ZP!, /H 3 #_ )T)  "+"P  ? T  ' -  !H#0  8@P  %\*
M  !=!@$ 7 $) %H #@!8 !, 5P 9 %8 ( !5 "8 4P K %( ,0!1 #8 4  [
M $\ 00!. $< 30!- $L 50!* %T 20!G $< <P!& (  10"0 $0 H0!# +(
M0P#( $, Y@!# /4 0P#_ )4-  "##P  =!   &D1  !@$0  6A   %8.  !4
M#0  4PH$ %,&"P!1 Q  3P$5 $X!&P!, 2$ 2P$G $H"+ !) C( 2 (W $<#
M/0!% T, 1 -* $,$40!"!%H 0 5D #\%<  ^!GX /0:. #P'GP [![$ .@?&
M #H'XP Z!_, .@C\ (X0  !\$@  ;A0  &(5  !:%0  5!0  % 3  !-$0
M2PX  $L-!@!*"@P 20@1 $<(%@!%"!T 1 @C $((* !!"2X 0 DS #\).0 ^
M"D  /0I' #P*3P Z"U@ .0MC #@,;P V#'X -0R. #0-GP S#;$ ,@W' #(-
MXP R#?0 ,@W^ (@3  !W%0  :1<  %X8  !5&   3Q@  $H6  !'%0  11,
M $,0 @!##@@ 0@T. $ -$@ _#1@ /0T? #P-)  [#2H .0TP #@.-P W#CT
M-@Y% #4.30 S#U< ,@]B #$0;@ O$'T +A". "T1H  L$;( *Q'( "L1Y@ K
M$?8 +!'_ (,6  !R&0  9!H  %D;  !1&P  2QL  $8:  !"&   /Q<  #X4
M   \$@0 .Q$* #H0$  X$!4 -Q ; #41(0 T$2< ,Q$M #(1,P P$3H +Q)"
M "X22P M$U0 *Q-? "H4;  I%'L *!2, "<5G@ F%;  )17& "45Y  E%?8
M)A7_ 'X9  !N&P  8!T  %8>  !-'@  1QX  $(=   ^'   .AH  #@8   W
M%@  -14' #04#0 R%!( ,!07 "\4'0 M%", +!4J "L5,  J%3< *18_ "@6
M2  G%U( )AA= "08:@ C&7D (AF* "$9G  @&:\ 'QG$ !\9X@ @&?0 (!G_
M 'H;  !J'@  71\  %,@  !*(   1"   #X?   Z'@  -QT  #0<   R&0
M,!D$ "X8"P L&!  *A@4 "D8&@ G&"  )ADF "49+0 D&C4 (QH] "(;1@ A
M&U  (!Q; !\=:  >'7< '1V( !P>FP ;'JT &A[# !H>X  :'?, &QW_ '<=
M  !G(   6B$  % B  !((@  02(  #LB   W(0  ,R   # ?   M'0  *QT
M "@="  F'0X )1T2 ",=%P A'1T (1TD " >*@ ?'C( 'A\Z !T?0P <($T
M&R%9 !HA9@ 9(74 &"*' !<BF0 6(JP %2+! !4BWP 5(?( %B'^ ',@  !D
M(@  5R,  $TD  !%)0  /B0  #DD   T(P  ,"(  "PB   I(0  )B$  "0A
M!@ B(0P ("$0 !XA%0 =(AL &R(A !LB*  :(R\ &2,X !@D00 7)$L %B57
M !4E9  4)G, $R:% !(FF  1)JL $2;  ! FW0 1)?$ $B7] ' B  !A)
M5"8  $HF  !")P  /"8  #8F   Q)0  +24  "DD   F)   (B4  !\E P =
M)@H &R8. !DG$@ 8)Q@ %R<? !8G)0 5*"T %"@U !,I/@ 2*4D $2E5 !$J
M8@ 0*G$ #RJ#  XJE@ .*JD #2J]  TJUP -*NX #BG[ &PD  !=)@  42@
M $@H  ! *0  .2@  #0H   O*   *R<  "<G   B*   'BD  !LJ   8*P<
M%BL- !0L$0 3+!8 $BP< !$M(P 0+2H $"TR  \N/  .+D8 #2Y2  TN7P ,
M+VX "R]_  HOD@ )+Z4 "2ZY  @NT  )+ND "B[W &@G  !:*0  3BH  $4K
M   ]*P  -RL  #$J   M*@  *2H  "0J   @*P  &RT  !@N   5+P0 $C$*
M ! R#@ /,A, #C(9  TR(  -,B< ##(O  LS.  *,T( "3-.  @S6P &-&H
M!31[  0SC@ #,Z(  C.V  (SS0 #,^< !#+S &0J  !6+   2RT  $(M   Z
M+0  -"T  "\L   K+   )BP  "(M   =+P  &3$  !4R   2- , #S8)  PX
M#0 *.!$ "3@6  @X'0 '."0 !C@L  0X-  #.#X  CE*   Y5P  .64  #EW
M   YBP  .)\  #BS   XR@  ..8  #?R %\M  !2+@  2"\  #\P   X+P
M,B\  "TO   I+P  )#   !\Q   :,P  %34  !(W   /.0, ##L(  @]#0 %
M/A   SX4   ^&@  /B$  #XH   ^,0  /SL  #]&   _4P  /V$  #]S   _
MAP  /IP  #ZP   ]QP  />0  #WR %HP  !.,@  1#(  #PR   U,@  ,#$
M "LQ   F,@  (#0  !LV   6.   $CL   \]   ,/P, "$$(  1##   0PX
M $02  !%%@  11T  $4D  !%+0  1C8  $9"  !&3@  1ET  $9N  !%@@
M19@  $2M  !$Q   0^,  $/R %4T  !*-0  034  #DU   S-   +C0  "@U
M   B-P  '3H  !<\   2/P  #T$   Q$   (1@$  T@&  !)"@  2@T  $L0
M  !,%   31D  $X@  !.*   3C(  $T]  !.2@  3E@  $UI  !-?0  3)0
M $RJ  !+P0  2^$  $KR % X  !&.   /3@  #<X   Q-P  *CD  "0[   >
M/0  &$   !-#   /1@  "TD   =+   "3@   % $  !1"   4@L  %,.  !4
M$0  514  %8;  !7(P  5RP  %<X  !71   5U(  %9C  !6=P  5HX  %6E
M  !4O0  4]T  %/P $L\  !"/   .SL  #4[   M/   )C\  !]"   910
M$T@   Y+   +3P  !5$   !4    5P   %@!  !:!0  6P@  %P,  !=#@
M7Q$  & 6  !B'0  8B8  &(Q  !B/@  84P  &%=  !A<   8(@  &"@  !?
MMP  7M0  %WN $=    _/P  .C\  #%    I0P  (48  !I*   33@  #E$
M  I5   $6    %L   !>    80   &,   !D 0  900  &<(  !H"P  :@X
M &P2  !N%P  ;R   &\J  !O-@  ;D4  &Y5  !N:   ;7\  &V8  !LL
M:\H  &KH $1$   ^0P  -40  "M'   C2P  &T\  !-4   .6   "%P   )@
M    9    &<   !K    ;0   &\   !P    <@   '0"  !U!@  =PH  'D.
M  !\$@  ?A@  '\B  !_+@  ?ST  'Y-  !]80  ?7<  'R0  ![J   >L
M 'G? $-'   Y20  +TP  "50   <50  %%L   Y@   '90   &H   !N
M<@   '8   !Y    ?    'X   !_    @0   (,   "%    AP,  (H(  ",
M#0  CQ$  )(9  "2)0  DC,  ))$  "15P  D&T  (^&  ".GP  C;4  (S-
M #U.   R40  *%8  !Y<   58@  #F@   =N    =    'D   !^    @@
M (8   ")    C    (X   "0    D@   )0   "6    F    )L   ">!@
MH0P  *01  "F&P  IBD  *8Z  "E30  I6(  *1[  "CE   H:L  *&_ #97
M   L7   (6(  !=I   /<   !W<   !^    A    (H   "/    E    )@
M  ";    G@   )\   "B    I    *8   "H    JP   *T   "P    LP0
M +<,  "[$@  NQ\  +LP  "[0P  NE@  +EP  "WBP  MZ$  +>S #!B   E
M:0  &G   !!X   )@    (@   "/    E@   )L   "A    I@   *H   "N
M    L    +$   "T    M@   +@   "[    O0   ,    ##    QP   ,L#
M  #/#   TQ4  -(E  #2.   T4X  -!E  #/?@  S98  ,RI /\   #_
M_P   /\  P#_  L _  1 /D &P#W "4 \P O .X . #I $  Y@!( .( 3@#?
M %0 W !9 -D 7@#5 &, TP!H -  ;0#. ', RP!Z ,@ @@#& (P PP"7 ,
MHP"^ +( O #( +H Z@"Y /\ N #_ +$ _P"J /\ IP#_ /\   #_    ^P
M /8   #M  < YP / .( %@#? "  W@ I -D ,P#1 #L S !" ,@ 2 #% $X
MP@!3 ,  6 "^ %T O !B +H 9P"Y &T MP!T +4 >P"R (4 L "0 *X G "L
M *H J0"] *< W@"F /D I0#_ *, _P"= /\ FP#_ /T   #V    ZP   -\
M  #1  , R@ , ,4 $@## !L P  D +X + "Y #4 M@ \ +, 0P"P $@ K@!.
M *P 4@"K %< J0!< *< 80"F &< I !M *( = "@ 'T G@"( )P E0": *,
MF "T )8 S0"5 /$ E #_ )4 _P"0 /\ C@#_ /,   #F    T0   ,(   "X
M    L0 ( *T #P"J !8 J  > *@ )P"F "\ H@ V )\ / "= $( FP!' )D
M3 "7 %$ E@!5 )0 6@"3 &  D0!F )  ;@". '8 C "! (H C0"( )L A@"L
M (4 P0"$ .8 @P#] (0 _P"# /\ @0#_ .0   #+    N@   *P   "B
MG  $ )@ # "6 !$ E  9 ), (0"2 "@ CP P (T -@"+ #P B0!! (@ 1@"&
M $L A0!/ (0 5 "" %H @0!@ '\ 9P!^ &\ ? !Z 'H A@!X )0 =P"D '4
MMP!T -0 <P#T '0 _P!T /\ = #_ ,L   "V    I@   )H   "2    B@
M (8 " "#  X @0 4 ($ &P"  ", ?P J 'T , ![ #8 >@ [ '@ 0 !W $4
M=0!) '0 3@!S %0 <0!: '  80!N &D ;0!S &L ?P!I (T : "= &< K@!F
M ,< 90#J &8 _P!F /\ 9P#_ +@   "D    E0   (H   "!    ?    '8
M! !T  P <@ 0 '$ %@!P !T <  D &X *@!M #  :P U &H .@!I #\ : !$
M &< 20!E $X 9 !4 &, 6P!A &, 8 !M %X >0!= (< 6P"6 %H J !9 +T
M60#? %D ^ !: /\ 6@#_ *@   "5    AP   'L   !S    ;@   &H  0!G
M  @ 90 . &0 $@!C !@ 8P ? &( )0!A "H 7P P %X -0!= #H 7  ^ %L
M1 !9 $D 6 !/ %< 5@!6 %X 5 !H %, <P!1 ($ 4 "1 $\ H@!. +4 3@#0
M $X \ !. /\ 3P#_ )P   ")    >P,  ' #  !H P  8@$  %\   !=  0
M6P + %D #P!8 !0 5P 9 %< ( !6 "4 50 J %, , !2 #0 40 Y %  /P!/
M $0 3@!+ $T 4@!+ %H 2@!C $D ;P!' 'P 1@", $4 G0!% +  1 #' $0
MZ !$ /H 10#_ )($  " !P  <0H  &8*  !>"@  60D  %4'  !4!   4@ '
M %  # !/ !  3@ 5 $T &P!, "  2P F $H *P!) #  2  U $< .@!& $
M10!& $, 3@!" %8 00!? $  :P ^ '@ /0"( #P F0 \ *L / #! #L X  [
M /0 .P#_ (D*  !X#   :@X  %\.  !7#@  40X  $T,  !+"P  2@@" $D$
M"0!(  T 1@ 1 $4 %@!$ !P 0P A $( )@!! "L /P Q #X -@ ] #P / !#
M #L 2@ Z %( .0!< #@ :  V '4 -0"% #0 E@ T *@ ,P"\ #, V  S .\
M,P#[ ((-  !Q#P  9!   %D1  !1$0  2Q$  $<0  !$#@  0@T  $$+!0!!
M!PL /P4. #X#$@ \ A@ .P(= #H#(@ Y R@ . ,M #<#,@ V!#D -00_ #0%
M1P S!5  ,09: # &9@ O!W, +@># "T'E0 L!Z< *P>Z "L'T@ K!^L *P?W
M 'T0  !L$0  7Q,  %04  !,%   1A0  $(3   ^$@  /!   #H. 0 Z#08
M.@H, #@)$  V"!0 -0@9 #0)'P R"20 ,0DI # )+P O"C8 +@H] "T*10 L
M"TX *PM9 "D,90 H#', )PR# "8-E0 E#:< ) V[ ",-T@ C#>L (PWW '@2
M  !H%   6Q8  %$7  !(%P  0A8  #T6   Y%0  -Q,  #41   S$ , ,PX(
M #(-#0 P#1$ +PT6 "T-&P L#2$ *PTG "H-+0 I#C0 * X[ "<.1  E#DX
M) ]9 ",090 A$', (!"$ !\0E@ >$*D '1"] !P0V  =$.X '1#Y ',4  !D
M%@  5Q@  $T9  !%&0  /QD  #H8   U%P  ,A8  # 5   N$P  +1$$ "P0
M"@ K$ X *1 2 "@0&  F$!X )1 D "00*@ C$3$ (A$Y "$10@ @$DL 'A)6
M !T38P <$W$ &A." !D4E0 8%*< %Q2[ !<3U  7$^X &!/Z ' 6  !@&0
M5!H  $H;  !"'   /!L  #8;   R&@  +QD  "P8   J%@  *!0! "83!P E
M$PP (Q,0 "(3%0 @$QH 'Q,A !X4)P =%"X '!4V !L5/P :%DD &194 !@7
M80 6%W  %1B! !08DP 3&*8 $ABZ !(7T@ 2%^P $Q?Z &P9  !=&P  41T
M $<=   _'@  .1T  #0=   O'   *QL  "@:   F&0  )!@  "(7!  @%PH
M'A<. !P7$@ :%Q< &1@> !D8)  8&2P %QDT !8:/0 5&D< %!M2 !,;7P 2
M'&X $1Q_ ! <D@ 0'*4 #QRY  X<T  .&^H #QOX &D;  !:'0  3A\  $4?
M   ](   -A\  #$?   M'@  *1T  "4=   C'   (!L  !T; 0 ;&P< &1P-
M !<<$  6'!4 %1P; !0=(@ 3'2D $AXQ !$>.@ 1'T4 $!]0  \@70 .(&P
M#2!\  T@CP ,(*( "R"U  L@R@ +(.4 #!_T &4=  !7'P  3"$  $(A   Z
M(0  -"$  "\A   J(   )A\  ",?   @'@  '1X  !D@   6( 0 %" + !(A
M#@ 1(1, $2(9 ! B'P /(B8 #B,O  XC-P -(T$ #"1-  LD60 *)&< "21X
M  @DBP '))X !R2Q  8DQP &(^, !R/Q &(?  !4(0  22,  $ C   X(P
M,B,  "PC   H(@  )"$  "$A   >(0  &B$  !8C   3) , $24(  \F#0 .
M)Q$ #2<6  PG'0 +)R, "B<K  DH-  (*#X !RA)  8H50 %*60 !"ET  ,I
MAP "*9L  2BO   HQ0 !*.$  2?P %XB  !1)   1B4  #TE   U)0  +R4
M "HD   F)   (B,  !\C   ;)   &"4  !0F   1* , #RD(  PL#  *+!
M""P4  <L&@ &+"$ !2PH  ,M,  "+3H  2U%   M4@  +F   "YQ   MA
M+9D  "VM   LP@  +.   "SP %HD  !-)@  0R<  #HG   S)P  +2<  "@F
M   D)@  (28  !TF   9)P  %2D  !$K   /+ , #2X'  DP#  &,0X  S$2
M  $R%P  ,AX  #(E   R+0  ,C8  #-"   S3@  ,UT  #-M   S@0  ,I8
M #*K   QP0  ,=\  #'P %8G  !**0  /RH  #<J   P*@  *RD  "<H   C
M*   'BD  !HJ   6+   $BX   \P   -,0( "C0'  4U"P "-@X  #<0   X
M%   .!H  #@B   X*@  .3,  #D^   Y2@  .5D  #EI   Y?0  .),  #BH
M   WOP  -]X  #;P %$K  !&+   /"P  #0L   N+   *BL  "4K   @+
M&RT  !<O   3,0  $#,   TU   )-P( !3H&  $["@  / T  #T/   ^$@
M/Q<  $ >  ! )0  0"\  $ Z  ! 1@  0%0  $!E   _>   /X\  #ZF   ^
MO0  /=P  #WP $TN  !"+P  .2\  #(O   M+@  *"X  "(O   =,   &#(
M !,U   0-P  ##H   D\   %/@   $$$  !""   0PL  $0-  !&$   1Q0
M $@9  !((0  2"H  $@U  !(00  2$\  $A@  !'<P  1XH  $:B  !%N0
M1=D  $3P $@R   ^,@  -C(  # Q   K,0  )3(  !\T   9-@  $SD  ! \
M   ,/P  "$(   -$    1@   $@"  !*!0  2P@  $P+  !.#@  3Q$  %$5
M  !2'   4B4  %(P  !2/   44H  %%:  !1;0  4(0  $^=  !.M0  3=(
M $WN $,V   [-@  -#4  "\T   G-0  (3@  !H[   4/@  $$$   Q$   '
M1P   DH   !-    3P   %$   !3 @  5 4  %4(  !7"P  60X  %L1  !=
M%P  71\  %TJ  !=-@  7$0  %Q4  !;9P  6WX  %J7  !9KP  6,L  %?J
M #\Y   X.0  ,S@  "LY   C/   '#\  !5#   01P  "TH   5.    40
M %0   !7    6@   %P   !=    7P   & $  !B!P  9 L  &8.  !H$@
M:QD  &LC  !J+@  :CP  &I-  !I7P  :'4  &>/  !FJ   9<(  &3C #T]
M   W/   +CT  "5    =1   %DD  !!-   *40  !%4   !:    70   &
M  !C    9@   &@   !J    :P   &T   !O @  <08  '0*  !V#@  >1,
M 'L;  ![)P  >C4  'E%  !X60  >&T  '>&  !VGP  =;<  '32 #Q!   R
M0@  *$4  "!*   73@  $%0   I9   "7@   &,   !G    :P   &\   !R
M    =0   '<   !Y    >P   'T   !_    @@   (0#  "'"0  B@X  (X3
M  "/'@  CBL  (X[  "-3@  BV,  (I\  "*E0  B*T  (?% #9'   L2P
M(D\  !E5   06P  "F$   %G    ;0   '(   !W    >P   '\   "#
MA@   (@   "*    C0   (\   "1    E    )<   ": 0  G0<  *$-  "E
M%   I"$  *0Q  "C1   HED  *!P  "?BP  G:(  )VW #!0   E50  &UL
M !)B   +:0   7    !W    ?0   (,   "(    C0   )$   "5    F
M )H   "<    GP   *$   "C    I@   *D   "L    L    +0'  "X#@
MNA@  +HG  "Y.0  N$X  +=E  "V?@  M98  +.K "E;   >8@  %&D   QQ
M   ">0   ($   ")    CP   )8   ";    H    *0   "H    JP   *P
M  "O    L@   +0   "V    N0   +P   #     Q    ,@   #-!P  TA
M -(=  #1+P  T$0  ,];  #-<P  RXT  ,JA /\   #_    ^P   /H   #\
M  @ ^  / /4 %P#T "  \0 J .L ,P#F #L X@!# -X 20#: $\ U@!4 -,
M60#0 %X S@!C ,L : #) &X Q@!U ,, ?0#! (8 O@"2 +L G@"Y *X M@##
M +0 Z "S /\ KP#_ *4 _P"> /\ FP#_ /T   #W    \@   /    #G  ,
MX0 , -P $@#8 !L U@ D -( +0#, #8 Q@ ] ,( 0P"_ $D O !. +H 4P"X
M %@ M@!= +4 8@"S &< L0!N *\ =@"L '\ J@"* *@ EP"E *8 HP"Y *$
MV0"@ /D G@#_ )@ _P"2 /\ CP#_ /,   #L    XP   -,   #(    P0 )
M +T #P"[ !8 N0 ? +< )P"S "\ KP W *P /0"J $, J !( *8 30"D %(
MHP!6 *$ 6P"? &$ G@!G )P ;P": '@ EP"# )4 D "3 )X D0"P )  R ".
M /  C0#_ (H _P"% /\ @@#_ .<   #=    Q@   +@   "N    J  $ *4
M# "A !( H0 9 *  (@"? "D FP P )@ -P"6 #T DP!" )( 1P"0 $L CP!0
M (T 50", %H B@!A (@ : "' '  A0![ (, B "! )8 ?P"G 'T O !\ .,
M? #] 'P _P!X /\ =@#_ -8   #     KP   *,   "9    DP   (\ "0"-
M  X BP 4 (H ' "* ", B  J (4 , "# #8 @@ [ (  0 !_ $4 ?@!* 'P
M3P![ %0 >@!: '@ 80!V &D =0!S ', @ !Q (X ;P"? &X L@!M ,\ ; #T
M &P _P!K /\ :0#_ ,    "K    FP   (\   "'    @    'P ! !Z  P
M>  1 '@ %P!X !X =P D '4 *@!S #  <0 U '  .@!N #\ ;0!$ &P 20!K
M $X :@!4 &@ 6P!G &, 90!M &0 > !B (< 8 "7 %\ J@!> ,( 7@#I %X
M_P!> /\ 70#_ *P   "9    B@   '\   !W    <0   &T   !J  @ :0 .
M &@ $@!G !@ 9P ? &< )0!E "H 8P O &( - !A #D 8  ^ %\ 0P!> $@
M70!. %L 50!: %T 6 !G %< <@!5 ($ 5 "1 %, HP!2 +@ 40#< %$ ^0!2
M /\ 4@#_ )T   "+    ?    '$   !I    9    &    !>  4 7  + %L
M#P!; !0 6@ 9 %H 'P!9 "4 5P J %8 +P!5 #0 5  X %, /0!2 $, 4 !)
M $\ 4 !. %@ 30!B $L ;0!* 'H 20"+ $@ G0!' +$ 1P#, $8 \ !' /\
M1P#_ )    !^    <    &8   !>    60   %8   !3  $ 4@ ( %  #0!/
M !  3P 5 $X &@!. "  30 E $P *@!* "X 20 S $@ . !' #X 1@!$ $4
M2P!$ %, 0P!= $$ : !  '4 /P"% #X EP ] *L /0## #T Y@ ] /L /@#_
M (<   !U P  : 8  %T'  !5!@  4 8  $P$  !* 0  20 $ $< "@!&  X
M10 1 $4 %@!$ !L 0P @ $( )0!! "H 0  O #\ -  ^ #H /0!  #L 1P Z
M $\ .0!9 #@ 9  W '$ -@"! #4 DP T *8 - "[ #0 W0 T /4 -0#_ 'X&
M  !M"0  8 L  %8,  !.#   2 L  $0*  !""   0 4! #\!!P ^  L /0 .
M #P $@ [ !< .P < #H (0 Y "4 -P J #8 ,  U #4 -  \ #, 0P R $P
M,0!5 #  8  O &T +@!] "T CP L *( + "V "P T  L .X + #\ '<*  !G
M#   6@X  % .  !)#@  0PX  #X-   [#   .0L  #@) P W!0@ -@(- #4!
M$  T !, ,P 8 #( '0 Q "( ,  G "\ +  N #( +0 X "P 0  K $D *@!2
M "D 70 H &L )P%Z "8!C  E )\ )0"R "4 R@ E .@ )0#W '(-  !B#@
M5A   $P1  !$$0  /A$  #D0   V#P  ,PX  #$- 0 P"P4 , @* "\&#0 N
M!1$ + 04 "L#&0 J QX *0,C "@$*0 G!"\ )@4U "4%/0 D!48 (P90 "(&
M7  A!VD ( =Y !\'BP >!YT '@>P !T&Q@ =!N, '07S &T.  !>$0  4A(
M $@3  ! $P  .A,  #42   Q$0  +A   "P/   J#@, *@T' "D+"P H"0X
M)PD1 "4(%@ D"!L (PD@ "())@ A"2P ( HS !\*.P >"T0 '0M/ !P,6P ;
M#&D &@QY !@,BP 8#)X %PRP !8,Q0 6#.$ %@OP &D0  !:$@  3A0  $45
M   ]%0  -Q4  #$4   M$P  *A(  "@1   F$ $ )! $ ",."  C#0P (@P/
M " ,$P ?#!@ '@T= !T-(P <#2H &PTR !H..@ 8#D0 %PY0 !8/7  5#VH
M$Q![ !(0C0 1$*  $1"S ! /R0 0#^0 $0_R &42  !7%   2Q8  $(7   Z
M%P  -!<  "\6   J%0  )Q0  "03   B$P  (!(# !X1!@ =$ D '! - !L/
M$  9$!4 &! ; !<0(0 6$"@ %1$P !01.0 3$4, $A). !$26@ 0$FD $!-Y
M  X3C  .$YX #1.Q  T2Q0 ,$N$ #1+Q &(4  !4%@  21@  #\9   W&0
M,1D  "P8   H%P  )!8  "$6   ?%0  '!0" !H3!  9$@8 %Q(+ !42#@ 4
M$A( $Q,8 !(3'P 1$R8 $10M ! 4-@ /%4$ #A5,  X65P -%F4 #!=U  L7
MAP *%YH "1:M  @6P0 (%MT "17N %\6  !1&   1AH  #T:   U&P  +QH
M "H:   E&0  (A@  !\8   <%P  &18! !<6 P 5%@0 $Q8) !$6#0 0%Q$
M#Q<6  X7'  .&", #1@J  P9,P ,&3P "QI'  H:4P )&F$ !QMQ  8;@P %
M&Y< !!JJ  ,:OP #&=H !!GL %P8  !.&@  0QP  #H<   S'   +!P  "<<
M   C&P  (!H  !T9   :&0  %Q@! !48 @ 2&00 $!L'  X;#  -'!  #!P3
M  L<&0 *'!\ "1TG  @=+P ''CD !AY#  0>4  #'UX  A]N  $?@   'Y4
M !ZI   >O0  '=@  !WL %@:  !+'   01X  #@>   P'@  *AX  "4=   A
M'   'AP  !L;   8&P  %AL! !,; @ 1' 0 #AX'  P?"P *( X "" 2  8A
M%P %(1T !"$D  (B+  !(C4  ")    C30  (UH  "-K   C?@  (Y,  "*G
M   BO   (=<  "'M %4=  !('P  /B   #4@   N(   *"   ",?   @'@
M'1T  !H=   6'0  $QX  !$? @ .( 0 #2('  HD"P &)0T !"40  (F%
M)AH  "8A   G*0  )S(  "<]   G20  *%<  "AG   G>P  )Y   ">E   F
MNP  )M8  "7M %$@  !%(0  .R(  #(B   L(@  )B$  "(A   >(   &Q\
M !@@   4(   $2(   \C   -)0, "B8&  8H"@ #*0T  "L/   L$@  +!<
M "P>   L)@  +2\  "TY   M1@  +50  "UD   M=P  +(T  "RD   KN@
M*]8  "KN $TB  !!)   ."0  # D   I)   )",  "$B   =(@  &2(  !4C
M   2)   #R8   TH   **@( !BP%  (N"0  +PL  # .   R$   ,Q4  #,;
M   S(@  ,RL  #,V   S0@  ,U   #-@   S<P  ,HH  #*A   QN   ,-8
M ##O $DE   ^)@  -"<  "TG   H)@  (R4  !\D   ;)0  %B8  !(H   0
M*@  #2P   HN   &, $  C($   T!P  -0H  #<,   X#@  .A(  #H7   Z
M'P  .B<  #HR   Z/@  .DP  #I<   Z;P  .88  #B>   XM@  -]0  #;O
M $0I   Z*0  ,2D  "LI   F*   (B<  !TH   8*0  $RL  ! N   -,
M"3(   4U   !-P   #D"   [!0  / @  #X+   _#0  01   $,4  !#&P
M0R,  $,N  !#.0  0T<  $)7  !":@  08$  $":   _L@  /L\  #[O #\L
M   V+   +RP  "HK   E*@  'RL  !DM   4+P  $#(   TU   (.   !#H
M   \    /P   $$   !# @  104  $8(  !("P  2@X  $P1  !-%@  31X
M $TH  !--   3$(  $Q1  !+9   2WL  $J4  !)K0  2,H  $?L #LP   S
M+P  +2\  "@M   B+P  &S$  !4T   0-P  #3H   @]   "0    $,   !&
M    2    $H   !,    3@$  $\$  !1!P  4PL  %4.  !8$@  61D  %@B
M  !8+@  5SP  %=+  !67@  5G,  %6-  !4IP  4L(  %+F #@S   Q,@
M+#$  "4R   =-0  %C@  !$\   ,0   !T0   !'    2@   $T   !0
M4P   %4   !7    60   %H   !< P  7@<  &$+  !D#@  9A,  &<<  !F
M)P  9C0  &5$  !D5P  9&L  &*%  !AGP  8+D  %[< #4W   P-0  *#<
M " Z   8/0  $4(   Q&   &2@   $\   !3    5@   %D   !<    7P
M &$   !D    90   &<   !I    ; $  &X&  !Q"P  = \  '<5  !W(
M=BT  '8]  !U3P  =&,  '-[  !RE0  <*\  &_) #4Z   K.P  (C\  !I#
M   22   #$T   52    5P   %P   !@    9    &@   !K    ;@   '$
M  !S    =0   '<   !Z    ?    '\   ""!   A@H  (H/  ",%P  BR0
M (HS  ")10  AUL  (9R  "%BP  @Z4  (*\ "]    E1   '$D  !-.   -
M5   !%H   !A    9@   &L   !O    =    'D   !]    @    (,   "%
M    AP   (H   ",    CP   )(   "6    F0(  )X)  "B$   HAH  *$I
M  "@.P  GU   )UG  ":@0  FID  )FO "E)   ?3@  %50   Y;   %8@
M &D   !P    =P   'T   ""    A@   (L   "/    DP   )4   "7
MF@   )T   "@    HP   *8   "J    K@   +(   "W"@  NQ$  +H?  "Y
M,   MT4  +5<  "T=   L8X  *^D ")4   86P  $&(   =J    <P   'L
M  ""    B0   )    "5    F@   )\   "C    I@   *@   "K    K@
M +    "S    M@   +H   "]    P@   ,<   #, 0  TPL  -05  #3)@
MT3H  -!1  #-:   RX$  ,J6 /P   #V    \@   /$   #S  4 ]  , /(
M$P#P !P [0 E .@ +@#B #8 W@ ^ -D 1 #4 $H T0!/ ,X 5 #+ %D R0!>
M ,8 8P#$ &D P0!P +X > "\ ($ N0"- +8 F@"S *L L0#  *\ Y@"N /\
MI0#_ )H _P"4 /\ CP#_ /0   #L    Z    .<   #?    V0 ) -( $ #/
M !< SP @ ,P * #& #  P  W +P /@"Y $0 MP!) +4 3@"S %, L0!7 *\
M70"M &( JP!I *D <0"G 'H I0"% *( DP"@ *( G0"V )L U "9 /D E@#_
M (T _P"( /\ A #_ .@   #?    V0   ,D   "_    N  $ +4 #0"S !(
ML0 : +  (@"M "H J0 Q *8 . "D #T H@!# *  2 "> $P G !1 )L 5@"9
M %P EP!B )4 :0"3 '( D0!] (\ BP"- )H BP"L (D Q0"( .X A@#_ '\
M_P!Z /\ > #_ -D   #-    NP   *X   "E    GP   )P "0"9  \ F0 5
M )D '0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8 B !+ (8 4 "% %4
M@P!; (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V .  =0#_ '( _P!N
M /\ ; #_ ,<   "U    I0   )D   "/    B0   (4 ! "$  P @@ 1 ((
M%P"" !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$ '4 20!S $\ <@!5
M '  7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P 90#U &0 _P!A /\
M8 #_ +0   "@    D    (4   !]    =P   ',   !P  @ ;P . &\ $@!O
M !@ ;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4 0P!C $@ 8@!. &$
M50!? %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J %< _P!6 /\ 5 #_
M *$   ".    ?P   '4   !L    :    &0   !A  0 8  + %\ #P!? !,
M7P 9 %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6 $, 50!) %, 4 !2
M %@ 40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H ^@!* /\ 2@#_ )(
M  "     <@   &<   !?    6@   %<   !5  $ 4P ' %( # !2 !  4@ 4
M %( &@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T 20!# $@ 2@!& %(
M10!< $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!  /\ 0 #_ (4   !T
M    9P   %T   !5    3P   $P   !*    2  $ $< "@!'  T 1@ 1 $8
M%0!& !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^ #T 10 \ $X .P!7
M #H 8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X -@#_ 'P   !K
M7@(  %0#  !- P  1P,  $,!  !!    /P ! #X !P ]  L /0 . #P $0 \
M !8 /  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0 00 S $D ,@!3 #$
M7@ P &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_ ',!  !D!0  5P<
M $T(  !&"   0 @  #L'   X!0  -P,  #8 !  U  @ -  , #0 #P T !(
M,P 6 #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K $4 *@!/ "D 6@ H
M &< )P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&  !>"0  4@L  $@,
M  ! #   .@L  #8+   R"@  , @  "X& @ N P8 +0 * "P #0 L !  *P 3
M "H %P I !P *  @ "< )0 F "L )0 R "0 .0 C $( (@!+ "( 5P A &0
M( !S !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9#   30T  $,.   \
M#@  -@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$"P E PX ) $0 "0!
M%  B 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %) !L!5  : 6$ &@%P
M !D!@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@  20\  $ 0   X$
M,A   "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?!PP '@8. !X%$0 <
M!14 &P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&4@ 5!U\ % =N !,'
M@  2!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A   #P1   U$0  +Q$
M "H1   F$   (A   " /   =#@( ' T% !H-!P :"PH &0H- !@)$  7"1(
M%@D7 !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0#%\ #PQN  X,@  .
M#)0 #0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3   R$P  +!,  "<2
M   C$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+ !,,#0 2#!  $@P4
M !$,&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX "P]M  H/?P )#Y,
M"0^F  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P%   *10  "44   A
M$P  '1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .#  .#@X #@\2  T0
M&  -$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J  82?  %$I  !!*D
M  ,1N  #$<\  A'H %42  !)%   /A4  #46   M%@  )Q8  "(5   >%
M&Q0  !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,$@X "Q(1  H2%0 )
M$QL "1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5>@  %8X  !6C   4
MMP  %,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<  "$6   <%@  &14
M !84 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T "!80  86$P %%AD
M!!<?  ,7)P "&#   1@[   91P  &54  !ED   9=P  &8P  !BB   8MP
M%\\  !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8   ;%P  &!8  !45
M @ 3%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.  (;$@ !&Q8  !L=
M   <)   '"T  !PX   =1   '5(  !UB   ==0  '8H  !R@   <M@  &]
M !KK $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9&0  %Q@  !07 P 2
M%@0 $!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @$   (!0  "$:   A
M(@  (2H  "$U   B00  (D\  ")?   B<@  (8@  "&?   @M@  ']$  !_M
M $@:   ]'   ,QT  "L=   D'0  (!P  !P;   8&@  %AD! !,9 0 1&0$
M#AH!  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@  )A(  "88   G'P
M)R<  "<R   G/@  )TL  "=<   G;@  )H4  ":=   EM   )-$  "/N $0=
M   Y'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P  !$<   .'0  #1\
M  HA   &(@$  R0$   F!@  * @  "H+   K#0  +1   "T5   M'   +20
M "XN   N.@  +D@  "U8   M:@  +8$  "R:   KL@  *M   "GO $ @   V
M(0  +2$  "8A   A(   '1\  !H>   6'@  $A\   \A   -(@  "B0   8F
M   "*    "L"   M!   +P8  # )   R#   - X  #42   U&   -2   #4J
M   U-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T  ##O #PC   R)
M*B0  "0C   @(@  '"$  !<A   3(P  $"4   TG   )*0  !2L   $N
M,    #(    T 0  -@0  #@&   Z"0  / T  #X0   ^%   /AP  #XF   ^
M,0  /C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM #<G   O)P  *"8
M ",E   ?)   &24  !0F   0*   #2L   DN   %,    #,    U    .
M #H    \    /@$  $ #  !"!P  1 H  $8-  !)$0  21<  $@A  !(+
M1SH  $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J   L*@  )R@  "(G
M   <*   %BH  !$M   -,   "3,   ,V    .0   #P    ^    00   $,
M  !&    2    $H   !, P  3@8  % *  !3#@  5!,  %0<  !3)P  4S0
M %-#  !250  46H  %"#  !/G@  3;D  $S@ # M   K+   )BL  !\L   8
M+@  $C(   TU   (.0   CT   !     0P   $8   !)    3    $X   !1
M    4P   %4   !7    60$  %P&  !?"@  8@X  &,5  !C'P  8BP  &$\
M  !@3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P  (C   !HS   3-P
M#CL   @_   !1    $@   !,    3P   %(   !5    6    %L   !=
M8    &(   !D    9@   &D   !M!0  < L  '00  !T&   <R4  '(T  !R
M10  <%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@  !0\   .00  !T<
M  !,    40   %4   !9    70   &$   !E    :    &L   !M    ;P
M '(   !T    =P   'H   !^    @@0  (8+  "*$0  B1P  (@K  "&/0
MA%(  (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](   (3@   %0   !:
M    8    &0   !I    ;@   '(   !V    >@   'T   "     @@   (4
M  "(    BP   (X   "2    E@   )L#  "@#   HA,  * A  "?,P  G4<
M )I>  "8=P  EX\  )6G "-#   92   $4X   E5    7    &,   !J
M<0   '8   ![    @    (8   "*    C@   )$   "3    E@   )D   "<
M    H    *,   "G    JP   +    "V!   O T  +H7  "Y*   MSP  +12
M  "R:@  KX4  *V< !Q.   35   "UP   %D    ;    '0   !\    @P
M (D   "/    E    )H   "?    H@   *0   "G    J@   *X   "Q
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M______________________________________________________\
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
MLVB\NZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\
MNZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[
MQ+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6H
MB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NS
MI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1
ML**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1L**'
MU:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN;9
MRPD;Y\X-.>C-$&#<R0V2R[LPJ\:X3[3 LV>]NZY[Q+6IB,NRIH?1KZ.'U:V@
MB-FKGHG<J9R*WJ>;C."EF8_CH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0
MY*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.39RPD:
MY,X-.>?.#F#:R@R2R[PNJ\6Y3;3 M&:]NJYZQ;6IA\NQIH?1KJ.'U:R@B-FJ
MGHG<IYR*WJ6;B^"BFHWBGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9
MC^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^/8RPD:X<\,
M.>7/#F#9R@R1R[XLJ\6Y3+6^M&>]N:Y[Q;2JA\RPIH?1K:.'U:N@B-FHGHC;
MI9V)W:.<BM^?FHOAFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;
MF8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN+8RPD:W- +.>/0
M#6#8RPN1R[\KJ\2Z3+6]LV>^N*Y[Q;2IA\RPIH?1K*.'U:F@A]BFGXC;HYV(
MW:"<B=Z=FXK@F)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWA
MF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>'7S D:VM$+.-[1#%_6
MRPN1R\ IK,*Y3;:\LVB^MZY[QK.IA\ROIH?1JJ.&U:>AA]BDGX?:H9Z'W)Z=
MB-V:G(G>E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,
MX)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C.#6S D9V=$+.-K3#%_4S N1
MR< IK<"Y3K:ZLVF_M:Y\QK*IA\RMIH;1J:.&U*6AAM>BH(;9GY^&VIN>A]R7
MG8C=DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<
MB]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B][5S D9V-(+-]C3"U[2S N3Q[\K
MK;ZX4+>YLFJ_M*U\QK"IA\RKIH;0IZ2%U*.BA=:?H878G*"%V9B?AMJ4GH?<
MD)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0
MG8K=D)V*W9"=BMV0G8K=D)V*W9"=BMW4S0D9UM(+-];4"U[0RPJ5Q+XMKKRX
M4;BWLFK LZU\QJZIA\RIIH;0I:2%TZ"CA-6=HH36F:&%V)6@A=F1GX?:CIZ)
MVXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;
MCIZ)VXZ>B=N.GHG;CIZ)VXZ>B=O3S0H8U=,+-M34"U_.RPF7P;XPK[JW4[BU
MLFS L*U]QZRJALNGIX7/HJ6$T9ZDA-.:HX35EJ*$UI.AA=>/H(;8BZ")V8N@
MB=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")
MV8N@B=F+H(G9BZ")V8N@B=G2S@H7T]0+-='3"F++S F9OKTSL;>W5;FRL6W!
MK:U]QJJJALNDJ(3.GZ>$T)NE@]*7I(/3DZ.$U)"CA=6,HH;6B:&(UXFAB->)
MH8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFA
MB->)H8C7B:&(UXFAB-?0SPH6T=0+-\[3"F7&R@N=N;PXLK2V6+JML6[!JJY]
MQJ>KA<FAJ83,G*B#SI>G@\^3IH/1D*6$THVEA=.*I(;3AZ.(U(>CB-2'HXC4
MAZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'
MHXC4AZ.(U(>CB-3.T H5SM0*.LK3"FC R ^AM;L^M*VU6[NIL6_!IJ]]Q*.M
MA,>=JX/*F*J#RY.I@\V0J(3.C:>$SXJGA<^'IH?0A::(T86FB-&%IHC1A::(
MT86FB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1
MA::(T86FB-',T D8RM0*/L73"FVXQ1:EKKE$M:>U7KNCLG# H;!]PY^NA,69
MK8/'E*R$R9"KA,J-JH7+BJJ%RXBIALR%J8?-@ZB)S8.HB<V#J(G-@ZB)S8.H
MB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)
MS8.HB<W(T0D;Q=4*0K_3"G*QQ!ZGI;E)MJ&V8+N>LW"^G;%]P9NPA,.5KX3$
MD:Z$QHVMA<>*K8;'B*R&R(:LA\B$JXG)@JN*R8*KBLF"JXK)@JN*R8*KBLF"
MJXK)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*K
MBLG$T@@@P-8)2+C4"GBISQ>8GKY'KIJV8KJ8M7&\E[-\OI>RA,"2L87"C;"%
MPXJOAL2(KX?$AJ^(Q82NB<6#KHK%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%
M@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6_
MU <ENM<)3J[:"W"@VQ.'E\TYFI+#6*B1O&RRD;=ZN9*T@[V.LX:_B[*'P(BQ
MA\"&L8C!A+&)P8.QBL&"L8O"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",
MPH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,+WP! 5
M^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VS
MDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6
M,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0
ML8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F]
M(%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+
MTK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/J
MMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",
MC=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\
MS*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2O
MBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$
MJL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6
MKHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E
M7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3
MV*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"
MHW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&
MF-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"Z
MOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_
MO[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@
MB,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.Y
MFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=KWP \5^, 6,/F](%/JN"=\S*A$J\:E7;3"I'"ZOJ)_O[R@B,.YFXC'
MMYB(RK65B<ZSDHK0L8^+T["-C=6OBH_7K8B3V:V&F-JKAIW:JX:=VJN&G=JK
MAIW:JX:=VJN&G=JKAIW:JX:=VJN&G=JKAIW:JX:=VJN&G=JKAIW:JX:=VJN&
MG=KWP0\5]\$6,/B^'U/JN"9\RZE#J\:F7+3"I&^ZOJ)^O[N@B,.YG8?(MIJ'
MS+.7B,^QE(G2L)**U:Z/C->MC8[9K(J2W*N)F=VGB)S;IXB<VZ>(G-NGB)S;
MIXB<VZ>(G-NGB)S;IXB<VZ>(G-NGB)S;IXB<VZ>(G-NGB)S;IXB<VZ>(G-OV
MP0X4]\$5,/B_'E/JN25\RZE"J\:G6[/"I6ZZOJ-^O[NAB,2XGH?)M9R'S;*9
MA]&PEHC4KI2)UZV2B]JKD(W<J8V2WZB-FM^CBYS<HXN<W*.+G-RCBYS<HXN<
MW*.+G-RCBYS<HXN<W*.+G-RCBYS<HXN<W*.+G-RCBYS<HXN<W*.+G-SVP0X4
M]L(5,/>_'E/JNB1\RZE!K,:G6K/"I6VZOJ-]O[NCB,2WH(?)M)V'SK&;A].O
MF8C6K9>)VJN5BMRIDXW?IY*1XJ21F>"@CIS<H(Z<W*".G-R@CIS<H(Z<W*".
MG-R@CIS<H(Z<W*".G-R@CIS<H(Z<W*".G-R@CIS<H(Z<W*".G-SUP@X4]<(4
M,/; '5/JNB-\RZI!K,:H6;/"IFVZOJ1]O[JDA\6WH8?*LY^'S["=A]2NFXC8
MJYF)W*F8B]^GF([BI9>2YJ"6F>"<DYO=G).;W9R3F]V<DYO=G).;W9R3F]V<
MDYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]WTP@T4]<,4,/;
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MT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G
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MI:N%R9^J@\N9J8/-E*B#SI"GA,^,IH70B::&T8:EA]*$I8K2@:6-TH"EC]*
MI8_2@*6/TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"E
MC]+LP0L,]<(2)/;!&D3WO2%JVK0IELV\**F[NT.SKK5AO*BQ<\&EKG_%H:V$
MQYNL@\F6JX/*D:J$RXZIA,R+J87-B*B&SH:HA\Z#J(G.@:>,SX"GC<^ IXW/
M@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<_?
MQ D+\L40(_/$%D/TP1QIWL(5C\' (ZRON4RVIK1EO:*R=<"@L(##G:Z$Q9>M
MA,:3K83'CZR$R(RKA<F)JX;*AZN&RH6JB,J#JHG+@:J+RX"JC,N JHS+@*J,
MRX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,O:Q0@*
MZ\D-(N[($D+OQA5HT-(*A[&^+ZZEN%2XG[5HO)VS=K^;L7_!F;"$PI2OA,.0
MKX7$C:Z%Q8JNAL:(K8;&AZV'QH6MB,>#K8G'@:V+QX"LB\> K(O'@*R+QX"L
MB\> K(O'@*R+QX"LB\> K(O'@*R+QX"LB\> K(O'@*R+QX"LB\?5Q@@)V<P*
M(.7/#4#8U0M?O=8+B*7$-*:<MUJXF;5KNY>T=[V6LW^^E;*%P)&QA<&.L87!
MB["&PHFPA\*(L(?#AK"(PX6OB<.#KXK$@J^+Q(&OB\2!KXO$@:^+Q(&OB\2!
MKXO$@:^+Q(&OB\2!KXO$@:^+Q(&OB\2!KXO$@:^+Q(&OB\32R @'T\\*'=74
M"SW"V0MCJ]X0@YO.,YF4Q%.FD;YGKY"Z=+20MWVYD;6$O(ZSAKZ,LH:_BK*'
MP(BRB,"&L8C!A;&)P82QBL&"L8O!@;&,PH"QC,* L8S"@+&,PH"QC,* L8S"
M@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,+.R@@&SM$*',;7"D&O
MZ@YAG>8<>)#:,HB+TDR4B<M?G(C&;J.(PWBHA<!\JX._?ZZ O8&P?[R#L7V\
MA+)\NX:S>[N'M'JZB+1YNHFU>+F+M7BYC+9XN8RV>+F,MGBYC+9XN8RV>+F,
MMGBYC+9XN8RV>+F,MGBYC+9XN8RV>+F,MGBYC+;)RP@&R-()(K/?"4*@_!5:
MD_ H:HOF.7>$WTF"@=A;BX#3:9%\T'&6><UVFG;+>IUTRGV><LE_H''(@:%P
MQX.B;\>%HV[&AJ-MQHBD;,6*I6S%BZ5LQ8NE;,6+I6S%BZ5LQ8NE;,6+I6S%
MBZ5LQ8NE;,6+I6S%BZ5LQ8NE;,6+I6S%BZ7$S@<*M]D')J/[#CV6_QY.C?HO
M6X;R/V> ZTYQ>^5;>7;@98!QW6R$;MIRB&O9=XMIUWJ-9]9^CF;5@(]EU(*0
M9-2$D6/3AI%BTXF28=*+DV'2C)-ATHR38=*,DV'2C)-ATHR38=*,DV'2C)-A
MTHR38=*,DV'2C)-ATHR38=*,DV'2C)/_L1@)_[$C'O^N,3K_J3Y9[:)+>=F:
M7)?(E7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9
MQ[B F\BX?I[)MWVBRK=\I\JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*
MM'NIRK1[J<JT>ZG*M'NIRK1[J<K_L1@)_[$C'O^N,3K_J3Y9[:)+>=F:7)?(
ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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MBI>DT8J7I-'_MA((_[<<'?^T*#G_L#1:ZJE ?=6D29S(I%6PQJI;L\.O8[?
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M_ZHG%_^G-2__HT1*^IU19>F77G[;E&V4SY)WIL62@;3$DXBVPY*-N,&/C[K
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M1,3K$F:QWQB!H- SE9?&4*.3P&.MD;MQLY&X>[B0MH*[CK2%O8NSAK^(LH?
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MS(R-JL>*D;'$B)2VPX66N,*#F;G"@9NYP7^>NL%]H;O!>Z2[P'JGN\!YJKS
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MG*+0=Y^DSG6BILUTIJC-<JFIS'&MJLQPLJO+<+:KRV^\J\APP*O$<<"JQ''
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M;$SNF6U+[9]N2^V?;DOMGVY+[9]N2^V?;DOMGVY+[9]N2^V?;DOMGV[1N0,
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MJE=L[JE==^>H8X'AI&V+UIYYELN5@Z+ BXZMMH.:MJY^JKND?+.\GGZUNIJ
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M23G_ITHX_[%*-_^^2S?_PDLW_\)+-__"2S?_PDLW_\)+-__"2S?_PDN_LP
MKKX  *#-  "2W@  B?\- 8'_&@5W_R,,;?\J$V3_,1E<_S@>5?] (E#_2"9,
M_T\I2/]5*T3_6RU"_V$O/_]G,3W_;3([_W,S.?]Z-3?_@C8U_XLW,_^4.#+_
MG#DQ_Z0Z,/^O.S#_LCLP_[([,/^R.S#_LCLP_[([,/^R.S#_LCNPN   H,<
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M_X-I5_U\<F#X=G]G]'&*;O!LE73M:)]YZF2J?>AAMX#F7\B"W6';@\QDW(3
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MD8""F8R*BY&'E9&+A**6AH.RF8.$RYB$@\Z6A(/0E(2"TI*$@=.0A('4CH2
MUHR$@-:,A(#6C(2 UHR$@-:,A(#6C(2 UHS_=Q(!_W0; _^"'@3_E"<(_Z R
M#?^G-!/ZKC@8[[4]'.:\1B'<OTPLSKE4/\.Q75"WJF5?K:1L;*.=='>9F'R!
MD9.&BHF/DI&"C)^6?8JOF'J+QYA\B<Z6?8C0E'Z&TI)_A=.0?X34CH"#UHR
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M8$/N[&!'X_%?2-OQ84G2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8TG2\F/^E0
MU*D  ,*U P"UP0, JL\% *#G"P&8_1H&C_XI$(;_-1M^_T E=/]&+6O_3#5C
M_U(Z7/]9/U;_8$-0_VA'3/]Q2D?_>TQ#_X=.0/^44#[_H5(]_[!4.__#53O^
MX54\^?!50/#T54/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5$/G]U3;H0  Q;
M +6Z @"HQP( G=8$ )/\#@&+_QT&@_\K#WK_-1=Q_SP?:/]")F#_22Q9_T\Q
M4_]6-4[_73A)_V4[1?]M/4'_=C\^_X!!._^+0SG_F$4X_Z1&-O^R1S7_Q$@U
M_]U)-/_P23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X23?^^$G)JP  MK0  *C!
M  ";SP  CM\! (?_$0%^_QT$=?\G"VS_+Q)D_S<87/\^'5;_12)0_TLE2_]2
M*$;_6"M!_U\M/O]G+SO_;S$X_W@S-O^"-#/_C38Q_YDW,/^E."__LCHN_\ [
M+O_3.RW_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/"W_ZSRXL   J+P  )K)  ",
MV0  @?4# 'G_$ %N_Q8#9?\?!E[_)PM7_S /4?\W$TO_/A=&_T490?],&SW_
M4ATY_U@?-O]?(33_9B(Q_VXD+_]W)2W_@"8K_XPH*?^7*2C_HBHG_ZTK)O^Y
M+";_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP  FL4  (O3  !]X@
M=?\% &G_# %?_Q$"5_\7 U#_'P5)_R8'1/\N"3__-@L[_ST--_]##S/_21$P
M_T\2+O]5$RS_6Q0J_V(5)_]I%B7_<A<C_WL8(?^&&1__D1H>_YP;'O^E'!W_
ML!T=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!V<P   C,X  'S>  !P]0  9?\
M %K_!@%1_PT!2?\1 D/_%P,]_Q\$./\F!33_+08P_S,'+?\Y!RK_/@@G_T,(
M)?])"2/_3@DA_U0)'_]:"AW_80H;_VD+&?]R#!?_? T6_X8-%/^/#A3_F@\4
M_YH/%/^:#Q3_F@\4_YH/%/^:#Q3_F@__7!P"_U<F _]1,@;_3CP(_U=%$/];
M3AG_7%@B_UMC*_]9;S+_5WHX_U2%/?]2D$'_4)E%_T^@1_].ITG_3:Y+_TRT
M3/]+NTW_2L-._TG-3_])W5#_2.E0_TCR4/M)]E#V2_E0\$W[3^I/^U#G3_Q0
MYT_\4.=/_%#G3_Q0YT_\4.=/_%#_7!P"_U@F _]2,@;_43H(_UI#$/]?31G_
M7U<C_UYA*_]<;3/_67DZ_U>$/_]4CD/_4I='_U"?2?]/IDO_3JU-_TVT3_],
MNU#_2\-1_TO.4O]*WU+_2>I3_4KR4_A+]E/Q3?A2ZT_Z4N50^E/B4?I3XE'Z
M4^)1^E/B4?I3XE'Z4^)1^E/_71L"_UDF _]3,0;_5#D(_UU"$/]B2QK_8E4C
M_V!?+/]?:S3_7'<[_UF"0/]6C$7_5)5(_U*>2_]1I4[_4*Q/_T^S4?].NU+_
M3<13_TS/5/]+X%7_2^M5^DSR5?1-]E7L4/A4YE'X5=]2^5;<4_E6W%/Y5MQ3
M^5;<4_E6W%/Y5MQ3^5;_7AL"_UHE _]4,0;_6#<(_V% $?]E21K_9E,C_V1=
M+?]B:#7_7W0\_UQ_0O]9BD?_5I-+_U2<3O]3I%#_4:M2_U"S5/]/NE7_3L16
M_TW05_]-XEC\3.U8]D[R6.Y0]5CF4_98WU3W6==5^%G35?A9TU7X6=-5^%G3
M5?A9TU7X6=-5^%G_7QH"_ULE _]5, ;_7#0(_V4]$?]J1QK_:U$D_VE:+?]F
M9#;_8W ]_U]\0_]<ATG_69%-_U>:4/]5HE/_4ZI5_U*R5_]1NEG_4,5:_T_2
M6_Q.Y%OX3^U<\%'R6^=4]%O>5?5<U5;V7<Y8]UW+6/==RUCW7<M8]UW+6/==
MRUCW7<M8]UW_8!H"_UPD _]6+P7_8#((_VH[$/]O1!K_<$XC_V]7+?]K83;_
M9VP^_V-X1?]@@TO_7(Y/_UJ84_]7H%;_5JE9_U2Q6_]3NES^4<9>_%#67_E0
MYU_R4NY?YU7Q7]U7\F#26/-ARUGU8L5;]6+#6_5BPUOU8L-;]6+#6_5BPUOU
M8L-;]6+_81D"_UTC _]:+07_92\(_V\X$/]T01G_=DLC_W54+?]Q73;_;&<_
M_VAS1O]D?TS_8(I2_UV55O]:GEG_6*=<_E:P7_U4NF#\4\=B^5+<8_-3Z&/I
M5>YCWECP9-!:\67(7/)FPEWR9KU>\F:[7O)FNU[R9KM>\F:[7O)FNU[R9KM>
M\F;_8AD"_UXC _]>*@7_:2T(_W0U#_]Z/AC_?$@B_WM1+/]X6C;_<V,__VUM
M1_]I>D[_9(94_V"16/]=G%S]6J5@^UBP8OI6NV7X5<IF]53@9^Q6ZF??6NUG
MT%SO:<9=[VJ_7^]JN6#O:K5A[VJS8>]JLV'O:K-A[VJS8>]JLV'O:K-A[VK_
M8Q@"_V B _]B)P7_;BH'_WDR#O]_/!?_@D8A_X)/*_]_6#7_>V ^_W5I1_]O
M=$[[:H%5^&:,6_5BEU_S7Z%C\%RK9NY:MFGL6<1JZ5C::^%:ZFO07>QMQ5_L
M;KQAZV^V8NQOL6/L;JUD[&ZK9.UMJV3M;:MD[6VK9.UMJV3M;:MD[6W_9!@"
M_V$B _]F)03_<B<'_WXP#?^%.Q;_B$4?_XA-*?^&53/_@EX]^WUF1O9V<$[R
M<GQ5[FV'7.IHDF+F9)QFXV&F:N!?LFW=7;]OVEW3<-)>ZG#$8.ERNF+H<[-D
MZ'.M9>ESJ6;I<J9GZG&D9^IPI&?J<*1GZG"D9^IPI&?J<*1GZG#_91<"_V(A
M _]I(P3_=R4&_X(O#/^*.13_CD,=_X],)O^-4S#YBELZ\X5C1.U_;$WH>7=5
MXW2"7=YNC6/9:9=ITV:A;L]CK''+8;ETR&'*=<5AY7:Y9.9WL&;E=ZIHYG>E
M:>9VHFKG=9]JZ'.>:^ESGFOI<YYKZ7.>:^ESGFOI<YYKZ7/_9A<!_V,A _]M
M( 3_>R,%_X<N"_^/.!+_DT$:_Y5*(_J442WSD5DW[(U@0>6':4K?@713UGI^
M7<]TB&7*;Y%LQ6N;<<%HIG6]9K)XNF7">K=EW7NN:.-[IVKC>Z)KY'J>;.5X
MFVWE=YEMYW:8;N=UF&[G=9ANYW68;N=UF&[G=9ANYW7_9Q8!_V0@ _]P'@/_
M?B(%_XLL"?^3-Q#_F$ 8_9I((/2:3BGLF%4SY95=/-V/9D?3B&]3RX%Y7L5[
M@V:_=8QNN7&6=+5NH7BP:ZQ\K6J[?JIJTG^D;.!^GFWA?9IOXGR7<.-ZE7#D
M>9-PY7>3<>9WDW'F=Y-QYG>3<>9WDW'F=Y-QYG?_:!8!_V0@ _]S' /_@2 $
M_XXK"/^7-0[_G3X5^)]$'.^@2R7GGU(MWYU:-].58T;*CFQ3PX=U7KN!?F>U
M>XAOKW>1=:ISG'JE<*A^H6^V@9YORH*;<-Z!EG'?@)-RX7Z1<^)\D'/C>HYS
MY'F.<^5XCG/E>(YSY7B.<^5XCG/E>(YSY7C_:18!_V8> _]V&@/_A!\#_Y(J
M!_^;- S^H#L2\Z-!&.JF2"#BIT\GV*)6-LR:8$7#DVE2NXUR7K.&>F>L@81O
MIGV-=J!YF'R;=J. EW2Q@Y1TQ821==V#CW;>@8UVX'^+=^%]BG?B>XEVY'J)
M=N1YB7;D>8EVY'F)=N1YB7;D>8EVY'G_:14!_VD= _]X&0+_AQX#_Y4H!O^>
M,@KZI#</[Z@]%.:L1!K=K4LDT*94-<:?7D2\F692M))O7:R,=V>DAX!OGH**
M=YA^E'V2>Z"!C7JMA(IYP(6(>MR$AWK=@H9ZWX"&>N!^A7KB?(5YXWJ%>>1Y
MA7GD>85YY'F%>>1YA7GD>85YY'G_:A4!_VL; O][%P+_BAP"_Y@F!?^B, CU
MJ#,,ZZXY$.*S0136L4<CRJM2-,"D7$.VGF11K9AL7*62=&:=C7UOEHB&=H^%
MD7V*@IR"A8"JA8%_O(: @-N%@(#=@X!_WH& ?N!_@'WA?8!]XWN ?.1Z@'SD
M>H!\Y'J ?.1Z@'SD>H!\Y'K_:Q4!_VT9 O]^%0+_C1L"_YLD _ZE+ ;QK"\(
MY[,T"]VZ.A#0M48AQ:]1,KJI6D*PHV)/IYUJ6YZ8<F66DWINCX^#=HB+CGR"
MB)F!?(:GA7F&N89WA]>%>(7=@WJ#WH%Z@N!_>X'A?7R XWM\?^-Z?'_C>GQ_
MXWI\?^-Z?'_C>GQ_XWK_:Q0!_W 8 O^!% '_D!D!_Y\B OJI)@3ML2D%XKHO
M!M:_-@_*ND0@O[1/,;2N6$"JJ&!.H:-G6IB>;V2/FG=MB): =8"2BWMZCY:
M=(ZDA'&-MH5OCM&%<8O=@W.)WX%UA^!^=H7A?7>$XWMW@^1Z=X/D>G>#Y'IW
M@^1Z=X/D>G>#Y'K_;!0!_W,6 O^%$P'_E!8!_Z(> ?6M( +GN"$"W<,F M##
M- W$OD(>N;E-+ZZS5CZDKEY,FJEE5Y&E;6*)H75K@)U^<GF:B'EREY1^;9:B
M@FF5LX1GELV#:9/>@FR/WX!OC.%^<(KB?'*(XWIRA^1Y<H?D>7*'Y'ERA^1Y
M<H?D>7*'Y'G_;1,!_W83 ?^($@'_F!, _Z<9 >^S%@'BP!4 U<H> <G',@R^
MPT <L[Y++*BZ5#R>M5Q)E+!C58JL:U^!J7)H>:5[;W*CA79KH)%[9I^??V*?
ML8%@G\J 8IS@?V67X7YHD^)\:I#C>VR-Y'EMC.5X;8SE>&V,Y7AMC.5X;8SE
M>&V,Y7C_;A,!_WL1 ?^-$ #_G1  ^JP1 -J["P#5R0L S<X; <+,+PJWR3T9
MK,5)*:' 4CB7O%I&C;AA48.U:%MZLG!D<J]Y:VNL@W%DJX]V7ZF>>ENIKWQ9
MJLE\6J?B>UZ@XWMAF^-Z8Y?D>6:4Y7=FDN9W9I+F=V:2YG=FDN9W9I+F=V:2
MYG?_<!(!_X . ?^2#@#RHPL V;,) ,^^"0#+S D Q-,7 +K2+ >PSSL6I<Q&
M)IK(4#6/Q%A!A<%?37R^9U9SO&]>:[EW962X@FM>MHYP6;6=<U6UKG54MLAU
M4[/G=E>KYG9:I.9V7*#G=5^<YW1@FNAT8)KH=&":Z'1@FNAT8)KH=&":Z'3_
M<A(!_X8, /N8"0#9J08 SK4' ,;!!P# SPD NML3 +':*06GV#<2G-1$(9+1
M33"'SE4\?<M=1W3)95!LQVU79<5V7E[$@6-9PXYH5,.=:U'#KFQ/Q,AM3L+M
M;5"XZV]3L.MP5:OJ<%BFZW!9H^MP6:/K<%FCZW!9H^MP6:/K<%FCZW#_=P\!
M_XT( -Z@ @#/K@4 Q+D% +O%!@"UTPH KN$6 :;A*0:=X#<1D]Y"'8G<3"E_
MVE0U===</VW59$AETVQ/7])V5%G2@5E4T8Y=4-&=8$W2L&)+T\EB2M+M8DO(
M\F9-O_%H3[CP:5&R\&E2K^]I4J_O:5*O[VE2K^]I4J_O:5*O[VG_?PH [98
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M1#[J_T0^YO]&/N;_1C[F_T8^YO]&/N;_1C[F_T;0GP  O:P  *ZU  "BP@
ME<\  (K= P"$_Q(!>_\> W3_*@EL_S,/9/\[%EW_0QM7_TH@4?]1)$S_6"=(
M_V J1/]H+$#_<2X\_WLQ.?^(,C7_EC0S_Z0V,?^V-R__T#@N_^\Y+?__.3'_
M_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SG!J   K[$  **]  "4R@  A]@
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M$A/_PQ(3_\,2$__#$A/_PQ*7O@  ALP  '?;  !IYP  7/T  %3_  !+_P4
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MB,%T;8GD<V^'ZG%PA.QO<H/M;7.![FMT@/!I=(#P:72 \&ET@/!I=(#P:72
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M64RR^UI.K?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P  W),  ,JB  "\K $
ML;4  *C  P"?RP8 EMD+ )'@&P&*WRP&@M\Y#GG>0Q=QW4T@:MQ6*&/;7R]=
MVF<U6-EQ.E/9>SY/V8A"2]F614C9ID=&VKI(1=O;1T38]$E"T_]-1,G_3T7"
M_U!'N_]21[O_4D>[_U)'N_]21[O_4D>[_U+FB@  SYL  +^G  "RL   I[L
M )S& P"3T08 B^H. (7H'P)^Z"T&=N@X#F[H019FYTH=7^=2(UGG6RE5YV0M
M4.=M,4SG>#5)YX0X1NB1.D/HH#Q Z;(^/^K+/C[H[SX]YO\_/>#_0C_7_T1
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M*B_Y_RHO^?\J+_G_*B_Y_RJYI@  JJX  )RY  ".Q0  @=$  '7>  !M^@D
M9?\1 5[_&@)7_R,#4O\L!4S_- =(_SP*0_]$##__3 X\_U,0./];$C7_8Q0R
M_VP6+_]W%RS_A!DI_Y,:)_^B'"7_M!TD_\P>(__M'B+__1\B__\?(O__'R+_
M_Q\B__\?(O__'R+__Q^LJP  G;8  (_"  " S@  <]P  &?I  !?_P8 6/\.
M %'_%0%+_QT"1O\F T'_+00\_S4%./\\!C3_0@<Q_TD(+O]0"2O_5PHH_U\*
M)?]I#"/_= T@_X(.'?^2#QO_HA :_[(1&?_($AC_Y1,7__H4%__Z%!?_^A07
M__H4%__Z%!?_^A2?LP  D+\  (#,  !RV@  9.0  %CU  !1_P$ 2O\+ $3_
M$ $^_Q<!.?\> C3_)0(P_RP#+/\R!"C_. 0E_SX%(O]$!1__2@4<_U$&&O]9
M!A?_8P<4_VX'$O]\"!#_C @/_YP(#O^L"0[_NPD-_],)#?_3"0W_TPD-_],)
M#?_3"0W_TPF1O   @<D  '+7  !DY   5.L  $O_  !$_P  /?\$ #?_#  Q
M_Q !+/\6 2C_' $D_R("(/\G AS_+ (9_S$#%O\V Q/_/ ,1_T(##_])! W_
M400+_UH$"?]F! ;_<P4#_X$% O^0!0'_G 4!_ZL% ?^K!0'_JP4!_ZL% ?^K
M!0'_JP7_1"0"_S\N _\\-@3_0#@$_T$]!O]!10C_05$-_T!=$_\_:AC_/'<<
M_SJ$(/\WD2/_-ILE_S6D)_\TK"C_-+4J_S.^*_\RR"O_,M4L_S'E+?\Q\2W_
M,?LM_S#_+?\P_RW_,_\M_S;_+/XX_RWY.O\N]CO_+O8[_R[V._\N]CO_+O8[
M_R[_12,"_S\N _\^- /_0C8$_T0[!O]$0PC_14\-_T1;$_]!:!G_/W4=_SR"
M(?\ZCR3_.)HG_S>C*?\VK"K_-K0L_S6]+?\TR"[_--8N_S/F+_\S\B__,OPP
M_S+_,/\S_R__-O\O_SG_+_D[_S#T/?\Q\3W_,?$]_S'Q/?\Q\3W_,?$]_S'_
M1B,"_T M _]!,@/_1C,$_T@X!O](0 C_24P._TA8%/]%91K_0G(?_T!_(_\]
MC";_.Y@I_SJA*_\YJBW_.+,N_S>]+_\VQS#_-M4Q_S;F,O\U\3+_-?LR_S7_
M,O\V_S+_.O\Q^CW_,_,^_S3M0/\TZD'_-.I!_S3J0?\TZD'_-.I!_S3_1R("
M_T$L _]%+P/_23 $_TPU!O]-/0C_3D@._TU4%?]+81O_2&X@_T5[)?]"B"C_
M/Y0K_SZ>+O\]IR__/*\Q_SRX,O\[PS/_.L\T_SKA-?\Z[C7_.O@U_SK_-?\Z
M_S7[/O\U\D'_-^M"_SCE1/\XX47_..%%_SCA1?\XX47_..%%_SC_2"("_T,L
M _](+ /_3BT$_U$Q!?]3.0C_544._U-1%?]171S_3FHA_TMW)O](@RO_18\N
M_T29,/]"HC/_0:LT_T&T-O] O3?_/\DX_S_;./\_ZCG_/_4Y_S__.?M _SCQ
M0_\ZZ$7_/.%'_SS:2/\]U4G_/=5)_SW52?\]U4G_/=5)_SW_22$"_T0J _]-
M* /_4RD$_U<M!?]9-@C_7$(._UM.%?]861S_564B_U)R*/]/?BW_3(HP_TJ4
M,_](GC;_1Z8X_T:O.?]%N#O_1<0\_T32//Q$Y3WX1/(]]47^//%%_S[F2/]
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M6ER1^UE>COQ87XW\5U^-_%=?C?Q77XW\5U^-_%?_:@H _WP  -R,  #-F
MPZ,# +JJ @"SLP$ K+P* *:]'0&>O"\&EKH\$8VX1QR%M5 G?;-9,':Q8#AO
MKV@_::UP16.K>4I>JH1/6JF04E6HGE52IZ]74:C&5U"GZE=0I?Q74Y_]5U6:
M_597EOY66)7^55B5_E58E?Y56)7^55B5_E7_;P0 YH(  -*1  #&G0  NZ8!
M +*N  "JMP$ HL(% )S$& "5PRH$C<(Y#87 1!A]ODXA=;Q6*FZZ7C)HN68X
M8K=N/EVV>$-8M8)'5+2/2U"TG4Y-LZY02[3%4$NSZE!*L?]13*O_4DZE_U)0
MH?]249[_45&>_U%1GO]149[_45&>_U'_=@  W8D  ,J7  "^H@  LZH  *FS
M  "@O ( F,8& )',$@"+S"4"A,LT"7S)0!)UR$H;;<=3(V?%7"IAQ&0P7,-M
M-E?"=CI3PH$_3\&.0DO!G45(P:Y&1\'%1D?!ZD9$OO])1;G_2D>S_TM)K?],
M2JO_3$JK_TQ*J_],2JO_3$JK_TSI?P  T9   ,*>  "UIP  JJ\  *"X  "6
MP0( C,L' (35#0" U1X!>=4N!7+4/ QLTT<49=)0&U_162%:T6(G5=!K+%'0
M=3!-SX$T2<^.-T;/G3E$T*X[0M#&.T/0ZCI S?T^/LO_0$##_T)!O?]#0KG_
M1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@  +BC  "KJP  H+0  )6^  "+R ,
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M$Q[__Q.FJ0  F+,  (J_  ![R@  ;M4  &#?  !4YP  3O\$ $G_#@!#_Q0
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M46I\_T]K>_]-;'G_3&QY_TQL>?],;'G_3&QY_TS_7@P _VP! .9Z  #6A@
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M1U22_T=4DO]'5)+_1U22_T?_;@  WG\  ,J-  "^F   LZ   *JG  "AK@
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M+3;*_RW%D   MIT  *BE  "<K0  C[8  (.^  !WQP  ;,\" &+6!P!:Y X
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M"!W_I@@<_[P(&__B"1K_^0D:__\)&?__"1G__PD9__\)&?__"1G__PFBIP
MD[$  (6[  !VQ@  :=   %O:  !.X   0^4  #[[ 0 Z_PP -O\3 #+_&P O
M_R, *_\J 2C_,0$D_S<!(?\_ A__1@(<_TX"&?]8 Q;_8P,3_W #$O^!!!'_
MDP00_Z<$#_^]!0[_X 4.__8%#O__!0[__P4.__\%#O__!0[__P65KP  AKH
M '?%  !HT   6ML  $SA  ! YP  -_,  #+_   N_P< *O\. ";_$P C_QH
M'_\@ !O_)@ 8_RL!%?\R 1+_. $0_T !#O]( 0S_4@$)_UT"!O]K @3_?0("
M_Y " ?^C @#_M@( _\T# /_L P#_[ , _^P# /_L P#_[ .(N0  >,0  &G0
M  !;W0  2^,  #[I   R[@  *_\  ";_   A_P  '?\( !K_#0 6_Q$ $_\6
M !#_&@ ._Q\ "_\D  G_*@ &_S   O\W 0#_0 $ _TH! /]6 0#_9 $ _W4!
M /^( 0#_F@$ _ZH! /^[ 0#_NP$ _[L! /^[ 0#_NP'_+RL!_RLR O\O,0+_
M,#0"_R\Y _\K00/_)TP$_R-8!?\A9@;_('0'_QZ""?\>C@O_'I@,_QZA#?\>
MJ0[_'K /_QVX#_\=P1#_'<L0_QW;$?\=Z!'_'?(1_QW\$?\>_Q'_'O\0_Q[_
M$/\?_Q'_'_\2_R'_$_\B_Q/_(O\3_R+_$_\B_Q/_+RL!_RXP O\R+P+_,S$"
M_S(V _\O/@/_*TD%_RE6!O\G8P?_)7$(_R1^"_\CB@S_(Y4._R*>#_\BIA#_
M(JT1_R*U$?\BO1+_(L<2_R+4$_\BY1/_(O 3_R+Z$_\B_Q/_(_\2_R/_$O\C
M_Q3_)/\5_B;_%OPG_Q;\)_\6_"?_%OPG_Q;_,"H!_S$M O\U*P+_-RT"_S8R
M _\T.@/_,D4%_R]2!O\M8 ?_+&T*_RIZ#/\IA@[_*)$0_RB:$?\HHA+_)ZH3
M_R>Q%/\GN13_)\,5_R?/%?\GX17_)^T5_R?X%?\H_Q7_*/\5_RC_%O\G_Q?\
M*?\8]BO_&?0L_QGT+/\9]"S_&?0L_QG_,2D!_S0I ?\Y* +_.RH"_SPN O\Z
M-@/_.4(%_S=/!O\U7 C_,VD+_S%V#O\P@A#_+XT2_RZ6%/\NGA7_+:86_RVM
M%O\MM1?_+;X8_RW*&/\MW!C_+>H8_RWU&/TN_QCZ+O\8^2W_&ODM_QSS+_\<
M[3'_'>HR_QWJ,O\=ZC+_'>HR_QW_,RD!_S@F ?\]) '_0"4"_T$I O]",P/_
M03X%_S]*!O\]5PG_.V0,_SEP#_\W?1+_-H@4_S61%O\UFA?_-*(9_S2I&?\S
ML1K_,[H;_S/%&_TSTQOZ,^8;]S3S&_,U_AOQ-/\=\#/_'^XS_R#G-O\AX3?_
M(=XX_R'>./\AWCC_(=XX_R'_-2<!_STB ?]"( '_1B !_T@E O]*+P/_23H$
M_T=&!O]%4@G_0U\-_T%K$?\_=Q3_/8(7_CR,&?P\E1K[.YT<^3NE'?@ZK1[V
M.K8>]3K '_,ZSA_P.N,?ZSOQ'^@Z_2'F.O\CY#K_)>$Z_R78//\FT#W_)LT^
M_R;-/O\FS3[_)LT^_R;_.20!_T$> ?]'&P'_2QL!_T\B ?]1*P+_438$_T]!
M!O],30G_2UH._$EF$OA'<A;U17T9\T.'&_%"D1WO0ID?[4&A(.Q!J2'J0+(B
MZ$"\(N= RB/D0=\CX$'O)-Q _"?80/\IU#__*L] _RK'0O\JPD/_*L!#_RK
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M0)I9[#^86?X_EUK_/I1;_SR16_\[CUO_.H];_SJ/6_\ZCUO_.H];_SK_3!(
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M1'=L_T)W:_] =VK_/W=J_SYW:O\^=VK_/G=J_S[_5 P _U\  /)L  #==@
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M/V-Z_S]C>O\_8WK_/V-Z_S__7@  Z6T  -9Y  #(A   OHP  +:3  "NEP
MIIL$ *"=%P":G2D"DYPW"(R:0Q"&F$T8@)95'WJ4729UDF4L<)!L,6R.=39G
MC7XZ8XN)/E^*E4%<B:-$6HFT15B)RT58B.U$6(C_0UF&_T%;@_] 78'_/EV
M_SY=@/\^78#_/EV _S[_8@  Y'$  ,]^  ##B   N9$  +"7  "GFP  GJ$
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M-TF:_S?B=   RH,  +R/  "PF   I9X  )ND  "0JP  A;$  'JX! !VN10
M<KDE 6VY,P1HN#\(8[A)#EZW4A-:MEH85K9B'%*U:R!.M'4D2[2 )TBSCBI%
MLYTL0K.N+4&SQ2Y!L^DM0+#^+S^O_S$^K?\R0*C_,D&F_S)!IO\R0:;_,D&F
M_S+5?   PHH  +66  "HG0  G:,  )*J  "'L0  ?+<  '"^ P!HP@X 9L,=
M &/#+0%>PSD$6L-$"%;"3@Q2PE<03\%?%$O!:1=(P7,:1<!^'4+ C" _P)LB
M/<"M(SS!Q",\P.DC.K[^)CB\_R@WN_\I.+C_*CBV_RLXMO\K.+;_*SBV_RO)
MA0  N9,  *R<  "@H@  E*H  (BQ  !\N   <;X  &;% P!;RP@ 5\T3 %;.
M(P!3SC(!4,X^ TW/2 5)SU((1L];"T//90Y SV\0/L][$SO/B14YSYD7-\^K
M&#;0PQ@VS^@8-,W[&S++_QTQRO\?,,G_(2_(_R$OR/\A+\C_(2_(_R&^CP
MKYH  **A  "6J0  BK   'VX  !QOP  9L8  %O, @!0T@< 1]H, $;<& !%
MW"< 1-TU 4'=0 (_WDL#/=Y5!#K?7P8XWVD'-=]V"3/@A LQX)0,+^&F#2[A
MO XMXN .+=[X#RO=_Q(JW/\4*=K_%BC:_Q8HVO\6*-K_%BC:_Q:SF   I:
M )FG  "+L   ?K@  ''   !ER   6<X  $[3  !$VP0 /^D- #WI%P [ZB,
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M @C_U0('__0"!___ @?__P('__\"!___ @?__P*1K0  @K@  '/"  !DS
M5M4  $C=   [X@  ,.<  "?N   C_P  (/\$ !S_#  9_Q$ %O\6 !/_&P 1
M_R$ #O\G  W_+@ *_S8 !_\^  3_2   _U0  /]B 0#_<P$ _X<! /^= 0#_
ML@$ _\H! /_J 0#_\P$ __,! /_S 0#_\P&$MP  =,$  &7,  !6V   1]\
M #GE   MZ@  (^X  !S]   8_P  %?\  !'_!  /_PL #?\.  G_$0 &_Q4
M _\:  #_(   _R8  /\N  #_-P  _T$  /]-  #_7   _VT  /^"  #_E@
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M)+A&\"6U1O\GLD;_)[!&_R>N1O\GJD?_)J=(_R:G2/\FITC_)J=(_R;_0!0
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M-(A;_S.'6_\QAEO_,(5;_R^%6_\OA5O_+X5;_R__2PP _U0  /M>  #B90
MV&L! ,]N!0#,< @ QG(2 +YS)@&W<S8$L7!$"JMN3Q&F:UD8H6EA'9UG:B*9
M97(GEF-Z*I-B@RZ08(PQC5^5-(I>H#:'7JTXA5V\.8-=U#F"7O X@5__-H!?
M_S2 7_\S?U__,7Y?_S!^7_\P?E__,'Y?_S#_30D _U8  .YA  #=:0  T6\
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M-&YJ_S)N:O\R;FK_,FYJ_S+_4P  ]%\  -YJ  #-<P  PWH  +M^  "U@0
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M,EE]_S+O8   VVX  ,=Z  "[@P  LHL  *B0  "?DP  E)8  (V9#@")FAX
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M*D2ANBM#H=HJ0Y_U*T*=_RM"G/\L0IO_+$27_RM$E_\K1)?_*T27_RO7<@
MPX   +:,  "JE   GYD  )2>  ")HP  ?J@  '"N  !JL X :+$= &6Q+ %A
ML3@#7;!#!EFP3 I5KU0.4J]=$4ZN915+KF\82*UY&T6MAAY"K)4@/ZRE(CZM
MN2,]K=@B/:OU(SRI_R4[I_\F.Z;_)CND_R8[I/\F.Z3_)CND_R;,>@  NX@
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M!B;4_PDETO\+)-'_#"/0_PTCT/\-(]#_#2/0_PVNE@  H)T  )2D  "&K
M>;0  &R[  !@P@  5,8  $C+   ^T   -=4$ "W="@ LX1, *^(? "GC*@ H
MY#4 )^0_ ";E2@ DYE4 (^9A 2'G;@$@YWX"'NB0 AWII (;Z;P"&NKB AKF
M_ (9Y?\#&>3_!!CC_P48X_\%&./_!1CC_P6CG0  EJ0  (BL  !ZM0  ;+T
M %_$  !3R@  1\X  #S3   RV@  *M\  "7N"0 C\!$ (?$9 !_Q(@ =\BL
M&_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!$?>  1#XE $/^:H!#OG& 0[Y[0$-
M]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9HP  BZP  'RU  !MO@  7\8  %+-
M  !%T@  .=@  "_>   FX@  '^H  !S[!@ 9_PX %_\3 !3_&@ 2_R$ $/\H
M  [_,  -_SD "_]#  G_3@ &_UP !/]L  +_@  !_Y8  /^M  #_R@  __
M /__  #__P  __\  /__  #__P"-JP  ?;4  &Z_  !@R   4M   $/7   W
MW0  *^(  "+F   9Z@  %?D  !+_   0_P@ #O\.  S_$0 )_Q8 !O\<  /_
M(@  _RH  /\S  #_/0  _TD  /]7  #_:0  _WX  /^5  #_K   _\<  /_H
M  #_^@  __H  /_Z  #_^@" M0  <+\  &')  !2TP  0]L  #7A   IY@
M'NH  !7N   0^   #O\   O_   (_P  !/\&  #_"@  _PX  /\1  #_%0
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M"-XM\0K;+/X,UBW_#M0L_P_2+/\0T2S_$,\L_Q#.+?\0SBW_$,XM_Q#_,AD
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M(9]'_R">1_\@GD?_'YM'_QZ:1_\>FD?_'II'_Q[_0 T _T8$ /],  #X4@(
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M)WM:_R9Z6O\E>EK_)7I:_R7_20  ^U(  .-<  #28P  QV@  ,!K  "Z:P(
MM6L- *YM'0"H;BX!HVT\!9UK2 J9:E$/E&A:%)!F8AB-96H<BF-R((=B>B.$
M88,F@6",*7Y?ERM[7J,M>5ZQ+W==Q"]U7N(O=5[Y+75?_RMU7_\I=5__*'5>
M_R9U7O\F=5[_)G5>_R;_2P  \%4  -Y?  #-9P  PVP  +MO  "U<   KV\*
M *AQ&@"C<BL!G7(Y!)AP10F3;D\.CVU8%(MK8!B':6<<A&AO((%G=R-]9H F
M>F2**7=CE"QU8Z$N<F*O+W!BP3!O8M\P;F/W+F]C_RQO8_\J;V/_*&]B_R=O
M8O\G;V+_)V]B_R?_30  ZU@  -EC  #):@  OW   +=S  "P=   J70' *-V
M%P">=R@!F'8W!)-U0@B.<TP.B7%5$X5P71B!;F4<?FUL'WML="-X:GTF=&F'
M*7%HDBQN9YXN;&>L,&IGOC%I9]PP:6?U+FEG_RQI9_\J:F?_*6IF_RAJ9O\G
M:F;_)VIF_R?_4   YUL  --F  #%;@  NW,  +-W  "K>0  I'@# )UZ% "8
M>R4!DWLT XYZ0 >)>$H-A'93$H!U6Q=\<V(;>')J'W5Q<B)R;WLF;VZ%*6QM
MD"QI;)PN9FRJ,&1LO#%C;-DP8VST+V-L_RUD;/\K9&O_*65J_RAE:O\H96K_
M*&5J_RC]4P  XU\  ,YI  #!<0  MW<  *][  "G?0  GGT  )A^$0"3@"(
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M+%)^MBU1?LXM47WO+%)]_RM2?/\I4WO_*%1Z_R=4>O\G5'K_)U1Z_R?H7@
MT&L  ,!V  "T?@  JX4  *&)  "7BP  B8T  (./" !^D!< >Y$G 7:1- -R
MD#\&;8])"VF.40]EC5D38HQ@%UZ+:!M;BG$>5XE[(52(AB11AY0G3X:B*4V&
MM"I+ALPJ2X7N*4R$_RE,@_\H3(/_)TV!_R9.@?\F3H'_)DZ!_R;A8P  R7
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M&#BC_QHWH?\;-Z#_'#>?_QPWG_\<-Y__'#>?_QS$>   M84  *F/  "=E0
MDIH  (:?  !ZHP  ;J@  &*L  !5L   4+(. $ZR&P!-LR@ 2[,U $FS/P%&
MLTD"1+-2!$&S6P8_LV0(/+-O"CJS>PPWLXH.-;*:#S.SK1 RL\40,K+I$#&P
M_A(PKO\4+ZW_%2^L_Q8OK/\6+ZS_%B^L_Q:[@0  KHX  *&5  "6F@  B:
M 'VF  !QJP  9:\  %FT  !.MP  0[P% $"]$0 _O1X /KXK #R^-@ [OT$
M.;]+ 3>_5 (UP%\",\!J!#' =P4OP(8&+<"7!RO J@@JP<((*L#G!RF]_0HH
MO/\,)[K_#2>Y_PXGN?\.)[G_#B>Y_PZRC   I90  )F:  "-H0  ?Z<  '*M
M  !FLP  6K@  $^[  !$OP  .L0" ##)"  NRA$ +<H= "S+*0 KRS4 *\Q
M "K-2@ HS58 )\YA ";.;P$DSG\!(\^1 B'/I0(@T+T"(,_D A_-^@,>R_\$
M'LK_!1W)_P8=R?\&'<G_!AW)_P:HE   G)H  )"A  ""J   =*\  &>V  !;
MO   3L   $/#   YQP  +\P  "?0!  ?U@H &]H0 !O;&@ :VR8 &MPQ !G=
M/  8W4@ &-Y5 !??8@ 6X'( %>"% !3AF@ 3XK$ $N// !+@]  2WO\!$=W_
M 1';_P(1V_\"$=O_ A';_P*>F@  DJ$  (2I  !VL0  :+@  %N_  !.Q
M0L@  #?,   MT   )-4  !S;   5WP4 %.D. !+J%  1ZQT $.LF  [L,  .
M[3H #>Y&  ON4P *[V( "?!T  CQB0 '\J  !?*Z  3QY  "\?T  N__  /M
M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !IN@  6\(  $W(  ! S   --$
M "K6   AVP  &>   !+D   /\ $ #?D*  OZ#P )^Q4 !_L<  3\)  !_"P
M /PW  #\0@  _%   /QA  #]=0  _(P  /RD  #\P0  _.L  /S_  #]_P
M_?\  /W_  #]_P")J0  >;(  &J[  !<Q   3LP  #_1   RUP  )]T  !WA
M   5Y0  #N@   KQ   (_0  !?\#  '_"0  _PX  /\2  #_%P  _Q\  /\G
M  #_,0  _SX  /]-  #_7P  _W4  /^-  #_I@  _\(  /_G  #__   __\
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M -< _P#G /\ \P#_ /T _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_&RD _QTF /\<)0#_&2< _Q,L /\.- #_"T !_PA. ?\%6P'_ V@!_P)T
M ?\"?P'_ H@!_P*1 ?\"F '_ I\!_P&E /\!K #_ ;( _P&Z /\!Q #_ =$
M_P#D /\ \0#_ /P _ '_ /P"_P#\ _\ _ 3_ ?P%_P'\!?\!_ 7_ ?P%_P'_
M'R8 _R$B /\@(0#_'B, _Q@G /\3, #_$3P!_PY* ?\-5P'_"V,!_PIO ?\*
M>@'_"H0!_PJ- ?\*E '_"IL!_PJB ?\*J '_"J\!_PJW ?\*P #_"LP _PK@
M /L*[P#W"OH ]0O_ ?4,_P'T#?\!] W_ O0-_P+T#?\"] W_ O0-_P+_(B(
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M"K\M_PN]+?\,O"W_#+PL_PR[+/\,NRS_#+LL_PS_,1$ _S4, /\V!P#_.@L
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M&(U'_QB-1_\7C4?_%XU'_Q?_/@( _T,  .M+  #=40  T50  ,I4 0#&4@4
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M''!:_QS_2   YU(  --;  #%8@  NV8  +-H  "L:   I68% )]G% "::24
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M)6!GM"9?9\DF7F?J)5YG_B-?9_\A7V;_'V!F_QY@9O\>8&;_'F!F_Q[O3P
MVEP  ,9E  "Z;0  L'(  *=U  "==   E',  (UT#0")=AP A7<K 8%W. -\
M=D,&>'5,"71T5 UQ<UL1;G)C%&MQ:Q=H<',:96]\'6)NAR!?;90B76RB)%IL
MLB59;,<E6&SH)5EL_2-9:_\A6FO_'UMK_QY;:O\>6VK_'EMJ_Q[K4P  TV
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M'T=_^AY(?O\>2'W_'4E\_QQ)?/\<27S_'$E\_QS680  PFX  +1X  "J@
MGX4  )2'  "(AP  >XD  '",  !KC@T :(\: &:/*0!BD#4!7X\_ UR/2 59
MCE (5HY8"U.-8 Y0C&@038QR$TJ+?19(BHH818J9&D.*JAM"BK\;08KA&T&(
M^1M!AO\;087_&T*%_QI"A/\:0H3_&D*$_QK-9P  O'0  *]^  "EA@  FHH
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M#"JE_PTJI?\-*J7_#2JE_PVU@   J(L  )R1  "1E@  A9P  'B@  !KI0
M7Z@  %.L  !(KP  /;(  #:U"P TM14 ,[8A #*V+  QMS< ,+=! "^X2P N
MN%4 ++A@ 2JX;0$IN7L")[F- B6YGP,DN;0#([G2 R.W] 0BM?\%(;3_!B&S
M_P<ALO\'(;+_!R&R_P>MB@  H)$  )67  "(G0  >Z,  &ZH  !AK0  5;$
M $JT   _MP  -+L  "N^ P DP@P (L(4 "+#'P APRH (,0T !_$/P >Q4H
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M  #H_P"1GP  @J<  '2O  !EMP  5[X  $G#   \QP  ,,L  "7/   <U
M%-D   [=   )X0   N4   #I!@  Z0T  .D1  #J&   ZR$  .TK  #O-P
M\44  /)6  #S:   \WX  /27  #UL   ]M   /?S  #W_P  ]_\  /?_  #W
M_P"%IP  =K   &:X  !8P0  2L@  #O,   NT0  (]8  !G<   1X   #.,
M  3G    Z@   /4   #T    ]04  /4+  #V#P  ]A0  /@=  #Z)P  _#0
M /]#  #_50  _VD  /^!  #_F@  _[(  /_/  #_[0  __D  /_Y  #_^0!X
ML   :+H  %G#  !+RP  .]$  "W8   AW0  %N(   [F   (Z@   .T   #P
M    ^    /\   #_    _P   /\   #_!@  _PP  /\0  #_&   _R(  /\P
M  #_0   _U,  /]I  #_@0  _YD  /^O  #_PP  _]4  /_5  #_U0#_$R@
M_Q,E /\1)0#_#2< _P8M /\ -0#_ $$ _P!/ /\ 7 #_ &D _P!T /\ ?@#_
M (@ _P"0 /\ EP#_ )T _P"D /\ J@#_ +  _P"W /\ P #_ ,P _P#? /\
M[ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_%B4 _Q8B
M /\4(0#_$", _PHH /\ , #_ #T _P!+ /\ 6 #_ &0 _P!P /\ >@#_ (0
M_P", /\ DP#_ )H _P"@ /\ I@#_ *T _P"T /\ O #^ ,@ _0#9 /L Z0#Z
M /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y /\ ^0#_ /D _P#_&B( _QH> /\8
M'0#_$QX _PXB /\*+ #_!SD _P-& /\ 4P#_ &  _P!K /\ =@#_ '\ _P"(
M /\ CP#_ )8 _P"= /\ HP#^ *D _ "P /H N0#W ,0 ]0#2 /, Y@#R /0
M\0#_ /  _P#O /\ [P#_ .\ _P#P /\ \ #_ /  _P#_'AT _QX9 /\<%P#_
M%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_"%L _P=F /\&<0#_!GH _P:# /X&
MBP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&M0#P!<  [07. .L%Y #I!O, Y@C_
M .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_ >0+_P'_(1@ _R$3 /\@$0#_&Q(
M_QP: /\:) #_%B\ _Q,\ /\120#_$%4 _ YA /D.:P#V#G4 ] Y^ /(.A@#P
M#HX [@Z5 .T.FP#K#J( Z@ZJ .@.LP#F#[T Y0_, .$/XP#=$/, V1'_ =82
M_P'4$_\!TQ/_ M(3_P+2$_\"TA/_ M(3_P+_)1, _R40 /\D#0#_(PX _R,4
M /\B'@#_'RD _QPU /D90P#T&$\ [Q=; .P79@#I%W  YA=Y .07@0#B%XD
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M"*@M_PBH+?\(J"W_"*@M_PC_+P@ _S$  /\U  #V-P  ZC8" .<S" #D+P\
MV2X; ,\Q+ #),SP Q#1) , U50&\-5\"NC5H K<U< .U-'@$LS2 !;$TB :P
M-) &KC29!ZPTH@BK-*P)J32Y":<TR@JE->4*H37X"Y\U_PR=-?\,G37_"YPU
M_PN<-?\+G#7_"YPU_PO_,P( _S4  /8Z  #E/@  W$   -0]! #2-PD RS@5
M ,,Z)@"]/38 N#Y$ ;0^4 &Q/5H#KCUC!*P]:P6I/',&ISQ["*8\@PFD.XL*
MHCN4"Z [G0R>.Z@-G3NT#IL[Q0Z9.^ .ECOT#Y0\_P^2//\/DCS_#I$\_PV1
M//\-D3S_#9$\_PW_-0  _SD  .I!  #=1@  T$<  ,E&  #&004 P$ 1 +E"
M(0"S1#( KT5  :M%2P*G154#I$1>!:%$9@>?0VX(G4-V"IM"?@N90H8-ET&/
M#I5!F0^30:01D4&P$I!!P!*.0=D2BT'Q$HE"_Q*(0O\1B$+_$(="_Q"'0O\/
MAT+_#X="_P__.   \ST  .-'  #23   R$X  ,!-  "[2@( MD<. +!)'0"K
M2RT IDP[ :),1P*>2U$$FTM:!IE*8@B626H*E$EQ#))(>0Z/2((/C4>+$8M'
ME1*)1J 4AT:L%85&NQ:$1M$6@D?N%H!'_Q5_1_\4?T?_$G]'_Q%_1_\1?T?_
M$7]'_Q'_.P  [D,  -Q,  #,40  P50  +E4  "T40  KDT+ *A/&0"C42D
MGE(W 9I20P*744X$E%%6!I%07@F.3V8+C$YM#8E.=0^'37X1A4V'$X),D16
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M&FU4LAML5,8;:E7F&VI5^QEJ5?\7:E7_%FI5_Q5K5?\4:U7_%&M5_Q3R0P
MWT\  ,M8  "]70  LV$  *MB  "B8   FUP  )5>$ "08!\ C&$N (AA.@*$
M8$4$@6!.!GY?5@E[7ET+>%UE#G9<;!!S7'03<%M]%6Y:B!=K6I09:5FA&V=9
ML!QE6<,<9%GC'&19^AID6?\89%G_%V59_Q5E6?\495G_%&59_Q3O1@  VE(
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M'%1G]AI49O\856;_%U5E_Q969?\55F7_%59E_Q7B40  RET  +MF  "O;
MIG$  )EP  ".;P  @VX  'UP!0!X<A( =7,A ')S+P%O<SH";'-$!&ER3 9F
M<E0(8W%;"V!P8PU=<&L06V]T$UAN?Q55;HL74VV9&5%MJ!I/;;L;3FW9&DYL
M]!E/:_\83VO_%U!J_Q90:O\54&K_%5!J_Q7=50  Q6$  +=J  "L<0  HG4
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M$CU__Q(]?O\1/7[_$3U^_Q'%9@  M7$  *I[  "?@@  DH(  (6"  !Y@P
M;88  %^*  !8C0$ 5(X/ %*/&P!0CR< 3Y S $V0/0%+D$4"29!. T:05@1$
MCU\%0H]H!S^/<PD]CH +.HZ/##B.H TWCK,.-H[,#C:-[PXUB_\.-8G_#S6(
M_P\VA_\/-H?_#S:'_P^^;0  L'D  *6"  "9AP  C(@  '^(  !RB@  9HT
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M QJK_P.HB   FX\  )&4  "$F@  =I\  &BB  !;I0  3ZD  $2M   YL
M+[,  ":V   >N04 &+L. !>[%@ 7O"  %KPJ !6]-0 4O4  $[Y+ !*^6  2
MOF< $;]X !"_C  0P*( #L"Z  [ X0 /O?L #[S_ !"Z_P$0NO\!$+K_ 1"Z
M_P&?CP  E)4  (>;  !YH0  :Z<  %ZL  !2L0  1;0  #JV   ON0  );P
M !V_   5PP  #\8%  O*#0 )RA0 ",H=  ?*)P 'RC( !LL^  7+2P $S%H
M \QJ  +,?@ !S)0  ,RK  #-R   S.T  ,S_  #+_P !RO\  <K_  '*_P"7
ME@  BIP  'RC  !NJ@  8+   %*V  !%N0  .;P  "Z_   CPP  &\8  !/*
M   -S0  "-$   '4"0  U X  -45  #6'@  V"<  -DQ  #;/@  W$L  -U;
M  #>;@  WH0  -^;  #?M   WMD  -_W  #?_P  W_\  -__  #?_P"-G0
M?Z4  '"L  !ALP  4[H  $6_   XP@  +,8  "')   8S0  $-$   O5   $
MV@   -X   #@ 0  X0D  .(.  #D$P  Y1L  .<D  #I+P  ZSP  .U+  #N
M70  [G$  .^)  #PH@  \+P  /#C  #O^0  \/\  /#_  #P_P"!I0  <JT
M &.U  !4O0  1L0  #?(   JS   ']   !75   .V@  !]X   #B    Y@
M .D   #J    [    .X%  #O#   \1   /,7  #U(   ^"L  /LY  #]2@
M_EX  /]T  #_C0  _Z8  /_   #_X0  __4  /_U  #_]0!TK@  9;<  %;
M  !'R   .,T  "K2   =V   $]T   SB   #Y@   .D   #L    \    /,
M  #T    ]@   /@   #Z    _0<  /\-  #_$@  _QL  /\H  #_-P  _TH
M /]>  #_=@  _X\  /^F  #_N@  _]$  /_1  #_T0#_#R0 _PXB /\+(0#_
M R0 _P I /\ ,@#_ #X _P!, /\ 60#_ &4 _P!P /\ >@#_ (0 _P", /\
MD@#_ )D _P"? /\ I0#_ *L _P"R /\ N@#_ ,4 _P#3 /\ YP#_ /0 _P#_
M /X _P#_ /\ _@#_ /X _P#^ /\ _@#_ /X _P#_$2$ _Q > /\-'0#_!Q\
M_P C /\ +0#_ #H _P!( /\ 50#_ &$ _P!L /\ =@#_ '\ _P"' /\ C@#_
M )4 _P"; /\ H0#_ *< _@"N /T M@#\ ,  ^P#- /D X@#X /  ]P#\ /8
M_P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#_%1T _Q,: /\0&0#_"QD _P =
M /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G /\ <0#_ 'H _@"# /P B@#Z )$
M^0"7 /@ G0#W *, ]0"J /0 L@#R +L \0#( .\ W #N .P [0#Z .L _P#J
M /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_&!D _Q85 /\3$P#_#A, _PL: /\'
M) #_ C  _P ^ /\ 2P#_ %< _P!B /P ; #X '4 ]0!^ /( A0#Q (P [P"3
M .X F0#L *  ZP"F .D K@#G +< Y@## .0 U #B .D X0#W -\ _P#= /\
MW0#_ -T _P#= /\ W0#_ -T _P#_&Q, _QH0 /\6#@#_$@X _Q(5 /\/'P#_
M#"L _PDX /\&10#[ U$ ]P)< /("9@#N G  Z@)X .<"@ #F X< Y .. .(#
ME0#A YP WP2C -T$JP#;!+0 V 7  -8%T #3!N< T CX ,X*_P#,"_\ RPS_
M ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+ /\:!P#_&0L _Q@1 /\6&0#_$B0
M^A P /,./@#N#4H Z0Q6 .4,80#B#&H W@US -L->P#9#8, U@V* -0-D0#2
M#9D T Z@ ,\.J0#-#K, RPZ_ ,H/T #&$>D PA+Y +\3_P"]$_\!O!/_ ;P3
M_P&\$_\!NQ/_ ;L3_P'_(@P _R$$ /\@  #_(04 _Q\, /\<$0#V&!P [!4H
M .43-@#?$D, V1-/ -,46@#0%60 S19M ,L6=0#)%WT QQ>% ,48C #$&)0
MPAF< , 9I0"^&:\ O1J[ +L:RP"X&^4!M!SV ;(=_P*P'?\"KQW_ JX=_P*N
M'?\"KAW_ JX=_P+_)@8 _R4  /\F  #[)P  \24# / A"P#H'!( WAD= -0;
M+0#-'3P R!]) ,4@50#!(5\ OR)H +PB< "Z(W@ N2-_ ;<CAP&U(X\!M"27
M ;(DH &Q)*H"KR2V JTEQ@*K)=\"J";S Z4F_P.C)O\#HB;_!*$F_P.A)O\#
MH2;_ Z$F_P/_*0  _R@  /8M  #G,   WR\  -DK! #6(@H SB,6 ,8F)P#
M*#8 NRI$ +@K3P"U+%D LBQB ; L:@&N+7(!K"UZ JHM@0*I+8H"IRV2 Z4M
MFP.D+:4$HBVQ!* MP 2?+=@$G"[O!9DN_P:7+_\&EB__!I4N_P65+O\%E2[_
M!94N_P7_+   _RX  .HU  #=.0  T3D  ,HV  #'+P8 P2T1 +HP(0"T,C$
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M#7]!LPY^0<8.?$'D#GI"^0UY0O\,>$+_"WA"_PMX0O\*>$'_"GA!_PKV-@
MYD   -%(  ##30  N4X  +%-  "I20  I$4& )]&$P":2", EDDR ))*/@&/
M2D@"C$I1 XI)602'26 %A4EH!X-(;PB!2'<*?T> "WU'B@UZ1Y4.>$:B#W9&
ML!!U1L(0<T;@$')']P]Q1_\.<4?_#7%'_PQQ1_\+<4;_"W%&_POS.0  X$0
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M%%Y4\A->5/\17U3_#U]4_PY?4_\-7U/_#5]3_PWG1   SU   +]8  "S70
MJ%\  )Q=  "26P  BU@  (5:"@"!6Q8 ?5PD 'I=,0!W73P!=%U& G%=3@1O
M7%4%;%Q=!VI<9 EH6VP+95IU#6-:?P]A68L17EF8$EQ8IQ1;6+@465G0%%E8
M\!-96/\16EC_$%I8_PY:5_\-6E?_#5I7_PWC2   RU,  +M;  "P80  I&(
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M#TIE_PY+9?\-2V3_#4MD_PW15   OEX  +%G  "F;0  EVP  (IK  !_:P
M<VL  &UM  !H;@P 97 7 &)Q) !@<3  7G$Z 5QQ0P)9<4L#5W%3!%5P6@92
M<&('4'!K"4YO=0M+;X(-26Z/#T=NGQ!%;K 11&['$4-MZA!$;/\/1&O_#D5K
M_PU%:O\-16K_#45J_PW+6   NF,  *UL  "A<0  DG   (5O  !Z;P  ;G
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M"#"!_PBW:P  JG8  *!_  "0?@  @GX  '9_  !J@   7H,  %.'  !*BP
M08X" #V0#@ [D!@ .I$C #F1+0 XDC< -Y)  #:220 TDU( ,Y-< 3&39P$O
MDW0"+9*# RN2E ,JDJ<#*)*]!"B2X0,GD/H$)X[_!2>-_P4GC/\%)XS_!2>,
M_P6Q=   I7X  )F%  "*A   ?80  &^%  !CB   6(L  $V/  !#DP  .I<
M #*:!P NFQ  +9L: "R<)  KG"X *ITX "F=00 HG4L )YY5 ":>80 EGFX
M(YY^ 2*>D $@GJ,!'YZY 1Z>W0$>G/@"'IK_ AZ9_P,>E_\#'I?_ QZ7_P.J
M?0  GH4  ).+  "%B@  =8L  &B.  !;D0  4)4  $:9   [G0  ,J   "JC
M   BI@D 'Z<1 !ZG&@ =J"0 '*@M !NH-P :J4$ &:E, !BI6  7JF8 %JIV
M !6JB0 4JIX $ZNT !*KTP 2J/4 $Z?_ 1.E_P$3I?\!$Z3_ 1.D_P&CA@
MEXP  (V1  !]D@  ;94  &"8  !4G   2*   #ZD   TIP  *JL  "&N   9
ML0  $K,'  ^U$  .M1< #K4A  VU*P -M38 #+9!  NV3@ *MEP ";9L  BV
M?P 'MI0 !K:J  6VQ0 &MNH ![7_  BT_P (L_\ ";+_  FR_P":C0  D),
M (28  !TG   9:   %>D  !+J   0*P  #6P   JLP  (;4  !BX   1NP
M#+X"  ; "P "P!$  <$9  #!(@  PBL  ,(V  ##0@  PU   ,1?  #$<0
MQ(<  ,2=  #$M0  Q-H  ,3V  ##_P  P_\  ,/_  ##_P"3E   AYH  'B@
M  !JI@  7*P  $^Q  !!M0  -;<  "FZ   ?O0  %L   !##   *Q@   \H
M  #,!0  S P  ,T1  #.&   SB$  - J  #1-0  TT,  -12  #48P  U7@
M -6/  #5IP  UL(  -;I  #6_0  UO\  -;_  #6_P"*FP  >Z(  &RI  !>
ML   4+8  $*Z   TO0  *,$  !W$   4QP  #<L   ;.    T@   -<   #9
M    V@4  -P+  #=$   WQ4  .$=  #C)P  Y3,  .="  #H5   Z&<  .E^
M  #IEP  ZJ\  .K.  #K[P  Z_X  .O_  #K_P!]HP  ;JL  %^R  !1N@
M0L   #3#   GQP  &\L  !+/   +TP   M@   #=    X0   .0   #E
MYP   .D   #K!P  [0T  .\1  #Q&0  ]"0  /<Q  #Y00  ^E4  /IJ  #[
MA   ^YT  /RV  #\T@  _>T  /WT  #]] !QK   8;4  %*]  !$Q   -,D
M ";-   :T@  $-@   C=    X0   .4   #H    [    .\   #Q    \P
M /4   #W    ^0$  /L(  #^#@  _Q4  /\A  #_+P  _T$  /]6  #_;0
M_X<  /^@  #_M@  _\H  /_4  #_U #_"R  _P<> /\ '0#_ "  _P E /\
M+@#_ #L _P!) /\ 5@#_ &( _P!M /\ =@#_ '\ _P"' /\ C@#_ )0 _P":
M /\ H #_ *8 _P"M /\ M0#_ +X _P#+ /\ X0#_ /  _@#] /T _P#] /\
M_0#_ /T _P#\ /\ ^0#_ /D _P#_#1T _PL: /\$&0#_ !H _P ? /\ *@#_
M #< _P!% /\ 40#_ %X _P!H /\ <@#_ 'H _P"" /\ B0#_ )  _P"6 /\
MG #^ *( _ "I /L L #Y +D ^ #& /8 V0#U .L ] #Y /, _P#R /\ \P#_
M /, _P#S /\ \P#_ /, _P#_$!D _PX5 /\(% #_ !0 _P 9 /\ )0#_ #(
M_P!  /\ 3 #_ %D _P!C /X ;0#\ '4 ^@!] /D A #W (L ]@"1 /0 EP#S
M )X \@"D /  K #N +0 [0#  .L SP#I .8 Z #U .8 _P#G /\ Y@#_ .4
M_P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,#P#_ Q  _P 5 /\ ( #_ "P _P Z
M /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X .T ?P#K (8 Z@", .@ DP#G )D
MY0"@ ., IP#A +  WP"Z -T R0#; .  V #P -< _@#5 /\ U #_ -, _P#3
M /\ TP#_ -, _P#_%1  _Q(, /\."0#_"PP _PD2 /\#&@#_ "8 _0 S /0
M0 #O $T ZP!8 .@ 80#E &H X@!R .  >@#> (  W "' -H C@#8 )4 U "<
M -( HP#0 *P S@"V ,P Q #* -D R #M ,< ^P#% /\ Q '_ ,,!_P#$ ?\
MQ '_ ,0!_P#_& L _Q4% /\0  #_$ 8 _P\- /\,% #\!Q\ \0,K .< .0#B
M $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-!'L RP2" ,H$B0#(!9  Q@68 ,0%
MH #"!JD P0:T +\&P0"]"-4 NPGL +@+_0"V#/\ M0W_ +0-_P"T#?\ M W_
M +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,& /H0#@#N#!8 XPDB -H), #3"CX
MS@M* ,H,50#'#5X Q0UG ,(.;P#!#G8 OPY^ +T/A0"\#XT NA"5 +@0G0"W
M$*< M1&R +,1P "R$=4 KA/N *L4_@"I%?\ IQ7_ *<5_P"F%/\!IA3_ :84
M_P'_'P  _QP  /H>  #K'@  XQP  -\5!0#>#@T TPX8 ,L1* #%$S< P!1$
M +P63P"Y%UD MQ=A +08:0"S&7$ L1EX *\:@ "N&H@ K!N0 *L;F0"I&Z,
MIQRN *8<O "D'<\ H1[J 9X>_ &<'_\!FQ__ 9H?_P&:'O\!F1[_ 9D>_P'_
M(@  _R$  .PG  #@*@  U"D  ,TD  #*' @ Q!D2 +T<(@"W'C$ LR ^ *\A
M20"M(E, JB-< *@D9 "F)&P I"1S *,D>@"A)8(!H"6+ 9XEE &=)9X!FR:J
M 9DFMP&8)LD"E2?F I(G^0*0*/\"CRC_ HXG_P*.)_\"CB?_ HXG_P+_)@
M\BD  .,Q  #2-   R#0  , P  "[*0( N",. +$F' "L*"L J"HX *0K1 "A
M+$X GRU7 )TM7P";+6<!F2UN 9@N=0&6+GT"E"Z& I,ND *1+IH#CRZF XTN
MLP.,+L4#BB_A!(<O]@2%+_\$A"__ X0O_P.#+_\#@R__ X,O_P/[*0  ZS$
M -DX  #)/   OSP  +8Y  "P,@  K"T+ *<O%P"B,28 GC,T )HT0 "8-4H
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M"FQ![@EK0O\(:D+_!VI!_P9J0?\&:D'_!6I!_P7M-P  UD(  ,1)  "W30
MJTT  *!*  "81P  DT(  (Y##0")11H AD8H (-'- " 2#\ ?DA( 7M(4 )Y
M2%<"=TA? W5(9@1S1VX%<4=V!F]'@ =M1HP):T:8"FE&I@MG1K8+9D;,"V5&
M[ MD1_\)9$;_"&1&_P=D1O\&9$7_!F1%_P;H.P  T$8  +]-  "S40  I5$
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M"512_PA44O\(5%+_!U12_P?:1@  PU   +58  "H6P  F5H  (U8  "$5P
M>U0  '96 0!Q5P\ ;ED; &Q:* !I6C, 9UL] 65;10%C6TT"85I5 U]:7 1=
M6F0%6UEL!EA9=@A668()5%B/"U)8G@Q06*X-3UC##4Y8Y Q.6/L+3U?_"4]7
M_PA/5O\(4%;_!U!6_P?32@  P%0  +)<  "C7@  E5T  (E<  !_6P  =ED
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M!S]D_P?#5P  LV$  *=I  "6:   AV<  'MG  !Q9P  96@  %QJ  !8; $
M5&X. %)O& !0;R0 3G N $UP. !+<4$ 2G%) 4AQ40%&<5D"1'!B T)P; 1
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M BV!CP,L@:$#*H&V RF!T@,I?_,#*7W_ RE\_P,I>_\#*7O_ RE[_P.Q:@
MI70  )5V  "%=0  >'4  &UU  !A=P  5WH  $Q^  !#@0  .X4  #6("0 R
MB1$ ,8D; #"))0 OBB\ +HHX "V+00 LBTH *HM4 "F+7P HBVL )HMZ 22+
MBP$CBYX!(HNS 2&,S@$ABO$!((C_ B"&_P(@A?\"(87_ B&%_P*K<@  H7P
M (][  " >@  <WH  &9\  !;?P  4((  $:&   \B@  -(T  "R1   FDPP
M))03 ".4'  BE28 (94O ""5.  ?ED( 'I9, !V66  <EF0 &I=T !F7A@ 8
MEYD %Y>N !67R0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0_P&E>P  F8,  (F!
M  ![@   ;((  %^$  !4B   28L  #^0   UE   +9<  "6:   =G@$ %J ,
M !2A$@ 4H1L $Z$E !*A+@ 1HC@ $:)# !"B3P /HEP #J-K  VC?0 -HY(
M#*.G  JBP  +HN8 #*#^  V?_P -GO\ #9W_  V=_P">A   DHD  (.(  !S
MB   98L  %B.  !,D@  09<  #>;   NG@  )*(  !RE   5J   #ZL$  JN
M#  'K1( !JT;  6M)  $KBX  JXY  &N10  KE(  *YA  "N<P  KH<  *Z=
M  "NM   KM4  *WT  "M_P  K/\  *O_  "K_P"6BP  C)   'N0  !KD@
M798  %":  !$GP  .:,  "^G   EJP  '*X  !2Q   .M   ";<   &X"0
MN X  +D4  "Y'   NB4  +HO  "[.@  O$<  +Q6  "\9P  O'L  +R1  "\
MJ0  O,0  +SK  "[_@  N_\  +O_  "[_P"0D@  @Y@  '.;  !CGP  5:,
M $>H   [K0  ,+$  "6T   ;MP  $KH   R]   %OP   ,,   #$ @  Q0H
M ,4.  #&%   QQL  ,@D  #*+@  S#H  ,U)  #-60  S6P  ,Z#  #.FP
MS;4  ,[:  #.]@  S?\  ,W_  #-_P"&F0  =Z   &FF  !:K   3+(  #ZV
M   PN0  )+P  !F_   1P@  "L4   +)    S    -    #1    T@$  -,(
M  #5#0  UQ$  -H8  #<(0  WRP  .$Z  #B2@  XUT  .1R  #DBP  Y:4
M .7   #EY@  Y?@  .7_  #E_P!ZH0  :ZD  %RO  !-M@  /[P  #"_   C
MPP  %\<   _*   'S@   -$   #6    W    -\   #@    X@   .0   #F
M P  Z D  .D.  #L%0  [AX  /$K  #T.@  ]4T  /9A  #W>0  ^),  /BM
M  #YQ@  ^>0  /GS  #Y\P!MJ@  7K(  $^Z  ! P0  ,<4  "+)   6S@
M#=(   38    W0   .$   #D    Z    .L   #M    [P   /$   #S
M]@   /@#  #Z"P  _1$  /\;  #_*0  _SL  /]/  #_9@  _W\  /^9  #_
MKP  _\,  /_6  #_U@#_!!P _P 9 /\ &0#_ !P _P B /\ *P#_ #@ _P!&
M /\ 4P#_ %X _P!I /\ <@#_ 'H _P"" /\ B0#_ (\ _P"5 /\ FP#_ *$
M_P"H /\ KP#_ +D _P#% /\ V0#^ .P _0#[ /L _P#[ /\ ^P#_ /H _P#T
M /\ \ #_ /  _P#_!Q@ _P$5 /\ % #_ !8 _P ; /\ )@#_ #0 _P!" /\
M3@#_ %H _P!D /\ ;0#_ '4 _P!] /\ A #_ (H _0"0 /P E@#Z )T ^0"C
M /@ JP#W +0 ]0"_ /0 S@#S .8 \0#V /  _P#O /\ [P#_ .X _P#N /\
MZ@#_ .H _P#_"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_ "X _P \ /\ 20#_
M %0 _@!? /L : #Y '  ]P!X /4 ?P#S (4 \@"+ /  D@#O )@ [0"? .P
MI@#J *X Z "Y .< QP#E -X XP#P .( _@#@ /\ X #_ .$ _P#A /\ X0#_
M .$ _P#_#1  _PD- /\!# #_  P _P 2 /\ ' #_ "@ _  V /D 0P#V $X
M\@!9 .\ 8@#L &L Z@!R .@ >0#F (  Y "& .( C #A ), WP": -T H0#;
M *H V "T -4 P #2 -, T #J ,X ^@#- /\ S0#_ ,T _P#, /\ S #_ ,P
M_P#_$ P _PP' /\# @#_  @ _P . /\ %@#V "( \  O .P / #I $@ Y0!3
M .$ 7 #> &4 VP!L -< <P#4 'H T@"  -  AP#. (X S "5 ,H G0#( *4
MQ@"O ,0 NP#" ,L P #E +X ]0"] /\ O #_ +P _P"\ /\ O #_ +P _P#_
M$04 _PX  /\*  #_" $ _P0* /@ $ #I !H XP H -X -0#9 $$ TP!, ,\
M5@#+ %\ R0!F ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0 +P F "Z *$ N "K
M +8 MP"T ,< L@#@ +$!\@"O O\ K@/_ *T$_P"M!/\ K03_ *T$_P#_%
M_Q   /\/  #R#0  Z@H  .D#"0#= !( U  ? ,T!+0#( CH Q -% , #4 "]
M!%D NP5A +D%: "W!F\ M09V +0'?0"R!X0 L0B, *\(E0"M"9X JPFH *H*
MM0"H"L4 I@O? *0-] "B#O\ H [_ )\._P"?#O\ GP[_ )\._P#_%P  _Q,
M .\8  #D&0  VQ8  -(0 @#/"0L R @6 ,$*) "\##( MPT^ +0.20"Q#E,
MKQ!; *T08P"K$&H J1%Q *@1> "F$8  I1&( *,2D0"A$IL H!.F )X3LP"<
M$\, FQ3> )<6] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6_P#_&@  ]!T  .4C
M  #5)0  RB0  ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X *<80P"E&4T HAE6
M * :70">&V4 G1ML )L<<P":''L F!R# )<=C0"5'9< DQZB )(>KP"0'K\
MCQ_8 (P@\0&)(/\!B"#_ 8<@_P&'(/\!AB#_ 88@_P'Z'@  ZR8  -HM  #*
M,   OBX  +4H  "P(@  KAL, *@=%P"C'R8 GR$S )PB/@"9(T@ ER11 )4D
M60"3)6  DB5G ) F;@".)G8 C29_ (LFB &*)Y,!B">> 88GJP&$)[L!@RC1
M 8 H[@%^*?\!?2G_ 7PH_P%\*/\!?"C_ 7PH_P'U)   XRX  ,\U  #!.
MM#8  *LQ  "E+   HB8& )XF$P"9*"$ E2HN )(K.0"/+$0 C2U, (LM5 ")
M+EP ARYC (8N:@&$+G(!@BYZ 8$OA %_+X\"?2^: GLOIP)Z+[<">"_, G8P
MZ@)U,/X"<S#_ G,P_P)S+_\"<R__ G,O_P+P*@  W#4  ,<[  "Z/P  K#P
M *(X  "<,P  F"\  )4N$ "0,!P C#(I (DS-0"&-#\ A#5) ((U40" -5@
M?C5? 7TU9@%[-FX!>35V G@U@ )V-8L#=#67 W(VI -P-K0$;S;(!&TVYP1L
M-OP#:S;_ VLV_P)J-O\":C7_ FHU_P+J,   TSH  ,)!  "S0P  I4$  )L^
M  "5.@  D#8  (PU#0"(-Q@ A#@E ($Z,0!_.SP ?#M% 'H\30!X/%4!=SQ<
M 74\8P%S/&H"<3QS G \? -N.X<#;#N4!&H[H01H.[$%9SS%!64\Y05D//H$
M9#S_ V,[_P-C._\#8SO_ F,[_P+E-0  S3\  +U&  "N1P  GT4  )5#  ".
M0   B3P  (0\"@" /10 ?3XB 'H_+@!X0#@ =4%" '-!2@!R05$!<$%9 6Y!
M8 )L06<":D%P VA!>0-G080$94&1!6-!GP5A0:X&8$'"!EY!X@9>0?D%74'_
M!%U _P-=0/\#74#_ UU _P/?.0  R$,  +E*  "I2P  FTD  )!'  "(1
M@T$  'Y!!@!Z0A$ =D,> '1%*@!Q134 ;T8_ &U&1P!K1D\!:D96 6A&70)F
M1F4"9$9M V)&=@1@1H($7D:.!5Q%G 9;1:P&64:_!UA&WP981O<%5T7_!%=%
M_P171/\#6$3_ UA$_P/:/0  Q$<  +5.  "D3@  EDP  (M+  "#20  ?44
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M TE0_P/*2   N5(  *I7  "85@  BE4  ']4  !V4P  ;%$  &=3  !B5 @
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M SQCD 0Z8J$$.6*T!3ACS04X8N\$.&'_!#A@_P,X7_\#.5[_ SE>_P.\50
MK5\  )Q@  "+7P  ?5\  ')?  !H7P  76   %5B  !/9   2V8* $EG$@!'
M:!T 16@G $1I,0!#:3D 0FI" $!J2@ _:E( /6I; 3QJ90$Z:G ".&I^ C9I
MC0,T:9\#,VFR S%IRP,Q:.T#,6?_ S%F_P,R9?\#,F3_ S)D_P.W6P  J60
M )9D  "&8P  >&,  &UC  !D9   664  %!H  !):P  0VT$ $!N#@ ^;Q@
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M !B$P0 8@^8 &('] !F _P$9?_\!&7[_ 1E^_P&F<   E7,  (1R  !V<0
M:W$  %YS  !4=@  27D  #]]   W@0  +X0  ">(   @BP4 &XT. !J-%0 9
MC1X &(XG !>.,  6CCD %8Y# !2/3P 3CUL $H]J !&/>P 0CX\ #X^D  Z/
MNP -C^  #HWZ  ^+_P 0BO\ $(G_ !")_P"A>@  CGD  'YW  !R=P  9'@
M %A[  !-?@  0H(  #F&   OB@  )XX  ""1   8E0  $I@%  Z:#@ -FA0
M#)H=  N:)@ +FC  "IH[  F:1@ (FE, !IMA  6:<@ $FH8  IJ;  ":L0 !
MF<\  IGP  *8_P $E_\ !9;_  66_P"9@0  AW\  'I^  !K?@  78$  %"%
M  !%B0  .XT  #&2   HE@  'YD  !B=   1H   #*,"  :E"@ !I1   *46
M  "F'P  IB@  *8R  "G/0  ITH  *=8  "G:   IWP  *>1  "FJ   IL,
M *7I  "E_   I?\  *3_  "D_P"1AP  @H8  '*&  !CB   58P  $F1   ]
ME@  ,IH  "B>   ?H@  %Z8  !"I   +K   !*\   "Q!@  L0P  +(1  "R
M%P  LQ\  +,H  "T,@  M3\  +5-  "U70  M7   +6&  "UG0  M;8  +7<
M  "T]P  M/\  +3_  "T_P"+CP  >HX  &J1  !;E0  39H  $"?   UI
M*J@  ""L   6L   #[0   FW   !N0   +T   "^    O@8  +\,  # $
MP18  ,(=  ##)P  Q3(  ,9   #&40  QV,  ,=X  #'D0  QZD  ,?'  #'
M[   Q_X  ,?_  #'_P"#EP  <9H  &&>  !2HP  1:D  #BN   LLP  (+<
M !:Z   .O0  !L    ##    QP   ,D   #*    S    ,T#  #."0  T X
M -(3  #4&P  V"4  -LR  #=0@  W50  -YI  #>@0  WIP  -^U  #?V0
MW_,  -__  #?_P!WGP  :*8  %FM  !*LP  .[@  "V[   ?OP  %,(   S&
M   #R0   ,P   #0    U0   -D   #:    W    -X   #@    X@4  .0+
M  #G$   ZA@  .TD  #P,@  \40  /)8  #S;P  ](H  /2D  #TOP  ]-\
M /3S  #T] !JJ   6Z\  $RW   ]O0  +<$  !_&   3R@  "\X   #2
MUP   -P   #@    Y0   .<   #I    ZP   .T   #O    \0   /,   #V
M!P  ^0X  /P6  #_(@  _S,  /]'  #_70  _W8  /^1  #_J0  _[X  /_8
M  #_VP#_ !@ _P 6 /\ %0#_ !@ _P > /\ )P#_ #8 _P!# /\ 3P#_ %H
M_P!D /\ ;0#_ '4 _P!] /\ A #_ (H _P"0 /\ E@#_ )P _P"C /\ JP#_
M +0 _@"_ /T SP#[ .< ^@#X /D _P#Y /\ ^0#_ /4 _P#N /\ Z0#_ .<
M_P#_ !0 _P 1 /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^ /\ 2@#_ %8 _P!@
M /\ : #_ '  _P!X /T ?@#\ (4 ^@"+ /D D0#X )@ ]P"> /4 I@#T *X
M\@"Y /$ QP#O .  [@#R .P _P#L /\ [ #_ .L _P#E /\ X #_ -X _P#_
M Q  _P . /\ #0#_  T _P 3 /\ '@#_ "L _P X /\ 10#^ %  ^P!: /@
M8P#U &L \P!R /$ >0#O '\ [@"& .P C #J )( Z0"9 .< H #F *D Y "S
M .$ P #@ -, W@#K -P ^P#; /\ V@#_ -H _P#9 /\ U #_ -( _P#_!PT
M_P ) /\ !@#_  D _P / /\ & #[ "4 ^  R /4 /P#R $H [0!4 .H 70#G
M &4 Y !L .( <P#@ 'H W@"  -P A@#: (T UP"4 -0 FP#2 *0 SP"M ,T
MN0#+ ,D R0#D ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_ ,< _P#_"@8 _P$
M /\   #_  0 _P + /0 $@#O !\ Z@ L .4 . #B $, W0!. -D 5P#4 %\
MT0!G ,X ;0#, '0 R@!Z ,@ @ #& (< Q0". ,, E@#! )X OP"H +T LP"Z
M ,( N0#; +< \ "U /\ M@#_ +4 _P"U /\ M0#_ +4 _P#_#   _P0  /\
M  #^    ]@ # .@ #0#@ !< V0 D -$ ,0#- #P R@!' ,8 40## %D P !@
M +X 9P"\ &X N@!T +D >P"W (( M0") +, D0"R )H L "D *X KP"L +T
MJ@#0 *@ ZP"G /L I@#_ *8 _P"E /\ I0#_ *4 _P#_#0  _P<  /0)  #J
M"0  X@0  -H !P#/ !$ R  < ,( *0"^ #4 NP!  +< 2@"T %, L@!; +
M8@"N &@ K !O *L =0"I 'T J "$ *8 C0"D )8 HP"@ *$ JP"? ;D G0/,
M )P$Z ":!OD F0?_ )@(_P"7"/\ EPC_ )<(_P#_$   ]Q   .@4  #<%0
MSA$  ,8-  #"! L O  4 +<!(0"R RX K@4Z *L&1 "H"$T I@A5 *0)7 "B
M"F, H IJ )\+<0"="W@ G N  )H,B0"9#), EPR> )4-J@"4#;@ D@W, ) .
MZ@".$/P C!#_ (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H  -T@  #,(0  OQT
M +<7  "S$0  L@L- *L-&0"G#B8 HP\S )\0/@"=$4< FA%0 )@25P"6$EX
ME1-E ),3; "2$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(%K4 AA;) (07YP""
M&/L @!G_ '\9_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I  # *@  LR8  *HB
M  "E'   I!4( * 4$P";%B$ EQ@M )09. "1&D( CQM+ (T<4@"+'%D B1U@
M (@=9P"&'F\ A1YW (,?@ ""'XL @!^7 'X@HP!](+( >R#% 'DAY !W(OD
M=B+_ '4B_P!T(?\ ="'_ '0A_P#O(0  VRL  ,<Q  "V,0  J2X  * J  ";
M)@  F"$! )4>$ "0(!L C2$H (DC,P"')#T A21& (,E3@"!)E4 ?R9< 'XF
M8P!\)VL >R=S 'DG? !X*(< =BB3 '0HH %R**\!<2G! 6\IX %M*?<!;"G_
M 6LI_P%K*?\!:RC_ 6LH_P'H*   T#(  , X  "N-P  H34  )@R  "2+0
MCBD  (LG# "'*!< @RHC ( K+P!^+#D ?"Q" 'HM2@!X+E$ =RY8 '4N8 !S
M+V< <B]O ' O>0%O+X,!;2^0 6LOG0%I+ZP!:#"^ 6<PVP%E,/4!9##_ 6,P
M_P%C+_\!8R__ 6,O_P'B+@  RC@  +H]  "H/   FCH  )$W  "*,P  AC
M (,N"0!_+Q, >S ? '@R*P!V,S4 =#,^ '(T1@!P-$X ;S55 &TU7 !L-60
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M.@X ;3P8 &L]) !I/B\ 9S\X &4_0 !D0$@ 8D!/ &% 5P!?0%X!74!F 5Q
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M D9(_P)'1_\"1T;_ D=&_P+&0P  MDP  *),  "13   A$L  'E*  !P20
M:48  &1'  !?208 7$H0 %I+&P!83"4 5DPO %5-. !334  4DU( %%.3P!/
M3E< 3DY? 4Q.:0%*3G,"2$V  D9-CP-%39\#0TVQ T)-R -!3>H#04S_ D%,
M_P)"2_\"0DK_ D)*_P+"1P  LT\  )Y/  "-3@  @$X  '5-  !L3   8TH
M %Y,  !:30( 5DX. %1/& !24"( 45$L $]1-0!.4CT 35)% $Q230!*4E0
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M 3)8_P&V5   I%D  )!8  " 6   <U<  &E7  !@6   5%D  $Y;  !(70
M0U\$ $!@#@ ^81< /6$@ #MB*0 Z8C( .6(Z #AC0@ W8TL -F-4 #1C70 S
M8V@ ,6-V 2]CA0$N8Y8!+&.I 2MCOP$J8^,!*F+[ 2I@_P$K7_\!*U__ 2M>
M_P&Q60  GEP  (M<  ![6P  ;UL  &5;  !<7   45X  $E@  !#8@  /&4
M #AG"@ U:!( -&@; #-I)  R:2T ,6DU "]J/0 N:D8 +6I/ "QJ60 K:V4
M*6MR "AK@@ F:Y, )&NG "-KO0 B:N  (VGY 2-G_P$C9O\!(V;_ 21E_P&L
M8   F&   (5@  !V7P  :E\  &%@  !78   36,  $1F   ]:   -FL  #!N
M!  L< X *G$5 "EQ'@ H<28 )W(O "9R-P E<D  )')* ")R5  A<V  ('-M
M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W !IP_P ;;_\ &V[_ 1MM_P&F9@
MD64  ']D  !Q9   9F0  %UD  !29@  2&D  #]L   W;P  ,',  "EV   B
M>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D &'Q# !=\3@ 6?%H %7QG !1]
M>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1>/\ $G?_ !)W_P">:P  BFH
M 'II  !M:0  8FD  %=J  !,;0  0W   #ET   Q>   *7L  ")_   ;@@
M%(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[  V'1@ ,AU, "X=A  J'<0 )
MAX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\ "8+_  F"_P"5<0  @V\  '1N
M  !I;@  7&\  %!R  !&=0  /'D  #)]   J@0  (H4  !N)   4C   #X\#
M  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3/@  DTL  )-9  "3:0  DWL
M )*0  "2I@  D;\  )'E  "0^@  C_\  (__  "/_P"-=P  ?74  '!T  !B
M=0  57@  $E\   _@   -(0  "N)   BC0  &I$  !.4   .EP  "9L   &=
M"   G0X  )T3  ">&@  GB(  )\K  "?-0  H$(  *!0  "@7P  H'$  *"'
M  "?G0  G[4  )[:  "=]@  G?\  )S_  "<_P"&?0  >'P  &E\  !;?P
M3H,  $&(   VC   +)$  ".6   :F@  $IX   VA   &I    *<   "I P
MJ0H  *H.  "K$P  K!D  *TB  "N*P  KS<  *]%  "O5   KV8  *][  "N
ME   KJL  *[)  "N[P  K?\  *W_  "M_P"!A   <80  &&'  !3BP  1I
M #F6   NFP  (Z   !JD   2J   #*P   2O    L@   +8   "W    MP(
M +@(  "Y#0  NA(  +L8  "](0  OBL  , X  # 2   P%H  ,%N  #!A@
MP:   ,&Z  #!XP  P/D  ,#_  # _P!YC0  :)   %F4  !+F@  /:   #&E
M   EJP  &J\  !&S   +N    KL   "^    P0   ,0   #%    Q@   ,<
M  #(!0  R@L  ,P/  #.%0  T!\  -,K  #5.@  U4P  -9@  #8=P  V)(
M -BL  #9R0  V>P  -G[  #8_P!PF0  8)X  %&D  !#J@  -;   "BV   <
MN@  $;X   G!    Q0   ,@   #+    SP   -(   #3    U@   -@   #;
M    W0   -\'  #B#0  Y1,  .@=  #L*@  [3P  .U1  #N9P  [X$  .^<
M  #PMP  \-,  /#L  #P] !GI@  6*T  $FT   ZN@  *KX  !S"   0Q@
M!\H   #.    T@   -8   #<    X    .,   #D    Y@   .@   #K
M[0   .\   #R @  ]0H  /@1  #\'   _RP  /\_  #_50  _VX  /^*  #_
MI   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_ !0 _P 9 /\ )0#_ #( _P _
M /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\ ?P#_ (4 _P"+ /\ D0#_ )@
M_P"> /X I@#] *X _ "Y /H R #Y .( ^ #T /< _P#V /\ ]@#_ .\ _P#G
M /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \ _P 4 /\ ( #_ "T _P Z /\
M1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y (  ]P"& /8 C #U )( \P"9
M /( H #P *D [@"S .T P0#K -8 Z@#N .D _@#G /\ YP#_ .4 _P#= /\
MU0#_ -$ _P#_  T _P * /\ " #_  D _P 0 /\ &P#_ "@ _P U /\ 0 #Z
M $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H Z0"  .< A@#F (T Y "3 .(
MFP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2 /\ T@#_ -( _P#. /\ R0#_
M ,8 _P#_  @ _P # /\   #_  , _P - /P %@#W "( \P N .\ .@#L $4
MZ !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z -, @ #1 (< SP". ,T E0#+
M )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\ OP#_ +X _P"^ /\ O0#_ +L
M_P#_    _P   /\   #_    ]@ ( .X $0#G !L X0 G -T ,P#9 #X TP!)
M ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,  >@"_ (  O0"( +L D "Y )@
MN "B +4 K0"S +L L0#. +  Z@"O /P K0#_ *T _P"N /\ K@#_ *X _P#_
M @  _P   /T   #R    Z    -X # #3 !4 S  A ,@ + #$ #@ P0!" +T
M2P"Z %, N !: +8 80"T &< L@!M +  = "O 'H K0"" *P B@"J ), J "=
M *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X _P"> /\ G@#_ )X _P#_!@
M^P   .X%  #B!   U0   ,L !@##  \ O0 9 +@ )0"T #$ L0 [ *X 10"L
M $T J0!5 *< 6P"E &( I !H *( ;@"A '4 GP!\ )X A0"< (X F@"8 )@
MI "6 +  E0#! ), W "2 /( D0#_ )  _P"0 /\ CP#_ (\ _P#]"@  \ X
M .$1  #.$   P@T  +L'  "W  H L0 2 *P '@"H "D I0 T *( /@"? $<
MG0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X )$#@ "0!(H C@25 (P%H0"*
M!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\ @PO_ (,+_P#V$   YA<  -(<
M  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=!R( F0DN )8*. "4"T$ D@Q*
M ) ,40".#5@ C U> (L-90")#6P B YT (8.?0"%#H< @PZ3 ($/GP" $*T
M?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_ '<2_P#O%P  VR$  ,8D  "T
M(P  J"   * <  ";%P  F1$$ )@.$ "3$!L CQ$G (P2,@")$SP AQ-$ (44
M3 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y%X, >!>/ '88G !T&*H <QF[
M '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:_P#G(   T"D  +PK  "K*@
MGB@  )8D  "0(   C1P  (P7# "(&!8 A!HB ($;+0!^'#< ?!U  'H=2 !Y
M'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\ ;B&+ &PAF !K(:< :2*X &@B
MSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@)@  R"\  +0Q  "C,   EBX
M (TK  "'*   A"0  ((@" !^(!( >R(> '@C*0!U)#, <R4\ '$E0P!P)DL
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M 4\U_P%/-/\!3S3_ 4\S_P'+-@  N#T  *,\  "2/   A3L  'LZ  !T-P
M;S4  &PS  !H- H 9343 &(V'@!@-R@ 7C<Q %TX.@!;.$$ 6CE( %DY4 !7
M.5< 5CI? %0Z: !3.G, 43I_ 4\ZC0%..IT!3#JN 4LZPP%*.N4!23K\ 4DY
M_P%).?\!23C_ 4HX_P''.@  LT   )X_  "./P  @3X  '<]  !P.P  :C@
M &8X  !B.0< 7SH1 %P[&P!:.R4 63PN %<]-P!6/3X 5#Y& %,^30!2/E4
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M 3M$_P&[10  ID@  ))'  ""1P  =D<  &M'  !C1@  6T,  %9%  !21P
M3D@* $Q)$@!*21P 2$HE $=*+@!&2S8 14L^ $-+1@!"3$T 04Q6 $!,7P ^
M3&H /$QV #M,A0$Y3)4!-TRG 39,O $U3-T!-4OW 35+_P$U2O\!-DG_ 39)
M_P&X20  HDL  (Y*  !^2@  <DH  &A*  !?20  54@  %!*  !,2P  24P'
M $9-$ !$3AD 0D\B $%/*P! 4#, /U [ #Y00P \44H .U%3 #I17  X46<
M-U%S #51@@ S49,!,E&E 3!1N@$O4=H!+U#V 2]/_P$P3O\!,$[_ 3!-_P&T
M30  G4T  (I-  !Z30  ;DT  &1-  !;30  44T  $M/  !&4   0E(# #]3
M#0 ]5!4 /%0> #I5)P Y52\ .%4W #=6/P V5D< -590 #-660 R5V0 ,%=Q
M "]7@  M5Y$ *U>C "I7N  I5]8 *5;U "E5_P J5/\!*E/_ 2I2_P&O40
MF%$  (51  !V4   :E   &!0  !840  3E(  $=3  !!50  .U@  #A9"@ U
M6A$ -%H: #-;(@ R6RL ,5LS "]<.P N7$, +5Q, "Q<5@ K76  *5UM "A=
M?  F78X )%VA "-=M0 B7=( (ESS ");_P C6O\ (UG_ "18_P"H50  DE0
M (!4  !Q5   9E0  %Q4  !450  2E8  $-8   \6P  -ET  #!@!0 M80X
M*V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-' "-C40 B9%P (61I !]D>0 >
M9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\ '&#_ !Q?_P"A60  C%@  'M8
M  !M6   8E@  %E8  !060  1UL  #Y>   W8   ,6,  "IF   D:0D (6H0
M "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL3  9;%@ %VQE !9L=  4;(8
M$VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_ !-G_P"970  A5T  '5<  !H
M7   7EP  %5<  !+7@  0F$  #ED   R9P  *VH  "1M   >< $ %W,+ !5T
M$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /=5( #G5?  UU;@ ,=8$ "W65
M  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP_P"18@  ?V$  '!A  !D80
M6F$  $]B  !%90  /&@  #-L   K;P  )'(  !UV   7>0  $7P$  U_#  +
M?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL  G]8  %_9P  ?WD  '^.  !_
MHP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")9P  >&<  &MF  !A9@  5&<
M $EI   _;0  -7$  "QU   D>0  '7P  !:    0@P  #(8"  :)"@ !B0\
M (D4  "*&P  BB,  (LL  "+-P  BT,  (M0  "+7P  BW$  (N&  "+G
MBK,  (G3  "(\P  B/\  (?_  "'_P"";0  <VP  &AL  !:;0  3F\  $)S
M   X=P  +GL  "6    =A   %8@  !",   +CP  !)(   "4!@  E0P  )40
M  "6%0  EQP  )@D  "8+@  F3D  )E'  "95@  F6@  )E]  "9E   F*L
M )?(  "6[@  EO\  )7_  "5_P![=   ;W,  &%S  !3=@  1GH  #M_   P
MA   )H@  !V-   4D@  #I8   F9   !G    *    "A    H@8  *(,  "D
M$   I10  *4<  "G)   J"\  *@]  "I3   J5X  *ER  "HB0  J*(  *B\
M  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^  !+@@  /H<  #*-   GD@
M'9<  !2<   .H   !Z0   "H    JP   *X   "O    L    +$$  "S"@
MM X  +43  "V&P  N"0  +HQ  "Z0   NE(  +ME  "[?0  NI<  +JQ  "Z
MT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#D   -I<  "J=   ?H@  %:<
M  VL   %L    +0   "W    NP   +X   "_    P    ,$   ## 0  Q <
M ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8  #0;@  T8@  -"D  #0P0
MT>8  -'X  #1_P!GCP  5Y0  $F:   [H0  +J<  "&M   6LP  #K@   :\
M    P    ,,   #&    RP   ,T   #.    T    -$   #4    U@   -H"
M  #<"0  WP\  .,7  #F)   YS8  .A)  #I7P  ZG@  .N4  #KKP  Z\P
M .SH  #L]@!?G@  4*0  $*K   TL@  )KD  !F^   .P@  !,4   #*
MS0   -$   #8    VP   -\   #@    X@   .0   #F    Z0   .L   #N
M    \04  /4-  #Y%@  _"4  /TY  #^3P  _V<  /^"  #_G0  _[4  /_+
M  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\ (@#_ "\ _P [ /\ 1P#_ %(
M_P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"& /\ C #^ ), _0"9 /L H0#Z
M *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\ \P#_ .D _P#@ /\ V #_ -,
M_P#_  X _P + /\ "@#_  L _P 1 /\ '0#_ "H _P V /\ 00#_ $P _P!6
M /X 7P#[ &8 ^0!M /< = #U 'H ] "  /( A@#P (T [P"4 .T FP#L *0
MZ@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_ -X _P#1 /\ S #_ ,@ _P#_
M  D _P $ /\  0#_  0 _P . /\ & #_ "0 _0 P /L .P#W $8 \P!0 .\
M60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@ (< W@". -P E0#: )X U@"H
M -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L _P#% /\ OP#_ +P _P#_  (
M_P   /\   #_    _0 + /< $P#Q !X [0 J .H -0#G $  X@!* -T 4@#9
M %H U0!A -( 9P#0 &T S@!S ,P >@#* (  R "' ,8 CP#$ )@ P@"A ,
MK0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W /\ LP#_ +  _P#_    _P
M /\   #Y    [@ % .4 #@#> !@ V  C -( +@#/ #D RP!# ,< 3 #$ %0
MP0!; +\ 80"\ &< NP!M +D <P"W 'H M0"! +0 B0"R )( L "; *\ IP"L
M +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\ I0#_ *0 _P#_    _P   /4
M  #J    W@   -  "@#( !( P@ = +X * "[ #, N0 ] +4 1@"R $T L !5
M *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0 @@"B (P H "6 )\ H0"= *X
MFP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_ )< _P#_    ]0   .<!  #4
M    R0   ,  ! "X  X LP 6 *\ (0"K "P J  V *8 /P"C $< H0!/ )\
M50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4 (8 D@"1 )  G ". *D C "X
M (L S0") .L B #] (@ _P"( /\ B #_ (@ _P#Y!@  Z0P  -0.  ###
MMPD  + "  "K  D I@ 0 *( &@"> "4 FP P )@ .0"6 $$ E !) )( 4 "0
M %8 C@!< (T 8@"+ &D B@!P (@ > "' ($ A0", (0 F "" *4 @ "T 'X
MR !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q#@  WA4  ,45  "T%   J1$
M *$.  ">"@  FP,, )< $P"3 !X D $I (T",P"* SP B 1# (8%2P"%!E$
M@P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F) '@)E@!W"J, =0JS ',+QP!R
M#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@  T!X  +D=  "I'   G1H  )46
M  "0$P  CPX# (X*#@")"Q< A@PC (,-+0" #38 ?@X^ 'P.1@![#DT >0]3
M '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1E !L$:( :Q*R &D2QP!H$^<
M9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0  + D  "@(P  E"$  (L?  "&
M&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$ =!4Z '(600!Q%D@ ;Q=/ &X7
M5@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C&I\ 81JO & :Q !>&^0 71S[
M %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I  "8*0  C"@  (,E  !](@
M>1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU &D>/0!H'D0 9A]+ &4?4@!C
M(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP 62*L %<BP !6(^$ 52/Y %0C
M_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2+@  A2T  'PK  !V*   <B8
M &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E.0!@)D$ 7R9( %TF3P!<)U8
M6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ % IO@!/*=X 3BGW $TI_P!-
M*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@  @#$  '8P  !P+0  :RL  &@I
M  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9+#T 6"Q$ %<M3 !5+5, 5"U;
M %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DONP!(+]L 2"_V $<O_P!'+O\
M1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4  '(T  !K,@  9B\  &(N  !?
M+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H 4C)" %$R20!0,E  3C-8 $TS
M80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"--8 0C3T $(T_P!",_\ 0C+_
M $(R_P# .   IS@  ),X  "#.   =S@  &TW  !F-@  83,  %TR  !9,@(
M5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_ $LW1@!*-TX 23A6 $<X7P!&
M.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=, /#GS #PX_P ]-_\ /3?_ #TV
M_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B.0  73<  %@V  !4-P  43@+
M $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\1 !%/$L 1#Q3 $(\7 !!/6<
M/SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR #<\_P X._\ .#O_ #@Z_P"V
M/0  GCX  (L^  !\/@  ;SX  &8]  !>/0  6#L  %,Z  !/.P  3#P( $D]
M$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00! 0$D /D%1 #U!6@ \060 .D%P
M #A!?P W08\ -4*A #1"M  R0LX ,D'P #) _P S0/\ ,S__ #0^_P"Q0
MFD   (=   !X00  ;$$  &)   !;0   5#\  $X_  !*0   1D$% $1"#@!"
M0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148 .45. #A&6  V1F( -49N #-&
M?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N1/\ +D/_ "Y#_P"L0P  ED,
M (-#  !T0P  :$,  %]#  !70P  4$,  $A#  !$10  048! #Y'#  \2!,
M.D@< #E))  X22P -DDT #5*.P T2D, ,TI, #)*50 P2U\ +TMK "U+>@ L
M2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\ *$C_ "E'_P"G1@  D48  ']&
M  !P1@  948  %M&  !41@  3$<  $1(   _2@  .TL  #=,"0 U31  ,TX8
M #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M04@ J4%P *%!H "=0=P E4(@
M)%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_ "--_P"A20  C$D  'I)  !L
M2@  84H  %A*  !02@  24L  $!,   [3@  -5   #%2!  M4PT +%04 "I4
M'  I520 *%4L "=5,P F53P )59% "163@ B5ED (59E !]6=  >5H4 '%:8
M !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2_P";30  ADT  '5-  !H30
M74T  %1-  !-3@  14\  #Q1   V4P  ,54  "M8   F6@D (UL0 ");%P A
M7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754 &%UA !==<  578$ %%V5 !-=
MJ@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"440  @%$  '!1  !D40  65$
M %%1  !)4@  05,  #A6   R60  *UL  "5>   ?80, &F,, !AD$0 79!D
M%F0A !5D*0 493$ $V4Z !)E1  195  $&5=  ]E:P .97T #661  QEI0 *
M9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50  >E4  &M5  !?50  5E4  $Y5
M  !$5P  /%D  #1<   L7P  )F(  !]E   9:   $VL% !!M#0 .;A( #6X:
M  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N90 $;G8  FZ*  !MGP  ;;8
M &S6  !L\P !:_\  FK_  -J_P"%6@  =%H  &9:  !<60  4UD  $A:   _
M70  -F   "YC   F9P  'VH  !EM   3<0  #G0#  IW"@ %=Q   7<5  !W
M'   =R0  '@M  !X-P  >$,  'A0  !X7@  >&\  'B$  !XF0  =[   ';-
M  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>  !97@  35\  $)B   Y90
M,&@  "=L   ?<   &'0  !)W   ->P  "'X   * "   @0T  ($1  ""%P
M@QX  (,F  "$,   A#L  (1(  "$5P  A&@  (1\  "$DP  @ZH  (+%  "!
MZP  @?X  (#_  " _P!W90  :60  %]C  !29   1V<  #QK   Q;P  *',
M "!W   8?   $7\   R#   &AP   (H   ", P  C D  (T.  ".$0  CQ<
M ) >  "1)P  DC(  )(_  "23@  DE\  ))S  "2BP  D:(  )&\  "0Y0
MC_P  ([_  "._P!Q:P  9FH  %AK  !+;0  /W$  #1V   J>P  ((   !>%
M   0B0  "XT   21    E0   )@   "9    F@,  )L(  "<#0  GA$  )\6
M  "@'@  HB@  *(U  "C1   HU4  *-I  "B@   HIH  *&S  "@V   H/8
M )__  "?_P!N<0  7W(  %%U  !$>0  -WX  "R$   AB@  %X\  !"4   *
MF0   9T   "@    I    *<   "H    J0   *H   "L!@  K0L  *\0  "P
M%0  LAX  +0I  "T.0  M$H  +5=  "U<P  M8X  +6H  "TQ@  L^T  ++_
M  "R_P!F>@  5WT  $F"   \AP  +XX  ".4   8F@  $)\   FD    J0
M *T   "P    M    +<   "X    N0   +L   "\    O@(  , (  #"#@
MQ!0  ,<>  #(+   R3T  ,I0  #*9@  RG\  ,J;  #*N   RMT  ,KU  #*
M_P!>A@  3XL  $&1   SF   )Y\  !NE   1JP  ";    "U    N0   +T
M  #!    Q@   ,@   #)    RP   ,P   #.    T    -(   #4!0  V0P
M -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,  #FJ   Y<4  .7G  #F]@!6
ME   2)L  #JB   LJ0  '[   !.V   +O    ,$   #%    R0   ,T   #2
M    U@   -H   #;    W@   .    #B    Y    .<   #I    [0   / *
M  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]EP  _:\  /W'  #]Y #_  X
M_P - /\ # #_  X _P 3 /\ '@#_ "H _P V /\ 0@#_ $T _P!7 /\ 7P#_
M &< _P!N /\ = #_ 'H _P"! /T AP#\ (T ^@"4 /D G #W *4 ]0"O /0
MO #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7 /\ S@#_ ,H _P#_  H _P &
M /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\ /0#_ $< _@!1 /L 60#Y &$
M]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ". .H E@#H )\ Y@"I ., M0#B
M ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\ P@#_ +X _P#_  , _P   /\
M  #_  $ _P - /\ % #] "  ^@ K /< -@#S $$ [P!+ .P 5 #H %L Y@!B
M ., : #A &X WP!T -P >@#: ($ V "( -0 D #2 )@ SP"B ,T K@#+ +P
MR0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_ +, _P#_    _P   /\   #_
M    ]P ( /  $ #K !H YP E .0 , #A #L W !% -4 30#1 %4 S@!; ,L
M8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"] )( NP"< +D IP"W +4 M0#(
M +, Y@"R /L L0#_ +  _P"N /\ J@#_ *< _P#_    _P   /X   #Q
MY0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^ ,  1P"\ $X N@!5 +< 6P"U
M &$ LP!G +( ;0"P ', K@!Z *P @@"J (L J "5 *< H "E *T HP"^ *$
MVP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_    _    .X   #@    T
M ,4 " "^ !  N0 9 +4 (P"S "X L  W *T 0 "J $@ J !/ *4 50"C %L
MH@!@ *  9@"? &P G0!S )L >P": (0 F ". )8 F@"5 *< DP"W )$ S "0
M .P CP#_ (X _P". /\ C@#_ (\ _P#\    [P   -L   #)    O0   +4
M @"N  P J0 3 *4 '0"B "< H  Q )T .@": $( F !) )8 3P"4 %4 DP!;
M )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@ E0"& *( A0"Q (, Q "! .0
M@ #Y '\ _P"  /\ @ #_ (  _P#T @  X D  ,<(  "W!P  K ,  *8   "@
M  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P BP!# (D 20"' %  A@!5 (0
M6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y )T > "L '8 O@!U -T <P#T
M ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0  "I$   G@X  )<+  "3!@
MD  + (P $0") !H A@ D (, +@"! #8 ?P ^ 'T 1 !\ $L >@!1 'D 5P!W
M %T =@!D '0 ; !S 74 <0&  &\"C0!N IH ; .J &L#NP!I!-8 : ;Q &@'
M_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">%@  DQ4  (L2  "&$   A P"
M (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)0 !R"48 < I, &\*4P!M"UD
M; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI &$-NP!@#=@ 7@[S %T._P!=
M#O\ 70[_ %T._P#4'   N1T  *0>  "5'0  B1P  ($:  ![%P  >!,  '@0
M!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I$$( 9Q%) &813P!D$58 8Q)=
M &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4N@!6%-4 517S %05_P!4%?\
M5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(  'DA  !S'@  ;QL  &X7  !M
M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX 7AA% %T82P!<&5( 6AE: %D9
M8@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.&]  31SQ $P<_P!,'/\ 31S_
M $T;_P##)@  JB<  )8G  "'*   >R<  '(F  !L)   :"$  &8>  !D&P@
M8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]! %8@2 !4($\ 4R!7 %$A7P!0
M(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT 1B/O $4C_P!%(O\ 1B+_ $8A
M_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F*0  8B8  %\D  !=(@0 6R$.
M %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F10!.)DP 3"94 $LG7 !))V8
M2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM #\H_P _*/\ 0"?_ $ G_P"W
M+0  GRX  (PO  !]+P  <2\  &@N  !A+0  72L  %HH  !7)P  5"<, %(H
M$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(+$D 1BQ1 $4L6@!$+&0 0BUO
M $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM_P Z+?\ .BS_ #HL_P"R,
MFS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\  %4L  !1+   3RT) $PM$0!*
M+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4< 03%/ $ Q5P ^,6$ /3)M #LR
M>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U,?\ -3'_ #4P_P"M,P  EC0
M (0U  !U-0  :34  & U  !9-   5#,  % P  !,,0  23$& $<R#P!%,Q8
M0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9, #HV50 Y-E\ -S9K #8V>  T
M-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\ ,#7_ # T_P"I-@  DC8  ( W
M  !R.   9C@  %TW  !6-P  4#8  $LT  !'-0  1#8# $$W#0 _.!0 /C@<
M #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z4P T.UT ,CMH # [=@ O.X<
M+3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_ "PX_P"D.   CCD  'PZ  !N
M.@  8SH  %HZ  !3.@  33H  $8X  !".@  /SL  #P\"P Z/!$ .#T9 #<]
M(0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N/UH +4!F "M =  I0(0 *$"7
M "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]_P"?.P  BCP  '@]  !J/0
M7ST  %8]  !//0  23T  $(]   \/@  .3\  #9!"  T00\ ,D(6 #%"'@ O
M0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@ )T5C "5%<0 C18( (D65 "!%
MJ  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":/@  A3\  '1   !G0   7$
M %-   !,0   1D   #Y!   X0P  -$4  #!& P M1PT *T@2 "I(&@ I2"(
M*$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA !]*;P =2G\ &TJ2 !I*I@ 8
M2KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@  @$(  '!#  !C0P  6$,  %!#
M  !)0P  0D0  #M%   U1P  ,$D  "M+   F30D )$X0 ").%@ A3QT ($\E
M !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0:P 64'P %%"/ !-0I  14+H
M$5#> !%/^  23O\ $TW_ !1-_P"/10  >T8  &M&  !?1P  54<  $U'  !&
M1P  /T<  #=*   Q3   *TX  "90   @4P, '%4, !I6$0 95A@ %U8@ !96
M)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /5WD #E>,  U7H  +5[8 "U;4
M  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*  !;2@  44H  $I*  !#2@
M.TP  #-.   L40  )E0  "%6   ;60  %5P' !%>#0 07A, $%X:  Y>(@ .
M7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G, !5Z&  ->FP "7K$  EW,  )=
M[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !73@  3DX  $=.   ^3P  -E$
M "Y4   G5P  (5H  !M=   58   $&,#  QF"P (9Q  !F<5  5G'  $9R0
M F<M  %G-P  9T(  &=.  !G7   9VT  &>   !FE0  9JP  &7'  !EZP
M9/P  &3_  !C_P!Z4@  :E,  %U2  !44@  2U(  $)3   Y50  ,%@  "A;
M   A7P  &F(  !1E   0:   #&L!  9N"0  ;PX  &\2  !O&   <!\  ' G
M  !Q,   <3L  '%(  !Q5@  <68  '%Y  !QCP  <*<  &_!  !OYP  ;OP
M &W_  !M_P!S6   95<  %I7  !15@  1E<  #Q:   R70  *F$  ")D   :
M:   %&P   YO   *<@  !'8   !X!0  > L  'D.  !Z$P  >QD  'P@  !]
M*0  ?3,  'U   !]3@  ?5X  'UR  !]B   ?*$  'RZ  ![X@  >OH  'G_
M  !X_P!M70  8%P  %=<  !+70  0%\  #5C   K9P  (VL  !IO   3<P
M#G<   A[   "?@   ((   "# 0  A 8  (4+  "&#P  B!,  (D9  "*(0
MBRL  (LW  ",1@  BU8  (MI  "+@   BYD  (JS  ")V   B/<  (C_  "'
M_P!H8P  7F(  %%B  !$90  .&D  "YN   D<P  &G@  !-]   -@0  !H4
M  ")    C0   )    "2    D@   )0%  "5"@  EPX  )@2  ":&   FR$
M )PM  "=/   G4P  )Q?  "<=@  FY$  )NK  ":R0  FO   )G_  "8_P!E
M:0  5VD  $EL   ]<0  ,'8  "5\   ;@0  $H<   R,   $D0   )4   "9
M    G0   *    "A    H@   *0   "E 0  IP<  *D,  "J$0  K1@  *\B
M  "O,   KT$  *]4  "O:P  KH4  *ZA  "NO@  K>8  *S\  "L_P!><0
M3W0  $)Y   U?P  *(4  !V,   3D@  #)@   .=    H@   *8   "J
MK@   +    "Q    LP   +0   "V    N    +H$  "\"@  OA   ,$7  ##
M)   PS4  ,1)  #$7@  Q7<  ,63  #%KP  Q=$  ,/R  ##_P!6?   1X(
M #J(   LCP  ()8  !2=   -HP   ZD   "N    L@   +<   "[    OP
M ,(   #"    Q0   ,8   #(    R@   ,T   #/    T@@  -4.  #;&
MW2<  -XZ  #?4   X&@  ."$  #AH0  X;T  .'B  #@] !.BP  0)(  #*9
M   EH0  &*@   ZO   %M0   +H   "_    Q    ,@   #.    T0   -0
M  #5    V    -H   #=    WP   .(   #D    YP   .L%  #O#@  ]!D
M /4K  #V00  ]U@  /AR  #YD   ^:L  /C$  #XX0#_  L _P ( /\ "0#_
M  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@ _P!2 /\ 6@#_ &( _P!I /\
M;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U *  \P"J /( MP#O ,D [0#F
M .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,( _P#_  0 _P   /\   #_  4
M_P - /\ %0#_ "$ _P L /\ . #_ $, _0!, /D 5 #W %P ] !C /( :0#P
M &\ [@!U .P >P#J (( Z ") .< D0#D )H X@"D .  L #= ,  V@#< -@
M] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_    _P   /\   #_    _P *
M /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@ 3@#D %8 X0!< -X 8P#< &@
MV0!N -4 = #2 'L T "" ,T B@#+ ), R "= ,8 J #$ +< P0#, ,  ZP"^
M /\ O0#_ +T _P"T /\ K@#_ *L _P#_    _P   /\   #Z    \@ % .H
M#@#E !8 X  A -T *P#; #8 TP _ ,X 2 #* $\ QP!6 ,0 7 #" &$ P !G
M +X ;0"\ ', N@!Z +@ @@"V (L M "6 +( H0"P *\ K@#! *T X "K /<
MJ@#_ *D _P"F /\ H0#_ )\ _P#_    _P   /<   #H    W    -  "@#*
M !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@ L@!/ +  50"N %L K !A *H
M9@"H &P IP!S *4 >P"C (0 H0". )\ F@"= *< FP"X )H T "9 .\ F #_
M )< _P"6 /\ E #_ )( _P#_    ]@   .0   #2    Q0   +L !0"U  X
ML  5 *P 'P"J "D J  R *4 .@"B $( H !) )X 3P"< %4 F@!: )@ 8 "6
M &8 E0!L ), = "2 'T D "' (X DP", *$ BP"P (H Q0"( .8 AP#[ (8
M_P"' /\ AP#_ (8 _P#X    Y0   ,T   "]    LP   *H   "C  H GP 1
M )L &0"9 ", EP L )4 - "2 #P D !# (X 20", $\ B@!4 (D 6@"' &
MA@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J 'L O !Z -L > #U '@ _P!X
M /\ > #_ '@ _P#M    T0(  +L"  "L 0  H@   )L   "6  4 D0 - (T
M% "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^ $D ?0!/ 'P 50!Z %L >0!A
M '< :0!U '$ = !\ '( B !Q )8 ;P"E &X M@!M ,X ; #N &L _P!K /\
M:P#_ &L _P#?"P  P@P  *X,  ">#   DPL  (P'  "( @  A0 ) ($ $ !_
M !< ?  @ 'H * !X #  =@ X '0 /@!S $0 <0!* '  4 !N %8 ;0!= &P
M9 !J &T : !W &< A !E )( 9 "A &, L@!A ,D 8 #I &  _ !@ /\ 8 #_
M &  _P#0$   MA$  *(2  "3$@  B!$  ( /  !\#0  >0D! '@#"P!U !$
M<P : '  (P!N 2L ; $S &H".0!I T  9P-& &8$3 !E!%( 8P59 &(%80!@
M!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8 5@GG %8*^P!5"O\ 50K_ %8*
M_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q$P  ;A   &T-!0!M"0T :@D4
M &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-2 !<#4\ 6PU6 %D-7@!8#F@
M5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J $T0_0!-$/\ 31#_ $T0_P"\
M&P  I1P  )(=  "#'@  =QT  &\<  !I&@  9A<  &04  !D$ @ 8@\0 %\0
M& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4$DP 4Q-3 %$36P!0$V4 3A1P
M $P4?0!+%(P 212< $<5K@!&%<4 117H $46_@!%%O\ 117_ $45_P"U'P
MGB$  (LB  !\(@  <2(  &@A  !B'P  7QT  %P:  !;%P( 6A4- %<6% !5
M%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@ 2QI0 $H:6 !(&F( 1QIM $4;
M>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^'/\ /AO_ #X;_P"O(P  F"0
M (8E  !W)@  ;"8  &,E  !=)   62(  %8?  !4'0  4QP+ %$<$@!.'1H
M31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!- $,@50!"(%\ 0"%J #\A=P ]
M(8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\ ."'_ #@A_P"J)@  E"<  ($I
M  !S*0  9RD  %\I  !8*   5"8  %$C  !/(@  3"(' $HB$ !((A< 1R,?
M $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF4P \)EP .B9G #DF=0 W)X0
M-2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_ #,E_P"E*0  CRH  'TL  !O
M+   9"T  %LL  !5*P  4"H  $PH  !*)@  1R<$ $0G#0!"*!0 02@< #\I
M(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V*UH -2ME #,K<@ Q*X( ,"R4
M "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ_P"A+   BRT  'DN  !K+P
M8"\  %@O  !1+@  3"X  $@L  !%*P  02L  #\L"P ]+!$ .RT9 #HN(0 Y
M+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@ ,#!C "XP<  L,(  *C"2 "DP
MI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<+@  AS   '8Q  !H,@  73(
M %4R  !.,0  2#$  $0P  ! +P  /#   #HQ"0 W,1  -C(6 #4R'@ S,R4
M,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A "DU;@ G-7X )360 ",UHP B
M-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0  @S,  '(T  !E-   6C4  %$U
M  !+-   130  $ T   Z,P  -S0  #0U!@ R-@X ,#<3 "\W&P N-R( +3@I
M "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y;  A.GP (#J. !XZH@ <.K<
M&SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8  &XW  !A-P  5S<  $XW  !(
M-P  0C<  #PW   U.   ,CD  "\Z @ L.PL *CP1 "D\&  H/1\ )CTF "4]
M+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;/WD &C^, !@_H  6/[4 %3[2
M !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY  !>.@  4SH  $LZ  !%.@
M/SH  #DZ   R/   +CX  "E    F00@ )$(. ")"%  A0AL ($,C !]#*@ >
M0S( '$,Z !M$0P :1$T &$19 !=$9P 51'< $T2* !)$G@ 11+, $$30 !!#
M\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:/0  4#T  $@]  !"/0  /#T
M #8^   O0   *D(  "5$   A1@, '4@, !M)$0 921< &$D> !=))@ 622X
M%4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'  U*FP ,2K  "DK*  M)[  ,
M2/\ #4?_  U'_P"#/@  <3\  &)   !60   34   $5    _0   .4$  #)"
M   K10  )D<  "%)   <2P  %DX' !-0#@ 24!, $5 9 !!0(0 /4"D #E Q
M  U0.P -448 "U%1  I17P )46\ !U"!  50E@ #4*L  E#%  -/Z  #3_L
M!4[_  9-_P!]0@  :T,  %U$  !21   2D0  $-#   \1   -44  "Y'   G
M2@  (4P  !Q/   740  $E0#  Y7"@ +6!  "E@5  A8'  '6"0 !E@L  58
M-@ #6$   5A,  !86@  6&D  %A\  !8D0  5Z<  %?   !6Y0  5OD  %7_
M  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'   X2   ,$H  "E-   B4
M'%,  !95   16   #5L"  E>"0 $7PX  %\2  !?&   8!\  & G  !@,
M8#L  &!'  !@5   8&,  &!V  !@BP  7Z(  %^[  !?X@  7OD  %W_  !=
M_P!O2P  84P  %5,  !,2P  1$L  #M,   R3@  *U$  "-4   <5P  %EL
M !%>   -8   "&,   )F!P  9PP  &</  !H$P  :1D  &HA  !J*0  :C0
M &I   !J30  :ET  &IO  !JA0  :IT  &FV  !HW0  :/<  &?_  !F_P!I
M40  7%   %)0  !*3P  /U   #53   M5@  )%D  !U=   68   $&0   QG
M   &:@   &X   !O P  < @  '$-  !R$   =!0  '4;  !V(P  =RP  '<X
M  !V1@  =E8  '9H  !V?@  =I<  '6Q  !TTP  <_4  '/_  !R_P!C5@
M6%4  %!4  !$50  .5@  "];   F7P  '6,  !5G   0;   "G    1S
M=@   'H   !\    ? ,  'X(  !_#   @1   ((4  "$&P  A20  (8O  "&
M/0  ADT  (5?  "%=0  A8\  (2I  "#R0  @O$  ('_  " _P!?6P  5EH
M $E;   ]7@  ,F$  "=F   >:P  %7    YU   )>0   7X   "!    A0
M (@   "*    BP   (T!  ".!@  D L  )$/  "3%   E1L  )<F  "7-
MET0  )=6  "6;   E88  )6B  "4P0  D^H  )+_  "2_P!=80  3V$  $)D
M   V:0  *FX  !]T   5>0  #G\   >$    B0   (X   "2    E@   )@
M  ":    FP   )T   "?    H0,  *,(  "E#0  IQ,  *D<  "J*   JCD
M *I+  "J80  J7H  *B9  "HM0  I]T  *?X  "F_P!6:   2&P  #IP   N
M=@  (GT  !>$   .B@  !Y    "6    F@   )\   "C    IP   *H   "K
M    K0   *\   "Q    LP   +4   "X!0  N@P  +T2  # '   P"T  ,!
M  "_50  OVX  +Z+  "^J   OLD  +WO  "\_@!.=   0'D  #)_   EAP
M&8X  !"5   'G    *(   "G    K    +    "U    N0   +P   "]
MOP   ,$   ##    Q@   ,@   #*    S0(  - +  #5$@  UB$  -<T  #8
M20  V6   -I\  #:F@  V[4  -O9  #;\@!&@@  .(D  "N0   =F   $J
M  JG    K@   +0   "Y    O@   ,(   #(    RP   ,X   #/    T@
M -0   #6    V@   -T   #?    X@   .8   #J"@  [Q,  / E  #R.@
M\U$  /1K  #TB0  ]:4  /6_  #UW0#_  8 _P # /\ !0#_  L _P 0 /\
M%P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_ %T _P!D /\ :@#_ '  _0!V
M /L ? #Y (, ]P"* /4 D@#S )L \ "F .X LP#K ,0 Z0#D .< ^0#F /\
MY0#_ -, _P#' /\ OP#_ +L _P#_    _P   /\   #_  ( _P + /\ $@#_
M !T _P H /\ ,P#_ #X _ !' /@ 3P#T %< \0!= .X 8P#L &D Z@!O .@
M=0#F 'P Y "# .( BP#? )4 W "? -D JP#5 +L T@#4 ,\ \@#- /\ S #_
M ,4 _P"Z /\ M #_ +  _P#_    _P   /\   #_    _P & /D #P#U !<
M\P B /$ +0#M #< YP!  .( 20#? %  VP!7 -< 70#4 &, T0!H ,\ ;@#,
M '4 R@!\ ,@ A #% (T P@"8 ,  I "] +( NP#& +D Z "X /T MP#_ +8
M_P"M /\ IP#_ *, _P#_    _P   /\   #U    ZP ! .0 # #> !, V0 <
M -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T 5@"[ %P N0!A +< 9P"U &T
MLP!T +$ ? "O (4 K0"0 *H G "H *H I@"[ *4 V@"C /4 HP#_ *( _P">
M /\ F@#_ )< _P#_    _@   .\   #?    T    ,< !P#!  \ O  7 +D
M( "W "H M0 S +  .P"M $, JP!) *@ 3P"F %4 I !: *, 8 "A &8 GP!M
M )T = "< 'T F@"( )@ E "6 *( E "R )( R0"1 .L D0#_ )  _P"0 /\
MC #_ (H _P#\    [    -D   #'    N@   +$  @"K  P IP 2 *0 &P"A
M "0 H  L )X -0"; #P F !# )8 20"4 $\ D@!4 )  6@"/ %\ C0!F (L
M;0") '8 B "  (8 C "$ )H @@"J ($ O@"  .  @ #Y '\ _P!_ /\ ?P#_
M 'X _P#Q    V    ,(   "S    J    *    "9  < E0 . )( %0"0 !X
MC@ F (T +@"* #8 AP ] (4 0P"$ $D @@!. ($ 5 !_ %D ?@!@ 'P 9P!Z
M &\ >0!Z '< A@!U )0 = "C '( M0!R ,\ <0#Q '  _P!P /\ < #_ '$
M_P#A    Q    +    "B    EP   )$   "+  ( A@ + (, $0"! !@ ?P A
M 'T *0!\ #  >0 W '@ /0!V $, = !) ', 3@!R %0 < !: &\ 8@!M &H
M:P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H &0 _0!C /\ 8P#_ &0 _P#/
M!0  M@<  *,(  "4"   B0<  ((#  !^    >P & '< #@!U !, <@ ; '$
M(P!O "L ;0 R &P . !J #X :0!$ &< 20!F $\ 90!6 &, 70!B &4 8 !O
M %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@ ^ !8 /\ 6 #_ %D _P#"#
MJ@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8  &T "@!K !  :0 6 &< '@!E
M "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L 6P!2 %H 60!8 &( 5P!L %4
M> !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !. _\ 3@3_ $X#_P"X$   H1(
M (X3  !_$P  =!,  &P2  !G$   90X  &,+ P!C!@P 8001 %X#&0!<!"$
M6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/ %$(5@!0"5\ 3@EI $T)=@!+
M"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\ 10S_ $4,_P"P%   F18  (<8
M  !X&0  ;1@  &47  !?%@  7!,  %H1  !:#@8 6@P- %<,% !5#!P 4PTD
M %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.50!(#UX 1P]H $4/=0!#$(0
M01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_ #X0_P"I&0  DAL  ($<  !R
M'0  9QT  %\<  !9&P  51D  %,6  !2$P  4A$* % 0$ !.$1@ 3!$@ $H2
M)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!%%L /Q1E #X5<@ \%8$ .A62
M #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5_P"C'   C1X  'L@  !M(0
M8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8& $D6#@!'%Q4 11<< $08) !"
M&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@ .1IC #<;;P U&WX ,QN0 #(;
MH@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"='P  B"(  '<C  !I)   7B0
M %8D  !0(P  2R(  $@@  !&'0  11P" $,<# !!'!( /QT9 #X=(0 \'B<
M.QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@ #$@;0 O('P +2&. "PAH  J
M(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@  A"4  ',F  !E)P  6R<  %,G
M  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [(1  .2(6 #@B'@ V(R4 -2,K
M #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE:P J)7H *"6, "8EGP D);,
M(R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<  &\I  !B*@  5RH  $\J  !)
M*0  1"@  $ G   ])@  .B4  #<F!@ U)@X -"<4 #(G&P Q*"( ,"@I "\H
M,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D*G@ (RJ* "$JG0 ?*K( 'BK,
M !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK  !?+   5"P  $PL  !&+
M02L  #PK   X*@  -2H  #(K P P*PP +BP1 "TL&  L+!\ *BTF "DM+0 H
M+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8 '2^( !POFP :+[  &"_* !@N
M[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;+P  42\  $DO  !#+P  /BX
M #DN   T+@  ,"X  "TO   K, H *3$0 "<Q%0 F,1P )3(C "0R*@ C,C$
M(3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2& !8TF@ 4,ZX $S/( !,S[  4
M,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0  3C(  $8R  ! ,0  .S$  #8Q
M   Q,0  *S,  "@T   E-08 (S8- "$V$@ @-QD 'S<@ !XW)P =."X &S@V
M !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$YF  0.:T #CC'  XXZP 0./\
M$#?_ !$V_P"#,0  <#(  &$T  !5-   2S0  $0T   ]-   .#0  #,T   M
M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14 &#T< !<](P 6/2L %3XS !0^
M/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +/JD "C[!  H]Y  +/?L ##S_
M  T[_P!]-   :S8  %TW  !1-P  2#<  $$W   [-P  -3<  # W   J.0
M)3L  " ]   </P  %T$& !1##0 20Q( $4,8 !%#'P 01"< #T0O  Y$.0 -
M1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4  D.]  -#X  #0_8 !$+_  9!
M_P!X.   9SD  %DZ  !..@  13H  #XZ   X.@  ,SH  "T[   G/0  (4
M !Q"   71   $T8#  ])"@ -2@\ #$H4  M*&P )2B, "$HK  =*-  %2CX
M!$I)  )*5@  2F4  $IW  !*BP  2J$  $FY  !)W0  2?4  $C_  !(_P!R
M/   8CT  %4^  !*/@  0CT  #P]   V/0  +SX  "E    C0@  '44  !='
M   32@  #TP"  M/"0 '4 T  U$1  !1%P  41X  %$F  !1+P  43D  %%$
M  !240  4F   %%R  !1AP  49T  %&U  !0V   4/4  $__  !/_P!L0
M74$  %%!  !'00  0$   #E    R00  *D,  "1&   >2   %TL  !).   .
M40  "U,!  96!P  5PP  %@0  !8$P  61D  %HA  !:*0  6C,  %H_  !:
M3   6EH  %IL  !:@0  69D  %FQ  !8T0  6/0  %?_  !7_P!E10  6$4
M $U%  !%1   /D0  #5%   M1P  )4H  !Y-   84   $E,   Y6   *60
M!%P   !>!   7PD  & -  !A$   8A4  &,;  !D(P  9"T  &0X  !D10
M9%0  &1F  !D>P  8Y,  &.M  !BS   8?(  &'_  !@_P!?2@  4TH  $I)
M  !#2   .4D  "],   G3P  'U(  !A5   260  #5T   A@   "8P   &8
M  !H 0  :04  &H*  !K#0  ;1$  &X6  !P'0  <28  '$Q  !P/@  <$X
M '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_  !L_P!:3P  4$X  $A-   ]
M3@  ,U$  "E4   @6   &%P  !%@   ,9   !F@   !K    ;P   '(   !T
M    =0   '<$  !X"0  >@T  'P0  !]%@  ?QX  ( H  " -0  @$4  ']6
M  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z_P!65   3E,  $)4   W5@
M+%H  ")?   88P  $6@   MM   #<@   '8   !Z    ?0   (    "#
MA    (8   "' @  B0<  (L,  "-$   D!8  )(?  "2+   DCL  ))-  "1
M8@  D7H  (^7  "/M   CN$  (S[  ",_P!560  2%H  #M=   O80  )&8
M !EL   1<@  "G<   )]    @@   (8   "+    C@   )$   "3    E0
M )<   "9    FP   )T$  "?"@  H@\  *06  "F(0  IC$  *9#  "E5P
MI'   *..  "CJP  H=   *#U  "?_P!.80  0&0  #-I   G;@  &W4  !%\
M   +@P   (D   ".    DP   )@   "=    H0   *0   "E    IP   *D
M  "K    K0   +    "R    M0@  +@.  "\%@  O"4  +PW  "[3   NF0
M +F!  "WH@  M\   +?J  "W_ !&:P  .7   "MW   ??P  $X8   N.   !
ME0   )L   "A    I@   *L   "P    LP   +<   "W    N@   +P   "_
M    P0   ,0   #'    R@   ,T%  #1#@  U!D  -0K  #40   TU@  --T
M  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(   7D0  #9D   .@    IP
M *X   "S    N    +T   #"    Q@   ,H   #*    S0   ,\   #2
MU0   -D   #=    WP   .,   #G!0  ZP\  .P?  #M,P  [DL  .]D  #O
M@@  \)\  /&Y  #QV #_    _P   /\ ! #_  D _P . /\ %0#_ !X _P I
M /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\ 90#] &L ^P!Q /D =P#X 'X
M]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@ ., ^ #B /\ VP#_ ,L _P#!
M /\ N0#_ +0 _P#_    _P   /\   #_    _P ) /\ $ #_ !D _P C /\
M+@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I &0 Y@!J .0 < #B '8 WP!]
M -T A@#9 (\ U0": -$ IP#. +8 RP#. ,D \ #' /\ Q0#_ +L _P"T /\
MK0#_ *D _P#_    _P   /\   #_    ^P " /8 #0#Q !, [0 > .P * #I
M #( XP [ -T 1 #8 $L TP!1 -  6 #- %T RP!C ,D : #& &\ Q !V ,(
M?@"_ (< O "2 +H GP"W *T M0#! +( Y "Q /T KP#_ *P _P"E /\ H #_
M )P _P#_    _P   /L   #N    Y    -P " #3 !  SP 8 ,L (@#) "L
MQ@ T ,$ /0"] $0 N@!+ +< 40"U %8 L@!< +  80"N &< K !N *H =@"H
M '\ I@"* *, E@"A *4 GP"V )T T0"< /, FP#_ )P _P"6 /\ DP#_ )
M_P#_    ]@   .<   #3    Q@   +T  P"X  T LP 3 +$ ' "O "4 K@ N
M *D -@"F #T HP!$ *$ 2@"? $\ G0!5 )L 6@": &  F !F )8 ;@"4 '<
MD@"! )  C@". )P C "M (H PP") .@ B #_ (D _P"' /\ A0#_ (( _P#S
M    XP   ,P   "\    L    *<   "A  @ G@ / )L %@"9 !\ F  G )8
M+P"3 #< D0 ] (X 0P", $D BP!. (D 5 "' %D A0!@ (0 9P"" &\ @ !Z
M 'X A@!\ )0 >@"D 'D N !X -@ =P#W '@ _P!X /\ =P#_ '4 _P#F
MRP   +<   "H    G@   )8   "/  0 BP , (@ $@"' !D A0 A (0 *0""
M #  ?P W 'T /0!\ $, >@!( 'D 30!W %, =@!9 '0 80!R &D <0!S &\
M?P!M (T ; "= &H KP!I ,@ : #M &D _P!I /\ :0#_ &D _P#2    N
M *4   "7    C0   (8   "!    ?  ( 'D #@!W !0 =@ < '0 (P!S "L
M<0 Q &\ -P!N #T ; !# &L 2 !J $X : !4 &< 6P!E &, 8P!M &( > !@
M (< 7P"6 %T J != +X 7 #D %P ^P!< /\ 7 #_ %P _P#"    J@$  )@#
M  ")!   ?P(  '@   !T    <  $ &T # !K !$ :0 7 &@ '@!F "4 90 L
M &, ,@!B #@ 8  ] %\ 0P!> $D 7 !/ %L 5@!: %X 6 !H %< <P!5 ($
M5 "1 %( HP!1 +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V!P  GPD  (T+  !^
M#   <PL  &P*  !H!P  90,  &, !P!A  T 7P 3 %T &@!< "$ 6P G %D
M+0!8 #, 5@ Y %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D $T ;P!, 'T 2@"-
M $D GP!( +( 1P#, $< [P!& /\ 1P#_ $< _P"L#   E0X  (,0  !U$
M:Q   &,/  !>#@  6PP  %H) @!9! H 5P / %4 %0!3 !P 4@ C %$ *0!/
M "\ 3@ U $T!.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#;0!# WH 0@.+ $ #
MG  _ Z\ /@/( #T$Z@ ]!?P /0;_ #X&_P"D$   CA(  'P3  !N%   9!0
M %P3  !6$@  4Q$  %$.  !0# 4 4 D, $\'$0!-!Q< 2P@? $D()0!("2L
M1PDQ $8). !$"CX 0PI% $(*30! "U4 /PM? #T+:P \"WD .@R* #@,G  W
M#*\ -0S' #4,Z0 U#?T -0W_ #8,_P"=$P  AQ4  '87  !I&   7A@  %88
M  !0%P  314  $H3  !)$0  20X' $@-#@!&#1, 1 T: $,.(0!"#B@ 0 XN
M #\.-0 ^#SP /0]# #L02P Z$%0 .!!> #80:P T$'D ,A"* #$0G  O$+
M+1#) "T1[  M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D'   61P  %$<  !,
M&P  1QH  $08  !#%0  0A," $$2"P! $1  /A(7 #P2'@ [$R4 .A,K #@3
M,@ W$SD -A1  #042  S%%$ ,11< # 5:  N%7< +!6( "H5F@ H%:X )Q7'
M "85Z@ G%?\ *!7_ "D5_P"1&@  ?1P  &T>  !@'P  5A\  $X?  !('@
M0QT  $ <   ^&@  /1@  #L7!P Y%@X .!<4 #87&P U&"( ,Q@H #(8+P Q
M&38 ,!D] "X91@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:F0 B&JT (1K% " :
MZ  A&OX (AK_ ",:_P"-'0  >1\  &DA  !<(@  4B(  $HB  !$(0  /R$
M #P@   Y'@  .!L  #4<!  T' T ,AP2 # =&  O'1\ +ATE "T>+  K'C,
M*AX[ "D?0P G'TT )A]7 "0?9  B'W( (!^$ !\?EP ='ZL &Q_# !L?YP ;
M'_T '1__ !X>_P")(   =2(  &4C  !9)   3R4  $<E  !!)   /",  #@C
M   U(@  ,R   # @ 0 N(0H +"$0 "LA%0 J(AP *"(C "<B*0 F(S  )2,X
M ",C00 B)$H (215 !\D80 =)'  &R2" !DDE0 7)*H %B3! !4DY0 6)/P
M%R/_ !DC_P"%(@  <20  &(F  !6)P  3"<  $0G   ^)P  .28  #4F   Q
M)0  +B0  "LE   I)0< )R8. "4F$P D)QD (R<@ "(G)P A*"X ("@V !XH
M/@ =*$@ &RE3 !DI7P 8*6X %BF  !0IE  2*:@ $2G  !$HY  1*/L $RC_
M !0G_P" )0  ;B<  %\H  !3*0  22H  $(I   [*0  -BD  #(H   N*
M*B@  "8I   D*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;+2L &BTS !@M/  7
M+44 %BY0 !0N70 2+FP $2Y^ ! ND@ .+J< #2V]  TMWP -+?D #BS_ ! L
M_P!\*   :BH  %LK  !0+   1BP  #\L   Y+   -"L  "\K   K*P  )BP
M "(N   ?+P  '# ) !HQ#@ 9,1, %S$: !8R(0 5,B@ %#(P !,R.0 2,T,
M$3-. ! S6P .,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (,O0 "C'_  LQ_P!W
M*P  9BT  %@N  !-+P  0R\  #PN   V+@  ,2X  "TN   I+@  (S   !\R
M   ;,P  %S4% !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L  XX-0 -.#\ ##A*
M  LX5P ).&4 !SAV  4XB@ #.)\  3>U  $WTP "-_$  S;_  4V_P!S+@
M8C   %0Q  !),0  03$  #DQ   T,0  +S   "LP   E,@  (#,  !LV   7
M.   $SH" ! \"0 -/0X ##T3  L]&0 */2$ "3TI  @],0 &/CL !3Y&  ,^
M4@ !/F$  #YR   ^A@  /9P  #VR   ]T   //   #S_   \_P!M,@  73,
M % T  !&-   /C0  #<T   R,P  +3,  "<T   B-@  '3@  !@Z   4/0
M$#\"  U!"  )0PT !D01  -$%@ "1!T  $0D  !$+0  1#8  $1!  !$3@
M1%P  $1M  !$@0  1)@  $.O  !#S0  0O   $+_  !"_P!H-@  6#<  $PX
M  !#.   .S<  #4V   P-@  *3<  ",Y   >.P  &#T  !-    00@  #44!
M  A'!P #20P  $D/  !*$P  2QD  $L@  !+*   2S(  $L]  !,20  3%<
M $MH  !+?0  2Y0  $JL  !*R@  2>\  $G_  !)_P!B.@  5#L  $D[  !
M.P  .3H  #,Y   L.@  )3P  !\_   900  $T0  !!'   ,20  "$P   )/
M!0  4 H  % -  !1$   4A4  %0;  !4(P  5"P  %0W  !41   5%(  %1C
M  !4=P  5(\  %.H  !2Q@  4NT  %'_  !1_P!</P  3S\  $4_   ^/@
M-ST  "\^   G0   ($,  !E&   320  #TP   M/   &4@   %0   !7 @
M6 <  %D+  !:#@  6Q$  %T6  !>'0  7R8  %\Q  !>/0  7DP  %Y=  !>
M<0  78D  %VC  !<P0  6^L  %K_  !:_P!61   2T,  $-"   \00  ,D(
M "E%   A2   &DL  !-.   .4@  "E4   -9    6P   %X   !@    8@(
M &,&  !E"@  9@X  &@1  !J%P  :Q\  &LI  !K-@  :T4  &M6  !J:@
M:H(  &F=  !HNP  9^<  &;_  !E_P!12   2$@  $%&   W1P  +$H  "--
M   ;40  $U4   Y9   (70   6$   !D    9P   &H   !L    ;@   '
M  !R!0  <PD  '4-  !W$0  >A@  'LA  ![+@  >CT  'I.  !Y8@  >7D
M 'B6  !WLP  =>   '3\  !S_P!.30  1TP  #M-   P3P  )E,  !Q8   3
M7   #6$   9F    :@   &\   !R    =@   'D   !\    ?0   '\   "!
M    @P(  (8'  "(#   BQ$  (X8  ".)   CC,  (U$  ",6   BV\  (J,
M  ")J@  B,\  (;W  "%_P!-40  05,  #15   I6@  'E\  !1E   -:@
M!7    !V    >P   '\   "#    AP   (H   "-    C@   )$   "3
ME0   )@   ":!0  G0P  * 1  "C&@  HR@  *(Z  "A3@  H&4  *"!  ">
MH   G<$  )ON  ":_P!&60  .5P  "UA   A9P  %FX   YU   %>P   ($
M  "'    C0   )(   "6    F@   )T   "?    H0   *0   "F    J
M *L   "N    L0,  +0+  "X$0  N1X  +DO  "X0P  MUH  +5V  "TEP
MM+4  +'B  "P_  _9   ,6D  "5O   8=P  #W\   :'    C@   )0   ":
M    H    *4   "J    K@   +$   "R    M0   +<   "Z    O    +\
M  ##    Q@   ,D   #."@  TA,  -(C  #1-P  T$\  ,YJ  #-B@  RJL
M ,O+  #+[P W<0  *7@  !V    1B0  ")$   ":    H0   *<   "M
MLP   +D   "^    P@   ,4   #&    R0   ,P   #.    T@   -4   #:
M    W@   .$   #E    Z@L  .L7  #J*P  ZD,  .I>  #J>@  ZYD  .NU
M  #KU0#_    _P   /\  0#_  < _P - /\ $@#_ !L _P E /\ +P#_ #H
M_P!# /\ 2P#_ %, _P!: /T 8 #[ &8 ^@!K /@ <@#V '@ ] "  /$ B0#O
M )( [ "= .D J@#F +P XP#< -\ ]P#= /\ S #_ +X _P"U /\ L #_ *T
M_P#_    _P   /\   #_    _P & /\ #0#_ !0 _P ? /\ *0#[ #, ]P ]
M /, 10#O $T [ !3 .@ 60#E %\ XP!E .  :@#= '$ V@!X -8 @ #2 (H
MSP"5 ,P H@#( +( Q0#) ,( [0#  /\ NP#_ +  _P"H /\ I #_ *$ _P#_
M    _P   /T   #Z    ^    /  "0#L !$ Z  9 .< (P#E "T W@ V -8
M/@#1 $8 S0!, ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P +P > "Y ($ MP"-
M +0 F@"Q *D K@"\ *P X0"J /P J #_ *  _P"9 /\ E@#_ )0 _P#_
M^0   /(   #G    VP   -$ ! #*  T QP 4 ,0 '0#" "8 OP O +L -P"W
M #\ M !% +$ 2P"N %$ K !6 *H 7 "H &$ I@!H *, < "A 'D GP"$ )T
MD0": *  F "Q )8 S "5 /$ E #_ )$ _P"+ /\ B #_ (8 _P#W    [
M -X   #)    O    +0   "O  H JP 0 *D %P"H "  IP H *( , "? #@
MG  ^ )H 1 "8 $H E@!/ )0 50"3 %H D0!A (\ : "- '$ BP![ (D B "'
M )< A0"H (, O@"! .0 @ #_ (  _P!\ /\ >P#_ 'D _P#I    UP   ,$
M  "Q    I@   )T   "7  4 E  - )( $@"0 !H CP B (X *@"+ #$ B0 X
M (< /@"% $, @P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D > !S '8 ?P!U (X
M<P"? '$ LP!P -  ;P#V &\ _P!O /\ ;0#_ &P _P#:    OP   *P   ">
M    DP   (P   "%    @@ ) '\ #P!^ !4 ?0 < 'P ) !Z "L =P Q '4
M-P!T #T <@!" '$ 2 !O $T ;@!3 &P 6@!K &( :0!L &< > !F (8 9 "7
M &( J@!A ,( 8 #K &$ _P!A /\ 80#_ &  _P#%    K0   )L   "-
M@P   'P   !W    <@ % '  # !N !$ ;  7 &P '@!K "4 :0 L &< ,0!F
M #< 9  ] &, 0@!B $@ 8 !. %\ 50!= %T 7 !F %H <@!9 (  5P"0 %8
MHP!5 +D 5 #> %0 ^P!4 /\ 50#_ %4 _P"V    GP   (T   !_    =0
M &X   !I    9@ ! &, "0!A  X 8  3 %\ &0!> "  70 F %L + !: #(
M6  W %< /0!6 $, 50!) %, 4 !2 %@ 40!A $\ ; !. 'H 3 "* $L G !*
M +$ 20#. $D \P!) /\ 20#_ $H _P"J 0  E 4  (('  !T"   :@@  &,&
M  !>!   6P   %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B %$ * !0 "T 3@ S
M $T . !, #X 2P!% $H 3 !( %0 1P!= $8 : !$ '4 0P"% $$ F !  *L
M0 #% #\ Z@ _ /\ 0 #_ $  _P"@"   B@L  'D-  !L#0  80T  %H-  !5
M"P  4@D  % &  !/ @@ 3@ - $P $@!+ !< 2@ > $D (P!' "D 1@ O $4
M- !$ #H 0@!! $$ 2 !  %  /@!: #T 9  \ '( .@"" #D E  X *< -P"^
M #8 XP V /D -@#_ #< _P"8#0  @PX  '(0  !E$0  6Q$  %,0  !.$
M2@X  $@-  !'"@, 1P<* $4$#@!$ A, 0@(: $$"( !  R4 /@,K #T$,0 \
M!#< .P0^ #H%10 Y!4X -P57 #8%8@ T!G  ,@:  #$&D@ P!J4 +P6[ "X%
MW0 N!O4 +0?_ "X'_P"1$   ?1$  &P3  !?%   510  $X4  !($P  1!(
M $$0  ! #@  0 T& $ *#  ^"1  / D6 #L*'  Y"B( . HH #<++@ V"S4
M-0L[ #,+0P R#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H#*4 )PR[ "4,W0 E
M#?4 )@W_ "<-_P"+$@  =Q0  &<6  !;%P  41@  $D7  !#%P  /Q4  #P4
M   Z$@  .1$! #D/"  X#@T -PX2 #4.&  T#A\ ,@XE #$/+  P#S( +Q Z
M "T00@ L$$L *A!5 "@080 F$&\ )!"  ",0DP A$*< 'Q"] !X0X  >$?<
M'Q#_ " 0_P"&%   <Q<  &,9  !7&@  31L  $4:  ! &@  .QD  #@8   U
M%@  -!0  #,2!  R$@L ,1(0 "\2%0 M$AP +!,B "L3*0 J$S  *!,W "<4
M/P F%$@ )!13 "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[ !@5W@ 8%?@ &13_
M !H4_P""%P  ;QH  %\<  !3'0  2AT  $(=   \'0  -QP  #0;   Q&@
M+QD  "X6   L%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D&"T (Q@T "(9/0 @
M&48 'AE1 !T970 ;&FL &1I\ !<:CP 5&J, %!FZ !(9VP 3&?8 %!G_ !48
M_P!]&@  :QT  %P?  !0(   1R   #\@   Y'P  -!\  #$>   M'0  *QP
M "D;   G&P4 )1L, "0<$0 B'!8 (1P= " =(P ?'2H 'ATR !P>.@ ;'D0
M&1Y. !<>6P 6'FD %!]Z !(>C0 1'J( $!ZX  X>V  /'O4 $!W_ !$=_P!Z
M'0  9Q\  %DA  !-(@  1"(  #PB   V(@  ,B$  "XA   J(   )R   "0?
M   B( ( (" * !XA#P =(10 '"$: !LB(0 9(B< &"(O !<B.  5(T$ %"-,
M !(C6  1(V< $"-X  XCBP -(Y\ #".T  LCT  +(O  #"+_  TA_P!V'P
M9"(  %8C  !+)   020  #HD   T)   +R,  "LC   H(P  )",  " C   =
M)   &R4' !DF#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G-0 1*#\ $"A*  XH
M5@ -*&0 #"AT  HHAP )*)L !R>Q  4GS  &)^P !R;^  @F_P!Q(@  8"0
M %,F  !()P  /R<  #<F   Q)@  +28  "DE   E)0  (B4  !TG   9*
M%BH$ !0K"P 2+!  $2P4 ! L&P 0+"( #BPI  XM,@ -+3L "RU&  HM4@ (
M+6  !BUP  0M@P "+9@  "RN   LR0  +.L  2O\  (K_P!M)0  72<  $\H
M  !%*0  /"D  #4I   O*   *R@  "<G   C)P  'R@  !LJ   7+   $RX"
M ! P"  .,0T #3$2  PQ%P +,1X "C$F  @R+@ ',C< !3)"  ,R3@ !,EP
M #)L   R?P  ,I4  #&L   QQP  ,.H  ##\   P_P!H*0  6"H  $PK  !!
M+   .2P  #(K   M*P  *2H  "4J   @*P  '"P  !<N   3,   $#("  XT
M!P *-PP !S<0  4W%  #-QL  C<B   W*@  .#,  #@^   X2@  .%@  #AH
M   X?   -Y(  #>I   VQ0  -NH  #;]   U_P!C+   5"X  $@O   ^+P
M-BX  # N   K+0  )RT  "(M   =+P  &#$  !0S   0-0  #C<!  HZ!P &
M.PL  CP.   ]$@  /A<  #X>   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^
M=P  /H\  #VG   ]PP  /.D  #S]   [_P!>,   4#$  $0R   [,@  -#$
M "XP   I+P  )#   !XR   9-   %#8  ! Y   -.P  "CT   5 !0  00H
M $(-  !#$   1!0  $4:  !&(@  1BL  $8U  !&00  1D\  $9?  !&<P
M18H  $6D  !$P   0^@  $/^  !"_P!8-   2S4  $$U   Y-0  ,C0  "TS
M   F-   (#4  !HX   4.@  $#T   U    )0@  !$4   !' P  2 <  $H+
M  !+#@  3!$  $X5  !/'   3R4  $\O  !//   3TH  $]:  !.;0  3H4
M $V@  !,O   2^<  $O^  !*_P!3.0  1SD  #XY   W.   ,3<  "DW   A
M.0  &SP  !4_   00@  #$4   =(   "2@   $T   !/    400  %('  !4
M"P  50X  %<1  !9%P  6A\  %DI  !9-@  640  %E4  !89P  6'\  %>:
M  !6MP  5>,  %3]  !4_P!./0  0ST  #P\   U.P  +#P  "0^   <00
M%40  !!(   +2P  !4X   !1    5    %<   !9    6P   %T"  !>!@
M8 L  &(.  !D$@  9Q@  &<B  !F+@  9CP  &9-  !E8   97<  &23  !C
ML0  8=T  &#\  !?_P!)0@  04$  #H_   P0   )D,  !Y&   52@  $$X
M  I2   #5@   %H   !=    8    &,   !E    9P   &D   !K 0  ;04
M &\*  !R#@  =1(  '<;  !V)@  =C4  '5&  !T60  =&\  '.+  !RJ0
M<,T  &_W  !N_P!&1@  0$4  #5&   J2   ($P  !=1   05@  "5H   %?
M    8P   &@   !K    ;P   '(   !U    =P   'D   ![    ?0   ( #
M  "#"   A@T  (D3  "*'0  BBL  (D\  "(3P  AF8  (6!  "$H   @L(
M ('P  !__P!&2P  .DP  "Y/   C4P  &%@  !!>   )9    &D   !O
M=    '@   !\    @0   (0   "'    B    (L   ".    D    ),   "6
M    F0<  )T-  "A%   H"$  * Q  ">1   G5L  )QV  "9E@  F;4  );E
M  "5_@ _4@  ,E4  "9:   ;8   $6<   EM    =    'L   "!    A@
M (L   "0    E    )<   "9    G    )\   "A    I    *<   "J
MK0   +$&  "U#0  N!8  +<F  "V.0  M5   +1J  "RB0  L*H  *[/  "M
M]0 W7   *V$  !YH   3<   "W@   "     AP   (X   "5    F@   )\
M  "D    J    *P   "M    L    +,   "U    N    +L   "_    PP
M ,<   #+!0  T0X  -$;  #0+@  ST4  ,U?  #+?@  R9X  ,B^  #%Z0 O
M:0  (W   !9Y   -@0   8L   "3    FP   *(   "H    K@   +0   "X
M    O0   ,    #"    Q0   ,@   #+    S@   -$   #6    VP   -\
M  #D    Z 8  .L1  #J(P  ZCH  .E4  #G<@  Y9,  ..S  #CU #_
M_P   /\   #_  0 _P + /\ $ #_ !< _P A /\ *P#_ #4 _P ^ /\ 1P#_
M $X _P!5 /P 6P#Z &$ ^ !F /8 ;0#T ', \@![ .\ A #M (X Z@"9 .8
MIP#C +D WP#5 -L ]P#6 /\ P #_ +( _P"J /\ I0#_ *( _P#_    _P
M /X   #\    _  # /X "P#_ !$ _P : /T ) #Y "X ]  X /  0 #L $@
MZ0!. .8 5 #B %H WP!? -P 90#8 &L U !R -  >P#- (4 R@"1 ,< G@##
M *X P #% +T ZP"[ /\ L #_ *0 _P"< /\ F #_ )4 _P#_    ^@   /0
M  #Q    \@   .H !0#G  X X@ 5 .$ '@#A "@ V  Q -  .0#+ $  R !'
M ,4 30#" %, OP!8 +T 7@"[ &0 N0!K +8 <P"T 'P L0"( *X E0"K *0
MJ "X *8 W "C /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y    [P   .<   #?
M    SP   ,@   #!  H OP 1 +P & "[ "$ N0 J +0 ,@"Q #H K@!  *L
M1@"H $P I@!1 *, 5@"A %P GP!C )T :@"; ', F0!^ )8 C "4 )L D@"M
M )  QP". /  C0#_ (8 _P"  /\ ?0#_ 'P _P#M    X    -$   "_
MLP   *H   "F  4 H@ - *$ $P"@ !L GP C )L *P"8 #( E0 Y ), /P"1
M $0 CP!* (X 3P", %4 B@!; (@ 8P"& &L A !V (( @@"  )( ?@"C 'P
MN@!Z .$ >0#_ '< _P!R /\ < #_ &\ _P#=    RP   +8   "G    G0
M )0   ".  $ BP * (D $ "( !4 AP = (< )0"$ "P @@ R '\ . !] #T
M>P!# 'D 2 !X $X =@!4 '4 6P!S &, <0!N &\ >@!M (D ; ": &H K@!I
M ,P : #V &< _P!E /\ 9 #_ &, _P#*    M    *$   "3    B0   ((
M  ![    >  % '8 # !U !$ =  8 ', 'P!R "4 <  L &X ,@!L #< :@ \
M &D 0@!H $@ 9@!. &4 50!C %T 8@!F &  <@!> (  70"2 %L I0!: +X
M60#I %D _P!9 /\ 6 #_ %@ _P"Y    H@   )    "#    >0   '$   !M
M    :0 ! &8 "0!E  X 9  3 &, &0!C "  80 F &  + !> #$ 7  W %L
M/ !: $( 6 !( %< 3P!6 %< 5 !@ %, ; !1 'D 4 "* $\ G@!. +0 30#:
M $T ^P!- /\ 30#_ $T _P"J    E    ((   !U    :P   &0   !@
M70   %H !0!8  P 5P 0 %8 %0!6 !L 50 A %, )P!2 "P 40 Q $\ -P!.
M #T 30!# $P 2@!* %( 20!; $@ 9@!& ', 10"$ $0 EP!# *P 0@#) $(
M\0!" /\ 0P#_ $, _P">    B0   '@#  !J!   800  %H#  !5 0  4@
M %   @!.  D 30 - $P $0!+ !< 2@ < $D (@!( "< 1P M $4 ,@!$ #@
M0P ^ $( 10!! $T /P!6 #X 80 ] &X .P!^ #H D0 Y *8 . "_ #@ Z  X
M /\ .0#_ #D _P"5 P  @ <  &\)  !B"@  6 L  %$*  !,"   208  $<#
M  !&  8 1  + $, #P!" !, 00 8 $$ '@ _ ", /@ I #T +@ [ #0 .@ Z
M #D 00 X $D -P!2 #8 70 T &H ,P!Z #( C  Q *$ , "X "\ W@ O /D
M+P#_ #  _P","0  > P  &@-  !<#@  4@X  $L.  !%#0  00P  #\*   ^
M" ( /00( #P!#0 [ !  .@ 5 #D &@ X "  -@ E #4 *P T #  ,P W #(
M/@ Q $8 +P!0 "X 6@ M &< *P!W "H B0 I )T * "S "< T0 G /( )P#_
M "< _P"&#   <@X  &,0  !6$0  31$  $41  ! $   / \  #D.   W#0
M-@L$ #8("@ U!@X - 42 #($%P Q!1P , 4B "\%*  N!BX +08T "L&/  J
M!D0 *0=. "<'60 F!V4 ) =U ",'AP B!YL ( :P " &RP ?!>T 'P;^ !\'
M_P" #@  ;1$  %X2  !2$P  2!,  $$3   [$P  -Q(  #01   R$   , \!
M # -!@ P"PL +PH0 "T*%  L"QD *@L? "D+)0 H#"L )PPR "8,.@ D#$,
M(PQ- "$-6  @#64 '@UU !P-B  :#9P &0VQ !@,R@ 7#.L %PW\ !@,_P![
M$0  :1,  %H5  !.%@  118  #T6   X%0  ,Q4  # 4   M$P  *Q(  "H0
M P J#P@ *0X- "@.$0 F#A8 )0\= "0/(P C#RD (1 Q " 0.0 >$$( '1!,
M !L06  9$&8 %Q!V !40B0 4$)X $A"S !$0S@ 1$.X $A#^ !(0_P!W$P
M914  %<7  !+&   0AD  #H9   T&   ,!<  "P7   I%@  )Q4  "84 0 E
M$@0 (Q(+ "(2#P A$A0 (!(: !X3(  =$R< '!,N !H3-@ 9%$  %Q1* !84
M5@ 4%&0 $A1T !$4AP 0%)P #A2Q  T4R@ -%.L #A/^  X3_P!S%0  81@
M %,:  !(&P  /QL  #<;   R&@  +1H  "D9   F&   )!@  "(7   @%@$
M'A8( !T6#0 ;%Q( &A<7 !D7'0 8&"0 %A@K !48-  4&#T $AE( !$95  0
M&6( #AER  T9A  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7_P!O&   7AH  % <
M  !%'0  /!T  #4=   O'0  *AP  "8;   C&P  (1H  !X:   <&@  &AL%
M !@;#  6'!  %1P5 !0<&P 3'"( $ATI !$=,0 0'3L #AU%  T>40 ,'EX
M"AYM  D>@  ''I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K&@  6QT  $T>  !"
M'P  .A\  #(?   M'P  *!X  "0>   A'0  'AT  !P=   8'@  %1\" !,@
M"0 2(0X $"$2 ! A&  .(1\ #B(F  TB+@ ,(C< "B)!  DB30 '(EH !2)I
M  ,B?  !(I$  "*H   AP   (>4  "#X   @_P!G'0  5Q\  $HA  ! (0
M-R(  # A   J(0  )B   "(@   ?'P  '!\  !D@   6(0  $B," ! D!P .
M)@P #"80  LF%0 *)AP "28B  @F*@ &)S, !"<]  ,G20 !)U8  "=F   G
M>0  )X\  ":F   FOP  )>0  "7Y   D_P!C(   5"(  $<C   ])   -"0
M "XC   H(P  )"(  "$B   >(0  &B(  !<C   3)   $"8"  XH!P +*@L
M""L.  8K$P $*Q@  BL?  $L)P  +#   "PZ   L10  +%,  "QC   L=@
M+(P  "ND   KO@  *N0  "KZ   I_P!?(P  4"4  $0F   Z)@  ,B8  "LF
M   F)0  (R0  !\D   ;)   %R4  !0G   1*0  #BL"  LM!@ '+PL !# .
M   P$0  ,14  #$<   Q(P  ,BP  #(V   R0@  ,D\  #)?   R<@  ,8D
M #&B   PO   ,.0  "_[   O_P!:)P  3"@  $ I   W*0  +RD  "DH   E
M)P  (28  !PG   8*   %"H  !$L   .+@  "S !  <R!0 #- D  #4,   V
M#P  -Q(  #@8   X(   ."@  #@R   Y/0  .4L  #E;   X;@  .(4  #>?
M   WN@  -N0  #7\   U_P!5*@  2"P  #TL   T+   +2L  "@J   D*0
M'BH  !DK   4+0  $2\   TQ   *-   !S8   (X!   .@<  #L*   ]#0
M/A   $ 4  ! &P  0"0  $ N  ! .0  0$<  $!6  ! :0  0(   #^;   ^
MMP  />,  #S\   \_P!0+P  0R\  #DO   R+P  +"T  "<L   @+0  &B\
M !4Q   1,P  #38   DX   %.P   #T   !  0  000  $,'  !%"P  1@X
M $@1  !*%@  2AX  $HH  !*-   24(  $E1  !)9   2'L  $B7  !'M
M1N   $7\  !$_P!*,P  /S,  #8S   P,0  *C   ",Q   <,P  %C4  !$X
M   -.P  "#X   -!    0P   $8   !(    2@   $P$  !.!P  3PL  %$.
M  !4$@  51D  %4B  !4+@  5#P  %1+  !37@  4W0  %*0  !1K@  4-<
M $_[  !._P!%-P  /#<  #4V   O-   )C4  !XW   7.@  $3T   Q!   '
M1    $@   !*    30   %    !3    50   %<   !8 @  6P8  %T+  !?
M#@  8A,  &(;  !B)P  8C0  &%%  !@5P  8&T  %^)  !=IP  7,P  %KX
M  !9_P!!/   .CL  #0Y   J.@  (3P  !A    10P  #$<   9+    3P
M %,   !6    60   %P   !?    80   &,   !E    9P$  &H%  !M"@
M< X  ',5  !R(   <BT  '$]  !P3P  ;V4  &Z   !MGP  :\$  &GQ  !H
M_P _0   .3X  "X_   D0@  &D8  !)*   ,3P  !%0   !8    70   &$
M  !E    :    &L   !N    <0   ',   !U    >    'L   !^ P  @0H
M (4/  "'%P  AB0  (4T  "$1@  @ET  (%V  !_E@  ?K8  'SG  !Z_P _
M1   ,T4  "A(   =3   $U(   Q7   #70   &,   !H    ;0   '$   !V
M    >@   'X   "!    @P   (8   ")    BP   (X   "2    E0$  )D)
M  ">$   GAH  )TI  "</   FE(  )AL  "6BP  E*H  )+4  "0^@ X2P
M+$X  "!3   560  #6    -G    ;@   '0   !Z    @    (0   "*
MC@   )(   "5    EP   )H   "=    H    *,   "G    JP   *\   "T
M"0  N!   +<>  "U,   LT8  +%@  "O?@  K*   *O!  "I[@ Q50  )%L
M !AA   .:0  !7$   !Y    @0   (@   "/    E    )H   "?    I
M *@   "I    K    *\   "S    M0   +D   "]    P0   ,8   #+
MT0H  -,4  #1)0  T#L  ,U4  #*<0  R)(  ,6S  ##W@ I8@  '&D  !%Q
M   '>P   (0   "-    E0   )T   "C    J0   *\   "T    N0   +P
M  "^    P@   ,4   #(    S    -    #4    V@   -\   #D    Z@
M .X,  #M&@  ["\  .I)  #H90  YH8  .2E  #BQ@#_    _P   /\   #\
M  $ _  ( /X #@#_ !0 _P = /\ )@#_ #  _P Z /\ 0@#_ $D _@!0 /L
M5@#Y %P ]@!B /0 : #R &\ \ !V .T ?P#J (D YP"5 .0 HP#@ +4 VP#0
M -4 ]@#* /\ M@#_ *@ _P"? /\ F@#_ )8 _P#_    ^P   /8   #S
M\P   /8 "0#Z  X _0 6 /L ( #W "H \@ S .T .P#I $, Y@!) .( 3P#>
M %4 VP!; -8 8 #2 &< SP!N ,P =@#) (  Q@", ,( F@"_ *H NP#! +@
MZ0"V /\ IP#_ )H _P"2 /\ C0#_ (H _P#Z    \0   .H   #G    YP
M .0  0#@  L VP 1 -H &@#; ", T0 L ,H - #& #L P@!" +\ 2 "\ $X
MN@!3 +@ 60"V %\ LP!F +$ ;@"N '< K "# *D D0"F *$ HP"U *  V ">
M /L E0#_ (L _P"% /\ @ #_ 'X _P#O    XP   -H   #3    Q@   +\
M  "Y  8 MP . +0 % "T !T LP E *X +0"K #0 IP [ *0 00"A $8 GP!,
M )T 40"; %< F0!> )< 90"5 &X DP!Y )  AP". )< C "I (D Q "( .\
MA0#_ 'P _P!V /\ <P#_ '( _P#@    T    ,8   "V    J0   *$   "=
M  $ F0 * )@ $ "8 !8 EP > )0 )@"1 "T CP T (P .@"* #\ B !% (<
M2@"% %  @P!6 ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@ '4 M@!S -\ <@#_
M &X _P!I /\ 9P#_ &4 _P#,    O@   *L   "=    DP   (H   "%
M@@ % (  #0!_ !$ ?P 8 (  ( !] "8 >@ M '< ,P!U #@ =  ^ '( 0P!P
M $D ;P!/ &T 5@!L %X :@!H &@ =0!G (0 90"6 &0 JP!B ,D 80#V &
M_P!< /\ 6P#_ %H _P"]    J0   )<   ")    ?@   '@   !S    ;P !
M &T "0!L  X :P 3 &L &0!J "  :  F &8 + !E #( 8P W &( / !@ $(
M7P!( %T 3P!< %< 6@!A %D ;0!7 'L 5@". %4 H@!3 +L 4@#I %( _P!0
M /\ 3P#_ $\ _P"M    F    (8   !X    ;@   &<   !C    8    %T
M!0!<  L 6P 0 %L %0!; !L 6@ A %@ )@!6 "P 5  Q %, -@!2 #P 40!"
M $\ 20!. %$ 30!; $L 9@!* '0 20"% $@ F0!' +$ 1@#8 $8 _ !% /\
M10#_ $4 _P"?    B0   '@   !L    8@   %L   !6    4P   %$  @!/
M  @ 3P - $X $0!. !8 30 < $P (0!* "8 20 L $@ ,0!' #< 10 ] $0
M1 !# $P 0@!5 $  8  _ &X /@!^ #T D@ \ *D .P#' #L \P [ /\ .P#_
M #P _P"3    ?@   &X   !A    6    %$   !,    20   $<   !%  4
M1  + $, #@!# !( 0P 7 $( '0!  "( /P G #X +  ] #( .P X #H /P Y
M $< . !0 #< 6P U &@ - !X #, C  R *( ,0"\ #$ YP Q /\ ,@#_ #,
M_P")    =@,  &8%  !9!P  4 <  $D&  !#!0  0 ,  #X!   \  , .P (
M #H #0 Z !  .0 4 #D &0 W !X -@ C #4 *  T "X ,P T #( .P P $,
M+P!, "X 5P M &0 + !S "L AP J )P *0"U "D W  I /L *0#_ "H _P"!
M!   ;@@  %\*  !3"P  2@L  $(+   ]"@  .0D  #8(   U!0  - (& #,
M"@ R  X ,0 1 #$ %0 P !H +P ? "X )  L "H *P P "H -P I #\ * !)
M "< 5  F &  ) !O ", @@ B )< (0"N "$ S  A /, (0#_ "( _P!["0
M: P  %H-  !.#@  10X  #T.   X#0  ,PT  # ,   N"P  +0D# "T&"  L
M! P *P(/ "H!$@ I 1< * $< "< (0 F "< )0 M "0 -  C 3T (@%& "$!
M40 ? 5T '@%L !P!?P ; )0 &@"J !H Q0 : .L &0#_ !H _P!U#   9 X
M %4/  !*$   0!   #D0   S$   +P\  "P.   I#@  )PT! "<,!0 G"@H
M)@@- "4'$  D!A0 (@89 "$&'P @!R0 'P<K !X',@ =!SH ' A$ !H(3P 9
M"%P %PAK !8(?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%_P!Q#@  7Q   %$1
M  !&$@  /1(  #82   P$@  *Q$  "@1   E$   (Q   "(.!  A#0< (0P+
M " +#@ ?"Q( '0L7 !P,'  ;#"( &@PI !D,,0 8##D %@U# !4-3P 3#5P
M$@UK ! -?@ /#9( #@VG  T,O@ -#.  #0SU  T,_P!M$   7!$  $X3  !#
M%   .A0  #(4   M%   *!,  "43   B$@  (!$  !X1 P <$ 4 ' \( !L/
M#  :#A  &0\4 !</&@ 6#R$ %1 H !00,  2$#D $1!$ ! 04  .$%T #1!K
M  P0?  +$)  "1"E  @0O  '$-\ !Q#T  </_P!I$0  6!0  $L5  ! %@
M-Q8  # 6   J%@  )A4  "(5   ?%   '1,  !H3 @ 9$@0 %Q(& !82"@ 5
M$@X %!(2 !(2&  1$QX $1,E ! 3+@ .$S< #11   P42P +%%@ "11G  <4
M>  &%(T !!2C  ,3NP "$]T  1+T  (2_P!E$P  518  $@7   ]&   -!@
M "T8   H&   (Q<  " 7   =%@  &A4  !@5 @ 6%00 %!4% !(6"  1%@T
M$!<0  X7%0 .%QL #1<B  P7*0 +&#( "1@\  <81P %&%0 !!AC  (8=0 !
M&(L  !>A   7N0  %]T  !;U   6_P!A%@  4A@  $4:   [&@  ,AH  "L:
M   E&@  (1D  !X8   ;&   &!<  !87 @ 4%P, $A@% ! 9!P .&PL #!L/
M  L;$P *&Q@ "!P?  <<)@ %'"\ !!PX  (<1   '5$  !U@   =<@  '(@
M !R@   ;N0  &]X  !KV   :_P!>&   3QH  $(<   X'   +QT  "D<   C
M'   'QL  !P:   9&0  %QD! !09 @ 2&@, $!L$  X=!P ,'@L "1\.  8@
M$0 %(!8  R <  $A(P  (2L  "$U   A0   (4X  "%=   A;P  (88  "">
M   @N   ']X  ![X   >_P!:&P  2QT  #\>   U'P  +1\  "<>   B'0
M'AT  !L<   8&P  %1L  !(<   0'0( #A\$  PA!@ )(@H !2,-  (D$
M)1,  "49   F(   )B@  "8R   F/0  )DH  "9:   F;   )H,  "6<   E
MMP  )-\  "/Y   C_P!5'@  1R   #PA   R(0  *R$  "4@   @'P  '1X
M !H=   6'@  $QX  ! @   .(0  #","  @E!0 %)PD  "@+   J#@  *Q$
M "P6   L'0  +"4  "PN   L.@  +$<  "Q6   L:0  +(   "N:   JM0
M*=\  "G[   H_P!1(@  1",  #@D   O)   *",  ",B   ?(0  '"   !<@
M   3(0  $",   XD   +)@  ""@   0J!   + <  "X)   P#   ,0\  #,3
M   S&0  ,R$  #,J   S-0  ,T,  #-2   S90  ,GL  #*7   QLP  ,-X
M "_[   N_P!,)0  /R8  #4G   M)@  )R4  "(D   >(P  &2,  !0D   1
M)@  #B@   LJ   '+    R\    Q @  ,P0  #4'   W"@  .0T  #H0   [
M%0  .QT  #LF   [,0  .SX  #M.   [8   .G<  #F2   XL   -]L  #;\
M   U_P!'*0  .RH  #(J   K*0  )2<  "$F   ;)P  %2@  !$J   .+
M"B\   8Q   !-    #8    X    .P$  #T$   _!P  00H  $,.  !%$0
M11@  $4A  !%+   1#D  $1(  !$6P  0W$  $*-  !!JP  0-(  #_Z   ^
M_P!"+0  ."X  "\M   I*P  )"H  !TJ   7+   $2X   TQ   )-   !#<
M   Z    /    #\   !!    1    $8   !( P  2@<  $P+  !.#@  4!,
M % <  !0)P  3S0  $]#  !/50  3FH  $V&  !,I   2LH  $GX  !(_P ^
M,@  -3$  "XO   I+@  ("X  !DQ   2,P  #C<   DZ   "/0   $    !$
M    1P   $D   !,    3P   %$   !3    50$  %@&  !:"P  70X  %\5
M  !>(   7BP  %T\  !<3@  6V,  %I^  !8G0  5\   %7R  !4_P Z-@
M,S0  "TR   D,P  &S8  !,Y   ./0  "$$   !%    20   $P   !0
M4P   %8   !9    6P   %T   !@    8@   &4   !H!0  :PL  &\0  !O
M&   ;B4  &TT  !M1@  :UL  &IU  !HE   9K8  &3I  !B_P X.0  ,C<
M "@Y   >.P  %3\   Y$   '20   $T   !2    5@   %H   !>    8@
M &4   !H    :P   &T   !P    <P   '8   !Y    ?00  ($+  "%$0
MA!T  ((L  " /@  ?E0  'YK  ![B@  >JH  '?6  !U_0 X/0  +#X  ")!
M   71@  #TL   =1    5P   %P   !B    9@   &L   !O    =    '@
M  ![    ?@   (    "#    A@   (H   "-    D0   )8#  ";#   G1,
M )LA  ":,P  ETD  )1B  "3?P  D*   ([%  ",\P Q1   )4@  !I-   0
M4P  "%H   !A    :    &X   !T    >0   '\   "$    B0   (T   "1
M    DP   )8   "9    G0   *    "D    J    *P   "R P  MPT  +<7
M  "U*   LCX  +!6  "L<P  JI0  *FT  "EY0 J3P  'E0  !);   *8@
M &H   !S    >P   ((   ")    C@   )0   ":    GP   *0   "F
MJ0   *T   "P    LP   +<   "[    P    ,4   #+    T00  -4.  #3
M'0  T#(  ,U+  #*9@  QH<  ,*I  #!RP B6P  %F(   QK   !=    'T
M  "'    D    )<   ">    I    *L   "Q    M@   +H   "\    P
M ,0   #(    RP   ,\   #4    V@   .    #F    ZP   /$&  #P$P
M[B<  .P_  #J6P  YWH  .2;  #@NP#_    ^P   /8   #S    ]  % /8
M# #Z !$ _P 9 /\ (@#_ "P _P U /\ /0#_ $4 _ !, /H 4@#W %@ ]0!>
M /, 9 #Q &H [@!R .P >@#I (4 Y0"1 .$ H #= +( V #. -( ]@#! /\
MK0#_ )X _P"6 /\ D #_ (P _P#Z    \@   .P   #I    Z0   .P !0#R
M  P ^  2 /< &P#U "4 \  N .L -P#F #X X@!% -T 2P#8 %  TP!6 -
M7 #- &( R@!J ,@ <@#% 'P P@"( +X E@"Z *@ MP"_ +0 Z "N /\ G0#_
M )  _P"( /\ @P#_ (  _P#P    Y0   -X   #:    VP   -P   #8  <
MT0 . -$ %0#2 !X RP G ,4 +P#  #< O0 ] +H 1 "W $D M0!/ +( 50"P
M %L K@!A *P :0"I ', IP!_ *0 C0"A )X G@"R )L U0"9 /P C #_ ((
M_P![ /\ =@#_ '0 _P#B    TP   ,H   #'    O    +8   "P  $ KP +
M *P $0"M !@ K0 @ *@ * "D "\ H  V )T / "; $( F0!' )< 30"5 %,
MDP!9 )$ 80"/ &H C !U (H @P"( )0 A@"G (, P@"" /  ? #_ ', _P!M
M /\ :@#_ &@ _P#/    P0   +D   "M    H    )@   "4    D0 & )
M#0"0 !( CP 9 (X (0"+ "@ B  O (8 -0"$ #H @@!  (  10!^ $L ? !2
M 'H 60!X &( =@!L '0 >0!R (D <0"= &\ M !M -\ ; #_ &4 _P!@ /\
M7@#_ %P _P"^    L0   *    "2    B0   ((   !\    >@ ! '@ "0!W
M  X >  4 '< &@!T "$ <@ G '  +0!N #, ;  X &L /@!I $0 : !* &8
M40!D %H 8P!D &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W %< _P!4 /\ 4@#_
M %$ _P"P    GP   (T   !_    =    &X   !J    9@   &4 ! !C  L
M8P 0 &, %0!C !L 80 A %\ )P!= "P 7  R %H -P!9 #T 5P!# %8 2P!5
M %, 4P!< %( : !0 '< 3P") $X GP!- +H 3 #I $L _P!) /\ 1P#_ $<
M_P"B    C0   'P   !N    90   %X   !9    5P   %4  0!4  < 4P -
M %, $0!4 !8 4@ ; %$ (0!/ "8 3@ K $P ,0!+ #< 2@ ] $D 1 !' $P
M1@!6 $0 80!# '  0@"! $$ EP!  *\ /P#7 #\ _P ^ /\ /0#_ #X _P"4
M    ?P   &\   !C    60   %$   !-    2@   $@   !'  0 1P * $8
M#@!& !$ 1P 6 $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W #T /@ \ $< .@!0
M #D 6P X &D -P!Z #8 CP U *< -0#& #0 ]0 T /\ - #_ #4 _P"(
M=    &4   !8    3P   $@   !#    /P   #T    \  ( /  ' #L #  [
M  \ .P 2 #H %P Y !P -P A #8 )@ U "P -  R #, .0 Q $$ , !+ "\
M5@ N &, +0!S "P B  L *  *P"[ "L Z@ K /\ *P#_ "P _P!_    ;
M %T!  !1 @  2 ,  $ #   [ @  -P   #0    S    ,@ % #( "0 R  T
M,0 0 #$ $P P !@ +P = "T (@ L "@ *P N "H -0 I #T * !& "< 40 F
M %X )0!N "0 @@ C )D (P"S "( W@ B /\ (P#_ "0 _P!W    900  %8&
M  !+!P  0@@  #H(   U!P  , 8  "T%   L P  *P # "H !P I  L *0 .
M "D $0 H !4 )P 9 "8 '@ E "0 )  J ", ,0 B #D (0!# "  3@ ? %H
M'@!I !T ?  < ), &P"L !L S0 ; /8 &P#_ !P _P!P!0  7P@  %$*  !&
M"P  /0L  #4+   P"P  *PH  "@)   E"   ) <" ",$!@ C @D (@$, "(
M#P A !( (  6 !\ &P > "  '0 F !P +@ ; #8 &@ _ !D 2@ 8 %< %P!F
M !8 >  5 (\ %0"F !0 PP 4 .X % #_ !4 _P!K"   6PL  $T,  !"#0
M.0T  #$-   L#0  )PT  ",,   A#   'PL! !X*!0 =" @ '08+ !P%#0 <
M!!  &P04 !D$&  9!!X & 0C !<$*P 6!#, %00\ !0$1P 3 U0 $@-C !$#
M=0 0 HH $ &B  \ O  / .4 #P#^ !  _P!G"P  5PT  $D.   ^#P  -0\
M "X/   H#P  ) X  " .   =#@  &PT! !D-!  8# < & L) !<)#  7"0X
M%@D2 !4)%@ 4"1L $PDA !()*  2"3  $0DZ ! )10 /"5( #@EA  T)<P ,
M"(@ "PB?  H'MP *!ML "@7V  H$_P!C#0  4PX  $80   [$0  ,A$  "L1
M   E$   (1   !T0   :#P  & \! !8.!  5#@< % T) !,-"P 3# T $@P0
M !$,%  0#!D $ P?  \,)P .#2\ #0TY  P-10 +#5$ "0U@  @-<0 &#88
M!0V=  0,M  ##-(  @SQ  (+_P!?#@  4!   $,1   X$@  +Q(  "@2   C
M$@  'A$  !L1   8$0  %1 " !00!0 2$ < $0\) ! /"@ 0#@P #@X.  X/
M$@ -#Q< #! =  P0)  *$"P "1 V  @000 &$$X !1!=  ,0;P !$(0  !"<
M   /M   #M0   [S   ._P!<$   31(  $ 3   V%   +10  "84   A$P
M'!,  !D2   6$@  %!$# !(1!@ 1$0@ $! *  X0"P -$0L #!$-  L2$0 *
M$A4 "1(:  @2(0 &$RD !1,S  ,3/@ "$TL  !-:   3;   $X(  !*;   2
MM   $=<  !'U   1_P!8$@  210  #T5   S%@  *Q8  "05   ?%0  &A0
M !<4   4$P$ $Q($ !$2!P 0$@D #A()  T2"0 +$PH "10-  <5#P &%A,
M!!88  ,6'P "%B<  !<P   7.P  %T@  !=8   7:@  %H   !:9   5M
M%=D  !3W   3_P!5%   1A8  #H7   P&   *!@  "(7   =%@  &18  !85
M   3% , $A,& ! 3!P /$P< #10'  L5"  )%@D !A@,  ,:#@ !&A$  !H6
M   ;'   &R0  !LM   ;.   &T8  !Q5   ;9P  &WT  !N7   :LP  &=L
M !CY   7_P!1%@  0Q@  #<9   N&@  )AH  " 9   ;&   &!<  !46 0 3
M%04 $14$  \5!  -%@0 "Q<%  D9!@ &&@@  AP*   >#0  (!   " 3   @
M&0  ("$  "$J   A-0  (4(  "%2   @9   ('H  !^5   ?L0  'ML  !WZ
M   <_P!-&0  /QL  #0<   K'   )!P  !X;   :&@  %Q@  !07 @ 2%P(
M$!@!  T9 0 +&@( "!P#  4=!  "'P8  "$(   C"P  )0X  "81   F%@
M)AX  "<G   G,@  )S\  "9.   F8   )G<  "62   DKP  (]H  "+[   A
M_P!('0  /!X  #$?   H'@  (AX  !T<   9&P  %AH  !(:   0&P  #1P
M  L=   ('P  !"$   $C @  )00  "<&   I"0  + P  "X/   N$P  +AH
M "XC   N+@  +CL  "Y*   M7   +7(  "R.   KK   *M0  "G[   H_P!$
M(   ."$  "XA   F(0  ("   !P>   8'0  %!T  ! >   .'P  "R$   <C
M   #)0   "<    I    + $  "X#   P!@  ,PH  #4-   V$0  -A<  #8?
M   V*0  -C8  #9%   U5P  -6T  #2)   RJ   ,<\  ##Z   O_P _)
M-"0  "LD   D(P  'R$  !L@   6(   $2$   XC   *)0  !B@   (J
M+0   "\    R    -    #<    Y P  .P8  #X*  ! #@  01(  $$:  !
M)0  0#$  $!    _4@  /F<  #V"   \H@  .L<  #GX   X_P Z*   ,"@
M "DG   C)0  'R,  !@D   2)0  #B@   HJ   %+0   #     S    -@
M #@    [    /@   $    !"    10(  $<&  !*"@  30X  $T5  !,'P
M3"L  $LZ  !*3   26$  $A\  !'FP  1;\  $/S  !"_P V+   +2L  "<I
M   C)P  &R@  !0J   .+0  "C    0S    -P   #H    ]    0    $,
M  !&    2    $L   !-    4    %,!  !6!@  60L  %L0  !;&0  6B4
M %DT  !81@  5UH  %5T  !4DP  4K4  %#J  !/_P S,   +"X  "<L   >
M+0  %B\  ! R   *-@   SH    _    0@   $8   !)    3    $\   !2
M    50   %@   !:    70   &    !C    9P8  &L,  !L$@  :QX  &LL
M  !I/0  9U(  &9J  !DB0  8:L  %_<  !=_P Q,P  +#$  "(R   9-0
M$3D   H]   "0@   $<   !,    4    %0   !8    6P   %\   !B
M90   &@   !K    ;@   '$   !U    >0   'T&  ""#0  @A8  ( D  !^
M-0  ?$D  'MA  !X?P  =I\  '/&  !P]P Q-@  )C@  !P[   20   "T4
M  )+    40   %8   !;    8    &4   !I    ;@   '(   !V    >0
M 'P   !^    @@   (4   ")    C@   ),   "8!@  G X  )L:  "8*P
MED   ))9  "1<P  C94  (NU  "(Z  K/@  ($$  !5'   -30   E0   !;
M    80   &@   !N    <P   'D   !^    @P   (@   ",    CP   )(
M  "5    F0   )T   "A    I0   *H   "P    MP<  +@1  "U(0  LC4
M *]-  "J:0  J(@  *:H  "BT0 C2   &$X   Y4   $7    &0   !M
M=0   'P   "#    B0   (\   "5    FP   *    "C    I@   *D   "M
M    L0   +4   "Y    O@   ,0   #*    T@   -H*  #6%@  TBD  ,Y!
M  #*7   Q7P  ,*=  #!O0 <50  $5P   =E    ;@   '<   !_    B
M )    "8    GP   *4   "M    LP   +@   "Z    O@   ,(   #&
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M_________________________________________P
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M_?[_;69T,0     #!"$   $                    !
M     0    $" P0%!@<("0H+# T.#Q 1$A,4%187&!D:&QP='A\@(2(C)"4F
M)R@I*BLL+2XO,#$R,S0U-C<X.3H[/#T^/T!!0D-$149'2$E*2TQ-3D]045)3
M5%565UA96EM<75Y?8&%B8V1E9F=H:6IK;&UN;W!Q<G-T=79W>'EZ>WQ]?G^
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MLW&[>[-QNWNS<;M[LW&[>[-QNWNS_ZLD!?^K+PW_NC@2\\E!&^3:22C8Z$Q
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MXY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\_ZL; O?
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M;53NM&U4[K1M5.ZT;53NM&U4[K1M5.ZT;53NM&U4[K1M_Z,0 /&Y# #.R0D
MQ-\+ +;W'P:L_S(2H/\['93_02>*_T<Q@?]..7K_6#]S_V)%;O]L26G_<TQF
M_WI/8_^ 46#_AE->_XQ47/^255K^F%=9_9U85_RD657[JUI4^[%;5/NQ6U3[
ML5M4^[%;5/NQ6U3[L5M4^[%;5/NQ6U3[L5M4^[%;\*\( ,V_!P# S0@ M.X.
M JG_(0B?_S$1DO\W&H?_/B)]_T4I=?]-,&[_535I_V Y9?]J/&'_<3Y?_W=
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M:?\J#F#_,A)9_SH54_]"%T[_21E+_U$:2/]8'$;_71U$_V,=0_]G'D'_;!]
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M?[.>C8#"GHN S)J+@=*2BH#8B8F VX:)@-N&B8#;AHF VX:)@-N&B8#;AHF
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M>%ZGY7A>I^5X7J?E>%ZGY7A>I^5X_WH5 O^.$@'_GQ, _[ 3 ._ $ #9U P
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MFR(W_Z0B-O^M(S7_N",U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_N2,U_[DCK;8
M )_$  "2T@  A.$  'W_#0%R_Q,":/\;!%__(P98_RL)4?\S"TS_.@U'_T$/
M0_]($4#_3A(]_U03._]:%#G_7Q0W_V45-?]K%C/_<A8Q_WH7+_^"%R[_BQ@L
M_Y,8*_^<&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9H;\  )+,
M  "$W   >/<  &[_"@%C_Q "6O\5 U+_'01+_R0&1O\L"$'_,PD\_SH*.?]
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MCW=GFXM^;I:(AG.0A8YXC(*6?(B H("$?ZN"@7^X@W]_RH2!@>%]@8'F=H&
MZV^ @.]J@(#O:H" [VJ @.]J@(#O:H" [VJ @.]J_V@< O]X%P+_AQ@"_Y0=
M O^?(P/XJ2H$[+$Q!^*W.0W5MT(<R;!.+;ZJ5SVTHU]*JYYG5:.8;E^<E'5F
MEI!\;9"-@W.+BHMXAHB4?(&&GH!]A*B">X2UA'F$QX1ZAN!_>X7F=WN%ZW![
MA.YK>X3N:WN$[FM[A.YK>X3N:WN$[FM[A.YK_VD; O]Z%@+_BA<"_Y<< O^C
M(0+TK2<#Z+4N!=Z]-0K0ND ;Q+1,++JN5CNOJ%Y)IJ)E5)Z=;%V7F7-FD)5Y
M;(J2@7*%D(EW?XV2?'N+FW]WBJ:"=(FS@W**Q(-TC.!_=(OE>'6)ZG%VB.UL
M=HCM;':([6QVB.UL=HCM;':([6QVB.UL_VL: O]]% +_C18!_YH: ?^F'@'P
ML2,"Y+LI ]G", G+O3\9P+A**K6R5#JJK%Q'H:=C4IFC:ER1GW%DBIMW:X28
M?W%^EH9V>9./>W22F7YPD*2!;9"Q@FN0P8)MDMU_;I'E>&^/ZG%PCNUL<([M
M;'".[6QPCNUL<([M;'".[6QPCNUL_VX8 O^ $@'_D!4!_YX7 ?NK&@'LMQX!
MX,,A =+&+0C&P3T8NKQ)**^W4CBELEI%G*UA49.I:%J+I6]BA*)U:7Z??&]X
MG81T<YN->6Z9EGQJF*)_9Y>N@&68OX%EF=A_:)CE>&F6ZG%JE.UL:I3M;&J4
M[6QJE.UL:I3M;&J4[6QJE.UL_W$6 O^#$0'_E!,!_Z(4 /6P% #FOA0 V<P5
M ,S**P? QCL6M<%')JJ\43:?N%A#EK-@3HVP9EB%K&U@?JIS9W>G>FQRI8)R
M;*.+=FBBE'EDH:!\8*"M?5^AO7Y>HM1]8:'F=F*=ZW!CF^YL8YON;&.;[FQC
MF^YL8YON;&.;[FQCF^YL_W03 ?^'$ '_F!  _J<0 .>W#0#6Q0L T- 1 ,7/
M* 6YRSD4KL=%(Z/#3S.9OU= C[M>2X:X9%1^M6M<=[)Q8W&P>&EKKH!M9JV)
M<F&KDW5=JYYX6ZJL>5FKO'E8K-)Y6JOH<URG[&Y=I.]J7:3O:EVD[VI=I.]J
M7:3O:EVD[VI=I.]J_WD1 ?^,#@#_G@T W*X( -*["0#,R D Q]8. +W5)02R
MTC81I\Y"()S*3"^2QU0\B,-<1W_!8E!WOFE7<+QP7FJ[=V-EN7]H8+B(;%RW
MDF]8MIYQ5;:K<U.WNW-2M])S5+?K;U:R[VI7K_%G5Z_Q9U>O\6=7K_%G5Z_Q
M9U>O\6=7K_%G_W\. ?^3"P#AI04 TK,' ,F^!P#"RP@ O-T. +3=(P.JVC,-
MG]9 ')332BJ*T%(W@,U:07C+84IPR6A1:LAO5V3&=EQ?Q7]@6L6(9%;$DF=3
MQ)YI4,2L:D_$O&M.Q=-J3\7M:%# \V11O?5A4;WU85&]]6%1O?5A4;WU85&]
M]6%1O?5A_X8* /":! #4J@0 R+8& +[!!0"WSPD L.,1 *CC)02?XC4-E> ^
M&8O>2"6!W% P>-I8.G#87T)IUF=)8]5N3U[4=E-9TW]75=.)6E+3DUU/TZ!?
M3=.M8$O4OF!*U=A@2]3M7DS1]UQ,S/E:3,SY6DS,^5I,S/E:3,SY6DS,^5I,
MS/E:_X\# -JB  #*KP, O;D$ +3&!0"KU D I.H4 9SI* :3Z30.B>@]&'_G
M1")WYDXJ;^97,FGE7SACY6<]7^1O0EKD=T56Y(!)4^2*2U#DE$Y-Y)]02^6L
M44GENU)(YL]22.;H4DCD^%%(X?Q/2.'\3TCA_$](X?Q/2.'\3TCA_$](X?Q/
MX9D  ,VI  "^LP( L[X# *C+!0"?V@D F/(8 I#R*@>&\C,.?/$[%G3Q0QUL
M\4LC9O%4*6'Q72U=\68Q6?%N-5;Q=C=3\7\Z4/*(/$WRDCY+\IU 2?.I04?S
MMD)&],=#1?3?0T3T\$-$\OI"1/+Z0D3R^D)$\OI"1/+Z0D3R^D)$\OI"T:(
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M'"__M1PN_[\<+O^_'"[_OQPN_[\<+O^_'"[_OQPN_[\<J;4  )K"  ",SP
M?]X  ';_!0!L_PX!8O\4 EK_&P-3_R0%3?\K!T?_,PE#_SH*/_]!"SO_1PPX
M_TT--?]3#C/_6 \Q_UX/+_]D$"W_:Q$K_W,1*?]\$B?_AA(E_Y 3)/^9$R/_
MHQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4G+X  (W+  !^V@  <.8
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M]UYBF?=>_W,0 ?^%# #ZE@H VZ4& -&Q" #+NP@ QL<+ +W'( *RQ3(+J,%
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M.4'O[SA [?TX0.S_.$#L_SA [/\X0.S_.$#L_SA [/\XRZ   +JK  "MM
MH<   );, 0"+V04 A/@1 7SX'P)T^"D&;/@R"F3X.P]>^4,36/E+%U/Y4QI0
M^5L=3?ID'TKZ;"%(^G0C1OI^)43[B"9!^Y,H0/N>*3[\JRH]_+DK._W+*SO]
MXBLZ_/0K.OSW*SK\]RLZ_/<K.OSW*SK\]RLZ_/<KO:@  *ZP  "AO   E<@
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M#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P  (C)  !YU@  :^,  %_V  !6_P
M3O\* $?_$ %!_Q8"//\= C?_) ,R_RH#+_\P!"O_-@4G_SL%)?] !2+_108@
M_TH&'O]0!AO_5@<9_UP'%_]D"!7_;0@3_W<($?^!"1#_BPD0_Y4)#_^8"0__
MF D/_Y@)#_^8"0__F D/_Y@)_TDG O]$,03_2S$$_U T!O]2.@C_4D,+_U%.
M#_]/7!/_36L6_TQY&?]+AQO_29,=_TB='_](IB#_1ZXA_T>U(O]&O2/_1L8C
M_T;0)/]&X"3_1NHE_T;S)?]&^B7_1O\E_T;_)?]&_R7_1O\D_4;_(_U&_R/]
M1O\C_4;_(_U&_R/]1O\C_TDG O]&+P/_32\$_U(R!O]5.0C_54(+_U1-#_]2
M61/_4&@7_T]W&O].A!W_3)$?_TN;(?]*I"+_2JPC_TFS)/])NR7_2,0F_TC-
M)O](W2?_2.@G_TCQ*/](^2C_2/\H_TC_*/Y(_RC[2/\G^4C_)OE(_R;Y2/\F
M^4C_)OE(_R;Y2/\F_THG O](+0/_4"T$_U4P!O]8-@C_64 +_UA+#_]55A/_
M5&88_U)T&_]1@1[_3XXA_TZ8(_]-H27_3:DF_TRQ)_]+N"C_2\$I_TO**O]*
MV2K_2N8K_TKP*_]*^"S_2O\L_4K_+/I*_ROW2O\I]4K_*/5*_RCU2O\H]4K_
M*/5*_RCU2O\H_TLF O]+*P/_4BL$_U@N!?];- C_73X+_UU)#_]:5!3_66(8
M_U=Q'?]5?B#_4XHC_U*5)O]1GBC_4*8J_T^N*_].M2S_3KTM_TW'+O]-TR__
M3.,P_TSM,/Q,]C'Z3/XQ]TS_,?5-_R_R3?\M\$W_*_!-_ROP3?\K\$W_*_!-
M_ROP3?\K_TLF O].*0/_5BD$_UPK!?]@,0?_8CL+_V)&#_]@413_7E\9_UQM
M'O]:>B/_6(8F_U:1*?]5FBS_4Z(N_U*J,/]1L3'_4;DS_U##-/Y/SC7[3]\V
M^$[K-_5.]3CR3OTX\$__->Y0_S/K4?\QZ5'_+^E1_R_I4?\OZ5'_+^E1_R_I
M4?\O_TPE O]1)P/_6B8#_V H!?]E+P?_:#D*_VA##_]G3A7_95H:_V)H(/]?
M=B7_78$J_UJ,+OY8EC'\5YXT^U6F-OE4K3CX4[4Z]U*^._51R3WS4=H^\%#H
M/^Q0\T#I4?T^Z%/_.^94_SCC5?\UX57_,^%5_S/A5?\SX57_,^%5_S/A5?\S
M_TTD O]4) /_72,#_V4E!/]J+0;_;38*_VY #O]M2Q3_:U8;_VAD(?YE<2C[
M8GTM^%^',O9<D3;S6IDZ\EBA/?!7J4#N5;%"[%2Y1.M3Q$;I4M)(Y5'E2>)2
M\DC?5/Q$W5;_0-M8_SW66?\ZTEG_.-)9_SC26?\XTEG_.-)9_SC26?\X_TXD
M O]8(0/_82 #_VHC!/]P*P7_<S0)_W0^#O]T2!3_<E(;^V]?(_9K;"KR9W<Q
M[V."-^Q@BSWI791!YEJ<1>18I$GB5JQ,X%2T3MU4OU#;5,U0UU/B4=)4\$[0
M5_M*SEK_1<U<_T+)7/\^Q5S_/,5<_SS%7/\\Q5S_/,5<_SS%7/\\_T\C O];
M'P+_91T"_VXA _]U*07_>3$(_WH[#/]Z1!/Z>4X;]'9;(^YQ9RSI;'(UY6A\
M/.%CA4/=8(Y(V5V73-5<GT_26J=1SUFP4\U8NE3+6,95R5?:5L57[%7#6_E/
MPE[_2L!?_T:]8/]"NF#_0+I@_T"Z8/] NF#_0+I@_T"Z8/] _U(A O]>'0+_
M:1H"_W,? _]Z)@3_?B\&_X$X"_N!01+S@$L:['Q7(^9W8RW@<6TXVFUW0--I
M@$;/98E+RV.13\A@F5+%7Z%5PEVJ5\!<LUF^7+]:O%O.6[A;Y5NW7O55MV+_
M3[5C_TJR9/]&L&3_0[!D_T.P9/]#L&3_0[!D_T.P9/]#_U4? O]A&@+_;1@"
M_W<= O]^) /_A"P%_H<U"?6(/A#MAT@8Y8-4(MY^7R[4>&DXSG-S0,EN?$?$
M:X1,P&B,4;UEE%2Z8YQ7MV*E6K1@KERR8+E>L%_'7JU?WU^L8O%9K&7^4ZIG
M_TZH9_]*IF?_1J9G_T:F9_]&IF?_1J9G_T:F9_]&_U<= O]D& +_<!8"_WL<
M O^#(@+_B2H$^8PR!^^..PWGCD06WHI1(=2$7"W,?F8XQ7AO0<!T=TB[<(!-
MMVV(4K-JD%:P:)A9K&:@7*IEJ5^G9+1@I6/"8:-CU6*B9>U=HFG[5Z%J_U&?
M:_],GFO_29YK_TF>:_])GFO_29YK_TF>:_])_UD< O]G%@'_<Q4!_WX: ?^'
M( +_C2<#])(O!NJ4. OAE$(3UH].(,R)62W%@V,WOGUK0+AY=$BS=7Q.KG*$
M4ZIOC%>G;91;HVN<7J!II6">:+!CFV>]9)EGSF28:>AAFFWY6IEN_U27;O]/
MEF[_2Y9N_TN6;O]+EF[_2Y9N_TN6;O]+_UL: O]I% '_=A0!_X$8 ?^*'0'\
MD20"\)<L!.6:- C<FC\1SY1,'\:.5RR^B& WMX)I0+%^<4BL>GE.IW> 4Z-T
MB%B?<9!<FV^87YAMH6*5;*QDDVRY9I%KR6:0;>1DD7'V7)%R_E:0<O]1D'+_
M39!R_TV0<O]-D'+_39!R_TV0<O]-_UT8 ?]K$P'_>1,!_X06 ?^.&P'XE2$!
MZYLH ^&@, ;5GCT0RIA*'L&25"NYC%XVL8=F/ZN";D>F?G9.H7M]4YQXA5B8
M=HU<E'257Y%RGF..<:EEBW"U9XEPQ6>(<.!FBG3T7HMV_%B*=O]2B7;_3HEV
M_TZ)=O].B7;_3HEV_TZ)=O]._U\7 ?]N$0'_>Q(!_X<4 /^1& 'TF1T!YZ C
M MVE*P3/H3L/Q9Q(';R64RJTD%PUK(MD/Z:';$>@@W--FX!Z4Y9]@E>2>HI<
MCGB28(IVG&.'=:9FA'2R:()TPFB =-MH@WCR8(1Z^UF$>?]4A'G_3X1Y_T^$
M>?]/A'G_3X1Y_T^$>?]/_V$5 ?]P$ '_?A$ _XH2 /^4%0#PG1D XZ4> =>H
M* /+I3D.P9]&&[>:42FOE5HTIY!B/J&+:D:;AW%,E81X4I"!?U>,?X=<B'V0
M8(1[F6. >J-F?7FP:'MYOVEZ>=9I?'SP87Y^^EI^??Y5?GW_47Y]_U%^??]1
M?GW_47Y]_U%^??]1_V,4 ?]R#P'_@1  _XT1 /R8$@#LH1, WZH6 -&L)@/'
MJ#<-O*-$&K.>3R>JF5@SHY1@/9R0:$66C&],D(EV4HN&?5>&A(5;@H*.7WZ
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M44R[]DY-NO]+3KG_24ZY_TE.N?])3KG_24ZY_TE.N?])[X4  -25  #'HP
MNJP! +"T  "GOP, GLD& )74"P"0U1T!B=0N!H#2/!!XT$89<<]/(6K.6"ED
MS5\O7\QG-%K+;CE6RG<]4LJ 0$_)BT-,R9=%2<FD1T?)LTA&RLA(1LKF1T?)
M]T5'R/]#2,?_0DC'_T)(Q_]"2,?_0DC'_T)(Q_]"WHT  ,N<  "]IP  L;
M *:Z  "<Q , D\\' (K=# "%WQT!?M\L!7;>-PMOWD,3:-U-&F+<52!=VUTF
M6-ME*E3:;2Y0VG8R3=J -4K:BS='VI<Y1=JD.T/;M#Q"W,@\0MOE.T+:]#I"
MV?XZ0]C_.4/8_SE#V/\Y0]C_.4/8_SE#V/\YT)8  ,&C  "RK   I[4  )S
M  "1R@, A]8' (#I$0!YZ2 "<NDL!6OI-@IDZ3\/7NE(%%GI41E5Z%H<4>EB
M($[I:R-+Z70E2.E])T;IB"I#Z9,K0>J@+4#JKRX^Z\ N/>S;+CWJ[RX]Z/PN
M/>?_+3WG_RT]Y_\M/>?_+3WG_RT]Y_\MQ9\  +6I  "HL0  G+P  )#'  "$
MT@$ >M\& '3T$P!M]" "9O0J!%_T- A:]3T+5/5%#T_U3!),]5442?9=%T;V
M91A$]FX:0?9W'#_W@1T]]XT?._>9(#GXIB$X^+4B-_G((C;YXR(V^/,B-O?\
M(C;W_"(V]_PB-O?\(C;W_"(V]_PBMZ8  *FN  "<N0  D,0  (//  !WVP
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M5EN6\U!=E_],7Y?_1V"6_T9@EO]&8);_1F"6_T9@EO]&_W # .N!  #6CP
MRIH! ,&C P"YJ@( L;(! *JW$0"CMR0"F[4T"I.R0!2*KTH>@ZU3)WRK6BYV
MJ&$U<*=H.VNE;T!GHW=$8J)_2%ZAB4Q:H)1/5Y^@452?KE-3G\!34I_=4E6?
M\TY7H/]*6:#_1EF?_T59G_]%69__15F?_T59G_]%_W4  ."&  #/DP  Q)\!
M +JG 0"QK@  J;8  *&]#0";O2 !E+PQ!XNZ/1"#MT@:?+50(G6S6"IOLE\P
M:K!F-F6O;3M@K74_7*Q^0UBKAT=5JI-*4:J?3$^JKDU-JL!-3:K<34ZJ\DE0
MJOY&4JG_0U*I_T)2J?]"4JG_0E*I_T)2J?]"\GP  ->,  #(F0  O:,  +*K
M  "IL@  H+L" )?$"0"2Q1L B\0L!(/".@Q[P405=+].'6Z]5B1HO%TJ8[MD
M,%^Z;#1:N70Y5KA\/%.WAS]/MY)"3+:?1$JVK49(ML!&2+?=14FV\D-*M?]!
M2[7_/DNT_SU+M/\]2[3_/4NT_SU+M/\]XH,  ,V2  #!GP  M*<  *JO  "@
MN   EL # (S*!P"&S10 @<TF GK,-0ASRT$/;,I*%V;)4QUAR%LC7,=B*%C&
M:BQ4QG(P4,5\,TW%AC9*Q)(Y1\2?.T7$KCQ$Q<$\0\7?/$3$\SM$P_\Y1<+_
M-T7!_S=%P?\W1<'_-T7!_S=%P?\WU8L  ,6:  "WI   JZP  *"T  "6O@
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M$2;_]A$F__81IZD  )FS  "+O@  ?LD  '#3  !DW@  6.<  %+_"0!-_Q$
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M1B<"_THI _]++P3_3#D&_TM%"/](40O_1EX._T1L$?]">1/_0845_T"/%_]
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M4&I^\TEM@/]#;H'_/V^!_SQO@?\\;X'_/&^!_SQO@?\\_V0( /]R  #A?P
MTXD! ,J2 P##F 0 O9X$ +:@$P"NH"<"I9TV"9V:0Q.6ETT<CY-5)(F172N$
MCF0Q?XQK-WJ*<CMVB'E <H:"1&Z%BT=J@Y5*9X*A362"KD]B@K]/88+:3V2$
M\DEFA?]#:(;_/VJ&_SQJAO\\:H;_/&J&_SQJAO\\_V<$ /9V  #<@@  SHT
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M/%:;_SI6F_\Z5IO_.E:;_SI6F_\Z\70  -F#  #(D   OIH  +.A  "JIP
MH:X  )>U!@"2MA@ C+4J X6T-PE^LD(1=[!,&'&N5!]LK5LE9ZMB*F*J:2]>
MJ7$S6JAZ-U:G@SI3IHX]4*:;0$VEJ4%+I;I"2Z;10DNE[3]-I?P\3J3_.4^D
M_S=/I/\W3Z3_-T^D_S=/I/\WY'H  ,^)  #"E0  MI\  *RE  "BK   F+,
M (Z[ @"(O1( @[TE 7R\,P9VNS\-;[I)%&JX41IEMUD?8+9@)%RU9RE8M&\L
M5+-X,%&S@C--LHTV2K*:.$BQJ#I&LKDZ1;+1.D:Q[3E'L/PV1[#_-$BO_S-(
MK_\S2*__,TBO_S-(K_\SVX(  ,>0  "[G   KJ,  *2J  "9L0  C[D  (3
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M)3O*_R4[RO\EPY,  +6>  "HI@  G:X  )&V  "%OP  ><<  &_.! !DU@D
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M@ 47_X\%%O^?!A7_KP84_\ &%/_6!A/_Z083_^D&$__I!A/_Z083_^D&EZ\
M (BZ  !ZQ0  ;,\  %[:  !0X   1.8  #SU   W_P0 ,_\- "__$P K_QH
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M1'AL\SYY;O\X>F__-'MP_S!\</\P?'#_,'QP_S!\</\P_UL( /]F  #G<@
MVGL  ,^" P#)AP4 Q(H& +R,%0"TBR@"K(DX!Z6%1!">@DX8F']7'I-\7R2.
M>68JBG=M+H9U=#*"='PV?W*$.7QQC3UY<)= =F^B0G-NKT1Q;L!%<&[917)P
M\3]S<O\Y=7/_-79T_S%V=/\Q=G3_,79T_S%V=/\Q_UT& /]I  #B=   U'T
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M-F6!_S-F@?\R9H'_,F:!_S)F@?\R_V0  .5R  #3?@  QX<  +Z/  "VE0
MKID  *:;# "@G!X F9LN!)*9.PJ+ED82A91/&7^15Q]ZCUXE=8YE*G&,;"YM
MBG,R:8E[-F:(A#EBAH\]7X6:/UR%J$%:A;="687,0EJ%ZC]<AOLZ7H;_-E^'
M_S)?A_\R7X?_,E^'_S)?A_\R_6@  .!V  #-@@  PHP  +F3  "PF0  J)T
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M+4N?_RU+G_\MW7D  ,F&  "\D@  L9H  *:@  "<I@  D:P  (:R  !]M@T
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MH! RVK$1,=O'$3':YQ$PV/82,-;_$R_4_Q,OU/\3+]3_$R_4_Q,OU/\3LYH
M *:A  ":J0  C;$  ("Z  !TP0  :,D  %S/  !2U0, 2-P( $7E$@!#Y1X
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M A#_JP,._[X##O_5 P[_[0,.__ ##O_P P[_\ ,.__ #DZX  (2X  !VP@
M9\P  %K5  !,W   /^$  #7F   M]   *O\" ";_"P C_Q$ (/\7 !W_'0 9
M_R, %O\I !3_+P 2_S4 $/\]  [_10$,_TX!"O]8 0?_90$%_W0! _^% 0+_
ME@$!_Z8! /^U 0#_Q@$ _\H! /_* 0#_R@$ _\H!AK<  '?!  !HS   6M<
M $O>   ^Y   ,ND  "?M   C_P  '_\  !O_!0 7_PP %/\0 !'_%  /_Q@
M#?\=  O_(@ (_R@ !?\N  +_-0  _ST  /]'  #_4@  _UX  /]M  #_?@$
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M_PCU*/\(]2C_"/4H_PCU*/\(_S(E ?\W(@'_.B$!_SLC ?\[*0+_.S0"_SE
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M-HA<]#"(7?\KB5[_*(E?_R6)7_\CB5__(XE?_R.)7_\C_U$) /]:  #U9
MX&P  -=Q P#0= 8 S74) ,1V%P"\=BH!M'0Z!:YQ1@RG;E$2HFM:&)YI8AV:
M9VDAEF5Q)9-D>"B08H KC6&(+HM@D3&(7YHSAEZE-8->LC>"7L(W@%[<.(!?
M\C.!8?\M@F+_*8)C_R:"9/\E@F3_)8)D_R6"9/\E_U,& /]=  #G9P  VV\
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M+7%N_RIQ;_\H<6__*'%O_RAQ;_\H_UD  .ME  #;<   S7@  ,1^  "\@@$
MMH0! *Z%#@"GAB  H(4P YJ"/0B3@$@/CGU1%8E[61J$>6 ?@'=G(WQU;B=Y
M='4J=G-]+G-RAC%P<9 T;7"<-VIOJ#EH;[<Z9V_+.F=PZ3=I<?HR:W+_+6QS
M_RIL<_\H;'/_*&QS_RAL<_\H_UP  .=H  #5<P  R7L  ,""  "XA@  L8@
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M*5N"_RE;@O\I[&8  -AS  #'?@  O(<  +..  "ID@  H)4  ):8 0"0F1,
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MG21!J*TE0*C )3^HWR4_IO0C0*7_(D"E_R% I/\@0*3_($"D_R! I/\@RGX
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M"BS3WPDKT?,**L_^"RG._PPIS?\-*<W_#2G-_PTIS?\-KI@  **?  "6I@
MB:X  'RV  !OO0  8\,  %?(  !,S0  0M(# #G9"0 UWQ  --\; #+@)P Q
MX3( ,.$] "[B1P MXE !*^): 2KC90(HXW$")N1_ R7DCP,CY:$$(N6T!"'E
MS00@Y.P$(.+[!!_A_P4?X/\%'^#_!1_@_P4?X/\%I)X  )BE  "+K@  ?;8
M '"^  !CQ@  5LL  $O0  ! U0  -MP  "_E!P M[1  *^X8 "GN(@ G[RL
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M  #_Q@  _]8  /_6  #_U@  _]8 @K4  '._  !DR0  5M,  $?;   ZX
M+N4  "/I   :[0  %?T  !+_   0_P( #O\)  O_#0 (_Q  !/\3  '_&
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M(J!)^!Z?2_\;GDO_&9U,_Q>=3/\6G4S_%IU,_Q:=3/\6_T<+ /]- @#_5 (
M]UH$ .M=!P#G70L X5P0 --='@#*73 !PUP_!+U:3 BW6%<,LU9@$:]4:12L
M4W$7J5%X&J=0@!RD3X<>HD^/(*!.F"&>3:$CG$VK))I-N"693,@FEDSB)I5.
M]2*43_\?E%#_')11_QJ44?\8E%'_&)11_QB44?\8_TD( /]0  #[6   Y5X
M -UB P#68P< U&$* ,IB&0#"8RP!NV([ [1@2 BO75,,JEM<$:9:9!6C6&P8
MH%=T&YU5>QV;5(,@F52+(I93DR244ITEDE&G)Y!1LRB.4<,IC5'=*HQ2\B:+
M5/\BBU7_'HM6_QR+5O\:BU;_&HM6_QJ+5O\:_TP$ /]3  #L7   WV(  -1F
M 0#.: 4 RV<( ,)G%@"Z:"@!LV<X ZUE10>H8U ,HV%9$9]?816;76@8F%QP
M&Y5:=QZ367\AD%B'(XY7CR6,5YDGB5:C*8=6KRJ%5;\KA%;5+(-7[RF#6/XD
M@UG_((1:_QZ$6O\<A%K_'(1:_QR$6O\<_TX! /]7  #E7P  V&8  ,YJ  #'
M; , PVL% +QL$@"T;24 K6PU Z=J0@>A9TT,G&56$9AC7A648F48D6!L&XY?
M=!Z,7GLAB5V#)(9<C":$6Y4H@5J@*G]:K"Q]6KLM?%K/+GM;["M\7/PF?%W_
M(GU>_Q]]7O\=?5[_'7U>_QU]7O\=_U   /59  #A8P  TFH  ,EN  #"< $
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M(&=N_R!G;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P  J8   *" !P"9@1<
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MG"A/A*HJ382\*DV$URI-@_$G3X/_)%"#_R)0@_\?4(/_'U"#_Q]0@_\?WFD
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M'#NCTAL[HN\;.Z#^&CN?_QD\G_\8/)__&#R?_Q@\G_\8Q'P  +:)  "JD@
MGY<  )6<  ")H0  ?:8  '&J  !DK@  6K$( %>Q% !5LB, 4[(P 5"R.P)-
MLD0#2[%-!4BQ50=%L5T)0[%E"T"P;PT^L'H/.["'$3FOEA,WKZ84-J^X%#6P
MT10UKN\4-*W^%#2L_Q0TJ_\4-*O_%#2K_Q0TJ_\4NX4  *^0  "CEP  F)T
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M 1C;_P(7VO\"%]K_ A?:_P(7VO\"H)P  )2C  "'JP  >;,  &RZ  !?P0
M4L8  $;*   [S@  ,=,  "G9   AW@4 'N@. !WH%0 ;Z1X &>DG !CJ,  6
MZCD %>M# !3L3@ 2[%H $>UG !#N=P 0[HH #N^>  [PLP -\,T #._L  SM
M_  ,Z_\ #.O_  SK_P ,Z_\ EZ,  (FK  ![M   ;;P  %_$  !2R@  1<X
M #G3   OV   )=T  !WA   8[ ( %O<+ !3W$0 1^!< $/@>  [Y)0 -^2T
M"_HU  G[/P '^TH !/Q7  /]9@ "_G<  /V+  #]GP  _+4  /S1  #\[0
M_/P  /S]  #\_0  _/T BZL  'VT  !NO0  8,8  %+-  !$T@  -]@  "S=
M   BX0  &>4  !/J   0^@  #O\&  W_#  *_Q  !_\4  3_&@ !_R   /\G
M  #_,   _SH  /]%  #_4P  _V(  /]U  #_B@  _Y\  /^S  #_QP  _^4
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M"[\S_@N],_\*NS/_"KHS_PFZ,_\)NC/_";HS_PFZ,_\)_SD0 /\]"P#_0 D
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M%HY+_Q2.3/\2CDS_$HY,_Q*.3/\2_T4  /]+  #I4P  WE@  --;  #-6P0
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M%W%=_Q=Q7?\7_4\  .59  #38@  QV@  +UL  "V;0  KVP  *=K"P"@;!D
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MG"-<:ZHE6FN[)EELTR9:;.\C6VS_'UQM_QQ=;?\:76W_&5UM_QE=;?\9Z%H
M -)F  ##;P  N'8  *][  "F?@  G7X  )%\  "*? \ A7T> (%]+0%\?#D#
M=WI#!G-Y2PEP>%,,;'=:$&EV81-F=6@68W1O&&%S>!M><H(>6W*-(%EQFB)7
M<:@D57&Y)51QT"54<>XB5G'^'E=Q_QQ7<?\:6''_&5AQ_QE8<?\9XUX  ,UI
M  "_<P  M'H  *M_  "B@@  F(,  (N!  "$@0T ?X(: 'N"*0%V@38"<H%
M!6Y_20AJ?E +9WU7#F1\7A%A>V847GIM%UMZ=AE9>8 <5GB+'U-XF"%1=Z8B
M4'>W(T]WSB-/=^PA4'?]'E%W_QM2=_\94G?_&5)W_QE2=_\9WF(  ,AN  "[
M=P  L'\  *>$  "=AP  DH<  (2'  !]APD >(@6 '2()@!PB#(";(<]!&B&
M1@9EA4X)8855#%Z$7 ];@V,268)K%5:!=!=3@'X:4(")'$Y_EAY,?Z4@2G^V
M(4E_S"%)?NL?2G[\'$M^_QI+?O\93'[_&$Q^_QA,?O\8U6<  ,-S  "V?
MK(0  **)  "8BP  C8T  'R-  !UC@0 ;X\2 &V0(0!ID"X!98\Y F*.0@1>
MCDL'6XU2"EB,60Q6BV$/4XMH$E"*<11-B7L72HF'&4B(E1M&B*,=1(BT'4.(
MRAU#A^H<1(;[&D2&_QA%AO\7187_%T6%_Q=%A?\7S6T  +UX  "Q@@  IXH
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M#2^F_PTOI?\-+Z7_#2^E_PTOI?\-MH0  *J.  ">E   E)D  (>>  ![HP
M;Z@  &.L  !7KP  2[(  $&U!@ ^MA$ /;8> #NV*0 ZMS0 .;<^ #>W1P V
MMU !-+=: 3*W9 (PMV\#+K=\!"RWBP4JMYP%*;>N!BBXQ04HM^8%)[7Y!R:S
M_P<FLO\()K+_"":R_P@FLO\(KXT  **4  "7F@  BZ   'ZF  !QJP  9;
M %FT  !-MP  0KL  #B^ 0 OP@D +<,2 "S#'@ KPRD *L0S "G$/0 HQ4<
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M  #F_P  YO\ DZ$  (6I  !WL0  :;D  %O   !.Q@  0<H  #7.   JT@
M(=8  !G;   2WP  #>,   OQ"  )\PX !_,3  3R&@ "\B(  /(J  #R-
M\C\  /),  #R7   \FT  /*"  #RF   \ZT  //&  #TY0  ]/8  /3[  #T
M^P  ]/L AZD  'FR  !JN@  7,(  $[)  ! S@  ,],  "C8   >W0  %>$
M  _D   *Z   !?,   /] 0  _ @  /L-  #[$0  ^Q8  /P>  #\)@  _#
M /T\  #^20  _EH  /YM  #_@@  _Y@  /^L  #_P   _]@  /_D  #_Y
M_^0 >[(  &R[  !=Q   3\T  $#2   RV0  )MX  !OB   2Y@  #.H   7M
M    ]    /\   #_    _P   /\$  #_"0  _PX  /\2  #_&   _R$  /\K
M  #_-P  _T8  /]8  #_:P  _X   /^5  #_I@  _[,  /^[  #_NP  _[L
M_QLF /\<) #_&B0 _Q4G /\0+0#_"C8 _P5# /\!4 '_ %X!_P!K ?\ =@'_
M ($ _P"* /\ D@#_ )H _P"@ /\ I@#_ *P _P"R /\ N0#_ ,( _P#- /\
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M ?\+BP'_"Y(!_PJ9 ?\*GP#_"J4 _PJK /\*L@#_"KL _0K& /L*U #W"N<
M\PKT / *_P#O"_\ [@S_ .T,_P'M#/\![0S_ >T,_P'M#/\!_R4; /\F& #_
M)1< _R$8 /\@(0#_'BL _QHW /\710#_%%$!_Q)> ?\1:0'_$70!_Q%] ?\0
MA@']$(X!_!"5 ?H0FP'Y$*$!]Q"H ?80KP'T$+< \Q#" /$0T #M$.4 Z!'R
M .81_@'D$O\!XQ+_ >(2_P'B$O\!X1+_ >$2_P'A$O\!_RD6 /\J$P#_*1(
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M"*@S_P>H,_\'IS/_!Z<S_P>G,_\'_S<' /\Z  #_/@  ^D$! /%!!@#Q/PT
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M#H!+_PZ 2_\._T,  .Q+  #=4P  SE@  ,1:  "]6@  N%<! +%4#@"J5AX
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MG!MH6:H<9EJZ'65:T1UE6NX;95O^%V9;_Q5F7/\39US_$F=<_Q)G7/\2[4X
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M'55GRAU59^@;5F?[&%=G_Q97:/\46&?_$UAG_Q-89_\3X5@  ,MC  "]:P
MLG(  *EV  "@>   EG<  (AS  "!<PL ?'07 'AT)@!T=#(!<',] FUS1@1J
M<DX'9W%5"61P7 MA<&,.7V]J$%QN<Q):;GP55VV(%U5LE!E3;*,;46RS'%!L
MR!Q/;.<;46SZ&%%L_Q52;/\44FS_$U)L_Q-2;/\3W%P  ,=G  "Y;P  KW8
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M$S^!_Q) @/\10(#_$$" _Q! @/\0QFL  +=V  "L?P  HH4  )>)  ",BP
M@8T  '..  !ECP  78\) %J0% !8D"$ 5I$M %.0. %1D$$"3I!) TR04 1*
MCU@%1X]@!T6.:0E"CG,+0(U_#3Z-C0\\C9P0.HVL$3F-P1$XC>$0.(OV$#B*
M_P\YB?\/.8G_#CF)_PXYB?\.OW(  +)]  "GA@  G(H  )&.  "&D0  >I,
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M!!^L_P0?K/\$JHL  )V1  "3EP  AYP  'JB  !MIP  8*L  %6O  !)L0
M/K0  #.W   JN@, )+P- "*]%0 AO2  (;TJ ""],P ?OCT 'KY' !V^4@ <
MOUX &K]L !F_?  8OXX %\"A !; M@ 4P-, %;[Q !6\_P$5N_\!%+K_ A2Z
M_P(4NO\"H9(  ):8  "*G@  ?:0  &^J  !BKP  5K0  $JW   ^N@  ,[T
M "K    AQ   &<<% !/+"P 1S!( $<P; !#,)0 /S2\ #LTZ  [-1@ -S5(
M#<Y@  S.<  +SH, "LZ7  G.K  (SL8 ",[H  C-^P )R_\ "<O_  G+_P )
MR_\ F)@  (V>  !_I0  <:P  &2S  !7N0  2KT  #[    RPP  *,8  !_*
M   7S0  $=$   S6!0 (V0P !MD2  7:&P $VB0  ]LN  ';.0  W$4  -U2
M  #>8@  WG,  -Z(  #?G0  W[,  -_.  #@[@  W_H  -__  #?_P  W_\
MCY\  (&F  !SK@  9;4  %B]  !*P@  /<4  #')   FS   '=   !34   .
MV0  "=T   /A    XP<  .,-  #D$@  Y1D  .8B  #G*P  Z38  .M#  #L
M4@  [&(  .UV  #NC   [J$  .^W  #OT0  [^L  /#V  #P]@  \/8 A*<
M '6O  !GMP  6;\  $O&   \R@  +\X  "32   :V   $MP   S@   %XP
M .<   #K    ZP   .T%  #N"P  \!   /$5  #S'@  ]"<  /<S  #Y0
M^E$  /MC  #\=P  _8T  /VC  #^M@  _LD  /_?  #_WP  _]\ =[   &BY
M  !:P0  3,H  #S/   NU   (MH  !?>   0X@  ">8   #I    [    /
M  #V    ]@   /<   #X    ^@<  /L-  #]$0  _QD  /\C  #_+P  _SX
M /]/  #_8@  _W<  /^-  #_GP  _ZX  /^Z  #_N@  _[H _Q8C /\5(0#_
M$B$ _PXD /\&*@#_ #, _P!! /\ 3@#_ %P _P!H /\ = #_ 'X _P"' /\
MCP#_ )8 _P"< /\ H@#_ *@ _P"N /\ M0#_ +T _P#' /\ U@#_ .< _@#S
M /X _@#] /\ _ #_ /L _P#[ /\ ^P#_ /L _P#[ /\ _QH@ /\9'@#_%AX
M_Q @ /\*)0#_!#  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"# /\ BP#_
M )( _P"8 /\ G@#_ *0 _P"J /\ L0#] +D ^P## /H T #X ., ]P#Q /8
M_ #T /\ ] #_ /, _P#S /\ \P#_ /, _P#S /\ _QT< /\<&0#_&1D _Q0;
M /\.(0#_#"P _PDY /\%1@#_ E, _P!? /\ :P#_ '4 _P!^ /\ A@#_ (X
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M /\C$ #_(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD _!!5 /@/8 #T#VH
M\0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B#J\ X ZX -X.Q0#<
M#MH UA#L -(1^@#/$O\ S1+_ <P2_P'+$_\!RA/_ <H2_P'*$O\!_R</ /\G
M# #_)0D _R8- /\E$P#_(QP _R H /L<-0#U&D( [QA/ .H76@#F%F4 XQ9N
M . 6=P#>%G\ W!:' -D6C@#6%I4 U!:< -(7HP#0%ZL SABU ,P8P0#+&-(
MQQKH <,;^ ' &_\!OAS_ ;T<_P*\'/\"O!O_ KP;_P*\&_\"_RL, /\K!0#_
M*P, _RT) /\L#@#_*14 ]R8@ .XC+0#G(3H X1]( -L?5 #5(%\ T2!H ,X@
M<0#,(7D RB&! <@AB '&(8\!Q"&6 <,AG@'!(J8!OR*O ;TBNP*\(\H"N2/C
M K4D] *S)/\#L23_ Z\D_P.O)/\#KB3_ ZXD_P.N)/\#_R\& /\O  #_,@
M_S," /DR" #W+PX ZRL6 .$G(@#8)S( T"E! ,LJ3@#&*ED PRIB < J:P&]
M*G,!NRIZ KDJ@@*X*HD"MBJ0 K0JF .S*J$#L2JJ Z\KM02N*\0$K"O;!*@L
M[P2F+/X%I"S_!*,M_P2B+?\$HBS_!*(L_P2B+/\$_S(  /\S  #Y.   Z3D
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M1P  P4$$ +H_$0"S02$ K4(Q *A#/@"D0TD!H$)3 IU!6P.;06($F$!J!99
M<0:4/W@'DC]_") _B J//I$+C3Z;#(L^I@V)/K,-B#[$#H8_X Z$/_0-@T#_
M"X- _PJ"0/\)@D'_"()!_PB"0?\(_SP  .M#  #<2@  S$\  ,-0  "\3@
MMTD! +%&#@"J2!P I$DL *!).@";244!F$A. I1'5P.21UX%CT9E!HU&; >+
M17,)B45["H=$@PN%1(T,@T27#H%#H@]_0Z\0?D/ $'Q$VA%[1/$/>D7_#7I&
M_PMZ1O\*>D;_"7I&_PEZ1O\)]3X  .9(  #33P  QU0  +U5  "V5   L%
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M#&93_PQF4_\,ZDD  -53  #%6@  NE\  +!B  "H8@  GU\  )9:  "/6A
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MD1)38I\34F*N%5%BPA508N$546+V$E%B_Q!28O\.4F+_#5)B_PU28O\-V58
M ,1@  "W:   K&X  *-Q  ":<P  CW$  ']K  !X:P4 <FL2 &YL'P!K;"P
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M$$!UO!! ==D00'3S#T!T_PY!<_\-07/_#$%S_PQ!<_\,QF0  +=N  "K=@
MHGP  )=_  ",@0  @8$  '*   !E?P  77\( %E_$P!7@"  58 K %.!-@!1
M@#X!3X!& DV 3@)+?U4#27]=!49_9@9$?G (0GY["3]^B L]?9<,/'VG#3I]
MN@XZ?M8-.GSQ#3I[_PPZ>_\+.GK_"SIZ_PLZ>O\+P&D  +)T  "G?   G8$
M )*$  "'A@  >X<  &Z'  !@AP  58<! %"(#@!.B!H 38DF $N), !)B3H
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M R.;_@,BFO\$(IG_!"*9_P0BF?\$K($  *"(  "5C@  BY(  '^6  !RF@
M99T  %F@  !.HP  0J0  #>F   NJ 4 *:D/ "BI&  GJB( )JHL "6J-0 D
MJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =JXL &ZN= !JKL0 9J\H &:KL 1FH
M_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD  '6>  !HH@  7*8
M %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ< %[<A !:W*@ 5MS0
M%+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -N<0 #;CG  ZV^P .
MM?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF  !>JP  4J\  $:R
M   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45  G%'@ (Q2@ !\4R
M  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8  ,;2  #%[P  Q?P
M ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3M   1K@  #J[   N
MO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0%@  T1X  -(G  #3
M,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_  #6X   UO,  -;^
M  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0  .<$  "W$   BQP
M&<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P  WQ0  .$<  #B)
MY"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #IQ0  Z>(  .GR  #I
M]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H  "#.   6T@  #]8
M  C;    WP   .,   #E    YP   .@!  #J!P  ZPT  .T1  #O&   \2$
M /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP  ^L(  /K:  #ZWP
M^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:   -WP  !>,   #F
M    Z0   .T   #O    \0   /,   #U    ]@(  /@)  #Z#@  _1,  /\<
M  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL  /^Y  #_O   _[P
M_Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_ %D _P!E /\ < #_
M 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L #_ +@ _P#" /\
MS@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_ /H _P#Z /\ _Q0<
M /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4 _P!A /\ ; #_ '8
M_P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[ +0 ^0"] /@ R0#W
M -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /  _P#P /\ _Q<8 /\5
M%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!< /\ 9P#_ '$ _P!Z
M /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +  \ "X .X PP#L -,
MZ@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E /\ _QH3 /\8$0#_
M%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X 8@#Z &P ]0!U /(
M?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T .( OP#@ ,T W@#C
M -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\ _QX0 /\<#0#_%PL
M_Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N!&8 Z@1O .8#=P#D
M!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%NP#0!LD S@?@ ,P(
M\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$, /\@!@#_' , _QT*
M /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6  W0UI -D-<0#5#7D
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M ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP  /\M  #M,@  XC0  -HS  #3+@,
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M!G- _P9S0/\&\3L  -]%  #,3   OT\  +90  "N3P  ITH  *!$!P":110
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MD0Q>4)X-7%"M#EM1P Y:4=X/6E'U#%I2_PI;4O\)6U'_"%M1_PA;4?\(WTH
M ,E3  "[6@  L%\  *9A  "=80  E%X  (A7  " 5@H >E<5 '97(@!S6"X
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M#4Q>N@Y+7M0.2U[Q#$Q>_PM,7?\*3%W_"4Q=_PA,7?\(SU0  +Y>  "Q90
MIVH  )UM  "4;0  B6P  'AE  !O9   :60. &5D&0!B9"4 8&4P %YE.@!<
M94(!6F5* EAD40)69%@#5&1?!%)D9P508W$'3F-["4QCB I*8Y<+2&.F#$=C
MN U&8]$-1F/O#$9B_PI'8O\)1V+_"4=B_PA'8O\(RE@  +IB  "N:0  HVX
M )IQ  "0<@  A'$  '1K  !I:0  8VD+ %]I%0!<:B$ 6FHM %AK-@!6:S\!
M56M' 5-J3@)1:E4#3VI=!$UJ905*:6X&2&EY!T9IA@E$:94*0VBE"T%IMPQ
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M!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0  F'X  (V   ""@0
M=H(  &F!  !;@0  48$  $B "@!%@1, 0X$> $*"*0!!@C( 0(([ #Z"0P ]
M@DL .X)3 3F"7 $W@F8"-8)Q S."?P,Q@8X$,(&?!"Z!L04M@<@%+8'I!"U_
M_ 4M?O\%+7W_!2U]_P4M??\%LVX  *AX  "=?P  DH,  (B&  !]AP  <(@
M &.)  !5B@  2XH  $&* @ [BPX .8L7 #B,(@ WC"P -HPU #2,/0 SC$8
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M 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@  6*$  $RD  ! I@
M-:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .L2L #;$U  VQ0  ,
ML4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P[P %K_X !J[_  :N
M_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL  $&M   UKP  *[$
M "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(  +XK  "^-@  OD$
M +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y   O?8  +W_  "]_P
MO?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V   JN   (+L  !>^
M   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB  #+*P  S34  ,Y!
M  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L  ,[X  #._@  SOX
MB)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >P@  %<8   [)   (
MS    -    #3    U0   -8&  #8#   V1$  -L6  #<'P  WB@  . T  #B
M00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J  #E\P  Y?, ?*,
M &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0  #-$   35    V@
M -X   #A    X@   .0   #E P  YPD  .D.  #K$@  [1H  .\D  #R,0
M]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #WWP  ]]\ <*P  &&T
M  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\   #B    Y0   .D
M  #L    [0   /    #Q    \P   /4$  #W"@  ^A   /P6  #_(0  _RX
M /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP  _[\ _PT< /\*&P#_
M AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\ ;0#_ '< _P!_ /\
MAP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"] /\ R0#^ -T _0#M
M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\ _Q 9 /\-%P#_!A8
M_P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_ '( _P![ /\ @@#_
M (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8 PP#T -( \P#G /(
M]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4 /\/$@#_"Q( _P 2
M /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T ^P!V /D ?0#W (0
M]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H ,L YP#A .4 \0#C
M /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1#@#_#0T _P</ /\"
M%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P .T > #K '\ Z0"%
M .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4 U@#9 -0 [ #2 /D
MT0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_#P4 _PX+ /\,$0#_
M!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .  <@#> 'D VP"  -D
MA@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0 ,4 Z ## /8 P0#_
M , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%   _Q,% /\1#0#_#A0
M^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,!7, R@5Z ,@%@0#&
M!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*Y0"U"_< LPW_ +$-
M_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH  /46!0#V$0T ZPX5
M .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT O0YT +L/>P"Y#X(
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M HDG_P&))_\!^BD  .PP  #=-@  S3@  ,0W  "^,@  NBL" +4E#@"N)QT
MJ"DK *0J. "@*D, G2M, )HK50"8*UP EBMC )0K:@&2*W$!D"QX 8\L@0&-
M+(H!BRR4 HHLGP*(+*L"ABRZ H4MS@.#+NH#@2[\ X N_P)_+O\"?R[_ GXN
M_P)^+O\"]"X  .0W  #2/0  Q3\  +L_  "T/   KS4  *DO"P"C+Q< GC$F
M )DR,P"6,CX DC-( ) S4 "-,U@ BS-> 8DS90&',VP!AC-S 80S? *",X4"
M@#./ W\SF@-],Z<#?#.U!'HSR01Y-.8$=S7Y!'8U_P-U-?\#=37_ W4U_P-U
M-?\#\#,  -T]  #*0P  OD4  +5&  "M0P  ICT  * V!@"9-A, E#@A ) Y
M+@",.3D B3E# (<Y3 "$.5,!@CE: 8 Y80%^.6@"?#EO GHY=P)Y.8 #=SF+
M!'4YE@1T.:,%<CFQ!7$YQ 9O.N(&;CKW!6X[_P1M._\$;3O_ VTZ_P-M.O\#
MZCD  -5"  #$2   N4L  *]+  "G20  GT0  )@^ 0"1/!  C#T= (@^*@"$
M/S4 @3\_ 'X_2 !\/T\!>C]6 7@_70%V/F0"=#YK G(^<P-P/GP#;SZ'!&T^
MDP5K/J &:CZN!FD_P =G/]X'9S_U!F9 _P5F0/\$9D#_!&8__P1F/_\$Y3T
M ,]&  "_3   M$\  *I0  "B3P  F4H  )%$  "*00T A$(9 (!#)@!]1#(
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M"%9,N0E53-$)5$SO"%1-_P953/\&54S_!55,_P553/\%U4@  ,)1  "U5P
MJEL  *!<  "77   C5D  (%3  !W3P0 <4\0 &Y0' !J4"@ :% R &50.P!C
M4$, 85!* 5]040%=4%@"7%!? EI09P-84'$$5U![!550B 934)8'4E"E"%!0
MMPE04,X)3U#M"%!0_P=04/\&4%#_!5!0_P504/\%T$L  +]4  "R6@  IUX
M )U@  "48   B5T  'Q7  !R5   ;%,. &A4&0!E5"0 8E0O &!4. !>5$
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M!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8  +1?  "H9@  GFH  )5M  "*;0
M?VP  &]G  !D9   6V(% %9B$ !48AL 4F,E %!C+P!.9#@ 361  $MD2 !*
M9$\!2&17 49D7P)%9&@"0V1S T%C?P0_8XX%/6.>!CQCL 8[9,8&.V3F!CMC
M^@4[8O\%.V+_!3QA_P0\8?\$OEL  +!C  "E:@  FV\  )%R  "&<@  >W$
M &QM  !@:P  56D  $]H#0!-:1< 2VDA $EJ*P!(:C0 1VH] $5K1 !$:TP
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M B=W_P(G=_\"KFP  *-V  "9?   CG\  (2"  !X@P  ;(0  %^$  !1A
M1X0  #R$   SA D ,(01 "^$&@ MA"0 +(4M "N%-0 JA3X *85' "B&4  G
MAEH )H9F "2&<P CAH, (8:5 ""&IP$>AKP!'H;> !Z$]0$>@O\!'H+_ 1Z!
M_P$>@?\!J'0  )Y]  "3@@  B84  'Z(  !QB@  98L  %B,  !,C0  0(X
M #:.   LCP  )9 , ".0$P BD!P (9 E ""1+@ ?D38 'I%  !V120 <D50
M&I%@ !F1;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4CO\ %(W_ !2,_P$4
MC/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5  !%EP  .9@  "Z9
M   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW !&>00 0GDP #YY8
M  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X "YK_  N9_P +F?\
MG(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \H   ,*$  ":C   =
MI0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J.  "JD0  :I0  "J
M7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_  "G_P  I_\ E8L
M (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@  )JL  !VM   4L
M#K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P  N#D  +A&  "X5
MN&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V_P  MO\ CY(  (*7
M  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8  !.X   -NP  !KX
M  #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX  ,@Z  #)1P  R5<
M ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0  R/T A9D  '>?  !H
MI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#   #QP   ,H   #-
M    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM  #=.0  WDD  -Y:
M  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0 >:$  &NH  !<KP
M3K4  $"[   QO@  ),$  !G%   0R   "<P   #/    TP   -D   #<
MW0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M*P  \#H  /%+  #Q
M7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H  %ZQ  !0N0  0;\
M #+$   DR   %\P   [0   &U0   -H   #>    X@   .8   #I    Z@
M .P   #N    \    /(   #T!@  ]@P  /D2  #\'   _RD  /\Z  #_30
M_V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!%P#_ !< _P : /\
M(0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![ /\ @P#_ (H _P"0
M /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4 _ #J /L ^ #Z /\
M^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_ !, _P 4 /\ &@#_
M "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\ ?@#_ (4 _@"+ /T
MD0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C .\ \P#N /\ [0#_
M .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \ _P 0 /\ %@#_ "(
M_P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T '\ \P"& /$ C #O
M )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$ [0#? /L W@#_ -T
M_P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P , /\ $@#_ !T _P I
M /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H Y0"  ., A@#A (P
MWP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#, /8 R@#_ ,H _P#)
M /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\ #@#_ !8 ]P B .\
M, #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z -  @ #. (< S "-
M ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$ NP#^ +D _P"X /\
MN #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X 1  Z  : ., * #=
M #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$ >@"_ ($ O0"( +L
MCP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[ *L%_P"J!O\ J0;_
M *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@ W0,2 -0#( #-!"T
MR 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q"'L KPB" *X)B@"L
M"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T._P"<#_\ FP__ )L/
M_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+ ,<+%@# #24 N@XR
M +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78 HA%] *$1A0"?$HX
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MF &!):0!@":R 7XFQ0%])^(!>R?W 7DH_P%X*/\!>"C_ 7@H_P%X*/\![RL
M -TS  #*.0  OCL  +0Z  "M-@  IB\  *$H!P";)Q, EB@@ )$I+0".*C@
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M V(YN0-A.M #8#KN V Z_P-?.O\"7SK_ E\Z_P)?.O\"W3L  ,=#  "Y20
MKDL  *1,  ";2@  DD4  (D_  "!.@D >SH4 '<[( !T/"L <CPU &\]/@!M
M/48 :SU- &D]4P!H/5H 9CUA 60]:0%C/7(!83U] F ]B0)>/98#73ZE UL^
MM@1:/LP$6C_L!%D__@-9/_\#63__ ED__P)9/O\"UC\  ,-'  "U3   JE
M *!0  "73P  CDL  (1%  !Z0 8 =3\1 '% ' !M0"@ :T$R &E!.P!G04(
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M!$E+^@1)2_\#2DO_ TI+_P-*2_\#R$D  +A1  "L5P  H5L  )A<  ".7
M@UD  '93  !K3@  9$T* %],$P!<31X 6DTH %A-,0!633H 5$U! %-.2 !2
M3D\ 4$Y7 4].7P%-3F@!3$YS DI/?P))3XT#1T^=!$9/K@1%3\,$1%#D!$1/
M^01%3_\#14__ T5._P-%3O\#Q$P  +55  "I6P  GUX  )5@  "+8   @%X
M ')7  !G4P  7E$' %E1$0!741L 5%$E %)2+P!14C< 3U(_ $Y21@!-4TT
M3%-5 $I370%)4V8!1U-P D53?0)$4XL#0E.; T%4K 1 5,$$/U3B!#]4^ -
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M C5<_P(U7/\"N%D  *IA  "@9P  EFP  (QN  "!;@  =FP  &=I  !<9@
M460  $AB"0!$8A$ 0F(; $%C)  _8RT /F,U #UD/0 \9$4 .V1- #ED50 X
M9%\ -F1I 35D=@$S9(4!,665 C!EIP(O9;L"+F7: BYD] (N8_\"+V/_ B]B
M_P(O8O\"LUX  *=F  "<;0  DW$  (AS  !]<P  <G(  &1P  !8;@  36P
M $)J P \:0X .FH6 #EJ(  X:B@ -FLQ #5K.0 T:T$ ,VQ) #)L4@ Q;%P
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M:P :?WH &7^, !=_GP 6?[, %7_. !5^[P 6?/\ %GO_ !9[_P 7>_\ I'(
M )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B   /(@  #*(   HB
M((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3BDP $HM8 !&+90 0
MBW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&_P .AO\ GWL  )2!
M  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(  "J2   ADP  &90
M !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0 ")=0  :77@ %EVX
M Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !DO\ F((  (Z(  "%
MC   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=   9G@  $J    VB
M @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(  "D5@  I&4  *-W
M  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\ D8H  (F.  ![D@
M;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1J@  #*P   6N
MKP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R3   LEL  +)L  "R
M@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)   '^5  !QF@  8Y\
M %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0   K@   "[    NP
M +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0   PT\  ,-@  ##=
MPXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=  !EHP  5Z@  $FM
M   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4   #'    R    ,D
M  #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$  -A3  #99@  V7P
M -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9K   2[(  #RW   N
MN@  (;T  !7    -Q   !<<   #*    S@   -(   #5    U@   -D   #;
M    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#  #N5@  [VL  .^$
M  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@  /KP  "_    @Q
M%,@   S,   "T    -0   #9    W@   .(   #E    Y@   .@   #I
M[    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_1@  _UH  /]Q  #_
MB0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7 /\ '0#_ "@ _P W
M /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4 _P"+ /\ D0#_ )<
M_P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X /\ ]P#_ /< _P#W
M /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\ %P#_ "0 _P R /\
M/P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "& /H C #Y )( ^ "8
M /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X Z@#_ .D _P#I /\
MYP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_ !\ _P L /\ .@#_
M $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X AP#L (T Z@"3 .D
MF@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_ -< _P#5 /\ U0#_
M -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D ^P F /< - #T $
M\@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#< (< V@"- -8 E #4
M )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,, _P## /\ PP#_ ,,
M_P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ? .H +0#F #H X@!%
M -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($ Q@"' ,0 C@#" )8
MP "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R /\ L@#_ +$ _P"Q
M /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H )0#3 #( S@ ^ ,H
M20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"! +0 B "R )  L "9
M *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\ H@#_ *( _P"B /\
M_Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$ "H OP W +L 0@"W
M $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8 @P"D (L H@"4 *
MG@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_ )0)_P"4"?\ _!$
M /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$ L@8N *X(.@"J"40
MIPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7#(8 E@R0 )0,F@"2
M#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1_P"'$?\ ]AD  .<@
M  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G *$0,P"=$3X FA%'
M )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$ B12+ (<4E@"&%:(
MA!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![&?\ [R$  -TI  #*
M+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09+0"1&C@ CAI! (L;
M20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V& 'P>D0!Z'IX >!^K
M '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\ Z"@  -(P  #"-0
MMS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&(C( @R,\ ($C1 !^
M(TL ?"12 'LD60!Y)%\ =R1F '8E;@!T)7< <R6! '$FC0!O)ID ;B:G &TG
MN !L)\X!:BCM 6DI_P%H*?\!:"G_ 6@H_P%H*/\!X2X  ,LV  "\.P  L3T
M *<]  "?.0  ES,  (\M  "()PP @R<6 '\H(@!\*2T >2HW '<J/P!U*D<
M<RM. '$K5 !P*UL ;BMB &PK:@!K+'( :2Q] &@LB0!F+98!92VD 60NM %C
M+LH!82_I 6 O_0%@+_\!8"__ 6 O_P%@+O\!VC0  ,4\  "W00  K$,  *)#
M  "90   D#H  (@T  " +@@ >BT2 '<N'@!S+RD <3 S &\P.P!M,$, :S%*
M &DQ40!G,5< 9C%> &0Q9@!C,F\ 83)Y & RA0%?,I(!73.A 5PSL0%;-,8!
M6C3F 5DU^P%9-?\!633_ 5DT_P%9-/\!TC@  ,!   "S10  J$@  )Y(  "5
M1@  BT   (([  !Y-00 <S,0 &\T&@!L-"4 :34O &<U-P!E-C\ 8S9& &(V
M30!@-E0 7S9; %TW8P!<-VL 6S=V 5DW@@%8.(\!5CB> 54XKP)4.<,"4SGD
M E,Z^0%3.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20  I$P  )I,  "12P
MAT8  'U   !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>.CP 73I# %LZ2@!:
M.U  6#M8 %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]K )./L$"33[A DT^
M^ )-/O\!33[_ 4T]_P%-/?\!R4   +A(  "L30  H5   )=1  ".3P  A$L
M 'E%  !N0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@ 5SY  %4_1@!4/TT
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M 3])_P$_2?\!O4H  *]2  "C6   F5L  )!=  "&7   >UD  &U3  !B3P
M5TP! %%*#0!.2A4 3$L? $I+* !)2S  1TLX $9,/P!%3$8 1$Q. $--5@!"
M35\ 0$UJ #]-=@$]3H0!/$Z4 3M.I0$Y3[D".4_4 CE/\@$Y3O\!.4[_ 3E-
M_P$Z3?\!NDX  *Q6  "A6P  EU\  (UA  "#80  >%X  &E8  !?5@  5%(
M $Q/"P!)3Q( 1U < $50)0!#4"T 0E U $%1/ ! 440 /U%, #Y25  \4ET
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M;@ L7WT *E^. "E?H  H7[,!)U_, "=?[0$G7O\!)UW_ 2A=_P$H7/\!K5P
M *)D  "8:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0  26<  #]E   U8PD
M,F,1 #!C&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H950 )V5? "9F:P D
M9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C_P$A8_\!J6(  )YJ
M  "5<   BG,  (!U  !U=0  :70  %QR  !/<0  1&\  #IN   P;0, *6P-
M "=L%  F;!P )6TD "1M+  C;30 (FT] "%N1@ @;E  'FY; !UN9P <;G8
M&FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8:_\ I&D  )IQ  "0
M=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X   K=P  (G8' !UV
M#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6 !-X8P 2>'( $7B#
M !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\ GW$  )5X  "+?
M@G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D@@  '((  !2""0 1
M@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#70 )@VP "(-^  :#
MD0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD  )!^  "&@P  ?84
M &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0  %8X   ^/ P *D P
M!I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@  CV4  (]V  "/B@
MCI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%  ""B0  =(P  &:/
M  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH   J;   "G D  )P.
M  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P  )UN  "<@0  G)<
M )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !XD   :I0  %R7  !/
MF@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H    J00  *D*  "I
M#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC  "L=P  JXX  *ND
M  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP  7YP  %&@  !$I
M-J8  "JH   >J0  %*L   VN   &L    +(   "U    M0   +4#  "V"0
MMPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]:P  O8$  +V9  "]
ML   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4  $:J   XK0  *J\
M !ZQ   3M   #+<   .Y    O    +\   #"    P@   ,,   #$    Q@8
M ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@  TG,  -*+  #2I
MT[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS   JM@  ';D  !*\
M   *OP   ,,   #&    R0   ,T   #/    T    -(   #4    U@   -D"
M  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60  .I\  #KE0  ZZP
M .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =P   $<0   G(
MS    ,\   #3    V0   -T   #@    X0   .,   #E    YP   .H   #L
M    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ  #_@P  _YL  /^N
M  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8 _P T /\ 00#_ $T
M_P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_ ), _P"9 /\ H #_
M *< _@"O /P N@#Z ,D ^0#A /@ \P#W /\ ]@#_ /4 _P#Q /\ Z0#_ .0
M_P#A /\ _P / /\ #0#_  T _P . /\ % #_ "$ _P N /\ / #_ $@ _P!3
M /\ 70#_ &8 _@!M /P =0#[ 'L ^0"" /@ B #W (X ]@"4 /0 FP#S *(
M\0"J .\ M #M ,$ ZP#5 .H [ #H /P YP#_ .4 _P#F /\ X #_ -D _P#4
M /\ _P + /\ " #_  8 _P ) /\ $ #_ !P _P I /\ -@#_ $( ^P!. /<
M5P#T &  \@!H .\ ;P#M '8 [ !\ .H @@#H (@ YP". .4 E0#C )P X0"D
M -\ K@#= +D V@#* -< Y #4 /8 T0#_ -  _P#0 /\ SP#_ ,L _P#' /\
M_P # /\   #_    _P $ /\ #0#Z !8 ]@ C /, , #P #P [0!' .D 40#E
M %H X@!B -\ :0#= &\ V@!V -@ ? #4 (( T@"( -  CP#- )8 RP"> ,D
MJ #' +, Q0#! ,( V #  .\ OP#^ +X _P"] /\ O #_ +P _P"\ /\ _P(
M /\   #_    _P   /0 !P#M !$ Z  < ., *0#? #4 VP!! -8 2P#1 %0
MS0!< ,H 8P#( &D Q@!O ,, =0#! 'L OP"" +X B "\ )  N@"8 +@ H@"U
M *P LP"Y +$ RP"O .< K@#X *P _P"K /\ K #_ *P _P"K /\ _P0  /\
M  #V    [@   .<   #?  P U@ 5 ,\ (@#* "X QP Z ,, 1 #  $T O !5
M +D 7 "W &, M0!I +, ;P"Q '4 KP![ *T @@"K (H J0"2 *< G "E *8
MHP"S *$ PP"? -X G@#R )T _P"< /\ G #_ )L _P"; /\ _P<  /8)  #I
M"P  WPH  -4$  #.  4 Q@ 0 ,  &@"[ "< MP R +, /0"P $8 K0!/ *H
M5@"H %P I@!C *0 : "B &\ H0!U )\ ? "= (0 FP"- )D EP"7 *( E0"N
M ), O0"1 -, D #M (\ _ ". /\ C0'_ (T!_P"- ?\ ^0X  .H2  #<%0
MS14  ,01  "^#   N@(* +0 $@"N !X J@ J *8 -0"B #\ H !( )T!4 ";
M E8 F0)< )<#8P"5 VD DP-O )$$=@"0!'\ C@6( (P%D@"*!IX B :J (8'
MN@"%",\ A KK ((+_ "!#/\ @ S_ ( ,_P" #/\ \14  . =  #-(   P2$
M +@=  "Q%P  K!   *@)#0"B!Q8 G0DC )D*+@"5"S@ DPQ! ) ,20".#5
MC U7 (H-70"(#6, APUJ (4.<0"##GH @@Z$ ( .CP!^#YL ? ^H 'L0N !Z
M$,X >!'L '82_P!U$O\ =!/_ '03_P!T$_\ Z!X  -,F  ##*@  N"H  *XH
M  "G(P  H!P  )L3 P"6#Q  D! ; (P1)P")$C( AA,[ (030P""%$L @!11
M 'X45P!\%%X >Q5E 'D5; !W%70 =A9^ '06B@!R%Y8 <1>D &\8M !N&,D
M;1GH &L:_ !J&_\ :AO_ &H;_P!J&_\ X"8  ,HM  "\,0  L#,  *<Q  "?
M+   ER8  ) ?  "*%PP A1@6 ($9(@!^&BP >QLV 'D;/@!W'$4 =1Q, ',<
M4P!Q'5D <!U@ &X=9P!M'G  :QYZ &H>A0!H'Y( 9Q^@ &4@L !D(<4 8R'D
M &(B^@!A(O\ 82+_ &$B_P!A(O\ URP  ,,T  "V.   JCD  *$X  "8-0
MD"\  (@H  " (0@ >R 2 '<A'0!T(B< <2(Q &\C.0!M(T$ :R-( &DC3@!H
M)%4 9B1; &4D8P!C)6L 8B5U &$E@0!?)HX 7B:= %TGK0!;*,$ 6RC@ %HI
M]P!9*?\ 62G_ %DI_P!9*/\ SS(  +XY  "Q/0  IC\  )P_  "3/   BC8
M ($P  !Y*@, <B8/ &XG&0!K*", :2@L &8I-0!E*3P 8RE# &$J2@!@*E$
M7BI7 %TJ7P!<*V@ 6BMR %DL?0!8+(L 5BV: %4MJ@!4+KT 4R[< %(O]0!2
M+_\ 4B[_ %(N_P!2+O\ RC8  +H]  "M0@  HD0  )A$  "/00  A3P  'LW
M  !R,0  :RP, &<M%0!D+1\ 82XH %\N,0!=+CD 7"]  %HO1@!8+TT 5R]4
M %8P7 !5,&0 4S%N %(Q>@!1,8@ 4#*7 $XRJ !-,[L 3338 $PT\P!,-/\
M3#3_ $PS_P!,,_\ QCH  +9"  "I1@  GDD  )5)  "+1P  @4(  '<]  !M
M-P  9#() & R$@!=,AP 6C(E %@S+0!6,S4 53,\ %,T0P!2-$H 4311 % T
M60!/-6$ 335L $PV=P!+-H4 2C>5 $@WI@!'.+@!1SC3 48X\0%&./\!1CC_
M $8X_P!&-_\ P3X  +)%  "F2@  G$T  ))-  "(2P  ?D<  '-"  !I/0
M7S<& %HV$ !7-Q@ 5#<B %(W*@!0-S( 3S@Y $TX0 !,.$< 2SA. $HY5@!)
M.5\ 2#II $<Z=0!%.X, 1#N3 $,\I %"/+8!03W0 4$]\ %!/?\!03S_ 4$\
M_P%!//\ OD(  *])  "C3@  F5   (]1  "%4   >TP  &]&  !E0@  6CT"
M %0[#@!1.Q4 3SL? $T[)P!+.R\ 23PV $<\/0!'/$0 1CU+ $4]5 !$/EP
M0SYG $(_<P! /X$ /S^1 #Y H@ ]0+4!/$'. 3Q![@$\0?\!/$#_ 3Q _P$]
M/_\!ND4  *Q,  "A40  EU0  (U5  "#5   >%$  &Q+  !A1P  5D(  $]
M# !,/Q, 24 < $= ) !&0"P 1$ S $- .@!"04( 04%) $!"40 _0EH /D-E
M #U#<0 [0W\ .D2/ #E$H  X1;,!-T7+ 3=%[ $W1?\!-T3_ 3A$_P$X0_\
MMTD  *E0  ">50  E%@  (M9  " 6   =E8  &A0  !=3   4T@  $I%"0!&
M1!$ 1$09 $)$(@!!12D /T4Q #Y%.  ]13\ /$9' #M&3P Z1U@ .4=B #A(
M;@ V2'P -4B- #1)G@ S2;$ ,DG) #%)ZP R2?X ,DC_ #)(_P S2/\ M$P
M *=4  "<60  DEP  (A=  !^70  <UH  &55  !;4@  4$X  $9*!0! 20X
M/DD6 #U)'@ [2B8 .DHN #E*-0 X2ST -TM$ #9+30 T3%8 ,TQ@ #),;  Q
M37H ,$V+ "Y-G  M3J\ +$[' "Q.Z0 L3?T +4W_ "U,_P M3/\ L%   *18
M  "970  CV$  (9B  ![80  <%\  &);  !86   3E4  $-1 0 [3PP .$\3
M #9/&P U3R, -% K #-0,@ R4#H ,5!" #!12@ N45, +5)= "Q2:0 K4G@
M*5*( "A3F@ G4ZT )E/% "93YP F4_P )U+_ "=1_P G4?\ K%4  *!<  "6
M8@  C68  (-G  !X9@  ;64  &!A  !57@  2EL  #]8   U5@@ ,540 #!6
M%P N5A\ +58G "Q6+P K5S8 *E<^ "E71P H5U  )EA: "589P D6'4 (UF&
M "%9F  @6:L 'UG" !]9Y0 ?6/H (%C_ "!7_P A5_\ J%H  )UB  "39P
MBFL  ']L  !U;   :FL  %UH  !190  1F,  #M@   Q7@, *ET- "A=$P F
M71L )5XC "1>*@ C7C( (EXZ "%>0P @7TP 'U]7 !Y?8P <8'$ &V"" !E@
ME0 88*D %V#  !9@X@ 77_D &%[_ !E>_P 97?\ I&   )EH  "0;@  AG
M 'QR  !R<@  9G$  %AN  !,;   06L  #9I   M9P  (V8( !]F#P =9A4
M'&8= !MF)0 :9BT &6<U !AG/@ 79T@ %F=3 !5H7P 3:&X $FA_ !%HD@ 0
M:*8 #VB]  YHX  09_< $&;_ !%E_P 19?\ GV<  )9O  ",<P  @G8  'AX
M  !M>   8'<  %-V  !&=   .W,  #%R   G<0  'G$  !9P"@ 3<!  $W 7
M !)P'P 1<2< $'$O !!Q.  .<4( #G%.  UQ6P ,<6D "W%Z  IQC0 (<:$
M!G&V  9PT@ '<.\ "&__  EN_P );O\ FV\  )%U  "'>0  ?GP  '1^  !F
M?@  67X  $U^  ! ?0  -7T  "I\   A?   &'P  !%\!  ,? P "GP1  E\
M&0 (?"$ !WPI  9\,@ $?#T  WQ(  %\50  ?&,  'QT  !\AP  >YP  'NQ
M  !ZRP  >>L  'GZ  !Y_P  >/\ EG<  (Q\  "#@   >8,  &R$  !>A0
M488  $6'   YAP  +8<  ".'   :AP  $H<   V( 0 &B0H  8D/  ")%
MB!L  (@C  ")+   B38  (E"  "(3@  B%T  (AM  "(@0  AY4  (>K  "&
MQ   A>8  (3X  "$_P  A/\ D'X  (>#  !^AP  <8D  &.+  !6C0  28\
M #R1   PD0  ))$  !J2   2DP  #90   :5    E@8  )8,  "5$   EA4
M )8=  "6)   EBX  )8Y  "61@  EE4  )9E  "6>   E8X  )6D  "4O
MD]\  )/U  "2_P  DO\ BX8  (.*  !UC0  9Y   %F4  !,EP  /YD  #*:
M   FFP  &YP  !*=   ,GP  !*    "B    HP$  *,'  "C#   HQ   *05
M  "D'   I24  *8O  "F/   IDL  *9;  "F;@  I80  *6;  "DLP  H]
M */O  "B_   HO\ AHT  'B1  !JE0  7)D  $Z=  !!H   ,Z(  ":C   ;
MI0  $:<   JI   !JP   *T   "O    L    +    "P!0  L0L  +(/  "S
M%   M!L  +4D  "W,   MS\  +=0  "W8@  MW@  +>0  "VJ0  ML(  +;D
M  "V]0  M?X >Y,  &V8  !?G0  4*(  $*F   TJ0  )JL  !JM   0KP
M";(   "T    MP   +H   "\    O0   +X   "^    P (  ,$(  #"#0
MQ!(  ,89  #))   RC(  ,M#  #+50  S&H  ,R#  #,G   R[4  ,S.  #,
MZ0  S/8 <)L  &&A  !2I@  1*L  #:P   GL@  &K4  !"X   'NP   +X
M  #!    Q    ,@   #+    RP   ,T   #.    T    -(   #5 P  V H
M -L0  #>&   XB0  .,U  #D2   Y5P  .9S  #FC0  YJ4  .:\  #FTP
MY^< 8Z0  %6J  !&L   .+4  "BY   :O   #\    7$    QP   ,L   #/
M    U    -@   #<    W0   -\   #A    XP   .4   #H    Z@   .T&
M  #Q#@  ]18  /@E  #Y.   ^4T  /IC  #[?   _)4  /RJ  #\NP  _<L
M_P / /\ #@#_  X _P 0 /\ %@#_ ", _P P /\ /0#_ $D _P!4 /\ 7@#_
M &8 _P!N /\ =@#_ 'P _P"" /\ B0#_ (\ _P"5 /X FP#] *, ^P"K /H
MM0#Y ,, ]P#; /8 \ #T /\ \P#_ /( _P#L /\ X@#_ -P _P#6 /\ _P ,
M /\ "0#_  @ _P * /\ $@#_ !X _P K /\ . #_ $0 _P!/ /\ 60#^ &$
M_ !I /H < #X '< ]P!] /8 @P#T (D \@"/ /$ E@#O )T [0"E .P KP#J
M +P Z #- .8 Z #D /H XP#_ .( _P#@ /\ U0#_ ,X _P#+ /\ _P & /\
M 0#_    _P $ /\ #@#_ !D _P E /T ,@#[ #X ]P!) /, 4P#P %P [@!C
M .P :@#J '$ Z !W .8 ?0#D (, X@") .  D #> )< W "? -D J0#6 +0
MTP#$ -  W@#. /, S #_ ,L _P#* /\ R #_ ,( _P"^ /\ _P   /\   #_
M    _P   /L "P#V !, \0 @ .T + #J #@ YP!# ., 30#@ %8 W != -D
M9 #5 &L T@!Q -  =@#. 'P S "# ,H B0#( )$ Q@"9 ,0 HP#! *T OP"[
M +T SP"[ .L N0#\ +< _P"W /\ M@#_ +0 _P"Q /\ _P   /\   #_
M]@   .X !0#G  \ X0 9 -L )0#5 #$ T@ \ ,X 1@#* $\ QP!7 ,0 7@#!
M &0 OP!J +T < "[ '8 N0!\ +@ @P"V (H LP"3 +$ G "O *< K0"S *L
MQ0"I .$ IP#U *8 _P"E /\ I #_ *0 _P"D /\ _P   /P   #Q    Z
M .    #4  L S  3 ,< 'P#" "H OP U +P /P"X $@ M0!0 +, 5P"P %X
MK@!D *P :0"K &\ J0!U *< ? "E (0 HP", *$ E@"? *$ G0"M )H O "8
M -( EP#N )4 _@"4 /\ E0#_ )4 _P"5 /\ _ $  / %  #C!P  U04  ,P
M  #%  0 O@ . +@ %P"S ", KP N *L . "I $$ I@!* *, 40"A %< GP!=
M )T 8P"; &D F@!O )@ =@"6 'T E "& )( D "0 )L C@"G (P M@"* ,D
MB #G (< ^0"' /\ A@#_ (8 _P"& /\ ] P  .00  #1$@  Q1$  +T.  "V
M"   L0 ( *L $0"F !L H0 F )X ,0": #H F !# )4 2@"3 %$ D0!7 (\
M70". &, C !I (H < "( '< A@"  (0 BP"" )8 @ "C 'X L0!] ,0 >P+A
M 'H#]0!Z!?\ >07_ '@&_P!X!O\ ZA,  -8:  #&'0  NAP  +$9  "J$P
MI T  )\%# "9 !0 E0 ? )$"*0"- S, BP0\ (@%1 "&!DL A 91 (('5P"!
M!UT ?P=C 'T(:@!["'( >@A\ '@)A@!V"9( = J@ ',*KP!Q"\$ < S? &\-
M]@!N#O\ ;0[_ &T._P!M#O\ X1P  ,LC  "\)@  L28  *@D  "@'@  F1@
M ),0 @"."PX B L7 (0,(@"!#2P ?@TU 'P./0!Z#D4 > Y+ '<.40!U#U@
M<P]> '$090!P$&X ;A!W &P0@@!K$(\ :1&= &@1K0!F$L  91+? &03]@!C
M%/\ 8Q3_ &(4_P!B%/\ UB0  ,,J  "U+@  JB\  * M  "8*   D"(  (D;
M  ""$P@ ?1$2 'D2' !V$R< <Q0P '$4. !O%3\ ;15& &P53 !J%E, :!99
M &<680!E%FD 9!=R &(7?@!A&(L 7QB9 %X9J0!<&;P 7!K8 %H;\P!:'/\
M61S_ %D<_P!9'/\ S2H  +TQ  "O-0  I#8  )LT  "2,0  B2L  ($E  !Y
M'0, <Q@. &\9& !L&B( :1LK &<;,P!E'#L 9!Q! &(=2 !@'4X 7QU5 %T=
M7 !<'F0 6QYN %D?>0!8'X< 5B"6 %4@I@!4(;@ 4R'2 %(B\0!2(_\ 4B/_
M %(B_P!2(O\ R"\  +@V  "K.@  H#P  )8[  "-.   @S(  'HM  !R)@
M:B , &8@$P!C(1T 82$F %\B+P!=(C8 6R(] %HC1 !8(TH 5R-1 %4C6 !4
M)&$ 4R1J %$E=@!0)8, 3R:3 $XGHP!,)[4 3"C. $LH[@!+*?\ 2RC_ $LH
M_P!+*/\ PS0  +,[  "G/P  G$$  ))   ")/@  ?SD  '4S  !L+0  8R<(
M %XF$0!<)AD 62<B %<G*P!5*#( 5"@Y %(H0 !1*$8 4"E- $XI50!-*5T
M3"IG $LJ<P!)*X  2"N0 $<LH0!&+;, 12W+ $4N[ !$+O\ 1"[_ $4M_P!%
M+?\ OC@  + _  "D0P  F44  (]%  "%0P  >SX  '$Y  !G-   7BX$ %@K
M#@!5*Q8 4BP? % L)P!/+"\ 32TV $PM/ !*+4, 22U* $@N4@!'+EH 1B]D
M $4O< !#,'X 0C"- $$QG@! ,K$ /S+( #\SZ@ _,_X /S+_ #\R_P _,O\
MNSP  *U#  "A1P  EDD  (Q)  "#2   >$0  &T^  !C.0  6C0  %(P# !/
M,!, 3# < $HP) !),2L 1S$R $8Q.0!$,4  0S)' $(R3P!!,U@ 0#-B #\T
M;0 ^-'L /36+ #PVG  [-J\ .C?& #DWZ  Y-_P .C?_ #HV_P Z-O\ MT
M *I&  ">2P  E$T  (I.  " 3   =4@  &I#  !@/@  5CD  $TU"0!)-!$
M1S49 $4U(0!#-2@ 034O $ U-@ _-CT /C9% #TW30 \-U4 .SA@ #HX:P Y
M.7D .#F) #<ZFP U.JT -3O$ #0[Y@ T._L -3O_ #4Z_P U.O\ M$,  *=*
M  "<3@  DE$  (A2  !^4   <TT  &=(  !<1   4C\  $@Z!@!$.0\ 03D6
M #\Y'@ ^.28 /#DM #LZ-  Z.CL .3M" #@[2@ W/%, -CQ= #4]:0 T/7<
M,SZ' #$^F0 P/ZL +S_" "\_Y  O/_H ,#__ # ^_P P/O\ L4<  *1-  "9
M4@  CU4  (96  !\50  <5(  &1,  !920  3T4  $5  P _/@T /#X3 #H^
M&P Y/B, -SXJ #8_,0 U/S@ -#]  #- 2  R0%$ ,4%; #!!9P N0G4 +4*%
M "Q#EP K0ZH *D/  "E$X@ J0_D *D/_ "M"_P K0O\ KDH  *%1  "75@
MC5D  (-:  !Y6@  ;E<  &%2  !73@  34L  $-'   Z0PH -D,1 #1#&  S
M0R  ,D0G #%$+P P1#8 +T4] "U%1@ L14\ *T99 "I&9  I1W( *$># "9'
ME0 E2*@ )$B^ "-(X  D2/< )4?_ "5'_P F1_\ JD\  )]5  "46@  BUX
M (%?  !W7@  :UP  %]8  !550  2U$  $!-   U2@< ,$D. "Y)%0 M21T
M+$DD "M**P J2C, *$H[ "=+0P F2TP )4M6 "1,8@ C3'  (4R  "!-DP ?
M3:8 'DV[ !U.W0 >3?8 'DS_ !],_P @2_\ IU,  )Q:  "27P  B&,  'YD
M  !T8P  :6$  %Q>  !26P  1U@  #Q5   R4@( *E , "=/$@ F4!D )5 @
M "10*  C4"\ (E$W "%10  @44D 'E)3 !U27P <4FT &E-] !E3D  84Z0
M%E.Y !53V0 64_0 %U+_ !A1_P 94?\ HUD  )A@  "/90  A6@  'MI  !Q
M:0  9F<  %ED  !-80  0E\  #A<   N6@  )5@( "!7#@ >5Q0 '5<< !Q8
M(P ;6"L &E@S !E8/  86$4 %EE0 !596P 466D $UIZ !):C0 16J$ $%JW
M  Y:U0 06?, $%G_ !%8_P 16/\ GU\  )5F  ",:P  @FT  'AN  !N;P
M8FT  %5J  !(:   /F8  #-E   I8P  (&$! !A@"P 58!  %& 7 !-@'@ 2
M8"8 $F N !%A-P 084  #V%+  YA6  -868 #&)V  MBB0 *89T "6&R  AA
MRP (8>L "6#]  I?_P +7_\ FV8  ))M  "(<0  ?G,  '5U  !J=   7',
M $]R  !#<   .&\  "UN   D;   &VL  !-K!  .:@P #6H2  QJ&0 +:B$
M"FHI  EJ,@ (:CP !VM'  5K4P $:V$  FMQ  !JA   :I@  &JM  !IQ@
M:><  &GX  !H_P  :/\ EVT  (US  "$=P  >WH  '![  !C>P  5GH  $EZ
M   ]>0  ,7@  "=W   ==@  %78   ]V @ )=@H !'8/  !V%0  =AP  '8D
M  !U+   =38  '5!  !U3@  =5P  '5L  !U?@  =),  '2H  !SP   <^,
M '+W  !R_P  <?\ DG4  (EZ  " ?@  =H   &F!  !;@@  3H(  $&"   U
M@P  *8(  !^!   6@0  $((   J"   "@P<  ((-  ""$0  @A<  ((>  ""
M)@  @B\  (([  ""1P  @E4  (%E  "!>   @8T  ("B  !_N@  ?]T  '[T
M  !]_P  ??\ C7P  (2!  ![A   ;H8  &"(  !2B@  18L  #F,   LC
M(8P  !>,   0C0  "8X   */    D ,  (\)  "/#@  CQ(  ) 8  "0'P
MD"@  ) R  "0/P  D$T  )!=  "/<   CX4  (Z<  ".LP  C=   (SP  "+
M_@  B_\ B(0  ("(  !RBP  9(T  %:0  !(DP  .Y4  "Z6   BE@  %Y<
M  ^8   (F0   )L   "=    G0   )T#  "="0  G0T  )X1  ">%P  GQ\
M )\I  "@-0  H$,  *!4  "@9@  GWL  )Z3  ">JP  G<8  )WI  "<^0
MG/\ @XL  '6.  !GD@  698  $N9   ]G   ,)X  ".?   7H   #J(   >D
M    I@   *@   "J    J@   *H   "K 0  JP<  *P,  "M$   KA8  *\>
M  "Q*0  L3@  +%(  "Q6@  L6\  +&(  "QH   L+H  *_=  "O\@  K_T
M>)$  &J6  !<F@  39\  #^C   QI@  (Z<  !>I   .JP  !:X   "P
ML@   +4   "W    MP   +@   "Y    N@   +P#  "]"0  O@X  , 4  ##
M'@  Q2L  ,4\  #&3@  QF(  ,9Z  #&E   QJT  ,;(  #%Y0  Q?, ;)D
M %Z>  !/I   0:@  #*L   DKP  %K$   VT   #MP   +H   "]    P
M ,0   #&    Q@   ,@   #)    RP   ,P   #.    T 8  -,-  #8$P
MW!X  -XM  #?0   X%0  .%K  #AA0  X9\  .&W  #ASP  X>8 8*$  %*G
M  !#K0  -+(  "6U   7N0  #;P   &_    PP   ,<   #*    SP   -,
M  #6    UP   -H   #<    WP   .$   #C    Y@   .D!  #L"P  \!(
M /,?  #T,0  ]D8  /=<  #X=   ^(\  /FF  #YN   ^,D _P - /\ "P#_
M  L _P . /\ $P#_ !\ _P L /\ .0#_ $4 _P!0 /\ 60#_ &( _P!J /\
M<0#_ '< _P!^ /\ A #^ (H _0"0 /P EP#Z )X ^0"G /< L0#V +X ]0#2
M /, [ #Q /X \ #_ /  _P#F /\ W #_ -( _P#- /\ _P ' /\ ! #_  (
M_P & /\ $ #_ !L _P G /\ ,P#_ #\ _P!* /X 5 #[ %T ^0!D /< :P#U
M '( \P!X /( ?@#P (0 [P"* .T D0#L )D Z@"A .@ JP#F +8 Y #' .(
MXP#@ /< W@#_ -T _P#9 /\ S #_ ,4 _P#! /\ _P   /\   #_    _P !
M /\ #0#_ !8 _  B /D +@#V #D \P!% .\ 3@#L %< Z0!> .8 90#D &P
MX@!R .  =P#? 'X W0"$ -L BP#8 )( U0"; -( I #/ *\ S0"^ ,L U0#)
M .\ QP#_ ,4 _P#$ /\ O@#_ +@ _P"U /\ _P   /\   #_    _@   /<
M"0#Q !$ ZP < .< * #D #, X0 ^ -T 2 #8 %$ TP!8 -  7P#. &4 S !K
M ,H <0#( '< Q@!] ,0 A #" (P P "4 +X G@"[ *@ N0"V +< R "U .8
MLP#Z +$ _P"P /\ L #_ *P _P"I /\ _P   /\   #Z    \0   .@  P#@
M  T V  6 -$ (@#- "T R@ W ,8 00#" $H OP!2 +T 60"Z %\ N !E +<
M:@"U '  LP!V +$ ?0"O (4 K0"- *L EP"I *$ IP"N *4 O@"B -@ H #R
M )\ _P"> /\ G@#_ )X _P"< /\ _P   /<   #K    X0   -8   #+  D
MQ0 1 +\ &P"[ "8 MP Q +0 .@"Q $, K@!+ *L 4@"I %@ IP!> *8 9 "D
M &D H@!P *  =@"> 'X G "& )H D "8 )L E@"G )0 M@"2 ,H D #I (\
M_ ". /\ C0#_ (P _P"- /\ ^    .D"  #; P  S $  ,0   "]  ( M@ -
M +  %0"K "  IP J *0 - "A #P G@!$ )P 2P": %( F !8 )8 70"5 &,
MDP!I )$ < "/ '< C0"  (L B@") )4 AP"A (4 KP"# ,$ @0#@ (  ]0!_
M /\ ?P#_ '\ _P!_ /\ [@H  -P.  #*$   O@X  +4+  "O P  J0 ' *,
M$ "> !@ F0 C )8 + "3 #4 D  ^ (X 10", $L B@!1 (@ 5P"& %T A0!C
M (, :@"! '$ ?P!Z 'T A ![ (\ >0"< '< J@!U +L = #4 '( \ !R /\
M<@#_ '$ _P!Q /\ XQ$  ,T7  "_&0  LQD  *H5  "C$   G0H  )<!"@"1
M !( C0 ; (D )0"% "\ @P W (  /@!^ $4 ?0!+ 'L 40!Y %< > != '8
M9 !T 6L <@%T ' "?P!N HL ; .8 &L#I@!I!+< : 7. &<'[ !F"/T 9@G_
M &4)_P!E"?\ UAH  ,0@  "V(P  JR,  *$@  "9&P  DA0  (P. 0"&!PT
M@ 04 'P&'@!Y!R@ =@@P '0(. !R"3\ < E% &\*3 !M"E( ; I8 &H+7P!H
M"V< 9PMP &4,>@!C#(< 8@R5 & -I !?#;8 7@W. %P.[0!<#_\ 6Q#_ %L0
M_P!;$/\ S2$  +PH  "O*P  I"L  )HI  "2)   B1\  ((8  ![$04 =0T/
M '$-%P!N#B$ :PXJ &D/,@!G$#D 91!  &001@!C$$T 81!3 %\16@!>$6(
M7!%K %L1=@!9$H, 6!*2 %83H@!5$[0 5!/+ %,4[ !2%?\ 4A;_ %(5_P!2
M%?\ QB@  +8N  "I,@  GS(  )4Q  ",+0  @R<  'HA  !R&@  :Q,+ &<3
M$P!D%!P 810E %\5+0!=%30 7!4[ %L60@!9%D@ 6!9/ %875@!5%UX 4Q=G
M %(8<@!0&'\ 3QF. $X:GP!,&K  2QO' $L;Z0!*'/T 2AS_ $H<_P!*'/\
MP2T  +$T  "E-P  FC@  ) W  "'-   ?2\  '0I  !L(P  9!P' %X9$ !;
M&A@ 61LA %<;*0!5&S  5!PW %(</0!1'$0 3QU+ $X=4@!-'5H 2QYC $H>
M;@!)'WP 1Q^+ $8@G !%(:X 1"'$ $,BY@!#(OP 0R+_ $,B_P!#(O\ O#(
M *TX  "A/   ESX  (T]  "#.@  >34  &\P  !F*@  7B0" %<@#0!4(!0
M42 = $\A)0!.(2P 3"$S $LB.@!)(D  2")' $<B3@!&(U< 1"-@ $,D:P!"
M)'D 026( #\FF0 ^)JL /2?! #TGXP ]*/H /2C_ #TG_P ])_\ N#8  *H]
M  ">0   E$(  (I"  " /P  =CL  &PV  !B,   62H  %$E"P!-)1$ 2R49
M $DE(0!')B@ 128O $0F-@!#)CT 0B=$ $$G2P _*%0 /BA= #TI:0 \*78
M.RJ& #DKEP X*ZD -RR_ #<LX  W+/@ -RS_ #<L_P X+/\ M3H  *=   "<
M1   D48  (=&  !]1   <T   &@[  !?-@  53$  $PK!P!'*0\ 12H6 $,J
M'@!!*B4 /RHL #XK,P ]*SD /"M! #LL2  Z+%$ .2U; #@N9@ V+G, -2^#
M #0OE0 S,*< ,C"] #$QW@ Q,?< ,C'_ #(P_P S,/\ L3X  *1$  "92
MCTH  (5*  ![20  <$4  &5   !;.P  4C8  $@Q! !"+@T /RX3 #TN&P [
M+B( .2\I #@O+P W+S8 -C ^ #4P1@ T,4\ ,S%9 #(R9  Q,G$ ,#.! "\T
MDP N-*8 +#6[ "PUVP L-?4 +37_ "TT_P N-/\ KD$  *)(  "73   C4X
M (-.  !Y30  ;DH  &)%  !80   3CP  $4W   ],PL .3,1 #<S&  V,Q\
M-#,F #,S+0 R-#0 ,30\ # U1  O-4P +C96 "TV8@ L-V\ *S=_ "HXD0 H
M.*0 )SFY "8YV  G.?0 *#G_ "@X_P I./\ JT4  )]+  "43P  BU(  (%3
M  !W4@  ;$\  %])  !61@  3$(  $(]   X. @ -#@/ #(X%0 Q.!T +S@D
M "XX*P M.3( +#DY "LZ00 J.DH *3M4 "@[7P G/&T )3Q] "0]CP C/:(
M(CVW "$^U  A/O, (CW_ ",]_P C//\ J$D  )U/  "24P  B58  ']7  !U
M5@  :E,  %U/  !33   2D@  $!$   V0 4 +ST- "T]$P K/1H *CXA "D^
M*  H/B\ )SXW "8_/P D/T@ (T!2 ") 70 A06H ($%Z !Y!C0 =0J  '$*U
M !M"T0 ;0O$ '$+_ !U!_P >0?\ I4T  )I3  "06   AEL  'U<  !R6P
M9U@  %M4  !14@  2$X  #U*   S1P  *D,+ "9#$  E0Q8 )$,> "-$)0 B
M1"P (40T "!%/  >144 '45/ !Q&6@ ;1F@ &49X !A'B@ 71YX %D>S !1(
MS@ 51^\ %D?_ !=&_P 71O\ HE(  )=8  "-70  A&   'IA  !P8   95X
M %E:  !/6   1%0  #E1   O3@  )DL& "!*#@ >2A, '4H: !Q*(0 ;2R@
M&DLP !E+.  72T( %DQ, !5,5P 43&4 $TUU !)-B  139P $$VQ  Y.S  /
M3>X $$W_ !%,_P 13/\ GE<  )1=  "+8@  @64  '=F  !M9@  8V0  %9A
M  !*7@  /UL  #58   K5@  (E0! !I2"@ 64A  %5(6 !12'0 34B0 $E(L
M !%2-  14CX $%-(  ]35  .4V( #51R  Q4A  +5)@ "52M  A4Q0 )5.<
M"E/[  M2_P +4O\ FUT  )%D  "(:   ?FL  '1L  !K;   7VH  %)G  !%
M9   .F(  #!@   F7@  '5T  !5;!0 06@P #EH1  Y:&  -6R  #%LG  M;
M,  *6SH "5M%  =;40 &6UX !%MM  -;@  !6Y0  %NH  !;P   6N(  %KV
M  %:_P "6?\ EV0  (YK  "$;@  >W   ')R  !G<0  67   $QN  ! ;
M-6L  "II   A9P  &&8  !%F 0 ,90H !V4/  1E%  #9!L  F0C  !D+
M9#4  &1   !D3   9%H  &1I  !D>P  9(\  &.D  !CNP  8MT  &+T  !B
M_P  8?\ DVP  (EQ  " =0  >'<  &UX  !@=P  4G8  $9U   Y=   +G0
M "-R   :<0  $G$   UQ   &<0@  ' -  !P$@  <!<  &\?  !O)@  ;S
M &\[  !O1P  ;U0  &]D  !O=0  ;HH  &V@  !MM@  ;-8  &OR  !K_P
M:_\ CG,  (5X  !]>P  <WT  &5^  !8?@  2WX  #Y^   R?@  )GT  !Q\
M   3?   #7P   9]    ?04  'P+  !\#P  ?!,  'P9  !\(0  ?"D  'PT
M  ![0   >TX  'M>  ![;P  >H0  'J:  !YL0  >,X  '?O  !V_@  =O\
MB7H  (%_  !X@@  :X,  %V%  !/A@  0H<  #6(   IAP  '8<  !2'   -
MB   !HD   "*    B@   (D&  ")#   B0\  (D3  ")&@  BB(  (HL  "*
M.   BD8  (E6  "):   B7P  (B4  "'JP  AL8  (7J  "%^P  A/\ A8(
M 'V&  !OB   88L  %.-  !%CP  .)$  "N1   ?D@  %)(   V3   $E
M )8   "7    F    )<   "7!0  EPL  )@.  "8$P  F1H  )DB  ":+@
MFCT  )E-  "97@  F7,  )B+  "8HP  E[P  );B  "6]P  E?\ @(D  '*,
M  !DCP  5I,  $B6   ZF0  +)H  !^;   4G   #)X   .?    H0   *,
M  "E    I0   *4   "E    I@(  *<(  "G#0  J!$  *D9  "K(P  JS$
M *M!  "L4P  K&<  *N   "JF@  JK,  *K0  "I[P  J?L =8\  &>4  !9
MF   2IP  #R?   MH@  (*,  !.E   +IP   :D   "K    K@   +$   "R
M    L@   +,   "T    M0   +8   "X!   N0L  +L0  "]&   OR0  +\U
M  # 1P  P%L  ,!R  # C0  P:8  ,#!  "_XP  OO, :I<  %N<  !-H0
M/J4  "^I   AJP  $ZT   NP    LP   +4   "X    O    +\   #!
MP0   ,,   #$    Q@   ,<   #)    RP   ,X(  #1#P  U1@  -@G  #9
M.0  VDT  -MD  #;?@  W)D  -RP  #<R0  W., 79\  $^E  ! J@  ,J\
M "*R   4M0  "K@   "[    OP   ,,   #&    RP   ,X   #1    T0
M -0   #6    V0   -L   #>    X    .0   #G!@  ZPX  .\9  #P*@
M\C\  /-5  #T;0  ](@  /2A  #TM@  ],< _P ) /\ !@#_  < _P , /\
M$0#_ !P _P H /\ - #_ $$ _P!, /\ 50#_ %T _P!E /\ ; #_ '( _@!X
M /P ?@#[ (0 ^@"+ /D D@#W )D ]@"B /0 K #S +D \0#+ /  Z #N /L
M[0#_ .P _P#A /\ T@#_ ,D _P#$ /\ _P ! /\   #_    _P $ /\ #@#_
M !< _P C /\ +P#_ #L _0!& /H 4 #W %@ ] !? /( 9@#P &P [P!R .T
M> #L 'X Z@"% .D C #G ), Y0"< ., I@#A +$ WP#! -T W0#; /0 V0#_
M -8 _P#/ /\ Q #_ +T _P"Y /\ _P   /\   #_    _P   /\ "P#\ !,
M]P > /0 *@#R #4 [@!  .D 2@#F %( XP!9 .  8 #> &8 W !L -H <@#7
M '@ U !^ -( A0#0 (T S@"5 ,P GP#) *H QP"X ,4 S0## .L P #^ +\
M_P"^ /\ M@#_ +  _P"M /\ _P   /\   #_    ^0   /( !@#K  \ Y@ 9
M .$ ) #> "\ V@ Y -, 0P#/ $P S !3 ,D 6@#' &  Q0!F ,, :P#! '$
MOP!W +T ?@"[ (8 N0". +< F "U *, LP"P +$ P@"N .  K #W *L _P"J
M /\ J #_ *, _P"@ /\ _P   /\   #U    ZP   .$   #6  P SP 3 ,H
M'@#& "D P@ S +\ /0"[ $4 N !- +8 5 "S %H L0!? +  90"N &H K !P
M *L =P"I '\ IP"' *4 D0"C )P H "I )X N "< ,X F@#N )D _P"7 /\
ME@#_ )8 _P"3 /\ _0   /$   #E    V0   ,T   #$  8 O0 / +< & "S
M "( L  L *T -@"I #X IP!& *0 30"B %, H !9 )\ 7@"= &0 FP!J )H
M< "8 '< E@"  )0 B@"1 )4 CP"B (T L "+ ,, B0#C (@ ^0"& /\ A@#_
M (8 _P"& /\ \P   .,   #1    Q0   +T   "V    K@ + *@ $@"D !P
MH  F )P +P": #< EP _ )4 1@"2 $P D0!2 (\ 6 "- %T BP!C (H :@"(
M '$ A@!Y (0 @P"" (\ ?P"; 'X J0!\ +L >@#5 '@ \@!X /\ =P#_ '<
M_P!W /\ YP<  -$,  ###0  N P  *X(  "H    H@ % )L #@"6 !4 D@ ?
M (X * "+ #$ B  Y (8 0 "$ $8 @@!, (  4@!_ %< ?0!= 'L 8P!Z &L
M> !S '8 ?0!T (@ <0"5 '  I !N +0 ; #* &L Z@!J /P :@#_ &H _P!J
M /\ VA   ,84  "X%@  K14  *02  "<#@  E@<  )  "0"* !  A0 8 ($
M(0!^ "H >P R 'D .0!W $  =0!& ', 3 !R %$ < !7 &X 7@!M &4 :P!N
M &D =P!G (, 90"1 &, GP!B *\ 8 #$ %\ Y !? ?@ 7@+_ %X"_P!> O\
MSA@  +T=  "P(   I1\  )L<  "3%P  BQ$  (0,  !^! L >0 2 '4 &P!R
M ", ;P K &T!,P!K 3H :0)  &<#1@!F TP 9 12 &,$60!A!&  7P5I %X%
M<P!<!G\ 6@:- %D'G !7"*T 5@C! %4)X0!4"_8 5 O_ %0+_P!4"_\ QA\
M +8E  "I*   GB@  )0E  "+(0  @QL  'L4  !T#@, ;@D- &D(% !F"1T
M9 HE &(*+0!@"S0 7@LZ %T+0 !;#$< 6@Q- %@,5 !7#5P 50UD %0-;P!2
M#7L 4 Z* $\.F@!.#JP 3 _" $P0XP!+$/D 2Q#_ $L1_P!+$/\ OR8  + K
M  "D+P  F2\  (\M  "&*0  ?20  '0>  !L%P  91$' %\.$ !<#Q< 6A ?
M %@0)P!6$"X 5! U %,0.P!2$4( 4!%( $\14 !.$5< 3!)@ $L2:P!)$G@
M2!.' $83EP!%%*D 1!2^ $,5WP!#%O@ 0Q;_ $,6_P!#%O\ NBL  *LQ  "@
M-   E34  (LT  "!,0  >"L  &\F  !F(   7AD! %<4#0!4%!, 410; $\5
M(P!.%2H 3!4Q $L6-P!)%CX 2!9$ $<73 !%%U0 1!== $,89P!!&'0 0!F#
M #\:E  ]&J8 /!N[ #L;VP ['/8 /!S_ #P<_P \'/\ M3   *@V  "<.0
MD3L  (<Z  !^-P  <S(  &HM  !A)P  62$  %$;"0!,&1  2AH7 $@:'P!&
M&B8 11LM $,;,P!"&SH 01Q! $ <2  ^'%  /1U9 #P>9  ['G$ .1^  #@?
MD@ W(*0 -B"X #4AU@ U(?0 -2+_ #4A_P V(?\ LC0  *0Z  "9/@  CS\
M (4_  ![/   <#@  &<R  !=+0  5"@  $PB!0!&'PX 0Q\4 $$?&P _'R(
M/B I #T@,  [(#8 .B$] #DA10 X(DT -R)7 #8C8@ T(VX ,R1^ #(DCP Q
M):( +R6V "\FT@ O)O( +R;_ # F_P P)O\ KS@  *(^  "60@  C$,  ()#
M  !X00  ;CT  &,X  !:,P  42X  $@H 0! ) P /2,1 #LD&  Y)!\ ."0F
M #8D+  U)3, -"4Z #,F0@ R)DH ,2=4 # G7P O*&P +BA[ "PIC0 K*J
M*BJT "DJSP I*_  *BO_ "HJ_P K*O\ K#P  )]"  "41@  BD<  (!'  !V
M10  ;$(  &$]  !7.   3C,  $0N   \*0D -R@0 #4H%0 S*!P ,B@C # H
M*0 O*3  +RHW "XJ/P M*T@ +"M2 "LL70 J+&H *"UY "<MBP F+IX )2ZS
M "0OS0 D+^X )2__ "4O_P F+O\ J3\  )U%  "220  B$L  'Y,  !T2@
M:D<  %Y"  !4/0  2SD  $$T   X+P8 ,BT- # M$P N+1D +2T@ "LM)P J
M+BX *2XU "DO/0 H+T8 )S!/ "4P6P D,6@ (S%W "(RB0 A,IT 'S.Q !XS
MRP >,^T 'S/_ " S_P A,O\ ID,  )I)  "030  AD\  'Q0  !S3P  :$P
M %Q&  !20P  23\  #\[   V-@( +C(, "LR$0 I,A< *#(> "8R)  E,RL
M)#,R ",T.@ B-$, (35- " U6  ?-F4 'C9U !PWAP ;-YL &C>O !DXR  9
M..L &CC_ !LW_P ;-_\ HT<  )A-  ".40  A%,  'M4  !Q4P  9E   %I,
M  !020  1T4  #U!   S/0  *CD) "4W#@ C-Q0 (C@; "$X(@ @."@ 'S@P
M !XY.  =.4$ '#I+ !HZ5@ 9.V, &#MR !8[A0 5/)D %#RM !,]Q@ 3/>D
M%#S] !4\_P 6._\ H$L  )51  "+50  @E@  'E9  !N6   9%8  %A1  !.
M3P  14L  #I'   P0P  )T % " ^#0 =/A$ '#X7 !L^'@ :/B4 &3XM !@_
M-0 6/SX %3]( !1 4P 30&  $D%P !%!@@ 009< #T&L  Y"Q  .0N< #T'\
M !!!_P 00/\ G5   )-6  ")6@  @%T  '9>  !L70  8EL  %97  !,50
M05$  #9.   L2P  (T@  !M%"0 71 \ %404 !1%&P 312( $D4I !%%,0 1
M13L $$9%  ]&4  .1UX #4=M  Q'?P +1Y, "4>G  A'O@ (1^  "4?V  I&
M_P +1O\ FE4  )!;  "'8   ?6(  '-C  !J8@  8&$  %->  !'6@  /%<
M #)5   H4@  'U   !=.!  13 P #TP1  Y,%P .3!X #4TE  Q-+@ +33<
M"DU"  E-30 '3EH !DYI  1.>P "3H\  4ZD  !-N@  3=L  4WR  %-_P "
M3/\ EEL  (UB  "$9@  >F@  '%I  !H:0  7&<  $]D  !"80  -U\  "U<
M   C6@  &E@  !)7 0 -5@D "54.  =5$P &51H !%4B  -5*@ "530  %4^
M  !52@  5E<  %9E  !5=P  58L  %6@  !5M@  5-0  %3Q  !3_0  4_\
MDV(  (IH  " ;   =VX  &]O  !C;@  5FP  $EJ   ]:   ,F8  "=E   =
M8P  %6(   YA   )8 @  V -  !?$0  7Q<  %\>  !?)@  7R\  %\Z  !?
M10  7U,  %]A  !><@  7H<  %V<  !=L@  7,\  %SO  !;_0  6_\ D&H
M (9O  !]<@  =70  &IU  !==   3W,  $)R   V<   *V\  "!N   7;0
M$&P   IL   ":P8  &L+  !J#P  :A0  &H:  !J(0  :2H  &DT  !I0
M:4X  &E<  !I;0  :((  &B8  !GK@  9LH  &7M  !E_   9/\ BW$  ()V
M  !Z>0  <'L  &)[  !5>P  2'H  #MZ   O>@  (WD  !EX   1=P  "G<
M  -W    =P(  '<(  !V#0  =A   '85  !V&P  =B,  '8N  !U.@  =4<
M '56  !U:   ='P  '22  !SJ@  <L0  ''I  !P^P  </\ AGD  ']]  !V
M?P  :($  %J"  !,@@  /X,  #*$   E@P  &H,  !&#   *@P   H,   "$
M    A0   (0#  "#"   @PT  (,0  "#%0  A!P  (0F  "$,@  A#\  (-/
M  "#8   @G4  (*,  "!I   @+T  '_C  !^^0  ?O\ @H   'J$  !LA@
M7H@  %"*  !"BP  -8T  ">-   ;C0  $8X   J.    CP   )$   "2
MD@   )(   "2 0  D@<  )(,  "2$   DQ4  ),=  "4*   E#8  )1%  "3
M5P  DVL  )."  "2G   D;8  )#8  "/\P  C_\ ?H<  '"*  !AC0  4Y
M $63   WE0  *98  !R7   1F   "9D   ";    G    )X   "@    H
M *    "@    H0   *$$  "B"0  HPX  *04  "E'0  IBH  *8Z  "F3
MI6   *5X  "ED@  I*P  *3)  "CZP  HOH <XX  &21  !6E0  1YD  #F<
M   JG@  ':   !&A   (HP   *4   "G    J0   *P   "N    K@   *X
M  "O    L    +$   "R    LP8  +4-  "W$P  N1X  +DN  "Z0   NE0
M +MJ  "ZA0  N:$  +F[  "ZW@  N?( 9Y4  %B9  !*G@  .Z(  "RF   =
MJ   $:H   >L    KP   +$   "T    N    +L   "\    O    +X   "_
M    P    ,(   #$    Q@   ,@#  #+"P  SQ(  -$@  #1,@  TD8  --=
M  #4=@  U)(  -6K  #5Q   U.( 6YT  $RB   ]IP  +ZP  !^O   1L0
M![4   "X    NP   +X   #"    QP   ,H   #,    S    ,X   #0
MT@   -4   #8    VP   -\   #B    Y@L  .L3  #L)   [3@  .Y.  #O
M9P  \((  /"<  #PL@  \<4 _P # /\  0#_  0 _P ) /\ #P#_ !@ _P D
M /\ , #_ #P _P!' /\ 40#_ %D _P!@ /T 9P#\ &T ^@!S /D >0#X '\
M]@"% /4 C #S )0 \@"= /  IP#N +, [ #$ .L X0#J /@ Z0#_ .< _P#9
M /\ RP#_ ,( _P"] /\ _P   /\   #_    _P   /\ # #_ !0 _P @ /\
M*P#^ #< ^@!" /8 2P#R %, \ !; .X 80#L &< Z@!M .@ <P#G 'D Y0!_
M ., A@#A (X WP"6 -T H #; *P V "[ -0 T0#3 /  T #_ ,X _P#( /\
MO0#_ +8 _P"R /\ _P   /\   #_    _P   /T " #W !  \P : .\ )@#M
M #$ Z  [ ., 10#@ $T W !5 -D 6P#6 &$ TP!G -$ ; #/ '( S0!X ,L
M?P#) (< QP"0 ,4 F@## *4 P "R +X Q0"\ .4 N@#[ +@ _P"W /\ L #_
M *D _P"E /\ _P   /\   #^    ]0   .P  P#E  T WP 5 -H ( #4 "H
MT  U ,L /@#( $< Q0!. ,( 50#  %L O@!A +P 9@"Z &P N !R +8 > "U
M (  LP"( +$ D@"N )X K "J *D NP"H -4 I@#S *0 _P"C /\ H0#_ )L
M_P"8 /\ _P   /L   #P    Y0   -@   #.  D QP 1 ,( &@"^ "0 NP N
M +< . "T $  L0!( *X 3@"L %0 J@!: *D 7P"G &4 I0!K *0 <0"B '@
MH "! )X BP"< )8 F0"C )< L@"6 ,< DP#H )( _@"1 /\ D #_ (T _P"+
M /\ ^0   .L   #=    SP   ,8   "\  0 M0 - +  %0"L !X J  H *4
M,0"B #D GP!! )T 2 "; $X F0!3 )< 60"6 %X E !D )( :@"0 '$ C@!Z
M (P @P"* (\ B "< (8 J@"$ +P @@#< ($ ]@"  /\ ?P#_ '\ _P!^ /\
M[    -H   #)    O@   +8   "N    IP ) *$ $ "< !@ F  B )4 *@"2
M #( D  Z (T 00"+ $< B0!- (< 4@"& %@ A != (( 9 "! &L ?P!S 'T
M?0![ (@ > "5 '8 HP!U +0 <P#, '$ [0!P /\ < #_ '  _P!P /\ WP4
M ,H*  "\"P  L0D  *@$  "A    FP # )0 # "/ !, B@ ; (< ) "$ "P
M@0 S '\ .@!] $$ >P!' 'D 3 !W %( =@!7 '0 70!R &0 < !M &\ =@!L
M (( :@"/ &D G0!G *X 90## &0 Y !C /H 8P#_ &( _P!C /\ T X  +\2
M  "R$P  IQ(  )T0  "5"P  CP,  (D !P""  X ?@ 5 'H '@!V "4 =  M
M '$ - !O #H ;@!  &P 1@!J $P :0!2 &< 6 !F %\ 9 !G &( <0!@ 'P
M7@") %P F !; *D 60"\ %@ W !8 /0 6 #_ %< _P!7 /\ QA8  +8:  "J
M'0  GQP  )49  "-%   A0\  'X)  !W 0H <@ 0 &X %P!J !\ :  G &4
M+@!D #0 8@ [ &  0 !? $8 70!, %P 4P!: %H 6 !B %< ; !5 '< 4P"%
M %( E !0 :4 3P&X $X"T@!-!/  307_ $T%_P!-!?\ OQT  + B  "C)0
MF24  (\B  "%'0  ?1@  '42  !N#0( 9P8, &,#$0!? AD 70,A %L$* !9
M!"\ 5P4U %8%.P!4!D$ 4P9' %$&3@!0!U4 3@=> $T(9P!+"', 20F! $@)
MD@!'"J, 10JV $0+T !$#.\ 0PW_ $,-_P!$#?\ N20  *HI  ">+   E"P
M (HJ  " )@  =R$  &X;  !F%   7P\% %D+#0!5"A, 4PL; %$+(@!/#"D
M30PO $P,-@!+#3P 20U" $@-20!&#5$ 10Y: $0.9 !"#G  0 Y_ #\/D  ^
M$*( /!"V #L0T0 [$?$ .Q'_ #L1_P \$?\ M"D  *8O  ":,@  D#(  (8Q
M  !\+0  <B@  &DC  !A'0  618  %$1" !,#Q  2A 6 $@0'0!&$"0 11 K
M $,1,0!"$3< 01$^ $ 110 ^$DT /1)6 #P280 Z$VT .1-\ #<4C0 V%)\
M-16S #05S0 S%NX -!;_ #06_P T%O\ KRX  *(T  "7-P  C#@  ((V  !X
M-   ;BX  &4J  !<)   5!X  $P8! !&% T 0A02 $ 4&0 _%"  /14G #P5
M+0 [%30 .18Z #@60@ W%DH -A=3 #477@ S&&H ,AEY # 9B@ O&IT +AJQ
M "T;R@ M&^P +1S_ "X;_P N&_\ K#(  )\X  "4.P  BCP  ( \  !V.0
M:S0  &(O  !9*@  4"4  $<?  ! &@H /!D0 #H9%@ X&1T -AHC #4:*0 T
M&C  ,QHW #(;/@ Q&T< +QQ0 "X=6P M'6< +!YV "H>B  I'YL *!^N "<@
MQP F(.H )R#^ "@@_P H(/\ J38  )T\  "2/P  AT$  'U   !T/@  :3H
M %\U  !6,   32L  $0E   [( < -AX. #,>$P R'AD ,!X@ "\>)@ N'RT
M+1\T "P@.P K($0 *B%. "DA6  G(F4 )B)T "4CA0 C(YD (B2M "$DQ0 A
M)>@ (B7] "(D_P C)/\ ICH  )H_  "/0P  A44  'M$  !R0P  9S\  %TZ
M  !3-@  2C$  $$L   X)@, ,2,, "XB$0 L(A8 *B(= "DB(P H(RH )R,Q
M "8D.0 E)4$ )"5+ ",F5@ B)F, (2=R !\G@P >*)< '2BK !LIPP ;*>8
M'"G[ !TI_P >*/\ HSX  )A#  "-1P  @TD  'I)  !P1P  9D0  %H_  !1
M.P  1S<  #XR   U+0  +"@) "@G#P G)Q0 )2<: "0G(0 C*"< (B@N "$I
M-@ @*3\ 'RI) !XJ5  =*V  &RMO !HL@0 9+)4 %RVI !8MP0 6+>0 %RWZ
M !@M_P 9+?\ H4$  )5'  "+2P  @DT  'A-  !N3   9$D  %A$  !/0
M1CT  #TX   S-   *B\& "0L#0 A+!( ("P8 !\M'@ >+24 '2TL !PN-  ;
M+CP &B]& !@O40 7,%X %C!M !4Q?P 3,9, $C&H !$ROP 1,N( $C+Y !,Q
M_P 3,?\ GD4  )-+  ")3P  @%$  '92  !M4   8DX  %9)  !-1@  1$,
M #L_   Q.@  )S8# !\R"P <,A  &S(5 !DR&P 8,B( %S,I !8S,0 5-#H
M%#1$ !,T3P 2-5P $35K ! V?0 /-I$ #C:F  TWO  --]T #3;V  XV_P /
M-O\ FTD  )%/  "'4P  ?E8  '56  !J50  8%,  %5/  !,3   0DD  #A%
M   N00  )#T  !PZ"  6. X %3@2 !0X&  3.1\ $CDF !$Y+@ 0.3< #SI!
M  XZ3  -.UD #3MH  L[>@ *.XT "3RB  <\N  '/-4 "#SP  D[_P *._\
MF$X  (Y4  "%6   ?%L  ');  !H6@  7E@  %-5  !)4@  /DX  #1+   J
M1P  (40  !A" P 20 L $#\0  X_%0 ./QP #4 C  Q *P +0#0 "D ^  E!
M2@ '058 !D%E  1!=@ #08H  4&?  !!M   0=   4'N  %!_  "0/\ E50
M (Q9  "#7@  >6   '!@  !F8   75X  %%;  !%5P  .E0  "]1   E3P
M'$P  !1*   .2 @ "T<.  A'$@ '1QD !D<@  5(*  #2#$  D@[  !(1P
M2%,  $AB  !(<P  2(8  $B;  !(L0  1\P  $?M  !'^P  1_\ DEH  (E@
M  " 8P  =V4  &YF  !E9@  660  $Q@  ! 70  -5L  "I9   @5P  %U4
M !!3   +4@< !5$-  %0$0  4!8  % =  !0)0  4"X  % X  !00P  4%
M %!>  !0;P  4(,  $^8  !/K@  3LD  $[K  !-^P  3?\ CV$  (9F  !]
M:0  =&P  &QM  !A:P  4VD  $9G   Z9   +V,  "1A   :7P  $EX   Q<
M   &7 8  %L+  !:#P  6A,  %H9  !9(0  62D  %DS  !9/P  64P  %E:
M  !9:P  6'X  %B4  !7JP  5\4  %;I  !5^P  5?\ C&@  ()M  !Z<
M<G(  &=R  !:<0  3'   #]N   S;0  *&L  !UJ   4:   #6<   =G
M9@,  &8)  !E#0  91$  &05  !D'   9"0  &0N  !D.@  8T<  &-5  !C
M9@  8WH  &*0  !AIP  8,$  %_F  !?^@  7O\ AV\  ']T  !X=P  ;G@
M &!X  !2=P  17<  #AV   K=@  ('0  !9S   .<P  !W(   !R    <@
M '$%  !Q"@  <0X  ' 1  !P%P  <!X  ' G  !P,P  ;T   &]0  !O8
M;G0  &Z+  !MH@  ;+P  &OB  !J^   :?\ @W<  'Q[  !S?0  97X  %=_
M  !)?P  /'\  "^    B?P  %WX   ]^   '?@   '\   !_    ?P   'X
M  !^!0  ?@H  'X-  !^$0  ?A<  'X@  !^*P  ?3D  'U(  !]60  ?&T
M 'R$  ![G   >K8  'G:  !X]0  =_\ @'\  '>"  !I@P  6X4  $V&   _
MB   ,HD  "2)   8B0  #XD   >*    BP   (P   "-    C0   (P   ",
M    C ,  (P(  "-#0  C1$  (T7  ".(@  CB\  (X_  "-4   C60  (Q[
M  ",E0  BZX  (K-  ")[P  B?\ >X4  &V(  !>B@  4(T  $*/   TD0
M)I(  !F3   .E   !I4   "6    F    )H   ";    FP   )L   ";
MFP   )P   "=!0  G0L  )X0  "?%P  H"0  * T  "@1@  H%D  )]P  "?
MB@  GJ4  )["  "=Z   G/D <(P  &&/  !3D@  1)8  #:9   GFP  &9P
M  ^=   %GP   *$   "C    I0   *@   "I    J0   *D   "J    JP
M *P   "M    K@$  + )  "R#P  LQ@  +0G  "T.0  M4T  +1D  "T?@
MLYH  +.T  "SU0  L_  9),  %67  !'FP  .)\  "FB   :I   #J8   2H
M    JP   *T   "P    M    +8   "X    N    +D   "Z    O    +T
M  "_    P    ,,   #%!P  R0\  ,H:  #++   S$   ,U6  #.;P  S8L
M ,RH  #,P@  S.( 6)L  $F@   ZI0  +*D  !RK   /K@  !+$   "T
MMP   +H   "^    PP   ,8   #(    R    ,H   #+    S0   ,\   #2
M    U0   -D   #=    X04  .8/  #G'@  Z#(  .E(  #J8   ZWL  .N7
M  #LK@  [,( _P   /\   #_    _P & /\ #0#_ !4 _P A /\ + #_ #@
M_P!# /\ 3 #^ %0 ^P!; /H 8@#X &@ ]@!N /4 = #T 'H \@"  /$ AP#O
M (\ [0"7 .L H0#I *T YP"] .4 V #D /, X@#_ .  _P#0 /\ Q #_ +P
M_P"V /\ _P   /\   #_    _P   /\ "0#_ !$ _P < /T )P#Y #( ]0 ]
M /$ 1@#M $\ ZP!6 .@ 7 #F &( Y !H ., ;@#A ', WP!Y -T @ #: (@
MV "1 -0 FP#2 *8 SP"T ,P R0#) .D R #_ ,< _P#! /\ MP#_ *\ _P"K
M /\ _P   /\   #_    _P   /@ !0#R  X [@ 7 .H (@#F "P X0 W -T
M0 #8 $D TP!0 -  5@#. %P S !B ,H 9P#( &T Q@!S ,0 >0#" ($ P "*
M +X E "\ )\ N0"L +8 O@"T -T LP#W +$ _P"P /\ J #_ *( _P"> /\
M_P   /\   #Y    [P   .8   #?  L U@ 2 -  ' #, "8 R  P ,0 .@#
M $( O0!* +L 4 "X %8 M@!; +4 80"S &8 L0!L +  <@"N 'H K "" *D
MC "G )@ I0"E *, M "@ ,L GP#N )T _P"< /\ F0#_ )0 _P"1 /\ _P
M /8   #J    W0   ,\   #'  8 P  / +L %P"W "  LP J +  ,P"M #L
MJ@!# *< 20"E $\ HP!5 *( 6@"@ %\ G@!E )T :P"; '( F0![ )< A0"4
M )  D@"= )  K ". +\ C #B (L ^@") /\ B0#_ (8 _P"# /\ ]    .0
M  #4    R    +\   "U  $ K@ + *D $@"E !L H0 C )X + "; #0 F  \
M )8 0P"4 $D D@!. )  4P". %D C0!> (L 9 ") &L AP!S (4 ?0"# (@
M@0"5 '\ I !] +4 >P#/ 'D \0!X /\ =P#_ '< _P!U /\ Y0   -$   ##
M    N    *\   "H    H  & )H #@"5 !4 D0 > (X )@"+ "T B  U (8
M/ "$ $( @@!' (  30!_ %( ?0!8 'L 7@!Y &4 > !M '8 =@!S ($ <0".
M &\ G0!M *X ; #$ &H YP!I /T : #_ &@ _P!I /\ U0,  ,,'  "V"
MJP8  *(   ";    E    (T "@"( !  @P 8 '\ ( !\ "< >@ N '< -0!U
M #L = !! '( 1P!P $P ;P!2 &T 6 !K %\ :0!F &< < !E 'L 8P"( &(
MEP!@ *< 7@"[ %T W !< /8 7 #_ %L _P!; /\ R0T  +D0  "L$0  H1
M )<-  "/"   B    (( !0![  T =P 2 ', &@!O "$ ;  H &H +P!H #4
M9P [ &4 00!C $8 8@!, &  4@!? %D 70!A %L :@!9 '4 5P"" %4 D0!4
M *( 4P"U %$ SP!0 .\ 4 #_ %  _P!0 /\ OQ0  + 8  "D&@  F1D  (\6
M  "'$0  ?PT  '<&  !Q  @ :P . &< % !D !L 80 B %X *0!= "\ 6P U
M %D .P!8 $$ 5@!& %4 30!3 %0 4@!< %  90!. '  3 !] $L C0!) )X
M2 "P $< QP!& .D 1@#[ $8 _P!% /\ N!L  *H@  ">(@  DR(  (D?  "
M&@  =Q4  &\0  !H"P  800* %T $ !9 !8 5@ = %0 (P!2 "H 4  P $\
M-0!. #L 3 !! $L 2 !) $\ 1P%7 $8!80!$ FP 0P)Y $$#B0!  YH /@2M
M #T$Q  \!>4 / ?X #P'_P \!_\ LB(  *4G  "9*0  CBD  (0G  ![(P
M<1X  &D8  !A$@  6@T# %,(# !/!1$ 3 47 $H&'@!(!B0 1P8J $4', !$
M!S8 0P@] $$(0P! "$L /@E3 #T)70 ["F@ .@IV #@+AP W"YD -0NL #0,
MP@ S#.0 ,PWY #,-_P T#?\ K2<  * L  "5+P  BR\  ( N  !W*@  ;24
M &0@  !<&@  5!0  $P/!@!&# T 0PP2 $$,&  _#!\ /@PE #P-*P [#3(
M.@TX #@-/P W#D< -@Y0 #0.6@ S#F8 ,0]T # /A0 N$)@ +1"K "P0PP K
M$>4 +!'Z "P1_P M$?\ JBP  )TQ  "2-   AS4  'TT  !T,0  :BL  & G
M  !8(0  3QL  $<6  ! $0D .Q / #D0%  W$!L -A A #00)P S$2T ,A$T
M #$1.P P$4, +A)- "T25P L$F, *A-Q "D3@@ G%)4 )A2I "45P  D%>,
M)1;Z "86_P F%?\ IC$  )HV  "/.0  A3H  'LY  !Q-@  9S$  %TM  !4
M*   3"(  $,=   [%P4 -10- #(3$0 Q%!< +Q0= "X4)  L%"H *Q4Q "H5
M.  I%D  *!9* "<75  F%V  )!AO ",8@  A&9, (!FG !\9O@ >&N  'QKX
M " :_P @&O\ HS0  )@Z  "-/0  @SX  'D]  !O.P  93<  %LR  !2+0
M22@  $ C   X'@$ ,!D* "P8#P J&!0 *1@: "<8(  F&2< )1DM "0:-0 C
M&CX (AM' "$;4@ @'%X 'QUL !T=?@ <'9$ &AZE !D>O  8']T &1_V !H?
M_P ;'O\ H3@  )4]  "+00  @4(  '="  !M0   8SP  %DW  !/,P  1BX
M #TI   U)   +2 ' "<=#0 E'1( (QT7 "$='0 A'20 (!XK !\>,@ >'SL
M'1]% !P@3P :(5P &2%J !@B>P 6(H\ %2*C !0CN@ 3(]H %"/U !4C_P 6
M(_\ GCP  )-!  ")1   ?T8  '5&  !L1   8D$  %<\  !-.   1#0  #PP
M   S*P  *B8# ",B"P @(1  'B$5 !PB&P ;(B$ &B(H !HC,  9(S@ &"1"
M !8E30 5)5D %"9H !,F>0 2)HT $2>B ! GN  .)]8 $"CT !$G_P 1)_\
MG$   )%%  "'2   ?4H  '1*  !J20  8$8  %5!  !,/@  0SH  #HV   Q
M,@  *"T  " I"0 ;)PX &2<2 !@G&  6)Q\ %2@E !0H+0 3*#8 $BE  !(I
M2P 1*E< $"IF  XK=P .*XL #2R?  PLM0 ++,\ #"SO  TL_P -*_\ F40
M (])  "%3   ?$X  '-/  !I3@  7DL  %-'  !*1   0D   #D]   O.
M)30  !TP!0 6+0P %"P0 !,M%0 2+1P $2TC ! M*@ /+C, #BX]  TO2  -
M+U4 ##!C  HP=  ),(@ "#&<  8QL0 &,<L !C'K  <P_  (,/\ ET@  (U-
M  "#40  >E,  '%4  !G4@  75   %),  !)2@  0$8  #5"   K/@  (CH
M !HW 0 2- D #S,.  XS$P -,QD #3,@  PT*  +-#$ "C4[  @U1@ '-5(
M!39@  0V<0 "-H0  #:9   VKP  -L@  #;H   V^0 !-?\ E$T  (I2  "!
M5@  >%@  &]9  !E6   6U4  %%2  !'3P  /$P  #%(   G1   'D$  !8_
M   0/ < "SH-  DZ$0 (.Q< !CL>  4[)@ $.RX  CLX  $\0P  /$\  #Q>
M   \;@  /($  #R7   \K   .\4  #OG   [^   ._\ D5(  (A8  !_7
M=ET  &U>  !C70  6EP  $Y8  !"5   -U$  "U.   C2P  &DD  !)&   -
M1 8 !T,,  -#$   0Q4  $,;  !#(P  0RL  $,U  !#0   0TT  $-;  !#
M:P  0WX  $.4  !"J@  0L,  $'F  !!^0  0?\ CE@  (9>  !]80  <V,
M &MD  !B8P  5V$  $E=   ]6@  ,E@  "=5   >4P  %5$   Y/   )304
M DT+  !,#@  3!,  $L8  !+'P  2R@  $LR  !+/0  2TD  $M7  !+9P
M2GL  $J0  !)IP  2<   $CD  !(^   1_\ BU\  (-D  !Z9P  <6D  &EJ
M  !>:0  4&8  $-D   W80  +%\  "%=   86P  $%D   I8   #5P,  %<)
M  !6#0  51   %45  !4&P  5",  %0M  !4.0  5$4  %13  !49   4W<
M %.-  !2I   4;T  %#B  !0^   3_\ B&<  ']K  !W;@  ;W   &5P  !7
M;@  2FP  #UK   P:0  )6@  !IF   19   "V,   1B    8@$  &$&  !@
M"P  8 X  %\2  !?%P  7QX  %XH  !>,P  7D   %Y/  !>7P  77(  %V(
M  !<H   6[D  %K?  !9]P  6/\ A&X  'QR  !U=0  :W8  %UU  !/=
M0G,  #5S   H<@  '7   !-O   ,;@  !&X   !N    ;@   &P"  !L!P
M:PL  &L.  !K$@  :AD  &HB  !J+0  :CH  &E)  !I6@  :6P  &B#  !G
MFP  9K4  &78  !D]0  9/\ @'4  'IY  !P>P  8GL  %1\  !&?   .7P
M "Q\   ?>P  %'H   UZ   $>@   'H   !Z    >@   'D   !Y 0  > 8
M '@+  !X#@  >!,  '@:  !X)0  >#(  '=!  !W4@  =V4  '9\  !UE0
M=*\  '/.  !R\0  <?\ ?GT  '6   !G@0  6((  $J#   \A   +H4  "&%
M   5A0  #84   .%    A@   (<   "(    B    (<   "'    AP   (<$
M  "'"0  APX  (@3  "('   B"D  (@X  "'2@  AUT  (9S  "&C0  A:<
M (3%  "#[   @OX >(0  &J&  !<B   38H  #^,   QC@  (X\  !:/   -
MD    I$   "2    DP   )4   "6    E@   )8   "6    E@   )<   "7
M    EP<  )@-  "9$P  FA\  )HM  ":/P  FE(  )IH  "9@P  F9\  )BZ
M  "7X@  EO@ ;8H  %^-  !0D   09,  #.6   DEP  %I@   V9   !FP
M )T   "?    H0   *0   "E    I    *4   "E    I@   *<   "H
MJ0   *H$  "L#   KA,  *XA  "N,P  KD<  *Y=  "N=@  KI,  *ZN  "M
MS0  K.\ 89$  %.5  !$F   -9P  ":?   7H0  #:,   "E    IP   *H
M  "L    L    +(   "T    LP   +0   "U    MP   +@   "Y    NP
M +T   "_ 0  PPL  ,45  #%)0  QCD  ,=/  #':   QH4  ,:B  #&O
MQMX 59D  $>=   XH@  *:8  !FH   -JP   *T   "Q    M    +<   "Z
M    OP   ,$   #$    PP   ,4   #&    R    ,H   #-    SP   -(
M  #6    VP   . ,  #A&   XRL  .1!  #E6@  YG0  .:1  #EK   Y<0
M_P   /\   #_    _P ! /\ "@#_ !( _P = /\ * #_ #0 _P ^ /T 2 #Z
M %  ]P!7 /4 70#T &, \@!I /  ;P#O '0 [0![ .L @0#I (D Z "2 .8
MG #D *@ X@"W -\ S0#< .X V0#_ -D _P#* /\ O@#_ +4 _P"P /\ _P
M /\   #_    _P   /\ !@#_  \ _  8 /@ (P#T "X \  X .L 0@#H $H
MY0!1 .( 6 #@ %T W@!C -P : #9 &X U@!T -0 >P#1 (( SP"+ ,T E0#*
M *$ R "O ,4 P0#" ., P #[ ,  _P"[ /\ L #_ *@ _P"D /\ _P   /\
M  #_    ^P   /,  0#M  P Z  3 ., '@#@ "@ V@ R -, / #/ $0 S !+
M ,D 40#& %< Q != ,( 8@#! &< OP!M +T = "[ 'L N0"$ +< C@"T )D
ML@"G *\ MP"M -  JP#R *H _P"I /\ H0#_ )L _P"7 /\ _P   /\   #T
M    Z0   .    #5  @ S@ 0 ,D & #% "( P0 K +P -0"Y #T M@!% +,
M2P"Q %$ KP!6 *X 6P"L &$ J@!F *D ;0"F '0 I !\ *( A@"@ )( G@"?
M )P K@"9 ,, EP#G )8 _P"5 /\ D@#_ (T _P"* /\ _    /    #C
MU    ,@   "_  , N0 - +, $P"O !P K  E *D +@"E #8 HP ^ *  1 ">
M $H G0!0 )L 50"9 %H EP!? )8 9@"4 &P D@!U )  ?@". (H BP"7 (D
MI@"' +@ A0#6 (0 ]@"" /\ @0#_ 'X _P!\ /\ [0   -T   #,    P0
M +@   "N    IP ) *( $ "> !< F@ ? )< )P"4 "\ D0 W (\ /0"- $,
MBP!) (D 3@"( %, A@!9 (0 7P"" &4 @ !M 'X =P!\ (( >@"/ '@ G@!U
M *\ <P#' '( [ !Q /\ < #_ '  _P!N /\ W0   ,D   "\    L0   *D
M  "A    F0 # ), # ". !( B@ 9 (< (0"$ "D @0 P '\ -P!] #T >P!"
M 'D 2 !X $T =@!2 '0 6 !R %\ <0!G &\ < !L 'L :@"( &@ EP!F *@
M90"\ &, X0!B /H 80#_ &$ _P!A /\ S0$  +P%  "O!0  I0(  )P   "4
M    C0   (8 " "!  X ?  4 '@ &P!U ", <@ I '  , !N #8 ;0 \ &L
M00!I $< : !, &8 4@!D %D 8P!@ &$ :0!? '0 70"! %L D !9 *$ 5P"T
M %8 T !5 /( 50#_ %0 _P!5 /\ P0P  +(.  "F#P  FPX  )(+  ")!0
M@@   'L  @!U  L <  0 &P %@!H !T 9@ C &, *@!A #  8  V %X .P!=
M $$ 6P!& %H 3 !8 %, 5@!; %0 9 !2 &X 40![ $\ B@!- )L 3 "N $L
MQ@!* .H 20#^ $D _P!) /\ N1(  *H6  ">%P  E!8  (H3  "!$   >0L
M '$#  !K  8 90 - &$ $0!= !@ 6@ > %@ ) !6 "H 5  P %, -@!1 #L
M4 !! $X 1P!- $X 2P!6 $D 7P!' &D 1@!V $0 A0!# )< 00"I $  OP _
M .( /P#X #X _P _ /\ LAD  *0>  "8'P  CA\  (0<  !Z&   <A(  &H.
M  !B"   7 $( %< #@!3 !, 4  9 $X 'P!, "4 2@ K $@ , !' #8 1@ \
M $0 0@!# $D 00!1 #\ 6@ ^ &4 / !R #H @0 Y ), . "E #8 N@ V -L
M-0#T #4 _P U /\ K"   )\D  "4)@  B28  '\D  !U(   ;!L  &05  !<
M$   5 P! $X&"@!* @\ 1P 4 $0 &@!" "  0  E #\ *P ^ 3$ / $W #L"
M/@ Y D4 . -- #8#5@ U!&$ ,P1N #$%?@ P!9  +P6C "T&N  L!M0 + ?P
M "P(_P L"/\ J"4  )LJ  "0+   ABT  'LK  !R)P  :"(  %\=  !7%P
M3Q(  $@.! !!"@L /@<0 #L&%0 Y!QL . <A #8()@ U""P ,P@R #().0 Q
M"4$ +PE) "X*4P L"EX *PML "D+?  H#(\ )@RB "4,MP D#-, (PWP "0-
M_P E#?\ I"H  )@O  "-,@  @S(  'DQ  !O+@  92D  %PD  !3'P  2QD
M $,3   \$ 8 -0T, #,,$0 Q#!8 +PP< "X-(@ M#2@ *PTN "H--0 I#3T
M)PY& "8.4  D#EP (P]J "(/>P @$(X 'Q"B !T0MP <$-0 '1'R !T1_P >
M$?\ H2\  )4S  "*-@  @#<  '8V  !M,P  8R\  %DJ  !0)0  2"   #\:
M   X%0  ,!$( "P0#@ J$!( *! 8 "<0'@ E$"0 )! J ",1,@ B$3H (1%#
M " 23@ >$EH '1-H !L3>  :$XL &!2@ !<4M0 6%-$ %A7Q !<5_P 8%/\
MGC,  ),W  "(.@  ?CL  '0[  !K.   830  %<O  !.*P  128  #TA   T
M'   +1<% "83#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4+P <%3< &Q5! !H6
M2P 9%E< %Q=E !87=@ 4&(D $QB> !(8LP 1&<X $1GO !(9_P 3&?\ G#8
M )$[  "&/@  ?#\  ',_  !I/0  7SD  %4U  !,,   0RP  #HG   R(@
M*AX! "(9"0 >%PX '!<2 !H7%P 9&!X &1@D !@9+  7&30 %AH^ !4:20 3
M&U4 $AMC !$<=  0'(< #QV<  X=L0 -'<L #1WL  X=_P /'?\ F3H  (\_
M  "$0@  >T0  '%#  !H0@  7CX  %,Z  !*-@  03(  #DM   Q*0  *"4
M " @!@ :'0P %QP0 !4<%0 4'1L %!TB !,=*0 2'C( $1\\ ! ?1@ 0(%,
M#B!A  TA<0 ,(84 "R*9  HBK@ )(L< "2+G  HB^P +(?\ ESX  (Q#  "#
M1@  >4@  '!(  !G1@  7$0  %(_  !).P  0#@  #@T   O,   )RP  !XG
M P 6(PH $B$. !$A$P 0(AD $"(@  \B)P .(R\ #20Y  PD1  +)5  "B5>
M  DF;P ')H( !B:6  0FK  #)L0 !";E  0F]P &)O\ E4(  (I'  "!2@
M>$P  &],  !E2P  6T@  %!$  !'00  /SX  #<[   M-@  )#$  !LM   3
M*@< #R@-  TG$0 -*!8 #"@=  LH)0 **2T "2DW  <J0@ &*DX !"M<  ,K
M;  !*W\  "N4   KJ0  *\$  "OC   K]@  *O\ DD8  (A+  !_3P  =E$
M &U1  !C4   6DT  $]*  !'1P  /D0  #-    I/   (#@  !<T   1,04
M#"\,  DN$  '+A4 !B\;  4O(P #+RL  C U   P/P  ,$P  #%9   Q:0
M,7P  #&1   QIP  ,+\  ##A   P]0  +_\ D$L  (90  !]5   =58  &M6
M  !B50  6%,  $Y0  !%30  .DD  "]%   E0@  '#X  !0[   ..04 "3<+
M  0V#P !-A,  #89   V(   -BD  #8R   W/0  -TD  #=7   W9P  -WD
M #>/   VI0  -KT  #;@   U]0  -?\ C5   (16  !\6@  <EL  &E;  !@
M6P  5UD  $Q6  ! 4@  -4X  "I+   @2   %T8  !!#   +000 !$ *   _
M#@  /A$  #X6   ^'0  /B8  #XO   ^.@  /D8  #Y4   ^9   /G8  #V,
M   ]HP  /+L  #S>   []0  ._\ BE<  ()<  !Y7P  <&$  &AA  !?80
M5%X  $=;   Z5P  +U4  "52   ;4   $DT   Q+   &2@,  $D)  !(#0
M1Q   $<4  !&&@  1B(  $8L  !&-P  1D,  $91  !&8   17,  $6)  !$
MH   1+@  $/<  !"]0  0O\ B%T  ']B  !W90  ;F<  &=H  !;9@  3F,
M $%A   T7@  *5P  !]:   55P  #E8   =4    4P$  %(&  !1"P  40X
M % 1  !/%@  3QX  $\G  !/,@  3S\  $]-  !.70  3F\  $Z%  !-G0
M3+4  $O8  !*]0  2O\ A64  'QI  !T;   ;6X  &)M  !4:P  1VD  #IG
M   M90  (F0  !AB   08   "5\   !>    7@   %T#  !<"   6PP  %H/
M  !:$P  61D  %DB  !9+0  63H  %E(  !86   6&L  %>!  !7F0  5K(
M %72  !4]   4_\ @6P  'EP  !S<P  :',  %IR  !,<0  /W   #)O   E
M;@  &FP  !%K   ):@   &H   !I    :0   &@   !G P  9@@  &8,  !F
M#P  910  &4<  !E)P  9#0  &1#  !D4P  9&4  &-[  !BE   8:T  &#-
M  !?\0  7O\ ?70  '=W  !N>0  7WD  %%Y  !#>0  -G@  "EX   <=P
M$78   IU    =0   '4   !V    =0   '0   !T    <P(  ','  !S#
M<A   '(5  !R(   <BP  '([  !Q3   <5\  '%T  !PC@  ;Z@  &[&  !L
M[0  :_\ >WL  ')^  !D?@  57\  $>    Y@0  *X(  !Z!   2@0  "H$
M  "!    @@   (,   "#    @P   ((   ""    @@   ((   ""!0  @@H
M ((/  ""%P  @B,  ((R  ""0P  @58  (%L  " A@  ?Z$  'Z]  !]Y@
M?/P =H(  &B#  !9A0  2X<  #R)   NB@  ((L  !.+   *BP   (P   "-
M    CP   )$   "2    D0   )$   "1    D0   )$   "2    D@(  ),)
M  "4#P  E!D  )0G  "4.   E$P  )-B  "3?   DY@  )*S  "1V   D/8
M:H@  %R*  !-C0  /Y   #"2   AE   %)4   J6    EP   )D   ";
MG0   )\   "@    H    *    "@    H0   *(   "C    I    *4   "F
M!P  J!   *@<  "H+0  J4   *E6  "I;P  J8L  *BH  "GQP  INP 7X\
M %"2  !!E@  ,YD  ".<   4G0  "I\   "A    HP   *8   "H    K
M *X   "O    KP   +    "P    L@   +,   "T    M@   +<   "Z
MO0<  +\0  "_'P  P#,  ,!)  # 8@  P'X  ,";  # MP  O]@ 4Y<  $2;
M   UGP  )J,  !:E   +IP   *H   "M    L    +,   "V    NP   +T
M  #     OP   ,$   #"    Q    ,8   #(    R@   ,P   #/    TP
M -H'  #;$P  W24  -X[  #?4P  X&X  -^,  #=J0  W<( _P   /\   #_
M    _P   /\ !P#_ !  _P 9 /\ ) #_ "\ _  Z /D 0P#U $L \P!2 /$
M60#O %X [0!D .L :0#I &\ YP!U .8 ? #D (0 X@"- .  EP#= *( V@"Q
M -4 Q0#2 .@ T #_ ,\ _P#$ /\ N #_ *\ _P"I /\ _P   /\   #_
M_P   /\  @#[  T ]P 5 /, 'P#O "D Z@ T .8 /0#B $4 W@!, -L 4P#8
M %@ U !> -( 8P#0 &D S@!N ,P =0#* 'T R "% ,8 D #" )L P "I +X
MN@"[ -D N0#W +@ _P"T /\ J0#_ *( _P"= /\ _P   /\   #_    ]@
M .X   #G  H X0 1 -P &@#7 ", T  N ,L -P#' #\ Q !& ,$ 30"_ %(
MO0!8 +L 70"Y &( N !H +8 ;@"T '4 L0!^ *\ B "M ), J@"A *@ L0"F
M ,@ I #M *( _P"B /\ FP#_ )4 _P"1 /\ _P   /P   #N    XP   -@
M  #-  4 Q@ . ,$ %0"] !X N0 G +4 , "R #@ KP!  *P 1@"J $P J !1
M *< 5@"E %L HP!A *$ 9P"? &X G@!V )L @ "9 (P EP"9 )0 J "2 +P
MD #? (X ^P". /\ BP#_ (8 _P"# /\ ^    .D   #<    S    ,$   "X
M    L@ * *P $0"H !@ I0 A *( *0"> #( G  Y )D /P"7 $4 E0!* )0
M4 "2 %4 D !: (\ 8 "- &< BP!O (D > "& (0 A "1 (( H "  +( ?0#,
M 'P \0![ /\ >@#_ '< _P!U /\ Y@   -,   #&    NP   +$   "G
MH0 % )L #0"7 !, DP ; )  (P", "L B@ R (@ . "& #X A !$ (( 20"!
M $X ?P!3 'T 60![ &  >0!H '< <0!U 'P <P") '  F !O *D ;0"_ &L
MY@!J /\ :0#_ &D _P!G /\ TP   ,,   "U    JP   *,   ";    D@
M (P "@"' !  @P 6 '\ '0!] "0 >@ K '@ ,@!V #@ =  ] '( 0@!Q $@
M;P!- &T 4P!L %D :@!A &@ :@!F '0 9 "! &$ D0!? *( 7@"V %P U0!;
M /< 6P#_ %H _P!: /\ Q0   +8"  "I @  GP   )8   ".    AP   (
M!0!Z  P =0 1 '$ & !N !X :P E &D *P!G #$ 9@ W &0 / !C $$ 80!'
M %\ 30!> %, 7 !; %H 9 !8 &X 5@![ %0 B@!2 )L 40"N %  R !/ .X
M3@#_ $X _P!- /\ NPH  *P-  "@#0  E0P  (P(  "# @  ?    '4   !N
M  @ :0 . &4 $P!B !D 7P ? %T )0!; "L 60 Q %@ -@!6 #L 50!! %,
M1P!1 $X 4 !5 $X 7@!, &@ 2@!U $@ A !' )4 10"H $0 OP!# .0 0@#\
M $( _P!" /\ LA$  *44  "9%0  CA,  (01  ![#0  <P@  &P   !E  ,
M7P + %L #P!7 !0 5  : %$ 'P!/ "4 3@ K $P , !+ #8 20 \ $@ 0@!&
M $@ 10!0 $, 60!! &, /P!O #X ?@ \ )  .P"C #H N  Y -D . #U #@
M_P X /\ K!<  )\;  "3'0  B1P  '\9  !U%0  ;!   &0,  !=!@  5@ &
M %$ # !- !  2@ 5 $< &@!% "  1  F $( *P!! #$ /P V #X /0 \ $0
M.P!+ #D 5  W %\ -@!K #0 >@ R (P ,0"> #  LP O ,X +P#O "X _P N
M /\ IQX  )HB  "/)   A"0  'HA  !Q'0  9Q@  %\3  !7#@  4 H  $D#
M" !%  T 00 1 #X %@ \ !L .@ A #D )@ W "P -@ R #0 .  S #\ ,0!'
M #  4  N %L +0!G "L =@ J (@ * "< "< L  F ,D )0#J "4!^P E ?\
MHB,  )8H  "+*@  @2H  '<H  !M)0  9"   %L;  !2%0  2Q   $,, @ ]
M!PD .0,. #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#-  J SL *01# "@$
M30 F!5@ )05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G !T(^  ="?\ GR@
M ),M  "(+P  ?B\  '0N  !J*P  828  %@A  !/'   1Q<  #\2   X#@0
M,0L* "X(#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C"3< (0I  " *2@ ?
M"U4 '0MB !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-^0 6#?\ G"T  ) Q
M  "&-   ?#0  '(S  !H,0  7RP  %4G  !,(P  1!T  #P8   T$P  +1 &
M "8-"P D# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30 &@X] !D.1P 7#E,
M%@YA !0/<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1$/\ F3$  (XU  "$
M.   >CD  ' X  !G-@  73(  %,M  !**   0B0  #D?   Q&@  *A4! ",1
M!P =$ T &P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z !,110 2$E$ $1)?
M ! 2;P .$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\ ES4  (PY  ""/
M>#T  &\]  !E.@  6S<  %(R  !)+@  0"H  #<E   O(0  *!P  " 8 P 9
M% H %1(. !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \50@ .%D\ #19<  P7
M;  +%W\ "1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@  (H]  " 0   =T$
M &U!  !D/P  6CP  % X  !',P  /C   #8K   N)P  )R,  !\?   7&@@
M$A<- ! 7$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *&TP "1M:  <<:0 %
M''P !!V1  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!  !_1   =44  &Q%
M  !C1   64$  $\]  !&.0  /C8  #4R   N+@  )2H  !TE   4(00 #QT+
M  T=$  ,'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H  R%7  $A9P  (7D
M "&.   AI   (;H  "';   A\@  (/X D$   (9%  !]2   =$H  &M*  !B
M20  6$8  $Y"  !%/P  /3P  #4Y   K-   (B\  !DK   2* 0 #20*  DC
M#@ &(Q( !2,9  0D(  ")"@  24Q   E/   )4@  "95   F90  )G<  ":,
M   FH@  )KD  ";9   E\@  )?X CD4  (1)  ![30  <T\  &I/  !@3@
M5TL  $U(  !$10  /$(  #$]   G.0  'C4  !4R   /+@, "BP*  4K#@ !
M*A$  "H6   J'@  *B8  "LO   K.0  *T4  "Q3   L8@  +'4  "R*   K
MH   *[<  "O6   J\@  *O\ C$D  ().  !Z4@  <50  &A4  !?4P  5E$
M $Q.  !#2P  -T<  "U#   C/P  &CP  !(X   ,-@, !C,)   R#0  ,A
M #$4   Q&P  ,2,  #$L   R-P  ,D,  #)0   R8   ,G(  #*'   QG@
M,;4  ##4   P\@  +_\ B4\  (!4  !X5P  ;UD  &99  !>60  55<  $E3
M   ^3P  ,DP  "A(   >10  %4(   Y    (/0(  3P(   [#   .@\  #D2
M   Y&   .2   #DI   Y-   .4   #E.   Y70  .6\  #B%   XG   -[,
M #?2   V\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=7P  4EP  $18   X
M50  +5(  ")/   83   $$H   I(   #1@$  $4&  !$"@  0PT  $(0  !!
M%0  01T  $$F  !!,0  03T  $%*  !!6@  06P  $"!   _F0  /[$  #[0
M   ]\@  //\ A%P  'Q@  !S8P  ;&4  &1F  !99   2V$  #Y>   R6P
M)ED  !Q6   25   #%(   11    3P   $X#  !-"   3 P  $L.  !+$@
M2AD  $HB  !*+   2CD  $I'  !*5@  26@  $E^  !(E@  1Z\  $;-  !%
M\0  1/\ @6,  'EG  !R:@  :VP  &!K  !2:0  1&8  #=D   J8@  'V
M !5>   -70  !EL   !:    60   %@   !7!   5@@  %8,  !5$   5!0
M %0=  !4)P  5#0  %1"  !34@  4V0  %)Y  !2D@  4:L  %#*  !/[P
M3O\ ?FH  '=N  !P<0  9G$  %AP  !*;P  /&T  "]L   B:@  %VD   YG
M   &9@   &4   !E    90   &,   !B    8@0  &$(  !A#0  8!   & 7
M  !@(0  7RX  %\\  !?30  7EX  %YT  !=C0  7*<  %O%  !:[0  6?\
M>W(  '5V  !K=P  778  $]V  !!=0  ,W4  "9T   9<P  $'(   =Q
M<0   '$   !Q    <0   &\   !O    ;@   &X"  !N"   ;0P  &T1  !M
M&@  ;28  &PU  !L1@  :U@  &MM  !JA@  ::$  &B^  !GZ   9OX >7H
M '!\  !A?   4WT  $1]   V?@  *'X  !M]   0?0  !WT   !]    ?0
M 'X   !_    ?@   'T   !]    ?    'P   !\    ? 8  'P,  !\$@
M?!T  'PL  !\/   ?$\  'ME  ![?@  >IH  'FV  !XWP  =_H <X   &6!
M  !6@P  2(0  #F&   KAP  '8<  !&'   'B    (@   ")    B@   (P
M  "-    C0   (P   ",    C    (P   ",    C0   (T$  ".#   CA,
M (\A  ".,@  CD8  (Y;  "-=   C9   (RM  "+S@  BO, :(8  %J(  !+
MBP  /(T  "V/   >D   $9$   >2    DP   )4   "7    F0   )L   "<
M    FP   )L   "<    G    )T   ">    G@   )\   "A P  H@P  *(6
M  "C)@  HSH  *-/  "C:   HH8  **B  "BP   H>@ 7(T  $V0   _DP
M,)8  "&9   2F@  !YL   "=    H    *(   "D    J    *H   "K
MJ@   *L   "L    K0   *X   "O    L0   +(   "T    MP$  +D-  "Y
M&@  NBT  +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4  $&8   RG   (Z
M !.B   (I    *<   "J    K    *\   "R    MP   +D   "[    N@
M +P   "]    OP   ,    #"    Q    ,8   #)    S0   -(!  #4#P
MU1\  -<U  #830  V&D  ->&  #7HP  UKT _P   /\   #_    _P   /\
M P#_  T _P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!. .L 5 #I %H YP!?
M .4 9 #C &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T SP"K ,T O0#+ .
MR0#[ ,< _P"] /\ L0#_ *D _P"C /\ _P   /\   #_    _P   /P   #V
M  L \0 1 .T &P#I "4 Y  P -\ .0#: $$ U0!( -$ 3@#/ %0 S0!9 ,L
M7@#) &, QP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C +8 M "T ,T L@#R
M +  _P"L /\ HP#_ )P _P"7 /\ _P   /\   #Z    \0   .@   #@  8
MV0 . -( %@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X $T M@!3 +0 6 "R
M %T L !B *X :0"L &\ J@!X *@ @@"F (X I "; *$ JP"? ,  G0#F )L
M_P": /\ E #_ (X _P"* /\ _P   /8   #H    W    ,X   #&  $ OP +
M +H $0"V !H L@ B *X *P"J #0 J  [ *4 00"C $< H0!, )\ 40"> %8
MG !< )H 8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+ +4 B0#3 (< ]P"&
M /\ A #_ '\ _P!\ /\ \@   .,   #2    Q0   +H   "Q    JP ' *4
M#@"A !0 G@ < )H )0"7 "T E  T )( .@"0 $  C@!% (T 2@"+ %  B0!5
M (@ 6P"& &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L =@#$ '0 ZP!S /\
M<P#_ '  _P!N /\ WP   ,P   "_    M    *L   "A    F@ " )0 "P"0
M !  C  7 (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L 1 !Y $D > !. '8
M5 !T %H <P!B '  :P!N '4 ; "# &H D@!H *, 9@"X &0 W@!C /L 8@#_
M &( _P!@ /\ S    +P   "O    I0   )T   "4    C    (8 !P"!  T
M?  2 '@ &0!U !\ <P F '$ +0!O #( ;0 X &L /0!J $( : !( &< 3@!E
M %0 8P!; &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8 RP!5 /( 5 #_ %0
M_P!4 /\ O@   +    "D    F0   )    "(    @0   'D  @!S  H ;P /
M &L % !G !H 90 @ &, )@!A "P 7P R %X -P!< #P 6P!" %D 1P!7 $X
M5@!5 %0 7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !( .@ 1P#_ $< _P!'
M /\ M D  *8+  ";#   D H  (8%  !^    =@   &\   !H  4 8P , %\
M$ !; !4 6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \ $T 0@!+ $@ 20!0
M $@ 6 !& &( 1 !N $( ?0!  (X /P"B #T N  ] -T / #X #P _P \ /\
MK!   )\2  "4$@  B1$  '\/  !V#   ;@4  &8   !@  $ 60 ( %4 #0!1
M !$ 3@ 6 $L &P!) "$ 2  F $8 *P!% #$ 0P V $( / !  $, /@!+ #T
M4P [ %T .0!I #< >  V (D - "< #, L0 R ,X ,@#Q #$ _P Q /\ IA8
M )H9  ".&@  A!H  'H6  !P$@  : X  %\*  !8 P  40 $ $P "@!(  X
M1  2 $$ %@ _ !L /0 A #P )@ Z "P .0 Q #< -P V #X - !& #, 3P Q
M %D +P!E "X <P L (4 *P"8 "H K0 I ,8 * #J "@ _@ H /\ H1P  )4@
M  "*(0  ?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<  $0 !@!   L /  /
M #@ $@ V !< -  < #, (0 Q "< ,  L "X ,P M #H *P!" "H 2P H %4
M)@!A "4 <  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ? /\ G2(  )$F  "&
M*   ?"<  '(E  !I(@  7QT  %<8  !.$P  1@X  #\+   X!0< -  , #$
M$  N !, +  8 "H '0 I "( )P H "8 +@ D #8 (P ^ "( 1P @ %( 'P!>
M !T ;0 < 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\ FB<  (XK  "$+0
M>2T  ' K  !F*   720  %0?  !+&@  0Q0  #L0   T#0( +0D) "D%#0 F
M Q  ) $3 "("&0 A AX ( (D !X#*@ = S( &P0Z !H%1  9!4\ %P9< !8&
M:@ 4!WP $P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL  (PO  "!,0  =S(
M &XQ  !D+@  6RH  %$E  !)(   0!L  #@6   Q$@  *0X$ ",,"0 ?"0T
M'0<0 !L'%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2"TT $0M: ! +:0 .
M#'L #@R0  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS  !_-@  =C8  &PU
M  !C,P  62\  % K  !')@  /B$  #8=   N&   )Q,  " 0!0 9#@H %0P.
M !0,$0 3#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH # ]8  L/9P *$'D
M"!"-  <0H@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^.@  =#L  &LZ  !A
M.   6#4  $XP  !%+   /2<  #4C   M'P  )AH  !X6 0 7$P8 $1 +  X.
M#@ .#Q, #1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5  8390 $$W8  Q.+
M  $4H   $[8  !/1   3[@  $_L D#8  (8[  !\/@  <S\  &H_  !@/0
M5SD  $TV  !$,0  /"X  #0J   L)@  )2(  !X>   6&@( $!4)  P3#@ *
M$Q( "107  @4'P '%28 !A4O  06.@ #%D8  1=3   78@  &'0  !B)   8
MGP  &+4  !?0   7[0  %_L CCH  (0_  ![0@  <D,  &A#  !?0@  5C\
M $P[  !#-P  .S0  #,P   L+   )"D  !LD   3'P( #1L)  D9#0 &&1$
M!!D6  (9'0 !&B0  !HM   ;.   &T0  !Q1   <8   '7(  !V'   <G0
M'+,  !S.   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(  !>1@  540  $M
M  !#/0  .SH  #,W   J,@  ("T  !<I   0)0( "R()  4@#0 !'Q   !\4
M   ?&P  ("(  " K   A-@  (4$  "%/   A7@  (G   "*%   AFP  (;(
M "'-   @[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=2P  5$D  $I&  !"
M0P  .D   "\[   E-P  '#,  !,O   -+ ( !RD(  $G#   )@X  "42   F
M&0  )B$  "8I   F,P  )S\  "=-   G7   )VT  ">"   GF0  )K   "7,
M   E[@  )/T B$@  '],  !V4   ;E$  &52  !<40  4T\  $I,  !!20
M-40  "M    A/   %SD  ! V   *,@$  S '   O"P  +@X  "T1   M%@
M+1X  "TG   M,0  +3T  "U*   M60  +6L  "V    LEP  +*\  "O+   J
M[@  *OX A4T  'U2  !U50  ;%<  &-7  !;5@  4U4  $=1   [30  ,$D
M "5&   <0P  $S\   T]   &.@   #@%   W"0  -@T  #4/   T%   -!L
M #0D   T+@  -#H  #1'   T5P  -&@  #1]   SE0  ,JT  #'*   Q[@
M,/\ @U,  'M8  !S6P  :ET  &)=  !;70  3UH  $)6   V4@  *D\  "!,
M   620  #D<   A$    0@   $$#   _!P  /@L  #T.   ]$0  /!@  #PA
M   \*P  /#<  #Q$   \4P  /&4  #MZ   ZD@  .JL  #G(   X[0  -_\
M@5H  'E>  !Q80  :6,  &)D  !78@  25X  #Q;   O6   )%4  !E3   0
M40  "D\   %-    3    $H   !)!   2 @  $<,  !&#P  1A0  $4<  !%
M)P  13,  $5   !%4   1&$  $1V  !#CP  0J@  $'&  ! [   /_\ ?F$
M '9E  !O:   :&H  %UI  !/9@  0F0  #1A   H7P  '5T  !);   +60
M E@   !6    5@   %0   !3    4@0  %$)  !0#0  4!   $\8  !/(@
M3RX  $\\  !/2P  3ET  $YR  !-BP  3*4  $O"  !)Z@  2/\ >VD  '1L
M  !N;P  9&\  %5M  !';   .6H  "QI   @9P  %&4   UD   #8@   &(
M  !A    8    %\   !>    70   %P$  !<"0  6PT  %L2  !;'   6B@
M %HV  !:1@  65@  %EM  !8A0  5Z   %:]  !5Z   4_X >7   '-T  !I
M=0  6W0  $QS   ^<P  ,'(  "-Q   6;P  #6X   1M    ;0   &T   !M
M    ;    &L   !J    :0   &D   !I P  : D  &@.  !H%0  9R$  &<O
M  !G/P  9E(  &9F  !E?P  9)H  &.W  !BX0  8?P =W@  &UZ  !?>@
M4'H  $)Z   S>P  )7L  !AZ   .>0  !'D   !Y    >0   'H   !Z
M>@   '@   !X    =P   '<   !W    =P$  '<(  !W#@  =Q@  '<F  !V
M-@  =DD  '5?  !U=P  =),  '.O  !RTP  <?< <7X  &-_  !4@   18(
M #:#   HA   &H0   Z#   $A    (0   "%    A@   (@   ")    B
M (<   "'    AP   (<   "'    B    (@   "(!P  B1   (D<  ")+
MB#\  (A5  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&  !(B   .8H  "J,
M   ;C0  #XT   2.    D    )$   "3    E0   )<   "8    E@   )<
M  "7    EP   )@   "8    F0   )H   ";    G0<  )T1  "=(0  G3,
M )U)  "<8@  G'\  )R<  "<N0  F^( 6HL  $N.   \D0  +9,  !Z5   0
ME@  !)@   ":    G    )X   "A    I    *8   "G    I@   *<   "G
M    J    *D   "J    K    *T   "O    L0   +,)  "S%0  M"<  +0]
M  "U50  M7   +2.  "TK   M,P 39(  #^6   OF@  ()T  !&?   %H0
M *,   "F    J0   *P   "O    LP   +4   "W    M@   +<   "X
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M______________________________________________\
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M^?K[_/W^_VUF=#$      P$A   !                     0
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M'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C]
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M________M8!5, H &6"R_______________________________/=#4+
M"E*G______________________________^6-        $^G____________
M__________________9I'0  "0P&"5*Q____________________________
M_\L[#A,U3%M-3%[#_____________________________ZE@-F"&G[:LJ;C9
M_____________________________^"7C;[E________________________
M_______________M^?__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________Z]G*O,?_________________________
M_________\^:@6U:1HCJ________________________________Q'P^)A
M %2P_______________________________@@SP      "Z'[?__________
M__________________^L4Q       !=MUO__________________________
M__N ,0        EAS/___________________________]): @        !=
MS/___________________________Z@U          !<T_______________
M_____________WT-          !4UO__________________________[GU%
M          !$U/___________________________*ID+P(   0B-TE8SO__
M_________________________^FD:T$H/V-_E:>ZVO__________________
M____________U;*LLLSD^O______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________Y;N7
M=V+(_________________________________]N>9S8*  *,____________
M____________________R'\_!0    !>S___________________________
M___9@3D        \JO____________________________^>3          C
MD/___________________________]QO&@         0??G_____________
M_____________Z](            ;^[__________________________X03
M            9.;_________________________[%$             5][_
M________________________N!4             2-;_________________
M________=!0             .,_________________________YHEH3
M        (\7_________________________WYM<+           #;K_____
M_____________________^^Q?54Y(A$' 0(1(K+_____________________
M_________]^_I9F8FJ"LO=K_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________^.^G8!\^___________________________
M______*WA%<P#@ =K/______________________________THI,%0
M<O/____________________________6?S8         2\G_____________
M______________J1/@          +ZO__________________________\!:
M            &I7__________________________XTD            "(3_
M________________________YUX              '?_________________
M________M"4              &K_________________________?0
M         %OT_______________________]*P               $SK____
M__________________^E                 #SA____________________
M__\P#                "W9_____________________YF*82<
M     "?7_______________________MOHE5)P           "7<________
M__________________[*G79=2CPR+2PP.4?>________________________
M_______]YMW6TM#3V>3_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________[]2[
MUO_________________________________GN(]J2R\5;_______________
M________________Y*%G- <     /,G____________________________6
M@CL         $I?__________________________^V%,0           &__
M_________________________Z9"             %#A________________
M________[&D              #?)________________________LR\
M         "*V________________________>0               !"G____
M___________________R-                 "9____________________
M__^I                  ",______________________]&
M      !______________________]\                   !T________
M_____________Y<                   !J_____________________\X
M                  !C______________________\I(@$
M  !A______________________^YHX!7-Q<           !H____________
M_______________ZTZZ4AGQU<7!R=X&4____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____]NZG8)I:=/______________________________\B393T9    '9[_
M___________________________;CDP3         &[_________________
M_________]M\+            $77_________________________XLJ
M         "*T________________________PD0               .7____
M____________________?0$               !_____________________
M___G-@                !J______________________^=
M      !8______________________]&                  !'^/______
M_____________^D                    UZ?___________________Y8
M                   EV____________________[P
M   8SO___________________^L                    /PO__________
M__________\                    *N?____________________\G
M               *M?____________________]P                   -
MN?_____________________@G(QP54(S)AL4#PT.$AHFO_______________
M______________GDV-+.S,O,S];@_/______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^O3O./_________________
M_______________2J85E2"P2 87____________________________QJW$\
M#P       $_@_________________________]5_-0           !^R____
M____________________XW4=              ")____________________
M____D",               !G_______________________50P
M      !(]O____________________^*                   NW?______
M______________\X                   7R/___________________[X
M                   $MO___________________YP
M    I?___________________[H                     D___________
M_________]P                     @O____________________\
M                =/____________________\3
M:/____________________]"                    8/______________
M______]Z                    7?_____________________1
M            8?______________________)                   9O__
M____________________R:R9B7UV<6QI9V9G:W!ZC/__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^+%JI%Y87?_____
M________________________W:9W4"P,     #'$____________________
M_____^"23A,           "/________________________TG =
M      !@_______________________N;P\                WXO______
M______________^6'                  4P/____________________]
M                    H____________________ZX
M    B?___________________YX                     <O__________
M_________[P                     7____________________]H
M                3?____________________H
M._____________________\.                    *OG_____________
M______\S                    &^G___________________]>
M            #]O___________________^/                    !M#_
M___________________0                     ,K_________________
M____*P                   ,C_____________________@
M         ,O_____________________]Q8!!04# 0       08-&,O_____
M__________________SKX=C/S,W/T-+4U]SBZO______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________QVL;_______________________________'&HX1H
M33(8 !6K__________________________^Y?$88          !Q________
M________________UWPO               [X______________________?
M9 D                ,M?____________________]T P
M    C?___________________\45                    :O__________
M_________YD                     2____________________[8
M                ,/W__________________]<
M&>?___________________8                     !=/_____________
M______\.                     ,'___________________\O
M             *____________________]2                     )[_
M__________________]Y                     ([_________________
M__^E                     (#____________________8
M         '3_____________________-@                   &W_____
M________________?                    &G_____________________
MUPT                  &C______________________W
M     &'_______________________]0/$9.5%E=861H;'!V?HG_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________^_5NZ.+<UJ5________________________
M___XOXYD02$%      !2_/______________________]YU6&
M   7P?_____________________E;!8                 C?__________
M__________]C                    7O___________________YT
M                -?S__________________Z$
M$=G__________________\H                      +O_____________
M_____^X                      *'___________________\,
M             (K___________________\M                     ';_
M__________________]-                     &3_________________
M__]O                     %+___________________^4
M         $#___________________^\                     ##_____
M_______________J#@                   "+_____________________
M1                    !7_____________________@0
M      OU____________________R L                   +L________
M_____________UX                   #E_____________________\D<
M                  #:______________________^= 0             '
M#A?%________________________U;F\P<?.U=OAYNWT^_______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M^-_/_____________________________^S&I8AM5#LA!P RWO__________
M_____________]>262D             H/______________________B38
M                9_____________________]F
M,O;__________________Y4                      \C_____________
M_____Z<                      *#__________________]<
M             'S___________________\                      %[_
M__________________\E                     $/_________________
M__](                     "S___________________]J
M         !C___________________^+                      7S____
M______________^O                      #A___________________5
M                      #/____________________)
M      "^____________________5                     "N________
M____________BP                    "?____________________RPX
M                  "2_____________________U<
M  "&_____________________ZH*                  !Y____________
M__________]M                  !F_______________________W50
M              !%_________________________VHC*S4_2E5@:G5^AY&<
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______HS[:=@VE.N?_________________________LLH-<.AT"
M>_______________________Q6TI                0/______________
M______^#&P                  !\O__________________Y(
M             )C__________________Z0                      &K_
M_________________]T                      $'_________________
M__\.                     !W___________________\Y
M          #H__________________]@                      #.____
M______________^%                      "W__________________^H
M                      "C___________________+
M      "0___________________O%@                    !]________
M____________/@                    !L____________________:0
M                  !:____________________F0
M  !)____________________TA8                    Y____________
M_________U@                    I_____________________Z(
M               9______________________56                   $
M______________________^[+P                  ^/______________
M________JRD                 S________________________\E'
M  <3("X^4FB$[?______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________35R?______________
M______________K2L))W74(H#   2O_______________________\5]11<
M            $=C____________________$4                    )__
M_________________Z(,                     &C_________________
M_Y0                      #;__________________]H
M          ?L__________________\5                      #$____
M______________](                      "B__________________]U
M                      "#__________________^=
M      !I___________________#                      !2________
M___________G#P                     ^____________________,P
M                   K____________________6
M   8____________________@0                     %____________
M________K                       ____________________WB(
M                \O___________________UP
MW____________________Y\                     S/______________
M_____^A*                    M_____________________^@%@
M            G/______________________>@(                 =___
M_____________________WH+               %3/__________________
M______^B5VAT@(V<J[S0Y_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________MX___
M________________________TJ-Z6#HI(QP6#@8  )__________________
M____K%(.                 &G__________________^1#
M         #3__________________WD                       #C____
M_____________\T                       "R__________________\3
M                      "%__________________]/
M      !=__________________^#                       Z________
M__________^R                       <___________________; P
M                   "____________________*@
M    ^___________________3P                      Y___________
M________=                       U/__________________FP
M                P/__________________Q <
MK?__________________\#,                     FO______________
M_____V<                     AO___________________Z,
M            <O___________________^-$                    7/__
M__________________^1!@                  0?__________________
M___K7P                  '?______________________RDL
M         /_______________________\M7   ,&"0Q/TY@=(NGQ_______
M____________________U^?R____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________Z]3-Q\*^NK>SL*VIJ*7_____
M_______________=?E,_,",9$0D"          #;_________________W8
M                      "G_________________[H
M      !U__________________\'                      !&________
M__________].                       :__________________^,
M                    _?_________________!
M    V__________________Q&0                      OO__________
M________1                       I/__________________:P
M                C?__________________D0
M>?__________________MP                      9O______________
M____WB$                     4____________________TH
M            /____________________W<                     *___
M_________________ZP*                    %O__________________
M_^=%                     /____________________^*
M         /_____________________630                   /W_____
M________________IRX                  -7_____________________
M_Y@J           &&"U%8.#_______________________^H8W2!CYRKN\WB
M^O__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________Y\NWJ9V5CHF$@'QX='!L:&60________
M_________[QJ2"T9"@                 Q__________________\
M                   #__________________]"
M    W/________________^.                        LO__________
M_______.                        C?__________________*0
M                :___________________6@
M3O__________________A@                      -/______________
M____K@                      'O__________________U!<
M            "O__________________^CT                      /__
M_________________V4                      /__________________
M_XX                      /___________________[P9
M         .____________________%.                     -C_____
M______________^+                     +_____________________,
M0P                   *'_____________________D1D
M     'K_____________________\G0*                $5__________
M_____________^AT$Q\L.$538G*%F[32]?__________________________
MU^CT________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________[]_/Q[NSK
MZ^SQ___________________9LIF'>6UD75912T9!/#@R+2@CQ/__________
M______]+)0L                     DO________________^(
M                9O_________________7
M/?__________________,P                      &/______________
M____;                        /__________________G0
M             /__________________R0P                      /;_
M________________\34                      -__________________
M_UL                      ,O__________________X(
M         +?__________________ZD&                     */_____
M_____________],O                     (W___________________]>
M                     '?___________________^3!P
M     %[____________________-0P                   $#_________
M____________AQ                   !S_____________________V%X
M                  #______________________[].       .'"P^4FJ&
MI<C________________________"?(R:I[;%UNC]____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________NX=?/R<.^NK:QK:FGIJ:G
MKO________________^^AFU;3$ W+R@B'!80"P0     %/______________
M___7!0                       /__________________-
M             /;_________________=@                       -+_
M________________L                        ++_________________
MX20                      );__________________U$
M         'S__________________WD                      &;_____
M_____________Z                       %'__________________\<C
M                     #S__________________^Y+
M     "?___________________]T                     !#_________
M__________^C%@                    #____________________83
M                  #_____________________B \
M  #_____________________RU,                   #_____________
M_________Z4X           )'31.:XS_______________________^9.4-1
M7VY]CJ"UR^7_____________________________Z_G_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Z\RYK*&9D8N&@7QX='!K:&9F:/'_
M________________844R(Q@.!@               )[_________________
M?@                       '7_________________PP
M         %+_________________^S<                      #+_____
M_____________VH                      !;__________________Y8
M                      #__________________[\;
M      #__________________^9"                      #_________
M__________]I                      #___________________^0 @
M                  #___________________^Y+
M  #T___________________H7                     #9____________
M________D1@                   "\____________________RE,
M              "=_____________________Y@N             ! I1F;$
M_____________________^Y_'0P:*#=&5VE^E:_,[O__________________
M_______GH*JYR-CI_/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________WU\.OFXM_;
MV-32T=#2U^#_________________SIZ*?'%I85M644Q(0SXZ-C(O+C'_____
M____________TB41 P                    #__________________T(
M                      #__________________WT
M      #__________________[ +                      #V________
M_________]TY                      #<__________________]B
M                  #%__________________^)
M  "O__________________^O(@                    "9____________
M_______62                     ""____________________<@
M              !I____________________H2@                   !.
M____________________TUP                    S________________
M_____Y8N               5,E)W_____________________^!R$P   0\?
M+T)8<(NHR.S________________________*;VY^CIZPP]CO____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________G@TLC NK6PK*BEHI^=
MFYN<H*?__________________X)D5DM#/#8P*R<B'1@3#@D$  #4________
M_________Y(                       "M_________________\P>
M                  "+__________________M2
M  !M__________________^                       !1____________
M______^I&P                     Z___________________00@
M               C___________________U:                      ,
M____________________CQ0                     ________________
M____N#X                     ____________________Y6T#
M            _____________________Y\W               0+U!T____
M_________________]UR%      &%RI!6G64MMK_____________________
M__^\6$149'6&FJ_(X_______________________________TLWA\?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________/OZ^_W______________________^ZYJ)V6CXJ&@G][>'9T<G-U
M>'^0_________________^M/.C H(1L5$ L' @         C____________
M______]I                        __________________^;"@
M                ___________________(.0
M___________________P8P                      ________________
M____B@X                     ____________________L#0
M            ____________________U5L                     ____
M_________________X4:                   #[/__________________
M_[%)               8.5V!_____________________^5['@      #"$X
M4F^/L]G_______________________^[6"DY25IL@)>PS>W_____________
M________________LYZTQ=?K____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________^N_GX=S9
MUM32T-#0T=/9X.OW__________________^XBGYW<6QH9&%>6UE85U=97F5Q
M__________________^_,1\6$ H%                ________________
M___M5@                      Z/__________________@@0
M            S/__________________JR\                     L___
M________________TE<                     F___________________
M]WP0                    A?___________________Z(W
M      4KE/___________________\MA @            PL4':>T?______
M______________6-,       #2,[5W:9ON7________________________#
M8Q@J.TQ?=(VGQN?_____________________________J'^6J+O0Y_______
M______________________________W_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________W<[%O[RYMK2S
ML;*RM;G R=7C____________________EVQD7EE544],2DA'1DA+4%EFH?__
M________________IR8.!P(                 5O__________________
MSE                      .O__________________]'D+
M        (?___________________Y\R                    #O______
M_____________\18                "#%:A/___________________^E_
M'P          !B=+<9K"Z?____________________^G20     "%R]*:(JN
MU?S________________________3=1XF.$I>=8^KR^__________________
M____________KG*%F*S"V_;__________________________________]_O
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________[^RJJ:CH:"?GZ&C
MIJRTP,W=[/___________________XI:4T]+2$9$0T)!0D-'3EEI??______
M_____________YXN!@                   /___________________\-6
M                   50?___________________^=[&@             )
M-&"+M/____________________^?/P         $)4IQF<+K____________
M___________&9@\    3*D1B@Z?-]?_________________________KCC4K
M/E%H@9V\WO______________________________OG9_E*G!W/G_________
M_________________________]+8\_______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M]O+P[^_O\?/X_?____________________________BPGYJ7EI:6F)N?I*RV
MPM'A[O____________________Z.4$I'141$1$5&1TM16FB#J?__________
M__________^F00$           <V8X^ZX?_____________________&90H
M      0G3'.<Q.S________________________EB"\  !,J1&*"ILST____
M________________________JU V2F%[EK36^O______________________
M________TH=\F+'+Z?___________________________________]3.[?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________[>7C
MX^3FZ.WQ^?_____________________________]L922DI69G:.ILKS0[?__
M________________________G5-'24U15F!SBJ_6_/__________________
M________LE8 &C50;8NNTO?_____________________________S6\^7WN9
MM]?Y________________________________[I^#IL+A________________
M_____________________^/.Z___________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________P                 
M
M
M        ____________________________________________________
M____________________________________________________________
M__________________________________________________________\
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MD14C0J&QP='P4B3A!Q9B<O$E-4."-**R_\0 &@$  P$! 0$
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MD;^U0[/PYPZSOXKR"-UEB:9D]9TKYK!GP/<C/MO0!ESXU;AMA:E;.>Z$]Q=
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MFU$'<DUN$+Y9W:;2[_JET7LOB"\U^E44<P-/2GK;Q)("!-&C=\;&J."8L%)
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M5\YP.E"1S3VHTMGR3NR=-_>E)+>K_P#4 D?J].1UW[5$,SJCK&Q4M]^-\_-
MTK9,ANX]0:[#R@HPP>>1R.:UW@\ <( 7.G6< ]*Q/[T0[H0%SID4Y)!Z$?%;
MCPFQ;A0R^O#'!]JQ-<')J_L_DN:***D>:%)E)$;$<\4JD3?A/UV- (\KG'[V
M8R@//)+DE5QMCK\Y%,,DZW*^:H&6ST'Z^U=>5IA* A U99CGG[?[TIO$;Q>C
M4TI;FR[#\ZZ3Z*"KLE$_O)FVR!L2??%)25XX5C<OC5E=.-\]_P"5%RC>9IAR
M(Y$4(SC&=\;9Y[FFU9K2Y9U8L8CJ)88&>W*B@34D=1B)6* *_+. 1M\TWJ60
MR^<LB3+G=P!AAN/D8ZTYY3/"L;%&C:)D;?!*]>?].V:18"#Z)8"L<L,2M)'.
MAWVSL>I4$[5I=$9Y*E21=^&8(Y+H397R+=-;$G;)Y'?XSGVKG';][N=9$67Z
M*/44D&RD@8Z]<U6P3136DL!E"1DAW&2"<+C8==^E*NEU6'ER&=8O-,2*-\8)
MP=(!R#MUK%<V1VJ.3=/LAJX+R--]\@)QJ&-^YY ;U*267U1QGS!&I8E4 R!S
MTYYXJ-=FR@F>"*\$]Q"P60",JJXW(SU-=:Y\LW&A1J\O2A8[#.Y ]\5KLZ^U
M:'2VI8II,-&Q'YBG^%AX_%%AOZ1(%SG[@!S_ )U76\THMYO,0$2+K"<M^_>K
M/@2/%Q^P\QD9]8!"L,$' &WMBA],G*TG?PST'C;*G"[@L0%(QDC.,G&:P:I'
M"5(&4R%]0R2?BMWQL*W#)@XR-MCMG?E6)7-PZB0KYKG9P"%![''MUJ4.CBT;
MJ#&9W2-'0(?*##)4>KKUI%WY<NEXVEE(49$FY&3R'Z5*D@F0F*-HI"IQV!.>
MYIAXYH6/F[$DY"8Q6T=::NTSD5Q-$RPVLK#6,>63L1O2?,>)9+9HD<$D$C8?
ME31R<9(]1YD9)^*Z(<2DX,2L, ML6/\ :@WM2Y'78&.-UUDH,-&_(?!I%JA?
M3- /2ITG2V2,]Z486N8$EE&NVCD ;U<_SILR2IZII G[QM"QJ#J7_B!WW&_.
MFC$G2I")8=7$'RR2+&VI&4%2/G]2:2<1W.@?A/S[D]ZGW$=O/!"3&\4RCF5)
M60=P>AKCB-[2*/0ADB&%D)YCGO1=BA*JX$:ECM%60>M<CTYY8Z5'LY78!H@7
M.-@1M\U/LHKA[LW,< E;(PNH!<'/,G^E1],+P*L8D:[4D,JY R>G.@%-)M%Y
MX.CD_:EP\FG5Y0'\ZV=8OP87'$[E'&/W8..?7O6TJ,^SS=5^1D+B>\:KC().
M3VV-9>&Y6SO/+E"B'2Q!+=/NY=P:NO%%P]K;03)NRR;#&<Y!&*RU]>HYE+P1
M3 0%]#9RC$CE^6]."LUB@W']R+(DUU>2WL4GTRF41..P/\7L#_>NW4,5GQ,P
M&5V,2AD$:9(;^U'!9YKF=5DTQF11'EMUD Y#V/\ BE7UI)8QS)) -#-Z9ER2
M0.0/SFJ^:.KF,MDB?PZXX7<VK3\1F7SSJSYLARJ@[8'3OWIWAMO%%"CM,4\J
M4N&=SAP=L;^V*RW$[X&V"BW6%T(U2?\ /VY>]:^RXM87]B#<JH8C)C;<C;H.
M=9DFE9'-B>-VNF+XHWG6,4P1)O*F',<@<J?ZU1^=):33*'0)%GS(P,Z1R!_E
M5S:XO+!HK!CY4390OMJ(P0">W>J.XG-PTM]/ ]M<J/7'_#*!ML?\T0^!8^&X
ME[917OT<D]I,FISK5"@4/OU[9&U94W\UW<R-Q*/1-YHRA&,!23C'QC>KSA-^
MW#91YUQYG#)UU([_ '1/MZ3[8-2N-<*MN,6[7=I(OG $!NC>QH3VOD(24)_5
MT_)9<*XG!Q.*3R@04.&C;&<=_BL]>\(NHT:TM$'EJ[2K(QY@\A_O:CPW;RV/
M%HOJY )+B,@*=CMORZG_ !5GQ+C#V7$Y((X7GE:-2JKRZY/^]JS6U_2.-XYM
M8N1[P*9FCOFNFU3>8 Q^!BG?%K!9K4, 5(;.<8IKP+*TXXA*R%2\H.#SZTYX
MQC+""0*6\H,Q%+_,R^,_/^\%0BAXIW@0B(84MJ&_OM^51I'$5LWEL%:/<9&?
M]Q3MM<Q-)&BKHC. Q'\1SVI+K')=,&!0:BG/;VK9T0X=,B7]FD AE5VD2=-1
M/7-(DG]"*&?((WQRZ4[/&%3R)W(*DM&PW_6H8F::(KI0G4<,1@XQ31TI<6^2
MX-T.&M&T,XND8>I3M@=?SIN[EB:.=H'9$<F0*/\ B1N0/;VJ%-&5AMW#@O*,
MD8'IVVIR5$CAC8N^D^N)D.#&^-QOT-)$WB7:[.1.40/,'_>!3&CC.XV. >0Y
M?K7;N26,L)U9K@['&-)[;"D,N&D^H)D.2K,KY8Y^?Z4B.-D 8%T'\8;[L \Q
MFG9N$$N6/0!5C699HWE+9$; [G_-,QQ^JXB:+,A./4^%0Y_4U(BMXY6!AN(9
M)2 -$FY/]JXB@7,D4T)/\3*-V  SZ32#=5D6ZMC%,H>6-P2 <=*W/@MBW!AG
MF'(-45A)964+?40,!(=@8RVD'H3S-:+PL(Q8RF!@T33,R8&,#M69O@Y-5EWP
MVT7%%%%2/."DR[1.?8TJD3'$3?!H!'D6MWN']9CB)Y+_ !?[^E-*9)>&R2$=
M=.HL"Q'L*=N1(9BB,&68'!7=5P=]_P JA<6D%MP@O&#+."K&4GV_*NM4SZ**
MDVE$L;R['GQ>63-!;HL4/(@D$Y8X]Q29G::<HZD,22Y5<G)YG%--H:UM;I6(
M:2!!I3;!&Q!'2E1/<B]B#Q&WC2+492VH$$[9/<YY4433CCI"X&\F58YF=(Y,
M%FR/3V8?!J4));'BL4MQ&=)#*=)#!EQG&.N^*C")1,C-(/IO-59-6<J,Y/SU
MY4X4MS,]S<L&M9)-6%8AF^[X(Y;BLA*I.WY$*CR"1B@A@;.DDZO+)^X9Y\LU
M*8+9PK%=R&1XBS%L#UJWV@$#IL!4*Y:9XFN9K>*&.;:.*/GI'\7]-Z[QDLOT
M*PS/+";<2(QV#9SD8_*F9>/?)60FM9(N*S74Y25;N(RJRMLC9QCVP<5(F>*2
MV2**&*.,2,VH*26VW;?GRQVI5U:,(76.1E"H)M!S@C.RFEW=Q";.RCM- :),
M2Y7 )+9/]_UIHK*5U1$NKR6>^(QIC"A N,:% V_^:M?"L2?MJU,<P;0^Y*D,
MW]NM5-L(GAF#/I.,8;GC/*M#X2MHTXU;A)P71Y 4)WP.6WZ?K69<*@RU'$Z^
M#<<>VX3<8(!P.8R.=837(@:-0@P>V1S[].=;KCY/[)GTMI.V&[;U@C@$NL8P
M^6.#C&^"/BIX^CS]']C_ ''))!HC!+.0S9TG8D]A7%T8;8@L,QOGKCWKD+ 1
MEE73@:4TG?5FC+-E-.VH:NP^*V=27%#4+% "^G&<^H$5WS(V7S( P# ZL#(/
MOBESEHT=&W5".0SUIMRY@TH%&,MDG!/:@TN1::XT6..7]U*P)&,#YQ7) ,2M
M/(&1<Z2!@_K^5</DY;R7]#:2QP2VW3XS3$P62$QNA +; =130G&^2SMT6:S.
MJZ9E$8*1#) VSUJ,\L4<L20VZZ$PNG.2>?/MFF52:%E3.!(=B#MSI21B82:I
MD0JWIZ9%(RH)<V2[96>0I:P%?)8R+&=LG'/WJ/87,\$[X9D49&5W.>F03UIO
M7(ERCH26QAB3R(KHUR-@-'@8; &[=S^O2G05%6F:'P<91Q"?SE;4T0.2!@[U
ML16/\(D?M&;UY.C !Z#:MA49]GFZK\G!0^,%D/#T-N%,JOE21G2<'>L!;%@Z
M@/@S)Y3G^$,>0]N5;SQFJMPQ=<[0J'!)49)Y[5B[-T43VMT\L*3,IAD*9PP/
M\NE;Q]'9I/PLT$G"+&Q,;2730 D$JSX4D<]/8\ZC<<O8+FUA6UB:X6)CI8D'
M?!ZFH?$.(F_D7AU]A989 _F1;B3 .WMFHG%"A6"5&(FB/J1-U7/\.!T&.8[5
MJ,>4V3V2X>1\G;BX:Z1(PBEM.G;!P1RS[_\ >B;]U"T<JQ)*Y5EQN01R&!RS
MRKEC($=9%>&5_L+*"!J.^1^>:3Y,*2N9A<QS-C25&=7+/\ZT^Z.O&E1<^'>(
MSR\3F2.V,<1B#21G *L#C(^:?XIQFS$Z0RQR <FS'G8GG599\2GAXQ]1=6SY
M:,(8U/J."/RZ\NOY5I+V%>(V:36JQF48QK&,CJIJ;I.VCARQ4)VRLXCP58H'
MDC8&!RNM0O,<JD7-K)86L9LE149=$H)QDX])_P![U71\1XA&R6GD_NU<8$GW
M;'=<]?:K_BJ_5\*+VX$G*0 _Q '<?.*&VJ3)RW1:4@54XCPR-XQZQAE.2,.#
MG^M8Z^O&OY9)W$R2Q-Y;*F 6W_H,5.MG)OI(K)IB;DZ8I3J'EX&6R.1WZU'\
M0VK6-PD.95CF"_O5)8$KT/;/YYIQ23HMA2A.D^S2>!"#'>C*APZZT&<JV,G/
M?G3GC#&JVU8 TMN>E-^!I-2WJ;>AUR<@LQQS./Z>U)\<*Q>T*JQ&&!P=A6?\
MS"N6HY_W@HIE:-@IWRO3K3J028#*-F&V-SFFO--P8E*@LJX!&P^*D<-FFA,P
M9"8X5+>LX/Y?I6VW1T3W15H5$K+,L-PA7(SFF8S':B4,0RAB%7<X_P"U/7LW
MU$\>8V1G494\P/:DV4>@2N8VE7=6P-R:1I2N-R*^[BBMXXY(GCE23[\ =37$
M9C&%8?NP=6&W.*=:R25Y J+'Y2YRV1J--(6](0,S.N" /YX[4SI330N5?(:-
MEF5IW&K2-SG.,?I7+M[IYQ%.CL5(.VY&1T(I$:0F.527$^VE>I^:Y/< M*D9
MGBRRGT;D%#NI)/L>U-*R<Y;15I'%+++%-*L3#'J?.?UYT_9Q&1I&C9C)"A8-
MJ.6 .^#\9IN>1'DQ"S2EE:/],$Y/<=*?T+]1";5)U2164L2?5Z>6WP*1ERW1
M^""2D$:2X'G')<2C(89YYK=^$-7[*)<8.LUE+FV4BVMI!&(%7]W*9-((/0G'
M.MAX:M#9V!B.G&LD:6R,;5B?1SZG(I8_U+:BBBI'G!2)L>4V>6*72)OPGSRP
M: 1Y(!'*JAM,-A+,Q,@3KONOS[5&,9:)XE+LNK!5\?J<\MJ[+Y$ *L-<3.1"
MX!)Q\5(:.WBC>%5NEG 75YH"X'0G??'.NH^A3VO@[:O<PK<0(L3><A2/HP9<
MX Y8W_M3%VW[1>PS!$3/%Y9@ (74&8$A>5+C-I!*LS,TT@.1(6R%(;4=NNV.
MM=2XN(+*2&VC!M!.X2X(S(JOOA<[@\^="X,2CNDVER2;YK:.!DMT7RM6F,J,
MA@N=]^>]-6L+N8A+"-<JGU9QD-R_+:NWEN]PE@+%%198=#&9L!6R1UY;#E\4
M[QJ*6*:R2Y06[&)430N2Q7GN/S_*DA1:I11P1 0^?+.)87& R LYP-U Z8J%
M/Q%[F(I;P^4+<:4C"*2BGIGF<U8VD\2H\-UF01P,T)R1ESRY?[O6;COY#=^1
MQ".97U;$YU$$[9)_+XK48V:C*I5+P3[F>4RP/$T@(A\MF'8$\_Z4IU,\$2QA
M4:"+,C$'#[G!/847 MT*8><3Y  8>_2E&?R(;I/)):> Q(H)U;GM_O.@KTE1
M"&;MI,*$&0HT^PK0>%1$OB.U>-VT%F52=S[#/:JCSI(XX@\>"^$.G?IOGL1M
M5GX:TW'&>'."PT%1G//\O>E+H67\;_9GH?B$$\)G"@,3C SC.XK#^8%7#KA@
MSY', $ #^E;GQ!_]IG&G4#@:>^XKS^-1&@?RBRDG;/Y[=O\ M4L?1YNCY@_W
M'0JZ,*=AN=&2!@;;>]*M67SIF*,&BAU+I((/8YI*1F7U(Z0DDD,YQA<;C;:A
M7U2E?+08RK:&QZ=.D#\MJV=,N>$(@/(%<JQ$C# /Q7?)EN\A98R^^,D+G\N]
M+^F=K63Z:0G2WJR,%@.OO4;2#"<DJX ![YZDT&^^4^197UO"T6&Y;C!/:FR\
M@THJ8\LY!QG!'2I,DCM+&S ATCQEN9[4VJ#REDSOJ(QW.#O0-.UR=)7Z;6Y"
MM#RV.XSGG^M=9(VC#"$Y;<$G8[42Z% \\%M1&PZ['^7*D)&9/+@\S())"CD#
MTH%UT1XC.DV8X\IRUAA\8]CM4AK=%5)9R\RYRH4+D,.>.7>G59TBC/EDE1N2
M1ACGE7/,$DAD*HFH[+G8#D:=F7'<[-#X4F@DO91!"R"--.6.YWK6"L?X.9OJ
MS&XPPBTD'GLU;"H3[/,U*K(9KQS*(>&P%N1G4?;JWZ;==ZR85%?7="5CG!Q)
MG))&_;WZ8Q6T\7*#PY=0.D2#)',<]ZPTBNZ?4QJD:B32)@JJTA(V.?SQFJX_
MM+Z:+<2VM+%FL;B2TB4R(Y"%AOC>J&19+VT9)E9F&0Q"C*]_UJ9PV^N+=9G6
M1T;')MP=SG_?>K#B?#[.RM(IX)YPLF"Z*V2XY\O>M73+Q>V52YOHK+#AJVEJ
MCF8-%)&6 7(QENQZYIR.1F>&.=%D$>IE)'+(.^?;G3=G(P9OK(3'#C2DB[X&
M^,CEBAQ/ZD.@2+'Z6 QL.8_K0[;Y-P5)Q9R1K5<2+-(CQ9D<D$[GOWQFI]GQ
M>[NHP;9#%<J<L8URDH&W(]>1_.J8PR8>%D;427#(,@Y[XWKEB]Q%>1"SFT,4
M*L7&D)V-.K1J>&,E:=FDMSKN5BOSGS=RY]+(W8^WO4N[MKWAMNQL;AY+9ON5
MP&,><Y([CVJ)PFTDXE;32W+QRS0N45\>F1<#8]]ZD6?%9X;26)K*68Q+E-.^
MI<' .>NV*F^>C@R)Q=+FA]^-6L4-M-<)@A@NI5U  C&01TISCW#5OX5N(GD$
M\*DQZ",-_O2J^VX,'X5!/;R.LVC4T3?8V>:D?J*Y9\>M^'116\A,L1'[LQ[L
MO_I;?IR_2E7-Q,;>=V/M%IX$$8L)5AA1%##UKCU[=?>E^*Y5BO+!I!E,MM_>
MI_A\1K:NL4!A]98J5QSWJK\:*SO9:'5=)).>U+N88W>4I+R.)9#-;R84[Z3T
M[BF KS1R7#2&(YTQ*K$AFSVKJIYCR"9% 5F)D&,H!N,G]/UKMM(;N='ABS';
M E!R7._J-;.]<JUX';BUB2:=$=A<*H92@)56W)!]MZCK,Q\S6Y4['/?WVHC!
ME\N2)E:1@2^20#4U)(F@)=$B*Y4L-P3VHL2CM[Y*T:BS"9B3JVP>>WSSH6Y5
M;E!9^;J08&0-B>E/)")<(-W<G)+:?C%)G@9'0"1LQ@8"$+OG;I3*QH:C2XMY
M)%N44E2'8?Q;'//IOBGDCC<N]S"R23,K@AR5;W'8_P!:)6.N4.DOF2#9BV<G
MNQ^/ZTW&^9(+>:65K4$;E<D8[8]]J!..Y6T%Q$J7+*R 2Q$* OVDG;8?I1:7
M!AM)&"3%"?O1M)SO_+\Z3(9FC4^69L,8Y-8RN3RQ1)&S,PQ+]/C4\:KG0?;N
M,YH\ DG]$AZ!B+&*01W"S,VE#I]+ CWV_7WK9>$BYX8?-C6-A(PTJN!62BN?
MJ.'(LMPY8>H ,/1@D;CXQ6P\*L[<)0R$ELG?EFL3Z.34KZ':\EO1114CSPI$
M_P""_P &ETB8 Q.#G!!!Q0"/+^'&"-O.@N44O(J%&!<*NQR2>0V-0(D,\CQR
MIJE#$AB< EF 7/ZT6MN\1=+:<^3K] E 0NP)!!&>>/ZU'O))[5;":U+/;7(T
M[MDJZL!N>><XKJ1]!&/+I]EA=K!Y+0K&BJ@BTG #Y(W)ZG?(IB=F80R0#T8+
M.G_M_P#D_K3EY'/>RD0J"RP)Y@U#F06VS\Y-'"9#FW4Q%BP:)LC'38?_ #1X
M''Z8_)'X[=FWX)P=U7*L\R\L@;[?)QFM/PDSQ<$O)6"EH4/DQ,WF-&,$X/8[
M\O\ %4W%X(8O#_#TG4N#-J 0Y(9AR]ADBG>"LT<XNQAGC4&XDU8V .K5G&0=
ML'N*3YB<^6*ECOX;_P#2%96J+=R>>ZK(5#:=8PP.=A[\L5Q!]5<W"S$Q<-BC
M DE;[@ZXTX]_ZGXKO$K:WDL9[OA^SQ,!,9AL,G)Q@[>U2462:UM[1Y#,40W$
MBQ^IV9!L"QV'M\4[HTWON39$XG,]Q&UW]4@@MVPEO)@2-RQG','>H:E@[RR*
MQ4C6,XP3CICI^=/!8_+$CQZF?,C,XPV,@?IDBN3ZG0K""ENF-(SCU8YCYIWX
M.B$5%42>(QQA8@RZYI8EDR&]*DYSM_O.G_";S#C5K&\BD"4#2.6!T%1[FX,_
MTIBTCR(@A8_Q;[CYJ7X9 N.-V;Q1Z0L@)RVX_P"U9?31B5^DV_U/0O$08\'N
M0IP<#^M8:.*-XL$,$*:M(V9L'<?IFM[QI_*X9.^CS, 94]=ZPC !LQ$A=648
M\T[ ]MJE#HX-']C1/S;/AHYX5@5=H]63\X_6F%=;A9UA@*C7KP-B!C?;J*@2
MQZ03;HNLG2Y  QMT^?\ -/0W-P)Q*HTRJH#9/3O6TB[QURGR.QV\<B@&0(N<
MC)',\Z8DC:'SXY7U/IV?XZ5TR1^6OF:HW4%AC=<9KO$HY&MX;C::)T+.R]#V
M-,<6U*I#JZ5TM+ID0G2W,,%%1^(VT%M,'A=I;7[AZ\%3OG-)\M92A$B:]B-\
MX/;YKLSW*R.KQ1N-&O#=-P,CW)./>A#VM.T*6-9%,RLS1Y&M0?4@QS^*&BAC
M$;Q,S $G..0_S4DW%J44V(F@N"-4L9V!]CG_ '%09I J=?-#^O?.#TH'%M\,
MD2>7<ME R,1J(ZDTNR(;3YJJLAC(&W/?:N>9,\Q"G<+CT@*?]VHD=VE7S 05
MY$@9(_WK2'^A?>%HO+OY=7W^7I;V(_M6J%9?PPP/$)4U,[!,EC\UJ*E+L\O4
M_>47C%U3A)U?<6 6L+>PE_)C$I58U5E7^$Y&Y]ZVGC@.W!6$8#-J&V!D_&:R
M%S)';QV=H)"- #,P4DD,>6W^[U3'T=6F=8A#9GFD)Q&'V!P-)_QTIJUBFC4(
M$+7 ;(<;J![5->]MTN)X$L46TC78C[CGF0?G-<*@3(D!U(VS%N:=!UJA>#:5
M(@7\\KLJ22/).V2[9]*C'+'2IZ"1T+AF$14QN<Y!).=AW '2D7%K';RG)6/0
MP4EAL>>?Y5RUBGG\N-&<Z"#HU:=L; -_FEX-2::I=(5YEO';,S7!D &"IW.,
M=3W]JKA$LTMQ<ET5DP?+D&2PQT]^5*N(A &CE&I&]658-JW TYWS[XJ7#>K&
M(5:V$K1 .N_J.>F>>^VU/QP)-P=KDTWA5@+6:%(O+2-QH75G (_SFF.%W9M+
M^YBNBI5Y"BE<$H!G 8#^M57[2F_:"3RL+=F4!HHSZCOL2.6<=*A7"NG$)KF0
M&02-J41RZ68'ED?%3V]_J<T=.YRDI/LON*7DAN9/V3<J R?O!C(!QL1N,'E3
MGAR/ATG#HRR1"=%*2:R-6>ISSWYUG#.C^<R"58D4Y\PY]6, CMUJ-=\/:6-Y
M8!/)%"0#.<@'(W..N*UMM44]JDMMT>G\$N#<V9D\ME4,0I;;4 < _G51XVRJ
MVSG4 I))4=MZ/ D]P]E/;W U1PL!$Y_B4_VI?C&&:=K9(%+G<E,\ZDN)'+CA
MLS[6982_NW+I@R*->L;G/0#F.0SFI,DB0VDEM;R*TC;NP&,=\?VHP?\ J(I8
M?WDQU$D@!3V^*:9Q$L<)"X"D^D[DCGCWJO9W<)$F'$/!P5+#UC!QN=N5=@(^
MA:)XA]0<G&V^>M-KQ*WA@>%H&E59,@$XS[\OBF[F:2:5975(\KA47ECY^,TJ
M?DPDY"BN(UBDCR00RN#DC?<?_%<BM$E5]4H:4Y.QQI(V'.EZ"PS)J:$'F1DC
M_<5P6_[QWC "D9'6F/\ D;DFN3:-#,R!5_\ R!=P*;B"L()8YTB8D[8.V.1(
MI_\ <Z%>%6A?8@'!!-,Y-W=*WI0 AESLH/QG:@I%^&$5[_U8NG0:E8!DYACG
M -/J@ B.IPDLDB,NH@8&_P"F34.6 K.KB2W96_\ S!3S.3S//'3:G8OLE5&9
MHM2L'!W!Y''?.U*@=-6A$%NDCL(<"9UU948$8'^_SK9>"Y/,X1G!'K89+9S[
MUCITB2)9(Y,[^KR\Y_.MEX,B:+A&A@00YYG-9GT0U;_M_P E[1114CRPI$QQ
M$Y]C2Z;G&J)AW!H!'DED\#QW,[SL=4^)8GY$-MM[CO4:[21;"VMY 66)6D#Y
MY,S>G/Z9^30L%G#)IE]3),X<Q_:RJ"=OTQ4HVS1?40JFJ-+4?4$G[=PV<CK7
M5Y/H7)1YLY#;-=/+-"^LE<2*F=0<C Y=-C^M0K>Y%M<E41RVGRQML.8(VY'W
MJQ\&W97CP@DD)68 $.F#L,K_ %I7%8X;/C-X%C8S12^8D87;20#G/R:5\T-2
MK(\;^."OAB8<'507:&;TJA4G1@_=CH=ZEQO+9<-N(U96EG?Z9B26TI&,]]R2
M<5&DC$2>1 RNLC8323DX_P ,,=*8D*1PSL)9#<K+KC;5A5; );YVQ^5:["MR
MYZ;+B&/]JV=^L<9%PMI"\BA=.IQJR1MSV_6D<*O8K*\BO(V>6TE@:(J ,A^>
M/FHW"[X\)_:$L$I8ED+ Y8E<Y)S[DX(]_:E27,,<<R);Q_173-+!(_I:*0XS
M@D=,G]*31*,']6-\ID<RSZ/+5BCQ#3]PV!W/3XI<H<1E76W9M/[P*-LC^^]-
M*(_-N=5P59MY&0:U8@;C'05+W15CB9D29%R8_P",-UWY'E0=#X&85584?(+.
MW)F)"YWQ@=NU6GAHX\0JD>AE\Q<,%P=CO^50+N.:VCBMY&Q'Y@90#EO^]6?A
M0^1Q]8G51EP%"^G![8[XI/IDLCN$G^AO>/\ _P!IN-\;#^M8 N$<'4=3##+V
M':MYXCQ^QKG(S@ X_,5@YWMWN3-IPC<\=.E3Q]'#HOM8J0L7+/&.>,#H* 4:
M7RX\ZR.3'ORKJ(\B,T1)RVZXYFN3(T4SLSM$VWN/^U;.NZ$O]NVY_B';!QO_
M "IPM%'<+K65H3@/$1L&]OFN/Y*JK+=!V))8!>M*+,TTOG2.CJ<Y9CL<8H,=
M\>!8MI#.C</ DAD)RCXR!G<8_.NW\$5OIBED?ZB;;RHVU% -QD]Z2JY32XUQ
M$[NIV^2/TI'#5D@A>1E4O)J,;@:CG;(^<#^=",/=W8K_ *6"-P+62:=E(>1Y
M,'8<ACF/FHBF&>6*W"O&[@N'.V6QMDT];W!M5TG3I<D^H9WV!]AR'+WIR9SY
M*.+A'6$@JAP2=1W%/H<?GR<M;<F(9DT3:@A'O[TB=,C693K* KD['?!%1Y9'
MBXI<VJABBR%4;/;W]JFFW:5 02^<X3OW%(KRN?DOO"4*I>2OMK:(9(Z[UJZR
MO@U6)F=D&WI60?Q+SQ[X[UJA49=GE:IWD9F/'P)X3&$U:_-&G3SS@UY[>OI5
MD*$H<("Q!.YYUZ]?V,-\L:W":UC;6HSC>H'_ )9X8,%8""-QASM6X3447T^J
MACAMDK,%P^::VEEE="P@<QR@XP03MM\=>].7<ZPD@Q$H#K4@>L#MGJ*W*^&>
M&J[-Y3DL<D&0D$]\4N+P[PV*(QK;*4)S@FGZB[*>[Q+P>?QW$ETTC0HD[DZB
MC9 QC?![XID3+(K"6(6RD%1Y>2Q(4C&YV&]>BIX=X>HP(F4=A(0/TKI\.\.*
M.K09#)Y9]1Y9)_O1ZB$M7C3;H\[N$D^@P&1295=2K;9P1L<>W2GFG@01W$#-
MYOJ+DGGG8CY _M6\/AOAIT_N2"ARN'(Q\5T^'.&^<9?IAK)SD$T>HAK60:Y1
M@H+;S)([>..:?6"RS@[E>6,]1UP>_2K,\'O0L4MG']-<1HP8LP8-DY_T^PK:
MV7#+6RC,=M$J(3DXJ08$Z 5EY#FEJ7?TH\UF"A9(1)YDS+B0X*X/4=NM6-GQ
M&&VX.+$1F5 GE*^<AL\LYWZUJ$\/\.5'7Z92'YDDDG\ZZG +!%"K#A0=0WY&
MFYIHU/41GVBG\ HR07:%65%8 9?5GG3_ (O:1)+9T]" -F0<U^*O+2QAM"_D
M+IU@ []L_P"32>(<.M^(*JW2LRKN &(%9W<V3>:,LN]K@P,HF)>=U61"GK9F
MU,!W^:;FRL,;C0#JUH2,Y&=\'H<5N8?#_#XF8I!@D%3ZCN#2%\.<-4__ ,?(
M]V)%:WHZ?=8_@P?G*P+,=4@;4&5MQ['/.G(HX/(=OK<G.2NC?X%;H>'^'*3B
MW&YS@DX%=7P_P]7#)!H8?\6(HWHW[V%4K//;:Y<$QQ,3&QW!Z]MJFV,TL*K+
M%A6UE"IVS_VK8GPWPTR"3R#K!R/6:=7@-@"#Y)SS^XT.:%+5XWTC%-O&VM,-
MDC(; .YY5Q08V'EJQD P5CV_T5M'\/\ #W8,83D<O4:6>!V)&#%G?/,\Z%-&
M'JH-&+DC^I@T"(>G;&<Y_*HL0!D*JLC*#S/,\MOY?RKT&'A%I#)KCB]6,9+&
MFCP&Q+A_*.H'(]1V-&]#AJXKAF"$HA8M#&1&S;*W+MG^5;WPTYDX<&*H,L?L
MY4IN"63*H,6R]SFIMK;1VJ%(1I4G./>LRDF0S:A9([:'J***P<H4B;\-ML[<
MN]+HH \N;PW?->2206<L,<I/[L\D&V1^>*EP\'XA^R^*PBWN5-Q)&H#X+%!S
M[_%>C8KF]4]1G;+6SEVCS&RX%Q*'B-N/H)%7S [2@@  #EBI_BSA/%;KB@GL
MH&>)41& 'W;G._MM6_(W^*Z/>EZCNP]]/>ITK1YK?<'XF+ZVEM+!T5$PQ7&H
M=/\ -0AX9XFX75;S#=!IVVWW.?89KU>BFLC1I?U":5)(\NLO#_$[9UC%FYP5
M#29P"@YC'4FG+[@/$)Y[DI8N4*JL?F'45&-P#G WR:]-Q7,;4>HS/OIWNKD\
MN;@'$K>62W%@9[=6UB7 U-V&>@IB;PSQ5Y5F%G.0JJ%77N"/;_>=>L8YYKM'
MJLU'^H9%X1Y;;^'^+O(QFMV3;2I<:@*L>#\!OH.)VMQ.')68/(2IP=L [[;5
MZ#12]1F9Z[)/BD5_&XY9N&3QP+JD.,#\ZQUMPOB2A@UF[*/2 0.72O0<;44E
M*N".+4/'':D8"/@EZ'9C#-@#;&QS[5VWX1?+<Q-/;S&('<?=MCYK?44_493W
MDZJCSX\"O/-FD6V;!"!,]-AG^]<' N(F64^2^%<@,>;+[5Z%B@4>HQK6S7@P
M\?!KM'*^3)H;((QL012/V/Q 6QA6%AI)9=]CL0?SWK=T4;V+W<GVCS^/@-_]
M/O$Q<+I"R;Y'^[T0^'[AX\26[I(&U9T\_P _R%>@44>HP6KFND>?#@?$'EUI
M;-&!@X8YYG?Y_.GY."7PE#JK!5(;&""?C'6MU1BC>P>LF9CP_:7R\3EN+E1'
8!Y96., J%W[&M/0.5%9;LY\F1Y';/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g769642g30x67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g30x67.jpg
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M0I$(,U)B<J%3L<$7)"4U0Y+A=(*BLK3_Q  9 0$! 0$! 0
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M6L_-_1;)([#V-??DI1S2,=$X-?*SRVWQ&Z_Y]C9:KAPB*6#B.(BL7([LS*S
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MLZ+FE/VDOY;FL9C_ &?P,N1'P[&3NV6.;%4B/G']<I[C7I]?<CI: B(@(B(
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M(@A>._AN?_6'\F)32A>._AN?_6'\F)32"(FY-@8)I(9\WBXY8W%CV/MQAS7
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M^Y?W$#' =0>#_BB7_P ;K\_$WWW^SR[(+)AZ#,7BJE"*6>:.M$V)LD\A?(X
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MSUEOWK/[4^@I/SUEOWK/[5-+3O7&Q$UXYHX[;XW.C,K26#0\SK78?+801-7
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M@I/SUEOWK/[5-+6MVF0O9 )&MM3!W@AS26D@>NO1!#18&[[]8,N;R9J%C/"
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CB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g769642g31l38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g31l38.jpg
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M4__:  P# 0 "$0,1 #\ ]4@
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MO8G&7N>YR,,@
M
M                                                         #Y*
M2BMY-)>;,6KD+>GNE)S?[IF(V,L&GJY6H^5*$8KS?-F)5N:U7Z]237EOLB44
ME'J;ZK<T:7UZD4_+?=F)4RM*/]7"4GZ\D:8$HI#'4SZF3KR^HHP7HMS%J7%:
MI]>I)^FYU E$1#&P &6
M     3:>ZY'?3NZ]/ZM66WD^9T :9;&EE:B_K(1E[N1E4LG0G];B@_5;FD!&
M:0SN4FIU:=1?HYQE[F<R+)[/D9-*]KTNE1M>4N9&:?)GJ2 &KI9;PJT_C$S*
M-[0J_5J)/RER(3689W#( !AD
M
M                                                    Z*]W1H[\
M<UQ>2YL#O#:BMVTEYLU%?*S>ZHP45YRYLP:M:I5>]2<I>\G%)]T>IN:V1H4]
MTI.;_=,&ME*LMU32@OFS !.*1#&Y<ZE2=1[U)RD_5G  DB
M                                                    #MHW%6C_
M %=227EX&=1RLERK04O6/(U@,36)9WI(:-Y0K?5FD_*7(R"+'?0NJU'ZDWMY
M/FB$T^2462(&LH95/E6AMZQ,^C6IUEO3FI$)B89B=NP &&0
M
M
M!PJU84H\522BO4UUQE$MU0CO^]+^1F(F6-MG*2BFY-)+Q9A5\G2ANJ:=27R1
MJ*U:I6>]2;D=99%/FC-F37OJ];=.7#'RCR,8 G$:8  &
M
M  /L6XO>+:?FCX ,ZADJU/E/:I'UZ_,V-O?T:W+BX)>4C0 C-(E*)E*01ZWN
MZU#E"6\?V7S1LK?)TJFRJKNY>?@5S282B6>!%J2WBTUYH$60
M
M                                                   <*M6%*/%4
MDHKU-9<Y1O>-NME^TS,1,L;TV=:M3HQXJDE%&LN<HWNJ$=E^U+J:Z<Y3DY3D
MY-^+.)9%(CRC-G*I.527%.3D_-G$ FB
M
M    .VA<5:#WIS:]/ V=MDX2V5=<#\UT-.#$UB68G241E&<5*+33\4?2-T*]
M2A+>G)KT\&;2VR<)[1K+@EYKH5S282BS8 1:DDXM-/Q0()
M
M                                       !A760IT=XP]N?IT1F(V,R
M4E&+E)I)>+-;=9-+>-NMW^T^AK[BXJ5Y;U);KP2Z(Z2R*?-";.=6I.K+BJ2<
MGZG  FB
M                                                   [K>YJV[_1
MRY>*?1FVM<A2K;1G^CGZ]&:,$9K$LQ.DI!H+6^JT-EOQP_9?X&XMKJE<+V'M
M+QB^I7-9A.)V[P 19
M
M-I)MO9( =5Q<4Z$=ZDMGX+Q9A7>24=X6_-_M/I\#53G*<G*;<I/Q9.M-^49L
MRKN_J5]XQ]B'DNK]YA@%D1I$ !E@
M
M                 #ZFTTTVFO%'P ;*TR<H[1N/:7[2ZFUISC4BI0DI1?BB
M,';;UZE"7%3EMYKP9":;\)19) 8=G?TZ^T9>Q4\GT?N,PKF-)@ ,
M
M                           &NO,C&&\*&TI?M>",Q&V-Z9=S<T[>.\WS
M\(KJS2W=Y4N'LWPP\(HZ)SE.3E-MR?5LXEM:Z1F=@ )(@
M
M                                            !GV>1G2VC6WG#S\4
M8 ,3&V8G23TJD*L%*G)2B_%'(C=O7J4)\5.6WFO!FZL[VG<+;ZM3]E_@5372
M<3ME  BR
M                                    '"K4A2@YU))11U7=W3MH\^<_
M"*-'<5ZE>?%4?N7@B5:[8F=,B]OYU]XPWC3\O%^\P@"V(T@  RP
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M
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M+YJIFK_)W.8S$DTKBM'AX>);-[-MN37+=OHRQB5=Z[L3KV>>>SG_ /$7J/\
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M/!^#,\JF-+(G8 #
M                             '"O6A1IN=1[)?:!]J3C3@Y3:45U;-)?
M7LKAN,=XTO+S]YUWEU.YGSY072)CEM:Z\H3( ":(
M                              -%J#2.#U#>6MUF<?3NKBU_J9RE)<//
M?P:WY^9O0 R  ,
M                                        ;3'Y#I3N'Z*?\S5@Q,;9
MB=)2#2X^_=':G5>]/P?D;J+4DG%II]&BF8TG$[  89
M                                                  .FZN(6]/BE
MS?A'S ^W-Q"WIN4W[EXLT-S<3N*G%-\O!>".-Q6G7J.=1[OP7D=9=6ND)G8
M"2(
M
M                             !F6%[*W?#/>5)^'E[C#!B8VSX2B$HSB
MI0:<7T:/IH+&\E;2V>[IOJOQ-[3G&I!2@TXOHRJU=)Q.W( $60
M                                                    .FZN(6]/
MBES?@O,#Y=W,+:GQ2YR?2/F:&O5G6J.=1[M_8*]6=:HYU'NW]AUEU:Z0F=@
M)(@
M
M                                  !DV-W*VGYTWU1C 3&V4GISC4@I
MP>\7XG(T%C=RMI^+IOJOQ-[3G&I!3@]XOHRFU=)Q.W( $60
M                                            X5ZL*--SF]DOM XW
M->%O2<Y_!>9'[BM.O4<YOGX+R.5U7G<57.?3P7DCI+JUTA,[  21
M
M
M                              R["[E;3VENZ;ZKR]3$!B8VRE$)*<5*
M+WB^:9]-'CKQV\N";WI/[#>)II-/=/Q*9C2<3L !AD
M                                  -I)MO9(#C4G&G!SF]HKJS07MS*
MYJ;OE!?51V9"[=Q/A@_T4>GKZF&6TKKNA,@ )H@
M                                         <*U:G1CQ5JD*<?.4DD"
M9B(W+F#4W.H<90WWN54:\*:<OMZ&LN-8T%O]'M:D_6<E'[MRR,5Y\0T\GJ'&
MQ_6O'Z_HE(()7U=?3W[JG1IKW-O[S KY[)UM^*[J)?N;1^XMCBWGRT;^N\>O
MU8F5E'15O+:E_6W%&'\4TBKJMS7K?UM:I/\ BDV=1..)\Y:E_P#4'_7'^?\
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M)0:ZVS>.N/ZN[II^4WP_>;",E**<6FGXIE4UF/+>IEIDC=+1/W/H ,)@
M                                                         ;'&
M7G=M4JK]A]&_ UP,3&V8G24@UF+O-]J-5\_U6_N-F4S&DXG8 ##(
M                                        :C*7G&W1I/V5]9^?H=^3
MN^ZBZ5-^V^K\D:8LI7WE&9]@ %B
M                        #XVHIMM)+Q9J;[46/M-UWW?37ZM+VOMZ$JUF
MWB%>7-CPQO):(;<^2DHQ;DTDNK9"+W5UU4W5I2A1C^U+VI?R-%=WUS=RWN:]
M2IZ2?)? OKQ;3Y[.1G]=PT[8XFWY1_GX+ O,_CK7=2N%4DOU:?M?W&EN]8OF
MK2U]TJK_  7\R(@OKQJ1Y[N3F]:Y.3ZNJQ]G]VUNM0Y*XW3N73B_"FN'[>IK
M*E2=23E4G*<GXR>[.(+HK%?$.9DS9,L[R6F?O  25
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M&\QMWW\.";_21^U&C.5.<J<U*#VDN:9BT;9B=).#HL[F-S2XERDN4EY'>4+
M                                             ,>^N5;4F^LWRBCM
MJU(TJ<IS>T41ZYKRKU7.7P7DB5:[8F=.N4G.3E)[M\VSX 7*P
M                                          !K<EF[+'[JK5XJJ_Q<
M.<O[OB13):IO+C>-LE;T_-<Y/X_R+:8;7\-#D^I<?C=K3N?E"9WM_:V4.*ZK
MPI^2;YOW+J1O(:OZQL*'^?5_DB)5)RJ3<ZDI2D^KD]VSB;5.-6//=Y_D>MY\
MG;']&/S9=]DKR^?^$UYS7[.^T?DN1B &Q$1':'(O>UYZK3N0 &4
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MXZJSN  &&0
M=UK7E;U5./3Q7FB0TJD:M.,X/>+(P9N-NNXJ<$W^CE]C\R%J[[I5G3>  J3
M                                        #796ZX(=S!^U+ZS\D9B-
MDSIB9*Z[^IP0?Z./VOS,( NB-*P &6
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M>YJ/VE]5^:\C9$7C)QDI1>S7-,D%E<*YHJ7ZZY27J57KKNG660 ""0
M                              ;23;>R0'3=UU;T7-\WT2\V1Z<G.;E)
M[R;W;.^_N7<5FU]1<HK\3&+JUU"$SL !)$
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MWV=P[>LI+ZKY27FCH 92B$E.*E%[Q:W3/IJ<1<\+[B;Y/ZOO\C;%$QJ4XG8
M##(                                :W+W/#'N(/F_K>[R,VZK*A1E-
M]5T7FR.SDYSE*3WDWNR=(WW1F7$ %J
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M1(+"X5Q03?UX\I$?.^RN';UU+]5\I+T(VC<)1.DB BU**<7NGS3!2F
M                        !A92X[FAP1?MSY>Y&8C8U^2N>_K<,7[$.2]?
M4PP"Z(TK  98                                         #Y.481<
MIR48I;MM[) ?2-Z@U)"TXK>Q<:EQTE/K&'\V:W4.I)5^*VQ\G&CTE47)R]WD
MB,&YAX__ "N\YZCZQK>+CS^/[?NYUJM2M5E4JSE.<GNY2>[9P -QYJ9F9W(
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M'^1LR,4YRISC.+VDGNB1VU:->C&I'QZKR95>-=TZR[  02
M            !\E)1BY2>R2W;([=5G7KRF^CZ+R1L,Q<;15&+YOG+W&I+:1[
MH6D !-$                                         .B]NZ-E;RKW$
MU"G'YOT7J(C?:&+6BL3:T]H<[BO3MJ,ZM>:A3BMW)D!U!GJN2FZ5+>G:I\H^
M,O5_R,?.9BME*WM;PH1?L4]_M?J:PW\.#I[V\O)>I>JSGWBQ=J_K_8 !LN(
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M=X38&BTSJK$ZCI.6-N4ZL5O.A4]FI'X>*]5NC>ED3$QN&I>EL<]-XU( #*"
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M&<[)CG'.I>UX?,Q\NG53S[Q\GT %;;
M          #/Q-QW5;NY/V)_8S !B8WV9CLE(,;'W'TBW3?UX\I&24:TL
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MU*M2;<J=*IS5.;ZR3ZOTWZ$M!&:Q;4S[+<>:^.)BDZWY0+M1UBL'92L+&?\
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M[63Y/_)O^1/(R4XJ46G%K=->)S<F.<<ZE[;A<VG+IU5\^\?)] !6W
M                                 &5CKCN+A;OV)<G_ #-^18WV+K]]
M;[2?MPY/\"N\>Z=998 *T@                    !PKU51HRJ2Z11&YS<Y
MRE)[MO=FQS-?>4:,7R7.1K"VD:C:%I  31
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M+BC_ *+W1+\5VI7]':.2LZ-S'QG3?=R_%?<61FK/EHY/2LU?J3$K@!$\1K_
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M&N6^R;WWY^*=N)**2BDDNB15CI:]NN_X0W^3R,>#%_#X)W,_6GYOH -EQP
M   (SJ_1N,U)3=2XI<%]&#5.O!\+W\.+S6Y)@8M6+1J5F/+?%;JI.I5AV==G
MM;&Y">2U!&,[BE+:WI<2FE^^WY^7EU\BSP"./'&.-0LY/)R<F_7D  3:X
M     232V==I*-I=R_P=OV)O]1_R(V"-Z1>-2OXW(OQLD9,<]UNI[K== 0_2
M6<X>&QO)<NE*;\/W7^!,#F9*32=2]SQ.53E8_B4_'[  $&R
M                        !DV%?N+B,F_9?*7N,8"8VRE(,/%U^^ME%OVH
M<G[O S"B8TL@ !@                #A6J*E2E.72*W.9J\S6V4:,7U]J7X
M&8C<L3V:RI-U*DIRZR>[.(!>K
M     "":JS?TRH[6UE_@T'[4E^N_Y&QU?FN[C*QM9>VUM5DO!?LD,-WCX?\
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MK>S+X>#^!?7)%G&S\'+@[S&X^<)$ ";3
M  G.E,W]+IJTNI?X1!>S)_KK^9!CE2J3I5(U*<G&<7NFNJ97DQQDC4MSA<R_
M$R==?'O'S6V#5:>RT,I:;RV5Q#E4C^*]#:G,M6:SJ7N<.6N:D9*3N)  86
M                                   #*QU?N+F+;]F7LLWY%B08ZMWU
MM%M^U'V65WCW3K+) !6D                ^2DHQ<F]DENR-W%5UJTZC_69
MM\O6X+?NT_:G]QI"VD>Z%I  31
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M\?>N?O+2LKNWOK:%Q9UH5J,UO&<'NF;%;Q;PX&?BY./.KQ^+O !)K@
M                    R<;>U<?=PN*#]J/5>$EXIEEX^\I7UI"XH/>,ET\4
M_)E5FYTSEGC;OAJM_1JKVFOV7^T:^?%UQN/+L>D\_P#AK_#O/T9_*?G^ZQ ?
M(M2BG%II\TT?3GO8@                                     9N)K=W
M<\#?LSY?'P,(^IM--=48F-QIF$H!U6M55J$*GBUS]YVE"P
M#HOJO<VTY)^UMLO>(&FR-;OKJ;3]F/LHQ@#8B-*P !@
M                  = 1O6.5^C6_P!#H2_355[;7ZL?[R5*3>=0HY/(KQ\<
MY+^S0ZIRWYPN^ZHR_P &I/:/[S\6:0 ZE:Q6-0\'GS6SY)R7\R  DI
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MZD:2?*/-^\V[:C%M]%S(U7J.K6G-_K/<G2.Z-G6 "U
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MZ/ZT5OMR90>MM-W6DM4Y#!W\HSK6E3AXXK93BTI1DO?%IEE;Q;LJMCFO=I
M25@    "8:)UM=8"<;:ZXKC&M\X;^U3]8_R^XNK&W]MDK.G=6-:-:A46ZE'[
MGY/T/,IO-*:EO=.7O>6TN.WF_P!+0D_9FOP?J6X\G3VES.;Z?&;=\?:WZO1
M-9I_-6>=L(W5A4XH])P?UH/R:-F;43MYVU9K/3;R  (@
M     ;33N3>,OXSDWW$_9J+T\_@:L&+5BT:E9BRVPWC)3S"W(M2BI1:::W37
MB?2,:+RG?T'95I?I*2WIM^,?+X$G.7>DTMJ7ON+R*\G%&2ON  @O
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M64Y,FNT.MP.!\7_V9/'Z_P!G*ZN*UW<5*]S4E5K5'Q3G)[MLZ@#6>AB-=H
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MT2W9],3*5.[M))=9>R9B-C259NI5G-]9/<X %ZH
M               XSG&$)3FTHQ6[;\$#PC^L\C]&L5:TW^EK]=O"/C\^GS((
M9F8O99#(5KA[\+>T%Y170PSIX:=%=/">H\K^*SS>/$=H^X !:T0
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MU>"K"LKGZ,XJ,I58)[TII=)-2W3Z-\/AS*T_)O[15A[^>C=2RVQMW.4+?O\
MI1JODZ<D^D9/?EX2][(UV=ZGRO8YVAW>.SE.HK)U%0OZ$>:<?U:L//9/=>:;
M7B1WM@U!A=3ZZOLKINRJ6MI62XW4Y.M4Y\53A_5WY<O3=\VQ%/-?8G)XO[G;
M!@\/I_7N1L=.7U&[Q^ZJ15*7$J$GOO2;\>'[FD^:9"P"V(U&FO,[G8 #+
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M/\U-_2^'?SBK_+7Z*XNNS&/-VN3:\HU*6_VI_@:6\[/,U0W='Z/<K]RIL_\
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M+AW:Y<*YKP/,FHL+?Z=S-UBLO0E;WMM+@J0?/U33\4ULT_)EE+Q93?'-):X
M$U8  -KIK.W6G\E"[M);KI4IM^S4CY/^9?\ @LM:YK&TKVRGQ4Y]8OK"7C%^
MIYK)#HK4M?3F351<4[.KLJ])>*\UZHMQWZ>T^'.Y_"C/7KK]:/S>@P=%E=4;
MVTI7-K4C4H58J4)+Q1WFT\U,:[2  ,                   '*G.5.I&<&X
MSBTTUX-'$!F)UX6AA[Z.1Q]*XCMQ-;37E)=3-()HO(?1[YVM1_HZ_3TEX?/I
M\B=G,RTZ+:>Z].Y7\5@B\^8[3]X "IO
M      S,55[N[2?2:X3>D7C)QDI+JGNB34IJI3C-=)+<JO'NG5R !!(
M#3YJIO5A372*W?Q-P1R[J=[<U)^#?+W$Z1W1LZ0 6H
M                 $<UI?\ T>P5K!_I*_7TBNOS_F2-O9;OH5CG;YY#)UJR
M?Z/?AA_"NG\_B7\>G5;?R<GUCE? P=,>;=OP]V  #HO&
M      8V2OK?&V-:[O*BIT*4>*3_  7J9)27:9JG\\W[L;*IOC[>75/E5GXR
M]RZ+YD+VZ8VVN)QIY&3I]O=H=5Y^XU#E9W5?>-)>S1I;\H1\O?YLTP!J3.^\
MO5TI%*Q6OB  &$@%C]C/9?>]H&7[RMWEM@K:2^DW*7.3_P G#SD_/P7-^"??
MV\=G%/0&H;?\VSJU,/?0<[=U.<J<H_6@WX[;II^3]-R/7&^E/X=NGJ]FL['N
MSZKVA:EG9.X=K86U/OKJNEO)1WV48K]IOSZ;-^&S])4= T=&]FFJ(=F5W=W6
M1OJ2=.JZ\)SXH<FH2BESX7+;QW,?LORN#U[V99#&:=H6F%S2QTL?7ITH;.EO
M&2C--<Y0;DWOU3;\>;I#L^U=G.QO6]SBLW0K?0744+VSWW6WA5I^&^W-/I)<
MO)JF9M>9^SV;%8KCB)^?NE_8;VOUH74M+:^N9W5E=-T:5U>/C=.3Y.G5<NL7
MTW?3H^733]I> N.Q;M&QV=TM=4U9W+E4HVTY[RC'=<=*:ZN#WY/\5N_OY2MC
MI&M=XW4.F<C;5+[*+O:]M0>ZG%K=5GM]1M\FGU?/JGO360R%YD:T:N0N[BZJ
MPA&G&=>HYM1BME%-OHO(G6L3]*/=7>\UCIGO,>);WM#UGD==:BGE\M&C3J<"
MI4Z5&.T:<$VU'S?5\WY_ C(!;$:[0IF9F=R  ,    YT*-2XJQI4*<ZE63VC
M""W;?N)_IOL[J5>&OFYNE#JK>F_:?\3\/A]A3FY&/!&[RW.'P,_,MTX:[^WV
MC\4&L+&ZR%=4;*A4KU7^K!;[>_R)Y@NS><E&IF;C@77N:+W?QET^7S+"QV/M
M<=;JA8T*="DO""Z^K?B_>91P\_JN2_;'VC\WL>#_ *:P8=6Y$]<_+V_O_G9K
M\5AL?BJ?#86M.CRV<DMY/WM\V;  YEK3:=VG<O1TQUQUZ:1J/L  12 WLFWT
M0.-3^KE[@(S_ $\P'_6Y_P"IG_(?T\P'_6Y_ZF?\BEP=C^ Q?.7D?_/<GY1_
M*?W71_3S ?\ 6Y_ZF?\ (WF*R5IE;2-S85E5I-[;KDT_)KP//9N-,9^YP-\J
MU!\=&7*K2;Y37X/R9#)P*]/T)[KN/Z]?KB,T1T_9_P#5LY+5V'QM[5M+NXG"
MO3VXHJG)[;K?JD8W]/,!_P!;G_J9_P BMM<S[_5%Y6A&7#45.2W7@X1-#PR_
M9?R,X^#CM6)F98S^M<BF2U*Q&HF?:?W7/_3S ?\ 6Y_ZF?\ (V>%U#C<S.I#
M'W"J3IK>47%Q>WGL^I0O#+R?R.^PO*]A=T[FTJ2IUJ;WC)?[]#-N!37T9[HX
M_7LT6CXE8U]G_P!>B :C2F7>;PM&\E3[NHVX3BNG$NK7H;<Y5JS69K+U&/)7
M)6+U\2  BF  #1YK2N)RZE*XME3K/_'4?9E\?!_'<K[.]GV0LN*ICI*]HKGP
MI;5%\/'X?(MT&Y@YV;#VB=Q\I<OF>C<7E][5U;YQVG^_XO.%2G.E4E"K"4)Q
M>SC);-/W'$OO.:?QV:IM7M!.IMM&K#E./Q_!E8ZDT-?XI3K6F]Y:+GO!>W%>
ML?Q7V';XWJ.+-VMVEX[G^@<CB;O3Z=?G'G\81( '0<(     9U?)7E_2L;3(
M7]S4M+5=W1C4G*<:$&^?#%ODO1'I35&O--]F79A88;L]O*%Y?WU+CIW--J3C
MORE7J>4WMLHOIMY1V/+IW6-2C2O;>I=T77MX5(RJ4E+A<XI\X[^&ZY;D;4BW
ME92\UWIZ"_)?T5?5,M5USEZU2A94HU8T95);.XE)-3G)O]5<^?B_<5QVSZ@I
M:X[3+^[P=&I<6Z4;:@Z<'*5906W$DN?-[[>FQ.NT_M9HZJPF(TAV?VU6SL[N
M-.A6@X]V^;48V\4OU>F[77DNF^]RZ(TGA^SC"T\/AY8ZMJVZMIU8RN9\$[NI
M%<UOU4$VN2\.?7=E/5-9ZI\KXK%HZ*SVCW>)KVSNK&LZ-[;5K:LENX5H.$OD
MSH/6&(J7W:_A]4:=UY@*&.S>(:[BZI4W'N9R4N%<VW^JF]GM*+]S/)[6S:?5
M<BZMNKLHO3I[QX  25@  G/9GJQX>[6/OI_\7UY>S)O^JF_'W/Q^?F74N?0\
MN%O]E6JOIMNL1?U-[FC']!.3YS@OU?>ON]Q?BO\ \9<7U/A[_P#=3\?W6* #
M8<(                     ?82<)QE!M2B]TUX,L_#WJR&.HW"VXI+:2\I+
MJ5>2;0]]W5W4LYOV*JXH?Q+^:^XU^13JKOY.QZ-RO@Y^B?%NWX^R;@ Y[V(
M                                 !O,14X[7A?6#V^!HS88:IPW$H>$
ME]J(VC<)5\MR "E,     =5W4[JVJ3\4N7O(V;G-5.&A&'[3W^1IBVD=D+
M)H@                                  TNK+[Z'B9QB]JM;]''W>+^7
MWE>&\UA>_2LK*E%[TZ"X%[_'^7P-&=+!3II][Q/JW)^/R)UXKV_?\P %SF
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M2]\=G_F,KM3IKN/9=3)-[36WB5)Z.U-DM)9^VR^&K=W<T7S3^K4CXPDO%/\
MOZHM;MT[0-(:ZTKAKJQM:T=3+^L]GA^CPY\5.<MMIIOG';W\MVG7_:[INGI3
MM#S.*MG'Z-"KWM%1>_#3FN.,?@GM\"'EG3%M65=4UB:  )*P   !%.4DHIMO
MDDO$ 2#3&E;[/34Z<>YM$]I5YKE[HKQ9)='Z"<U"\SL7&/6%MT;_ (_Y?/R+
M*ITX4J<:=*,80BMHQBMDEZ'(Y?J<4^AA[S\WJO2_].VS:R\KM7Y>\_?\OU^Y
MJ=/Z=Q^#H\-G2WK-;3K3YSE\?!>B-P <&][7GJM.Y>TQ8J8:Q3'&H@ !%8
M   !QJ?U<O<<CC4_JY>XS \XF[U!_P FX+_PC_\ ,F:0W>H/^3<#_P"$?_FS
M/0V^M7_/9\]Q?4O]T?K#KT_3A4HY?O(QEPV4Y+=;[-2CLS4&YTW_ %.9_P#
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M[;,[C76     #2YB?%=</A&.Q@';=3[RXJ3\Y,ZB^(U"N0 &6
M                      QLG=*RL*]Q+_%Q;7J_!?/8R2*:[N^&C0M(OG-]
MY+W+DOQ^1/'7KM$-7FY_X?!;)[^WWH=.3G.4I/>4GNWYL^ '5>!  &
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M3=%-H[K*^  $60Z[F?=V]2?E%G8867GPV;7[32_$S'>26C !>J
M                         *SU#=_3,O<5$]X*7!'W+E_?\2?YJZ^A8NYK
MI[2C':/O?)%7FYQ:^;/.>OY^U<,??/\ 3^H #<>9                   /
MC:2;;V2\3Z0WM1SGYJT]*WHRVN;W>E';JH?K/Y/;XF)G4;68<4Y;Q2ONJ_7F
M=>>U!6K4Y;VM+]%07[J\?B]W\B.@&E,[G;V&.D8ZQ2OB  &$P
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M3_:297=.KD "M(-5FY\Z4/>S:FCRT^*\DOV4E_O\R5/+$^&$ "Y6
M                          "*Z\NN&WM[:+YSDYR]RY+[_L(8;C5ES](S
M=9)[QI)4U\.OVMFG.GAKTTAX7U/-\;DWGVCM_( !:T
M "@.T+-?GG4MQ.G+>VH?H:7DTGS?Q>[^1;FO\Q^9M,W5:$N&O57<TO/BEX_!
M;OX'GXHS6]G;](P><L_=  #7=P             "Q>S+3/&XYB^A[*?^#PDN
MK_;_ )?/R(UHK 2SV54)IJTH[3K27EX1][_F7?2IPI4XTZ<5&$4HQBELDEX'
M(]3Y?1'P:>9\O5?Z=]+^-;^*RQ]&/'VS\_P_7[G( 'GWN
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M"N?9NK9OHU4BOL?X$N.7EKTWF'O?3\WQN-2_OK7\NP "MN
M                  !O\7/CLH><=T: V^$GO3JP\FG_ +_(A?PE7RV0 *DP
MC=W+CN:LO.3)'.7#"4GX+<B[>[;99C1L  L0
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M6+%7#2,=(U$  (K
M        !!^T[ ?3K#\Y6T/\)MH_I$E]>G_=U]VY4QZ0DE*+C))IK9I^)1VM
ML(\)FZE*G%JUJ_I*+_=?A\'R^1WO2N3U1\&WMX>*_P!2^G=%HY>..T]I^_VG
M\?\ /+0  [+R0             NCL@RWTS3]2QJ2WJV<]EO^Q+FOMXE\B>%#
M]F&4_-NJ[>,Y;4;I=Q/WOZO^TE\R^#;Q6W5Y?U'#\+/,QXGN  L:
M           -MI2X^CYNWW>T:F]-_'I]NQ8Y4E&HZ56%2'UH24E[T6Q0J*M1
MIU8?5G%27N9I<JO>)>I] R[QWQ_*=_S_ /CF #4>@
M             #8866US./G$UYDXV7#>T_5[&+>&8\I  "A8Z+Z7#9U7^[M\
MR.F]RTMK.2_::7^_R-$6T\(6  31
M"):]K^Q:VZ?5N;^Y?B2TK[6=;O<W.._*E",/Q_$OXT;NY7K.3HXLQ\YB/Z_T
M:, '1>+                   (5VM9+Z%I>5O"6U2\FJ?KPKG+[DOB34I?M
MAR/TG45*SC+>%I22:_>ES?V<)7DG56[Z?B^)GC[.Z!@ U'J@
M!DXVSJY"_H6ENMZM::@O3U+^Q=E2QV/H6=NMJ5&"BO7S?O?4KWLEQ'%5N,K5
MCRA^AH[^?ZS^6R^++,/.^J9^O)\./$?J][_IKA?!P3R+1WOX^[^_[  .4]*
M                                                       $:U_A
MOSO@:CIQWN;;>K2VZOSC\5]J1)068LDXKQ>OF%/(P5Y&*V*_B8>;@2'7>(_-
M&H*\*<=K>M^FI>23ZKX/?["/'L,=XR4B]?$OE.?#;!DMBOYB=  )J0
M    <J4Y4JD*E-N,XM2BUX-'I3!7\<IA[.]AMM7I1FTO![<U\'NCS27+V-Y'
MZ1@+BRD]YVE7=+]V7-?:I%V&=3IRO5L75BB_R_JGX -EYT
M     L?2M?O\';-OG!.#^#Y?9L5P3305;BM;J@W]2:FOBMOP-?DQNFW8]#R=
M')Z?G$_NE( .>]B                                '.A+@K0EY23.
M#*4@XTI<5*$O-)@UUC S<OT-./G+<TYL\V_;I1\DV:PNIX0GR  DB
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M+?K/@^?+\2&2-TF&WP;_  ^12WVPLL '*>^
M         !(K"7%9TG^[L#JQ+WLHKR;0*)\K(\,',O>Z2\HK\3 ,O*O>]GZ)
M+[#$+J^$)\@ ,L                                -9J:IW6"NWYQX?
MF]OQ*U)[K>IP891_;JQ7WO\  @1O\6/H;>1]=OOD17Y1^X #9<0
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MU2,]_1^R_O7R-WT_+\//7[>SD>N<?X_"O\Z]_P"7]MJ> !ZI\T
M   'HW2-Y]/TSC;AO>4J$5)_O+D_M3-N0CL@NN_TGW+?.WKS@EZ/:7_J9-S=
MK.XB7C^33HRVK]H "2@                .RVJ=U<4JBZPFI?)G6 S$ZG<+
M=3W6ZZ QL94[W'6M3]JE%_89)R)C79]'I;JK%H]P &&0
M               &YPKWMIKRE^ .&#?LUEZI_>"FWE9'A@Y![WE7W[&.=UV]
M[JL_WW]YTEL>$  &6                                $4U]4VH6=/]
MJ4I?)+^9#24Z]GO=6L/*#?S?]Q%CI<>-8X>(]7MU<N_X?H  N<T
M         %!]IMS])UG?\]XTN&FOA%;_ &[D7-CJ2O\ 2M09.OONJES4DO=Q
M/8UQHVG<R]E@KT8ZU^40  PM          !N=&VGT[4V.HM;Q[U3DO2/M/[B
M^"I>R6V[W/7%=KE1H/;WR:7W;EM'G/5K]6:*_*'O_P#3&'HXDW_[3^G;]P '
M+>C
M     P\Q:*^Q-Y:M;]]2E!>]I[?:9@,UF:SN$;UB]9K/B7FYIIM/DT#9ZFMO
MH>H,C02V4:\N'W-[K[&C6'M*6ZJQ:/=\BR4G'>:3YB=  )(           M'
ML1N>>5M6_P#)U$OFG^!:92O8Y7[K5-6EORK6TH[>J<7^#+J-O%/T7F/4Z]/(
MF?GH !8YX                  +)TQ4[S!6C\HN/R;7X&T-%HN?%@X+]B<E
M]N_XF].5DC5Y?0.%;JX])^R/T  0;(
M #9X-_I*J]$#AA7M<3_@_% IOY65\,.N]Z]1_O/[SK.53G4E[V<2Z$  !@
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MGW:_2X<K85OVZ+C\I;_B0$];PK=6"D_8^7^KX_A\W+'V[_GW  ;3F@
M    D_9G6[G6N.?A-S@_C!E^GG/1M3NM5XF7_P!337SEM^)Z,-G#X>>]7C_V
MUG[  %SD@                  G.A);XNO'RK/[D20BN@9?X-=Q\IQ?V/\
MD2HYF;Z\O=>ESOB4^[^H "IO@                               ,O&R
MX:\G^[^*!U6KVJ/W A,=THEU/JSX 31
M     !76K7OG[GTX5_LHTYM=4O?/7?OC_91JCJX_J0^?\R=\C)]\_J  FU@
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M:%I=K\?^++"7E6:_V?[BK3U'ID[X]?Q_5\X_U#&N??\ #](  ;[B
M   SL#/N\YCI_LW--_*2/2QYBQTN&_MI>56+^T].FQ@\2X7K$?2I/W@ +W%
M                 !+] /E?+^!_VB7$.T _TE\O2'XDQ.;R/]R7M_1Y_P#P
MZ?C^L@ *72                                <J;V;!QZ QID !E@
M                                %;:H_P"7KS^)?<C5FUU2ML]=^^/]
ME&J.KC^I#Y]R_P#?R??/ZR  FUP                C?:-O_0O*;?L1_MHD
MA'>T&/%HW*K_ .4G_M(C;Q*[C_[M?OC]7GT &D]B             +YT=_S7
MQ>W^0C]QN#1Z(EQZ4QC_ /E;?)M&\/&Y_P#<M]\OK7#G?'QS_P#S'Z  *FP
M             7)\@ #;;W;W8    #[NTFMWL_ ^
M                      0+M>_Y'L?/O_\ TLJLM'M@EMCL?'SJR?R7]Y5Q
MZ?TS_P#7C\7SG_44_P#YUONC]  '0<,          ';:;_2J.W7CC]YZ?/,6
M/CQ7]M'SJQ7VGITV,'NX?K'FGX_T  7N(                  "6: _KKW^
M&'XDQ(=H!?I+U^D/Q)B<WD?[DO;>C_\ ZE?Q_60 %+I@
M                /J6X#)+ZS]Y\.57E4FO5G$,
M              KK5JVS]SZ\+_V4:<WFLH[9RJ_VH1?V;?@:,ZN+ZD/ <Z-<
MG)]\_J  FU0                TFMH<>DLNO_IYOY+?\#=FNU'3[[3^3IKK
M*VJ+_99B?"S%.KUG[8>;  :+V8             NSLYJ=YI"Q\X\<?\ ;9)2
M&=E%;O--5*>_.E<27P:3_$F9Y'EUZ<]X^V7U3TN_7P\4_P#\Q^78 !K-X
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MG/1M/O=58F/_ -33?REO^!Z,-C!XEP?6)^G6/L  7N,
M "7Z 7*^?\"_M$N(KH&.UM>2\YQ7V/\ F2HYN?\ W)>X])C7$I^/ZR  I=$
M                              !SHK>3]P.RS7%4:] 1F68<+A;7%5?O
M/[SK.Z\6UW67[S.DS'@  98                                0/7,=
MLO!_M45][(\2G7L-KNUGYP:^3_O(L=/#.Z0\+ZG7IY5X^T !:T
M       Z[BFJM"I3?2<7'YH[ &?#RY.+A.49=4]F?#8:BH?1<_DJ&VW=W-2*
M]W$]C7FB]K6>J(D !AD          %E=CUQ[&3MF^CA42^:?X%CE/=E=UW&I
M^Z;Y7%&4-O5;2_!EPGF/4Z=/(F?GI]&_T[E^)P:Q_P!9F/Z_U  <]W
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MMNG^!&N>L32?DG?@Y+4SUC7TY[-U;_\ 2B__ .9R_MLR^U__ )RV_P#X6/\
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M"/"H[]?N74EFSQ:)Z;3W]M0KX?!OBM7KI'T??<_E"==KW_)6(_BE_91RPO\
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M^*!V85;W%1_N_B"JT]TZ^'1D5M>U??\ @8QF99;7LO5)F&65\(R  RP
M                           BFOJ>]"SJ?LRE'YI?R(:3W6]/CP\9?L58
MO[&OQ($='C3NCQGK5>GE3/SB/V  7N2                  "@NTNV^C:SR
M"VVC4<:B^,5O]NY&"P^VFU[O-V5TERK4'#WN,G^$D5X:=XU:7KN'?KP4G[
M$&R          #8:=O/H&<L;IO:-.M%R_AWV?V;GH$\W%^:4OOSCIZPN=]Y2
MI*,W^]'D_M1Q/6,?U<GX/8?Z4S]\F"?LG^D_T;4 '#>R
M     'V$I0DI0DXRB]TT]FF=EQ<5[F:G<UJE::6W%4DY/;XG4#.S4;V  P
M                                 &KU1>?0-/9"XWVE&C)1?[SY+[6C
M:$%[6K[N<-;V<7[5Q5XFOW8_WM&QQ<?Q,U:_:TO4<_\ #\7)D^4?G/:/S50
M#U[Y4             +0[$;;V\K<M=%3II_-O\"U"#]C]KW&E'6:YW%><T_1
M;1^],G!N8XU6'E.??KY%I_SL  FTP                  63IBGW>"M%YQ<
MOFV_Q-H8V,I]UCK6G^S2BOL,DY-IW:9?1./7HQ5K\HC]  $5H
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MGQ?+G^!BTZB96X:?$R5I\YB%F);))=$ #D/H@
M           -UA5M:R?G('9BH[64/7=_:"BWE9'AU9J.]O"7E(TQOLK'BLI^
MC3^TT)93PC;R  FB                                %696C]'R5U2\
M(U))>[?D6F5]K*CW6;J2VY581G]FWX&UQ9^E,.%Z]CWAK?Y3^K1@ WGDP
M               ?)14HN,ENFMFCS3G+)XW,7MF]_P!!5E!>J3Y/Y;'I<I7M
M@QWT74D+N*VA=TE)O]Z/LO[.$IS1N-NMZ3DZ<LT^<?H@H -9Z$
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M"=.C0M*#FMG.,&W\-WL0DU\V3JB(BV_PTZ'"X\XYM::=,SK_ )3;]0 &NWP
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M76NN[CQVM5?NLC9*6MTT_$B\EPR:?@]BS&C9\ !8@
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MX?'T.?ZCQOC8NJ/,.[Z!S_X3D=%Y^C?M/W^TKD !YA]%
M#)NK^\NJ5.G=75>M3I_4C4J.2C[DS&!G<L36)G<@ ,,@               .
M^TN[BSJ][9UZM"IMMQ4YN+V\MT==6I.M5E4JSE.I-[RE)[MOS;. ,[GPQTQO
M?N  PR             !!^U+-?0\9''4)?I[KG/;K&FOYOE\R97MU2LK2M<W
M$E"C2BYR?HB@\]DZN8RMQ>UMTZDO9C^S%=%\CI>F<;XN3KGQ7]7G_P#4//\
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M&^ !0L".WT>"[JK][?Y\R1&DS$.&Z4OVHHG3RC9@@ M0
M                #KN*4:]"I2G]6<7%_%'8 3$3&I5)5A*E4G3FMI1;BUZH
MXFWU7;?1\W7V6T:FU1?'K]NYJ#K5GJB)?.\^*<62V.?:=  )*@
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M:"MO_BKEKRIQ?VO\"7G/Y%MWU\GLO1,/P^-U?]IW_0 !KNN
M                   &RPD=ZU27E';Y_P#L:TW.%AM;SEYRV^1&WA*OEL
M4IAK,W#V*4_)M&S,3*0X[*?G'9F:]I8GPT( +U8
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M_1M[6]63^J_V'Z>7R+./*<GCVX]^BSZ=P.=CYV&,M/QCY2  UVZ
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MBS2)Z[M-Z="[BN<7W<O=U7X_,V.-;IOKYN1ZU@^+Q^N/->_X>Z'  Z#QH
M               !\E%2BXR2<6MFGXGT >>M<8-X'4%>VBG]&G^DH/\ <?A\
M'NO@: O?M)T_^>\#*I0AQ7EKO4I;+G)?K1^*^U(H@U,E>F7J^#R/CXHF?,>0
M %;<              M#L_U@KB-/&96I^G7LT:TG]?\ =;\_)^/OZU>$]GNN
MI1R./3D4Z;-[@<_+P<OQ,?XQ\X>D05YH36JK*GCLS4VJ_5I7$G];TD_/U\?O
ML,\MGP7P6Z;OI/"YN+FX_B8I^^/>/O  4-L
M                .NXKTK:A.M<5(TZ4%Q2G)[)(S$;\$S$1N7VK4A1I3J59
MQA3@N*4I/9)>;*?UUJR6:K.TLI2CCJ;]SJOS?IY+_=-;:OJ9JI*TLG*GCXOW
M.J_-^GDO]U$3T' X'P__ &9//M'R_N\+ZWZW_$;X_'GZ/O/S_M^OW  .L\N
M             !DXNQK9+(6]G:QXJU::A%?B_1=0Q,Q$;E/NQ[ _2+VKE[B'
MZ.W_ $='?QFUS?P7W^A;I@X3&T<1B[:QME^CHPX=_P!I^+?JWS,XW:5Z8T\E
MR\\Y\LW]O;[@ $FL                   2?0EIQW=:ZDO9IQX(^]_W?>1@
MLC3%I]#P]",EM.HN\E[W_=L4<BW337S=;T;!\7DQ:?%>_P"S:@ YSV8
M                             ,C'PX[RDO!/?Y$A-1A(;UJD_P!E;?/_
M -C;E5Y[IU\  ()   T^:I[5H3\)+;Y&N-WEZ?%:\2ZP>YI"ZD]D)\@ )(@
M                              !BY6T5[CZ]N^LX^SZ/P^TR@9B=3N$;
MTB]9K;Q*HY1<9.,ELT]FCX;O5UE]$RTYQ6U.NN->_P ?MY_$TAU:6ZHB7S[/
MAG#DMCM[  )*0                  "C>T[3OYGS+NK>&UE=MSCLN4)_K1_
M%>_T+R-7J7#T<[AZ]C7V7&MX3V^I-='_ +^&Y"]>J&WPN3_#Y.KVGR\W@R,A
M9U\?>U[2Z@X5Z,G"2]?Y&.:;U<3$QN  !D             "?:*UQ*S5.QS,
MY3MOJTZ[YNGZ2\U]WW0$%.?!3/7IO#;X?-R\/)\3%/?\I^]Z/I5(5:<:E*<9
MPDMXRB]TUYHY%(Z4U9>8&:IO>O8M^U1D_J^L7X/["WL+F++,VJKV%937ZT7R
ME!^37@>:Y7"OQYW/>/F^A>F^KX>?74=K^\?M\VP !INJ
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M C6G]9XO+J--U/HMR_\ %57MN_1]']_H24XN3%?%/3>-2]?@Y&+D5Z\5HF
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M&SLZ-O3^K3BH[^?FSO .5,[[OH%:Q6(K'B  !D
M          .^PI]Y=TX^&^[^!T&SPE/>=2H_!<*,6G4,PVP *%@     &KS=
M/^KJ+^%_[_,VACW]+O;2I%=4MU\#-9U+$^$> !>K
M               (WK:P[^RC=TUO.AREZQ?\G^))#C4A&I3E":4H2333\42I
M;HM$J.5@CD8K8I]U2 R\M92L+^M;RZ1?LOSCX,Q#JQ.XW#P%Z32TUMY@ !E
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MG%I=%NVV^26RZLZ<QB[[#9&O896UJVEY0EPU*56.THO^7KXD]^R&IUMA@ ,
M  $AP6K\MB%&%.OW]NO\56]I)>CZHCP(7QUR1TWC<+L.?)@MUXK3$_8M_"]H
M&+O>&%ZI659_M^U!_P"<OQ2)=0KTKBDJEO5A5IOI*$E)/XH\Y&589"\Q]7O+
M&YJT)>/!)K?WKQ.7F])I;OCG3TG$_P!49:?1Y%>K[8[3^WZ/0X*EQ?:-DK?:
M-]1HW<5^M_5R^:Y?82K'=H.&N=E<.M:3_P#F0XH_-;G,R^GY\?\ QW]ST/']
M=X6?_GTS]O;^WYI@##LLI8WR3L[RWK>D*B;^1F&G-9K.I=6MZWC=9W  #"0
M        .@ &KO\ 4&)L-_I60MX276*GQ2^2W9&<EVD8ZCO&QMJ]S+P<OT<?
MQ?V&QCXN;)]6LM+/ZCQ>/_N9(C\Y_E'=.C$R&2L\=2[R^N:5"/AQRV;]RZLJ
M3*:]S-[Q1HU(6E-^%%<_])\_EL1>O6JUZCJ5ZDZE1]93DVW\6=##Z1>>^2=?
M<X/*_P!4XJ]N/3<_.>T?O^BS<UVD6])2IXBW=>?A5K>S'X+J_L(#F,[D<Q4X
MK^YG4CONJ:Y07N2Y&M!UL'#Q8/J1W^;S/,]5Y7,[9;=OE':/\^\ !LN<
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M2+5FM,WJJUQ=MF;OOJ&-H*A;P2V2223D_.326[?D1TNI$Q&I47F)M,P  D@
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MKS*7][O]+O;BLGX3J-KY&&"^F''3ZM8C\&EEY>?-_N7F?OF0 %K6
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MV9UW%-5J,Z;_ %D9K.I8F$:!]DG%M/DUR9\+U8
M               Q,I94\A8U+>I^LO9E^R_!E8W-"I;7%2C6CPU(/9HMDC&L
ML5W]#Z;0C^EIK:HE^M'S^'W&SQ\G3/3/B7$]9X/QL?QJ?6K^<?V0D &^\B
M                      &@U9IBRU':<%PN[N8+]%7BO:CZ/S7H;\&)B)[2
MG2]L=NJLZEYOU#@K[ WKM[^EMOSA4CSC47FF:L]+Y?&6F6LIVN0HQJT9>#ZQ
M?FGX,I?66A[S RG<6W%=8[?^L2]JGZ27X]/<:U\4U[P]%P_4*YOH7[6_5$
M5.D     !=NA.U#$0[+*N@LO3JX]UXSMXY&*[RG&%6HW*4X]5LI/IOOMX%)
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MDZ*]O+I^E\+^*R[M]6//[-A",8048)*,5LDO!'T YKVP
M                     $@QU+N;6"?UG[3--8T>^N81\-]W[B1%=Y]DZP
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M\EYO;<O=\3C5XN*,=?\ [( "#9
M  .5*#J5(PCUD]@-MAJ/#2E5?67)>XV)QI05.G&$>D5L<BB9W*R.P ##(
M          $>OJ/<7,XKZKYQ]Q(3 R]#CH=XE[4.ON)4G4L3'9I0 7*P
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M>.XVVE<5.<W[O)>XWP-BN.*N'R.=ES]IG4?( !-I
M        'VG"52<80BY2D]DEU;#/EWX^TJWUU"WH+><GU\$O-EEXVRI8^SA;
MT5RCU?C)^+9@Z;Q$<9:[U$G<U%[<O+T1N#GY\O7.H\/8^E>G_P -3XE_K3^4
M?+]P &NZX                                     &RPU'BJ2JM<H\E
M[S7)-M)<VR1VE%4*$*?BES]Y"\ZA*L.T %28                ))2BT^::
MV8 $;N:3H5YTWX/E[CJ-QF*'%356*YQY/W&G+ZSN%<QH !E@
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M1A$I65I'OE_CJGM3^;Z?#8W@+:TK7PY6;FYLW:T]OD  FU0
M                   FVDL)]&A&]NX_II+]'%_J+S]YAZ3P?>N-[>1_1KG3
M@U];U?H3,T^1F_X5>E]']-UKD98^Z/Z_L  TWI
M                 "YOD!G8BAWE?O&O9AS^)NSHLJ'<6\8?K=9>\[RFT[E9
M$:  19                  !\E%2BXR6Z:V9'+FDZ%:=-^#Y>J)(:_+T..D
MJL5[4.3]Q.DZE&8:8 %J
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M+HD:N?-T_1KY=_TKTOXLQFS1]'VCY_V_5]2222227))'T T7J@
M                              SL30[VOQR7LPY_'P,%)MI+FV2.RH*W
MMXP_6ZR]Y&TZA*L.X %*8                     "24DTUNGR8 $<NZ#H5
MY0?3JGYHZ3>92W[VAQQ7MPY^]&C+JSN%<QH !)@
M                  !BY&QHY"VE0N([Q?--=8OS1767QE?&7+I5EO%\X32Y
M219YC7]E1O[:5"YAQ0?1^*?FB[#FG'.I\.9ZCZ=7EUZH[6CW_I*JP;'-8FMB
M[CAJ>U2E]2HER?\ >:XZ-9BT;AXW)CMBM-+QJ8  95@
M
M                  !O=-X&>0FJ]PG&TB_<Y^B]/4[--Z?E>N-S=IQM5S4>
MCJ?W$ZA"-.$80BHQBMDDMDD:N;/T_1KY=_TOTJ<NLV:/H^T?/^WZE.$:5.,*
M<5&$5LDER2.0!HO51&NT
M !RIP<YQC%;R;V0&=B+?O*KJR7LPZ>K-R==M15"C&G'PZOS9V%%IW*R(T  P
MR                        &@R-OW%=\*]B7-?R-^=%[05Q0E']9<XOU)5
MG4L3&T=!]::;36S74^%RL
M   '3=6U*ZH3HW$%.G+JF0#/X.KC*CG#>I:M^S/R]&6*<:D(U*<H5(J4)+9Q
M:W31;BRSCG[&ASN!CYE>_:T>)5("2:ATY.TXKBQ3G;]90ZN'\T1LZ-+Q>-P\
M9R.-DXU^C)&I  24
M                                             !RIPE4G&%.+E.3V
M22W;#,1MQ)5IO3CJ\-UD(M4^L*3_ %O5^GH9NG=.1M>&YOTIU^L:?50]_FR3
M&GFY'_&CTOIOI&M9>1'W1^_[/B2222V2\$?0#3>C
M                       -KA[?K7DO2/\ ,U]K1=>M&"\>K\D2.$5""C%;
M12V1"\^R58?0 5)@                            #49>VX9=]!<GRE[_
M #-:2>I"-2G*$UO&2V9';FC*A6E"7AT?FBVD[[(3#J !-$
M                             C&H--1K\5QCTH5>LJ?12]WDR3@G2\TG
M<*.3QL?)IT9(5)4A.E4E"I%QG%[.+6S1Q+)S6%M\G#>2[NNE[-1+G[GYH@.3
MQUQCJW=W,-M_JR7U9>YF_BS1D^]X[G>FY.)._-?G^[$ !<YP
M
M           !N,'@;C)24Y;TK;QJ-=?=YD;6BL;E;APWS6Z,<;EK["RKW]=4
M;:#G+Q?@EYMD^P6#H8N'$]JERU[51KIZ+R,['V-"PH*C;048^+\9/S;,DT,N
M>;]H\/7>G^E4XWT[][?I]W[@ *'6
M            ,W%VW?5N.2]B'VLQ,Z9AL,7;=S1XI+VY\_<C, *9G:R.P #
M                             !AY*V[^CQ17Z2'->J\C,!F)T(L#/RMK
MW53O8+V)/GZ,P"Z)VK  98
M     .FZMJ-W0E1N*<:E.75,[@([,36+1J?"!YS35:SXJUGQ5J'5Q_6C_-$>
M+=-%FM.6]_Q5:&U"X?/=+V9>]?B;F+D^UWG>=Z)O=^-_+]E?@R;^PN+"MW=U
M3<'X/PE[F8QMQ,3WAYNU+4GIM&I  91
M                                              .5*G.K4C"E&4YR
M>RC%;MFRP^$NLG)2A'NZ&_.K)<OAYDYQ.(M<93VH0WJ->U4E]9_R*<F>M.WN
MZG"]+R\KZ4]J_/\ 9I,'I:,.&MD]I2ZJBNB]_G[B512C%1BDDN22\#Z#0O>U
MYW+UO&XF+BUZ<<?O( "#8
M      '.E3E5J1A!;R;V)%;T8T*,:<>B\?-F)BK7NJ?>S7MR7+T1GE5YWV3K
M  ""0                                  .-6G&K3E":WBUL1VYHRH5
MI0EX='YHDABY"V5Q1]G^LCSC_(E6VF)C;0 ---I\F@7*P
M                                '5=6U&ZHNE<4XU*;\)(A^8TK4I<5
M7'-U8=>[E]9>[S)J"RF2U/#4Y7!P\J-9([_/W5'.,H2<9Q<9+DTULT?"S<IB
M+3(Q_3T]JGA4CRDOYD-RVG+NQXITU](H+]:"YKWHW<>>M^T]I>6Y?I.;C_2K
M]*OV?UAI  7N4
M                    #E3ISJS4*<93F^2C%;MDEQ&E*M7:ID).E#_)Q^L_
M?Y$+WK2-RV./Q<O)MTXXW^B/6EK7O*RI6U.52;\%X>_R)AAM*TJ/#5R#56IU
M5-?57O\ ,D%G9T+*DJ=K2C3AZ=7[WXG>:>3D3;M7L]/P_1L>'Z67Z5OR_N^1
MBHQ48I**Y)+P/H!K.T
M      &;C+7OZO'-?HX]?5^1C6]*5>K&$.K^PD5"E&C2C""Y(A:VDJQMS !4
MF                                        U66M.M>FOXE^)JR4M)I
MI\TS0Y"U=O5WC_5RZ/R]"VEO9"88@ )H@
M                       U&5P%GD-Y.'<UG_C(+;?WKQ(AE-/WMAO+@[ZB
MOUZ?/;WKP+&!=CSVIV]G-Y7I6#D]]:M\X5$"R,G@+&_WE*GW55_XRGR?Q71D
M4R6F+VUWE12N*2\8?6^7\MS;IGK;['G.3Z3R,'>(ZH^S]FB!]E%QDXR3375/
MP/A>Y8
M  #LMZ%6XJ*G0ISJ3?A%;DCQNDJ]3:=_45&/[$.<OGT7VD+9*T\RV>/Q,W(G
M6.N_T_FC,(2G)1A%RD^226[9(L7I6YN-IWDOH]/]GK-_R)=C\9:6$=K6C&+\
M9/G)_$S#4OR9GM5Z'B^A4K]+/.Y^4>&%CL9:8^'#;4E&7C-\Y/XF: :TS,]Y
M=VE*XZ]-(U  #"0
M   $MWLNH-IB;3I7J+^%?B8F=,Q&V5CK7Z/2WDOTDNOIZ&6 4S.U@ #
M                                    '"O2C6I2A-<G]AS $:N*,J%5
MPGU71^:.LD-]:JYI;=)KZK(_.+A)QDMI+DT75MM7,:?  28
M                                        &'?XRSOU_A-",I?MKE)?
M$C.0TA..\K"LIK]BIR?S)D"RF6U/$M/D<#!R/KU[_/W57>6-U9RX;JA.GZM<
MG[GT,8MR<(SBXSBI1?5-;IFEOM,X^YW<(.A-^--[+Y=#9IRH_P"4.'R/0;QW
MPVW]D_Y^RO02*]TG>T=W;3A7CY?5E\GR^TT=S:U[6?#<4:E*7[T=MS8K>MO$
MN-FXN;!_N5F/\^;I !-K@
M !EV6,O+W;Z-;U)K]K;:/S?(Q,Q'>4Z4M>>FD;EB E5CI"K+:5[7C!?LT^;^
M?_N2&QP=A9;.E0C*:_7J>T_[O@46Y%*^.[J8/1>1E[V^C'V_L@EAAKZ^V="A
M)0?Z\_9C_?\  DN.TC1I[2OJKJR_8ARC\^K^PE ->_(O;QV=OC^C<?%WO]*?
MM\?R=-K;4+6GW=M2A3AY16VYW &OO;K5K%8U'@  9
M                                 .ZUH2N*JA'IXOR09=V.M'<5.*7]
M7'KZ^AO4DELN2.%&G&E34(+:*.93:=IQ&@ $60
M                       ,#)6??1=2FOTBZKS1G@S$Z-(L#:92SZUJ2_B2
M^\U9=$[5S&@ &6
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MV=*V@Y+]:?M/[38KET *9M,^73QXJ8XU2(B/L  83
M                                      #[%.32BMV^B ^TJ<JLU""W
MDR0V=O&VI<*YR?UGYG5C[16]/BESJ2Z^GH995:V^R<1H !!(
M                                       TN2L^Z;J4E^C?5>1NA)*2
M::W3ZHS$Z8F-HL#,R%F[>7%#G2?3T]##+HG:  #+
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M:T^97UP8J?5K$?@=.@ (K0
M                               -SC+/NEWM5?I'T7D<,99;;5JRY]8Q
M?WFS*[6]H3K  "M(
M           !\G&,X.,TG%\FF:&^M)6T]USIOH_P-^<:D(U(.$UO%]42K;3$
MQM& 9-[:2MI^=-]&8Q=$[0  &
M
M
M#9XRQXMJU9>SUC%^/J?,;8\>U6LO8_5B_$VY7:WM"<0  K2
M                                                '&I"-2#A-;Q?
M5&BO;25M/SIOHS?G&I"-2#A-)Q?5$JVTQ,;1@&7?6<K>6ZW=-]'Y>\Q"V)V@
M  RP
M
M                                 !LL=8\>U6LO8\(OQ/N.L.+:K77L
M]8Q?C[S;%=K>T)Q  "M(
M                          'R<8SBXR2<7U3-)?V4J#<X;NE]QO TFFFM
MT_ S6VF)C:+ V-_8.GO4HK>'BO(UQ=$[0UH !E@
M
M
M #[%.32BFV^B0'PVV.L-MJM=<_"+_$YX^P5+:I66]3P7D; KM;VA.(  5I
M
M          !K+_'[[U+=<_&'\C9@S$Z8F-HL^74&\OK&-=.=/:-3[&:6I"5.
M;C--275,NK;:$QIQ !E@
M
M                                     .ZVMYW$^&"Y>+?1!EUTJ<JL
MU"";DS>6-E&W7%+:51^/E[CMM+:%M#:"WD^LO%G<56MM*(T  @D
M
M        !T7=K3N8;2Y2722\#O \".7-O4MY\-1<O!^#.DD]6G"K!PJ14HLT
MM[83H;RAO*GY^*]Y;6V_*$PP@ 31
M
M                                        2W>RYLVECCND[A>Z'\S$
MSIF(VQ[*RG</BEO&GY^?N-U2I0I04*:2BCFDDMER0*IMM.(T  BR
M
M                 -;>XY2WG;[*7C'P?N-3*+C)QDFFNJ9*#'NK2G<1]I;2
M\)+J3K?7E&:H\#ONK6I;RVFMX^$ET9T%OE$  8
M
M                                         .RA1G7GPTX[O[C)L["=
M?:4]X4_/Q9N:-*%&'#3BDB%K:2B-L>RLH6ZXG[53S\O<98!7,[3  8
M
M                         ?)QC.+C))Q?5,U5YC7'>=OS7[/C\#; S$S#
M$QM%FFGLULT"075G3N%NUPS_ &D::YM:EN_;6\?"2Z%M;1*,QIT  DB
M
M                                                   9MICZE;:4
M_8AZ]68F=,L6E3G5FHTXN4O0V]GCH4MI5MIS\O!&70H4Z$.&G'9>+\6=A7-]
M^$HJ  @D
M                                               ))234DFGX, #6
M7>,3WE;O9_LOI\#5U(2IR<9Q<9+P9)SKKT*=>/#4BGZ^*)Q?7E&:HT#/NL;4
MI[RI>W#[48!9$Q/A'0 #+
M
M       <H0E.2C"+E)^" XG;;V]2O+:G'?S?@C86N,Z2N'_FK\39PA&$5&"4
M8KP1";_)**L2TQ].CM*?MS\WT1F %<SM/P  P
M
M                        &-<V=*ONY+AG^TC) B=#07-C5H;O;CA^TC%)
M28ES84JV[BN"?FOY%D7^:,U:$&3<V=:ANY1WC^TNAC%D3M$  8
M
M                         +F^0 )-O9+=F=;8ZK5V=3]''UZ_(VMO:TK=
M?HX^U^T^I&;Q"41MK+7&U*FTJSX(^7B;6A0IT([4XI>OBSL!5-IE*(T  PR
M
M                                                        !AW.
M/HU=W%<$O./3Y&8#,3KP-!<6-:ANW'BC^U$Q24F-<6-&MNW'AEYQY$XO\T>E
M'P9MQC:U/=P_21].OR,-II[-;,G$Q/A'3X #+
M
M !RITYU)<,(N3\D@.)]2;>R6[]#8V^+G+G7EPKR7-FRH6]*@OT<$GY^)";Q"
M45:FVQM6ISJ?HX^O4VEO:4J"]B/M?M/J=X(3:92B-  (L@
M
M                                                     !U5K>E6
M7Z2"?KXG: -57Q36[H3W])?S-?5HU*+VJ0<?>24-*2:DDT_!DXO,(]*+ WM?
M'4*F[BG3?[O3Y&OK8VM3W<-JB].OR)Q:)8U+"!]E%Q>TDT_)H^$D0
M
M     '.E2G5>U.$I/T1G4,74ESJR4%Y+FS$S$,Q&VN.^A:5JWU(/;S?)&YH6
M5"CS4.*7G+F9)";_ "2BK74,7"/.M)S?DN2,^G3A3CPTXJ*]$<@0F9EF(T
MPR
M
M                       .-2G"HMJD(R7JC"K8NE+=TY.#^:,\&8F8\,::
M*MCJ]/I%37[IB2BXO:2:?DR4'&=.%1;3BI+U1*+_ #8Z48!O*N-H3^KQ0?H^
M1AU<75C_ %<HS7R9.+Q+&I:\';5MZM+^LIR7KMR.HDP  ,
M                                        #OI6=>K]6G+;S?(S*6*D
M_P"MJ)>D>9B;1#.I:PYTZ4ZKVIPE)^B-Y2L+>G^IQ/SES,I)16R22]"$W^3/
M2TM'%U9\ZCC!?-F=1QU"GSDG-_O&8",VF4M0^1BHK:*27DCZ 19
M
M
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MN#'7+/3#!I8RA'ZW%-^KV,NG1ITOZN$8^Y',$9F99T  PR
M
M
M                                             <94X2^M"+]Z  ZI
M6=O+K2C\.1U2QMN^D6O<P#.Y8TZY8JB^DYKY'!XE?JUG\8@&>J34.#Q,_"K%
M^]'!XNLOUZ?V_P @"46EC4.J5C5CUE#YO^1U.WDO&(!*)1=;@UY'$ D!]2W
M Y*FWXH[(VTY='$ P.V./JRZ2A\W_([(XJJ^LX?: 1F99B'-8F7C57PB=D<3
M']:K)^Y $.J4M0YQQ=!=95'\3LCC[:/ZC?O; ,=4FH=L;6A'I2A\MSMC&,?J
MQ2]R ,,OH
F                                               __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g769642g36i96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g36i96.jpg
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M,B!H86ER;&EN92!R=6QE<R!C:&%N9V5D('1O(# N,C4N)B-X03LF(WA!.^*
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M-C=R<[+!PN$D8G6"LR5#4Z*T\/$TP],G1(-&8V1VA/_$ !L! 0$! 0$! 0$
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M7"XMD>R41PM<.(#\$N(\PQYUFY3(Z?DJY#:FUZ=FJ&[;S202RO!D!E>YSSD
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M@:UDPC#0S9R2<'ZPZ%2/\']9+'K:\T;7'F)K?SKF]!<R1@!_)[OS4@_C+_\
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MB_5:GS78/O9)[ /_ -HNKI7^'&DLFH[;=)M1S53:*H94"%M((]MS'!P!=MG
MR!T*M*?^(S6\5(V%[;3-(!CGI*9P>?/WKPW^2F?(KJCE%UARA45=>I*YU@CC
MEYW$',TV]A#0, !QVMGPE)C4B)N3&=*9B,82;^)GE#N6DK9;[589G4U=<0]\
ME2SZ<4;<##? 23QZ,'TBGN3#DBO'*91SWNOO/8E)SIB$\S75$LKQ@DX+ANW\
M25;?\46@KEJ6V6Z\V2G?55-N#XYJ>,9>Z-V#M-'3@@[AOW^94ER<\KNHN3ZV
MU%IHZ:DJ:5TID$56QVU$\X!Q@@] W%,/N?8[IJ5U/M]F+EEY-&\G%9;(&W4W
M'LV-[]HT_-;&R0,?2=GBO0'\)W^BZ3_Q";_=8O/G*##K;4]"S6.JJ:=M)-**
M:F:8RQK00YW>,Z&;OI'B3Q.]>AOX4X98>2YPFC?&75\KF[32,C99O'FW%74O
M9R:-=3B.'GS^(;_3%J3_ %XO_18O7W);_HUTG_X52_\ I-7DC^(:CJ?E@U [
ML>;9D=$6'8.'#F6#(\.\+UUR9Q/AY.M+13,='(RUTS7,<,%I$3<@CH*SJ?<A
MO1_Y,E<_Q;0OEY,Z5[ 2V*YQ/?YAS<C<_F1^:KS^#ZNAAU9?*.1S1-44;7Q@
M].P_>!^K/X+T?KK35-J[2=QLE8[8CJH\-DQDQO!RUWX. *\17FPZJY,]2QRS
MQ5-NK::0F"LB!YN3HRQV,.!'$'PX(33K+"<4U;PSC/R>^U'=>2QS<GNI)(7M
MDC=;*DAS3D'^B=TKR#7\J'*)K. 6:.OJJGGALNAH:9K'RCP$L;G'FX+TIIZQ
M7&R_P_RV>X0.%RCL]2UT+>^<'.;(0W=Q.\#<L3I[*MUQU8U+B(>7N0;_ $N:
M:_O!_P!QR]VKPSR#4=3\K>G3V/-B.=Q?WA[T;#MY\"]S+6O]YCPOW9?SRM7^
M?5'_ .),_P#5"_H:OY^6NWU@Y0*2$TE0)1<F LYMVT/Z4=&%_0-77\D\+YB\
MM?QC?Y?TY_=9?]\+U*O+7\8W^7].?W67_?"QH_?=/$?\<IQ_"1502<G-93,F
M8ZHBN$CI(P[OFAS&;)(\!P?R*V_XJ[A#2\ESJ61PYZLJXHXV])V27D_DW^87
MFO24&L--VAFLM+NJ8J1LKZ:6>G&V&%H:2)&$$;)R-Y!'XK4U'J75'*'=Z87.
M>INM8T;$$$,0[W/'98P8R=V3C/!=>G]O=;S]:M/97*R/X1*9\G*'<:@ \W%;
M7M<?.Z2/'^!_):O\6?\ I/@_\-B_WY%=W\/?)Y/H;3,\UV:UMYN+FOF8#GF6
M-!V8\^'>2?.<="I?^+&EJ'<I5-*V"4Q.MT0#PPX)#Y,C*F.49:G"Y8SCHU*\
M_P"&_P#T,Z=__P"C_P"HE63^(BGDJ>1W43(@2YK89"!X&S,<?Y I_#M#+3\C
MNGHYXWQ2 3G9>T@X,\A!P?""#^*G=VM]/=K766^M9SE+51.AE;X6N!!_Q7&9
MK._:].,7IQ'L>._X7*V&DY5Z:.9P::FEFACSTNP'8_)I7L]>%M><GFI>3B_]
MD1Q5+J2"42TESIVG9W'+22/H.'@/X9&]=&JY>->U=L-#VRA8Y[=@U$5.ULQZ
M-Q&X'S@ KMGI]2=V+S:6KTHG'*''Y<ZV&X<K&I9Z9S71BI$66\"6,:P_S:5Z
M6O\ 64&E_P"'2DCU#2FIC-I@I33$[)?*^, -ST8._/1LY5)<C7(]=]47JFN>
MH:.:DL43Q+(:AI:^JP<[+0=^#TNX8SC>K]_B&H;56<EMQ;>*T4+(7,EIWANU
MF89V6!O3G)'FSGH3.8N,5T\9K+.?-Y6Y-]+:SNO95XT,RH$]"YL;Y*>H$4G?
M G R1D8&\>A2^/DCY3=:WB.;4_/1 88:JXU0?L-\#6@D_@  H/R=G6AJZIF@
MW77G@T.J!0N<!C.[:QN\.,^=2V[:KY8=,0-J[M57VDIPX-YVIIPZ//0"7-(_
M-=,KOBG+';7-O6&A-+46C=+T5DMQ<Z*G:=J1PPZ5Y.7./I/Y# Z%Y5_BK_TJ
MO_N,/_,K<Y .5ZKUK53V34,<0NL41FBJ(F[+9V@@.!;P#AD'=N(SN&-]4_Q5
M4M0>5#G1!*8GT40:\,.#@NS@KEIQ,9\N^KE&6E>+T!_#W_H>TW_LY?\ UGKM
M<I^J#H[0UUO<<;99Z=@;"QW R.<&MSY@2"?,%R>0*&6#DBTY'/&^.012$M>T
M@C,KR-Q\Q"Z?*KIA^L-!7:RP.:RIGC#X"XX'.,<'-!\ )&,^=<IK?SZNT7T^
M.]/(FE[7JCECUA)2U5V?-,&.J)IJIY,<+ 0.]8-PWN #1A2WE)Y!AHO15??C
MJ(UKJ7FQS'87-AVU(UGTMLXQM9X="@FF+YJ7DHU=+.VC-+7M8Z":FK(CLR,)
M!QQ&1EH((/1X%+=1:HU_RPV^I9%0B&QT,3ZF9M-&YL)+&EW?.))>[=N:.G&[
MI7IG=$\=GBQVSC-Q>3>_A#_TC7+_ ,+D_P#5B4I_C+__ $;2?^O5?X1*-_PC
M4T[.4*YR/AE;&+:]I<6D 'G8]V?#N*E/\8U-/+1:6DBAD?&Q]2'.:TD-)$>,
MGHS@_DL3_P KI'_!+H_P>_YFWS^_C_TVK[_C _S'LW_B(_\ 2>OW^$*GFAT7
M>73121M?7Y:7-(VOZ-O#PK[_ (NZ>:;0UI,,4D@9< 7%C2=D<V\9/@6?_E=/
M_@1_^#3Z.K/32_\ ZU33^*K_ $4R?WV'_F40_@YIYHH=4R2PR,C>:8-<YI <
M1SF0#^(_-3/^*2"6?DJF$$3Y"VKA<X,:3@;]YQT)E_RF/_"J[^#S_.Z_?W%O
M_J!7URE<G-DU_01PW9CXJJ#/,5<.!)'GHW[BWS'\,*B_X/Z:=FJ+]*^&5L78
M;6[9:0,[8W9\.Y=#EFU5K[0O*77W2U2U?:"H9#S398S+2G$;0X>!IV@X[B#O
M5RB9U.)33RC'2^U'"!<IG(C?=%4$UTAJ(;G:(B-N:(%DD8)P"YAZ,D;P3^"G
MO\+&O[I67:?2UVJ9:NF%.9J1\KBYT1:1EF3OV2#D>#'G4"UERVZKUG8Y+%+3
M4-/!58;**.)_.2@'.SO<=V1T;U9?\,/)M=++75.IK_324;I(#!24\HV9"'$%
MSW-XMX  '?O/FSK*]D[^[GA74CI]GHE$1>5[A$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MSG.P!P](5>RN#I7N' DE6!\HB("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M3-++''&^;>(LN +@.DXX'H6SJRXT]31104]_N=U=SFVX5#2V-HP<8!.<[_\
M%:.DW6J*XMJ+S4U$#8',DBYF/:VG YP? J.ARJ?Y^73_ /E?^DQ112WE"K[-
M=[G)<K74U,E3.YHDCDCV6M#6!H(/X!1) 1$0$1$!$1 1$0$1$!$1 1$0%+N2
M< ZYH,C/>R?^FY1%2#0-UIK+JBDKJYSFT\8>'%K=H[V$#=Z2@L*N?<:S3FIG
M:OIV-IX0[L&26-K'[7?;.SCS[/IRM:[VRT7*S:/CO%QEI724C(H611[1>YP9
MO)X #=^:K:]72IN5;.^:JJ)H3(YT8E>7;()., G=N4BO6H*&K9I(0ND)ML;&
MU&68P06YQX?HE0:LNGK?;=27"VWFOF8RF(YOL>';?-D @ <!N(XK>N>BZ<5-
MC=;*R;L6Z2&-IJH]E\1!WY'3_P#?A76AU=:':FU%4B>>E;7QQLIZUD.T^+98
M =W'>?\ !:.H]0VFZ45CHWU]QG;22O,]2]N)2#P>,GP]''"HYFI]/V^WUC*"
MWRW!UQY\0\W4PAC9,Y&TPCHSC\UVAH"A=6R6EE=6&[LBV^<-/BG+L9V=KC^/
M_P"%\7S5E&RRT-)3UU1>*VGJV5+*FHAYLL:TYV<G>3Y_/Z%N7755LN-0^NBU
M'>Z$/:":&%IW. QWKLX"@K>FD-)612NC8]T,@<8Y!EKL'@1X-RM>R7ZJO&BK
M_5ZECI^U[6;%,!&&@OP>];Z#LX/A556\T[KA3FX.D[%,C>>+-[MG._'GQE6)
MJ.\:3O-/34W;"XTU'3,V8::" !@/A.1O/_WX516:(B B(@(B("(B B(@(B("
M(B B(@*]'37QM1I>GME.);5)2Q"K#H@6!N!G)/ [/0J+4QUCJ@5]-:8+5654
M<4-&V*=@<YC2\#?NSO02VVTML=+KVGIYXZ6V_P!&#(QNTV/<[:P!QWYP H;J
M73=OHK1;KM:*^2>WU<AB+IF8<QPSOP/0?R6/3%ZI+?IK45%4N>)ZV)C80&Y!
M(VLY/1Q"SMO]O;H^Q6^1CIIJ.N[(FB+>]<S:<<9\X*#<H])66ZTE8VT7&ODJ
MJ>%TPDEI]B&4#H'2%@H=+6Z/3-'=KO4UX95EVR:2 /9" <9>5)Y-;6=M=75
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M;+JZJ=0,HG5$IHV/YQL)=WH=X<>'>5K(@(B("(B B(@(B("(B B(@(B("(B
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M/&Y]G_<EBL45G?)4/&Y]G_<GR5#QN?9_W)8K%%9WR5#QN?9_W)\E0\;GV?\
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M/&Y]G_<EBL45G?)4/&Y]G_<GR5#QN?9_W)8K%%9WR5#QN?9_W)\E0\;GV?\
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M/&Y]G_<EBL45G?)4/&Y]G_<GR5#QN?9_W)8K%%9WR5#QN?9_W)\E0\;GV?\
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M/&Y]G_<EBL45G?)4/&Y]G_<GR5#QN?9_W)8K%%9WR5#QN?9_W)\E0\;GV?\
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M/&Y]G_<EBL45G?)4/&Y]G_<GR5#QN?9_W)8K%%9WR5#QN?9_W)\E0\;GV?\
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M/&Y]G_<EBL45G?)4/&Y]G_<GR5#QN?9_W)8K%%9WR5CQN?9_W)\E0\;GV?\
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M)$#XJKG8JC#HW9;))#CAX3O/\O,NQH:6T.FJ66R*II:@-'.TTSB<8/$9]/\
MT6\=?=E$55N.KX#IZ>6<974UQS^O/%_@ER(B]#YXB(@(B("(B B(@(B("(B
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M_E^V?WJ+_?"O7EOY87LK*BPZ0?S#H)"RJKVMP\O!WLC\ !&]W3T;MYHK3O\
ME^V?WJ+_ 'PI5RQZ0NFE]8U[[A%FEKJB2HIJAF]DC7.+L9Z'#.\?\,*91$Y1
M;6.64833F?*!JW[Q7/VARV=<U4]QL>E+A72NJ*ZHI)N>GDWODV:B1K=H].
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MWQ/3X<Y73MU)!-J^^RS1,D?&V!K2X9P"S?\ X!=>BMM-2\W(VG@%2&!CI6L
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MU$3G\^YS-HGZ0V6=&=^]:LVL*V&SZ=;55=NI*Z[1&=]54,+(H(P ?HEV]W?
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M=2TMJMK[%74]8R22>2V0<VZ'9&6EY#G @G<.'%6*IDUAV$1%EH1$0$1$!$1
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M$1%%$1$'Q#%'#&&0L9&P9(:T8&_>=R211R.8Z2-CG,.TPN&2T^$>!?:("(B
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MS8B])_)+I3[+4>T.3Y)=*?9:CVAR=7$Z&3SA302U-1'!3L=)-(X,8QHR7$G
M 7J/DWTG%I2P,@<&NKY\25,@Z7?5'F'#\STKXL')YIVQ7..OH*23LF,'8=)*
M7AI.[(!Z5+5SSSW<0ZZ6EMYD1$7-V$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%IRVJWRU!J)
M:"D?.>,CH6EWYXRMQ$6)F.P!@8&X(B(@B(@(B("(B B(@(B("(B B(@(B("(
MJFU;J2_Z@U\[2&DJMMO93LVZNLV<N&X$X\ &6C=@DGCA6(M)FELHH5I&SZET
M_<*DWW43+K9NQW/$D[=B2*0$;R3GO=G:Z? M-_*_I%M88>S*@Q!VQV0*=QBS
MZ>/\DV^A?JL%%'K[K*R6,6Q]QK&QPW$$T\S1M,( !VB1P&'#?YUQ*#E:TC6.
MJ@+BZ 0-+]J:)S1(!]7PGS<?,FV2X3Q%%]':[L6K9IX+142&>%NVZ*5A8XMS
MC:'A&<?FN15<KNDJ>E;,:R9[B]S.:9"2\8XDCH'^*;9+A/T4:J=<6"GTS!?Y
M*X=K9W<W&]K'%SG[^]V0,Y[T[O,M73'*)8-173M=133Q5Q!<R*HA,9> ,G'1
MPWX2I+A+T4+N_*;IFTU%PIZVLD;4T4@BDB$1+G..?H^$#&\\!N\(7V.4C3AT
MUV];4RNH1,*=^S"XOC>1D!S>C<./!-LEPF*+A:BU9:=/V>FN=QJ'"DJ'-;$Z
M-A>7EP)& /,,KN,<'-#AG!&=XPI2OU$1 1$0?CG!K2X\ ,J"Z#Y3+5K"Z3V^
MF@J*6IC89&-F+?Z1H.#C!XC=NZE.)_ZB3_5*\OV"VU5MT3;M:6@'LRU7![)P
M/[<1V>/FR2#YG^9;QB)AG*:>@=.:KI[Y?;[:X*>6*2TRMBD>\C#R2X9&/]4J
M1*A=':B+!RG7^U')<UE1 2/HEW.8)'FS_)<"@H;M5:?H;K9+5J634;I!.;GS
MFU%*,G(QGA_URKL2,GIE%54-54NY=Z6.H>]A=:071;7>AV"3N7*L]5,[47*P
M.?D(CII=COSWI#9.'@6=J[EU(J)Y/[5-1:"EUS+<JVHN=+25(IH7OS%&UH<T
M @C)W@NXA:,6EF57)7)K.:[W$W\M=4BH[(. 1(6[/\O#Q5V>TW+5UAJV:PZG
MTS:HJ6.:.[3&)\CG$&, M&1X?I?R4O5%7>Y5%WN?))7UIS4S/S(XC&T0^,;7
MXXS^*V[=:F\HO*#JJ&_UE8*.U2]CTU-#+L!O?.;M?_)GTE-O";EU(O/5#?+Q
M0<GFM[;#<Y7=JJME/3U+Y,/YMTA:YK7>ANX><X7WI2P4EVUO8^T=)?8;;31"
M6XOJW/8.>:"1O/278R!UIL-ST$B\_P 6H9]"T^O-.U-1*96?TEN<]Y+L28;D
M$](:YCO_ "E6UR:6J6SZ(M5-5.D=4F+G92]Q)#G]\1O\&<?@I.-+&5I,B(LM
M"(B B(@(B("(B B([.R=DX/04!%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(
MO5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK
M^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(
M-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_
M:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDY
MNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/
MQ(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W
M5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'X
MDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>
MJ/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K
M<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5
M'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T
M1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E
M%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(
MO5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK
M^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(
M-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_
M:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDY
MNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/
MQ(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W
M5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'X
MDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>
MJ/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K
M<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5
M'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T
M1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E
M%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(
MO5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK
M^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(
M-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_
M:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDY
MNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/
MQ(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W
M5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'X
MDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>
MJ/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K
M<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5
M'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T
M1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E
M%K<W5_:(O5'XDYNK^T1>J/Q(-E%K<W5_:(O5'XDYNK^T1>J/Q(-E%K".KSOJ
M(L?[(_$ME 5&TUP@T5RYWB:^.YBBN<1YJH<.]&T6N!SX,M+5>2YU[L=KOD#8
M;O04]9&TY:)6 EOH/$?@M8S23%H1R@ZIM=\TC?[7IZXQ5M>*%U0YM,=L")KV
MA_?#=P)W944;?--CD#-#V51]E=C<WV-M#G>?VN.SQX[\^!6[8]-V:Q-D%HMM
M-2<X,/=&SOG#P$\2/,M!N@]+-KNS&V*@$^UM9YOO<^'9X?R5B8CA*E35\HI!
MI[DFI+G%M<Y.X/CD&<QNEB(!'@V2-RDVN+?1R<N6DHGTT+HGTX+F%@V7;)DV
M<CS8'Y*U;E9K=<YZ.:X4<-1+1OYRG=(W)C=N.1^0_)*FS6ZINM-<ZBCADKZ9
MNS#.YN7,&_<#^)_--Z;58T$;(/XBZX0M:P/H-IP:,9.PS?\ R4:Y'KUINV6/
M5$=\FI(JF1[R6S !TL6SC8;GZ6_/>CPJ\VV:W-O#KL*.$7)S.;-1L]^6^#/X
M*M^3GDUB@M-?!K&T4DTKJQTT!<X/(:6@<6G<"1P5C**Y*FT&T?J*MTKR84DL
M5)322UUW>*66L;F*'#&@R?GM#/F<NJZ>LEY:=+]L;S;[K4M809*)@:V,8>=D
MX)R=Y/H*NFLL%IK+2RUU5NI9+>P ,IS&-AF.&!T?@M.W:/T];9:66AM%)!+3
M.<Z)[6=\TD8)SQ)QX4WP;95[R>4L$W+)K:6:&.22)QV'.:"6Y=@X\&5Q^3RP
MQWVS\HUF8QK6R56S"W@&/:Z0L]&\!7316:W45PJZZDHX8JRJWSS-;ATGI*6R
MS6ZU254EMHH:=]4_G)C&W!D=OWG\S^:FXVO/FCJVIUI>-&:=JXW\S9.<EJ=K
M@X,=WH(\P#6_B5Z25;\E>D;C:;UJ&]WVFAIJVX3$QQ1O:X,87%QWC=O)'Z59
M"9S<\+C%0(B+#0B(@_'MVF.:>!&%&M*:,H-/:9J+&U\E71U#I#)S^,N#P 1N
M'# 4F1+*0G1W)O:=,TEWI8I:BKIKFP1RQU!& P!PQN ^L=ZYU%R7&@9V)0ZJ
MOU/:MHN%)%,&X!.2 X='X*QT6MTIMA"=9\GM)J2\4MUBN-;;;C SFN?I78<Y
MN_IX@[SO\Z^=/\FULL<=[CHZJL<RZTW8\O..#BT;)!<#C>27$[U.$4W3V*AP
M=,Z7H['I6.P!SZJC#)&.YX#+VO))!Q_K$*&CD>HA&:(7Z\"R&3G3;Q*-@G.?
M_O=E6@B;I@J$6N^B;?<+EIRJ9)+3,L;LT\,0&R0-G .=^.\"Y=_Y-J:OOU1>
M+5=[C9JVI&S4&D?@2>?P@G'A\ZGJ)NF"H5%K[10L')=46K35!-<'RU+):E[A
MSDQQO+P!Q(P!@#@3YRN%I]ER.JK"W1\^K7TS9!VP%VR(&QY&1@[LXVOY85](
MM1GPFU3?*3IQNH^5K3U/%13F-L37UL_-GFS&UQ<&DXQG (_\P5R(BS,WPL10
MB(HHB(@(B("(B B(@(B("(B BUXZVEDK):2.IA=5Q-#I(6O!>P'@2WB MA 1
M%KUM;34+(WUE1% R21L3#(X-#GG@T><H-A$1 1$0$1$!$1 1:@N-*;HZW<[_
M -L;"*@QX/\ 5EVSG/#B%]T%;37"E94T,\=13OSLR1N#FG!P<'TA"VPB(@(B
M("(B BU*"XTM?)5LI9><=2RF"88(V7@ D;^.XC@MM 1$0$6N*VF->:$5$79@
MCYXP[0V]C.-K'@SN7Y<Z^FME!/6UTHBIH6[4CR"<#T#>@V47XQP>QKFG+7#(
M*_4!$1 1$0$1$!$7S+(R&)\DKVLC8"YSG' :!Q)/@0?2+%25,%93LJ*2:.>!
MXRV2-P<UP\Q"RH"(B B(@(B("(B BU.V-+VU[6\[_P!MYCLCF\'^KVMG.>'%
M9*ZLIJ"DDJJV>."GCWODD=LM;OQO/I09T0$. (((.\$(@(M2U7&ENM"RLH)>
M=IWES6OP1DM<6G<=_$%;: B(@(B("+4CN-+)<YK>R7-9%&V9\>#N:XD YX<0
M5MH"(HCRDZNDTA:Z6KAI&51FFYHM<\MQWI.>'F5B+XA)F(BY2Y%1WRX5?B2#
MUYZD^7"K\20>O/4M=/)SZV'JO%%1WRX5?B2#UYZD^7"K\20>O/4G3R.MAZKQ
M14=\N%7XD@]>>I/EPJ_$D'KSU)T\CK8>J\45'?+A5^)(/7GJ3Y<*OQ)!Z\]2
M=/(ZV'JO%%1WRX5?B2#UYZD^7"K\20>O/4G3R.MAZKQ14=\N%7XD@]>>I/EP
MJ_$D'KSU)T\CK8>J\45'?+A5^)(/7GJ3Y<*OQ)!Z\]2=/(ZV'JO%%4FE>6%E
MSO=/17.@CHH)SL"=LI<&N/#.1P/#*MM9G&<>[>.49=A$11H1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%CJ)XJ>)TM1*R*)O%[W!
MH'XE9%2%UIG<H?+!666Y3S"R6B,N,#'%H>1L@_B7.X\<!6(M)FET4=935L7.
M4=3#41YQM1/#Q^86=0)FD[1H""[ZBL,,T;HJ"3:I'3%T3RW#@=^2#WN./25H
M:-Y1+KJ&:*LDL/8NGV1/-57N?D,>QA<=GPMR,*[?."_59B*ICRE:AJ+14:AM
M^FHGZ;A>09)*C$SV X+@.C\C_)2>YZINM5:[15:0L9N8N,1FYR641,@&[<\^
M'?C&>@IMDW0F2*M[!KR]5EQO5CK[#''J*@I^R(J>.<;$WT<#:/#Z33G/3T*,
M<B=^U+57.X4\U%+64$E6[LFIFJMHTIP>] )R=^.";93="X[9=;?=62NME;35
M;8G;#S!('AKO <'<5N*G] ZLLEDTCJ2[16>.W0TM9L&*&5TAG>=S1WW#CZ!O
M62?E+U+;*"DO5ZTJR&PU+F[,D=1F1K7;P2/./"!GS93;/D;H6XBKO5W*-+9=
M06JWVVUNNC+C2"H@YI^'O<XN# !CAN!)Z 5^Z*UY<KEJNJTYJ2SMMERCBYY@
M9)M@C<<'CT'.0<;BFV:M=T+#)P,G@N-'JO3\E8*2.^6QU27; B%2PN+O!C/%
M8.4""2IT3>X8*EE-(^E>!*]X8T;N!<> /#/G7G:QTM+J^P6K35@L4++['(9:
MNXO<&XC!._/$COANZ,;@<JXXW%I.5/5*+EZ>N%#649@H*^.N=18IYGM=DA[1
M@[7GW+J+#0B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("QU$
MT=/3RSS.#(HFE[W'H &2?Y+(N/JVV5%YL%5;J2=L#JD"-\CL[HR1M@><MR/Q
M2$GLKFT3LH:ZRZLDGC$]UK)(ZR/;!+89CB('S-V&?FIE?;G>#JZELMHDI863
M43JA\TT9>8\/ R "-H[P,;N.>C"^KSH2Q5MEJJ.DM=!2SOB+8IV0-#HW?V79
M SQPMBBLE8W4-ONM941220VTT<P:#W\A<UQ</-N/YK=Q/+$8S'"-W.Y7BNT?
MJZAJZFF%;;!)').R$[,\1B+MS<]ZX@\=^%F-3<;;I+3SZV6CK3/5T4;-JFQS
M<;L#I)RX?6W+LC3#WC5<<U0T1WK<TM&^,&+8W^'PK5[G;O56*UT-QJ:#G*"K
MII6/@:\!T<1''/\ :./0EPE2Q7.^W ZNJ;6VY45I9&V-U*VJ@+^S"X9=AQ<
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M4YS$7/F:,$MX][@'COR3YES;YJFNLU2)9+]9JJ5M0R.6V0Q]^&.>&G#MLG:
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MK-=+;74UW$QJJB69G>29P!@_SZ0<DY5KHBS,W-K$5%"(BBB(B B(@(B("(B
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M,9QP7*L<%*_16D9W7FGM5SIHY)*22HV2Q^_#VD$C.XC@<A672T=+2!PI::&
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M,$,=+(7AN=V0#T]:ERYYY[N(==+2V\R(B+F["(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@([.#LD
M^<91$&G7T$=PIGT]:R">%X(<Q\9(P?Q44JN3NBEK:>I@JY83 X%K W:;N86
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M;3D[;RZ&[TSQ9RX5^"?^S[.<[6[HP>"@U-RFPS<H4Q;J&SNTBVVFL  =SX
MS)P^AG*"VT4(I.5C0U7<J6@IM2T,E758YE@+N^SP&<8!/G6UJ+E(TAIR[-ME
M[OU)25Y /,O))&>&< @?B@EJ*/VS5=JO^GZ^YZ;N$-=#3B1O.1Y+1(UN<;_P
M7GW1G*)RLZKTI5ZAMDVGA1TKGM>R9FPX[#0XXR[P%!ZB14#9^5N]W_3&C+G%
M46FU3W"MEI:R.I#L3[+FC^A\^_I\*LW4/*=HW3MV-LO.H*.EKAC:B=M$MSPS
M@$#\4$Q18:*J@K:2&JHYF34\S0^.1ARUS3P(*S("(B B(@(B("(B B(@(B("
M(B B(@(B(.?J)DLFG[FRFSS[J641XX[6P<?S5??PZS4[]!R10EO/QU;^>:..
M2!@G\,?DK15?7;DET]77&>LIY;A;I)R3*RCF#&.SQW$''H&Y:B8JI9F)NT1L
MSF5G*]KNKMY#J-ENDCD>S>TOV6 CT[37?D5%[#I2TW'D=N5]K9YG7&DVQ 3,
M=F#9=D,#>'?$]/UMRO"U:2MFFM,W"@L5*6F:%^TXG:DE=LD#)Z?1P5;<GW)/
M17/2]/+J*&Z4-9SKN=IP\QB5H=WI<TCP=(PMQE#.UQ]3<_J"R<E,=PGF;+5R
M/@?,TXDQSD3 X'PXP<KLT.FZ#3G++!8;8)FVNYVM[:B%TA.T"UX(SQ_L ^;)
M5EW31EIN,]@D>V6%MD>'TD<+@UHQLX!!!R.\:LU1I:@GUA2ZD>Z?MA3P&G8T
M.'-[)VN(QG/?'I4W+M57R*Z6M,FJ]1U+X'&>T5YCI#SCN\;F1N\9W[ATKA:1
MT=;=06'6EPN+JATU'+.:=K9"UC'!I=M8Z3N W] 5O4O)Y9Z35S]0TLM;#522
MF9\#)<0O><Y);C)WDG&>)6Y8M&6RRVZ[T5(ZI,-S>]\_./!(VQ@[.[=N/G3>
M1BJZANMKFY&].1:FBKK@9*IT5/2T\A:Z<M>\-:X_5 ('Y+\T+ ^S\LE/24UG
MFL,%50N=)1/J>>#L D.R">EO#HW^%6%-R:V.72M'87.JQ3T<KIH)Q*!,QY))
M(.,=/@\"R6#D\M-FOL-YBJ;C4W&-CF.FJJCG#)D8R[(X@;AC";HY-LJBL7^A
MS7O]^;_OQK#JG3%-9]':0O\ 0U5:R\5TD7.U)F.UW[,C'@V<8&.A7'2\G=FI
MM.7:RQOK.P[E+STQ,@VP[(/>G&X=Z.@K9N^A[5=;%:;34NJA2VQT;H"QX#CL
M-V1M'&_=Z%=\6FU7(T]2:,Y9-,4UD?4,BK('BHYR0N,AP_)/IP#X,A8-"Z=M
MNO[AJNY:K,M15QU)A8TS%O8S-^" #T<!G=WJMBYZ6H+CJ>VWVH=.*VWM+8@U
MP#"#GB,;^)Z5'[WR5V*Z72JKVS7"ADJ\FH91SAC)<\<@@\>E3<NU4?9U55\@
MU9%4ROFBI;JV&![CGO, X'F!)_-2[4L#-2<I>E].7>23M.VWMGY@/+1,_8<>
MC_5 _ XXJP*[0-DJM)1Z<;%+3VUCQ(.9?AY<#G))!R3E-5:#L^I(Z+LSLF"I
MHVAD%33R;$K6CHS@Y\/#T)NA-LJ[L].S27*E?[/8:EU-:W6Q]0]CWES*=X8'
M!QSD[OSPY0RT:>.I=.VB"ATY<I+S/5F6INTNUS$L1<[.7$X\'G[T\25=%-H2
MDTY8+X=/1OJ[S64TC.?KGB1TA(.&DD 8)_/=E5#2:4N#+%345KTUJ2DU.V0;
M5:9#'3CON(.<</1Z3TZQFTF$OO?8W)MRHT5QC88;'<:$P/:"2&F-H &__5C_
M %%=WD(H976&XW^L'_:[U5OG)_[H) _^8O\ Y+6Y9;)<[MI"PVR&AFN-UYZ,
M25$3"6QD,P]SB. )(X_\%9%DMT5HL]%;Z?\ JJ6%L+?/LC&?Q6)G[+41RW41
M%AL1$0$1$!$1 10>SZMK*O6<E'/'$VS5#YJ>BE .T^6'9V\G.,'OL>A-=:LK
M]/7RW14M/%-0F)]15@M)>(VN:"6[^@.S^"UMFZ9WQ5IPOPL:7!Q:"X<#C>H_
M<;Y+'J;3=%2&&2BN<=1(]^,DAC&N:6G/3E<^"[7O4596]S\E'0VREF= *JHB
M,KYWM^ELM! #0=V>E2C="8HHO<[C>[-I"[UMQ[ DK:1CGPR0M<&2  8+FDY!
MSG=E:(O=]M539'WA]OJZ&Z3,IP:>)T4D3WMRW<7$.&XYX)M-R;(H'=J[5E!>
M[1;^V%I>;B^5K7]AO'-[#=K>.<WY73GN=UM][TS;:V6EG?7OJ!4211%@PR,N
M;L@N..C/%7:;DI1<V]Q7:6*,66II*>0.[\U,+I 1YL.&%P-.7.^S:OKK7<:B
M@JJ:CIVOFDIX'1ELKSWK-[C_ &03^2D1:S-328HB**(B("(B B(@(B(/QK&M
M)+6@$\2!Q7ZB("(B OQ[&O #VAP&_>,K]1 1$0$1$!$1 1$0%#+LYK.5.QFK
MP(74$S:8NX<]M#:QY]E3-<Z^V6@OE(*:Y0"5C7![' EKF.'!S7#>#Z%8FDF+
MAPZR[7RW:JM5%6=K9+?<)Y8V<U&\2L:UI<,DNQG<.A<:AJJ.DMFLWW&2J9 Z
M].9BE<6RO)$0#&D$').[B-Q.]22W:0H*.XT]=+4W&MJ:?/,.K*M\HBR,'9!W
M<%FGTM;)Z*Y4LL<CHJ^H[*E[\APEW8<TCAC9"U<,5*+::;);M>P4E/;ZVV4=
M5022.IJBI$P>YKVX> 'NP<$CBL-'53?(S<YW3R<\UE6!(7G:']*\#>I=;-+4
M-!=&7(2UE17-C=#SU3.Z1Q:2-V_P8W8\)\*TJG0=FJ.RV2=F=BU+G2/I14.$
M(>[B\,X [\^8INA-LN28NWVJ+=:;C-.;?!:(ZOF62N9STCG;.7%I!( '#PE9
M;Y0B&ZZ;TRRKK&VRI=42RYG=SD@8-IL6WG:V>^X9S@!=^ZZ7H+B:-Y?54U32
M,YJ&HI9C'(UF/H[0XC=TKXJ-)VR>UTU$\5 [&D,T50)W<^R0DDO$F<Y.3E+A
M=LN+;Z<6+7$UIMTLW:ZHMKJIU.^5T@BD:_9VFEQ) (/#PA1-MO?!R7T.HH[A
M7]N8S$Z.<SN(8TRAFP&YV=G!Z1O/%6;9M.T5J?42Q.J*BJJ &RU-3*99'-'
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MY\9YPG#SAO?=Z!X%>G*1JQ*RT547;7]14Z@O=)1:CL%BBM<QIHX[BW;DJY0
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M.\YP1NSCBIRBD95-K.$3%2K.GY/;DS1QM$U?2RU1O8NCI@PL:YO/"0C9WX)
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M^HJXGOJ*?O PM:!N<W W9(QG@5DJ]$W5FD-'T=NJZ(7?3SX96F<.YB8MC+'
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MR&(O=GFXVG>&#H4G13=Q2QA$3:O;MH6MK;;KRFCJJ9KM0/:^ NVL1XC:WO\
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MSC8QQ79B_P!.E1__ *ZS_P"I<HQ5\FNHW:3N>FJ>>Q"EJ)WS=L)&/-3-F3G
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MWWTC002-D#<? I14WO55TUOJ"PV%UKI::W1T\G9=3$^1P,C"=G8#AG)!WY&
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M[77QVJ>YOL]1*ZN93$.#VR- #<G(8<Y+<[_"LELT=6TM9H.9]13ENGZ&6EJ
M"[,CG0L8"S=PRT\<+JU=@J)N4&WWYLL0I:>WS4CHSG;+GO:X$;L8PT]*3,)&
M.5?I^R+MU_<9.36&XLIZ<:GDK!:>QBT\V*OG=@C&<XP"[&>"QWO7=0[4]TM-
M)?\ 3]D9:Q&Q\MR&TZJF<W:(:W;;LL&0"=YRMV#0%1'REOO9JX>T7/&O91;]
MH5AC$9?PQC&3QSDK8JM-7RUZHNUTTUVIJ:>ZEDE137#;88Y6MV=ICF@Y! &0
M1Q'%7[*5J5S\^UQCRB7>X:8TG766CH'5]VKWT$L<KR8@YHD!<UPW[.6!W3NW
M<=Z[VF+W?8M:UNFM224-5**%MPIZFDB=$"PO+',<TN=O!X'/!9KIIVZW5VE)
MZR6WLJK77&KJ1 US8W-V'M 8#DY[X<<9WG=P6X+!4?*.=0\[%V*;4*#F]^WM
M\]MYX8QCSJ3.--1&=W/L:O*!<.P:S2C>Q*.I[)O,4&:B+;,66/.VSZKQC<?2
MN,V^:PO6H]3VVQ/M%)3VF=K(YZF)\CI"Z)K@S9#AC>3EW@(P.)4CUC8*B]U.
MG9*:6*,6VYQUL@DSWS&M>"&X''OAQ33-@J+5?]45T\L3XKK51SQ-9G+0V)K"
M'9''(Z,J1,1"S&4Y>S^F3D_O[]4:.MEXFA;!-4QDR1M.0U[7%KL>;+3A1F"]
MZPONH-2V^R/L]'3VJJ$4=14Q/D=)F-K@S9#AC>3EWG&!N*D7)S8*C3&C;?:*
MR6*6>FYS:?%G9.U(YPQD \"H-8(M4=V6O)-,3VHL=<6QOAKVO 8[F68D:YF\
M\<%I'0-X5B(N:9F9K&_S_1W;;JRYWS0E#=X*JSV2<R/AKIJ\ET<#F.<QVP-I
MH.7-R,N& >E<^SZ]KYK!K<NJ[5<JNP0<]!740/,5 =$Y[<MVCO!:00'+]EY.
M*VALNE8K9445=5V:>:HFBN#7"&KDESM.. <$$DMW'"STFB+R^EURZX5-M%5J
M*D9#$VF:YL<+FQ/9@Y&2.^;OXG><#@K]CY_%G_\ IQ\^7\N;?ZO6=QY+;U=J
MVIM%)#4VQU0RFCA>Z2*,QN)&WM@;9!!SC /A4UY.VW8:5M[KU54E0Y]/$Z$T
M\3H]EFP,!VTYVT[SC'H62JT\^KT!)IV:9K));;V"Z5HR XQ;&T/",[U]:(I+
MU06*"BU ;>9J9C(8G41>0YC6@9=M ;SC@%F9B8=,<9C*Y]$&HV:AFY5M=PZ<
MFM]*"VA=-4U<;I=DB$[+6L!&<[\DG=C@<K/0\H-U-OLM9<*:DB9'>)+)> P.
M(CE!V62,).YNUC.<_271J=.ZIMVM+_?=/55H?%<Q PTE:'@?T<>SM;31D$'.
M[>"#T$+6N&D8+/R1ZBH;Y6MEGJ&5%QK*MK=EO9#CSFTT> .#<=)QYUJ\9[^Q
MSK*+KV_'A(K5?JNY:\O5L@;#VJM=/$R639.VZI?WV <XP&8R,9R5%>4 :A/*
MCHZ.U5]! R5E7S#9H'O (B&WS@#QM#'#&,'PKN<CUMJ:+1--5W1Q?=;J]UQJ
MWD8)?)O'HPW9&/,LVM[!=J^]:?O6GY:(5UJ?-_0UI<(Y&2LV3O:"01@$*149
M-S$Y87^?O1BO;?W\L=3!99:"*K?8H!/55$;G,C E?DMC!!))X NW#PK:BY0Z
MRWZ"OESO-/2NNUIKWVMXB<60S2AS6M?OWM;WX)W]!4EH+!61Z]J+_4RTYCFM
M<5&Z./.1(V1SG$9'T=^[?E<.7D^FJ]/:KMM561Q272[/N=+-&"[F3ECF;0.,
MD%F\> \5;QGO[&=N<7./M:5AUW4MU79[767[3]\BNG.,S:QLOI9&L+AD;;MI
MAP1G<<J1\I.JSI:UT1@?21U=?5-I(9:Q^S!#D$ND><CO0 =V=YPLE@AU6*^
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M1%%$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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;J+A2P/M]G#9)6L)$4F<$X^NO6Z(K3.4S+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g769642g55f74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g55f74.jpg
M_]C_X  02D9)1@ ! 0$!' $<  #_[1<04&AO=&]S:&]P(#,N,  X0DE-! 0
M     #P< 5H  QLE1QP"   "   < E  #$IA<V]N($-O;&]M81P"!0 74&]W
M97)0;VEN="!0<F5S96YT871I;VXX0DE-!"4      !"R)>6>P1T&^O+@7B%[
MCDW/.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! !'!D6  $  0$<&18  0 !.$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           !S   !L4          0                         !
M          ;%   !S                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !S     !29VAT;&]N9P  !L4    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   <P
M    4F=H=&QO;F<   ;%     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    #.$))300,      RA     0   *     J   !X
M3L    R% !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M#A53T:Y'*ZAD]88VS*Z3U#&&&'6"AKGUNL>[;2UGZ.K9;MW6VT_IOITU>O\
MH;E>O>YEMH(B;7R"?/\ 1'W%K&[O_2?^$0[#O:YC2YP?[-)($CW;#[&>RKWH
M\'BAS\7&R'8+A'6&OQ;JK*JW6?I3N:VI[FOOIVVLI]:VVW]_\_\ F/T)NE=4
M'2JO3;TSK%UMPK]M[1;M96*J'>B[<UVQF_UOTE?K6VV6?V"N:\VA\[2''>)
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M^G]&OZ7\K]__ (/TDB@W;F56WM8T,K;8"7 %S0Z#.[V1[G,W']Y&IMNL>/T
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M%(?2K_HWTF\<_P#6_P"7^XDI_]D .$))300A      !5     0$    / $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0
M &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      4I-30 J
M    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@
M P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    T   "P
MAVD !     $   #     [    1P    !   !'     %!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*0 R,#(T.C V.C$X(#$Q.C4Y.C$S $IA<V]N($-O
M;&]M80       Z !  ,    !__\  * "  0    !   &Q: #  0    !   !
MS          & 0,  P    $ !@   1H !0    $   $Z 1L !0    $   %"
M 2@  P    $  @   @$ !     $   %* @( !     $              $@
M   !    2     $X0DE- _T       @          /_A 5)%>&EF  !-30 J
M    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@
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M 2@  P    $  @   @$ !     $   %* @( !     $              $@
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M*"@H*"@H*"@H*"@H_\  $0@ H@)B P$B  (1 0,1 ?_$ !P   $% 0$!
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M<GW.F>H?A/TC._#^#PC/F9QP<:<SX\P9?-A]3':#553,.W8Z"Q_"?JW5NO\
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MTTDEG'$A*4U<;B.2+'-"ZTSGP-G=1Z?C2F9,R#%>1TB6U+.REP9!^7A2._\
M<*O4MB$=229?\2RIH3D9.6C8\<:S2J50HNY1MNN0>0!VXU#RE3!FQDACPQ'
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MHI5=6.V,P8Z +ZKY'>@/;G_GOI.' <HRIAJSE6MC(OE*UD^H7W[=QJ-A09,
M\E\G&R<LJ&EF,;+N<&F?:231X _GG4I<5Y56*2,S-VY!8[>?>N?;N-5;3N9
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M*..-6<F7T[)49'J,:$AWA(8;=I)+;22%_P!;K4%Y\G%;9 D;Q!F =W8EB5+
M"MW![5QR./NA\:#(RHLD,D$L,)EEA&X$@C@E#7%L;L<_/&NEDO;,X6PZ=LB@
M@CRWG:.B6EDN0\W=K1[CM^4^XXTW()H\)E;&E$QX+02%B+)K;N%7V[FAS[#4
M?H>)CRPQ^:#')D9!9%5]_P#]N&JB!1[<?KIN3(>/J.1$G5TEBC9%2-?2R 63
MO)/JY(!KB@.+UG7.EW#SXO4)45I(<>XP) H8CS' !IEY YOW:B >?9<39D(
MDC"TY VB[!8@$G<:'(^_?C4;RX?+/EMN;EF9E>5R5/!Y-FBO^@ TO%2:-YW)
M6:8>AI$DW$ <@%>.;8CYJK)U=*=R61E1,F024MS1D;@1[UP+ -<UI:X\,T$D
M<$:TK6/0 KD#C]:X'[?MH11#(RB QIN+(Z $<D7?P22=.%?Z:-!&XC6U\M5
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MK_\ D(6:1 1* $1R?;W_ -]777D+1Q$2%>XKBB3\ZH<5LI^JX;1B J9;D7S
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M. 2N%DR H!YIBQ L#C@ CV_CG4)RJ$CIXHA')B3H!M1&=E9?L"**^JB:OGY
MI_HNSZ'8%E9(@"/,4CGDT P!X[#@:8FD>8/]1(0Q=5DVDD"UO:IJS[_\.GS,
ML&1AI&SK'D$,$/!50I]1!%]]H/8V>=4CN1D8KNL625B:>.MK[0U$T ;/ NQ^
MNH+*G^*KD8.2&=B&#JX:(C:RA!ML]U8FZ%F^2-.P/+U21VCA*P@\EI1P_(*D
MJ2 >Q!%_'!!&HN,N)-B-+)C;LGSOZJ;0DAIBS7LX)H[J^2+KV&EIU;#QFZ6'
MA4+'-D)+(5()8/R6LV!5!@?;:*[#375,2>&+'5!<(E=E2"+:T6[=18V30+*>
MPHB^*&I&"LTPQ<2<QG"1;# ["RJ*#4.X((X-51[ZJH)&R\B?+3&]3,667TLC
M-?#*;W41SV]]9QGV:MZ<R)VW=/"H,JSN"*Y+C: RO:@V#7QJRZ'E9DTV-(\9
M;'9]I!1E=2&(L[J(O@T>WR=4_G8?3G@&1&YDC$LGJ#2DD@_E//\ =Z0.  U<
M&@9N'ZNL&;:%1Y$%F4,C2"11_3:S1 L,* L]]:ITU7BS(3%P(99%=AYJH H)
MY/ _WU0208WU#8DL2A\5A(%"D*IYHCV^=:3Q(BR84:.%(,@X/V!.LGDY"]/A
M9YI9Y7DF)2./=(U'V9GX )[<@<@#6?C_ !$^6<RGS!./,;\AX[@5Q\]KU RL
MQNG20RYG4&DZEDL)H8BP4&UV>6."1&2+^Q/?4.+&?(GZA%B+L@$4BHU&/S'4
M+L(<,';DDV#M((%@WJ5%]2_3^G+BC&R\@!HI,]CN$)-EC18L1N%; U#@< <:
MU"4OJ/4#)"(C/ \R-OG9Y2ABC)&Y@?8 6?U [::P4.1E*5#?X:\(FC>U.^0,
M .YW]A?:N>_&D0GJN3/]7"F1DS8N.ZPW <<LQ]+*8B=I!*!P6-C=7O>G\C(Z
MO-E9L$O^&X^/"S*&>8"4J5&P@J;4LQ;DCBCW[F;UQ%[2\/I@_P 7:9YHVQ1(
M)F-U))Z'4QOQ3(-PH'[_ &U1')P<_IV/OQL7)CV;YY,>8)#$)G4A6#,#94*:
M(]N.^KCJ$SX_3YH<6)L6"3;>=*Z/"2YYY9F- \$%1WXU%SXI50]/Q,-<*;'R
M0 %:-DEB;_\ R;#W7U$D4#:FOG5QO.V3B')ARMBO##BI21)Q_4L4;9OR_I[U
MH3&3%ZRD&/T^<SK -KPJWD!6);O87N.35]M&1 IR)8<S(9A]./- #*B@D^M3
MV!X-<DCCG3\2Y20^3BS(V,P4@2,S$"Q=$'M0_G6MM:^D?,Z3$5@Q\MI,Q)RQ
MD=)"41PVZC1[#V'SI+YK]&DR,S!P(LF,/''+LW>:-U*-H_+_ )>...YTE&EQ
M8\A,:::60C:ADC 5& [EMO-DWV.EY<F9/D8Z-&T^,\$;M?DF#>6)WUMW[EH>
M]&^VEEZK);R-G*,?)R8)I"J2R0QQ#R48^L KR;HH>2>:(U%R7RH\#(C'E2M!
M.KQ@/M.P_(W DA0>_?X.IQZ?D8\6"L BBB7'#.ZJ$7>-@"U= ;; %>W?3F1-
M-&[(JPQPJ WFEOS]]UBO85SICK7 K/%$.!E(\>=E)%%U*7':"08PD974JFWE
M3W[ GD;VTJ,YV3-.V3T\8D?U,$@H$-+2KN9B#S5=R%'I"\WJ7,SINGVU05MP
MEI6 )/(((4B[L?'<:JNF0R]2RIL]Z6,N61L9TD7A%IY'X)L@$#M8Y]M9F+>]
M+!GQLW,6:)Y%D(D03Q,0*)*E+'!(()YXU&ZT28!$DBMC!XF9W-G>KC:H^"QH
M;N:OMHPLN:?&Z<#F0&7-3SUD78_F@&BM*:[?W=N*U>IEP10G$E@,.$D8]2+N
M-W?MR.>>WOK6]=,]JZ;'A.2L>:YB3-DC6DF);?SQ[@=AVKM^FM5XI*KT:4R%
M-@Y;?^6O>_VUCESLC%ZL(DFP98II%&,TC4\8! -J>68EC==J'>SK8>*/,'3!
MY2AO6 PNFJC^7[]M<\Y_*$[9Z+(6!\DX2Q/F&!2A1N%+=KL=JY%7[V/F%)DS
MQXS$8V3YA8(FZ$MWL[]I(('!')'M7<:=Z;+]1+ME<8\GFF';D,$-_"W6X5VH
M?[7IA'3,ZMU>#%RI9)_-0I-*Q*G9+91:(%C:Z>WM=ZU'39GJ(F!2=DJ%I<>%
M00[-L+4QVJ%,9 /RP N]<QLW;U/+Q,)H8YT7RLAX@[R1PB,.H+GG=RQX)HL.
M#R=.]'P>LQ9,W^)12)'&OE8S1,-CH2&M@2?7QW+4*-5=:>Q8(X9Y$ESCD9#1
MCZQU($:J.0*'%^WR;HDT*-<&,F.'*=?J42HY&<^?D(7IAY:(@*B@WJL6&!%<
MWJD:#-ACQXAB9,6-*SX_FP-YKE;<J$MBH*V>."-O KM?X>_*CS5*J\D>Z?8[
M".R;(4\FCVY^^I,"038,;0A8BX+(T6UO++#DJ:*WR>>;O5ZX9GZ5_2U.)U(Y
M>,,J2,2D-']*T(+'L\C-W86EC[< "[D#'CBF$J1"3(E("L%[,=Q)8W=61^E_
M?1F2SKC/-E2PJID\J-U8M&H#&B]UM/*W_ [ZD$9;3;(/*WL0L3N" .+-CBS?
ML"+'OJ=3:RNIC968\TJK#&\<C1F1Y-RJMBSP13<>]T1J \38N/%/E]3QYUC\
MIXAC.2)0%-DD\43R*]@.^IYZ;_A\,S]1R&2-YQ)MQ4+$MNOA6!#[@3N(4$<U
MVL3>C3]/AQ"W1<3+RW](WM&T9;V_-)M'I Y [5VO6;EKF,[5V/'+)+AJN*\4
MQ5I0LD8B"@)VMN>+ -#CW^"U(XEDB S)GQ4 >.8+N\^B"2'7]"10H_MJ0W6L
MC/>9XH!YF*TD3HLH96:JJ^S#N?:J%CMJ)@-<*ICH<E/+7:V/&/)4<]O;VKCY
M'&M27NK.>TCR?.DBBB>5X()-US.Y)X]-&_4O/)-_SHAFE\IO+R8P;&W(5![D
M\ '[5SJ02XV>>%1V4,8PP] ^#7_.-,C&$T5@5'">47TK^@!'/_O5G2\$Y<R0
MP2NT\49!"KYO(+&@O Y[\^VJC_#YL6:7/ER</*RDX>2>(?TD7>R")58$$[P!
M9Y![>VK@K&\#PD"6.0D.Q/<7V_;C4"'ID?U<YFQTE?(',T0\N58S0.YR&#D;
M4/L;%Z+O[/>%@4S<?':29D;"DE+"%(8W4U6Y1RM;JX'/<_&DB6<9$LN3$I=%
M*(\:>HAF#>FSQ^7F^Y U)\^+%#XF'%*?,VM*TTG<@ *"/RJ#\**X^=2(EFW1
M8\,6,89 #+SN8J=P*@5V][LW9X'O/VG;=#MHT#MHUY7)EO&TD&--@YF7,<>#
M$66=Y=^T !?<#EN2.!JFB^KFR<8/E[]\;Q%O/D4.Y8TI4W0*AQN^1Q7&KKQJ
MV/')TZ3)A$E2%5;?6PD@754?Y_8V=9?IDA>8_2Y+'=LECF0#<8Q:[3:_Y@_Q
MWX[:]&$WBNDK)R&R'C!A#!6*PK^5MU;.3P2/4;[V.>>-/LI(=)E\N46&B/.T
MC^+%4;['[]],0328^4T$4TY=Y?,"H$#%CSQQ;>[>X[@\<:1%CY+Y"EI\5\E5
M+22^DI&3R1Z39._FB:H'MQK?2]'8\IY,.9AM9HI-CE'5:YH%MW(#&UXLWIYG
ME82F>( .!Z&( +6>*([GGO\ ;OI/4<-<9HYL2YI)&44' 4T2WJX)%DCL#7?V
MY[YN/BM&(5C^C!V>4'$93U$;PV[\M\$<$'M?;3>^C82:20J5CC9F!W!JV@@T
M!\_/MIK$CCD3SX!&(W(FIAOW\'L& VV./G4D3X2 MF10X\:BHY#*Y#?<@'D'
MBF[V?YBP1Q1O_P#%PL9$C;;'D0H-^U0 ;)(NQ?)X[=]-_H[/8ZD4N^1G![JP
M))%<\]Z_?]]/9+MU')R'=6< '&&QJ\L4"UG@[N0?>N*]]-8Y7^HL10B,&O*;
M=9^?L;OY[<Z;G09F*<21D@A;BXQ=N3ZF)%<-9![=_OI>]H=A=9_+6,L)(Z5H
MUEL @@$$D L!?<\:;@ECE7:IL,@F0,GED*2=HV&B"*/%?Q=:<I!,R.BQ;FVH
MRVNZE -'W/'?V 'QI,0A$3_2^O8^W@E^5I:-GN*JK]M(L<C:.%8D\Z15EI4#
M&E6P   .W-<?.@812,K#.2Q1E9B2 #0%A?V[<:X)$=!#C,%B>V:.1&(H&FW-
M57=]SSSW[Z,K'DE@7Z625'L!1&P (+4:-@=K(OC5",: Q8T,)D:U3M+3LA/P
MPNS?W_TUS*Z<K8*P^;.Q1PZ@$W6Z^"3W_?MVYT]C*,O(E\^-9UC61H5>@6='
M(W#L10'%=_D:##Y6-!'Y@ 8?G9N 354#9/8FVL_<ZDNZ&#'ORW@BBDDF=A*(
M_J-H'L6/=JX':ASIR.%AC+-"D,D2HN^%'"NC5ZBP)[$4;+7SVTT\T+0SM 3,
M4]3F%N]"R >!9%>_\:>56F$>2D;;7CO<R ;03R#\&_\ OJ\K/[3^E11+GX\L
M2Q*A?NH ;=N(((_8?K7OJX\3SB''@+P>;&S[6%FQ?IN@#??L=4_2HT_Q"(S$
MSAG5XBQ_(:JOVH_R=:/JC"HT)Y-G_;7'+C*,]L\(H\?'(@4( 21L ')//VN]
M1<M3.(G=Y(V0VNU0#9!HV0=IK</WTK(QEAZ@I6 11"0,-BA@[-NMJ_M-DVW?
MG3V;+'A%7,Q<S&]I<>@ 5P#\FA^I&MQ<N4:.=I!!)"4\TQEF+%PH%#WKY^:X
MTO)6=LG;Y)FB# HQ*CRV[6 ?S59//QIP1KD1Y BR'1K9 3=*>0:_2_GVKVU"
M(RMTNR2*6:+:@VD@ @V0;/!*D>H7K7;,*2>1<-6:1ILBVBLTAL$EB0IH4 3W
M!X^3IN$;9)8GPG*+$CU=NS-98,+KN.UD$Z=P%AB2;+RHI"T5Q(LC T>SR&J
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MU[6/>O\ SI%<7R7D,JA)'<[9IBFSU**/?FK%#_OI,1>?%.2BN_J9HUC8D4:
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M%YBQJ'D)]0X'O7O^]ZU74<I<1$D:+S#R !WUEND0;^I(?($D:Y&Y9?,##CW
MNP>]\?.K/QI'GS8V%%TS(CQRV0!-(Z[B(MIO;?&Z]O?VO[:YY27*1+KTF#J:
M.@?Z7U>VX@?ZUJNS?$L./.T)PM\^VXUW#UGXNN.>+/&J6NJX67CALU<K#BC
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MG7P#]."X7@\$]]4T"LT+1?400RES&AD;@DV11/<T#Q]M<L+_ !Y6:1NH-%#
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M7 (.@ZY<O3%V+LEV%F0QVY((KBP;->^I+NS:Z-XGD9G43%FP[9<=DD3S /S
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M)..&@Z7GP]5Q?(?)BDRAM< @*Y4\@[?;C5=XGA$43+Y/F./R*??^*_WU$@.
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M+%],V-%.OUQ)FL7=;;/(Y_<#YUF>GY>3@]4ZU#)()>F-D&:%WF\PKQ^4+QM
M(/O_ .HF3DX74HEZ?XGQQD9W3W,I.*UN%KTNJ^]6+ -UQSJXS>F11]*'5>D=
M._Q)L>)ACI'+:2HWYMJ T>/D$\:U,?'C+VW+.SLF9@=3AQD@E\B3(7^CD1&]
MS $V".#^4\:8ZUB8&)TF*+(SY,5<^01(V.^S?(26-#D6:-\?;XU43=,RLGJ6
M+U3Z,CIF,J>3AHA41/SO+*17!;MWL>W.KO,Z=GYLAZ9#)C8O3V3:'@8EQ8Y9
M3V!Y/'Q[Z:DLU5J5@8.'T_H><\H"GJ+"1AV+E0 7('8FK_C4'PG'.\.//!FI
MD8DDV^,H*V@M^4WWK3?7<WI^%D=)PYFR9(X(/(B9@6,FT $O\]O]].=+GQ>G
M=3Z?TOIPQXT=?,\D.0X%U87XX/\ &DE\;^V;-\M/XH:0=6A*LJ((P-RI;V2>
MQ]AQ\>_<:K'C\UY#+(6<L!P:H#V_T/.K3Q6K-E#RCLD"+3$T&]7Y2:-7JKB1
M49O0RCD*I4&A]Z[CL :UQP_&&)IFCA 9WCC$A"HIKEEL]NYNCQ5W>N0,!D&5
M90/,MPRGDK?L/L:YUT-)OA\O?M+#^F[ 4"2/?V%?-Z7CN!#!+C2D!OZJA35]
MC0K@CY'WUM"1)"L4S'<9O-IP$+;A1-CCX'<\?KJ/)CR?6#(CE>*/B((UN".]
MU0 /-6;H#BN=/9<#3XDJ'RD>7=M;V0E30 ^0"?<]C\Z:;&:2*,SY,<D915,:
M@?U&'<\\!3QP*(K0G*)BX A.Z*:7ZR*!ICDY$:NT9< +N!VLJ[5;T_J20:&I
M>'BG(7J.4RT(,5HEE",UNH8<GO(19]C1XTYD,5PL@3$902((R3*#YD?]W:@0
M5-?]CV/##/-"T?EKBP1CRX8\>@ M^D\=O_9O4U528GCV0RXZI$6BI2%Y4E>5
M.[N#M'?OQ>B# 6"&1+)5FM%WC:!NN@!P!VH4*KWTEY9(<1PT3,R>E1$I+5V'
M)^U"R:O3ZD!$4(9 7C!!/*V0"YX/8<\?'[Z=(7TB Q9^*B;B@8,7#63SP#?)
MX][U<>,,49O2GQS0,@(!/L?8_P ZJL".^L8P=^5)HU0D]7>B-PX7YKU>]#5[
MU]6:"/8 2">#[\:YV_SE118<B3]$K'E$AA8"4J;NN#I0(*BJU &=]+C9"=!B
MAGSHF ;&O8-S-S9KCN3?V.K%4CEB\P)Y4M6ZHVY ?< ZU9JNF&4G#@XL7H(_
MH@ _W$D?/Q_WU%QV*Y$ZLU[B&47^Q_V&I!.I9ITEVA9HZA]3B+@S0Q0[B9PZ
MV77:: ^"#1T_TJ"7'6''GFFR9&>VE(]B2:_:]/3DF$(OI=E)5JO]-5V ^7!#
MCPY$B2SAOZCH2*^"/]-;G.+E>QT_,?*S^K&25E6#*WOP>%4$4.??9[:OO$4Z
M8V:DT?3ERIFA_P"HYV(J@D46HC^X\5??29XU>-90JK/*@#L%[]Z-?OIKQABY
M$V3B28[ ^6+*,U*PY[\7_'SSVUBV991SUJ:19\E,V27"RXJG8 K)CTNZ(\%[
M)KTVW!YXL \:8L)]4T:.L,<NW>2&WL?S-PQKD=B!S?&FLM((X<^/'^J%K++6
MX5N[$?E8KV(L"P"?L=2.@]27'Z6L'3X8V3' +JW]-A&1:&FVWQ0LD6%/N--6
M=+CEJ[,Y3QQY+@21B6-*:,I7)!W;S[KRHJJY]^*.GYJX>0RNKE4&T.6]!)<[
MD4  $*=H'%T0.2#J/GY$,SR8L>7$,2%6;*G)MD!<[MU<;B>QH]CP=2X989<G
M)DZ?$\200 R[XG14))*TE=[+;NQ[7WU?[-\K#&ZI$QE3+V8TL9]09AM OTF_
M:Q1H\\Z>FZAAPXGU<N7 ,;;N$OF J15V#[]M4'4'R@F4SQM-7#U2I&Q4 _FH
M>6*)OO\ P=*C#,T4RS&:9I'0@% X4$$_V@T+ _2KYYU/"&UTW5<13'ME\SS'
MV#8"Q#?! Y!'N/;W['4HPQRLLA 8A2 1\?\ *UEECG/G2,L:2A@52&<EVL"B
MW&W=NXYL#;]^.X8Q:R8DS6D6868I#?EL?S"CQ?8T1?-^^GC]&VDER\>%C'^:
M15W!(Q;5S[?M[Z:BRY)IX%.,Q0RA:9@U*#88_'([>VJ_ZJ+R?_D!+"HS1LX)
M%]K'?VT09,L>1'*J%4$J$)OV@JS;26M2>]D5WH<ZGC)#:Y\88YFPL=T_ZL,N
M^,$\%MK#G^=5/AM9A(AR OG;"7"&Q^VM!XA@,^+$5<JT;[P/\WI(H_SK)P]5
M3"SECD8K.>WH.P6: +=@3\7SK7Q[RP\8G7*JQ<["CZUU#K+YN3CQ2NN$T,\1
M0;T) *WWO=^G?5GGYK=&Z)GYSM-.%#2$D+Z154+H4._.G^IXV+UWR6QNIMTW
M.QI5D<Q!&W5[,&'(_@]M<'2NI&7)CR^HX_4.G3($CQQ %<?)8DD-V/L.^MW*
M7O\ ^_\ &Y>-(?2,V/.Z7CG,DA>=0-TL)*VQ (H5P:9>?>]5WUDF+U&27JG2
M=F3)-]#A92#SFD0WZFV]E%62:[ZTK=*6/?'@QI!(1;2A!N#[=H/WH ?QJFP/
M"/6&Q.E?XMUN208Q)GA1CME(8E"6X)KTW=W6K,L.;LMY3?"73QTZ3/Q526HP
M9AD< .6)]( ^-H[_ #IY)I9LIC*I[<.3P3J9U#*Q^FX:8^^-&F.TF^.?;]=4
MF9TG*ES?/7+*J(ML45D $FR6H@\T-3'^5N67MB_II/&(4QX0V+),SD1B0TBL
M%)#&N>X%#[_N*D/$LV+%U'*3&R9N?I0ZB^P*CD%CR.U]QWXU;>(A">K=$2>=
M4?=(40BP[;??[#@ZR_0)ILB%1F0S974\&9O.ERQ'&4=@K,%"DJ>'VCGBJ)US
MPXQBXR5'7.;$CZ9"[3,TN\)C88D>1U7:"621"P 8&VL4" +O5RLW3\B*2&/'
M9Y$E6-BO(''(8?VU?9@";NM0L;#@E?Z_ ?*DR$=YRLTKS46_/$AWA-UKMH,5
M7GCG5IT#"ER\"-,J;,"(V\>8?+F"V&6.2C1KL?D#GO>K<M<EA&%*C8VSRDQY
M(W9&C0@JH!%<CY%<5QIG#2=6\LUE-O8SR1DJF\<  $D@<?S>F\ RXN.^+/BO
M'Y0-2 6& /' -V1[:GY!:!9Y^G9<3CR[\IQ5&C9*D71/_K6KQ1 R,7$SL&:/
M*^E/3'B=E9?3Y1])4@CB@03?%<#5?TU98IL>#J&,D0>7>^3BR;(\J=5"C>A4
M,!2@C;P:YXJ[F7#:>=TZBD3HBI((X^2IYW<5P.U5]^VFI<+#FB7'DC26/'4*
M(F&Y>*VV#WJ@0=)UHDYX=P8(1UN?*CE5XED(EBCG,@O8A4E6Y1K X!JC?OID
M9[YQ^JC$V5BQRJKO P!%DJ20?8'X]N>=)ZECR9)SC%%$CY"K#?EAD 8 ,U6-
MW '?X^-2!&Z8V+@0>:N/$3OEDVI)(P/IX3T[:_[=JTT<D864<695@Q7DP$0)
M JR;I 5=5&XDDMNW$V:V[>>_&M\1_P#]L/W8>UZQ\1Q).K+(4D&3C2 BE8[N
M"H) _MHOWX]/VUK_ !&?_P 81=%F '-<ZYY2>4TN-U5##AG(@DEW",1C\I')
MX^?C6>S/#^-DM'G9\T^6H<[(5_+3BBK<<K_&KN3&:7"ECEEFC<KZ'A8!@?;N
M-5&!DRQ],RXH(FGZE&I/DV5LG\O//P==<=SF5UEWVYD]'"KC)TN,8RB<22)&
MSIN'_P#$BSV[ZA9/1>EYO41#U/+R9<G%;S4\U_6IN]I8?V]N-2N@S=;ARF@\
M0B%%:-3"ZEO,#>X/%'_G?3. D<?5,G)R\C%RL@CR'90$.X&P#SSP1QK<MF^6
MIR>P.I84GB7'CR\,MEH0U ;T1;.UN1P??Y[ZTOBF&6>-8UFDB5_RLI['4+PU
M!CYC?XTZ9*M&SPJCIL!IJWUW/VO3O5)\B>>U0% 0H&ZJ'OKG><^/3%U;PIL2
M\C+E,DT@.$X0T=H/ /.M)XSRH\7"PY9I?+6..2<OYA'"J"1M ._@GCC4>/!,
MT<DCRQC&*[-A6S?-DF_?M5:M/$:7@01*SHP4LC(Q4;E' )!!H_ (OMK.64N4
M9O;+RY4T;Y>/AR>2#$)$M?,WT+.^Z"@C@ L-W/:KU(SACB'"ZKB1I']1"4=E
MCMF6C55[^KV/-ZI91FY^'%A2Q29F5-(B9;2P+$JQ@GUE6 NZ% BB =6DN'D-
MB8^-#E>=.&DDRID;;M9C95&H @'[5P+'.K%I@01MT](7Q]L,9CVK-$_L0;*D
M;AR>QY'-]M3XC#)GP0*-\;3>52V+(/)!':A9U&P1(^08GDS)!Y D>:<#:9"S
M-M#@G<0&JU%#;W[#5CCIEY'48!$9(DB-;D/I*US?^O\ &K;P;X0'"2+@O-BH
MWFOD@/LHK&) $()-\TG%&R;XK3F9A0SH8YU6199 :D ))'*[;[$$7^VB>"6'
M Q,-O0(4\M%Q5]*T3M<BA5BB1R!_NSE,,:%(BD:AE:<".4)(I4DMM)XJR.Y'
M!/?4QZ2'CD3/*$2)G9DWC<VTDW5<U]S?MI((:.3)C<Y0@0,T44@*!B>-\@^!
M[#^=).R29$C1?.C"^?$7+K$"I*A0/3N(:R:[&M/X65+^>/.F,@&V2,TM,">2
MH[$\'57GIS$D:66&-5*ME M"TG!8BR11Y%??YK5+G9,5KC29T0;#1<A,N4&M
MYD:PW*@7:*JW1!OVU=]/'_Y2')RD2T,@#G<64/=D<\'_ $TG#Z.T.;DP2ODO
M@K()F;(8RJS'LD:NI79[T#8)K@"M2W5-_;?CL-&@=M&O*Y*+Q.BNV+YCJH&X
M_E))[<#6<D*OE(@B#IWWGG:=:OKO2SU!\9E[Q%CWKOJEPO#$^(93&03(;-L/
M_'_O7I^/+&8\U9?3'^),:3"\[,.9&BR2Q+(QBY"DFU!XHD5R#_K0U4>&\3J/
M3_%N1DQ]0Q#%BJ4RI%5XVKN X/I/8V?S#YUZOC=*RAE(TOE")19%7N/_ /S5
M/U[I'6I>H3MT[!P3CR0[BS.0[2\4&]JJ_P#AUTQ^:7^-/;+Q9V;U'(P,HY4N
M3+'(]C 4&')@+4-X:MK CN+['YXD];ZC!$/+Z8#//CMN$+;@%)-%@=M%O:K]
MSK4]/\)1/'!EYL9BZD<80R^5(=GM=#MW&F^M>'L]ND2P=*6 3F,HID/V-<CG
M_P :3Y,-DO&E'T:5CTB/*S%#Y 9][+5HNX^GB^0 !]ZU+\)86$>J29.'BRJN
M3(\SRDAMLET?FKJ^#_%:F8/A&7%P,7'9(Y!C@;06X!KGOR;^^K/$Z9FQ)&H@
MAB0&BJ/5#[<:SEGC=^-6[J/XHG ZK'%YB@F&R@7<3SP3_!KYY^-5+("2RK-'
M$FV23(C8 @'=^I-!1P11W"N1QINN=,GRIC+"!(2@0([  <FSVOL?]/Y@/T++
M-[5C"DFUW<'['CG6,<IXZV>E*CX3)*XRGBF@C+F%P2C-R25)L\$\FN*JN^G6
MJ<P%X?ZR(\AF4ER;84%/L#?':QV''%NW1,XIZI-\A #$MW%V>>_:O^7IK_ ,
M[:R7'178'#E2GW6NQ(L7]_?MJ^4^T4[,9(8W=7878*P^:3Z";  )NMPKY/O=
M:>#JZ^:DI9$8JUH5OCM8'^WO?Z:M)_#^1*K*JA59#&0)*XL=B!P:OMI4G1,]
MP1:+08*R$;EOX)!'L.XU?/'[52KN1UBG+,H8*6="%D)6QM':A5]R0016G: 2
M7'"F.E"*6YN^./<T.?\ EZMEZ+ER,C2Q1H48D 3%A[T1P*/;_71_@>8S/N$"
M 6$H77'<?S\>VI,Y]BFB!^HCV0I''-6/L7<&L E:!%," W(/!'O=AZ;+ABA4
M-NCDNQ&J6W%"N/?VK4^7P[DM&QNI@K*C1R%"@9:X8<CGG^/C3W1NC9N!GQMN
M3Z3R=AB&T;&W$EA0]^+[<@FS8I<XFT#H>+EY>;#FB'(Q(0ZD"144L+L^GOR1
MR31H\?.M#U^:.&* R,%MJ%^YK4](V5@>-5GBG#ZAF8"ITF2&/(#7<HL5_!]Z
M/[:Y>7EERC/9>/CX<N;U"*)O/R8PLIC_ #-MNC^M-I'3Y8,CI:MB*\4=E"91
M3 C@V3W_ %LZ<\0=#Z[D'!/3UQO_ (Y,KWD-'O8J4VT%/'J)Y]P.-3,?I/51
M,T<L.&,/LJHYW=_S'@#]@/WUV\IKM9EJJP[.GXL\TTB+WVLX)"W??GMVTF/-
MH8/U?T\,LRW("Y*DGML;M^Q/O]N8GB#P9UO-QLA\63#.8T@,9F=ML:$40.#1
M_P"P]KO5GC>&NN1X,0RL^+,EC18_*=0J, >2>.]4.W'W]]VX:WM)G85U'(EQ
M_+81!HBW]20OM2&,"V=F/% #4;H,\TTKG.@C4D!T\D[@%//J<>D_HI.K/I_1
M.JC!:/JLF-DDD%8E6D6NP^_\:G#I>6T0_P"E&_N ;_[:Y^4DTN]\F9'62$JK
M#?N';X^!I?B88\L\4&7+%L\OS?*8^HA""6'R!QQ7QICIO0,W&:0Y$R36WHIC
MP/O?OJ;XEZ=E9T)^C@Q'E$;(/J2:(;NI ]C0OGM?QSBW&7BIO:CE$LN&S8<F
M,(B31BMF">HF_2;+$#T[>+/>M,3XX^EC""27-C#11>:X4.U-6X$ !;%77Z<'
M5CD^&)C@318BPQ2NQ85Z0OI*@<#@;:%CG4K#Z+E8BQ1*1*B>CS)"+VB]M@ 6
M!P/]?G5F4^Q2H7BB#Y<@2,,)Y?,D5E! X %  >D,:/!X!/?3:PQY&7#)CNDB
MRHLN0':W<E3M !!VK3-W ;GVKFY;H>:3M/E,C1%7VTHW6#8L$_/<\:<_P?-0
M(T8B+"DV^8:*_)L62*_WU?*?8J,W"\S$/U+9+F2-H6\MR13;A944IH'O5UIO
MRW\Y)HBTD918UB$0LH +]7!%FC1^#\\7C]&SG55E>*1!9(_+NX%#WKFS_&GY
MNG9@C3Z9(%D[/O8D5SR/OVU/*#/C#EPHRT07<JTJ/(Y1B#0!)LCT@>Q /MJ*
M8'E6.1<?(@F,<H?<0Q7<0Q6_[C9<*1\G6F3IF=M7S5A)]]I[?/?]]-3]$S).
M%,*!&M*Y/^HX]QJS*"KBZ'#F8DJJ[X\4B@!8K4UQ6[W!XHT1QQ\5-P.E92NF
MZ;R2LP=O+ ;S0. &)%]J^_'?O;C]+ZHTB'^G&A4VB/\ E)KY'J]^>/T.I72^
MG]3QBBSS))&I%7WKC_WJ7+CL.>+,;J>3AXR](FABD6=6E,IX,8!L#TGD\?'Z
MC6 QLD=92.3#PI% 8X[33.HE@:N#3<GN;]P?F[UZMDJ[JHC"GGFS7&LEF]!Z
MT>N2Y&'EP+AE1MC?DAB>3^7OWYO]M7X<Y)JI6>Z9T8=,RO/4-DRR@^9,6LFS
M? ^-3>EYDF1--<7EL@/R&%'L>/?OP=7&1X6ESL*&+.8%UIB8IWC]7N05HUKD
MWAG*:/'C&1,%C;ETR"KD?<E3?_.==;\LR[O)))TJ\+JC!9,J.*3S$)5E'J)X
MNM03UOJ/5,O&1\ G'W%78D%4([F_MQW^XU>P]#Z[_CTCO+AKTE80J163(\E\
MN3M%?%6=6,G2>H+!*,=\;S2M*7!H'^-3SPE]'/VQN5CIE3/F/FK/AQBDCC56
MVL" :8\ ]P?U/:M.8V-D=2G,TL[+ ')A9"+4< #]>"#WUJ%\.3;E):(*%K8O
M"_?BM/KT3(C 6,PA1[75?Z:O^::XI)/;GBZ"5X<67& ::$EU&U23QV%]K[7[
M7K/3G =,>#'EQ<+J=F2-)5/(:2W4USM)+>U7S7 UK>M]/GS1&(O+9 CQR1NV
MT.&%=P"?XU CZ1U'=E!OH;:+9!*REBC?+#BZ/M8_77'#*3'E9PSO5NL8$73L
M>49T2K/.J1,B*V]E]6R,R4+I3SQ1_;4+$@&$99US,^7&=/,^GBF66*9U "D,
M3>Y@/REC=CX&M'TGPSGX^+A'-E@FRH%=2Q9G8^KT$.>0*'(H]S^[^/X>R<?!
M^GQA!$L?IC&\MQ^I!K_6M;F>,XV=]JUHYRN]5>-RX4%!NI;NR.WMSIF:!XY^
M)&"R JDGFA@IO[_W'XOMJ^;P_,\"!)1CLLGF%4;<'[V#8[<Z:CZ%F!9#(N,[
M[PZ6Y(![>Z\< =O]-6?)/M-*-Y<;$PI<OU0XFYA.0&64L[JH(-CT[G8D4>]C
MMS)$H7I\3SQF+*ACWG%A?>X )'!%!CV[?(U:_P""9R*8\<XZ#:U2NQ<J3V])
M%$>_?2!T+J<O3#C9F1%-(46-I;VEJ-[O2!M)^ ?_ 'GRF^U0TD:20X_U*VCU
M(9%VGL":'OP1VO33C:%!S%-R K2[;/\ E%]^W?5Q+T3*(D.Z-]R[2"Y KX[:
MB8_AG+68C=C0XX>Z ,A8 4*NMI_G5F6/V;0VQ7R,E!FO'-C)*&2*2(>CCV-]
M[_[ZU/7T+]/](LAP1S6J;_\ 3V1 <UL>+&E:38(_,E=;VURQHU[]OWU?=7PW
MS<,11OL;<&NZ[:YY92V:6,=/E.0H'%&F'?G365%]3CB""=\:44=\?YA\C5^_
M0)R[N)(]Q[78T1]#ROS2O 7JCMO_ ,:W,\9[=<LL?2CQ6R<+$>!8_P#$_*8M
M$9+WA2>>?M>G\<=';*Q<N7I42YT5R1L%!:,L*)!^=6L7AV1,DS^8N\_!/'^G
MVTJ;H>0=S1RQ[S_F)Y_TTN6-]L;BDZKUMO.BA;?4SA511V%]R=(A::24KY1K
M<0#NNQ\ZGOX5R%A+Q- ^0/4H<D -_P#[4>/V.I&)T+J*(AR,C&,E>KRU('[7
MJ^6$G#4RD5>:<Q9CB0QI'C"(,)@>2_/MJW\5Q%NDX[%3(8E+[1+Y8)V^YL<?
M.G&Z+EF7\\!C(Y[W>K'/Z>,H0;XXY1&"I5S0((%^WVUSN4W-,VQBL3'QQ%@0
M9<N=DE@8_/=6C15L [5)W5R*L$5S8OGDZ@9).,N-(RLL:9Y4"27'(+D6J@$!
MNU=[]C9UK<#H,6+-/( A61B5BV^A.221[V2>3^E5J)D>'I5R(EP_IX\0  I1
M!0 4-OM[#OJS.6\DO/+.R%(8EE;&)>,"O,D +*MC=9/:B3SI73'>6/'ZCFXY
M^DFA+Q1,S+("0NT[ .Q]1Y([KZ?BUZEX8S"CKA9 D>2R999"C1FUH(5':@2;
M[\#4W_\ 3\GD8JB2C' L10N7JA_F/)Y]SSK5SQJ[C/00X^3GI%@Y "1JF/N
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$T'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g769642g62f25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g62f25.jpg
M_]C_X  02D9)1@ ! 0$ VP#;  #_[1\84&AO=&]S:&]P(#,N,  X0DE-! 0
M     #P< 5H  QLE1QP"   "   < E  #$IA<V]N($-O;&]M81P"!0 74&]W
M97)0;VEN="!0<F5S96YT871I;VXX0DE-!"4      !"R)>6>P1T&^O+@7B%[
MCDW/.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      !  VVH]  $  0#;:CT  0 !.$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           #"@  !5\          0                         !
M          5?   #"@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   #"@    !29VAT;&]N9P  !5\    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   PH
M    4F=H=&QO;F<   5?     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    #.$))300,     !2J     0   *    !;   !X
MJJ   !2. !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M8 ]U<;0+#OKL;[6O=ZGZ:K>[%_TG^$K3OSC-K/L5+:F%NCZB"QI-3/M-M?\
MH]MUK]GZ+9L^G_/>B4=#ZTP#9UN\G=N<'5UD'<_<_EKGM_1E^RO=Z?\ UM2=
MT/J_KVVU=:OK;;:ZST_3K>&M)::Z6>J'[65M9L]GTT/;G_G/P5[V+_,C_&0T
M@#"Q@W&HL=D/O;8]U4 ,J-EE6QFUO^@I;3ZG_!(/VJUP:UF*PVL]![ U@+W;
MW8[[:[[K!MK=D//Y]=?T/5]6S_!ZG3NF]3Q;_4RNJ69U>PM])]=;!N.S]+NJ
M:UV[V?\ 36FD<<OWSM^Q(SPLGV@=;W_K<7_H#5Z::W8-5E;&,%C=[FUL]-NX
M_3_1N]S?=^^GM_BK*K6_Q4L>C6R$&R!0O9__TO2%,N+*2\-+RUI<&-Y<0"=K
M?ZR@I/!..\-#G$L=#6':XF#[6/ENQ_[CTXL4=VD[K%K&^_IN9Z@G<QK&N'M/
MOV6!^U__  ?^D13U*P7/K.#E;&%S1:&-+26[IV^_=L=M_1/_ ,(L2,NVNE]>
M#E[RQS;:ZLZ;="ST_4LKM]+=Z63Z[=[OYCT]G^#5>[I5]N6[)/1<RN^[:QUK
M,T-T-?HNLMV%O[F^S;ZF^[]*E2]Z']JV;0_]GYFTR"-C=P(#'M]GJ?1?ZFWZ
M7\Y6K=%QNI;::WTETS7: 'B"6^X,<]ON^E])9M/U8Z9C6,L8_(!98VRL.O?M
M#FG=#6;MOZ1P][/\(M5Q#02[0#E(TIH]2S?29Z55K:;"X-LL/+ 6FS=6UP/J
M.=MV+"R.I9F2T-M?+8 <( W1K-D ;O<GZGEC+S'6 N#&>RMKHD ?2X_><$"N
MA]A8&\V':S0F7Z?H_8';?:[<I\8B .^^H<OF9Y93D 3P \/IEI_A",F"TNB,
MJM?;46[+8!;D@R6R6[:=A&W])L5.S"RZWW5NJ)=CM#K2W4!I^B_^5N6UT3'+
M<9C[7"2?4J#'#W5_F&W9_.;;'/VIV20X=UG*XY', 015W8_P75/,ILFVVG$L
MLIK]:UK265C\YWYHT3J&:W?@VMBQTLB*3ML_ZV[\URJ$:5L[$#1LB_!P< =0
MIZ5DXGV"UH>[V@N?N(MW>M[G>[V;?^G^D1,@9UO2<?$.#80UT$![]P%>STCN
M^E[]W_@:0KR+L@#9U6IKB&E_JL#6P6M^B3[F_P#">]-7C9+CC,LIZBQC&>QX
MR 2TN=?'KM]OZ1E+=O\ A/YZJO\ EIV+]7$1WX3=K>:A[^6>0DP]R/"8@"0_
MK?/Q?,ESK>HVWX=XP7.=0T60'. #W#](QVW^K[40NS?V[Z_V1VS^8]7<[;Z<
M_P YM^A]+W*M6S.%S;W8^=2TN#Q5]H!9N!G:]@9]&Z[V/_2?X3U/YOU/3;[,
M^RTUFOJOI-L-7J&T;8G8ZV''UW4^SU?_ #W^C3N/I0V(^UB^[F[XY:RC/:'S
M0]/[KTJ2Y[&KRO48RRCJ((>TESKVN8"TO<UV[<U^UWT+F[%8Z3A#UF7.&;4Z
MBMH:S(LED6!VZG8WVN]'_P!)IE-AV56M_BK*K6_Q*06SV?_3](4GM+\=S "X
MN8X!K7;29!&UK_S/ZZBI6-<_&>QH:YSF.#6OG:200&OC\Q.+%'=YNOH&$S$8
M:^BL:'G:QK,T_1+!Z8]73=]-U7\C_!_X-)_1,<4UUMZ,WT:-[VEV<Z&EXJ]9
MSRUWN?\ H:_IO_P?J*PWHUS /\DX1#=&M;8X.C^</O(]VZY/^Q[JWO%?3,1S
M 'L83<\;JW'B]I#_ %7.;[][T;7M?%Z)TBZ^OU>G5-EQ]4C-=;LV^G7635OV
MV>H^KT=G_I1;N/@U86 W$QMQ942YNX[G$E_K/_M;G(.#TRAM;7Y&'5CWL,!M
M3BYNT%KF'\S=[JZWOW-_G:J[%HH'710-$'LX?4,'IXP;<BE@KO$.,%Q!,@/:
MUL[-CU#ZOUL]=USW.#OH5-DAKC#G6$Q]/TF?YGJ+:NQZ;F/98P$6 M<0!.NG
MTOWDL;&IQ:64TMAK 8)U=KJYSG?RT1,\-$WV8988^Z)PB(C>7]Z)_=C_ -)F
M6-.[\USV[2\?2C7;_F;U4AV+M=;;4'N'IXS'#:-QV-?LV>[9<_WV?Z-75C=5
MZ/=?9;EUO]6U[FAM)AH#=*]H>X_VD8431-*SF48\4(<<ATNOK_6=6FQUE3+'
M-V%P!+00X#X/'TE+*C[#=N </3=+2_TP=/H^M_@MW^D_,0\5AQZ*,9[]]K*P
M)\=L N3]1IR+NFW58S*K+WL(K9D2:G']V[;+O3_JID@-1T+-C)%$[BK\_P#!
M<1G3\@G':&UL>736W>QK:GE]>2^W%JK>[]"ZBNQE;&?I?])_/6JTS"OP;ZW4
M%OI>ML9ZKFS[_3#[-/3;OM8US/\ "7[_ -)_VKR%2_8_6"Y[#TSI8H=8';"7
MR-VUK[=&^^ST_;Z?Z-+]E]:#J+:>F=.:64UD5VN?N9:2Z^ZOUF-M_1T7V/\
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M0>+J_P#_V3A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O
M '  ( !# %, -@    $ .$))300B      %*34T *@    @ " $2  ,    !
M  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (
M   >    ?@$R  (    4    G $[  (    -    L(=I  0    !    P
M .P   #;     0   -L    !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C R-#HP-CHQ." Q,3HT-SHT,@!*87-O;B!#;VQO;6$       .@ 0 #
M     ?__  "@ @ $     0  !5^@ P $     0   PH         !@$#  ,
M   !  8   $:  4    !   !.@$;  4    !   !0@$H  ,    !  (   (!
M  0    !   !2@("  0    !              !(     0   $@    !.$))
M30/]       (          #_X0%217AI9@  34T *@    @ " $2  ,    !
M  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (
M   >    ?@$R  (    4    G $[  (    -    L(=I  0    !    P
M .P   #;     0   -L    !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C R-#HP-CHQ." Q,3HT-SHT,@!*87-O;B!#;VQO;6$       .@ 0 #
M     ?__  "@ @ $     0  !5^@ P $     0   PH         !@$#  ,
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M!@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06%AH=)1\:&R,<%A8@
M+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*$R@:%AHH*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*/_
M !$( 6,"<P,!(@ "$0$#$0'_Q  <  $  04! 0              ! $#!08'
M @C_Q !0$  ! P,# @,&! ,$! L'! ,! @,$  41!A(A$S%!46$'%"(S<9$5
M,E*!(T*A%K'!T21B<_ T-39#4W*"D[+"X1<E5%62HO$()C=C=':#_\0 &P$!
M 0$! 0$! 0            $" P0%!@?_Q  U$0 " @$# @,&!@(" @,
M 0(1 Q(A,01!!1-1(F%Q@9'P%#*AL<'1(^$5,U+Q)(*R_]H # ,!  (1 Q$
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MRLB.X6T.N)2I""YC:"=PQD]S2F+1L=*TR+KN(F5&9FI5T7(3LQ<QIEP-)"'
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MD+;B!H!+:D(3RHYRL[B3X8''K6I2+AJ^U:MEV6!=[I.G/6R2M"KBPAMJ1(2
M4F+X8 /(SBFFQJ2.YTKAS&JKM!:?M=RFWB-%7(9?]YFM_P"F,Q\("TA*1G<X
M\=B.,X*CV%=@L%YA7VVIFVUQ2V2I39"T*0M"TDA25)4 0001@U'%HJDF9&J*
M!*2 2"1W'A5:AS;G#A.MMRWTLJ6,I*\@']^U1)O@2DHJY.C#O?B\6ZQXD:X(
MD%QM;A$AH82!CQ3SSFJP-3I+:%7..J,VM9;3(2=S2B"0>>X['O5AZZQ4WBYS
M!*94&(@;:^,?&3E1 \^PK',K<F1+-$M3(E>[I*WE+20TE93CDG@X))P*]*@F
MO:7\'RGF<)/RY>NW/=+X^K-IG7AB,M#3*5RI*QN0TQ\1(\R>P'K6.9O-U?GO
M1V;8QEE(4XDR.V>PSC&:B&WRM+Q79,#;*;4C^.DI *5>"AC^4>57E),:T1H,
M%X.S;B2I3X/<'E;G[#M^U948KC<ZO+E;]IN+795\J>]V_P"C(V6_1KFKIA*F
M) S_  U_S8."4GL15N[VE1GM72 VVJ8U^9M? =&,=_!0\#4.\0TO.0+1;=K3
MT<=7K8Y92.!^Y-9>QSS/ADN@)DM*+3R!_*L=_P#.LOV?:B=(/S/\67=KO[U_
M*^^YB;%*9F75Z3<' U< 2VU%<X+2/3/<GS%96]07)C3*XRDIEQW$N-*5V[\@
M^A&:E26HQ*79*&26SE*W /A/F">U1S>K8%;3<(H/EU4_YUFVW<4=%",(.&22
MW[\/_P!D^E 00"#D'QI7,]1Y<_(KZ5%J6O\ (KZ5$'C6HF)'A[Y1J+4I[Y2J
MBUM'&7(I2E4R*4I0"E*4![8^8*E"HK'S!4KPK+-PX I2HUQD&+">>2,K2GX1
MYJ/ 'WQ42O8K:BK9%4/Q"X%)YB15<CP6Y_DG^_Z5DZCV^.(D-MG.5)&5*\U'
MDG[U(JMF<<6E;Y8I6$O]\-O<:APF3*N3_P MD=@/U*]*@]+5B$=?WF M??W?
M;@?3./\ &N,LR3I)NO0]L.DE**E*2C?%OG[]3::5BM.7<7:(M:VBQ)966WFC
M_*H?X5E:W&2DM2.&3'+')PERA2M>O-XF_B8M5E8;=E[-[CCI^!H>&?7M45Y>
MJ+8CWAU46XLIY6TVG:H#TX_W\JYO,DW2;H],.CE))N23?";W?W[Z-K%:CKW3
MPN,-4V*C_2V4Y4 /F)'A]16PV>Y1[K 1*BGX5<*2>Z3X@U-JSA'-"NS,8<N3
MI,VI;-?='']$7DVF[)2XK$5\A#@\O)7[?W9KL%<:UG;!:[Z^VV-K+G\5OR /
MA^QS72]&7 W'3\9Q:LNH'27]1Q_=@_O7CZ&;C*6&78^QXSBCEA#K,?$N?X_H
MS50KS;6;M;W(DA3B6UD$EL@'@Y\0:FUIVK+Q=A<V[;96G$J. IX(SDGP!/ '
MK7LS3C"'M*SY'28LF7*EC=-;V^U=S8;%:6+-",6*MU;965Y<()R?H!Y59U!8
MHU\:9;EN/(#2BH%H@9SYY!K2IMRU'IF4P;C)3):=YVD[@K'<9P"#S6RZJOLJ
M';(RK6PM;TI.Y*@@JV)P#G'GS7!9L;@XRC278]LNDZB.:&2$TW*ZDG]21<]+
MPKC!A17G9"6XB=C90I()& .<CTK(OVUI^TFW+4X&"T&MP(W8 QY=_P!JT&<Y
MJNU0D7*3,RV2-R"0K;GME.,?:LU,U6Z-'M7%E"4RW5]''<)5SD_T_K4CFQ7+
M5&G7Z&LG2=2U#1-26JE3X?)G=/V2-8X[K,1;RT.+WDND$YQCP JQ?]-0;TI*
MY(6V^D8#K9P<>1\ZU61<+]86X%PFS1)CRB"MHC\O&<=N./*MIU9>Q:;47&L&
M4]\#*<9Y\\>G^5:C/%+&XRC278Q+#U,,\9PG<I<->[9F,@:"ML=X./NO2=IR
M$*P$GZXK/7JTL76&W'=6ZP674/,NLD!;2T'*2,@C]B",&E@;FHMC1NCY=EK&
MY>4@;<_R\ =JR-=L,(P5P56>/JL^7+.LL]5?3Y&"MNF8D"='FI?DNRFNL5..
MJ22ZITI*E*P ,_ D#& !X5G:4KJ>44I2@'A2E* 4I2@%*4H!2E* 5[9^8*\5
M[9^8*%7))I2E8.I@Y6F(4A]]_J2&WW9C<[>A8!2XA 0,9!&-HP0<]S5B]PK/
M-U!':D7)4:\+C*;8:9DAMTHWI65)3W."V/,8R"#7/]=:VOL.^:J$&[0K6QI]
MAEUJ(^PE:K@5C)Y)R!_*-OB:]Z19ESO;A<+C*DD*-GCO]!;*<MI<_P";"L9&
MTGN.3XUO2ZMG/4KI'0F=*VYNQ2[4OK.L2G%//.*7A:G"0=^4@ $$ C ':L5)
MAV1,>1'>U))0\Q(")#JIB-P6XD)2VM)&P9&,)V]^1SDUH&NO:)?;=J*Z.6:8
M5V^VS6(CC*H[*6]RB M)*E]51Y/*$X&/WK&ZE_XTUS__ +':O_+547W(YKL=
M;3HVT0@A:'9#$9E,;X"Z-G^CG+:B2,YXP>>15Q-FLMNALSUR^G$B(DD/N/)"
M E]>]PE7;OV\JUCV\71+-@MMF#4E]5WFH:<:C-EQU3""%N[4CD\ #]ZY=.GN
M/^Q'55B:7*A(LMQ;"(TEC:ZN*Z^DM)6%<IP59_[('8T46U8<DG5':(ND=/MP
MHMQC7"0+:RF/+"TR$]%?00D(<4<<C8A.><<9QGFK\/25HE1VYELN$P-/EUUM
M^,^G"FWE]12$JQ^0J)4#W&>#6D1;EJ87#6\#\6BJM.G882EE4%L%Y1BJ(& ,
M)3N&XC!\NU1;?JZ]3(^G[;'O=NT\V-/-W1R4]&1L=63C8$G"4I&,G;S2GZC4
MO0Z3,T9;Y4PO^\3FFU/LREQVWL-N.M%.Q:@023A"0><''GS4V]Z=B7>3UI#D
MA"S%>AK#2@ MIW&X'(/BD$$>5<8UA[3=0053YMHN;$J-;$1@]T([0C.+6 5?
M$M?44%9XV)X'WK(:RUEJN!=M;RK==6&H&GWX?3B+BI7U0Z$[DE?<#DGS]132
MRZXG3KEI"W3GDON.26WT-,-H<;6 4=%2E((!!&<J.<@CTKQ9=-VR.8$BW3'W
M3#<D*2X'DKZA>5O<2LXY&[!XP1BL=[7+\Y9?9Q<I,;=[[*;$6,E RHN._"-O
MJ 2?VKE6A[^O25NUO9[6S.M_1MGXK;Q/C%ISJ(:"'5;5=P5@'[U$FT'))T=Q
MN>FK?<K]"N\L.*DQ&'8Z$A6$%#@PH$8YX'G6*T][/;/8[M'N##UQDO16UM1$
MRY2G41DK_,$ ]L]N<US.XZIUO&5);3J*.2C3J+_N]P1P1D%H<]CCN<FE]]H^
MJY5P<3:5QX:(UKBS2%JCH0XMUL+)6IY:2$ G;\&2/'PJZ7ZDUQ]#JEUT=9Y<
M>[KG*?W3G6Y+TGJ[5M%K!;V*Q\(1C(^ISG-3='0+9 L32;'(]ZAO+7(]Y+O5
M+ZEJ)4LJ\23FN>6O4.J+SJK432YT2-;+; CR7(@80]N4Y&*BA*QP4[LG/.<#
M'!K%675UZFVS2ELCWB!8$R+,Y<79JXK>Q:DK*0VE)PE( ^(X':II=%4D=RKR
MXVAQ.UQ*5)\E#(K@>L/:3J&&F:_9[O'E)MD6,Y(7&C,B.XMP YW.+WJ"@> @
M<9\:FZNUGJMFX:ODVNZL18=DB0I:(RHJ7.H74 J3N/(&2?7MC%-##FCLXML$
M*W"'&W>?23_E4E*0A(2D!*1V &*XAJ[7^H+9J5YX7!B/8V4QB1%:9E=,K *@
M^@J#B<D\%/ACO7;TD*2".Q&:DD^Y8:=]**D @@C(/A6KI@N6&XNRX\9V9$6G
M:E*#E; SDA(\4DUM%*1EI,Y<*R4^&N&:=;;NVQ#F/AM]^[R25EM+*_A/9*>W
M85#MK=R@2HX:0829P#;CTG"RIWE6[:#P3G !K?:BW."U<(:X[V0%<A2>Z5#L
M1ZBNJRKTY/)+HY4GJW7';X^KW]3756=MW449B6^]-V,J>>ZRLI/.$@)[#Q-3
M-+1(SL&2_P"[M%#\EQ204# 2#@ ?:L>B5(L\BY.WA*U/.-!#,A""4+"4G R.
MQ)J;9+Q;8EH@Q_>D./!M(+;0*U;CWX'K6I:G';<Y87B62Y;<\\]DOT-C' XI
M2E>8^J>7/R*^E1:E.?D5]*BUI&)'A[Y:JBU*>^6JHM;1QER*4I5,"@I2A12E
M* ]L?,%2JBL?,%2JRS<.!6/NG\21 8\%/[U?1(*O[P*R%0)7_'$#_J.G_P -
M6/)G+^7Z?N3ZHI00E2E'  R35?.HUSS^&R]GYNDO'UP:PW2L[15M(U_131FN
M3KV^,NRG"EHG^5M/&!_OX5M-8+0N/[*P-OZ5?^(UEYN_W*1TOF=-6WZX.*Y8
M=L:?S/5UCU=1*/9.E\%LC7=%?QY%[FI^4_+(1Z@>/]:VBN<:>N-SL^GXTW##
MUK#A2X@ AQ&5$$Y^M;G?[LBUVA<Q*0Z3@-)_43VKGT^6*Q[]M_J>CKNFF^HJ
M.]NE\MJ?O,7"_P!&U_<$+X]ZCH<1G_5P,?T-;16AH%V.L+*NYKCE]:%G8T,;
M$8.0:WRM=.[4OC_LY=?#2X.T_97'NM?P:I"1^$:T=C-_#%N+9=2GP#@[X_K]
MZVL5K.H,?VKT]C\VYS[;:V:M8=G*/H_]F.K>I8\CY<=_DVOV1H?M5C QH,H#
ME*RV3]1D?W&J>RE\EBX1SV2I+@_?(/\ <*R'M- .G$9\)"<?958/V5$_B$X?
MR](9^]>*7L]8J[_T?8Q_Y/"9)]G_ "=)JW(#GN[O1^;M.SZXXJYX5H^J7+]:
M[R)L-;\B 2%=(9*4^:2!X>M>[+D\N-M6?$Z7I_Q$]":3]_?W&MZD;NZ)41S4
MR7'& <#8I(&/$ C@&NJ6YYF1 CNQ?D+;!1],<5S:]W2Y:K]WB1K:MM*%;CC)
MY[9)P !R:S=^MEXMUFMZ;/(>/N[>QY#7<GON \><UXL$]$ISC<EM\3[768O.
MABQ9&H3WV7"7RNK,7K9G4*D2E2\JM:72I(24\)S\.<<_>LC#ML;4&B&HULRT
MXPO.'#_..^3ZY[UC+EJBY76V+MR;8L/N@(<4D*)/T&.*VO0UI>M-FV2AM>=6
M7%(_3P !]>*F.,<F5Z;::WLO43GT_31UU&<9;)=_>T:Z]9[[=&HD:\I9C0(8
MRIW<,E('?N><#TKRB:W/N,G4$Y*C;8)#<5K]:O#_ #^WE6;UJ[+EF/9[>VYN
MDD=9T).U*/(G_?MZU74EA)TD(%M1DQRE:4^*\9S^YR36I8FG+3O7KW?9?(QC
MZE.,/-J.ITJVJ+>[^+X^!CTZUG,H8E3;26[>\K"7$J.?_7^E;NTM+K:'$$%"
MP%)(\0:YC.N$N\62#96+:^F2T4A2BGCX01^W[UTBVQ_=+?%C$[BRTEO/G@ ?
MX5UZ;)*3:;M;?4\GB.#'BC%J*C*WLG>W9DBE!2O8?)%!2E *4I0"E*4 I2E
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M2W%G2_PU+5N2[* W+9;5U.J0<>!"4DX^$<^%-+&I&^S](Z<N#ZGYUAM<AY2
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M?VJI68G/3QR0TV>#>Y:[C.C)<0<)8SD92/YCCOGU\,5L"4A*0E( 2!@ >%5
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ME+=:+BN;#ZP<4"G:592 ?(8JK%E;AJJHF9=3TL8Y?+;N?N,XY\M7T-<Q]DJ
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M/F"I599N' I2E0T*4I0"E*4 I2E *4I0 4%*4 I2E *"E* 4I2@%*4H!2E*
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M / !0[>/%0)6F7V9#4-*D+D.DJ2K.!M &?ZFMVT_:Q:;>(^X+45%2E@8R?\
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M[FIM<OT?>I<2ZQF'77'(TA01L620,G (_>M@]H%WDPQ'APUJ;4\"I2D_FQG
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M=7>L5[=^ WMWGX?BSC&*;T/9LT]>C+BRV^C\,ASH[C<Z.S&<<2E$;JOJ6AP
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M+MLR,E"7$@1E..E:&P2!E(2=N1V^E;IIZQ_A.HKR]'C,1K?)9C!I#("1O0'
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M HXSP C<>_<=L4TDU(ZS2M/T/JQW55TO*XS;/X+%Z+<=Y(.]Q:FPM>3G&!N
M[5N%2J-)V*U+4TIZ9;9CS61;V3TQ@XZRLX)/FD=L>)]!6=OKZV+:YT3AYTI9
M;/DI1V@_MG/[5B-3Q'7+:Q9K:D?+*U)\T(QQ]22*Y-^TD^#LHM8I23INZ?I2
MMM>_T.;@J7^7X4>?B:KTD'N,_7FKA&.",$4KZRPQ?Y]V?BY=9D3K"]"]W/S?
M+?VJ+?2 _*2D^AJGYO@< SX$>-7:\K3N01X^'I4GB27L+Y=F;P]7*4DLS_\
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M(-O_ -9S_A5V]QUR;:ZEGEY&'6_523N']V*A3)*2U!O,?*F4)PZ!WZ2L9/\
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MPHOE'33CYGQ'^)U-N_DC;GBL.47*7+:8MDB_HLCDV(DN/J>0]^5SK#<OXPC
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MP*4I4-"E*4 I2E *4I0"E*4 I2@H!2E* 4H*4 H*?2E *4%* "GG2E *4%*
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GI2A!0>-*4!2J^%*4**"E*$*544I0H\*#QI2A *4I0%#W-*4H#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g769642g66t55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g66t55.jpg
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M*"@H*"@H*"@H*/_  !$( /\!D ,!(@ "$0$#$0'_Q  <  $  @,! 0$
M        !08#! <! @C_Q !0$  ! P," @,*"0D%!P0#   !  (#! 41$B$&
M,0<3(A0505%687&!D=,6(S(U<W63M-$7,S9459*QLK,W0U)TT@A"8G*4E:$T
M4\'P1:+"_\0 &0$! 0$! 0$               $" P0%_\0 ,!$!  (" 0(#
M!@8!!0        $" Q$Q!"$2$T$%(C)1<? 4,V&AL<'1%5*!D?'_V@ , P$
M A$#$0 _ /U2B(@*JW2[,I.-Z6CFO+(();;4R/IW/C'5N8Z'2\9&<Z3(=\C#
M3ML5:D0<FEXDG?;I)J;B&04$D=9-13=9&Z4R,9#U,3]MW.+I7B,C406@C8A=
M1,L[: 2]SF2IZL.,+7 9=C<9.RV$0:-DN'?.@[H,#Z=PEDA?&\@EKF/<P[@D
M'=I6\H7A'YMJ?K"M^\R*:5GE(X$1%%$15/BKI%X4X4N$5#?[S#2U<@#A%H?(
MYH/(NT@Z1Z<*Q$SPDS$<K8BQ4=5!6TL-51S1ST\S ^.6-P<U[2,@@CF%E441
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1:4MVH(:]U%+5PLJF0.J71EV"V)I +CX@-0Y^-!NHH-W%MD;3&=U<&QAQ
M#@Z)X<S#0XN<W&6M#7-=J( PX'."%.#<;((7A'YMJ?K"M^\R*:4+PC\VU/UA
M6_>9%-*SRE>!$111?DOIPZ*^+:[I%N-SM5NGNE'<7MDCEB()8=(&AP)[.,;'
MEC&_/'ZT1;I>:3N&,F.+QJ50Z(^':WA3H\L]GND@?6T['&0-=J#"Y[GZ0?#C
M5CU*WHBS,[G;41J-0(B**(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B*(X@XFLG#K&.OEUHZ#K/D-GE#7/\ ^5O,^I.29URE
MU5^*+#6WJX.:UU/'0R6RKM[Y#([K!U_5]H-TXVZL;9WU>#&\AP]Q18^(FR&Q
M7:BKC'N]L,H<YGI;S'K"F$UHB=\*'6<*7>KK:VXOFM[*VMI9J&2,%YCCCD9$
MW6#C+G Q9TD $.QG;)NAI&&@%)KE;&&"/4QY:_ &-G#<'T+81!7."J-D-GJ8
MVR3N'=M8S+YGN..Z9-\D\_/S4^V%H<PATF6# R]QSZ=]_6HGA'YMJ?K"M^\R
M*:5GE*\,(IV!@;JEP#J_..S[<\O,O3 T]9VI.WSQ([;T;[>I9445CZENH.U2
M9#=/RSC'MY^=>"!H#!JE[!R,R.W].^_K65$&(T["US=4N'')^,=GU;[+TPM+
MG.U29<-)[9QZM]CYUD1!C; T%A#I.QL,R..?3OOZU\]SLT!NJ7 =J_..S[<\
MO,LR(,1@:=?:D[?/$CMO1OMZEZ(6AP=JDR&Z?EG'\>?G61$&(4[ &#5+V#D9
MD=OZ=]_6AIV$/&J7M')^,=MZ-]O4LJ(,9A:7.=JDRYND]LX]6^Q\Z"!H+#JD
M['+,CM_3OOZUD1!A[G9HTZI<:M6>M=GVYY>9?1@:2\ZI.WSQ([;T;[>I89;C
M10U3::6LIV5+ODQ.D <?5G*VE(F)6:S',,8A:'-=JDRUND=LX]>^Y\Z\%.P-
M8-4O9.1F1W_G?=9451B-.TAXU2]LY/QCMO1OMZE[U+=1.J3);I^6<8]O/SK(
MB#$(&C1VI.QRS([?T[[^M>=SLT%NJ7!=J_.NS[<\O,LR(,9A:2\ETG;&#A[A
MCT;[>I!"T.8[5)EHP,O./7ONLB(,0IV!K6ZI<-.1\8[/KWW0P-(D&J7MG)^,
M=MZ-]O4LJ(,?4MU%VJ3.G3\LXQ[>?G7@@:.K[4G8Y9D=OZ=]_6LJ(,)IV%CF
MZI<$ZOSCL^W/+S+Z,+2YY+I,O&#AY 'HWV]2R(@QB%H<PATF6# R\X/IWW]:
M^13L#6MU2X!U?G'9]N?_  LR(,1@:1)VI.WS^,=MZ-]O4O>I;JSJDSIT_+.,
M>WGYUD1!B$#0&#5+V#D9D=OZ=]_6O#3L+7-U2X<<GXQV?5OLLR(,9A:7/=JD
MRX8.'G ]&^WJ1L+06$.D[ P,O<<^G??UK(B#"*=@8&ZI< ZOSCL^W/+S+TP-
M/6=J3M\\2.V]&^WJ65$&/J6Z@[5)D-T_+.,>WGYUX*=H#!JE[!R,R.W].^_K
M65$!5+I&FFH[--56@Q17CL-$K&Q&I$.L:^KZSLDX+L [>M6U4'I8ALIMS*BM
MI>':FYTYCE;'=.YPY].)6"1K'3 AN=6G)VRX;@D%:KRS?B6QT7U-PNULFNM\
MI6LK2YD,3Y&1"8,$,76!Q9R!E$C@"<X+?,KLJ+T0RT]19;I44%):*&AEKW.@
MI;;)3R-A;U<8TR.@[!?D$\R=):"2KC=*GN.V5=4#$WJ(7R9E=I8-+2>T? -M
MREN2G#91<TIN-+W/35+'1TE-64]-45CFU5(^-VB*.!VAT?6$M+G3'#M1&&\L
M\NAFK8V@%7(R4,ZL2%K(W2/&1R#6@DGS ++2-X1^;:GZPK?O,BFE \$3-J++
M--&) Q]=6. DC<QW_J9.;7 $>@A3RL\I7@1$447R^1C"T/>UI<<#)QD^(+Z7
MXG_VD'WK\J=Q%W,X@;I[@!SH$.D8T>#GG./#E;QT\<Z<\N3RXWI^V$5+Z&'7
MAW1E83Q'UW?$PG5UV>LT:SU>K.^=&GGOX]U=%F8U.FXG<;$1%%$1$!$1 1$0
M<'O]CO'PBJHY*2IFGEF<YKVL)#P3L0?%_!=OM<<T-MI(JIVNH9$QLCLYRX 9
M/M6RB\^'IXQ3,Q/+Z'6>T+=72E+5B/"(B+T/GB(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("H72Q6U\-K%/:K37SSR%ADK::G@D$,(D:9&YE=@.+02
M,M(SCES%]52Z4[>^Y<&54,5--5/;)%*(8X63AVEX=VHW.:'MVW;D'Q;K5>6;
M_#+SHQ8YE@FUMNS<U!<.^<5/'(06,W @[.GQ$[\_!A6R:*.:)\4S&R1/:6O8
MX9#@=B"/"%S_ *$.Y'<+54E)<^^,QJ1%4GN5U-U,D<$40CT.).0QC"3DY)*Z
M$EN2GPH@\,V0P-A-JHW1M?UFDQ ]K &3X]@!Z !X%+HBRTA>$?FVI^L*W[S(
MII0O"/S;4_6%;]YD4TK/*5X$18:RKIZ&F?45M1%3T[,:I97AC6Y.!DG8;E16
M98YH(9BPS11R%AU-+F@Z3XQXE$?"[ASR@M'_ %L?^I/A=PWY06C_ *V/_4KJ
M4W";10GPNX<\H+1_UL?^I9Z'B&RU]2VGH;Q;JFH?G3%#4L>XX&3@ YY)J3<)
M1$111$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0%4>.^';K?8S'255OJ*!S6B6UW&G+H9G-<7:NL80]IY;'4W;ESS;ES_I:XLF
MX7AMQI+Q3T555&1L5-)0=TNJ2-/)QEC;&&YW+CCM#Q;ZKO?9F^M=VWP!?X)Y
MZFQ=Y*:S5%$2UT-)-$Z D'!#0-+P=L]IC<C<9"NJH71+2RU%IJ+K>18:F\SU
M3W/J;:1*6@@'0^34[M#)V#M(! &RN-Z@J*JS5]/12=552T\C(I,XTO+2&G/F
M.$MR4X[LW==/IU=T0Z=?5YUC&K_#Z?,LRY4_AN\/HG0R69T])W'4T=/32FF:
M^)\D<(;([00S2"R09&7@.Y%=-,4XH!%'.&U C#1,YFKM8YD9W66D;PC\VU/U
MA6_>9%-*!X(;*RRS-GD$LHKJP.>&Z0X]TR;XR<*>5GE*\"(BBB_&_P#M \9<
M3MZ3;A1&XUU#2V^1G<D,$KHV@:01)L1DG).?!G'@7[(51X\X>L]VJ+-/=+50
MUDS:V*,/G@:]V@Y);DCEYN2WCM%9W+GEI-XU$L70W>+G?NC6QW*^AQKYHG:W
MN&#( ]S6O(_XF@'SYRKFO&,;&QK(VAK&C :!@ >(+U9F=RW$:C0B(HHB(@(B
M(,53*^%@,=/+.2<:8RT$>?M$+6[MJ/V76?O1?ZUO(I,?JU%HCT_E&NN<K9V0
MFV5G6/:YX&J+D" ?]_\ X@LG=M1^RZS]Z+_6O9OGJD^@F_FC6ZLQ$]^[I::Q
M$3X8[_7Y_5KTU1),YPDI)X !SD+#G]UQ6PB+<.4SL1$1!$1 1$0$11-5Q'::
M6N[DJ*Z-E1G!;@X!\1.,#UE6*S;B&+Y*8XW>8CZI9$&XV11L1$0$1$!$1 1$
M0$1$!$1 1$0%S+IFK:NBDH32FRD3459"P7*KIX.KG=U75S-ZT'5HP[('^(9\
M"Z:J5T@7EUJJZ$3\(5%^I)"UHF@C9*8G.D#7 M=N.SN#R)&"1S6J<L7^%N='
M%TBNUBDFAHK91ADYC<RW5<53&XAK27%T8 #M^7/ 'C"M*A.$:JGJ[;))262J
MLT8E(ZBIIV0N<<#M@-)!!Y9\RFU)Y:KP(B**A>$?FVI^L*W[S(II0O"/S;4_
M6%;]YD4TK/*5X$59Z29IH>#:YU-/-3R%\+.LAD,;VATS&G#A@C8D9"^/@10?
MM/B/_OE7[Q-=DW.]0M*A>)__ ,1]81?_ "M#X$4'[3XC_P"^5?O%\2\!6N;1
MUM?Q"_0X/;JO56=+AR(^,YIV-S\EL15;X$4'[3XC_P"^5?O$^!%!^T^(_P#O
ME7[Q.QN?DM**F<.T9M/'ERMT%;<JBD[V4]0&5E;+4Z7F69I(,CB1D-;R\2N:
M3&EB=B(BBB(B B(@TIOGJD^@F_FC6ZM*;YZI/H)OYHUNK,<RW?BOT_N1$1:8
M$1$!$1 1$0%R&[<)7?OU-'' 9FRR.<R74,$$YR?%YUUY</OQN'PBJ34F;NT3
M'3C.>?9T^;EC"]G1^+<ZE\'V[Y?@IYE9GOZ3K^I=HMM.ZDM]+3O?K=%$V,N\
M9 QE;"U[;U_>ZE[K_P#4]4WK?^; S_Y6PO)/+[>/7AC0B(HV(B("(B B(@(B
M("(B B(@*N\?V.HXAX9FM](8#(Z2*0Q5#G-BG:QX<8WENX:X#!QGGR/)6)<^
MZ5[M56Q]LBMLM;'658DA;U;AU+P2UI:YI.2_M M+.T,$[C+3:\]F;:UW2O1O
MP]5\.6FL@K(J*F%15.GBHJ%[WP4K"QC=#"X [EKG'8#+S@*U2R,BB?)*]K(V
M N<YQP !S)*J/1=:Y;/8JFDJ65D=2VI)ECG: UCM#1\46[.8<:LCF2[(!R!;
M*F"&JII:>IB9-!*PQR1R-#FO:1@@@\P1X$MR5X4X<=.EIIY*:TR.DB;43F.6
M7JR8(6QN+N1[9$S,,..9R1A6YU73LH^ZY9F14V@2&21P:T-\9)Y*OOX&L@$P
MIH'T?7F02]S.ZO6R1K&OC.!\DB-G+<8V(5F#&A@8&@- P!C;"C2"X)GBJ;--
M-3RLEA?7UCF/8X.:X=TR;@CFIY0O"  ME2 ,#OA6?>9%-*SRE>%6Z3?T,K/I
MJ;^O&K2JMTF_H96?34W]>-6E/1(Y$1?C[I5Z7>,J?I$NU-;KG-;:2W53Z>&G
MC8W!#'$:G9!U:L9WVW6J4F\ZAG)DC'&Y?L%%7NCR]U/$?!%EN]="(:JKIFR2
M, P-7A('B/,>8JPK,QKLW$[C:K4W]J%Q^IJ7^O4*TJK4W]J%Q^IJ7^O4*TI*
M5$1%&A:ETK>X*9LHA?,Y\C8FL80"7..!N3A;:BN(OS%%_G8/YPLWG59F'3%6
M+7B).^%P_8M1]O%_J3OA</V+4?;Q?ZE*HIX9^?\ '^%\RO\ LC]_\H*2IN+J
M^"<6:?3'&]A'7Q9)<6G_ !?\)6QWPN'[%J/MXO\ 4J3<^DN6GN\L--1124<3
MRPESB'OP<$CP#V%=%HJB.LHX*F'/53,;(W/B(R%RQY*Y)F*V^_\ IZ^HP9,%
M:VRXXB)XY_RT.^%P_8M1]O%_J6:VW!]7/4P34LE-- &ES7N:[(=G&"TGQ%;Z
MBJ#](;K]'!_!ZZ=XF.[S1-;UM[L1J/U^<?JE41%T<!$1 1$0%X6-+PXM:7#D
M<;A>K4FN=##5-II:RG94.Y1ND =YME8B9X9M:M?BEMHB*-"(B B(@(B("(B
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MBI8S)+(1G 'B'A)Y >$E0G2>0."ZPDX EI]S]/&G2%9J+C#@VZ6*2OA@[KC
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I8) $8.D@;C)T@KLML@?2VZEIY9.LDBB9&Y_^(@ $^M;"("(B B(@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g769642g72h13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g72h13.jpg
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\
M$0@ _P'U P$B  (1 0,1 ?_$ !P  0 " P$! 0             %!@,$!P(!
M"/_$ %@0  $$ @ # P4*" D)!0D!  $  @,$!1$&$B$3,4$'%")18146,D)2
M<72!D:$7(S0VDK&RTC-#8G)S@I.ST20U4U15HL'"TT5&5E>4)29$9&6$E:/#
MXO_$ !D! 0$! 0$!               " 0,$!?_$ #41  (! @,#"P,#!0$
M       ! @,1$B$Q!$&1$Q0R46%QH;'1X? B@<$%4O$5(S-"LM+_V@ , P$
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M";)A[+4W-*8WM#71-<XN;&0/%K2UI]H4B@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( H
M6C^=V7^BU?VIE-*%H_G=E_HM7]J9 32(O%ATC()'01B24-)8PNY0X^ WX?.@
M2OD>U'G.8EI(.4H@CH0;#/\ %:GGV>_V)6_]=_\ X7YEX?Q].7"TWRTZSI'1
M@N)C:23\^EYJVTJDKV_!]+8_TV6TR<<25NU/R9^L*UB&U"):LT<T1Z!\;@X'
MZPLJY1Y%Y\E6X2L18[%5YJS;]CE<;/9?'[N7E*Z;CI;<T!=?JLK2\V@QDO:
MCU[T/;T7:$U(\E6A*FW=K+M7E>YM(H_B*W)C^'\G<@Y>VKU99F<PV.9K"1OZ
MPJ99XDSCJV=EJF)KZ\\5:L9:^X0YYA&W.#N8G\8[IH?.K.!T-%5>%.*V9<91
M]LQUC6L-@$!/XQCA'%VC"/C.$DA;T[]M [QO5S?&0J9_$UZ_HTG\AN">!\<@
M$KS%%H. +=.#B>8?!'MV@+HBYV..;+LCE"PUS2KO$\0Y#S&M'-V5EQ.]'0(D
M:1X'7M4Z_-VW\*V\C%V?;69G18X<O0\[^S@<?6'$M?OU.]B LZ*NW+>0=G8<
M33N0P=C3%F2>>'M'3'FY=  M  T2[7RFZTHC'<8VV1&*]2$EF6=\=5PE#1+_
M )481S]/0 VWKZ6QOQZ("\HJ3)Y0*U>2&.]3D@<^<0.(D#FM(FEBD?OIMC'1
M;)Z='M[NY6O$7#D,53NF%T'G$39>S?\ "8'#>C[>J VT1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!%K3T*\\A?*QQ<>FP]P_45'T<=6?:R#7-D+63
MAK1VK^@[-AUW^LE2VT=(QBTW?3L]R918JU>.M&60@AI.^KB?UK*J(=MP1$0P
M(B( B(@"(B (B( B(@"(B (B( B(@"(B *%H_G=E_HM7]J932A:/YW9?Z+5_
M:F0$TB+XXAK2YQ  ZDGP0'U44>2;@UHTW&66-^2W(V6@?,!)H*Z>=U_]8A_3
M"YUQ)Y46TLYYMA:'NI0J/Y;]B-_7?<60^#W-[SX=.4=>[53<\K7(>T1HK$Y6
M7>7CAW X[AS&BAAZY@JA[I.4R/D)<X[)+G$D]?:I-1^+S>-RN/@O4+L$U6=H
M>QX>.H^8]0?6#U"WHY&2-W&]KQW;:=K+%8DWJ?)HHYX9(IF,DBD:6O8\;:X'
MH00>\+%YC4[)\?FL'9R/$CV]F-.<-:<1XD<K>OL'J7J]:BHTK%NRXM@@C=+(
MX#>FM!).OF"A;7%^*JP9">=UEM:CH3S"M(6 GETT$#TCZ;>@_P""&F]/A*,M
MR"RVO%'-'9-ISF, ,LG9EFW].O3E[_D-]06U+2JRML-EK0/;8 $P=&#V@ T
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MTYPP#8'B7#1\=C6T!)283%25V028RBZ%D+Z[8W0,+6QOUS, UT:=#8[CH*0
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M@Z!$1 %"T?SNR_T6K^U,II0M'\[LO]%J_M3(":1$0!$1 $1$ 1$0!$1 $1$
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M01$7I/FA$1 <P\L.0LXG*8&]5SM/&OC;*!!:R/FK9CSQ.)(Y7"0::YNCK7:
M[[U(^12/*^\\6<O9EL"VYD\$DEE\Y>TQ,YG@N +6O>'N#"/1#M+6X]S%^2Z*
MD47%.,9"7M,M'#Q7X[33K1!Y7EO<>A#3UZ^"E?)35MT>%V5+3LN:]=PAJ#*0
M10RB%K&@#E9UUO?P_2^K2Z/HG)=,N2+Q/-'7@DFG>UD4;2][W'0: -DE1;^)
ML-'3CMR9"!E>0D->\EH.ALGKX $$GN'BN=CI<ET6CD,OC\=-!%>MPP23G4;7
MNUS=0-^P;<T;/39 \5KNXCPX-H'(U]UB&RCFZ@\W)H>L\WH]-^ET[^BVPNB6
M4+1_.[+_ $6K^U,I2E:@NU8K-25DT$HYF2,.PX*+H_G=E_HM7]J98:32(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (BA<SF
M_-K H8Z'SS*O&VPM/HQCY4A^*/O*F4E%79=.G*H\,3;S.6JXFN)++G%[SRQ0
ML',^5WR6CQ*BJF)M9>Q'>XB:T,8>:#'M.V1_RG_*=]P6UAL)YM8=?R4WGF5>
M-.F(]&,?)C'Q1]Y4TH47/.6G5ZG=U(T5AI:[WZ=7?J^P(B+J>4+1QWY9E/I#
M?[J-;RT<=^693Z0W^ZC4O5'2&DN[\HWD1%1S"(B (B( B(@"(M6?'UIY#)+%
MS//>>8A8[[C5;>8\=^5Y3Z0W^ZC6\M 8>@"XBN 7'9TX]3]OL6W7@CK1\D+>
M5N]ZWM9&ZU+FXO-/YQ,B(BHYA$1 <@XZ\JEWA[B^YBH7X..*&2*NUMU\K9 7
MQ"3MW%H([,;#>4#9/B%T[ARVZ]@<?;DM5[;YH&2&>NPLCD)&^9H)) /ALJF<
M29;B#A;,9VX[%NRN(NB-]>9V3CK1U.6,-<QW:. :"X%W,W?PNO<%9^ NV]Y>
M#\[OLR-CS.+M+;).T;,[E&W!Q^%OU^/>KE:QSBWB=R6R$ LT+,!B9,)8G,,;
MWEC7[!&B0"0#ZP"J+)PIF^SF,<M1W:P6J<=>>Y+,VM#,R ;$CF%S].A<[E('
M\)H$!HWT%%*=BW%,I&2P&5R?G#8XJ\,%BJ[&2&>8]HR)LAY9F@-(+G-+CRDC
MXO7O U1PAEVV,;,'4"[$.>*H,SQYRUTS7DR'D] AK1K7/Z1)7046XF9@1%\-
M8^7&8AE>RZ-T[I9IY.S)+6NDE=(6M) ) +] Z'0=P6A@:IJ<49F-UFQ8)K5G
M<\[@YP]*;IT Z*QJ%H_G=E_HM7]J924LB:1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 18K5B&I7DGLRLBAC&W/>= !5O\ RSBG
M_2TL$?ZLML?\K#]I^M1*=LEJ=J5%S6)NT5O^:OL,MK+6LM8DH\.N:&,/+/D'
M#;(O6UGRG?<%*X;$U<37='6:YSWGFEFD/,^5WRG'Q*VJE:&I7C@JQ,BAC&FL
M8- !95D89XI:FU*R:P4U:/B^_P!-$$1%T. 1$0!:.._+,I](;_=1K+8Q]6Q(
M9)H&O>>FRL(P^/!)%6,$G9]JEWN=8N"33;S[/<WT6*M7BK1ED# QI.]#UK*J
M.;MN"(B&!$1 $1$ 1$0!$1 $1$ 1$0'%?+1PKCSE7Y:UDY_.;; (Z]K&37X(
M>S#=F,Q-)A)Z$D[WL].]=7X6O>Z?#>,O<L+18K1R@0!PCT6@CE#FM=KU; /L
M6#B3A]N=[#FRN7H=CS#_ -GVC!S[U\+7?K73U;*WL+C*V&Q-/&T&%E2I$V&)
MKG%Q#6C0V3WJF[JQ"C:39N(B*2PB(@"A:/YW9?Z+5_:F4TH6C^=V7^BU?VID
M!-(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (BPV;#*[0Z1LI!
M.OQ<3I#]C04T-2;R1F11YR]5KVL+;8<[>AYI+LZ[_BK/6NQ6)"R-E@'6_P 9
M!(P?:X *5)/>4Z<TKM,V5H9G+5<37$EISB]YY8HF#F?*[Y+1XE:F9S?FU@4,
M=#YYE7C;86GT8Q\J0_%'WE,-A/-K!OY*;SS*O&G3$>C&/DQCXH^\J7)MX8G6
M%*,5CJZ;EO?HNW@:M3$VLO89>XB:T,8>:#'@[9'ZG/\ E.^X*R(BJ,%$YU*L
MJCST6BW((B*CF$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!0M'\[LO]%J_M3*:4+1_.[+_ $6K^U,@)I$1 $1$ 1$0!$1 $1$ 4+*[
M(=J_DS&-8WF.FNJDD#U$]J%-+":E<DDUX23U)+ EWN+@TM2O8FYE+N/AL29?
M%QN>#MOFAZ=2/]*K'6Y_-X^TD9*_E&WL;RM<?6!LZ^TJ.P52N[%5R:\).CU+
M!ZRI1K0QH:T!K1T  T L4G)7957"I-(^HB+3D$1$ 1$0!%\<YK&DN(:!XDZ4
M?8SF*K;[?)4XR/!TS=_9M8Y):E1A*?15R110#N,,)LMAMNL.]4$+Y/U!?/?,
M9/R7"YB;U$U^S:?K<0HY6&YG;FM;?%KOR\RP(J_[J9Z7^ X?$8/<ZQ<8/N:"
MFN*9>]V'K ^H22N'Z@G*+<GP'-FNE)+[I^5S0R/&F!@S,<<MYP=5=+%-J"1W
M*X$ CHWKU![ED9Q#)Q&#!PJX]AOEFR$D;FMB];6M< 7/^X+C^5IWX\QDFV:]
MF68W)R7LK/ ?N1QYFC1Z'O\ 'O76_)-%)#P77;-%)$\SS'ED86G1D=HZ/5>>
MG4G4G*#5D?1VC9Z.S4858RQ-[MW7>WK]RPX;$U<37='6:YSWGFEFD/,^5WRG
M'Q*WT1>M)15D?(G.4WBD[L(B+20B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MOC^Q;U:S)-(6OIV(1K?-(6:^;HXE;**5&V\N4TU:WGZA$14<PB(@"(B (B(
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M>6J_EV'=*T=\E.4/W_5.BLD/$V+<\1SSNJ2_(M,,1'V]/O5(/E3R/AP/F/\
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9 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g769642g72u41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g72u41.jpg
M_]C_X  02D9)1@ ! 0 #Z /H  #_X4?$:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ
M-C0U,3DL(#(P,C O,#@O,C4M,3<Z-30Z,# @(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*(" @(" @(" @(" @
M>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B
M"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN
M<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.G!D
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @
M>&UL;G,Z<&1F>#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&9X+S$N,R\B"B @
M(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @
M(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B"B @(" @(" @(" @('AM;&YS
M.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R
M+S$N,"\B/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R-"TP-BTQ.%0Q
M,CHP.#HQ.2LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z
M0W)E871E1&%T93XR,#(T+3 V+3$X5#$R.C X.C$W*S U.C,P/"]X;7 Z0W)E
M871E1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R-"TP-BTQ
M.%0Q,CHP.#HQ.2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @
M/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B R-2XP("A7:6YD
M;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.E1H=6UB;F%I
M;',^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'AM<$=);6<Z=VED=&@^,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SIH96EG:'0^,3$V/"]X;7!'26UG.FAE:6=H
M=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM
M<$=);6<Z9F]R;6%T/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SII;6%G
M93XO.6HO-$%!45-K6DI29T%"06=%05-!0DE!040O-U%!<U5':'9D1SEZ84<Y
M=TE$375-04$T46ML3D$K,$%!04%!04)!05-!04%!045!)B-X03M!44))04%!
M04%104(O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"9U5&
M0F=K1T)164I#=V='0F=G3$1!;TM#=V]+)B-X03M$0D%-1$%W341!=U%$0310
M14$X3T1"351&0E%417AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%
M0D%91VA54D92;V9(>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G061!
M14%!=T52)B-X03M!04E205%-4D%F+T5!84E!04%!2$%114)!445!04%!04%!
M04%!05%&07=)1T%104A#06M+0W=%04%G241!445"05%%04%!04%!04%!)B-X
M03M!44%#07=11D)G8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-
M4D)!049)4DEX459%1T4R16EC645537!':$)X5WA1:5!")B-X03M5=$AH37A:
M:3A#4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*
M0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL
M.5=:,FAP86UT<V)7-799,U(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y
M3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V
M=F]204%)0T%1241"455%0E%914-!341B445!06A%1$)#15--545&55).:$EG
M6GAG6D5Y)B-X03MO8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW
M3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X
M03LP*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B
M,E(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L
M-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2
M040X03E5-'%X4'I$-54X>6%L<6-T>%IA)B-X03LW2G Q<39X96Y"1S R>DEK
M<4]31FM685 V<3=!1&11,U59<6XK;E<Y>F$R,6QA5#-,6%5S3G-S8S W1&57
M4TU)<&M053%9,5!81E5B)B-X03MI<G-69&ER<U9D:7)S5F1I<G-65WET27-B
M3D=O95%$-%5*-&=N=W)V5$%E5WE99UAU.'<O3DQZ6C4S,'4T,#)#>E$V5F%4
M=%=/.6A!)B-X03MU,FYU9V9G=%-P5#1E43,T,#539$9)-&UT33AK=TYO,F)C
M+U19344U151N47)U-B]J-7,W,$<K.'<S3FIA4V%V<'-D:F134DLQ,&E4)B-X
M03M#44I)5G%607 T+S52<#1N3$Q..'1N16Q'04=X,SEZ>GIZ2G)8-3=W*UE.
M4V@P<E-O,S!33U(O,&9D>')"2DMY=4573&Q'.'%616)+)B-X03LW4#-)4&IL
M:E5G3$18=CA!;DEJ;EE'-C!P3T11>&TW+T%(3G52-C5N;S9T>'5%64HV3F0Q
M2%=N*W1I<C!N>4I0-75N.'-7<W9M,D=+)B-X03M$6$=-;C%I2T0W250Q1T56
M86)C:DA3=%!W-EE&4FYM1S0Q1T138C)7>E)+>#(P<FE6<$=2,5I52D)50DAR
M5#4U2TE(5G%Y1UDU0690)B-X03LY:&5+*U5F3D=Q5&$Y;V-C3W181C504%!'
M<W1T3&944TDT6D-81$E7:T90.6IM=WI9.%EH665C,$=Q,55S.5-V:#,U:6@X
M-F5U96-,)B-X03MR>FA"-5AU6B],,7)&3G)Y3D@Y6'1Q:5)'6#%&-6IL2C9!
M0DM6,U!4,WI81W5J,#!383,O04(Y>GHK-#@W+VXS939F>C O>69B,GIY)B-X
M03M!<VMP;59M,D5G0VA*5VEO95-X-W-T2TUD=2M,2D4S9FYF.$%02G!K4TAY
M2VM%4W!(2SAO=31*:7IE:VIV1'A,<%0T>7DX=CEV07)B)B-X03LK879Z,'5Z
M=U1Y<$9P=G!P9FXQ:%!$3TI8:G-*1W-X=UIG5C4S6E%F9V%!131Q<7 U,R]/
M=%I9235027-:5G1P6E9U-&HO=31,5VY0)B-X03MB.3$X9C195E-76#AW4#A!
M;DE'.35'>3AJ<F%Z5TYX16PQ8G1.159L4FM74F=R>4919&I3<UHK1W4K-'=+
M.6,X=EAE<EAM:5=6,7)&)B-X03MK3D\Q4U=*5W9,14]*0D9*,U5/=%%C5E1$
M1EA9<3=&6%EQ-T9867$W1EA9<7!T+W942"]Q4"MT8U96359D:7)S5F1I<G-6
M9&ER<U9D)B-X03MI<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E4R+S-P:B\Q2"]7=4MQ;4MU)B-X
M03MX5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A69TAN:GHQ-6<P6'I#=6TV8W1P-D@Q4TLT)B-X03M:<FE+4U)Y
M.'-S>45!<$Q%04%):#)Z2S K;D=113(V:G1,=$TV66=#4$9B2E!*;70S970K
M6$QB57)X63!U6EAN4U%1:&Q3<TTW>$%Q)B-X03M'6GE+:$LY5&Q'4TA$26@R
M1VUY*TIJ:E!L>$,P-WE$93=&6%EQ-T9867$W1E=*95ET63@K5RMP>G=A2G!5
M5C-A26M,4E1Y04-R34@Y)B-X03M682MT2%AI1E9G840K6'9Y0E90.5!L=C59
M3$=3*VE70SAE,D1855-M;U-9:$,V1')S<E9&831&4C)+=7A6,DMU>%8R2V](
M6$Y9=$Y&)B-X03LP:3<Q5S=$=&)78V)3>7)%=DYY1C=!9GA*04A5:T-P>%1%
M5V%9>"M8+W=#66MN;6$V=3=#.7-V<60O8G(Y66I%5$=71G)D,C1R5U-I)B-X
M03LX6D90=VM%1&PY<&8R9W172$U-9W-/6').1E!4>4%L5S1T;757=4=W1#@P
M4$\K<#9065)1-D<V>'9*255V=%=#<DUL:T)X-$MW26%-)B-X03M34VLX5CE4
M669-<FQ'5$Y14$0V:4A/,&UJ-#5$:E!"13E4,3DS-BM8,TIN-4TQ,WI6-6@X
M=3)U<%A.=D)P<E1+84]Y4U-E=6\R13AC)B-X03M:84UX<$HY<%%X3S-I2T5Z
M4$=E5D0W5V]X>%)*0G5F=3)(-F8P2C4K:DQX>"LY,4\T3F5Q>')$1W8P56I,
M+SA!1%E01%!74BMX2&I2)B-X03M(2T5F=% V82MX<V%,8F9T>EA4;G@K=%1R
M*T-/;W@X260U*UI8.'I,=6HO<%DO<656*U@O041P<D=O968O=T)&4U=L,SE3
M;6ME,V93)B-X03LO<DYY3'%Y14\U=5IN371#1%5C=U1X;WDX0W@O=DLT:35M
M3E-O9&)0-C-.>3%(1$A)2E%-:6581$@Y5#%4.4,R9BLO3'(O<$QU=CA!)B-X
M03MQ<&QV:$1Z*UHO5S10-6U89$@O4W@O53@O=T1/;FXX*U9F34UD;EI7:S V
M5VE,4'%"=3=I-"]E=WE!:6QQ2DI05$I'+WAS0W9)8V5T)B-X03M3=%5P4FA)
M1#%B*UIC>D1G;FYX>6QC0G<K55%F=3(O065L,G1W='AB43-#;SAA>DES9VIL
M57AY2T=&84]J8G%W<G5$,'I*9%EQ67$W)B-X03M&6%EQ-T9867$P-W!':E!)
M=U)&0DQ->&]!0C%*2GA!45-!3$Q&=%0X<39,-6PQ3DY2=7)*:6E2<D0Y86%A
M-6AA5TY'6FQ6231P27=&)B-X03LU4TUE8F)N=W!1-61'6F=+0C-C2V5+3V-G
M;4E-4C%)*S<Y9C)D52\P<E-R1%-B0TMW<TEV4G1)95)J:DQ--4)D:3=%<S5:
M:E9M2C-/)B-X03M616MM>35K24-);V)!279!>61I<G-69&ER<U9E2B]K<G K
M=GAE979-;'IQ*VE8*VUQ.55S6G T<FA%9$))96)45%-Y<VLX:B]!06M&)B-X
M03ME9$XV1E)S8G-H1D)Q:&1M,W1M571Q;3,K.4UF*V\O-C%X5E5X5C)+=7A6
M,DMU>%9X04E)27%$<U%E;$U64VY4.4DX=6573$<T3FIB)B-X03M2,D9Q-VU7
M64E#874R=T$V;G=614A46E9(8DEY26E,3%I%5'E3035L8W1V9F%J.&0T5W1,
M22]9<S!B:DLT+S1U9%1T+W%+9FU4,'EV)B-X03MH32ME=S=V,2]Q8FI/1U!A
M4'%L,SE09U P;C1$<7 V-W%0;&Y19$5:=%<Y1S(P<&E,9C!$15I&8WEB0TY)
M158R:THS4$963S%4,$)Y)B-X03MW05)(8T=N,35*9%I34'A+6E=6-V%8,7!$
M95=C>7HR<S9I4T=A33%6;%!19S5*<E9S5F1I<6ML;F%*9%,S85%2<F142W%4
M6$-Q;VMD)B-X03M9-CA&6G=+:TQY3DLY2S1Q<31Q9W(W4F1*=C=M>G5R,C!I
M=4QJ5#5$3EI3>4M'84IY2V-L2BM14'I!4%5#:6M%;S-&1'-69&ER<U9D)B-X
M03MI<E1-<4M88VA6559::G-!0C%*3TM#86904&UJ>D1E>C-E<U8Q93A345A.
M,C%P8D<W;FIO1FUC,B]'1&UO2'=H4V\T-71-8TE#1SEC)B-X03M64$LV;E!Q
M2F%I:'AE1GA$<'17,VLK:#@Q8C%B<U9D:7)S5F1I<G-69&ER>4@X<')X8C,X
M>B]0.3-(<6,Q,T1*4$5Q,F,P5C!J44=.)B-X03MP1DM.-GE):4933U!&4V%J
M=WDR9C!H<6@Y4F5V6E4R<6)F-S!X+S9J+W)81E941EA9<3=&6%EQ-T9816A1
M4U111&-K.4%-5E-84W)I)B-X03LQ,7EB.4MP2VLY;F)Y4$A9>&]W9%$V16\X
M<C!**T]U=T(S564U3U5X2$=E23AU;C8S3'E(=VAW1#9J.5(O=T(W*W9V4'54
M<DQN165F)B-X03MF;3<U2C$W>D1B861F-D4V4'%/;$=93%I3.%%S>5A(05!2
M,DLX5U@P>%1C5D9D.')Y-'A/4$-82S!E<4]$2GAH4"]Y+SAR5"M74$Q&)B-X
M03MV<&QZ8VDV=D]C:SDS36]O;G%Z35A92G-0:%=T06%#=E=G-D-C66=#9S U
M8VAN27E037-I=W1B<U9D:7)S5F1I<G-69&ER<U9D:7)S)B-X03M64RLY2#%U
M-U-W+S-1;T4Q-31&86M2>"\W3F=39EE5-S5:2%E7-"M4,7DT3VY-+V](>"]2
M-7!H;&)K3WA6,DMU>%8R2W5X5C)+=7A6)B-X03LT-2M51W!'*R].2#AW2E=S
M:%I-,'-".4=33C!U1D)A5"LY0EIK570Y<6DY9757>DAP1%9!*V]V4V9-+VUZ
M5'9,;'9"4&925%-2,T1T)B-X03M'<&A#2&E64796=6)*44AJ>'(T:U8X8W%B
M56)P*V]186A$6EAS05E1,V1S3&E)3TM(:$M%6F5854$P4%-U2V\S1EA9<3=&
M6%EQ.&8X)B-X03LQ2'IO;C5Q,F-&=G%33&0S3D1O:V9Q0DQA3S!P5UI*-V9L
M>61M.4YU6%5Y54A!<G<O9#!Y-"M-55)W.5A0=RM"-$5U24AX3#)0-"]()B-X
M03LV3V<K84Q/-#%Y,7503#%P9%!:3F-1<V)U.6I&5VE29U)'9T96,VM98C!)
M4$5(8T5G-%IN:5!#4&DQ65)W4CA1+W=#8C<K<"M(,VQJ)B-X03LO=T-6+VM8
M5W9,:VPU8V%J2VM!;4%G:C V,F)N07=I3D)C35-&*TEG55%!06A0=&(P0T1"
M:4U!451E-UIR.5A(3DE'35)':%@T.3-2)B-X03MN*UA/0S=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1E9S:VE24G1*27=73D%79&HP04%Q4V-1145G0WEH
M3DMJ:SE"<FU:4W,Y,C-R)B-X03M/<#9Q0T%%42]W0W%G05!V6$IZ3SED>E1G
M0G)I4$]7+S9H.$%J8V<S=7A6,DMU>%8R2W5X5C)+=7A6-#DK4S!(<2MD=D]M
M<7IA:'!U)B-X03MO,W0U3D@Y66LP<UA(0TUR2DM!<VAM=#1K-45$.6E1,4%Q
M469T1S-*>416:C5L-BLX8V(P-7%'<'5+9T=L45(S.6E2;%1A<TE!=4EW)B-X
M03M.9T5F.6$T<7$T<3=&6%EQ-T98;"]M,SAS>DXU;V)75G9N3FYF>7!,3F$X
M;2MU1S9J-&E+3S)L+UI2=4%026US44)+-U4T62MA031H)B-X03M097@P-S-:
M8515>CA/5TMH=VYC;751-B]S*W@V3'!L:S%R069665-857I'5S9L1W=A4G9$
M+TI504MV<TUT>'=O8C@S1'I:94TW8E)')B-X03MW.3,T-6]V2G1,<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&EQ6%A49EAR;U=-6G)"15$Y-G<V1VTV
M=R].=&DS*U1T*S%L9S)&)B-X03LO2G@U;FIL=VIK4'$O5BMV>3DV6357-41S
M5F1I<G-69&ER<U9D:7)S5F1I<GAF.$%*0S!M<W906&Y,5#=L3$]#-'-74T52
M5V-C2$IK)B-X03MA-&YL16LX,%%J9#50,VY(-&\Q,G T6F1K-4)Q>#AY.6]Y
M;'15,B\S<&HO,4@O5W5+<6U+=7A6,DMO92LQ0S)S;W<P>$ID>GAH:%%C)B-X
M03MP2D<O;%)2=50K<G9T:TIZ165B6FEX4VUD=C)$,V]E>7,W:5,T*W8S-$%U
M849B94)4>5="1#%&96AD=C)M*V=B9%EW:5-E2UA0-VUZ)B-X03M*:T%(0D0V
M97 W>BMR=4AX5$1,6$AD:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9E
M869N0G Y,60S=6E'4%0W:2MH:FIV4%5&)B-X03MV8E,S4V]Z3F(X3U%I4U1I
M4T$Q2RLK6F5K;$5%.%1P*S))6G!1:C181F0Y17HO2T]Y=7)444PV3V4P;7-K
M82MD-$E:-%I,8SA$0D-#)B-X03M6:FM60T%81&1U=&-H<5-$4&)K-4A:8TUK
M8T%'4RM,9FXW,F-::G5W9&ER<U9D:7)S5F1I<G-69&ER<U915FYO;6I75C5D
M6#%N65<Q)B-X03MT93-X1%AT,41#:V-S>D-T1$LV9TTU1F8R:FAS;W!&5'IW
M=U%V4%!)<U5-4VPU2EA)5E964E5S>DA905E%<6%3>%-Y47EX3W-K56M4)B-X
M03M.2$EP1$MY<U5)24DR24EX5EAX5F).25DT;6-),&A516E.2V-M.6AY24@S
M;D%4451%5V$U24%Y835C-U)X4C)%6B]B;$EM;7 O<4EF)B-X03M40CDK8F9,
M2S=M9C90,G525TM036U:.'1H.'IV.6=6<E143&$R:V%A<E185&EJ,U5P-5-%
M9&%6,D-R+VMQ05!B2E)X9V(Y5T=43DM1)B-X03MR;$AU2$PX95HS4F5485A9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9)B-X03MQ;U@Y:F)8.6Y.6C-+;&]*,4M32T-63D0T
M155)3TMO94A3-T\S:G,W2T%01F)7<TAO=TEK:VDP4TU)<6EO644P03<T<7)F
M;RM$*V5B)B-X03LO:V9.+W=!,31Q.'DO3GI6+TTR:EAU;7!P<VPS86%D4%%2
M6%9U.'-Z>EAX63A,5FM,3E%&44-Q,"M-,4925&5R2UHW8T%V9'ID1D1")B-X
M03M,:3A5:V)B9FHX92]V1S)0-6UA175N,E5U<G<S;'9Q8G$P9#5B43-$3DA(
M2VE)-VYK,#1(1V@R-C S52]&,75P=VDY04=N,C5&43AX)B-X03M"+S1V;2\U
M<G=+,&)+,$1H1$I+2%E&;%@V>$Y5:&%!:T1N,C5$1E<O,&9"+U!.+WE0;2\U
M<GA6,S909R]N;2\U2'IF.#$T<3<Y2'=F)B-X03MZ>F8X:C5V*V$X5EDS<&9M
M;GDU<4XO1&%W3F1R4&-Z5%=Y3$IC34%'=#1X3%AI2FEA3VIB549D<4Y1:6U&
M5U-F;RM$*V5B+VMF3B]Z)B-X03M89U8S-E!G+VYM+S5(>F8X,31Q-SE(=V9Z
M>F8X:C5V*V$X5F0K:C10-35V*U(X,R]!1%AI<G8P9D(O4$XO=T%J-78X06UV
M1E5"<&,K)B-X03MM6#EX<4U-1#-(<39F8R]6<FQ7=4I$4GA%:V=+.%I'*T5Q
M-#8P3F$W67%J+T%.2'=F>GIF.&HU=BMA.%9D*VHT4#4U=BM2.#,O3F5+)B-X
M03MU+U(X2#@X,R])*V(O;79&6&9O*T0K96(O:V9.+W=!,31Q<W5,5S)H9VMM
M6G!Y<U-S-4%U2E)52TLY5VM69G9/2W!*-5(Q+U%V33%N)B-X03M*8S9A8G=2
M259*33@P9THY4W)#;D=6+T%I:"]545-Q;C,V4&<O;FTO-4AZ9C@Q-'$W.4AW
M9GIZ9CAJ-78K83A69"MJ-% U-78K4C@S)B-X03LO3F5+=2]2.$@X.#,O22MB
M+VUV1E5Q.'EA<&\O;#=4,78W.#-2=#)K15@W=6%1<T-W2D=Z4TQ8-TY+0W Y
M<U91+VQB6'1%.'=,8TI:)B-X03M#.5$R66I%;G)Z=6$X*U%&1U-A44AE3G$W
M*S1Q<$)*5E!F,&9"+U!.+W=!:C5V.$%M=D%R5&%B8G-P6&Y/2VEL4F-403<K
M0C4T<6ES)B-X03M69&EQ;3,K.4UF.$%Q4#A!<EA&5E1&6&YN-6\K44Y9.'@S
M3FYF86)*2&-346]B6G10=3-+,C9#5G9I=45O1RM+:'!)2U9+1#1A155A)B-X
M03MR3FE-=T%$5S=M-DQ6>'=K:WA%<D9B+VHU<W<P6%)266%,6C9D951N57!B
M94E2>3-D=W%L-5='-TUW,S9N>$I0:5-D>F$T4E101EAL)B-X03ME<F519D]T
M>BM9-F%V1F1K465Q2G)F5V<V:')A,U4W,EEG<E9Q9VQA531.6&LS>&1A94-8
M2&0K;G5C-D]O>$1!64=(<G8V=G@Y>C%4)B-X03M,;D)D:7)S5E=E:$)Z5B]4
M6&UH2E)Q0V],9F%O9F5U*TMR.%9D:7)S5F1I<G-65W!&1VA9;V=5=654:T%#
M<#A4:7$W1EA9<3=&6%EQ)B-X03LT9TU#0TMG-T5(<%1&5G-C5553.%DP5D8X
M1D%!,D9/,W--5EA9<3=&6%EQ-T96<GAX>6-E84(K2D1,>4%.1TA1:79C67$U
M230P1D55)B-X03M+3G1L04A1041P-T1&5C)+=7A6,DMU>%948B]E;5 X03%(
M+U=U2W%M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+)B-X
M03MU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5DE03E9T
M-7=M5T0O1'0S1&)&5TIN17%Q4W=+3TMC;5-51#1I<$9&)B-X03LV:F5Q,7A6
M3DY/:'8Q=$Q--FA):VPW2&)Q;#(P66]R5$96.5)L-F9#5U4P,GA61C1Q-T98
M67$W1EA9<3=&6%EQ-T9867$W1E5Q.# K)B-X03M:9$TX<S9$9#8U<5IC5TYM
M14UX:D%:=FID67A116HY<'@S=V=785%4471)<F8X-"]Y>6UL:&A(;4,Q:G5*
M,E)%:&M9<3-/4FEG53%&)B-X03M0=$-H3F%$>'!K=D108VIJ2&5L96MF.$%/
M45 U6#9J3&-23G%:<T1B<GER96]99S1(<49V5&]7-6-216$O341R=&A/2U1%
M6EEP>%IF)B-X03MM,RM7.3=F4C)&<G(Y=$QE5%1X,FM504Q";6UM2E=.1G%O
M<GE)<#1F9FME07-U360V5&8Y1$$O;'-80W@S8SAP4$E*-F-,3GE91V-+)B-X
M03MO.350<7 T95!*9D4P;#124C1G6C%$<D]N>5=K1GI*371S<S9">$AC1EDU
M1E!2:V174'=S<F9#=S=(8DE5>EDS-6TO3G9Y4C5A,4<Y)B-X03LP-U8W,'<S
M9&IB3&1Y4D)#4S9V5VMC9CAZ,$%*2&=2=FMH06QI6F=C,&IT+RMC:69Y,VYB
M:VMT,G1O<W9O>5@W,C57,E$X-#!*85%M)B-X03ML0C9Y:S S<'941#1262M,
M1FPO;%1Z=C5D.#%,95!O='=B:4]Y:U-/4U%Q5E9H2D=*16M3=E9'0F]$-&<U
M1U533V)-4T)4-TEP9&ER)B-X03MS5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-64R]8+T%.0B]O<5@Y3RMH*VI/
M569R9E=U)B-X03M0<&-V5E@P=5A,8BLX-# Y.$EV;V=S16XO=T-H9E P<&(K
M="MG4#!J>50V=E@P3V9,,3(T53DO5W)8.&1S;C8R0C1B-DQD52\V1C<U)B-X
M03M7+S92+U%04#9S9G$S4#!A+U9Q4R]:<"MZ+V5F-3!X2$=P-&5T2V-(+U%U
M9C%Y2#9V*V=0<FXQ:4@P4%0Y2#%06' K-7!49B]!1F4R)B-X03M(,7(V4$I7
M2"]1=F9R>54O=R\V=C%D=E5P.5AR-DAO2GDV9CA5.&9E;&%D.$AQ6# K5'HV
M."\V1F,Y1TAN.5HK<3AR>C9V-F8Q+VAY)B-X03LY52MR=W!V,"MZ5&)J+VQ:
M6C8R0C1%*V(O;U=V.4MA8CEF.$%Q+W(O04M,6#9V.$%8+U8Y3#!052]W0C-E
M<#A(,6ET83AV:7 W57E0)B-X03MR6DAG=F1M3&8X<54O=T%*6%9F,$XO:&(V
M,G8Q<BLU*W%F6%!34VQA9D0V=G X4&9)97$O3FPV8395;5AK4#A!=T0O=50O
M=V@V4' K)B-X03MP8B]7+U%R=W Y5FHK<BMN6"]D6&\X95!(-&$X=3EC17(V
M<&I84FQE4EI/>%8R2W5X5C)+=7A6,DMU>%8R2W5X5B\O6CPO>&UP1TEM9SII
M;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @(" @
M/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HS.60Q,3%E82UF.#(X+6,U-#DM
M.&-F,2UE.3$U9C<X8F5B8C(\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @
M(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,SED,3$Q96$M9C@R."UC-30Y
M+3AC9C$M93DQ-68W.&)E8F(R/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @
M(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-#0R.#DQ.&0M,38W
M,2TT960P+3DQ-C@M,#$S8S1A-V(V.#DR/"]X;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT
M/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV
M961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HT,&)F-&%C8BTS,F0V+31B-#@M
M8C5D92TW,3 W-F8X.#DV.30\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @
M(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-#!B9C1A8V(M,S)D-BTT
M8C0X+6(U9&4M-S$P-S9F.#@Y-CDT/"]S=%)E9CID;V-U;65N=$E$/@H@(" @
M(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-#0R.#DQ
M.&0M,38W,2TT960P+3DQ-C@M,#$S8S1A-V(V.#DR/"]S=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S
M<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X
M;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F%F86$W-3-D+3-C,#<M
M.#@T9"UA93!C+3DU,F1B,S4W8V9C,#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-"TP-BTQ.%0Q,3HT.#HQ
M-"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@,C@N,B H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C,Y9#$Q,65A+68X,C@M8S4T.2TX8V8Q
M+64Y,35F-SAB96)B,CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R-"TP-BTQ.%0Q,CHP.#HQ.2LP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@26QL=7-T<F%T;W(@,C4N," H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES
M=&]R>3X*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R
M:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @
M(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<]
M(G@M9&5F875L="(^9'-P,# X83PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SID97-C
M<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE($YA;64Z(" @(" @
M(" @(" @(" @9'-P,# X82YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @
M("!$96QT828C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,3@M2G5N+3(P
M,C0@,3$Z-#DZ,3<F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,3@M2G5N
M+3(P,C0@,#(Z,3DZ,3<F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N
M-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,C@N,BXP)B-X03M'<F%P
M:&EC('1Y<&4Z(" @(" @(" @($QI;F4@0VAA<G0F(WA!.R8C>$$[XH"B(#<@
M8FQA8VL@<G5L97,@8VAA;F=E9"!T;R!O=F5R<')I;G0N)B-X03LF(WA!.^*
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M%B-"4I&A,S1#56)C<I*4T>$D)5:"A++!1'65M,+3\/_$ !H! 0 # 0$!
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M:JC;(SL)J@$..8F%XY R XGZB2.[ N07FYC>UK6B)VTAV<\CKQP@EHB("(B
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M^Q<622TU"[LP1UPYY;N^MN0KJSW*&[4#*NGCJ8F.)!94P/AD:0<$%K@".?\
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MO/:&=?>E*1$5&@H[OI%GV3OQ:I"CN^D6?9._%J"0B(@(B("(B B(@(B("(B
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M$!$1 1$0$1$!$1 1$0$1$!$1 1%X5U5'14<U3.<1Q-+C[?8/:D1OHB9BL;E
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M&48<T/J)'MR/[+@?O77(M<O$6RQJ7)P?HW%P=IMCF>OF(B+!Z B(@(B("(B
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MF!;M:6M+L$9SG#3W8]JL%5SV6*:MHJE]35E])(^6,=ID9=NSGCD8<0!W!6B
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MFKJRECFD<7.DCCJ)&,))Y/HM S[%$UTM%XF=0ZI$156$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g769642g76l04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g76l04.jpg
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M $T# 2(  A$! Q$!_\0 '    @,! 0$!              8%!P@"! ,!_\0
M1A   0(% 00$!@\&!P       0(#  0%!A$'$B%!41,7,=(45%:5HM$(%2(C
M-U5A<72!E*&QM,$E-E-VD9(T<G.SPN'P_\0 & $  P$!
M 0(#  3_Q  ?$0 " @(" P$              0(1$B$Q40-!82+_V@ , P$
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MPV\1L[1:5LDX&=QBJ*Y2)ZAU28IU5EURTXPK96VO\1S![01VQ8'L;_A5I_\
MHO\ ^V8OS6JQJ9=-L3<],#H*E3V%O,S*$Y40D%10KFDX^H[QQ!1RQE111<XV
M98H-\W+0) 25&K$S*2@45]&WC&3VG>(D>M2]O*.=]'U0E012D2R?8Z]:E[>4
6<[Z/J@ZU+V\HYWT?5"5! Q0<GV?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g769642g77q77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g77q77.jpg
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M 2(  A$! Q$!_\0 '  !  (# 0$!              0% P8' 0((_\0 41
M 0,# 0,"#@\&!00" P   0 " P0%$1(&(3$3% <B,C,T-D%157%T@93B%187
M-6%E<G65L;.TP=+3(U.1D[+")$)2<^$E8H+1H:*2\/'_Q  : 0$  P$! 0
M             @,$ 04&_\0 ,A$!  (! @,%!@<!  ,       $" P01!3$R
M$C,T47$305*1L<$4%2%A@='PH193X?_:  P# 0 "$0,1 #\ _5*$X&3P1?,F
M3&[2UKG8.&N. ?@*"(R[6Y\,,K+A2.BFDY*-XF:0]_\ I:<[S\ 6>*KIIB!#
M40R$N+!I>#EPXCQCNA:)-LI>*J"=]3';65E;#4P53F3O+6&40@21_LQO8V$
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M@<X.;++GE'9S_FSO'#X%<H"(B B(@(B("(B B(@(B("PUE73T4!GK*B&GA!
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M1$!$1 1$0$1$!$0G R@(M<9M=1O=;FBGJ6R5TT\+&2&.,M=%+R;\ZGC_ #<
M,N([BD63:6BO-0Z&C9.7LSKU!O2# ()P3C.K ''+7 @:3@/-L_>5GEM']YB5
MC/6\E*YFC..[E5FVLC&VB)KGM#G5M'I!.\_XF+@L]=V5)YOJ4;3M'Z+,58M.
MTHL]';9JJ2J=01BID=&Z25IPY_)O#V@D;R X X_Y6-UKLCHPPV:C+1)RH')C
M<[!;GAQP2/%N6=%7VY7^RKY/NE904E5)4TUO@BJ),ZY&- <<G)WX[IWGOG>K
M*FJN7D+=&G SQ54I=KZ^[Y/XKM;3,HWQUBLS"S1$5K,(B("(B B(@(B("(B
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MXVR.S;JAD,[HZJUME;4!L;69A>7=.0=Q:!D'N=U;MT,Z3F>P]K@_Q6 Q[O\
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M 1$0$1$!$1 1$0$1$')=HZ/9>\[>7J':JYSVV6W\WFI@^[R4P>#'OE8W4&@
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M_%.<3?O'?Q6WMP\;V,^:+LK#*VXWB>2EJZ..61K8X9G%P(:7?M,Y/3.SOQW
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MVZ?G-!33ZFNY2-KR6\#D=Q!(1$0$1$!% NEXH;6Z)M=.8S("6X8YV&@@.<[
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M7FC?IE:HB*]B$6I7ZTUM7M/#4PTID8.:&&JUM'-N3F>^8;SJ&N,M;TH.>!P
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K1!K>Q++W'%<F[0<LYW.W&FDF,>I\1 (Z5CG!H&\<=^,X&<+9$1 1$0?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g769642g81q05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g81q05.jpg
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M8FQA8VL@<G5L97,@8VAA;F=E9"!T;R!O=F5R<')I;G0N)B-X03LF(WA!.^*
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MLK/3-#9"5G6!L=$C,U)3E*'#)&*"\!=#<I*BH[3!16-DA*3"TN'_Q  9 0$
M P$!                 0(#! 7_Q  L$0 " @$$  0%!0$!         0(1
M Q(A,4$R46%Q!!,BH;&!D<'1X?!2_]H # ,!  (1 Q$ /P#^J:4I0"E*4 I2
ME *4I0%%;\5Z;<01SV\>J2PR*'1TTRY*LI&00>SY@BO?E)9>]]6^JKG\.OG
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MJ NZ4I0"E*4!2\<?F7Q!^S[C[MJNJI>-OS,U_P#9]Q]VU72^U% *4I0"E*4
MI2E *4I0"E*4 JACXCT*V[2&&YC0+*^\1Q,1OWG?T&,[MV?7FKZJ3@WW"'RF
MY^_DH!Y5:/[\/T+_ ,J>56C^_#]"_P#*KNE 4GE5H_OP_0O_ "IY5:/[\/T+
M_P JNZ4!B^%-?-IITL?$6M17UV9W9)(K9T C)\U<;1SQ5SY5:/[\/T+_ ,JN
MZ4!2>56C^_#]"_\ *GE5H_OP_0O_ "J[I0%)Y5:/[\/T+_RIY5:/[\/T+_RJ
M[I0$+3-4LM425K"=9A$VQ\ @J< X(//H14VJ71O=_B'XZ'[E:NJ 4I2@%*4H
M"EX-]PE'HN+@?-/)5U5+P=[BL/1>78^:YDJZH!2E* 4I2@.=S(8K>60&,%$+
M R-M7D.\\\#UU0Z7K]U<7]G#>6*VT%U&3#-N9A(X,AV@;1C*('\[!PV.HK03
M11S1/%,BR1.I5T<9# \B".\5&MM-L;619+6RMH752BM'$JD+G. 0.F>>* ^2
M:G;1:G#I\AE6YF4M'F%]C8!) ?&W. 3C.?54RJ36_=[AWY1+]P]7=20A7R1%
MD1D<95A@CTBOM*@DYVT$=M;Q00*$BB4(BCN4# %=*4H!2E* 4I2@%*4H!2E*
M 52<)_DNH?M"Z^]:KNJ3A/\ )=0_:%U]ZU 7=*4H!2E* J.,1GA'7!Z;&<?^
M6U6D!S#&?2H-5W%0W<+ZP/39S#_P-4ZQ.;*W/IC4_P"5 =J4I0"E*4 H2 "3
MT%*4!BK'CD7UT4MK6%HEN4B9NWR=CO"JM@#VW]."5/3&.IY:F^U.VL9[:&Z,
MJM<.(XV$+LFXD !G *KDD ;B,]U=7LK629)I+:%ID;>KM&"RM@#(/<< #/J%
M5?%OY#9?M"T^_2I1#X+NE*5!(KE:6T-I#V5L@2/<S[1Z68L3^\DFNM* 4I2@
M%*4H!2E* 4I2@%*4H"ET;W?XA^.A^Y6KJJ71O=_B'XZ'[E:NJ 4I2@%*4H"E
MX/\ <B8>B_O1_P#E2U=52\'^Y-Q^T+[_ -5+5U0"E*4 I2E *4I0%)K?N]P[
M\HE^X>KNJ36_=[AWY1+]P]7=2R%V*4I4$BE*4 I2E *4I0"E*4 I2E *A:3!
M;6\=PMG,)5>>25_.#;79BQ'+IS-3'4.C*20&&.76J'A7AJ/A\W1CN7G,Y'ME
MV[0,X^$\^M62C3;>YE.613BHQN+NW?'D7]*4JIJ*4I0%=Q(-W#NJ#TVLH_\
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MPZ@>DC'2JOBW\ALOVA:??I5-#PA<B_\ &9+BWP]RL[H%+=F%>!@%)]/88Y]
MPZ[>=GQE SQZ9,+B9%CU"V!B7;LDS,GMLC/+NP14KDB7!H:4I4$BE*4 I2E
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M3'("<*1C/M<GESQWUIY&7F;>10Z,C9 88.TD']Q',5766AV%GXGV$<NVT39
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MU%4A2E*J9'Y5Q)<ZC%X3;,W\[M9H]J(TMIKM(X%>=U1I!&0C-(?-PP9?-&<
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M18W 92ZXR#6=TJZ]D-3NM'N])B2PML]GE#A<' SGESZ\O\ZU2*J(JHH55&
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M"1)7B$C(D;XR2%S(GG'EA@:\V'@_T:R:)T-U))&T3!Y)<D]FT+(#RZ#Q>(?
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MT^&0#'-P6)PKKS)YGE(X_P"(US/"FA[6 TRW&YB^5!!4E@Q*D>UY@'EBKNE
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M&1CG^B .[) ^6/&NB7US;PVMQ,_;LL:R>+R!%D92RQLQ7"N0/:G!Z>D9T9.
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L2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g769642g94f07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g94f07.jpg
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MDK+_V@ , P$  A$#$0 _ .J0
M
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M98Z:S7"MM]#-%(]\E+(Z)9)$5$T5<W)=29:L^4M2N].%+WW*[SHD%*_19O\
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M(U8F^XN$ &;4
M
M
M
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M5Q,+Z.I-\Q;K#U@ R;@
M
M
M                                                         %9_
M2.M,EUW);OO#5?+2+'5HB<S'>,ON:KE]Q9ACJ(8JFGE@J&-DAE:K'L<F:.:J
M9*B^XFLXG*MHWHF'#FX%B*##6Z?:ZFMD;%25&E22R.7)&H],FJJ\B:6CGZCN
M=->PXSW6-Q2]X7N-15V&DGN5B>Y7QNA:KY($_NO:FO5_>35SY$?L6ZUCK#M&
MV@H[Y.V"%-!L51$R56(G(BO:JHB<V9TWIQ/Q5ER:>I.CFMH=D;HF)Z;".#[E
M=ZN1K711*D#57)9)5148U/:O[,UY#AC -EEQ)C6S6J-JO6JJF-?ER,SS>[W-
M15]QLZVOQMNFW.)L[KE>ZAJY,9''^3CSY<FHC&>M=1TMN"[D:X'B?=KXL<M^
MJ&:",8NDVF8NUJ+RN7E7W)RJL1C2K/=,YU[1B.4-S](QJKN.8@T4V)#_ )S"
M@OHH2LCW4G->Y&NDH)F,1?TES8N2>Y%7W'5>-["S$^$KM99'I&E; Z-KU3-&
M.VM=[G(BG"5QMV(< 8G:E1'4VRZT<FE%*W-,\M6DQVQS5_!44C2_%6:IU\UO
M%W<FZ75T]%N?8CFJYHX8OJ^=FD]<DTG,5K4]JJJ(B<ZG&^X+^=W#7ZP[_+<;
MBVMW1-VFNIJ.LK*BIM\+D5\[XVQ4T/.Y48B(YVW)-:^X\6X?;JNGW9;%$^FG
M18*EZ/SC5-')CD55YBU:[E9C*E[[]ZS$<G0'TK/S5N_7H?\ S%:_0[_M5?\
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M[B:W23/3?DJZ.6U%=D==&&IO?ZI=6CN3F:0  R;
M
M
M
M                     8)Z*EJ':5130RNYWQHY?VF< ?,;&1L1D;6L:FQ&
MIDB'T  ,<\$-0S0J(HY6?W7M1R?M,@ _(V-C8C(VM:Q-2(U,D0_0       ?
MCFHYJM<B*U=2HO*?H PT]+3TVEP>"*+2VZ#$;G^!F               ,#J.
MF=.DSJ>%9DV/5B:7XF<  J9IDNM##!24].YSH((HG.^\K&(U5]N1F
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MB>@ ?C6HUJ(U$1$U(B'Z
M
M
M
M
M
M
M
M
M
M
M
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M3:R7J']P H$ %D
M
M
M
M
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M&N!^Y*CM%=2YY:^0E=VPW;Z'"SZ^GN25M9%4M@EWG^A;FU5R1<O&Y->P")@
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M6:3WKR-3D3/G74!X02:^6>V)A^"\V26KX.ZH6EDBJT;IH[1TLT5NI4R(R
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MH<JJZ-,VKJ7U<AM5@IXK!BR*'ZYF6.+1EFKU30>]'[6IEGGR[=A6J5U4E/#
ME1*D4+UDC:CLD8Y=JIS+J0]U9B2\UD+H:JYU4L3F:#F.D545/6GN F#F2W^W
MOBF;<[5=*&WZ+D7-*>:)C=BIJT<T]Q[[I54='#AR6.GO4D;*.)U.M#*C8E=^
MDBIDOC9[2OIL0W>>@X%-<JI]+EH[VZ1514YEYT]0MV(+M;:=:>@N-3!"NO08
M]41/9S>X8#%-2E9B*X5#:5])ODJN6&1,G,7ES]>>9O*:DJ.+:L9O$NFMR8J-
MT%SRWM=9$I99)I7RRO<^5ZZ3GN7-57G53<_:[$&67UQ6]:H&C 555555S50
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M8XI4<FO)B\J<_M(">ZZ7>X75[77*LGJ59]U)'9HWV)L0\(
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MY^W]Y$#/6UE37SK/6U$M1,NI7RO5RY>U3 !EIOOK[ *;[Z^P 8@
M
M
M
M
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MJ%[RTP,BK.*N;TK'U"]XXJYO2L?4+WEI@9%6<5<WI6/J%[QQ5S>E8^H7O+3
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M 9  $
M
M
M
M
M    " (
M
M
M
M                                                 !%MU*JGHMSO
M$531SR05$5'(Z.6)RM<Q43:BIK128C,X1,XC*4@X*^W>+>D][[=+\0^W>+>D
M][[=+\1OP)[N;TJ.SO4'!7V[Q;TGO?;I?B-[@O=9Q1AZ^15E5=*VZ4OW9J6K
MJ'2->WERTE71=S*G[4U$3H3W3&U5[.V 5MBO&5)?]QR]7W#%=)&YM,JH^-ZL
ME@?FF;5R7-KD_P#YJ.4_MWBWI/>^W2_$5II39:^O%'>H."OMWBWI/>^W2_$/
MMWBWI/>^W2_$7X$]U/2H[.]0<58'W6\38<OD=76W*MNM$[Q9Z6KJ'2(YO.U7
M*NB[UI[SKW">([9BJRP72S5"34TB:TV.C=RM<G(J?[U&=].:-=/5C4Z-P #-
MJ   @"
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M>S[5&MRGE+ROM#[+OL?XHG->_;XML #J>4
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M77K]13_,:5U.=%]+EJ1#J0 '$]$  ! $
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MM55%6UUUN4+:>HJLFL@;_P!VQ.3]B?@2H TI2*1B'/K:UM:^_8 !=D
M  %7;JW]=TOZNG\3BT2KMU;^NZ7]73^)QR;;_BEZ_P!A_P#5Q\)0D 'B/M@
M                                                    /9:+E4VJ
MM954<FC(W:G(Y.94YCQ@F)F)S"MJQ>)K:,Q*\,-WVFOM%OL"Z$S=4D2KK8O^
MJ>LVY0=JN%3:ZUE51R*R5OX.3F5.5"Z,-W=EZM<=6R-T2JNBYKDU:2;<EY4/
M9V7:>+&[;J^,^U/LR=DGB4_)/R;0 '8\<
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M0 .-Z   " (
M           'XY4:U7.5$1$S55Y#](WCQR_4\$.DK8JBJBBE5%R\15U_N0K>
MV[6;-='3XNI%.[ZO]Z:V"B=:ZR%ZNK8H9%C<U_BJJYHNW+8;..2I6]2Q.FI5
MI4A1S8D7\LCL]JI_=([BZU4%)]3S4M-%!*VMAC18VHW-N>Q<MNQ#VPIGCVK3
M/+_W>W7_ /.8Q:T6Q/N=DZ>G.E$T[3UCWPW:5]&ZJ6F2J@6H35O22)I?AM/V
MKK*:C:CJNHA@:NI%D>C<_P 2)6Z%,/NI:2[VZ&6-9\H;A&B*JO555JN1=:+Z
MS\9PFJQ7>7I;:>O= L<3$GE1N]-T<]2*U=NW,<:<<XYH]$KO3,3^&(SGESYX
M_3]>B9LECDB25DC'1JF:/1<T5.?,P4UPHJF58J:KIY9$VM9(CE3W(I&J2#ZF
MLUXDO5-'';GR)(REB?IHF>2*U-2;5RU'DN+)&5]BF^IX;<G#(V-?'(W25JYY
MM5&IS>L3K3$1R179*VF8B?A/+MGOS]^$QJJZDI'-2JJH(5=]U))$;G^)EDFC
MCA6621C8D3-7N<B)ESYD8N]%/0WBLNCJ"&YT<T;4>QV6^0HU->BBZE1=N1Y+
MY4,KI\-PT%-'/0S(^1E.]V]L=HM311=2[->HF=6:YS']SA%-DK?=W9Y3UGEX
M1F8]WZ_%+Z2LIJQBNI*B*=J:E6-Z.R_ ^;E5MH;?4U4FML,:ORY\DV&@H+=7
MIB*GK?J^EH(4C=',D,VEOB?HZD:FQ3/CY7)A*OT>9F?LTT)XD[DVF.BD:%.-
M33B<Q./TYX\'OPYPEUEI9*Z19*B5F^/5>32UY>Y%R-39L235M^?2S11LHI=\
MX)*F><F@N2\OM4]N(Z[ZNPU+)!_2.C2*%$VJYVI,OW^XBMPJ'T=FM2P6JXPR
M6Q[9%EDA1&JGZ>:Y\IGJ7W,1$]'3L^A&M%K3'YIF(]W]G$>:77BY345RM-/$
MUBLJY7,>KD7-$1,]6L^*:ZSU]\?34#(W4--FVHG<BKF_^XS7R<J_[758O:M?
M56!*6=T6_O?O<K=J9LU*A[,%U#(Z%UKDA;3UM$NA+&GZ7,].=%VEHO,ZDUSR
M_P".C.=&M=GC4QF<?S,9_AC9<KW6W6Y4]N;;FQ4DB,_+H_2=FF?(I[+->)JB
MNGMURITIKA$U'Y-=I,D9_>:IYL,?U[B/]89_"?%0J3[H%*D*YK34CEF5.3-=
M2+^.9%9F(BV?'^5KTI:;:>[$8K$Y_2)^;V8>JYG55SH*N19)J2;Q7.VK&],V
M_P"J&[(W0ZL>7-&[%I(U=[<]7["2&NE/+';+EVFL1>)CQB)\X  :.<     ?
M,CV1QN?(YK&-3-SG+DB)SJI@X?2<(; E5!O[DS;'OB:2IZD/)BC^SES_ %=_
M[E(K>;71TV (:J&%K:MK(9DG3^DTG*W-=+;RJ8ZFI-<XCI&79L^STU8C>G&9
MPFS*VE?4NIV5,+JANV)'HKD]VT^JJI@I8]\JIHH6;-*1R-3]I%<0VRDMC;')
M0P,AE971,WQJ>,Y%SSTEVKGZS.R&*X8WK65S&RLI:=F\1R)FU-+6YV2\O(1Q
M+9W9CFF-GI,;\3.[B9]_*<?RDE-40U,224TL<L:_I,<CD_%#4X.K9Z[#\-36
M2Z<JN>CGJB)J1RHFSU(>&WPQT..:JFHF-CII:-)I8V)DU'H_)%RY-1H622MW
M/:&*),VSUF]2)I:.;5D=FBKR(N2(5G5F)S/AG^&M-EK:N[$]9KB?&(F+?WWI
M]35]'52.92U4$SV[6QR(Y4_ ^JJLIJ1J.JZB&!JZD61Z-S_$B\UKN$M7;I*>
MT45 ZFF:Y98IT55CV.;DC4S14,MNIX+CBV]NKXHYW4R11PLD:CD8U6JJJB+S
MJ6C4MTQS93LVG&;;W*(S/29ZX\.7BDBU,",B>LT6C*J-C733)ZKL1.<^GS1Q
MOC9)(QKY%R8USD17+ZN<C&)*2GH6V&&EC;%"ETC<C6[$5=)5]FLSXC5/M%AQ
M,]>_2:O_ )29U)C.?#'S5KL];8Q/*8M/EEZ;;6U$V)[S2R2:4$#(5C9DGBZ3
M5538NN%&RI2G=5T[:A=6]K(FE^&>9'&2O@Q!BR6'^DCIHG-]J1JJ&LMENJJW
M"[(H[-1RK41*[A3ZA-\5Z_IKXN>>?)F4C5F.4<^O[MYV:EOQ3.(Q7M'6L3GG
MC_E8 /+:HYXK;2QUCD=4,B:V147/-R)K7,]1T1SAYUHQ,PTF)*N:-]OH:218
MYZR=&Z;=K6-UO5/=^\]=^N'U7:*FK1$<]C<F-7])RZD3\50U5TUXXLJ.^ZD,
MRM]N6O\ 8>?%M8K[S:Z%E//4LB=PN:.!ND[)NINKFS,+7F(M/Z._3T8M.G7'
M+$S/G/TPVN&+I/<J.9*V-D5;3RNAF8S8BIL5/5D>%URO-7>[G1VUM V.C6-/
MRZ/S=I-SVHOJ4\5LN"QXT>KJ.JI(;E$B:-0S1SE8FU-?-^U3\I$N:XMQ$EJ6
MC37!OBU".7+Q%RRR]^TIOS,1&?''REKP*UO>V(C\,3&>D<XB?YAMK;B!LEMK
MY[C%P>:@<YE0QJZ29I_=]IYZ:JQ'7TS:NFAMU-"]-*.&?3<]6\F:IJ3,\%^L
MTEOP9=M*9:BKG>D\\F66DNDBKDG(B(A+J&6.:B@EA5%C?&US53FR+UWK3NVG
MP9:G"TZSJ:<1.9Q[N41^^6LLUZ=<+=5R20[Q64BN9-"JYHUR)^Y3T8;KI;G9
M*2LG:QLLK55R,143:J:OP-'8U26X8LJ8M<#WI&U4V*YK'([]Z&QP-_92W?\
M(O\ $HT[S,QGW_NC:-*E*VFL>-?TS69F'GQ5?:ZV03OH:'29!H[Y/-J9XRHB
M(U$7-RZ_8AO+A'+-;YV4TBQ3NC70>W:UV6I?Q-+NA?V3K/\ FC_C:2)OW4]A
M>,[]HF?"/Y96W8T:7K&)S/ZXW?JUV&Z];G9:6J?_ $CFY2)_QHN2_M139$;P
M)_5U<B?<2MF1GLS0DA;2F9I$RIM-(IJVK7ID !=@        %7;JW]=TOZNG
M\3BT2KMU;^NZ7]73^)QR;;_BEZ_V'_U<?"4) !XC[8
M                                    "68+PH^[R)55B.90-7V+*O,G
MJYU+Z>G;4MNU8:^T4V>DZFI.(A\8,PK)>94J:I'1T#%UKL61>9/5SJ6U!#'3
MPLB@8V.)B:+6M3)$0_88F0Q,BA8UD;$T6M:F2(A]GN:&A71KB.KX?;MOOME\
MVY1'2  &[A
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M$UK&-3)K6IDB)S'V#HT="FC&*O.VO;=7:[;VI/3P\  &SD
M
M    TF-;Q)A_"5WNT,399:.F?,QCUR1RHFK/U&[(ANO?FQQ-^HR?N)KSF$6G
M$2XHQ%?+AB*[U%SO%2^HK)US<YVQ$Y$1.1$Y$/BVV6Z71CWVRVUM8QBY/=3P
M/D1J\RZ*+D> V-OOUWML&\6ZZU])#GI;W!4/C;GSY(NT[_@\KK/-ZOLAB3H]
M>.Q2_"2#!&Y;B3$U[CHI+=66ZF3QIJJKIW1MC;ZLT32=S(G[$UD>^UN(^D%W
M[;)\0^UN(^D%W[;)\1$[RT;OBZLQMA6UX0W$;_;+- D<3:15?([6^5V:9N<O
M*O[MB:CCDMW<;^N\;3XIL53>*N9U39Y$BX7.^1C7[[%DN2JN7-GZRLK]9J^P
M76HMMWIGTU9 [1>Q_P"Q47E1>14VE=.-W,3/-?5G>B+1').\3V6Z73<YP ZV
M6VMK&QTM6CUIX'2(U5J7;=%%R(?]D,2='KQV*7X3!1XBO=#3,IZ*\7*GIV9Z
M,454]C6YKFN2(N2:U,WVMQ'T@N_;9/B+1$PI,UE(\#;EF(\3WR.CFM]9;:5/
M&GJJJG=&UC?4CD32=S(G[$.P,'X8MF$K)#:[- D4#-;G+K?*[E<Y>55_]$U'
M#GVMQ'T@N_;9/B+J^BU>KI<\57B.Y7.MK(V42.:VHG?(B+IMUHBJNLRU:VF,
MS+?0O6)Q$<Y=*  Y7:   @" #YD8V2-S'IFUR*BIZB"8'JOJFCO]),NN@>Z3
M)>7)%1?X4_$GI5^-8:FAQ!7)21/<RY0-:NBB[=),_?XO[3EVF9IC4CP_EZGV
M;6-;?V>W^K$^4_3+[W-YIJ6^OBJ<TX=!OK<_TE15R7\-(W6"TX=B&^W1=;5E
MWB->=$7N1IXL84DUE6QUU$Q7/I8^#JK4YDU?O<;_  '0K0X:ID>U6R2YRN14
MR76NK]B(8Z%9B\:<_P"GG_?.79MNK6^C;::_Z\5\IG/RB$/PE>JNV6ZO;16V
M2KT9EEE?GDUC<OVKJ4FU)B.EFPXMXD:Z.)J+ILVJCD7+13GUY?B1_ D4C<.7
MEKF.1RR29(J;?$/);;=4UNYM/!!&Y9TE5Z,RUNR<BY#2M>E8QSY2MM6EH:VK
M:;1C%JQ,YZQ,<_<V3L85\--'7U-DD9;9%3*5)45V2[%RR[O:8\?3,J&6":%V
ME').CVKSHNBJ&OK[ZVYX7BLM+1U3K@YD<3H][U-T537^P]6*J&6EMV&:;15[
MX)&,<K4SUHC<R+7M:EHSF,1YY-/0II:U+;NY;-HQGK&.4\YG_E^NGDI=T&]3
MPQ;\^*BTTCSRTLFL7+,W4.*(I,*R7E8LE9FU8=/]//)$SR]:+LY3P4,;^,RX
MO5CM!:9/&RU;(R,5=OJ(K]+AN/-*2HJVS-RY&9+_ *?PD[]]/,QXS,?KX(C0
MTMHFM;]:UI/_ .,1SA9MHJGUULIJJ6'>73,1^AI9Y(NS7[#V&ANV%Z&YU+9I
MI*F-S6)&C8I-%J(FS5D;FFA;3T\4+%<K8VHQ%<N:Y(F6L[:3;I9XFK&EC>I/
M7PQT_7/-E !=B     /)=:&.Y6ZHHY\T9,W154Y%Y%]RY*1*VT&*[/3\!HUH
MIZ9JKO<DB_<15_WSDX!E?2B\[V<3[G5H[5;2I.GB)K//$QGGW0N[6*[/N%KN
M*)37"HIXM[ECE71:YVOQDY.7]B&?#MDN-+?ZZOKF4S$J8=%&PKJ:N::LO8FT
MEH*QL]8MO-)V_4FG#Q'3'3PSGX([@>T5-GM,M/6HQ)'3*]$:[-,LD3_0T]!9
M,06B6LH[6^EX#4/5S9I%\:-%U9HG/E[=A.@3P*XB(\$1M^IOWM,1.]UB8Y<N
MB$T>&J^#!=PM:I&M3+-IL\;4J9MY>3[JF:YX;K)[/95I9(V7*W-;DCE\5RHB
M:L_:B$P!'H],8]V%O6.MO;W+K,^<8G],(:EHO-YNU%4WUE-3T]&[3;'"N:O=
MFB\Z\R#&N':ZXU\-9:E8DBQ.AETG:.;5S3]RJGX$R G9ZS6:SXHK]H:M+UO6
M(C$8B,<N:)WK#4T^$:2V43V)+3JUZHJY->J(N?[553Q+9+O676TU=124-)%2
M2M58H5UY(J*J_LU(3D"=GI,Y^'R*?:&K2,<IZ_/JAF([;>[LD](^BMTD3I/R
M54KLGQLSS3UYY:M1]7?#=<QMHJK5*Q];;XVQ92:DD1/]KJ]9,0)V>LYF?$K]
MH:E(K%8B(C/+OF,3E&5H+S=K/<:>\+30NG8UL,<6M&*FO-5U[5RY3136'$M7
M86VR=:2."GRT$1WC2Y+JS7D1$]A88%MGK;K,]DZ?VAJ:?Y:QUS'+I/3DBMUL
M=94U^'98DCT*%6[]F[+++1V<^Q3RU-ENE+B2MKZ*FHZR.J3)'5"_T6SD]W)R
M$T G0K//^]E:;?J5C&(F,3'G.?W06CPQ<(<+W>@?O+JBIF1T:H[)%1%1<_5L
M/?>*BJL.#*6*%Z,N"-B@9HII9NU9HG/J125F*6GAF?&^:*.1T:Z3%<U%5J\Z
M<PX$5C%)YXPMZ=:]XG5B)C.]CO.,>7)CMO"$M]-PU46IWMN^JG][+7^T](!M
M$8C#AM.9F0 $H
M
M
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MDB;<^;]ZF\,;YHXWL8^1C7OU-:KD17>PK:L6QGP::>I>F8IXQB?@R  LS
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M UZQ6^(K-?=/]@ !=B
M
M
M
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MPF'RB#A,/E$,P P\)A\H@X3#Y1#, ,/"8?*(.$P^40S ##PF'RB#A,/E$,P
MP\)A\H@X3#Y1#, ,/"8?*(.$P^40S ##PF'RB#A,/E$,P P\)A\H@X3#Y1#,
M ,/"8?*(.$P^40S ##PF'RB#A,/E$,P P\)A\H@X3#Y1#, ,/"8?*(.$P^40
MS ##PF'RB#A,/E$,P P\)A\H@X3#Y1#, ,/"8?*(.$P^40S ##PF'RB#A,/E
M$,P P\)A\H@X3#Y1#, ,/"8?*(.$P^40S ##PF'RB#A,/E$,P P\)A\H@X3#
MY1#, ,/"8?*(.$P^40S ##PF'RB#A,/E$,P P\)A\H@X3#Y1#, ,/"8?*(.$
MP^40S ##PF'RB#A,/E$,P P\)A\H@X3#Y1#, ,/"8?*(.$P^40S ##PF'RB#
MA,/E$,P P\)A\H@X3#Y1#, ,/"8?*(.$P^40S ##PF'RB#A,/E$,P P\)A\H
M@X3#Y1#, ,/"8?*(.$P^40S ##PF'RB#A,/E$,P P\)A\H@X3#Y1#, ,/"8?
M*(.$P^40S ##PF'RB#A,/E$,P P\)A\H@X3#Y1#, ,/"8?*(.$P^40S ##PF
M'RB#A,/E$,P P\)A\H@X3#Y1#, ,/"8?*(.$P^40S ##PF'RB#A,/E$,P P\
M)A\H@X3#Y1#, ,/"8?*(.$P^40S ##PF'RB#A,/E$,P P\)A\H@X3#Y1#, ,
M/"8?*(.$P^40S ##PF'RB#A,/E$,P P\)A\H@X3#Y1#, ,/"8?*(.$P^40S
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MX
M
M
M
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M$Q.)  $
M
M
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MHYZ_DYT1&IGS.R_>6 =6EJUU8WJO,VK9-39;[FI'TD !HY@
M
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MIJ<Z97T<UU,.I  <;T0  $ 0
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MKY/W62BYIFFP]S1UJZM=ZKX;;-CU-DU-R_Z3W?H -7(
M
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MD_VNO7ZBG^8THLO3Z)/]KKU^HI_F-*:G*DKZ,YU(=2  XGI   ( @
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MM2D12MX\<^<?\8  78@     5=NK?UW2_JZ?Q.+1*NW5OZ[I?U=/XG')MO\
MBEZ_V'_U<?"4) !XC[8                              #<X9L%3?:S>
MXLV4[%_*S*FIJ<WK7U%JUF\[M>K/5U::59O><1#YPW8JF^UF]0)H0MR6654U
M,3_5?471;Z2.AHH:6%7K'$U&HKW9K^)\6NWTUKHF4M'&C(F_BY>=5Y5/6>WL
MVSQHQ[WQ/VC]HVVR^(Y5CI'\@ .EY@
M
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M-V+ZT+R^B3_:Z]?J*?YC2NI6(K*^C:TWC,NI  <;T   $ 0
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M(^//ECO^V&FM3ZF2JSELL=#&C5_*+(Q7*O,B-[S<@%ZQB,,+WWYSC'G_ #D
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MS9]GKHQWEX_VA]HWVRW:L=(  =#S@
M
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M7C(F62HG.9ZLVF.G)MH12)YSS6P #E=H  " (
M
M
M
M
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MN+D^C%AF^63%%WFO-GN%!%)1HQCZFG=&CG:;5R153:=&@BVM-HQA:FSQ6<Y
M 8N@  ! $
M
M
M
M
M            0!  ! ^*:7I[C3MZ?".*:7I[C3MZ?"!/ 0/BFEZ>XT[>GPCB
MFEZ>XT[>GP@3P$#XII>GN-.WI\(XII>GN-.WI\($\! ^*:7I[C3MZ?".*:7I
M[C3MZ?"!/ 0/BFEZ>XT[>GPCBFEZ>XT[>GP@3P$#XII>GN-.WI\(XII>GN-.
MWI\($\! ^*:7I[C3MZ?".*:7I[C3MZ?"!/ 0/BFEZ>XT[>GPCBFEZ>XT[>GP
M@3P$#XII>GN-.WI\(XII>GN-.WI\($\! ^*:7I[C3MZ?".*:7I[C3MZ?"!/
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M@3P$#XII>GN-.WI\(XII>GN-.WI\($\! ^*:7I[C3MZ?".*:7I[C3MZ?"!/
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M@3P$#XII>GN-.WI\(XII>GN-.WI\($\! ^*:7I[C3MZ?".*:7I[C3MZ?"!/
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MS
M
M
M
M
M
M
M
M
M
M
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M2O=8 (5:=T[#-SN$-'#5RQRRKHL6:-6-5>1,^0FI$Q,=5HF)Z  (2
M
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M]JK?^I)_F/--+\S+6_*JP '2XP
M                           +HW*-TK+>;+B.;5J93U;U_!CU_<OXE+@K
M:L6C$K4M-9S#M$%'[E&Z5P7>;-B*;.#4RGJGK]SF:]>;F7DY=6R\$7-,TUH<
MUJS6<2[:7BT9@ !58
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M?].8]F'L-5ELK^%5V(;E<E1BL;%,Y$C3/+6K4VKJVD;T8PF*SG,I* #-L
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MS+6_*JP '2XP
M                OW<(NM\K;7-35T3I;5 FC3U+UR<B^33^\B<_)L]D!W,=
MSZ?$]0VMKT?#9XW:W;%G5/T6^KG7_79T91TL%%2Q4U)$R&GB:C61L3)&HACJ
M6CHZ-&D_F9@ 8.D
M                "M=WGQL-6J)ZY4\MSB;*O_#HO_W[BRB,;I6'W8DP?74,
M"(M4B)-!ZWMUHGO3-/>4U(F:3$.[[-U:Z.U:=[\HB?[/Z-EBBFI:G#-T@K6M
MX*ZFDT\]C41JKG[LL_<<<%Z7>\WG&NYFD%ED7ZRI<H;K1(F4TB)JS;RY+EFJ
M<NM.3):->QT;W,D:K7M7)6N3)44XMIM%IB8?:_\ IK9;;-35I>W//3MCQ_7]
ME@[@]/35&/X5JD:KHH))(47^^F2?N5R^XL_=[1&X4M\S=51%<(EB5-N>B_\
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M)J 0V(
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M)WP)4QK$Z1B9JC5U+E[LT/324\5)2PTU.U&0PL2-C4Y&HF2(,\DQ$Y90 56
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M$1#( 8.D
M              $$Q9@%U9=?KS#%<ZT7Q/O/;_1S?\Z?OU+GRHI':UF,7297
MS ]CO4S=25+4CS=ZUS7/]B%N@SG2B>G)Z6E]J:E*Q6]8MCIG.8CMF)B<>[*J
M(K+CJ_4_ 966["UH=J?%1HF^.;S)HJO[V^\GV$\-6["]K;0VN)6MSTI)':WR
M.YW+_O(W()KIQ7GXLMHV_4UZ\/$5KVCES[SXS^L@ +N(
M
M
M
M
M
M
M
M
M
M
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M>W_+'A0MZ*+V_P"6##I,'-GA0MZ*+V_Y8\*%O11>W_+!ATF#FSPH6]%%[?\
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M>W_+!ATF#FSPH6]%%[?\L>%"WHHO;_E@PZ3!S9X4+>BB]O\ ECPH6]%%[?\
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$##__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g769642g96l94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g96l94.jpg
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M*"@H*"@H*"@H*/_  !$( -H!H ,!(@ "$0$#$0'_Q  <  $  @,! 0$
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M;@'#[P@)%$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<M-+;+W^Y)(B+4Y B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MH"-'U4ZM$VVU8YI0BHIIW;^@1$5C,(B( B(@"(B *"R\F=;GL<W&Q0NQA/\
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MY(Y6R0Z(+HW<WVZ(\UNGF6O,XG%PGH]GN:'"V*APV(;3KV766,>XEY([D]0
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MG8[*W\@Z*?C+AK(LQUX2N@D$DKJDA,37M^%CW $-.][&^GGY*Y(@"(B (B(
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H2_-=<1,["II!$14- B(@"(B (B( B(@"(B (B( B(@"(B (B(#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g769642g98g45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g98g45.jpg
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %" @\# 2(
M A$! Q$!_\0 '0 !  (" P$!              0%!@<! P@""?_$ %<0  $#
M @,#! P- @(&!PD!  $  @,$$042(083,11!49$'%2(U4E1A<7.!P=$6(S(T
M-E-RDI.4H;&S"$)BLA@S0U56@B0W=97#TN,E1W2%HL+3X?#Q_\0 &@$!  (#
M 0                $" P0%!O_$ #<1 0 ! @(%"@4$ @,!       ! A$#
M400%$A,R%2$Q05)A<8&AP084,Y'A(C31\$)#4['QDO_:  P# 0 "$0,1 #\
M]4HB("(B B(@(B("*/B%;2X;135F(5$5-2PMS22RO#6L'225YX[(W]1T<+Y:
M+8:F;,X7:<0JFG+YV1\3YW=15J:)JZ%*\2FCI>B*VLIJ&F?45U1#34[-72S/
M#&M\Y.@6NL?[..PF#N<P8LZOE;Q90Q&4>IVC#UKQQM)M-C6TU6:G'L3JJZ6]
MQO7W:W[+>#1Y  JA9Z<".N6K5I4_XP]4U_\ 4[@S''D&S^(SMYC-*R+]LRKA
M_5''FUV2?EZ>V(O_ !+S.BR;FC)C^8Q,WJS#_P"IS I' 8A@6)TXYS"]DMNL
MM6<[/=FG87&W-9'C<=',[_9US##;_F/<_JO#2*LX%,K1I-<=+])J>>*IA9-3
MRLEB>+M>QP<UPZ01Q78OSTV4VRV@V3J1-L_BM31ZW=&UUXW_ &F&[3ZPO1?8
MV_J*H,2?%0[:0,PZI=9HK803 X_XFZEGGU'F6*K!F.CG9Z-(IJYIYGH!%\4\
MT53!'-3RLEAD:',D8X.:X'@01Q"^UA; B(@(B("(B B*#CM=VMP:MK W,Z&)
MSFM\)UM!ZS9!"Q#$ZF>N?AV",C?4LMOZB07CIP> ('RG$<&]=E\MV9I9^ZQ:
MHJL2E/$SRD,]4;;- ]2FX!APPS"X:<G/,>[FD/&21VKG'SE6"# ^RA&S"-A3
M'AC>21QS,RMA.2UR2>'E6E::NQR>GBE%<X![0ZV_DTN+K=O9F^A,OIF>U:6P
MSO;2>B9^RU-+QJ\*(FAV-3Z'A:557&+%[6.58[X^?QY$Y5COCY_'D4E%H?/8
MV?H[W(FA]GUE&Y5COCY_'D3E6.^/G\>1243Y[&S]#D30^SZRC<JQWQ\_CR)R
MK'?'S^/(I*)\]C9^AR)H?9]91N58[X^?QY$Y5COCY_'D4E$^>QL_0Y$T/L^L
MHW*L=\?/X\B<JQWQ\_CR*2B?/8V?H<B:'V?64'MACG*C!RYU\F>^_DZ;+MY5
MCOCY_'D7R.^Q] /\Q4M3.FXT=?HI1J;1)O>GUE&Y5COCY_'D3E6.^/G\>124
M4?/8V?HOR)H?9]91N58[X^?QY$Y5COCY_'D4E$^>QL_0Y$T/L^LHW*L=\?/X
M\B<JQWQ\_CR*2B?/8V?H<B:'V?64;E6.^/G\>1.58[X^?QY%)1/GL;/T.1-#
M[/K*-RK'?'S^/(G*L=\?/X\BDHGSV-GZ'(FA]GUE&Y5COCY_'D3E6.^/G\>1
M243Y[&S]#D30^SZRC<JQWQ\_CR)RK'?'S^/(I*)\]C9^AR)H?9]91N58[X^?
MQY$Y5COCY_'D4E$^>QL_0Y$T/L^LHW*L=\?/X\B<JQWQ\_CR*2B?/8V?H<B:
M'V?64;E6.^/G\>1.58[X^?QY%)1/GL;/T.1-#[/K*-RK'?'S^/(NN+%<4;4R
MPSUL^9@!NR9]C>_3YE-53)WUJ?L,]JV=$TG$Q<39JGF<S6NK='T; V\*+3?.
M7J]$1=%YP1$0$1$!4.VVUF%;&X%-BN-S[N%G<LC;J^9_,Q@YR?TXFP4W:'&:
M'9[!:S%<5F$-%2QF21Y_0 <Y)L .<E>%NRAMYB&WVT<F(5I='21W924H-VPQ
M^UQT)//Y@ ,F'A[<]S#BXN[CO2NRAV3,:V_Q NK9#387&Z]/0QN[AG07>$[R
MGU66"HBW(B(BT.?,S5-Y$1=U%%'/600SSLIHI)&L?,\$MC!-BX@:D#CIJI0Z
M46PMG>Q_1XURN6@QMF(0PB%K64S&Q2/EF<X1Q_'N8,UF$D NUL!>]QT8?V+\
M:K8*9\=5A;)*C<989*@MD!F:XQ-(RZ%V1P Z1K8:JNU"VQ4P1%G5'V,,9JZ2
MFFBJ\*#JAD+F1.J"'WFB,L3",ORG-:ZP_P )O86)P53$Q/0B8F.D1$4H;*[$
M?9:Q;8*K932E]=@+W?&T;G:QWXNC)^2?)P/ZCV;LUCV';2X-3XK@M2RIHYQ=
MKF\0>=KAS$<X*_.A;"[#/9(J^Q_CX<\OFP2J<&UE,#?3ZQH\(?J-.@C#B86U
MSQTMC!QIIYJNA[H11\/K:;$:&GK:&9D]+4,$L4K#</:1<$*0M1OB(B B(@*C
MVW^C-9YX_P"1JO%1[;_1FK\\?\C4%XB(@P;LS?0F7TS/:M+89WMI/1,_9;I[
M,WT)E],SVK2V&=[:3T3/V7.UCPTO1?#O'B>$>Z2B(N4]2*504%37OD;2QYS&
MW.^[@T-%P+DD])"BJRP?$^UL5>&QL>^HA$;<[&O:#G:ZY:X$'1JM3:_ZNA3$
MFJ*?T=+Y[3UY=3M%,XNGUC:""2+7O:]P+:W/-JCL&KV[TF$98FASG"1I;8WM
M8WL3H=!KH5;P;14T=)3P2T\L[A&Z&25Q:U[8W,+2QC@. )N+\+67(V@H&/E#
M*1Y@? (W0Y(VLF< ZSG #0BXU&NBR[&'FU=[I'9_M_')BZ(BP-T1$01!WV/H
M!_F*EJ(.^Q] /\Q4M6J4P^OQ$1%5<7;'3RR02S,83%%;.[P;FP74K+":VG@I
MJREK(Y70U(;=T1 <TM=<<=.E6IB)GG5KF:8O3%_[SH=3334L\D,\99)&;.:>
M8KEM),ZDDJ6L^)C>UCC?G<"1I_RE9'4;6"9E0PP/$4QG+HL]VDORY;]-LOZK
MZEVGIY*N:1[*U[)9V36=-8Q "7N&D6(:-X+#3@>%UDV,._$U=]CVYZ.?Q8IE
M.NATT.G!3*/#*JL+1 QAOG^5(UM@T7<3<Z  \2LBGVKAD=*YL50TF6*5FH[E
MS!&"X^%?)P=?B#>_'JDVI8TS<ECJ(B_?]UO3>\D3&@WO?1S+VOIIT*=C#CIJ
M-]CS'-1:?%C4\$D$CF2 7;8G*X.&HN-1HN9:6:*FAJ'LM%*7-8;\2VU]/6%D
MTNU43Z.HB;3.:9#P-BUXR,;9P\F2X.O'F4?&\?IL4JJ)TL54^"&HDE>V5X<2
MU[FG(WH L0%$T46FU2:<;&F8BJBV?/W?RJ9<(KXIC%)2R-D$0GR\^0Z _JNQ
MV!8DV.5YI7%L9<UUG D%ORM ;FW/T*]CVR J!6<B:RL8V1K2TDM(<]KQ?,2=
M#FX>%I91HL>H:=L3J>FJ=Y32320-=(,HW@ [HVN;6]:ML86:D8ND]=']^_A]
M^YC5B1< V"^XX)9&R&.-[A&W.X@?);<"Y\ER%D6&XU3T.S7)2Z5\SW5#70M=
M9A#V,:"_36VI'E"DU>U<,L4D4,=9%&^"2'-OBYPS.:YNI))ME(_YCYE6**+<
M]2\XV+>U-'-?INQ6>"2"5\<@&9AL<K@X=8T7#()9&2.9&]S8VYWD#Y(N!<^L
M@+*I]K(I()F,IY&%\I>1H0\$M.OE&7CKS<%\U&UAJ(:N.3E0W\<L8<V34 R!
M[1Y@ 6VZ'%-BCM(C&QYB+X?JQ0@CB"%PK7:/$V8K7-J&-D#MV&O+S\IUR;@7
MLT:\!ISZ754L=41$VAM8=4U4Q-46D1$55A5,G?6I^PSVJV53)WUJ?L,]JWM7
M_5\G&U[^U\X]WJ]$1=AXT1$0$18QV3=IV[(;#XMC)+=]!%E@:?[I7=RP>74@
MGR J8B_,B9M%Y><?ZH]OG8SM -F,.F_]G8:^]26G26HYP?(P:><NZ M% 7-A
MJ5]SS25$\DT[W22R.+WO<;EQ)N259;*U5'08]25N(M<^GI7&?=MXR/8"YC.!
ML"X-!-C8$\5O4T[,6AS*JMNJ\H8P^L(JB*2H/)?G'Q9^)UMW7@ZZ:KI?%(R.
M-[XWM9("6.(L'6-C8\^JV*W:W!IIXI:B(OBJZS#JBOAJH6U#B(=XR4E^49BY
MN[<; 7+W#IO64N-85/A5IA0TV*F(YIGX>Q\0^-<2T,#2T.+2VQMI8BXO=+R;
M,9L*7W#%)/(&0QOD>03E8TDV N=!Y 2L\KL:V=IL-B[71T]171T\K&234,1[
MHF#)F;NPTN&6?B'6O\IUU&PC:+"<$VHQO&*.GE<'5![7PP$0Y(W2YB;EK@!D
M;DRVU$AZ$O.2-F,U!L]M)BNSKYG815" S92[-$R09FF[7 .!LYIU#A8CF*DT
MVV6/TTD#X<1<U\+J=\9,;#8P!PB.HURYW<>-];J]DQ_ :&.:#"Z6DEA9"XP/
MJ:".1^\-9F;F+FDFU.2W6XOY0"I+<;V3CEH-S0TAI8ZYKYF2T]Y#&*ES[CN.
MZ:8LK<I?TC+H"GDM'BQR/:W:*E%+*VLDC:TP20N,++'<,=%$1=NN5KG-\O/<
MK'%FE/C.%3X2!**&FQ8P]U,_#V/C_P!;(7-:P-+0XM,=G "V4BXNIE?C>SM-
MAP[6Q4U17,IY&1R34,1U+Z<LS-W8;F ;/Q#K9K9G72]NI%K];7Z^HHWRR,CB
M8Y\CR&M:T7))X !99M77X)5X=.W"V00R#$)7P1PTX83 7R$9R6W! +  '$6X
MM!%S=''MD,E-,S#XVU(?%+(.2C+FDD:^8 <,L;6%K!;_ &AMP4W1LQFUXVGF
M<V9S89"V$9I"&FS!<-N>@7('G(74MA#:VBBHH]V:1[QAS:-L+Z%C@"VK;)W0
M+<K@8Q<$WUOP)N<'Q=],_%:U] W+1NF>86VM9F8Y1U62)N3$0]#?TI;?.;-)
ML=B<MV/#IL/<X_)/%\0\^KAYG=(7II?G#@V)5.#XM1XC02&.JI)6S1.Z'--Q
MZE^A.RN-0;1[-X;C%)_J:V!LP;>^4D:M/E!N/4M;&IM-VYHU=XV9ZEJB(L#9
M$1$!4>V_T9J_/'_(U7BH]M_HS5^>/^1J"\1$08-V9OH3+Z9GM6EL,[VTGHF?
MLMT]F;Z$R^F9[5I;#.]M)Z)G[+G:QX:7HOAWCQ/"/=)1$7*>I$1$!$1 1$0$
M1$$0=]CZ ?YBI:B#OL?0#_,5+5JE,/K\1$157$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0%4R=]:G[#/:K95,G?6I^PSVK>U?\ 5\G&U[^U\X]WJ]$1=AXT1$0%
MYQ_K"QTLHL!P&)^DKWUDP\C>X9^[^I>CEXQ_JEQ UG98JH";BBI88 .B[=Y_
MXBRX,7J8-(FU#4:(NZBI*BNJF4U'#)/._P"3'&TN<=+G3S E;CGLCH-D^V>'
MX:[#JO>8C61RR"E<PB^1]B&NYSEN[U%2:C826DE<*S$Z6. RMCCF:Q[Q('O<
MR)X %\KLCW7Y@WI("@4M+M11@QTC<1B% '5 $3C:(.:<SFD=+0ZY',#T%0Z#
M&L:%4PT>(UC9Q"V%I;,01&P7:T&^@;:X'-;15YU^;KAVT^SLKH:MU14Q020U
M7(HV6+M[-KW((T TM<\Y'-<BQDV-;''55#\6I^14HE$TPB?</CEBC<T-M<ZS
ML(.EQ>]K*DH*G%(,.KW4-141T;BUM5DD(:[-F#<POKIF'F)Z5,I]K\<AEJIN
MV53)43P<G,TDCB]C=XR0Y3?0ES!?IN>FZ<Z(MUKN3L?3,FW-17T5'NKQ33S3
M@1F7E$\0M<-LWXAQ/$V%^>PI)=FJC?X+#33Q5#\4+(XGL/Q8D=E[C/PNTO <
M.(/DL3%I<;Q<3C<8C5[UXW?^M-R"\OMQ\-SG><DKHJ\0KY.3PU-5.[D9RPM+
MS\418=ST?) OY!T!3%R9I9)%LU04^"8IB,U:VKC929J0L8]EY-\(SF!UTO<<
MQS"_ A=3MGJ5N"L>R*>>N=0<O=)RID;&L+G"S8RTF2P;J0X:FUM-:6MQ3%J^
M.6>LJZN>-X$+WR/<YI%R\-)X<076Z;E=E#7XU)A5514=75]KXHR^6%LI#&L+
MV@Z7X%SFZ#B2%%I3>$G&<&IV8UAM'A/*7,K8*=[!*,[\T@',T:ZG0"YYM5:?
M 23>N9VSI0'F!E.<I.]?*R1S1W-PW_5N!-SS<5!G@VKK<:BCG9BDF+438WQM
M?F$L((#F9><'4$ :]"Z:B;:1XAJIY<0LYHJ(Y'/-@(V]RX'FRMDT\CQ;Y0NY
M\SFR2,6V=@PS9N2IDJ6RX@V>F8^-@<!$V6%\EB2+.-@W4<X/-8G&%.J\7Q&L
MHHJ.JKJF:EBRY(GR$M;E&5MAY!H/)HNK$J&HPVMEI*UC8ZB(Y7L#VNR'G!L3
M8C@1Q!T.JF.]6>Y&7KC^DC'37[#5^$2OS/PRJNP=$<H+@/O"3K7D=;W_ *0*
M\P[<8O0$V94T&\MTN9(VWZ/<J8L7IEEP)M7#UFB(M)T1$1 5'MO]&:OSQ_R-
M5XJ/;?Z,U?GC_D:@O$1$&#=F;Z$R^F9[5I;#.]M)Z)G[+=/9F^A,OIF>U:,P
MVC)P^E/*JD7B;H'#H\RY^L(C9IN]#\/S,5XEHOS1[K-%$Y$?&ZG[P]R<B/C=
M3]X>Y<NT9O3[5792T43D1\;J?O#W)R(^-U/WA[DM&9M5=E+11.1'QNI^\/<G
M(CXW4_>'N2T9FU5V4M%$Y$?&ZG[P]R<B/C=3]X>Y+1F;5792T43D1\;J?O#W
M)R(^-U/WA[DM&9M5=D'?8^@'^8J6H/:\;W><IJ<^7+?..'4OOD1\;J?O#W*T
MVGK4IVXOS):*)R(^-U/WA[DY$?&ZG[P]RK:,U]JKLI:*)R(^-U/WA[DY$?&Z
MG[P]R6C,VJNREHHG(CXW4_>'N3D1\;J?O#W):,S:J[*6BK*ZGDAA8YE74@F6
M-ORAP+P#S=!4CD1\;J?O#W*=F+7NKO*KVV4M%$Y$?&ZG[P]R<B/C=3]X>Y1:
M,UMJKLI:*)R(^-U/WA[DY$?&ZG[P]R6C,VJNREHHG(CXW4_>'N3D1\;J?O#W
M):,S:J[*6BB<B/C=3]X>Y.1'QNI^\/<EHS-JKLI:*)R(^-U/WA[DY$?&ZG[P
M]R6C,VJNREHHG(CXW4_>'N3D1\;J?O#W):,S:J[*6JF3OK4_89[5+Y$?&ZG[
MP]R@,CW6)5+3(^3N6&[S<\ZW= B-[T]3C:\F9T;GCKCW>LT1%UWD!$1 7A;L
M_O,G9?VE+N(F8WJB8/8O=*\/_P!1U,:;LPX]<6;+N96^6\++_J"L^!Q2UM)X
M6M5;;-8C!A]74<L;*::III*:1\(!DC#Q;,T$@&QM<7%Q<7%[JI1;32CF9IVY
MV>CGJZFE%93UAI!302QT4;6ESFN;*\QB4!KB"&BQ-KDVO:T/ MI(L.PFCH7L
MF,;*BJFG:P"THDA8R,'77*YKCKPOIJK"BV/BBPIN(5;WR;RDF>8)&M:6.Y*Z
M:-P+7DD<#9P;I;35=U!LSA<VW>T5/6!E/@F'U<D S5+8@W-,8V />1<M;F?8
MF[A&1SJEX7M4[F;:X4V.5CX:R62>FC@=,(PW<.;O 'Q,+W!I >" "!>]@PV(
MI-G=H*"AP=U+7TLTE0R;XJ6'*"V%[F;X7/\ =ECLW0CXQY\]G5;+8?38(V.N
MDFI:^DBJ)ZU[:?>.)94-@$;;R 6N;WL#QU/!=%=L;&R>F8R:H,M7(&114U,'
M,  CS%SWR#*?C.!-N%R =$6/U)>)[;44@:*)E6'O?2B>5S;.FCC=.7M)=(]Q
MN)(AJXWR6T  78S;/"(:"&.&GK73,J34 2M#FQW9."&W>6V)EC-@UOR=2ZP4
M.HV&IX'RL?BLF=S6NI[4S7!]Z;?C,1(0T6[FXS=*C[/[,05^R.(5DI9VPD$C
MZ)IJ&,-H0'R?%DYGAS2X M!L6%/TI_5=-CVVC? ULM17,D$]'4OO&)632119
M)'/;O&W)(:X&]S;B#JJN3%*&H=M/N9)XF5C(WP.G<72/+96%S223Q&9VKC\D
M"Y.IG5^Q5%3LJ&0XO/)4QNJXPQU&&,<ZGB;*^[MX; M< #;B#< :KC%=BJ+#
M)L3948T7]KHI'3MBIVO=G9-%$  )+929;@D@]R;MX719'ZGW3;18-2[64>+1
M35SXZ:FI8<DE!$YSS%&QAL3*=V3NP0]IS-OIPN>J@VJH>TQP[%8)JF(PD:,:
M"' L#&7!!+0QC>Z-S?+W)R-7UB.QL<5=%"R:H,M1*\1QTU,'1M8P@.+GOE&4
M\38FUK7(OIS6;#04IG:_%)#+NWR0 4S2'AM(VI[IPDLWN7Y=,VNO!.8_4B8/
MM'2T&SAI/^E,J R=IAC:W=3/> &2O=F!#HR+CN3JT6(N54;6XKV\VGQ7%,TS
MFU=3),S?&[PPN):#J> L/4KFNV;IJ+#\4+)34LCHHJZGJLH8'?\ 2&PN: ''
M3NS\H!P+. Y\15HMTPK-^B1;<_I9>6]EFF X/I)FG[H/L6HUN;^DZF,_90DE
M TI\/ED)\[F-_P#N5<3AE;"XX>Q$1%HNF(B("H]M_HS5^>/^1JO%1[;_ $9J
M_/'_ "-07B(B#!NS-]"9?3,]JTMAG>VD]$S]ENGLS?0F7TS/:M+89WMI/1,_
M9<[6/#2]%\.\>)X1[I*(BY3U(B(@(B("(B B(@(B("(B B(@(B((F)_-X_3Q
M?R-4M1,3^;Q^GB_D:I:M/#"D<<^$>XB(JKB(B B(@(B("(B B(@*ID[ZU/V&
M>U6RJ9.^M3]AGM6]J_ZODXVO?VOG'N]7HB+L/&B(B O)O]7N$FFVSPG%&MM'
M6T>Z)Z7QN-_T>Q>LEJ/^I[9IV.=C:6M@9FJ<)E%4+#4Q_)D'FL0[_E63"FU3
M%C4[5$O&*(BW7-27XA6/ACB?5U#HHVEC&&1Q:UI!%@+Z"Q/6NI\\TF\WDLCM
MX_>/S.)S.UU/2=3KY2NM$'=)5U$F;>5$S\PRNS/)N+WL?6 ?.NV/$JZ)A9'6
MU+&E[9"&RN +F_)=QXBPL>91$02):^KFE=)+55#Y'&Y<Z0DDVM>]^C1=;9YF
MF,MED!C%F$./<BY.G1Q/6NM$'<:JH<273RDDN))>=2X6=U@6/2ON?$*RH8UE
M15U$K6L$0#Y'. 8""&ZGA< V\@49$$N/$Z^)I;'753&F02V;*X#..#N/$=/%
M?$M=5RR.?+53O>ZY+G2$DW&4ZWYQIYE'1!.EQ:NF@GAGJI96S!C7F1V9Q:RY
M:VYUL";VX:#H4%$0%Z4_HYPDYMH\8>WN;14D;NDZN>/\B\UKW3V!=FCLQV,L
M)IYF9*NJ::V<$6.:34 ^4-#!ZEBQIM39GT>F]=\FP41%IN@(B("H]M_HS5^>
M/^1JO%1[;_1FK^U'_(U!>(B(,&[,WT)E],SVK2V&=[:3T3/V6Z>S-]"9?3,]
MJTMAG>VD]$S]ESM8\-+T7P[QXGA'NDHB+E/4B(B B(@(B("(B B(@(B("(B
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M2I<7&_=2.+G6\ERD7.9.1$4H$1$!$1 1$0$1$'=1&U7"?\0"[]M_HS5^>/\
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M+'T#971;YSHQ/9^5F]%V#)W3;P_*-OE@:G163]I9H:"FFJ**&.::N-$8^4W
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MT%3'*QKXWQ.:YKA<.!!N".<+ZJVM?23M>T.:YC@01<$6*(@^XVAD;6M :T
M "P 7TB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
.B B(@(B("(B B(@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g769642g98o36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769642g98o36.jpg
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M@;'!PS9#<J&S)#-"%M)B8X*R)92BI,+AXO_$ !H! 0 # 0$!
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MQX]<*B()X\>N$QX]<*B()X\>N$QX]<*B()X\>N$QX]<*B()X\>N%*KGC-),
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M97M0>I1$0$1$!$1!R*K^+;-^XU7^2G777(JOXMLW[C5?Y*=== 1$0$1$!$1
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M(J5GU)%;  XB^1HT'VKF3?ZGTM</Z>_L^EUMHTM%E9S+DEL9E(#2XA@(!=<
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M1T<U1+4-:R)A<22\#1_ZU[$;0M?IB9F.SIHM&.!\D;7QU+7,< 6N!>00?/\
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M1=D@FX98ZUPIK]?[OO*7_0C\?P_JNW[-JZYYS25K&NIWPN!F>S2Y[#E"X:"
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'$1 1$0?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
